---
layout: null
---
# ESC Guidelines 2023

<!-- 2023_Acute_Coronary_Syndromes.md -->

# ESC Guidelines: Acute Coronary Syndromes (2023)

**Source**: `2023_Acute_Coronary_Syndromes.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 107

---

## Table of Contents

- [2023 ESC Guidelines for the management of acute coronary syndromes](#2023-esc-guidelines-for-the-management-of-acute-co) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 8)*
  - [2. Introduction](#2-introduction) *(p. 9)*
    - [2.1. Definitions | Acute coronary syndromes and myocardial infarction](#21-definitions-|-acute-coronary-syndromes-and-myoc) *(p. 11)*
    - [2.2. Epidemiology of acute coronary syndromes](#22-epidemiology-of-acute-coronary-syndromes) *(p. 13)*
    - [2.3. Number and breakdown of classes of recommendations](#23-number-and-breakdown-of-classes-of-recommendati) *(p. 13)*
    - [2.4. What is new](#24-what-is-new) *(p. 14)*
  - [3. Triage and diagnosis](#3-triage-and-diagnosis) *(p. 16)*
    - [3.1. Clinical presentation and physical examination](#31-clinical-presentation-and-physical-examination) *(p. 16)*
      - [3.1.1. Clinical presentation](#311-clinical-presentation) *(p. 16)*
      - [3.1.2. History taking and physical examination](#312-history-taking-and-physical-examination) *(p. 18)*
    - [3.2. Diagnostic tools | Electrocardiogram](#32-diagnostic-tools-|-electrocardiogram) *(p. 18)*
      - [3.2.1. Acute coronary syndrome with persistent ST-segment elevation (suspected ST-elevation myocardial infarction)](#321-acute-coronary-syndrome-with-persistent-st-seg) *(p. 19)*
      - [3.2.2. Acute coronary syndrome without persistent ST-segment elevation (non-ST elevation acute coronary syndrome)](#322-acute-coronary-syndrome-without-persistent-st-) *(p. 19)*
    - [3.3. Diagnostic tools | Biomarkers](#33-diagnostic-tools-|-biomarkers) *(p. 20)*
      - [3.3.1. High-sensitivity cardiac troponins](#331-high-sensitivity-cardiac-troponins) *(p. 20)*
      - [3.3.2. Central laboratory vs. point of care](#332-central-laboratory-vs-point-of-care) *(p. 20)*
      - [3.3.3. Confounders of cardiac troponin concentration](#333-confounders-of-cardiac-troponin-concentration) *(p. 20)*
      - [3.3.4. Rapid ‘rule-in’ and ‘rule-out’ algorithms](#334-rapid-‘rule-in’-and-‘rule-out’-algorithms) *(p. 20)*
        - [3.3.4.1. European Society of Cardiology 0 h/1 h and 0 h/2 h algorithms](#3341-european-society-of-cardiology-0-h/1-h-and-0-) *(p. 21)*
          - [3.3.4.1.1. Rule-out](#33411-rule-out) *(p. 21)*
          - [3.3.4.1.2. Rule-in](#33412-rule-in) *(p. 21)*
          - [3.3.4.1.3. Observe](#33413-observe) *(p. 21)*
        - [3.3.4.2. Practical guidance on how to implement the European Society of Cardiology 0 h/1 h algorithm](#3342-practical-guidance-on-how-to-implement-the-eu) *(p. 23)*
      - [3.3.5. Other biomarkers](#335-other-biomarkers) *(p. 23)*
    - [3.4. Diagnostic tools | Non-invasive imaging](#34-diagnostic-tools-|-non-invasive-imaging) *(p. 23)*
      - [3.4.1. Echocardiography](#341-echocardiography) *(p. 23)*
      - [3.4.2. Computed tomography](#342-computed-tomography) *(p. 23)*
      - [3.4.3. Cardiac magnetic resonance imaging with or without stress testing](#343-cardiac-magnetic-resonance-imaging-with-or-wit) *(p. 23)*
    - [3.5. Differential diagnosis for acute chest pain](#35-differential-diagnosis-for-acute-chest-pain) *(p. 24)*
  - [4. Initial measures for patients presenting with suspected acute coronary syndrome | Initial treatment](#4-initial-measures-for-patients-presenting-with-su) *(p. 24)*
    - [4.1. Pre-hospital logistics of care](#41-pre-hospital-logistics-of-care) *(p. 24)*
      - [4.1.1. Time to treatment](#411-time-to-treatment) *(p. 24)*
      - [4.1.2. Healthcare systems and system delays](#412-healthcare-systems-and-system-delays) *(p. 24)*
      - [4.1.3. Emergency medical services](#413-emergency-medical-services) *(p. 24)*
      - [4.1.4. General practitioners](#414-general-practitioners) *(p. 25)*
      - [4.1.5. Organization of ST-elevation myocardial infarction treatment in networks](#415-organization-of-st-elevation-myocardial-infarc) *(p. 25)*
    - [4.2. Emergency care](#42-emergency-care) *(p. 25)*
      - [4.2.1. Initial diagnosis and monitoring](#421-initial-diagnosis-and-monitoring) *(p. 25)*
      - [4.2.2. Acute pharmacotherapy](#422-acute-pharmacotherapy) *(p. 25)*
        - [4.2.2.1. Oxygen](#4221-oxygen) *(p. 25)*
        - [4.2.2.2. Nitrates](#4222-nitrates) *(p. 25)*
        - [4.2.2.3. Pain relief](#4223-pain-relief) *(p. 25)*
        - [4.2.2.4. Intravenous beta-blockers](#4224-intravenous-beta-blockers) *(p. 25)*
  - [5. Acute-phase management of patients with acute coronary syndrome](#5-acute-phase-management-of-patients-with-acute-co) *(p. 26)*
    - [5.1. Selection of invasive strategy and reperfusion therapy](#51-selection-of-invasive-strategy-and-reperfusion-) *(p. 26)*
    - [5.2. Acute coronary syndrome managed with invasive strategy](#52-acute-coronary-syndrome-managed-with-invasive-s) *(p. 26)*
      - [5.2.1. Primary percutaneous coronary intervention strategy for ST-elevation myocardial infarction](#521-primary-percutaneous-coronary-intervention-str) *(p. 26)*
        - [5.2.1.1. Invasive strategy in ST-elevation myocardial infarction late presenters](#5211-invasive-strategy-in-st-elevation-myocardial-) *(p. 28)*
      - [5.2.2. Immediate invasive strategy for non-ST elevation acute coronary syndrome](#522-immediate-invasive-strategy-for-non-st-elevati) *(p. 28)*
      - [5.2.3. Routine vs. selective invasive strategy](#523-routine-vs-selective-invasive-strategy) *(p. 28)*
        - [5.2.3.1. Early vs. delayed invasive strategy for non-ST elevation acute coronary syndrome](#5231-early-vs-delayed-invasive-strategy-for-non-st) *(p. 28)*
      - [5.2.4. Summary of invasive strategies for patients with non-ST elevation acute coronary syndrome](#524-summary-of-invasive-strategies-for-patients-wi) *(p. 28)*
    - [5.3. Fibrinolysis and pharmaco-invasive strategy in patients with ST-elevation myocardial infarction](#53-fibrinolysis-and-pharmaco-invasive-strategy-in-) *(p. 30)*
      - [5.3.1. Benefit and indication of fibrinolysis](#531-benefit-and-indication-of-fibrinolysis) *(p. 30)*
        - [5.3.1.1. Pre-hospital fibrinolysis](#5311-pre-hospital-fibrinolysis) *(p. 30)*
        - [5.3.1.2. Angiography and percutaneous coronary intervention after fibrinolysis (pharmaco-invasive strategy)](#5312-angiography-and-percutaneous-coronary-interve) *(p. 30)*
          - [5.3.1.2.1. Comparison of fibrinolytic agents](#53121-comparison-of-fibrinolytic-agents) *(p. 30)*
          - [5.3.1.2.2. Hazards of fibrinolysis and contraindications](#53122-hazards-of-fibrinolysis-and-contraindication) *(p. 30)*
    - [5.4. Patients not undergoing reperfusion](#54-patients-not-undergoing-reperfusion) *(p. 30)*
      - [5.4.1. Patients who are not candidates for invasive coronary angiography](#541-patients-who-are-not-candidates-for-invasive-c) *(p. 30)*
      - [5.4.2. Patients with coronary artery disease not amenable to revascularization](#542-patients-with-coronary-artery-disease-not-amen) *(p. 30)*
  - [6. Antithrombotic therapy](#6-antithrombotic-therapy) *(p. 31)*
    - [6.1. Antiplatelet therapy in the acute phase](#61-antiplatelet-therapy-in-the-acute-phase) *(p. 33)*
      - [6.1.1. Oral antiplatelet therapy](#611-oral-antiplatelet-therapy) *(p. 33)*
      - [6.1.2. Timing of loading dose of oral antiplatelet therapy](#612-timing-of-loading-dose-of-oral-antiplatelet-th) *(p. 34)*
        - [6.1.2.1. Pre-treatment in patients with suspected ST-elevation myocardial infarction](#6121-pre-treatment-in-patients-with-suspected-st-e) *(p. 34)*
        - [6.1.2.2. Pre-treatment in patients with non-ST-elevation acute coronary syndrome](#6122-pre-treatment-in-patients-with-non-st-elevati) *(p. 34)*
        - [6.1.2.3. Summary of pre-treatment strategies](#6123-summary-of-pre-treatment-strategies) *(p. 34)*
      - [6.1.3. Intravenous antiplatelet drugs](#613-intravenous-antiplatelet-drugs) *(p. 34)*
    - [6.2. Anticoagulant treatment in the acute phase](#62-anticoagulant-treatment-in-the-acute-phase) *(p. 35)*
      - [6.2.1. Anticoagulation in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention](#621-anticoagulation-in-patients-with-st-elevation-) *(p. 35)*
      - [6.2.2. Anticoagulation in patients with non-ST-elevation acute coronary syndrome undergoing angiography and percutaneous coronary intervention if indicated](#622-anticoagulation-in-patients-with-non-st-elevat) *(p. 35)*
    - [6.3. Maintenance antithrombotic therapy after revascularization](#63-maintenance-antithrombotic-therapy-after-revasc) *(p. 36)*
      - [6.3.1. Shortening dual antiplatelet therapy](#631-shortening-dual-antiplatelet-therapy) *(p. 37)*
      - [6.3.2. De-escalation from potent P2Y12 inhibitor to clopidogrel](#632-de-escalation-from-potent-p2y12-inhibitor-to-c) *(p. 37)*
      - [6.3.3. Summary of alternative antiplatelet strategies to reduce bleeding risk in the first 12 months after acute coronary syndrome](#633-summary-of-alternative-antiplatelet-strategies) *(p. 38)*
    - [6.4. Long-term treatment](#64-long-term-treatment) *(p. 40)*
      - [6.4.1. Prolonging antithrombotic therapy beyond 12 months](#641-prolonging-antithrombotic-therapy-beyond-12-mo) *(p. 40)*
    - [6.5. Antiplatelet therapy in patients requiring oral anticoagulation](#65-antiplatelet-therapy-in-patients-requiring-oral) *(p. 41)*
      - [6.5.1. Acute coronary syndrome patients requiring anticoagulation](#651-acute-coronary-syndrome-patients-requiring-ant) *(p. 41)*
      - [6.5.2. Patients requiring vitamin K antagonists or undergoing coronary artery bypass surgery](#652-patients-requiring-vitamin-k-antagonists-or-un) *(p. 43)*
    - [6.6. Antithrombotic therapy as an adjunct to fibrinolysis](#66-antithrombotic-therapy-as-an-adjunct-to-fibrino) *(p. 43)*
    - [6.7. Antithrombotic therapy in patients not undergoing reperfusion](#67-antithrombotic-therapy-in-patients-not-undergoi) *(p. 43)*
  - [7. Acute coronary syndrome with unstable presentation](#7-acute-coronary-syndrome-with-unstable-presentati) *(p. 43)*
    - [7.1. Out-of-hospital cardiac arrest in acute coronary syndrome](#71-out-of-hospital-cardiac-arrest-in-acute-coronar) *(p. 44)*
      - [7.1.1. Systems of care](#711-systems-of-care) *(p. 44)*
    - [7.2. Cardiogenic shock complicating acute coronary syndrome](#72-cardiogenic-shock-complicating-acute-coronary-s) *(p. 44)*
  - [8. Management of acute coronary syndrome during hospitalization](#8-management-of-acute-coronary-syndrome-during-hos) *(p. 45)*
    - [8.1. Coronary care unit/intensive cardiac care unit](#81-coronary-care-unit/intensive-cardiac-care-unit) *(p. 45)*
      - [8.1.1. Monitoring](#811-monitoring) *(p. 45)*
      - [8.1.2. Ambulation](#812-ambulation) *(p. 45)*
      - [8.1.3. Length of stay in the intensive cardiac care unit](#813-length-of-stay-in-the-intensive-cardiac-care-u) *(p. 46)*
    - [8.2. In-hospital care](#82-in-hospital-care) *(p. 46)*
      - [8.2.1. Length of hospital stay](#821-length-of-hospital-stay) *(p. 46)*
      - [8.2.2. Risk assessment](#822-risk-assessment) *(p. 46)*
        - [8.2.2.1. Clinical risk assessment](#8221-clinical-risk-assessment) *(p. 46)*
        - [8.2.2.2. Imaging risk assessment](#8222-imaging-risk-assessment) *(p. 46)*
        - [8.2.2.3. Biomarkers for risk assessment](#8223-biomarkers-for-risk-assessment) *(p. 46)*
        - [8.2.2.4. Bleeding risk assessment](#8224-bleeding-risk-assessment) *(p. 46)*
        - [8.2.2.5. Integrating ischaemic and bleeding risks](#8225-integrating-ischaemic-and-bleeding-risks) *(p. 46)*
  - [9. Technical aspects of invasive strategies](#9-technical-aspects-of-invasive-strategies) *(p. 47)*
    - [9.1. Percutaneous coronary intervention](#91-percutaneous-coronary-intervention) *(p. 47)*
      - [9.1.1. Vascular access](#911-vascular-access) *(p. 47)*
      - [9.1.2. Intravascular imaging/physiology of the infarct-related artery](#912-intravascular-imaging/physiology-of-the-infarc) *(p. 47)*
        - [9.1.2.1. Intravascular imaging](#9121-intravascular-imaging) *(p. 47)*
        - [9.1.2.2. Intravascular physiology](#9122-intravascular-physiology) *(p. 48)*
      - [9.1.3. Timing of revascularization with percutaneous coronary intervention](#913-timing-of-revascularization-with-percutaneous-) *(p. 48)*
      - [9.1.4. Balloons and stents](#914-balloons-and-stents) *(p. 49)*
      - [9.1.5. Embolic protection and microvascular salvage strategies](#915-embolic-protection-and-microvascular-salvage-s) *(p. 49)*
        - [9.1.5.1. Thrombus aspiration](#9151-thrombus-aspiration) *(p. 49)*
        - [9.1.5.2. Interventions to protect the microcirculation](#9152-interventions-to-protect-the-microcirculation) *(p. 49)*
    - [9.2. Coronary artery bypass grafting](#92-coronary-artery-bypass-grafting) *(p. 49)*
      - [9.2.1. Indication and timing of coronary artery bypass grafting in acute coronary syndrome patients](#921-indication-and-timing-of-coronary-artery-bypas) *(p. 49)*
      - [9.2.2. Technical considerations specific to acute coronary syndrome patients](#922-technical-considerations-specific-to-acute-cor) *(p. 49)*
    - [9.3. Spontaneous coronary artery dissection](#93-spontaneous-coronary-artery-dissection) *(p. 49)*
      - [9.3.1. Intravascular imaging](#931-intravascular-imaging) *(p. 50)*
      - [9.3.2. Revascularization](#932-revascularization) *(p. 50)*
  - [10. Management of patients with multivessel disease](#10-management-of-patients-with-multivessel-disease) *(p. 50)*
    - [10.1. Management of multivessel disease in acute coronary syndrome complicated by cardiogenic shock](#101-management-of-multivessel-disease-in-acute-cor) *(p. 50)*
    - [10.2. Patients with multivessel coronary artery disease undergoing primary percutaneous coronary intervention](#102-patients-with-multivessel-coronary-artery-dise) *(p. 51)*
    - [10.3. Timing of non-infarct-related artery revascularization in acute coronary syndrome](#103-timing-of-non-infarct-related-artery-revascula) *(p. 52)*
      - [10.3.1. Patients presenting with ST-elevation myocardial infarction and multivessel coronary artery disease](#1031-patients-presenting-with-st-elevation-myocard) *(p. 52)*
      - [10.3.2. Patients presenting with non-ST-elevation acute coronary syndrome and multivessel coronary artery disease](#1032-patients-presenting-with-non-st-elevation-acu) *(p. 52)*
    - [10.4. Evaluation of non-infarct-related artery stenosis severity (angiography vs. physiology)](#104-evaluation-of-non-infarct-related-artery-steno) *(p. 52)*
    - [10.5. Hybrid revascularization](#105-hybrid-revascularization) *(p. 53)*
  - [11. Myocardial infarction with non-obstructive coronary arteries](#11-myocardial-infarction-with-non-obstructive-coro) *(p. 53)*
  - [12. Special situations](#12-special-situations) *(p. 56)*
    - [12.1. Type 2 myocardial infarction and acute myocardial injury](#121-type-2-myocardial-infarction-and-acute-myocard) *(p. 56)*
    - [12.2. Complications](#122-complications) *(p. 56)*
      - [12.2.1. Heart failure](#1221-heart-failure) *(p. 56)*
      - [12.2.2. Mechanical complications](#1222-mechanical-complications) *(p. 57)*
      - [12.2.3. Left ventricular thrombus](#1223-left-ventricular-thrombus) *(p. 57)*
      - [12.2.4. Post-acute coronary syndrome pericarditis](#1224-post-acute-coronary-syndrome-pericarditis) *(p. 57)*
      - [12.2.5. Arrhythmias](#1225-arrhythmias) *(p. 57)*
        - [12.2.5.1. Atrial fibrillation](#12251-atrial-fibrillation) *(p. 57)*
        - [12.2.5.2. Ventricular arrhythmias](#12252-ventricular-arrhythmias) *(p. 58)*
      - [12.2.6. Bleeding](#1226-bleeding) *(p. 58)*
        - [12.2.6.1. Management of bleeding](#12261-management-of-bleeding) *(p. 58)*
    - [12.3. Comorbid conditions](#123-comorbid-conditions) *(p. 59)*
      - [12.3.1. Patients at high bleeding risk and with blood disorders (anaemia and thrombocytopaenia)](#1231-patients-at-high-bleeding-risk-and-with-blood) *(p. 59)*
      - [12.3.2. Chronic kidney disease](#1232-chronic-kidney-disease) *(p. 60)*
      - [12.3.3. Diabetes mellitus](#1233-diabetes-mellitus) *(p. 60)*
      - [12.3.4. Older adults with frailty and multimorbidity](#1234-older-adults-with-frailty-and-multimorbidity) *(p. 60)*
        - [12.3.4.1. The older person](#12341-the-older-person) *(p. 60)*
        - [12.3.4.2. Frailty and multimorbidity](#12342-frailty-and-multimorbidity) *(p. 60)*
      - [12.3.5. Pregnancy](#1235-pregnancy) *(p. 61)*
      - [12.3.6. Drug abuse](#1236-drug-abuse) *(p. 61)*
      - [12.3.7. Patients with cancer](#1237-patients-with-cancer) *(p. 61)*
      - [12.3.8. Coronavirus disease (COVID-19)](#1238-coronavirus-disease-(covid-19)) *(p. 61)*
  - [13. Long-term treatment](#13-long-term-treatment) *(p. 62)*
    - [13.1. Cardiac rehabilitation](#131-cardiac-rehabilitation) *(p. 64)*
      - [13.1.1. Comprehensive cardiac rehabilitation](#1311-comprehensive-cardiac-rehabilitation) *(p. 64)*
      - [13.1.2. Digital health](#1312-digital-health) *(p. 64)*
      - [13.1.3. Adherence and persistence](#1313-adherence-and-persistence) *(p. 64)*
    - [13.2. Lifestyle management](#132-lifestyle-management) *(p. 64)*
      - [13.2.1. Tobacco](#1321-tobacco) *(p. 64)*
      - [13.2.2. Nutrition and alcohol](#1322-nutrition-and-alcohol) *(p. 64)*
      - [13.2.3. Physical activity and exercise](#1323-physical-activity-and-exercise) *(p. 65)*
      - [13.2.4. Psychological considerations](#1324-psychological-considerations) *(p. 65)*
      - [13.2.5. Resumption of activities](#1325-resumption-of-activities) *(p. 65)*
    - [13.3. Pharmacological treatment](#133-pharmacological-treatment) *(p. 65)*
      - [13.3.1. Antithrombotic therapy](#1331-antithrombotic-therapy) *(p. 65)*
      - [13.3.2. Lipid-lowering therapy](#1332-lipid-lowering-therapy) *(p. 65)*
      - [13.3.3. Beta-blockers](#1333-beta-blockers) *(p. 66)*
      - [13.3.4. Nitrates and calcium channel blockers](#1334-nitrates-and-calcium-channel-blockers) *(p. 67)*
      - [13.3.5. Renin–angiotensin–aldosterone system inhibitors](#1335-renin–angiotensin–aldosterone-system-inhibito) *(p. 67)*
      - [13.3.6. Medications for diabetes](#1336-medications-for-diabetes) *(p. 67)*
        - [13.3.6.1. Sodium–glucose co-transporter 2 inhibitors](#13361-sodium–glucose-co-transporter-2-inhibitors) *(p. 67)*
        - [13.3.6.2. Glucagon-like peptide-1 receptor agonists](#13362-glucagon-like-peptide-1-receptor-agonists) *(p. 68)*
      - [13.3.7. Proton pump inhibitors](#1337-proton-pump-inhibitors) *(p. 68)*
      - [13.3.8. Vaccination](#1338-vaccination) *(p. 68)*
      - [13.3.9. Anti-inflammatory drugs](#1339-anti-inflammatory-drugs) *(p. 68)*
      - [13.3.10. Hormone replacement therapy](#13310-hormone-replacement-therapy) *(p. 68)*
  - [14. Patient perspectives](#14-patient-perspectives) *(p. 69)*
    - [14.1. Patient-centred care](#141-patient-centred-care) *(p. 69)*
    - [14.2. Shared decision-making](#142-shared-decision-making) *(p. 70)*
    - [14.3. Informed consent](#143-informed-consent) *(p. 70)*
    - [14.4. Research participation and consent in the acute setting](#144-research-participation-and-consent-in-the-acut) *(p. 71)*
    - [14.5. Patient satisfaction and expectations](#145-patient-satisfaction-and-expectations) *(p. 71)*
    - [14.6. Patient-reported outcome measures and patient-reported experience measures](#146-patient-reported-outcome-measures-and-patient-) *(p. 72)*
    - [14.7. Preparation for discharge](#147-preparation-for-discharge) *(p. 72)*
  - [15. Key messages](#15-key-messages) *(p. 72)*
  - [16. Gaps in evidence](#16-gaps-in-evidence) *(p. 74)*
  - [17. Sex differences](#17-sex-differences) *(p. 76)*
  - [18. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#18-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 77)*
  - [19. Quality indicators](#19-quality-indicators) *(p. 82)*
  - [20. Supplementary data](#20-supplementary-data) *(p. 82)*
  - [21. Data availability statement](#21-data-availability-statement) *(p. 82)*
  - [22. Author information](#22-author-information) *(p. 82)*
  - [Appendix](#appendix) *(p. 82)*
  - [24. References](#24-references) *(p. 83)*
  - [24. References](#24-references) *(p. 83)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2023 ESC Guidelines for the management 
of acute coronary syndromes
Developed by the task force on the management of acute coronary 
syndromes of the European Society of Cardiology (ESC)
Authors/Task Force Members: Robert A. Byrne  *†, (Chairperson) (Ireland), 
Xavier Rossello  
‡, (Task Force Co-ordinator) (Spain), J.J. Coughlan  
‡, 
(Task Force Co-ordinator) (Ireland), Emanuele Barbato  
(Italy), Colin Berry  
(United Kingdom), Alaide Chieffo  
(Italy), Marc J. Claeys  
(Belgium), 
Gheorghe-Andrei Dan  
(Romania), Marc R. Dweck  
(United Kingdom), 
Mary Galbraith  
(United Kingdom), Martine Gilard (France), 
Lynne Hinterbuchner  
(Austria), Ewa A. Jankowska  
(Poland), Peter Jüni 
(United Kingdom), Takeshi Kimura (Japan), Vijay Kunadian  
(United Kingdom), 
Margret Leosdottir  
(Sweden), Roberto Lorusso  
(Netherlands), 
Roberto F.E. Pedretti  
(Italy), Angelos G. Rigopoulos  
(Greece), 
Maria Rubini Gimenez  
(Germany), Holger Thiele (Germany),  
Pascal Vranckx (Belgium), Sven Wassmann (Germany), Nanette Kass Wenger 
(United States of America), Borja Ibanez  *†, (Chairperson) (Spain), and ESC 
Scientific Document Group
* Corresponding authors: Robert A. Byrne, Department of Cardiology and Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, Dublin, Ireland, and School of Pharmacy 
and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland. Tel: +353-1-2483190, E-mail: robertabyrne@rcsi.ie; and Borja Ibanez, Clinical Research 
Department, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, and Cardiology Department, IIS-Fundación Jiménez Díaz University Hospital, Madrid, 
Spain, CIBERCV, ISCIII, Madrid, Spain. Tel: +3491 4531200, E-mail: bibanez@cnic.es
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
and Heart Failure Association (HFA).
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, E-Cardiology, Myocardial and Pericardial Diseases, Thrombosis.
Patient Forum  
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC 
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the 
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; 
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from 
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case 
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices at the time of prescription.
This article is co-published with permission in European Heart Journal and European Heart Journal - Acute Cardiovascular Care. All rights reserved. © The European Society of Cardiology 
2023. The articles are identical except for stylistic differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions, please e-mail: 
journals.permissions@oup.com
https://doi.org/10.1093/eurheartj/ehad191
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Sigrun Halvorsen, (Clinical Practice Guidelines Review Co-ordinator) (Norway), 
Stefan James, (Clinical Practice Guidelines Review Co-ordinator) (Sweden), Magdy Abdelhamid (Egypt), 
Victor Aboyans (France), Nina Ajmone Marsan (Netherlands), Sotiris Antoniou (United Kingdom), 
Riccardo Asteggiano (Italy), Maria Bäck (Sweden), Davide Capodanno (Italy), Ruben Casado-Arroyo (Belgium), 
Salvatore Cassese (Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France), 
Gregory Ducrocq (France), Volkmar Falk (Germany), Laurent Fauchier (France), Tobias Geisler (Germany), Diana 
A. Gorog (United Kingdom), Lene Holmvang (Denmark), Tiny Jaarsma (Sweden), Hywel Wynne Jones (United 
Kingdom), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), 
Konstantin A. Krychtiuk (Austria), Ulf Landmesser (Germany), George Lazaros (Greece), Basil S. Lewis (Israel), 
Bertil Lindahl (Sweden), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Mamas A. Mamas (United 
Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United 
Kingdom), Christian Mueller (Switzerland), Lis Neubeck (United Kingdom), Josef Niebauer (Austria), Jens 
Cosedis Nielsen (Denmark), Alexander Niessner (Austria), Valeria Paradies (Netherlands), Agnes A. Pasquet 
(Belgium), Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), 
Bianca Rocca (Italy), Giuseppe M.C. Rosano (Italy), Leyla Elif Sade (United States of America / Türkiye), 
François Schiele (France), Jolanta M. Siller-Matula (Austria), Christian Sticherling (Switzerland), Robert F. Storey 
(United Kingdom), Matthias Thielmann (Germany), Christiaan Vrints (Belgium), Stephan Windecker 
(Switzerland), Rune Wiseth (Norway), and Adam Witkowski (Poland)
All experts involved in the development of these guidelines have submitted declarations of interest. These have 
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The 
report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary documents that include background information and 
evidence tables.
Keywords 
Guidelines • Acute cardiac care • Acute coronary syndrome • Antithrombotic therapy • Fibrinolysis • High- 
sensitivity troponin • Invasive strategy • MINOCA • Myocardial infarction • Non-ST-elevation myocardial infarction 
• Patient-centred care • Percutaneous coronary intervention • Recommendations • Reperfusion therapy • 
Revascularization • Secondary prevention • ST-segment elevation myocardial infarction • Unstable angina
Table of contents
1. Preamble .............................................................................................................. 3727
2. Introduction ....................................................................................................... 3728
2.1. Definitions | Acute coronary syndromes and myocardial 
infarction .............................................................................................................
3730
2.2. Epidemiology of acute coronary syndromes ..............................
3732
2.3. Number and breakdown of classes of recommendations ...
3732
2.4. What is new .............................................................................................
3733
3. Triage and diagnosis ........................................................................................ 3735
3.1. Clinical presentation and physical examination .........................
3735
3.1.1. Clinical presentation ...................................................................... 3735
3.1.2. History taking and physical examination .............................. 3737
3.2. Diagnostic tools | Electrocardiogram ............................................
3737
3.2.1. Acute coronary syndrome with persistent ST-segment 
elevation (suspected ST-elevation myocardial infarction) ......... 3738
3.2.2. Acute coronary syndrome without persistent ST- 
segment elevation (non-ST elevation acute coronary 
syndrome) ...................................................................................................... 3738
3.3. Diagnostic tools | Biomarkers ...........................................................
3739
3.3.1. High-sensitivity cardiac troponins ............................................ 3739
3.3.2. Central laboratory vs. point of care ....................................... 3739
3.3.3. Confounders of cardiac troponin concentration ............. 3739
3.3.4. Rapid ‘rule-in’ and ‘rule-out’ algorithms ................................ 3739
3.3.4.1. European Society of Cardiology 0 h/1 h and 0 h/2 h 
algorithms ..................................................................................................
3740
3.3.4.1.1. Rule-out .............................................................................
3740
3.3.4.1.2. Rule-in ................................................................................
3740
3.3.4.1.3. Observe .............................................................................
3740
3.3.4.2. Practical guidance on how to implement the 
European Society of Cardiology 0 h/1 h algorithm .................
3742
3.3.5. Other biomarkers .......................................................................... 3742
3.4. Diagnostic tools | Non-invasive imaging .......................................
3742
3.4.1. Echocardiography ........................................................................... 3742
3.4.2. Computed tomography ............................................................... 3742
3.4.3. Cardiac magnetic resonance imaging with or without 
stress testing ................................................................................................. 3742
3.5. Differential diagnosis for acute chest pain ..................................
3743
4. Initial measures for patients presenting with suspected acute 
coronary syndrome | Initial treatment ........................................................ 3743
4.1. Pre-hospital logistics of care ..............................................................
3743
4.1.1. Time to treatment ......................................................................... 3743
ESC Guidelines                                                                                                                                                                                          3721


<!-- PAGE 3 -->

### Page 3

4.1.2. Healthcare systems and system delays .................................. 3743
4.1.3. Emergency medical services ....................................................... 3743
4.1.4. General practitioners .................................................................... 3744
4.1.5. Organization of ST-elevation myocardial infarction 
treatment in networks .............................................................................. 3744
4.2. Emergency care .......................................................................................
3744
4.2.1. Initial diagnosis and monitoring ................................................ 3744
4.2.2. Acute pharmacotherapy .............................................................. 3744
4.2.2.1. Oxygen .......................................................................................
3744
4.2.2.2. Nitrates ......................................................................................
3744
4.2.2.3. Pain relief ...................................................................................
3744
4.2.2.4. Intravenous beta-blockers ..................................................
3744
5. Acute-phase management of patients with acute coronary 
syndrome .................................................................................................................. 3745
5.1. Selection of invasive strategy and reperfusion therapy .........
3745
5.2. Acute coronary syndrome managed with invasive strategy
3745
5.2.1. Primary percutaneous coronary intervention strategy for 
ST-elevation myocardial infarction ...................................................... 3745
5.2.1.1. Invasive strategy in ST-elevation myocardial infarction 
late presenters .........................................................................................
3747
5.2.2. Immediate invasive strategy for non-ST elevation acute 
coronary syndrome .................................................................................... 3747
5.2.3. Routine vs. selective invasive strategy .................................... 3747
5.2.3.1. Early vs. delayed invasive strategy for non-ST 
elevation acute coronary syndrome ..............................................
3747
5.2.4. Summary of invasive strategies for patients with non-ST 
elevation acute coronary syndrome ................................................... 3747
5.3. Fibrinolysis and pharmaco-invasive strategy in patients with 
ST-elevation myocardial infarction ..........................................................
3749
5.3.1. Benefit and indication of fibrinolysis ....................................... 3749
5.3.1.1. Pre-hospital fibrinolysis ........................................................
3749
5.3.1.2. Angiography and percutaneous coronary 
intervention after fibrinolysis (pharmaco-invasive strategy)
3749
5.3.1.2.1. Comparison of fibrinolytic agents ..........................
3749
5.3.1.2.2. Hazards of fibrinolysis and contraindications ....
3749
5.4. Patients not undergoing reperfusion .............................................
3749
5.4.1. Patients who are not candidates for invasive coronary 
angiography .................................................................................................... 3749
5.4.2. Patients with coronary artery disease not amenable to 
revascularization .......................................................................................... 3749
6. Antithrombotic therapy ................................................................................ 3750
6.1. Antiplatelet therapy in the acute phase .......................................
3752
6.1.1. Oral antiplatelet therapy ............................................................. 3752
6.1.2. Timing of loading dose of oral antiplatelet therapy ......... 3753
6.1.2.1. Pre-treatment in patients with suspected ST- 
elevation myocardial infarction ........................................................
3753
6.1.2.2. Pre-treatment in patients with non-ST-elevation 
acute coronary syndrome ..................................................................
3753
6.1.2.3. Summary of pre-treatment strategies ...........................
3753
6.1.3. Intravenous antiplatelet drugs ................................................... 3753
6.2. Anticoagulant treatment in the acute phase ..............................
3754
6.2.1. Anticoagulation in patients with ST-elevation myocardial 
infarction undergoing primary percutaneous coronary 
intervention ................................................................................................... 3754
6.2.2. Anticoagulation in patients with non-ST-elevation acute 
coronary syndrome undergoing angiography and percutaneous 
coronary intervention if indicated ....................................................... 3754
6.3. Maintenance antithrombotic therapy after revascularization
3755
6.3.1. Shortening dual antiplatelet therapy ....................................... 3756
6.3.2. De-escalation from potent P2Y12 inhibitor to 
clopidogrel ..................................................................................................... 3756
6.3.3. Summary of alternative antiplatelet strategies to reduce 
bleeding risk in the first 12 months after acute coronary 
syndrome ........................................................................................................ 3757
6.4. Long-term treatment ............................................................................
3759
6.4.1. Prolonging antithrombotic therapy beyond 12 months
3759
6.5. Antiplatelet therapy in patients requiring oral 
anticoagulation .................................................................................................
3760
6.5.1. Acute coronary syndrome patients requiring 
anticoagulation ............................................................................................. 3760
6.5.2. Patients requiring vitamin K antagonists or undergoing 
coronary artery bypass surgery ............................................................ 3762
6.6. Antithrombotic therapy as an adjunct to fibrinolysis .............
3762
6.7. Antithrombotic therapy in patients not undergoing 
reperfusion .........................................................................................................
3762
7. Acute coronary syndrome with unstable presentation .................. 3762
7.1. Out-of-hospital cardiac arrest in acute coronary syndrome
3763
7.1.1. Systems of care ................................................................................ 3763
7.2. Cardiogenic shock complicating acute coronary syndrome
3763
8. Management of acute coronary syndrome during hospitalization
3764
8.1. Coronary care unit/intensive cardiac care unit .........................
3764
8.1.1. Monitoring ......................................................................................... 3764
8.1.2. Ambulation ........................................................................................ 3764
8.1.3. Length of stay in the intensive cardiac care unit ............... 3765
8.2. In-hospital care ........................................................................................
3765
8.2.1. Length of hospital stay ................................................................. 3765
8.2.2. Risk assessment ............................................................................... 3765
8.2.2.1. Clinical risk assessment ........................................................
3765
8.2.2.2. Imaging risk assessment .......................................................
3765
8.2.2.3. Biomarkers for risk assessment .......................................
3765
8.2.2.4. Bleeding risk assessment .....................................................
3765
8.2.2.5. Integrating ischaemic and bleeding risks .......................
3765
9. Technical aspects of invasive strategies .................................................. 3766
9.1. Percutaneous coronary intervention .............................................
3766
9.1.1. Vascular access ................................................................................ 3766
9.1.2. Intravascular imaging/physiology of the infarct-related 
artery ................................................................................................................ 3766
9.1.2.1. Intravascular imaging .............................................................
3766
9.1.2.2. Intravascular physiology .......................................................
3767
9.1.3. Timing of revascularization with percutaneous coronary 
intervention ................................................................................................... 3767
9.1.4. Balloons and stents ........................................................................ 3768
9.1.5. Embolic protection and microvascular salvage strategies
3768
9.1.5.1. Thrombus aspiration ............................................................
3768
9.1.5.2. Interventions to protect the microcirculation ..........
3768
9.2. Coronary artery bypass grafting ......................................................
3768
9.2.1. Indication and timing of coronary artery bypass grafting in 
acute coronary syndrome patients ..................................................... 3768
9.2.2. Technical considerations specific to acute coronary 
syndrome patients ...................................................................................... 3768
9.3. Spontaneous coronary artery dissection .....................................
3768
9.3.1. Intravascular imaging ..................................................................... 3769
9.3.2. Revascularization ............................................................................. 3769
10. Management of patients with multivessel disease ........................... 3769
10.1. Management of multivessel disease in acute coronary 
syndrome complicated by cardiogenic shock .....................................
3769


<!-- PAGE 4 -->

### Page 4

10.2. Patients with multivessel coronary artery disease 
undergoing primary percutaneous coronary intervention ............
3770
10.3. Timing of non-infarct-related artery revascularization in 
acute coronary syndrome ...........................................................................
3771
10.3.1. Patients presenting with ST-elevation myocardial 
infarction and multivessel coronary artery disease ...................... 3771
10.3.2. Patients presenting with non-ST-elevation acute 
coronary syndrome and multivessel coronary artery disease . 3771
10.4. Evaluation of non-infarct-related artery stenosis severity 
(angiography vs. physiology) .......................................................................
3771
10.5. Hybrid revascularization ...................................................................
3772
11. Myocardial infarction with non-obstructive coronary arteries . 3772
12. Special situations ............................................................................................ 3775
12.1. Type 2 myocardial infarction and acute myocardial injury
3775
12.2. Complications .......................................................................................
3775
12.2.1. Heart failure ................................................................................... 3775
12.2.2. Mechanical complications ......................................................... 3776
12.2.3. Left ventricular thrombus ......................................................... 3776
12.2.4. Post-acute coronary syndrome pericarditis ..................... 3776
12.2.5. Arrhythmias .................................................................................... 3776
12.2.5.1. Atrial fibrillation ....................................................................
3776
12.2.5.2. Ventricular arrhythmias ....................................................
3777
12.2.6. Bleeding ............................................................................................ 3777
12.2.6.1. Management of bleeding ..................................................
3777
12.3. Comorbid conditions .........................................................................
3778
12.3.1. Patients at high bleeding risk and with blood disorders 
(anaemia and thrombocytopaenia) ..................................................... 3778
12.3.2. Chronic kidney disease .............................................................. 3779
12.3.3. Diabetes mellitus .......................................................................... 3779
12.3.4. Older adults with frailty and multimorbidity ................... 3779
12.3.4.1. The older person .................................................................
3779
12.3.4.2. Frailty and multimorbidity ................................................
3779
12.3.5. Pregnancy ........................................................................................ 3780
12.3.6. Drug abuse ...................................................................................... 3780
12.3.7. Patients with cancer .................................................................... 3780
12.3.8. Coronavirus disease (COVID-19) ........................................ 3780
13. Long-term treatment ................................................................................... 3781
13.1. Cardiac rehabilitation .........................................................................
3783
13.1.1. Comprehensive cardiac rehabilitation ................................. 3783
13.1.2. Digital health .................................................................................. 3783
13.1.3. Adherence and persistence ..................................................... 3783
13.2. Lifestyle management .........................................................................
3783
13.2.1. Tobacco ........................................................................................... 3783
13.2.2. Nutrition and alcohol ................................................................. 3783
13.2.3. Physical activity and exercise .................................................. 3784
13.2.4. Psychological considerations ................................................... 3784
13.2.5. Resumption of activities ............................................................ 3784
13.3. Pharmacological treatment ..............................................................
3784
13.3.1. Antithrombotic therapy ............................................................ 3784
13.3.2. Lipid-lowering therapy ............................................................... 3784
13.3.3. Beta-blockers ................................................................................. 3785
13.3.4. Nitrates and calcium channel blockers ............................... 3786
13.3.5. Renin–angiotensin–aldosterone system inhibitors ......... 3786
13.3.6. Medications for diabetes ........................................................... 3786
13.3.6.1. Sodium–glucose co-transporter 2 inhibitors ...........
3786
13.3.6.2. Glucagon-like peptide-1 receptor agonists ..............
3787
13.3.7. Proton pump inhibitors ............................................................. 3787
13.3.8. Vaccination ...................................................................................... 3787
13.3.9. Anti-inflammatory drugs ........................................................... 3787
13.3.10. Hormone replacement therapy .......................................... 3787
14. Patient perspectives ..................................................................................... 3788
14.1. Patient-centred care ...........................................................................
3788
14.2. Shared decision-making .....................................................................
3789
14.3. Informed consent ................................................................................
3789
14.4. Research participation and consent in the acute setting ....
3790
14.5. Patient satisfaction and expectations ..........................................
3790
14.6. Patient-reported outcome measures and patient-reported 
experience measures .....................................................................................
3791
14.7. Preparation for discharge .................................................................
3791
15. Key messages .................................................................................................. 3791
16. Gaps in evidence ............................................................................................ 3793
17. Sex differences ............................................................................................... 3795
18. ‘What to do’ and ‘What not to do’ messages from the 
Guidelines ................................................................................................................. 3796
19. Quality indicators .......................................................................................... 3801
20. Supplementary data ...................................................................................... 3801
21. Data availability statement ......................................................................... 3801
22. Author information ...................................................................................... 3801
23. Appendix ........................................................................................................... 3801
24. References ........................................................................................................ 3802
Tables of Recommendations
Recommendation Table 1 — Recommendations for clinical and 
diagnostic tools for patients with suspected acute coronary 
syndrome .................................................................................................................. 3738
Recommendation Table 2 — Recommendations for non-invasive 
imaging in the initial assessment of patients with suspected acute 
coronary syndrome .............................................................................................. 3742
Recommendation Table 3 — Recommendations for the initial 
management of patients with acute coronary syndrome ................... 3745
Recommendation Table 4 — Recommendations for reperfusion 
therapy and timing of invasive strategy ....................................................... 3750
Recommendation Table 5 — Recommendations for antiplatelet and 
anticoagulant therapy in acute coronary syndrome .............................. 3758
Recommendation Table 6 — Recommendations for  
alternative antithrombotic therapy regimens ........................................... 3759
Recommendation Table 7 — Recommendations for fibrinolytic 
therapy ....................................................................................................................... 3762
Recommendation Table 8 — Recommendations for cardiac arrest 
and out-of-hospital cardiac arrest ................................................................. 3763
Recommendation Table 9 — Recommendations for cardiogenic 
shock .......................................................................................................................... 3764
Recommendation Table 10 — Recommendations for in-hospital 
management ............................................................................................................ 3766
Recommendation Table 11 — Recommendations for technical 
aspects of invasive strategies ............................................................................ 3769
Recommendation Table 12 — Recommendations for management 
of patients with multivessel disease .............................................................. 3772
Recommendation Table 13 — Recommendations for myocardial 
infarction with non-obstructive coronary arteries ................................. 3775
Recommendation Table 14 — Recommendations for acute 
coronary syndrome complications ................................................................ 3777
Recommendation Table 15 — Recommendations for acute 
coronary syndrome comorbid conditions ................................................. 3781
ESC Guidelines                                                                                                                                                                                          3723


<!-- PAGE 5 -->

### Page 5

Recommendation Table 16 — Recommendations for long-term 
management ............................................................................................................ 3787
Recommendation Table 17 — Recommendations for patient 
perspectives in acute coronary syndrome care ....................................... 3791
List of tables
Table 1 Classes of recommendations .......................................................... 3728
Table 2 Levels of evidence ................................................................................ 3728
Table 3 Definitions of terms related to invasive strategy and 
reperfusion therapy commonly used in this document ....................... 3731
Table 4 New recommendations .................................................................... 3733
Table 5 Revised recommendations ............................................................... 3734
Table 6 Dose regimen of antiplatelet and anticoagulant drugs in 
acute coronary syndrome patients ............................................................... 3751
Table 7 Suggested strategies to reduce bleeding risk related to 
percutaneous coronary intervention ............................................................ 3760
Table 8 Gaps in evidence .................................................................................. 3793
Table 9 ‘What to do’ and ‘What not to do’ ............................................. 3796
List of figures
Figure 1 Central illustration .............................................................................. 3729
Figure 2 The spectrum of clinical presentations, electrocardiographic 
findings, and high-sensitivity cardiac troponin levels in patients with 
acute coronary syndrome ................................................................................. 3730
Figure 3 Classification of patients presenting with suspected acute 
coronary syndrome: from a working to a final diagnosis .................... 3732
Figure 4 An overview of the initial triage, management and 
investigation of patients who present with signs and symptoms 
potentially consistent with acute coronary syndrome ......................... 3736
Figure 5 The A.C.S. assessment for the initial evaluation of patients 
with suspected acute coronary syndrome ................................................. 3737
Figure 6 The 0 h/1 h or 0 h/2 h rule-out and rule-in algorithms using 
high-sensitivity cardiac troponin assays in patients presenting to the 
emergency department with suspected NSTEMI and without an 
indication for immediate invasive angiography ......................................... 3741
Figure 7 Modes of presentation and pathways to invasive 
management and myocardial revascularization in patients presenting 
with STEMI .............................................................................................................. 3746
Figure 8 Selection of invasive strategy and reperfusion therapy in 
patients presenting with NSTE-ACS ............................................................ 3748
Figure 9 Antithrombotic treatments in acute coronary syndrome: 
pharmacological targets ...................................................................................... 3752
Figure 10 Recommended default antithrombotic therapy regimens 
in acute coronary syndrome patients without an indication for oral 
anticoagulation ....................................................................................................... 3755
Figure 11 Alternative antiplatelet strategies to reduce bleeding risk in 
the first 12 months after an ACS .................................................................. 3757
Figure 12 Antithrombotic regimens in patients with acute coronary 
syndrome and an indication for oral anticoagulation ................................
3761
Figure 13 A practical algorithm to guide intravascular imaging in 
acute coronary syndrome patients ............................................................... 3767
Figure 14 Algorithm for the management of acute coronary 
syndrome patients with multivessel coronary artery disease ............ 3770
Figure 15 Underlying causes for patients with a working diagnosis of 
myocardial infarction with non-obstructive coronary arteries ......... 3773
Figure 16 Evaluation of patients with a working diagnosis of 
MINOCA .................................................................................................................. 3774
Figure 17 Long-term management after acute coronary syndrome
3782
Figure 18 Lipid-lowering therapy in ACS patients .................................. 3785
Figure 19 A person-centred approach to the ACS journey .............. 3789
Figure 20 Acute coronary syndrome patient expectations ................ 3790
Abbreviations and acronyms
AβYSS
Beta Blocker Interruption After 
Uncomplicated Myocardial Infarction
ACCOAST
A Comparison of Prasugrel at the Time of 
Percutaneous Coronary Intervention or as 
Pretreatment at the Time of Diagnosis in 
Patients with Non-ST Elevation Myocardial 
Infarction
ACE
Angiotensin-converting enzyme
ACS
Acute coronary syndrome
AF
Atrial fibrillation
AFIRE
Atrial Fibrillation and Ischemic Events With 
Rivaroxaban in Patients With Stable Coronary 
Artery Disease
AMI
Acute myocardial infarction
ARB
Angiotensin receptor blocker
ARC-HBR
Academic Research Consortium for High 
Bleeding Risk
ARNI
Angiotensin receptor/neprilysin inhibitor
ASCVD
Atherosclerotic cardiovascular disease
ASSENT 3
ASsessment of the Safety and Efficacy of a New 
Thrombolytic 3
ATLANTIC
Administration of Ticagrelor in the Cath Lab or 
in the Ambulance for New ST Elevation 
Myocardial Infarction to Open the Coronary 
Artery
AUGUSTUS
An Open-Label, 2 × 2 Factorial, Randomized 
Controlled, Clinical Trial to Evaluate the Safety 
of Apixaban Versus Vitamin K Antagonist and 
Aspirin Versus Aspirin Placebo in Patients With 
Atrial Fibrillation and Acute Coronary 
Syndrome or Percutaneous Coronary 
Intervention
AV
Atrioventricular
BARC
Bleeding Academic Research Consortium b.i.d.
Bis in die (twice a day)
BBB
Bundle branch block
BEACON
Better Evaluation of Acute Chest Pain with 
Coronary Computed Tomography Angiography
BETAMI
BEtablocker Treatment After Acute 
Myocardial Infarction in Patients Without 
Reduced Left Ventricular Systolic Function
BMS
Bare metal stent
BNP
Brain natriuretic peptide
CABG
Coronary artery bypass grafting
CAD
Coronary artery disease
CAPITAL-RCT
Carvedilol Post-Intervention Long-Term 
Administration in Large-scale Randomized 
Controlled Trial
CAPRICORN
CArvedilol Post-infaRct survIval COntRolled 
evaluatioN
CCS
Chronic coronary syndrome


<!-- PAGE 6 -->

### Page 6

CCTA
Coronary computed tomography angiography
CCU
Coronary care unit
CHA2DS2-VASc
Congestive heart failure, Hypertension, Age, 
Diabetes, Stroke or TIA-Vascular disease
CHAMPION PCI
Cangrelor versus Standard Therapy to 
Achieve Optimal Management of Platelet 
Inhibition
CHAMPION 
PHOENIX
A Clinical Trial Comparing Cangrelor to 
Clopidogrel Standard Therapy in Subjects 
Who Require Percutaneous Coronary 
Intervention
CHAMPION 
PLATFORM
Cangrelor Versus Standard Therapy to 
Achieve Optimal Management of Platelet 
Inhibition
CKD
Chronic kidney disease
CMR
Cardiac magnetic resonance
CI
Confidence interval
COACT
Coronary Angiography after Cardiac Arrest
COLCOT
Colchicine Cardiovascular Outcomes Trial
COMFORTABLE- 
AMI
Comparison of Biolimus Eluted From an Erodible 
Stent Coating With Bare Metal Stents in Acute 
ST-Elevation Myocardial Infarction
COMPARE-ACUTE
Comparison Between FFR Guided 
Revascularization Versus Conventional 
Strategy in Acute STEMI Patients With MVD
COMPASS
Cardiovascular Outcomes for People Using 
Anticoagulation Strategies
COMPLETE
Complete vs. Culprit-only Revascularization to 
Treat Multivessel Disease After Early PCI for 
STEMI
COVID-19
Coronavirus disease 2019
CR
Cardiac rehabilitation
CRT
Cardiac resynchronization therapy— 
defibrillator/pacemaker
CS
Cardiogenic shock
CT
Computed tomography
CV
Cardiovascular
CVD
Cardiovascular disease
CvLPRIT
Complete versus Lesion-only Primary PCI Trial cTn
Cardiac troponin
CULPRIT-SHOCK
Culprit Lesion Only PCI versus Multivessel PCI 
in Cardiogenic Shock
DANAMI-3– 
PRIMULTI
Third Danish Study of Optimal Acute 
Treatment of Patients with ST-Segment 
Elevation Myocardial Infarction—Primary PCI 
in Multivessel Disease
DANBLOCK
Danish Trial of Beta Blocker Treatment After 
Myocardial Infarction Without Reduced 
Ejection Fraction
DAPT
Dual antiplatelet therapy
DAT
Dual antithrombotic therapy
DCB
Drug-coated balloon
DES
Drug-eluting stent(s)
DM
Diabetes mellitus
ECG
Electrocardiography/gram
ECMO
Extracorporeal membrane oxygenation eGFR
Estimated glomerular filtration rate
ED
Emergency department
EMS
Emergency medical service(s)
EPHESUS
Eplerenone Post-AMI Heart failure Efficacy and 
SUrvival Study
ESC
European Society of Cardiology
EXAMINATION
Everolimus-Eluting Stents Versus Bare-Metal 
Stents in ST Segment Elevation Myocardial 
Infarction
ExTRACT-TIMI 25
Enoxaparin and Thrombolysis Reperfusion for 
Acute myocardial infarction Treatment 
Thrombolysis In Myocardial Infarction—Study 25
FAME
Fractional Flow Reserve versus Angiography 
for Multivessel Evaluation
FAMOUS-NSTEMI
Fractional flow reserve (FFR) versus 
angiography in guiding management to 
optimise outcomes in non-ST segment 
elevation myocardial infarction
FAST-MI
French Registry of Acute ST-elevation and 
non-ST-elevation Myocardial Infarction
FFR
Fractional flow reserve
FLOWER-MI
Flow Evaluation to Guide Revascularization in 
Multivessel ST-Elevation Myocardial Infarction
FMC
First medical contact
GLP-1RA
Glucagon-like peptide-1 receptor agonist
GP
Glycoprotein
GRACE
Global Registry of Acute Coronary Events
HBR
High bleeding risk
HCR
Hybrid coronary revascularization
HF
Heart failure
HFrEF
Heart failure with reduced ejection fraction
HOST-REDUCE-P­
OLYTECH-ACS
Harmonizing Optimal Strategy for Treatment 
of Coronary Artery Diseases Trial— 
Comparison of REDUCTION of PrasugrEl 
Dose & POLYmer TECHnology in ACS 
Patients
HR
Hazard ratio
HR-QoL
Health-related quality of life hs-cTn
High-sensitivity cardiac troponin
IABP
Intra-aortic balloon counter pulsation/pumping
IABP-SHOCK II
Intraaortic Balloon Pump in Cardiogenic Shock II
ICA
Invasive coronary angiography
ICCU
Intensive cardiac care unit
ICD
Implantable cardioverter defibrillator
ICU
Intensive care unit
IMPROVE-IT
Improved Reduction of Outcomes: Vytorin 
Efficacy International Trial
INR
International normalized ratio
IRA
Infarct-related artery
ISAR-REACT 5
Intracoronary stenting and Antithrombotic 
regimen Rapid Early Action for Coronary 
Treatment
ISIS-4
Fourth International Study of Infarct Survival i.v.
Intravenous
IVUS
Intravascular ultrasound
LAD
Left anterior descending
LBBB
Left bundle branch block
LD
Loading dose
LDL-C
Low-density lipoprotein-cholesterol
LIMA
Left internal mammary artery
LMWH
Low-molecular-weight heparin
LoDoCo2
Low-dose Colchicine trial-2
LV
Left ventricular(cle)
LVAD
Left ventricular assist device
LVEF
Left ventricular ejection fraction
MACE
Major adverse cardiovascular events
ESC Guidelines                                                                                                                                                                                          3725


<!-- PAGE 7 -->

### Page 7

MASTER DAPT
Management of High Bleeding Risk Patients 
Post Bioresorbable Polymer Coated Stent 
Implantation With an Abbreviated Versus 
Prolonged DAPT Regimen
MATRIX
Minimizing Adverse Haemorrhagic Events by 
Transradial Access Site and Systemic 
Implementation of angioX
MCS
Mechanical circulatory support
MD
Maintenance dose
MI
Myocardial infarction
MINOCA
Myocardial infarction with non-obstructive 
coronary arteries
MRA
Mineralocorticoid receptor antagonist
MVD
Multivessel disease
MVO
Microvascular obstruction
NOAC
Non-vitamin K antagonist oral anticoagulant
NORSTENT
Norwegian Coronary Stent Trial
NPV
Negative predictive value
NRT
Nicotine replacement therapy
NSTE
Non-ST elevation
NSTE-ACS
Non-ST elevation acute coronary syndrome
NSTEMI
Non-ST-elevation myocardial infarction
NT-pro BNP
N-terminal pro B-type natriuretic peptide
NYHA
New York Heart Association o.d.
Once a day
OAC
Oral anticoagulant/ation
OASIS-5
Fifth Organization to Assess Strategies in Acute 
Ischemic Syndromes
OASIS-6
The Safety and Efficacy of Fondaparinux Versus 
Control Therapy in Patients With ST Segment 
Elevation Acute Myocardial Infarction
OAT
Occluded Artery Trial
OCT
Optical coherence tomography
ODYSSEY 
OUTCOMES
Evaluation of Cardiovascular Outcomes After 
an Acute Coronary Syndrome During 
Treatment With Alirocumab
OHCA
Out-of-hospital cardiac arrest
OR
Odds ratio
PARADISE-MI
Prospective ARNI vs ACE Inhibitor Trial to 
Determine Superiority in Reducing Heart 
Failure Events After MI
PCI
Percutaneous coronary intervention
PCSK9
Proprotein convertase subtilisin/kexin type 9
PE
Pulmonary embolism
PEGASUS-TIMI 54
PrEvention with TicaGrelor of SecondAry 
Thrombotic Events in High-RiSk Patients with 
Prior AcUte Coronary Syndrome— 
Thrombolysis In Myocardial Infarction
PEPCAD NSTEMI
Bare Metal Stent Versus Drug Coated Balloon 
With Provisional Stenting in Non-ST-Elevation 
Myocardial Infarction
PLATO
PLATelet inhibition and patient Outcomes
POC
Point of care
POPular Genetics
Cost-effectiveness of CYP2C19 Genotype 
Guided Treatment With Antiplatelet Drugs in 
Patients With ST-segment-elevation Myocardial 
Infarction Undergoing Immediate PCI With 
Stent Implantation: Optimization of Treatment
PPCI
Primary percutaneous coronary intervention
PPI
Proton pump inhibitor
PPV
Positive predictive value
PRAMI
Preventive Angioplasty in Myocardial Infarction
PREM
Patient-reported experience measure
PROM
Patient-reported outcome measure
QI
Quality indicator
RAAS
Renin–angiotensin–aldosterone system
RAPID-CTCA
Rapid Assessment of Potential Ischaemic heart 
Disease with CTCA
RCT
Randomized controlled trial
REALITY
Restrictive and Liberal Transfusion  
Strategies in Patients With Acute Myocardial 
Infarction
REBOOT-CNIC
TREatment With Beta-blockers After 
myOcardial Infarction withOut Reduced 
Ejection fracTion
REDUCE-SWEDE­
HEART
Evaluation of Decreased Usage of Betablockers 
After Myocardial Infarction in the 
SWEDEHEART Registry
REMINDER
Double-Blind, Randomized, 
Placebo-Controlled Trial Evaluating The Safety 
And Efficacy Of Early Treatment With 
Eplerenone In Patients With Acute Myocardial 
Infarction
REVELATION
REVascularization With PaclitaxEL-Coated 
Balloon Angioplasty Versus Drug-Eluting 
Stenting in Acute Myocardial InfarcTION
RIVAL
RadIal Vs femorAL access for coronary 
intervention
ROMICAT II
Multicenter Study to Rule Out Myocardial 
Infarction by Cardiac Computed Tomography
ROSC
Return of spontaneous circulation
RR
Relative risk
RV
Right ventricular
SAPT
Single antiplatelet therapy
SBP
Systolic blood pressure s.c.
Subcutaneous
SCAD
Spontaneous coronary artery dissection
SHOCK
Should We Emergently Revascularize 
Occluded Coronaries for Cardiogenic Shock
SGLT2
Sodium–glucose co-transporter 2
SMART-DECISION
Long-term Beta-blocker Therapy After Acute 
Myocardial Infarction
SPECT
Single-photon emission computerized 
tomography
STE
ST elevation
STEMI
ST-elevation myocardial infarction
STOPDAPT-2-ACS
ShorT and OPtimal Duration of Dual 
AntiPlatelet Therapy-2 Study for the Patients 
With ACS
STREAM
Strategic Reperfusion Early After Myocardial 
Infarction
SWEDEHEART
Swedish Web-System for Enhancement and 
Development of Evidence-Based Care in Heart 
Disease Evaluated According to 
Recommended Therapies
TALOS-AMI
TicAgrelor Versus CLOpidogrel in Stabilized 
Patients With Acute Myocardial Infarction
TAT
Triple antithrombotic therapy


<!-- PAGE 8 -->

### Page 8

TICO
Ticagrelor Monotherapy After 3 Months in the 
Patients Treated With New Generation 
Sirolimus Stent for Acute Coronary Syndrome
TIMI
Thrombolysis In Myocardial Infarction
TLR
Target lesion revascularization
TOMAHAWK
Immediate Unselected Coronary Angiography 
Versus Delayed Triage in Survivors of 
Out-of-hospital Cardiac Arrest Without 
ST-segment Elevation
TOPIC
Timing of Platelet Inhibition After Acute 
Coronary Syndrome
TOTAL
Trial of routine aspiration ThrOmbecTomy 
with PCI vs. PCI ALone in patients with STEMI
TRITON-TIMI 38
TRial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet InhibitioN 
with Prasugrel Thrombolysis In Myocardial 
Infarction 38
TROPICAL-ACS
Testing Responsiveness to Platelet Inhibition 
on Chronic Antiplatelet Treatment For Acute 
Coronary Syndromes
TTE
Transthoracic echocardiography
TWILIGHT
Ticagrelor With Aspirin or Alone in High-Risk 
Patients After Coronary Intervention
UA
Unstable angina
UFH
Unfractionated heparin
VA-ECMO
Veno-arterial extracorporeal membrane 
oxygenation
VALIANT
VALsartan In Acute myocardial iNfarcTion
VF
Ventricular fibrillation
VKA
Vitamin K antagonist
VT
Ventricular tachycardia
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeut­
ic approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals and the European Society of 
Cardiology (ESC) makes its Guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription, and, where appropriate, to respect the ethical rules of 
their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated. ESC Policies and Procedures for for­
mulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines).
The Members of this Task Force were selected by the ESC to 
represent professionals involved with the medical care of patients 
with this pathology. The selection procedure aimed to include 
members from across the whole of the ESC region and from rele­
vant ESC Subspecialty Communities. Consideration was given to 
diversity and inclusion, notably with respect to gender and country 
of origin. The Task Force performed a critical evaluation of diag­
nostic and therapeutic approaches, including assessment of the 
risk-benefit ratio. The strength of every recommendation and the 
level of evidence supporting them were weighed and scored ac­
cording to predefined scales as outlined below. The Task Force fol­
lowed ESC voting procedures, and all approved recommendations 
were subject to a vote and achieved at least 75% agreement among 
voting members.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules and 
can be found on the ESC website (http://www.escardio.org/ 
Guidelines) and have been compiled in a report published in a supple­
mentary document with the guidelines. The Task Force received its en­
tire financial support from the ESC without any involvement from the 
healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible 
for the approval process. ESC Guidelines undergo extensive review 
by the CPG Committee and external experts, including members 
from across the whole of the ESC region and from relevant ESC 
Subspecialty Communities and National Cardiac Societies. After appro­
priate revisions, the guidelines are signed off by all the experts involved 
in the Task Force. The finalized document is signed off by the CPG 
Committee for publication in the European Heart Journal. The guidelines 
were developed after careful consideration of the scientific and medical 
knowledge and the evidence available at the time of their writing. Tables 
of evidence summarizing the findings of studies informing development 
of the guidelines are included. The ESC warns readers that the technical 
language may be misinterpreted and declines any responsibility in this 
respect.
Off-label use of medication may be presented in this guideline if a 
sufficient level of evidence shows that it can be considered medically ap­
propriate for a given condition. However, the final decisions concerning 
an individual patient must be made by the responsible health profes­
sional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
ESC Guidelines                                                                                                                                                                                          3727


<!-- PAGE 9 -->

### Page 9

### 2 Introduction

The major aspects of the management of patients with acute coronary 
syndromes described in this European Society of Cardiology (ESC) 
Guideline are summarized in Figure 1.
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2023
© ESC 2023
Table 1 Classes of recommendations
©ESC 2023
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2023


<!-- PAGE 10 -->

### Page 10

Aim for complete 
revascularization
2
3
4
1
5
ACS encompasses a spectrum
Think secondary prevention
Abnormal
ECG?
Clinical context?
Stable patient?
Think ‘A.C.S.’ at initial assessment
Think antithrombotic therapy
Primary PCI
Fibrinolysis
(If timely primary PCI not feasible)
Immediate angiography ± PCI
AND
OR
OR
OR
Early (<24 h) angiography should be considered
Aspirin
UFH
LMWH
Bivalirudin
Fondaparinux
P2Y12 inhibitor
STEMI
OR
Very high-risk NSTE-ACS
High-risk NSTE-ACS
Antiplatelet therapy
+
Anticoagulant therapy
PCI
Antithrombotic 
therapy
Lipid lowering 
therapy
Smoking 
cessation
Cardiac 
rehabilitation
Risk factor management
Psychosocial considerations
CABG
Based on clinical status, co-morbidities,
and disease complexity
OR
Consider adjunctive tests to guide revascularization
Think invasive management
Think revascularization
Intravascular imaging
Intravascular physiology
Unstable angina
NSTEMI
STEMI
Figure 1 Central illustration. ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; ECG, electrocardiogram; LMWH, low molecular- 
weight heparin; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PPCI, primary percutaneous coronary 
intervention; STEMI, ST-elevation myocardial infarction; UFH, unfractionated heparin. Patients with acute coronary syndrome (ACS) can initially present with 
a wide variety of clinical signs and symptoms and it is important that there is a high degree of awareness of this amongst both the general public and healthcare 
providers. If ACS is suspected, think ‘A.C.S.’ for the initial triage and assessment. This involves performing an electrocardiogram (ECG) to assess for 
Abnormalities or evidence of ischaemia, taking a targeted clinical history to assess the clinical Context of the presentation, and carrying out a targeted clinical 
examination to assess for clinical and haemodynamic Stability. Based on the initial assessment, the healthcare provider can decide whether immediate invasive 
management is required. Patients with ST-elevation myocardial infarction (STEMI) require primary percutaneous coronary intervention (PPCI) (or fibrinoly­
sis if PPCI within 120 min is not feasible); patients with non-ST-elevation ACS (NSTE-ACS) with very high-risk features require immediate angiography ± PCI 
if indicated; patients with NSTE-ACS and high-risk features should undergo inpatient angiography (angiography within 24 h should be considered). A com­
bination of antiplatelet and anticoagulant therapy is indicated acutely for patients with ACS. The majority of patients with ACS will eventually undergo re­
vascularization, most commonly with PCI. Once the final diagnosis of ACS has been established, it is important to implement measures to prevent recurrent 
events and to optimize cardiovascular risk. This consists of medical therapy, lifestyle changes and cardiac rehabilitation, as well as consideration of psycho­
social factors.
ESC Guidelines                                                                                                                                                                                          3729


<!-- PAGE 11 -->

### Page 11

2.1. Definitions | Acute coronary 
syndromes and myocardial infarction
Acute coronary syndromes (ACS) encompass a spectrum of condi­
tions that include patients presenting with recent changes in clinical 
symptoms or signs, with or without changes on 12-lead electrocardio­
gram (ECG) and with or without acute elevations in cardiac tropo­
nin (cTn) concentrations (Figure 2). Patients presenting with 
suspected ACS may eventually receive a diagnosis of acute myocar­
dial infarction (AMI) or unstable angina (UA). The diagnosis of 
myocardial infarction (MI) is associated with cTn release and is 
made based on the fourth universal definition of MI.1 UA is defined 
as myocardial ischaemia at rest or on minimal exertion in the ab­
sence of acute cardiomyocyte injury/necrosis. It is characterized by 
specific clinical findings of prolonged (>20 min) angina at rest; new 
onset of severe angina; angina that is increasing in frequency, longer 
in duration, or lower in threshold; or angina that occurs after a re­
cent episode of MI. ACS are associated with a broad range of clinical 
presentations, from patients who are symptom free at presentation 
to patients with ongoing chest discomfort/symptoms and patients
Increasing chest pain/symptoms
Oligo/
asymptomatic 
Persistent chest pain/symptoms
Cardiogenic shock/
acute heart failure 
Cardiac arrest
Normal 
ST segment depression 
ST segment elevation
Malignant arrhythmia
Clinical presentation
ECG
findings hs-cTn levels
The ACS spectrum
Final diagnosis
Working diagnosis
Non-elevated
Unstable angina 
NSTE-ACS
NSTEMI
Rise and fall 
STEMI
STEMI
Figure 2 The spectrum of clinical presentations, electrocardiographic findings, and high-sensitivity cardiac troponin levels in patients with acute coronary 
syndrome. ACS, acute coronary syndrome; ECG, electrocardiogram; hs-cTn, high-sensitivity cardiac troponin; NSTE-ACS, non-ST-elevation acute coronary 
syndrome; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.


<!-- PAGE 12 -->

### Page 12

with cardiac arrest, electrical/haemodynamic instability, or cardio­
genic shock (CS) (Figure 2).
Patients presenting with suspected ACS are typically classified based 
on ECG at presentation for the purposes of initial management. After 
this, patients can be further classified based on the presence or absence 
of cardiac troponin elevation (once these results are available), as de­
monstrated in Figures 2 and 3. These features (ECG changes and cardiac 
troponin elevation) are important in the initial triage and diagnosis of 
patients with ACS, helping to risk stratify patients and guide the initial 
management strategy. However, after the acute management and sta­
bilization phase, most aspects of the subsequent management strategy 
are common to all patients with ACS (regardless of the initial ECG 
pattern or the presence/absence of cardiac troponin elevation at 
presentation) and can therefore be considered under a common 
pathway. A glossary of the terms related to invasive strategies and 
reperfusion therapy commonly used in this document, and their 
associated definitions, is provided in Table 3.
While they are closely related, it is important to recognize that ACS 
is not the same as MI.1 AMI is defined as cardiomyocyte necrosis in the 
clinical setting of acute myocardial ischaemia. This includes MI due to 
atherothrombotic events (Type 1 MI) and also other potential causes 
of myocardial ischaemia and myocyte necrosis (Type 2–5 MI) 
(Supplementary data online, Table S1). Myocardial injury is another 
distinct entity, used to describe troponin release due to mechanisms 
other than myocardial ischaemia and not meeting the criteria for MI 
outlined in Supplementary data online, Table S1. Myocardial injury 
can be acute or chronic depending on whether there is evidence of 
dynamic change in the elevated troponins on serial testing. Some 
causes of myocardial injury include myocarditis, sepsis, takotsubo car­
diomyopathy, heart valve disease, cardiac arrhythmias, and heart fail­
ure (HF).
The focus of this guideline is largely centred on the management of 
patients who will eventually receive a diagnosis of Type 1 MI. 
However, at every stage of the management of patients presenting 
with ACS, physicians must carefully consider other differential diag­
noses in their clinical assessment because they are common, asso­
ciated with different underlying pathological mechanisms, have 
different prognoses, and frequently require different treatment ap­
proaches. More information is provided in the Supplementary 
data online. In general, detailed information regarding the results 
of individual trials will not be provided in the main guideline. 
However, where appropriate, this information is provided in the 
Supplementary data online evidence tables.
Table 3 Definitions of terms related to invasive strat­
egy and reperfusion therapy commonly used in this 
document
Term
Definition
First medical contact (FMC)
The time point when the patient is initially 
assessed by a physician, paramedic, nurse, 
or other trained emergency medical 
services worker who can obtain and 
interpret the ECG and deliver initial 
interventions (e.g. defibrillation). FMC can 
be either in the pre-hospital setting or 
upon patient arrival at the hospital (e.g. 
the emergency department)
STEMI diagnosis
The time at which a patient with ischaemic 
symptoms is interpreted as presenting 
with ACS and ST-segment elevation (or 
ST-segment elevation equivalent)
Primary PCIa
Emergent PCI with balloon, stent, or 
other approved device, performed on the 
IRA without previous fibrinolytic 
treatment
Primary PCI strategya
Emergency coronary angiography and PCI 
of the IRA if indicated
Rescue PCIa
Emergency PCI performed as soon as 
possible in cases of failed fibrinolytic 
treatment
Routine early PCI strategy 
after fibrinolysisa
Coronary angiography, with PCI of the 
IRA if indicated, performed between 2 h 
and 24 h after successful fibrinolysis
Pharmaco-invasive strategya
Fibrinolysis combined with rescue PCI (in 
cases of failed fibrinolysis) or routine early 
PCI strategy (in cases of successful 
fibrinolysis)
Immediate invasive strategy
Emergency coronary angiography (i.e. as 
soon as possible) and PCI/CABG of the 
IRA if indicated
Early invasive strategy
Early coronary angiography (<24 h from 
diagnosis of ACS) and PCI/CABG of the 
IRA if indicated
Selective invasive strategy
Coronary angiography ± PCI/CABG 
based on clinical assessment and/or 
non-invasive testing
© ESC 2023
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; ECG, 
electrocardiogram; IRA, infarct-related artery; PCI, percutaneous coronary intervention; 
STE-ACS, ST-segment-elevation acute coronary syndrome. 
aCABG may also be indicated instead of PCI in certain circumstances.
ESC Guidelines                                                                                                                                                                                          3731


<!-- PAGE 13 -->

### Page 13

2.2. Epidemiology of acute coronary 
syndromes
Cardiovascular disease (CVD) is the most common cause of mortality 
and morbidity worldwide, with a substantial portion of this burden 
borne by low- and middle-income countries.2,3 ACS is often the first 
clinical manifestation of CVD. In 2019, there were an estimated 5.8 mil­
lion new cases of ischaemic heart disease in the 57 ESC member coun­
tries.3 The median age-standardized incidence estimate per 100 000 
people was 293.3 (interquartile ratio 195.8–529.5). CVD remains the 
most common cause of death within ESC member countries, account­
ing for just under 2.2 million deaths in females and just over 1.9 million 
deaths in males in the most recent year of available data. Ischaemic 
heart disease is the most common cause of CVD death, accounting 
for 38% of all CVD deaths in females and 44% in males.3
2.3. Number and breakdown of classes of 
recommendations
The total number of recommendations in this guideline is 193. A sum­
mary of the recommendations according to Class of Recommendation 
and Level of Evidence (LoE) is also provided. As per Class of 
Recommendation, there were 106 Class I, 70 Class II, and 17 Class III 
recommendations. As per LoE, there were 56 LoE A, 64 LoE B, and 
73 LoE C recommendations.
STEMI
NSTE-ACS
STEMI
NSTEMI
Unstable angina 
Non-ACS diagnosis hs-cTn levels
± Angiography
± Imaging
Final diagnosisb
Working diagnosisa
Further investigations
Clinical presentation
If a patient has signs/symptoms suggestive of ACS,
perform an ECG
within 10 min of FMC
ECG
Figure 3 Classification of patients presenting with suspected acute coronary syndrome: from a working to a final diagnosis. ACS, acute coronary syndrome; 
ECG, electrocardiogram; FMC, first medical contact; hs-cTn, high-sensitivity cardiac troponin; MI, myocardial infarction; NSTE-ACS, non-ST-elevation acute 
coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction: STEMI, ST-elevation myocardial infarction. aThe working ACS diagnosis can be clas­
sified as STEMI or NSTE-ACS on the basis of available clinical information and ECG findings. This allows for initial triage and assessment. bThe final diagnosis is 
based on symptoms, ECG and troponin for the diagnosis of MI as well as the results of other tests (i.e. imaging and/or angiography) to facilitate understanding 
of the mechanism and subclassification of the type of MI. Patients initially assigned a working diagnosis of STEMI or NSTE-ACS may eventually receive a final 
non-ACS diagnosis.


<!-- PAGE 14 -->

### Page 14

2.4. What is new
Table 4 New recommendations
Recommendations
Classa
Levelb
Recommendations for antiplatelet and anticoagulant therapy in acute coronary syndrome
If patients presenting with ACS stop DAPT to undergo coronary artery bypass grafting, it is recommended they resume DAPT after surgery 
for at least 12 months.
I
C
In older ACS patients, especially if HBR, clopidogrel as the P2Y12 receptor inhibitor may be considered.
IIb
B
Recommendations for alternative antithrombotic therapy regimens
In patients who are event-free after 3–6 months of DAPT and who are not high ischaemic risk, single antiplatelet therapy (preferably with a 
P2Y12 receptor inhibitor) should be considered.
IIa
A
P2Y12 inhibitor monotherapy may be considered as an alternative to aspirin monotherapy for long-term treatment.
IIb
A
In HBR patients, aspirin or P2Y12 receptor inhibitor monotherapy after 1 month of DAPT may be considered.
IIb
B
In patients requiring OAC, withdrawing antiplatelet therapy at 6 months while continuing OAC may be considered.
IIb
B
De-escalation of antiplatelet therapy in the first 30 days after an ACS event is not recommended.
III
B
Recommendations for cardiac arrest and out-of-hospital cardiac arrest
Evaluation of neurological prognosis (no earlier than 72 h after admission) is recommended in all comatose survivors after cardiac arrest.
I
C
Transport of patients with out-of-hospital cardiac arrest to a cardiac arrest centre according to local protocol should be considered.
IIa
C
Recommendations for technical aspects of invasive strategies
In patients with spontaneous coronary artery dissection, PCI is recommended only for patients with symptoms and signs of ongoing 
myocardial ischaemia, a large area of myocardium in jeopardy, and reduced antegrade flow. 
I
C
Intravascular imaging should be considered to guide PCI.
IIa
A
Intravascular imaging (preferably optical coherence tomography) may be considered in patients with ambiguous culprit lesions.
IIb
C
Recommendations for multivessel disease in ACS patients presenting in cardiogenic shock
Staged PCI of non-IRA should be considered.
IIa
C
Recommendations for multivessel disease in haemodynamically stable STEMI patients undergoing primary PCI
It is recommended that PCI of the non-IRA is based on angiographic severity.
I
B
Invasive epicardial functional assessment of non-culprit segments of the IRA is not recommended during the index procedure.
III
C
Recommendations for acute coronary syndrome complications
Implantation of a permanent pacemaker is recommended when high-degree AV block does not resolve within a waiting period of at least 5 
days after MI.
I
C
Cardiac magnetic resonance imaging should be considered in patients with equivocal echocardiographic images or in cases of high clinical 
suspicion of LV thrombus.
IIa
C
Following an acute anterior MI, a contrast echocardiogram may be considered for the detection of LV thrombus if the apex is not well 
visualized on echocardiography.
IIb
C
In selected patients with high-degree AV block in the context of an anterior wall MI and acute heart failure, early device implantation (cardiac 
resynchronization therapy—defibrillator/pacemaker) may be considered.
IIb
C
In patients with recurrent life-threatening ventricular arrhythmias, sedation or general anaesthesia to reduce sympathetic drive may be 
considered.
IIb
C
Recommendations for acute coronary syndrome comorbid conditions
It is recommended to base the choice of long-term glucose-lowering treatment on the presence of comorbidities, including heart failure, 
chronic kidney disease, and obesity.
I
A
For frail older patients with comorbidities, a holistic approach is recommended to individualize interventional and pharmacological 
treatments after careful evaluation of the risks and benefits.
I
B
An invasive strategy is recommended in cancer patients presenting with high-risk ACS with expected survival ≥6 months.
I
B
A temporary interruption of cancer therapy is recommended in patients in whom the cancer therapy is suspected to be a contributing cause 
of ACS.
I
C
A conservative non-invasive strategy should be considered in ACS patients with poor cancer prognosis (i.e. with expected life survival <6 
months) and/or very high bleeding risk.
IIa
C
Aspirin is not recommended in cancer patients with a platelet count <10 000/μL.
III
C
Continued
ESC Guidelines                                                                                                                                                                                          3733


<!-- PAGE 15 -->

### Page 15

Clopidogrel is not recommended in cancer patients with a platelet count <30 000/μL.
III
C
In ACS patients with cancer and <50 000/μL platelet count, prasugrel or ticagrelor are not recommended.
III
C
Recommendations for long-term management
It is recommended to intensify lipid-lowering therapy during the index ACS hospitalization for patients who were on lipid-lowering therapy 
before admission.
I
C
Low-dose colchicine (0.5 mg once a day) may be considered, particularly if other risk factors are insufficiently controlled or if recurrent 
cardiovascular disease events occur under optimal therapy.
IIb
A
Combination therapy with a high-dose statin plus ezetimibe may be considered during index hospitalization.
IIb
B
Recommendations for patient perspectives in acute coronary syndrome care
Patient-centred care is recommended by assessing and adhering to individual patient preferences, needs and beliefs, ensuring that patient 
values are used to inform all clinical decisions.
I
B
It is recommended to include ACS patients in decision-making (as much as their condition allows) and to inform them about the risk of 
adverse events, radiation exposure, and alternative options. Decision aids should be used to facilitate the discussion.
I
B
It is recommended to assess symptoms using methods that help patients to describe their experience.
I
C
Use of the ‘teach back’ technique for decision support during the securing of informed consent should be considered.
IIa
B
Patient discharge information should be provided in both written and verbal formats prior to discharge. Adequate preparation and 
education for patient discharge using the teach back technique and/or motivational interviewing, giving information in chunks, and checking 
for understanding, should be considered.
IIa
B
Assessment of mental well-being using a validated tool and onward psychological referral when appropriate should be considered.
IIa
B
© ESC 2023
ACS, acute coronary syndrome; AV, atrioventricular; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; IRA, infarct-related artery; LV, left ventricular(cle); MI, myocardial infarction; 
OAC, oral anticoagulant/ation; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.
Table 5 Revised recommendations
Recommendations in 2017 and 2020 versions
Classa
LoEb
Recommendations in 2023 version
Classa
LoEb
Recommendations for imaging for patients with suspected NSTE-ACS
In patients with no recurrence of chest pain, normal ECG 
findings, and normal levels of cardiac troponin (preferably 
high sensitivity), but still with suspected ACS, a 
non-invasive stress test (preferably with imaging) for 
inducible ischaemia or CCTA is recommended before 
deciding on an invasive approach.
I
B
In patients with suspected ACS, non-elevated (or 
uncertain) hs-cTn, no ECG changes and no recurrence of 
pain, incorporating CCTA or a non-invasive stress 
imaging test as part of the initial workup should be 
considered.
IIa
A
Recommendations for timing of invasive strategy in NSTE-ACS
An early invasive strategy within 24 h is recommended in 
patients with any of the following high-risk criteria: 
• Diagnosis of NSTEMI suggested by the diagnostic 
algorithm recommended in Section 3
• Dynamic or presumably new contiguous ST/T-segment 
changes suggesting ongoing ischaemia
• Transient ST-segment elevation
• GRACE risk score >140.
I
A
An early invasive strategy within 24 h should be 
considered in patients with at least one of the following 
high-risk criteria: 
• Confirmed diagnosis of NSTEMI based on current 
recommended ESC hs-cTn algorithms
• Dynamic ST-segment or T wave changes
• Transient ST-segment elevation
• GRACE risk score >140.
IIa
A
Recommendations for antiplatelet and anticoagulant therapy in STEMI
A potent P2Y12 inhibitor (prasugrel or ticagrelor), or 
clopidogrel if these are not available or are contraindicated, 
is recommended before (or at latest at the time of) PCI, and 
maintained over 12 months, unless there are 
contraindications such as excessive risk of bleeding.
I
A
Pre-treatment with a P2Y12 receptor inhibitor may be 
considered in patients undergoing a primary PCI strategy.
IIb
B
Recommendations for long-term antithrombotic therapy
After stent implantation in patients undergoing a strategy 
of DAPT, stopping aspirin after 3–6 months should be 
considered, depending on the balance between the 
ischaemic and bleeding risks.
IIa
A
In patients who are event-free after 3–6 months of DAPT 
and who are not high ischaemic risk, SAPT (preferably 
with a P2Y12 receptor inhibitor) should be considered.
IIa
A
Continued


<!-- PAGE 16 -->

### Page 16

New/revised concepts 
• ACS should be considered a spectrum, which encompasses both 
non-ST-elevation (NSTE)-ACS and ST-elevation MI (STEMI).
• A section on the management of ACS in patients with cancer is 
provided.
• A section on patient perspectives is provided.
3. Triage and diagnosis
3.1. Clinical presentation and physical 
examination
3.1.1. Clinical presentation
Acute chest discomfort—which may be described as pain, pressure, 
tightness, heaviness, or burning—is the leading presenting symptom 
prompting consideration of the clinical diagnosis of ACS and the initi­
ation of testing aligned with specific diagnostic algorithms (Figure 4).
Chest pain descriptors should be classified as cardiac, possibly car­
diac, and likely non-cardiac. Further information on the suggested use 
of these terms is provided in the Supplementary data online. The use 
of the descriptor ‘atypical’ should be avoided. Chest pain-equivalent 
symptoms include dyspnoea, epigastric pain, and pain in the left or right 
arm or neck/jaw.
Misdiagnosis or delayed diagnosis is sometimes due to an incomplete 
history or difficulty in eliciting symptoms from the patient. In order to 
understand the complexity of ACS-related symptomatology, careful 
history taking and comprehensive interaction with the patient are 
crucial and may help to facilitate an early and accurate diagnosis. 
Further information is provided in the Supplementary data online, in­
cluding Figure S1, which outlines some of the most common symptoms 
of ACS in women and men.
Recommendations for cardiac arrest and out-of-hospital cardiac arrest
Delayed as opposed to immediate angiography should be 
considered among haemodynamically stable patients 
without ST-segment elevation successfully resuscitated 
after out-of-hospital cardiac arrest.
IIa
B
Routine immediate angiography after resuscitated cardiac 
arrest is not recommended in haemodynamically stable 
patients without persistent ST-segment elevation (or 
equivalents).
III
A
Targeted temperature management (also called 
therapeutic hypothermia), aiming for a constant 
temperature between 32 and 36 C for at least 24 h, is 
indicated in patients who remain unconscious after 
resuscitation from cardiac arrest (of presumed cardiac 
cause).
I
B
Temperature control (i.e. continuous monitoring of core 
temperature and active prevention of fever [i.e. >37.7°C]) 
is recommended after either out-of-hospital or in-hospital 
cardiac arrest for adults who remain unresponsive after 
return of spontaneous circulation.
I
B
Recommendations for in-hospital management
When echocardiography is suboptimal/inconclusive, an 
alternative imaging method (CMR preferably) should be 
considered.
IIa
C
When echocardiography is suboptimal/inconclusive, 
CMR imaging may be considered.
IIb
C
Recommendations for management of multivessel disease in haemodynamically stable STEMI patients undergoing primary PCI
Routine revascularization of non-IRA lesions should be 
considered in STEMI patients with multivessel disease 
before hospital discharge.
IIa
A
Complete revascularization is recommended either 
during the index PCI procedure or within 45 days.
I
A
Recommendations for acute coronary syndrome comorbid conditions
Glucose-lowering therapy should be considered in ACS 
patients with blood glucose >10 mmol/L (>180 mg/dL), 
with the target adapted to comorbidities, while episodes 
of hypoglycaemia should be avoided.
IIa
B
Glucose-lowering therapy should be considered in 
patients with ACS with persistent hyperglycaemia, while 
episodes of hypoglycaemia should be avoided.
IIa
C
© ESC 2023
ACS, acute coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic resonance; DAPT, dual antiplatelet therapy; ECG, electrocardiography/gram; 
ESC European Society of Cardiology; GRACE, Global Registry of Acute Coronary Events; hs-cTn, high-sensitivity cardiac troponin; IRA, infarct-related artery; NSTE-ACS, non-ST-elevation 
acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy; STEMI, ST-elevation myocardial 
infarction. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3735


<!-- PAGE 17 -->

### Page 17

It is important that awareness of the symptoms associated with 
ACS is high among the general population, in particular red flag 
symptoms such as prolonged chest pain (>15 min) and/or recurrent 
pain within 1 h, which should prompt patients or other members of 
the public to seek urgent medical help. Continuous education, pro­
motion, and advocacy efforts are important to make sure that this 
information is as widely available as possible to the general 
population.
ACS
presentation
Initial A.C.S.
assessment
ECG
Physical examination
Clinical history
Vital signs hs-cTna levels
Non-immediate angiography
Echo
Intravascular imaging hs-cTna levels
Non-invasive imaging
ECG
monitoring
PCI
CABG
Long-term medical therapy
Lifestyle measures
Smoking cessation
STEMI
NSTE-ACS
with very high-risk featuresb
NSTE-ACS
without very high-risk featuresb
Immediate angiography ± 
PPCI or fibrinolysis if timely
PPCI not feasible
PPCI
ATT
Fibrinolysis
Immediate angiography 
± PCI
Consider angiography within 24 h for NSTE-ACS
with high risk features
Working diagnosis
Early invasive angiography according to patient risk
Further management
Further investigations
PCI
ATT
PCI
ATT
Figure 4 An overview of the initial triage, management and investigation of patients who present with signs and symptoms potentially consistent with acute 
coronary syndrome. ACS, acute coronary syndrome; ATT, antithrombotic therapy; CABG, coronary artery bypass grafting; ECG, electrocardiogram; hs-cTn, 
high-sensitivity cardiac troponin; NSTE-ACS, non-ST-elevation acute coronary syndrome; PPCI, primary percutaneous coronary intervention; STEMI, 
ST-elevation myocardial infarction. The ‘A.C.S.’ assessment is detailed in Figure 5. aResults of hs-cTn measurements are not required for the initial stratifi­
cation of ACS and the initial emergency management (i.e. for patients with a working diagnosis of STEMI or very high-risk NSTE-ACS) should not be delayed 
based on this. bFor patients with NSTE-ACS with very high-risk features, immediate angiography is recommended. For patients with NSTE-ACS with high- 
risk features, early invasive angiography (i.e. <24 h) should be considered and inpatient invasive angiography is recommended. See Recommendation Table 4 
for details.


<!-- PAGE 18 -->

### Page 18

3.1.2. History taking and physical examination
Patients with suspected ACS present in a broad range of clinical scen­
arios, including in the community, at the emergency department (ED), 
or in the inpatient setting. It is crucial to take a focused medical history 
and accurately characterize the presenting symptoms in order to 
manage the patient via the appropriate care pathway as soon as 
possible.
Prompt assessment of vital signs is recommended at first medical 
contact (FMC), at the same time as acquisition of an initial ECG 
(Figure 5). In patients presenting with suspected ACS, physical examin­
ation is recommended and is useful both to eliminate differential diag­
noses and to identify very high-risk and high-risk ACS features. This may 
be particularly relevant for patients presenting with cardiac arrest, signs 
of CS, and/or haemodynamic or electrical instability.4 Focused physical 
examination should include checking for the presence of all major 
pulses, measurement of blood pressure in both arms, auscultation of 
the heart and lungs, and assessing for signs of HF or circulatory 
compromise.
3.2. Diagnostic tools | Electrocardiogram
The resting 12-lead ECG is the first-line diagnostic tool in the assess­
ment of patients with suspected ACS. It is recommended that an 
ECG is obtained immediately upon FMC and interpreted by a qualified 
emergency medical technician or physician within 10 min.4,5 It should 
be repeated as necessary, especially if symptoms have waned at FMC. 
Based on the initial ECG, patients with suspected ACS can be differen­
tiated into two working diagnoses: 
• Patients with acute chest pain (or chest pain-equivalent 
signs/symptoms) and persistent ST-segment elevation 
(or ST-segment elevation equivalents) on ECG (working 
diagnosis: ST-segment elevation MI: STEMI). The vast major­
ity of these patients will sustain myocardial necrosis and troponin ele­
vation, fulfilling the criteria for an MI, but MI will not be the final 
diagnosis in all patients with a working diagnosis of STEMI.
• Patients with acute chest pain (or chest pain-equivalent 
signs/symptoms) but without persistent ST-segment 
A
C
S
Abnormal
ECG?
Clinical context?
Stable patient?
Perform an ECG to assess 
for evidence of ischaemia  
or other abnormalities
Consider the clinical 
context and available 
investigations
Perform an exam to assess 
if the patient is clinically 
and vitally stable
Figure 5 The A.C.S. assessment for the initial evaluation of patients with suspected acute coronary syndrome. ECG, electrocardiogram. This figure sum­
marizes the initial ‘A.C.S. assessment’ that can be performed for a patient presenting with suspected ACS. ‘A’ stands for ‘Abnormal ECG?’: an ECG should be 
performed within 10 min of FMC and assessed for evidence of abnormalities or ischaemia. ‘C’ stands for ‘Clinical Context?’: it is important to consider the 
clinical context of the patient’s presentation and the results of any investigations that are available. This should also include a targeted history with the aim of 
determining the patient’s symptoms and elucidating any other relevant background information. ‘S’ stands for ‘Stable Patient?’: the patient should be quickly 
assessed to determine if they are clinically stable—this should include assessment of the clinical vital signs, including heart rate, blood pressure, and oxygen 
saturations, if possible, as well as checking for potential signs of CS.
ESC Guidelines                                                                                                                                                                                          3737


<!-- PAGE 19 -->

### Page 19

elevation (or ST-segment elevation equivalents) on ECG 
(working diagnosis: non-ST-elevation [NSTE]-ACS). 
These patients may exhibit other ECG alterations, including transient 
ST-segment elevation, persistent or transient ST-segment depres­
sion, and T wave abnormalities, including hyperacute T waves, T 
wave inversion, biphasic T waves, flat T waves, and pseudo- 
normalization of T waves. Alternatively, the ECG may be normal. 
The majority of patients in this category who subsequently display 
a typical rise and fall in cardiac troponin levels (i.e. fulfilling MI criteria 
as per the fourth universal definition of MI) will receive a final diagno­
sis of non-ST-elevation MI (NSTEMI). In other patients, the troponin 
level will remain below the 99th centile and they will receive a final 
diagnosis of UA, although with high-sensitivity troponin assays this 
diagnosis has become less common. It is also important to recognize 
that NSTEMI or UA will not be the final diagnosis in all patients with 
an initial working diagnosis of NSTE-ACS.
3.2.1. Acute coronary syndrome with persistent 
ST-segment elevation (suspected ST-elevation 
myocardial infarction)
The priority for these patients is the implementation of reperfusion ther­
apy as soon as possible (see Section 5). In the appropriate clinical context, 
ST-segment elevation (measured at the J-point) is considered suggestive 
of ongoing coronary artery acute occlusion in the following cases:
New ST elevation at the J-point in at least two contiguous leads: 
• ≥2.5 mm in men <40 years, ≥2 mm in men ≥40 years, or ≥1.5 mm 
in women regardless of age in leads V2–V3
• and/or ≥1 mm in the other leads (in the absence of left ventricular 
[LV] hypertrophy or left bundle branch block [LBBB]).
In patients with suspected inferior STEMI, it is recommended to re­
cord right precordial leads (V3R and V4R) in order to assess for 
ST-segment elevation.6 Posterior leads (V7–V9) can also be recorded 
to investigate for posterior STEMI, particularly in patients with ongoing 
symptoms and an inconclusive standard 12-lead ECG.
The diagnosis of ongoing acute coronary artery occlusion on ECG 
can sometimes be challenging, and some cases may warrant prompt 
management and triage for immediate reperfusion therapy despite 
the absence of ST-segment elevation. It is also important to recognize 
that while the most sensitive sign for ongoing acute coronary 
artery occlusion is ST-segment elevation, there are other ECG find­
ings that can be suggestive of ongoing coronary artery occlusion (or 
severe ischaemia). If these findings are present, prompt triage for 
immediate reperfusion therapy is indicated (see Supplementary data 
online, Figure S2).
ST-segment depression in leads V1–V3 (especially when the terminal 
T wave is positive) and/or ST-segment elevation in V7–V9 are highly 
suggestive of posterior coronary artery occlusion (often the left cir­
cumflex artery).1,7 ST-segment elevation in V3R and V4R is highly sug­
gestive of ongoing RV ischaemia.8 ST depression ≥1 mm in ≥6 surface 
leads (inferolateral ST depression), coupled with ST-segment elevation 
in aVR and/or V1, suggests multivessel ischaemia or left main coronary 
artery obstruction, particularly if the patient presents with haemo­
dynamic compromise.9–11
Bundle branch block (BBB). In patients with a high clinical sus­
picion of ongoing myocardial ischaemia, the presence of LBBB, right 
bundle branch block (RBBB), or a paced rhythm precludes an accurate 
assessment of the presence or absence of ST-segment elevation. 
Therefore, patients presenting with these ECG patterns in combination 
with signs/symptoms that are highly suspicious for ongoing myocardial 
ischaemia should be managed similarly to those with clear ST-segment 
elevation, regardless of whether the BBB is previously known (see 
Supplementary data online).4
3.2.2. Acute coronary syndrome without persistent 
ST-segment elevation (non-ST elevation acute 
coronary syndrome)
While the ECG in the setting of NSTE-ACS may be normal in more 
than one-third of patients, characteristic ECG abnormalities are fre­
quently present and increase the diagnostic probability of ACS.12–16
These ECG abnormalities include ST depression and T wave changes 
(especially biphasic T waves or prominent negative T waves 
[Wellens’ sign, related to severe proximal left anterior descending ar­
tery stenosis]), (see Supplementary data online, Figure S3).
Recommendation Table 1 — Recommendations for 
clinical and diagnostic tools for patients with suspected 
acute coronary syndrome
Recommendations
Classa
Levelb
It is recommended to base the diagnosis and initial 
short-term risk stratification of ACS on a 
combination of clinical history, symptoms, vital signs, 
other physical findings, ECG, and hs-cTn.1,17,18
I
B
ECG
Twelve-lead ECG recording and interpretation is 
recommended as soon as possible at the point of 
FMC, with a target of <10 min.5,19
I
B
Continuous ECG monitoring and the availability of 
defibrillator capacity is recommended as soon as 
possible in all patients with suspected STEMI, in 
suspected ACS with other ECG changes or ongoing 
chest pain, and once the diagnosis of MI is made.20,21
I
B
The use of additional ECG leads (V3R, V4R, and V7– 
V9) is recommended in cases of inferior STEMI or if 
total vessel occlusion is suspected and standard leads 
are inconclusive.22–24
I
B
An additional 12-lead ECG is recommended in cases 
with recurrent symptoms or diagnostic uncertainty.
I
C
Continued


<!-- PAGE 20 -->

### Page 20

3.3. Diagnostic tools | Biomarkers
3.3.1. High-sensitivity cardiac troponins
After excluding clinical and ECG signs suggestive of STEMI or very high- 
risk NSTE-ACS, biomarkers play a complementary role in the diagnosis, 
risk stratification, and management of patients with suspected ACS. 
Measurement of a biomarker of cardiomyocyte injury, preferably high- 
sensitivity cardiac troponin (hs-cTn), is recommended in all patients 
with suspected ACS.15,17,25–27,53,54 If the clinical presentation is com­
patible with myocardial ischaemia, then a rise and/or fall in cTn above 
the 99th percentile of healthy individuals points to a diagnosis of MI 
as per the criteria in the fourth universal definition of MI.1 In patients 
with MI, levels of cTn rise rapidly (i.e. usually within 1 h if using high- 
sensitivity assays) after symptom onset and remain elevated for a vari­
able period of time (usually several days).1,15,26,53,55–58
Advances in technology have led to a refinement in cTn assays and 
have improved their accuracy in detecting and quantifying cardiomyo­
cyte injury.1,12–15,18,26,34,35,53,55–60 Data from large multicentre studies 
have consistently shown that hs-cTn assays increase diagnostic accuracy 
for MI at the time of presentation in comparison to conventional assays, 
especially in patients presenting early after chest pain onset, enabling 
more rapid ‘rule-in’ and ‘rule-out’ of MI.1,12–15,26,34,35,53,55–58 Overall, 
hs-cTn T and hs-cTn I subunit assays appear to provide comparable 
diagnostic accuracy in the early diagnosis of MI.28,32,61,62 The use of 
the terms ‘normal’ and ‘abnormal’ to describe hs-cTn levels should 
be avoided; instead, the terms ‘non-elevated’ and ‘elevated’ should be 
used to refer to hs-cTn levels below and above the 99th percentile. 
Some of the clinical implications of hs-cTn assays are detailed in 
Supplementary data online, Table S2.
It is also important to consider that there are other clinical conditions 
apart from Type 1 MI in which elevations in cTn can be observed (see 
Supplementary data online, Section 3.3.1 and Table S3).
3.3.2. Central laboratory vs. point of care
The vast majority of cTn assays that run on automated platforms in the 
central laboratory are sensitive (i.e. allow for the detection of cTn in 
∼20–50% of healthy individuals) or high-sensitivity (i.e. allow for the de­
tection of cTn in ∼50–95% of healthy individuals) assays. 
High-sensitivity assays are recommended over lower-sensitivity assays, 
as they provide higher diagnostic accuracy at an identical low 
cost.1,12,15,25–27,57,63
The majority of currently used point-of-care (POC) tests cannot be 
considered high-sensitivity assays.64 The advantage of POC tests is a 
shorter turnaround time. However, this is counterbalanced by lower 
sensitivity, lower diagnostic accuracy, and lower negative predictive va­
lue (NPV). A randomized trial in low-risk chest pain patients with sus­
pected NSTE-ACS and onset of symptoms ≥2 h before ambulance 
presentation reported that the use of a pre-hospital rule-out strategy 
(with a single POC conventional troponin T test) resulted in a signifi­
cant reduction of 30-day healthcare costs and a comparable major ad­
verse cardiovascular event (MACE) rate in comparison to an ED 
rule-out strategy (with evaluation as per standard local practice).65
Overall, automated assays have been more thoroughly evaluated 
than POC tests and are currently preferred.1,12–15,26,34,35,53,55–58
However, this is a rapidly developing field and it will be important to 
re-evaluate this preference when more extensively validated high- 
sensitivity POC tests are clinically available.66–68
3.3.3. Confounders of cardiac troponin concentration
In patients presenting with suspected NSTE-ACS, four clinical variables 
affect hs-cTn concentrations beyond the presence or absence of MI. 
These variables are: age (concentrations in healthy very young vs. 
‘healthy’ very old individuals differ by up to 300%); renal dysfunction 
(differences between otherwise healthy patients with very high vs. 
very low estimated glomerular filtration rate [eGFR] of up to 300%); 
time from chest pain onset (>300%); and, to a lesser extent, sex 
(≈40%).28,34,35,69–76 Despite the potential baseline differences in 
hs-cTn values based on these four variables, absolute changes in 
hs-cTn levels are still of diagnostic and prognostic value. Current data 
on the use of sex-specific hs-cTn values in the diagnosis of MI have 
been controversial and failed to demonstrate a clear clinical bene­
fit.74,75,77–80 Therefore, until automated tools (i.e. risk assessment cal­
culators) incorporating the effect of all four clinical variables (age, 
eGFR, time from chest pain onset, and sex) are available, the use of uni­
form cut-off concentrations should remain the standard of care for the 
early diagnosis of MI.28,30,31,34,35,73,81,82
3.3.4. Rapid ‘rule-in’ and ‘rule-out’ algorithms
Due to their higher sensitivity and diagnostic accuracy for the detection 
of MI at presentation, the time interval to the second cTn assessment 
can be shortened with the use of hs-cTn assays. This substantially re­
duces the delay to diagnosis, translating into shorter stays in the ED, 
lower costs, and less diagnostic uncertainty for patients.15,83–88 It is re­
commended to use the 0 h/1 h algorithm (best option) or the 0 h/2 h 
Blood sampling
It is recommended to measure cardiac troponins 
with high-sensitivity assays immediately after 
presentation and to obtain the results within 60 min 
of blood sampling.15,25–27
I
B
It is recommended to use an ESC algorithmic 
approach with serial hs-cTn measurements (0 h/1 h 
or 0 h/2 h) to rule in and rule out NSTEMI.28–44
I
B
Additional testing after 3 h is recommended if the 
first two hs-cTn measurements of the 0 h/1 h 
algorithm are inconclusive and no alternative 
diagnoses explaining the condition have been 
made.45,46
I
B
The use of established risk scores (e.g. GRACE risk 
score) for prognosis estimation should be 
considered.47–49
IIa
B
Triage for emergency reperfusion strategy
It is recommended that patients with suspected 
STEMI are immediately triaged for an emergency 
reperfusion strategy.50–52
I
A
© ESC 2023
ACS, acute coronary syndrome; ECG, electrocardiogram; ESC, European Society of 
Cardiology; FMC, first medical contact; GRACE, Global Registry of Acute Coronary 
Events; hs-cTn, high-sensitivity cardiac troponin; MI, myocardial infarction; NSTEMI, 
non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3739


<!-- PAGE 21 -->

### Page 21

algorithm (second-best option) (Figure 6). These algorithms have been 
derived and validated in large multicentre diagnostic studies using cen­
tral adjudication of the final diagnosis for all currently available hs-cTn 
assays.27–39,62,70,73,82,89–93 Optimal thresholds for rule-out were se­
lected to allow a sensitivity and NPV of at least 99%. Optimal thresholds 
for rule-in were selected to allow a positive predictive value (PPV) of at 
least 70%. These algorithms were developed from large derivation co­
horts and then validated in large independent validation cohorts. The 
previous ESC 0 h/3 h algorithm was considered as an alternative,40,56
but three recent large diagnostic studies suggested that the ESC 0 h/ 
3 h algorithm appears to balance efficacy and safety less well than 
more rapid protocols using lower rule-out concentrations, including 
the ESC 0 h/1 h algorithm.41–43 The very high safety and high efficacy 
of applying the ESC 0 h/1 h algorithm was recently confirmed in three 
real-life implementation studies, including one randomized controlled 
trial (RCT).44,94,95 Therefore, the ESC 0 h/3 h algorithm is an alternative 
for cases where the ESC 0 h/1 h or 0 h/2 h algorithms are not available. 
Of note, patients assigned to the ‘rule-out’ pathway using the ESC 0 h/ 
1 h or 0 h/2 h algorithms have a very low rate of clinical events through 
to 30 days.95,96
3.3.4.1. European Society of Cardiology 0 h/1 h and 0 h/2 h 
algorithms
The ESC 0 h/1 h and 0 h/2 h algorithms are based on two underlying 
concepts: firstly, hs-cTn is a continuous variable and the probability 
of MI increases with increasing hs-cTn values.28,30,31,34,35,73,82
Secondly, early absolute changes in the levels within 1 h or 2 h can be 
used as surrogates for absolute changes over 3 h or 6 h and provide in­
cremental diagnostic value to the single cTn assessment at presenta­
tion.27,28,30,31,34,35,73,82,97 The cut-off concentrations within the 0 h/ 
1 h and 0 h/2 h algorithms are assay specific (Supplementary data 
online, Table S4).27,28,30,31,34,35,73,82
3.3.4.1.1. Rule-out. The NPV for MI in patients assigned to the 
‘rule-out’ pathway has exceeded 99% in several large validation 
cohorts.28–30,34,35,73 Assignment to the rule-out pathway does not al­
ways equal outpatient management. However, when used in conjunc­
tion with clinical and ECG findings, the 0 h/1 h and 0 h/2 h algorithms 
will enable the identification of appropriate candidates for early dis­
charge and outpatient management. Even after the ruling out of MI, 
elective non-invasive or invasive imaging may be appropriate according 
to clinical and risk assessment, and an alternative diagnosis to MI should 
be identified.
3.3.4.1.2. Rule-in. The PPV for MI in patients meeting the ‘rule-in’ 
pathway criteria in several studies has been ∼70–75%. Most of the 
‘rule-in’ pathway patients with diagnoses other than MI still have condi­
tions that require specialist cardiology input and either coronary angi­
ography or non-invasive imaging in order to establish an accurate 
final diagnosis.28,30,31,34,35,73,82 Therefore, the vast majority of patients 
triaged towards the ‘rule-in’ pathway by these algorithms will require 
hospital admission and invasive coronary angiography (ICA).
3.3.4.1.3. Observe. Patients who do not qualify for the ‘rule-out’ or 
‘rule-in’ pathways are assigned to the ‘observe’ pathway. These patients re­
present a heterogeneous group and have been shown to have a mortality 
rate that is comparable to rule-in patients.98 Therefore, an individual as­
sessment based on the particular risk profile of the patient (i.e. risk scores) 
is of paramount importance for patients in this group. Additionally, a third 
measurement of cTn at 3 h (± echocardiography) is recommended as the 
next step in order to guide further management.45,46
Most patients in the observe zone with a high degree of clinical 
suspicion of ACS (e.g. relevant increase in cTn from presentation 
to 3 h) are candidates for ICA. Conversely, most patients with a 
low to intermediate likelihood for ACS according to clinical judg­
ment are candidates for non-invasive imaging after transfer from 
the ED to the ward. Computed tomography (CT) angiography can 
be used to aid diagnosis and, in particular, to identify patients with 
non-obstructed coronary arteries who can be discharged if other 
relevant diseases have been excluded. CT angiography can also iden­
tify patients with obstructive coronary disease in whom revascular­
ization may be considered. In the appropriate clinical context, if 
alternative conditions have been identified that explain the cTn va­
lues (i.e. rapid ventricular rate response to atrial fibrillation [AF], 
marked anaemia, or a hypertensive emergency), further diagnostic 
testing (i.e. ICA) may not be required.
The same concepts apply to the 0 h/2 h algorithm. Cut-off levels for 
both the 0 h/1 h and 0 h/2 h algorithms are also assay specific, and these 
cut-off levels are shown in Supplementary data online, Table S4.99
The ESC 0 h/1 h and 0 h/2 h algorithms should always be integrated 
with a detailed clinical assessment and a 12-lead ECG. Repeat blood 
sampling is mandatory in cases where there is ongoing or recurrent 
chest pain. Recently, artificial intelligence models that include serial 
hs-cTn measurements in conjunction with individual risk profiles have 
been proposed to be useful to facilitate a personalized diagnostic evalu­
ation of patients with suspected MI. Similarly, risk-assessment models 
combining hs-cTn values at presentation and after early or late resam­
pling have been developed to predict MI events during the first 30 days. 
These models may facilitate alternative hs-cTn cut-offs based on the 
balance between NPV and PPV best suited to individual clinical sites.27
A diagnostic approach to the use of the ESC 0 h/1 h and 0 h/2 h algo­
rithms is shown in Figure 6.


<!-- PAGE 22 -->

### Page 22

Patient presents with a suspected NSTEMI and 
without an indication for immediate invasive angiography
Appropriate management can be determined based on the hs-cTn levels and clinical situation
Take hs-cTn at 0 h and 1 h/2 h
Very low initial hs-cTna
Low initial hs-cTn and no increase in 1 h/2 h hs-cTn
Patients who do not meet the criteria for either of the other two pathways 
Observe pathway
Rule-out pathway
Rule-in pathway
High initial hs-cTn
OR
OR
Increase in 1 h/2 h hs-cTn
Figure 6 The 0 h/1 h or 0 h/2 h rule-out and rule-in algorithms using high-sensitivity cardiac troponin assays in patients presenting to the emergency de­
partment with suspected NSTEMI and without an indication for immediate invasive angiography. hs-cTn, high-sensitivity cardiac troponin; NSTEMI, 
non-ST-elevation myocardial infarction. Patients are classified into one of three pathways as per the results of their hs-cTn values at 0 h (time of initial blood 
test) and 1 h or 2 h later. Patients with a very low initial hs-cTn value or patients with a low initial value and no 1 h/2 h change in hs-cTn are assigned to the 
‘rule-out’ pathway. Patients with a high initial hs-cTn value or a 1 h/2 h change in hs-cTn are assigned to the ‘rule-in’ pathway. Patients who do not meet the 
criteria for the rule-out or rule-in strategies are assigned to the ‘observe’ pathway, and these patients should have hs-cTn levels checked at 3 h ± echocar­
diography in order to decide on further management. Cut-offs are assay specific (see Supplementary material online, Table S4) and derived to meet 
pre-defined criteria for sensitivity and specificity for NSTEMI. Potential management and testing options for each of the three strategies are provided in 
the relevant sections of the main text.12–15,26,27,53,55–58,100,101 aOnly applicable if the chest pain onset was >3 h prior to the 0 h hs-cTn measurement.
ESC Guidelines                                                                                                                                                                                          3741


<!-- PAGE 23 -->

### Page 23

3.3.4.2. Practical guidance on how to implement the European 
Society of Cardiology 0 h/1 h algorithm
In order to maximize the safety and feasibility of implementing the 0 h/ 
1 h algorithm, blood samples for hs-cTn at 0 h and 1 h should be ob­
tained irrespective of other clinical details and pending results (see ca­
veats of using rapid algorithms in Supplementary data online, Section 3.3. 
2.2). This may result in unnecessary cTn measurements in the ∼10– 
15% of patients with very low 0 h concentrations and chest pain onset 
>3 h, but substantially facilitates the process and thereby further in­
creases patient safety. Similarly, the 0 h blood sample should be ob­
tained immediately after admission to the ED.
3.3.5. Other biomarkers
The use of biomarkers other than cTn for the diagnosis of ACS is not 
recommended (unless cTn is not available). Among the multitude of 
additional biomarkers evaluated for the diagnosis of NSTEMI, only cre­
atine kinase myocardial band isoenzyme, myosin-binding protein C, and 
copeptin may have clinical relevance when used in combination with 
(standard) cTn T/I, although in most clinical situations their incremental 
value above and beyond cTn is limited.45,46,83,102–114
3.4. Diagnostic tools | Non-invasive imaging
3.4.1. Echocardiography
In emergency rooms and chest pain units, transthoracic echocardiog­
raphy (TTE) performed or interpreted by trained healthcare profes­
sionals should be routinely available. In cases of suspected ACS with 
diagnostic uncertainty, TTE can be useful to identify signs suggestive of 
ongoing ischaemia or prior MI. However, this should not result in rele­
vant delays in transfer to the cardiac catheterization laboratory if there 
is suspicion of an acute coronary artery occlusion. TTE can also be useful 
to suggest alternative aetiologies associated with chest pain (i.e. acute 
aortic disease, RV signs in pulmonary embolism [PE]). All patients pre­
senting with CS or haemodynamic instability should undergo emergency 
TTE to try to identify the underlying cause—in particular, to assess LV 
and RV function and look for evidence of mechanical complications.
3.4.2. Computed tomography
Upon clinical presentation, CT is often the diagnostic tool of choice for 
ruling out alternative potentially life-threatening differential diagnoses 
of ACS, like PE or aortic dissection (this should be an ECG-gated con­
trast CT angiogram with full coverage of the thoracic aorta and the 
proximal head and neck vessels). Generally, CT does not have a role 
in patients presenting with suspicion of ongoing acute coronary occlu­
sion, for whom emergency ICA is the priority.
Coronary CT angiography (CCTA) has been investigated in many trials 
for the assessment of patients presenting to the ED with suspected 
NSTE-ACS. However, trials investigating CCTA in the era of hs-cTn as­
says may be of greater relevance for contemporary practice. The 
BEACON (Better Evaluation of Acute Chest Pain with Coronary 
Computed Tomography Angiography) study showed no reduction of in- 
hospital duration of stay or hospital admission in the CCTA arm com­
pared with patients investigated with hs-cTn, with similar results to those 
observed in the ROMICAT II (Rule Out Myocardial Ischemia/Infarction by 
Computer Assisted Tomography) and RAPID-CTCA (Rapid Assessment 
of Potential Ischaemic Heart Disease with CTCA) trials.115–117 In the lat­
ter study, a default approach using early non-invasive CCTA in patients 
with suspected NSTE-ACS did not improve clinical outcomes at 1 year 
and was associated with a modest increase in the duration and cost of 
the hospital stay. A default approach using CCTA as the first-line imaging 
investigation in patients with suspected NSTE-ACS is therefore not 
recommended. However, CCTA may provide added value in certain clin­
ical settings (i.e. for patients in the observe zone in whom cTn and ECG 
results remain inconclusive). A normal CCTA (ruling out both obstructive 
and non-obstructive plaque) has a high NPV to exclude ACS and is asso­
ciated with excellent clinical outcomes.
The systematic use of CCTA in rule-out patients after hospital dis­
charge may identify the presence of obstructive or non-obstructive pla­
que and guide preventative medical therapies.118 CCTA can also be 
used to risk stratify selected low-risk NSTEMI patients. Such patients, 
who are found to have normal coronary arteries, non-obstructive cor­
onary disease, or distal obstructive disease, may then not require 
ICA.119–121 Of note, the utility of CCTA may be limited in patients 
with tachycardia, established coronary artery disease (CAD), previous 
stents, or extensive coronary calcification.
3.4.3. Cardiac magnetic resonance imaging with or 
without stress testing
Cardiac magnetic resonance (CMR) imaging delineates cardiac struc­
ture and function, and also has the ability to provide assessments of 
myocardial perfusion and the pattern of myocardial injury. CMR is 
the imaging test of choice when poor echocardiographic windows pre­
clude diagnostic echocardiographic evaluation. CMR allows direct visu­
alization of infarcted regions, providing information on scarring and 
viability that can be differentiated from other forms of myocardial injury 
(e.g. myocarditis). CMR is therefore of particular clinical value in estab­
lishing a diagnosis of AMI where there is diagnostic uncertainty. CMR 
can also be useful in identifying the culprit vascular territory and in con­
firming a diagnosis of myocarditis or takotsubo cardiomyopathy, 
amongst other differentials. CMR is of particular value in establishing 
a diagnosis in patients presenting with a working diagnosis of myocardial 
infarction with non-obstructive coronary arteries (MINOCA) following 
invasive angiography and is the gold standard for the assessment of LV 
thrombus.
Recommendation Table 2 — Recommendations for 
non-invasive imaging in the initial assessment of patients 
with suspected acute coronary syndrome
Recommendations
Classa
Levelb
Emergency TTE is recommended in patients with 
suspected ACS presenting with cardiogenic shock or 
suspected mechanical complications.
I
C
In patients with suspected ACS, non-elevated (or 
uncertain) hs-cTn levels, no ECG changes and no 
recurrence of pain, incorporating CCTA or a 
non-invasive stress imaging test as part of the initial 
workup should be considered.116,122–127
IIa
A
Emergency TTE should be considered at triage in 
cases of diagnostic uncertainty but this should not 
result in delays in transfer to the cardiac 
catheterization laboratory if there is suspicion of an 
acute coronary artery occlusion.
IIa
C
Routine, early CCTA in patients with suspected ACS 
is not recommended.117
III
B
© ESC 2023
ACS, acute coronary syndrome; CCTA, coronary computed tomography angiography; 
ECG, electrocardiogram; hs-cTn, high-sensitivity cardiac troponin; TTE, transthoracic 
echocardiography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 24 -->

### Page 24

Cardiac magnetic resonance can also assess myocardial perfusion 
with pharmacological stress. This can be used as an alternative to 
CCTA in the assessment of patients in the observe zone following 
ECG and hs-cTn assessments, particularly in those with advanced, es­
tablished CAD, in whom assessments of myocardial perfusion and via­
bility may provide more useful information than CCTA. Some 
additional information on CMR, single-photon emission computerized 
tomography (SPECT) perfusion imaging and stress echocardiography 
is provided in the Supplementary data online.
Depending on local expertise and availability, other forms of stress 
imaging (e.g. SPECT, nuclear, stress echo) can be used to assess patients 
in the observe zone.
3.5. Differential diagnosis for acute chest 
pain
Several cardiac and non-cardiac conditions that may mimic ACS should 
be considered in the differential diagnosis of acute chest pain as part of 
the clinical assessment. More information about the differential diagno­
sis of acute chest pain is provided in the sections on MINOCA and Type 
2 MI and in the Supplementary data online, Table S5.
4. Initial measures for patients 
presenting with suspected acute 
coronary syndrome | Initial 
treatment
4.1. Pre-hospital logistics of care
Individuals experiencing acute chest pain in the community represent 
an undifferentiated population, often presenting ad hoc to first med­
ical responders in the pre-hospital setting. These patients should 
undergo immediate risk assessment and triage following local proto­
cols established within the emergency medical service (EMS) 
(Figures 7 and 8).
If the first responding medical professional suspects ACS, a 12-lead 
ECG should be acquired and analysed as soon as possible. It is recom­
mended that all medical and paramedical personnel caring for ACS pa­
tients within the EMS setting have access to defibrillation equipment 
and are trained in basic cardiac life support. Patients with suspected 
ACS are initially categorized on the basis of the 12-lead ECG and 
triaged into two initial treatment pathways: (i) one for patients with 
an ECG consistent with STEMI (persistent ST-segment elevation or 
equivalent ECG patterns) (Figure 7); and (ii) one for patients without 
ST-segment elevation or equivalent ECG patterns (suspected 
NSTE-ACS) (Figure 8). The initial ECG-guided risk stratification should 
also trigger treatment decisions in the pre-hospital setting, including the 
choice of target hospital, and serve to determine the sequence of initial 
investigations and interventions (including pharmacological), in particu­
lar, the timing of ICA.
An initial diagnosis of suspected STEMI portends a higher risk of im­
mediate, life-threatening complications (e.g. ventricular fibrillation 
[VF]). Accordingly, there is an indication for initiating an emergency re­
perfusion strategy and direct transfer to a centre with 24/7 PCI capabil­
ities. Patients who present with an ECG without ST-segment elevation 
(or equivalent ECG patterns) but have ongoing ischaemic symptoms 
should undergo pre-hospital triage in accordance with protocols for pa­
tients in the STEMI pathway, since they also face immediate risks, in­
cluding ventricular arrhythmias.
4.1.1. Time to treatment
Time to treatment is vital for the care of patients triaged to the STEMI 
pathway. Components of the total ischaemic time, contributors to delays 
in initial management, and the selection of reperfusion strategy for STEMI 
patients are shown in Figure 7. Treatment times reflect the efficiency and 
quality of care of a system taking care of patients with suspected STEMI. 
The multidisciplinary STEMI treatment pathway should be subject to 
continuous clinical audit in order to assess the treatment times for indi­
vidual patients and identify opportunities for healthcare improvement 
through quality indicators (QIs). If projected QIs are not met, interven­
tions are needed to improve the performance of the system.
Recognition of ischaemic symptoms by individuals in the community 
has pivotal importance in activation of the out-of-hospital pathway, and 
this is especially relevant to first responders without healthcare training. 
The recommended action should be to contact the EMS rather than to 
self-present to an ED or primary care clinician.
The time from symptom onset to ‘first call for help’ is associated with 
socioeconomic factors and sex.128 In order to avoid delays through fail­
ure to recognize and act on symptoms of a ‘heart attack’, community 
education initiatives should target less well-served groups (i.e. those 
from deprived communities, ethnic minority groups) and use targeted 
public health messaging (i.e. avoiding stereotyped messaging that under­
pins a negative bias based on sex, ethnicity, or social background, and 
using language and images that will resonate with those groups). 
System delays are representative of the quality of care and it is recom­
mended to measure these as QIs.
4.1.2. Healthcare systems and system delays
For patients with suspected STEMI, the system delay (the time from 
when the patient contacts the healthcare system to reperfusion) is 
amenable to improvement by organizational measures, whereas patient 
delay is multifactorial. System delay is a predictor of mortality in STEMI 
patients treated with primary PCI (PPCI).129–131 When a working diag­
nosis of STEMI is made in the pre-hospital setting (EMS), immediate ac­
tivation of the catheterization laboratory team reduces treatment 
delays and mortality.132–136
When a STEMI working diagnosis is made by the EMS in the pre- 
hospital setting and the patient is triaged for emergency invasive manage­
ment, they should bypass the ED and go straight to the catheterization 
laboratory. Bypassing the ED is associated with a significant saving in the 
time from FMC to wire crossing and may be associated with improved 
survival.137–139 For patients presenting to a non-PCI centre with a sus­
pected STEMI, the ‘door-in to door-out time’—defined as the duration 
between arrival of the patient at the hospital to discharge of the patient 
in an ambulance ‘en route’ to the PCI centre—is also an important clinical 
performance measure, and a door-in to door-out time of ≤30 min is re­
commended to expedite reperfusion therapy.140
4.1.3. Emergency medical services
At a national level, an EMS with an easily recalled and well-publicised un­
ique medical dispatching number (112 for most European Union coun­
tries) is important to speed-up system activation. Parallel circuits 
for the referral and transport of patients with suspected STEMI that by­
pass the EMS should be avoided. The ambulance system plays a critical 
role in the early management of patients with suspected STEMI, including 
immediately establishing the initial diagnosis, triage, and treatment.129,141
Ambulances in the EMS must be equipped with ECG recorders, de­
fibrillators, telemetry devices, and at least one person trained in ad­
vanced life support. The quality of the care provided depends on the 
ESC Guidelines                                                                                                                                                                                          3743


<!-- PAGE 25 -->

### Page 25

training of the staff involved. Ambulance personnel must be trained to 
recognize ischaemic symptoms, administer oxygen when appropriate, 
secure intravenous (i.v.) access, effectively relieve pain, administer fi­
brinolysis when indicated, and provide basic life support.142
Ambulance staff should record an ECG as soon as possible for diagnos­
tic purposes and either interpret the ECG or transmit it so that it can be 
reviewed by experienced staff to establish or refute a working diagnosis 
of STEMI. Regular and structured training of ambulance staff is manda­
tory for a high-quality pre-hospital service.
4.1.4. General practitioners
In some countries, primary care clinicians (general practitioners) play an 
important role in the early care of patients with suspected ACS and 
may provide the FMC. Education and training of general practitioners 
in emergency, pre-hospital care is essential for the delivery of optimal 
pre-hospital care in this setting. The responsibilities of the primary 
care clinicians may include diagnosis, activation of the EMS, risk stratifi­
cation, and initiation of pre-hospital treatment. However, in most set­
tings, consultation with a general practitioner instead of a direct call to 
the EMS will increase the pre-hospital delay. Therefore, the public 
should be educated to call the EMS directly rather than a primary 
care physician for symptoms suggestive of ACS.
4.1.5. Organization of ST-elevation myocardial 
infarction treatment in networks
It is recommended that a regional reperfusion strategy is established to 
maximize the efficiency of care for patients with a working diagnosis of 
STEMI.143 The optimal treatment of patients with a working diagnosis 
of STEMI should be based on the implementation of networks between 
hospitals with various levels of clinical service provision (the ‘hub and 
spoke’ model), linked by a prioritized and efficient ambulance service. 
A PCI centre is a multidisciplinary acute care centre that provides emer­
gency invasive management 24/7 for patients presenting with suspected 
STEMI. This centre should also provide intensive care facilities, and 
more advanced centres should offer cardio-thoracic services, advanced 
haemodynamic support, and surgery.
The goal of STEMI networks is to provide optimal care while minimizing 
delays, thereby improving clinical outcomes. Cardiologists should actively 
collaborate with all stakeholders, particularly emergency physicians, in estab­
lishing such networks. The main features of such a network are detailed in 
Supplementary data online, Table S6. It is recommended that the EMS should 
transport patients with a working diagnosis of STEMI to hospitals with a 24/7 
service for PCI, bypassing non-PCI-capable hospitals.144Further information 
on this topic is provided in the Supplementary data online.
Geographic areas where the expected transfer time to the primary 
PCI centre makes it impossible to routinely achieve the maximal allow­
able delays indicated in the recommendations should develop protocols 
for rapid fibrinolysis at the place of STEMI diagnosis, with the aim of 
treatment within 10 min of FMC, followed by immediate transfer to 
a centre with 24/7 service for PCI. Such networks increase the propor­
tion of patients receiving reperfusion with the shortest possible treat­
ment delay.145–147 The quality of care, time delays, and patient 
outcomes should be measured and reported to the healthcare profes­
sionals contributing to the EMS.
4.2. Emergency care
4.2.1. Initial diagnosis and monitoring
Management of ACS starts from the point of FMC, when a working 
diagnosis of ACS is established. The working diagnosis of ACS is usually 
based on symptoms consistent with myocardial ischaemia and the signs 
on a 12-lead ECG (see Section 3.2). It is recommended to initiate ECG 
monitoring as soon as possible in all patients with suspected ACS in or­
der to detect life-threatening arrhythmias and to allow prompt defibril­
lation if indicated.
4.2.2. Acute pharmacotherapy
4.2.2.1. Oxygen
Oxygen supplementation is recommended in ACS patients with hypox­
aemia (oxygen saturations <90%). Oxygen supplementation in patients 
who are not hypoxic (oxygen saturations >90%) is not associated with 
clinical benefits and is therefore not recommended.148,149
4.2.2.2. Nitrates
Sublingual nitrate may be helpful to relieve ischaemic symptoms. 
However, a reduction in chest pain after nitroglycerine administra­
tion can be misleading and is not recommended as a diagnostic man­
oeuvre.150 In patients with an ECG compatible with ongoing STEMI 
and symptom relief after nitroglycerine administration, it is recom­
mended to obtain another 12-lead ECG. Complete normalization 
of ST-segment elevation, along with relief of symptoms, after nitro­
glycerine administration is suggestive of coronary spasm, with or 
without associated MI. Nitrates should not be given to patients 
with hypotension, marked bradycardia or tachycardia, RV infarction, 
known severe aortic stenosis, or phosphodiesterase 5 inhibitor use 
within the previous 24–48 h.
4.2.2.3. Pain relief
Intravenous opioids (e.g. morphine 5–10 mg) should be considered for 
the relief of severe chest pain. Other forms of pain relief (e.g. nitrous 
oxide/oxygen plus i.v. acetaminophen/paracetamol) have been re­
ported to be inferior to morphine.151 However, morphine may en­
hance nausea and vomiting and slow the gastrointestinal absorption 
of oral medicines, which may delay the onset of action of orally admi­
nistered antiplatelet therapy.152,153 Evidence from small-scale trials sug­
gests that i.v. morphine may also reduce myocardial and microvascular 
damage when given to patients with ongoing acute coronary artery oc­
clusion, though co-administration with metoclopramide appears to 
negate this effect. Conversely, morphine has also been reported to re­
duce antiplatelet activity after administration of ticagrelor, though this 
effect was rescued by metoclopramide administration.154,155 The posi­
tive effects of morphine on myocardial damage may potentially be re­
lated to reduced oxygen consumption as a result of decreased 
preload and negative inotropy and chronotropy.
Platelet inhibition induced by oral P2Y12 receptor antagonists may 
be delayed in patients with ongoing MI. Morphine may also further re­
duce absorption, delay the onset of action, and decrease the antipla­
telet effect of oral P2Y12 receptor inhibitors in MI patients, although 
this effect may vary between the different P2Y12 inhibitors.153,156– 
158 Further research is ongoing in this area, but at present it should 
be noted that currently available clinical data have not demonstrated 
any increase in the risk of adverse clinical outcomes as a result of any 
interaction between morphine and antiplatelet agents in the setting of 
ACS.159–161
4.2.2.4. Intravenous beta-blockers
Few RCTs testing early i.v. beta-blockers have been performed in 
the era of invasive management for patients with a working diagnosis 
of STEMI. Not all beta-blockers appear to exert the same


<!-- PAGE 26 -->

### Page 26

cardio-protective effect in the context of ongoing acute coronary oc­
clusion, with metoprolol demonstrating the greatest protective effect 
in experimental studies.162 Intravenous metoprolol is also the most 
widely tested beta-blocker in trials enrolling patients undergoing 
PPCI.163,164 While the long-term clinical benefits associated with early 
i.v. metoprolol administration are not clear, it is safe when used in pa­
tients without signs of acute HF and has been consistently associated 
with a reduction in the incidence of VF and microvascular obstruction 
(MVO).163–171 Based on these data, i.v. beta-blockers (preferably meto­
prolol) should be considered at the time of presentation in patients 
with a working diagnosis of STEMI undergoing PPCI with no signs of 
acute HF, a systolic blood pressure (SBP) >120 mmHg, and without 
other contraindications.163–166,169 Administration of i.v. beta-blockers 
in patients with suspected NSTE-ACS has not been tested.
5. Acute-phase management of 
patients with acute coronary 
syndrome
5.1. Selection of invasive strategy and 
reperfusion therapy
The definitions of the terms related to invasive strategy and reperfusion 
therapy are presented in Table 3.
Depending on the initial assessment of the ECG, the clinical context 
and haemodynamic stability, patients with suspected ACS should be 
classified as either: 
(i) Patients with a working diagnosis of STEMI. These patients should 
be triaged for immediate reperfusion therapy (i.e. a PPCI strategy 
or fibrinolysis if PPCI is not possible within 120 min of diagnosis) 
(Figure 7).
Or
(ii) Patients with a working diagnosis of NSTE-ACS. For these patients: 
• An inpatient invasive strategy is recommended.
• An immediate invasive strategy is recommended when any very 
high-risk feature is present (Figure 8).
• An early (i.e. within 24 h) invasive strategy should be considered 
when any high-risk features are present (Figure 8).
5.2. Acute coronary syndrome managed 
with invasive strategy
Invasive management strategies are time sensitive. It is recommended that 
patients triaged to an immediate invasive strategy (those with high suspi­
cion of ongoing acute coronary artery occlusion [i.e. persistent 
ST-segment elevation or equivalents] or NSTE-ACS with any very high- 
risk characteristics) receive emergency angiography as soon as possible. 
High-risk NSTE-ACS patients (e.g. ruled in as NSTEMI as per the 0 h/1 h 
or 0 h/2 h ESC algorithms, with dynamic ST-segment or T wave changes, 
with transient ST-segment elevation, or with a Global Registry of Acute 
Coronary Events [GRACE] risk score >140) should be considered for 
an early invasive strategy (i.e. undergoing angiography within 24 h).
5.2.1. Primary percutaneous coronary intervention 
strategy for ST-elevation myocardial infarction
In patients with a working diagnosis of STEMI, a PPCI strategy (i.e. im­
mediate angiography and PCI as needed) is the preferred reperfusion 
strategy, provided it can be performed in a timely manner (i.e. within 
Recommendation Table 3 — Recommendations for the 
initial management of patients with acute coronary 
syndrome
Recommendations
Classa
Levelb
Hypoxia
Oxygen is recommended in patients with 
hypoxaemia (SaO2 <90%).
I
C
Routine oxygen is not recommended in patients 
without hypoxaemia (SaO2 >90%).148,172
III
A
Symptoms
Intravenous opioids should be considered to relieve 
pain.
IIa
C
A mild tranquilizer should be considered in very 
anxious patients.
IIa
C
Intravenous beta-blockers
Intravenous beta-blockers (preferably metoprolol) 
should be considered at the time of presentation in 
patients undergoing PPCI with no signs of acute heart 
failure, an SBP >120 mmHg, and no other 
contraindications.163–167,169
IIa
A
Pre-hospital logistics of care
It is recommended that the pre-hospital 
management of patients with a working diagnosis of 
STEMI is based on regional networks designed to 
deliver reperfusion therapy expeditiously and 
effectively, with efforts made to make PPCI available 
to as many patients as possible.145
I
B
It is recommended that PPCI-capable centres deliver 
a 24/7 service and are able to perform PPCI without 
delay.173,174
I
B
It is recommended that patients transferred for PPCI 
bypass the emergency department and CCU/ICU 
and are transferred directly to the catheterization 
laboratory.137,175–178
I
B
It is recommended that EMS transfer patients with 
suspected STEMI to a PCI-capable centre, bypassing 
non-PCI centres.
I
C
Continued
It is recommended that ambulance teams are trained 
and equipped to identify ECG patterns suggestive of 
acute coronary occlusion and to administer initial 
therapy, including defibrillation, and fibrinolysis when 
applicable.142
I
C
It is recommended that all hospitals and EMS 
participating in the care of patients with suspected 
STEMI record and audit delay times and work 
together to achieve and maintain quality targets.
I
C
© ESC 2023
CCU, cardiac care unit; ECG, electrocardiogram; EMS, emergency medical services; ICU, 
intensive care unit; i.v., intravenous; PPCI, primary percutaneous coronary intervention; 
SaO2, saturation of oxygen; SBP, systolic blood pressure; STEMI, ST-elevation myocardial 
infarction. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3745


<!-- PAGE 27 -->

### Page 27

120 min of the ECG-based diagnosis, Figure 7). RCTs have shown that if 
the delay to treatment is similar, PPCI is superior to fibrinolysis in reducing 
mortality, non-fatal reinfarction, and stroke.52,179 However, in some cir­
cumstances, PPCI is not an immediate option and fibrinolysis should be 
initiated expeditiously as part of a pharmaco-invasive strategy, provided 
the patient has presented within 12 h of symptom onset (see Section 5.3).
There is a lack of contemporaneous data to inform the treatment delay 
limit at which the advantage of PCI over fibrinolysis is lost. For simplicity, an 
absolute time of 120 min from STEMI diagnosis to PCI-mediated reperfu­
sion (i.e. wire crossing of the infarct-related artery [IRA]) rather than a rela­
tive PCI-related delay over fibrinolysis has been chosen. Given the 
recommended time interval of 10 min from STEMI diagnosis to administra­
tion of a bolus of fibrinolytics (see below), the 120 min absolute time delay 
would correspond to a relative PCI-related delay in the range of 110– 
120 min. This is within the range of the times identified as the limit of delay 
below which PCI should be chosen in older studies and registries.176,180–184
For patients who undergo fibrinolysis, rescue PCI is indicated if fibrin­
olysis fails (i.e. ST-segment resolution <50% within 60–90 min of fi­
brinolytic administration) or in the presence of haemodynamic or 
electrical instability, worsening ischaemia, or persistent chest 
pain.184,185 Patients with successful fibrinolysis should undergo early 
invasive angiography (i.e. within 2–24 h from the time of the lytic bolus 
injection) (see Section 5.3).186
Patients with a working diagnosis of STEMI who present to a 
non-PCI centre should be immediately transferred to a PCI-capable 
centre (Figure 7) for a timely PPCI strategy. If PPCI is not feasible within 
120 min, patients should undergo immediate fibrinolysis followed by 
transfer to a PCI centre without waiting for signs of reperfusion. For 
patients presenting after 12 h from symptom onset, a PPCI strategy 
is preferred over fibrinolysis in all cases.
Emergency coronary artery bypass grafting (CABG) surgery should 
be considered for patients with a patent IRA but with unsuitable anat­
omy for PCI, and either a large myocardial area at jeopardy or with CS. 
In patients with MI-related mechanical complications who require cor­
onary revascularization, CABG is recommended at the time of surgical 
repair. In STEMI patients with failed PCI or with an acute coronary oc­
clusion not amenable to PCI, emergency CABG is infrequently per­
formed because the benefits of surgical revascularization in this 
setting are less certain.185,187,188 Because there will be a delay to reper­
fusion with CABG in this situation, the probability of myocardial salvage 
to a degree sufficient to impact on prognosis is considered low. In add­
ition, the surgical risks of CABG in this setting may be elevated.
Onset of symptoms
FMC
location
Mode of 
FMC
Patient self presents to hospital
PCI centre
Non-PCI centre
Ambulance
Patient calls 
EMS
or or
Patient with symptoms of ACS and
ECG consistent with STEMI
Total 
ischaemic 
time
Patient self 
presents
Patient calls
 EMS
PPCI
strategy
Reperfusion
PPCI
strategy
Fibrinolysis strategy
Immediate transfer 
to PCI centre for primary PCI
Immediate transfer 
to PCI centre
 after fibrinolysis
Patient delay
System delay
EMS delay
Total ischaemic time
YES
NO
Aim: 
<60 min to wire crossing 
Determine 
therapeutic 
strategy
Aim:
<90 min to wire crossing
Aim:
<10 min to lytic bolus
PCI possible in <120 min?
Total ischaemic time and sources of delay to reperfusion
Figure 7 Modes of presentation and pathways to invasive management and myocardial revascularization in patients presenting with STEMI. ACS, acute 
coronary syndrome; ECG, electrocardiogram; EMS, emergency medical services; FMC, first medical contact; PCI, percutaneous coronary intervention; 
PPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.


<!-- PAGE 28 -->

### Page 28

5.2.1.1. Invasive strategy in ST-elevation myocardial infarction late 
presenters
While routine immediate angiography and PCI (if indicated) are clearly 
associated with clinical benefit in patients presenting within 12 h of 
symptom onset, the value of a routine PPCI strategy in STEMI patients 
presenting later than 12 h after symptom onset is less well established.
A small RCT in 347 STEMI patients presenting 12–48 h after symp­
tom onset and without persistent symptoms reported that a routine 
PPCI strategy improved myocardial salvage and long-term survival com­
pared with conservative treatment.189,190 This observation is supported 
by a recent analysis of data from three nationwide observational studies 
from the FAST-MI (French Registry of Acute ST-elevation and 
non-ST-elevation Myocardial Infarction) programme, which showed a 
significant lower rate of all-cause death at 1 month (2.1% vs. 7.2%) 
and after a median follow-up of 58 months (30.4% vs. 78.7%) with an in­
vasive strategy in comparison to conservative treatment.191 However, in 
stable patients with persistent occlusion of the IRA 3–28 days after MI, 
the large (n = 2166) Occluded Artery Trial (OAT) reported no clinical 
benefit from routine coronary intervention with medical management in 
comparison to medical management alone.192,193 A meta-analysis of 
trials testing whether late recanalization of an occluded IRA is beneficial 
also showed no benefit of reperfusion.194 Therefore, routine PCI of an 
occluded IRA in STEMI patients presenting >48 h after onset of symp­
toms and without persistent symptoms is not indicated.192,193 These pa­
tients should be managed in the same way as patients with chronic total 
occlusion according to the ESC Guidelines for the diagnosis and manage­
ment of chronic coronary syndromes (CCS).195
5.2.2. Immediate invasive strategy for non-ST 
elevation acute coronary syndrome
An immediate invasive strategy refers to emergency (i.e. as soon as pos­
sible) angiography and PCI if indicated. This is recommended for pa­
tients with a working diagnosis of NSTE-ACS and any of the 
following very high-risk criteria: 
• Haemodynamic instability or CS.
• Recurrent or ongoing chest pain refractory to medical treatment.
• Acute HF presumed secondary to ongoing myocardial ischaemia.
• Life-threatening arrhythmias or cardiac arrest after presentation.
• Mechanical complications.
• Recurrent dynamic ECG changes suggestive of ischaemia (particularly 
with intermittent ST-segment elevation).
5.2.3. Routine vs. selective invasive strategy
A routine invasive strategy with inpatient coronary angiography is re­
commended for patients with a confirmed diagnosis of NSTEMI or a 
working diagnosis of NSTE-ACS and a high index of suspicion for 
UA. In patients with a working diagnosis of NSTE-ACS, multiple 
RCTs comparing routine vs. selective invasive strategies have been 
conducted and their results have been pooled in several meta- 
analyses.196–200 The available evidence indicates that a routine invasive 
strategy does not reduce all-cause mortality risk in the overall popula­
tion of NSTE-ACS patients, but reduces the risk of composite ischae­
mic endpoints, particularly in high-risk patients. A routine invasive 
strategy can increase the risk of peri-procedural complications and 
bleeding. However, most of the available evidence is based on old 
RCTs that were conducted before the implementation of several im­
portant developments in PCI, including radial access, modern 
drug-eluting stents (DES), complete functional revascularization for 
multivessel disease (MVD), improved co-adjuvant pharmacological 
therapies, and contemporary biomarker assays.
5.2.3.1. Early vs. delayed invasive strategy for non-ST elevation acute 
coronary syndrome
An early invasive strategy refers to routine invasive angiography (and 
PCI if needed) within 24 h of presentation. This should be considered 
in patients with a working diagnosis of NSTE-ACS and any of the fol­
lowing high-risk criteria: 
• A confirmed diagnosis of NSTEMI based on current recommended 
ESC hs-cTn algorithms.
• Dynamic ST-segment or T wave changes.
• Transient ST-segment elevation.
• A GRACE risk score >140.
Several meta-analyses have pooled data from multiple RCTs assessing 
different timing intervals of invasive angiography among NSTE-ACS pa­
tients. None of these studies observed superiority of early invasive strat­
egies compared with routine invasive strategies for death or non-fatal MI, 
although early invasive strategies were associated with a lower risk 
of recurrent/refractory ischaemia and a shorter duration of hospital 
stay.201–203 A collaborative meta-analysis comparing an early vs. a delayed 
invasive strategy using a modified individual patient data approach ob­
served no difference in mortality overall but a survival benefit in high-risk 
patients, including those with a GRACE risk score >140 and those with 
positive troponin, although tests for interaction were inconclusive.202
The largest meta-analysis to date (17 RCTs >10 000 patients) reported 
that, in all-comers with NSTE-ACS, early ICA only significantly reduced 
the risk of recurrent ischaemia and duration of stay, with no significant re­
ductions in all-cause mortality, MI, admission for HF, or repeat revascular­
ization.203 The main limitation of the interpretation of meta-analyses of 
these RCTs is the variability of the time to invasive angiography in the in­
dividual trials: while invasive angiography was virtually always performed 
within 24 h of randomization in the early invasive strategy groups, the 
time from randomization to angiography was heterogeneous in the de­
layed invasive groups. In many trials, delayed angiography was performed 
within 24 h of randomization (albeit later than in the early angiography 
arm of the respective trial). Additionally, the diagnosis of NSTEMI was 
not based on the current recommended ESC hs-cTn algorithms. 
Moreover, studies assessing the value of a GRACE risk score >140 to 
guide the timing of ICA and revascularization in the era of hs-cTn for 
the diagnosis of NSTEMI are lacking. Further detail on the interaction be­
tween treatment effect according to GRACE score and its components in 
individual trials is provided in the Supplementary data online. Data from 
observational studies is concordant with trial data, without a strong signal 
of benefit with early versus delayed coronary angiography.204
A selective invasive approach after appropriate ischaemia testing or 
detection of obstructive CAD by CCTA is recommended in patients 
without very high- or high-risk features and a low index of suspicion 
for NSTE-ACS. These patients should be managed as per the ESC 
Guidelines for the management of CCS.195 A selective invasive ap­
proach is also appropriate for patients with NSTEMI or UA who are 
not deemed good candidates for coronary angiography.
5.2.4. Summary of invasive strategies for patients 
with non-ST elevation acute coronary syndrome
In summary, very high-risk NSTE-ACS patients are recommended to 
undergo an immediate invasive strategy with emergency angiography 
ESC Guidelines                                                                                                                                                                                          3747


<!-- PAGE 29 -->

### Page 29

and PCI if required. High-risk NSTE-ACS patients are recommended 
to undergo an inpatient invasive strategy and should be considered 
for an early invasive strategy (i.e. within 24 h). For patients who do 
not meet any of the very high-risk or high-risk criteria (generally 
patients with clinical suspicion for NSTE-ACS and non-elevated tro­
ponins or patients with elevated troponins not meeting the criteria 
for MI), the strategy can be tailored based on the degree of clinical 
suspicion. For patients with a high index of suspicion for UA, an 
FMC
FMC
location
PCI centre
Non-PCI centre
Ambulance
Immediate transfer
Early/inpatient transfer or
Very high riska
Very high risk
Risk stratify and determine 
therapeutic 
strategy 
Inpatient transfer
In patients without very-high or high-risk features and a low index of suspicion for unstable angina
(if required)
High riska
High risk
Non-high risk
Selective invasive strategy 
(Class I)
Inpatient invasive
 strategy
(Class I)
Inpatient invasive
 strategy
(Class I)
Early (<24 h)
invasive strategy
(Class IIa)
Immediate invasive strategy
(Class I)
Non-high risk
Patient with symptoms of ACS and ECG consistent with NSTE-ACS
Haemodynamic instability or cardiogenic shock
Recurrent or ongoing chest pain refractory to medical treatment
Acute heart failure presumed secondary to ongoing myocardial ischaemia
Life-threatening arrhythmias or cardiac arrest after presentation
Mechanical complications
Recurrent dynamic ECG changes suggestive of ischaemia
Confirmed diagnosis of NSTEMI based on ESC algorithms
GRACE risk score >140
Transient ST-segment elevation
Dynamic ST-segment or T wave changes
Figure 8 Selection of invasive strategy and reperfusion therapy in patients presenting with NSTE-ACS. ACS, acute coronary syndrome; CS, cardiogenic 
shock; ECG, electrocardiogram; FMC, first medical contact; GRACE, Global Registry of Acute Coronary Events; hs-cTn, high-sensitivity cardiac troponin; 
NSTE-ACS, non-ST-elevation acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; UA, 
unstable angina. This figure summarizes the selection of invasive strategy and reperfusion therapy in patients presenting with ACS. aRisk criteria: Patients 
who meet any one of the ‘very high-risk’ NSTE-ACS criteria should undergo an immediate invasive strategy; these very high-risk criteria include haemo­
dynamic instability or CS, recurrent or refractory chest pain despite medical treatment, life-threatening arrhythmias, mechanical complications of MI, HF 
clearly related to ACS, and recurrent dynamic ST-segment or T wave changes, particularly with intermittent ST-segment elevation. Patients with 
NSTE-ACS who meet any of the ‘high-risk’ criteria (confirmed NSTEMI as per the hs-cTn-based ESC algorithm, NSTE-ACS with GRACE score >140, dy­
namic ST-segment or T wave changes, or transient ST-segment elevation) should be considered for early invasive angiography (i.e. within 24 h) and should 
undergo an inpatient invasive strategy. An invasive strategy during hospital admission is recommended in NSTE-ACS patients with high-risk criteria or with a 
high index of suspicion for UA. In selected patients a selective invasive strategy can also be an option. See Recommendation Table 4 for full details.


<!-- PAGE 30 -->

### Page 30

inpatient invasive strategy is recommended. Conversely, for patients 
with a low index of suspicion, a selective invasive approach is 
recommended.
5.3. Fibrinolysis and pharmaco-invasive 
strategy in patients with ST-elevation 
myocardial infarction
5.3.1. Benefit and indication of fibrinolysis
Fibrinolytic therapy is an important reperfusion strategy for STEMI pa­
tients presenting within 12 h of symptom onset when PPCI cannot be 
performed in a timely manner; it prevents 30 early deaths per 1000 pa­
tients treated within 6 h of symptom onset.205 The largest absolute treat­
ment benefit is seen among those patients at the highest risk, including the 
elderly. Successful reperfusion is generally associated with significant im­
provement in ischaemic symptoms, ≥50% ST-segment resolution, 
and haemodynamic stability. The doses of fibrinolytic agents and concomi­
tant antithrombotic therapies are given in the Fibrinolysis and Pharmaco- 
invasive Strategy provided in the Supplementary data online, Section 6.3.
5.3.1.1. Pre-hospital fibrinolysis
If trained medical or allied health staff can interpret the ECG on site, or 
transmit the ECG for remote interpretation, it is recommended to ini­
tiate fibrinolytic therapy in the pre-hospital setting. A fibrin-specific 
agent (i.e. tenecteplase, alteplase, or reteplase) is the preferred agent. 
The goal is to start fibrinolytic therapy within 10 min of the STEMI diag­
nosis. Fibrinolytic therapy initiation should not be delayed by waiting for 
the results of cardiac biomarker testing. In a meta-analysis of six rando­
mized trials (n = 6434), pre-hospital fibrinolysis compared with in- 
hospital fibrinolysis reduced early mortality by 17%, particularly when 
administered in the first 2 h after symptom onset.51,206 These, and 
more recent, data support the pre-hospital initiation of fibrinolytic 
treatment when a reperfusion strategy is indicated.145,207–209 The 
STREAM (Strategic Reperfusion Early After Myocardial Infarction) trial 
demonstrated that pre-hospital fibrinolysis followed by an early PCI 
strategy was associated with a similar outcome to transfer for PPCI 
in STEMI patients presenting within 3 h of symptom onset who could 
not undergo PPCI within 1 h of FMC, although a slight excess of intra­
cranial bleeding was observed with the investigational strategy.184,210
This excess in intracranial bleeding was blunted by halving the dose 
of tenecteplase in patients >75 years of age.
5.3.1.2. Angiography and percutaneous coronary intervention after 
fibrinolysis (pharmaco-invasive strategy)
It is recommended that patients should be transferred to a PCI centre 
immediately after initiation of lytic therapy (Figure 7). In cases of failed 
fibrinolysis or evidence of re-occlusion or re-infarction with recurrence 
of ST-segment elevation, immediate angiography and rescue PCI are in­
dicated.185,211 In this setting, re-administration of fibrinolysis is not 
beneficial and is discouraged.185 Even if it is likely that fibrinolysis is suc­
cessful (e.g. ST-segment resolution >50% at 60–90 min; typical reper­
fusion arrhythmia; and disappearance of chest pain), routine early 
angiography (i.e. within 2–24 h) is recommended. Several randomized 
trials have shown that routine early angiography with subsequent PCI 
(if required) after fibrinolysis reduced the rates of re-infarction and re­
current ischaemia in comparison to a ‘watchful waiting’ strategy (i.e. a 
strategy in which angiography and revascularization were performed 
only in patients with spontaneous or induced severe ischaemia or LV 
dysfunction, or in patients with a positive outpatient ischaemia 
test).186,209,212–215 A network meta-analysis including 15 357 STEMI pa­
tients treated with fibrinolytic therapy (n = 4212), PPCI (n = 6139), or 
fibrinolysis followed by routine immediate or early PCI (n = 5006) in­
vestigated whether STEMI patients should be transferred to a 
PCI-capable facility immediately (defined as a facilitated PCI approach) 
or within a day (e.g. <24 h, defined as a pharmaco-invasive ap­
proach).209 After PPCI, the pharmaco-invasive strategy was the second 
most favourable approach, with an odds ratio (OR) for death of 0.79 
(95% confidence interval [CI], 0.59–1.08) compared with conventional 
fibrinolytic therapy. This supports the safety of transferring STEMI pa­
tients to a PCI-capable centre for angiography within 2–24 h. The bene­
fit of routine early PCI after fibrinolysis was demonstrated without an 
increased risk of adverse events (stroke or major bleeding), and across 
the spectrum of the investigated patient subgroups.209,216 Therefore, 
early angiography with subsequent PCI if required is the recommended 
standard of care after successful fibrinolysis (Figure 7). Observational 
analysis of registry data has also provided some further support for 
the use of a pharmaco-invasive strategy.130
The optimal time delay between successful fibrinolysis and PCI has 
not been clearly defined; there has been a wide variation in this time 
delay in trials, ranging from a median of 1.3 to 17 h.184,185,206,215,217
Based on these data, a time window for PCI of 2–24 h after successful 
lysis is recommended.
5.3.1.2.1. Comparison of fibrinolytic agents. Some information on 
comparisons of fibrinolytic agents is provided in the Supplementary 
data online, Section 6.3.1.
5.3.1.2.2. Hazards of fibrinolysis and contraindications. Some infor­
mation regarding the hazards of, and contraindications to, fibrinolysis is 
provided in the Supplementary data online, Section 6.3.2.
5.4. Patients not undergoing reperfusion
The management of ACS patients not undergoing reperfusion is dis­
cussed in the Supplementary data online, Section 5.2.
5.4.1. Patients who are not candidates for invasive 
coronary angiography
Information regarding the management of NSTE-ACS patients who are 
not candidates for invasive angiography is provided in the 
Supplementary data online, Section 5.2.1.
5.4.2. Patients with coronary artery disease not 
amenable to revascularization
Information regarding the management of ACS patients with CAD that 
is not amenable to revascularization is provided in the Supplementary 
data online, Section 5.2.2.
ESC Guidelines                                                                                                                                                                                          3749


<!-- PAGE 31 -->

### Page 31

### 6 Antithrombotic therapy

Antithrombotic treatment is an important component of the manage­
ment of all patients presenting with ACS. The specific choice and com­
bination of therapy, the time of its initiation, and the treatment duration 
depend on various patient and procedural factors. Treatment decisions 
must be made weighing the benefits of antithrombotic therapy against 
the risk of bleeding, including severe, life-threatening bleeding.231,232
Recommended anticoagulant and antiplatelet drugs and their dosing 
(for use during and after ACS) are summarized in Table 6 and illustrated 
in Figure 9.
Recommendation Table 4 — Recommendations for re­
perfusion therapy and timing of invasive strategy
Recommendations
Classa
Levelb
Recommendations for reperfusion therapy for patients with 
STEMI
Reperfusion therapy is recommended in all patients 
with a working diagnosis of STEMI (persistent 
ST-segment elevation or equivalentsc) and symptoms 
of ischaemia of ≤12 h duration.51,182
I
A
A PPCI strategy is recommended over fibrinolysis if 
the anticipated time from diagnosis to PCI is 
<120 min.52,218,219
I
A
If timely PPCI (<120 min) cannot be performed in 
patients with a working diagnosis of STEMI, 
fibrinolytic therapy is recommended within 12 h of 
symptom onset in patients without 
contraindications.176,183
I
A
Rescue PCI is recommended for failed fibrinolysis 
(i.e. ST-segment resolution <50% within 60–90 min 
of fibrinolytic administration) or in the presence of 
haemodynamic or electrical instability, worsening 
ischaemia, or persistent chest pain.184,185
I
A
In patients with a working diagnosis of STEMI and a 
time from symptom onset >12 h, a PPCI strategy is 
recommended in the presence of ongoing symptoms 
suggestive of ischaemia, haemodynamic instability, or 
life-threatening arrhythmias.220
I
C
A routine PPCI strategy should be considered in 
STEMI patients presenting late (12–48 h) after 
symptom onset.189–191,221
IIa
B
Routine PCI of an occluded IRA is not recommended 
in STEMI patients presenting >48 h after symptom 
onset and without persistent symptoms.189,192,193
III
A
Transfer/interventions after fibrinolysis
Transfer to a PCI-capable centre is recommended in 
all patients immediately after fibrinolysis.184– 
186,212,213,222–224
I
A
Emergency angiography and PCI of the IRA, if 
indicated are recommended in patients with 
new-onset or persistent heart failure/shock after 
fibrinolysis.185,225
I
A
Angiography and PCI of the IRA, if indicated, is 
recommended between 2 and 24 h after successful 
fibrinolysis.186,212,213,217,224
I
A
Continued
Invasive strategy in NSTE-ACS
An invasive strategy during hospital admission is 
recommended in NSTE-ACS patients with high-risk 
criteria or a high index of suspicion for unstable 
angina.196–200
I
A
A selective invasive approach is recommended in 
patients without very high- or high-risk NSTE-ACS 
criteria and with a low index of suspicion for 
NSTE-ACS.196–200
I
A
An immediate invasive strategy is recommended in 
patients with a working diagnosis of NSTE-ACS and 
with at least one of the following very high-risk 
criteria: 
• Haemodynamic instability or cardiogenic shock
• Recurrent or refractory chest pain despite medical 
treatment
• In-hospital life-threatening arrhythmias
• Mechanical complications of MI
• Acute heart failure presumed secondary to 
ongoing myocardial ischaemia
• Recurrent dynamic ST-segment or T wave changes, 
particularly intermittent ST-segment elevation.
I
C
An early invasive strategy within 24 h should be 
considered in patients with at least one of the 
following high-risk criteria: 
• Confirmed diagnosis of NSTEMI based on current 
recommended ESC hs-cTn algorithms
• Dynamic ST-segment or T wave changes
• Transient ST-segment elevation
• GRACE risk score >140202,226–230
IIa
A
© ESC 2023
ACS, acute coronary syndrome; ECG, electrocardiogram; ESC, European Society of 
Cardiology; GRACE, Global Registry of Acute Coronary Events; hs-cTn, high-sensitivity 
cardiac troponin; IRA, infarct-related artery; MI, myocardial infarction; NSTE-ACS, 
non-ST-elevation acute coronary syndrome; NSTEMI, non-ST-elevation myocardial 
infarction; PPCI, primary percutaneous coronary intervention; STEMI, ST-elevation 
myocardial infarction. 
aClass of recommendation. 
bLevel of evidence. 
cST-segment elevation equivalents are presented in Supplementary data online, Figure S2.


<!-- PAGE 32 -->

### Page 32

Table 6 Dose regimen of antiplatelet and anticoagulant drugs in acute coronary syndrome patients
I. Antiplatelet drugs
Aspirin
LD of 150–300 mg orally or 75–250 mg i.v. if oral ingestion is not possible, followed by oral MD of 75–100 mg o.d.; no specific dose adjustment in 
CKD patients.
P2Y12 receptor inhibitors (oral or i.v.)
Clopidogrel
LD of 300–600 mg orally, followed by an MD of 75 mg o.d.; no specific dose adjustment in CKD patients. 
Fibrinolysis: at the time of fibrinolysis an initial dose of 300 mg (75 mg for patients older than 75 years of age).
Prasugrel
LD of 60 mg orally, followed by an MD of 10 mg o.d. In patients with body weight <60 kg, an MD of 5 mg o.d. is recommended. In patients aged 
≥75 years, prasugrel should be used with caution, but a MD of 5 mg o.d. should be used if treatment is deemed necessary. No specific dose 
adjustment in CKD patients. Prior stroke is a contraindication for prasugrel.
Ticagrelor
LD of 180 mg orally, followed by an MD of 90 mg b.i.d.; no specific dose adjustment in CKD patients.
Cangrelor
Bolus of 30 mcg/kg i.v. followed by 4 mcg/kg/min infusion for at least 2 h or the duration of the procedure (whichever is longer). 
In the transition from cangrelor to a thienopyridine, the thienopyridine should be administered immediately after discontinuation of cangrelor 
with an LD (clopidogrel 600 mg or prasugrel 60 mg); to avoid a potential DDI, prasugrel may also be administered 30 min before the cangrelor 
infusion is stopped. Ticagrelor (LD 180 mg) should be administered at the time of PCI to minimize the potential gap in platelet inhibition during 
the transition phase.
GP IIb/IIIa receptor inhibitors (i.v.)
Eptifibatide
Double bolus of 180 mcg/kg i.v. (given at a 10-min interval) followed by an infusion of 2.0 mcg/kg/min for up to 18 h. 
For CrCl 30–50 mL/min: first LD, 180 mcg/kg i.v. bolus (max 22.6 mg); maintenance infusion, 1 mcg/kg/min (max 7.5 mg/h). Second LD (if PCI), 
180 mcg/kg i.v. bolus (max 22.6 mg) should be administered 10 min after the first bolus. Contraindicated in patients with end-stage renal disease 
and with prior ICH, ischaemic stroke within 30 days, fibrinolysis, or platelet count <100 000/mm3.
Tirofiban
Bolus of 25 mcg/kg i.v. over 3 min, followed by an infusion of 0.15 mcg/kg/min for up to 18 h. 
For CrCl ≤60 mL/min: LD, 25 mcg/kg i.v. over 5 min followed by a maintenance infusion of 0.075 mcg/kg/min continued for up to 18 h. 
Contraindicated in patients with prior ICH, ischaemic stroke within 30 days, fibrinolysis, or platelet count <100 000/mm3.
II. Anticoagulant drugs
UFH
Initial treatment: i.v. bolus 70–100 U/kg followed by i.v. infusion titrated to achieve an aPTT of 60–80 s. 
During PCI: 70–100 U/kg i.v. bolus or according to ACT in case of UFH pre-treatment.
Enoxaparin
Initial treatment: for treatment of ACS 1 mg/kg b.i.d. subcutaneously for a minimum of 2 days and continued until clinical stabilization. In patients 
whose CrCl is below 30 mL per minute (by Cockcroft–Gault equation), the enoxaparin dosage should be reduced to 1 mg per kg o.d. 
During PCI: for patients managed with PCI, if the last dose of enoxaparin was given less than 8 h before balloon inflation, no additional dosing is 
needed. If the last s.c. administration was given more than 8 h before balloon inflation, an i.v. bolus of 0.3 mg/kg enoxaparin sodium should be 
administered.
Bivalirudin
During PPCI: 0.75 mg/kg i.v. bolus followed by i.v. infusion of 1.75 mg/kg/h for 4 h after the procedure. 
In patients whose CrCl is below 30 mL/min (by Cockcroft–Gault equation), maintenance infusion should be reduced to 1 mg/kg/h.
Fondaparinux
Initial treatment: 2.5 mg/d subcutaneously. 
During PCI: A single bolus of UFH is recommended. 
Avoid if CrCl <20 mL/min.
© ESC 2023
ACS, acute coronary syndrome; ACT, activated clotting time; aPPT, activated partial thromboplastin time; b.i.d., bis in die (twice a day); CKD, chronic kidney disease; CrCl, creatinine 
clearance; DDI, drug–drug interactions; ICH, intracranial haemorrhage; i.v. intravenous; LD, loading dose; MD, maintenance dose; o.d., once a day; PPCI, primary percutaneous coronary 
intervention; s.c. subcutaneous; UFH, unfractionated heparin.
ESC Guidelines                                                                                                                                                                                          3751


<!-- PAGE 33 -->

### Page 33

6.1. Antiplatelet therapy in the acute 
phase
6.1.1. Oral antiplatelet therapy
Antiplatelet drugs play a key role in the acute phase of treatment for 
ACS. Table 6 summarizes the dosing regimens of the available oral 
and i.v. antiplatelet drugs. The choice of antiplatelet regimen should 
take the bleeding risk of the patient into account. Factors associated 
with an elevated bleeding risk have been detailed by the Academic 
Research Consortium on High Bleeding Risk (ARC-HBR).233 The 
presence of one major or two minor ARC-HBR risk factors indicates 
high bleeding risk (HBR). Of note, the presence of multiple major risk 
factors is associated with a progressive increase in the bleeding risk.234
Aspirin treatment is started with a loading dose (LD) as soon as pos­
sible, followed by maintenance treatment (Table 6).235 Current evi­
dence supports an aspirin maintenance dose (MD) of 75–100 mg 
once a day (o.d.).236,237
Based on the results of the phase III PLATelet inhibition and patient 
Outcomes (PLATO) and TRial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet InhibitioN with Prasugrel 
Eptifibatide
Tirofiban
Clopidogrel
Aspirin
Ticagrelor
Prasugrel
Cangrelor
Rivaroxaban
Apixaban
Edoxaban
UFH
Enoxaparin
Dabigatran
Bivalirudin
Fondaparinux
GP IIb/IIIa
TxA2
P2Y12 receptor
Thromboxane receptor
Thrombin receptor
ADP
P
P
Plaque rupture or plaque erosion
Platelet activation
TF:FVIIa
Aggregation of activated platelets
Fibrinogen
Fibrin
FXa
Thrombin
Mature fibrin clot
Figure 9 Antithrombotic treatments in acute coronary syndrome: pharmacological targets. ADP, adenosine diphosphate; FVIIa, Factor VIIa; FXa, Factor Xa; 
GP, glycoprotein; TF, tissue factor; TxA2, thromboxane A2; UFH, unfractionated heparin. Drugs with oral administration are shown in blue and drugs with 
preferred parenteral administration in red.


<!-- PAGE 34 -->

### Page 34

Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) studies, 
dual antiplatelet therapy (DAPT) including aspirin and a potent P2Y12 
receptor inhibitor (prasugrel or ticagrelor) is recommended as the de­
fault DAPT strategy for ACS patients.238,239 Clopidogrel, which is char­
acterized by less effective and more variable platelet inhibition, should 
only be used when prasugrel or ticagrelor are contraindicated/not avail­
able, or in some patients considered otherwise at HBR (e.g. ≥1 major 
or ≥2 minor ARC-HBR criteria).233,240–242 In addition, the use of clopi­
dogrel may be considered in older patients (e.g. ≥70 years).242,243
Prasugrel should be considered in preference to ticagrelor for ACS 
patients who proceed to PCI. The Intracoronary Stenting and 
Antithrombotic Regimen Rapid Early Action for Coronary Treatment 
(ISAR-REACT) 5 RCT is the largest head-to-head comparison of 1-year 
DAPT with prasugrel vs. DAPT with ticagrelor in patients with ACS 
planned for invasive evaluation, >80% of whom underwent PCI.244 A 
treatment strategy with prasugrel (LD given as soon as possible after ran­
domization for patients undergoing PPCI and after delineation of coron­
ary anatomy for patients presenting with NSTE-ACS) vs. ticagrelor (LD 
given as soon as possible after randomization in all cases) significantly re­
duced the composite endpoint of death, MI, or stroke (6.9% vs. 9.3%, P =  
0.006) without any increase in bleeding complications (4.8% vs. 5.4%, P =  
0.46). Limitations of this study include an open-label design and limited 
data on medically managed or CABG-treated patients.
6.1.2. Timing of loading dose of oral antiplatelet 
therapy
Both aspirin and oral P2Y12 inhibitors achieve platelet inhibition more 
rapidly following an oral LD. Pre-treatment refers to a strategy in which 
an antiplatelet drug, usually a P2Y12 receptor inhibitor, is given before 
coronary angiography and, therefore, before the coronary anatomy is 
known. Although a potential benefit with pre-treatment in the setting 
of ACS has been hypothesized, large-scale randomized trials supporting 
a routine pre-treatment strategy with P2Y12 receptor inhibitors are 
lacking. Caution in relation to pre-treatment may be of particular rele­
vance in patients at HBR (e.g. those receiving an oral anticoagulant 
[OAC]).
6.1.2.1. Pre-treatment in patients with suspected ST-elevation 
myocardial infarction
The Administration of Ticagrelor in the Cath Lab or in the Ambulance 
for New ST Elevation Myocardial Infarction to Open the Coronary 
Artery (ATLANTIC) trial is the only randomized study testing the 
safety and efficacy of different timings of P2Y12 receptor inhibitor initi­
ation in patients with a working diagnosis of STEMI undergoing PPCI.245
In this trial, patients were randomized to receive a ticagrelor LD either 
during transfer to a PPCI centre or immediately before angiography.245
The median difference between the timing of P2Y12 receptor inhibitor 
loading with the two treatment strategies was 31 min. In this study, the 
pre-treatment strategy failed to meet the pre-specified primary end­
point of improved ST-segment elevation resolution or Thrombolysis 
In Myocardial Infarction (TIMI) flow before intervention. Rates of major 
and minor bleeding events were identical in both treatment arms. 
These results were supported by real-world data obtained from the 
SWEDEHEART (Swedish Web-System for Enhancement and 
Development of Evidence-Based Care in Heart Disease Evaluated 
According to Recommended Therapies) registry in STEMI patients.246
Prasugrel pre-treatment has not been directly investigated in patients 
with STEMI.
6.1.2.2. Pre-treatment in patients with non-ST-elevation acute 
coronary syndrome
The randomized A Comparison of Prasugrel at the Time of 
Percutaneous Coronary Intervention or as Pretreatment at the Time 
of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction 
(ACCOAST) trial not only demonstrated a lack of benefit with respect 
to ischaemic outcomes with prasugrel pre-treatment, but also a sub­
stantially higher bleeding risk.247 In this study, the median time from first 
LD to the start of coronary angiography in the pre-treatment group 
was 4.4 h. With respect to pre-treatment data for ticagrelor, the 
ISAR-REACT 5 trial showed that a ticagrelor-based strategy with rou­
tine pre-treatment was inferior to a prasugrel-based strategy with a de­
ferred LD in NSTE-ACS patients.244 The DUBIUS (Downstream 
Versus Upstream Strategy for the Administration of P2Y12 Receptor 
Blockers) trial also attempted to address this question but was stopped 
early for futility as there was no difference between upstream vs. down­
stream oral P2Y12 administration in patients with NSTE-ACS (both 
NSTEMI and UA) scheduled for coronary angiography within 72 h of 
hospital admission.248
6.1.2.3. Summary of pre-treatment strategies
In patients with a working diagnosis of STEMI undergoing PPCI, pre- 
treatment with a P2Y12 receptor inhibitor may be considered.245 In pa­
tients with a working diagnosis of NSTE-ACS, routine pre-treatment 
with a P2Y12 receptor inhibitor before knowing the coronary anatomy 
in patients anticipated to undergo an early invasive strategy (i.e. <24 h) 
is not recommended.244,245,247 For patients with a working diagnosis of 
NSTE-ACS, where there is an anticipated delay to invasive angiography 
(i.e. >24 h), pre-treatment with a P2Y12 receptor inhibitor may be con­
sidered according to the bleeding risk of the patient. In all ACS patients 
proceeding to PCI who did not receive P2Y12 receptor inhibitor pre- 
treatment, an LD is recommended at the time of PCI.
6.1.3. Intravenous antiplatelet drugs
Peri-interventional i.v. antiplatelet drugs include P2Y12 receptor inhibi­
tors (cangrelor) and glycoprotein (GP) IIb/IIIa inhibitors (eptifibatide 
and tirofiban). Most of the trials evaluating GP IIb/IIIa inhibitors in 
PCI-treated ACS patients pre-date the era of routine DAPT, in particu­
lar, early initiation of DAPT including an LD of a potent P2Y12 receptor 
inhibitor.249,250 There is no strong evidence for any additional benefit 
with the routine use of GP IIb/IIIa inhibitors in ACS patients scheduled 
for coronary angiography. Nevertheless, their use should be considered 
for bailout if there is evidence of no-reflow or a thrombotic complica­
tion during PCI. Another potential use for GP IIb/IIIa inhibitors is in the 
setting of high-risk PCI in patients who have not been pre-treated with 
P2Y12 receptor inhibitors.
Cangrelor is a direct reversible, short-acting P2Y12 receptor inhibitor 
that has been evaluated during PCI for CCS and ACS in clinical trials 
against clopidogrel, both with administration before (Cangrelor versus 
Standard Therapy to Achieve Optimal Management of Platelet 
Inhibition [CHAMPION PCI]) and after (CHAMPION PLATFORM 
and CHAMPION PHOENIX [A Clinical Trial Comparing Cangrelor 
to Clopidogrel Standard Therapy in Subjects Who Require 
Percutaneous Coronary Intervention]) PCI.251–253 A meta-analysis of 
these trials showed that the benefit of cangrelor with respect to major 
ischaemic endpoints was counterbalanced by an increase in minor 
bleeding complications.254 It is also important to note that the benefit 
of cangrelor with respect to ischaemic endpoints was attenuated in 
CHAMPION PCI with upfront administration of clopidogrel, and 
ESC Guidelines                                                                                                                                                                                          3753


<!-- PAGE 35 -->

### Page 35

data for its use in conjunction with ticagrelor or prasugrel treatment are 
limited. Due to its proven efficacy in preventing intra-procedural and 
post-procedural stent thrombosis in P2Y12 receptor inhibitor-naïve pa­
tients, cangrelor may be considered on a case-by-case basis in P2Y12 re­
ceptor inhibitor-naïve ACS patients undergoing PCI, including in 
patients for whom it may not be feasible to give oral drugs in the setting 
of emergent PCI (e.g. CS patients and/or patients on mechanical 
ventilation).
6.2. Anticoagulant treatment in the acute 
phase
Anticoagulation is an important component of the initial treatment of 
ACS and of the peri-procedural treatment for ACS patients managed 
with an invasive strategy. Therefore, parenteral anticoagulation is re­
commended for all ACS patients at the time of diagnosis.255 Table 6
provides an overview of the relevant anticoagulant drugs and their dos­
ing in ACS patients.
In general, a crossover between anticoagulants should be avoided in 
patients with ACS (especially between unfractionated heparin [UFH] 
and low-molecular-weight heparin [LMWH]), with the exception of 
adding UFH to fondaparinux when a patient presenting with 
NSTE-ACS proceeds to PCI after a period of fondaparinux treatment 
(see below for further detail).256,257 Anticoagulants should generally be 
discontinued immediately after PCI, except in specific clinical settings 
such as the confirmed presence of LV aneurysm with thrombus forma­
tion or AF requiring anticoagulation. In addition, for bivalirudin in pa­
tients with STEMI undergoing PCI, a full dose post-PCI infusion is 
recommended.
In this section of the guideline, we summarize the recommendations 
for anticoagulant treatment in the acute phase for patients with STEMI 
undergoing PPCI and for patients with NSTE-ACS undergoing angiog­
raphy (and PCI if indicated).
6.2.1. Anticoagulation in patients with ST-elevation 
myocardial infarction undergoing primary 
percutaneous coronary intervention
Unfractionated heparin has been established as the standard of care in 
patients with STEMI undergoing PPCI due to its favourable risk/benefit 
profile. In these patients, anticoagulation should be given during the in­
vasive procedure. High-quality evidence with respect to the benefit of 
administering anticoagulation at an earlier time point in patients under­
going a PPCI strategy is lacking.
Alternatives to UFH that should be considered in patients with 
STEMI undergoing PPCI include enoxaparin (a LMWH) and bivalirudin 
(a direct thrombin inhibitor). The ATOLL (STEMI Treated With 
Primary Angioplasty and Intravenous Lovenox or Unfractionated 
Heparin) trial reported a reduction in the primary endpoint at 30 
days (incidence of death, complication of MI, procedure failure, or ma­
jor bleeding) with enoxaparin in comparison to UFH in patients with 
STEMI undergoing PPCI.258
In the BivaliRudin with prolonged full-dose Infusion durinG primary 
PCI versus Heparin Trial 4 (BRIGHT-4), 6016 patients with STEMI 
undergoing PPCI were randomized to either bivalirudin (with a full 
dose post-PCI infusion) or UFH.259 The use of GP IIb/IIIa inhibitors 
was restricted to patients who experienced thrombotic complications. 
The primary endpoint (a composite of all-cause mortality or Bleeding 
Academic Research Consortium [BARC] type 3–5 bleeding at 30 
days), the individual components of the primary endpoint, and definite 
or probable stent thrombosis were all significantly reduced in the 
bivalirudin group.259 Based on the totality of the available data, bivalir­
udin with a full-dose post-PCI infusion should be considered as an alter­
native to UFH, although further studies to confirm these findings in 
non-East Asian populations are required. Bivalirudin is also the recom­
mended alternative to UFH in patients presenting with ACS who have a 
history of heparin-induced thrombocytopaenia. Additional information 
about bivalirudin, including evidence tables summarizing the relevant 
clinical trials, is provided in the Supplementary data online.
Based on the results of the OASIS-6 (The Safety and Efficacy of 
Fondaparinux Versus Control Therapy in Patients With ST Segment 
Elevation Acute Myocardial Infarction) trial, fondaparinux is not recom­
mended in patients with STEMI undergoing PPCI.260
To summarize, parenteral anticoagulation is recommended for pa­
tients with STEMI undergoing PPCI and UFH is the default choice of 
anticoagulant at present. Enoxaparin and bivalirudin should be consid­
ered as alternatives to UFH in these patients but fondaparinux is not 
recommended.
6.2.2. Anticoagulation in patients with 
non-ST-elevation acute coronary syndrome 
undergoing angiography and percutaneous coronary 
intervention if indicated
Patients with NSTE-ACS are also recommended to receive parenteral 
anticoagulation. In patients with NSTE-ACS who are anticipated to 
undergo immediate or early (i.e. <24 h from the time of diagnosis) in­
vasive angiography and PCI if indicated, parenteral anticoagulation at 
the time of diagnosis is recommended, and UFH has been historically 
established as the anticoagulant of choice. However, in a meta-analysis 
of trials comparing UFH with enoxaparin, mortality and major bleeding 
was not different between both agents in patients with NSTE-ACS or 
stable patients scheduled for PCI.261 Therefore, enoxaparin should be 
considered as an alternative to UFH in these patients (especially in cases 
where monitoring of clotting times is complex).
NSTE-ACS patients who do not undergo early invasive angiography 
(i.e. within 24 h of diagnosis) will have an extended initial treatment 
phase consisting of only pharmacological treatment. In these patients, 
fondaparinux therapy is recommended in preference to enoxaparin 
while awaiting invasive angiography, based on the favourable outcomes 
demonstrated with fondaparinux in comparison to enoxaparin in the 
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes 
(OASIS-5) trial.262 Of note, guiding catheter thrombus formation was 
of concern with fondaparinux and, therefore, a full-dose bolus of 
UFH should be given if the patient proceeds to PCI. The potential im­
pact of contemporary changes in clinical practice (including radial ac­
cess, early catheterization, and infrequent GP IIb/IIIa inhibitor 
therapy) on the treatment effect observed in OASIS-5 should also be 
considered. If fondaparinux is not available, enoxaparin should be con­
sidered for these patients.
Intravenous enoxaparin should also be considered as an anticoagu­
lant for PCI in patients with NSTE-ACS in whom subcutaneous (s.c.) 
enoxaparin was used while awaiting coronary angiography.261
In summary, parenteral anticoagulation is recommended for patients 
with NSTE-ACS. For patients with NSTE-ACS undergoing immediate 
or early angiography (± PCI if indicated), UFH is recommended but en­
oxaparin should be considered as an alternative to UFH. For patients 
with NSTE-ACS who are not anticipated to undergo early angiography, 
fondaparinux (with a UFH bolus at time of PCI) is recommended in 
preference to enoxaparin, although enoxaparin should be considered 
if fondaparinux is not available.


<!-- PAGE 36 -->

### Page 36

6.3. Maintenance antithrombotic therapy 
after revascularization
While continuation of anticoagulation after PCI is not necessary in the 
vast majority of patients (i.e. those without an indication for long-term 
OAC), post-interventional antiplatelet treatment is mandatory in ACS 
patients. Following PCI, a default DAPT regimen consisting of a potent 
P2Y12 receptor inhibitor (prasugrel or ticagrelor) and aspirin is 
generally recommended for 12 months, irrespective of the stent 
type, unless there are contraindications.236,238,239,244,263 In specific clin­
ical scenarios, the default DAPT duration can be shortened (<12 
months), extended (>12 months), or modified (switching DAPT, 
DAPT de-escalation). The recommended default antithrombotic treat­
ment options for ACS patients without an indication for OAC are 
shown in Figure 10.
Routine 
antiplatelet pretreatment
ACS
(Class I)
PPCI
(Class IIb)
ACS
+
(Class I)
(Class I)
Proceeding to PCI
(Class IIa)
Prasugrel
Ticagrelor
>
NSTE-ACSb
(Class III)
Anticoagulation
Choice of 
P2Y12 inhibitorc 
Default DAPT
strategy for the first 12 months after ACSc
Default strategy beyond the first
12 months after ACS
Invasive Coronary Angiography
If prasugrel and ticagrelor 
are unavailable, contraindicated, 
or cannot be tolerated
Angiography 
<24 h
(Class I)
UFH
PPCI
(Class IIa)
Enoxaparin
PPCI
(Class III)
Fondaparinux
Aspirin
Aspirin
P2Y12 inhibitor
(Class I)
Aspirin
P2Y12 inhibitor
Prasugrel
Ticagrelor
Clopidogrel
P2Y12 inhibitor
1
3
6
Time
(months)
9
12
NSTE-ACS
STEMI
(Class IIa)
Enoxaparin
Angiography
<24 h
(Class I)
Fondaparinuxa
Angiography
>24 h
(Class I)
UFH
PPCI
PPCI
(Class IIa)
Bivalirudin
Figure 10 Recommended default antithrombotic therapy regimens in acute coronary syndrome patients without an indication for oral anticoagulation. 
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, per­
cutaneous coronary intervention; PPCI, primary percutaneous coronary intervention; UFH, unfractionated heparin. Algorithm for antithrombotic therapy in 
ACS patients without an indication for oral anticoagulation undergoing invasive evaluation. aFondaparinux (plus a single bolus of UFH at the time of PCI) is 
recommended in preference to enoxaparin for NSTE-ACS patients in cases of medical treatment or logistical constraints for transferring the NSTE-ACS 
patient to PCI within 24 h of symptom onset. bRoutine pre-treatment with a P2Y12 receptor inhibitor in NSTE-ACS patients in whom coronary anatomy 
is not known and early invasive management (<24 h) is planned is not recommended, but pre-treatment with a P2Y12 receptor inhibitor may be considered in 
NSTE-ACS patients who are not expected to undergo an early invasive strategy (<24 h) and do not have HBR. cClopidogrel is recommended for 12 months 
DAPT if prasugrel and ticagrelor are not available, cannot be tolerated, or are contraindicated, and may be considered in older ACS patients (typically defined 
as older than 70–80 years of age).
ESC Guidelines                                                                                                                                                                                          3755


<!-- PAGE 37 -->

### Page 37

6.3.1. Shortening dual antiplatelet therapy
Several RCTs and meta-analyses have compared standard 12-month 
DAPT with ≤6 months DAPT followed by aspirin monotherapy in 
ACS patients.264–267 In some of these trials, the reduction in bleeding 
events associated with abbreviated DAPT regimens came at the cost 
of an increase in the rates of ischaemic complications. In a large-scale 
network meta-analysis, 3-month DAPT but not 6-month DAPT was as­
sociated with higher rates of MI or stent thrombosis in ACS patients.264
A number of large RCTs have investigated DAPT duration further 
shortened to 1–3 months followed by P2Y12 receptor inhibitor mono­
therapy in patients with and without ACS.268–271 In general, low to 
intermediate ischaemic risk patients were included, and early mono­
therapy with clopidogrel or ticagrelor was used. Some trials included 
a comparison with more prolonged DAPT than usual in the control 
arm. Patients with STEMI tended to be excluded or under-represented.
The TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk 
Patients After Coronary Intervention) trial examined the effect of tica­
grelor monotherapy vs. ticagrelor plus aspirin for 1 year after 3 months 
of DAPT (ticagrelor and aspirin) on clinically relevant bleeding. This 
study enrolled ‘high-risk’ patients as per the trial inclusion criteria, 
which meant that the enrolled patients had at least one clinical feature 
and one angiographic feature associated with a high risk of ischaemic or 
bleeding events. However, in order to be randomized the patients were 
also required to have not experienced a major bleeding or ischaemic 
event in the 3 months following hospital discharge.271 STEMI patients 
were excluded from this study. Bleeding events (BARC type 2, 3, or 
5 bleeding) were significantly reduced by omitting aspirin after 3 
months, without a signal of increased ischaemic risk. A dedicated sub­
group analysis suggested these findings were consistent in 4614 patients 
with NSTEMI/UA.272 In the TICO (Ticagrelor Monotherapy After 3 
Months in the Patients Treated With New Generation Sirolimus 
Stent for Acute Coronary Syndrome) trial, ticagrelor monotherapy 
vs. ticagrelor plus aspirin for up to 1 year after 3 months of DAPT (ti­
cagrelor and aspirin) was tested in 3056 ACS patients (36% STEMI).273
Net adverse clinical events and major bleeding events were significantly 
reduced with ticagrelor monotherapy, and major adverse cardiac and 
cerebrovascular events were not significantly different. Limitations of 
this study included the selected population assessed and the lower 
than expected event rates. A study-level meta-analysis of outcomes 
in a population of patients (with both ACS and CCS) fitted with a 
DES also reported a beneficial effect of shortened DAPT for 1–3 
months on major bleeding events, as well as a neutral effect on death, 
MI, and stroke.274
The STOPDAPT-2-ACS (ShorT and OPtimal Duration of Dual 
AntiPlatelet Therapy-2 Study for the Patients With ACS) trial investi­
gated a short DAPT strategy in ACS patients.275 At 1–2 months, pa­
tients were randomized to either clopidogrel monotherapy or 
continued DAPT for 12 months. Non-inferiority of the investigational 
strategy for the composite endpoint of cardiovascular (CV) or bleeding 
events was not proven, suggesting that systematic very short duration 
DAPT (i.e. <3 months) followed by clopidogrel monotherapy is not a 
useful strategy in ACS patients.
The MASTER DAPT (Management of High Bleeding Risk Patients Post 
Bioresorbable Polymer Coated Stent Implantation With an Abbreviated 
Versus Prolonged DAPT Regimen) trial examined a strategy of abbre­
viated DAPT (1 month) followed by either aspirin or P2Y12 inhibitor 
monotherapy vs. DAPT ≥3 months (standard therapy) in a cohort of 
4579 HBR patients (49% ACS, 12% STEMI) undergoing PCI with a bioab­
sorbable polymer-coated stent.276 Net adverse clinical events and major 
adverse cardiac or cerebral events were comparable between the 
groups, whereas major or clinically relevant non-major bleeding events 
were significantly reduced in the abbreviated therapy group.
6.3.2. De-escalation from potent P2Y12 inhibitor to 
clopidogrel
The need to switch between oral P2Y12 receptor inhibitors is not 
uncommon as a consequence of bleeding complications (or concern re­
garding bleeding), non-bleeding side effects (e.g. dyspnoea on ticagrelor, 
allergic reactions), and socioeconomic factors.277,278 As such, switching 
between oral P2Y12 receptor inhibitors may be considered in selected 
cases.
P2Y12 receptor inhibitor de-escalation (i.e. switching from prasugrel/ 
ticagrelor to clopidogrel) in ACS patients may be considered as an al­
ternative strategy to the default treatment regimen in order to reduce 
the risk of bleeding events. However, it is important to note that there 
is a potential risk of increased ischaemic events with de-escalation and 
this strategy is not recommended in the first 30 days after the index 
ACS event. In the TROPICAL-ACS (Testing Responsiveness to 
Platelet Inhibition on Chronic Antiplatelet Treatment For Acute 
Coronary Syndromes) trial (44% NSTE-ACS, 56% STEMI), an approach 
of DAPT de-escalation from prasugrel to clopidogrel (at 2 weeks after 
ACS) was guided by platelet function testing and was non-inferior to 
standard treatment with prasugrel at 1 year after PCI in terms of net 
clinical benefit.279 In the Cost-effectiveness of CYP2C19 Genotype 
Guided Treatment With Antiplatelet Drugs in Patients With 
ST-segment-elevation Myocardial Infarction Undergoing Immediate 
PCI With Stent Implantation: Optimization of Treatment (POPular 
Genetics) trial, DAPT de-escalation from ticagrelor/prasugrel to clopi­
dogrel guided by CYP2C19 genotyping in ACS patients undergoing 
PPCI within the previous 48 h was non-inferior to standard treatment 
with ticagrelor or prasugrel at 12 months with respect to thrombotic 
events and resulted in a lower incidence of bleeding.280
The single-centre TOPIC (Timing of Platelet Inhibition After Acute 
Coronary Syndrome) trial used an unguided de-escalation approach in 
645 ACS patients (60% NSTE-ACS, 40% STEMI) from ticagrelor/prasu­
grel to clopidogrel after 1 month of DAPT with ticagrelor/prasugrel 
and aspirin. Net adverse clinical events and bleeding events were reduced, 
whereas the rate of ischaemic endpoints was unchanged.281 The 
TALOS-AMI (TicAgrelor versus CLOpidogrel in Stabilised Patients with 
Acute Myocardial Infarction) trial investigated unguided de-escalation in 
2697 ACS patients (46% NSTEMI/UA, 54% STEMI) from ticagrelor to clo­
pidogrel after 1 month of DAPT with ticagrelor and aspirin.282 This uni­
form unguided de-escalation strategy led to significant 12-month 
reductions in net adverse clinical events and bleeding events. The 
HOST-REDUCE-POLYTECH-ACS (Harmonizing Optimal Strategy for 
Treatment of Coronary Artery Diseases Trial—Comparison of 
REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS 
Patients) trial tested a different method of de-escalation—a reduction 
in prasugrel dose rather than switching to clopidogrel. In this trial, 2338 
low-risk ACS patients <75 years of age (14% STEMI, 25% NSTEMI, and 
61% UA) were randomized to low-dose prasugrel (5 mg daily) or 
standard-dose prasugrel (10 mg daily) after 1 month of DAPT with 
standard-dose prasugrel.283 Prasugrel dose de-escalation was associated 
with fewer net adverse clinical events and bleeding events, mainly by re­
ducing bleeding events without an increase in ischaemic events. It should 
be noted that the TALOS-AMI and HOST-REDUCE-POLYTECH-ACS 
trials only included East Asian populations.


<!-- PAGE 38 -->

### Page 38

6.3.3. Summary of alternative antiplatelet strategies 
to reduce bleeding risk in the first 12 months after 
acute coronary syndrome
Considering the totality of evidence from the scientific literature, alterna­
tives to the default strategy of 12 months DAPT in patients with ACS in­
clude shortening the DAPT duration to 1 or 3–6 months (depending on 
the balance of bleeding and ischaemic risks) and de-escalating DAPT from 
prasugrel/ticagrelor-based DAPT to clopidogrel-based DAPT. However, 
it should be noted that much of the evidence on these strategies in ACS 
patients is derived from trials powered primarily for bleeding outcomes, 
many of which had a non-inferiority design and were, therefore, not pow­
ered to detect potentially relevant differences in ischaemic outcomes. The 
patient populations enrolled in these studies were also often relatively se­
lected, often excluding or under-representing the highest risk ACS pa­
tients. As such, it is important to reflect that even meta-analyses of the 
available randomized evidence cannot overcome the potential selection 
bias at the point of entry in the relevant randomized trials.
These important limitations explain why these strategies should at 
present remain considered as alternative strategies to the default of 
12 months DAPT. From a practical perspective, this means that these 
strategies should not be employed as a default strategy in the wider 
ACS population but can be considered when there is a specific motiv­
ation for their use (i.e. aiming to reduce the risk of bleeding events in 
HBR patients or if there are other specific concerns regarding a 
12-month 
potent 
P2Y12 
inhibitor-based 
DAPT 
regimen). 
De-escalation of antiplatelet therapy in the first 30 days is not recom­
mended, but de-escalation of P2Y12 receptor inhibitor therapy may be 
considered as an alternative strategy beyond 30 days after an ACS, in 
order to reduce the risk of bleeding events. DAPT abbreviation strat­
egies (followed preferably by P2Y12 inhibitor monotherapy within the 
first 12 months post-ACS) should be considered in patients who are 
event-free after 3–6 months of DAPT and who are not high ischaemic 
risk, with the duration of DAPT guided by the ischaemic and bleeding 
risks of the patient. For HBR patients, aspirin or P2Y12 receptor inhibi­
tor monotherapy after 1 month of DAPT may be considered. Please 
see Recommendation Table 6 for full details. These alternative antipla­
telet strategies to reduce bleeding risk in the first 12 months after ACS 
are also summarized in Figure 11.
0
1
3
6
9
12
Antiplatelet strategies to reduce bleeding risk in the first 12 months after ACS
Abbreviated DAPT strategies
DAPT de-escalation strategies
Time
(Months)
In HBR
patients only
1 month 
DAPT
3 month 
DAPT
6 month 
DAPT
P2Y12 inhibitor or 
aspirin monotherapy
In HBR and 
non-HBR patients
Potent P2Y12 inhibitor-based DAPT
Aspirin + Prasugrel
Aspirin + Clopidogrel
Aspirin + Ticagrelor
OR
De-escalation
Change from potent P2Y12
inhibitor to clopidogrel
Figure 11 Alternative antiplatelet strategies to reduce bleeding risk in the first 12 months after an ACS. ACS, acute coronary syndrome; DAPT, dual 
antiplatelet therapy; HBR, high bleeding risk; PFT, platelet function test.
ESC Guidelines                                                                                                                                                                                          3757


<!-- PAGE 39 -->

### Page 39

To summarise, antiplatelet strategies to reduce bleeding risk in the first 
12 months after an ACS can be divided into abbreviated DAPT strategies 
and DAPT de-escalation strategies. Twelve-month DAPT (preferably 
with prasugrel or ticagrelor) remains the default strategy for patients 
with ACS (Figure 10) and these strategies should only be used as alterna­
tives to this strategy, in general driven by a motivation to reduce the risk 
of bleeding events (i.e. if the patient is HBR or if there are other specific 
concerns regarding 12-month potent P2Y12 inhibitor-based DAPT).
The specific alternative antiplatelet strategies employed (i.e. choice 
of P2Y12 inhibitor, duration of DAPT, choice of SAPT agent) to reduce 
bleeding risk should be chosen based on the bleeding risk of the patient 
(HBR or not) and these recommendations are summarized in 
Recommendation Table 6.
Recommendation Table 5 — Recommendations for 
antiplatelet and anticoagulant therapy in acute coronary 
syndrome
Recommendations
Classa
Levelb
Antiplatelet therapy
Aspirin is recommended for all patients without 
contraindications at an initial oral LD of 150–300 mg 
(or 75–250 mg i.v.) and an MD of 75–100 mg o.d. for 
long-term treatment.284,285
I
A
In all ACS patients, a P2Y12 receptor inhibitor is 
recommended in addition to aspirin, given as an initial 
oral LD followed by an MD for 12 months unless 
there is HBRc.238,239,263,286
I
A
A proton pump inhibitor in combination with DAPT 
is recommended in patients at high risk of 
gastrointestinal bleeding.287,288
I
A
Prasugrel is recommended in P2Y12 receptor 
inhibitor-naïve patients proceeding to PCI (60 mg 
LD, 10 mg o.d. MD, 5 mg o.d. MD for patients aged 
≥75 years or with a body weight <60 kg).239
I
B
Ticagrelor is recommended irrespective of the 
treatment strategy (invasive or conservative) 
(180 mg LD, 90 mg b.i.d. MD).238
I
B
Clopidogrel (300–600 mg LD, 75 mg o.d. MD) is 
recommended when prasugrel or ticagrelor are not 
available, cannot be tolerated, or are 
contraindicated.263,289
I
C
If patients presenting with ACS stop DAPT to 
undergo CABG, it is recommended they resume 
DAPT after surgery for at least 12 months.
I
C
Prasugrel should be considered in preference to 
ticagrelor for ACS patients who proceed to 
PCI.244,290
IIa
B
GP IIb/IIIa receptor antagonists should be considered 
if there is evidence of no-reflow or a thrombotic 
complication during PCI.
IIa
C
In P2Y12 receptor inhibitor-naïve patients 
undergoing PCI, cangrelor may be considered.251–254
IIb
A
In older ACS patients,d especially if HBR,c clopidogrel 
as the P2Y12 receptor inhibitor may be 
considered.242,243,291
IIb
B
Continued
Pre-treatment with a P2Y12 receptor inhibitor may 
be considered in patients undergoing a primary PCI 
strategy.244,245
IIb
B
Pre-treatment with a P2Y12 receptor inhibitor may 
be considered in NSTE-ACS patients who are not 
expected to undergo an early invasive strategy 
(<24 h) and do not have HBRc.263
IIb
C
Pre-treatment with a GP IIb/IIIa receptor antagonist 
is not recommended.292
III
A
Routine pre-treatment with a P2Y12 receptor 
inhibitor in NSTE-ACS patients in whom coronary 
anatomy is not known and early invasive 
management (<24 h) is planned is not 
recommended.244,247,248,293–295
III
A
Anticoagulant therapy
Parenteral anticoagulation is recommended for all 
patients with ACS at the time of diagnosis.255,296
I
A
Routine use of a UFH bolus (weight-adjusted i.v. 
bolus during PCI of 70–100 IU/kg) is recommended 
in patients undergoing PCI.
I
C
Intravenous enoxaparin at the time of PCI should be 
considered in patients pre-treated with 
subcutaneous enoxaparin.256,261,297
IIa
B
Discontinuation of parenteral anticoagulation should 
be considered immediately after an invasive 
procedure.
IIa
C
Patients with STEMI
Enoxaparin should be considered as an alternative to 
UFH in patients with STEMI undergoing PPCI.258,261,298
IIa
A
Bivalirudin with a full-dose post PCI infusion should 
be considered as an alternative to UFH in patients 
with STEMI undergoing PPCI.259,299,300–303
IIa
A
Fondaparinux is not recommended in patients with 
STEMI undergoing PPCI.260
III
B
Patients with NSTE-ACS
For patients with NSTE-ACS in whom early invasive 
angiography (i.e. within 24 h) is not anticipated, 
fondaparinux is recommended.262,304
I
B
For patients with NSTE-ACS in whom early invasive 
angiography (i.e. within 24 h) is anticipated, enoxaparin 
should be considered as an alternative to UFH.256
IIa
B
Combining antiplatelets and OAC
As the default strategy for patients with atrial 
fibrillation and CHA2DS2-VASc score ≥1 in men and 
≥2 in women, after up to 1 week of triple 
antithrombotic therapy following the ACS event, 
dual antithrombotic therapy using a NOAC at the 
recommended dose for stroke prevention and a 
single oral antiplatelet agent (preferably clopidogrel) 
for up to 12 months is recommended.305–310
I
A
During PCI, a UFH bolus is recommended in any of 
the following circumstances: 
• if the patient is on a NOAC
• if the INR is <2.5 in VKA-treated patients.
I
C
Continued


<!-- PAGE 40 -->

### Page 40

6.4. Long-term treatment
By default, DAPT consisting of a potent P2Y12 receptor inhibitor in add­
ition to aspirin is recommended for a minimum of 12 months after an 
ACS event; exceptions include patients for whom surgery is urgently 
needed, patients in whom OAC is indicated, and patients in whom the 
risk of bleeding is too high for other reasons.238,239,263 After PCI for 
ACS, ischaemic and bleeding events both markedly decrease over time. 
Further information regarding long-term antithrombotic strategies (i.e. 
beyond 12 months) is provided in the Supplementary data online.
6.4.1. Prolonging antithrombotic therapy beyond 12 
months
Prolonged 
antithrombotic 
therapy 
options: 
See 
Supplementary data online, Figure S4; Tables S7 and S8 for additional in­
formation.314–319
In patients with an indication for OAC with VKA in 
combination with aspirin and/or clopidogrel, careful 
regulation of the dose intensity of VKA with a target 
INR of 2.0–2.5 and a time in the therapeutic range 
>70% should be considered.305–308,311
IIa
B
When rivaroxaban is used and concerns about HBR 
prevail over ischaemic stroke, rivaroxaban 15 mg o.d. 
should be considered in preference to rivaroxaban 
20 mg o.d. for the duration of concomitant SAPT or 
DAPT.307
IIa
B
In patients at HBR,c dabigatran 110 mg b.i.d. should 
be considered in preference to dabigatran 150 mg 
b.i.d. for the duration of concomitant SAPT or 
DAPT, to mitigate bleeding risk.305
IIa
B
In patients requiring anticoagulation and treated 
medically, a single antiplatelet agent in addition to an 
OAC should be considered for up to 1 year.308,312
IIa
B
In patients treated with an OAC, aspirin plus 
clopidogrel for longer than 1 week and up to 1 
month should be considered in those with high 
ischaemic risk or with other anatomical/procedural 
characteristics that are judged to outweigh the 
bleeding risk.e
IIa
C
In patients requiring OAC, withdrawing antiplatelet 
therapy at 6 months while continuing OAC may be 
considered.313
IIb
B
The use of ticagrelor or prasugrel as part of triple 
antithrombotic therapy is not recommended.
III
C
© ESC 2023
ACS, acute coronary syndrome; b.i.d., bis in die (twice a day); CHA2DS2-VASc, Congestive 
heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Stroke or transient ischaemic 
attack, Vascular disease; DAPT, dual antiplatelet therapy; GP, glycoprotein; HBR, high 
bleeding risk; INR, international normalized ratio; i.v., intravenous; LD, loading dose; MD, 
maintenance dose; NOAC, non-vitamin K antagonist oral anticoagulant; NSTE-ACS, 
non-ST-elevation acute coronary syndrome; OAC, oral anticoagulant; PPCI, primary 
percutaneous coronary intervention; SAPT, single antiplatelet therapy; STEMI, 
ST-elevation myocardial infarction; UFH, unfractionated heparin; VKA, vitamin K 
antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cHBR should be assessed in a structured manner, e.g. presence of a single major or two 
minor characteristics as defined by ARC-HBR (see section 8.2.2.3 in Supplementary data 
online). 
dThe definition of older patients varies across trials, ranging from 70 to 80 years of age. 
Frailty and comorbidities should also be taken in consideration. 
eSee Antiplatelet therapy in patients requiring oral anticoagulation Section 6.2 in 
Supplementary data online for more information on high-risk features of stent-driven 
recurrent events.
Recommendation Table 6 — Recommendations for  
alternative antithrombotic therapy regimens
Recommendations
Classa
Levelb
Shortening/de-escalation of antithrombotic therapy
In patients who are event-free after 3–6 months of 
DAPT and who are not high ischaemic risk, single 
antiplatelet therapy (preferably with a P2Y12 
receptor inhibitor) should be considered.264,268– 
271,273,274,276,313,320
IIa
A
De-escalation of P2Y12 receptor inhibitor treatment 
(e.g. with a switch from prasugrel/ticagrelor to 
clopidogrel) may be considered as an alternative 
DAPT strategy to reduce bleeding risk.279–282,321,322
IIb
A
In HBR patients, aspirin or P2Y12 receptor inhibitor 
monotherapy after 1 month of DAPT may be 
considered.276,313
IIb
B
De-escalation of antiplatelet therapy in the first 30 
days after an ACS event is not recommended.238,323
III
B
Prolonging antithrombotic therapy
Discontinuation of antiplatelet treatment in patients 
treated with an OAC is recommended after 12 
months.324,325
I
B
Adding a second antithrombotic agent to aspirin for 
extended long-term secondary prevention should be 
considered in patients with high ischaemic risk and 
without HBRc.314–318
IIa
A
Adding a second antithrombotic agent to aspirin for 
extended long-term secondary prevention may be 
considered in patients with moderate ischaemic risk 
and without HBRc.314–318
IIb
A
P2Y12 inhibitor monotherapy may be considered as 
an alternative to aspirin monotherapy for long-term 
treatment.326,327
IIb
A
© ESC 2023
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; 
OAC, oral anticoagulant. 
aClass of recommendation. 
bLevel of evidence. 
cThe evidence supporting this approach (prolonged treatment with a second 
antithrombotic agent) is based on trials in which the duration of prolonged treatment 
was as follows: mean of 23 months (COMPASS), mean of 18 months (DAPT trial), and 
median of 33 months (PEGASUS-TIMI 54). Therefore, the benefits and risks associated 
with continuation of these respective treatments beyond these time points is at present 
unclear.
ESC Guidelines                                                                                                                                                                                          3759


<!-- PAGE 41 -->

### Page 41

6.5. Antiplatelet therapy in patients 
requiring oral anticoagulation
6.5.1. Acute coronary syndrome patients requiring 
anticoagulation
In 6–8% of patients undergoing PCI, long-term OAC is indicated 
and should also be continued during the invasive procedure. 
Interruption of the long-term OAC and bridging with parenteral antic­
oagulants may lead to an increase in thrombo-embolic episodes and 
bleeds.328–330 In patients undergoing PCI, it is unknown whether it is 
safer to bridge non-vitamin K antagonist (VKA) OACs (NOACs) with 
parenteral anticoagulants or to continue NOACs without additional 
parenteral anticoagulation. In VKA-treated patients, no parenteral antic­
oagulation is needed if the international normalized ratio (INR) is 
>2.5.311,331,332 Strategies to minimize PCI-related complications in pa­
tients on OAC are listed in Table 7.
Evidence on the management of ACS patients with an indication for 
long-term OAC undergoing PCI is derived from subgroups of 
RCTs.305–309,333 Patients with STEMI (who generally carry a higher 
atherothrombotic risk) were under-represented (∼10% of the study 
populations) in the major RCTs.305,307–309 Pivotal trials testing the 
benefit of NOACs as part of the antithrombotic regimen in patients 
with an indication for long-term anticoagulation undergoing PCI are dis­
cussed in the Supplementary data online.
All of these trials were individually powered to address the safety of 
the tested strategy with regard to bleeding events, but not to reliably as­
sess differences in individual ischaemic endpoints. In a meta-analysis of all 
four NOAC-based RCTs comparing dual antithrombotic therapy (DAT) 
with triple antithrombotic therapy (TAT) in AF patients undergoing PCI 
(encompassing 10 234 patients), the primary safety endpoint 
(International Society on Thrombosis and Haemostasis major or clinically 
relevant non-major bleeding) was significantly lower with DAT vs. TAT 
(relative risk [RR] 0.66, 95% CI, 0.56–0.78; P <0.001).310 There were 
no significant differences in all-cause and CV death, stroke, or trial- 
defined major adverse cardiovascular events (MACE). However, DAT 
was associated with a borderline increased risk of MI (RR 1.22, 95% 
CI, 0.99–1.52; P = 0.07) and a significant increase in stent thrombosis 
(RR 1.59, 95% CI, 1.01–2.50; P = 0.04). This translates into an absolute 
reduction in major bleeding events of 2.3% compared with an absolute 
increase in stent thrombosis of 0.4%, without an effect on overall 
MACE. When interpreting the results of these studies, an important gen­
eral point is that the treatment effect is confounded by the use of 
NOACs in the DAT treatment arms and VKAs in the TAT arms.
Secondary analyses from the AUGUSTUS (An Open-Label, 2 × 2 
Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety 
of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin 
Placebo in Patients With Atrial Fibrillation and Acute Coronary 
Syndrome or Percutaneous Coronary Intervention) trial indicate that 
the stent thrombosis rate was highest within the first 30 days after ran­
domization, with higher rates in the non-aspirin group.334 Aspirin treat­
ment reduced ischaemic events (CV death, MI, stroke, stent 
thrombosis) but also increased major bleeding events in the first 30 
days. Aspirin treatment did not impact on ischaemic event rates after 
30 days and for up to 6 months, but did increase the bleeding risk during 
this time period.334,335 In the MASTER DAPT trial, 4579 HBR patients 
were allocated to 1 month vs. 6 months of DAPT after implantation of a 
biodegradable-polymer sirolimus-eluting stent; half of the patients pre­
sented with ACS and a third were on OAC treatment.276 A sub-analysis 
of this study reported that stopping DAPT after 1 month and stopping 
single antiplatelet therapy (SAPT) after 6 months while maintaining 
OAC was safe with respect to ischaemic events in patients taking clin­
ically indicated long-term OAC therapy.313
In patients with ACS, the indication for OAC should be re-assessed 
and treatment continued only if a compelling indication exists (e.g. par­
oxysmal, persistent, or permanent AF with a CHA2DS2-VASc 
[Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mel­
litus, Stroke or transient ischaemic attack, Vascular disease] score ≥1 in 
men and ≥2 in women; mechanical heart valve; or recent/a history of 
recurrent or unprovoked deep vein thrombosis or PE). Although 
they have been tested in a minority of patients in the major RCTs, in 
the absence of robust safety and efficacy data, the use of prasugrel or 
ticagrelor as part of TAT is not recommended. The intensity of OAC 
should be carefully monitored, with a target INR of 2.0–2.5 in patients 
treated with VKA (with the exception of individuals with a mechanical 
prosthetic valve in the mitral position).
Overall, in patients with AF without mechanical prosthetic valves or 
moderate to severe mitral stenosis, the evidence supports the use of 
NOACs over VKAs as they reduce bleeding risk. DAT with a NOAC 
at the recommended dose for stroke prevention and SAPT (preferably 
clopidogrel, which was used in >90% of patients in the major RCTs) is 
recommended as the default strategy for up to 12 months after up to 1 
week of TAT (with NOAC and DAPT consisting of aspirin and clopido­
grel) (Figure 12)—the up to 1 week duration of TAT is based on the 
median treatment duration in the investigational arm of the 
AUGUSTUS trial.308 Although none of the available RCTs were de­
signed to detect differences in ischaemic events, the numerically higher 
risk of stent thrombosis and MI is offset by the lower risk of bleeding, 
with a resultant neutral effect on total mortality.310,336–338
Table 7 Suggested strategies to reduce bleeding risk 
related to percutaneous coronary intervention
• Anticoagulant doses adjusted to body weight and renal function, 
especially in women and older patients
• Radial artery approach as default vascular access
• Proton pump inhibitors in patients on dual antiplatelet therapy at 
higher-than-average risk of gastrointestinal bleeds (i.e. history of 
gastrointestinal ulcer/haemorrhage, anticoagulant therapy, chronic 
non-steroidal anti-inflammatory drug/corticosteroid use), or two or 
more of: 
(a) Age ≥65 years
(b) Dyspepsia
(c) Gastro-oesophageal reflux disease
(d) Helicobacter pylori infection
(e) Chronic alcohol use
• In patients on OAC: 
(a) PCI performed without interruption of VKAs or NOACs
(b) In patients on VKAs, do not administer UFH if INR >2.5
(c) In patients on NOACs, regardless of the timing of the last 
administration of NOACs, add low-dose parenteral 
anticoagulation (e.g. enoxaparin 0.5 mg/kg i.v. or UFH 60 IU/kg)
• Aspirin is indicated but avoid pre-treatment with P2Y12 receptor 
inhibitors
• GP IIb/IIIa receptor inhibitors only for bailout or peri-procedural 
complications
© ESC 2023
GP, glycoprotein; INR, international normalized ratio; i.v., intravenous; NOAC, non-vitamin 
K antagonist oral anticoagulant; OAC, oral anticoagulation/anticoagulant; PCI, 
percutaneous coronary intervention; UFH, unfractionated heparin; VKA, vitamin K 
antagonist.


<!-- PAGE 42 -->

### Page 42

At variance with the default strategy, DAT may be shortened to 6 
months by withdrawing the antiplatelet therapy in certain patients; 
for example, in patients with multiple HBR factors. In patients with 
high ischaemic risk or other anatomical/procedural characteristics 
that outweigh the bleeding risk, TAT should be prolonged for up to 
1 month, followed by DAT for up to 12 months.
There is currently limited evidence to support the use of OAC with 
ticagrelor or prasugrel as DAT after ACS and/or PCI as an alternative to 
TAT; ticagrelor was used in 5–12% and prasugrel in 1–2% of patients, 
respectively, in the four pivotal RCTs.305,307–309,339
In medically managed ACS patients, current data support DAT over 
TAT, with a single antiplatelet agent (most commonly clopidogrel) for at 
least 6 months.308 In the AUGUSTUS trial, ∼24% of enrolled patients pre­
sented with medically managed ACS.308 In these patients, apixaban signifi­
cantly reduced bleeding events compared with a VKA, while no significant 
differences were observed in death or ischaemic events. The use of aspirin, 
in comparison to placebo, led to more bleeding events but no significant 
differences in death, hospitalization, or ischaemic events were observed.308
Regarding the need to continue with any antiplatelet agent beyond 
12 months after ACS and/or PCI in patients with an indication for 
OAC, the AFIRE (Atrial Fibrillation and Ischemic Events With 
Rivaroxaban in Patients With Stable Coronary Artery Disease) trial 
randomized 2236 AF patients treated with PCI or CABG more than 
1 year earlier or with documented CAD to receive either rivaroxaban 
monotherapy or combination therapy with rivaroxaban plus a single 
antiplatelet agent.324 Rivaroxaban monotherapy was non-inferior to 
combination therapy for the primary efficacy composite endpoint of 
stroke, systemic embolism, MI, UA requiring revascularization, or over­
all death, and superior with regard to the primary safety endpoint of 
major bleeding. This trial and another prematurely terminated trial sup­
port the recommendation to stop antiplatelet therapy after 12 months 
and continue with OAC monotherapy in most patients.325
0 weeks up to 1 week up to 1 month
6 months
3 months
9 months
12 months
Beyond
12 months
Patients with ACS and an indication for OAC
Default strategy
TAT: (N)OAC + DAPT
(Class I)
DAT: (N)OAC + SAPT
(Class I)
DAT: (N)OAC + SAPT
(Class I)
TAT: (N)OAC + DAPT
(Class IIa)
(N)OAC monotherapy
(Class I)
(N)OAC monotherapy
(Class I)
DAT: 
(N)OAC + SAPT
(Class I)
(N)OAC
monotherapy
(Class IIb)
Strategy to reduce ischaemic riska
Time from ACS
Figure 12 Antithrombotic regimens in patients with acute coronary syndrome and an indication for oral anticoagulation. ACS, acute coronary syndrome; 
ARC-HBR, Academic Research Consortium for High Bleeding Risk; DAPT, dual antiplatelet therapy; DAT, dual antithrombotic therapy; NOAC, non-vitamin 
K antagonist oral anticoagulant; OAC, oral anticoagulation/anticoagulant; SAPT, single antiplatelet therapy; TAT, triple antithrombotic therapy; VKA, vitamin K 
antagonist. OAC: preference for a NOAC over VKA for the default strategy and in all other scenarios if no contraindications. For both TAT and DAT regimens, 
the recommended doses for the NOACs are as follows: Apixaban 5 mg b.i.d., Dabigatran 110 mg or 150 mg b.i.d., Edoxaban 60 mg o.d., Rivaroxaban 15 mg or 20 
mg o.d. NOAC dose reductions are recommended in patients based on certain criteria for each of the NOACs (including renal function, body weight, concomi­
tant medications and age). SAPT: preference for a P2Y12 receptor inhibitor (usually clopidogrel) over aspirin. See Bleeding risk assessment in Supplementary data 
online, Section 8.2.2.3 for details on the ARC-HBR criteria. In addition, patients with a PRECISE-DAPT score of ≥25 are regarded as high bleeding risk. aSee 
Supplementary material online, Table S9 for examples of high-risk features of stent-driven recurrent events.
ESC Guidelines                                                                                                                                                                                          3761


<!-- PAGE 43 -->

### Page 43

6.5.2. Patients requiring vitamin K antagonists or 
undergoing coronary artery bypass surgery
In patients for whom a VKA is mandated (e.g. patients with mechanical 
prosthetic valves), DAT with a VKA and SAPT (preferably clopidogrel) 
is indicated after an up to 1-week period of TAT (with aspirin and clo­
pidogrel).306 A network meta-analysis has reported that compared 
with TAT (consisting of VKA plus aspirin and clopidogrel), DAT 
(VKA plus clopidogrel) was associated with a trend towards a reduction 
in TIMI major bleeding, with no significant difference observed in 
MACE.336
In ACS patients undergoing CABG with an established indication for 
OAC, anticoagulation in combination with SAPT should be resumed 
after CABG as soon as possible and TAT should be avoided.
6.6. Antithrombotic therapy as an adjunct 
to fibrinolysis
ISIS-2 (Second International Study Of Infarct Survival) demonstrated 
that the benefits of aspirin and fibrinolytics (i.e. streptokinase) were 
additive.340 The first dose of aspirin (162–325 mg) should be chewed 
or given i.v. and a low dose (75–100 mg) given orally daily from the 
next day thereafter. Clopidogrel added to aspirin reduces the risk of 
CV events and overall mortality in patients treated with fibrinolysis 
and should be added to aspirin following lytic therapy.341,342 Based 
on the available RCTs, there is insufficient evidence to support or refute 
improved outcomes with ticagrelor or prasugrel in patients with STEMI 
treated with thrombolytics.343–345 There is no evidence that adminis­
tration of GP IIb/IIIa receptor inhibitors improves myocardial perfusion 
or outcomes in patients treated with fibrinolysis, and it may increase 
the risk of bleeding events.346
Parenteral anticoagulation is recommended until revascularization, if 
performed. Despite an increased risk of major bleeding, the net clinical 
benefit favoured enoxaparin over UFH in the ASsessment of the 
Safety and Efficacy of a New Thrombolytic 3 (ASSENT 3) trial (n =  
6095).347 In the large Enoxaparin and Thrombolysis Reperfusion for 
Acute myocardial infarction Treatment–Thrombolysis In Myocardial 
Infarction 25 (ExTRACT–TIMI 25) trial (n = 20 506), a lower dose 
of enoxaparin was given to patients ≥75 years old and to those 
with impaired renal function (estimated creatinine clearance 
<30 mL/min). Enoxaparin was associated with a reduction in the 
risk of death and re-infarction at 30 days when compared with a 
weight-adjusted UFH dose, but at the cost of a significant increase 
in non-cerebral bleeding complications. The net clinical benefit (i.e. ab­
sence of death, non-fatal infarction, and intracranial haemorrhage) fa­
voured enoxaparin.348,349 In the large OASIS-6 trial, fondaparinux was 
superior to placebo or UFH in preventing death and re-infarction, es­
pecially in patients who received streptokinase.260,350 In a large trial 
with streptokinase, significantly fewer re-infarctions were seen with bi­
valirudin given for 48 h compared with UFH, although at the cost of a 
modest non-significant increase in non-cerebral bleeding complica­
tions.351 Bivalirudin has not been studied with fibrin-specific agents, 
and there is no evidence to support direct thrombin inhibitors as an 
adjunct to fibrinolysis.260,350
Weight-adjusted i.v. tenecteplase, low-dose aspirin, clopidogrel given 
orally, and enoxaparin i.v. followed by s.c. administration until the time 
of PCI (revascularization) represents the most extensively studied 
antithrombotic regimen as part of a pharmaco-invasive strat­
egy.184,186,213,346,352 Further information on fibrinolytic therapy, includ­
ing antithrombotic co-therapies and contraindications is provided in 
Supplementary data online, Tables S10 and S11.
6.7. Antithrombotic therapy in patients 
not undergoing reperfusion
Patients with a final diagnosis of ACS who do not undergo reperfusion 
should receive a P2Y12 receptor inhibitor in addition to aspirin, maintained 
over 12 months unless there is HBR. Among ACS patients who are med­
ically managed without revascularization, the combination of aspirin and ti­
cagrelor for up to 12 months has demonstrated a benefit in comparison to 
aspirin and clopidogrel.238,361The combination of aspirin and prasugrel can 
also be justified in preference to aspirin and clopidogrel if coronary angiog­
raphy has been performed and CAD is confirmed.239,362 As such, potent 
P2Y12 inhibitor-based DAPT is a reasonable option for patients with a final 
diagnosis of ACS not undergoing reperfusion, unless concerns over the 
bleeding risk prevail (e.g. based on ARC-HBR criteria).238,361 A DAPT regi­
men based on clopidogrel and aspirin may provide a good net clinical bene­
fit among older ACS patients.242,363 Further information regarding 
antithrombotic therapy in ACS patients who do not undergo reperfusion 
is provided in the Supplementary data online.
7. Acute coronary syndrome with 
unstable presentation
In some cases, ACS patients can present with haemodynamic com­
promise (i.e. out-of-hospital cardiac arrest [OHCA] and/or CS).
Recommendation Table 7 — Recommendations for 
fibrinolytic therapy
Recommendations
Classa
Levelb
Fibrinolytic therapy
When fibrinolysis is the reperfusion strategy, it is 
recommended to initiate this treatment as soon as 
possible after diagnosis in the pre-hospital setting 
(aim for target of <10 min to lytic bolus).206,353–355
I
A
A fibrin-specific agent (i.e. tenecteplase, alteplase, or 
reteplase) is recommended.356,357
I
B
A half-dose of tenecteplase should be considered in 
patients >75 years of age.184
IIa
B
Antiplatelet co-therapy with fibrinolysis
Aspirin and clopidogrel are recommended.340–342
I
A
Anticoagulation co-therapy with fibrinolysis
Anticoagulation is recommended in patients treated 
with fibrinolysis until revascularization (if performed) 
or for the duration of hospital stay (up to 8 
days).260,347,348,350,357–360
I
A
Enoxaparin i.v. followed by s.c. is recommended as 
the preferred anticoagulant.347,348,357–360
I
A
When enoxaparin is not available, UFH is 
recommended as a weight-adjusted i.v. bolus, 
followed by infusion.357
I
B
In patients treated with streptokinase, an i.v. bolus of 
fondaparinux followed by an s.c. dose 24 h later 
should be considered.260
IIa
B
© ESC 2023
i.v., intravenous; s.c, subcutaneous; UFH, unfractionated heparin. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 44 -->

### Page 44

7.1. Out-of-hospital cardiac arrest in acute 
coronary syndrome
While a small minority of all patients with ACS present as OHCA, ACS 
is the most common cause of OHCA.364–366 In patients with OHCA, 
resuscitation efforts should follow the European Resuscitation 
Council Guidelines.367 The majority of adult cardiac arrest cases are 
associated with obstructive CAD and ACS should be included in the 
differential diagnosis.365,368 Therefore, ICA can be part of the post- 
resuscitation management for patients who are estimated to have a 
high probability of acute coronary occlusion (e.g. persistent 
ST-segment elevation or equivalents and/or haemodynamic and/or 
electrical instability).367,369 Neurological status (e.g. comatose vs. non- 
comatose) and survival probability (i.e. favourable benefit/risk ratio vs. 
futility) should also be included in the decision-making algorithm.
Despite the lack of dedicated trials, patients with return of spontan­
eous circulation (ROSC) and persistent ST-segment elevation should, in 
general, undergo a PPCI strategy (immediate ICA and PCI if indicated), 
based on the overall clinical situation and a reasonable benefit/risk ratio. 
Based on registry reports, emergent ICA and PCI are associated with 
good outcomes in this setting, particularly in patients who are non- 
comatose at initial assessment.368,370,371
The management of patients with ROSC without evidence of 
ST-segment elevation should be individualized according to haemo­
dynamic and neurological status. In OHCA with an initial shockable 
rhythm and without ST-segment elevation or equivalents and without 
CS, routine immediate ICA is not superior to a delayed invasive strategy 
based on data from the COACT (Coronary Angiography after Cardiac 
Arrest) and TOMAHAWK (Immediate Unselected Coronary 
Angiography Versus Delayed Triage in Survivors of Out-of-hospital 
Cardiac Arrest Without ST-segment Elevation) RCTs.372,373 Smaller, 
underpowered trials (EMERGE [EMERGEncy versus delayed coronary 
angiogram in survivors of out-of-hospital cardiac arrest with no obvious 
non-cardiac cause of arrest], PEARL [A Pilot Randomized Clinical Trial 
of Early Coronary Angiography Versus No Early Coronary 
Angiography for Post-Cardiac Arrest Patients Without ECG ST 
Segment Elevation], and COUPE [Coronariography in OUt of 
hosPital Cardiac arrEst]) have also pointed to the same conclu­
sion.372–377 Further detail on these trials is provided in the 
Supplementary data online, Evidence Tables.
Based on data from the COACT and TOMAHAWK trials, it appears 
reasonable to delay ICA in haemodynamically stable patients with re­
suscitated OHCA without ST-segment elevation or equivalents. Initial 
evaluation in the ED or intensive cardiac care unit (ICCU) should focus 
on excluding non-coronary causes (cerebrovascular events, respiratory 
failure, non-cardiogenic shock, PE, or intoxication). Echocardiography is 
also useful in the evaluation of these patients. The decision to perform 
selective coronary angiography (and PCI if indicated) should also con­
sider factors associated with poor neurological outcome and the likeli­
hood of ACS.
In patients who remain unresponsive after ROSC, monitoring of 
core temperature and actively preventing fever (defined as a tempera­
ture >37.7°C) is recommended to improve neurological out­
come.367,378–385 A recent study compared device-based temperature 
control of 36°C for 24 h followed by targeting of 37°C for either 12 
or 48 h (for total intervention times of 36 and 72 h, respectively) or un­
til the patient regained consciousness in 789 patients with OHCA of a 
presumed cardiac cause (∼45% with ST segment elevation on ECG; im­
mediate coronary angiography performed in 92% and PCI in 43%). This 
study reported comparable outcomes with both strategies with 
respect to the primary endpoint (death, severe disability, or coma) at 
90 days.384 In all comatose survivors, evaluation of neurological progno­
sis no earlier than 72 h after admission is recommended.367,378–383,386
7.1.1. Systems of care
There is increasing evidence suggesting that specialized hospitals for pa­
tients following OHCA (referred to as cardiac arrest centres) may be 
associated with clinical benefits.367 See Supplementary data online, 
Section 7.1.1 for expanded information on this topic.
7.2. Cardiogenic shock complicating acute 
coronary syndrome
Early revascularization with either PCI or CABG is recommended for 
patients with AMI complicated by CS, based on the results of the 
SHOCK (Should We Emergently Revascularize Occluded Coronaries 
Recommendation Table 8 — Recommendations for 
cardiac arrest and out-of-hospital cardiac arrest
Recommendations
Classa
Levelb
Cardiac arrest and OHCA
A PPCI strategy is recommended in patients with 
resuscitated cardiac arrest and an ECG with 
persistent ST-segment elevation (or 
equivalents).368,387,388
I
B
Routine immediate angiography after resuscitated 
cardiac arrest is not recommended in 
haemodynamically stable patients without persistent 
ST-segment elevation (or equivalents).373–377
III
A
Temperature control
Temperature control (i.e. continuous monitoring of 
core temperature and active prevention of fever [i.e. 
>37.7°C]) is recommended after either 
out-of-hospital or in-hospital cardiac arrest for adults 
who remain unresponsive after return of 
spontaneous circulation.378–385,389
I
B
Systems of care
It is recommended that healthcare systems 
implement strategies to facilitate transfer of all 
patients in whom ACS is suspected after resuscitated 
cardiac arrest directly to a hospital offering 24/7 PPCI 
via one specialized EMS.390–392
I
C
Transport of patients with OHCA to a cardiac arrest 
centre according to local protocols should be 
considered.391,393
IIa
C
Evaluation of neurological prognosis
Evaluation of neurological prognosis (no earlier than 
72 h after admission) is recommended in all 
comatose survivors after cardiac arrest.386
I
C
© ESC 2023
ACS, acute coronary syndrome; ECG, electrocardiogram; EMS, emergency medical 
services; OHCA, out-of-hospital cardiac arrest; PPCI, primary percutaneous coronary 
intervention. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3763


<!-- PAGE 45 -->

### Page 45

for Cardiogenic Shock) trial.394–396 While most patients will proceed to 
PCI at the time of diagnostic angiography if myocardial revascularization 
is indicated, surgical revascularization represents a valuable treatment 
option in patients in whom attempted PCI of the IRA has failed or if 
the coronary anatomy is not amenable to PCI.395,397,398 In the presence 
of CS due to AMI-related mechanical complications, surgical or percu­
taneous treatment may also be indicated and the strategy should be 
decided based on discussion between members of the Heart Team.
In the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock 
II) trial, intra-aortic balloon pump (IABP) use was not associated with 
lower 30-day mortality.399 Therefore, in the absence of mechanical com­
plications, the routine use of an IABP is not recommended for CS com­
plicating AMI. The role of mechanical circulatory devices (veno-arterial 
extracorporeal membrane oxygenation [VA-ECMO], micro-axial 
pump) in the AMI setting is not well established and large-scale rando­
mized trials are warranted.400,401 The Extracorporeal Membrane 
Oxygenation in the Therapy of Cardiogenic Shock trial randomized 
122 patients (51% with STEMI) with rapidly deteriorating or severe CS 
to either immediate implementation of VA-ECMO or an initially conser­
vative strategy (which allowed for downstream use of VA-ECMO).402
The immediate implementation of VA-ECMO did not result in improved 
clinical outcomes.402 However, the interpretation of this trial is challen­
ging because of the ∼40% crossover rate to VA-ECMO in the conserva­
tive arm, the inclusion of heterogenous phenotypes of CS, and inclusion 
of crossover in the combined primary endpoint. As a result of these lim­
itations, this trial cannot adequately answer if mechanical circulatory sup­
port (MCS) is able to reduce mortality in this setting.
It is important to note that while there is still a lack of high-quality 
randomized data supporting the use of MCS in ACS patients presenting 
with CS, some recent observational analyses have reported that the use 
of intravascular LV assist devices may be associated with an increased 
risk of adverse events in comparison to IABP in this setting, including 
mortality and bleeding.401,403 Therefore, while MCS may be considered 
in selected patients with ACS and severe/refractory CS, caution should 
be exercised in this regard until further randomized data are available. 
The management of patients with CS complicating AMI and MVD is 
presented in Section 10.
8. Management of acute coronary 
syndrome during hospitalization
8.1. Coronary care unit/intensive cardiac 
care unit
Following reperfusion, it is recommended to admit high-risk ACS pa­
tients (including all STEMI patients) to a coronary care unit (CCU) or 
ICCU. Conditions in patients with ACS that act as acute risk modifiers 
include ongoing myocardial ischaemia (e.g. failed reperfusion), acute HF 
and/or hypoperfusion, CS, cardiac arrest with coma, malignant (life- 
threatening) cardiac arrhythmias, high-degree atrioventricular block, 
and acute renal failure (with oliguria). All ICCUs must have appropriate 
diagnostic facilities to guide the delivery of pharmacological and invasive 
treatment. The staff should be thoroughly familiar with the manage­
ment of all aspects of ACS, including: arrhythmias, HF, mechanical 
circulatory support, invasive and non-invasive haemodynamic monitor­
ing (arterial and pulmonary artery pressures), respiratory monitoring, 
mechanical ventilation, and temperature control.408 The CCU/ICCU 
should also be able to manage patients with renal and pulmonary dis­
ease. The desirable organization, structure, and criteria of CCU/ 
ICCUs have been detailed in an ESC–Acute CardioVascular Care 
Association position paper.408
8.1.1. Monitoring
It is recommended to initiate ECG monitoring as soon as possible in all 
patients with ACS in order to detect life-threatening arrhythmias and al­
low prompt defibrillation if indicated. ECG monitoring for arrhythmias 
and new ST-segment elevation/depression is recommended for at least 
24 h after symptom onset in all high-risk patients with ACS, including 
all STEMI patients.409 Longer monitoring could be considered in patients 
at intermediate to high risk of cardiac arrhythmias (i.e. those with more 
than one of the following criteria: haemodynamically unstable, presenting 
with major arrhythmias, left ventricular ejection fraction [LVEF] <40%, 
failed reperfusion, additional critical coronary stenoses of major vessels, 
or complications related to PCI). Further monitoring for arrhythmias will 
be dependent on the estimated risk. When a patient leaves the ICCU or 
equivalent, monitoring may be continued by telemetry. It is recom­
mended that personnel adequately equipped and trained to manage life- 
threatening arrhythmias and cardiac arrest accompany patients who are 
transferred between facilities during the time window in which they re­
quire continuous rhythm monitoring.409
8.1.2. Ambulation
Early ambulation (i.e. out of bed on day 1) is recommended in the ma­
jority of patients with ACS. This is facilitated by using radial access for 
Recommendation Table 9 — Recommendations for 
cardiogenic shock
Recommendations
Classa
Levelb
Immediate coronary angiography and PCI of the IRA 
(if indicated) is recommended in patients with CS 
complicating ACS.394,396,404
I
B
Emergency CABG is recommended for ACS-related 
CS if PCI of the IRA is not feasible/unsuccessful.394,395
I
B
In cases of haemodynamic instability, emergency 
surgical/catheter-based repair of mechanical 
complications of ACS is recommended, based on 
Heart Team discussion.
I
C
Fibrinolysis should be considered in STEMI patients 
presenting with CS if a PPCI strategy is not available 
within 120 min from the time of STEMI diagnosis and 
mechanical complications have been ruled out.184,354
IIa
C
Continued
In patients with ACS and severe/refractory CS, 
short-term mechanical circulatory support may be 
considered.402
IIb
C
The routine use of an IABP in ACS patients with CS 
and without mechanical complications is not 
recommended.399,405–407
III
B
© ESC 2023
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CS, cardiogenic 
shock; IABP, intra-aortic balloon pump; IRA, infarct-related artery; PPCI, primary 
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 46 -->

### Page 46

invasive management. Patients with extensive myocardial damage, HF, 
hypotension, or arrhythmias may initially rest in bed before assessment 
of myocardial function and clinical stabilization. Prolongation of bed rest 
and limitation of physical activity may occasionally be required in pa­
tients with large infarcts or severe complications.
8.1.3. Length of stay in the intensive cardiac care unit
The optimal length of stay in the ICCU and hospital should be individua­
lized according to the patient’s clinical situation, taking into account 
their baseline cardiac risk and comorbidities, baseline mental/functional 
status, and social support.410,411 Of note, the majority of adverse in- 
hospital events occur early after admission and the initiation of 
treatment.
8.2. In-hospital care
8.2.1. Length of hospital stay
The impact of both successful reperfusion and knowledge of the coron­
ary anatomy (due to increasing rates of ICA) has resulted in progressive 
reductions in the length of stay after ACS, alongside significant reduc­
tions in 30-day mortality, suggesting that discharge within 72 h is not as­
sociated with late mortality.411–417 Candidates for early discharge after 
PCI can be identified using simple criteria.413,414 In one study, patients 
meeting the following criteria were considered to be ‘low risk’ and suit­
able for early discharge: age <70 years, LVEF >45%, one- or two-vessel 
disease, successful PCI, and no persistent arrhythmias.413 A recently 
published consensus document also presents a template and flow chart 
to support reasonable decision-making regarding post-procedural 
length of stay for a broad spectrum of patients undergoing PCI.418
Early (i.e. same day) transfer to a local hospital following successful 
PPCI is routine practice. This can be done safely under adequate mon­
itoring and supervision in selected patients (i.e. patients without signs or 
symptoms consistent with ongoing myocardial ischaemia, without ar­
rhythmias, who are haemodynamically stable, who are not requiring 
vasoactive or mechanical support, and who are not scheduled for fur­
ther revascularization).419
8.2.2. Risk assessment
Early and late risk stratification soon after presentation is useful to aid 
decision-making in patients presenting with ACS.
8.2.2.1. Clinical risk assessment
All patients with ACS (in particular, patients with STEMI) should have 
an early assessment of short-term risk, including an evaluation of the ex­
tent of myocardial damage, the achievement of successful reperfusion, 
and the presence of clinical markers of high risk of further events (i.e. 
older age, tachycardia, hypotension, Killip class >I, anterior MI, previous 
MI, elevated initial serum creatinine, history of HF, peripheral arterial 
disease or anaemia). Several risk scores have been developed based 
on readily identifiable parameters in the acute phase before reperfu­
sion.420,421 A number of prognostic models that aim to estimate the 
longer-term risk of all-cause mortality, or the combined risk of all-cause 
mortality or MI, have also been developed. These models have been 
formulated into clinical risk scores and, among these, the GRACE risk 
score offers the best discriminative performance and is therefore re­
commended for risk assessment.48,421–425 Additional information re­
garding the GRACE score is provided in the Supplementary data online.
8.2.2.2. Imaging risk assessment
LV dysfunction is a key prognostic factor for patients with ACS.426 It is 
recommended that the LVEF is determined before hospital discharge in 
all patients with ACS. Routine echocardiography after PPCI is recom­
mended to assess resting LV, RV, and valvular function. In addition, 
echocardiography can be used to exclude early post-infarction mechan­
ical complications and LV thrombus. In the limited number of cases in 
which echocardiography is suboptimal or inconclusive, CMR may be 
a valuable alternative.427–431
In patients presenting days after an acute ACS event with a com­
pleted MI, the presence of recurrent angina or documented ischaemia 
and proven viability in a large myocardial territory may help to guide the 
strategy of planned revascularization of an occluded IRA.192,432,433
In patients with a pre-discharge LVEF of ≤40%, re-evaluation of the 
LVEF 6–12 weeks after complete revascularization and optimal medical 
therapy is recommended to assess the potential need for primary pre­
vention implantable cardioverter defibrillator (ICD) implantation.434
Additional parameters that are measured by imaging in these patients 
and that have been used as endpoints in clinical trials include: (i) infarct 
size (CMR, SPECT, and positron emission tomography); (ii) myocar­
dium at risk (SPECT, CMR); (iii) MVO (CMR); and (iv) intra-myocardial 
haemorrhage (CMR). Infarct size, MVO and intra-myocardial haemor­
rhage are predictors of both long-term mortality and HF in STEMI sur­
vivors.435–438
8.2.2.3. Biomarkers for risk assessment
Beyond diagnostic utility, initial cTn levels add prognostic information in 
addition to clinical and ECG variables in terms of predicting the risk of 
short- and long-term mortality. While hs-cTn T and I have comparable 
diagnostic accuracy, hs-cTn T has slightly greater prognostic accuracy 
regarding mortality.61,439–441 Serial measurements are useful to identify 
peak levels of cTn for risk stratification purposes in patients with estab­
lished MI. The higher the hs-cTn levels, the greater the risk of 
death.31,55,442 However, evidence is limited regarding the optimal 
time points of serial hs-cTn measurement. Serum creatinine and 
eGFR should also be determined in all patients with ACS because 
they affect prognosis and are key elements of the GRACE risk score.443
Similarly, natriuretic peptides (brain natriuretic peptide [BNP] and 
N-terminal pro-BNP [NT-pro BNP]) provide prognostic information 
in addition to cTn regarding the risk of death and acute HF, and the de­
velopment of AF.444 Additional information on the use of biomarkers 
for this purpose is presented in the Supplementary data online.
8.2.2.4. Bleeding risk assessment
Major bleeding events are associated with increased mortality in pa­
tients with ACS.231 Further detail on scores that may be considered 
for estimation of bleeding risk is provided in the Supplementary data 
online, including Table S12.
8.2.2.5. Integrating ischaemic and bleeding risks
Major bleeding events affect prognosis in a similar way to spontaneous 
ischaemic complications.445,446 Given the trade-off between ischaemic 
and bleeding risks for any antithrombotic regimen, risk scores may be 
useful to tailor antithrombotic duration and intensity, in order to maxi­
mize ischaemic protection and minimize bleeding risk in the individual 
patient. Specific risk scores have been developed for patients on 
DAPT following PCI, in the settings of both CCS and ACS. Further de­
tail on available scores is provided in the Supplementary data online.
ESC Guidelines                                                                                                                                                                                          3765


<!-- PAGE 47 -->

### Page 47

### 9 Technical aspects of invasive

strategies
9.1. Percutaneous coronary intervention
9.1.1. Vascular access
Timely PCI with concomitant antithrombotic drugs has reduced the 
ischaemic risk in patients with ACS. However, this strategy is also 
associated with an increased bleeding risk, which affects prognosis 
at least as much as ischaemic complications and is associated with im­
paired survival.448,449 Among patients undergoing PCI, access-related 
bleeding accounts for 30–70% of total bleeding events.450 There is 
strong evidence demonstrating that reducing access-site bleeding 
events with the use of radial access translates into significant clinical 
benefits.448,449 The largest randomized trials on this topic in patients 
with ACS are the RadIal Vs femorAL access for coronary intervention 
(RIVAL) trial with 7021 ACS patients and the Minimizing Adverse 
Haemorrhagic Events by TRansradial Access Site and Systemic 
Implementation of angioX (MATRIX) trial with 8404 ACS patients 
(47.6% with STEMI).451,452 These trials have demonstrated signifi­
cantly lower rates of access site-related bleeding, surgical access 
site repair, and blood transfusion with radial compared with femoral 
access. In the MATRIX trial, no significant interaction was observed 
between the type of ACS and the benefit associated with the radial 
approach, suggesting that the results of this trial can be extended 
to patients across the entire spectrum of ACS.453 In a cost- 
effectiveness analysis of the MATRIX trial, radial access was also as­
sociated with significant savings in terms of quality-adjusted life years 
and PCI-related costs.454 Therefore, radial access is recommended as 
the preferred approach in ACS patients undergoing invasive assess­
ment with or without PCI. However, femoral access may still be se­
lectively chosen instead of radial access in certain patients (i.e. 
depending on the haemodynamic situation and other technical as­
pects during the index PCI procedure).
9.1.2. Intravascular imaging/physiology of the 
infarct-related artery
9.1.2.1. Intravascular imaging
As a diagnostic tool, intravascular imaging is useful in ACS patients 
without significant obstructive CAD on coronary angiography. 
Excluding an atherothrombotic cause in the main coronary arteries 
for the ACS may have important clinical implications, not only for im­
mediate invasive management but also for potentially lifelong 
antithrombotic therapies. Intravascular imaging is also useful in cases 
where there is ambiguity regarding the culprit lesion. Culprit lesion 
ambiguity can be present in more than 30% of patients with sus­
pected NSTE-ACS and over 10% of patients may have multiple cul­
prit lesions.455,456 The recommendations for intravascular imaging 
in ACS are presented in Figure 13.
The role of intravascular imaging is well established as a tool to guide 
and optimize PCI. Evidence in support of intravascular ultrasound 
(IVUS) guidance in ACS generally derives from subgroup analyses of all- 
comers trials. Meta-analysis of available randomized trials confirms the 
superiority of IVUS guidance in the reduction of MACE, although a de­
finitive, large-scale, multinational trial is missing.457–459 Smaller RCTs 
have evaluated the role of optical coherence tomography (OCT) 
(see Supplementary data online).460
Recommendation Table 10 — Recommendations for 
in-hospital management
Recommendations
Classa
Levelb
Logistical issues for hospital stay
It is recommended that all hospitals participating in 
the care of high-risk patients have an ICCU/CCU 
equipped to provide all required aspects of care, 
including treatment of ischaemia, severe heart failure, 
arrhythmias, and common comorbidities.
I
C
It is recommended that high-risk patients (including all 
STEMI patients and very high-risk NSTE-ACS 
patients) have ECG monitoring for a minimum of 24 h.
I
C
It is recommended that high-risk patients with 
successful reperfusion therapy and an uncomplicated 
clinical course (including all STEMI patients and very 
high-risk NSTE-ACS patients) are kept in the CCU/ 
ICCU for a minimum of 24 h whenever possible, after 
which they may be moved to a step-down monitored 
bed for an additional 24–48 h.
I
C
Discharge of selected high-risk patients within 48– 
72 h should be considered if early rehabilitation and 
adequate follow-up are arranged.411,413,415,447
IIa
A
Same-day transfer in selected stable patients after 
successful and uneventful PCI should be 
considered.419
IIa
C
Imaging
Routine echocardiography is recommended during 
hospitalization to assess regional and global LV 
function, detect mechanical complications, and 
exclude LV thrombus.
I
C
When echocardiography is suboptimal/inconclusive, 
CMR imaging may be considered.
IIb
C
© ESC 2023
ACS, acute coronary syndrome; CCU, cardiac care unit; CMR, cardiac magnetic resonance; 
ECG, electrocardiogram; ICCU, intensive cardiac care unit; LV, left ventricular; NSTE-ACS, 
non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary 
intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 48 -->

### Page 48

9.1.2.2. Intravascular physiology
Intracoronary physiology is increasingly being used in patients with 
ACS to assess the haemodynamic significance of intermediate severity 
non-IRA stenoses (see Section 10). However, PCI of the IRA should 
not be deferred based on invasive epicardial functional assessment 
in patients with ACS. The coronary microcirculation begins to re­
cover within 24 h of PPCI and acute functional assessment of the 
IRA may underestimate the true haemodynamic severity of the cor­
onary stenosis.461 Beyond 1 week from the acute event, fractional 
flow reserve (FFR) measurement has been reported to reliably predict 
abnormal nuclear imaging results.462 Additional information about the 
role of intracoronary physiology in the IRA is presented in the 
Supplementary data online.
9.1.3. Timing of revascularization with percutaneous 
coronary intervention
In some patients with ACS undergoing ICA, an initial conservative man­
agement strategy with optimized guideline-directed medical therapy 
may be considered on a case-by-case basis. The specific circumstances 
include ACS patients with small calibre vessels, an occluded small side 
branch, or concerns regarding non-compliance with antithrombotic 
Working diagnosis: ACS
Clear culprit lesion,
suitable for PCI
No clear culprit lesion
PCI of culprit lesion
Consider further investigations as required
Treat as per imaging findings
Intravascular imaging to guide PCI
(Class lla)
Intravascular imaging
Potential ambiguous 
angiographic findings 
Multivessel disease
Hazy lesion/calcification 
Tortuosity/eccentricity
Potential further investigations
Left ventriculography
Echocardiography
Cardiac MRI
Potential intravascular imaging findings
Coronary plaque pathology
Erosion
Nodule
Rupture
IVUS
or
OCT
Intravascular imaging
(preferably OCT) in patients with ambiguous culprit lesions
(Class llb)
Coronary angiography
SCAD
No lesion
Figure 13 A practical algorithm to guide intravascular imaging in acute coronary syndrome patients. ACS, acute coronary syndrome; IVUS, intravascular 
ultrasound; MRI, magnetic resonance imaging; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; SCAD, spontaneous coronary 
artery dissection.
ESC Guidelines                                                                                                                                                                                          3767


<!-- PAGE 49 -->

### Page 49

therapy. In the context of complex CAD and anticipated complex PCI, 
an initial conservative strategy in medically stabilized patients without 
ongoing symptoms allows time for Heart Team discussion regarding 
the optimal revascularization strategy.
9.1.4. Balloons and stents
New-generation DES are associated with superior safety and improved 
efficacy compared with bare metal stents (BMS) and first-generation 
DES. The Norwegian Coronary Stent Trial (NORSTENT)—the largest 
clinical trial comparing outcomes of patients treated with new- 
generation DES or BMS—reported that the primary endpoint of death 
or MI was comparable in both treatment groups. Both target lesion re­
vascularization (TLR) and stent thrombosis were reduced in the DES 
group and there was no treatment effect by ACS presentation inter­
action for the primary endpoint.463 The COMFORTABLE-AMI 
(Comparison of Biolimus Eluted From an Erodible Stent Coating 
With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) 
and EXAMINATION (Everolimus-Eluting Stents Versus Bare-Metal 
Stents in ST Segment Elevation Myocardial Infarction) trials have also 
reported the clinical superiority of DES over BMS in terms of lower 
rates of re-infarction, target lesion revascularization, and stent throm­
bosis.464,465 This clinical benefit was preserved at longer-term follow- 
up.466–468
A strategy of drug-coated balloon (DCB) angioplasty without 
stenting has also been proposed for patients with NSTE-ACS. In the 
small, 
prospective, 
randomized, 
single-centre 
REVELATION 
(REVascularization With PaclitaxEL-Coated Balloon Angioplasty 
Versus Drug-Eluting Stenting in Acute Myocardial InfarcTION) trial, 
DCB PCI vs. DES PCI was investigated in 120 patients undergoing 
PPCI. The primary endpoint of target vessel FFR at 9 months was 
not significantly different between the two groups.469 In the small 
PEPCAD NSTEMI (Bare Metal Stent Versus Drug Coated Balloon 
With Provisional Stenting in Non-ST-Elevation Myocardial Infarction) 
trial, 210 patients were randomized to compare a DCB with primary 
stent treatment (BMS or DES).470 During a mean follow-up period of 
9.2 months, DCB treatment was non-inferior to treatment with a stent, 
with a target lesion failure (primary study endpoint) rate of 3.8% vs. 
6.6% (P = 0.53). Given the limitations of these studies (in particular, 
the relatively small sample sizes), the use of DCB in NSTE-ACS requires 
further investigation in order to better inform future guideline 
recommendations.471
9.1.5. Embolic protection and microvascular salvage 
strategies
9.1.5.1. Thrombus aspiration
Large RCTs have failed to demonstrate a clinical benefit with routine 
manual thrombus aspiration in comparison to conventional PPCI.472– 
474 In an individual patient data meta-analysis, thrombus aspiration 
was associated with fewer CV deaths and with more strokes or transi­
ent ischaemic attacks in the subgroup of patients with high thrombus 
burden (TIMI thrombus Grade 3).475 However, in a sub-analysis from 
TOTAL (a Trial of routine aspiration ThrOmbecTomy with PCI vs. 
PCI ALone in patients with STEMI), routine thrombus aspiration did 
not improve outcomes at 1 year and was also associated with an in­
creased rate of stroke in patients with high thrombus burden.476 In pa­
tients with NSTE-ACS and thrombus-containing lesions, PCI with 
adjunctive thrombus aspiration was not associated with a reduction 
in MVO 4 days after the index procedure or with fewer MACE after 
up to 1 year of follow-up.477 Based on these data, routine thrombus 
aspiration is not recommended, but in cases of large residual thrombus 
burden after opening the vessel with a guide wire or a balloon, throm­
bus aspiration may be considered.
9.1.5.2. Interventions to protect the microcirculation
The damage inflicted on the myocardium during AMI is the result of is­
chaemia and subsequent reperfusion (ischaemia/reperfusion injury). In 
patient-level pooled analyses, infarct size and MVO are independent 
predictors of long-term mortality and HF in survivors of 
STEMI.436,478 Strategies to reduce ischaemia/reperfusion injury in gen­
eral (and MVO in particular) remain an unmet clinical need. Further in­
formation regarding interventions to protect the microcirculation that 
are under clinical or experimental investigation is presented in the 
Supplementary data online.
9.2. Coronary artery bypass grafting
9.2.1. Indication and timing of coronary artery bypass 
grafting in acute coronary syndrome patients
There are no dedicated RCTs comparing percutaneous vs. surgical re­
vascularization in patients with ACS. In the setting of STEMI, CABG 
should be considered only when PPCI is not feasible, particularly in 
the presence of ongoing ischaemia or large areas of jeopardized 
myocardium.479
In patients requiring immediate revascularization in the setting of 
very high-risk NSTE-ACS, PCI is usually preferred for reasons of time­
liness, unless concomitant mechanical complications dictate a prefer­
ence for surgical intervention.
In other patients with ACS, the choice of revascularization modality 
should be made according to the number of diseased vessels and  the gen­
eral principles of myocardial revascularization.250 In patients with MVD, 
the choice of revascularization modality will be influenced by the overall 
anatomical disease complexity and the presence of comorbidities (includ­
ing diabetes) in patients with low predicted surgical risk and mortality who 
are considered suitable for either modality. This is based on data from two 
large-scale individual patient meta-analyses.480,481
9.2.2. Technical considerations specific to acute 
coronary syndrome patients
The patient profile, including the need for emergency or extremely ex­
peditious revascularization, may influence both the technique of CABG 
(including on-pump beating heart CABG) and the choice and use of 
CABG conduits. The need for prompt surgical revascularization in 
emergency circumstances does not facilitate the use of full arterial re­
vascularization due to the prolonged period required for graft harvest­
ing. Accordingly, the use of total venous graft-based CABG or the use 
of single left internal mammary artery plus additional venous grafts may 
be useful in this setting.397
9.3. Spontaneous coronary artery 
dissection
Spontaneous coronary artery dissection (SCAD) is an infrequent cause 
of ACS in general but accounts for a significant proportion of ACS cases 
in young/middle-aged women.482 The pathophysiology underlying SCAD 
is different to that of Type 1 MI and there are some differences in its man­
agement and outcomes. For these reasons, it is of paramount importance 
that an accurate diagnosis is established. Until evidence from ongoing 
prospective trials becomes available, patients with SCAD should receive 
the same pharmacological therapy as other ACS patients.483


<!-- PAGE 50 -->

### Page 50

9.3.1. Intravascular imaging
There are no RCTs to guide management strategies in patients with 
SCAD. The use of intravascular imaging is based on observations re­
ported from clinical cohort studies and expert opinion.482,484,485 In 
cases of diagnostic uncertainty after angiography, the use of intracor­
onary imaging with OCT or IVUS has to be carefully considered. 
There should be sufficient diagnostic uncertainty to justify coronary 
instrumentation, and even if this is the case, other factors like vessel 
tortuosity, vessel diameter, and a distal lesion location may prohibi­
tively increase the risk.482 If the decision is made to perform intravas­
cular imaging, it is imperative to ensure the guide wire is located within 
the true lumen of the coronary artery before advancing the imaging 
catheter.482 In patients with a diagnosis of SCAD on angiography 
and a plan for medical therapy, additional coronary instrumentation 
and intravascular imaging is not recommended on safety 
grounds.482,484,485
9.3.2. Revascularization
Conservative medical management, as opposed to PCI, is generally re­
commended for patients with SCAD.482 In an international case series, 
coronary complications following PCI occurred in >30% of pa­
tients.486–488 In a pooled analysis of three SCAD-PCI cohorts including 
215 patients (94% female) drawn from Dutch, Spanish, and UK regis­
tries, and a matched cohort of conservatively managed SCAD patients 
(n = 221), PCI was associated with complications in ≈40% of cases (in­
cluding 13% with serious complications). PCI is recommended only for 
SCAD with associated symptoms and signs of ongoing myocardial is­
chaemia, a large area of myocardium in jeopardy, and reduced ante­
grade flow. Useful strategies for these patients may include minimal 
plain balloon angioplasty to restore flow, followed by a conservative 
strategy, targeted stenting to seal the proximal and distal ends of the 
dissection, and/or extended stent lengths to prevent propagation of 
the haematoma. In patients with SCAD, CABG is recommended 
when dissection affects the left main or two proximal vessels, if PCI 
is not feasible or unsuccessful, and if there are symptoms and signs of 
ongoing myocardial ischaemia. In a small observational study, patients 
with SCAD treated with CABG had favourable early clinical outcomes, 
with an event rate up to 5 years similar to that of patients treated con­
servatively, despite a significant (68%) rate of graft occlusion at 5 
years.486 The rate of graft occlusion over time can be explained by 
the fact that CABG in these patients may be technically challenging as 
the dissected coronary artery is more prone to anastomosis failure, 
and because spontaneous healing over time may restore the flow in 
the anastomosed vessel.486,489 For this reason, vein grafts should be 
considered in these patients in order to preserve arterial conduits for 
future use.485
10. Management of patients with 
multivessel disease
Approximately half of ACS patients have coronary MVD.500
Management of non-IRA disease varies depending on the clinical 
setting.
10.1. Management of multivessel disease in 
acute coronary syndrome complicated by 
cardiogenic shock
Cardiogenic shock may occur in up to 4–11% of ACS patients, and oc­
curs more frequently in the presence of complete coronary occlu­
sion.501,502 Ischaemia-related HF, acute severe mitral regurgitation, 
and mechanical complications are the major precipitating causes of 
CS in ACS. Irrespective of the mode of presentation (i.e. with or with­
out ST-segment elevation or equivalent ECG patterns), these patients 
should be transferred as soon as possible to a tertiary care centre (e.g. a 
shock centre) where ICA can be performed, supported by specialists 
with relevant experience (the Shock Team).503,504
In the SHOCK trial, which compared emergency revascularization 
with initial medical stabilization in 302 patients with acute MI compli­
cated by CS, ∼60% had anterior MI and 85% had MVD.394 Among 
the patients assigned to emergency revascularization, 64% underwent 
PCI and 36% underwent CABG. There were no differences in mortality 
at 30 days (primary endpoint), but at 6 months mortality was lower in 
the group assigned to revascularization than in the group assigned to 
medical therapy. Based on this evidence, immediate coronary angiog­
raphy, and PCI if feasible, is recommended in patients with acute MI 
complicated by CS. In patients with coronary anatomy unsuitable for 
PCI, emergency CABG is recommended.394
Nearly 80% of ACS patients with CS have MVD. Based on the Culprit 
Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock 
(CULPRIT-SHOCK) trial including ACS patients (both with and with­
out ST-segment elevation or equivalent), PCI during the index 
Recommendation Table 11 — Recommendations for 
technical aspects of invasive strategies
Recommendations
Classa
Levelb
Radial access is recommended as the standard 
approach, unless there are overriding procedural 
considerations.451,452
I
A
PCI with stent deployment in the IRA during the 
index procedure is recommended in patients 
undergoing PPCI.490–494
I
A
Continued
Drug-eluting stents are recommended in preference 
to bare metal stents in all cases.463,466,468
I
A
In patients with spontaneous coronary artery 
dissection, PCI is recommended only for patients 
with symptoms and signs of ongoing myocardial 
ischaemia, a large area of myocardium in jeopardy, 
and reduced antegrade flow.
I
C
Intravascular imaging should be considered to guide 
PCI.495–499
IIa
A
Coronary artery bypass grafting should be 
considered in patients with an occluded IRA when 
PPCI is not feasible/unsuccessful and there is a large 
area of myocardium in jeopardy.
IIa
C
Intravascular imaging (preferably optical coherence 
tomography) may be considered in patients with 
ambiguous culprit lesions.
IIb
C
The routine use of thrombus aspiration is not 
recommended.472–474
III
A
© ESC 2023
IRA, infarct-related artery; PCI, percutaneous coronary intervention; PPCI, primary 
percutaneous coronary intervention. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3769


<!-- PAGE 51 -->

### Page 51

procedure should be restricted to the IRA only.404
In the 
CULPRIT-SHOCK trial, IRA-only PCI was associated with a significant 
reduction in all-cause death or renal replacement therapy at 30-day 
follow-up (RR 0.83, 95% CI, 0.71–0.96).404 At 1-year follow-up, mortal­
ity did not differ significantly between the two groups.505
For patients undergoing emergency CABG, appropriate peri- 
operative strategies (particularly in relation to prophylactic or on- 
demand mechanical circulatory support) may be considered based on 
pre-operative clinical status (e.g. age, comorbidities, electrical instability, 
the extent of jeopardized myocardium, the duration of ischaemia from 
the time of symptom onset, right ventricular involvement, and the feasi­
bility of cardiac surgery from technical/logistical perspectives). Figure 14
shows the algorithm for the management of patients with ACS and 
MVD.
10.2. Patients with multivessel coronary 
artery disease undergoing primary 
percutaneous coronary intervention
Multivessel disease is evident in approximately half of patients undergo­
ing PPCI and is associated with an adverse prognosis.506,507
Over the past decade, a series of RCTs have provided clinical evidence 
that supports preventive revascularization of non-IRA after successful 
PPCI of the IRA. The pivotal clinical trials (in chronological order) include 
PRAMI (Preventive Angioplasty in Myocardial Infarction), CvLPRIT 
(Complete versus Lesion-only Primary PCI Trial), DANAMI-3– 
PRIMULTI (Third Danish Study of Optimal Acute Treatment of 
Patients with ST-Segment Elevation Myocardial Infarction—Primary 
PCI in Multivessel Disease), COMPARE-ACUTE (Comparison 
Cardiogenic shock
STEMI
Patient with ACS undergoing PCI of IRA with an angiographically significant stenosis in ≥ 1 non-IRA
Complete revascularization,
either during the index procedure or within
45 daysa
(Class I)
NSTE-ACS
Immediate PCI of IRA only
(Class I)
Staged complete revascularization
(Class IIa)
Complete revascularizationb
(Class IIa)
Functional invasive evaluation of the non-IRA
during the index procedure
(Class IIb)
Figure 14 Algorithm for the management of acute coronary syndrome patients with multivessel coronary artery disease. CABG, coronary artery bypass 
grafting; IRA, infarct-related artery; MVD, multivessel disease; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary inter­
vention; STEMI, ST-elevation myocardial infarction; TIMI, Thrombolysis In Myocardial Infarction.aIn patients presenting with STEMI and MVD without CS, 
complete revascularization either during the index PCI procedure or within 45 days, with PCI of non-IRA based on angiographic severity, is recommended. 
bIn patients presenting with NSTE-ACS and MVD, complete revascularization, preferably during the index procedure should be considered. Functional in­
vasive evaluation of non-IRA severity during the index procedure may be considered.


<!-- PAGE 52 -->

### Page 52

Between FFR Guided Revascularization Versus Conventional Strategy in 
Acute STEMI Patients With MVD), and COMPLETE (Complete vs. 
Culprit-only Revascularization to Treat Multivessel Disease After Early 
PCI for STEMI) (further details on these trials is provided in the 
Supplementary data online evidence tables).508–511
In a systematic review of 10 randomized trials that included 7030 pa­
tients with STEMI and MVD, complete revascularization was associated 
with reduced CV mortality compared with IRA-only PCI.512 All-cause 
mortality was comparable in both groups. Complete revascularization 
was also associated with a reduced composite of CV death or new MI, sup­
porting complete revascularization in patients with STEMI and MVD.512
10.3. Timing of non-infarct-related artery 
revascularization in acute coronary 
syndrome
10.3.1. Patients presenting with ST-elevation 
myocardial infarction and multivessel coronary 
artery disease
The previous ESC STEMI Guidelines recommended non-IRA PCI dur­
ing the index procedure. The primary rationale for this recommenda­
tion was that all trials available until then had performed MVD PCI in 
that time frame. However, in the COMPLETE trial, non-IRA PCI in pa­
tients allocated to complete revascularization was performed either 
during hospitalization (67% of cases) or after discharge (33% of cases), 
at a mean time of 23 days after discharge but always within 45 days.511
No treatment effect by timing of PCI interaction was observed. Given 
that the optimal timing of revascularization (immediate vs. staged) has 
still not been investigated in adequately sized randomized trials with a 
superiority design, no recommendation in favour of an immediate vs. 
a staged (i.e. either during index hospitalization or within 45 days of dis­
charge) non-IRA PCI strategy can be formulated. No surgical studies 
have specifically investigated non-IRA revascularization.
10.3.2. Patients presenting with non-ST-elevation 
acute coronary syndrome and multivessel coronary 
artery disease
While there are a large number of studies providing evidence for patients 
presenting with STEMI and MVD, there are fewer data guiding the man­
agement of patients presenting with NSTE-ACS and MVD.513 Currently, 
there is no dedicated trial comparing complete revascularization against 
IRA-only PCI for these patients. Observational studies and meta-analyses 
of non-randomized studies suggest that complete revascularization is as­
sociated with fewer deaths and MACE during follow-up in comparison to 
IRA-only PCI.514,515 However, given that these are analyses of treatment 
effects based on non-randomized studies, the results should be consid­
ered as hypothesis-generating at best and this remains a gap in evidence.
10.4. Evaluation of non-infarct-related 
artery stenosis severity (angiography vs. 
physiology)
Overestimation of the severity of non-IRA lesions during the PPCI proced­
ure when assessed by quantitative coronary angiography as compared 
with a repeated angiogram performed within 9 months has been re­
ported.516 Microvascular constriction may also occur in the non-IRAs, 
leading to some variation in functional measurements between baseline 
and follow-up, although the impact on decision-making may be mo­
dest.517–520 A sub-analysis of the FAME (Fractional Flow Reserve versus 
Angiography for Multivessel Evaluation) trial reported that 65% of lesions 
in the angiographic severity range of 50–70% diameter stenosis, and 20% of 
lesions in the range 71–90%, have an FFR value above 0.80.521
The PRIME-FFR registry included 533 ACS patients and reported that 
systematic FFR measurement led to a change in the management strategy 
in 38% of cases (e.g. from CABG to PCI or to medical treatment), without 
an impact on MACE, death/MI, or angina symptoms at 1 year.522 A sub­
group analysis of the FAME trial in 328 patients with ACS (UA or 
NSTEMI) and MVD reported that the adoption of FFR to guide PCI re­
sulted in similar risk reductions of MACE compared with patients with 
stable angina, with a lower number of stents implanted and less contrast 
media use.523 The FAMOUS-NSTEMI (Fractional Flow Reserve Versus 
Angiographically Guided Management to Optimise Outcomes in 
Unstable Coronary Syndromes) trial randomized 350 patients with 
NSTE-ACS and at least one coronary stenosis (with diameter stenosis 
>30%) to either angiography-guided or FFR-guided management (medical 
therapy, PCI, or CABG), and demonstrated that a higher proportion of 
patients in the FFR-guided management group were initially treated 
with medical therapy. The FLOWER-MI (Flow Evaluation to Guide 
Revascularization in Multivessel ST-Elevation Myocardial Infarction) study 
randomized 1171 patients undergoing PPCI with MVD to complete re­
vascularization guided by FFR or angiography. Compared with an 
angiography-guided approach, an FFR-guided strategy did not reduce 
the risk of death, MI, or urgent revascularization at 1 year.524 PCI was per­
formed in 66.2% of patients in the FFR-guided group and in 97.1% of the 
angiography-guided group. In FLOWER-MI, complete revascularization 
during the index procedure was only performed in 4% of patients in 
both groups, and functional evaluation was mainly undertaken at the 
time of the second procedure.524 However, based on the study design, 
complete revascularization could also be performed during a separate 
staged procedure as early as possible before hospital discharge and within 
5 days of the initial procedure.
A meta-analysis of 10 RCTs (including 3031 patients undergoing PPCI) 
assessed outcomes in patients with complete revascularization vs. 
IRA-only PCI according to whether the decision to carry out non-IRA 
preventive PCI was based on angiography alone or on angiography plus 
FFR.525 Preventive PCI of the non-IRA was associated with a significant 
reduction in cardiac death and non-fatal MI only when the decision to 
proceed with non-IRA PCI was based solely on angiography. Similar find­
ings were reported in another meta-analysis of seven RCTs including a 
total of 6597 patients undergoing PPCI.526 In patients randomised to 
the complete revascularization arm, an angiography-guided strategy 
(≥70% diameter stenosis) for non-IRA lesions was associated with lower 
rates of recurrent MI, whereas an FFR-guided (≤0.80 for lesions with 
≤90% diameter stenosis) guided approach was not. In another 
meta-analysis, which pre-dated the FLOWER-MI trial, there was no het­
erogeneity in the primary outcome when complete revascularization was 
performed using an FFR-guided strategy (OR 0.78, 95% CI, 0.43–1.44) or 
an angiography-guided strategy (OR 0.61, 95% CI, 0.38–0.97; P = 0.52 for 
interaction).512 A pooled post-hoc patient-level analysis of three RCTs 
(FAME, DANAMI-3–PRIMULTI, and FAMOUS-NSTEMI) in ACS pa­
tients treated with a functionally complete revascularization strategy 
(i.e. PCI of the stenosis with FFR ≤0.80, deferral to medical therapy sten­
osis with FFR >0.80) reported that the residual SYNTAX score (a proxy 
of the residual coronary stenosis deferred to medical therapy) was not 
associated with MACE at 2 years, suggesting that it may be safe to defer 
the management of functionally non-significant stenoses in the 
non-IRA.527 The FRAME AMI (FFR Versus Angiography-Guided 
Strategy for Management of AMI With Multivessel Disease) trial com­
pared selective PCI guided by FFR (PCI if FFR ≤0.80) to routine PCI 
ESC Guidelines                                                                                                                                                                                          3771


<!-- PAGE 53 -->

### Page 53

guided by angiography (PCI if diameter stenosis >50%) of the non-IRA(s) 
in patients presenting with AMI who had undergone successful PCI of the 
IRA (47% STEMI, 53% NSTEMI).528 This study reported that at a median 
follow-up of 3.5 years, the primary endpoint (death, MI, or repeat revas­
cularization) occurred less frequently in patients randomized to the 
FFR-guided strategy, mainly driven by differences in patients presenting 
with NSTEMI. However, the trial was terminated early, with only 562 
out of an intended 1292 patients enrolled, and there was a relatively small 
number of primary outcome events.
10.5. Hybrid revascularization
Hybrid coronary revascularization (HCR) is defined as combined or 
consecutive procedures consisting of an internal mammary artery graft 
to the left anterior descending artery (LAD) and PCI to the other 
non-LAD vessels for the treatment of MVD.529 The preferred surgical 
technique for HCR is a minimally invasive left anterior mini- 
thoracotomy or robotic-assisted left internal mammary artery 
(LIMA)-LAD. The rationale for HCR is to combine the prognostic ben­
efits of a LIMA for grafting of the LAD with the potential benefits of 
contemporary PCI with DES for disease in arteries that would other­
wise be revascularized using vein grafts (which are prone to occlu­
sion).530 There is limited evidence from RCTs to support hybrid 
revascularization. Clinical decision-making in this regard should involve 
the Heart Team. Clinical criteria supporting an HCR strategy in ACS pa­
tients with an indication for CABG may include MVD with LAD suitable 
for CABG and non-LAD lesions suitable for PCI, atheroma in the as­
cending aorta, an unprotected left main coronary artery that is unsuit­
able for PCI, complex LAD disease, advanced age, low LVEF (≤30%), 
frailty, diabetes mellitus, renal failure, prior sternotomy, and the lack 
of available bypass conduits.
11. Myocardial infarction with 
non-obstructive coronary arteries
Myocardial infarction with non-obstructive coronary arteries 
(MINOCA) refers to the clinical situation when a patient presents 
with symptoms suggestive of ACS, demonstrates troponin elevation, 
and has non-obstructive coronary arteries at the time of coronary angi­
ography (defined as coronary artery stenosis <50% in any major epicar­
dial vessel). The reported prevalence of MINOCA varies widely across 
studies (from around 1% to 14% of patients with ACS undergoing angi­
ography).533 MINOCA can be considered as an umbrella term that en­
compasses a heterogeneous group of underlying causes. This includes 
both coronary and non-coronary pathologies, with the latter including 
both cardiac and extra-cardiac disorders (Figure 15).4,18,534–537
Recommendation Table 12 — Recommendations for 
management of patients with multivessel disease
Recommendations
Classa
Levelb
It is recommended to base the revascularization 
strategy (IRA PCI, multivessel PCI/CABG) on the 
patient’s clinical status and comorbidities, as well as 
their disease complexity, according to the principles 
of management of myocardial 
revascularization.480,481
I
B
Multivessel disease in ACS patients presenting in cardiogenic 
shock
IRA-only PCI during the index procedure is 
recommended.404,505
I
B
Staged PCI of non-IRA should be considered.c
IIa
C
Continued
Multivessel disease in haemodynamically stable STEMI patients 
undergoing PPCI
Complete revascularization is recommended either 
during the index PCI procedure or within 45 
days.508–511,531
I
A
It is recommended that PCI of the non-IRA is based 
on angiographic severity.511,524
I
B
Invasive epicardial functional assessment of 
non-culprit segments of the IRA is not 
recommended during the index procedure.
III
C
Multivessel disease in haemodynamically stable NSTE-ACS 
patients undergoing PCI
In patients presenting with NSTE-ACS and MVD, 
complete revascularization should be considered, 
preferably during the index procedure.513,514
IIa
C
Functional invasive evaluation of non-IRA severity 
during the index procedure may be 
considered.518,527,528,532
IIb
B
© ESC 2023
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; IRA, 
infarct-related artery; MVD, multivessel disease; NSTE-ACS, non-ST-elevation acute 
coronary syndrome; PCI, percutaneous coronary intervention; PPCI, primary 
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence. 
cBased on ischaemia, symptoms, patient comorbidities, and clinical condition.


<!-- PAGE 54 -->

### Page 54

When a diagnosis is not established following coronary angiography, 
MINOCA represents a working diagnosis as opposed to a final diagno­
sis. It is vital for clinicians to perform further assessments and investiga­
tions to establish the underlying cause of the MINOCA, which will allow 
a final diagnosis to be established and patients to be managed appropri­
ately. Failure to identify the underlying cause of MINOCA may result in 
inadequate or inappropriate therapy.
ICA is the recommended definitive diagnostic test for ACS pa­
tients. If the underlying cause of MINOCA is not established using 
ICA alone, further evaluation using left ventriculography (including 
measurement of LV end-diastolic pressure), functional assessment 
with measurement of microvascular function/coronary reactivity, 
and intravascular imaging can be useful to identify the underlying 
cause.456,538,539 The term ‘functional coronary angiography’ refers 
to the combination of coronary angiography with adjunctive tests 
(e.g. testing for coronary microvascular dysfunction and vasoreactiv­
ity) (Figure 16).
Non-coronary, cardiac causes
Coronary embolism
Coronary microvascular dysfunction
Coronary spasm
Coronary thrombosis
Myocardial bridging
Plaque rupture/erosion
Spontaneous coronary artery dissection
Coronary causes
Acute respiratory distress syndrome
Allergic/hypersensitivity reactions
End-stage renal failure
Inﬂammation
Pulmonary embolism
Sepsis
Stroke
Non-cardiac causes
Cardiac trauma
Cardiomyopathy
Cardiotoxins
Myocarditis
Strenuous exercise
Takotsubo cardiomyopathy
Transplant rejection
Figure 15 Underlying causes for patients with a working diagnosis of myocardial infarction with non-obstructive coronary arteries. This figure outlines 
some of the potential differential diagnoses in patients with a working diagnosis of MINOCA after coronary angiography, but this list is not exhaustive.
ESC Guidelines                                                                                                                                                                                          3773


<!-- PAGE 55 -->

### Page 55

Cath lab assessment
Step 1
Clinical history
Assessments to considera
Ward assessment
Step 2
Post discharge care
Step 3
Detailed angiographic 
assessment ± LV
angiography (incl. LVeDP)
Physical exam
Intravascular imaging
(IVUS/OCT)
ECG assessment
Assess for coronary microvascular dysfunction
± vasoreactivity (ACh testing)
Clinical history
Assessments to considera
CMRI
Physical exam
Blood testsb
ECG assessment
CTPA/CT brainc
Echocardiography
Assessments to considera
The MINOCA diagnostic algorithm
Follow-up clinic evaluation
Repeat echocardiography
Repeat
CMRI
Cardiac rehabilitation
Figure 16 Evaluation of patients with a working diagnosis of MINOCA. ACh, acetylcholine; CMRI, cardiac magnetic resonance imaging; CT, computed 
tomography; CTPA, computed tomography pulmonary angiogram; ECG, electrocardiogram; IVUS, intravascular ultrasound; LV, left ventricular; LVeDP, 
left ventricular end-diastolic pressure; MINOCA, myocardial infarction with non-obstructive coronary arteries; NSTE-ACS, Non-ST elevation acute coron­
ary syndrome; NTpro BNP, N terminal pro brain natriuretic peptide; OCT, optical coherence tomography; STEMI, ST-elevation myocardial infarction; UA, 
unstable angina. Patients presenting with STEMI present directly to catheter lab as per the current standard of care pathway (1). In this context, when non- 
obstructive coronary arteries are identified then further assessment should be considered. When patients are subsequently admitted to the ward then in­
vestigations as shown in (2) should be considered. Patients presenting with NSTE-ACS or UA are often stabilized on the ward (2) prior to transfer to the 
cath lab (1). In this context the order in which the investigations are carried out will vary depending on the location these patients are managed during first 
contact. MINOCA patients require follow-up review (3) and may require repeat assessment using echocardiography and magnetic resonance imaging, de­
pending on the initial findings. aOptions for adjunctive tests. Patients will not require all investigations but instead the appropriate tests should be selected 
based on their presentation and clinical course. bExamples of potential blood tests include: full blood count, renal profile, troponin, C-reactive protein, 
D-dimer, NT-pro BNP. cA CT scan of the brain should be considered if a cranial pathology (i.e. intracranial bleed) is suspected that might have resulted 
in ST elevation.


<!-- PAGE 56 -->

### Page 56

If the underlying cause of MINOCA is not established using functional 
coronary angiography, then non-invasive imaging (i.e. echocardiog­
raphy, CMR, CT) is recommended, as clinically appropriate. CMR is 
one of the key diagnostic tools to determine the underlying cause of 
MINOCA.540–544 CMR can identify the underlying cause in up to 87% 
of patients with a working diagnosis of MINOCA and should be per­
formed as soon as possible after presentation in these patients to maxi­
mize its diagnostic yield, ideally during the index admission.545
Diagnosis of the underlying cause of MINOCA will enable the appro­
priate treatment to be initiated based on the final diagnosis. Secondary 
prevention therapies should be considered for those with evidence of 
coronary atherosclerotic disease and to control risk factors. The man­
agement of takotsubo syndrome is not informed by any prospective 
RCTs, and treatment is largely supportive and empiric.546,547 The treat­
ment of patients with myocarditis has been covered by previous ESC 
documents.548,549 Ischemia with non-obstructive coronary arteries 
(INOCA) has also been described in the context of CCS.550,551
Additional information about MINOCA is provided in the 
Supplementary data online, including Table S13.
12. Special situations
12.1. Type 2 myocardial infarction and 
acute myocardial injury
Pathological processes other than atherothrombosis commonly under­
lie the presentation of patients with acute chest pain with troponin ele­
vation. These include Type 2 MI and myocardial injury as defined in the 
fourth universal definition of MI.1 Type 2 MI is an ischaemic myocardial 
injury in the context of a mismatch between oxygen supply and demand 
that is not related to acute coronary atherothrombosis. This may occur 
in the context of atherosclerosis and an oxygen supply/demand imbal­
ance, with an oxygen supply/demand imbalance alone, secondary to 
vasospasm or coronary microvascular dysfunction, or secondary to 
non-atherosclerotic coronary dissection. These causes of Type 2 MI 
can be divided into those with underlying coronary (e.g. coronary em­
bolus, dissection, spasm, microvascular dysfunction) or non-coronary 
mechanisms (supply demand mismatch due to hypoxia, hypotension, 
anaemia, tachycardia, bradycardia).1 Type 2 MI is common and asso­
ciated with a prognosis similar to Type 1 MI.12
Myocardial injury is characterized by myocyte necrosis and tropo­
nin elevation due to mechanisms other than myocardial ischaemia and 
can be acute (e.g. sepsis, myocarditis, takotsubo) or chronic (e.g. HF, 
cardiomyopathies, severe valve heart disease). Myocardial injury is in­
creasingly appreciated in the era of hs-cTn assays, which are not spe­
cific for MI. In patients who have elevated hs-cTn values and do not 
have evidence of acute myocardial ischaemia, a diagnosis of myocar­
dial injury can be made. It is important to recognize that this diagnosis 
can change if subsequent investigations indicate that the patient meets 
the criteria for MI.
Despite some common risk factors, the pathophysiology of Type 2 
MI is different to that of Type 1 MI. Therefore, the natural history and 
appropriate management strategy of these two conditions also differs 
in some important respects. Type 2 and Type 1 MI require diagnostic 
distinction, which is best achieved by following an algorithmic ap­
proach.1,553 Once patients with suspected Type 2 MI and myocardial 
injury have been stabilized and any precipitating illnesses have been 
treated, targeted echocardiography and/or coronary angiography (in­
vasive or CCTA) can be used to identify contributory (and prognos­
tically important) cardiac conditions and to guide appropriate 
long-term cardiovascular treatments.12 Due to the lack of robust sci­
entific evidence investigating management strategies and the wide 
range of precipitating causes, there are currently no specific recom­
mended pharmacological interventions for patients with Type 2 MI. 
Therefore, management should instead focus on identifying and treat­
ing any precipitating conditions (e.g. anaemia, hypoxia) alongside strict 
control of CV risk factors.
12.2. Complications
12.2.1. Heart failure
Acute HF may occur as a complication of ACS. Acute HF as a result of 
ACS significantly increases the risk of other in-hospital complications, 
including worsening of renal function, respiratory failure, pneumonia, 
and death. De novo acute HF complicating ACS should be distinguished 
from pre-existing HF exacerbated by ACS.554–556 This can be challen­
ging and the presence of acute HF may impede the straightforward 
diagnosis of ACS. Patients with ACS and acute HF are more likely to 
present with resting dyspnoea and clinical signs/symptoms of fluid over­
load. In some clinical scenarios, increased troponin levels in patients 
with acute HF may reflect myocardial injury due to HF rather than myo­
cardial necrosis due to ischaemia.
Patients with ACS complicated by acute HF require urgent and co- 
ordinated management of both conditions. The management of acute 
HF should follow current recommendations included in the ESC 
Guidelines on HF and ancillary documents.557–559 The use of diuretics, 
vasodilators, inotropic agents, and vasopressors should be considered 
according to the established algorithms. Mechanical circulatory support 
may also be considered in selected cases. Invasive respiratory support 
and/or renal replacement therapy may be required in some circum­
stances.557–559
Patients presenting with acute HF (including patients with CS) com­
plicating ACS require immediate ICA.250,394,396 These patients should 
also undergo emergency echocardiography/chest ultrasonography to 
gather information about LV and RV function, regional wall motion ab­
normalities, valvular function, and possible mechanical complica­
tions.250,557,560 In patients with ACS, CS may occur as a result of 
Recommendation Table 13 — Recommendations for 
myocardial infarction with non-obstructive coronary 
arteries
Recommendations
Classa
Levelb
In patients with a working diagnosis of MINOCA, 
CMR imaging is recommended after invasive 
angiography if the final diagnosis is not clear.544,545
I
B
Management of MINOCA according to the final 
established underlying diagnosis is recommended, 
consistent with the appropriate disease-specific 
guidelines.546,550,552
I
B
In all patients with an initial working diagnosis of 
MINOCA, it is recommended to follow a diagnostic 
algorithm to determine the underlying final diagnosis.
I
C
© ESC 2023
CMR, cardiac magnetic resonance; MINOCA, myocardial infarction with non-obstructive 
coronary arteries. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3775


<!-- PAGE 57 -->

### Page 57

extensive ischaemia due to MVD, acute severe mitral regurgitation, and 
mechanical complications. Patients with ACS and CS should be trans­
ferred as soon as possible to a PCI centre where immediate coronary 
angiography, and PCI of the IRA if needed, can be performed.404,505 In 
patients with CS complicating ACS in whom the coronary anatomy is 
not suitable for PCI, emergency CABG is recommended. 
Management of MVD in this context is detailed in Section 10.
The clinical benefit of percutaneous MCS devices and/or VA-ECMO 
in the context of ACS remains unclear.402,561 Micro-axial MCS devices 
have not been associated with lower 30-day mortality in comparison to 
IABP in observational studies.400 In a large retrospective registry of 48  
306 patients (>80% ACS) undergoing PCI with MCS, micro-axial MCS 
support was associated with higher mortality and bleeding rates in com­
parison to IABP.562 Similar results were observed in another 
propensity-matched registry analysis confined to patients with CS, 
where micro-axial MCS support was also associated with more compli­
cations and higher mortality than IABP.563 In the IABP-SHOCK II trial, 
the routine use of IABP in patients with ACS and CS did not reduce 
30-day, 1-year, or 6-year mortality.399,405,407 Based on these data, a 
benefit of LVAD in patients with ACS has not been demonstrated, 
and given that observational data have suggested that this may be asso­
ciated with harm, caution is advised in this regard until further RCT evi­
dence is available.
12.2.2. Mechanical complications
Mechanical complications may occur in the first days following MI, 
most commonly in patients presenting with STEMI. The incidence 
of mechanical complications has fallen significantly in the era of 
PPCI.564 A recent large epidemiological investigation including almost 
9 million ACS patients reported an overall prevalence of mechanical 
complications in 0.27% of STEMI cases and 0.06% of NSTEMI cases, 
with in-hospital mortality rates of 42.4% and 18%, respectively.564
Mechanical complications are life-threatening and therefore require 
prompt identification and management (Supplementary data online, 
Table S14). Sudden hypotension, the recurrence of chest pain, new 
cardiac murmurs suggestive of acute mitral regurgitation or a ven­
tricular septal defect, pulmonary congestion, or jugular vein distension 
should raise suspicion of a mechanical complication. Immediate echo­
cardiographic assessment is indicated when mechanical complications 
are suspected.
The use of temporary MCS for mechanical complications, either to 
improve pre-operative clinical/haemodynamic status or prophylactical­
ly, represents a new trend in management. However, this approach re­
quires more data and evidence in order to determine if it provides a 
clinical benefit.565–568 Surgery is currently regarded as the treatment 
of choice for patients with ACS and mechanical complications, although 
percutaneous strategies are occasionally used in selected candidates 
with a prohibitive risk profile or contraindications to a surgical ap­
proach.569–572 A multidisciplinary approach to the management of 
these patients is of paramount importance, and should apply to all 
stages of care, from the initial stabilization of the patient to discussion 
and application of the therapeutic strategy, including palliative 
care.573,574 Patients with ACS-related mechanical complications should 
be considered for IABP while awaiting surgery.
12.2.3. Left ventricular thrombus
While the incidence of LV thrombus following AMI has declined due to 
advances in reperfusion and antithrombotic therapies, it remains 
relatively common, particularly following anterior STEMI, where it 
can be present in >9% of patients according to a large 
meta-analysis.575,576
Echocardiography remains the first-line imaging test for the detec­
tion of LV thrombus. In patients where the apex is not well visualized 
on regular echocardiography, contrast echocardiography may be con­
sidered for improved image quality. CMR is the gold standard imaging 
modality for the diagnosis and assessment of LV thrombi. 
Contemporary CMR data report LV thrombi in up to 6.3% of all 
STEMI patients and in 12.2% of those with anterior STEMI, suggesting 
that the incidence of LV thrombi may be underestimated with echocar­
diography.577 Patients with LV thrombi that were not evident on echo­
cardiography but were detected by CMR appear to have similar clinical 
outcomes to patients with LV thrombi that were evident on echocar­
diography.578 Therefore, CMR should be considered in patients with 
equivocal echocardiographic images or in patients considered to be 
at a particularly high risk of LV thrombus.
The timing of imaging for LV thrombus may also be relevant, given 
that the identification of LV thrombus has been reported to increase 
in the first 2 weeks post-MI.579 While more contemporary data are re­
quired, these data suggest that a high proportion of LV thrombi may 
develop following hospital discharge, indicating that delayed imaging 
at 2 weeks in high-risk patients may be of value.
Once an LV thrombus has been diagnosed, OAC therapy (warfarin 
or NOAC) should be considered for 3–6 months, guided by repeated 
echocardiography or CMR and with consideration of bleeding risk 
and the need for concomitant antiplatelet therapy.580,581 However, 
there are a lack of prospective randomized data on the optimal antic­
oagulation regimen, anticoagulation duration, and the combination of 
oral anticoagulation with antiplatelet agents in patients with LV 
thrombus following MI.581 The choice of therapy should be tailored 
to the patient’s clinical status and the results of follow-up 
investigations.
12.2.4. Post-acute coronary syndrome pericarditis
Pericardial complications that may develop after an AMI include early 
infarct-associated pericarditis (occurring from a few hours to 4 days 
after AMI, mostly transient), late pericarditis or post-cardiac injury 
(Dressler) syndrome (typically occurring 1–2 weeks after AMI), and 
pericardial effusion.548,582 This topic is discussed further in the 
Supplementary data online.
12.2.5. Arrhythmias
12.2.5.1. Atrial fibrillation
Atrial fibrillation is the most frequent supraventricular arrhythmia in pa­
tients with ACS.583 AF may be pre-existing, first time detected, or of 
new onset during ACS management. Patients with AF have a greater 
number of comorbidities compared with patients without AF and are 
at higher risk of complications.584 In most cases, AF is well tolerated 
and no specific treatment is required, apart from anticoagulation.585
Prompt treatment is required for AF causing acute haemodynamic in­
stability, with electrical cardioversion being the preferred approach. 
Adequate rate control can be achieved by administration of beta- 
blockers depending on the presence of HF and low ejection fraction. 
For patients with depressed LVEF, amiodarone or digoxin could be 
used (preferably amiodarone). In cases of hypotension, digoxin is pre­
ferred over amiodarone or beta-blockers. Patients with AF and risk fac­
tors for thrombo-embolism should be adequately treated with chronic 
oral anticoagulation.585 ACS patients with documented AF of any


<!-- PAGE 58 -->

### Page 58

length have worse short- and long-term prognoses when compared 
with patients in sinus rhythm.584,586 There is some evidence to suggest 
that transient, self-terminating AF during STEMI may be a predictor of 
an increased risk of stroke during long-term follow-up.584,587
12.2.5.2. Ventricular arrhythmias
With the widespread increased uptake of emergency reperfusion ther­
apies for patients with STEMI, the incidence of malignant arrhythmias 
(ventricular tachycardia [VT] and ventricular fibrillation [VF]) has signifi­
cantly declined. Nevertheless, 6–8% of patients with STEMI develop 
haemodynamically significant VT or VF.588 The typical arrhythmia presen­
tation is unstable, frequently polymorphic, and relatively fast VT, often 
degenerating into VF. Urgent reperfusion is most important as ischaemia 
is often the trigger for these arrhythmias. Early administration of i.v. or 
oral beta-blockers reduces the incidence of malignant arrhyth­
mias.163,164,169,589 Beta-blockers or amiodarone are recommended if ma­
lignant arrhythmias occur and lidocaine may be considered if these are 
contraindicated.163,164,169,589,590 The prognostic role of early VT/VF 
within the first 48 h of STEMI is still controversial. Several studies have 
suggested that patients with early VT/VF have increased 30-day mortality 
but no increase in long-term arrhythmic risk.591–593 Another study has 
suggested that while malignant ventricular arrhythmias occurring at the 
time of reperfusion do not confer poor prognosis, sustained VT or VF 
occurring during ongoing ischaemia or late after reperfusion (>48 h) is 
associated with an increase in long-term mortality.594 Sustained VT/VF 
late after reperfusion (>48 h) requires an evaluation for ICD implant­
ation for secondary prevention of sudden cardiac death. Ventricular pre­
mature beats are very frequent during the first 24 h after reperfusion for 
STEMI and no specific therapy is required.
Primary prevention of sudden cardiac death with ICD implantation 
within 40 days after MI is generally not indicated. Patients should be re- 
evaluated for ICD implantation post-revascularization after a period of 
6–12 weeks on evidence-based treatments, although patients with a 
pre-existing impaired LVEF may be considered for ICD implantation 
for primary prevention even within the early post-infarction period. 
Some patients may develop electrical storm and/or incessant VT des­
pite complete revascularization and treatment with anti-arrhythmic 
drugs. Overdrive stimulation may help to control this situation; how­
ever, recurrence of VT/VF upon cessation of stimulation is frequent 
and catheter ablation of such triggers appears to be the preferred treat­
ment option in centres with that expertise. Successful radiofrequency 
ablation has been shown to abolish recurrent VT/VF.595
Non-sustained monomorphic VT is the most common form of ven­
tricular arrhythmia in the early phase of ACS, and usually does not re­
quire anti-arrhythmic treatment. Accelerated idioventricular rhythm at 
reperfusion is frequent and does not require intervention given its be­
nign nature.596
12.2.6. Bleeding
Bleeding is associated with a poor prognosis in ACS patients.231,597,598
The mechanisms by which bleeding increases the risk of death are com­
plex and multifactorial.599 While intracranial or massive haemorrhage 
directly threatens life through fatal brain damage or sudden cardiocir­
culatory collapse, other less severe forms of haemorrhage may increase 
the risk of death through indirect mechanisms. Blood transfusion may 
increase systemic inflammation and represents one of the possible links 
between bleeding and subsequent mortality.600 Bleeding is also a major 
driver of unplanned DAPT discontinuation and the interruption of 
other medication (e.g. statins, beta-blockers).601,602
12.2.6.1. Management of bleeding
See Supplementary data online, Section 12.1.3.1.
Recommendation Table 14 — Recommendations for 
acute coronary syndrome complications
Recommendations
Classa
Levelb
Heart failure
IABP should be considered in patients with 
haemodynamic instability/cardiogenic shock due to 
ACS-related mechanical complications.
IIa
C
LV thrombus
CMR imaging should be considered in patients with 
equivocal echocardiographic images or in cases of 
high clinical suspicion of LV thrombus.577,578
IIa
C
Oral anticoagulant therapy (VKA or NOAC) should 
be considered for 3–6 months in patients with 
confirmed LV thrombus.603
IIa
C
Following an acute anterior MI, a contrast 
echocardiogram may be considered for the 
detection of LV thrombus if the apex is not well 
visualized on echocardiography.604
IIb
C
Atrial fibrillation
Intravenous beta-blockers are recommended when 
rate control is needed in the absence of acute HF or 
hypotension.605
I
C
Intravenous amiodarone is recommended when rate 
control is needed in the presence of acute HF and no 
hypotension.606
I
C
Immediate electrical cardioversion is recommended 
in patients with ACS and haemodynamic 
instability and when adequate rate control 
cannot be achieved promptly with pharmacological 
agents.
I
C
Intravenous amiodarone is recommended to 
facilitate electrical cardioversion and/or decrease risk 
for early recurrence of AF after electrical 
cardioversion in unstable patients with recent-onset 
AF.607,608
I
C
In patients with documented de novo AF during the 
acute phase of ACS, long-term oral anticoagulation 
should be considered depending on the CHA2DS2- 
VASc score, after taking the HAS-BLED score and 
the need for concomitant antiplatelet therapy into 
consideration. NOACs are the preferred 
drugs.583,584,587
IIa
C
Ventricular arrythmias
ICD therapy is recommended to reduce sudden 
cardiac death in patients with symptomatic HF 
(NYHA Class II–III) and LVEF ≤35% despite optimal 
medical therapy for >3 months and at least 6 weeks 
after MI who are expected to survive for at least 1 
year with good functional status.434,609,610
I
A
Continued
ESC Guidelines                                                                                                                                                                                          3777


<!-- PAGE 59 -->

### Page 59

12.3. Comorbid conditions
12.3.1. Patients at high bleeding risk and with blood 
disorders (anaemia and thrombocytopaenia)
Anaemia is more prevalent in elderly/frail ACS patients and in patients 
with multimorbidity (i.e. HF, chronic kidney disease [CKD], diabetes 
mellitus, cancer, and autoimmune diseases). In some cases, severe an­
aemia may precipitate Type 2 MI. Persistent or worsening anaemia in 
patients with ACS is associated with an increased risk of recurrent is­
chaemic events, death, and major bleeding.623–625 According to the 
ARC-HBR, haemoglobin <11 g/dL at the time of PCI constitutes a ma­
jor criterion for HBR, whereas haemoglobin between 11 and 13 g/dL 
(12 g/dL for women) is a minor criterion.
There is no established strategy for treating anaemia in patients with 
ACS. The efficacy and safety of blood transfusion in this clinical scenario 
remains unknown. In the majority of studies investigating different 
transfusion protocols, a liberal blood transfusion strategy has been de­
fined as any red blood cell transfusion at a haemoglobin level <9–10 g/ 
dL, while a restrictive blood transfusion strategy has been defined as any 
transfusion at a haemoglobin level <7–8 g/dL. Observational data sug­
gest that a liberal blood transfusion strategy may be associated with an 
increase in all-cause mortality.626–630 The open-label Restrictive and 
Liberal Transfusion Strategies in Patients With Acute Myocardial 
Infarction (REALITY) trial enrolled 668 ACS patients who were rando­
mized to management with a restrictive (triggered by haemoglobin ≤8) 
or a liberal (triggered by haemoglobin ≤10) transfusion strategy.631 The 
composite outcome (all-cause death, stroke, recurrent MI, or emer­
gency revascularization) at 30 days occurred in a comparable number 
of patients in both arms (11% vs. 14%, RR 0.79, with a one-sided 
97.5% CI of 0.00–1.19), meeting the pre-specified non-inferiority criter­
ion. All components of the composite endpoint were numerically high­
er in the liberal transfusion strategy arm. The trial was not powered to 
detect superiority of the restrictive strategy, and the CI included what 
may be a clinically important harm. The pre-specified 1-year follow-up 
of the REALITY trial yielded contradictory conclusions to the 30-day 
outcomes: at 1 year, the restrictive transfusion strategy (vs. a liberal 
Intravenous beta-blocker and/or amiodarone 
treatment is recommended for patients with 
polymorphic VT and/or VF unless 
contraindicated.611–614
I
B
Prompt and complete revascularization is 
recommended to treat myocardial ischaemia that 
may be present in patients with recurrent VT and/or 
VF.368,388
I
C
Transvenous catheter pacing termination and/or 
overdrive pacing should be considered if VT cannot 
be controlled by repeated electrical cardioversion.
IIa
C
Radiofrequency catheter ablation at a specialized 
ablation centre followed by ICD implantation should 
be considered in patients with recurrent VT, VF, or 
electrical storm despite complete revascularization 
and optimal medical therapy.
IIa
C
Treatment of recurrent VT with haemodynamic 
relevance (despite repeated electrical cardioversion) 
with lidocaine may be considered if beta-blockers, 
amiodarone, and overdrive stimulation are not 
effective/applicable.615
IIb
C
In patients with recurrent life-threatening 
ventricular arrhythmias, sedation or general 
anaesthesia to reduce sympathetic drive may be 
considered.616
IIb
C
ICD implantation or the temporary use of a wearable 
cardioverter defibrillator may be considered <40 
days after MI in selected patients (incomplete 
revascularization, pre-existing LVEF dysfunction, 
occurrence of arrhythmias >48 h after STEMI onset, 
polymorphic VT or VF).
IIb
C
Treatment of asymptomatic and haemodynamically 
irrelevant ventricular arrhythmias with 
anti-arrhythmic drugs is not recommended.
III
C
Bradyarrhythmias
In cases of sinus bradycardia with haemodynamic 
intolerance or high-degree AV block without stable 
escape rhythm:
• i.v. positive chronotropic medication (adrenaline, 
vasopressin, and/or atropine) is 
recommended.617,618
I
C
• temporary pacing is recommended in cases of 
failure to respond to atropine.
I
C
• urgent angiography with a view to 
revascularization is recommended if the patient 
has not received previous reperfusion therapy.
I
C
Implantation of a permanent pacemaker is 
recommended when high-degree AV block does not 
resolve within a waiting period of at least 5 days 
after MI.
I
C
Continued
In selected patients with high-degree AV block in the 
context of an anterior wall MI and acute HF, early 
device implantation (CRT-D/CRT-P) may be 
considered.619,620
IIb
C
Pacing is not recommended if high-degree AV block 
resolves after revascularization or spontaneously.620–622
III
B
© ESC 2023
ACS, acute coronary syndrome; AF, atrial fibrillation; AV, atrioventricular; CHA2DS2-VASc, 
Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes, previous Stroke/ 
transient ischaemic attack/thrombo-embolism (doubled), Vascular disease, Age: 65–74, 
Sex 
(female); 
CMR, 
cardiac 
magnetic 
resonance; 
CRT-D/CRT-P, 
cardiac 
resynchronization 
therapy—defribillator/pacemaker; 
HAS-BLED, 
Hypertension, 
Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile 
INR, Elderly, Drug/alcohol usage; HF, heart failure; IABP, intra-aortic balloon pump; ICD, 
implantable cardioverter defibrillator; LV, left ventricular; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulant; 
NYHA, New York Heart Association; STEMI, ST-elevation myocardial infarction; VF, 
ventricular fibrillation; VKA, vitamin K antagonist; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 60 -->

### Page 60

approach) did not achieve non-inferiority in terms of MACE. In add­
ition, a post-hoc analysis of MACE between day 30 and 1 year demon­
strated an increased risk in the restrictive transfusion strategy group.632
Therefore, no formal recommendation as to the optimal transfusion 
strategy (liberal vs. restrictive) in patients with ACS can be made at 
present.
Although there are several classifications to grade the severity 
of thrombocytopaenia, clinically relevant thrombocytopaenia can 
be defined as a platelet count <100 000/μL or a relative drop in platelet 
count of 50% from baseline in the context of ACS. Thrombocytopaenia 
increases the risk of death, major bleeding events, and life-threatening 
thrombotic events.633,634 The ARC-HBR criteria define a platelet count 
<100 000/μL as a major criterion for HBR. Management of GP IIb/IIIa 
inhibitor- and heparin-induced thrombocytopaenia is discussed in the 
Supplementary data online.
12.3.2. Chronic kidney disease
Moderate to severe CKD (stages III–V) is present in more than 30% of 
ACS patients.635 Patients with ACS and concomitant CKD receive less 
interventional and pharmacological treatment and have a worse prog­
nosis than patients with normal kidney function.636–638 Likely contrib­
uting factors to this worse prognosis include a larger number of 
comorbidities and an increased risk of in-hospital complications, includ­
ing serious bleeding complications.639 Although evidence from RCTs is 
lacking, data from observational and registry-based studies indicate 
that ACS patients with moderate to severe CKD have a better 
prognosis with early revascularization than with medical therapy 
alone.640,641
The type and dose of antithrombotic agent (see Supplementary data 
online, Table S15) and the amount of contrast agent should be consid­
ered based on kidney function.635,642 In relation to supplementary i.v. 
hydration during and after revascularization, the evidence around 
choice, timing, and duration of treatment is somewhat conflicting.643
Taking the clinical circumstances and patient characteristics into consid­
eration, i.v. hydration should be considered as part of the management 
of ACS patients with a low eGFR undergoing invasive management to 
minimize the risk of contrast-induced nephropathy.250,635,642,644,645 For 
recommendations on long-term treatment in patients with ACS and 
concomitant CKD, please refer to the 2021 ESC Guidelines on cardio­
vascular disease prevention.646
12.3.3. Diabetes mellitus
ACS patients with diabetes mellitus (DM) may more commonly pre­
sent with non-specific symptoms, which can lead to delays in both diag­
nosis and access to treatment.647,648 Both treatment in the acute phase 
and risk factor management post-ACS is poorer in patients with DM 
and these patients tend to have more advanced CAD at diagnosis. 
These factors likely contribute to the worse long-term prognosis asso­
ciated with ACS in patients with DM, particularly in patients requiring 
insulin treatment.649–651
All patients with ACS, regardless of a history of DM, should have 
their glycaemic status evaluated during hospitalization. Given that 
the ACS itself may give rise to hyperglycaemia due to catechol­
amine-induced stress, a diagnosis of DM made during hospitalization 
should be subsequently confirmed. While several studies have shown 
the benefits of managing hyperglycaemia (>11.0 mmol/L or 200 mg/ 
dL) in hospitalized ACS patients, the risk of hypoglycaemia-related 
events when using intensive insulin therapy should not be ne­
glected.652–654
Glucose lowering is important in order to prevent microvascular 
complications in patients with DM. However, recent trial evidence 
has shown that the reduction in the risk of new ACS events, HF, 
and renal impairment with glucose-lowering medications like so­
dium–glucose co-transporter 2 (SGLT2) inhibitors or glucagon-like 
peptide-1 receptor agonists (GLP-1-RA) is independent of baseline 
glycosylated haemoglobin (HbA1c) levels.655–657 This should be taken 
into consideration when choosing glucose-lowering therapy for pa­
tients with DM and concomitant CAD. For further details, please re­
fer to the 2023 ESC Guidelines on diabetes and cardiovascular 
diseases and the 2021 ESC Guidelines on cardiovascular disease 
prevention.646,658
12.3.4. Older adults with frailty and multimorbidity
12.3.4.1. The older person
Older adults represent an increasing proportion of ACS patients. One 
of the major predictors of adverse outcomes following ACS is age, but 
patients aged ≥75 years are often excluded from or under-represented 
in clinical trials.659,660 Older age is associated with frailty, multimorbid­
ity, and a greater risk of both ischaemic and bleeding events in patients 
with ACS.661 Hs-cTn assays have an excellent diagnostic performance 
in the older person, but the specificity of the test is lower than in young­
er patients, and elevated cTn levels are more commonly associated with 
conditions other than ACS in older patients.662
There are limited data on the optimal management of older adults 
with ACS.663 A small RCT enrolling older patients (≥80 years) with 
NSTE-ACS reported the superiority of an invasive vs. a conservative 
strategy in the reduction of the composite of MI, need for urgent revas­
cularization, stroke, and death. No treatment effect was shown for all- 
cause death and the benefit associated with the invasive strategy was 
diluted with increasing age.664 In the absence of robust clinical trial 
evidence, decisions regarding how to manage older patients should 
be individualized based on patient characteristics (i.e. ischaemic and 
bleeding risks, estimated life expectancy, comorbidities, the need for 
non-cardiac surgery, quality of life, frailty, cognitive and functional im­
pairment, patient values and preferences, and the estimated risks and 
benefits of an invasive strategy).
In the context of STEMI, PPCI has drastically improved outcomes for 
all ages. However, data are limited in the ‘very old’ cohort, with lack of 
formal assessment of frailty or comorbidity.665 In the context of CS and 
cardiac arrest, age is an independent predictor of mortality following 
PCI.666,667 In the absence of robust RCT data, PPCI should be consid­
ered for all patients with STEMI. When PPCI cannot be performed in a 
timely manner, fibrinolysis may be a reasonable strategy in these pa­
tients. For details regarding pharmacotherapy in older patients, please 
see the Supplementary data online.
12.3.4.2. Frailty and multimorbidity
Geriatric syndromes (i.e. frailty and multimorbidity) are associated with 
adverse outcomes in older patients with ACS.668,669 Frailty is a syn­
drome characterized by reduced biological reserve, leading to a failure 
of homeostatic mechanisms following stressor events, including ACS. 
There is a lack of consensus on which frailty assessment tool is optimal 
in older patients with CV disease.670,671
Frail patients with NSTE-ACS less frequently receive ACS pharma­
cotherapies and invasive assessment, have more complex coronary dis­
ease, have longer durations of hospital stay, and are at higher risk of 
death.672 Specifically, frail patients are reported to have a higher rate 
of a composite of all-cause mortality, MI, stroke, unplanned 
ESC Guidelines                                                                                                                                                                                          3779


<!-- PAGE 61 -->

### Page 61

revascularization, and major bleeding.673 Frail older adults with 
NSTE-ACS have poor health-related quality of life (HRQoL) at baseline. 
Invasive management appears to be associated with modest improve­
ments in HRQoL through to 1 year follow-up in these patients. This im­
provement in HRQoL is most marked in frail and pre-frail patients, who 
receive a proportionally larger benefit than robust patients.674 In older 
adults with NSTE-ACS referred for coronary angiography, the pres­
ence of multimorbidity is associated with an increased risk of long-term 
adverse CV events, driven by a higher risk of all-cause mortality.675
Undiagnosed cognitive impairment is also common in older patients 
with NSTE-ACS undergoing ICA, and these patients are more likely 
to experience MACE at 1 year.676
In the absence of robust RCT data to inform healthcare professionals 
about the management of frail patients presenting with ACS, it is re­
commended to adapt a holistic approach to individualize interventional 
and pharmacological treatments after careful evaluation of risks vs. ben­
efits. To aid in decision-making, the routine assessment of frailty (e.g. 
Rockwood Frailty Score) and comorbidity (e.g. Charlson index) in 
ACS patients is recommended. Following risk stratification using frailty 
assessment and evaluation of the comorbidity burden, it may be rea­
sonable to offer optimal medical therapy plus an invasive strategy to frail 
patients at high risk of future CV events and low risk of complications, 
and to offer optimal medical therapy alone to those who are deemed to 
be at low risk of future events with a high risk of developing procedural 
complications. For those patients for whom any form of treatment 
might be futile, then a palliative end-of-life care approach should be 
considered.
12.3.5. Pregnancy
Acute coronary syndrome diagnostic criteria are the same for preg­
nant and non-pregnant patients.677 Pregnant women with STEMI 
should not be managed differently to non-pregnant women. Given 
the high mortality associated with STEMI in pregnancy, PPCI is the 
preferred reperfusion therapy.678 The management plan for pregnant 
women with ACS should be determined by a multidisciplinary team 
consisting of cardiologists, obstetricians, anaesthesiologists, and neo­
natologists, and these patients should be treated in an intensive care 
unit that can provide maternal monitoring and obstetric care.678,679
ACS treatment should not be delayed for delivery. Delivery should 
be ideally postponed for at least 2 weeks post-ACS as there is in­
creased risk of maternal mortality during this time.678 It has been de­
monstrated that SCAD is the most common cause of AMI in 
pregnancy, and this tends to occur mainly in the late pregnancy or 
early post-partum periods.680,681 Further details are provided in the 
Supplementary data online.
12.3.6. Drug abuse
Acute coronary syndrome in the setting of drug abuse is covered in the 
Supplementary data online.
12.3.7. Patients with cancer
The four most common types of cancer in patients with ACS are pros­
tate, breast, colon, and lung.682 Patients with a history of cancer should 
be treated like all other ACS patients, but the management of ACS pa­
tients with active cancer has some specific issues that need to be taken 
into consideration. Outcomes vary across types of cancer and the 
balance between the ischaemic and bleeding risks should be considered 
on an individual basis.
The percentage of ACS patients with a current diagnosis of cancer is 
rising, and currently constitutes ∼3% of patients in large observational 
studies.683 Patients with active cancer presenting with ACS pose im­
portant challenges as there are significant gaps in scientific knowledge. 
Therefore, recommendations based on solid evidence are scarce. 
Patients with active cancer presenting with ACS tend to be older, 
with a larger number of comorbidities and more extensive CAD. 
These patients often have concomitant haematologic and coagulation 
abnormalities that may present a challenge with respect to both the 
use of antithrombotic therapy and the performing of PCI.684
Observational studies have reported that ACS in patients with cancer 
is associated with increased risk of major CV events, bleeding, and car­
diac and non-cardiac mortality.682,683,685,686 As per the ARC-HBR cri­
teria, patients with active cancer diagnosed in the past 12 months are 
considered as HBR.
The diagnosis of ACS in patients with cancer should be based on the 
same principles as in patients without cancer. The management of ACS 
in patients with cancer can be challenging because of frailty, increased 
bleeding risk, thrombocytopaenia, and increased thrombotic risk.687
Temporary interruption of cancer treatment and an urgent multidiscip­
linary approach is recommended.688 Cancer patients with ACS have 
been reported to less frequently undergo invasive management; how­
ever, invasive management (and PCI with DES if needed) is recom­
mended in ACS patients with cancer, as long as the prognosis is >6 
months or, irrespective of the prognosis, if the patient is unstable.689
Retrospective data have reported both a lower use of invasive manage­
ment in cancer patients with STEMI, and better outcomes in patients 
who do undergo invasive management.682,686,689 Invasive management 
in patients with advanced cancer or life expectancy <6 months has 
been reported to not demonstrate a mortality benefit compared 
with a conservative approach and therefore a conservative strategy 
should be considered in these patients.690 When the coronary anatomy 
is not amenable for PCI, CABG surgery can be considered after a multi­
disciplinary team discussion and where the cancer prognosis is >12 
months. Given that they are considered to be HBR, the preferred 
P2Y12 inhibitor for ACS patients with active cancer is clopidogrel.687
Potential drug–drug interactions with cancer therapies should be 
checked when using ticagrelor or clopidogrel, since some 
pharmacokinetic-based drug–drug interactions via CYP450 may occur.
When acute ischaemia is provoked by cancer therapy, alternative 
cancer therapies should be considered after a multidisciplinary team 
discussion. Some specific cancer treatments can have cardiotoxic vas­
cular effects that can lead to ACS (Supplementary data online, 
Table S16). Following ACS, a review of the cancer medications is re­
commended, and any cancer drug associated with thrombosis and MI 
should be stopped. Cancer therapies that are not associated with MI 
can be restarted once revascularization (when indicated) has been com­
pleted and the patient is stabilized on ACS medical therapy without 
complications. Additional information can be found in the 
Supplementary data online, including Supplementary data online, 
Table S16 and in the 2022 ESC Guidelines on cardio-oncology.684
12.3.8. Coronavirus disease (COVID-19)
A section on the impact of Coronavirus disease (COVID-19) on ACS 
management is presented in the Supplementary data online.


<!-- PAGE 62 -->

### Page 62

### 13 Long-term treatment

Secondary prevention after ACS is central to increase quality of life and 
to decrease morbidity and mortality. This should start as early as pos­
sible after the index event.716–718 The topic is covered in detail in the 
2019 CCS Guidelines and the 2021 Prevention Guidelines.195,646
Optimal medical therapy and treatment targets are well defined and 
are summarized in Figure 17. A figure aimed at educating patients on im­
proving their ‘heart health’ after an ACS event is provided in the 
Supplementary data online, Figure S5.
Recommendation Table 15 — Recommendations for 
acute coronary syndrome comorbid conditions
Recommendations
Classa
Levelb
Chronic kidney disease
The use of low- or iso-osmolar contrast media (at 
the lowest possible volume) is recommended for 
invasive strategies.691–693
I
A
It is recommended to assess kidney function using 
eGFR in all patients with ACS.
I
C
It is recommended to apply the same diagnostic and 
therapeutic strategies in patients with CKD (dose 
adjustment may be necessary) as in patients with 
normal kidney function.
I
C
Hydration during and after angiography should be 
considered in patients at risk of contrast-induced 
nephropathy, especially in patients with acute kidney 
injury and/or CKD with eGFR <30 mL/min/ 
1.73 m2.694–697
IIa
B
Diabetes
It is recommended to base the choice of long-term 
glucose-lowering treatment on the presence of 
comorbidities, including heart failure, CKD, and 
obesity.698–704
I
A
It is recommended to assess glycaemic status at initial 
evaluation in all patients with ACS.705–707
I
B
It is recommended to frequently monitor blood 
glucose levels in patients with known diabetes 
mellitus or hyperglycaemia (defined as glucose levels 
≥11.1 mmol/L or ≥200 mg/dL).
I
C
Glucose-lowering therapy should be considered in 
patients with ACS with persistent hyperglycaemia, 
while episodes of hypoglycaemia should be 
avoided.708,709
IIa
C
Older adults
It is recommended to apply the same diagnostic and 
treatment strategies in older patients as in younger 
patients.662,664,665,710,711
I
B
It is recommended to adapt the choice and dosage of 
antithrombotic agent, as well as of secondary 
prevention medications, to renal function, 
co-medications, comorbidities, frailty, cognitive 
function, and specific contraindications.363,712
I
B
For frail older patients with comorbidities, a holistic 
approach is recommended to individualize 
interventional and pharmacological treatments after 
careful evaluation of the risks and benefits.668,673,676
I
B
Continued
Patients with cancer
An invasive strategy is recommended in cancer 
patients presenting with high-risk ACS with expected 
survival ≥6 months.682,689,690
I
B
A temporary interruption of cancer therapy is 
recommended in patients in whom the cancer 
therapy is suspected to be a contributing cause of 
ACSc.713,714
I
C
A conservative non-invasive strategy should be 
considered in ACS patients with poor cancer 
prognosisd (i.e. with expected survival <6 months) 
and/or very high bleeding risk.690
IIa
C
Aspirin is not recommended in cancer patients with a 
platelet count <10 000/μL.715
III
C
Clopidogrel is not recommended in cancer patients 
with a platelet count <30 000/μL.
III
C
In ACS patients with cancer and <50 000/μL platelet 
count, prasugrel or ticagrelor are not recommended.
III
C
© ESC 2023
ACS, acute coronary syndrome; CKD, chronic kidney disease; eGFR, estimated glomerular 
filtration rate. 
aClass of recommendation. 
bLevel of evidence. 
cAnticancer therapies associated with high risk of ACS (very common [>10%]) include: 
capecitabine, paclitaxel, cisplatin, carfilzomib, bevacizumab, ramucirumab, aflibercept, 
axitinib, sorafenib, pazopanib, cabozantinib, lenvatinib, ponatinib, and erlotinib. 
dRelated to advanced cancer stage and/or severe irreversible non-CV comorbidities.
ESC Guidelines                                                                                                                                                                                          3781


<!-- PAGE 63 -->

### Page 63

Smoking cessation
Healthy diet
Regular exercise
Healthy weight
Support healthy 
lifestyle choices
Continue optimal pharmacological  and cardio-protective treatment
Reach and sustain risk 
factor treatment targets
Discharge on cardioprotective medications,
start lifestyle management and refer to cardiac rehab
Arrange OPD review to 
manage comorbidities 
and discuss patient goals 
and preferences
1
2
3
Psychosocial management
Antithrombotic therapy
Lipid-lowering therapy
Annual influenza vaccination
Long term treatment after ACS
Treatment goals
Promote drug adherence and persistence
+
other treatments as appropriatea
Systolic BP
<130 mmHg 
and diastolic 
BP <80 mmHg
(if tolerated)b
LDL-C <1.4 mmol/L 
(<55 mg/dL)
HbA1c <53 mmol/mol 
(<7%)c
Figure 17 Long-term management after acute coronary syndrome. ACS, acute coronary syndrome; HbA1c, glycosylated haemoglobin; LDL-C, low- 
density lipoprotein cholesterol; OPD, outpatient department. aSee Recommendation Table 16 for other pharmacological treatments after ACS. bFor pa­
tients ≥70 years of age the systolic target should be <140 mmHg and down to 130 mmHg if tolerated.646 cFor patients with diabetes mellitus.


<!-- PAGE 64 -->

### Page 64

13.1. Cardiac rehabilitation
13.1.1. Comprehensive cardiac rehabilitation
Secondary prevention is most effectively provided through cardiac re­
habilitation (CR).716,717 All ACS patients should participate in a com­
prehensive CR programme, which should start as early as possible 
after the ACS event.716,717,719 CR may be performed in inpatient or 
outpatient settings, taking age, frailty, results of prognostic risk stratifi­
cation, and comorbidities into account.716 Comprehensive CR is a 
multidisciplinary intervention, supervised and performed by a team 
and usually co-ordinated by a cardiologist.716 The core components 
of CR include patient assessment, management and control of CV 
risk factors, physical activity counselling, prescription of exercise train­
ing, dietary advice, tobacco counselling, patient education, psychosocial 
management, and vocational support.716 Several studies have found 
that CR programmes after atherosclerotic cardiovascular disease 
(ASCVD) events or revascularization reduce CV hospitalizations, MI, 
CV mortality and, in some studies, all-cause mortality.720–725 Despite 
proven benefits, the rates of referral to, participation in, and implemen­
tation of CR programmes are low.726–730 Another identified issue is 
that many patients adopt healthier lifestyles during CR but relapse to 
pre-morbid habits when returning to everyday life.731 Therefore, there 
is an unmet need for complementary pathways to the classical centre- 
based CR model. In addition to alternatives to CR, there is also a need 
for stronger endorsement of CR by physicians, cardiologists, and 
healthcare professionals.732,733 It is also important to initiate and estab­
lish a strong partnership between patients and healthcare professionals 
as early as possible.732–734
13.1.2. Digital health
Telerehabilitation may be an effective strategy to maintain a healthy life­
style over time and can support or even partially replace conventional, 
centre-based CR.729 Telerehabilitation means rehabilitation from a dis­
tance, covering all CR core components, including telecoaching, social 
interaction, telemonitoring, and e-learning.735,736 Studies in patients 
with CAD have shown that telerehabilitation can be equivalent to trad­
itional CR in terms of achieving functional improvement, managing risk 
factors, and increasing patient well-being.737–741 Few data are available 
about the effect of telerehabilitation on recurrent events.742
Nevertheless, in a meta-analysis no significant difference was found be­
tween mortality following telehealth interventions and centre-based 
supervised CR.743 Also, most trials have only focused on one of the 
CR core components—exercise training and/or physical activity.742
Therefore, more research on the impact of telerehabilitation on out­
comes is still needed, as are investigations into health and digital literacy 
in CR.
13.1.3. Adherence and persistence
Promotion of both adherence (the extent to which a patient adheres to 
a prescribed treatment or lifestyle advice) and persistence (the length of 
time between initiation and discontinuation of a prescribed treatment 
or lifestyle advice) are key in preventing recurrent CV events after ACS. 
Adherence to medication has been shown to be sub-optimal, ranging 
from 50% in primary prevention to 66% in secondary prevention. It 
is estimated that 9% of ASCVD events in Europe occur as a result of 
sub-optimal medication adherence.646 Contributors to sub-optimal ad­
herence and persistence are multidimensional and include: polyphar­
macy, drug regimen complexity, the doctor–patient relationship, a 
lack of patient-centred care and disease acceptance, concern regarding 
side effects, cognitive ability, mental and physical disorders, financial 
aspects, living alone, and depression.646,744–749 Polypills, which include 
guideline-recommended treatments for secondary prevention, have 
been shown to increase adherence in post-ACS patients and may im­
prove therapeutic targets.750–752 The Secondary Prevention of 
Cardiovascular Disease in the Elderly (SECURE) study is the only 
RCT testing the impact of a strategy based on a polypill (containing as­
pirin, ramipril, and atorvastatin) vs. usual care on hard outcomes in ACS 
patients. The polypill strategy was associated with a significant reduc­
tion in major CV events, driven by a significant 33% reduction in CV 
mortality.753 The use of technology to improve medication adherence 
is also generating interest: mobile phone applications and mobile health 
(mHealth) tools may improve medication adherence, but clinical trials 
of sufficient size and duration are needed.754–756 Finally, it is important 
to recognize that adherence has complex underlying psychological dri­
vers, and therefore a whole-systems approach is mandatory. This 
should include the education of health professionals, the use of patient- 
reported outcomes and experience measures, patient education, and 
patient-centred care.734,757,758
13.2. Lifestyle management
Lifestyle management is one of the cornerstones of comprehensive 
CR.716 While most of the evidence regarding the benefits of a 
healthy lifestyle on prognosis comes from primary prevention, 
studies in secondary prevention settings indicate similar beneficial 
effects.716,724,759–763
13.2.1. Tobacco
Tobacco abstinence is associated with a reduced risk of re-infarction 
(30–40%) and death (35–45%) after ACS.763–765 Measures to promote 
cessation of smoking are therefore a priority after ACS. Interventions 
for smoking cessation should begin during hospitalization using a com­
bination of behavioural interventions, pharmacotherapy, and counsel­
ling.18,766 Many patients continue or resume smoking after ACS, in 
particular patients with depression and environmental exposures.646
During encounters with smokers, the ‘very brief advice’ evidence-based 
intervention should be used to facilitate dialogue between the patient 
and healthcare worker.646 Drug interventions, including nicotine- 
replacement therapy (NRT), bupropion and varenicline, should be con­
sidered along with behavioural support. All forms of NRT are effective, 
and the anti-depressant bupropion aids in long-term smoking cessation 
with similar efficacy to NRT.646,766 Varenicline is the most effective 
medical treatment to support smoking cessation and is safe to use in 
ACS patients.767–770 An average weight gain of 5 kg can be expected 
when a person quits smoking, but it is important to recognize that 
the CV risk from continued smoking outweighs the CV risk from gain­
ing weight.646
E-cigarettes have been used to help smokers quit, but evidence on 
their impact on successful smoking cessation is insufficient, particularly 
with regard to whether using e-cigarettes actually helps the person re­
main tobacco free. While e-cigarettes do contain nicotine, they do not 
contain as many tobacco chemicals as cigarettes. Caution should be gi­
ven with respect to the use of e-cigarettes, as current evidence suggests 
they are harmful to CV health by increasing arterial stiffness, heart rate 
and blood pressure, and by causing endothelial dysfunction.771
13.2.2. Nutrition and alcohol
A healthy diet and eating habits influence CV risk. Adopting a 
Mediterranean-style diet can help reduce CV risk in all individuals, in­
cluding persons at high CV risk and patients with ASCVD.761,762,772
ESC Guidelines                                                                                                                                                                                          3783


<!-- PAGE 65 -->

### Page 65

Supplementary data online, Table S17 summarizes the characteristics of 
a healthy diet that should be adhered to. For further details on nutrition, 
please refer to the 2021 ESC Guidelines on cardiovascular disease 
prevention.646
With regard to alcohol consumption, recent data suggest that alco­
hol abstainers have the lowest risk of CVD outcomes, that any amount 
of alcohol uniformly increases blood pressure and body mass index, and 
that a weekly consumption of >100 g of alcohol is associated with de­
creased life expectancy.773–775 Accordingly, it is recommended to re­
strict alcohol consumption to a maximum of 100 g per week (same 
limit for men and women).646
13.2.3. Physical activity and exercise
Based on extensive data from the general population, sedentary behav­
iour, defined as time spent sitting or lying with low energy expenditure, 
while awake, is an independent risk factor for all-cause mortality.776,777
According to recommendations from the World Health Organization, 
adults with chronic conditions should limit their amount of sedentary 
time, replacing it with physical activity of any intensity (including light in­
tensity).646,778 General physical activity recommendations include a 
combination of regular aerobic physical activity and resistance exercise 
throughout the week, which also forms the basis of recommendations 
for patients post-ACS.646,778 However, it is important to recognize that 
daily physical activity does not replace participation in exercise-based 
CR. With support from multiple randomized trials, exercise training 
is a pivotal part of comprehensive CR and participation in exercise- 
based CR should be offered to all patients after ACS.779
Cardiorespiratory fitness is a strong predictor of future prognosis 
both in the general population and in post-ACS patients.780
13.2.4. Psychological considerations
There is a two-fold risk of anxiety and mood disorders in patients 
with heart disease. Depression, anxiety, and psychological stress 
are associated with worse outcomes. Psychological and pharmaco­
logical interventions can have a beneficial effect and should be consid­
ered for ACS patients with depression, anxiety, and stress.781 It is 
recommended that all patients have their mental well-being assessed 
using validated tools before discharge, with consideration of onward 
psychological referral when appropriate.782 For further details, 
please refer to the 2021 ESC Guidelines on cardiovascular disease 
prevention.646
13.2.5. Resumption of activities
Information on the resumption of activities, sexual activity, and 
environmental factors is presented in the Supplementary data online, 
Section 13.1.2.
13.3. Pharmacological treatment
13.3.1. Antithrombotic therapy
Recommendations for antithrombotic therapy are included in Section 6.
13.3.2. Lipid-lowering therapy
Dyslipidaemia should be managed according to the current dyslipidae­
mia guidelines, with a combination of lifestyle and pharmacological 
interventions.783 Trials have consistently demonstrated that lower low- 
density lipoprotein-cholesterol (LDL-C) levels after ACS are associated 
with lower CV event rates.784 The current treatment goal for second­
ary prevention is to lower LDL-C to <1.4 mmol/L (<55 mg/dL) and to 
achieve a ≥50% LDL-C reduction from baseline. For patients who ex­
perience a second CV event within 2 years (not necessarily of the same 
type as the first event), an LDL-C goal of <1.0 mmol/L (<40 mg/dL) ap­
pears to confer additional benefit.783,785,786
After an ACS event, lipid-lowering treatment should be initiated as 
early as possible, both for prognostic benefit and to increase patient 
adherence after discharge. It is recommended that a high-intensity sta­
tin (e.g. atorvastatin or rosuvastatin) is initiated as early as possible 
after hospital admission, preferably before planned PCI, and pre­
scribed up to the highest tolerated dose in order to reach the LDL-C 
goals.783,787 The intensity of statin therapy should be increased in pa­
tients who were receiving low- or moderate-intensity statin treatment 
before the ACS event. In IMPROVE-IT (Improved Reduction of 
Outcomes: Vytorin Efficacy International Trial), ezetimibe treatment 
early after ACS (within 10 days) was added on top of prior statin ther­
apy or initiated concomitantly in statin-naïve patients (two-thirds of 
patients) and compared with statin monotherapy.788 Treatment with 
ezetimibe was shown to be safe and provided long-term benefits for 
CV outcomes. As such, if patients are on a maximally tolerated statin 
dose, or have no prior statin treatment, and have LDL-C levels which 
indicate it is unlikely that targets will be reached with statin therapy 
alone, initiating ezetimibe in addition to a statin (or statin plus ezeti­
mibe combination treatment) may be considered during the ACS 
hospitalization.783,788 In the ODYSSEY OUTCOMES (Evaluation of 
Cardiovascular Outcomes After an Acute Coronary Syndrome During 
Treatment With Alirocumab) trial, treatment with the proprotein con­
vertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab was in­
itiated as early as 1 month after ACS.786 Treatment with PCSK9 
inhibitors has been shown to be safe and effective in lowering LDL-C 
in patients hospitalized with ACS.789–791 Recent data have also shown 
improvements in plaque phenotype and plaque regression in ACS pa­
tients treated with PCSK9 inhibitors.792,793 Combined with the data 
from trials on the long-term benefits of PCSK9 inhibitors and observa­
tional data on the importance of lowering LDL-C early after ACS, 
PCSK9 inhibitor treatment should be initiated during ACS hospitaliza­
tion in patients who were not at their LDL-C goal despite being on 
statin and ezetimibe treatment before admission.785,786,794–796
In all cases, lipid levels should be re-evaluated 4–6 weeks after each 
treatment or dose adjustment to determine whether treatment goals 
have been achieved and to check for any safety issues; the therapeutic 
regimen can then be adapted accordingly. If the LDL-C goals are not 
achieved with the maximum tolerated dose of a statin alone after 4– 
6 weeks following ACS, adding ezetimibe is recommended.783,788
Initiation of PCSK9 inhibitor treatment is recommended in patients 
who do not reach their LDL-C goal despite maximum tolerated statin 
and ezetimibe therapy.783,785,786 Finally, icosapent ethyl, at a dose of 2 g 
b.i.d., can be used in combination with a statin in patients with ACS and 
triglyceride levels of 1.5–5.6 mmol/L (135–499 mg/dL) despite statin 
treatment.783,797 An algorithm for lipid-lowering management in ACS 
patients is outlined in Figure 18.
For a detailed description of the different lipid-lowering drug classes 
and respective trial data, please refer to the Supplementary data online.


<!-- PAGE 66 -->

### Page 66

13.3.3. Beta-blockers
The clinical benefit of beta-blockers after ACS in patients with reduced 
LVEF is supported by evidence from contemporary trials.557,798–800
However, the evidence for prescribing beta-blockers after uncompli­
cated ACS in patients with LVEF >40% is less well established. With 
the exception of the CAPRICORN (CArvedilol Post-infaRct survIval 
COntRolled evaluatioN) trial, which only recruited patients with 
LVEF ≤40%, all large RCTs testing the benefits of post-MI beta-blocker 
maintenance were performed in the pre-reperfusion era.801 Pooled 
data demonstrated that post-MI beta-blocker therapy reduced the 
Prior treatment
LDL-C <1.4 mmol/L
or 55 mg/dLa
Add ezetimibe
(Class I)
LDL-C <1.4 mmol/L
or 55 mg/dLa
LDL-C <1.4 mmol/L
or 55 mg/dLa
On highest tolerated statin and ezetimibe,
add PCSK9i
(Class I)
LDL-C <1.4 mmol/L
or 55 mg/dLa
Lipid lowering therapy in ACS patients
Y
Y
N
N
N
No change in therapy
No change in therapy
Y
No change in therapy
Y
No change in therapy
Add
PCSK9i
(Class I)
N
LLT-naive,
irrespective of
LDL-C values
Initiate high-potency high-dose statin
(Class I)
Combination therapy with statin and ezetimibe
(Class IIb)
Change to high-potency high-dose statin
(Class I)
On low-potency/
low-dose statin,
irrespective 
of LDL-C values
On highest tolerated statin
On highest tolerated statin and ezetimibe
Combination therapy with statin and ezetimibe
(Class IIb)
On highest tolerated statin,
add ezetimibe
(Class I)
On highest tolerated statin and ezetimibe, add PCSK9i
(Class I)
During admission
Outpatient follow-up
After 4–6 weeks
After further 4–6 weeks
Figure 18 Lipid-lowering therapy in ACS patients. ACS, acute coronary syndrome; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor. aConsider LDL-C <1.0 mmol/L if recurrent event.
ESC Guidelines                                                                                                                                                                                          3785


<!-- PAGE 67 -->

### Page 67

risk of death by >20%. These trials mostly enrolled patients with STEMI, 
making the evidence for their benefit in NSTEMI less robust. In addition, 
since these trials were performed, the clinical scenario has changed dra­
matically, with improvements in invasive strategies and associated 
pharmacotherapy resulting in an improved prognosis for patients 
with ACS.718 Modern observational studies and meta-analyses of these 
trials have yielded mixed results, with some studies suggesting a benefit 
of beta-blocker therapy irrespective of LVEF, and others reaching the 
opposite conclusion.557,800,802–804
There is only one small, open-label trial, CAPITAL-RCT (Carvedilol 
Post-Intervention 
Long-Term 
Administration 
in 
Large-scale 
Randomized Controlled Trial), that randomized 801 STEMI patients 
with successful PPCI and preserved LVEF to carvedilol or control.805
During a 3-year follow-up, the incidence of a composite of all-cause death, 
MI, hospitalization for HF, and hospitalization for ACS was not significantly 
different between the two groups. However, the trial was underpowered 
and therefore this scientific question remains open. There are four on­
going pragmatic prospective large-scale RCTs in Europe randomizing 
ACS patients without reduced LVEF to beta-blocker or control: 
REBOOT-CNIC (TREatment With Beta-blockers After myOcardial 
Infarction withOut Reduced Ejection fracTion), 8468 ACS patients with 
LVEF >40%; REDUCE-SWEDEHEART (Evaluation of Decreased Usage 
of Betablockers After Myocardial Infarction in the SWEDEHEART 
Registry), 5000 ACS patients with LVEF ≥50% (NCT03278509); 
BETAMI (BEtablocker Treatment After Acute Myocardial Infarction in 
Patients Without Reduced Left Ventricular Systolic Function), 10 000 
ACS patients with LVEF >40%; and DANBLOCK (Danish Trial of Beta 
Blocker Treatment After Myocardial Infarction Without Reduced 
Ejection Fraction), 3570 ACS patients with LVEF >40%.806–808
The duration of beta-blocker therapy after uncomplicated ACS is 
also another controversial topic. There are some observational studies 
suggesting that the clinical benefit of beta-blocker therapy is restricted 
to the first year after the index ACS event, but the non-randomized na­
ture of the studies limits their conclusions.809 There are two ongoing 
large-scale RCTs testing the impact of beta-blocker withdrawal after 
6–12 months following uncomplicated ACS in patients with preserved 
LVEF: AβYSS (Beta Blocker Interruption After Uncomplicated 
Myocardial Infarction; NCT03498066) and SMART-DECISION 
(Long-term Beta-blocker Therapy After Acute Myocardial Infarction; 
NCT04769362).810
13.3.4. Nitrates and calcium channel blockers
Intravenous nitrates may be useful during the acute phase in STEMI pa­
tients with hypertension or HF, provided there is no hypotension or RV 
infarction. In the ISIS-4 (Fourth International Study of Infarct Survival) 
trial, oral nitrates had no survival benefit in MI patients.811 Their use 
is therefore restricted to the control of residual angina, as recom­
mended in the 2019 ESC Guidelines for the diagnosis and management 
of chronic coronary syndromes.195 Calcium channel blocker use was 
not associated with prognostic benefit in a systematic review including 
28 trials.812 Calcium channel blocker use can be considered in the con­
text of residual angina and for blood pressure control as recommended 
in the 2021 ESC Guidelines on CVD prevention and the 2019 ESC 
Guidelines for the diagnosis and management of CCS.195,646
13.3.5. Renin–angiotensin–aldosterone system 
inhibitors
Angiotensin-converting enzyme (ACE) inhibitors have been demon­
strated to improve outcomes in post-MI patients with additional 
conditions, such as clinical HF and/or LVEF ≤40%, diabetes, CKD, 
and/or hypertension.813–817 A systematic overview of (old) trials of 
ACE inhibition early in STEMI showed that their use is associated 
with a small but significant reduction in 30-day mortality, especially in 
anterior MIs.818
In the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial, 
valsartan was found to be non-inferior to captopril in patients with a 
recent MI plus HF and/or LVEF ≤40%.819
There is established evidence that patients with heart failure with re­
duced ejection fraction (HFrEF), regardless of aetiology, benefit from 
ACE inhibitors.820–823
Angiotensin receptor/neprilysin inhibitors 
(ARNI) have been shown to be superior to ACE inhibitors in patients 
with established HF (of different aetiologies) and LVEF ≤40%.824
However, in the more recent PARADISE-MI (Prospective ARNI vs 
ACE Inhibitor Trial to Determine Superiority in Reducing Heart 
Failure Events After MI), a dedicated study in patients with recent 
ACS (1–7 days) complicated by HF and/or LVEF ≤40%, an ARNI com­
bination (sacubitril plus valsartan) was not associated with a significantly 
lower incidence of death from CV causes or incident HF in comparison 
to the active comparator ramipril.825
In general, ACE inhibitors (or sacubitril plus valsartan as a replace­
ment for them) are recommended for patients with established 
HFrEF regardless of the aetiology.557 These agents may be considered 
for patients with HF with mildly reduced ejection fraction.557 Patients 
who tolerate neither ACE inhibitors nor ARNI are recommended to 
be treated with an angiotensin receptor blocker.
In the Eplerenone Post-AMI Heart failure Efficacy and SUrvival Study 
(EPHESUS), the mineralocorticoid receptor antagonist (MRA) eplere­
none was associated with reduced mortality and CV hospitalizations 
in patients with a recent MI and LV dysfunction with symptoms of ei­
ther 
HF 
or 
diabetes.826
The 
Double-Blind, 
Randomized, 
Placebo-Controlled Trial Evaluating The Safety And Efficacy Of Early 
Treatment With Eplerenone In Patients With Acute Myocardial 
Infarction (REMINDER) trial randomized 1012 patients with acute 
STEMI without HF to eplerenone or placebo within 24 h of symptom 
onset.827 The primary endpoint was the composite of CV mortality, re- 
hospitalization, or extended initial hospital stay due to diagnosis of HF, 
sustained VT or VF, ejection fraction ≤40%, or elevated BNP/NT-pro 
BNP at 1 month or more after randomization. Eplerenone was asso­
ciated with a significant reduction in the primary composite endpoint, 
although this difference was primarily driven by BNP levels.827
13.3.6. Medications for diabetes
13.3.6.1. Sodium–glucose co-transporter 2 inhibitors
Pharmacological blockade of SGLT2 induces glycosuria with lowering of 
plasma glucose levels, improving glycaemic control without hypogly­
caemia, and leading to reductions in weight and blood pressure.828 In 
patients with type 2 diabetes and established ASCVD, three trials 
(with empagliflozin, canagliflozin, and dapagliflozin) have demonstrated 
significant CV benefits.656,829,830 In a meta-analysis of these three trials, 
MACE were reduced by 11%, with no clear effect on stroke or MI. This 
benefit was only seen in patients with established ASCVD.698 The ben­
efits of SGLT2 inhibitors may relate more to cardio-renal haemo­
dynamic effects than to atherosclerosis.646 Further recommendations 
for patients with diabetes can be found in the current ESC Guidelines 
on diabetes, pre-diabetes,and cardiovascular diseases.831
In patients with HF regardless of their LVEF, dapagliflozin and empa­
gliflozin have been shown to significantly reduce the risk of worsening 
HF or CV death, both in the presence or absence of type 2


<!-- PAGE 68 -->

### Page 68

diabetes.702,703,832,833 In the EMMY (EMpagliflozin in patients with acute 
MYocardial infarction) trial, empagliflozin led to a significant improve­
ment in NT-pro BNP reduction over 26 weeks post-MI, accompanied 
by a significant improvement in echocardiographic functional and 
structural parameters.834 Ongoing outcome trials in ACS populations 
will be useful to better define the role of these agents in the absence 
of HF.835
13.3.6.2. Glucagon-like peptide-1 receptor agonists
In a systematic review and meta-analysis of seven trials (56 004 patients 
with type 2 diabetes) testing different GLP1-RAs, their use was asso­
ciated with reductions in the incidence of MACE, CV death, all-cause 
mortality, MI, and stroke.699
13.3.7. Proton pump inhibitors
Proton pump inhibitors (PPIs) reduce the risk of upper gastroduodenal 
bleeding in patients treated with antiplatelet agents.287,836,837 Therapy 
with a PPI is indicated for patients receiving any antithrombotic regimen 
who are at high risk of gastrointestinal bleeding (for details see Section 
8.2.2.3, Bleeding risk assessment, in the Supplementary data online).
PPIs that inhibit CYP2C19, particularly omeprazole and esomepra­
zole, may reduce the pharmacodynamic response to clopidogrel, 
though there is no strong evidence that this results in an increased 
risk of ischaemic events or stent thrombosis in clinical trials and propen­
sity score-matched studies.287,288,838–842 Importantly, no interaction 
between the concomitant use of PPIs and aspirin, prasugrel or ticagre­
lor has been observed.
13.3.8. Vaccination
An annual influenza vaccination in patients with stable ASCVD appears 
to be associated with reduced incidence of MI, an improved prognosis 
in patients with HF, and decreased CV risk in adults aged 65 years and 
older.843,844 In addition, influenza vaccination given early after an MI or 
in high-risk CAD has been shown to result in a lower risk of all-cause 
death and CV death at 12 months.845–847 Therefore, influenza vaccin­
ation is recommended for all ACS patients and should be given prefer­
entially during index hospitalization during influenza season for those 
not protected by a seasonal influenza vaccination.
13.3.9. Anti-inflammatory drugs
Inflammation plays a central role in the pathogenesis of atherosclerosis 
and acute coronary events. Several recent trials have tested the role of 
the anti-inflammatory agent colchicine in acute and chronic coronary 
syndromes.848,849 In the Colchicine Cardiovascular Outcomes Trial 
(COLCOT), which enrolled 4745 patients with a recent ACS event, 
low-dose colchicine (0.5 mg daily) was associated with a significant re­
duction of the primary composite endpoint (CV death, resuscitated 
cardiac arrest, MI, stroke, or urgent revascularization) in comparison 
to placebo.850 Of note, pneumonia was more frequent in the colchicine 
group. The Low-dose Colchicine trial-2 (LoDoCo2) enrolled 5522 pa­
tients with CCS (84% of whom had prior ACS) who were randomized 
to colchicine (0.5 mg daily) or placebo.851 The primary endpoint (com­
posite of CV death, MI, stroke, or ischaemia-driven coronary revascu­
larization) rate was significantly lower in the colchicine group; however, 
the incidence of non-CV death was higher in the colchicine group. The 
benefits of colchicine in reducing CV events have been shown to be 
consistent irrespective of history and timing of prior ACS.852
13.3.10. Hormone replacement therapy
For further information on hormone replacement therapy in patients 
with ACS, please see the Supplementary data online.
Recommendation Table 16 — Recommendations for 
long-term management
Recommendations
Classa
Levelb
Cardiac rehabilitation
It is recommended that all ACS patients participate in 
a medically supervised, structured, comprehensive, 
multidisciplinary exercise-based cardiac rehabilitation 
and prevention programme.721–724,853,854
I
A
Lifestyle management
It is recommended that ACS patients adopt a healthy 
lifestyle, including: 
• stopping all smoking of tobacco
• healthy diet (Mediterranean style)
• alcohol restriction
• regular aerobic physical activity and resistance 
exercise
• reduced sedentary time724,761,763,772,773,776,777,855– 
858
I
B
In smokers, offering follow-up support, nicotine 
replacement therapy, varenicline or bupropion, 
individually or in combination, should be 
considered.859–864
IIa
A
Pharmacological treatment
Lipid-lowering therapy
It is recommended that high-dose statin therapy is 
initiated or continued as early as possible, regardless 
of initial LDL-C values.787,865–867
I
A
It is recommended to aim to achieve an LDL-C level 
of <1.4 mmol/L (<55 mg/dL) and to reduce LDL-C 
by ≥50% from baseline.868,869
I
A
If the LDL-C goal is not achieved despite maximally 
tolerated statin therapy after 4–6 weeks, the addition 
of ezetimibe is recommended.788
I
B
If the LDL-C goal is not achieved despite maximally 
tolerated statin therapy and ezetimibe after 4–6 
weeks, the addition of a PCSK9 inhibitor is 
recommended.785,786,795,796
I
A
It is recommended to intensify lipid-lowering 
therapyc during the index ACS hospitalization for 
patients who were on lipid-lowering therapy before 
admission.
I
C
For patients with a recurrent atherothrombotic 
event (recurrence within 2 years of first ACS 
episode) while taking maximally tolerated 
statin-based therapy, an LDL-C goal of <1.0 mmol/L 
(<40 mg/dL) may be considered.785,786
IIb
B
Combination therapy with high-dose statin plus 
ezetimibe may be considered during index 
hospitalization.788
IIb
B
Continued
ESC Guidelines                                                                                                                                                                                          3787


<!-- PAGE 69 -->

### Page 69

### 14 Patient perspectives

14.1. Patient-centred care
The management of patients with ACS should not only consider the 
best available evidence with regard to clinical management strategies, 
but also should be mindful of the provision of care that is respectful 
of and responsive to individual patient preferences, needs, and values, 
ensuring that these values are included in clinical decision-making.881
Patient-centred care should be guided by ethical values when consid­
ering a patient’s physical, emotional, and psychological needs. Adopting 
a person-centred care approach after an ACS event improves patient 
outcomes and enhances quality of life.882 Patients who are regarded 
as equal partners in their ACS medical management are more likely 
to actively engage and participate in their own healthcare.883
Educating and involving patients in their care should be seen as a con­
tinuous process. Engaging and educating the patient is a key component 
of ACS care and should take place throughout their patient journey, 
from admission to hospital discharge and cardiac rehabilitation 
(Figure 19).
Beta-blockers
Beta-blockers are recommended in ACS patients 
with LVEF ≤40% regardless of HF symptoms.801,870– 
872
I
A
Routine beta-blockers for all ACS patients regardless 
of LVEF should be considered.798,873–878
IIa
B
RAAS system inhibitors
Angiotensin-converting enzyme (ACE) inhibitorsd 
are recommended in ACS patients with HF 
symptoms, LVEF ≤40%, diabetes, hypertension, and/ 
or CKD.195,813–817,879
I
A
Mineralocorticoid receptor antagonists are 
recommended in ACS patients with an LVEF ≤40% 
and HF or diabetes.826,880
I
A
Routine ACE inhibitors for all ACS patients 
regardless of LVEF should be considered.816,817
IIa
A
Adherence to medication
A polypill should be considered as an option to 
improve adherence and outcomes in secondary 
prevention after ACS.753
IIa
B
Imaging
In patients with pre-discharge LVEF ≤40%, repeat 
evaluation of the LVEF 6–12 weeks after an ACS (and 
after complete revascularization and the institution 
of optimal medical therapy) is recommended to 
assess the potential need for sudden cardiac death 
primary prevention ICD implantation.
I
C
Cardiac magnetic resonance imaging should be 
considered as an adjunctive imaging modality in order 
to assess the potential need for primary prevention 
ICD implantation.
IIa
C
Vaccination
Influenza vaccination is recommended for all ACS 
patients.843,845–847
I
A
Continued
Anti-inflammatory drugs
Low-dose colchicine (0.5 mg once daily) may be 
considered, particularly if other risk factors are 
insufficiently controlled or if recurrent cardiovascular 
disease events occur under optimal therapy.850,851
IIb
A
© ESC 2023
ACS, acute coronary syndrome; CKD, chronic kidney disease; HF, heart failure; ICD, 
implantable cardioverter defibrillator; LDL-C, low-density lipoprotein-cholesterol; LVEF, 
left ventricular ejection fraction; PCSK9, proprotein convertase subtilisin/kexin type 9; 
RAAS, renin–angiotensin–aldosterone system. 
aClass of recommendation. 
bLevel of evidence. 
cIncrease statin potency/dose if the patient was on low-potency/low-dose statin, add 
ezetimibe if the patient was only on statins at highest tolerated dose, or add PCSK9 
inhibitor if the patient was on statins plus ezetimibe. 
dAngiotensin receptor blockers in cases of intolerance.


<!-- PAGE 70 -->

### Page 70

14.2. Shared decision-making
Shared decision-making is a process, during which the patient and a 
healthcare professional work together to make an informed decision 
about the patient’s care.884 During this process, information is pro­
vided, comprehension checked, and the patient is given an opportunity 
to ask questions in order to equip them with the tools needed to make 
an informed decision.
Using a shared decision-making approach during the consent process 
allows the patient’s preferences to be established.884 Discovery of the 
patient’s concerns, goals, preferences, and values should be a central 
component of this process. The use of validated decision aids and 
audio-visual tools may also be helpful to facilitate informed consent 
and promote patient involvement.884–887
14.3. Informed consent
Informed consent should include the components listed in 
Supplementary data online, Table S18.885,888 Informed consent is an op­
portunity to educate patients about the proposed procedure, the asso­
ciated risks and benefits, and any available alternative interventions or 
treatments.886,887 Assessment of the patient’s understanding of the in­
formation given to them during the informed consent process using the 
‘teach back’ technique should be considered (Supplementary data 
online, Figure S6).885,889–891 The teach back method assesses under­
standing by asking patients to state in their own words what they 
need to know or do about their health.
Informed consent is an ethical and legal obligation for medical practi­
tioners and is required before any invasive procedure. The information 
Premorbid condition
Consider all risk factors
Establish medical history and prior medications
Consider psychosocial factors
Hospital admission
Individualize care at triage
Perform a person-centred clinical assessment
Employ shared decision-making
Preparing for discharge
Explain regarding 
long-term treatment
Educate about 
lifestyle modification
Consider mental and emotional health
At every stage, consider physical and psychosocial needs
Taking a person-centred approach to the ACS journey
Figure 19 A person-centred approach to the ACS journey. ACS, acute coronary syndrome.
ESC Guidelines                                                                                                                                                                                          3789


<!-- PAGE 71 -->

### Page 71

should be provided in a simple and clear format. In patients undergoing 
emergency invasive angiography, a shortened informed consent pro­
cess is appropriate. If a shortened informed consent process has 
been used, it is important that there is contact with the patient and/ 
or family member after the intervention when the patient is physically 
and psychologically stable or following the death of the patient.892
Further information can be found in the Supplementary data online.
14.4. Research participation and consent in 
the acute setting
With unstable ACS patients, it is often challenging to obtain their con­
sent for emergency procedures—and even more challenging to enrol 
in clinical trials due to a number of factors, including the necessity for 
prompt clinical care, increased pain and stress levels, and impairment 
of consciousness. Where clinical trials are conducted, patient involve­
ment in enrolment decisions is paramount, if possible.893,894 A short 
witnessed verbal consent, followed by written consent after the acute 
phase, has been shown to be less stressful and more positively re­
ceived than written consent in the acute setting.894 The research 
and consent process must follow the ethical and legal requirements 
in the relevant country. Further information can be found in the 
Supplementary data online.
14.5. Patient satisfaction and expectations
Focusing healthcare around the needs and preferences of patients has 
the potential to improve clinical outcomes, quality of care and patient 
satisfaction, while decreasing healthcare costs and health disparities.881
Patient perception of care is built on interpersonal interactions, the 
quality of clinical communication, delivery of care, and the administra­
tive management of care. ACS patient expectations are summarized 
in Figure 20
and further information can be found in the 
Supplementary data online, Table S19.
...their ACS symptoms to be recognised
...high quality, effective and safe care delivered by professionals
…the right care at the right time
…their physical, mental and emotional wellbeing to be considered
…clear, comprehensible 
information
…shared decision making and respect 
for their preferences
…consideration of,
and support for,
their family and carers
…attention to both
 their physical and 
environmental needs
…a clean and safe hospital environment
ACS patients expect…
Figure 20 Acute coronary syndrome patient expectations. ACS, acute coronary syndrome.


<!-- PAGE 72 -->

### Page 72

14.6. Patient-reported outcome measures 
and patient-reported experience 
measures
Understanding and measuring patient expectations and health out­
comes using patient-reported outcome measures (PROMs) and pa­
tient-reported experience measures (PREMs) is central to improving 
patient satisfaction and delivering patient-centred care.895 The quality 
of care for ACS patients should be measured during the patient’s jour­
ney from initial presentation until discharge. Further information can be 
found in the Supplementary data online. Further information on 
PROMs and PREMs is also provided in the Supplementary data online.
14.7. Preparation for discharge
Many ACS patients may not be fully aware of what has happened to 
them and how to best manage their healthcare after discharge, leading 
to them both wanting and needing more information upon dis­
charge.896 Cognitive impairment can occur as a complication of ACS 
and some patients may have difficulty with instructions for care when 
transitioning towards discharge home.897 Therefore, discharge infor­
mation should be provided in both verbal and written formats and 
should include a discharge letter outlining the key components of the 
evidence-based 
discharge 
plan 
(Supplementary 
data 
online, 
Table S20).898–901 Some important messages aimed at patients on 
how to improve their heart health after ACS are demonstrated in 
Supplementary data online, Figure S5. Moreover, following an ACS 
event, anxiety and depression are frequently encountered and confer 
an increased risk of non-adherence to medications and lifestyle changes, 
subsequent MACE, and death.902–904 Non-adherence also generally in­
creases over time, which has additional impact on clinical outcomes.905
Assessing and identifying these patients and intervening with onward 
psychological referral is recommended.858 Further information can be 
found in the Supplementary data online. A summary of patient con­
cerns and educational needs throughout their ACS journey is also pro­
vided in Supplementary data online, Figure S7.
15. Key messages
Epidemiology of ACS
Acute coronary syndromes encompass a spectrum of conditions that 
include patients with a recent change in clinical symptoms or signs, 
with or without changes on 12-lead ECG and with or without acute ele­
vations in cardiac troponin concentrations. ACS are commonly classi­
fied based on ECG at presentation and the presence or absence of 
troponin elevation into UA, NSTEMI, or STEMI. The incidence of 
STEMI is decreasing whereas the incidence of NSTEMI is increasing. 
While there are some sex differences in the epidemiology of ACS, wo­
men and men receive equal benefit from invasive and non-invasive man­
agement strategies and, in general, should be managed similarly.
Diagnostic tools (ECG, troponin, and non-invasive imaging)
Chest pain/discomfort is the most common symptom initiating the ACS 
diagnostic and therapeutic pathway. High-sensitivity troponin measure­
ments and rapid ‘rule-in’ and ‘rule-out’ algorithms should be used in patients 
with suspected NSTE-ACS. MI is not the only condition resulting in cardi­
omyocyte injury and cardiac troponin elevation, and other conditions 
should also be considered in the differential diagnosis. Non-invasive imaging 
can be useful to increase diagnostic accuracy and optimize risk assessment.
STEMI management networks
Co-ordination between EMS and hospitals with common written proto­
cols is central to the management of STEMI. EMS should transfer patients 
immediately to 24/7 high-volume PCI centres regardless of the initial 
treatment strategy (PPCI or pre-hospital fibrinolysis). EMS should always 
alert the PCI centre immediately after selection of the reperfusion strat­
egy, and patient transfer to the PCI centre should bypass the ED.
Invasive strategy and reperfusion therapy
An invasive strategy is recommended for patients with ACS. Invasive strat­
egies are time sensitive. For STEMI and very high-risk NSTE-ACS, an im­
mediate invasive strategy is recommended. For patients with NSTE-ACS 
an inpatient invasive strategy is recommended; in NSTE-ACS patients 
with high-risk characteristics, an early invasive strategy (<24 h) should 
be considered. If timely (within 120 min from time of diagnosis) PPCI can­
not be performed in patients with STEMI, fibrinolytic therapy is indicated 
within 12 h of symptom onset in patients without contraindications.
Antithrombotic therapy
Antithrombotic therapy is indicated in all ACS patients, regardless of the 
management strategy. This consists of both antiplatelet and anticoagulant 
therapy. Aspirin is recommended for all ACS patients at an initial loading 
dose and a longer-term maintenance dose. In addition to aspirin, a P2Y12 
receptor inhibitor is recommended, and should be maintained over 12 
Recommendation Table 17 — Recommendations for 
patient perspectives in acute coronary syndrome care
Recommendations
Classa
Levelb
Patient-centred care is recommended by assessing 
and adhering to individual patient preferences, needs 
and beliefs, ensuring that patient values are used to 
inform all clinical decisions.744,881,906,907
I
B
It is recommended to include ACS patients in 
decision-making (as much as their condition allows) 
and to inform them about the risk of adverse events, 
radiation exposure, and alternative options. Decision 
aids can be used to facilitate the discussion.908,909
I
B
It is recommended to assess symptoms using 
methods that help patients to describe their 
experience.910
I
C
Use of the ‘teach back’ technique for decision 
support during the securing of informed consent 
should be considered.885,889–891
IIa
B
Continued
Patient discharge information should be provided in 
both written and verbal formats prior to discharge. 
Adequate preparation and education for patient 
discharge using the teach back technique and/or 
motivational interviewing, giving information in 
chunks, and checking for understanding should be 
considered.885,896,911
IIa
B
Assessment of mental well-being using a validated 
tool and onward psychological referral when 
appropriate should be considered.903,904,912,913
IIa
B
© ESC 2023
ACS, acute coronary syndrome. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3791


<!-- PAGE 73 -->

### Page 73

months unless there are concerns regarding HBR. Regarding P2Y12 recep­
tor inhibitor choice, prasugrel and ticagrelor are recommended in prefer­
ence to clopidogrel, and prasugrel should be considered in preference to 
ticagrelor for ACS patients who undergo PCI. Pre-treatment (i.e. treat­
ment with a P2Y12 receptor inhibitor prior to coronary angiography) in pa­
tients with NSTE-ACS is not recommended routinely but may be 
considered for patients with STEMI undergoing PPCI. Parenteral anticoa­
gulation is recommended for all patients at the time of diagnosis. 
Discontinuation of parenteral anticoagulation should be considered imme­
diately after the invasive procedure. Some patients with ACS will also have 
an indication for long-term OAC, most commonly AF. In these patients, 
TAT for up to 1 week, followed by DAT using a NOAC at the recom­
mended dose for stroke prevention and a single oral antiplatelet agent 
(preferably clopidogrel), is recommended as the default strategy.
ACS with unstable presentation
A PPCI strategy is recommended in patients with resuscitated cardiac 
arrest and an ECG with persistent ST elevation (or ST elevation equiva­
lents), whereas routine immediate angiography is not recommended in 
patients with an ECG without persistent ST elevation (or equivalents). 
Temperature control (i.e. continuous monitoring of core temperature 
and active prevention of fever [i.e. >37.7°C]) is recommended in pa­
tients with OHCA who remain unresponsive after ROSC. In patients 
with CS complicating ACS, emergency coronary angiography is recom­
mended, whereas the routine use of IABP in ACS patients with CS and 
no mechanical complications is not.
Early care
Following reperfusion, it is recommended to admit high-risk ACS patients, 
including all STEMI patients, to a CCU/ICCU. ECG monitoring for ar­
rhythmias and ST-segment changes is recommended for at least 24 h after 
symptom onset in all high-risk patients with ACS. It is recommended that 
all hospitals participating in the care of high-risk ACS patients have an 
ICCU/CCU equipped to provide all required aspects of care including 
treatment of ischaemia, severe HF, arrhythmias, and common co- 
morbidities. It is also recommended that the LVEF is determined before 
hospital discharge in all patients with ACS. Discharge of high-risk ACS pa­
tients within 48–72 h should be considered in selected patients if early re­
habilitation and adequate follow-up are arranged.
Technical aspects during PPCI
Routine radial access and use of DES are the standard of care during PCI 
for ACS. Intravascular imaging should be considered to guide PCI and 
may be considered in patients with ambiguous culprit lesions. 
Routine thrombus aspiration is not recommended. CABG should be 
considered in patients with an occluded IRA when PCI is not feasible 
or unsuccessful and there is a large area of myocardium in jeopardy. 
In patients presenting with SCAD, PCI is recommended only for pa­
tients with symptoms and signs of ongoing myocardial ischaemia, a large 
area of myocardium in jeopardy, and reduced antegrade flow.
Management of patients with MVD
For patients with MVD, it is recommended to base the revascularization 
strategy (IRA PCI, multivessel PCI/CABG) on the patient’s clinical status 
and comorbidities, as well as their disease complexity, according to the 
principles of management of myocardial revascularization. For patients 
with MVD presenting with CS, IRA-only PCI during the index procedure 
is recommended. For patients with STEMI undergoing PPCI, complete re­
vascularization is recommended either during the index PCI or within 45 
days. In patients presenting with NSTE-ACS and MVD, complete revascu­
larization should be considered, preferably during the index procedure. 
For patients with STEMI, it is recommended that decisions regarding 
PCI of non-IRA are based on angiographic severity, whereas for patients 
with NSTE-ACS, functional invasive evaluation of non-IRA severity during 
the index procedure may be considered.
MINOCA
The term MINOCA refers to the situation where patients present with 
symptoms suggestive of ACS and demonstrate troponin elevation and 
non-obstructive coronary arteries at the time of coronary angiography, 
i.e. coronary artery stenosis <50% in any major epicardial vessel. 
MINOCA is best considered as a working diagnosis that encompasses a 
heterogenous group of underlying causes (both cardiac and extra-cardiac) 
and is found in 1–14% of patients with ACS. In all patients with an initial 
working diagnosis of MINOCA, it is recommended to follow a diagnostic 
algorithm to determine the underlying cause. CMR imaging is a key diag­
nostic tool in patients with a working diagnosis of MINOCA.
Special patient subsets
Chronic kidney disease: moderate to severe CKD is present in >30% of 
ACS patients. These patients receive less interventional and pharmaco­
logical treatment and have a worse prognosis in comparison to patients 
with normal kidney function. It is recommended to apply the same diag­
nostic and therapeutic strategies in patients with CKD (dose adjustment 
may be necessary) as for patients with normal kidney function.
Older adults: in general, older adults should undergo the same diag­
nostic and treatment strategies, including invasive angiography and re­
vascularization, as younger patients.
Patients with cancer: management of ACS in patients with cancer can 
be challenging for several reasons, including frailty, increased bleeding 
risk, thrombocytopaenia, and increased thrombotic risk. An invasive 
strategy is recommended in cancer patients presenting with high-risk 
ACS with expected survival ≥6 months. A conservative non-invasive 
strategy should be considered in ACS patients with poor cancer prog­
nosis (with expected survival <6 months) and/or very high bleeding risk.
Long-term treatment
Secondary prevention after ACS should be offered to every patient and 
should start as early as possible after the index event. This includes car­
diac rehabilitation, lifestyle management, and pharmacological treat­
ment, and has been shown to both increase quality of life and 
decrease morbidity and mortality. 
Patient perspectives
Some of the key first steps in the timely diagnosis and treatment of ACS 
are reliant on a comprehensive assessment of symptoms. An incom­
plete history or poorly elicited symptoms can result in delay or misdiag­
nosis. Patient-centred care is recommended as a critical tenet of 
routine clinical management and involves consideration of a patient’s 
physical, emotional, and psychological needs.
The provision of care that is respectful of, and responsive to, individ­
ual patient preferences, needs and values, is important in the manage­
ment of patients with ACS. It is recommended, as much as possible, 
to include ACS patients in decision-making. Preparing for discharge be­
gins on admission. Educating and informing the patient using the teach 
back method and educationally appropriate material should be inte­
grated into the patient care pathway.
Quality indicators
Acute coronary syndrome QIs aim to audit practice and improve clin­
ical outcomes in real-life patients by demonstrating the gap between 
optimal guideline-based treatment and actual care of ACS patients. 
Subsequent measures to improve QI attainment can be implemented 
based on the local, regional, and global assessment of QIs.


<!-- PAGE 74 -->

### Page 74

### 16 Gaps in evidence

Table 8 Gaps in evidence
Section
Gaps in evidence
Research recommendations to address 
these gaps
3
Triage and diagnosis
• Observe zone: how can we improve the guidance for and 
management of patients assigned to the observe zone of 
the 0 h/1 h and 0 h/2 h ESC algorithms to improve their 
poor outcome?
• No testing rule: what is the added value of biomarkers 
other than hs-cTn for rapid rule-out of NSTE-ACS 
compared with usual care?
• There is insufficient evidence to set sex-specific 
thresholds for troponin levels.
• The role of non-invasive anatomy (e.g. CCTA) or 
functional imaging (e.g. stress testing strategies) for 
low-risk NSTE-ACS patients should be further evaluated.
• Observe zone: prospectively evaluate changes in the 
0 h/1 h and 0 h/2 h ESC algorithms to improve the 
outcomes of patients assigned to the observe zone.
• No testing rule: randomization of patients to 
strategies with and without new biomarkers to 
evaluate whether their use improves clinical 
outcomes.
• Prospectively evaluate the impact of using 
sex-specific cut-offs on the diagnosis, treatment, 
and outcomes of patients presenting to the ED with 
suspected ACS.
• Adequately powered RCTs testing whether 
non-invasive imaging improves clinical outcomes in 
patients presenting with NSTE-ACS.
4
Initial measures for 
patients presenting with 
suspected STEMI | Initial 
treatment
• The impact of early i.v. beta-blockers on clinical outcomes 
in patients with a working diagnosis of STEMI remains 
unclear.
• Infarct size and microvascular obstruction are the main 
determinants of long-term prognosis. Interventions 
which serve to limit infarct size are needed.
• Patients randomized to i.v. beta-blockers (ideally 
metoprolol) or placebo before PPCI, with hard 
endpoints evaluated.
• Translate cardio-protective therapies from 
experimental to clinical setting by executing 
adequately powered trials.
5
Acute-phase management 
of patients with NSTE-ACS
• The comparison of routine or selective invasive 
assessment in low-risk NSTE-ACS has not been 
adequately evaluated.
• The optimal timing of invasive angiography in high-risk 
NSTE-ACS patients remains uncertain.
• Low-risk patients should be randomized to routine 
or selective invasive strategy.
• RCTs testing different time intervals to perform 
angiography within the 72 h window after the initial 
presentation.
6
Antithrombotic therapy
• Whether pre-treatment with oral P2Y12 receptor 
inhibitors prior to ICA improves clinical outcomes in 
NSTE-ACS patients is uncertain.
• Whether platelet function testing or genetic testing to 
guide de-escalation of oral P2Y12 receptor inhibitors after 
the first month of therapy following PCI improves clinical 
management and outcomes remains unclear.
• The optimal long-term antithrombotic regimen in 
NSTE-ACS patients who have undergone PCI is 
unknown.
• After stopping DAPT, a head-to-head comparison based 
on superiority between aspirin monotherapy and 
clopidogrel monotherapy is required.
• Randomize patients to pre-treatment with oral 
P2Y12 receptor inhibitors or no pre-treatment, 
prior to ICA.
• Randomize ACS patients to prasugrel or ticagrelor, 
both without pre-treatment.
• A strategy based on platelet function testing or 
genetic testing should be prospectively tested in 
patients who may benefit from de-escalating 
antithrombotic therapy.
• RCTs evaluating the benefit-risk balance for 
ischaemic bleeding events for different periods of 
antithrombotic duration.
• A head-to-head randomized comparison testing for 
superiority is needed to compare aspirin vs. 
clopidogrel monotherapy after DAPT.
7
Acute coronary syndrome 
with unstable presentation
• The role of percutaneous MCS devices in patients 
presenting with ACS and CS remains unclear.
• Randomized comparisons between standard of care 
and percutaneous MCS devices in ACS with CS.
8
Management of acute 
coronary syndrome during 
hospitalization
• Clinical improvement through the use of risk stratification 
based on risk prediction models.
• Patients randomized to a particular intervention or 
to usual care based on validated risk prediction 
models.
9
Technical aspects of 
invasive strategies
• Does intravascular imaging-guided revascularization 
strategy improve clinical outcomes in patients  
with ACS?
• Does intracoronary physiology assessment of myocardial 
reperfusion after PPCI improve risk stratification and/or 
stratified medicine for limiting microvascular dysfunction 
and reperfusion injury/MVO post ACS?
• RCTs evaluating the efficacy of an intravascular 
imaging-guided revascularization strategy to 
improve meaningful clinical outcomes in patients 
with ACS.
• Prospectively evaluate whether intracoronary 
physiology assessment of myocardial reperfusion 
better stratifies patient risk.
Continued
ESC Guidelines                                                                                                                                                                                          3793


<!-- PAGE 75 -->

### Page 75

• In ACS patients with an IRA that is unsuitable for stent 
implantation, does drug-coated balloon treatment of the 
IRA improve clinical outcomes?
• Microvascular obstruction associated with PPCI 
represents an unmet clinical need in patients with ACS. 
Development of therapies for the prevention and 
treatment of MVO is urgently needed.
• Does early implementation of MCS in the management of 
high-risk ACS patients improve clinical outcomes?
• Does intracoronary hypothermia reduce infarct size and 
improve clinical outcomes in STEMI patients undergoing 
PPCI?
• What is the optimal antiplatelet strategy in patients 
presenting with SCAD? Specific gaps in knowledge 
surround antithrombotic treatment in the acute and 
post-ACS periods, including the optimal combination and 
duration of treatment.
• Patients with an IRA unsuitable for stent 
implantation randomized to drug-coated balloon 
treatment or usual care to evaluate clinical 
outcomes.
• Pre-clinical and clinical research is needed to 
evaluate cardio-protective therapies aimed at 
reducing microvascular obstruction.
• RCTs evaluating the benefit of using MCS in 
high-risk patients.
• Randomized trials are needed to demonstrate both 
whether intracoronary hypothermia reduces 
myocardial infarct size, and if this translates into 
clinical improvement.
• RCTs evaluating several antiplatelet strategies in 
patients with SCAD with the aim of determining 
which results in the greatest clinical benefit.
10
Management of patients 
with multivessel disease
• Does complete revascularization of NSTE-ACS with 
multivessel CAD improve clinical outcomes vs. 
culprit-only PCI?
• Does management of non-infarct-related CAD with 
intravascular imaging guidance to identify rupture-prone 
atherosclerotic plaque improve clinical outcomes?
• Does FFR-guided management improve clinical outcomes 
vs. standard angiography-guided management in 
NSTE-ACS?
• What is the optimal timing of coronary revascularization 
(immediate vs. index hospitalization vs. staged) for 
non-IRA revascularization in STEMI and NSTE-ACS?
• Does intensive medical therapy improve outcomes in 
patients with MVD compared with standard secondary 
prevention?
• The clinical utility of hybrid coronary revascularization in 
ACS patients with multivessel CAD is uncertain.
• Patients with NSTE-ACS and MVD randomized to 
complete vs. culprit-only PCI.
• RCTs testing whether the use of intravascular 
imaging to guide the management of 
non-infarct-related lesions improves clinical 
outcomes.
• Patients randomized to FFR-guided management vs. 
standard angiography-guided management in 
NSTE-ACS.
• Three-arm study comparing the clinical benefits of 
immediate, in-hospital and staged coronary 
revascularization strategies.
• Patients with MVD randomized to intensive 
secondary prevention vs. usual care to evaluate 
whether the former strategy improves clinical 
outcomes.
• RCTs assessing the clinical benefit of hybrid 
revascularization.
12
Special situations
• How to better differentiate Type 2 from Type 1 MI 
before invasive assessment.
• The optimal management strategy in older adults with 
NSTE-ACS is not known.
• The optimal management strategy in older frail, comorbid 
adults with NSTE-ACS is not known.
• The optimal management strategy in older frail, comorbid 
adults with STEMI is not known.
• Optimal antiplatelet therapy and its duration to manage 
ACS in pregnant patients are not known.
• The optimal management strategy for pregnant women 
with NSTE-ACS is not known.
• There is a need to further evaluate the contribution of 
social determinants of health.
• Prospective evaluation of diagnostic strategies 
aimed at better classifying patients according to 
their type of MI (Type 1 vs. Type 2).
• Further studies recruiting older adults should be 
conducted to evaluate whether the current 
standard of care also benefits this subset of patients.
• Older frail, comorbid patients should not be 
systematically excluded from RCTs.
• Prospective data are needed to better understand 
which antiplatelet therapy regimen is best for 
pregnant women.
• Observational data are needed in patients with ACS 
to evaluate the real impact of social determinants of 
health on clinical outcomes. Randomized 
interventions aimed at reducing social inequalities 
are needed to evaluate how to reduce this gap.
13
Long-term treatment
• To evaluate the uptake, safety, and outcomes for 
alternative forms of cardiac rehabilitation, with a focus on 
telemedicine and eHealth.
• How to improve referral for and uptake of CR, especially 
for groups with low participation, including women, older 
persons, and ethnic minorities.
• Remote cardiac rehabilitation methods need 
randomized data to evaluate their true potential.
• Further monitoring is needed to increase the 
participation of historically under-represented 
patients in CR.
Continued


<!-- PAGE 76 -->

### Page 76

### 17 Sex differences

There are currently no data supporting the differential management of 
ACS based on sex. However, several studies have reported that wo­
men presenting with ACS are treated differently than men.914–918
This includes being less likely than men to receive ICA, timely revascu­
larization, CR, and secondary prevention medications.914–918
Healthcare providers and policymakers should be conscious of this 
potential gender bias in the management of ACS and make a concerted 
effort to ensure that women with ACS receive evidence-based care.
In order to ensure the generalizability of the findings yielded by 
RCTs, patient recruitment should be reflective of real-world popula­
tions from different socioeconomic backgrounds.919 Several studies 
have reported that a disproportionately low proportion of women 
are recruited to CV trials.920–922
Alongside historic under- 
representation of other subsets of patients, including older patients 
and ethnic minorities, this suggests an underlying recruitment bias.923
Increased representation of female patients in future clinical trials is re­
quired to better inform the optimal management of women with 
ACS.924
• The role of personalized medicine in the short- and 
long-term treatment of ACS needs to be further studied.
• How to address additional risk from non-traditional risk 
factors, e.g. cardio-obstetrics, cardio-oncology, and 
inflammatory conditions, needs further attention.
• Inflammation as a treatment target in patients with 
atherosclerosis still needs unravelling, as well as the use of 
biomarkers of inflammation (high-sensivity C-reactive 
protein, interleukins 1 and 6) to guide treatment of 
residual risk.
• The role of lipoprotein (a) in guiding treatment and as an 
independent treatment target needs to be studied further.
• The added cardio-protective role of beta-blockers in 
post-ACS patients without reduced LVEF on otherwise 
optimal medical therapy needs to be clarified.
• The added cardio-protective role of ACE inhibitors/ARBs 
in post-ACS patients without reduced LVEF on otherwise 
optimal medical therapy needs to be clarified.
• The future role of new treatment options, using mRNA- 
and siRNA-based therapies targeting lipid metabolism 
and inflammation, needs to be explored.
• It has to be determined whether SGLT2 inhibitors—in 
the specific group of patients with ACS without heart 
failure or diabetes—improve clinical outcomes, 
regardless of diabetes status.
• Patients randomized to personalized strategies vs. 
usual care are needed to determine the role of 
precision medicine in ACS.
• Prospective cohorts are needed to evaluate 
non-traditional risk factors and residual risk.
• RCTs testing whether management based on the 
use of biomarkers of inflammation improves clinical 
outcomes.
• RCTs testing whether lipoprotein (a) measurement 
to guide medical management further improves 
clinical outcomes.
• Patients randomized to beta-blocker and no 
beta-blocker use to evaluate treatment efficacy in 
patients with ACS and LVEF >40%.
• RCTs evaluating the benefit of using ACE inhibitors/ 
ARBs vs. placebo on top of standard care in ACS 
patients with LVEF >40%.
• Randomized data are needed to evaluate the role of 
mRNA- and siRNA-based therapies in the current 
context of lipid management and lipid targets.
• ACS patients without HF or diabetes should be 
randomized to SGLT2 inhibitors vs. standard of 
care.
14
Patient perspectives
• The feasibility of performing short witnessed verbal 
consent followed by written consent after the acute 
phase needs further evaluation.
• There is a need to assess the contribution of social 
determinants of health on ACS incidence and prognosis.
• The use of validated patient-reported outcome and 
experience measures in evidence-based medicine should 
be increased.
• Quality of life is a relevant outcome not captured in most 
trials.
• Use of validated decision aids and audio-visual tools can 
be helpful to make informed choices that consider 
patients’ values and preferences and promote patient 
involvement.
• Studies comparing verbal vs. written consent to 
evaluate safety endpoints and any ethical concerns.
• The influence of social determinants of health on 
clinical outcomes should be evaluated, as well as 
those interventions aimed at reducing social 
inequalities.
• PROMs/PREMs should have a more prominent role 
in RCTs evaluating patients with ACS.
• Include quality of life as a prominent outcome in 
clinical trials.
• Testing the use of validated decision aids and 
audio-visual tools to improve decisions around 
informed choices.
19
Quality indicators
• There is a lack of implementation studies evaluating 
whether prospectively monitoring and reporting ESC QIs 
for ACS improve clinical outcomes.
• Implementation studies evaluating a quality of care 
programme based on the evaluation of ESC QIs for 
ACS.
General
• Patients included in clinical trials represent a relatively 
small proportion of real-life patients.
• Conduct clinical trials that enrol more 
representative patient populations (e.g. pragmatic 
clinical trials).
© ESC 2023
Ongoing trials addressing some of these gaps in evidence are presented in the Supplementary data online. 
ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; CR, 
cardiac rehabilitation; CS, cardiogenic shock; DAPT, dual antiplatelet therapy; ED, emergency department; ESC, European Society of Cardiology; FFR, fractional flow reserve; HF, heart failure; ICA, 
invasive coronary angiography; IRA, infarct-related artery; i.v., intravenous; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MI, myocardial infarction; MINOCA, 
myocardial infarction with non-obstructive coronary arteries; mRNA, messenger ribonucleic acid; MVD, multivessel disease; MVO, microvascular obstruction; NSTE-ACS, non-ST-elevation 
acute coronary syndrome; PCI, percutaneous coronary intervention; PPCI, primary percutaneous coronary intervention; PREM, patient-reported experience measure; PROM, 
patient-reported outcome measure; QI, quality indicator; RCT, randomized controlled trial; SCAD, spontaneous coronary artery dissection; SGLT2, sodium-glucose co-transporter 2; siRNA, 
small interfering ribodeoxynucleic acid; STEMI, ST-elevation myocardial infarction.
ESC Guidelines                                                                                                                                                                                          3795


<!-- PAGE 77 -->

### Page 77

18. ‘What to do’ and ‘What not to 
do’ messages from the Guidelines
Table 9 ‘What to do’ and ‘What not to do’
Recommendations for clinical and 
diagnostic tools for patients with suspected 
acute coronary syndrome
Classa
Levelb
It is recommended that patients with suspected 
STEMI are immediately triaged for an emergency 
reperfusion strategy.
I
A
It is recommended to base the diagnosis and initial 
short-term risk stratification of ACS on a 
combination of clinical history, symptoms, vital signs, 
other physical findings, ECG, and hs-cTn.
I
B
Twelve-lead ECG recording and interpretation is 
recommended as soon as possible at the point of first 
medical contact, with a target of <10 min.
I
B
Continuous ECG monitoring and the availability of 
defibrillator capacity is recommended as soon as 
possible in all patients with suspected STEMI, in 
suspected ACS with other ECG changes or ongoing 
chest pain, and once the diagnosis of MI is made.
I
B
The use of additional ECG leads (V3R, V4R, and V7– 
V9) is recommended in cases of inferior STEMI or if 
total vessel occlusion is suspected and standard leads 
are inconclusive.
I
B
An additional 12-lead ECG is recommended in 
cases with recurrent symptoms or diagnostic 
uncertainty.
I
C
It is recommended to measure cardiac troponins 
with high-sensitivity assays immediately after 
presentation and to obtain the results within 60 min 
of blood sampling.
I
B
It is recommended to use an ESC algorithmic 
approach with serial hs-cTn measurements (0 h/1 h 
or 0 h/2 h) to rule in and rule out NSTEMI.
I
B
Additional testing after 3 h is recommended if the 
first two hs-cTn measurements of the 0 h/1 h 
algorithm are inconclusive and no alternative 
diagnoses explaining the condition have been made.
I
B
Recommendations for non-invasive imaging in the initial 
assessment of patients with suspected acute coronary 
syndrome
Emergency TTE is recommended in patients with 
suspected ACS presenting with cardiogenic shock or 
suspected mechanical complications.
I
C
Routine, early coronary computed tomography 
angiography in patients with suspected ACS is not 
recommended.
III
B
Continued
Recommendations for the initial management of patients with 
acute coronary syndrome
It is recommended that the pre-hospital 
management of patients with a working diagnosis of 
STEMI is based on regional networks designed to 
deliver reperfusion therapy expeditiously and 
effectively, with efforts made to make PPCI available 
to as many patients as possible.
I
B
It is recommended that PPCI-capable centres deliver 
a 24/7 service and are able to perform PPCI without 
delay.
I
B
It is recommended that patients transferred for PPCI 
bypass the emergency department and CCU/ICU 
and are transferred directly to the catheterization 
laboratory.
I
B
Oxygen is recommended in patients with 
hypoxaemia (SaO2 <90%).
I
C
It is recommended that EMS transfer patients with 
suspected STEMI to a PCI-capable centre, bypassing 
non-PCI centres.
I
C
It is recommended that ambulance teams are trained 
and equipped to identify ECG patterns suggestive of 
acute coronary occlusion and to administer initial 
therapy, including defibrillation, and fibrinolysis when 
applicable.
I
C
It is recommended that all hospitals and EMS 
participating in the care of patients with suspected 
STEMI record and audit delay times and work 
together to achieve and maintain quality targets.
I
C
Routine oxygen is not recommended in patients with 
oxygen saturation >90%.
III
A
Recommendations for reperfusion therapy and timing of 
invasive strategy
Recommendations for reperfusion therapy for patients with 
STEMI
Reperfusion therapy is recommended in all patients 
with a working diagnosis of STEMI (persistent 
ST-segment elevation or equivalents) and symptoms 
of ischaemia of ≤12 h duration.
I
A
A PPCI strategy is recommended over fibrinolysis if 
the anticipated time from diagnosis to PCI is 
<120 min.
I
A
If timely PPCI (<120 min) cannot be performed in 
patients with a working diagnosis of STEMI, 
fibrinolytic therapy is recommended within 12 h of 
symptom onset in patients without 
contraindications.
I
A
Rescue PCI is recommended for failed fibrinolysis 
(i.e. ST-segment resolution <50% within 60–90 min 
of fibrinolytic administration) or in the presence of 
haemodynamic or electrical instability, worsening 
ischaemia, or persistent chest pain.
I
A
Continued


<!-- PAGE 78 -->

### Page 78

In patients with a working diagnosis of STEMI and a 
time from symptom onset >12 h, a PPCI strategy is 
recommended in the presence of ongoing symptoms 
suggestive of ischaemia, haemodynamic instability, or 
life-threatening arrhythmias.
I
C
Routine PCI of an occluded IRA is not recommended 
in STEMI patients presenting >48 h after symptom 
onset and without persistent symptoms.
III
A
Transfer/interventions after fibrinolysis
Transfer to a PCI-capable centre is recommended in 
all patients immediately after fibrinolysis.
I
A
Emergency angiography and PCI of the IRA, if 
indicated is recommended in patients with 
new-onset or persistent heart failure/shock after 
fibrinolysis.
I
A
Angiography and PCI of the IRA, if indicated, is 
recommended between 2 and 24 h after successful 
fibrinolysis.
I
A
Invasive strategy in NSTE-ACS
An invasive strategy during hospital admission is 
recommended in NSTE-ACS patients with high-risk 
criteria or with a high index of suspicion for unstable 
angina.
I
A
A selective invasive approach is recommended in 
patients without very high- or high-risk features and a 
low index of suspicion for NSTE-ACS.
I
A
An immediate invasive strategy is recommended in 
patients with a working diagnosis of NSTE-ACS and 
with at least one of the following very high-risk 
criteria: 
• Haemodynamic instability or cardiogenic shock
• Recurrent or refractory chest pain despite medical 
treatment
• In-hospital life-threatening arrhythmias
• Mechanical complications of MI
• Acute heart failure presumed secondary to 
ongoing myocardial ischaemia
Recurrent dynamic ST-segment or T wave changes, 
particularly intermittent ST-segment elevation.
I
C
Recommendations for antiplatelet and anticoagulant therapy in 
acute coronary syndrome
Antiplatelet therapy
Aspirin is recommended for all patients without 
contraindications at an initial oral LD of 150–300 mg 
(or 75–250 mg i.v.) and an MD of 75–100 mg o.d. for 
long-term treatment.
I
A
In all ACS patients, a P2Y12 receptor inhibitor is 
recommended in addition to aspirin, given as an initial 
oral LD followed by an MD for 12 months unless 
there is high bleeding risk.
I
A
A proton pump inhibitor in combination with dual 
antiplatelet therapy is recommended in patients at 
high risk of gastrointestinal bleeding.
I
A
Continued
Prasugrel is recommended in P2Y12 receptor 
inhibitor-naïve patients proceeding to PCI (60 mg 
LD, 10 mg o.d. MD, 5 mg o.d. MD for patients aged 
≥75 years or with a body weight <60 kg).
I
B
Ticagrelor is recommended irrespective of the 
treatment strategy (invasive or conservative) 
(180 mg LD, 90 mg twice a day MD).
I
B
Clopidogrel (300–600 mg LD, 75 mg o.d. MD) is 
recommended when prasugrel or ticagrelor are not 
available, cannot be tolerated, or are contraindicated.
I
C
If patients presenting with ACS stop DAPT to 
undergo CABG, it is recommended they resume 
DAPT after surgery for at least 12 months.
I
C
Pre-treatment with a glycoprotein IIb/IIIa antagonist 
is not recommended.
III
A
Routine pre-treatment with a P2Y12 receptor 
inhibitor in NSTE-ACS patients in whom coronary 
anatomy is not known and early invasive 
management (<24 h) is planned is not 
recommended.
III
A
Anticoagulant therapy
Parenteral anticoagulation is recommended for all 
patients with ACS at the time of diagnosis.
I
A
Routine use of a UFH bolus (weight-adjusted i.v. 
bolus during PCI of 70–100 IU/kg) is recommended 
in patients undergoing PCI.
I
C
Patients with STEMI
Fondaparinux is not recommended in patients with 
STEMI undergoing PPCI.
III
B
Patients with NSTE-ACS
For patients with NSTE-ACS in whom early invasive 
angiography (i.e. within 24 h) is not anticipated, 
fondaparinux is recommended.
I
B
Combining antiplatelets and OAC
As the default strategy for patients with atrial 
fibrillation and CHA2DS2-VASc score ≥1 in men and 
≥2 in women, after up to 1 week of triple 
antithrombotic therapy following the ACS event, 
dual antithrombotic therapy using a non-vitamin K 
antagonist oral anticoagulant at the recommended 
dose for stroke prevention and a single oral 
antiplatelet agent (preferably clopidogrel) for up to 
12 months is recommended.
I
A
During PCI, a UFH bolus is recommended in any of 
the following circumstances: 
• if the patient is on a NOAC
• if the INR is <2.5 in VKA-treated patients.
I
C
The use of ticagrelor or prasugrel as part of triple 
antithrombotic therapy is not recommended.
III
C
Continued
ESC Guidelines                                                                                                                                                                                          3797


<!-- PAGE 79 -->

### Page 79

Recommendations for alternative antithrombotic therapy 
regimens
Discontinuation of antiplatelet treatment in patients 
treated with an oral anticoagulant is recommended 
after 12 months.
I
B
De-escalation of antiplatelet therapy in the first 30 
days after ACS is not recommended.
III
B
Recommendations for fibrinolytic therapy
When fibrinolysis is the reperfusion strategy, it is 
recommended to initiate this treatment as soon as 
possible after diagnosis in the pre-hospital setting 
(aim for target of <10 min to lytic bolus).
I
A
A fibrin-specific agent (i.e. tenecteplase, alteplase, or 
reteplase) is recommended.
I
B
Antiplatelet co-therapy with fibrinolysis
Aspirin and clopidogrel are recommended.
I
A
Anticoagulation co-therapy with fibrinolysis
Anticoagulation is recommended in patients treated 
with fibrinolysis until revascularization (if performed) 
or for the duration of hospital stay (up to 8 days).
I
A
Enoxaparin i.v. followed by subcutaneous is 
recommended as the preferred anticoagulant.
I
A
When enoxaparin is not available, unfractionated 
heparin is recommended as a weight-adjusted i.v. 
bolus, followed by infusion.
I
B
Recommendations for cardiac arrest and out-of-hospital 
cardiac arrest
A PPCI strategy is recommended in patients with 
resuscitated cardiac arrest and an ECG with 
persistent ST-segment elevation (or equivalents).
I
B
Temperature control (i.e. continuous monitoring of 
core temperature and active prevention of fever [i.e. 
>37.7°C]) is recommended after either 
out-of-hospital or in-hospital cardiac arrest for adults 
who remain unresponsive after return of 
spontaneous circulation.
I
B
Routine immediate angiography after resuscitated 
cardiac arrest is not recommended in 
haemodynamically stable patients without persistent 
ST-segment elevation (or equivalents).
III
A
Systems of care
It is recommended that healthcare systems 
implement strategies to facilitate transfer of all 
patients in whom ACS is suspected after resuscitated 
cardiac arrest directly to a hospital offering 24/7 PPCI 
via one specialized EMS.
I
C
Evaluation of neurological prognosis
Evaluation of neurological prognosis (no earlier than 
72 h after admission) is recommended in all 
comatose survivors after cardiac arrest.
I
C
Continued
Recommendations for cardiogenic shock
Immediate coronary angiography and PCI of the IRA 
(if indicated) is recommended in patients with CS 
complicating ACS.
I
B
Emergency CABG is recommended for  
ACS-related CS if PCI of the IRA is not feasible/ 
unsuccessful.
I
B
In cases of haemodynamic instability, emergency 
surgical/catheter-based repair of mechanical 
complications of ACS is recommended, based on 
Heart Team discussion.
I
C
The routine use of an intra-aortic balloon pump in 
ACS patients with CS and without mechanical 
complications is not recommended.
III
B
Recommendations for in-hospital management
It is recommended that all hospitals participating in 
the care of high-risk patients have an ICCU/CCU 
equipped to provide all required aspects of care, 
including treatment of ischaemia, severe heart failure, 
arrhythmias, and common comorbidities.
I
C
It is recommended that high-risk patients (including all 
STEMI patients and very high-risk NSTE-ACS 
patients) have ECG monitoring for a minimum of 24 h.
I
C
It is recommended that high-risk patients with 
successful reperfusion therapy and an uncomplicated 
clinical course (including all STEMI patients and very 
high-risk NSTE-ACS patients) are kept in the CCU/ 
ICCU for a minimum of 24 h whenever possible, after 
which they may be moved to a step-down monitored 
bed for an additional 24–48 h.
I
C
Recommendations for technical aspects of invasive strategies
Radial access is recommended as the standard 
approach, unless there are over-riding procedural 
considerations.
I
A
PCI with stent deployment in the IRA during the 
index procedure is recommended for patients 
undergoing PPCI.
I
A
Drug-eluting stents are recommended in preference 
to bare metal stents in all cases.
I
A
In patients with spontaneous coronary artery 
dissection, PCI is recommended only for patients 
with symptoms and signs of ongoing myocardial 
ischaemia, a large area of myocardium in jeopardy, 
and reduced antegrade flow.
I
C
The routine use of thrombus aspiration is not 
recommended.
III
A
Recommendations for management of patients with 
multivessel disease
It is recommended to base the revascularization 
strategy (IRA PCI, multivessel PCI/CABG) on the 
patient’s clinical status and comorbidities, as well as 
their disease complexity, according to the principles 
of management of myocardial revascularization.
I
B
Continued


<!-- PAGE 80 -->

### Page 80

Multivessel disease in ACS patients presenting in cardiogenic 
shock
IRA-only PCI during the index procedure is 
recommended.
I
B
Multivessel disease in haemodynamically stable STEMI patients 
undergoing PPCI
Complete revascularization is recommended either 
during the index PCI procedure or within 45 days.
I
A
It is recommended that PCI of the non-IRA is based 
on angiographic severity.
I
B
Invasive epicardial functional assessment of 
non-culprit segments of the IRA is not 
recommended during the index procedure.
III
C
Recommendations for myocardial infarction with 
non-obstructive coronary arteries
In patients with a working diagnosis of MINOCA 
CMR imaging is recommended after invasive 
angiography if the final diagnosis is not clear
I
B
Management of MINOCA according to the final 
established underlying diagnosis is recommended, 
consistent with the appropriate disease-specific 
guidelines.
I
B
In all patients with an initial working diagnosis of 
MINOCA, it is recommended to follow a diagnostic 
algorithm to determine the underlying final diagnosis.
I
C
Recommendations for acute coronary syndrome complications
Atrial fibrillation
Intravenous beta-blockers are recommended when 
rate control is needed in the absence of acute HF or 
hypotension.
I
C
Intravenous amiodarone is recommended when rate 
control is needed in the presence of acute HF and no 
hypotension.
I
C
Immediate electrical cardioversion is recommended 
in patients with ACS and haemodynamic instability 
and when adequate rate control cannot be achieved 
promptly with pharmacological agents.
I
C
Intravenous amiodarone is recommended to 
facilitate electrical cardioversion and/or decrease risk 
of early recurrence of AF after electrical 
cardioversion in unstable patients with recent-onset 
AF.
I
C
Ventricular arrythmias
Implantable cardioverter defibrillator use is 
recommended to reduce sudden cardiac death in 
patients with symptomatic HF (NYHA Class II–III) 
and LVEF ≤35% despite optimal medical therapy for 
>3 months and at least 6 weeks after MI who are 
expected to survive for at least 1 year with good 
functional status.
I
A
Intravenous beta-blocker and/or amiodarone 
treatment is recommended for patients with 
polymorphic VT and/or VF unless contraindicated.
I
B
Continued
Prompt and complete revascularization is 
recommended to treat myocardial ischaemia that may 
be present in patients with recurrent VT and/or VF.
I
C
Bradyarrhythmias
In cases of sinus bradycardia with haemodynamic 
intolerance or high-degree AV block without stable 
escape rhythm:
• i.v. positive chronotropic medication (adrenaline, 
vasopressin, and/or atropine) is recommended.
• temporary pacing is recommended in cases of 
failure to respond to atropine.
• urgent angiography with a view to 
revascularization is recommended if the patient 
has not received previous reperfusion therapy.
I
C
Implantation of a permanent pacemaker is 
recommended when high-degree AV block does not 
resolve within a waiting period of at least 5 days after 
MI.
I
C
Pacing is not recommended if high-degree AV block 
resolves after revascularization or spontaneously.
III
B
Treatment of asymptomatic and haemodynamically 
irrelevant ventricular arrhythmias with 
anti-arrhythmic drugs is not recommended.
III
C
Recommendations for acute coronary syndrome comorbid 
conditions
Chronic kidney disease
The use of low- or iso-osmolar contrast media (at 
the lowest possible volume) is recommended for 
invasive strategies.
I
A
It is recommended to assess kidney function using 
eGFR in all patients with ACS.
I
C
It is recommended to apply the same diagnostic and 
therapeutic strategies in patients with CKD (dose 
adjustment may be necessary) as in patients with 
normal kidney function.
I
C
Diabetes
It is recommended to base the choice of long-term 
glucose-lowering treatment on the presence of 
comorbidities, including heart failure, CKD, and 
obesity.
I
A
It is recommended to assess glycaemic status at initial 
evaluation in all patients with ACS.
I
B
It is recommended to frequently monitor blood 
glucose levels in patients with known diabetes 
mellitus or hyperglycaemia (defined as glucose levels 
≥11.1 mmol/L or ≥200 mg/dL).
I
C
Older adults
It is recommended to apply the same diagnostic and 
treatment strategies in older patients as in younger 
patients.
I
B
Continued
ESC Guidelines                                                                                                                                                                                          3799


<!-- PAGE 81 -->

### Page 81

It is recommended to adapt the choice and dosage of 
antithrombotic agent, as well as of secondary 
prevention medications, to renal function, 
co-medications, comorbidities, frailty, cognitive 
function, and specific contraindications.
I
B
For frail older patients with comorbidities, a holistic 
approach is recommended to individualize 
interventional and pharmacological treatments after 
careful evaluation of the risks and benefits.
I
B
An invasive strategy is recommended in cancer 
patients presenting with high-risk ACS with expected 
life survival ≥6 months.
I
B
A temporary interruption of cancer therapy is 
recommended in patients in whom the cancer 
therapy is suspected to be a contributing cause of 
ACS.
I
C
Aspirin is not recommended in cancer patients with a 
platelet count <10 000/μL.
III
C
Clopidogrel is not recommended in cancer patients 
with a platelet count <30 000/μL.
III
C
In ACS patients with cancer and <50 000/μL platelet 
count, prasugrel or ticagrelor are not recommended.
III
C
Recommendations for long-term management
It is recommended that all ACS patients participate in 
a medically supervised, structured, comprehensive, 
multidisciplinary exercise-based cardiac 
rehabilitation and prevention programme.
I
A
It is recommended that ACS patients adopt a healthy 
lifestyle, including: 
• stopping all smoking of tobacco
• healthy diet (Mediterranean style)
• alcohol restriction
• regular aerobic physical activity and resistance 
exercise
• reduced sedentary time
I
B
Pharmacological treatment
Lipid-lowering therapy
It is recommended that high-dose statin therapy is 
initiated or continued as early as possible, regardless 
of initial LDL-C values.
I
A
It is recommended to aim to achieve an LDL-C level 
of <1.4 mmol/L (<55 mg/dL) and to reduce LDL-C 
by ≥50% from baseline.
I
A
If the LDL-C goal is not achieved despite maximally 
tolerated statin therapy and ezetimibe after 4–6 
weeks, the addition of a PCSK9 inhibitor is 
recommended
I
A
If the LDL-C goal is not achieved despite maximally 
tolerated statin therapy after 4–6 weeks, the addition 
of ezetimibe is recommended.
I
B
It is recommended to intensify lipid-lowering therapy 
during the index ACS hospitalization for patients 
who were on lipid-lowering therapy before 
admission.
I
C
Continued
Beta-blockers
Beta-blockers are recommended in ACS patients 
with LVEF ≤40% regardless of HF symptoms.
I
A
RAAS system inhibitors
Angiotensin-converting enzyme inhibitors are 
recommended in ACS patients with HF symptoms, 
LVEF ≤40%, diabetes, hypertension, and/or CKD.
I
A
Mineralocorticoid receptor antagonists are 
recommended in ACS patients with an LVEF ≤40% 
and HF or diabetes.
I
A
Imaging
In patients with pre-discharge LVEF ≤40%, repeat 
evaluation of the LVEF 6–12 weeks after an ACS (and 
after complete revascularization and the institution 
of optimal medical therapy) is recommended to 
assess the potential need for sudden cardiac death 
primary prevention ICD implantation.
I
C
Vaccination
Influenza vaccination is recommended for all ACS 
patients.
I
A
Recommendations for patient perspectives in acute coronary 
syndrome care
Patient-centred care is recommended by assessing 
and adhering to individual patient preferences, needs 
and beliefs, ensuring that patient values are used to 
inform all clinical decisions.
I
B
It is recommended to include ACS patients in 
decision-making (as much as their condition allows) 
and to inform them about the risk of adverse events, 
radiation exposure, and alternative options. Decision 
aids should be used to facilitate the discussion.
I
B
It is recommended to assess symptoms using 
methods that help patients to describe their 
experience.
I
C
© ESC 2023
ACS, acute coronary syndrome; AV, atrioventricular; CABG, coronary artery bypass 
grafting; CCU, cardiac care unit; CHA2DS2-VASc, Congestive heart failure, 
Hypertension, Age ≥75 years, Diabetes mellitus, Stroke or transient ischaemic attack, 
Vascular disease; CKD, chronic kidney disease; CMR, cardiac magnetic resonance; CS, 
cardiogenic shock; DAPT, dual antiplatelet therapy; ECG, electrocardiogram; ESC, 
European Society of Cardiology; HF, heart failure; hs-cTn, high-sensitivity cardiac 
troponin; ICU, intensive care unit; IRA, infarct-related artery; i.v., intravenous; LD, 
loading dose; LDL-C, low-density lipoprotein cholesterol; MD, maintenance dose; 
MINOCA, myocardial infarction with non-obstructive coronary arteries; LVEF, left 
ventricular ejection fraction; MI, myocardial infarction; NSTE-ACS, non-ST-elevation 
acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; NYHA, 
New York Heart Association; o.d., once daily; OAC, oral anticoagulant; PCI, 
percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 
9; PPCI, primary percutaneous coronary intervention; RAAS, renin–angiotensin– 
aldosterone system; STEMI, ST-elevation myocardial infarction; UFH, unfractionated 
heparin; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 82 -->

### Page 82

### 19 Quality indicators

Quality indicators are tools that can be used to evaluate care quality, 
including structures, processes, and outcomes of care.925 They may 
also serve as a mechanism for enhancing adherence to guideline recom­
mendations, through associated quality improvement initiatives and the 
benchmarking of care providers.926,927 As such, the role of QIs in im­
proving care and outcomes for CVD is increasingly recognized by 
healthcare authorities, professional organizations, payers, and the 
public.925
The ESC understands the need for measuring and reporting quality 
and outcomes of CV care and has established methods for the develop­
ment of the ESC QIs for the quantification of care and outcomes for 
CVDs.925 To date, the ESC has developed QI suites for a number of 
CVDs in parallel with the writing of the ESC Clinical Practice 
Guidelines. Previous QIs for the management of AMI have been tested 
in numerous large registries.928–933 A systematic review of these studies 
has shown that there is room for improvement in terms of levels of at­
tainment of QIs.934
The ESC aims to harmonize its QIs for various CV conditions and in­
tegrate them with ESC registries.935,936 This integrative approach pro­
vides ‘real-world’ data about the patterns and outcomes of care for 
CVD across Europe.
20. Supplementary data
Supplementary data are available at European Heart Journal online.
21. Data availability statement
No new data were generated or analysed in support of this research.
22. Author information
Author/Task Force Member Affiliations: Xavier Rossello, 
Cardiology Department, Hospital Universitari Son Espases, Palma de 
Mallorca, Spain, Clinical Research Department Centro Nacional de 
Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Health 
Research Institute of the Balearic Islands (IdiSBa), Universitat de les 
Illes Balears (UIB), Palma de Mallorca, Spain; J.J. Coughlan, 
Cardiovascular Research Institute, Mater Private Network, Dublin, 
Ireland; Emanuele Barbato, Clinical and Molecular Medicine, 
Sapienza University, Rome, Italy; Colin Berry, British Heart 
Foundation, Glasgow Cardiovascular Research Centre, University of 
Glasgow, Glasgow, United Kingdom, Cardiology, NHS Golden 
Jubilee, Clydebank, United Kingdom, Cardiology, NHS Greater 
Glasgow and Clyde Health Board, Glasgow, United Kingdom; Alaide 
Chieffo, IRCCS San Raffaele Scientific Institute, IRCCS San Raffaele 
Scientific Institute, Milan, Italy, University Vita-Salute San Raffaele, 
Milan, Italy; Marc J. Claeys, Cardiology, Antwerp University 
Hospital, Edegem, Belgium; Gheorghe-Andrei Dan, Colentina 
University Hospital, Cardiology Dpt., “Carol Davila” University of 
Medicine Bucharest, Romania; Marc R. Dweck, British Heart 
Foundation Centre for Cardiovascular Sciences, Chancellors Building, 
Little France Crescent, Little France, Edinburgh, United Kingdom; 
Mary Galbraith (United Kingdom), ESC Patient Forum, Sophia 
Antipolis, France; Martine Gilard, Cardiology, INSERM UMR 1304 
GETBO- Brest University, Brest, France; Lynne Hinterbuchner, 
Department of Cardiology, Clinic of Internal Medicine II, Paracelsus 
Medical 
University 
of 
Salzburg, 
Salzburg, 
Austria; 
Ewa 
A. Jankowska, Institute of Heart Diseases, Wroclaw Medical 
University, Wroclaw, Poland, Institute of Heart Diseases, University 
Hospital in Wroclaw, Wroclaw, Poland; Peter Jüni, Nuffield 
Department of Population Health, University of Oxford, Oxford, 
United Kingdom; Takeshi Kimura, Department of Cardiology, 
Hirakata Kohsai Hospital, Osaka, Japan; Vijay Kunadian, 
Translational and Clinical Research Institute, Faculty of Medical 
Sciences, Newcastle University, Newcastle upon Tyne, United 
Kingdom, Cardiothoracic Centre, Freeman Hospital, Newcastle upon 
Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, 
United Kingdom; Margret Leosdottir, Department of Cardiology, 
Skane University Hospital, Malmö, Sweden, Department of Clinical 
Sciences, Malmö, Lund University, Malmö, Sweden; Roberto 
Lorusso, Cardio-Thoracic Surgery, Maastricht University Medical 
Centre, Maastricht, Netherlands, Cardiovascular Research Institute 
Maastricht, Maastricht, Netherlands; Roberto F.E. Pedretti, 
Cardiovascular Department, IRCCS MultiMedica, Milan, Italy; 
Angelos G. Rigopoulos, Adult Cardiology, Mitera General 
Hospital-Hygeia Group, Athens, Greece; Maria Rubini Gimenez, 
Department of Internal Medicine and Cardiology, Heart Center 
Leipzig at the University of Leipzig, Leipzig, Germany, Cardiovascular 
Research Institute Basel, University Hospital Basel, Basel, Switzerland; 
Holger Thiele, Internal Medicine/Cardiology; Heart Center Leipzig 
at University of Leipzig, Leipzig, Germany, Leipzig Heart Science, 
Leipzig, Germany; Pascal Vranckx, Cardiology and Critical Care 
Medicine, Jessa Ziekenhuis, Hasselt, Belgium, Faculty of Medicine and 
Life Sciences, University of Hasselt, Hasselt, Belgium; Sven 
Wassmann, Cardiology, Cardiology Pasing, Munich, Germany; 
Faculty of Medicine, University of the Saarland, Homburg/Saar, 
Germany; Nanette Kass Wenger, Department of Medicine 
(Cardiology), Emory University School of Medicine, Atlanta, GA, United 
States of America, Consultant, Emory Heart and Vascular Center 
Emory University, School of Medicine, Atlanta, GA, United States of 
America, Founding Consultant, Emory Women’s Heart Center, Emory 
University School of Medicine, Atlanta, GA, United States of America.
23. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Sigrun Halvorsen (CPG Review 
Co-ordinator) (Norway), Stefan James (CPG Review Co-ordinator) 
(Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Nina 
Ajmone Marsan (Netherlands), Sotiris Antoniou (United Kingdom), 
Riccardo Asteggiano (Italy), Maria Bäck (Sweden), Davide Capodanno 
(Italy), 
Ruben 
Casado-Arroyo 
(Belgium), 
Salvatore 
Cassese 
(Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), 
Jean-Philippe Collet (France), Gregory Ducrocq (France), Volkmar 
Falk (Germany), Laurent Fauchier (France), Tobias Geisler 
(Germany), Diana A. Gorog (United Kingdom), Lene Holmvang 
(Denmark), Tiny Jaarsma (Sweden), Hywel Wynne Jones (United 
Kingdom), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), Dipak Kotecha (United Kingdom), Konstantin 
A. Krychtiuk (Austria), Ulf Landmesser (Germany), George Lazaros 
(Greece), Basil S. Lewis (Israel), Bertil Lindahl (Sweden), Ales Linhart 
(Czech Republic), Maja-Lisa Løchen (Norway), Mamas A. Mamas 
ESC Guidelines                                                                                                                                                                                          3801


<!-- PAGE 83 -->

### Page 83

(United Kingdom), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Christian 
Mueller (Switzerland), Lis Neubeck (United Kingdom), Josef Niebauer 
(Austria), Jens Cosedis Nielsen (Denmark), Alexander Niessner 
(Austria), Valeria Paradies (Netherlands), Agnes A. Pasquet (Belgium), 
Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark), 
Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Giuseppe 
M. C. Rosano (Italy), Leyla Elif Sade (United States of America/ 
Türkiye), François Schiele (France), Jolanta M. Siller-Matula (Austria), 
Christian Sticherling (Switzerland), Robert F. Storey (United 
Kingdom), Matthias Thielmann (Germany), Christiaan Vrints 
(Belgium), Stephan Windecker (Switzerland), Rune Wiseth (Norway), 
and Adam Witkowski (Poland).
ESC National Cardiac Societies actively involved in the review 
process of the 2023 ESC Guidelines for the management of acute cor­
onary syndromes:
Algeria: Algerian Society of Cardiology, Mohammed El Amine 
Bouzid; Armenia: Armenian Cardiologists Association, Hamlet 
Hayrapetyan; Austria: Austrian Society of Cardiology, Bernhard 
Metzler; Belgium: Belgian Society of Cardiology, Patrizio Lancellotti; 
Bosnia and Herzegovina: Association of Cardiologists of Bosnia 
and Herzegovina, Mugdim Bajrić; Bulgaria: Bulgarian Society of 
Cardiology, Kiril Karamfiloff; Cyprus: Cyprus Society of Cardiology, 
Andreas Mitsis; Czechia: Czech Society of Cardiology, Petr Ostadal; 
Denmark: Danish Society of Cardiology, Rikke Sørensen; Egypt: 
Egyptian Society of Cardiology, Tamer Elwasify; Estonia: Estonian 
Society of Cardiology, Toomas Marandi; Finland: Finnish Cardiac 
Society, Essi Ryödi; France: French Society of Cardiology, 
Jean-Philippe Collet; Georgia: Georgian Society of Cardiology, 
Archil Chukhrukidze; Germany: German Cardiac Society, Julinda 
Mehilli; Greece: Hellenic Society of Cardiology, Periklis Davlouros; 
Hungary: Hungarian Society of Cardiology, Dávid Becker; Iceland: 
Icelandic Society of Cardiology, Ingibjörg Jóna Guðmundsdóttir; 
Ireland: Irish Cardiac Society, James Crowley; Israel: Israel Heart 
Society, Yigal Abramowitz; Italy: Italian Federation of Cardiology, 
Ciro Indolfi; Kazakhstan: Association of Cardiologists of 
Kazakhstan, Orazbek Sakhov; Kosovo (Republic of): Kosovo 
Society of Cardiology, Shpend Elezi; Kyrgyzstan: Kyrgyz Society of 
Cardiology, Medet Beishenkulov; Latvia: Latvian Society of 
Cardiology, Andrejs Erglis; Lebanon: Lebanese Society of 
Cardiology, Nicolas Moussallem; Libya: Libyan Cardiac Society, 
Hisham Benlamin; Lithuania: Lithuanian Society of Cardiology, 
Olivija Dobilienė; Luxembourg: Luxembourg Society of Cardiology, 
Philippe Degrell; Malta: Maltese Cardiac Society, Matthew Mercieca 
Balbi; Moldova (Republic of): Moldavian Society of Cardiology, 
Aurel Grosu; Morocco: Moroccan Society of Cardiology, Zouhair 
Lakhal; Netherlands: Netherlands Society of Cardiology, Jurriën 
ten Berg; North Macedonia: The National Society of Cardiology 
of North Macedonia, Hristo Pejkov; Norway: Norwegian Society of 
Cardiology, Kristin Angel; Poland: Polish Cardiac Society, Adam 
Witkowski; Portugal: Portuguese Society of Cardiology, Manuel De 
Sousa Almeida; Romania: Romanian Society of Cardiology, Ovidiu 
Chioncel; San Marino: San Marino Society of Cardiology, Luca 
Bertelli; Serbia: Cardiology Society of Serbia, Sinisa Stojkovic; 
Slovakia: Slovak Society of Cardiology, Martin Studenčan; 
Slovenia: Slovenian Society of Cardiology, Peter Radšel; Spain: 
Spanish Society of Cardiology, Jose Luis Ferreiro; Sweden: Swedish 
Society of Cardiology, Annica Ravn-Fischer; Switzerland: Swiss 
Society of Cardiology, Lorenz Räber; Syrian Arab Republic: 
Syrian Cardiovascular Association, Mohammed Yassin Bani Marjeh; 
Tunisia: Tunisian Society of Cardiology and Cardiovascular Surgery, 
Majed Hassine; Türkiye: Turkish Society of Cardiology, Aylin 
Yildirir; Ukraine: Ukrainian Association of Cardiology, Alexander 
Parkhomenko; United Kingdom of Great Britain and 
Northern Ireland: British Cardiovascular Society, Adrian Paul 
Banning.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
24. References
1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth univer­
sal definition of myocardial infarction (2018). Eur Heart J 2019;40:237–269. https://doi. 
org/10.1093/eurheartj/ehy462
2. GBD 2017 Causes of Death Collaborators. Global, regional, and national 
age-sex-specific mortality for 282 causes of death in 195 countries and territories, 
1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. 
Lancet 2018;392:1736–1788. https://doi.org/10.1016/s0140-6736(18)32203-7
3. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European 
Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022;43: 
716–799. https://doi.org/10.1093/eurheartj/ehab892
4. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC 
Guidelines for the management of acute myocardial infarction in patients presenting 
with ST-segment elevation: the Task Force for the management of acute myocardial 
infarction in patients presenting with ST-segment elevation of the European Society 
of Cardiology (ESC). Eur Heart J 2018;39:119–177. https://doi.org/10.1093/ 
eurheartj/ehx393
5. Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV, Kirk JD, et al. Frequency 
and consequences of recording an electrocardiogram >10 minutes after arrival in an 
emergency room in non-ST-segment elevation acute coronary syndromes (from the 
CRUSADE Initiative). Am J Cardiol 2006;97:437–442. https://doi.org/10.1016/j.amjcard. 
2005.09.073
6. Lopez-Sendon J, Coma-Canella 
I, Alcasena S, 
Seoane 
J, Gamallo 
C. 
Electrocardiographic findings in acute right ventricular infarction: sensitivity and speci­
ficity of electrocardiographic alterations in right precordial leads V4R, V3R, V1, V2, and 
V3. J Am Coll Cardiol 1985;6:1273–1279. https://doi.org/10.1016/s0735-1097(85) 
80213-8
7. Schmitt C, Lehmann G, Schmieder S, Karch M, Neumann F-J, Scho¨mig A. Diagnosis of 
acute myocardial infarction in angiographically documented occluded infarct vessel: 
limitations of ST-segment elevation in standard and extended ECG leads. Chest 
2001;120:1540–1546. https://doi.org/10.1378/chest.120.5.1540
8. Kosuge M, Kimura K, Ishikawa T, Hongo Y, Shigemasa T, Sugiyama M, et al. Implications 
of the absence of ST-segment elevation in lead V4R in patients who have inferior wall 
acute myocardial infarction with right ventricular involvement. Clin Cardiol 2001;24: 
225–230. https://doi.org/10.1002/clc.4960240310
9. Yan AT, Yan RT, Kennelly BM, Anderson FA, Budaj A, López-Sendón J, et al. 
Relationship of ST elevation in lead aVR with angiographic findings and outcome in 
non-ST elevation acute coronary syndromes. Am Heart J 2007;154:71–78. https:// 
doi.org/10.1016/j.ahj.2007.03.037
10. Hirano T, Tsuchiya K, Nishigaki K, Sou K, Kubota T, Ojio S, et al. Clinical features of 
emergency electrocardiography in patients with acute myocardial infarction caused 
by left main trunk obstruction. Circ J 2006;70:525–529. https://doi.org/10.1253/circj. 
70.525
11. Yamaji H, Iwasaki K, Kusachi S, Murakami T, Hirami R, Hamamoto H, et al. Prediction 
of acute left main coronary artery obstruction by 12-lead electrocardiography. ST seg­
ment elevation in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol 
2001;38:1348–1354. doi: doi:10.1016/S0735-1097(01)01563-7
12. Chapman AR, Shah ASV, Lee KK, Anand A, Francis O, Adamson P, et al. Long-term 
outcomes in patients with type 2 myocardial infarction and myocardial injury.


<!-- PAGE 84 -->

### Page 84

Circulation 2018;137:1236–1245. https://doi.org/10.1161/CIRCULATIONAHA.117. 
031806
13. Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbücher 
D, et al. Effect of definition on incidence and prognosis of type 2 myocardial infarction. J 
Am Coll Cardiol 2017;70:1558–1568. https://doi.org/10.1016/j.jacc.2017.07.774
14. Neumann JT, Sorensen NA, Rubsamen N, Ojeda F, Renné T, Qaderi V, et al. 
Discrimination of patients with type 2 myocardial infarction. Eur Heart J 2017;38: 
3514–3520. https://doi.org/10.1093/eurheartj/ehx457
15. Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Chapman AR, et al. High-sensitivity 
troponin in the evaluation of patients with suspected acute coronary syndrome: a 
stepped-wedge, cluster-randomised controlled trial. Lancet 2018;392:919–928. 
https://doi.org/10.1016/S0140-6736(18)31923-8
16. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, et al. The se­
cond Euro Heart Survey on acute coronary syndromes: characteristics, treatment, 
and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. 
Eur Heart J 2006;27:2285–2293. https://doi.org/10.1093/eurheartj/ehl196
17. Twerenbold R, Boeddinghaus J, Nestelberger T, Wildi K, Rubini Gimenez M, 
Badertscher P, et al. Clinical use of high-sensitivity cardiac troponin in patients with sus­
pected myocardial infarction. J Am Coll Cardiol 2017;70:996–1012. https://doi.org/10. 
1016/j.jacc.2017.07.718
18. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC 
Guidelines for the management of acute coronary syndromes in patients presenting 
without persistent ST-segment elevation. Eur Heart J 2021;42:1289–1367. https:// 
doi.org/10.1093/eurheartj/ehaa575
19. Rokos IC, French WJ, Koenig WJ, Stratton SJ, Nighswonger B, Strunk B, et al. 
Integration of pre-hospital electrocardiograms and ST-elevation myocardial infarction 
receiving center (SRC) networks: impact on door-to-balloon times across 10 inde­
pendent regions. JACC Cardiovasc Interv 2009;2:339–346. https://doi.org/10.1016/j. 
jcin.2008.11.013
20. O’Doherty M, Tayler DI, Quinn E, Vincent R, Chamberlain DA. Five hundred patients 
with myocardial infarction monitored within one hour of symptoms. Br Med J (Clin Res 
Ed) 1983;286:1405–1408. https://doi.org/10.1136/bmj.286.6375.1405
21. Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, et al. Incidence of 
and outcomes associated with ventricular tachycardia or fibrillation in patients under­
going primary percutaneous coronary intervention. JAMA 2009;301:1779–1789. 
https://doi.org/10.1001/jama.2009.600
22. Kulkarni AU, Brown R, Ayoubi M, Banka VS. Clinical use of posterior electrocardio­
graphic leads: a prospective electrocardiographic analysis during coronary occlusion. 
Am Heart J 1996;131:736–741. https://doi.org/10.1016/s0002-8703(96)90280-x
23. Casas RE, Marriott HJL, Glancy DL. Value of leads V7-V9 in diagnosing posterior wall 
acute myocardial infarction and other causes of tall R waves in V1-V2. Am J Cardiol 
1997;80:508–509. https://doi.org/10.1016/s0002-9149(97)00404-9
24. Zalenski RJ, Rydman RJ, Sloan EP, Hahn KH, Cooke D, Fagan J, et al. Value of posterior 
and right ventricular leads in comparison to the standard 12-lead electrocardiogram in 
evaluation of ST-segment elevation in suspected acute myocardial infarction. Am J 
Cardiol 1997;79:1579–1585. https://doi.org/10.1016/s0002-9149(97)00202-6
25. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diag­
nosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 
361:858–867. https://doi.org/10.1056/NEJMoa0900428
26. Reichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti S, Balmelli C, et al. Introduction 
of high-sensitivity troponin assays: impact on myocardial infarction incidence and prog­
nosis. Am J Med 2012;125:1205–1213.e1. https://doi.org/10.1016/j.amjmed.2012.07. 
015
27. Neumann JT, Twerenbold R, Ojeda F, Sörensen NA, Chapman AR, Shah ASV, et al. 
Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J 
Med 2019;380:2529–2540. https://doi.org/10.1056/NEJMoa1803377
28. Boeddinghaus J, Twerenbold R, Nestelberger T, Badertscher P, Wildi K, Puelacher C, 
et al. Clinical validation of a novel high-sensitivity cardiac troponin I assay for early diag­
nosis of acute myocardial infarction. Clin Chem 2018;64:1347–1360. https://doi.org/10. 
1373/clinchem.2018.286906
29. Neumann JT, Sorensen NA, Rubsamen N, Ojeda F, Schock A, Seddighizadeh P, et al. 
Evaluation of a new ultra-sensitivity troponin I assay in patients with suspected myo­
cardial infarction. Int J Cardiol 2019;283:35–40. https://doi.org/10.1016/j.ijcard.2018.12. 
001
30. Neumann JT, Sorensen NA, Schwemer T, Ojeda F, Bourry R, Sciacca V, et al. Diagnosis 
of myocardial infarction using a high-sensitivity troponin I 1-hour algorithm. JAMA 
Cardiol 2016;1:397–404. https://doi.org/10.1001/jamacardio.2016.0695
31. Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, et al. 
One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity car­
diac troponin T. Arch Intern Med 2012;172:1211–1218. https://doi.org/10.1001/ 
archinternmed.2012.3698
32. Boeddinghaus J, Twerenbold R, Nestelberger T, Koechlin L, Wussler D, Meier M, et al. 
Clinical use of a new high-sensitivity cardiac troponin I assay in patients with suspected 
myocardial infarction. Clin Chem 2019;65:1426–1436. https://doi.org/10.1373/ 
clinchem.2019.304725
33. Boeddinghaus J, Lopez-Ayala P, Nestelberger T, Koechlin L, Münch T, Miro O, et al. 
Prospective validation of the ESC 0/1h-algorithm using high-sensitivity cardiac tropo­
nin I. Am J Cardiol 2021;158:152–153. https://doi.org/10.1016/j.amjcard.2021.08.007
34. Boeddinghaus J, Nestelberger T, Twerenbold R, Neumann JT, Lindahl B, Giannitsis E, 
et al. Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis 
of myocardial infarction. Eur Heart J 2018;39:3780–3794. https://doi.org/10.1093/ 
eurheartj/ehy514
35. Twerenbold R, Badertscher P, Boeddinghaus J, Nestelberger T, Wildi K, Puelacher C, 
et al. 0/1-Hour triage algorithm for myocardial infarction in patients with renal dysfunc­
tion. Circulation 2018;137:436–451. https://doi.org/10.1161/CIRCULATIONAHA. 
117.028901
36. Boeddinghaus J, Reichlin T, Cullen L, Greenslade JH, Parsonage WA, Hammett C, et al. 
Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarc­
tion by use of high-sensitivity cardiac troponin I. Clin Chem 2016;62:494–504. https:// 
doi.org/10.1373/clinchem.2015.249508
37. Wildi K, Cullen L, Twerenbold R, Greenslade JH, Parsonage W, Boeddinghaus J, et al. 
Direct comparison of 2 rule-out strategies for acute myocardial infarction: 2-h accel­
erated diagnostic protocol vs 2-h algorithm. Clin Chem 2017;63:1227–1236. https:// 
doi.org/10.1373/clinchem.2016.268359
38. Nestelberger T, Boeddinghaus J, Greenslade J, Parsonage WA, Than M, Wussler D, 
et al. Two-hour algorithm for rapid triage of suspected acute myocardial infarction 
using a high-sensitivity cardiac troponin I assay. Clin Chem 2019;65:1437–1447. 
https://doi.org/10.1373/clinchem.2019.305193
39. Koechlin L, Boeddinghaus J, Nestelberger T, Lopez-Ayala P, Wussler D, Shrestha S, 
et al. Performance of the ESC 0/2h-algorithm using high-sensitivity cardiac troponin 
I in the early diagnosis of myocardial infarction. Am Heart J 2021;242:132–137. 
https://doi.org/10.1016/j.ahj.2021.08.008
40. Wildi K, Nelles B, Twerenbold R, Rubini Giménez M, Reichlin T, Singeisen H, et al. 
Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction. 
Am Heart J 2016;181:16–25. https://doi.org/10.1016/j.ahj.2016.07.013
41. Badertscher P, Boeddinghaus J, Twerenbold R, Nestelberger T, Wildi K, Wussler D, 
et al. Direct comparison of the 0/1h and 0/3h algorithms for early rule-out of acute 
myocardial infarction. Circulation 2018;137:2536–2538. https://doi.org/10.1161/ 
CIRCULATIONAHA.118.034260
42. Chapman AR, Anand A, Boeddinghaus J, Ferry AV, Sandeman D, Adamson PD, et al. 
Comparison of the efficacy and safety of early rule-out pathways for acute myocardial 
infarction. 
Circulation 
2017;135:1586–1596. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.116.025021
43. Chapman AR, Fujisawa T, Lee KK, Andrews JP, Anand A, Sandeman D, et al. Novel 
high-sensitivity cardiac troponin I assay in patients with suspected acute coronary syn­
drome. Heart 2019;105:616–622. https://doi.org/10.1136/heartjnl-2018-314093
44. Chew DP, Lambrakis K, Blyth A, Seshadri A, Edmonds MJR, Briffa T, et al. A rando­
mized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: 
the rapid assessment of possible acute coronary syndrome in the emergency depart­
ment with high-sensitivity troponin T study (RAPID-TnT). Circulation 2019;140: 
1543–1556. https://doi.org/10.1161/CIRCULATIONAHA.119.042891
45. Nestelberger T, Wildi K, Boeddinghaus J, Twerenbold R, Reichlin T, Giménez MR, et al. 
Characterization of the observe zone of the ESC 2015 high-sensitivity cardiac troponin 
0h/1h-algorithm for the early diagnosis of acute myocardial infarction. Int J Cardiol 
2016;207:238–245. https://doi.org/10.1016/j.ijcard.2016.01.112
46. Lopez-Ayala P, Nestelberger T, Boeddinghaus J, Koechlin L, Ratmann PD, Strebel I, 
et al. Novel criteria for the observe-zone of the ESC 0/1h-hs-cTnT algorithm. 
Circulation 
2021;144:773–787. 
https://doi.org/10.1161/CIRCULATIONAHA.120. 
052982
47. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. 
Predictors of hospital mortality in the global registry of acute coronary events. Arch 
Intern Med 2003;163:2345–2353. https://doi.org/10.1001/archinte.163.19.2345
48. Fox KA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should pa­
tients with acute coronary disease be stratified for management according to their 
risk? Derivation, external validation and outcomes using the updated GRACE risk 
score. BMJ Open 2014;4:e004425. https://doi.org/10.1136/bmjopen-2013-004425
49. Wenzl FA, Kraler S, Ambler G, Weston C, Herzog SA, Räber L, et al. Sex-specific 
evaluation and redevelopment of the GRACE score in non-ST-segment elevation 
acute coronary syndromes in populations from the UK and Switzerland: a multination­
al analysis with external cohort validation. Lancet 2022;400:744–756. https://doi.org/ 
10.1016/s0140-6736(22)01483-0
50. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. 
Lancet 1986;1:397–402.
51. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute 
myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771–775. 
https://doi.org/10.1016/s0140-6736(96)02514-7
52. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic 
therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. 
Lancet 2003;361:13–20. https://doi.org/10.1016/s0140-6736(03)12113-7
53. Reichlin T, Twerenbold R, Maushart C, Reiter M, Moehring B, Schaub N, et al. Risk 
stratification in patients with unstable angina using absolute serial changes of 3 high- 
ESC Guidelines                                                                                                                                                                                          3803


<!-- PAGE 85 -->

### Page 85

sensitive troponin assays. Am Heart J 2013;165:371–378.e3. https://doi.org/10.1016/j. 
ahj.2012.11.010
54. Anand A, Lee KK, Chapman AR, Ferry AV, Adamson PD, Strachan FE, et al. 
High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: a 
stepped-wedge cluster randomized controlled trial. Circulation 2021;143: 
2214–2224. https://doi.org/10.1161/CIRCULATIONAHA.120.052380
55. Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J 2014;35: 
552–556. https://doi.org/10.1093/eurheartj/eht530
56. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC 
Guidelines for the management of acute coronary syndromes in patients presenting 
without persistent ST-segment elevation: Task Force for the management of acute 
coronary syndromes in patients presenting without persistent ST-segment elevation 
of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315. https:// 
doi.org/10.1093/eurheartj/ehv320
57. Mueller C, Giannitsis E, Mockel M, Huber K, Mair J, Plebani M, et al. Rapid rule out of 
acute myocardial infarction: novel biomarker-based strategies. Eur Heart J Acute 
Cardiovasc Care 2017;6:218–222. https://doi.org/10.1177/2048872616653229
58. Mockel M, Giannitsis E, Mueller C, Huber K, Jaffe AS, Mair J, et al. Rule-in of acute myo­
cardial infarction: focus on troponin. Eur Heart J Acute Cardiovasc Care 2017;6:212–217. 
https://doi.org/10.1177/2048872616653228
59. Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, et al. Clinical 
and therapeutic profile of patients presenting with acute coronary syndromes who do 
not have significant coronary artery disease. The Platelet Glycoprotein IIb/IIIa in 
Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial in­
vestigators. Circulation 2000;102:1101–1106. https://doi.org/10.1161/01.cir.102.10. 
1101
60. Westermann D, Neumann JT, Sorensen NA, Blankenberg S. High-sensitivity assays for 
troponin in patients with cardiac disease. Nat Rev Cardiol 2017;14:472–483. https://doi. 
org/10.1038/nrcardio.2017.48
61. Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, et al. Direct 
comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute 
myocardial infarction. Eur Heart J 2014;35:2303–2311. https://doi.org/10.1093/ 
eurheartj/ehu188
62. Boeddinghaus J, Nestelberger T, Twerenbold R, Koechlin L, Meier M, Troester V, et al. 
High-sensitivity cardiac troponin I assay for early diagnosis of acute myocardial infarc­
tion. Clin Chem 2019;65:893–904. https://doi.org/10.1373/clinchem.2018.300061
63. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et al. Sensitive troponin I assay in 
early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868–877. https:// 
doi.org/10.1056/NEJMoa0903515
64. Collinson PO, Saenger AK, Apple FS; IFCC C-CB. High sensitivity, contemporary and 
point-of-care cardiac troponin assays: educational aids developed by the IFCC 
Committee on Clinical Application of Cardiac Bio-Markers. Clin Chem Lab Med 
2019;57:623–632. https://doi.org/10.1515/cclm-2018-1211
65. Camaro C, Aarts GWA, Adang EMM, van Hout R, Brok G, Hoare A, et al. Rule-out of 
non-ST-segment elevation acute coronary syndrome by a single, pre-hospital troponin 
measurement: a randomized trial. Eur Heart J 2023;44:1705–1714. https://doi.org/10. 
1093/eurheartj/ehad056
66. Pickering JW, Young JM, George PM, Watson AS, Aldous SJ, Troughton RW, et al. 
Validity of a novel point-of-care troponin assay for single-test rule-out of acute myo­
cardial infarction. JAMA Cardiol 2018;3:1108–1112. https://doi.org/10.1001/jamacardio. 
2018.3368
67. Apple FS, Schulz K, Schmidt CW, van Domburg TSY, Fonville JM, de Theije FK. 
Determination of sex-specific 99th percentile upper reference limits for a point of 
care high sensitivity cardiac troponin I assay. Clin Chem Lab Med 2021;59: 
1574–1578. https://doi.org/10.1515/cclm-2021-0262
68. Sorensen NA, Neumann JT, Ojeda F, Giannitsis E, Spanuth E, Blankenberg S, et al. 
Diagnostic evaluation of a high-sensitivity troponin I point-of-care assay. Clin Chem 
2019;65:1592–1601. https://doi.org/10.1373/clinchem.2019.307405
69. Azmy C, Guerard S, Bonnet X, Gabrielli F, Skalli W. EOS orthopaedic imaging system 
to study patellofemoral kinematics: assessment of uncertainty. Orthop Traumatol Surg 
Res 2010;96:28–36. https://doi.org/10.1016/j.rcot.2009.12.003
70. Chapman AR, Lee KK, McAllister DA, Cullen L, Greenslade JH, Parsonage W, et al. 
Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes 
in patients with suspected acute coronary syndrome. JAMA 2017;318:1913–1924. 
https://doi.org/10.1001/jama.2017.17488
71. Hillinger P, Twerenbold R, Wildi K, Rubini Gimenez M, Jaeger C, Boeddinghaus J, et al. 
Gender-specific uncertainties in the diagnosis of acute coronary syndrome. Clin Res 
Cardiol 2017;106:28–37. https://doi.org/10.1007/s00392-016-1020-y
72. Miller-Hodges E, Anand A, Shah ASV, Chapman AR, Gallacher P, Lee KK, et al. 
High-sensitivity cardiac troponin and the risk stratification of patients with renal im­
pairment presenting with suspected acute coronary syndrome. Circulation 2018; 
137:425–435. https://doi.org/10.1161/CIRCULATIONAHA.117.030320
73. Twerenbold R, Neumann JT, Sorensen NA, Ojeda F, Karakas M, Boeddinghaus J, et al. 
Prospective validation of the 0/1-h algorithm for early diagnosis of myocardial infarc­
tion. J Am Coll Cardiol 2018;72:620–632. https://doi.org/10.1016/j.jacc.2018.05.040
74. Rubini Gimenez M, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, 
Hillinger P, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac 
troponin T in suspected myocardial infarction. JAMA Cardiol 2016;1:912–920. https:// 
doi.org/10.1001/jamacardio.2016.2882
75. Mueller-Hennessen M, Lindahl B, Giannitsis E, Biener M, Vafaie M, deFilippi CR, et al. 
Diagnostic and prognostic implications using age- and gender-specific cut-offs for high- 
sensitivity cardiac troponin T-sub-analysis from the TRAPID-AMI study. Int J Cardiol 
2016;209:26–33. https://doi.org/10.1016/j.ijcard.2016.01.213
76. Sorensen NA, Neumann JT, Ojeda F, Schäfer S, Magnussen C, Keller T, et al. Relations 
of sex to diagnosis and outcomes in acute coronary syndrome. J Am Heart Assoc 2018; 
7:e007297. https://doi.org/10.1161/JAHA.117.007297
77. Rubini Gimenez M, Badertscher P, Twerenbold R, Boeddinghaus J, Nestelberger T, 
Wussler D, et al. Impact of the US Food and Drug Administration-approved sex- 
specific cutoff values for high-sensitivity cardiac troponin T to diagnose myocardial in­
farction. Circulation 2018;137:1867–1869. https://doi.org/10.1161/circulationaha.117. 
031940
78. Lee KK, Ferry AV, Anand A, Strachan FE, Chapman AR, Kimenai DM, et al. Sex-specific 
thresholds of high-sensitivity troponin in patients with suspected acute coronary syn­
drome. J Am Coll Cardiol 2019;74:2032–2043. https://doi.org/10.1016/j.jacc.2019.07. 
082
79. Kimenai DM, Lindahl B, Jernberg T, Bekers O, Meex SJR, Eggers KM. Sex-specific ef­
fects of implementing a high-sensitivity troponin I assay in patients with suspected 
acute coronary syndrome: results from SWEDEHEART registry. Sci Rep 2020;10: 
15227. https://doi.org/10.1038/s41598-020-72204-2
80. Peacock WF, Baumann BM, Rivers EJ, Davis TE, Handy B, Jones CW, et al. Using sex- 
specific cutoffs for high-sensitivity cardiac troponin T to diagnose acute myocardial in­
farction. Acad Emerg Med 2021;28:463–466. https://doi.org/10.1111/acem.14098
81. Zhao Y, Izadnegahdar M, Lee MK, Kavsak PA, Singer J, Scheuermeyer F, et al. 
High-sensitivity cardiac troponin-optimizing the diagnosis of acute myocardial infarc­
tion/injury in women (CODE-MI): rationale and design for a multicenter, stepped- 
wedge, cluster-randomized trial. Am Heart J 2020;229:18–28. https://doi.org/10. 
1016/j.ahj.2020.06.013
82. Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, et al. Utility 
of absolute and relative changes in cardiac troponin concentrations in the early diag­
nosis of acute myocardial infarction. Circulation 2011;124:136–145. https://doi.org/10. 
1161/CIRCULATIONAHA.111.023937
83. Wildi K, Boeddinghaus J, Nestelberger T, Twerenbold R, Badertscher P, Wussler D, 
et al. Comparison of fourteen rule-out strategies for acute myocardial infarction. Int 
J Cardiol 2019;283:41–47. https://doi.org/10.1016/j.ijcard.2018.11.140
84. Ambavane A, Lindahl B, Giannitsis E, Roiz J, Mendivil J, Frankenstein L, et al. Economic 
evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarc­
tion using the high-sensitivity cardiac troponin T assay in the emergency department. 
PLoS One 2017;12:e0187662. https://doi.org/10.1371/journal.pone.0187662
85. Boeddinghaus J, Nestelberger T, Twerenbold R, Wildi K, Badertscher P, Cupa J, et al. 
Direct comparison of 4 very early rule-out strategies for acute myocardial infarction 
using high-sensitivity cardiac troponin I. Circulation 2017;135:1597–1611. https://doi. 
org/10.1161/CIRCULATIONAHA.116.025661
86. Ljung L, Lindahl B, Eggers KM, Frick M, Linder R, Löfmark HB, et al. A rule-out strategy 
based on high-sensitivity troponin and HEART score reduces hospital admissions. Ann 
Emerg Med 2019;73:491–499. https://doi.org/10.1016/j.annemergmed.2018.11.039
87. Odqvist M, Andersson PO, Tygesen H, Eggers KM, Holzmann MJ. High-sensitivity tro­
ponins and outcomes after myocardial infarction. J Am Coll Cardiol 2018;71: 
2616–2624. https://doi.org/10.1016/j.jacc.2018.03.515
88. Twerenbold R, Jaeger C, Rubini Gimenez M, Wildi K, Reichlin T, Nestelberger T, et al. 
Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac 
stress testing, and time to discharge in suspected acute myocardial infarction. Eur 
Heart J 2016;37:3324–3332. https://doi.org/10.1093/eurheartj/ehw232
89. Greenslade J, Cho E, Van Hise C, Hawkins T, Parsonage W, Ungerer J, et al. Evaluating 
rapid rule-out of acute myocardial infarction using a high-sensitivity cardiac troponin I 
assay at presentation. Clin Chem 2018;64:820–829. https://doi.org/10.1373/clinchem. 
2017.283887
90. Pickering JW, Than MP, Cullen L, Aldous S, ter Avest E, Body R, et al. Rapid rule-out of 
acute myocardial infarction with a single high-sensitivity cardiac troponin T measure­
ment below the limit of detection: a collaborative meta-analysis. Ann Intern Med 2017; 
166:715–724. https://doi.org/10.7326/M16-2562
91. Shah AS, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, et al. High-sensitivity 
cardiac troponin I at presentation in patients with suspected acute coronary syn­
drome: a cohort study. Lancet 2015;386:2481–2488. https://doi.org/10.1016/S0140- 
6736(15)00391-8
92. Boeddinghaus J, Nestelberger T, Lopez-Ayala P, Koechlin L, Buechi M, Miro O, et al. 
Diagnostic performance of the European Society of Cardiology 0/1-h algorithms in 
late presenters. J Am Coll Cardiol 2021;77:1264–1267. https://doi.org/10.1016/j.jacc. 
2021.01.004
93. Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, deFilippi C, McCord J, et al. 
Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial


<!-- PAGE 86 -->

### Page 86

infarction with high-sensitivity cardiac troponin T. Ann Emerg Med 2016;68:76–87.e4. 
https://doi.org/10.1016/j.annemergmed.2015.11.013
94. Stoyanov KM, Hund H, Biener M, Gandowitz J, Riedle C, Löhr J, et al. RAPID-CPU: a 
prospective study on implementation of the ESC 0/1-hour algorithm and safety of dis­
charge after rule-out of myocardial infarction. Eur Heart J Acute Cardiovasc Care 2019;9: 
39–51. https://doi.org/10.1177/2048872619861911
95. Twerenbold R, Costabel JP, Nestelberger T, Campos R, Wussler D, Arbucci R, et al. 
Outcome of applying the ESC 0/1-hour algorithm in patients with suspected myocar­
dial infarction. J Am Coll Cardiol 2019;74:483–494. https://doi.org/10.1016/j.jacc.2019. 
05.046
96. Nestelberger T, Boeddinghaus J, Wussler D, Twerenbold R, Badertscher P, Wildi K, 
et al. Predicting major adverse events in patients with acute myocardial infarction. J 
Am Coll Cardiol 2019;74:842–854. https://doi.org/10.1016/j.jacc.2019.06.025
97. Rubini Gimenez M, Wildi K, Wussler D, Koechlin L, Boeddinghaus J, Nestelberger T, 
et al. Early kinetics of cardiac troponin in suspected acute myocardial infarction. Rev 
Esp Cardiol (Engl Ed) 2021;74:502–509. https://doi.org/10.1016/j.rec.2020.04.008
98. Chiang CH, Chiang CH, Lee GH, Gi W-T, Wu Y-K, Huang S-S, et al. Safety and efficacy 
of the European Society of Cardiology 0/1-hour algorithm for diagnosis of myocardial 
infarction: systematic review and meta-analysis. Heart 2020;106:985–991. https://doi. 
org/10.1136/heartjnl-2019-316343
99. Vigen R, Kutscher P, Fernandez F, Yu A, Bertulfo B, Hashim IA, et al. Evaluation of a 
novel rule-out myocardial infarction protocol incorporating high-sensitivity troponin 
T in a US hospital. Circulation 2018;138:2061–2063. https://doi.org/10.1161/ 
circulationaha.118.033861
100. Katus H, Ziegler A, Ekinci O, Giannitsis E, Stough WG, Achenbach S, et al. Early diag­
nosis of acute coronary syndrome. Eur Heart J 2017;38:3049–3055. https://doi.org/10. 
1093/eurheartj/ehx492
101. Koechlin L, Boeddinghaus J, Lopez-Ayala P, Nestelberger T, Wussler D, Mais F, et al. 
Diagnostic discrimination of a novel high-sensitivity cardiac troponin I assay and deriv­
ation/validation of an assay-specific 0/1h-algorithm. Am Heart J 2023;255:58–70. 
https://doi.org/10.1016/j.ahj.2022.10.007
102. Kaier TE, Twerenbold R, Puelacher C, Marjot J, Imambaccus N, Boeddinghaus J, et al. 
Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the 
early diagnosis of acute myocardial infarction. Circulation 2017;136:1495–1508. https:// 
doi.org/10.1161/CIRCULATIONAHA.117.028084
103. Boeddinghaus J, Reichlin T, Nestelberger T, Twerenbold R, Meili Y, Wildi K, et al. Early 
diagnosis of acute myocardial infarction in patients with mild elevations of cardiac 
troponin. Clin Res Cardiol 2017;106:457–467. https://doi.org/10.1007/s00392-016- 
1075-9
104. Hillinger P, Twerenbold R, Jaeger C, Wildi K, Reichlin T, Gimenez MR, et al. Optimizing 
early rule-out strategies for acute myocardial infarction: utility of 1-hour copeptin. Clin 
Chem 2015;61:1466–1474. https://doi.org/10.1373/clinchem.2015.242743
105. Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, et al. Copeptin improves early 
diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010;55:2096–2106. https:// 
doi.org/10.1016/j.jacc.2010.01.029
106. Möckel M, Searle J, Hamm C, Slagman A, Blankenberg S, Huber K, et al. Early discharge 
using single cardiac troponin and copeptin testing in patients with suspected acute cor­
onary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 
2015;36:369–376. https://doi.org/10.1093/eurheartj/ehu178
107. Mueller C, Mockel M, Giannitsis E, Huber K, Mair J, Plebani M, et al. Use of copeptin for 
rapid rule-out of acute myocardial infarction. Eur Heart J Acute Cardiovasc Care 2018;7: 
570–576. https://doi.org/10.1177/2048872617710791
108. Mueller-Hennessen M, Lindahl B, Giannitsis E, Vafaie M, Biener M, Haushofer AC, et al. 
Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in 
comparison to other algorithms for rapid rule-out of acute myocardial infarction. Int J 
Cardiol 2019;276:261–267. https://doi.org/10.1016/j.ijcard.2018.10.084
109. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, et al. 
Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am 
Coll Cardiol 2009;54:60–68. https://doi.org/10.1016/j.jacc.2009.01.076
110. Stallone F, Schoenenberger AW, Puelacher C, Rubini Gimenez M, Walz B, 
Naduvilekoot Devasia A, et al. Incremental value of copeptin in suspected acute myo­
cardial infarction very early after symptom onset. Eur Heart J Acute Cardiovasc Care 
2016;5:407–415. https://doi.org/10.1177/2048872616641289
111. Vargas KG, Kassem M, Mueller C, Wojta J, Huber K. Copeptin for the early rule-out of 
non-ST-elevation myocardial infarction. Int J Cardiol 2016;223:797–804. https://doi. 
org/10.1016/j.ijcard.2016.08.304
112. Wildi K, Zellweger C, Twerenbold R, Jaeger C, Reichlin T, Haaf P, et al. Incremental 
value of copeptin to highly sensitive cardiac troponin I for rapid rule-out of myocardial 
infarction. Int J Cardiol 2015;190:170–176. https://doi.org/10.1016/j.ijcard.2015.04.133
113. Zellweger C, Wildi K, Twerenbold R, Reichlin T, Naduvilekoot A, Neuhaus JD, et al. 
Use of copeptin and high-sensitive cardiac troponin T for diagnosis and prognosis in 
patients with diabetes mellitus and suspected acute myocardial infarction. Int J 
Cardiol 2015;190:190–197. https://doi.org/10.1016/j.ijcard.2015.04.134
114. Restan IZ, Sanchez AY, Steiro OT, Lopez-Ayala P, Tjora HL, Langørgen J, et al. Adding 
stress biomarkers to high-sensitivity cardiac troponin for rapid non-ST-elevation 
myocardial infarction rule-out protocols. Eur Heart J Acute Cardiovasc Care 2022;11: 
201–212. https://doi.org/10.1093/ehjacc/zuab124
115. Dedic A, Lubbers MM, Schaap J, Lammers J, Lamfers EJ, Rensing BJ, et al. Coronary CT 
angiography for suspected ACS in the era of high-sensitivity troponins: randomized 
multicenter study. J Am Coll Cardiol 2016;67:16–26. https://doi.org/10.1016/j.jacc. 
2015.10.045
116. Hoffmann U, Truong QA, Schoenfeld DA, Chou ET, Woodard PK, Nagurney JT, et al. 
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med 
2012;367:299–308. https://doi.org/10.1056/NEJMoa1201161
117. Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O’Brien R, et al. Early com­
puted tomography coronary angiography in patients with suspected acute coronary 
syndrome: randomised controlled trial. BMJ 2021;374:n2106. https://doi.org/10. 
1136/bmj.n2106
118. Lee KK, Bularga A, O’Brien R, Ferry AV, Doudesis D, Fujisawa T, et al. Troponin-guided 
coronary computed tomographic angiography after exclusion of myocardial infarction. 
J Am Coll Cardiol 2021;78:1407–1417. https://doi.org/10.1016/j.jacc.2021.07.055
119. Kofoed KF, Engstrom T, Sigvardsen PE, Linde JJ, Torp-Pedersen C, de Knegt M, et al. 
Prognostic value of coronary CT angiography in patients with non-ST-segment eleva­
tion acute coronary syndromes. J Am Coll Cardiol 2021;77:1044–1052. https://doi.org/ 
10.1016/j.jacc.2020.12.037
120. Linde JJ, Hove JD, Sorgaard M, Kelbæk H, Jensen GB, Kühl JT, et al. Long-term clinical 
impact of coronary CT angiography in patients with recent acute-onset chest pain: the 
randomized controlled CATCH trial. JACC Cardiovasc Imaging 2015;8:1404–1413. 
https://doi.org/10.1016/j.jcmg.2015.07.015
121. Linde JJ, Kelbæk H, Hansen TF, Sigvardsen PE, Torp-Pedersen C, Bech J, et al. Coronary 
CT angiography in patients with non-ST-segment elevation acute coronary syndrome. 
J Am Coll Cardiol 2020;75:453–463. https://doi.org/10.1016/j.jacc.2019.12.012
122. Samad Z, Hakeem A, Mahmood SS, Pieper K, Patel MR, Simel DL, et al. A meta-analysis 
and systematic review of computed tomography angiography as a diagnostic triage 
tool for patients with chest pain presenting to the emergency department. J Nucl 
Cardiol 2012;19:364–376. https://doi.org/10.1007/s12350-012-9520-2
123. Litt HI, Gatsonis C, Snyder B, Singh H, Miller CD, Entrikin DW, et al. CT angiography 
for safe discharge of patients with possible acute coronary syndromes. N Engl J Med 
2012;366:1393–1403. https://doi.org/10.1056/NEJMoa1201163
124. Hulten E, Pickett C, Bittencourt MS, Villines TC, Petrillo S, Di Carli MF, et al. Outcomes 
after coronary computed tomography angiography in the emergency department: a 
systematic review and meta-analysis of randomized, controlled trials. J Am Coll 
Cardiol 2013;61:880–892. https://doi.org/10.1016/j.jacc.2012.11.061
125. Gaibazzi N, Reverberi C, Badano L. Usefulness of contrast stress-echocardiography or 
exercise-electrocardiography to predict long-term acute coronary syndromes in pa­
tients presenting with chest pain without electrocardiographic abnormalities or 
12-hour troponin elevation. Am J Cardiol 2011;107:161–167. https://doi.org/10.1016/ 
j.amjcard.2010.08.066
126. Lim SH, Anantharaman V, Sundram F, Chan ES-Y, Ang ES, Yo SL, et al. Stress myocar­
dial perfusion imaging for the evaluation and triage of chest pain in the emergency de­
partment: a randomized controlled trial. J Nucl Cardiol 2013;20:1002–1012. https://doi. 
org/10.1007/s12350-013-9736-9
127. Nabi F, Kassi M, Muhyieddeen K, Chang SM, Xu J, Peterson LE, et al. Optimizing evalu­
ation of patients with low-to-intermediate-risk acute chest pain: a randomized study 
comparing stress myocardial perfusion tomography incorporating stress-only imaging 
versus cardiac CT. J Nucl Med 2016;57:378–384. https://doi.org/10.2967/jnumed.115. 
166595
128. Jackson AM, Zhang R, Findlay I, Robertson K, Lindsay M, Morris T, et al. Healthcare 
disparities for women hospitalized with myocardial infarction and angina. Eur Heart J 
Qual Care Clin Outcomes 2020;6:156–165. https://doi.org/10.1093/ehjqcco/qcz040
129. Terkelsen CJ, Sørensen JT, Maeng M, Jensen LO, Tilsted HH, Trautner S, et al. System 
delay and mortality among patients with STEMI treated with primary percutaneous 
coronary intervention. JAMA 2010;304:763–771. https://doi.org/10.1001/jama.2010. 
1139
130. Jortveit J, Pripp AH, Halvorsen S. Outcomes after delayed primary percutaneous cor­
onary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial 
infarction in Norway. Eur Heart J Cardiovasc Pharmacother 2022;8:442–451. https://doi. 
org/10.1093/ehjcvp/pvab041
131. Larsen AI, Løland KH, Hovland S, Bleie Ø, Eek C, Fossum E, et al. 
Guideline-recommended time less than 90 minutes from ECG to primary percutan­
eous coronary intervention for ST-segment-elevation myocardial infarction is asso­
ciated with major survival benefits, especially in octogenarians: a contemporary 
report in 11 226 patients from NORIC. J Am Heart Assoc 2022;11:e024849. https:// 
doi.org/10.1161/jaha.122.024849
132. Fordyce CB, Al-Khalidi HR, Jollis JG, Roettig ML, Gu J, Bagai A, et al. Association of rapid 
care 
process 
implementation 
on 
reperfusion 
times 
across 
multiple 
ST-segment-elevation myocardial infarction networks. Circ Cardiovasc Interv 2017; 
10:e004061. https://doi.org/10.1161/circinterventions.116.004061
133. Stowens JC, Sonnad SS, Rosenbaum RA. Using EMS dispatch to trigger STEMI alerts 
decreases door-to-balloon times. West J Emerg Med 2015;16:472–480. https://doi. 
org/10.5811/westjem.2015.4.24248
ESC Guidelines                                                                                                                                                                                          3805


<!-- PAGE 87 -->

### Page 87

134. Squire BT, Tamayo-Sarver JH, Rashi P, Koenig W, Niemann JT. Effect of prehospital 
cardiac catheterization lab activation on door-to-balloon time, mortality, and false- 
positive activation. Prehosp Emerg Care 2014;18:1–8. https://doi.org/10.3109/ 
10903127.2013.836263
135. Shavadia JS, Roe MT, Chen AY, Lucas J, Fanaroff AC, Kochar A, et al. Association be­
tween cardiac catheterization laboratory pre-activation and reperfusion timing metrics 
and outcomes in patients with ST-segment elevation myocardial infarction undergoing 
primary percutaneous coronary intervention: a report from the ACTION registry. 
JACC Cardiovasc Interv 2018;11:1837–1847. https://doi.org/10.1016/j.jcin.2018.07.020
136. Kontos MC, Gunderson MR, Zegre-Hemsey JK, Lange DC, French WJ, Henry TD, 
et al. Prehospital activation of hospital resources (PreAct) ST-segment-elevation myo­
cardial infarction (STEMI): a standardized approach to prehospital activation and direct 
to the catheterization laboratory for STEMI recommendations from the American 
Heart Association’s mission: lifeline program. J Am Heart Assoc 2020;9:e011963. 
https://doi.org/10.1161/jaha.119.011963
137. Bagai A, Jollis JG, Dauerman HL, Peng SA, Rokos IC, Bates ER, et al. Emergency depart­
ment bypass for ST-segment-elevation myocardial infarction patients identified with a 
prehospital electrocardiogram: a report from the American Heart Association 
Mission: Lifeline program. Circulation 2013;128:352–359. https://doi.org/10.1161/ 
circulationaha.113.002339
138. Scholz KH, Friede T, Meyer T, Jacobshagen C, Lengenfelder B, Jung J, et al. Prognostic 
significance of emergency department bypass in stable and unstable patients with 
ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2020; 
9:34–44. https://doi.org/10.1177/2048872618813907
139. Meisel SR, Kleiner-Shochat M, Abu-Fanne R, Frimerman A, Danon A, Minha S, et al. 
Direct admission of patients with ST-segment-elevation myocardial infarction to the 
catheterization laboratory shortens pain-to-balloon and door-to-balloon time inter­
vals but only the pain-to-balloon interval impacts short- and long-term mortality. J 
Am Heart Assoc 2021;10:e018343. https://doi.org/10.1161/jaha.120.018343
140. Wang TY, Nallamothu BK, Krumholz HM, Li S, Roe MT, Jollis JG, et al. Association of 
door-in to door-out time with reperfusion delays and outcomes among patients trans­
ferred for primary percutaneous coronary intervention. JAMA 2011;305:2540–2547. 
https://doi.org/10.1001/jama.2011.862
141. Huber K, De Caterina R, Kristensen SD, Verheugt FWA, Montalescot G, Maestro LB, 
et al. Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in 
patients with ST-elevation myocardial infarction. Eur Heart J 2005;26:2063–2074. 
https://doi.org/10.1093/eurheartj/ehi413
142. Welsh RC, Chang W, Goldstein P, Adgey J, Granger CB, Verheugt FW, et al. Time to 
treatment and the impact of a physician on prehospital management of acute ST ele­
vation myocardial infarction: insights from the ASSENT-3 PLUS trial. Heart 2005;91: 
1400–1406. https://doi.org/10.1136/hrt.2004.054510
143. Jollis JG, Al-Khalidi HR, Roettig ML, Berger PB, Corbett CC, Doerfler SM, et al. Impact 
of regionalization of ST-segment-elevation myocardial infarction care on treatment 
times and outcomes for emergency medical services-transported patients presenting 
to hospitals with percutaneous coronary intervention: mission: lifeline accelerator-2. 
Circulation 2018;137:376–387. https://doi.org/10.1161/circulationaha.117.032446
144. Fosbol EL, Granger CB, Jollis JG, Monk L, Lin L, Lytle BL, et al. The impact of a statewide 
pre-hospital STEMI strategy to bypass hospitals without percutaneous coronary inter­
vention capability on treatment times. Circulation 2013;127:604–612. https://doi.org/ 
10.1161/circulationaha.112.118463
145. Kalla K, Christ G, Karnik R, Malzer R, Norman G, Prachar H, et al. Implementation of 
guidelines improves the standard of care: the Viennese registry on reperfusion strat­
egies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006; 
113:2398–2405. https://doi.org/10.1161/circulationaha.105.586198
146. Henry TD, Sharkey SW, Burke MN, Chavez IJ, Graham KJ, Henry CR, et al. A regional 
system to provide timely access to percutaneous coronary intervention for 
ST-elevation myocardial infarction. Circulation 2007;116:721–728. https://doi.org/10. 
1161/circulationaha.107.694141
147. Le May MR, So DY, Dionne R, Glover CA, Froeschl MPV, Wells GA, et al. A citywide 
protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 
2008;358:231–240. https://doi.org/10.1056/NEJMoa073102
148. Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. Oxygen therapy in 
suspected acute myocardial infarction. N Engl J Med 2017;377:1240–1249. https://doi. 
org/10.1056/NEJMoa1706222
149. Stewart RAH, Jones P, Dicker B, Jiang Y, Smith T, Swain A, et al. High flow oxygen and 
risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, 
cluster randomised, crossover trial. BMJ 2021;372:n355. https://doi.org/10.1136/bmj. 
n355
150. Henrikson CA, Howell EE, Bush DE, Miles JS, Meininger GR, Friedlander T, et al. Chest 
pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern 
Med 
2003;139:979–986. 
https://doi.org/10.7326/0003-4819-139-12-200312160- 
00007
151. Charpentier S, Galinski M, Bounes V, Ricard-Hibon A, El-Khoury C, Elbaz M, et al. 
Nitrous oxide/oxygen plus acetaminophen versus morphine in ST elevation myocar­
dial infarction: open-label, cluster-randomized, non-inferiority study. Scand J Trauma 
Resusc Emerg Med 2020;28:36. https://doi.org/10.1186/s13049-020-00731-y
152. Silvain J, Storey RF, Cayla G, Esteve J-B, Dillinger J-G, Rousseau H, et al. P2Y12 receptor 
inhibition and effect of morphine in patients undergoing primary PCI for ST-segment 
elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 
2016;116:369–378. https://doi.org/10.1160/th15-12-0944
153. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, et al. 
Morphine is associated with a delayed activity of oral antiplatelet agents in patients 
with ST-elevation acute myocardial infarction undergoing primary percutaneous cor­
onary intervention. Circ Cardiovasc Interv 2015;8:e001593. https://doi.org/10.1161/ 
circinterventions.114.001593
154. Saad M, Meyer-Saraei R, de Waha-Thiele S, Stiermaier T, Graf T, Fuernau G, et al. 
Impact of morphine treatment with and without metoclopramide coadministration 
on ticagrelor-induced platelet inhibition in acute myocardial infarction: the randomized 
MonAMI trial. Circulation 2020;141:1354–1356. https://doi.org/10.1161/circulationaha. 
119.042816
155. Stiermaier T, Schaefer P, Meyer-Saraei R, Saad M, de Waha-Thiele S, Pöss J, et al. 
Impact of morphine treatment with and without metoclopramide coadministration 
on myocardial and microvascular injury in acute myocardial infarction: insights from 
the randomized MonAMI trial. J Am Heart Assoc 2021;10:e018881. https://doi.org/ 
10.1161/jaha.120.018881
156. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, et al. Morphine de­
lays and attenuates ticagrelor exposure and action in patients with myocardial infarc­
tion: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 
2016;37:245–252. https://doi.org/10.1093/eurheartj/ehv547
157. Zhang Y, Wang N, Gu Q. Effects of morphine on P2Y(12) platelet inhibitors in patients 
with acute myocardial infarction: a meta-analysis. Am J Emerg Med 2021;41:219–228. 
https://doi.org/10.1016/j.ajem.2020.11.003
158. Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, et al. Morphine and car­
diovascular outcomes among patients with non-ST-segment elevation acute coronary 
syndromes undergoing coronary angiography. J Am Coll Cardiol 2020;75:289–300. 
https://doi.org/10.1016/j.jacc.2019.11.035
159. Kubica A, Kosobucka A, Niezgoda P, Adamski P, Buszko K, Lesiak M, et al. ANalgesic 
Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myo­
cardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicen­
tre, open-label, phase II, randomised clinical trial. BMJ Open 2021;11:e043330. https:// 
doi.org/10.1136/bmjopen-2020-043330
160. Batchelor R, Liu DH, Bloom J, Noaman S, Chan W. Association of periprocedural 
intravenous morphine use on clinical outcomes in ST-elevation myocardial infarction 
(STEMI) treated by primary percutaneous coronary intervention: systematic review 
and meta-analysis. Catheter Cardiovasc Interv 2020;96:76–88. https://doi.org/10.1002/ 
ccd.28561
161. Bonin M, Mewton N, Roubille F, Morel O, Cayla G, Angoulvant D, et al. Effect and 
safety of morphine use in acute anterior ST-segment elevation myocardial infarction. 
J Am Heart Assoc 2018;7:e006833. https://doi.org/10.1161/jaha.117.006833
162. Clemente-Moragón A, Gómez M, Villena-Gutiérrez R, Lalama DV, García-Prieto J, 
Martínez F, et al. Metoprolol exerts a non-class effect against ischaemia-reperfusion 
injury by abrogating exacerbated inflammation. Eur Heart J 2020;41:4425–4440. 
https://doi.org/10.1093/eurheartj/ehaa733
163. Ibanez B, Macaya C, Sánchez-Brunete V, Pizarro G, Fernández-Friera L, Mateos A, et al. 
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction 
patients undergoing primary percutaneous coronary intervention: the effect of meto­
prolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) 
trial. Circulation 2013;128:1495–1503. https://doi.org/10.1161/circulationaha.113. 
003653
164. Roolvink V, Ibáñez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, et al. Early 
intravenous beta-blockers in patients with ST-segment elevation myocardial infarction 
before primary percutaneous coronary intervention. J Am Coll Cardiol 2016;67: 
2705–2715. https://doi.org/10.1016/j.jacc.2016.03.522
165. Pizarro G, Fernández-Friera L, Fuster V, Fernández-Jiménez R, García-Ruiz JM, 
García-Álvarez A, et al. Long-term benefit of early pre-reperfusion metoprolol admin­
istration in patients with acute myocardial infarction: results from the 
METOCARD-CNIC trial (effect of metoprolol in cardioprotection during an acute 
myocardial infarction). J Am Coll Cardiol 2014;63:2356–2362. https://doi.org/10.1016/ 
j.jacc.2014.03.014
166. García-Ruiz JM, Fernández-Jiménez R, García-Alvarez A, Pizarro G, Galán-Arriola C, 
Fernández-Friera L, et al. Impact of the timing of metoprolol administration during 
STEMI on infarct size and ventricular function. J Am Coll Cardiol 2016;67:2093–2104. 
https://doi.org/10.1016/j.jacc.2016.02.050
167. Hoedemaker NP, Roolvink V, de Winter RJ, van Royen N, Fuster V, García-Ruiz JM, 
et al. Early intravenous beta-blockers in patients undergoing primary percutaneous 
coronary intervention for ST-segment elevation myocardial infarction: a patient- 
pooled meta-analysis of randomized clinical trials. Eur Heart J Acute Cardiovasc Care 
2020;9:469–477. https://doi.org/10.1177/2048872619830609
168. Sterling LH, Filion KB, Atallah R, Reynier P, Eisenberg MJ. Intravenous beta-blockers in 
ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Int J 
Cardiol 2017;228:295–302. https://doi.org/10.1016/j.ijcard.2016.11.133


<!-- PAGE 88 -->

### Page 88

169. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, et al. Early 
intravenous beta-blockers in patients with acute coronary syndrome–a meta-analysis 
of randomized trials. Int J Cardiol 2013;168:915–921. https://doi.org/10.1016/j.ijcard. 
2012.10.050
170. Elgendy IY, Elgendy AY, Mahmoud AN, Mansoor H, Mojadidi MK, Bavry AA, et al. 
Intravenous β-blockers for patients undergoing primary percutaneous coronary inter­
vention: a meta-analysis of randomized trials. Int J Cardiol 2016;223:891–897. https:// 
doi.org/10.1016/j.ijcard.2016.08.293
171. García-Prieto J, Villena-Gutiérrez R, Gómez M, Bernardo E, Pun-García A, 
García-Lunar I, et al. Neutrophil stunning by metoprolol reduces infarct size. Nat 
Commun 2017;8:14780. https://doi.org/10.1038/ncomms14780
172. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. Air versus oxygen 
in ST-segment-elevation myocardial infarction. Circulation 2015;131:2143–2150. 
https://doi.org/10.1161/circulationaha.114.014494
173. Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, et al. Reperfusion 
therapy for ST elevation acute myocardial infarction in Europe: description of the cur­
rent situation in 30 countries. Eur Heart J 2010;31:943–957. https://doi.org/10.1093/ 
eurheartj/ehp492
174. Hall M, Laut K, Dondo TB, Alabas OA, Brogan RA, Gutacker N, et al. Patient and hos­
pital determinants of primary percutaneous coronary intervention in England, 2003– 
2013. Heart 2016;102:313–319. https://doi.org/10.1136/heartjnl-2015-308616
175. Widimsky P, Fajadet J, Danchin N, Wijns W. “Stent 4 Life” targeting PCI at all who will 
benefit the most. A joint project between EAPCI, Euro-PCR, EUCOMED and the ESC 
Working Group on Acute Cardiac Care. EuroIntervention 2009;4:555–557. doi: doi:10. 
4244/EIJV4I5A94
176. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, et al. Hospital 
delays in reperfusion for ST-elevation myocardial infarction: implications when select­
ing a reperfusion strategy. Circulation 2006;114:2019–2025. https://doi.org/10.1161/ 
circulationaha.106.638353
177. Steg PG, Cambou JP, Goldstein P, Durand E, Sauval P, Kadri Z, et al. Bypassing the 
emergency room reduces delays and mortality in ST elevation myocardial infarction: 
the USIC 2000 registry. Heart 2006;92:1378–1383. https://doi.org/10.1136/hrt.2006. 
101972
178. Baran KW, Kamrowski KA, Westwater JJ, Tschida VH, Alexander CF, Beahrs MM, et al. 
Very rapid treatment of ST-segment-elevation myocardial infarction: utilizing prehos­
pital electrocardiograms to bypass the emergency department. Circ Cardiovasc Qual 
Outcomes 2010;3:431–437. https://doi.org/10.1161/circoutcomes.110.942631
179. Huynh T, Perron S, O’Loughlin J, Joseph L, Labrecque M, Tu JV, et al. Comparison of 
primary percutaneous coronary intervention and fibrinolytic therapy in 
ST-segment-elevation myocardial infarction: Bayesian hierarchical meta-analyses of 
randomized controlled trials and observational studies. Circulation 2009;119: 
3101–3109. https://doi.org/10.1161/circulationaha.108.793745
180. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic ther­
apy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003;92: 
824–826. https://doi.org/10.1016/s0002-9149(03)00891-9
181. Betriu A, Masotti M. Comparison of mortality rates in acute myocardial infarction trea­
ted by percutaneous coronary intervention versus fibrinolysis. Am J Cardiol 2005;95: 
100–101. https://doi.org/10.1016/j.amjcard.2004.08.069
182. Boersma E. Does time matter? A pooled analysis of randomized clinical trials compar­
ing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute 
myocardial infarction patients. Eur Heart J 2006;27:779–788. https://doi.org/10.1093/ 
eurheartj/ehi810
183. Pinto DS, Frederick PD, Chakrabarti AK, Kirtane AJ, Ullman E, Dejam A, et al. Benefit 
of transferring ST-segment-elevation myocardial infarction patients for percutaneous 
coronary intervention compared with administration of onsite fibrinolytic declines as 
delays 
increase. 
Circulation 
2011;124:2512–2521. 
https://doi.org/10.1161/ 
circulationaha.111.018549
184. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. 
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J 
Med 2013;368:1379–1387. https://doi.org/10.1056/NEJMoa1301092
185. Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. 
Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. 
N Engl J Med 2005;353:2758–2768. https://doi.org/10.1056/NEJMoa050849
186. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al. Routine 
early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 
360:2705–2718. https://doi.org/10.1056/NEJMoa0808276
187. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, Foody JoAnne M, Krumholz HM, 
Phillips CO, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic ther­
apy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am 
Coll Cardiol 2007;49:422–430. https://doi.org/10.1016/j.jacc.2006.09.033
188. Sutton AG, Campbell PG, Graham R, Price DJA, Gray JC, Grech ED, et al. A rando­
mized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis 
in ST-segment elevation myocardial infarction: the Middlesbrough Early 
Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004;44: 
287–296. https://doi.org/10.1016/j.jacc.2003.12.059
189. Schömig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, et al. 
Mechanical reperfusion in patients with acute myocardial infarction presenting more 
than 12 hours from symptom onset: a randomized controlled trial. JAMA 2005;293: 
2865–2872. https://doi.org/10.1001/jama.293.23.2865
190. Ndrepepa G, Kastrati A, Mehilli J, Antoniucci D, Schömig A. Mechanical reperfusion 
and long-term mortality in patients with acute myocardial infarction presenting 12 
to 48 hours from onset of symptoms. JAMA 2009;301:487–488. https://doi.org/10. 
1001/jama.2009.32
191. Bouisset F, Gerbaud E, Bataille V, Coste P, Puymirat E, Belle L, et al. Percutaneous myo­
cardial revascularization in late-presenting patients with STEMI. J Am Coll Cardiol 2021; 
78:1291–1305. https://doi.org/10.1016/j.jacc.2021.07.039
192. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. 
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J 
Med 2006;355:2395–2407. https://doi.org/10.1056/NEJMoa066139
193. Menon V, Pearte CA, Buller CE, Steg PhG, Forman SA, White HD, et al. Lack of benefit 
from percutaneous intervention of persistently occluded infarct arteries after the 
acute phase of myocardial infarction is time independent: insights from Occluded 
Artery Trial. Eur Heart J 2009;30:183–191. https://doi.org/10.1093/eurheartj/ehn486
194. Ioannidis JPA, Katritsis DG. Percutaneous coronary intervention for late reperfusion 
after myocardial infarction in stable patients. Am Heart J 2007;154:1065–1071. 
https://doi.org/10.1016/j.ahj.2007.07.049
195. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 
ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur 
Heart J 2020;41:407–477. https://doi.org/10.1093/eurheartj/ehz425
196. O’Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, et al. 
Early invasive vs conservative treatment strategies in women and men with unstable 
angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA 
2008;300:71–80. https://doi.org/10.1001/jama.300.1.71
197. Mehta SR, Cannon CP, Fox KAA, Wallentin L, Boden WE, Spacek R, et al. Routine vs 
selective invasive strategies in patients with acute coronary syndromes: a collaborative 
meta-analysis of randomized trials. JAMA 2005;293:2908–2917. https://doi.org/10. 
1001/jama.293.23.2908
198. Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JGP, et al. Long-term 
outcome of a routine versus selective invasive strategy in patients with 
non-ST-segment elevation acute coronary syndrome a meta-analysis of individual pa­
tient data. J Am Coll Cardiol 2010;55:2435–2445. https://doi.org/10.1016/j.jacc.2010.03. 
007
199. Fanning JP, Nyong J, Scott IA, Aroney CN, Walters DL. Routine invasive strategies ver­
sus selective invasive strategies for unstable angina and non-ST elevation myocardial 
infarction in the stent era. Cochrane Database Syst Rev 2016;2016:CD004815. 
https://doi.org/10.1002/14651858.CD004815.pub4
200. Elgendy IY, Mahmoud AN, Wen X, Bavry AA. Meta-analysis of randomized trials of 
long-term all-cause mortality in patients with non-ST-elevation acute coronary syn­
drome managed with routine invasive versus selective invasive strategies. Am J 
Cardiol 2017;119:560–564. https://doi.org/10.1016/j.amjcard.2016.11.005
201. Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong Y-H, Kozinski M, et al. Optimal 
timing of coronary invasive strategy in non-ST-segment elevation acute coronary syn­
dromes: a systematic review and meta-analysis. Ann Intern Med 2013;158:261–270. 
https://doi.org/10.7326/0003-4819-158-4-201302190-00006
202. Jobs A, Mehta SR, Montalescot G, Vicaut E, van’t Hof AWJ, Badings EA, et al. Optimal 
timing of an invasive strategy in patients with non-ST-elevation acute coronary syn­
drome: a meta-analysis of randomised trials. Lancet 2017;390:737–746. https://doi. 
org/10.1016/s0140-6736(17)31490-3
203. Kite TA, Kurmani SA, Bountziouka V, Cooper NJ, Lock ST, Gale CP, et al. Timing of 
invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of ran­
domized controlled trials. Eur Heart J 2022;43:3148–3161. https://doi.org/10.1093/ 
eurheartj/ehac213
204. Eggers KM, James SK, Jernberg T, Lindahl B. Timing of coronary angiography in patients 
with non-ST-elevation acute coronary syndrome: long-term clinical outcomes from 
the nationwide SWEDEHEART registry. EuroIntervention 2022;18:582–589. https:// 
doi.org/10.4244/eij-d-21-00982
205. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collabora­
tive overview of early mortality and major morbidity results from all randomised trials 
of more than 1000 patients. Lancet 1994;343:311–322. https://doi.org/10.1016/ 
S0140-6736(94)91161-4
206. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and pre­
hospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000; 
283:2686–2692. https://doi.org/10.1001/jama.283.20.2686
207. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien P-Y, Cristofini P, et al. Impact of 
time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: 
data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851–2856. 
https://doi.org/10.1161/01.Cir.0000103122.10021.F2
208. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous 
coronary intervention in patients with ST-segment elevation acute myocardial infarc­
tion (ASSENT-4 PCI): randomised trial. Lancet 2006;367:569–578. https://doi.org/10. 
1016/s0140-6736(06)68147-6
ESC Guidelines                                                                                                                                                                                          3807


<!-- PAGE 89 -->

### Page 89

209. Fazel R, Joseph TI, Sankardas MA, Pinto DS, Yeh RW, Kumbhani DJ, et al. Comparison 
of reperfusion strategies for ST-segment-elevation myocardial infarction: a multivari­
ate network meta-analysis. J Am Heart Assoc 2020;9:e015186. https://doi.org/10. 
1161/jaha.119.015186
210. Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, et al. 
ST-segment-elevation 
myocardial 
infarction 
patients 
randomized 
to 
a 
pharmaco-invasive strategy or primary percutaneous coronary intervention: strategic 
Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. 
Circulation 2014;130:1139–1145. https://doi.org/10.1161/circulationaha.114.009570
211. Arbel Y, Ko DT, Yan AT, Cantor WJ, Bagai A, Koh M, et al. Long-term follow-up of the 
trial of routine angioplasty and stenting after fibrinolysis to enhance reperfusion in 
acute myocardial infarction (TRANSFER-AMI). Can J Cardiol 2018;34:736–743. 
https://doi.org/10.1016/j.cjca.2018.02.005
212. Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, et al. Immediate 
angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the 
Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction 
(CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008; 
371:559–568. https://doi.org/10.1016/s0140-6736(08)60268-8
213. Bøhmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of 
immediate angioplasty versus ischemia-guided management after thrombolysis in 
acute myocardial infarction in areas with very long transfer distances results of the 
NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial 
infarction). J Am Coll Cardiol 2010;55:102–110. https://doi.org/10.1016/j.jacc.2009.08. 
007
214. Scheller B, Hennen B, Hammer B, Walle J, Hofer C, Hilpert V, et al. Beneficial effects of 
immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 
2003;42:634–641. https://doi.org/10.1016/s0735-1097(03)00763-0
215. Le May MR, Wells GA, Labinaz M, Davies RF, Turek M, Leddy D, et al. Combined angio­
plasty and pharmacological intervention versus thrombolysis alone in acute myocardial 
infarction (CAPITAL AMI study). J Am Coll Cardiol 2005;46:417–424. https://doi.org/10. 
1016/j.jacc.2005.04.042
216. Abdel-Qadir H, Yan AT, Tan M, Borgia F, Piscione F, Di Mario C, et al. Consistency of 
benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. 
Heart 2015;101:1554–1561. https://doi.org/10.1136/heartjnl-2015-307815
217. Madan M, Halvorsen S, Di Mario C, Tan M, Westerhout CM, Cantor WJ, et al. 
Relationship between time to invasive assessment and clinical outcomes of patients 
undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myo­
cardial infarction: a patient-level analysis of the randomized early routine invasive clin­
ical trials. JACC Cardiovasc Interv 2015;8:166–174. https://doi.org/10.1016/j.jcin.2014.09. 
005
218. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A 
comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial in­
farction. N Engl J Med 2003;349:733–742. https://doi.org/10.1056/NEJMoa025142
219. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty 
versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. 
Circulation 2003;108:1809–1814. https://doi.org/10.1161/01.Cir.0000091088.63921. 
8c
220. Gierlotka M, Gasior M, Wilczek K, Hawranek M, Szkodzinski J, Paczek P, et al. 
Reperfusion by primary percutaneous coronary intervention in patients with 
ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of 
symptoms (from a prospective national observational study [PL-ACS]). Am J Cardiol 
2011;107:501–508. https://doi.org/10.1016/j.amjcard.2010.10.008
221. Busk M, Kaltoft A, Nielsen SS, Bottcher M, Rehling M, Thuesen L, et al. Infarct size and 
myocardial salvage after primary angioplasty in patients presenting with symptoms 
for<12 h vs. 12–72 h. Eur Heart J 2009;30:1322–1330. https://doi.org/10.1093/ 
eurheartj/ehp113
222. Borgia F, Goodman SG, Halvorsen S, Cantor WJ, Piscione F, Le May MR, et al. Early 
routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in 
ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J 2010;31: 
2156–2169. https://doi.org/10.1093/eurheartj/ehq204
223. D’Souza SP, Mamas MA, Fraser DG, Fath-Ordoubadi F. Routine early coronary angio­
plasty versus ischaemia-guided angioplasty after thrombolysis in acute ST-elevation 
myocardial infarction: a meta-analysis. Eur Heart J 2011;32:972–982. https://doi.org/ 
10.1093/eurheartj/ehq398
224. Fernandez-Avilés F, Alonso JJ, Castro-Beiras A, Vázquez N, Blanco J, Alonso-Briales J, 
et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia- 
guided conservative approach for acute myocardial infarction with ST-segment eleva­
tion (GRACIA-1): a randomised controlled trial. Lancet 2004;364:1045–1053. https:// 
doi.org/10.1016/s0140-6736(04)17059-1
225. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, et al. One-year 
survival following early revascularization for cardiogenic shock. JAMA 2001;285: 
190–192. https://doi.org/10.1001/jama.285.2.190
226. Lemkes JS, Janssens GN, van der Hoeven NW, van de Ven PM, Marques KMJ, Nap A, 
et al. Timing of revascularization in patients with transient ST-segment elevation myo­
cardial infarction: a randomized clinical trial. Eur Heart J 2019;40:283–291. https://doi. 
org/10.1093/eurheartj/ehy651
227. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand J-P, Faxon DP, et al. Early versus 
delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009;360: 
2165–2175. https://doi.org/10.1056/NEJMoa0807986
228. Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, Kløvgaard L, et al. 
Early versus standard care invasive examination and treatment of patients with 
non-ST-segment elevation acute coronary syndrome. Circulation 2018;138: 
2741–2750. https://doi.org/10.1161/circulationaha.118.037152
229. Butt JH, Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, et al. 
Importance of risk assessment in timing of invasive coronary evaluation and treatment 
of patients with non-ST-segment-elevation acute coronary syndrome: insights from 
the VERDICT trial. J Am Heart Assoc 2021;10:e022333. https://doi.org/10.1161/jaha. 
121.022333
230. Barbarawi M, Kheiri B, Zayed Y, Barbarawi O, Chahine A, Haykal T, et al. Meta-analysis 
of optimal timing of coronary intervention in non-ST-elevation acute coronary syn­
drome. Catheter Cardiovasc Interv 2020;95:185–193. https://doi.org/10.1002/ccd. 
28280
231. Vranckx P, White HD, Huang Z, Mahaffey KW, Armstrong PW, Van de Werf F, et al. 
Validation of BARC bleeding criteria in patients with acute coronary syndromes: the 
TRACER trial. J Am Coll Cardiol 2016;67:2135–2144. https://doi.org/10.1016/j.jacc. 
2016.02.056
232. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann F-J, Schömig A, et al. 
Periprocedural bleeding and 1-year outcome after percutaneous coronary interven­
tions: appropriateness of including bleeding as a component of a quadruple end point. 
J Am Coll Cardiol 2008;51:690–697. https://doi.org/10.1016/j.jacc.2007.10.040
233. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining 
high bleeding risk in patients undergoing percutaneous coronary intervention: a con­
sensus document from the Academic Research Consortium for High Bleeding Risk. Eur 
Heart J 2019;40:2632–2653. https://doi.org/10.1093/eurheartj/ehz372
234. Doomun D, Doomun I, Schukraft S, Arroyo D, Cook S, Huwyler T, et al. Ischemic and 
bleeding outcomes according to the academic research consortium high bleeding risk 
criteria in all comers treated by percutaneous coronary interventions. Front Cardiovasc 
Med 2021;8:620354. https://doi.org/10.3389/fcvm.2021.620354
235. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of 
antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by pro­
longed antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106. 
https://doi.org/10.1136/bmj.308.6921.81
236. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC fo­
cused update on dual antiplatelet therapy in coronary artery disease developed in col­
laboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery 
disease of the European Society of Cardiology (ESC) and of the European Association 
for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213–260. https://doi.org/ 
10.1093/eurheartj/ehx419
237. Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, et al. Comparative 
effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med 2021;384: 
1981–1990. https://doi.org/10.1056/NEJMoa2102137
238. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor 
versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 
1045–1057. https://doi.org/10.1056/NEJMoa0904327
239. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. 
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J 
Med 2007;357:2001–2015. https://doi.org/10.1056/NEJMoa0706482
240. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, et al. Bleeding and stent 
thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity 
for risk stratification after percutaneous coronary intervention. Eur Heart J 2015;36: 
1762–1771. https://doi.org/10.1093/eurheartj/ehv104
241. Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG, et al. Expert position paper 
on the role of platelet function testing in patients undergoing percutaneous coronary 
intervention. Eur Heart J 2014;35:209–215. https://doi.org/10.1093/eurheartj/eht375
242. Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, et al. 
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with 
non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open- 
label, non-inferiority trial. Lancet 2020;395:1374–1381. https://doi.org/10.1016/ 
s0140-6736(20)30325-1
243. Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, et al. Ticagrelor versus 
clopidogrel in elderly patients with acute coronary syndromes: a substudy from the 
prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. 
Circ 
Cardiovasc 
Qual 
Outcomes 
2012;5:680–688. 
https://doi.org/10.1161/ 
circoutcomes.111.964395
244. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. 
Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 
2019;381:1524–1534. https://doi.org/10.1056/NEJMoa1908973
245. Montalescot G, van’t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. 
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 
2014;371:1016–1027. https://doi.org/10.1056/NEJMoa1407024
246. Koul S, Smith JG, Götberg M, Omerovic E, Alfredsson J, Venetsanos D, et al. No benefit 
of ticagrelor pretreatment compared with treatment during percutaneous coronary


<!-- PAGE 90 -->

### Page 90

intervention in patients with ST-segment-elevation myocardial infarction undergoing 
primary percutaneous coronary intervention. Circ Cardiovasc Interv 2018;11: 
e005528. https://doi.org/10.1161/circinterventions.117.005528
247. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay J-F, et al. 
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. 
N Engl J Med 2013;369:999–1010. https://doi.org/10.1056/NEJMoa1308075
248. Tarantini G, Mojoli M, Varbella F, Caporale R, Rigattieri S, Andò G, et al. Timing of oral 
P2Y(12) inhibitor administration in patients with non-ST-segment elevation acute cor­
onary syndrome. J Am Coll Cardiol 2020;76:2450–2459. https://doi.org/10.1016/j.jacc. 
2020.08.053
249. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, et al. 
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of 
all major randomised clinical trials. Lancet 2002;359:189–198. https://doi.org/10.1016/ 
s0140-6736(02)07442-1
250. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 
ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165. 
https://doi.org/10.1093/eurheartj/ehy394
251. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. 
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 
361:2318–2329. https://doi.org/10.1056/NEJMoa0908628
252. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of 
platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 
368:1303–1313. https://doi.org/10.1056/NEJMoa1300815
253. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, et al. 
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361: 
2330–2341. https://doi.org/10.1056/NEJMoa0908629
254. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, et al. Effect of 
cangrelor on periprocedural outcomes in percutaneous coronary interventions: a 
pooled analysis of patient-level data. Lancet 2013;382:1981–1992. https://doi.org/10. 
1016/s0140-6736(13)61615-3
255. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated 
heparin and low-molecular-weight heparin in acute coronary syndrome without ST 
elevation: a meta-analysis. Lancet 2000;355:1936–1942. https://doi.org/10.1016/ 
s0140-6736(00)02324-2
256. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin 
vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute 
coronary syndromes managed with an intended early invasive strategy: primary results 
of the SYNERGY randomized trial. JAMA 2004;292:45–54. https://doi.org/10.1001/ 
jama.292.1.45
257. Cohen M, Mahaffey KW, Pieper K, Pollack CV, Antman EM, Hoekstra J, et al. A sub­
group analysis of the impact of prerandomization antithrombin therapy on outcomes 
in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment 
elevation acute coronary syndromes. J Am Coll Cardiol 2006;48:1346–1354. https:// 
doi.org/10.1016/j.jacc.2006.05.058
258. Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, et al. 
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary 
intervention for ST-elevation myocardial infarction: the international randomised 
open-label ATOLL trial. Lancet 2011;378:693–703. https://doi.org/10.1016/s0140- 
6736(11)60876-3
259. Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, et al. Bivalirudin plus a high-dose in­
fusion versus heparin monotherapy in patients with ST-segment elevation myocardial 
infarction undergoing primary percutaneous coronary intervention: a randomised trial. 
Lancet 2022;400:1847–1857. https://doi.org/10.1016/s0140-6736(22)01999-7
260. Yusuf S, Mehta SR, Chrolavicius S, Cohen M, Grines CL, Goodman S, et al. Effects of 
fondaparinux on mortality and reinfarction in patients with acute ST-segment eleva­
tion myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295: 
1519–1530. https://doi.org/10.1001/jama.295.13.joc60038
261. Silvain J, Beygui F, Barthélémy O, Pollack C, Cohen M, Zeymer U, et al. Efficacy and 
safety of enoxaparin versus unfractionated heparin during percutaneous coronary 
intervention: systematic review and meta-analysis. BMJ 2012;344:e553. https://doi. 
org/10.1136/bmj.e553
262. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes 
Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syn­
dromes. N Engl J Med 2006;354:1464–1476. https://doi.org/10.1056/NEJMoa055443
263. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of 
pretreatment with clopidogrel and aspirin followed by long-term therapy in patients 
undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 
358:527–533. https://doi.org/10.1016/s0140-6736(01)05701-4
264. Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, et al. 
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in pa­
tients with or without acute coronary syndromes: an individual patient data pairwise 
and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 
2017;38:1034–1043. https://doi.org/10.1093/eurheartj/ehw627
265. Hahn J-Y, Song YB, Oh J-H, Cho D-K, Lee JB, Doh J-H, et al. 6-month versus 12-month 
or longer dual antiplatelet therapy after percutaneous coronary intervention in pa­
tients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non- 
inferiority trial. Lancet 2018;391:1274–1284. https://doi.org/10.1016/s0140-6736(18) 
30493-8
266. Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, et al. Six 
months versus 12 months dual antiplatelet therapy after drug-eluting stent implant­
ation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, 
non-inferiority trial. BMJ 2018;363:k3793. https://doi.org/10.1136/bmj.k3793
267. De Luca G, Damen SA, Camaro C, Benit E, Verdoia M, Rasoul S, et al. Final results of 
the randomised evaluation of short-term dual antiplatelet therapy in patients with 
acute coronary syndrome treated with a new-generation stent (REDUCE trial). 
EuroIntervention 2019;15:e990–e998. https://doi.org/10.4244/eij-d-19-00539
268. Hahn J-Y, Song YB, Oh J-H, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor 
monotherapy vs dual antiplatelet therapy on cardiovascular events in patients under­
going percutaneous coronary intervention: the SMART-CHOICE randomized clinical 
trial. JAMA 2019;321:2428–2437. https://doi.org/10.1001/jama.2019.8146
269. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin 
for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopi­
dogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months 
after implantation of a drug-eluting stent: a multicentre, open-label, randomised 
superiority trial. Lancet 2018;392:940–949. https://doi.org/10.1016/s0140-6736(18) 
31858-0
270. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 
1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplate­
let therapy on cardiovascular and bleeding events in patients receiving PCI: the 
STOPDAPT-2 randomized clinical trial. JAMA 2019;321:2414–2427. https://doi.org/ 
10.1001/jama.2019.8145
271. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor 
with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381: 
2032–2042. https://doi.org/10.1056/NEJMoa1908419
272. Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, et al. Ticagrelor 
alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in pa­
tients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. 
Eur Heart J 2020;41:3533–3545. https://doi.org/10.1093/eurheartj/ehaa670
273. Kim BK, Hong SJ, Cho YH, Yun KHo, Kim YH, Suh Y, et al. Effect of ticagrelor mono­
therapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in pa­
tients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 
2020;323:2407–2416. https://doi.org/10.1001/jama.2020.7580
274. Giacoppo D, Matsuda Y, Fovino LN, D’Amico G, Gargiulo G, Byrne RA, et al. Short 
dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged 
dual antiplatelet therapy after percutaneous coronary intervention with second- 
generation drug-eluting stents: a systematic review and meta-analysis of randomized 
clinical trials. Eur Heart J 2021;42:308–319. https://doi.org/10.1093/eurheartj/ehaa739
275. Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al. 
Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet ther­
apy with 12 months of dual antiplatelet therapy in patients with acute coronary syn­
drome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol 2022;7: 
407–417. https://doi.org/10.1001/jamacardio.2021.5244
276. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, et al. Dual antiplatelet therapy 
after PCI in patients at high bleeding risk. N Engl J Med 2021;385:1643–1655. https:// 
doi.org/10.1056/NEJMoa2108749
277. Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, et al. 
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among 
myocardial infarction patients: insights from the treatment with adenosine diphos­
phate receptor inhibitors: longitudinal assessment of treatment patterns and events 
after acute coronary syndrome (TRANSLATE-ACS) observational study. Am Heart J 
2017;183:62–68. https://doi.org/10.1016/j.ahj.2016.10.006
278. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International 
expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. 
Circulation 2017;136:1955–1975. https://doi.org/10.1161/circulationaha.117.031164
279. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de- 
escalation of antiplatelet treatment in patients with acute coronary syndrome under­
going percutaneous coronary intervention (TROPICAL-ACS): a randomised, open- 
label, multicentre trial. Lancet 2017;390:1747–1757. https://doi.org/10.1016/s0140- 
6736(17)32155-4
280. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van’t Hof AWJ, van der 
Harst P, et al. A genotype-guided strategy for oral P2Y(12) inhibitors in primary 
PCI. N Engl J Med 2019;381:1621–1631. https://doi.org/10.1056/NEJMoa1907096
281. Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, et al. Benefit of 
switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing 
of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 
2017;38:3070–3078. https://doi.org/10.1093/eurheartj/ehx175
282. Kim CJ, Park MW, Kim MC, Choo EH, Hwang B-H, Lee KY, et al. Unguided de- 
escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial 
infarction undergoing percutaneous coronary intervention (TALOS-AMI): an 
investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. 
Lancet 2021;398:1305–1316. https://doi.org/10.1016/s0140-6736(21)01445-8
ESC Guidelines                                                                                                                                                                                          3809


<!-- PAGE 91 -->

### Page 91

283. Kim HS, Kang J, Hwang D, Han J-K, Yang H-M, Kang H-J, et al. Prasugrel-based de- 
escalation of dual antiplatelet therapy after percutaneous coronary intervention in pa­
tients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open- 
label, multicentre, non-inferiority randomised trial. Lancet 2020;396:1079–1089. 
https://doi.org/10.1016/s0140-6736(20)31791-8
284. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised 
trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke 
in high risk patients. BMJ 2002;324:71–86. https://doi.org/10.1136/bmj.324.7329.71
285. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary 
prevention of vascular disease: collaborative meta-analysis of individual participant 
data from randomised trials. Lancet 2009;373:1849–1860. https://doi.org/10.1016/ 
s0140-6736(09)60503-1
286. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopi­
dogrel in addition to aspirin in patients with acute coronary syndromes without 
ST-segment elevation. N Engl J Med 2001;345:494–502. https://doi.org/10.1056/ 
NEJMoa010746
287. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel 
with or without omeprazole in coronary artery disease. N Engl J Med 2010;363: 
1909–1917. https://doi.org/10.1056/NEJMoa1007964
288. Gargiulo G, Costa F, Ariotti S, Biscaglia S, Campo G, Esposito G, et al. Impact of proton 
pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month 
dual-antiplatelet therapy duration: insights from the PROlonging Dual-antiplatelet 
treatment after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J 
2016;174:95–102. https://doi.org/10.1016/j.ahj.2016.01.015
289. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. 
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin 
in individuals undergoing percutaneous coronary intervention for acute coronary syn­
dromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376: 
1233–1243. https://doi.org/10.1016/s0140-6736(10)61088-4
290. Coughlan JJ, Aytekin A, Lahu S, Ndrepepa G, Menichelli M, Mayer K, et al. Ticagrelor or 
prasugrel for patients with acute coronary syndrome treated with percutaneous cor­
onary intervention: a prespecified subgroup analysis of a randomized clinical trial. JAMA 
Cardiol 2021;6:1121–1129. https://doi.org/10.1001/jamacardio.2021.2228
291. Szummer K, Montez-Rath ME, Alfredsson J, Erlinge D, Lindahl B, Hofmann R, et al. 
Comparison between ticagrelor and clopidogrel in elderly patients with an acute cor­
onary syndrome: insights from the SWEDEHEART registry. Circulation 2020;142: 
1700–1708. https://doi.org/10.1161/circulationaha.120.050645
292. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, et al. Early 
versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 
2009;360:2176–2190. https://doi.org/10.1056/NEJMoa0901316
293. Dworeck C, Redfors B, Angerås O, Haraldsson I, Odenstedt J, Ioanes D, et al. 
Association of pretreatment with P2Y12 receptor antagonists preceding percutan­
eous coronary intervention in non-ST-segment elevation acute coronary syndromes 
with outcomes. JAMA Netw Open 2020;3:e2018735. https://doi.org/10.1001/ 
jamanetworkopen.2020.18735
294. Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, et al. Early and 
sustained dual oral antiplatelet therapy following percutaneous coronary intervention: 
a randomized controlled trial. JAMA 2002;288:2411–2420. https://doi.org/10.1001/ 
jama.288.19.2411
295. Dawson LP, Chen D, Dagan M, Bloom J, Taylor A, Duffy SJ, et al. Assessment of pre­
treatment with oral P2Y12 inhibitors and cardiovascular and bleeding outcomes in pa­
tients with non-ST elevation acute coronary syndromes: a systematic review and 
meta-analysis. 
JAMA 
Netw 
Open 
2021;4:e2134322. 
https://doi.org/10.1001/ 
jamanetworkopen.2021.34322
296. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence 
of myocardial infarction and death in patients with unstable angina. A meta-analysis. 
JAMA 1996;276:811–815. doi: doi:10.1001/jama.1996.03540100055028
297. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, et al. Assessment 
of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial in­
farction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602–1608. https:// 
doi.org/10.1161/01.cir.100.15.1602
298. Collet JP, Huber K, Cohen M, Zeymer U, Goldstein P, Pollack C, et al. A direct com­
parison of intravenous enoxaparin with unfractionated heparin in primary percutan­
eous coronary intervention (from the ATOLL trial). Am J Cardiol 2013;112: 
1367–1372. https://doi.org/10.1016/j.amjcard.2013.07.003
299. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. 
Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355: 
2203–2216. https://doi.org/10.1056/NEJMoa062437
300. Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, et al. 
Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 
2015;373:997–1009. https://doi.org/10.1056/NEJMoa1507854
301. Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al. Abciximab and 
heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 
2011;365:1980–1989. https://doi.org/10.1056/NEJMoa1109596
302. Erlinge D, Omerovic E, Fröbert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin 
versus heparin monotherapy in myocardial infarction. N Engl J Med 2017;377: 
1132–1142. https://doi.org/10.1056/NEJMoa1706443
303. Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs heparin with or with­
out tirofiban during primary percutaneous coronary intervention in acute myocardial 
infarction: the BRIGHT randomized clinical trial. JAMA 2015;313:1336–1346. https:// 
doi.org/10.1001/jama.2015.2323
304. Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht H-J, et al. Low-dose vs 
standard-dose unfractionated heparin for percutaneous coronary intervention in 
acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 rando­
mized trial. JAMA 2010;304:1339–1349. https://doi.org/10.1001/jama.2010.1320
305. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrom­
botic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377: 
1513–1524. https://doi.org/10.1056/NEJMoa1708454
306. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJGL, Herrman J-P, et al. 
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy 
and undergoing percutaneous coronary intervention: an open-label, randomised, con­
trolled trial. Lancet 2013;381:1107–1115. https://doi.org/10.1016/s0140-6736(12) 
62177-1
307. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. 
Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J 
Med 2016;375:2423–2434. https://doi.org/10.1056/NEJMoa1611594
308. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic 
therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 
380:1509–1524. https://doi.org/10.1056/NEJMoa1817083
309. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. 
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after suc­
cessful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a ran­
domised, open-label, phase 3b trial. Lancet 2019;394:1335–1343. https://doi.org/10. 
1016/s0140-6736(19)31872-0
310. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and ef­
ficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fib­
rillation following percutaneous coronary intervention: a systematic review and 
meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical 
trials. Eur Heart J 2019;40:3757–3767. https://doi.org/10.1093/eurheartj/ehz732
311. Dewilde WJ, Janssen PW, Kelder JC, Verheugt FWA, De Smet BJGL, Adriaenssens T, 
et al. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral 
anticoagulation during percutaneous coronary intervention: subgroup analysis from 
the WOEST trial. EuroIntervention 2015;11:381–390. https://doi.org/10.4244/ 
eijy14m06_07
312. Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, et al. 
Antithrombotic therapy in patients with atrial fibrillation and acute coronary syn­
drome treated medically or with percutaneous coronary intervention or undergoing 
elective percutaneous coronary intervention: insights from the AUGUSTUS trial. 
Circulation 2019;140:1921–1932. https://doi.org/10.1161/circulationaha.119.043308
313. Smits PC, Frigoli E, Tijssen J, Jüni P, Vranckx P, Ozaki Y, et al. Abbreviated antiplatelet 
therapy in patients at high bleeding risk with or without oral anticoagulant therapy 
after coronary stenting: an open-label, randomized, controlled trial. Circulation 2021; 
144:1196–1211. https://doi.org/10.1161/circulationaha.121.056680
314. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. 
Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 
2017;377:1319–1330. https://doi.org/10.1056/NEJMoa1709118
315. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al. Rivaroxaban 
with or without aspirin in patients with stable coronary artery disease: an international, 
randomised, double-blind, placebo-controlled trial. Lancet 2018;391:205–218. https:// 
doi.org/10.1016/s0140-6736(17)32458-3
316. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve 
or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 
371:2155–2166. https://doi.org/10.1056/NEJMoa1409312
317. Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, et al. Ischaemic risk and 
efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients 
with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 2016; 
37:1133–1142. https://doi.org/10.1093/eurheartj/ehv531
318. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of 
ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372: 
1791–1800. https://doi.org/10.1056/NEJMoa1500857
319. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in pa­
tients with stable coronary disease and diabetes. N Engl J Med 2019;381:1309–1320. 
https://doi.org/10.1056/NEJMoa1908077
320. Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, et al. P2Y12 inhibitor 
monotherapy or dual antiplatelet therapy after coronary revascularisation: individual 
patient level meta-analysis of randomised controlled trials. BMJ 2021;373:n1332. 
https://doi.org/10.1136/bmj.n1332
321. Shoji S, Kuno T, Fujisaki T, Takagi H, Briasoulis A, Deharo P, et al. De-escalation of dual 
antiplatelet therapy in patients with acute coronary syndromes. J Am Coll Cardiol 2021; 
78:763–777. https://doi.org/10.1016/j.jacc.2021.06.012


<!-- PAGE 92 -->

### Page 92

322. Laudani C, Greco A, Occhipinti G, Ingala S, Calderone D, Scalia L, et al. Short duration 
of DAPT versus de-escalation after percutaneous coronary intervention for acute cor­
onary syndromes. JACC Cardiovasc Interv 2022;15:268–277. https://doi.org/10.1016/j. 
jcin.2021.11.028
323. Giustino G, Mehran R, Dangas GD, Kirtane AJ, Redfors B, Généreux P, et al. 
Characterization of the average daily ischemic and bleeding risk after primary PCI 
for STEMI. J Am Coll Cardiol 2017;70:1846–1857. https://doi.org/10.1016/j.jacc.2017. 
08.018
324. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic ther­
apy for atrial fibrillation with stable coronary disease. N Engl J Med 2019;381: 
1103–1113. https://doi.org/10.1056/NEJMoa1904143
325. Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, et al. 
Open-label randomized trial comparing oral anticoagulation with and without single 
antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease 
beyond 1 year after coronary stent implantation. Circulation 2019;139:604–616. 
https://doi.org/10.1161/circulationaha.118.036768
326. Chiarito M, Sanz-Sánchez J, Cannata F, Cao D, Sturla M, Panico C, et al. Monotherapy 
with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with estab­
lished atherosclerosis: a systematic review and meta-analysis. Lancet 2020;395: 
1487–1495. https://doi.org/10.1016/s0140-6736(20)30315-9
327. Koo BK, Kang J, Park KW, Rhee T-M, Yang H-M, Won KB, et al. Aspirin versus clopi­
dogrel for chronic maintenance monotherapy after percutaneous coronary interven­
tion (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, 
multicentre trial. Lancet 2021;397:2487–2496. https://doi.org/10.1016/s0140- 
6736(21)01063-1
328. Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, Belle L, et al. Antiplatelet 
therapy in patients with anticoagulants undergoing percutaneous coronary stenting 
(from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol 2009;104: 
338–342. https://doi.org/10.1016/j.amjcard.2009.03.053
329. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, et al. Management of 
antithrombotic therapy in atrial fibrillation patients presenting with acute coronary 
syndrome and/or undergoing percutaneous coronary or valve interventions: a joint 
consensus document of the European Society of Cardiology Working Group on 
Thrombosis, European Heart Rhythm Association (EHRA), European Association of 
Percutaneous Cardiovascular Interventions (EAPCI) and European Association of 
Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and 
Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35:3155–3179. 
https://doi.org/10.1093/eurheartj/ehu298
330. Ruiz-Nodar JM, Marín F, Hurtado JA, Valencia J, Pinar E, Pineda J, et al. Anticoagulant 
and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutan­
eous coronary intervention and stent implantation implications for bleeding risk and 
prognosis. J Am Coll Cardiol 2008;51:818–825. https://doi.org/10.1016/j.jacc.2007.11. 
035
331. Beyer-Westendorf J, Gelbricht V, Förster K, Ebertz F, Kohler C, Werth S, et al. 
Peri-interventional management of novel oral anticoagulants in daily care: results 
from the prospective Dresden NOAC registry. Eur Heart J 2014;35:1888–1896. 
https://doi.org/10.1093/eurheartj/eht557
332. Kiviniemi T, Karjalainen P, Pietilä M, Ylitalo A, Niemelä M, Vikman S, et al. Comparison 
of additional versus no additional heparin during therapeutic oral anticoagulation in pa­
tients undergoing percutaneous coronary intervention. Am J Cardiol 2012;110:30–35. 
https://doi.org/10.1016/j.amjcard.2012.02.045
333. Fiedler KA, Maeng M, Mehilli J, Schulz-Schüpke S, Byrne RA, Sibbing D, et al. Duration 
of triple therapy in patients requiring oral anticoagulation after drug-eluting stent im­
plantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:1619–1629. https://doi.org/ 
10.1016/j.jacc.2015.02.050
334. Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, et al. Stent 
thrombosis in patients with atrial fibrillation undergoing coronary stenting in the 
AUGUSTUS 
trial. 
Circulation 
2020;141:781–783. 
https://doi.org/10.1161/ 
circulationaha.119.044584
335. Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk/ 
benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and 
late after an acute coronary syndrome or percutaneous coronary intervention: insights 
from 
AUGUSTUS. 
Circulation 
2020;141:1618–1627. 
https://doi.org/10.1161/ 
circulationaha.120.046534
336. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Safety and 
efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing per­
cutaneous coronary intervention: a network meta-analysis of randomized controlled 
trials. JAMA Cardiol 2019;4:747–755. https://doi.org/10.1001/jamacardio.2019.1880
337. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Optimal an­
tithrombotic regimens for patients with atrial fibrillation undergoing percutaneous 
coronary intervention: an updated network meta-analysis. JAMA Cardiol 2020;5: 
582–589. https://doi.org/10.1001/jamacardio.2019.6175
338. Capodanno D, Di Maio M, Greco A, Bhatt DL, Gibson CM, Goette A, et al. Safety and 
efficacy of double antithrombotic therapy with non-vitamin K antagonist oral anticoa­
gulants in patients with atrial fibrillation undergoing percutaneous coronary 
intervention: a systematic review and meta-analysis. J Am Heart Assoc 2020;9: 
e017212. https://doi.org/10.1161/jaha.120.017212
339. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, et al. 2018 Joint 
European consensus document on the management of antithrombotic therapy in atrial 
fibrillation patients presenting with acute coronary syndrome and/or undergoing per­
cutaneous cardiovascular interventions: a joint consensus document of the European 
Heart Rhythm Association (EHRA), European Society of Cardiology Working Group 
on Thrombosis, European Association of Percutaneous Cardiovascular Interventions 
(EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the 
Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin 
America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of 
Southern Africa (CASSA). Europace 2019;21:192–193. https://doi.org/10.1093/ 
europace/euy174
340. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral as­
pirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: 
ISIS-2. Lancet 1988;2:349–360.
341. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to 
aspirin in 45,852 patients with acute myocardial infarction: randomised placebo- 
controlled 
trial. 
Lancet 
2005;366:1607–1621. 
https://doi.org/10.1016/s0140- 
6736(05)67660-x
342. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, 
et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarc­
tion with ST-segment elevation. N Eng J Med 2005;352:1179–1189. https://doi.org/10. 
1056/NEJMoa050522
343. Osman M, Kheiri B, Shigle AJ, Saleem M, Osman K, Sengupta PP, et al. Ticagrelor after 
pharmacological thrombolysis in patients with ST-segment elevation myocardial in­
farctions: insight from a trial sequential analysis. J Thromb Thrombolysis 2019;48: 
661–667. https://doi.org/10.1007/s11239-019-01953-3
344. Berwanger O, Lopes RD, Moia DDF, Fonseca FA, Jiang L, Goodman SG, et al. 
Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis: 
TREAT trial. J Am Coll Cardiol 2019;73:2819–2828. https://doi.org/10.1016/j.jacc. 
2019.03.011
345. Kheiri B, Osman M, Abdalla A, Haykal T, Barbarawi M, Zayed Y, et al. Ticagrelor versus 
clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarc­
tion: a systematic review and meta-analysis of randomized clinical trials. J Thromb 
Thrombolysis 2018;46:299–303. https://doi.org/10.1007/s11239-018-1706-2
346. Sánchez PL, Gimeno F, Ancillo P, Sanz JJ, Alonso-Briales JH, Bosa F, et al. Role of the 
paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction 
undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial. Circ 
Cardiovasc Interv 2010;3:297–307. https://doi.org/10.1161/circinterventions.109. 
920868
347. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enox­
aparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute 
myocardial infarction. Lancet 2001;358:605–613. https://doi.org/10.1016/s0140- 
6736(01)05775-0
348. Giraldez RR, Nicolau JC, Corbalan R, Gurfinkel EP, Juarez U, Lopez-Sendon J, et al. 
Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocar­
dial infarction undergoing fibrinolysis regardless of the choice of lytic: an 
ExTRACT-TIMI 25 analysis. Eur Heart J 2007;28:1566–1573. https://doi.org/10.1093/ 
eurheartj/ehm179
349. White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky L, et al. 
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial in­
farction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J 
2007;28:1066–1071. https://doi.org/10.1093/eurheartj/ehm081
350. Peters RJ, Joyner C, Bassand JP, Afzal R, Chrolavicius S, Mehta SR, et al. The role of 
fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a 
subgroup analysis of the OASIS-6 trial. Eur Heart J 2008;29:324–331. https://doi.org/ 
10.1093/eurheartj/ehm616
351. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients 
receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised 
trial. Lancet 2001;358:1855–1863. https://doi.org/10.1016/s0140-6736(01)06887-8
352. Fernández-Avilés F, Alonso JJ, Peña G, Blanco J, Alonso-Briales J, Lopez-Mesa J, et al. 
Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial 
infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, 
controlled trial. Eur Heart J 2007;28:949–960. https://doi.org/10.1093/eurheartj/ 
ehl461
353. Björklund E, Stenestrand U, Lindbäck J, Svensson L, Wallentin L, Lindahl B. Pre-hospital 
thrombolysis delivered by paramedics is associated with reduced time delay and mor­
tality in ambulance-transported real-life patients with ST-elevation myocardial infarc­
tion. Eur Heart J 2006;27:1146–1152. https://doi.org/10.1093/eurheartj/ehi886
354. Bonnefoy E, Steg PG, Boutitie F, Dubien P-Y, Lapostolle F, Roncalli J, et al. Comparison 
of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction 
(CAPTIM) trial: a 5-year follow-up. Eur Heart J 2009;30:1598–1606. https://doi.org/ 
10.1093/eurheartj/ehp156
355. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, et al. 
Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a 
ESC Guidelines                                                                                                                                                                                          3811


<!-- PAGE 93 -->

### Page 93

randomised study. Lancet 2002;360:825–829. https://doi.org/10.1016/s0140-6736(02) 
09963-4
356. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) 
Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute 
myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354: 
716–722. https://doi.org/10.1016/s0140-6736(99)07403-6
357. GUSTO investigators. An international randomized trial comparing four thrombolytic 
strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682. https://doi. 
org/10.1056/nejm199309023291001
358. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AAJ, Arntz HR, et al. 
Efficacy and safety of tenecteplase in combination with the low-molecular-weight hep­
arin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of 
the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS rando­
mized trial in acute myocardial infarction. Circulation 2003;108:135–142. https://doi. 
org/10.1161/01.Cir.0000081659.72985.A8
359. Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L, et al. 
Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfrac­
tionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis 
and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). 
Circulation 2001;104:648–652. https://doi.org/10.1161/hc3101.093866
360. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JCL, Hamer B, Bassand J-P, et al. 
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: 
results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. 
Circulation 2002;105:1642–1649. https://doi.org/10.1161/01.cir.0000013402.34759. 
46
361. James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, et al. Ticagrelor versus 
clopidogrel in patients with acute coronary syndromes intended for non-invasive man­
agement: substudy from prospective randomised PLATelet inhibition and patient 
Outcomes (PLATO) trial. BMJ 2011;342:d3527. https://doi.org/10.1136/bmj.d3527
362. Wiviott SD, White HD, Ohman EM, Fox KAA, Armstrong PW, Prabhakaran D, et al. 
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment ele­
vation myocardial infarction with or without angiography: a secondary, prespecified 
analysis of the TRILOGY ACS trial. Lancet 2013;382:605–613. https://doi.org/10. 
1016/s0140-6736(13)61451-8
363. Savonitto S, Ferri LA, Piatti L, Grosseto D, Piovaccari G, Morici N, et al. Comparison of 
reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute 
coronary syndromes undergoing early percutaneous revascularization. Circulation 
2018;137:2435–2445. https://doi.org/10.1161/circulationaha.117.032180
364. Patterson T, Perkins GD, Hassan Y, Moschonas K, Gray H, Curzen N, et al. Temporal 
trends in identification, management, and clinical outcomes after out-of-hospital car­
diac arrest: insights from the myocardial ischaemia national audit project database. 
Circ Cardiovasc Interv 2018;11:e005346. https://doi.org/10.1161/circinterventions.117. 
005346
365. Byrne R, Constant O, Smyth Y, Callagy G, Nash P, Daly K, et al. Multiple source sur­
veillance incidence and aetiology of out-of-hospital sudden cardiac death in a rural 
population in the West of Ireland. Eur Heart J 2008;29:1418–1423. https://doi.org/ 
10.1093/eurheartj/ehn155
366. Kroupa J, Knot J, Ulman J, Bednar F, Dohnalova A, Motovska Z. Characteristics and sur­
vival determinants in patients after out-of-hospital cardiac arrest in the era of 24/7 cor­
onary intervention facilities. Heart Lung Circ 2017;26:799–807. https://doi.org/10.1016/ 
j.hlc.2016.11.012
367. Perkins GD, Graesner JT, Semeraro F, Olasveengen T, Soar J, Lott C, et al. European 
Resuscitation Council Guidelines 2021: executive summary. Resuscitation 2021;161: 
1–60. https://doi.org/10.1016/j.resuscitation.2021.02.003
368. Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J, et al. 
Immediate percutaneous coronary intervention is associated with better survival after 
out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hos­
pital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010;3:200–207. https://doi.org/10. 
1161/circinterventions.109.913665
369. Nolan JP, Sandroni C, Böttiger BW, Cariou A, Cronberg T, Friberg H, et al. European 
Resuscitation Council and European Society of Intensive Care Medicine guidelines 
2021: post-resuscitation care. Intensive Care Med 2021;47:369–421. https://doi.org/ 
10.1007/s00134-021-06368-4
370. Rab T, Kern KB, Tamis-Holland JE, Henry TD, McDaniel M, Dickert NW, et al. Cardiac 
arrest: a treatment algorithm for emergent invasive cardiac procedures in the resusci­
tated comatose patient. J Am Coll Cardiol 2015;66:62–73. https://doi.org/10.1016/j.jacc. 
2015.05.009
371. Gorjup V, Radsel P, Kocjancic ST, Erzen D, Noc M. Acute ST-elevation myocardial in­
farction after successful cardiopulmonary resuscitation. Resuscitation 2007;72: 
379–385. https://doi.org/10.1016/j.resuscitation.2006.07.013
372. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen 
MM, et al. Coronary angiography after cardiac arrest without ST segment elevation: 
one-year outcomes of the COACT randomized clinical trial. JAMA Cardiol 2020;5: 
1358–1365. https://doi.org/10.1001/jamacardio.2020.3670
373. Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, et al. Angiography after 
out-of-hospital cardiac arrest without ST-segment elevation. N Engl J Med 2021;385: 
2544–2553. https://doi.org/10.1056/NEJMoa2101909
374. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, 
et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J 
Med 2019;380:1397–1407. https://doi.org/10.1056/NEJMoa1816897
375. Kern KB, Radsel P, Jentzer JC, Seder DB, Lee KS, Lotun K, et al. Randomized pilot clin­
ical trial of early coronary angiography versus no early coronary angiography after car­
diac arrest without ST-segment elevation: the PEARL study. Circulation 2020;142: 
2002–2012. https://doi.org/10.1161/circulationaha.120.049569
376. Hauw-Berlemont C, Lamhaut L, Diehl JL, Andreotti C, Varenne O, Leroux P, et al. 
Emergency vs delayed coronary angiogram in survivors of out-of-hospital cardiac ar­
rest: results of the randomized, multicentric EMERGE trial. JAMA Cardiol 2022;7: 
700–707. https://doi.org/10.1001/jamacardio.2022.1416
377. Viana-Tejedor A, Andrea-Riba R, Scardino C, Ariza-Solé A, Bañeras J, García-García C, 
et al. Coronary angiography in patients without ST-segment elevation following 
out-of-hospital cardiac arrest. Rev Esp Cardiol (Engl Ed) 2022;76:94–102. https://doi. 
org/10.1016/j.rec.2022.05.013
378. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to 
improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549–556. 
https://doi.org/10.1056/NEJMoa012689
379. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. 
Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypo­
thermia. N Engl J Med 2002;346:557–563. https://doi.org/10.1056/NEJMoa003289
380. Belliard G, Catez E, Charron C, Caille V, Aegerter P, Dubourg O, et al. Efficacy of 
therapeutic hypothermia after out-of-hospital cardiac arrest due to ventricular fibril­
lation. Resuscitation 2007;75:252–259. https://doi.org/10.1016/j.resuscitation.2007.04. 
014
381. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted 
temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med 2013; 
369:2197–2206. https://doi.org/10.1056/NEJMoa1310519
382. Vaahersalo J, Hiltunen P, Tiainen M, Oksanen T, Kaukonen K-M, Kurola J, et al. 
Therapeutic hypothermia after out-of-hospital cardiac arrest in Finnish intensive 
care units: the FINNRESUSCI study. Intensive Care Med 2013;39:826–837. https:// 
doi.org/10.1007/s00134-013-2868-1
383. Nolan JP, Sandroni C, Andersen LW, Böttiger BW, Cariou A, Cronberg T, et al. 
ERC-ESICM guidelines on temperature control after cardiac arrest in adults. 
Resuscitation 2022;172:229–236. https://doi.org/10.1016/j.resuscitation.2022.01.009
384. Hassager C, Schmidt H, Møller JE, Grand J, Mølstrøm S, Beske RP, et al. Duration of 
device-based fever prevention after cardiac arrest. N Engl J Med 2023;388:888–897. 
https://doi.org/10.1056/NEJMoa2212528
385. Wolfrum S, Roedl K, Hanebutte A, Pfeifer R, Kurowski V, Riessen R, et al. Temperature 
control after in-hospital cardiac arrest: a randomized clinical trial. Circulation 2022;146: 
1357–1366. https://doi.org/10.1161/circulationaha.122.060106
386. Sandroni C, Geocadin RG. Neurological prognostication after cardiac arrest. Curr Opin 
Crit Care 2015;21:209–214. https://doi.org/10.1097/mcc.0000000000000202
387. Garot P, Lefevre T, Eltchaninoff H, Morice M-C, Tamion F, Abry B, et al. Six-month 
outcome of emergency percutaneous coronary intervention in resuscitated patients 
after cardiac arrest complicating ST-elevation myocardial infarction. Circulation 2007; 
115:1354–1362. https://doi.org/10.1161/circulationaha.106.657619
388. Spaulding CM, Joly LM, Rosenberg A, Monchi M, Weber SN, Dhainaut J-FA, et al. 
Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N 
Engl J Med 1997;336:1629–1633. https://doi.org/10.1056/nejm199706053362302
389. Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullén S, et al. Hypothermia 
versus normothermia after out-of-hospital cardiac arrest. N Engl J Med 2021;384: 
2283–2294. https://doi.org/10.1056/NEJMoa2100591
390. Callaway CW, Schmicker R, Kampmeyer M, Powell J, Rea TD, Daya MR, et al. 
Receiving hospital characteristics associated with survival after out-of-hospital cardiac 
arrest. Resuscitation 2010;81:524–529. https://doi.org/10.1016/j.resuscitation.2009.12. 
006
391. Wnent J, Seewald S, Heringlake M, Lemke H, Brauer K, Lefering R, et al. Choice of hos­
pital after out-of-hospital cardiac arrest – a decision with far-reaching consequences: a 
study in a large German city. Crit Care 2012;16:R164. https://doi.org/10.1186/cc11516
392. Kragholm K, Malta Hansen C, Dupre ME, Xian Y, Strauss B, Tyson C, et al. Direct trans­
port to a percutaneous cardiac intervention center and outcomes in patients with 
out-of-hospital cardiac arrest. Circ Cardiovasc Qual Outcomes 2017;10:e003414. 
https://doi.org/10.1161/circoutcomes.116.003414
393. Yeo JW, Ng ZHC, Goh AXC, Gao JF, Liu N, Lam SWS, et al. Impact of cardiac arrest 
centers on the survival of patients with nontraumatic out-of-hospital cardiac arrest: a 
systematic review and meta-analysis. J Am Heart Assoc 2022;11:e023806. https://doi. 
org/10.1161/jaha.121.023806
394. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early re­
vascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl 
J Med 1999;341:625–634. https://doi.org/10.1056/nejm199908263410901
395. White HD, Assmann SF, Sanborn TA, Jacobs AK, Webb JG, Sleeper LA, et al. 
Comparison of percutaneous coronary intervention and coronary artery bypass


<!-- PAGE 94 -->

### Page 94

grafting after acute myocardial infarction complicated by cardiogenic shock: results 
from the Should We Emergently Revascularize Occluded Coronaries for 
Cardiogenic Shock (SHOCK) trial. Circulation 2005;112:1992–2001. https://doi.org/ 
10.1161/circulationaha.105.540948
396. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, et al. Early revas­
cularization and long-term survival in cardiogenic shock complicating acute myocardial 
infarction. JAMA 2006;295:2511–2515. https://doi.org/10.1001/jama.295.21.2511
397. Liakopoulos OJ, Schlachtenberger G, Wendt D, Choi Y-H, Slottosch I, Welp H, et al. 
Early clinical outcomes of surgical myocardial revascularization for acute coronary syn­
dromes complicated by cardiogenic shock: a report from the north-Rhine-Westphalia 
surgical myocardial infarction registry. J Am Heart Assoc 2019;8:e012049. https://doi. 
org/10.1161/jaha.119.012049
398. Thielmann M, Wendt D, Slottosch I, Welp H, Schiller W, Tsagakis K, et al. Coronary 
artery bypass graft surgery in patients with acute coronary syndromes after primary 
percutaneous coronary intervention: a current report from the north-Rhine 
Westphalia surgical myocardial infarction registry. J Am Heart Assoc 2021;10: 
e021182. https://doi.org/10.1161/jaha.121.021182
399. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich H-G, Hausleiter J, et al. Intraaortic 
balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 
367:1287–1296. https://doi.org/10.1056/NEJMoa1208410
400. Schrage B, Ibrahim K, Loehn T, Werner N, Sinning J-M, Pappalardo F, et al. Impella sup­
port for acute myocardial infarction complicated by cardiogenic shock. Circulation 
2019;139:1249–1258. https://doi.org/10.1161/circulationaha.118.036614
401. Miller PE, Bromfield SG, Ma Q, Crawford G, Whitney J, DeVries A, et al. Clinical out­
comes and cost associated with an intravascular microaxial left ventricular assist device 
vs intra-aortic balloon pump in patients presenting with acute myocardial infarction 
complicated by cardiogenic shock. JAMA Intern Med 2022;182:926–933. https://doi. 
org/10.1001/jamainternmed.2022.2735
402. Ostadal P, Rokyta R, Karasek J, Kruger A, Vondrakova D, Janotka M, et al. 
Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: results 
of the ECMO-CS randomized clinical trial. Circulation 2022;147:454–464. https://doi. 
org/10.1161/circulationaha.122.062949
403. Kim Y, Shapero K, Ahn SS, Goldsweig AM, Desai N, Altin SE. Outcomes of mechanical 
circulatory support for acute myocardial infarction complicated by cardiogenic shock. 
Catheter Cardiovasc Interv 2022;99:658–663. https://doi.org/10.1002/ccd.29834
404. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI strategies 
in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017; 
377:2419–2432. https://doi.org/10.1056/NEJMoa1710261
405. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich H-G, Hausleiter J, et al. 
Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by 
cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open- 
label trial. Lancet 2013;382:1638–1645. https://doi.org/10.1016/s0140-6736(13) 
61783-3
406. Unverzagt S, Buerke M, de Waha A, Haerting J, Pietzner D, Seyfarth M, et al. 
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction compli­
cated by cardiogenic shock. Cochrane Database Syst Rev 2015;2015:Cd007398. 
https://doi.org/10.1002/14651858.CD007398.pub3
407. Thiele H, Zeymer U, Thelemann N, Neumann F-J, Hausleiter J, Abdel-Wahab M, et al. 
Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarc­
tion: long-term 6-year outcome of the randomized IABP-SHOCK II trial. Circulation 
2018;139:395–403. https://doi.org/10.1161/circulationaha.118.038201
408. Bonnefoy-Cudraz E, Bueno H, Casella G, De Maria E, Fitzsimons D, Halvorsen S, et al. 
Editor’s Choice – acute cardiovascular care association position paper on intensive 
cardiovascular care units: an update on their definition, structure, organisation and 
function. Eur Heart J Acute Cardiovasc Care 2018;7:80–95. https://doi.org/10.1177/ 
2048872617724269
409. Winkler C, Funk M, Schindler DM, Hemsey JZ, Lampert R, Drew BJ. Arrhythmias in 
patients with acute coronary syndrome in the first 24 hours of hospitalization. 
Heart Lung 2013;42:422–427. https://doi.org/10.1016/j.hrtlng.2013.07.010
410. Wasfy JH, Kennedy KF, Masoudi FA, Ferris TG, Arnold SV, Kini V, et al. Predicting 
length of stay and the need for postacute care after acute myocardial infarction to im­
prove healthcare efficiency. Circ Cardiovasc Qual Outcomes 2018;11:e004635. https:// 
doi.org/10.1161/circoutcomes.118.004635
411. Melberg T, Jørgensen M, Ørn S, Solli T, Edland U, Dickstein K. Safety and health status 
following early discharge in patients with acute myocardial infarction treated with pri­
mary PCI: a randomized trial. Eur J Prev Cardiol 2015;22:1427–1434. https://doi.org/10. 
1177/2047487314559276
412. Berger AK, Duval S, Jacobs DR Jr, Barber C, Vazquez G, Lee S, et al. Relation of length 
of hospital stay in acute myocardial infarction to postdischarge mortality. Am J Cardiol 
2008;101:428–434. https://doi.org/10.1016/j.amjcard.2007.09.090
413. Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR, et al. Safety 
and cost-effectiveness of early discharge after primary angioplasty in low risk patients 
with acute myocardial infarction. J Am Coll Cardiol 1998;31:967–972. https://doi.org/10. 
1016/s0735-1097(98)00031-x
414. De Luca G, Suryapranata H, van’t Hof AW, de Boer M-J, Hoorntje JCA, Dambrink 
J-HE, et al. Prognostic assessment of patients with acute myocardial infarction treated 
with primary angioplasty: implications for early discharge. Circulation 2004;109: 
2737–2743. https://doi.org/10.1161/01.Cir.0000131765.73959.87
415. Novobilsky K, Stipal R, Cerny P, Horak I, Kaucak V, Mrozek J, et al. Safety of early dis­
charge in low risk patients after acute ST-segment elevation myocardial infarction, 
treated with primary percutaneous coronary intervention. Open label, randomized 
trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2019;163:61–66. 
https://doi.org/10.5507/bp.2018.041
416. Albanese M, Alpaslan K, Ouarrak T, Merguet P, Schneider S, Schöls W. In-hospital 
major arrhythmias, arrhythmic death and resuscitation after successful primary percu­
taneous intervention for acute transmural infarction: a retrospective single-centre 
cohort study. BMC Cardiovasc Disord 2018;18:116. https://doi.org/10.1186/s12872- 
018-0851-z
417. Yndigegn T, Gilje P, Dankiewicz J, Mokhtari A, Isma N, Holmqvist J, et al. Safety of early 
hospital discharge following admission with ST-elevation myocardial infarction treated 
with percutaneous coronary intervention: a nationwide cohort study. EuroIntervention 
2022;17:1091–1099. https://doi.org/10.4244/eij-d-21-00501
418. Seto AH, Shroff A, Abu-Fadel M, Blankenship JC, Boudoulas KD, Cigarroa JE, et al. 
Length of stay following percutaneous coronary intervention: an expert consensus 
document update from the society for cardiovascular angiography and interventions. 
Catheter Cardiovasc Interv 2018;92:717–731. https://doi.org/10.1002/ccd.27637
419. Estévez-Loureiro 
R, 
Calviño-Santos 
R, 
Vázquez 
JM, 
Barge-Caballero 
E, 
Salgado-Fernández J, Piñeiro M, et al. Safety and feasibility of returning patients early 
to their originating centers after transfer for primary percutaneous coronary interven­
tion. Rev Esp Cardiol 2009;62:1356–1364. https://doi.org/10.1016/s1885-5857(09) 
73529-7
420. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. 
TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical 
score for risk assessment at presentation: an intravenous nPA for treatment of infarct­
ing myocardium early II trial substudy. Circulation 2000;102:2031–2037. https://doi. 
org/10.1161/01.cir.102.17.2031
421. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. 
Prediction of risk of death and myocardial infarction in the six months after presenta­
tion with acute coronary syndrome: prospective multinational observational study 
(GRACE). BMJ 2006;333:1091. https://doi.org/10.1136/bmj.38985.646481.55
422. Aragam KG, Tamhane UU, Kline-Rogers E, Li J, Fox KAA, Goodman SG, et al. Does 
simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of 
the TIMI and GRACE risk scores. PLoS One 2009;4:e7947. https://doi.org/10.1371/ 
journal.pone.0007947
423. D’Ascenzo F, Biondi-Zoccai G, Moretti C, Bollati M, Omedè P, Sciuto F, et al. TIMI, 
GRACE and alternative risk scores in Acute Coronary Syndromes: a meta-analysis 
of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 pa­
tients. Contemp Clin Trials 2012;33:507–514. https://doi.org/10.1016/j.cct.2012.01.001
424. Gale CP, Manda SO, Weston CF, Birkhead JS, Batin PD, Hall AS. Evaluation of risk 
scores for risk stratification of acute coronary syndromes in the Myocardial 
Infarction National Audit Project (MINAP) database. Heart 2009;95:221–227. 
https://doi.org/10.1136/hrt.2008.144022
425. D’Ascenzo F, De Filippo O, Gallone G, Mittone G, Deriu MA, Iannaccone M, et al. 
Machine learning-based prediction of adverse events following an acute coronary syn­
drome (PRAISE): a modelling study of pooled datasets. Lancet 2021;397:199–207. 
https://doi.org/10.1016/s0140-6736(20)32519-8
426. Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, et al. The prog­
nostic importance of left ventricular function in patients with ST-segment elevation 
myocardial infarction: the HORIZONS-AMI trial. Eur Heart J Acute Cardiovasc Care 
2014;3:67–77. https://doi.org/10.1177/2048872613507149
427. de Waha S, Eitel I, Desch S, Fuernau G, Lurz P, Stiermaier T, et al. Prognosis after 
ST-elevation myocardial infarction: a study on cardiac magnetic resonance imaging ver­
sus clinical routine. Trials 2014;15:249. https://doi.org/10.1186/1745-6215-15-249
428. Larose E, Côté J, Rodés-Cabau J, Noël B, Barbeau G, Bordeleau E, et al. 
Contrast-enhanced cardiovascular magnetic resonance in the hyperacute phase of 
ST-elevation myocardial infarction. Int J Cardiovasc Imaging 2009;25:519–527. https:// 
doi.org/10.1007/s10554-009-9451-4
429. Stiermaier T, Jobs A, de Waha S, Fuernau G, Pöss J, Desch S, et al. Optimized prognosis 
assessment in ST-segment-elevation myocardial infarction using a cardiac magnetic 
resonance imaging risk score. Circ Cardiovasc Imaging 2017;10:e006774. https://doi. 
org/10.1161/circimaging.117.006774
430. de Waha S, Desch S, Eitel I, Fuernau G, Zachrau J, Leuschner A, et al. Impact of early vs. 
late microvascular obstruction assessed by magnetic resonance imaging on long-term 
outcome after ST-elevation myocardial infarction: a comparison with traditional prog­
nostic markers. Eur Heart J 2010;31:2660–2668. https://doi.org/10.1093/eurheartj/ 
ehq247
431. van Kranenburg M, Magro M, Thiele H, de Waha S, Eitel I, Cochet A, et al. Prognostic 
value of microvascular obstruction and infarct size, as measured by CMR in STEMI pa­
tients. JACC Cardiovasc Imaging 2014;7:930–939. https://doi.org/10.1016/j.jcmg.2014. 
05.010
432. van Loon RB, Veen G, Baur LHB, Kamp O, Bronzwaer JGF, Twisk JWR, et al. Improved 
clinical outcome after invasive management of patients with recent myocardial 
ESC Guidelines                                                                                                                                                                                          3813


<!-- PAGE 95 -->

### Page 95

infarction and proven myocardial viability: primary results of a randomized controlled 
trial (VIAMI-trial). Trials 2012;13:1. https://doi.org/10.1186/1745-6215-13-1
433. van Loon RB, Veen G, Baur LH, Twisk JW, van Rossum AC. Long-term follow-up of 
the viability guided angioplasty after acute myocardial infarction (VIAMI) trial. Int J 
Cardiol 2015;186:111–116. https://doi.org/10.1016/j.ijcard.2015.03.152
434. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 
the prevention of sudden cardiac death: the Task Force for the management of pa­
tients with ventricular arrhythmias and the prevention of sudden cardiac death of 
the European Society of Cardiology (ESC). Endorsed by: Association for European 
Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793–2867. 
https://doi.org/10.1093/eurheartj/ehv316
435. Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, et al. Cardiac MRI endpoints 
in myocardial infarction experimental and clinical trials: JACC Scientific Expert Panel. J 
Am Coll Cardiol 2019;74:238–256. https://doi.org/10.1016/j.jacc.2019.05.024
436. Stone GW, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM, et al. Relationship 
between infarct size and outcomes following primary PCI: patient-level analysis from 
10 randomized trials. J Am Coll Cardiol 2016;67:1674–1683. https://doi.org/10.1016/j. 
jacc.2016.01.069
437. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ische­
mia/reperfusion injury. J Am Coll Cardiol 2015;65:1454–1471. https://doi.org/10.1016/j. 
jacc.2015.02.032
438. Eitel I, de Waha S, Wöhrle J, Fuernau G, Lurz P, Pauschinger M, et al. Comprehensive 
prognosis assessment by CMR imaging after ST-segment elevation myocardial infarc­
tion. J Am Coll Cardiol 2014;64:1217–1226. https://doi.org/10.1016/j.jacc.2014.06.1194
439. Haaf P, Reichlin T, Twerenbold R, Hoeller R, Rubini Gimenez M, Zellweger C, et al. Risk 
stratification in patients with acute chest pain using three high-sensitivity cardiac 
troponin assays. Eur Heart J 2014;35:365–375. https://doi.org/10.1093/eurheartj/ 
eht218
440. Tveit SH, Myhre PL, Hoff NJS, Le TM, Seljeflot I, Røysland R, et al. Superiority of high 
sensitivity cardiac troponin T vs. I for long-term prognostic value in patients with chest 
pain; data from the Akershus Cardiac Examination (ACE) 3 study. Clin Biochem 2020; 
78:10–17. https://doi.org/10.1016/j.clinbiochem.2019.12.016
441. Welsh P, Preiss D, Hayward C, Shah ASV, McAllister D, Briggs A, et al. Cardiac tropo­
nin T and troponin I in the general population. Circulation 2019;139:2754–2764. 
https://doi.org/10.1161/circulationaha.118.038529
442. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use 
high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33: 
2252–2257. https://doi.org/10.1093/eurheartj/ehs154
443. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau J-L, et al. 
Relation between renal dysfunction and cardiovascular outcomes after myocardial in­
farction. N Engl J Med 2004;351:1285–1295. https://doi.org/10.1056/NEJMoa041365
444. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations 
for the use of natriuretic peptides in acute cardiac care: a position statement from the 
Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute 
Cardiac Care. Eur Heart J 2012;33:2001–2006. https://doi.org/10.1093/eurheartj/ 
ehq509
445. Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, et al. Balancing the 
risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. 
Am Heart J 2017;186:91–99. https://doi.org/10.1016/j.ahj.2017.01.010
446. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. 
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary 
syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event 
Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 
2017;38:804–810. https://doi.org/10.1093/eurheartj/ehw525
447. Newby LK, Hasselblad V, Armstrong PW, Van de Werf F, Mark DB, White HD, et al. 
Time-based risk assessment after myocardial infarction. Implications for timing of dis­
charge and applications to medical decision-making. Eur Heart J 2003;24:182–189. 
https://doi.org/10.1016/s0195-668x(02)00301-9
448. Kwok CS, Khan MA, Rao SV, Kinnaird T, Sperrin M, Buchan I, et al. Access and non- 
access site bleeding after percutaneous coronary intervention and risk of subsequent 
mortality and major adverse cardiovascular events: systematic review and 
meta-analysis. Circ Cardiovasc Interv 2015;8:e001645. https://doi.org/10.1161/ 
circinterventions.114.001645
449. Ndrepepa G, Neumann FJ, Richardt G, Schulz S, Tölg R, Stoyanov KM, et al. Prognostic 
value of access and non-access sites bleeding after percutaneous coronary interven­
tion. Circ Cardiovasc Interv 2013;6:354–361. https://doi.org/10.1161/circinterventions. 
113.000433
450. Rao SV, Cohen MG, Kandzari DE, Bertrand OF, Gilchrist IC. The transradial approach 
to percutaneous coronary intervention: historical perspective, current concepts, and 
future directions. J Am Coll Cardiol 2010;55:2187–2195. https://doi.org/10.1016/j.jacc. 
2010.01.039
451. Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, et al. Radial versus femoral 
access for coronary angiography and intervention in patients with acute coronary syn­
dromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011;377: 
1409–1420. https://doi.org/10.1016/s0140-6736(11)60404-2
452. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, et al. Radial versus fem­
oral access in patients with acute coronary syndromes undergoing invasive manage­
ment: a randomised multicentre trial. Lancet 2015;385:2465–2476. https://doi.org/ 
10.1016/s0140-6736(15)60292-6
453. Vranckx P, Frigoli E, Rothenbühler M, Tomassini F, Garducci S, Andò G, et al. Radial 
versus femoral access in patients with acute coronary syndromes with or without 
ST-segment elevation. Eur Heart J 2017;38:1069–1080. https://doi.org/10.1093/ 
eurheartj/ehx048
454. Lee P, Liew D, Brennan A, Stub D, Lefkovits J, Reid CM, et al. Cost-effectiveness of 
radial access percutaneous coronary intervention in acute coronary syndrome. Am J 
Cardiol 2021;156:44–51. https://doi.org/10.1016/j.amjcard.2021.06.034
455. Kerensky RA, Wade M, Deedwania P, Boden WE, Pepine CJ. Revisiting the culprit le­
sion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angio­
graphic core laboratory. J Am Coll Cardiol 2002;39:1456–1463. https://doi.org/10.1016/ 
s0735-1097(02)01770-9
456. Johnson TW, Räber L, di Mario C, Bourantas C, Jia H, Mattesini A, et al. Clinical use of 
intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiog­
raphy findings, and guiding interventional decision-making: an expert consensus docu­
ment of the European Association of Percutaneous Cardiovascular Interventions. Eur 
Heart J 2019;40:2566–2584. https://doi.org/10.1093/eurheartj/ehz332
457. di Mario C, Koskinas KC, Räber L. Clinical benefit of IVUS guidance for coronary stent­
ing: the ULTIMATE step toward definitive evidence? J Am Coll Cardiol 2018;72: 
3138–3141. https://doi.org/10.1016/j.jacc.2018.10.029
458. Gao XF, Wang ZM, Wang F, Gu Y, Ge Z, Kong X-Q, et al. Intravascular ultrasound 
guidance reduces cardiac death and coronary revascularization in patients undergoing 
drug-eluting stent implantation: results from a meta-analysis of 9 randomized trials and 
4724 patients. Int J Cardiovasc Imaging 2019;35:239–247. https://doi.org/10.1007/ 
s10554-019-01555-3
459. Darmoch F, Alraies MC, Al-Khadra Y, Moussa Pacha H, Pinto DS, Osborn EA. 
Intravascular ultrasound imaging-guided versus coronary angiography-guided percu­
taneous coronary intervention: a systematic review and meta-analysis. J Am Heart 
Assoc 2020;9:e013678. https://doi.org/10.1161/jaha.119.013678
460. Jia H, Dai J, He L, Xu Y, Shi Y, Zhao L, et al. EROSION III: a multicenter RCT of 
OCT-guided reperfusion in STEMI with early infarct artery patency. JACC Cardiovasc 
Interv 2022;15:846–856. https://doi.org/10.1016/j.jcin.2022.01.298
461. Cuculi F, De Maria GL, Meier P, Dall’Armellina E, de Caterina AR, Channon KM, et al. 
Impact of microvascular obstruction on the assessment of coronary flow reserve, in­
dex of microcirculatory resistance, and fractional flow reserve after ST-segment ele­
vation myocardial infarction. J Am Coll Cardiol 2014;64:1894–1904. https://doi.org/10. 
1016/j.jacc.2014.07.987
462. De Bruyne B, Pijls NH, Bartunek J, Kulecki K, Bech J-W, De Winter H, et al. Fractional 
flow reserve in patients with prior myocardial infarction. Circulation 2001;104: 
157–162. https://doi.org/10.1161/01.cir.104.2.157
463. Bønaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygård O, et al. Drug-eluting 
or bare-metal stents for coronary artery disease. N Engl J Med 2016;375:1242–1252. 
https://doi.org/10.1056/NEJMoa1607991
464. Räber L, Kelbæk H, Ostojic M, Baumbach A, Heg D, Tüller D, et al. Effect of 
biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovas­
cular events among patients with acute myocardial infarction: the COMFORTABLE 
AMI randomized trial. JAMA 2012;308:777–787. https://doi.org/10.1001/jama.2012. 
10065
465. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. 
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial 
infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 
2012;380:1482–1490. https://doi.org/10.1016/s0140-6736(12)61223-9
466. Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, et al. 
Clinical outcomes in patients with ST-segment elevation myocardial infarction treated 
with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year re­
sults of a randomised trial. Lancet 2016;387:357–366. https://doi.org/10.1016/s0140- 
6736(15)00548-6
467. Brugaletta S, Gomez-Lara J, Ortega-Paz L, Jimenez-Diaz V, Jimenez M, 
Jiménez-Quevedo P, et al. 10-Year follow-up of patients with everolimus-eluting ver­
sus bare-metal stents after ST-segment elevation myocardial infarction. J Am Coll 
Cardiol 2021;77:1165–1178. https://doi.org/10.1016/j.jacc.2020.12.059
468. Räber L, Yamaji K, Kelbæk H, Engstrøm T, Baumbach A, Roffi M, et al. Five-year clinical 
outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: ran­
domized comparison of biodegradable polymer-based biolimus-eluting stents with 
bare-metal stents in patients with acute ST-segment elevation myocardial infarction. 
Eur Heart J 2019;40:1909–1919. https://doi.org/10.1093/eurheartj/ehz074
469. Vos NS, Fagel ND, Amoroso G, Herrman J-PR, Patterson MS, Piers LH, et al. 
Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial in­
farction: the REVELATION randomized trial. JACC Cardiovasc Interv 2019;12: 
1691–1699. https://doi.org/10.1016/j.jcin.2019.04.016
470. Scheller B, Ohlow MA, Ewen S, Kische S, Rudolph TK, Clever YP, et al. Bare metal or 
drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial


<!-- PAGE 96 -->

### Page 96

infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention 2020;15: 
1527–1533. https://doi.org/10.4244/eij-d-19-00723
471. Belkacemi A, Agostoni P, Nathoe HM, Voskuil M, Shao CL, Van Belle E, et al. First re­
sults of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial 
infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus 
bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percu­
taneous coronary intervention with 6-month angiographic, intravascular, functional, 
and clinical outcomes. J Am Coll Cardiol 2012;59:2327–2337. https://doi.org/10.1016/ 
j.jacc.2012.02.027
472. Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. 
Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J 
Med 2013;369:1587–1597. https://doi.org/10.1056/NEJMoa1308789
473. Lagerqvist B, Fröbert O, Olivecrona GK, Gudnason T, Maeng M, Alström P, et al. 
Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med 
2014;371:1111–1120. https://doi.org/10.1056/NEJMoa1405707
474. Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. Randomized trial of pri­
mary PCI with or without routine manual thrombectomy. N Engl J Med 2015;372: 
1389–1398. https://doi.org/10.1056/NEJMoa1415098
475. Jolly SS, James S, Džavík V, Cairns JA, Mahmoud KD, Zijlstra F, et al. Thrombus aspir­
ation in ST-segment-elevation myocardial infarction: an individual patient 
meta-analysis: thrombectomy trialists collaboration. Circulation 2017;135:143–152. 
https://doi.org/10.1161/circulationaha.116.025371
476. Jolly SS, Cairns JA, Lavi S, Cantor WJ, Bernat I, Cheema AN, et al. Thrombus aspiration 
in patients with high thrombus burden in the TOTAL trial. J Am Coll Cardiol 2018;72: 
1589–1596. https://doi.org/10.1016/j.jacc.2018.07.047
477. Thiele H, de Waha S, Zeymer U, Desch S, Scheller B, Lauer B, et al. Effect of aspiration 
thrombectomy 
on 
microvascular 
obstruction 
in 
NSTEMI 
patients: 
the 
TATORT-NSTEMI trial. J Am Coll Cardiol 2014;64:1117–1124. https://doi.org/10. 
1016/j.jacc.2014.05.064
478. de Waha S, Patel MR, Granger CB, Ohman EM, Maehara A, Eitel I, et al. Relationship 
between microvascular obstruction and adverse events following primary percutan­
eous coronary intervention for ST-segment elevation myocardial infarction: an individ­
ual patient data pooled analysis from seven randomized trials. Eur Heart J 2017;38: 
3502–3510. https://doi.org/10.1093/eurheartj/ehx414
479. Corrigendum to: 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur 
Heart J 2019;40:3096. https://doi.org/10.1093/eurheartj/ehz507
480. Sabatine MS, Bergmark BA, Murphy SA, O’Gara PT, Smith PK, Serruys PW, et al. 
Percutaneous coronary intervention with drug-eluting stents versus coronary artery 
bypass grafting in left main coronary artery disease: an individual patient data 
meta-analysis. Lancet 2021;398:2247–2257. https://doi.org/10.1016/s0140-6736(21) 
02334-5
481. Head SJ, Milojevic M, Daemen J, Ahn J-M, Boersma E, Christiansen EH, et al. Mortality 
after coronary artery bypass grafting versus percutaneous coronary intervention with 
stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 
2018;391:939–948. https://doi.org/10.1016/s0140-6736(18)30423-9
482. Adlam D, Alfonso F, Maas A, Vrints C. European Society of Cardiology, Acute 
Cardiovascular Care Association, SCAD study group: a position paper on spontan­
eous coronary artery dissection. Eur Heart J 2018;39:3353–3368. https://doi.org/10. 
1093/eurheartj/ehy080
483. Alfonso F, de la Torre Hernández JM, Ibáñez B, Sabaté M, Pan M, Gulati R, et al. 
Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in pa­
tients with Spontaneous Coronary Artery Dissection) randomized clinical trial. Rev 
Esp Cardiol (Engl Ed) 2022;75:515–522. https://doi.org/10.1016/j.rec.2021.08.003
484. Jackson R, Al-Hussaini A, Joseph S, van Soest G, Wood A, Macaya F, et al. Spontaneous 
coronary artery dissection: pathophysiological insights from optical coherence tomog­
raphy. JACC Cardiovasc Imaging 2019;12:2475–2488. https://doi.org/10.1016/j.jcmg. 
2019.01.015
485. Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, et al. 
Spontaneous coronary artery dissection: current state of the science: a scientific state­
ment from the American Heart Association. Circulation 2018;137:e523–e557. https:// 
doi.org/10.1161/cir.0000000000000564
486. Tweet MS, Eleid MF, Best PJM, Lennon RJ, Lerman A, Rihal CS, et al. Spontaneous cor­
onary artery dissection: revascularization versus conservative therapy. Circ Cardiovasc 
Interv 2014;7:777–786. https://doi.org/10.1161/circinterventions.114.001659
487. Saw J, Aymong E, Sedlak T, Buller CE, Starovoytov A, Ricci D, et al. Spontaneous cor­
onary artery dissection: association with predisposing arteriopathies and precipitating 
stressors and cardiovascular outcomes. Circ Cardiovasc Interv 2014;7:645–655. https:// 
doi.org/10.1161/circinterventions.114.001760
488. Lettieri C, Zavalloni D, Rossini R, Morici N, Ettori F, Leonzi O, et al. Management and 
long-term prognosis of spontaneous coronary artery dissection. Am J Cardiol 2015; 
116:66–73. https://doi.org/10.1016/j.amjcard.2015.03.039
489. Hayes SN, Tweet MS, Adlam D, Kim ESH, Gulati R, Price JE, et al. Spontaneous cor­
onary artery dissection: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;76: 
961–984. https://doi.org/10.1016/j.jacc.2020.05.084
490. Nordmann AJ, Hengstler P, Harr T, Young J, Bucher HC. Clinical outcomes of primary 
stenting versus balloon angioplasty in patients with myocardial infarction: a 
meta-analysis of randomized controlled trials. Am J Med 2004;116:253–262. https:// 
doi.org/10.1016/j.amjmed.2003.08.035
491. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of 
angioplasty with stenting, with or without abciximab, in acute myocardial infarction. 
N Engl J Med 2002;346:957–966. https://doi.org/10.1056/NEJMoa013404
492. Belle L, Motreff P, Mangin L, Rangé G, Marcaggi X, Marie A, et al. Comparison of im­
mediate with delayed stenting using the minimalist immediate mechanical intervention 
approach in acute ST-segment-elevation myocardial infarction: the MIMI study. Circ 
Cardiovasc Interv 2016;9:e003388. https://doi.org/10.1161/circinterventions.115. 
003388
493. Kelbæk H, Høfsten DE, Køber L, Helqvist S, Kløvgaard L, Holmvang L, et al. Deferred 
versus conventional stent implantation in patients with ST-segment elevation myocar­
dial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. Lancet 
2016;387:2199–2206. https://doi.org/10.1016/s0140-6736(16)30072-1
494. Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, Eteiba H, et al. A rando­
mized trial of deferred stenting versus immediate stenting to prevent no- or slow- 
reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am 
Coll Cardiol 2014;63:2088–2098. https://doi.org/10.1016/j.jacc.2014.02.530
495. Hong SJ, Kim BK, Shin DH, Nam CM, Kim JS, Ko Y-G, et al. Effect of intravascular 
ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the 
IVUS-XPL randomized clinical trial. JAMA 2015;314:2155–2163. https://doi.org/10. 
1001/jama.2015.15454
496. Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, et al. Intravascular ultrasound versus 
angiography-guided drug-eluting stent implantation: the ULTIMATE trial. J Am Coll 
Cardiol 2018;72:3126–3137. https://doi.org/10.1016/j.jacc.2018.09.013
497. Gao XF, Ge Z, Kong XQ, Kan J, Han L, Lu S, et al. 3-Year outcomes of the ULTIMATE 
trial comparing intravascular ultrasound versus angiography-guided drug-eluting stent 
implantation. JACC Cardiovasc Interv 2021;14:247–257. https://doi.org/10.1016/j.jcin. 
2020.10.001
498. Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P, et al. 
Optical coherence tomography to optimize results of percutaneous coronary inter­
vention in patients with non-ST-elevation acute coronary syndrome: results of the 
multicenter, randomized DOCTORS study (Does Optical Coherence Tomography 
Optimize Results of Stenting). Circulation 2016;134:906–917. https://doi.org/10. 
1161/circulationaha.116.024393
499. Kala P, Cervinka P, Jakl M, Kanovsky J, Kupec A, Spacek R, et al. OCT guidance during 
stent implantation in primary PCI: a randomized multicenter study with nine months of 
optical coherence tomography follow-up. Int J Cardiol 2018;250:98–103. https://doi. 
org/10.1016/j.ijcard.2017.10.059
500. Secemsky EA, Butala N, Raja A, Khera R, Wang Y, Curtis JP, et al. Temporal changes 
and institutional variation in use of percutaneous coronary intervention for 
ST-elevation myocardial infarction with multivessel coronary artery disease in the 
United States: an NCDR research to practice project. JAMA Cardiol 2021;6: 
574–580. https://doi.org/10.1001/jamacardio.2020.5354
501. Holmes DR Jr, Berger PB, Hochman JS, Granger CB, Thompson TD, Califf RM, et al. 
Cardiogenic shock in patients with acute ischemic syndromes with and without 
ST-segment elevation. Circulation 1999;100:2067–2073. https://doi.org/10.1161/01. 
cir.100.20.2067
502. Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardio­
genic shock complicating myocardial infarction: an update 2019. Eur Heart J 2019;40: 
2671–2683. https://doi.org/10.1093/eurheartj/ehz363
503. Papolos AI, Kenigsberg BB, Berg DD, Alviar CL, Bohula E, Burke JA, et al. Management 
and outcomes of cardiogenic shock in cardiac ICUs with versus without shock teams. J 
Am Coll Cardiol 2021;78:1309–1317. https://doi.org/10.1016/j.jacc.2021.07.044
504. Rab T, Ratanapo S, Kern KB, Basir MB, McDaniel M, Meraj P, et al. Cardiac shock care 
centers: JACC review topic of the week. J Am Coll Cardiol 2018;72:1972–1980. https:// 
doi.org/10.1016/j.jacc.2018.07.074
505. Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, et al. 
One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med 2018; 
379:1699–1710. https://doi.org/10.1056/NEJMoa1808788
506. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, et al. Impact 
of multivessel disease on reperfusion success and clinical outcomes in patients under­
going primary percutaneous coronary intervention for acute myocardial infarction. Eur 
Heart J 2007;28:1709–1716. https://doi.org/10.1093/eurheartj/ehm184
507. Dziewierz A, Siudak Z, Rakowski T, Zasada W, Dubiel JS, Dudek D. Impact of multi­
vessel coronary artery disease and noninfarct-related artery revascularization on out­
come of patients with ST-elevation myocardial infarction transferred for primary 
percutaneous coronary intervention (from the EUROTRANSFER Registry). Am J 
Cardiol 2010;106:342–347. https://doi.org/10.1016/j.amjcard.2010.03.029
508. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. Randomized 
trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013;369: 
1115–1123. https://doi.org/10.1056/NEJMoa1305520
509. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, et al. 
Complete revascularisation versus treatment of the culprit lesion only in patients 
with ST-segment elevation myocardial infarction and multivessel disease 
ESC Guidelines                                                                                                                                                                                          3815


<!-- PAGE 97 -->

### Page 97

(DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015; 
386:665–671. https://doi.org/10.1016/s0140-6736(15)60648-1
510. Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh 
CE, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarc­
tion. N Engl J Med 2017;376:1234–1244. https://doi.org/10.1056/NEJMoa1701067
511. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al. Complete 
revascularization with multivessel PCI for myocardial infarction. N Engl J Med 2019; 
381:1411–1421. https://doi.org/10.1056/NEJMoa1907775
512. Bainey KR, Engstrøm T, Smits PC, Gershlick AH, James SK, Storey RF, et al. Complete 
vs culprit-lesion-only revascularization for ST-segment elevation myocardial infarction: 
a systematic review and meta-analysis. JAMA Cardiol 2020;5:881–888. https://doi.org/ 
10.1001/jamacardio.2020.1251
513. Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, et al. Single-staged 
compared with multi-staged PCI in multivessel NSTEMI patients: the SMILE trial. J 
Am Coll Cardiol 2016;67:264–272. https://doi.org/10.1016/j.jacc.2015.10.082
514. Siebert VR, Borgaonkar S, Jia X, Nguyen HL, Birnbaum Y, Lakkis NM, et al. 
Meta-analysis comparing multivessel versus culprit coronary arterial revascularization 
for patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 
2019;124:1501–1511. https://doi.org/10.1016/j.amjcard.2019.07.071
515. Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, et al. Complete versus 
culprit-only lesion intervention in patients with acute coronary syndromes. J Am Coll 
Cardiol 2018;72:1989–1999. https://doi.org/10.1016/j.jacc.2018.07.089
516. Hanratty CG, Koyama Y, Rasmussen HH, Nelson GIC, Hansen PS, Ward MR. 
Exaggeration of nonculprit stenosis severity during acute myocardial infarction: impli­
cations for immediate multivessel revascularization. J Am Coll Cardiol 2002;40:911–916. 
https://doi.org/10.1016/s0735-1097(02)02049-1
517. Gibson CM, Ryan KA, Murphy SA, Mesley R, Marble SJ, Giugliano RP, et al. Impaired 
coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. 
J Am Coll Cardiol 1999;34:974–982. https://doi.org/10.1016/s0735-1097(99)00335-6
518. Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, et al. Fractional flow 
reserve for the assessment of nonculprit coronary artery stenoses in patients with 
acute myocardial infarction. JACC Cardiovasc Interv 2010;3:1274–1281. https://doi. 
org/10.1016/j.jcin.2010.08.025
519. Musto C, De Felice F, Rigattieri S, Chin D, Marra A, Nazzaro MS, et al. Instantaneous 
wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions 
during the index procedure in patients with ST-segment elevation myocardial infarc­
tion: the WAVE study. Am Heart J 2017;193:63–69. https://doi.org/10.1016/j.ahj. 
2017.07.017
520. Erbay A, Penzel L, Abdelwahed YS, Klotsche J, Schatz A-S, Steiner J, et al. Feasibility and 
diagnostic reliability of quantitative flow ratio in the assessment of non-culprit lesions 
in acute coronary syndrome. Int J Cardiovasc Imaging 2021;37:1815–1823. https://doi. 
org/10.1007/s10554-021-02195-2
521. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. 
Angiographic versus functional severity of coronary artery stenoses in the FAME study 
fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 
2010;55:2816–2821. https://doi.org/10.1016/j.jacc.2009.11.096
522. Van Belle E, Baptista SB, Raposo L, Henderson J, Rioufol G, Santos L, et al. Impact of 
routine fractional flow reserve on management decision and 1-year clinical outcome of 
patients with acute coronary syndromes: PRIME-FFR (Insights From the POST-IT 
[Portuguese Study on the Evaluation of FFR-Guided Treatment of Coronary 
Disease] and R3F [French FFR Registry] Integrated Multicenter Registries – 
Implementation of FFR [Fractional Flow Reserve] in Routine Practice). Circ 
Cardiovasc Interv 2017;10:e004296. https://doi.org/10.1161/circinterventions.116. 
004296
523. Sels JW, Tonino PA, Siebert U, Fearon WF, Van’t Veer M, De Bruyne B, et al. Fractional 
flow reserve in unstable angina and non-ST-segment elevation myocardial infarction 
experience from the FAME (Fractional flow reserve versus Angiography for 
Multivessel Evaluation) study. JACC Cardiovasc Interv 2011;4:1183–1189. https://doi. 
org/10.1016/j.jcin.2011.08.008
524. Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, et al. 
Multivessel PCI guided by FFR or angiography for myocardial infarction. N Engl J 
Med 2021;385:297–308. https://doi.org/10.1056/NEJMoa2104650
525. Wald DS, Hadyanto S, Bestwick JP. Should fractional flow reserve follow angiographic 
visual inspection to guide preventive percutaneous coronary intervention in 
ST-elevation myocardial infarction? Eur Heart J Qual Care Clin Outcomes 2020;6: 
186–192. https://doi.org/10.1093/ehjqcco/qcaa012
526. Gallone G, Angelini F, Fortuni F, Gnecchi M, De Filippo O, Baldetti L, et al. 
Angiography- vs. physiology-guided complete revascularization in patients with 
ST-elevation myocardial infarction and multivessel disease: who is the better gatekeep­
er in this setting? A meta-analysis of randomized controlled trials. Eur Heart J Qual Care 
Clin Outcomes 2020;6:199–200. https://doi.org/10.1093/ehjqcco/qcaa007
527. Kobayashi Y, Lønborg J, Jong A, Nishi T, De Bruyne B, Høfsten DE, et al. Prognostic 
value of the residual SYNTAX score after functionally complete revascularization in 
ACS. J Am Coll Cardiol 2018;72:1321–1329. https://doi.org/10.1016/j.jacc.2018.06.069
528. Lee JM, Kim HK, Park KH, Choo EH, Kim CJ, Lee SH, et al. Fractional flow reserve ver­
sus angiography-guided strategy in acute myocardial infarction with multivessel 
disease: a randomized trial. Eur Heart J 2023;44:473–484. https://doi.org/10.1093/ 
eurheartj/ehac763
529. Harskamp RE, Bonatti JO, Zhao DX, Puskas JD, de Winter RJ, Alexander JH, et al. 
Standardizing definitions for hybrid coronary revascularization. J Thorac Cardiovasc 
Surg 2014;147:556–560. https://doi.org/10.1016/j.jtcvs.2013.10.019
530. Doenst T, Haverich A, Serruys P, Bonow RO, Kappetein P, Falk V, et al. PCI and CABG 
for treating stable coronary artery disease: JACC review topic of the week. J Am Coll 
Cardiol 2019;73:964–976. https://doi.org/10.1016/j.jacc.2018.11.053
531. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al. 
Randomized trial of complete versus lesion-only revascularization in patients undergo­
ing primary percutaneous coronary intervention for STEMI and multivessel disease: 
the CvLPRIT trial. J Am Coll Cardiol 2015;65:963–972. https://doi.org/10.1016/j.jacc. 
2014.12.038
532. Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, et al. Fractional flow 
reserve vs. angiography in guiding management to optimize outcomes in 
non-ST-segment elevation myocardial infarction: the British Heart Foundation 
FAMOUS-NSTEMI randomized trial. Eur Heart J 2015;36:100–111. https://doi.org/ 
10.1093/eurheartj/ehu338
533. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients 
presenting with suspected myocardial infarction and nonobstructive coronary arteries. 
Circulation 2015;131:861–870. https://doi.org/10.1161/circulationaha.114.011201
534. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio ALP, et al. ESC 
working group position paper on myocardial infarction with non-obstructive coronary 
arteries. Eur Heart J 2017;38:143–153. https://doi.org/10.1093/eurheartj/ehw149
535. Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, et al. 
Contemporary diagnosis and management of patients with myocardial infarction in 
the absence of obstructive coronary artery disease: a scientific statement from the 
American Heart Association. Circulation 2019;139:e891–e908. https://doi.org/10. 
1161/cir.0000000000000670
536. Matta A, Nader V, Canitrot R, Delmas C, Bouisset F, Lhermusier T, et al. Myocardial 
bridging is significantly associated to myocardial infarction with non-obstructive coron­
ary arteries. Eur Heart J Acute Cardiovasc Care 2022;11:501–507. https://doi.org/10. 
1093/ehjacc/zuac047
537. Pargaonkar VS, Kimura T, Kameda R, Tanaka S, Yamada R, Schwartz JG, et al. Invasive 
assessment of myocardial bridging in patients with angina and no obstructive coronary 
artery disease. EuroIntervention 2021;16:1070–1078. https://doi.org/10.4244/eij-d-20- 
00779
538. Ford TJ, Ong P, Sechtem U, Beltrame J, Camici PG, Crea F, et al. Assessment of vascular 
dysfunction in patients without obstructive coronary artery disease: why, how, and 
when. JACC Cardiovasc Interv 2020;13:1847–1864. https://doi.org/10.1016/j.jcin.2020. 
05.052
539. Occhipinti G, Bucciarelli-Ducci C, Capodanno D. Diagnostic pathways in myocardial 
infarction with non-obstructive coronary artery disease (MINOCA). Eur Heart J 
Acute Cardiovasc Care 2021;10:813–822. https://doi.org/10.1093/ehjacc/zuab049
540. Eitel I, Behrendt F, Schindler K, Kivelitz D, Gutberlet M, Schuler G, et al. Differential 
diagnosis of suspected apical ballooning syndrome using contrast-enhanced magnetic 
resonance imaging. Eur Heart J 2008;29:2651–2659. https://doi.org/10.1093/eurheartj/ 
ehn433
541. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, 
Aldrovandi A, et al. Clinical characteristics and cardiovascular magnetic resonance find­
ings in stress (takotsubo) cardiomyopathy. JAMA 2011;306:277–286. https://doi.org/ 
10.1001/jama.2011.992
542. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. 
Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert 
recommendations. J Am Coll Cardiol 2018;72:3158–3176. https://doi.org/10.1016/j. 
jacc.2018.09.072
543. Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, et al. Comprehensive car­
diac magnetic resonance imaging in patients with suspected myocarditis: the 
MyoRacer-trial. J Am Coll Cardiol 2016;67:1800–1811. https://doi.org/10.1016/j.jacc. 
2016.02.013
544. Reynolds HR, Maehara A, Kwong RY, Sedlak T, Saw J, Smilowitz NR, et al. Coronary 
optical coherence tomography and cardiac magnetic resonance imaging to determine 
underlying causes of myocardial infarction with nonobstructive coronary arteries in 
women. Circulation 2021;143:624–640. https://doi.org/10.1161/circulationaha.120. 
052008
545. Pathik B, Raman B, Mohd Amin NH, Mahadavan D, Rajendran S, McGavigan AD, et al. 
Troponin-positive chest pain with unobstructed coronary arteries: incremental diag­
nostic value of cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc 
Imaging 2016;17:1146–1152. https://doi.org/10.1093/ehjci/jev289
546. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al. Current 
state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce 
on Takotsubo Syndrome of the Heart Failure Association of the European Society of 
Cardiology. Eur J Heart Fail 2016;18:8–27. https://doi.org/10.1002/ejhf.424
547. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International ex­
pert consensus document on Takotsubo syndrome (Part II): diagnostic workup,


<!-- PAGE 98 -->

### Page 98

outcome, and management. Eur Heart J 2018;39:2047–2062. https://doi.org/10.1093/ 
eurheartj/ehy077
548. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC 
Guidelines for the diagnosis and management of pericardial diseases: the Task Force 
for the diagnosis and management of pericardial diseases of the European Society of 
Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic 
Surgery (EACTS). Eur Heart J 2015;36:2921–2964. https://doi.org/10.1093/eurheartj/ 
ehv318
549. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current 
state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a 
position statement of the European Society of Cardiology Working Group on 
Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636–2648,2648a-2648d. 
https://doi.org/10.1093/eurheartj/eht210
550. Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, et al. Stratified 
medical therapy using invasive coronary function testing in angina: the CorMicA trial. 
J Am Coll Cardiol 2018;72:2841–2855. https://doi.org/10.1016/j.jacc.2018.09.006
551. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, et al. An EAPCI 
expert consensus document on ischaemia with non-obstructive coronary arteries in 
collaboration with European Society of Cardiology Working Group on Coronary 
Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders 
International Study Group. Eur Heart J 2020;41:3504–3520. https://doi.org/10.1093/ 
eurheartj/ehaa503
552. Cerrato E, Giacobbe F, Quadri G, Macaya F, Bianco M, Mori R, et al. Antiplatelet ther­
apy in patients with conservatively managed spontaneous coronary artery dissection 
from the multicentre DISCO registry. Eur Heart J 2021;42:3161–3171. https://doi. 
org/10.1093/eurheartj/ehab372
553. McCarthy CP, Raber I, Chapman AR, Sandoval Y, Apple FS, Mills NL, et al. Myocardial 
injury in the era of high-sensitivity cardiac troponin assays: a practical approach for clin­
icians. JAMA Cardiol 2019;4:1034–1042. https://doi.org/10.1001/jamacardio.2019.2724
554. Bahit MC, Lopes RD, Clare RM, Newby LK, Pieper KS, Van de Werf F, et al. Heart fail­
ure complicating non-ST-segment elevation acute coronary syndrome: timing, predic­
tors, and clinical outcomes. JACC Heart Fail 2013;1:223–229. https://doi.org/10.1016/j. 
jchf.2013.02.007
555. Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. 
Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the 
ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1242–1254. https:// 
doi.org/10.1002/ejhf.890
556. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, Ló pez-Sendó n J, et al. 
Determinants and prognostic impact of heart failure complicating acute coronary syn­
dromes: observations from the Global Registry of Acute Coronary Events (GRACE). 
Circulation 2004;109:494–499. https://doi.org/10.1161/01.Cir.0000109691.16944.Da
557. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 
Eur Heart J 2021;42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368
558. Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, 
pathophysiology and contemporary management of cardiogenic shock—a position 
statement from the Heart Failure Association of the European Society of 
Cardiology. Eur J Heart Fail 2020;22:1315–1341. https://doi.org/10.1002/ejhf.1922
559. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. 
The use of diuretics in heart failure with congestion—a position statement from the 
Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 
2019;21:137–155. https://doi.org/10.1002/ejhf.1369
560. Lancellotti P, Price S, Edvardsen T, Cosyns B, Neskovic AN, Dulgheru R, et al. The use 
of echocardiography in acute cardiovascular care: recommendations of the European 
Association of Cardiovascular Imaging and the Acute Cardiovascular Care Association. 
Eur Heart J Cardiovasc Imaging 2015;16:119–146. https://doi.org/10.1093/ehjci/jeu210
561. Thiele H, Jobs A, Ouweneel DM, Henriques JPS, Seyfarth M, Desch S, et al. 
Percutaneous short-term active mechanical support devices in cardiogenic shock: a 
systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 
2017;38:3523–3531. https://doi.org/10.1093/eurheartj/ehx363
562. Amin AP, Spertus JA, Curtis JP, Desai N, Masoudi FA, Bach RG, et al. The evolving land­
scape of impella use in the United States among patients undergoing percutaneous 
coronary intervention with mechanical circulatory support. Circulation 2020;141: 
273–284. https://doi.org/10.1161/circulationaha.119.044007
563. Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, et al. 
Association of use of an intravascular microaxial left ventricular assist device vs 
intra-aortic balloon pump with in-hospital mortality and major bleeding among pa­
tients with acute myocardial infarction complicated by cardiogenic shock. JAMA 
2020;323:734–745. https://doi.org/10.1001/jama.2020.0254
564. Elbadawi A, Elgendy IY, Mahmoud K, Barakat AF, Mentias A, Mohamed AH, et al. 
Temporal trends and outcomes of mechanical complications in patients with acute 
myocardial infarction. JACC Cardiovasc Interv 2019;12:1825–1836. https://doi.org/10. 
1016/j.jcin.2019.04.039
565. Schrage B, Becher PM, Goßling A, Savarese G, Dabboura S, Yan I, et al. Temporal 
trends in incidence, causes, use of mechanical circulatory support and mortality in car­
diogenic shock. ESC Heart Fail 2021;8:1295–1303. https://doi.org/10.1002/ehf2.13202
566. Watkins AC, Maassel NL, Ghoreishi M, Dawood MY, Pham SM, Kon ZN, et al. 
Preoperative venoarterial extracorporeal membrane oxygenation slashes risk score 
in advanced structural heart disease. Ann Thorac Surg 2018;106:1709–1715. https:// 
doi.org/10.1016/j.athoracsur.2018.07.038
567. Ronco D, Matteucci M, Ravaux JM, Marra S, Torchio F, Corazzari C, et al. Mechanical 
circulatory support as a bridge to definitive treatment in post-infarction ventricular 
septal rupture. JACC Cardiovasc Interv 2021;14:1053–1066. https://doi.org/10.1016/j. 
jcin.2021.02.046
568. Matteucci M, Fina D, Jiritano F, Meani P, Raffa GM, Kowalewski M, et al. The use of 
extracorporeal membrane oxygenation in the setting of postinfarction mechanical 
complications: outcome analysis of the Extracorporeal Life Support Organization 
Registry. Interact Cardiovasc Thorac Surg 2020;31:369–374. https://doi.org/10.1093/ 
icvts/ivaa108
569. Assenza GE, McElhinney DB, Valente AM, Pearson DD, Volpe M, Martucci G, et al. 
Transcatheter closure of post-myocardial infarction ventricular septal rupture. Circ 
Cardiovasc Interv 2013;6:59–67. https://doi.org/10.1161/circinterventions.112.972711
570. Kilic A, Sultan I, Chu D, Wang Y, Gleason TG. Mitral valve surgery for papillary muscle 
rupture: outcomes in 1342 patients from the society of thoracic surgeons database. 
Ann Thorac Surg 2020;110:1975–1981. https://doi.org/10.1016/j.athoracsur.2020.03. 
097
571. Valle JA, Miyasaka RL, Carroll JD. Acute mitral regurgitation secondary to papillary 
muscle tear: is transcatheter edge-to-edge mitral valve repair a new paradigm? Circ 
Cardiovasc Interv 2017;10:e005050. https://doi.org/10.1161/circinterventions.117. 
005050
572. Terashima M, Fujiwara S, Yaginuma GY, Takizawa K, Kaneko U, Meguro T. Outcome 
of percutaneous intrapericardial fibrin-glue injection therapy for left ventricular free 
wall rupture secondary to acute myocardial infarction. Am J Cardiol 2008;101: 
419–421. https://doi.org/10.1016/j.amjcard.2007.09.086
573. Damluji AA, van Diepen S, Katz JN, Menon V, Tamis-Holland JE, Bakitas M, et al. 
Mechanical complications of acute myocardial infarction: a scientific statement from 
the American Heart Association. Circulation 2021;144:e16–e35. https://doi.org/10. 
1161/cir.0000000000000985
574. Gong FF, Vaitenas I, Malaisrie SC, Maganti K. Mechanical complications of acute myo­
cardial infarction: a review. JAMA Cardiol 2021;6:341–349. https://doi.org/10.1001/ 
jamacardio.2020.3690
575. Robinson AA, Jain A, Gentry M, McNamara RL. Left ventricular thrombi after STEMI in 
the primary PCI era: a systematic review and meta-analysis. Int J Cardiol 2016;221: 
554–559. https://doi.org/10.1016/j.ijcard.2016.07.069
576. Levine GN, McEvoy JW, Fang JC, Ibeh C, McCarthy CP, Misra A, et al. Management of 
patients at risk for and with left ventricular thrombus: a scientific statement from the 
American Heart Association. Circulation 2022;146:e205–e223. https://doi.org/10. 
1161/cir.0000000000001092
577. Bulluck H, Chan MHH, Paradies V, Yellon RL, Ho HH, Chan MY, et al. Incidence and 
predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute 
ST-segment elevation myocardial infarction treated by primary percutaneous coron­
ary intervention: a meta-analysis. J Cardiovasc Magn Reson 2018;20:72. https://doi.org/ 
10.1186/s12968-018-0494-3
578. Velangi PS, Choo C, Chen KA, Kazmirczak F, Nijjar PS, Farzaneh-Far A, et al. Long-term 
embolic outcomes after detection of left ventricular thrombus by late gadolinium en­
hancement cardiovascular magnetic resonance imaging: a matched cohort study. Circ 
Cardiovasc Imaging 2019;12:e009723. https://doi.org/10.1161/circimaging.119.009723
579. Funke Küpper AJ, Verheugt FW, Peels CH, Galema TW, Roos JP. Left ventricular 
thrombus incidence and behavior studied by serial two-dimensional echocardiography 
in acute anterior myocardial infarction: left ventricular wall motion, systemic embolism 
and oral anticoagulation. J Am Coll Cardiol 1989;13:1514–1520. https://doi.org/10.1016/ 
0735-1097(89)90341-0
580. Zhang Z, Si D, Zhang Q, Jin L, Zheng H, Qu M, et al. Prophylactic rivaroxaban therapy 
for left ventricular thrombus after anterior ST-segment elevation myocardial infarc­
tion. JACC Cardiovasc Interv 2022;15:861–872. https://doi.org/10.1016/j.jcin.2022.01. 
285
581. Dalia T, Lahan S, Ranka S, Goyal A, Zoubek S, Gupta K, et al. Warfarin versus direct 
oral anticoagulants for treating left ventricular thrombus: a systematic review and 
meta-analysis. Thromb J 2021;19:7. https://doi.org/10.1186/s12959-021-00259-w
582. Verma BR, Montane B, Chetrit M, Khayata M, Furqan MM, Ayoub C, et al. Pericarditis 
and post-cardiac injury syndrome as a sequelae of acute myocardial infarction. Curr 
Cardiol Rep 2020;22:127. https://doi.org/10.1007/s11886-020-01371-5
583. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial in­
farction: a systematic review of the incidence, clinical features and prognostic implica­
tions. Eur Heart J 2009;30:1038–1045. https://doi.org/10.1093/eurheartj/ehn579
584. Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L, et al. All types of 
atrial fibrillation in the setting of myocardial infarction are associated with impaired 
outcome. Heart 2016;102:926–933. https://doi.org/10.1136/heartjnl-2015-308678
585. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 
ESC Guidelines for the diagnosis and management of atrial fibrillation developed in col­
laboration with the European Association for Cardio-Thoracic Surgery (EACTS). The 
Task Force for the diagnosis and management of atrial fibrillation of the European 
ESC Guidelines                                                                                                                                                                                          3817


<!-- PAGE 99 -->

### Page 99

Society of Cardiology (ESC). Developed with the special contribution of the European 
Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498. https:// 
doi.org/10.1093/eurheartj/ehaa612
586. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA, et al. Atrial fibrillation 
and death after myocardial infarction: a community study. Circulation 2011;123: 
2094–2100. https://doi.org/10.1161/circulationaha.110.990192
587. Siu CW, Jim MH, Ho HH, Miu R, Lee SWL, Lau CP, et al. Transient atrial fibrillation 
complicating acute inferior myocardial infarction: implications for future risk of ische­
mic stroke. Chest 2007;132:44–49. https://doi.org/10.1378/chest.06-2733
588. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, et al. 
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute 
myocardial infarction. Crit Care Med 2011;39:78–83. https://doi.org/10.1097/CCM. 
0b013e3181fd6ad7
589. Piccini JP, Hranitzky PM, Kilaru R, Rouleau JL, White HD, Aylward PE, et al. Relation of 
mortality to failure to prescribe beta blockers acutely in patients with sustained ven­
tricular tachycardia and ventricular fibrillation following acute myocardial infarction 
(from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am 
J Cardiol 2008;102:1427–1432. https://doi.org/10.1016/j.amjcard.2008.07.033
590. Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymorphous ventricu­
lar tachycardia associated with acute myocardial infarction. Circulation 1991;84: 
1543–1551. https://doi.org/10.1161/01.cir.84.4.1543
591. Liang JJ, Fender EA, Cha YM, Lennon RJ, Prasad A, Barsness GW, et al. Long-term out­
comes in survivors of early ventricular arrhythmias after acute ST-elevation and 
non-ST-elevation myocardial infarction treated with percutaneous coronary interven­
tion. Am J Cardiol 2016;117:709–713. https://doi.org/10.1016/j.amjcard.2015.12.002
592. Mehta RH, Yu J, Piccini JP, Tcheng JE, Farkouh ME, Reiffel J, et al. Prognostic significance 
of postprocedural sustained ventricular tachycardia or fibrillation in patients undergo­
ing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). 
Am J Cardiol 2012;109:805–812. https://doi.org/10.1016/j.amjcard.2011.10.043
593. Masuda M, Nakatani D, Hikoso S, Suna S, Usami M, Matsumoto S, et al. Clinical impact 
of ventricular tachycardia and/or fibrillation during the acute phase of acute myocardial 
infarction on in-hospital and 5-year mortality rates in the percutaneous coronary inter­
vention era. Circ J 2016;80:1539–1547. https://doi.org/10.1253/circj.CJ-16-0183
594. Podolecki T, Lenarczyk R, Kowalczyk J, Jedrzejczyk-Patej E, Chodor P, Mazurek M, et al. 
Prognostic significance of complex ventricular arrhythmias complicating ST-segment 
elevation myocardial infarction. Am J Cardiol 2018;121:805–809. https://doi.org/10. 
1016/j.amjcard.2017.12.036
595. Komatsu Y, Hocini M, Nogami A, Maury P, Peichl P, Iwasaki YK, et al. Catheter ablation 
of refractory ventricular fibrillation storm after myocardial infarction. Circulation 2019; 
139:2315–2325. https://doi.org/10.1161/circulationaha.118.037997
596. Terkelsen CJ, Sørensen JT, Kaltoft AK, Nielsen SS, Thuesen L, Bøtker HE, et al. 
Prevalence and significance of accelerated idioventricular rhythm in patients with 
ST-elevation myocardial infarction treated with primary percutaneous coronary inter­
vention. Am J Cardiol 2009;104:1641–1646. https://doi.org/10.1016/j.amjcard.2009.07. 
037
597. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, et al. A risk score 
to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 
55:2556–2566. https://doi.org/10.1016/j.jacc.2009.09.076
598. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, et al. Associations of 
major bleeding and myocardial infarction with the incidence and timing of mortality in 
patients presenting with non-ST-elevation acute coronary syndromes: a risk model 
from the ACUITY trial. Eur Heart J 2009;30:1457–1466. https://doi.org/10.1093/ 
eurheartj/ehp110
599. Rao SV. The conundrum of reducing ischemic and bleeding events after PCI. J Am Coll 
Cardiol 2015;65:1421–1423. https://doi.org/10.1016/j.jacc.2015.02.012
600. Kwok CS, Sherwood MW, Watson SM, Nasir SB, Sperrin M, Nolan J, et al. Blood trans­
fusion after percutaneous coronary intervention and risk of subsequent adverse out­
comes: a systematic review and meta-analysis. JACC Cardiovasc Interv 2015;8:436–446. 
https://doi.org/10.1016/j.jcin.2014.09.026
601. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual 
antiplatelet treatment and cardiac events after percutaneous coronary intervention 
(PARIS): 2 year results from a prospective observational study. Lancet 2013;382: 
1714–1722. https://doi.org/10.1016/s0140-6736(13)61720-1
602. Reidenberg MM. Drug discontinuation effects are part of the pharmacology of a drug. J 
Pharmacol Exp Ther 2011;339:324–328. https://doi.org/10.1124/jpet.111.183285
603. Abdelnabi M, Saleh Y, Fareed A, Nossikof A, Wang L, Morsi M, et al. Comparative study 
of oral anticoagulation in left ventricular thrombi (no-LVT trial). J Am Coll Cardiol 2021; 
77:1590–1592. https://doi.org/10.1016/j.jacc.2021.01.049
604. Weinsaft JW, Kim J, Medicherla CB, Ma CL, Codella NCF, Kukar N, et al. 
Echocardiographic algorithm for post-myocardial infarction LV thrombus: a gatekeep­
er for thrombus evaluation by delayed enhancement CMR. JACC Cardiovasc Imaging 
2016;9:505–515. https://doi.org/10.1016/j.jcmg.2015.06.017
605. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, et al. The evidence 
regarding the drugs used for ventricular rate control. J Fam Pract 2000;49:47–59
606. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, et al. Acute treatment of 
recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous 
amiodarone: a randomized, digoxin-controlled study. Eur Heart J 1995;16:521–528. 
https://doi.org/10.1093/oxfordjournals.eurheartj.a060945
607. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous 
conversion and maintenance of sinus rhythm by amiodarone in patients with heart fail­
ure and atrial fibrillation: observations from the veterans affairs Congestive Heart fail­
ure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998;98: 
2574–2579. https://doi.org/10.1161/01.cir.98.23.2574
608. Hofmann R, Steinwender C, Kammler J, Kypta A, Wimmer G, Leisch F, et al. 
Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with ad­
vanced congestive heart failure or cardiogenic shock. Wien Klin Wochenschr 2004; 
116:744–749. https://doi.org/10.1007/s00508-004-0264-0
609. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic im­
plantation of a defibrillator in patients with myocardial infarction and reduced ejection 
fraction. N Engl J Med 2002;346:877–883. https://doi.org/10.1056/NEJMoa013474
610. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an 
implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 
352:225–237. https://doi.org/10.1056/NEJMoa043399
611. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: 
sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 
2000;102:742–747. https://doi.org/10.1161/01.cir.102.7.742
612. Miwa Y, Ikeda T, Mera H, Miyakoshi M, Hoshida K, Yanagisawa R, et al. Effects of land­
iolol, an ultra-short-acting beta1-selective blocker, on electrical storm refractory to 
class III antiarrhythmic drugs. Circ J 2010;74:856–863. https://doi.org/10.1253/circj.cj- 
09-0772
613. Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, 
et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricu­
lar fibrillation. N Engl J Med 1999;341:871–878. https://doi.org/10.1056/ 
nejm199909163411203
614. Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA, et al. 
Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyar­
rhythmias. J Am Coll Cardiol 1996;27:67–75. https://doi.org/10.1016/0735-1097(95) 
00427-0
615. Gorenek B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, 
Huber K, et al. Cardiac arrhythmias in acute coronary syndromes: position paper 
from the joint EHRA, ACCA, and EAPCI task force. Europace 2014;16:1655–1673. 
https://doi.org/10.1093/europace/euu208
616. Kalarus Z, Svendsen JH, Capodanno D, Dan GA, De Maria E, Gorenek B, et al. Cardiac 
arrhythmias in the emergency settings of acute coronary syndrome and revasculariza­
tion: an European Heart Rhythm Association (EHRA) consensus document, endorsed 
by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), 
and European Acute Cardiovascular Care Association (ACCA). Europace 2019;21: 
1603–1604. https://doi.org/10.1093/europace/euz163
617. Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior 
myocardial infarction. J Am Coll Cardiol 1984;4:35–38. https://doi.org/10.1016/s0735- 
1097(84)80315-0
618. Brady WJ, Swart G, DeBehnke DJ, Ma OJ, Aufderheide TP. The efficacy of atropine in 
the treatment of hemodynamically unstable bradycardia and atrioventricular block: 
prehospital and emergency department considerations. Resuscitation 1999;41: 
47–55. https://doi.org/10.1016/s0300-9572(99)00032-5
619. Kusumoto FM, Calkins H, Boehmer J, Buxton AE, Chung MK, Gold MR, et al. HRS/ 
ACC/AHA expert consensus statement on the use of implantable cardioverter- 
defibrillator therapy in patients who are not included or not well represented in clinical 
trials. Circulation 2014;130:94–125. https://doi.org/10.1161/cir.0000000000000056
620. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 
2021;42:3427–3520. https://doi.org/10.1093/eurheartj/ehab364
621. Jim MH, Chan AO, Tse HF, Barold SS, Lau CP. Clinical and angiographic findings of 
complete atrioventricular block in acute inferior myocardial infarction. Ann Acad 
Med 
Singap 
2010;39:185–190. 
https://doi.org/10.47102/annals-acadmedsg. 
V39N3p185
622. Gang UJ, Hvelplund A, Pedersen S, Iversen A, Jons C, Abildstrom SZ, et al. High-degree 
atrioventricular block complicating ST-segment elevation myocardial infarction in the 
era of primary percutaneous coronary intervention. Europace 2012;14:1639–1645. 
https://doi.org/10.1093/europace/eus161
623. Vicente-Ibarra N, Marín F, Pernías-Escrig V, Sandín-Rollán M, Núñez-Martínez L, 
Lozano T, et al. Impact of anemia as risk factor for major bleeding and mortality in pa­
tients with acute coronary syndrome. Eur J Intern Med 2019;61:48–53. https://doi.org/ 
10.1016/j.ejim.2018.12.004
624. Younge JO, Nauta ST, Akkerhuis KM, Deckers JW, van Domburg RT. Effect of anemia 
on short- and long-term outcome in patients hospitalized for acute coronary syn­
dromes. Am J Cardiol 2012;109:506–510. https://doi.org/10.1016/j.amjcard.2011.09. 
046
625. Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, et al. Relationship be­
tween baseline haemoglobin and major bleeding complications in acute coronary syn­
dromes. Eur Heart J 2010;31:50–58. https://doi.org/10.1093/eurheartj/ehp401


<!-- PAGE 100 -->

### Page 100

626. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical prac­
tice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 
2016;316:2025–2035. https://doi.org/10.1001/jama.2016.9185
627. Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood 
transfusion with increased mortality in myocardial infarction: a meta-analysis and 
diversity-adjusted study sequential analysis. JAMA Intern Med 2013;173:132–139. 
https://doi.org/10.1001/2013.jamainternmed.1001
628. Carson JL, Stanworth SJ, Dennis JA, Trivella M, Roubinian N, Fergusson DA, et al. 
Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database 
Syst Rev 2021;12:CD002042. https://doi.org/10.1002/14651858.CD002042.pub5
629. Cooper HA, Rao SV, Greenberg MD, Rumsey MP, McKenzie M, Alcorn KW, et al. 
Conservative versus liberal red cell transfusion in acute myocardial infarction (the 
CRIT Randomized Pilot Study). Am J Cardiol 2011;108:1108–1111. https://doi.org/ 
10.1016/j.amjcard.2011.06.014
630. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NMA, et al. 
Transfusion practice and outcomes in non-ST-segment elevation acute coronary syn­
dromes. Am Heart J 2008;155:1047–1053. https://doi.org/10.1016/j.ahj.2008.01.009
631. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, Cachanado M, 
Durand-Zaleski I, et al. Effect of a restrictive vs liberal blood transfusion strategy on 
major cardiovascular events among patients with acute myocardial infarction and an­
emia: the REALITY randomized clinical trial. JAMA 2021;325:552–560. https://doi.org/ 
10.1001/jama.2021.0135
632. Gonzalez-Juanatey JR, Lemesle G, Puymirat E, Ducrocq G, Cachanado M, Arnaiz JA, 
et al. One-year major cardiovascular events after restrictive versus liberal blood trans­
fusion strategy in patients with acute myocardial infarction and anemia: the REALITY 
randomized 
trial. 
Circulation 
2022;145:486–488. 
https://doi.org/10.1161/ 
circulationaha.121.057909
633. Gore JM, Spencer FA, Gurfinkel EP, López-Sendón J, Steg PG, Granger CB, et al. 
Thrombocytopenia in patients with an acute coronary syndrome (from the Global 
Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2009;103:175–180. 
https://doi.org/10.1016/j.amjcard.2008.08.055
634. Vora AN, Chenier M, Schulte PJ, Goodman S, Peterson ED, Pieper K, et al. Long-term 
outcomes associated with hospital acquired thrombocytopenia among patients with 
non-ST-segment elevation acute coronary syndrome. Am Heart J 2014;168:189–­
196.e1. https://doi.org/10.1016/j.ahj.2014.04.010
635. Szummer K, Lundman P, Jacobson SH, Schön S, Lindbäck J, Stenestrand U, et al. 
Relation between renal function, presentation, use of therapies and in-hospital com­
plications in acute coronary syndrome: data from the SWEDEHEART register. J 
Intern Med 2010;268:40–49. https://doi.org/10.1111/j.1365-2796.2009.02204.x
636. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting 
enzyme inhibitor therapy in patients with end-stage renal disease and an acute myo­
cardial infarction. J Am Coll Cardiol 2003;42:201–208. https://doi.org/10.1016/s0735- 
1097(03)00572-2
637. Panchal HB, Zheng S, Devani K, White CJ, Leinaar EF, Mukherjee D, et al. Impact of 
chronic kidney disease on revascularization and outcomes in patients with 
ST-elevation myocardial infarction. Am J Cardiol 2021;150:15–23. https://doi.org/10. 
1016/j.amjcard.2021.03.057
638. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. 
Association of estimated glomerular filtration rate and albuminuria with all-cause and 
cardiovascular mortality in general population cohorts: a collaborative meta-analysis. 
Lancet 2010;375:2073–2081. https://doi.org/10.1016/s0140-6736(10)60674-5
639. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Piñero G, Avezum A, et al. Creatinine 
clearance and adverse hospital outcomes in patients with acute coronary syndromes: 
findings from the global registry of acute coronary events (GRACE). Heart 2003;89: 
1003–1008. https://doi.org/10.1136/heart.89.9.1003
640. Szummer K, Lundman P, Jacobson SH, Schö n S, Lindbä ck J, Stenestrand U, et al. 
Influence of renal function on the effects of early revascularization in 
non-ST-elevation myocardial infarction: data from the Swedish Web-System for 
Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated 
According to Recommended Therapies (SWEDEHEART). Circulation 2009;120: 
851–858. https://doi.org/10.1161/circulationaha.108.838169
641. Huang HD, Alam M, Hamzeh I, Virani S, Deswal A, Aguilar D, et al. Patients with severe 
chronic kidney disease benefit from early revascularization after acute coronary syn­
drome. Int J Cardiol 2013;168:3741–3746. https://doi.org/10.1016/j.ijcard.2013.06.013
642. Kume K, Yasuoka Y, Adachi H, Noda Y, Hattori S, Araki R, et al. Impact of 
contrast-induced acute kidney injury on outcomes in patients with ST-segment eleva­
tion myocardial infarction undergoing primary percutaneous coronary intervention. 
Cardiovasc Revasc Med 2013;14:253–257. https://doi.org/10.1016/j.carrev.2013.07.009
643. Bangalore S, Briguori C. Preventive strategies for contrast-induced acute kidney injury: 
and the winner is…. Circ Cardiovasc Interv 2017;10:e005262. https://doi.org/10.1161/ 
circinterventions.117.005262
644. Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, et al. Use of intra­
venous iodinated contrast media in patients with kidney disease: consensus statements 
from the American College of Radiology and the National Kidney Foundation. Kidney 
Med 2020;2:85–93. https://doi.org/10.1016/j.xkme.2020.01.001
645. Schweiger MJ, Chambers CE, Davidson CJ, Zhang S, Blankenship J, Bhalla NP, et al. 
Prevention of contrast induced nephropathy: recommendations for the high risk pa­
tient undergoing cardiovascular procedures. Catheter Cardiovasc Interv 2007;69: 
135–140. https://doi.org/10.1002/ccd.20964
646. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC 
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 
42:3227–3337. https://doi.org/10.1093/eurheartj/ehab484
647. Ängerud KH, Brulin C, Näslund U, Eliasson M. Longer pre-hospital delay in first myo­
cardial infarction among patients with diabetes: an analysis of 4266 patients in the nor­
thern Sweden MONICA Study. BMC Cardiovasc Disord 2013;13:6. https://doi.org/10. 
1186/1471-2261-13-6
648. Fu R, Li S-D, Song C-X, Yang J-A, Xu H-Y, Gao X-J, et al. Clinical significance of diabetes 
on symptom and patient delay among patients with acute myocardial infarction–an 
analysis from China Acute Myocardial Infarction (CAMI) registry. J Geriatr Cardiol 
2019;16:395–400. https://doi.org/10.11909/j.issn.1671-5411.2019.05.002
649. Rossello X, Ferreira JP, McMurray JJ, Aguilar D, Pfeffer MA, Pitt B, et al. Editor’s choice– 
impact of insulin-treated diabetes on cardiovascular outcomes following high-risk 
myocardial infarction. Eur Heart J Acute Cardiovasc Care 2019;8:231–241. https://doi. 
org/10.1177/2048872618803701
650. Wallert J, Mitchell A, Held C, Hagström E, Leosdottir M, Olsson EMG. Cardiac rehabili­
tation goal attainment after myocardial infarction with versus without diabetes: a na­
tionwide registry study. Int J Cardiol 2019;292:19–24. https://doi.org/10.1016/j.ijcard. 
2019.04.049
651. Ritsinger V, Jensen J, Ohm D, Omerovic E, Koul S, Fröbert O, et al. Elevated admission 
glucose is common and associated with high short-term complication burden after 
acute myocardial infarction: insights from the VALIDATE-SWEDEHEART study. 
Diab Vasc Dis Res 2019;16:582–584. https://doi.org/10.1177/1479164119871540
652. Weston C, Walker L, Birkhead J. Early impact of insulin treatment on mortality for 
hyperglycaemic patients without known diabetes who present with an acute coronary 
syndrome. Heart 2007;93:1542–1546. https://doi.org/10.1136/hrt.2006.108696
653. Ritsinger V, Malmberg K, Mårtensson A, Rydén L, Wedel H, Norhammar A. Intensified 
insulin-based glycaemic control after myocardial infarction: mortality during 20 year 
follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute 
Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol 2014;2:627–633. 
https://doi.org/10.1016/s2213-8587(14)70088-9
654. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus con­
ventional glucose control in critically ill patients. N Engl J Med 2009;360:1283–1297. 
https://doi.org/10.1056/NEJMoa0810625
655. Rossello X, Yellon DM. A new era in the management of type 2 diabetes: is cardiopro­
tection at long last a reality? Int J Cardiol 2017;228:198–200. https://doi.org/10.1016/j. 
ijcard.2016.11.246
656. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, 
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 
2117–2128. https://doi.org/10.1056/NEJMoa1504720
657. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. 
Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375: 
311–322. https://doi.org/10.1056/NEJMoa1603827
658. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC 
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collab­
oration with the EASD. Eur Heart J 2020;41:255–323. https://doi.org/10.1093/ 
eurheartj/ehz486
659. Sinclair H, Batty JA, Qiu W, Kunadian V. Engaging older patients in cardiovascular re­
search: observational analysis of the ICON-1 study. Open Heart 2016;3:e000436. 
https://doi.org/10.1136/openhrt-2016-000436
660. Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S, Battler A, et al. Age, clinical 
presentation, and outcome of acute coronary syndromes in the Euroheart acute cor­
onary syndrome survey. Eur Heart J 2006;27:789–795. https://doi.org/10.1093/ 
eurheartj/ehi774
661. Lopes RD, White JA, Tricoci P, White HD, Armstrong PW, Braunwald E, et al. Age, 
treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syn­
drome patients: insights from the EARLY ACS trial. Int J Cardiol 2013;167:2580–2587. 
https://doi.org/10.1016/j.ijcard.2012.06.053
662. Reiter M, Twerenbold R, Reichlin T, Haaf P, Peter F, Meissner J, et al. Early diagnosis of 
acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. 
Eur Heart J 2011;32:1379–1389. https://doi.org/10.1093/eurheartj/ehr033
663. Mills GB, Ratcovich H, Adams-Hall J, Beska B, Kirkup E, Raharjo DE, et al. Is the con­
temporary care of the older persons with acute coronary syndrome evidence-based? 
oeab044
664. Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, et al. Invasive versus 
conservative strategy in patients aged 80 years or older with non-ST-elevation myo­
cardial infarction or unstable angina pectoris (After Eighty study): an open-label rando­
mised controlled trial. Lancet 2016;387:1057–1065. https://doi.org/10.1016/s0140- 
6736(15)01166-6
665. Bueno H, Betriu A, Heras M, Alonso JJ, Cequier A, Garcia EJ, et al. Primary angioplasty 
vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA 
ESC Guidelines                                                                                                                                                                                          3819


<!-- PAGE 101 -->

### Page 101

(TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and 
pooled analysis with previous studies. Eur Heart J 2011;32:51–60. https://doi.org/10. 
1093/eurheartj/ehq375
666. Kunadian V, Qiu W, Ludman P, Redwood S, Curzen N, Stables R, et al. Outcomes in 
patients with cardiogenic shock following percutaneous coronary intervention in the 
contemporary era: an analysis from the BCIS database (British Cardiovascular 
Intervention Society). JACC Cardiovasc Interv 2014;7:1374–1385. https://doi.org/10. 
1016/j.jcin.2014.06.017
667. Kunadian V, Bawamia B, Maznyczka A, Zaman A, Qiu W. Outcomes following primary 
percutaneous coronary intervention in the setting of cardiac arrest: a registry database 
study. Eur Heart J Acute Cardiovasc Care 2015;4:6–15. https://doi.org/10.1177/ 
2048872614534079
668. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardi­
ology: definition, assessment and clinical implications for general cardiology. A consen­
sus document of the Council for Cardiology Practice (CCP), Association for Acute 
Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied 
Professions (ACNAP), European Association of Preventive Cardiology (EAPC), 
European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases 
(VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), 
Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, 
WG Thrombosis, of the European Society of Cardiology, European Primary Care 
Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216–227. https://doi.org/10. 
1093/eurjpc/zwaa167
669. Walker DM, Gale CP, Lip G, Martin-Sanchez FJ, McIntyre HF, Mueller C, et al. Editor’s 
choice–frailty and the management of patients with acute cardiovascular disease: a 
position paper from the Acute Cardiovascular Care Association. Eur Heart J Acute 
Cardiovasc Care 2018;7:176–193. https://doi.org/10.1177/2048872618758931
670. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 
2013;381:752–762. https://doi.org/10.1016/s0140-6736(12)62167-9
671. Chung KJNC, Wilkinson C, Veerasamy M, Kunadian V. Frailty scores and their utility in 
older patients with cardiovascular disease. Interv Cardiol 2021;16:e05. https://doi.org/ 
10.15420/icr.2020.18
672. Gu SZ, Qiu W, Batty JA, Sinclair H, Veerasamy M, Brugaletta S, et al. Coronary artery 
lesion phenotype in frail older patients with non-ST-elevation acute coronary syn­
drome undergoing invasive care. EuroIntervention 2019;15:e261–e268. https://doi. 
org/10.4244/eij-d-18-00848
673. Batty J, Qiu W, Gu S, Sinclair H, Veerasamy M, Beska B, et al. One-year clinical out­
comes in older patients with non-ST elevation acute coronary syndrome undergoing 
coronary angiography: an analysis of the ICON1 study. Int J Cardiol 2019;274:45–51. 
https://doi.org/10.1016/j.ijcard.2018.09.086
674. Beska B, Coakley D, MacGowan G, Adams-Hall J, Wilkinson C, Kunadian V, et al. Frailty 
and quality of life after invasive management for non-ST elevation acute coronary syn­
drome. Heart 2022;108:203–211. https://doi.org/10.1136/heartjnl-2021-319064
675. Beska B, Mills GB, Ratcovich H, Wilkinson C, Damluji AA, Kunadian V, et al. Impact of 
multimorbidity on long-term outcomes in older adults with non-ST elevation acute 
coronary syndrome in the North East of England: a multi-centre cohort study of pa­
tients undergoing invasive care. BMJ Open 2022;12:e061830. https://doi.org/10.1136/ 
bmjopen-2022-061830
676. Gu SZ, Beska B, Chan D, Neely D, Batty JA, Adams-Hall J, et al. Cognitive decline in 
older patients with non-ST elevation acute coronary syndrome. J Am Heart Assoc 
2019;8:e011218. https://doi.org/10.1161/jaha.118.011218
677. Ismail S, Wong C, Rajan P, Vidovich MI. ST-elevation acute myocardial infarction in 
pregnancy: 2016 update. Clin Cardiol 2017;40:399–406. https://doi.org/10.1002/clc. 
22655
678. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková 
R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular dis­
eases during pregnancy. Eur Heart J 2018;39:3165–3241. https://doi.org/10.1093/ 
eurheartj/ehy340
679. Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll 
Cardiol 2008;52:171–180. https://doi.org/10.1016/j.jacc.2008.03.049
680. Elkayam U, Jalnapurkar S, Barakkat MN, Khatri N, Kealey AJ, Mehra A, et al. 
Pregnancy-associated acute myocardial infarction: a review of contemporary experi­
ence in 150 cases between 2006 and 2011. Circulation 2014;129:1695–1702. https:// 
doi.org/10.1161/circulationaha.113.002054
681. Elkayam U, Goland S, Pieper PG, Silverside CK. High-risk cardiac disease in pregnancy: 
Part I. J Am Coll Cardiol 2016;68:396–410. https://doi.org/10.1016/j.jacc.2016.05.048
682. Bharadwaj A, Potts J, Mohamed MO, Parwani P, Swamy P, Lopez-Mattei JC, et al. Acute 
myocardial infarction treatments and outcomes in 6.5 million patients with a current 
or historical diagnosis of cancer in the USA. Eur Heart J 2020;41:2183–2193. https:// 
doi.org/10.1093/eurheartj/ehz851
683. Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans AACM, 
et al. Outcome after ST elevation myocardial infarction in patients with cancer treated 
with primary percutaneous coronary intervention. Am J Cardiol 2013;112:1867–1872. 
https://doi.org/10.1016/j.amjcard.2013.08.019
684. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 
European Hematology Association (EHA), the European Society for Therapeutic 
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society 
(IC-OS): developed by the Task Force on cardio-oncology of the European Society 
of Cardiology (ESC). Eur Heart J 2022;43:4229–4361. https://doi.org/10.1093/ 
eurheartj/ehac244
685. Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, et al. 
Percutaneous coronary intervention in cancer patients: a report of the prevalence 
and outcomes in the United States. Eur Heart J 2019;40:1790–1800. https://doi.org/ 
10.1093/eurheartj/ehy769
686. Pothineni NV, Shah NN, Rochlani Y, Saad M, Kovelamudi S, Marmagkiolis K, et al. 
Temporal trends and outcomes of acute myocardial infarction in patients with cancer. 
Ann Transl Med 2017;5:482. https://doi.org/10.21037/atm.2017.11.29
687. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al. 
Evaluation and management of cancer patients presenting with acute cardiovascular 
disease: a Consensus Document of the Acute CardioVascular Care (ACVC) associ­
ation and the ESC Council of Cardio-Oncology-Part 1: acute coronary syndromes 
and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;10:947–959. 
https://doi.org/10.1093/ehjacc/zuab056
688. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, 
et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur 
Heart J 2019;40:1756–1763. https://doi.org/10.1093/eurheartj/ehy453
689. Mohamed MO, Van Spall HGC, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY, et al. 
Effect of primary percutaneous coronary intervention on in-hospital outcomes among 
active cancer patients presenting with ST-elevation myocardial infarction: a propensity 
score matching analysis. Eur Heart J Acute Cardiovasc Care 2021;10:829–839. https://doi. 
org/10.1093/ehjacc/zuaa032
690. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary inter­
vention in metastatic cancer patients with acute coronary syndrome over a 10-year 
period. J Cancer Res Clin Oncol 2016;142:471–479. https://doi.org/10.1007/s00432- 
015-2056-5
691. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic ef­
fects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491–499. 
https://doi.org/10.1056/NEJMoa021833
692. Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, et al. Renal toxicity evaluation and 
comparison between visipaque (Iodixanol) and hexabrix (Ioxaglate) in patients with re­
nal insufficiency undergoing coronary angiography: the RECOVER study: a randomized 
controlled trial. J Am Coll Cardiol 2006;48:924–930. https://doi.org/10.1016/j.jacc.2006. 
06.047
693. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, et al. 
Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double- 
blind trial of contrast-induced nephropathy in patients with chronic kidney disease. 
Circulation 2007;115:3189–3196. https://doi.org/10.1161/circulationaha.106.671644
694. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium 
bicarbonate vs sodium chloride for the prevention of contrast medium-induced ne­
phropathy in patients undergoing coronary angiography: a randomized trial. JAMA 
2008;300:1038–1046. https://doi.org/10.1001/jama.300.9.1038
695. Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AYJ, Jorgensen M, et al. 
Haemodynamic-guided fluid administration for the prevention of contrast-induced 
acute kidney injury: the POSEIDON randomised controlled trial. Lancet 2014;383: 
1814–1823. https://doi.org/10.1016/s0140-6736(14)60689-9
696. Giacoppo D, Gargiulo G, Buccheri S, Aruta P, Byrne RA, Cassese S, et al. Preventive 
strategies for contrast-induced acute kidney injury in patients undergoing percutan­
eous coronary procedures: evidence from a hierarchical Bayesian network 
meta-analysis of 124 trials and 28240 patients. Circ Cardiovasc Interv 2017;10: 
e004383. https://doi.org/10.1161/circinterventions.116.004383
697. Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, et al. 
Prophylactic hydration to protect renal function from intravascular iodinated contrast 
material in patients at high risk of contrast-induced nephropathy (AMACING): a pro­
spective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 
2017;389:1312–1322. https://doi.org/10.1016/s0140-6736(17)30057-0
698. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors 
for primary and secondary prevention of cardiovascular and renal outcomes in type 2 
diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. 
Lancet 2019;393:31–39. https://doi.org/10.1016/s0140-6736(18)32590-x
699. Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. 
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in pa­
tients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular 
outcome trials. Lancet Diabetes Endocrinol 2019;7:776–785. https://doi.org/10.1016/ 
s2213-8587(19)30249-9
700. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. 
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 
2019;380:2295–2306. https://doi.org/10.1056/NEJMoa1811744
701. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, 
et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383: 
1436–1446. https://doi.org/10.1056/NEJMoa2024816


<!-- PAGE 102 -->

### Page 102

702. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. 
Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 
2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
703. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular 
and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383: 
1413–1424. https://doi.org/10.1056/NEJMoa2022190
704. Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empa­
gliflozin on worsening heart failure events in patients with heart failure and a preserved 
ejection fraction: the EMPEROR-preserved trial. Circulation 2021;144:1284–1294. 
https://doi.org/10.1161/circulationaha.121.056824
705. Ferrannini G, De Bacquer D, De Backer G, Kotseva K, Mellbin L, Wood D, et al. 
Screening for glucose perturbations and risk factor management in dysglycemic pa­
tients with coronary artery disease–a persistent challenge in need of substantial im­
provement: a report from ESC EORP EUROASPIRE V. Diabetes Care 2020;43: 
726–733. https://doi.org/10.2337/dc19-2165
706. Shahim B, De Bacquer D, De Backer G, Gyberg V, Kotseva K, Mellbin L, et al. The prog­
nostic value of fasting plasma glucose, two-hour postload glucose, and HbA(1c) in pa­
tients with coronary artery disease: a report from EUROASPIRE IV: a survey from the 
European Society of Cardiology. Diabetes Care 2017;40:1233–1240. https://doi.org/10. 
2337/dc17-0245
707. Ritsinger V, Tanoglidi E, Malmberg K, Näsman P, Rydén L, Tenerz Å, et al. Sustained 
prognostic implications of newly detected glucose abnormalities in patients with acute 
myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with 
Acute Myocardial Infarction cohort. Diab Vasc Dis Res 2015;12:23–32. https://doi.org/ 
10.1177/1479164114551746
708. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- 
and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute 
coronary events. Eur Heart J 2005;26:1255–1261. https://doi.org/10.1093/eurheartj/ 
ehi230
709. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, et al. 
U-shaped relationship of blood glucose with adverse outcomes among patients with 
ST-segment elevation myocardial infarction. J Am Coll Cardiol 2005;46:178–180. 
https://doi.org/10.1016/j.jacc.2005.03.052
710. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in 
older people: a meta-analysis of individual participant data from 28 randomised con­
trolled trials. Lancet 2019;393:407–415. https://doi.org/10.1016/s0140-6736(18) 
31942-1
711. Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, et al. Effect of 
simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary 
syndrome among patients 75 years or older: a secondary analysis of a randomized clin­
ical trial. JAMA Cardiol 2019;4:846–854. https://doi.org/10.1001/jamacardio.2019.2306
712. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. 
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. 
N Engl J Med 2012;367:1297–1309. https://doi.org/10.1056/NEJMoa1205512
713. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complica­
tions of cancer therapy: best practices in diagnosis, prevention, and management: Part 
2. J Am Coll Cardiol 2017;70:2552–2565. https://doi.org/10.1016/j.jacc.2017.09.1095
714. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020;17: 
503–522. https://doi.org/10.1038/s41569-020-0347-2
715. Long M, Ye Z, Zheng J, Chen W, Li L. Dual anti-platelet therapy following percutan­
eous coronary intervention in a population of patients with thrombocytopenia at 
baseline: a meta-analysis. BMC Pharmacol Toxicol 2020;21:31. https://doi.org/10.1186/ 
s40360-020-00409-2
716. Ambrosetti M, Abreu A, Corrà U, Davos CH, Hansen D, Frederix I, et al. Secondary 
prevention through comprehensive cardiovascular rehabilitation: from knowledge to 
implementation. 2020 update. A position paper from the Secondary Prevention and 
Rehabilitation Section of the European Association of Preventive Cardiology. Eur J 
Prev Cardiol 2020;28:460–495. https://doi.org/10.1177/2047487320913379
717. Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, et al. Standardization 
and quality improvement of secondary prevention through cardiovascular rehabilita­
tion programmes in Europe: the avenue towards EAPC accreditation programme: a 
position statement of the Secondary Prevention and Rehabilitation Section of the 
European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2020;28: 
496–509. https://doi.org/10.1177/2047487320924912
718. Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs: challenges for 
research and for patient care. J Am Coll Cardiol 2015;66:1273–1285. https://doi.org/10. 
1016/j.jacc.2015.07.018
719. Frederix I, Dendale P, Schmid JP. Who needs secondary prevention? Eur J Prev Cardiol 
2017;24:8–13. https://doi.org/10.1177/2047487317706112
720. Rea F, Ronco R, Pedretti RFE, Merlino L, Corrao G. Better adherence with 
out-of-hospital healthcare improved long-term prognosis of acute coronary syn­
dromes: evidence from an Italian real-world investigation. Int J Cardiol 2020;318: 
14–20. https://doi.org/10.1016/j.ijcard.2020.06.017
721. Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf MI, Hackbusch M, et al. 
Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease pa­
tients treated according to contemporary evidence based medicine: update of the 
Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol 2020;27: 
1756–1774. https://doi.org/10.1177/2047487320905719
722. Santiago de Araújo Pio C, Marzolini S, Pakosh M, Grace SL. Effect of cardiac rehabili­
tation dose on mortality and morbidity: a systematic review and meta-regression ana­
lysis. Mayo Clin Proc 2017;92:1644–1659. https://doi.org/10.1016/j.mayocp.2017.07. 
019
723. van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D. Lessons 
from contemporary trials of cardiovascular prevention and rehabilitation: a systematic 
review and meta-analysis. Int J Cardiol 2017;232:294–303. https://doi.org/10.1016/j. 
ijcard.2016.12.125
724. Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. 
Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database 
Syst Rev 2021;11:Cd001800. https://doi.org/10.1002/14651858.CD001800.pub4
725. Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, et al. 
Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database 
Syst Rev 2016;2016:CD001800. https://doi.org/10.1002/14651858.CD001800.pub3
726. Benzer W, Rauch B, Schmid JP, Zwisler AD, Dendale P, Davos CH, et al. 
Exercise-based cardiac rehabilitation in twelve European countries: results of the 
European cardiac rehabilitation registry. Int J Cardiol 2017;228:58–67. https://doi.org/ 
10.1016/j.ijcard.2016.11.059
727. Clark RA, Conway A, Poulsen V, Keech W, Tirimacco R, Tideman P. Alternative mod­
els of cardiac rehabilitation: a systematic review. Eur J Prev Cardiol 2015;22:35–74. 
https://doi.org/10.1177/2047487313501093
728. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Lifestyle 
and impact on cardiovascular risk factor control in coronary patients across 27 coun­
tries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V 
registry. 
Eur 
J 
Prev 
Cardiol 
2019;26:824–835. 
https://doi.org/10.1177/ 
2047487318825350
729. Frederix I, Vanhees L, Dendale P, Goetschalckx K. A review of telerehabilitation for 
cardiac patients. J Telemed Telecare 2015;21:45–53. https://doi.org/10.1177/ 
1357633x14562732
730. Conraads VM, Deaton C, Piotrowicz E, Santaularia N, Tierney S, Piepoli MF, et al. 
Adherence of heart failure patients to exercise: barriers and possible solutions: a pos­
ition statement of the Study Group on Exercise Training in Heart Failure of the Heart 
Failure Association of the European Society of Cardiology. Eur J Heart Fail 2012;14: 
451–458. https://doi.org/10.1093/eurjhf/hfs048
731. De Bacquer D, Astin F, Kotseva K, Pogosova N, De Smedt D, De Backer G, et al. Poor 
adherence to lifestyle recommendations in patients with coronary heart disease: re­
sults from the EUROASPIRE surveys. Eur J Prev Cardiol 2021;29:383–395. https://doi. 
org/10.1093/eurjpc/zwab115
732. Dalal HM, Taylor RS. Telehealth technologies could improve suboptimal rates of par­
ticipation in cardiac rehabilitation. Heart 2016;102:1155–1156. https://doi.org/10. 
1136/heartjnl-2016-309429
733. Lavie CJ, Arena R, Franklin BA. Cardiac rehabilitation and healthy life-style interven­
tions: rectifying program deficiencies to improve patient outcomes. J Am Coll Cardiol 
2016;67:13–15. https://doi.org/10.1016/j.jacc.2015.09.103
734. Fors A, Taft C, Ulin K, Ekman I. Person-centred care improves self-efficacy to control 
symptoms after acute coronary syndrome: a randomized controlled trial. Eur J 
Cardiovasc Nurs 2016;15:186–194. https://doi.org/10.1177/1474515115623437
735. Frederix I, Caiani EG, Dendale P, Anker S, Bax J, Böhm A, et al. ESC e-Cardiology 
Working Group Position Paper: overcoming challenges in digital health implementa­
tion in cardiovascular medicine. Eur J Prev Cardiol 2019;26:1166–1177. https://doi. 
org/10.1177/2047487319832394
736. Rosselló X, Stanbury M, Beeri R, Kirchhof P, Casadei B, Kotecha D. Digital learning and 
the future cardiologist. Eur Heart J 2019;40:499–501. https://doi.org/10.1093/ 
eurheartj/ehy884
737. Frederix I, Solmi F, Piepoli MF, Dendale P. Cardiac telerehabilitation: a novel cost- 
efficient care delivery strategy that can induce long-term health benefits. Eur J Prev 
Cardiol 2017;24:1708–1717. https://doi.org/10.1177/2047487317732274
738. Avila A, Claes J, Buys R, Azzawi M, Vanhees L, Cornelissen V. Home-based exercise 
with telemonitoring guidance in patients with coronary artery disease: does it improve 
long-term physical fitness? Eur J Prev Cardiol 2020;27:367–377. https://doi.org/10.1177/ 
2047487319892201
739. Claes J, Cornelissen V, McDermott C, Moyna N, Pattyn N, Cornelis N, et al. Feasibility, 
acceptability, and clinical effectiveness of a technology-enabled cardiac rehabilitation 
platform (physical activity toward health-I): randomized controlled trial. J Med 
Internet Res 2020;22:e14221. https://doi.org/10.2196/14221
740. Kraal JJ, Peek N, Van den Akker-Van Marle ME, Kemps HM. Effects of home-based 
training with telemonitoring guidance in low to moderate risk patients entering cardiac 
rehabilitation: short-term results of the FIT@Home study. Eur J Prev Cardiol 2014;21: 
26–31. https://doi.org/10.1177/2047487314552606
741. Maddison R, Rawstorn JC, Stewart RAH, Benatar J, Whittaker R, Rolleston A, et al. 
Effects and costs of real-time cardiac telerehabilitation: randomised controlled non- 
inferiority trial. Heart 2019;105:122–129. https://doi.org/10.1136/heartjnl-2018-


<!-- PAGE 103 -->

### Page 103

742. Scherrenberg M, Wilhelm M, Hansen D, Völler H, Cornelissen V, Frederix I, et al. The 
future is now: a call for action for cardiac telerehabilitation in the COVID-19 pandemic 
from the secondary prevention and rehabilitation section of the European Association 
of Preventive Cardiology. Eur J Prev Cardiol 2020;28:524–540. https://doi.org/10.1177/ 
2047487320939671
743. Huang K, Liu W, He D, Huang B, Xiao D, Peng Y, et al. Telehealth interventions versus 
center-based cardiac rehabilitation of coronary artery disease: a systematic review and 
meta-analysis. Eur J Prev Cardiol 2015;22:959–971. https://doi.org/10.1177/ 
2047487314561168
744. Wolf A, Vella R, Fors A. The impact of person-centred care on patients’ care experi­
ences in relation to educational level after acute coronary syndrome: secondary out­
come analysis of a randomised controlled trial. Eur J Cardiovasc Nurs 2019;18:299–308. 
https://doi.org/10.1177/1474515118821242
745. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: 
truth and consequences. Am J Med Sci 2016;351:387–399. https://doi.org/10.1016/j. 
amjms.2016.01.010
746. Arlt AD, Nestoriuc Y, Rief W. Why current drug adherence programs fail: addressing 
psychological risk factors of nonadherence. Curr Opin Psychiatry 2017;30:326–333. 
https://doi.org/10.1097/yco.0000000000000345
747. Easthall C, Taylor N, Bhattacharya D. Barriers to medication adherence in patients 
prescribed medicines for the prevention of cardiovascular disease: a conceptual frame­
work. Int J Pharm Pract 2019;27:223–231. https://doi.org/10.1111/ijpp.12491
748. Seabury SA, Dougherty JS, Sullivan J. Medication adherence as a measure of the quality 
of care provided by physicians. Am J Manag Care 2019;25:78–83.
749. Pedretti RFE, Hansen D, Ambrosetti M, Back M, Berger T, Ferreira MC, et al. How to 
optimize the adherence to a guideline-directed medical therapy in the secondary pre­
vention of cardiovascular diseases: a clinical consensus statement from the European 
Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2022;30:149–166. 
https://doi.org/10.1093/eurjpc/zwac204
750. Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, et al. A poly­
pill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 
2014;64:2071–2082. https://doi.org/10.1016/j.jacc.2014.08.021
751. Selak V, Webster R, Stepien S, Bullen C, Patel A, Thom S, et al. Reaching cardiovascular 
prevention guideline targets with a polypill-based approach: a meta-analysis of rando­
mised clinical trials. Heart 2019;105:42–48. https://doi.org/10.1136/heartjnl-2018- 
313108
752. Castellano JM, Fuster V, Jennings C, Prescott E, Bueno H. Role of the polypill for sec­
ondary prevention in ischaemic heart disease. Eur J Prev Cardiol 2017;24:44–51. https:// 
doi.org/10.1177/2047487317707324
753. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. 
Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387: 
967–977. https://doi.org/10.1056/NEJMoa2208275
754. Palmer MJ, Barnard S, Perel P, Free C. Mobile phone-based interventions for improving 
adherence to medication prescribed for the primary prevention of cardiovascular dis­
ease in adults. Cochrane Database Syst Rev 2018;6:CD012675. https://doi.org/10.1002/ 
14651858.CD012675.pub2
755. Guerriero C, Cairns J, Roberts I, Rodgers A, Whittaker R, Free C. The cost- 
effectiveness of smoking cessation support delivered by mobile phone text messaging: 
Txt2stop. Eur J Health Econ 2013;14:789–797. https://doi.org/10.1007/s10198-012- 
0424-5
756. Gandapur Y, Kianoush S, Kelli HM, Misra S, Urrea B, Blaha MJ, et al. The role of 
mHealth for improving medication adherence in patients with cardiovascular disease: 
a systematic review. Eur Heart J Qual Care Clin Outcomes 2016;2:237–244. https://doi. 
org/10.1093/ehjqcco/qcw018
757. Fortuna RJ, Nagel AK, Rocco TA, Legette-Sobers S, Quigley DD. Patient experience 
with care and its association with adherence to hypertension medications. Am J 
Hypertens 2018;31:340–345. https://doi.org/10.1093/ajh/hpx200
758. Keenan J. Improving adherence to medication for secondary cardiovascular disease 
prevention. 
Eur 
J 
Prev 
Cardiol 
2017;24:29–35. 
https://doi.org/10.1177/ 
2047487317708145
759. Geidl W, Schlesinger S, Mino E, Miranda L, Pfeifer K. Dose-response relationship be­
tween physical activity and mortality in adults with noncommunicable diseases: a sys­
tematic review and meta-analysis of prospective observational studies. Int J Behav Nutr 
Phys Act 2020;17:109. https://doi.org/10.1186/s12966-020-01007-5
760. Ekblom O, Ek A, Cider Å, Hambraeus K, Börjesson M. Increased physical activity post- 
myocardial infarction is related to reduced mortality: results from the SWEDEHEART 
registry. J Am Heart Assoc 2018;7:e010108. https://doi.org/10.1161/jaha.118.010108
761. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, Quintana-Navarro GM, Fuentes F, 
Garcia-Rios A, et al. Long-term secondary prevention of cardiovascular disease with 
a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled 
trial. Lancet 2022;399:1876–1885. https://doi.org/10.1016/s0140-6736(22)00122-2
762. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, 
traditional risk factors, and the rate of cardiovascular complications after myocardial 
infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779–785. 
https://doi.org/10.1161/01.cir.99.6.779
763. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in 
patients with coronary heart disease: a systematic review. JAMA 2003;290:86–97. 
https://doi.org/10.1001/jama.290.1.86
764. Chow CK, Jolly S, Rao-Melacini P, Fox KAA, Anand SS, Yusuf S. Association of diet, 
exercise, and smoking modification with risk of early cardiovascular events after acute 
coronary 
syndromes. 
Circulation 
2010;121:750–758. 
https://doi.org/10.1161/ 
circulationaha.109.891523
765. United States Public Health Service Office of the Surgeon General. Smoking Cessation: 
A Report of the Surgeon General. In: US Department of Health and Human Services; 
2020.
766. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA 
Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With 
Coronary Artery Disease: A Report of the American College of Cardiology/American 
Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/ 
AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/ 
AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients 
With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the 
Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for 
the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, 
and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and 
Management of Patients Undergoing Noncardiac Surgery. Circulation 2016;134: 
e123–e155. https://doi.org/10.1161/cir.0000000000000404
767. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking 
cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; 
2013:CD009329. https://doi.org/10.1002/14651858.CD009329.pub2
768. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for 
smoking cessation in hospitalized patients with acute coronary syndrome. Circulation 
2016;133:21–30. https://doi.org/10.1161/circulationaha.115.019634
769. Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ. Varenicline and adverse car­
diovascular events: a systematic review and meta-analysis of randomized controlled 
trials. J Am Heart Assoc 2016;5:e002849. https://doi.org/10.1161/jaha.115.002849
770. Windle SB, Dehghani P, Roy N, Old W, Grondin FR, Bata I, et al. Smoking abstinence 1 
year after acute coronary syndrome: follow-up from a randomized controlled trial of 
varenicline in patients admitted to hospital. CMAJ 2018;190:E347–E354. https://doi. 
org/10.1503/cmaj.170377
771. Kavousi M, Pisinger C, Barthelemy JC, De Smedt D, Koskinas K, Marques-Vidal P, et al. 
Electronic cigarettes and health with special focus on cardiovascular effects: position 
paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev 
Cardiol 2020;28:1552–1566. https://doi.org/10.1177/2047487320941993
772. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention 
of cardiovascular disease with a mediterranean diet supplemented with extra-virgin ol­
ive oil or nuts. N Engl J Med 2018;378:e34. https://doi.org/10.1056/NEJMoa1800389
773. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk 
thresholds for alcohol consumption: combined analysis of individual-participant data 
for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391: 
1513–1523. https://doi.org/10.1016/s0140-6736(18)30134-x
774. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association be­
tween alcohol and cardiovascular disease: Mendelian randomisation analysis based 
on individual participant data. BMJ 2014;349:g4164. https://doi.org/10.1136/bmj.g4164
775. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, et al. Conventional and gen­
etic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 
men and women in China. Lancet 2019;393:1831–1842. https://doi.org/10.1016/ 
s0140-6736(18)31772-0
776. Ekelund U, Tarp J, Steene-Johannessen J, Hansen BH, Jefferis B, Fagerland MW, et al. 
Dose-response associations between accelerometry measured physical activity and 
sedentary time and all cause mortality: systematic review and harmonised 
meta-analysis. BMJ 2019;366:l4570. https://doi.org/10.1136/bmj.l4570
777. Patterson R, McNamara E, Tainio M, de Sá TH, Smith AD, Sharp SJ, et al. Sedentary 
behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident 
type 2 diabetes: a systematic review and dose response meta-analysis. Eur J 
Epidemiol 2018;33:811–829. https://doi.org/10.1007/s10654-018-0380-1
778. WHO Guidelines Review Committee. WHO Guidelines on Physical Activity and 
Sedentary Behaviour. World Health Organization, 2020.
779. Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise 
intensity assessment and prescription in cardiovascular rehabilitation and beyond: why 
and how: a position statement from the Secondary Prevention and Rehabilitation 
Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 
2022;29:230–245. https://doi.org/10.1093/eurjpc/zwab007
780. De Schutter A, Kachur S, Lavie CJ, Menezes A, Shum KK, Bangalore S, et al. Cardiac 
rehabilitation fitness changes and subsequent survival. Eur Heart J Qual Care Clin 
Outcomes 2018;4:173–179. https://doi.org/10.1093/ehjqcco/qcy018
781. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for 
depression in patients with coronary artery disease. Cochrane Database Syst Rev 2011; 
2011:Cd008012. https://doi.org/10.1002/14651858.CD008012.pub3


<!-- PAGE 104 -->

### Page 104

782. Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P, et al. 
Psychological interventions for coronary heart disease: cochrane systematic review 
and meta-analysis. Eur J Prev Cardiol 2018;25:247–259. https://doi.org/10.1177/ 
2047487317739978
783. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ 
EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce car­
diovascular risk. Eur Heart J 2020;41:111–188. https://doi.org/10.1093/eurheartj/ 
ehz455
784. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. 
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence 
from genetic, epidemiologic, and clinical studies. A consensus statement from the 
European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38: 
2459–2472. https://doi.org/10.1093/eurheartj/ehx144
785. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. 
Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J 
Med 2017;376:1713–1722. https://doi.org/10.1056/NEJMoa1615664
786. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and 
cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379: 
2097–2107. https://doi.org/10.1056/NEJMoa1801174
787. Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, 
et al. Meta-analysis of time-related benefits of statin therapy in patients with acute cor­
onary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2014; 
113:1753–1764. https://doi.org/10.1016/j.amjcard.2014.02.034
788. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. 
Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 
2015;372:2387–2397. https://doi.org/10.1056/NEJMoa1410489
789. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. 
Evolocumab for early reduction of LDL cholesterol levels in patients with acute cor­
onary syndromes (EVOPACS). J Am Coll Cardiol 2019;74:2452–2462. https://doi.org/ 
10.1016/j.jacc.2019.08.010
790. Trankle CR, Wohlford G, Buckley LF, Kadariya D, Ravindra K, Markley R, et al. 
Alirocumab in acute myocardial infarction: results from the Virginia Commonwealth 
University Alirocumab Response Trial (VCU-AlirocRT). J Cardiovasc Pharmacol 2019; 
74:266–269. https://doi.org/10.1097/fjc.0000000000000706
791. Iannuzzo G, Gentile M, Bresciani A, Mallardo V, Di Lorenzo A, Merone P, et al. 
Inhibitors of protein convertase subtilisin/kexin 9 (PCSK9) and acute coronary syn­
drome (ACS): the state-of-the-art. J Clin Med 2021;10:1510. https://doi.org/10.3390/ 
jcm10071510
792. Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, et al. Effect of alirocumab 
added to high-intensity statin therapy on coronary atherosclerosis in patients with 
acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA 2022; 
327:1771–1781. https://doi.org/10.1001/jama.2022.5218
793. Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of evolo­
cumab on coronary plaque phenotype and burden in statin-treated patients following 
myocardial infarction. JACC Cardiovasc Imaging 2022;15:1308–1321. https://doi.org/10. 
1016/j.jcmg.2022.03.002
794. Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al. Low-density 
lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients 
and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J 2021;42: 
243–252. https://doi.org/10.1093/eurheartj/ehaa1011
795. Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, et al. Efficacy of 
evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: 
a prespecified secondary analysis from the FOURIER trial. JAMA Cardiol 2020;5: 
952–957. https://doi.org/10.1001/jamacardio.2020.0882
796. O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. 
Long-term evolocumab in patients with established atherosclerotic cardiovascular dis­
ease. Circulation 2022;146:1109–1119. https://doi.org/10.1161/circulationaha.122. 
061620
797. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. 
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J 
Med 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792
798. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β blockade after myocardial in­
farction: systematic review and meta regression analysis. BMJ 1999;318:1730–1737. 
https://doi.org/10.1136/bmj.318.7200.1730
799. Martínez-Milla J, Raposeiras-Roubín S, Pascual-Figal DA, Ibáñez B. Role of beta- 
blockers in cardiovascular disease in 2019. Rev Esp Cardiol (Engl Ed) 2019;72: 
844–852. https://doi.org/10.1016/j.rec.2019.04.014
800. Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, et al. Effect of 
oral β-blocker treatment on mortality in contemporary post-myocardial infarction pa­
tients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2019; 
5:12–20. https://doi.org/10.1093/ehjcvp/pvy034
801. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with 
left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357: 
1385–1390. https://doi.org/10.1016/s0140-6736(00)04560-8
802. Kim J, Kang D, Park H, Kang M, Park TK, Lee JM, et al. Long-term β-blocker therapy and 
clinical outcomes after acute myocardial infarction in patients without heart failure: 
nationwide cohort study. Eur Heart J 2020;41:3521–3529. https://doi.org/10.1093/ 
eurheartj/ehaa376
803. Raposeiras-Roubín S, Abu-Assi E, Redondo-Diéguez A, González-Ferreiro R, 
López-López A, Bouzas-Cruz N, et al. Prognostic benefit of beta-blockers after acute 
coronary syndrome with preserved systolic function. Still relevant today? Rev Esp 
Cardiol (Engl Ed) 2015;68:585–591. https://doi.org/10.1016/j.rec.2014.07.028
804. Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, et al. β-blockers and 
mortality after acute myocardial infarction in patients without heart failure or ventricu­
lar dysfunction. J Am Coll Cardiol 2017;69:2710–2720. https://doi.org/10.1016/j.jacc. 
2017.03.578
805. Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, et al. Long-term 
use of carvedilol in patients with ST-segment elevation myocardial infarction treated 
with primary percutaneous coronary intervention. PLoS One 2018;13:e0199347. 
https://doi.org/10.1371/journal.pone.0199347
806. Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabés JA, 
Sánchez PL, et al. Rationale and design of the pragmatic clinical trial tREatment with 
Beta-blockers after myOcardial infarction withOut reduced ejection fracTion 
(REBOOT). Eur Heart J Cardiovasc Pharmacother 2021;8:291–301. https://doi.org/10. 
1093/ehjcvp/pvab060
807. Munkhaugen J, Ruddox V, Halvorsen S, Dammen T, Fagerland MW, Hernæs KH, et al. 
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients 
without reduced left ventricular ejection fraction (BETAMI): rationale and design of 
a prospective, randomized, open, blinded end point study. Am Heart J 2019;208: 
37–46. https://doi.org/10.1016/j.ahj.2018.10.005
808. Kristensen AMD, Bovin A, Zwisler AD, Cerquira C, Torp-Pedersen C, Bøtker HE, et al. 
Design and rationale of the Danish trial of beta-blocker treatment after myocardial in­
farction without reduced ejection fraction: study protocol for a randomized con­
trolled trial. Trials 2020;21:415. https://doi.org/10.1186/s13063-020-4214-6
809. Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, et al. β blockers and mor­
tality after myocardial infarction in patients without heart failure: multicentre pro­
spective cohort study. BMJ 2016;354:i4801. https://doi.org/10.1136/bmj.i4801
810. Zeitouni M, Kerneis M, Lattuca B, Guedeney P, Cayla G, Collet JP, et al. Do patients 
need lifelong β-blockers after an uncomplicated myocardial infarction? Am J 
Cardiovasc Drugs 2019;19:431–438. https://doi.org/10.1007/s40256-019-00338-4
811. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral cap­
topril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with 
suspected acute myocardial infarction. Lancet 1995;345:669–685. https://doi.org/10. 
1016/S0140-6736(95)90865-X
812. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction 
and unstable angina: an overview. BMJ 1989;299:1187–1192. https://doi.org/10.1136/ 
bmj.299.6709.1187
813. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical 
trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left 
ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333: 
1670–1676. https://doi.org/10.1056/nejm199512213332503
814. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of cap­
topril on mortality and morbidity in patients with left ventricular dysfunction after 
myocardial infarction–results of the survival and ventricular enlargement trial. N Engl 
J Med 1992;327:669–677. https://doi.org/10.1056/nejm199209033271001
815. The AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors 
of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342: 
821–828. https://doi.org/10.1016/0140-6736(93)92693-N
816. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients 
with stable coronary artery disease: randomised, double-blind, placebo-controlled, 
multicentre trial (the EUROPA study). Lancet 2003;362:782–788. https://doi.org/10. 
1016/s0140-6736(03)14286-9
817. The Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, 
Pogue Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, 
ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 
145–153. https://doi.org/10.1056/nejm200001203420301
818. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibi­
tors in the early treatment of acute myocardial infarction: systematic overview of in­
dividual data from 100,000 patients in randomized trials. Circulation 1998;97: 
2202–2212. https://doi.org/10.1161/01.cir.97.22.2202
819. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. 
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, 
left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1906. https://doi. 
org/10.1056/NEJMoa032292
820. Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine 
activation on prognosis in severe congestive heart failure (follow-up of the 
CONSENSUS trial). Am J Cardiol 1990;66:D40–D45. https://doi.org/10.1016/0002- 
9149(90)90475-g
821. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme in­
hibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273: 
1450–1456. https://doi.org/10.1001/jama.1995.03520420066040
ESC Guidelines                                                                                                                                                                                          3823


<!-- PAGE 105 -->

### Page 105

### 822 Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM,

et al. Comparative effects of low and high doses of the angiotensin-converting enzyme 
inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 
100:2312–2318. https://doi.org/10.1161/01.cir.100.23.2312
823. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients 
with reduced left ventricular ejection fractions and congestive heart failure. N Engl J 
Med 1991;325:293–302. https://doi.org/10.1056/nejm199108013250501
824. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. 
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 
371:993–1004. https://doi.org/10.1056/NEJMoa1409077
825. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin 
receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med 2021;385: 
1845–1855. https://doi.org/10.1056/NEJMoa2104508
826. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a se­
lective aldosterone blocker, in patients with left ventricular dysfunction after myocar­
dial infarction. N Engl J Med 2003;348:1309–1321. https://doi.org/10.1056/ 
NEJMoa030207
827. Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, et al. Early 
eplerenone treatment in patients with acute ST-elevation myocardial infarction with­
out heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J 2014;35: 
2295–2302. https://doi.org/10.1093/eurheartj/ehu164
828. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond 
glycaemic control. Nat Rev Cardiol 2020;17:761–772. https://doi.org/10.1038/s41569- 
020-0406-8
829. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. 
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 
2017;377:644–657. https://doi.org/10.1056/NEJMoa1611925
830. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and 
cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357. https:// 
doi.org/10.1056/NEJMoa1812389
831. Nikolaus M, Massimo F, Katharina S, Dirk M-W, Ramzi AA, Manuel JA, et al. 2023 ESC 
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur 
Heart J 2023; https://doi.org/10.1093/eurheartj/ehad192
832. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in 
heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461. 
https://doi.org/10.1056/NEJMoa2107038
833. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. 
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl 
J Med 2022;387:1089–1098. https://doi.org/10.1056/NEJMoa2206286
834. von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. 
Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J 2022;43: 
4421–4432. https://doi.org/10.1093/eurheartj/ehac494
835. Harrington J, Udell JA, Jones WS, Anker SD, Bhatt DL, Petrie MC, et al. Empagliflozin in 
patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am 
Heart J 2022;253:86–98. https://doi.org/10.1016/j.ahj.2022.05.010
836. Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC, et al. Lansoprazole for the 
prevention of recurrences of ulcer complications from long-term low-dose aspirin use. 
N Engl J Med 2002;346:2033–2038. https://doi.org/10.1056/NEJMoa012877
837. Casado Arroyo R, Polo-Tomas M, Roncalés MP, Scheiman J, Lanas A. Lower GI bleed­
ing is more common than upper among patients on dual antiplatelet therapy: long- 
term follow-up of a cohort of patients commonly using PPI co-therapy. Heart 2012; 
98:718–723. https://doi.org/10.1136/heartjnl-2012-301632
838. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the 
proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics 
of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475–484. https://doi.org/10. 
1177/0091270008315310
839. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, et al. Impact of pro­
ton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 
101:714–719. https://doi.org/10.1160/TH08-12-0808
840. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of ome­
prazole on the antiplatelet action of clopidogrel associated with aspirin: the rando­
mized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll 
Cardiol 2008;51:256–260. https://doi.org/10.1016/j.jacc.2007.06.064
841. O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. 
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or with­
out a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374: 
989–997. https://doi.org/10.1016/s0140-6736(09)61525-7
842. Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association 
of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and tica­
grelor: insights from the platelet inhibition and patient outcomes trial. Circulation 
2012;125:978–986. https://doi.org/10.1161/circulationaha.111.032912
843. Yedlapati SH, Khan SU, Talluri S, Lone AN, Khan MZ, Khan MS, et al. Effects of influ­
enza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular 
disease: a systematic review and meta-analysis. J Am Heart Assoc 2021;10:e019636. 
https://doi.org/10.1161/jaha.120.019636
844. Liprandi ÁS, Liprandi MIS, Zaidel EJ, Aisenberg GM, Baranchuk A, Barbosa ECD, et al. 
Influenza vaccination for the prevention of cardiovascular disease in the Americas: con­
sensus document of the Inter-American Society of Cardiology and the World Heart 
Federation. Glob Heart 2021;16:55. https://doi.org/10.5334/gh.1069
845. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute cor­
onary syndromes and planned percutaneous coronary interventions (FLUVACS) 
study. Eur Heart J 2004;25:25–31. https://doi.org/10.1016/j.ehj.2003.10.018
846. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, 
Sukonthasarn A, et al. Influenza vaccination reduces cardiovascular events in patients 
with acute coronary syndrome. Eur Heart J 2011;32:1730–1735. https://doi.org/10. 
1093/eurheartj/ehr004
847. Fröbert O, Götberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al. 
Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo- 
controlled, multicenter trial. Circulation 2021;144:1476–1484. https://doi.org/10.1161/ 
circulationaha.121.057042
848. Chen Y, Zhang H, Chen Y, Li M, Luo W, Liu Y, et al. Colchicine may become a new 
cornerstone therapy for coronary artery disease: a meta-analysis of randomized con­
trolled trials. Clin Rheumatol 2022;41:1873–1887. https://doi.org/10.1007/s10067-022- 
06050-0
849. Razavi E, Ramezani A, Kazemi A, Attar A. Effect of treatment with colchicine after 
acute coronary syndrome on major cardiovascular events: a systematic review and 
meta-analysis of clinical trials. Cardiovasc Ther 2022;2022:8317011. https://doi.org/ 
10.1155/2022/8317011
850. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and 
safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381: 
2497–2505. https://doi.org/10.1056/NEJMoa1912388
851. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine 
in patients with chronic coronary disease. N Engl J Med 2020;383:1838–1847. https:// 
doi.org/10.1056/NEJMoa2021372
852. Opstal TSJ, Fiolet ATL, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, et al. 
Colchicine in patients with chronic coronary disease in relation to prior acute coron­
ary syndrome. J Am Coll Cardiol 2021;78:859–866. https://doi.org/10.1016/j.jacc.2021. 
06.037
853. Ji H, Fang L, Yuan L, Zhang Q. Effects of exercise-based cardiac rehabilitation in pa­
tients with acute coronary syndrome: a meta-analysis. Med Sci Monit 2019;25: 
5015–5027. https://doi.org/10.12659/msm.917362
854. Candelaria D, Randall S, Ladak L, Gallagher R. Health-related quality of life and 
exercise-based cardiac rehabilitation in contemporary acute coronary syndrome pa­
tients: a systematic review and meta-analysis. Qual Life Res 2020;29:579–592. https:// 
doi.org/10.1007/s11136-019-02338-y
855. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. The 
effects of a smoking cessation intervention on 14.5-year mortality: a randomized clin­
ical trial. Ann Intern Med 2005;142:233–239. https://doi.org/10.7326/0003-4819-142- 
4-200502150-00005
856. Becerra-Tomás N, Blanco Mejía S, Viguiliouk E, Khan T, Kendall CWC, Kahleova H, 
et al. Mediterranean diet, cardiovascular disease and mortality in diabetes: a systematic 
review and meta-analysis of prospective cohort studies and randomized clinical trials. 
Crit Rev Food Sci Nutr 2020;60:1207–1227. https://doi.org/10.1080/10408398.2019. 
1565281
857. Liu Y, Lee DC, Li Y, Zhu W, Zhang R, Sui X, et al. Associations of resistance exercise 
with cardiovascular disease morbidity and mortality. Med Sci Sports Exerc 2019;51: 
499–508. https://doi.org/10.1249/mss.0000000000001822
858. Saeidifard F, Medina-Inojosa JR, West CP, Olson TP, Somers VK, Bonikowske AR, et al. 
The association of resistance training with mortality: a systematic review and 
meta-analysis. Eur J Prev Cardiol 2019;26:1647–1665. https://doi.org/10.1177/ 
2047487319850718
859. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement 
therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018;5: 
CD000146. https://doi.org/10.1002/14651858.CD000146.pub5
860. Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N. Antidepressants 
for smoking cessation. Cochrane Database Syst Rev 2020;4:CD000031. https://doi.org/ 
10.1002/14651858.CD000031.pub5
861. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine recep­
tor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016;2016: 
CD006103. https://doi.org/10.1002/14651858.CD006103.pub7
862. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different 
doses, durations and modes of delivery of nicotine replacement therapy for smoking 
cessation. Cochrane Database Syst Rev 2019;4:CD013308. https://doi.org/10.1002/ 
14651858.Cd013308
863. Woolf KJ, Zabad MN, Post JM, McNitt S, Williams GC, Bisognano JD. Effect of nicotine 
replacement therapy on cardiovascular outcomes after acute coronary syndromes. 
Am J Cardiol 2012;110:968–970. https://doi.org/10.1016/j.amjcard.2012.05.028
864. Suissa K, Larivière J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety 
of smoking cessation interventions in patients with cardiovascular disease: a network 
meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10: 
e002458. https://doi.org/10.1161/circoutcomes.115.002458


<!-- PAGE 106 -->

### Page 106

865. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, et al. Early in­
tensive vs a delayed conservative simvastatin strategy in patients with acute coronary 
syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307–1316. https://doi.org/10. 
1001/jama.292.11.1307
866. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late 
benefits of high-dose atorvastatin in patients with acute coronary syndromes: results 
from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405–1410. https://doi.org/ 
10.1016/j.jacc.2005.03.077
867. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects 
of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the 
MIRACL study: a randomized controlled trial. JAMA 2001;285:1711–1718. https:// 
doi.org/10.1001/jama.285.13.1711
868. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and 
safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 
170,000 participants in 26 randomised trials. Lancet 2010;376:1670–1681. https:// 
doi.org/10.1016/s0140-6736(10)61350-5
869. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B. Efficacy and 
safety of LDL-lowering therapy among men and women: meta-analysis of individual 
data from 174,000 participants in 27 randomised trials. Lancet 2015;385: 
1397–1405. https://doi.org/10.1016/s0140-6736(14)61368-4
870. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a rando­
mised trial. Lancet 1999;353:9–13. https://doi.org/10.1016/S0140-6736(98)11181-9
871. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol 
on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658. https:// 
doi.org/10.1056/nejm200105313442201
872. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: 
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure 
(MERIT-HF). Lancet 1999;353:2001–2007. https://doi.org/10.1016/S0140-6736(99) 
04440-2
873. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then 
oral metoprolol in 45,852 patients with acute myocardial infarction: randomised 
placebo-controlled trial. Lancet 2005;366:1622–1632. https://doi.org/10.1016/s0140- 
6736(05)67661-1
874. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, et al. Clinical outcomes 
with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J 
Med 2014;127:939–953. https://doi.org/10.1016/j.amjmed.2014.05.032
875. Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, et al. Meta-analysis of relation 
between oral β-blocker therapy and outcomes in patients with acute myocardial in­
farction who underwent percutaneous coronary intervention. Am J Cardiol 2015; 
115:1529–1538. https://doi.org/10.1016/j.amjcard.2015.02.057
876. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of beta- 
blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol 2015;66: 
1431–1441. https://doi.org/10.1016/j.jacc.2015.07.047
877. Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, et al. β-blocker ther­
apy and cardiac events among patients with newly diagnosed coronary heart disease. J 
Am Coll Cardiol 2014;64:247–252. https://doi.org/10.1016/j.jacc.2014.04.042
878. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-blocker use 
and clinical outcomes in stable outpatients with and without coronary artery disease. 
JAMA 2012;308:1340–1349. https://doi.org/10.1001/jama.2012.12559
879. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on car­
diovascular and microvascular outcomes in people with diabetes mellitus: results of the 
HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–259. https://doi.org/ 
10.1016/S0140-6736(99)12323-7
880. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spir­
onolactone on morbidity and mortality in patients with severe heart failure. N Engl J 
Med 1999;341:709–717. https://doi.org/10.1056/nejm199909023411001
881. Hirpa M, Woreta T, Addis H, Kebede S. What matters to patients? A timely question 
for value-based care. PLoS One 2020;15:e0227845. https://doi.org/10.1371/journal. 
pone.0227845
882. Ebrahimi Z, Patel H, Wijk H, Ekman I, Olaya-Contreras P. A systematic review on im­
plementation of person-centered care interventions for older people in 
out-of-hospital settings. Geriatr Nurs 2021;42:213–224. https://doi.org/10.1016/j. 
gerinurse.2020.08.004
883. Gluyas H. Patient-centred care: improving healthcare outcomes. Nurs Stand 2015;30: 
50–57, quiz 59. https://doi.org/10.7748/ns.30.4.50.e10186
884. Kok MM, von Birgelen C. Involving the patient’s perspective and preferences concern­
ing coronary angiography and percutaneous coronary intervention. EuroIntervention 
2020;15:1228–1231. https://doi.org/10.4244/eijv15i14a221
885. Astin F, Stephenson J, Probyn J, Holt J, Marshall K, Conway D. Cardiologists’ and pa­
tients’ views about the informed consent process and their understanding of the an­
ticipated treatment benefits of coronary angioplasty: a survey study. Eur J Cardiovasc 
Nurs 2020;19:260–268. https://doi.org/10.1177/1474515119879050
886. Flynn D, Knoedler MA, Hess EP, Murad MH, Erwin PJ, Montori VM, et al. Engaging pa­
tients in health care decisions in the emergency department through shared decision- 
making: a systematic review. Acad Emerg Med 2012;19:959–967. https://doi.org/10. 
1111/j.1553-2712.2012.01414.x
887. Grant EV, Summapund J, Matlock DD, Vaughan Dickson V, Iqbal S, Patel S, et al. Patient 
and cardiologist perspectives on shared decision making in the treatment of older 
adults hospitalized for acute myocardial infarction. Med Decis Making 2020;40: 
279–288. https://doi.org/10.1177/0272989x20912293
888. Shah P, Thornton I, Turrin D, Hipskind JE. Informed consent. In: StatPearls. Treasure 
Island (FL): StatPearls Publishing, Copyright © 2022, StatPearls Publishing LLC, 2022.
889. Prochnow JA, Meiers SJ, Scheckel MM. Improving patient and caregiver new medica­
tion education using an innovative teach-back toolkit. J Nurs Care Qual 2019;34: 
101–106. https://doi.org/10.1097/ncq.0000000000000342
890. Klingbeil C, Gibson C. The Teach Back Project: a system-wide evidence based practice 
implementation. J Pediatr Nurs 2018;42:81–85. https://doi.org/10.1016/j.pedn.2018.06. 
002
891. Ha Dinh TT, Bonner A, Clark R, Ramsbotham J, Hines S. The effectiveness of the teach- 
back method on adherence and self-management in health education for people with 
chronic disease: a systematic review. JBI Database System Rev Implement Rep 2016;14: 
210–247. https://doi.org/10.11124/jbisrir-2016-2296
892. Dickert NW, Scicluna VM, Adeoye O, Angiolillo DJ, Blankenship JC, Devireddy CM, 
et al. Emergency consent: patients’ and surrogates’ perspectives on consent for clinical 
trials in acute stroke and myocardial infarction. J Am Heart Assoc 2019;8:e010905. 
https://doi.org/10.1161/jaha.118.010905
893. Dickert NW, Miller FG. Involving patients in enrolment decisions for acute myocardial 
infarction trials. BMJ 2015;351:h3791. https://doi.org/10.1136/bmj.h3791
894. Olsson A, Ring C, Josefsson J, Eriksson A, Rylance R, Fröbert O, et al. Patient experi­
ence of the informed consent process during acute myocardial infarction: a sub-study 
of the VALIDATE-SWEDEHEART trial. Trials 2020;21:246. https://doi.org/10.1186/ 
s13063-020-4147-0
895. El-Haddad C, Hegazi I, Hu W. Understanding patient expectations of health care: a 
qualitative study. J Patient Exp 2020;7:1724–1731. https://doi.org/10.1177/ 
2374373520921692
896. Scott JT, Thompson DR. Assessing the information needs of post-myocardial infarc­
tion patients: a systematic review. Patient Educ Couns 2003;50:167–177. https://doi. 
org/10.1016/s0738-3991(02)00126-x
897. Saczynski JS, McManus DD, Waring ME, Lessard D, Anatchkova MD, Gurwitz JH, et al. 
Change in cognitive function in the month after hospitalization for acute coronary syn­
dromes: findings from TRACE-CORE (Transition, Risks, and Actions in Coronary 
Events-Center for Outcomes Research and Education). Circ Cardiovasc Qual 
Outcomes 2017;10:e001669. https://doi.org/10.1161/circoutcomes.115.001669
898. Goldman JD, Harte FM. Transition of care to prevent recurrence after acute coronary 
syndrome: the critical role of the primary care provider and pharmacist. Postgrad Med 
2020;132:426–432. https://doi.org/10.1080/00325481.2020.1740512
899. Huriani E. Myocardial infarction patients’ learning needs: perceptions of patients, family 
members and nurses. Int J Nurs Sci 2019;6:294–299. https://doi.org/10.1016/j.ijnss. 
2019.05.001
900. Messerli AW, Deutsch C. Implementation of institutional discharge protocols and 
transition of care following acute coronary syndrome. Cardiovasc Revasc Med 2020; 
21:1180–1188. https://doi.org/10.1016/j.carrev.2020.02.013
901. Schiele F, Lemesle G, Angoulvant D, Krempf M, Kownator S, Cheggour S, et al. 
Proposal for a standardized discharge letter after hospital stay for acute myocardial 
infarction. Eur Heart J Acute Cardiovasc Care 2020;9:788–801. https://doi.org/10. 
1177/2048872619844444
902. Murphy B, Le Grande M, Alvarenga M, Worcester M, Jackson A. Anxiety and depres­
sion after a cardiac event: prevalence and predictors. Front Psychol 2019;10:3010. 
https://doi.org/10.3389/fpsyg.2019.03010
903. Ceccarini M, Manzoni GM, Castelnuovo G. Assessing depression in cardiac patients: 
what measures should be considered? Depress Res Treat 2014;2014:148256. https:// 
doi.org/10.1155/2014/148256
904. Moser DK. “The rust of life”: impact of anxiety on cardiac patients. Am J Crit Care 2007; 
16:361–369. https://doi.org/10.4037/ajcc2007.16.4.361
905. Turgeon RD, Koshman SL, Dong Y, Graham MM. P2Y12 inhibitor adherence trajec­
tories in patients with acute coronary syndrome undergoing percutaneous coronary 
intervention: prognostic implications. Eur Heart J 2022;43:2303–2313. https://doi. 
org/10.1093/eurheartj/ehac116
906. Poitras ME, Maltais ME, Bestard-Denommé L, Stewart M, Fortin M. What are the ef­
fective elements in patient-centered and multimorbidity care? A scoping review. BMC 
Health Serv Res 2018;18:446. https://doi.org/10.1186/s12913-018-3213-8
907. Hochhalter AK, Song J, Rush J, Sklar L, Stevens A. Making the Most of Your Healthcare 
intervention for older adults with multiple chronic illnesses. Patient Educ Couns 2010; 
81:207–213. https://doi.org/10.1016/j.pec.2010.01.018
908. Hess EP, Knoedler MA, Shah ND, Kline JA, Breslin M, Branda ME, et al. The chest pain 
choice decision aid: a randomized trial. Circ Cardiovasc Qual Outcomes 2012;5:251–259. 
https://doi.org/10.1161/circoutcomes.111.964791
909. Hess EP, Hollander JE, Schaffer JT, Kline JA, Torres CA, Diercks DB, et al. Shared de­
cision making in patients with low risk chest pain: prospective randomized pragmatic 
trial. BMJ 2016;355:i6165. https://doi.org/10.1136/bmj.i6165
910. van Oosterhout REM, de Boer AR, Maas A, Rutten FH, Bots ML, Peters SAE. Sex dif­
ferences in symptom presentation in acute coronary syndromes: a systematic review 
ESC Guidelines                                                                                                                                                                                          3825


<!-- PAGE 107 -->

### Page 107

and meta-analysis. J Am Heart Assoc 2020;9:e014733. https://doi.org/10.1161/jaha.119. 
014733
911. Hedegaard U, Kjeldsen LJ, Pottegård A, Henriksen JE, Lambrechtsen J, Hangaard J, et al. 
Improving medication adherence in patients with hypertension: a randomized trial. Am 
J Med 2015;128:1351–1361. https://doi.org/10.1016/j.amjmed.2015.08.011
912. Bauer LK, Caro MA, Beach SR, Mastromauro CA, Lenihan E, Januzzi JL, et al. Effects of 
depression and anxiety improvement on adherence to medication and health beha­
viors in recently hospitalized cardiac patients. Am J Cardiol 2012;109:1266–1271. 
https://doi.org/10.1016/j.amjcard.2011.12.017
913. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. 
Depression and the risk for cardiovascular diseases: systematic review and meta ana­
lysis. Int J Geriatr Psychiatry 2007;22:613–626. https://doi.org/10.1002/gps.1723
914. Redfors B, Angerås O, Råmunddal T, Petursson P, Haraldsson I, Dworeck C, et al. 
Trends in gender differences in cardiac care and outcome after acute myocardial in­
farction in Western Sweden: a report from the Swedish Web System for 
Enhancement of Evidence-Based Care in Heart Disease Evaluated According to 
Recommended Therapies (SWEDEHEART). J Am Heart Assoc 2015;4:e001995. 
https://doi.org/10.1161/jaha.115.001995
915. Anand SS, Xie CC, Mehta S, Franzosi MG, Joyner C, Chrolavicius S, et al. Differences in 
the management and prognosis of women and men who suffer from acute coronary 
syndromes. J Am Coll Cardiol 2005;46:1845–1851. https://doi.org/10.1016/j.jacc.2005. 
05.091
916. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al. 
Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute 
coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk 
Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early 
Implementation of the American College of Cardiology/American Heart Association 
Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005;45: 
832–837. https://doi.org/10.1016/j.jacc.2004.11.055
917. Bugiardini R, Yan AT, Yan RT, Fitchett D, Langer A, Manfrini O, et al. Factors influen­
cing underutilization of evidence-based therapies in women. Eur Heart J 2011;32: 
1337–1344. https://doi.org/10.1093/eurheartj/ehr027
918. Samayoa L, Grace SL, Gravely S, Scott LB, Marzolini S, Colella TJF. Sex differences in 
cardiac rehabilitation enrollment: a meta-analysis. Can J Cardiol 2014;30:793–800. 
https://doi.org/10.1016/j.cjca.2013.11.007
919. Rossello X, Mas-Lladó C, Pocock S, Vicent L, van de Werf F, Chin CT, et al. Sex differ­
ences in mortality after an acute coronary syndrome increase with lower country 
wealth and higher income inequality. Rev Esp Cardiol (Engl Ed) 2022;75:392–400. 
https://doi.org/10.1016/j.rec.2021.05.006
920. Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, 
elderly patients, and racial minorities in the randomized trials used for cardiovascular 
guidelines. JAMA Internal Medicine 2014;174:1868–1870. https://doi.org/10.1001/ 
jamainternmed.2014.4758
921. Cho L, Vest AR, O’Donoghue ML, Ogunniyi MO, Sarma AA, Denby KJ, et al. Increasing 
participation of women in cardiovascular trials. J Am College Cardiol 2021;78:737–751. 
https://doi.org/10.1016/j.jacc.2021.06.022
922. Gong IY, Tan NS, Ali SH, Lebovic G, Mamdani M, Goodman SG, et al. Temporal trends 
of women enrollment in major cardiovascular randomized clinical trials. Can J Cardiol 
2019;35:653–660. https://doi.org/10.1016/j.cjca.2019.01.010
923. Rossello X, Ferreira JP, Caimari F, Lamiral Z, Sharma A, Mehta C, et al. Influence of sex, 
age and race on coronary and heart failure events in patients with diabetes and post- 
acute coronary syndrome. Clin Res Cardiol 2021;110:1612–1624. https://doi.org/10. 
1007/s00392-021-01859-2
924. Mas-Llado C, González-Del-Hoyo M, Siquier-Padilla J, Blaya-Peña L, Coughlan JJ, García 
de la Villa B, et al. Representativeness in randomised clinical trials supporting acute cor­
onary syndrome guidelines. Eur Heart J Qual Care Clin Outcomes 2023. https://doi.org/ 
10.1093/ehjqcco/qcad007
925. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European Society of 
Cardiology methodology for the development of quality indicators for the quantifica­
tion of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes 2022;8: 
4–13. https://doi.org/10.1093/ehjqcco/qcaa069
926. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the United 
Kingdom after removal of financial incentives. N Engl J Med 2018;379:948–957. https:// 
doi.org/10.1056/NEJMsa1801495
927. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality 8 
years into global payment. N Engl J Med 2019;381:252–263. https://doi.org/10.1056/ 
NEJMsa1813621
928. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indicators 
for the care and outcomes of adults with atrial fibrillation. Europace 2021;23:494–495. 
https://doi.org/10.1093/europace/euaa253
929. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, et al. 2020 Update of the 
quality indicators for acute myocardial infarction: a position paper of the Association 
for Acute Cardiovascular Care: the study group for quality indicators from the ACVC 
and the NSTE-ACS guideline group. Eur Heart J Acute Cardiovasc Care 2021;10: 
224–233. https://doi.org/10.1093/ehjacc/zuaa037
930. Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomström-Lundqvist C, et al. 
European Society of Cardiology Quality Indicators for the care and outcomes of car­
diac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in 
collaboration with the European Heart Rhythm Association of the European Society 
of Cardiology. Europace 2022;24:165–172. https://doi.org/10.1093/europace/euab193
931. Aktaa S, Gencer B, Arbelo E, Davos CH, Désormais I, Hollander M, et al. European 
Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: devel­
oped by the Working Group for Cardiovascular Disease Prevention Quality Indicators 
in collaboration with the European Association for Preventive Cardiology of the 
European Society of Cardiology. Eur J Prev Cardiol 2022;29:1060–1071. https://doi. 
org/10.1093/eurjpc/zwab160
932. Schiele F, Gale CP, Simon T, Fox KAA, Bueno H, Lettino M, et al. The 2020 ESC-ACVC 
quality indicators for the management of acute myocardial infarction applied to the 
FAST-MI registries. Eur Heart J Acute Cardiovasc Care 2021;10:207–215. https://doi. 
org/10.1093/ehjacc/zuab010
933. Rossello X, Medina J, Pocock S, Van de Werf F, Chin CT, Danchin N, et al. Assessment 
of quality indicators for acute myocardial infarction management in 28 countries and 
use of composite quality indicators for benchmarking. Eur Heart J Acute Cardiovasc Care 
2020;9:911–922. https://doi.org/10.1177/2048872620911853
934. Rossello X, Massó-van Roessel A, Perelló-Bordoy A, Mas-Lladó C, Ramis-Barceló MF, 
Vives-Borrás M, et al. Assessment of the ESC quality indicators in patients with acute 
myocardial infarction: a systematic review. Eur Heart J Acute Cardiovasc Care 2021;10: 
878–889. https://doi.org/10.1093/ehjacc/zuab042
935. Batra G, Aktaa S, Wallentin L, Maggioni AP, Wilkinson C, Casadei B, et al. Methodology 
for the development of international clinical data standards for common cardiovascu­
lar conditions: European Unified Registries for Heart Care Evaluation and Randomised 
Trials (EuroHeart). Eur Heart J Qual Care Clin Outcomes 2021;9:161–168. https://doi. 
org/10.1093/ehjqcco/qcab052
936. Rossello X, Massó-van Roessel A, Chioncel O, Tavazzi L, Ferrari R, Vahanian A, et al. 
EURObservational Research Programme: a bibliometric assessment of its scientific 
output. Eur Heart J Qual Care Clin Outcomes 2022;8:804–811. https://doi.org/10. 
1093/ehjqcco/qcac041

<!-- 2023_CVD_Diabetes.md -->

# ESC Guidelines: CVD Diabetes (2023)

**Source**: `2023_CVD_Diabetes.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 98

---

## Table of Contents

- [2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes](#2023-esc-guidelines-for-the-management-of-cardiova) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 8)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. Central figure](#21-central-figure) *(p. 10)*
    - [2.2. What is new](#22-what-is-new) *(p. 11)*
  - [3. Diagnosis of diabetes](#3-diagnosis-of-diabetes) *(p. 15)*
    - [3.1. Laboratory criteria for diagnosing diabetes and pre-diabetes](#31-laboratory-criteria-for-diagnosing-diabetes-and) *(p. 15)*
      - [3.1.1. Fasting glucose](#311-fasting-glucose) *(p. 15)*
      - [3.1.2. Two-hour oral glucose tolerance test and random glucose](#312-two-hour-oral-glucose-tolerance-test-and-rando) *(p. 15)*
      - [3.1.3. Glycated haemoglobin](#313-glycated-haemoglobin) *(p. 16)*
    - [3.2. Classifying diabetes](#32-classifying-diabetes) *(p. 17)*
      - [3.2.1. Type 1 diabetes](#321-type-1-diabetes) *(p. 17)*
      - [3.2.2. Type 2 diabetes](#322-type-2-diabetes) *(p. 17)*
      - [3.2.3. Monogenic diabetes](#323-monogenic-diabetes) *(p. 17)*
      - [3.2.4. Secondary diabetes and stress hyperglycaemia](#324-secondary-diabetes-and-stress-hyperglycaemia) *(p. 17)*
      - [3.2.5. Gestational diabetes](#325-gestational-diabetes) *(p. 17)*
      - [3.2.6. Further sub-group classification of type 2 diabetes](#326-further-sub-group-classification-of-type-2-dia) *(p. 17)*
    - [3.3. Screening for diabetes](#33-screening-for-diabetes) *(p. 17)*
  - [4. Cardiovascular risk assessment in patients with type 2 diabetes](#4-cardiovascular-risk-assessment-in-patients-with-) *(p. 18)*
    - [4.1. Assessing cardiovascular risk in type 2 diabetes](#41-assessing-cardiovascular-risk-in-type-2-diabete) *(p. 18)*
      - [4.1.1. Cardiovascular risk categories in type 2 diabetes](#411-cardiovascular-risk-categories-in-type-2-diabe) *(p. 18)*
      - [4.1.2. SCORE2-Diabetes: estimating 10-year cardiovascular disease risk](#412-score2-diabetes:-estimating-10-year-cardiovasc) *(p. 18)*
  - [5. Cardiovascular risk reduction in patients with diabetes: targets and treatments](#5-cardiovascular-risk-reduction-in-patients-with-d) *(p. 19)*
    - [5.1. Lifestyle and diabetes](#51-lifestyle-and-diabetes) *(p. 19)*
      - [5.1.1. Weight reduction](#511-weight-reduction) *(p. 20)*
      - [5.1.2. Change in diet or nutrition](#512-change-in-diet-or-nutrition) *(p. 20)*
      - [5.1.3. Increasing physical activity and exercise](#513-increasing-physical-activity-and-exercise) *(p. 21)*
      - [5.1.4. Smoking cessation](#514-smoking-cessation) *(p. 21)*
    - [5.2. Glycaemic targets](#52-glycaemic-targets) *(p. 22)*
      - [5.2.1. Role of glycated haemoglobin](#521-role-of-glycated-haemoglobin) *(p. 22)*
      - [5.2.2. Additional glycaemic targets](#522-additional-glycaemic-targets) *(p. 22)*
      - [5.2.3. Glycaemic control following vascular events](#523-glycaemic-control-following-vascular-events) *(p. 22)*
    - [5.3. Atherosclerotic cardiovascular disease risk reduction by glucose-lowering medications in diabetes](#53-atherosclerotic-cardiovascular-disease-risk-red) *(p. 23)*
      - [5.3.1. Glucose-lowering medications with cardiovascular efficacy demonstrated in dedicated cardiovascular outcomes trials](#531-glucose-lowering-medications-with-cardiovascul) *(p. 23)*
        - [5.3.1.1. Sodium–glucose co-transporter-2 inhibitors](#5311-sodium–glucose-co-transporter-2-inhibitors) *(p. 23)*
        - [5.3.1.2. Glucagon-like peptide-1 receptor agonists](#5312-glucagon-like-peptide-1-receptor-agonists) *(p. 24)*
        - [5.3.1.3. Pioglitazone](#5313-pioglitazone) *(p. 26)*
      - [5.3.2. Glucose-lowering medications with cardiovascular safety but not incremental efficacy demonstrated in dedicated cardiovascular outcomes trials](#532-glucose-lowering-medications-with-cardiovascul) *(p. 26)*
        - [5.3.2.1. Dipeptidyl peptidase-4 inhibitors](#5321-dipeptidyl-peptidase-4-inhibitors) *(p. 26)*
        - [5.3.2.2. Lixisenatide and exenatide](#5322-lixisenatide-and-exenatide) *(p. 26)*
        - [5.3.2.3. Insulin](#5323-insulin) *(p. 26)*
        - [5.3.2.4. Glimepiride](#5324-glimepiride) *(p. 27)*
      - [5.3.3. Cardiovascular considerations of older glucose-lowering medications not tested in dedicated cardiovascular outcomes trials](#533-cardiovascular-considerations-of-older-glucose) *(p. 27)*
        - [5.3.3.1. Metformin](#5331-metformin) *(p. 27)*
        - [5.3.3.2. Sulphonylureas](#5332-sulphonylureas) *(p. 27)*
      - [5.3.4. Special considerations](#534-special-considerations) *(p. 27)*
        - [5.3.4.1. Hypoglycaemia and cardiovascular risk](#5341-hypoglycaemia-and-cardiovascular-risk) *(p. 27)*
        - [5.3.4.2. Effects on weight](#5342-effects-on-weight) *(p. 28)*
      - [5.3.5. Implications of results from cardiovascular outcomes trials of glucose-lowering medications](#535-implications-of-results-from-cardiovascular-ou) *(p. 28)*
    - [5.4. Blood pressure and diabetes](#54-blood-pressure-and-diabetes) *(p. 30)*
      - [5.4.1. Screening and diagnosis](#541-screening-and-diagnosis) *(p. 30)*
      - [5.4.2. Treatment targets](#542-treatment-targets) *(p. 30)*
      - [5.4.3. Management of hypertension](#543-management-of-hypertension) *(p. 31)*
        - [5.4.3.1. Effects of lifestyle intervention and weight loss](#5431-effects-of-lifestyle-intervention-and-weight-) *(p. 31)*
        - [5.4.3.2. Pharmacological treatments in patients with diabetes](#5432-pharmacological-treatments-in-patients-with-d) *(p. 32)*
        - [5.4.3.3. Blood pressure changes with glucose-lowering agents](#5433-blood-pressure-changes-with-glucose-lowering-) *(p. 32)*
      - [5.4.4. Sex-specific aspects](#544-sex-specific-aspects) *(p. 32)*
    - [5.5. Lipids and diabetes](#55-lipids-and-diabetes) *(p. 33)*
      - [5.5.1. Treatment targets](#551-treatment-targets) *(p. 33)*
      - [5.5.2. Lipid-lowering agents](#552-lipid-lowering-agents) *(p. 33)*
        - [5.5.2.1. Statins](#5521-statins) *(p. 33)*
        - [5.5.2.2. Ezetimibe](#5522-ezetimibe) *(p. 33)*
        - [5.5.2.3. Proprotein convertase subtilisin/kexin type 9 inhibitors](#5523-proprotein-convertase-subtilisin/kexin-type-9) *(p. 34)*
        - [5.5.2.4. Fibrates and other TG-lowering drugs](#5524-fibrates-and-other-tg-lowering-drugs) *(p. 34)*
      - [5.5.3. Novel cholesterol-lowering drugs](#553-novel-cholesterol-lowering-drugs) *(p. 34)*
        - [5.5.3.1. Inclisiran](#5531-inclisiran) *(p. 34)*
        - [5.5.3.2. Bempedoic acid](#5532-bempedoic-acid) *(p. 34)*
    - [5.6. Antithrombotic therapy and diabetes](#56-antithrombotic-therapy-and-diabetes) *(p. 35)*
      - [5.6.1. Patients without a history of symptomatic atherosclerotic cardiovascular disease or revascularization](#561-patients-without-a-history-of-symptomatic-athe) *(p. 35)*
      - [5.6.2. Patients with atherosclerotic cardiovascular disease and/or revascularization without an indication for long-term oral anticoagulation](#562-patients-with-atherosclerotic-cardiovascular-d) *(p. 36)*
        - [5.6.2.1. Chronic coronary syndromes](#5621-chronic-coronary-syndromes) *(p. 36)*
        - [5.6.2.2. Acute coronary syndrome](#5622-acute-coronary-syndrome) *(p. 37)*
          - [5.6.2.2.1. Peri-procedural management](#56221-peri-procedural-management) *(p. 37)*
          - [5.6.2.2.2. Post-procedural management](#56222-post-procedural-management) *(p. 37)*
          - [5.6.2.2.3. Prolonging DAPT post-ACS](#56223-prolonging-dapt-post-acs) *(p. 37)*
          - [5.6.2.2.4. Shortening or de-escalating DAPT post-ACS in diabetes](#56224-shortening-or-de-escalating-dapt-post-acs-in) *(p. 37)*
      - [5.6.3. Patients with atherosclerotic cardiovascular disease and/or revascularization requiring long-term oral anticoagulation](#563-patients-with-atherosclerotic-cardiovascular-d) *(p. 39)*
      - [5.6.4. Preventing gastrointestinal bleeding](#564-preventing-gastrointestinal-bleeding) *(p. 39)*
    - [5.7. Multifactorial approach to risk-factor management in diabetes](#57-multifactorial-approach-to-risk-factor-manageme) *(p. 40)*
  - [6. Management of coronary artery disease and diabetes](#6-management-of-coronary-artery-disease-and-diabet) *(p. 41)*
    - [6.1. Chronic coronary syndromes and diabetes](#61-chronic-coronary-syndromes-and-diabetes) *(p. 41)*
      - [6.1.1. Clinical presentation](#611-clinical-presentation) *(p. 41)*
      - [6.1.2. Screening and diagnosis](#612-screening-and-diagnosis) *(p. 41)*
      - [6.1.3. Management](#613-management) *(p. 42)*
        - [6.1.3.1. Pharmacotherapy](#6131-pharmacotherapy) *(p. 42)*
          - [6.1.3.1.1. Glucose-lowering medication](#61311-glucose-lowering-medication) *(p. 42)*
          - [6.1.3.1.2. Other medications](#61312-other-medications) *(p. 42)*
        - [6.1.3.2. Revascularization](#6132-revascularization) *(p. 42)*
    - [6.2. Acute coronary syndromes and diabetes](#62-acute-coronary-syndromes-and-diabetes) *(p. 42)*
      - [6.2.1. Clinical presentation and diagnosis](#621-clinical-presentation-and-diagnosis) *(p. 42)*
      - [6.2.2. Management](#622-management) *(p. 43)*
        - [6.2.2.1. Pharmacotherapy](#6221-pharmacotherapy) *(p. 43)*
        - [6.2.2.2. Glucose control in patients with acute coronary syndrome](#6222-glucose-control-in-patients-with-acute-corona) *(p. 43)*
        - [6.2.2.3. Reperfusion strategies in ST-elevation myocardial infarction](#6223-reperfusion-strategies-in-st-elevation-myocar) *(p. 43)*
        - [6.2.2.4. Optimal timing of invasive strategy in non-ST-elevation acute coronary syndrome](#6224-optimal-timing-of-invasive-strategy-in-non-st) *(p. 43)*
    - [6.3. Ischaemia with no obstructive coronary artery disease in diabetes](#63-ischaemia-with-no-obstructive-coronary-artery-d) *(p. 44)*
  - [7. Heart failure and diabetes](#7-heart-failure-and-diabetes) *(p. 44)*
    - [7.1. Definition and pathophysiology](#71-definition-and-pathophysiology) *(p. 44)*
    - [7.2. Epidemiology and prognosis](#72-epidemiology-and-prognosis) *(p. 44)*
    - [7.3. Screening and diagnosis](#73-screening-and-diagnosis) *(p. 45)*
    - [7.4. Treatment of heart failure in patients with diabetes](#74-treatment-of-heart-failure-in-patients-with-dia) *(p. 46)*
      - [7.4.1. Treatment of heart failure with reduced ejection fraction](#741-treatment-of-heart-failure-with-reduced-eject) *(p. 46)*
        - [7.4.1.1. Sodium–glucose co-transporter-2 inhibitors](#7411-sodium–glucose-co-transporter-2-inhibitors) *(p. 47)*
        - [7.4.1.2. Angiotensin receptor–neprilysin inhibitor and angiotensin-converting enzyme inhibitors](#7412-angiotensin-receptor–neprilysin-inhibitor-and) *(p. 47)*
        - [7.4.1.3. Mineralocorticoid receptor antagonists](#7413-mineralocorticoid-receptor-antagonists) *(p. 47)*
        - [7.4.1.4. Beta-blockers](#7414-beta-blockers) *(p. 47)*
        - [7.4.1.5. Angiotensin-II receptor blockers](#7415-angiotensin-ii-receptor-blockers) *(p. 47)*
        - [7.4.1.6. Ivabradine](#7416-ivabradine) *(p. 48)*
        - [7.4.1.7. Hydralazine and isosorbide dinitrate](#7417-hydralazine-and-isosorbide-dinitrate) *(p. 48)*
        - [7.4.1.8. Digoxin](#7418-digoxin) *(p. 48)*
        - [7.4.1.9. Diuretics](#7419-diuretics) *(p. 48)*
        - [7.4.1.10. Device therapy and surgery](#74110-device-therapy-and-surgery) *(p. 48)*
      - [7.4.2. Treatment of heart failure with mildly reduced ejection fraction](#742-treatment-of-heart-failure-with-mildly-reduced) *(p. 48)*
      - [7.4.3. Treatment of heart failure with preserved ejection fraction](#743-treatment-of-heart-failure-with-preserved-ejec) *(p. 49)*
    - [7.5. Safety profile of glucose-lowering agents in patients with heart failure and diabetes](#75-safety-profile-of-glucose-lowering-agents-in-pa) *(p. 49)*
      - [7.5.1. Sodium–glucose co-transporter-2 inhibitors](#751-sodium–glucose-co-transporter-2-inhibitors) *(p. 49)*
      - [7.5.2. Glucagon-like peptide-1 receptor agonists](#752-glucagon-like-peptide-1-receptor-agonists) *(p. 50)*
      - [7.5.3. Dipeptidyl peptidase-4 inhibitors](#753-dipeptidyl-peptidase-4-inhibitors) *(p. 51)*
      - [7.5.4. Insulin](#754-insulin) *(p. 51)*
      - [7.5.5. Metformin](#755-metformin) *(p. 51)*
      - [7.5.6. Sulphonylureas](#756-sulphonylureas) *(p. 51)*
      - [7.5.7. Thiazolidinediones](#757-thiazolidinediones) *(p. 51)*
      - [7.5.8. Special consideration: hypoglycaemia and risk of heart failure hospitalization](#758-special-consideration:-hypoglycaemia-and-risk-) *(p. 51)*
  - [8. Arrhythmias: atrial fibrillation, ventricular arrhythmias, and sudden cardiac death and diabetes](#8-arrhythmias:-atrial-fibrillation,-ventricular-ar) *(p. 54)*
    - [8.1. Atrial fibrillation and diabetes](#81-atrial-fibrillation-and-diabetes) *(p. 54)*
      - [8.1.1. Epidemiology of atrial fibrillation and its association with diabetes](#811-epidemiology-of-atrial-fibrillation-and-its-as) *(p. 54)*
      - [8.1.2. Screening and managing atrial fibrillation in patients with diabetes](#812-screening-and-managing-atrial-fibrillation-in-) *(p. 54)*
      - [8.1.3. Preventing stroke in patients with atrial fibrillation and diabetes](#813-preventing-stroke-in-patients-with-atrial-fibr) *(p. 56)*
    - [8.2. Ventricular arrhythmias and risk of sudden cardiac death and diabetes](#82-ventricular-arrhythmias-and-risk-of-sudden-card) *(p. 56)*
  - [9. Chronic kidney disease and diabetes](#9-chronic-kidney-disease-and-diabetes) *(p. 57)*
    - [9.1. Chronic kidney disease definitions, staging, and screening](#91-chronic-kidney-disease-definitions,-staging,-an) *(p. 57)*
    - [9.2. Management of cardiovascular disease risk and kidney failure in patients with chronic kidney disease and diabetes](#92-management-of-cardiovascular-disease-risk-and-k) *(p. 58)*
    - [9.3. Blood pressure and glycaemic control in patients with diabetes and chronic kidney disease](#93-blood-pressure-and-glycaemic-control-in-patient) *(p. 61)*
    - [9.4. Roles for antithrombotic therapy and invasive strategies in managing atherosclerotic cardiovascular disease in patients with diabetes and chronic kidney disease](#94-roles-for-antithrombotic-therapy-and-invasive-s) *(p. 61)*
  - [10. Aortic and peripheral arterial diseases and diabetes](#10-aortic-and-peripheral-arterial-diseases-and-dia) *(p. 62)*
    - [10.1. The impact of diabetes on peripheral atherosclerosis](#101-the-impact-of-diabetes-on-peripheral-atheroscl) *(p. 62)*
      - [10.1.1. Diabetes and lower-extremity artery disease](#1011-diabetes-and-lower-extremity-artery-disease) *(p. 62)*
      - [10.1.2. Diabetes and carotid artery disease](#1012-diabetes-and-carotid-artery-disease) *(p. 64)*
    - [10.2. Diabetes and aortic aneurysm](#102-diabetes-and-aortic-aneurysm) *(p. 64)*
  - [11. Type 1 diabetes and cardiovascular disease](#11-type-1-diabetes-and-cardiovascular-disease) *(p. 65)*
    - [11.1. Cardiovascular risk assessment in type 1 diabetes](#111-cardiovascular-risk-assessment-in-type-1-diabe) *(p. 65)*
    - [11.2. Managing cardiovascular risk](#112-managing-cardiovascular-risk) *(p. 65)*
      - [11.2.1. Exercise and lifestyle](#1121-exercise-and-lifestyle) *(p. 66)*
      - [11.2.2. Lipid lowering](#1122-lipid-lowering) *(p. 66)*
      - [11.2.3. Blood pressure](#1123-blood-pressure) *(p. 66)*
      - [11.2.4. Antiplatelet therapy](#1124-antiplatelet-therapy) *(p. 66)*
    - [11.3. Glucose-lowering agents beyond insulin](#113-glucose-lowering-agents-beyond-insulin) *(p. 66)*
    - [11.4. Renal protection in type 1 diabetes](#114-renal-protection-in-type-1-diabetes) *(p. 66)*
  - [12. Person-centred care](#12-person-centred-care) *(p. 66)*
  - [13. Practical guidance](#13-practical-guidance) *(p. 68)*
  - [14. Key messages](#14-key-messages) *(p. 68)*
  - [15. Gaps in evidence](#15-gaps-in-evidence) *(p. 69)*
  - [16. Sex differences](#16-sex-differences) *(p. 70)*
  - [17. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#17-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 71)*
  - [18. Quality indicators](#18-quality-indicators) *(p. 75)*
  - [19. Supplementary data](#19-supplementary-data) *(p. 75)*
  - [20. Data availability statement](#20-data-availability-statement) *(p. 75)*
  - [21. Author information](#21-author-information) *(p. 75)*
  - [Appendix](#appendix) *(p. 76)*
  - [Acknowledgements](#acknowledgements) *(p. 76)*
  - [References](#references) *(p. 77)*
  - [References](#references) *(p. 77)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2023 ESC Guidelines for the management of 
cardiovascular disease in patients with diabetes
Developed by the task force on the management of cardiovascular 
disease in patients with diabetes of the European Society of 
Cardiology (ESC)
Authors/Task Force Members: Nikolaus Marx  *†, (Chairperson) (Germany), 
Massimo Federici  *†, (Chairperson) (Italy), Katharina Schütt  
‡, (Task Force 
Co-ordinator) (Germany), Dirk Müller-Wieland  
‡, (Task Force Co-ordinator) 
(Germany), Ramzi A. Ajjan  
(United Kingdom), Manuel J. Antunes  
(Portugal), 
Ruxandra M. Christodorescu (Romania), Carolyn Crawford (United Kingdom), 
Emanuele Di Angelantonio  
(United Kingdom/Italy), Björn Eliasson  
(Sweden), 
Christine Espinola-Klein (Germany), Laurent Fauchier (France), Martin Halle  
(Germany), William G. Herrington  
(United Kingdom), 
Alexandra Kautzky-Willer  
(Austria), Ekaterini Lambrinou  
(Cyprus), 
Maciej Lesiak  
(Poland), Maddalena Lettino  
(Italy), Darren K. McGuire  
(United States of America), Wilfried Mullens (Belgium), Bianca Rocca  
(Italy), 
Naveed Sattar  
(United Kingdom), and ESC Scientific Document Group
* Corresponding authors: Nikolaus Marx, Department of Internal Medicine I, Cardiology, RWTH Aachen University, Aachen, Germany. Tel: +49 241 80-89300, E-mail: nmarx@ukaachen.de; 
and Massimo Federici, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, and Center for Atherosclerosis, Policlinico Tor Vergata, Rome, Italy. Tel: +39 06 
20902085, E-mail: federicm@uniroma2.it
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
and Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Hypertension.
Working Groups: Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Thrombosis.
Patient Forum  
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC 
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the 
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; 
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from 
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case 
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices at the time of prescription.
© The European Society of Cardiology 2023. All rights reserved. For permissions please e-mail: journals.permissions@oup.com.
https://doi.org/10.1093/eurheartj/ehad192
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Eva Prescott, (Clinical Practice Guidelines Review Co-ordinator) (Denmark), 
Francesco Cosentino, (Clinical Practice Guidelines Review Co-ordinator) (Sweden), Magdy Abdelhamid (Egypt), 
Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Riccardo Asteggiano (Italy), Iris Baumgartner 
(Switzerland), Sergio Buccheri (Sweden), Hector Bueno (Spain), Jelena Čelutkienė (Lithuania), Alaide Chieffo 
(Italy), Christina Christersson (Sweden), Andrew Coats (United Kingdom), Bernard Cosyns (Belgium), 
Martin Czerny (Germany), Christi Deaton (United Kingdom), Volkmar Falk (Germany), Brian A. Ference (United 
Kingdom), Gerasimos Filippatos (Greece), Miles Fisher (United Kingdom), Heikki Huikuri (Finland), Borja Ibanez 
(Spain), Tiny Jaarsma (Sweden), Stefan James (Sweden), Kamlesh Khunti (United Kingdom), Lars Køber 
(Denmark), Konstantinos C. Koskinas (Switzerland), Basil S. Lewis (Israel), Maja-Lisa Løchen (Norway), John 
William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), 
Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Gianfranco Parati (Italy), Agnes A. Pasquet 
(Belgium), Carlo Patrono (Italy), Steffen E. Petersen (United Kingdom), Massimo Francesco Piepoli (Italy), 
Amina Rakisheva (Kazakhstan), Xavier Rossello (Spain), Peter Rossing (Denmark), Lars Rydén (Sweden), 
Eberhard Standl (Germany), Lale Tokgozoglu (Türkiye), Rhian M. Touyz (Canada/United Kingdom), 
Frank Visseren (Netherlands), Massimo Volpe (Italy), Christiaan Vrints (Belgium), and Adam Witkowski (Poland)
All experts involved in the development of these guidelines have submitted declarations of interest. These have 
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The 
report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary documents that include background information and 
evidence tables.
Keywords 
Guidelines • Aortic and peripheral arterial diseases • Arrhythmias • Atrial fibrillation • Cardiovascular disease • 
Cardiovascular risk assessment • Chronic kidney disease • Coronary artery disease • Diabetes mellitus • Heart failure 
• Patient-centred care • Pharmacological treatment • Prevention • Risk factors
Table of contents
1. Preamble ................................................................................................................. 4050
2. Introduction .......................................................................................................... 4050
2.1. Central figure .............................................................................................. 4052
2.2. What is new ................................................................................................ 4053
3. Diagnosis of diabetes ......................................................................................... 4057
3.1. Laboratory criteria for diagnosing diabetes and pre-diabetes 4057
3.1.1. Fasting glucose .................................................................................... 4057
3.1.2. Two-hour oral glucose tolerance test and random 
glucose ................................................................................................................ 4057
3.1.3. Glycated haemoglobin ..................................................................... 4058
3.2. Classifying diabetes ................................................................................... 4059
3.2.1. Type 1 diabetes .................................................................................. 4059
3.2.2. Type 2 diabetes .................................................................................. 4059
3.2.3. Monogenic diabetes .......................................................................... 4059
3.2.4. Secondary diabetes and stress hyperglycaemia .................... 4059
3.2.5. Gestational diabetes ......................................................................... 4059
3.2.6. Further sub-group classification of type 2 diabetes ............ 4059
3.3. Screening for diabetes ............................................................................. 4059
4. Cardiovascular risk assessment in patients with type 2 diabetes .. 4060
4.1. Assessing cardiovascular risk in type 2 diabetes .......................... 4060
4.1.1. Cardiovascular risk categories in type 2 diabetes ................ 4060
4.1.2. SCORE2-Diabetes: estimating 10-year cardiovascular 
disease risk ........................................................................................................ 4060
5. Cardiovascular risk reduction in patients with diabetes: targets 
and treatments .......................................................................................................... 4061
5.1. Lifestyle and diabetes ............................................................................... 4061
5.1.1. Weight reduction .............................................................................. 4062
5.1.2. Change in diet or nutrition ........................................................... 4062
5.1.3. Increasing physical activity and exercise .................................. 4063
5.1.4. Smoking cessation ............................................................................. 4063
5.2. Glycaemic targets ...................................................................................... 4064
5.2.1. Role of glycated haemoglobin ...................................................... 4064
5.2.2. Additional glycaemic targets ......................................................... 4064
5.2.3. Glycaemic control following vascular events ......................... 4064
5.3. Atherosclerotic cardiovascular disease risk reduction by 
glucose-lowering medications in diabetes ............................................... 4065
5.3.1. Glucose-lowering medications with cardiovascular 
efficacy demonstrated in dedicated cardiovascular outcomes 
trials ..................................................................................................................... 4065
5.3.1.1. Sodium–glucose co-transporter-2 inhibitors ................ 4065
5.3.1.2. Glucagon-like peptide-1 receptor agonists .................... 4066
5.3.1.3. Pioglitazone .................................................................................. 4068
5.3.2. Glucose-lowering medications with cardiovascular safety 
but not incremental efficacy demonstrated in dedicated 
cardiovascular outcomes trials ................................................................. 4068
5.3.2.1. Dipeptidyl peptidase-4 inhibitors ....................................... 4068
5.3.2.2. Lixisenatide and exenatide .................................................... 4068
5.3.2.3. Insulin ............................................................................................. 4068
5.3.2.4. Glimepiride .................................................................................. 4069
5.3.3. Cardiovascular considerations of older glucose-lowering 
medications not tested in dedicated cardiovascular outcomes 
trials ..................................................................................................................... 4069


<!-- PAGE 3 -->

### Page 3

5.3.3.1. Metformin .................................................................................... 4069
5.3.3.2. Sulphonylureas ........................................................................... 4069
5.3.4. Special considerations ...................................................................... 4069
5.3.4.1. Hypoglycaemia and cardiovascular risk ........................... 4069
5.3.4.2. Effects on weight ....................................................................... 4070
5.3.5. Implications of results from cardiovascular outcomes 
trials of glucose-lowering medications .................................................. 4070
5.4. Blood pressure and diabetes ................................................................ 4072
5.4.1. Screening and diagnosis ................................................................... 4072
5.4.2. Treatment targets ............................................................................. 4072
5.4.3. Management of hypertension ....................................................... 4073
5.4.3.1. Effects of lifestyle intervention and weight loss ........... 4073
5.4.3.2. Pharmacological treatments in patients with diabetes 4074
5.4.3.3. Blood pressure changes with glucose-lowering agents 4074
5.4.4. Sex-specific aspects ........................................................................... 4074
5.5. Lipids and diabetes .................................................................................... 4075
5.5.1. Treatment targets ............................................................................. 4075
5.5.2. Lipid-lowering agents ....................................................................... 4075
5.5.2.1. Statins ............................................................................................. 4075
5.5.2.2. Ezetimibe ...................................................................................... 4075
5.5.2.3. Proprotein convertase subtilisin/kexin type 9 
inhibitors ....................................................................................................... 4076
5.5.2.4. Fibrates and other TG-lowering drugs ............................ 4076
5.5.3. Novel cholesterol-lowering drugs .............................................. 4076
5.5.3.1. Inclisiran ......................................................................................... 4076
5.5.3.2. Bempedoic acid .......................................................................... 4076
5.6. Antithrombotic therapy and diabetes .............................................. 4077
5.6.1. Patients without a history of symptomatic atherosclerotic 
cardiovascular disease or revascularization ........................................ 4077
5.6.2. Patients with atherosclerotic cardiovascular disease and/ 
or revascularization without an indication for long-term oral 
anticoagulation ................................................................................................ 4078
5.6.2.1. Chronic coronary syndromes .............................................. 4078
5.6.2.2. Acute coronary syndrome .................................................... 4079
5.6.2.2.1. Peri-procedural management ...................................... 4079
5.6.2.2.2. Post-procedural management ..................................... 4079
5.6.2.2.3. Prolonging DAPT post-ACS ........................................ 4079
5.6.2.2.4. Shortening or de-escalating DAPT post-ACS in 
diabetes .................................................................................................... 4079
5.6.3. Patients with atherosclerotic cardiovascular disease 
and/or revascularization requiring long-term  
oral anticoagulation ....................................................................................... 4081
5.6.4. Preventing gastrointestinal bleeding .......................................... 4081
5.7. Multifactorial approach to risk-factor management in diabetes 4082
6. Management of coronary artery disease and diabetes ....................... 4083
6.1. Chronic coronary syndromes and diabetes .................................. 4083
6.1.1. Clinical presentation ......................................................................... 4083
6.1.2. Screening and diagnosis ................................................................... 4083
6.1.3. Management ......................................................................................... 4084
6.1.3.1. Pharmacotherapy ...................................................................... 4084
6.1.3.1.1. Glucose-lowering medication ..................................... 4084
6.1.3.1.2. Other medications ........................................................... 4084
6.1.3.2. Revascularization ....................................................................... 4084
6.2. Acute coronary syndromes and diabetes ....................................... 4084
6.2.1. Clinical presentation and diagnosis ............................................ 4084
6.2.2. Management ......................................................................................... 4085
6.2.2.1. Pharmacotherapy ...................................................................... 4085
6.2.2.2. Glucose control in patients with acute coronary 
syndrome ...................................................................................................... 4085
6.2.2.3. Reperfusion strategies in ST-elevation myocardial 
infarction ....................................................................................................... 4085
6.2.2.4. Optimal timing of invasive strategy in non-ST- 
elevation acute coronary syndrome ................................................. 4085
6.3. Ischaemia with no obstructive coronary artery disease in 
diabetes .................................................................................................................. 4086
7. Heart failure and diabetes ............................................................................... 4086
7.1. Definition and pathophysiology .......................................................... 4086
7.2. Epidemiology and prognosis ................................................................. 4086
7.3. Screening and diagnosis .......................................................................... 4087
7.4. Treatment of heart failure in patients with diabetes ................. 4088
7.4.1. Treatment of heart failure with reduced  
ejection fraction .............................................................................................. 4088
7.4.1.1. Sodium–glucose co-transporter-2 inhibitors ................ 4089
7.4.1.2. Angiotensin receptor–neprilysin inhibitor and 
angiotensin-converting enzyme inhibitors ...................................... 4089
7.4.1.3. Mineralocorticoid receptor antagonists .......................... 4089
7.4.1.4. Beta-blockers .............................................................................. 4089
7.4.1.5. Angiotensin-II receptor blockers ........................................ 4089
7.4.1.6. Ivabradine ..................................................................................... 4090
7.4.1.7. Hydralazine and isosorbide dinitrate ................................ 4090
7.4.1.8. Digoxin .......................................................................................... 4090
7.4.1.9. Diuretics ........................................................................................ 4090
7.4.1.10. Device therapy and surgery ............................................... 4090
7.4.2. Treatment of heart failure with mildly reduced ejection 
fraction ............................................................................................................... 4090
7.4.3. Treatment of heart failure with preserved ejection 
fraction ............................................................................................................... 4091
7.5. Safety profile of glucose-lowering agents in patients with 
heart failure and diabetes ............................................................................... 4091
7.5.1. Sodium–glucose co-transporter-2 inhibitors ......................... 4091
7.5.2. Glucagon-like peptide-1 receptor agonists ............................ 4092
7.5.3. Dipeptidyl peptidase-4 inhibitors ................................................ 4093
7.5.4. Insulin ...................................................................................................... 4093
7.5.5. Metformin ............................................................................................. 4093
7.5.6. Sulphonylureas .................................................................................... 4093
7.5.7. Thiazolidinediones ............................................................................. 4093
7.5.8. Special consideration: hypoglycaemia and risk of heart 
failure hospitalization .................................................................................... 4093
8. Arrhythmias: atrial fibrillation, ventricular arrhythmias, and sudden 
cardiac death and diabetes ................................................................................... 4096
8.1. Atrial fibrillation and diabetes .............................................................. 4096
8.1.1. Epidemiology of atrial fibrillation and its association with 
diabetes .............................................................................................................. 4096
8.1.2. Screening and managing atrial fibrillation in patients with 
diabetes .............................................................................................................. 4096
8.1.3. Preventing stroke in patients with atrial fibrillation and 
diabetes .............................................................................................................. 4098
8.2. Ventricular arrhythmias and risk of sudden cardiac death and 
diabetes .................................................................................................................. 4098
9. Chronic kidney disease and diabetes ......................................................... 4099
9.1. Chronic kidney disease definitions, staging, and screening ...... 4099
9.2. Management of cardiovascular disease risk and kidney failure 
in patients with chronic kidney disease and diabetes ......................... 4100
9.3. Blood pressure and glycaemic control in patients with 
diabetes and chronic kidney disease .......................................................... 4103
9.4. Roles for antithrombotic therapy and invasive strategies in 
managing atherosclerotic cardiovascular disease in patients with 
diabetes and chronic kidney disease .......................................................... 4103
ESC Guidelines                                                                                                                                                                                          4045


<!-- PAGE 4 -->

### Page 4

10. Aortic and peripheral arterial diseases and diabetes ........................ 4104
10.1. The impact of diabetes on peripheral atherosclerosis ........... 4104
10.1.1. Diabetes and lower-extremity artery disease .................... 4104
10.1.2. Diabetes and carotid artery disease ....................................... 4106
10.2. Diabetes and aortic aneurysm .......................................................... 4106
11. Type 1 diabetes and cardiovascular disease ......................................... 4107
11.1. Cardiovascular risk assessment in type 1 diabetes .................. 4107
11.2. Managing cardiovascular risk .............................................................. 4107
11.2.1. Exercise and lifestyle ...................................................................... 4108
11.2.2. Lipid lowering ................................................................................... 4108
11.2.3. Blood pressure ................................................................................. 4108
11.2.4. Antiplatelet therapy ....................................................................... 4108
11.3. Glucose-lowering agents beyond insulin ...................................... 4108
11.4. Renal protection in type 1 diabetes ............................................... 4108
12. Person-centred care ....................................................................................... 4108
13. Practical guidance ............................................................................................. 4110
14. Key messages ..................................................................................................... 4110
15. Gaps in evidence ............................................................................................... 4111
16. Sex differences .................................................................................................. 4112
17. ‘What to do’ and ‘What not to do’ messages from the Guidelines 4113
18. Quality indicators ............................................................................................. 4117
19. Supplementary data ......................................................................................... 4117
20. Data availability statement ............................................................................ 4117
21. Author information ......................................................................................... 4117
22. Appendix .............................................................................................................. 4118
23. Acknowledgements ......................................................................................... 4118
24. References ........................................................................................................... 4119
Tables of Recommendations
Recommendation Table 1 — Recommendations for diagnosing 
diabetes ........................................................................................................................ 4060
Recommendation Table 2 — Recommendations for assessing 
cardiovascular risk in patients with type 2 diabetes ................................. 4061
Recommendation Table 3 — Recommendations for reducing 
weight in patients with type 2 diabetes with or without 
cardiovascular disease ............................................................................................ 4062
Recommendation Table 4 — Recommendations for nutrition in 
patients with type 2 diabetes with or without cardiovascular disease 4063
Recommendation Table 5 — Recommendations for physical 
activity/exercise in patients with type 2 diabetes with or without 
cardiovascular disease ............................................................................................ 4063
Recommendation Table 6 — Recommendations for smoking 
cessation in patients with type 2 diabetes with or without 
cardiovascular disease ............................................................................................ 4064
Recommendation Table 7 — Recommendations for glycaemic 
targets in patients with diabetes ........................................................................ 4064
Recommendation Table 8 — Recommendations for 
glucose-lowering treatment for patients with type 2 diabetes and 
atherosclerotic cardiovascular disease to reduce cardiovascular risk 4072
Recommendation Table 9 — Recommendation for 
glucose-lowering treatment for patients with type 2 diabetes 
without atherosclerotic cardiovascular disease or severe 
target-organ damage to reduce cardiovascular risk .................................. 4072
Recommendation Table 10 — Recommendations for blood 
pressure management in patients with diabetes ........................................ 4074
Recommendation Table 11 — Recommendations for the 
management of dyslipidaemia in patients with diabetes ......................... 4076
Recommendation Table 12 — Recommendations for patients with 
diabetes without a history of symptomatic atherosclerotic 
cardiovascular disease or revascularization ............................................................. 4077
Recommendation Table 13 — Recommendations for 
antithrombotic therapy in patients with diabetes and acute or 
chronic coronary syndrome without indications for long-term oral 
anticoagulation .......................................................................................................... 4080
Recommendation Table 14 — Recommendations for 
antithrombotic therapy in patients with diabetes and acute or 
chronic coronary syndrome and/or post-percutaneous coronary 
intervention requiring long-term oral anticoagulation ............................. 4081
Recommendation Table 15 — Recommendations for gastric 
protection in patients with diabetes taking antithrombotic drugs ..... 4081
Recommendation Table 16 — Recommendations for a 
multifactorial approach in patients with type 2 diabetes with and 
without cardiovascular disease ........................................................................... 4082
Recommendation Table 17 — Recommendations for 
revascularization in patients with diabetes ................................................... 4084
Recommendation Table 18 — Recommendations for glycaemic 
control in patients with diabetes and acute coronary syndrome ....... 4085
Recommendation Table 19 — Recommendations for heart failure 
screening and diagnosis in patients with diabetes ...................................... 4088
Recommendation Table 20 — Recommendations for heart failure 
treatments in patients with heart failure with reduced ejection 
fraction and diabetes .............................................................................................. 4090
Recommendation Table 21 — Recommendations for heart failure 
treatments in patients with diabetes and left ventricular ejection 
fraction over 40% .................................................................................................... 4091
Recommendation Table 22 — Recommendations for 
glucose-lowering medications in patients with type 2 diabetes with 
and without heart failure ...................................................................................... 4094
Recommendation Table 23 — Recommendations for atrial 
fibrillation in patients with diabetes ................................................................. 4098
Recommendation Table 24 — Recommendations for patients with 
chronic kidney disease and diabetes ................................................................ 4103
Recommendation Table 25 — Recommendations for peripheral 
arterial and aortic diseases in patients with diabetes ............................... 4106
Recommendation Table 26 — Recommendations for patients with 
type 1 diabetes .......................................................................................................... 4108
Recommendation Table 27 — Recommendations for 
person-centred care in diabetes ........................................................................ 4110
List of tables
Table 1 Classes of recommendations ............................................................. 4051
Table 2 Levels of evidence ................................................................................... 4051
Table 3 New recommendations ....................................................................... 4053
Table 4 Revised recommendations .................................................................. 4056
Table 5 Revised concepts 2023 Guidelines .................................................. 4057
Table 6 Biochemical diagnostic criteria for diabetes and pre-diabetes 
according to the World Health Organization and the American 
Diabetes Association .............................................................................................. 4058
Table 7 Cardiovascular risk categories in type 2 diabetes ..................... 4060
Table 8 Blood pressure measurement ........................................................... 4073
Table 9 Heart failure phenotypes according to ejection fraction 
distribution .................................................................................................................. 4086
Table 10 Risk factors for developing heart failure in patients with 
diabetes ........................................................................................................................ 4086
Table 11 KDIGO staging by glomerular filtration rate 
and urinary albumin-to-creatinine ratio categories with


<!-- PAGE 5 -->

### Page 5

colour chart for risk of initiation of maintenance kidney replacement 
therapy .......................................................................................................................... 4099
Table 12 ‘What to do’ and ‘What not to do’ ............................................. 4113
List of figures
Figure 1 Management of cardiovascular disease in patients with type 
2 diabetes: clinical approach and key recommendations ........................ 4052
Figure 2 Diagnosis of diabetes and pre-diabetes ........................................ 4058
Figure 3 Cardiovascular risk categories in patients with type 2 
diabetes ........................................................................................................................ 4061
Figure 4 Simple guide to glycaemic targets in patients with type 2 
diabetes and cardiovascular disease ................................................................. 4065
Figure 5 Meta-analysis of cardiovascular outcomes trial results of 
sodium–glucose co-transporter-2 inhibitors among patients with 
type 2 diabetes with or at high risk for atherosclerotic cardiovascular 
disease ........................................................................................................................... 4066
Figure 6 Meta-analysis of cardiovascular outcomes trials with 
glucagon-like peptide-1 receptor agonists (sensitivity analysis 
removing ELIXA). Risk of major adverse cardiovascular events and 
its components ......................................................................................................... 4067
Figure 7 Glucose-lowering treatment for patients with type 2 
diabetes to reduce cardiovascular risk based on the presence of 
atherosclerotic cardiovascular disease/severe target-organ damage 
and 10-year cardiovascular disease risk estimation via 
SCORE2-Diabetes ................................................................................................... 4070
Figure 8 Glucose-lowering treatment for patients with type 2 
diabetes and atherosclerotic cardiovascular disease to reduce 
cardiovascular risk .................................................................................................... 4071
Figure 9 Screening and diagnosis of hypertension in patients with 
diabetes ........................................................................................................................ 4073
Figure 10 Recommended low-density lipoprotein-cholesterol 
targets by cardiovascular risk categories in patients with type 2 
diabetes ........................................................................................................................ 4075
Figure 11 Mechanisms contributing to altered platelet activation and 
atherothrombosis in patients with diabetes ................................................. 4078
Figure 12 Recommendations for antiplatelet therapy in patients with 
diabetes with acute or chronic coronary syndrome undergoing 
percutaneous coronary intervention or coronary artery bypass 
grafting without indications for long-term oral anticoagulation .......... 4080
Figure 13 Assessment of lifestyle risk-factor components and 
stepwise lifestyle recommendations in patients with diabetes ............ 4083
Figure 14 Diagnostic algorithm for heart failure in patients with 
diabetes ........................................................................................................................ 4087
Figure 15 Absolute risk reduction with sodium–glucose 
co-transporter-2 inhibitors in relation to patient risk based on rate 
of heart failure-related endpoints in the placebo arm of the 
respective trials ......................................................................................................... 4092
Figure 16 Glucose-lowering treatment of patients with heart failure 
and type 2 diabetes ................................................................................................. 4095
Figure 17 Screening for atrial fibrillation in patients with diabetes .... 4097
Figure 18 Pharmacological management to reduce cardiovascular or 
kidney failure risk in patients with type 2 diabetes and chronic kidney 
disease ........................................................................................................................... 4101
Figure 19 Absolute benefits and harms of sodium–glucose 
co-transporter-2 inhibitors in patients with and without diabetes .... 4102
Figure 20 Screening for and managing lower-extremity artery 
disease in patients with diabetes ....................................................................... 4105
Figure 21 Person-centred care approach for patients with diabetes 
with or without cardiovascular disease .......................................................... 4109
Abbreviations and acronyms
2hPG
2 h plasma glucose
ABI
Ankle–brachial index
ABPM
Ambulatory blood pressure monitoring
ACCORD
Action to Control Cardiovascular Risk in 
Diabetes
ACE-I
Angiotensin-converting enzyme inhibitor
ACS
Acute coronary syndrome
ADA
American Diabetes Association
ADAPTABLE
Aspirin Dosing: A Patient-Centric Trial Assessing 
Benefits and Long-term
ADDITION
Anglo-Danish-Dutch Study of Intensive 
Treatment In People with Screen Detected 
Diabetes in Primary Care
ADJUNCT ONE
The Efficacy and Safety of Liraglutide as Adjunct 
Therapy to Insulin in the Treatment of Type 1 
Diabetes
ADVANCE
Action in Diabetes and Vascular Disease: 
Preterax and Diamicron MR Controlled 
Evaluation
AF
Atrial fibrillation
ARB
Angiotensin-II receptor blocker
ARNI
Angiotensin receptor–neprilysin inhibitor
ARR
Absolute risk reduction
ASA
Acetylsalicylic acid
ASCEND
A Study of Cardiovascular Events iN  
Diabetes
ASCVD
Atherosclerotic cardiovascular disease
ATTACK
Aspirin to Target Arterial Events in Chronic 
Kidney Disease b.i.d.
Twice a day b.p.m.
Beats per minute
BANTING
Evaluation of Evolocumab Efficacy in Diabetic 
Adults With Hypercholesterolemia/Mixed 
Dyslipidemia
BARC
Bleeding Academic Research Consortium
BARI 2D
Bypass Angioplasty Revascularization 
Investigation 2 Diabetes
BERSON
Safety and Efficacy of Evolocumab in 
Combination With Statin Therapy in Adults 
With Diabetes and Hyperlipidemia or Mixed 
Dyslipidemia
BMI
Body mass index
BNP
B-type natriuretic peptide
BP
Blood pressure
CABG
Coronary artery bypass graft
CAC
Coronary artery calcium
CAD
Coronary artery disease
CANVAS
Canagliflozin Cardiovascular Assessment  
Study
CARMELINA
Cardiovascular and Renal Microvascular 
Outcome Study With Linagliptin in Patients 
With Type 2 Diabetes Mellitus
CAROLINA
Cardiovascular Outcome Study of Linagliptin 
Versus Glimepiride in Patients With Type 2 
Diabetes
CCB
Calcium channel blocker
CCS
Chronic coronary syndrome
CGM
Continuous glucose monitoring
ESC Guidelines                                                                                                                                                                                          4047


<!-- PAGE 6 -->

### Page 6

CHA2DS2-VASc
Congestive heart failure, Hypertension, Age ≥75 
years (2 points), Diabetes mellitus, Stroke or 
transient ischaemic attack (2 points), Vascular 
disease, Age 65–74 years, Sex category (female)
CHAP
Chronic Hypertension and Pregnancy
CHD
Coronary heart disease
CI
Confidence interval
CKD
Chronic kidney disease
CKD-EPI
Chronic kidney disease epidemiology/CKD 
Epidemiology Collaboration
CKD-MBD
Chronic kidney disease–mineral bone disorder
CLEAR
Cholesterol Lowering via Bempedoic Acid, an 
ACL-Inhibiting Regimen
CLTI
Chronic limb-threatening ischaemia
COMPASS
Cardiovascular Outcomes for People Using 
Anticoagulation Strategies
CPG
Clinical Practice Guidelines
CREDENCE
Canagliflozin and Renal Events in Diabetes with 
Established Nephropathy Clinical Evaluation
CRT
Cardiac resynchronization therapy
CRT-D
Cardiac resynchronization therapy with an 
implantable defibrillator
CRT-P
Cardiac resynchronization therapy-pacemaker
CT
Computed tomography
CTA
Computed tomography angiography
CURRENT- 
OASIS
Clopidogrel Optimal Loading Dose Usage to 
Reduce Recurrent EveNTs/Optimal Antiplatelet 
Strategy for InterventionS
CV
Cardiovascular
CVD
Cardiovascular disease
CVOT
Cardiovascular outcomes trial
DAPA-CKD
Dapagliflozin and Prevention of Adverse 
Outcomes in Chronic Kidney Disease
DAPA-HF
Dapagliflozin and Prevention of Adverse 
Outcomes in Heart Failure
DAPT
Dual antiplatelet therapy
DAT
Dual antithrombotic therapy
DBP
Diastolic blood pressure
DCCT
Diabetes Control and Complications Trial
DD
Double diabetes
DECLARE-TIMI 
58
Dapagliflozin Effect on Cardiovascular Events 
−Thrombolysis In Myocardial Infarction 58
DELIVER
Dapagliflozin Evaluation to Improve the  Lives of 
Patients with Preserved Ejection Fraction Heart 
Failure
DES
Drug-eluting stent
DEVOTE
A Trial Comparing Cardiovascular Safety of 
Insulin Degludec vs Insulin Glargine in Patients 
With Type 2 Diabetes at High Risk of 
Cardiovascular Events
DIAL
Diabetes lifetime-perspective prediction
DIGAMI
Diabetes Mellitus Insulin-Glucose Infusion in 
Acute Myocardial Infarction
DiRECT
Diabetes Remission Clinical Trial
DPP-4
Dipeptidyl peptidase-4
EACTS
European Association for Cardio-Thoracic 
Surgery
EASD
European Association for the Study of Diabetes
ECG
Electrocardiogram
EDC
Pittsburgh Epidemiology of Diabetes 
Complications
EDIC
Epidemiology of Diabetes Interventions and 
Complications eGFR
Estimated glomerular filtration rate
ELIXA
Evaluation of Lixisenatide in Acute Coronary 
Syndrome
EMMY
Impact of EMpagliflozin on cardiac function and 
biomarkers of heart failure in patients with acute 
MYocardial infarction
EMPA-KIDNEY
The Study of Heart and Kidney Protection With 
Empagliflozin
EMPA-REG 
OUTCOME
Empagliflozin Cardiovascular Outcome Event 
Trial in Type 2 Diabetes Mellitus Patients
EMPA-RESPONSE- 
AHF
Empagliflozin on Clinical Outcomes in Patients 
With Acute Decompensated Heart Failure
EMPEROR- 
Preserved
EMPagliflozin outcomE tRial in Patients With 
chrOnic heaRt Failure With Preserved Ejection 
Fraction
EMPEROR- 
Reduced
Empagliflozin Outcome Trial in Patients with 
Chronic Heart Failure with Reduced Ejection 
Fraction
EMPULSE
A Study to Test the Effect of Empagliflozin in 
Patients Who Are in Hospital for Acute Heart 
Failure
EORP
EURObservational Research Programme
ER
Extended release
ESC
European Society of Cardiology
ESH
European Society of Hypertension
EXAMINE
Cardiovascular Outcomes Study of Alogliptin in 
Patients With Type 2 Diabetes and Acute 
Coronary Syndrome
EXSCEL
Exenatide Study of Cardiovascular Event 
Lowering
FIDELIO-DKD
Efficacy and Safety of Finerenone in Subjects 
With Type 2 Diabetes Mellitus and Diabetic 
Kidney Disease
FIGARO-DKD
Efficacy and Safety of Finerenone in Subjects 
With Type 2 Diabetes Mellitus and the Clinical 
Diagnosis of Diabetic Kidney Disease
FLOW
Effect of Semaglutide Versus Placebo on the 
Progression of Renal Impairment in Subjects 
With Type 2 Diabetes and Chronic Kidney 
Disease
FOURIER
Further Cardiovascular Outcomes Research 
with PCSK9 Inhibition in Subjects with Elevated 
Risk
FPG
Fasting plasma glucose
GDM
Gestational diabetes mellitus
GFR
Glomerular filtration rate
GLOBAL- 
LEADERS
A Clinical Study Comparing Two Forms of 
Antiplatelet Therapy After Stent  
Implantation
GLP-1 RA
Glucagon-like peptide-1 receptor agonist
GRACE
Global Registry of Acute Coronary Events
HARMONY 
Outcomes
Effect of Albiglutide, When Added to Standard 
Blood Glucose Lowering Therapies, on Major 
Cardiovascular Events in Subjects With Type 2 
Diabetes Mellitus
HAS-BLED
Hypertension, Abnormal renal/liver function, 
Stroke, Bleeding history or predisposition, Labile 
international normalized ratio, Elderly (>65 
years), Drugs/alcohol concomitantly


<!-- PAGE 7 -->

### Page 7

HbA1c
Glycated haemoglobin
HBPM
Home blood pressure monitoring
HCP
Healthcare professional
HDL-C
High-density lipoprotein-cholesterol
HF
Heart failure
HFmrEF
Heart failure with mildly reduced ejection 
fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HMOD
Hypertension-mediated organ damage
HR
Hazard ratio
ICD
Implantable cardioverter defibrillator
IFG
Impaired fasting glucose
IGT
Impaired glucose tolerance
IHD
Ischaemic heart disease
IMPROVE-IT
Improved Reduction of Outcomes: Vytorin 
Efficacy International Trial
INR
International normalized ratio
IPD
Individual participant data
ISAR-REACT 5
Intracoronary Stenting and Antithrombotic 
Regimen: Rapid Early Action for Coronary 
Treatment
ISCHEMIA
International Study of Comparative Health 
Effectiveness with Medical and Invasive 
Approaches
ISCHEMIA-CKD
International Study of Comparative Health 
Effectiveness with Medical and Invasive 
Approaches–Chronic Kidney Disease
ISTH
International Society of Thrombosis and 
Haemostasis i.v.
Intravenous
J-DOIT3
Japan Diabetes Optimal Integrated Treatment 
Study for 3 Major Risk Factors of Cardiovascular 
Diseases
KDIGO
Kidney Disease: Improving Global Outcomes
KRT
Kidney replacement therapy
LDL-C
Low-density lipoprotein-cholesterol
LEAD
Lower-extremity artery disease
LEADER
Liraglutide Effect and Action in Diabetes: 
Evaluation of Cardiovascular Outcome Results
LIBERATES
Improving Glucose Control in Patients with 
Diabetes Following Myocardial Infarction: The 
Role of a Novel Glycaemia Monitoring Strategy
Look AHEAD
Action for Health in Diabetes
LV
Left ventricular
LVEF
Left ventricular ejection fraction
MACE
Major adverse cardiovascular events
MI
Myocardial infarction
MRA
Mineralocorticoid receptor antagonist
NNH
Number needed to harm
NNT
Number needed to treat
NO
Nitric oxide
NOAC
Non-Vitamin K Antagonist Oral Anticoagulant
NSTE-ACS
Non-ST-elevation acute coronary syndrome
NT-proBNP
N-terminal pro-B-type natriuretic peptide
NYHA
New York Heart Association o.d.
Once a day
OAC
Oral anticoagulant
OARS
Open-ended questions, Affirmation, Reflective 
listening, and Summarizing
ODYSSEY 
DM-DYSLIPIDE­
MIA
Efficacy and Safety of Alirocumab Versus Usual 
Care on Top of Maximally Tolerated Statin 
Therapy in Patients With Type 2 Diabetes and 
Mixed Dyslipidemia
ODYSSEY 
OUTCOMES
Evaluation of Cardiovascular Outcomes After an 
Acute Coronary Syndrome During Treatment 
With Alirocumab
OGTT
Oral glucose tolerance test
OMT
Optimal medical therapy
OR
Odds ratio
ORIGIN
Outcome Reduction With Initial Glargine 
Intervention
ORION
Inclisiran for Participants With Atherosclerotic 
Cardiovascular Disease and Elevated 
Low-density Lipoprotein Cholesterol
PA
Physical activity
PAD
Peripheral arterial diseases
PARAGON-HF
Efficacy and Safety of LCZ696 Compared to 
Valsartan, on Morbidity and Mortality in Heart 
Failure Patients With Preserved Ejection 
Fraction
PCI
Percutaneous coronary intervention
PCSK9
Proprotein convertase subtilisin/kexin type 9
PEGASUS-TIMI 
54
Prevention of Cardiovascular Events in Patients 
With Prior Heart Attack Using Ticagrelor 
Compared to Placebo on a Background of 
Aspirin
PIONEER 6
Trial Investigating the Cardiovascular Safety of 
Oral Semaglutide in Subjects With Type 2 
Diabetes
PROactive
PROspective pioglitAzone Clinical Trial In 
macroVascular Events
QI
Quality indicator
QTc
Correct QT interval
RAS
Renin–angiotensin system
RCT
Randomized controlled trial
REDUCE-IT
Reduction of Cardiovascular Events with 
Icosapent Ethyl–Intervention
REWIND
Researching Cardiovascular Events With a 
Weekly Incretin in Diabetes
ROS
Reactive oxygen species
RPG
Random plasma glucose
RR
Relative risk
SAPT
Single antiplatelet therapy
SAVOR-TIMI 53
Saxagliptin Assessment of Vascular Outcomes 
Recorded in Patients with Diabetes Mellitus 
−Thrombolysis In Myocardial Infarction 53
SBP
Systolic blood pressure s.c.
Subcutaneous
SCD
Sudden cardiac death
SCORED
Effect of Sotagliflozin on Cardiovascular and 
Renal Events in Participants With Type 2 
Diabetes and Moderate Renal Impairment Who 
Are at Cardiovascular Risk
SCORE2- 
Diabetes type 2 diabetes-specific 10-year CVD risk score
SCORE2-OP
SCORE2-older persons
SGLT2
Sodium–glucose co-transporter-2
SMART
Specific, Measurable, Achievable, Realistic, 
Timely
ESC Guidelines                                                                                                                                                                                          4049


<!-- PAGE 8 -->

### Page 8

SOLOIST-WHF
Effect of Sotagliflozin on Cardiovascular Events in 
Patients with Type 2 Diabetes Post Worsening 
Heart Failure
STEMI
ST-elevation myocardial infarction
STRONG-HF
Safety, Tolerability and Efficacy of Rapid 
Optimization, Helped by NT-proBNP testinG, of 
Heart Failure Therapies
SUSTAIN 6
Trial to Evaluate Cardiovascular and Other 
Long-term Outcomes With Semaglutide in 
Subjects With Type 2 Diabetes
T1DM
Type 1 diabetes mellitus
T2DM
Type 2 diabetes mellitus
TAT
Triple antithrombotic therapy
TBI
Toe–brachial index
TcPO2
Transcutaneous oxygen pressure
TECOS
Trial Evaluating Cardiovascular Outcomes with 
Sitagliptin
TG
Triglyceride
THEMIS
Effect of Ticagrelor on Health Outcomes in 
Diabetes Mellitus Patients Intervention Study
TIMI
Thrombolysis in Myocardial Infarction
TOD
Target-organ damage
TRACK
Treatment of CVD with Low Dose Rivaroxaban 
in Advanced CKD
TRL
Triglyceride-rich lipoprotein
TROPICAL-ACS
Testing Responsiveness to Platelet Inhibition on 
Chronic Antiplatelet Treatment for Acute 
Coronary Syndromes
TSAT
Transferrin saturation
TZD
Thiazolidinedione
UACR
Urine albumin-to-creatinine ratio
UKPDS
United Kingdom Prospective Diabetes Study
VADT
Veterans Affairs Diabetes Trial
VALUE
Valsartan Antihypertensive Long-term Use 
Evaluation
VERTIS CV
Evaluation of Ertugliflozin Efficacy and Safety 
Cardiovascular Outcomes Trial
VKA
Vitamin K antagonist
WHO
World Health Organization
WIfI
Wound, Ischaemia, foot Infection
1. Preamble
Guidelines evaluate and summarize available evidence, with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeut­
ic approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals and the European Society of 
Cardiology (ESC) makes its Guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription, and, where appropriate, to respect the ethical rules of 
their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated. ESC Policies and Procedures for 
formulating and issuing ESC Guidelines can be found on the ESC web­
site (https://www.escardio.org/Guidelines).
The Members of this Task Force were selected by the ESC to re­
present professionals involved with the medical care of patients with 
this pathology. The selection procedure aimed to include members 
from across the whole of the ESC region and from relevant ESC 
Subspecialty Communities. Consideration was given to diversity and in­
clusion, notably with respect to gender and country of origin. The Task 
Force performed a critical evaluation of diagnostic and therapeutic ap­
proaches, including assessment of the risk-benefit ratio. The strength of 
every recommendation and the level of evidence supporting them were 
weighed and scored according to pre-defined scales as outlined below. 
The Task Force followed ESC voting procedures, and all approved re­
commendations were subject to a vote and achieved at least 75% 
agreement among voting members.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules and 
can be found on the ESC website (http://www.escardio.org/ 
Guidelines), and have been compiled in a report published in a supple­
mentary document with the guidelines. The Task Force received its en­
tire financial support from the ESC without any involvement from the 
healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises and 
co-ordinates the preparation of new guidelines and is responsible for the 
approval process. ESC Guidelines undergo extensive review by the CPG 
Committee and external experts, including members from across the 
whole of the ESC region and from relevant ESC Subspecialty 
Communities and National Cardiac Societies. After appropriate revisions, 
the guidelines are signed off by all the experts involved in the Task Force. 
The finalized document is signed off by the CPG Committee for publica­
tion in the European Heart Journal. The guidelines were developed after 
careful consideration of the scientific and medical knowledge and the evi­
dence available at the time of their writing. Tables of evidence summarizing 
the findings of studies informing development of the guidelines are in­
cluded. The ESC warns readers that the technical language may be misin­
terpreted and declines any responsibility in this respect.
Off-label use of medication may be presented in the current 
Guidelines if a sufficient level of evidence shows that it can be consid­
ered medically appropriate for a given condition. However, the final de­
cisions concerning an individual patient must be made by the 
responsible health professional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
Patients with diabetes are at increased risk of developing cardiovascular 
disease (CVD) with its manifestations of coronary artery disease (CAD), 
heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and 
peripheral artery diseases. In addition, diabetes is a major risk factor for 
developing chronic kidney disease (CKD), which in itself is associated


<!-- PAGE 9 -->

### Page 9

with developing CVD. The combination of diabetes with these 
cardio-renal comorbidities enhances the risk not only for cardiovascular 
(CV) events but also for CV and all-cause mortality. The current 
European Society of Cardiology (ESC) Guidelines on the management 
of cardiovascular disease in patients with diabetes are designed to guide 
prevention and management of the manifestations of CVD in patients 
with diabetes based on data published until end of January 2023. Over 
the last decade, the results of various large cardiovascular outcome trials 
(CVOTs) in patients with diabetes at high CV risk with novel glucose- 
lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhi­
bitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but 
also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), 
such as finerenone have substantially expanded available therapeutic op­
tions, leading to numerous evidence-based recommendations for the 
management of this patient population.
The current Guidelines—in contrast to the previous 2019 ESC 
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases— 
only focus on CVD and diabetes and, given the lack of clear evidence, 
leave aside the aspect of pre-diabetes. In addition, this version of the 
Guidelines gives recommendations on stratifying CV risk, as well as 
on screening, diagnosis, and treatment of CVD in patients with dia­
betes. For all other aspects concerning the management of patients 
with diabetes, we refer to the recommendations from diabetes associa­
tions, e.g. the European Association for the Study of Diabetes (EASD) 
or the American Diabetes Association (ADA).1
These Guidelines offer evidence-based recommendations to manage 
CV risk in patients with diabetes and provide guidance for the treatment 
of atherosclerotic cardiovascular disease (ASCVD) in patients with dia­
betes. To individualize treatment strategies, the current Guidelines 
introduce a novel, dedicated, type 2 diabetes mellitus (T2DM)-specific, 
Table 1 Classes of recommendations
©ESC 2023
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2023
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2023
© ESC 2023
ESC Guidelines                                                                                                                                                                                          4051


<!-- PAGE 10 -->

### Page 10

10-year CVD risk score (SCORE2-Diabetes) for patients with T2DM 
without ASCVD or severe target-organ damage (TOD). This score, 
which now extends the established SCORE2 prediction algorithm for 
T2DM, provides data on the 10-year risk of fatal and non-fatal CVD 
events (myocardial infarction [MI], stroke) based on individual patient 
characteristics. SCORE2-Diabetes serves as a guide for clinical decision- 
making in patients with T2DM at low, moderate, high, or very high risk, 
but without clinically overt ASCVD or severe TOD.
Given the high prevalence of undetected diabetes in patients with CVD, 
as well as the elevated risk and therapeutic consequences if both co­
morbidities co-exist, these Guidelines recommend systematic screening 
for diabetes in all patients with CVD. In addition, all patients with diabetes 
need to be evaluated for risk and presence of CVD and CKD. Based on 
evidence from large CVOTs, the current Guidelines provide clear recom­
mendations on how to treat patients with diabetes and clinical manifesta­
tions of cardiovascular-renal disease. As such, in patients with diabetes and 
ASCVD, treatment with GLP-1 RAs and/or SGLT2 inhibitors is 
recommended to reduce CV risk, independent of glucose control and in 
addition to standard of care, e.g. antiplatelet, anti-hypertensive, or 
lipid-lowering therapy. A special focus of these Guidelines is on managing 
HF in diabetes, a field that has been underestimated for years. Based on 
data from large CVOTs, it is recommended to treat patients with diabetes 
and chronic HF (independent of left ventricular ejection fraction [LVEF]) 
with SGLT2 inhibitors to reduce HF hospitalization. Finally, in patients 
with diabetes and CKD, it is recommended to treat with an SGLT2 inhibi­
tor and/or finerenone, since these agents reduce CV and kidney failure risk 
on top of standard of care (Figure 1).
Managing patients with diabetes and CVD requires an interdisciplin­
ary approach, which should involve healthcare clinicians from different 
disciplines and areas of expertise to support shared decision-making 
and implement a personalized treatment strategy to reduce each pa­
tient’s disease burden. Ultimately, our common goal in managing 
CVD in patients with diabetes is to improve patients’ prognosis and 
health-related quality of life.
Patient presentation
Cardiovascular disease
Type 2 diabetes mellitus
Evaluation
Diagnosis
Treatment
Type 2 diabetes mellitus?
(Class I)
GLP-1 RAa
(Class I)
SGLT2 inhibitorb
(Class I)
SGLT2 inhibitorc
(Class I)
Finerenone
(Class I)
SGLT2 inhibitord
(Class I)
CVD and type 2 diabetes mellitus
Type 2 diabetes mellitus and ASCVD
Type 2 diabetes mellitus and HF
All therapies are recommended independent of glucose control and in addition to standard of care
Type 2 diabetes mellitus and CKD
To reduce cardiovascular risk independent of glucose control
To reduce heart failure hospitalization in all patients with T2DM and HF
(HFpEF, HFmrEF, HFrEF)
To reduce cardiovascular and kidney failure risk
Cardiovascular disease?
(Class I)
Chronic kidney disease?
(Class I)
Confirmed
Confirmed
Confirmed
Figure 1 Management of cardiovascular disease in patients with type 2 diabetes: clinical approach and key recommendations. ASCVD, atherosclerotic 
cardiovascular disease; CKD, chronic kidney disease; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure; 
HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection 
fraction; s.c. subcutaneous; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. aGLP-1 RAs with proven cardiovascular benefit: lir­
aglutide, semaglutide s.c., dulaglutide, efpeglenatide. bSGLT2 inhibitors with proven cardiovascular benefit: empagliflozin, canagliflozin, dapagliflozin, sotagli­
flozin. cEmpagliflozin, dapagliflozin, sotagliflozin in HFrEF; empagliflozin, dapagliflozin in HFpEF and HFmrEF. dCanagliflozin, empagliflozin, dapagliflozin.
2.1. Central figure


<!-- PAGE 11 -->

### Page 11

2.2. What is new
Table 3 New recommendations
Recommendations
Classa
Levelb
Cardiovascular risk assessment in diabetes—Section 4
In patients with T2DM without symptomatic ASCVD 
or severe TOD, it is recommended to estimate 
10-year CVD risk via SCORE2-Diabetes.
I
B
Weight reduction in patients with diabetes—Section 5.1.1
It is recommended that individuals living with 
overweight or obesity aim to reduce weight and 
increase physical exercise to improve metabolic 
control and overall CVD risk profile.
I
A
Glucose-lowering medications with effects on weight 
loss (e.g. GLP-1 RAs) should be considered in 
patients with overweight or obesity to reduce 
weight.
IIa
B
Bariatric surgery should be considered for high and 
very high risk patients with BMI ≥35 kg/m2 (≥Class II) 
when repetitive and structured efforts of lifestyle 
changes combined with weight-reducing medications 
do not result in maintained weight loss.
IIa
B
Increasing physical activity and exercise in patients with 
diabetes—Section 5.1.3
It is recommended to adapt exercise interventions to 
T2DM-associated comorbidities, e.g. frailty, 
neuropathy, or retinopathy.
I
B
It is recommended to introduce structured exercise 
training in patients with T2DM and established CVD, 
e.g. CAD, HFpEF, HFmrEF, HFrEF, or AF to improve 
metabolic control, exercise capacity, and quality of 
life, and to reduce CV events.
I
B
The use of behavioural theory-based interventions, 
such as goal-setting, re-evaluation of goals, 
self-monitoring, and feedback, should be considered 
to promote physical activity behaviour.
IIa
B
It may be considered to use wearable activity 
trackers to increase physical activity behaviour.
IIb
B
Smoking cessation in patients with diabetes—Section 5.1.4
Nicotine replacement therapy, varenicline, and 
bupropion, as well as individual or telephone 
counselling, should be considered to improve 
smoking cessation success rate.
IIa
B
Glycaemic targets—Section 5.2
Tight glycaemic control should be considered for 
reducing CAD in the long term, preferably using 
agents with proven CV benefit.
IIa
B
Continued
Atherosclerotic cardiovascular disease risk reduction by 
glucose-lowering medications in diabetes—Section 5.3
It is recommended to prioritize the use of 
glucose-lowering agents with proven CV benefits 
followed by agents with proven CV safety over 
agents without proven CV benefit or proven CV 
safety.
I
C
If additional glucose control is needed, metformin 
should be considered in patients with T2DM and 
ASCVD.
IIa
C
If additional glucose control is needed, pioglitazone 
may be considered in patients with T2DM and 
ASCVD without HF.
IIb
B
Blood pressure and diabetes—Section 5.4
Regular BP measurements are recommended in all 
patients with diabetes to detect and treat 
hypertension to reduce CV risk.
I
A
Lipids and diabetes—Section 5.5
A PCSK9 inhibitor is recommended in patients at 
very high CV risk, with persistently high LDL-C levels 
above target despite treatment with a maximum 
tolerated statin dose, in combination with ezetimibe, 
or in patients with statin intolerance.
I
A
If a statin-based regimen is not tolerated at any 
dosage (even after re-challenge), a PCSK9 inhibitor 
added to ezetimibe should be considered.
IIa
B
If a statin-based regimen is not tolerated at any 
dosage (even after re-challenge), ezetimibe should be 
considered.
IIa
C
High-dose icosapent ethyl (2 g b.i.d.) may be 
considered in combination with a statin in patients 
with hypertriglyceridaemia.
IIb
B
Antithrombotic therapy in patients with diabetes—Section 5.6
Clopidogrel 75 mg o.d. following appropriate loading 
(e.g. 600 mg or at least 5 days already on 
maintenance therapy) is recommended in addition to 
ASA for 6 months following coronary stenting in 
patients with CCS, irrespective of stent type, unless a 
shorter duration is indicated due to the risk or 
occurrence of life-threatening bleeding.
I
A
In patients with diabetes and ACS treated with 
DAPT who are undergoing CABG and do not 
require long-term OAC therapy, resuming a P2Y12 
receptor inhibitor as soon as deemed safe after 
surgery and continuing it up to 12 months is 
recommended.
I
C
Adding very low-dose rivaroxaban to low-dose ASA 
for long-term prevention of serious vascular events 
should be considered in patients with diabetes and 
CCS or symptomatic PAD without high bleeding risk.
IIa
B
Continued
ESC Guidelines                                                                                                                                                                                          4053


<!-- PAGE 12 -->

### Page 12

In patients with ACS or CCS and diabetes 
undergoing coronary stent implantation and having 
an indication for anticoagulation prolonging triple 
therapy with low-dose ASA, clopidogrel, and an 
OAC should be considered up to 1 month if the 
thrombotic risk outweighs the bleeding risk in the 
individual patient.
IIa
C
In patients with ACS or CCS and diabetes 
undergoing coronary stent implantation and having 
an indication for anticoagulation prolonging triple 
therapy with low-dose ASA, clopidogrel, and an 
OAC up to 3 months may be considered if the 
thrombotic risk outweighs the bleeding risk in the 
individual patient.
IIb
C
When clopidogrel is used, omeprazole and 
esomeprazole are not recommended for gastric 
protection.
III
B
Multifactorial approach in patients with diabetes—Section 5.7
Identifying and treating risk factors and comorbidities 
early is recommended.
I
A
Multidisciplinary behavioural approaches that 
combine the knowledge and skills of different 
caregivers are recommended.
I
C
Principles of motivational interviewing should be 
considered to induce behavioural changes.
IIa
C
Telehealth may be considered to improve risk 
profile.
IIb
B
Management of coronary artery disease in patients with 
diabetes—Section 6
Myocardial revascularization in CCS is 
recommended when angina persists despite 
treatment with anti-anginal drugs or in patients with 
a documented large area of ischaemia (>10% LV).
I
A
Complete revascularization is recommended in 
patients with STEMI without cardiogenic shock and 
with multivessel CAD.
I
A
It is recommended to assess glycaemic status at initial 
evaluation in all patients with ACS.
I
B
Complete revascularization should be considered in 
patients with NSTE-ACS without cardiogenic shock 
and with multivessel CAD.
IIa
C
Glucose-lowering therapy should be considered in 
patients with ACS with persistent hyperglycaemia, 
while episodes of hypoglycaemia should be avoided.
IIa
C
Routine immediate revascularization of non-culprit 
lesions in patients with MI and multivessel disease 
presenting with cardiogenic shock is not 
recommended.
III
B
Continued
Heart failure and diabetes—Section 7
Evaluation for heart failure in diabetes
If HF is suspected, it is recommended to measure 
BNP/NT-proBNP.
I
B
Systematic survey for HF symptoms and/or signs of 
HF is recommended at each clinical encounter in all 
patients with diabetes.
I
C
Diagnostic tests in all patients with suspected heart failure
12-lead ECG is recommended.
I
C
Transthoracic echocardiography is recommended.
I
C
Chest radiography (X-ray) is recommended.
I
C
Routine blood tests for comorbidities are 
recommended, including full blood count, urea, 
creatinine and electrolytes, thyroid function, lipids, 
and iron status (ferritin and TSAT).
I
C
Pharmacological treatment indicated in patients with HFrEF 
(NYHA class II–IV) and diabetes
SGLT2 inhibitors (dapagliflozin, empagliflozin, or 
sotagliflozin) are recommended in all patients with 
HFrEF and T2DM to reduce the risk of HF 
hospitalization and CV death.
I
A
An intensive strategy of early initiation of 
evidence-based treatment (SGLT2 inhibitors, ARNI/ 
ACE-Is, beta-blockers, and MRAs), with rapid 
up-titration to trial-defined target doses starting 
before discharge and with frequent follow-up visits in 
the first 6 weeks following a HF hospitalization is 
recommended to reduce re-admissions or mortality.
I
B
Other treatments indicated in selected patients with HFrEF 
(NYHA class II–IV) and diabetes
Hydralazine and isosorbide dinitrate should be 
considered in self-identified Black patients with 
diabetes and LVEF ≤35% or with an LVEF <45% 
combined with a dilated LV in NYHA class III–IV 
despite treatment with an ACE-I (or ARNI), a 
beta-blocker, and an MRA, to reduce the risk of HF 
hospitalization and death.
IIa
B
Digoxin may be considered in patients with 
symptomatic HFrEF in sinus rhythm despite 
treatment with sacubitril/valsartan or an ACE-I, a 
beta-blocker, and an MRA, to reduce the risk of 
hospitalization.
IIb
B
Heart failure treatments in patients with diabetes and LVEF 
>40%
Empagliflozin or dapagliflozin are recommended in 
patients with T2DM and LVEF >40% (HFmrEF and 
HFpEF) to reduce the risk of HF hospitalization or 
CV death.
I
A
Continued


<!-- PAGE 13 -->

### Page 13

Special considerations for glucose-lowering medications in 
patients with T2DM with and without HF
It is recommended to switch glucose-lowering 
treatment from agents without proven CV benefit or 
proven safety to agents with proven CV benefit.
I
C
Atrial fibrillation and diabetes—Section 8.1
Opportunistic screening for AF by pulse taking or 
ECG is recommended in patients with diabetes <65 
years of age (particularly when other risk factors are 
present) because patients with diabetes exhibit a 
higher AF frequency at a younger age.
I
C
Systematic ECG screening should be considered to 
detect AF in patients aged ≥75 years, or those at high 
risk of stroke.
IIa
B
Chronic kidney disease and diabetes—Section 9
Intensive LDL-C lowering with statins or a statin/ 
ezetimibe combination is recommended.
I
A
A SGLT2 inhibitor (canagliflozin, empagliflozin, or 
dapagliflozin) is recommended in patients with 
T2DM and CKD with an eGFR ≥20 mL/min/1.73 m2 
to reduce the risk of CVD and kidney failure.
I
A
Finerenone is recommended in addition to an ACE-I 
or ARB in patients with T2DM and eGFR >60 mL/ 
min/1.73 m2 with a UACR ≥30 mg/mmol (≥300 mg/ 
g), or eGFR 25–60 mL/min/1.73 m2 and UACR 
≥3 mg/mmol (≥30 mg/g) to reduce CV events and 
kidney failure.
I
A
Low-dose ASA (75–100 mg o.d.) is recommended in 
patients with CKD and ASCVD.
I
A
Treatment with intensive medical or an initial invasive 
strategy is recommended in people with CKD, 
diabetes, and stable moderate or severe CAD, due to 
similar outcomes.
I
B
Kidney specialist advice may be considered for 
managing a raised serum phosphate, other evidence 
of CKD-MBD, and renal anaemia.
IIb
C
Combined use of an ARB with an ACE-I is not 
recommended.
III
B
Continued
Aortic and peripheral arterial diseases and diabetes—Section 10
In patients with diabetes and aortic aneurysm, it is 
recommended to implement the same diagnostic 
work-up and therapeutic strategies (medical, surgical, 
or endovascular) as in patients without diabetes.
I
C
Type 1 diabetes and cardiovascular disease—Section 11
In patients with T1DM, it is recommended that 
adjustment of glucose-lowering medication follows 
principles of patient self-management under the 
guidance of the diabetes healthcare multidisciplinary 
team.
I
C
Avoiding hypoglycaemic episodes is recommended, 
particularly in those with established CVD.
I
C
Statins should be considered for LDL-C lowering in 
adults older than 40 years with T1DM without a 
history of CVD to reduce CV risk.
IIa
B
Statins should be considered for use in adults 
younger than 40 years with T1DM and other risk 
factors of CVD or microvascular end-organ damage 
or 10-year CVD risk ≥10% to reduce CVD risk.
IIa
B
The use of the Scottish/Swedish risk prediction 
model may be considered to estimate 10-year CVD 
risk in patients with T1DM.
IIb
B
© ESC 2023
ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial 
fibrillation; ARB, angiotensin-II receptor blocker; ARNI, angiotensin receptor–neprilysin 
inhibitor; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; b.i.d., 
twice a day; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; 
CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, chronic 
coronary syndrome; CKD-MBD, chronic kidney disease–mineral bone disorder; CV, 
cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; ECG, 
electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like 
peptide-1 receptor agonist; HF, heart failure; HFmrEF, heart failure with mildly reduced 
ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart 
failure with reduced ejection fraction; LDL-C, low-density lipoprotein-cholesterol; LV, 
left ventricular/ventricle; LVEF, left ventricular ejection fraction; MI, myocardial infarction; 
MRA, mineralocorticoid receptor antagonist; NSTE-ACS, non-ST-elevation acute 
coronary syndrome; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, 
New York Heart Association; OAC, oral anticoagulant; o.d., once daily; PAD, peripheral 
arterial disease; PCSK9, proprotein convertase subtilisin/kexin type 9; T1DM, type 1 
diabetes mellitus; T2DM, type 2 diabetes mellitus; TOD, target-organ damage; TSAT, 
transferrin saturation; SCORE2-Diabetes, type 2 diabetes-specific 10-year CVD risk 
score; SGLT2, sodium–glucose co-transporter-2; STEMI, ST-elevation myocardial 
infarction; UACR, urinary albumin-to-creatinine ratio. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4055


<!-- PAGE 14 -->

### Page 14

Table 4 Revised recommendations
2019
Classa
Levelb
2023
Classa
Levelb
Change in diet and nutrition in patients with diabetes—Section 5.1.2
A Mediterranean diet, rich in polyunsaturated 
and monounsaturated fats, should be 
considered to reduce CV events.
IIa
B
It is recommended to adopt a Mediterranean or plant-based diet 
with high unsaturated fat content to lower CV risk.
I
A
Atherosclerotic cardiovascular disease risk reduction by glucose-lowering medications in diabetes—Section 5.3
Empagliflozin, canagliflozin, or dapagliflozin 
are recommended in patients with T2DM and 
CVD, or at very high/high CV risk to reduce 
CV events.
I
A
SGLT2 inhibitors with proven CV benefit are recommended in 
patients with T2DM and ASCVD to reduce CV events, 
independent of baseline or target HbA1c and independent of 
concomitant glucose-lowering medication.
I
A
In patients with T2DM without ASCVD or severe TOD but with 
a calculated 10-year CVD risk ≥10%, treatment with an SGLT2 
inhibitor or GLP-1 RA may be considered to reduce CV risk.
IIb
C
Liraglutide, semaglutide, or dulaglutide are 
recommended in patients with T2DM and 
CVD, or at very high/high CV risk to reduce 
CV events.
I
A
GLP-1 RAs with proven CV benefit are recommended in patients 
with T2DM and ASCVD to reduce CV events, independent of 
baseline or target HbA1c and independent of concomitant 
glucose-lowering medication.
I
A
In patients with T2DM without ASCVD or severe TOD but with 
a calculated 10-year CVD risk ≥10%, treatment with an SGLT2 
inhibitor or GLP-1 RA may be considered to reduce CV risk.
IIb
C
Antithrombotic therapy in patients with diabetes—Section 5.6
When low-dose aspirin is used, proton pump 
inhibitors should be considered to prevent 
gastrointestinal bleeding.
IIa
A
When antithrombotic drugs are used in combination, proton 
pump inhibitors are recommended to prevent gastrointestinal 
bleeding.
I
A
When a single antiplatelet or anticoagulant drug is used, proton 
pump inhibitors should be considered to prevent gastrointestinal 
bleeding, considering the bleeding risk of the individual patient.
IIa
A
Multifactorial approach to risk-factor management in patients with diabetes—Section 5.7
A multifactorial approach to diabetes 
management with treatment targets should 
be considered in patients with diabetes and 
CVD.
IIa
B
A multifactorial approach to managing T2DM with treatment 
targets is recommended.
I
B
Heart failure and diabetes—Section 7
GLP-1 RAs (lixisenatide, liraglutide, 
semaglutide, exenatide, dulaglutide) have a 
neutral effect on the risk of HF hospitalization, 
and may be considered for diabetes treatment 
in patients with HF.
IIb
A
GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER, 
dulaglutide, efpeglenatide) have a neutral effect on the risk of HF 
hospitalization, and should be considered for glucose-lowering 
treatment in patients with T2DM at risk of or with HF.
IIa
A
Insulin may be considered in patients with 
advanced, systolic HFrEF.
IIb
C
Basal insulins (glargine and degludec) have a neutral effect on the 
risk of HF hospitalization, and should be considered for 
glucose-lowering treatment in patients with T2DM at risk of or 
with HF.
IIa
B
Atrial fibrillation and diabetes—Section 8.1
Screening for AF by pulse palpation should be 
considered in patients aged >65 years with 
diabetes and confirmed by ECG, if any 
suspicion of AF, as AF in patients with diabetes 
increases morbidity and mortality.
IIa
C
Opportunistic screening for AF by pulse taking or ECG is 
recommended in patients ≥65 years of age.
I
B
Continued


<!-- PAGE 15 -->

### Page 15

### 3 Diagnosis of diabetes

Diabetes mellitus, a common metabolic condition, affected 537 million 
individuals worldwide in 2021 (10.5% prevalence), and this is expected 
to rise to 783 million cases by 2045 (12.2% prevalence).2
Diabetes is suspected in the presence of specific symptoms, includ­
ing polyuria, polydipsia, fatigue, blurred vision, weight loss, poor 
wound healing, and recurrent infections. However, the condition 
can be asymptomatic and is therefore undiagnosed in over 40% of 
adults worldwide (ranging from 24% to 75% across regions).3
Abnormal glucose metabolism has been divided into two clinical cat­
egories: diabetes and pre-diabetes, which are biochemical definitions 
(discussed below).
3.1. Laboratory criteria for diagnosing 
diabetes and pre-diabetes
Several biochemical tests are used to diagnose diabetes, including fast­
ing glucose, 2 h glucose (during the glucose tolerance test), random glu­
cose, and glycated haemoglobin (HbA1c).4–7
3.1.1. Fasting glucose
Fasting glucose levels ≥7.0 mmol/L (≥126 mg/dL) is diagnostic of dia­
betes, although two tests are usually recommended to diagnose in 
the absence of hyperglycaemic symptoms. In patients with typical symp­
toms, a single test is adequate, and it should be noted that fasting is de­
fined as no caloric intake for at least 8 h.
While international guidelines agree on the cut-off value for diagnos­
ing diabetes, they are divided on the criteria for diagnosing pre-diabetes. 
The World Health Organization (WHO) defines pre-diabetes as fasting 
glucose 
levels 
6.1–6.9 mmol/L 
(110–125 mg/dL) 
with 
levels 
<6.1 mmol/L (<110 mg/dL) regarded as normal.5 However, the ADA 
has more stringent criteria, with glucose levels 5.6–6.9 mmol/L (100– 
125 mg/dL) falling into the pre-diabetes range and only those with glu­
cose <5.6 mmol/L (<100 mg/dL) classified as having normal glucose 
metabolism.7,8
3.1.2. Two-hour oral glucose tolerance test and random 
glucose
Following an oral glucose load equivalent to 75 g glucose, 2 h glucose 
≥11.1 mmol/L (≥200 mg/dL) is diagnostic of diabetes. Two-hour glu­
cose 7.8–11.0 mmol/L (140–199 mg/dL) indicates impaired glucose tol­
erance, and the individual is diagnosed with pre-diabetes. However, an 
oral glucose tolerance test (OGTT) is not routinely performed, as it is 
time-consuming and inconvenient, and is therefore usually reserved for 
unclear cases. Of note, OGTT should be performed under resting con­
ditions, as exercise during the test can invalidate the results.
Chronic kidney disease and diabetes—Section 9
Treatment with the GLP-1 RAs liraglutide and 
semaglutide is associated with a lower risk of 
renal endpoints and should be considered for 
diabetes treatment if eGFR is >30 mL/min/ 
1.73 m2.
IIa
B
A GLP-1 RA is recommended at an eGFR >15 mL/min/1.73 m2 
to achieve adequate glycaemic control, due to low risk of 
hypoglycaemia and beneficial effects on weight, CV risk, and 
albuminuria.
I
A
© ESC 2023
AF, atrial fibrillation; ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ER, 
extended release; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; SGLT2, sodium– 
glucose co-transporter-2; T2DM, type 2 diabetes mellitus; TOD, target-organ damage. 
aClass of recommendation. 
bLevel of evidence.
Table 5 Revised concepts 2023 Guidelines
Focus of the Guidelines is prevention and management of 
cardiovascular disease in diabetes
The aspect of pre-diabetes is no longer covered in the current 
Guidelines.
Cardiovascular risk assessment in diabetes
For patients without ASCVD or severe target-organ damage, a novel 
T2DM-specific risk score (SCORE2-Diabetes) is introduced.
CV risk categories in T2DM are now defined based on the presence of 
ASCVD or severe target-organ damage or the 10-year CVD risk using 
SCORE2-Diabetes.
Atherosclerotic cardiovascular risk reduction by 
glucose-lowering medications in diabetes
Based on various meta-analyses including data from CVOTs with SGLT2 
inhibitors and GLP-1 RAs, the current Guidelines give separate 
recommendations for patients with and without ASCVD/severe 
target-organ damage.
Special attention is given on the aspect of proven CV benefit and/or 
safety of glucose-lowering medications.
Heart failure and diabetes
Detailed recommendations are given on HF screening and diagnosis in 
patients with diabetes.
Based on data from outcome trials in patients with HF (HFrEF, HFmrEF, 
HFpEF) with and without diabetes, the current Guidelines provide 
recommendations for the treatment of HF in patients with diabetes 
across the whole spectrum of left ventricular ejection fraction.
Detailed recommendations are given for the use of glucose-lowering 
medications in patients with HF and diabetes.
Arrhythmias and diabetes
Given that patients with diabetes exhibit a higher AF frequency at a 
younger age, the concept of opportunistic screening for AF by pulse 
taking or ECG in patients with diabetes <65 years of age (particularly 
when other risk factors are associated) is introduced.
Chronic kidney disease and diabetes
A dedicated section on managing CV risk in patients with CKD and 
diabetes is introduced covering aspects of screening (including regular 
screening with eGFR and UACR) and treatment.
© ESC 2023
AF, atrial fibrillation; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney 
disease; CV, cardiovascular; CVD, cardiovascular disease; CVOT, cardiovascular outcomes 
trial; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1 RA, 
glucagon-like peptide-1 receptor agonist; HF, heart failure; HFmrEF, heart failure with 
mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; 
HFrEF, heart failure with reduced ejection fraction; SCORE2-Diabetes, type 2 
diabetes-specific 10-year CVD risk score; SGLT2, sodium–glucose co-transporter-2; 
T2DM, type 2 diabetes mellitus; UACR, urinary albumin-to-creatinine ratio.
ESC Guidelines                                                                                                                                                                                          4057


<!-- PAGE 16 -->

### Page 16

Following on, a random glucose ≥11.1 mmol/L (≥200 mg/dL) is also 
diagnostic of diabetes in the presence of symptoms. In the absence of 
symptoms, two random glucose levels ≥11.1 mmol/L (≥200 mg/dL) 
are required to diagnose diabetes. One-hour OGTT ≥8.6 mmol/L 
(≥155 mg/dL) has been suggested as a better predictor of diabetes 
than 2 h OGTT ≥11.1 mmol/L (≥200 mg/dL), and is associated with 
vascular complications and mortality.9 However, further validation is 
required before this new measure is widely adopted.
3.1.3. Glycated haemoglobin
Following high-quality epidemiological studies, it was suggested that 
HbA1c could be used to diagnose diabetes, and this was subsequently 
endorsed by international guidelines.10 It should be noted that epi­
demiological studies have relied on the adult population, though 
HbA1c is also used in younger individuals as a diagnostic test.11
Advantages of HbA1c include ease of measurement, limited 
within-individual variability, and the convenience of anytime testing 
without the need for fasting or a cumbersome OGTT.
However, HbA1c is not accurate in specific groups where the rela­
tionship between HbA1c and glucose levels is altered for any reason 
(Supplementary data online, Table S1).12,13 Moreover, in cases of short­
er diabetes duration, such as early type 1 diabetes mellitus (T1DM) or 
Diabetes ruled out (normal glucose metabolism)
Pre-diabetes (IGT)c
Diabetesb
Values indicative of diabetes or pre-diabetes
Fasting glucose ≥7.0 mmol/L (≥126 mg/dL), or
 HbA1c ≥48 mmol/mol (≥6.5%), or 
OGTT (2 h) glucosea ≥11.1 mmol/L (≥200 mg/dL)
Fasting glucose 5.6–6.9 mmol/L (100–125 mg/dL), or
 HbA1c 39–47 mmol/mol (5.7–6.4%), or 
OGTT (2 h) glucose 7.8–11.0 mmol/L (140–199 mg/dL)
Fasting glucose ≥5.6 mmol/L (≥100 mg/dL), or 
HbA1c ≥39 mmol/mol (≥5.7%), or 
OGTT (2 h) glucose ≥7.8 mmol/L (≥140 mg/dL)
N
Diagnosis of diabetes and pre-diabetes
Y
Figure 2 Diagnosis of diabetes and pre-diabetes. HbA1c, glycated haemoglobin; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test. aRule 
out stress hyperglycaemia (often manifests as elevated glucose and normal HbA1c). bIn the presence of symptoms, a single test is enough; in the absence of 
symptoms, two abnormal tests are required to make the diagnosis. cAmerican Diabetes Association criteria are used in this scheme for the diagnosis of 
pre-diabetes.
Table 6 Biochemical diagnostic criteria for diabetes 
and pre-diabetes according to the World Health 
Organization and the American Diabetes Association
Glycaemic marker
WHO criteria 
(2011, 2019)5,6
ADA criteria 
(2021)7
Diabetes
FPG
≥7.0 mmol/L (≥126 mg/dL)
2hPG (OGTT)
≥11.1 mmol/L (≥200 mg/dL)
HbA1c
≥6.5% (≥48 mmol/mol)
RPG
≥11.1 mmol/L (≥200 mg/dL)
Pre-diabetes
FPG
6.1–6.9 mmol/L 
(110–125 mg/dL)
5.6–6.9 mmol/L 
(100–125 mg/dL)
2hPG (OGTT)
7.8–11.0 mmol/L (140–199 mg/dL)
HbA1c
6.0–6.4% 
(42–47 mmol/mol)
5.7–6.4% 
(39–47 mmol/mol)
© ESC 2023
ADA, American Diabetes Association; 2hPG, 2 h plasma glucose; FPG, fasting plasma 
glucose; HbA1c, glycated haemoglobin; RPG, random plasma glucose; OGTT, oral 
glucose tolerance test; WHO, World Health Organization.


<!-- PAGE 17 -->

### Page 17

acute pancreatic damage, HbA1c can lead to false-negative results. 
Another practical limitation is the lack of test availability in some parts 
of the world due to financial constraints.
Guidelines agree that HbA1c ≥48 mmol/mol (≥6.5%) is diagnostic of 
diabetes, while the diagnosis of pre-diabetes uses two different cut-off 
values. The WHO criteria define pre-diabetes as HbA1c 42–47 mmol/ 
mol (6.0–6.4%), while the ADA recommends a wider range of 39– 
47 mmol/mol (5.7–6.4%).5,7 Notably, the combination of HbA1c and 
fasting glucose in the diabetes range is diagnostic of diabetes and a se­
cond test is not required, even if the individual is asymptomatic. 
However, if the two are discordant, the number in the diabetes range 
should be repeated or, preferably, an OGTT performed, which remains 
the gold standard for diagnosing diabetes in unclear cases. The criteria 
used for diagnosing diabetes and pre-diabetes are summarized in 
Table 6. It should be noted that data from 73 studies on 294 998 indi­
viduals without known diabetes suggest that HbA1c is as good as or 
better than fasting, random, or post-load glucose levels for predicting 
CV risk.14
A diagram for the diagnosis of diabetes is shown in Figure 2.
3.2. Classifying diabetes
After abnormal glucose metabolism is diagnosed, the next step is to as­
certain the type of diabetes in order to start the appropriate therapies 
(Supplementary data online, Table S2).
3.2.1. Type 1 diabetes
Type 1 diabetes constitutes 5–10% of individuals with diabetes and is 
secondary to destruction of pancreatic β-cells by an autoimmune pro­
cess, with subsequent insulin deficiency. Recent guidance on diagnosing 
T1DM has been published.13
Briefly, individuals aged <35 years presenting with diabetes should be 
suspected of having T1DM, although this condition can occur at any 
age. A short history of osmotic symptoms accompanied by weight 
loss and raised glucose levels in a younger individual is highly suggestive 
of T1DM. Antibody testing helps to confirm the diagnosis, although this 
can be negative in 5–10% of individuals with T1DM, while C-peptide 
helps to assess endogenous insulin production in unclear cases 
(Supplementary data online, Table S2).
Pancreatic β-cell function can partially recover after the diagnosis of 
T1DM, and this can last several years, often referred to as the ‘honey­
moon period’. However, if this persists beyond 5 years, an alternative 
type of diabetes needs to be considered.15 Of importance, the combin­
ation of T1DM with insulin resistance, which can be referred to as dou­
ble diabetes (DD), increases the risk of vascular complications, although 
the exact definition of DD is yet to be determined.16
3.2.2. Type 2 diabetes
Type 2 diabetes is the most common cause of diabetes (90% of the dia­
betes population) and is usually caused by insulin resistance coupled 
with ‘relative’ insulin deficiency, resulting in raised glucose levels. 
Individuals with T2DM can be asymptomatic and can be diagnosed after 
presenting with CV complications (Supplementary data online, 
Table S2). Therefore, it is mandatory to screen all patients with CVD 
for the presence of diabetes.
3.2.3. Monogenic diabetes
This comprises many mutations that cause glucose mishandling. A full 
description can be found elsewhere.17 Briefly, monogenic diabetes 
should be suspected in the presence of a strong family history of abnor­
mal glucose metabolism in an autosomal dominant manner (i.e. succes­
sive generations with diabetes at a young age).17
Patients diagnosed with diabetes before the age of 6 months and 
those not fitting the T1DM or T2DM profiles should be suspected of 
having monogenic diabetes.
3.2.4. Secondary diabetes and stress hyperglycaemia
Diabetes can occur secondary to various conditions and therapies 
(Supplementary data online, Table S2). Stress hyperglycaemia is not un­
common in hospitalized patients and can occur in individuals with acute 
coronary syndrome (ACS) or HF.18 Stress hyperglycaemia without dia­
betes is associated with adverse in-hospital outcomes, and should be 
suspected in those with raised glucose levels during admission and nor­
mal HbA1c.19 Such individuals are best investigated using OGTT a few 
weeks after discharge to rule out diabetes or impaired glucose toler­
ance. Some studies suggest performing OGTT before hospital dis­
charge but robust data supporting this approach are lacking.20,21
3.2.5. Gestational diabetes
Gestational diabetes mellitus (GDM) is defined as diabetes diagnosed 
in the second or third trimester of pregnancy that was not overt dia­
betes before gestation.7 While there is still no worldwide consensus 
regarding the best testing strategy, the ‘one-step’ 75 g OGTT, also 
recommended by the WHO, is the preferred test in many coun­
tries.22 In women with GDM, repeat testing is required in the post- 
partum period to rule out persistent abnormal glucose metabolism. 
Women with GDM will require lifelong annual diabetes screening gi­
ven the high risk of developing diabetes.23–25 Also, evidence suggests 
that women with a history of GDM are at increased CV risk, even 
with normal post-partum glucose levels. Given that GDM is an im­
portant precursor of future cardiometabolic complications, women 
with a history of GDM should regularly be screened not only for dia­
betes, but also for CV health.26–29
3.2.6. Further sub-group classification of type 2 
diabetes
For information regarding further sub-group classification of T2DM, 
see Supplementary data online, Section 1.1.1.
3.3. Screening for diabetes
Criteria for diabetes testing differ widely across regions, and a com­
prehensive global screening programme is yet to be developed. It is 
generally agreed, however, that individuals in high-risk groups (those 
living with overweight or obesity, or having markers of insulin resist­
ance, such as acanthosis nigricans or fatty liver disease) should be 
regularly screened, particularly after age 45 years. The ADA devel­
oped a relatively simple 7-point scoring system based on age, sex, 
weight, physical activity (PA), history of GDM, presence of hyperten­
sion, and family history of diabetes; it is advised that those scoring ≥5 
are screened for diabetes.7
The prevalence of diabetes is increased among patients with CVD, 
with 23–37% of patients with ACS and 10–47% of patients with HF di­
agnosed with diabetes. This results in worse clinical outcomes com­
pared with individuals with normal glucose metabolism.30–33
Therefore, individuals with ASCVD and/or HF and/or AF, particularly 
those admitted to hospital with an acute event, should be tested for dia­
betes; those with suspected stress hyperglycaemia (raised glucose levels 
ESC Guidelines                                                                                                                                                                                          4059


<!-- PAGE 18 -->

### Page 18

during admission with normal HbA1c) should undergo post-discharge 
glucose testing, preferably with OGTT, to rule out persistent abnormal 
glucose metabolism.
Although OGTT has been previously advocated for diabetes screen­
ing in individuals with CVD, practicalities and low reproducibility of the 
test limited widespread use.34,35 Importantly, evidence indicates that 
HbA1c, or fasting glucose, are stronger predictors of vascular complica­
tions than 2 h OGTT and it is therefore best to adopt these simple 
measures for general screening, particularly given their high reproduci­
bility.35–38
4. Cardiovascular risk assessment 
in patients with type 2 diabetes
Individuals with T2DM are at a two- to four-fold higher risk of develop­
ing CVD during their lifetime alongside its manifestations CAD, stroke, 
HF, and AF, as well as peripheral artery diseases (PAD).40,41 In addition, 
many patients with CVD have undiagnosed T2DM. Given that having 
diabetes and CVD, especially at a younger age, has a major impact on 
prognosis, it is of utmost importance to screen patients with CVD 
for diabetes and to assess CV risk in individuals with diabetes, and evalu­
ate them for CV and kidney disease.42
4.1. Assessing cardiovascular risk in type 2 
diabetes
When assessing CV risk in individuals with T2DM, it is important to 
consider medical and family history, symptoms, findings from examin­
ation, laboratory and other diagnostic test results, and the presence 
of ASCVD or severe TOD. There is not enough robust evidence to 
suggest that assessment of coronary artery calcium (CAC) or intima 
media thickness help reclassify CV risk in people with T2DM. Severe 
TOD is defined as: 
(i) Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2 
irrespective of albuminuria, or
(ii) eGFR 45–59 mL/min/1.73 m2 and microalbuminuria (urinary 
albumin-to-creatinine ratio [UACR] 30–300 mg/g; stage A2), or
(iii) Proteinuria (UACR >300 mg/g; stage A3), or
(iv) Presence of microvascular disease in at least three different sites 
(e.g. microalbuminuria (stage A2) plus retinopathy plus neur­
opathy; see Section 9.1 for CKD screening).43–45
4.1.1. Cardiovascular risk categories in type 2 
diabetes
Individuals with T2DM should be categorized into different CV risk 
groups based on the following criteria (Table 7):
4.1.2. SCORE2-Diabetes: estimating 10-year 
cardiovascular disease risk
In patients aged ≥40 years with T2DM without ASCVD or severe TOD, 
it is recommended to estimate 10-year CVD risk using the 
SCORE2-Diabetes algorithm (Figure 3). In these patients, risk factors 
for ASCVD should be evaluated on an individual basis. In the 2021 
ESC Guidelines on cardiovascular disease prevention in clinical practice, 
the ADVANCE (Action in Diabetes and Vascular disease: preterAx and 
diamicroN MR Controlled Evaluation) or DIAL (Diabetes lifetime- 
perspective prediction) models were suggested for estimating CVD 
risk among patients with diabetes.46–48 However, these models have 
some limitations for use in Europe, as they do not allow for substantial 
variations of risk across countries, meaning they may misestimate risk 
in these circumstances. Furthermore, these models have been developed 
from a narrow set of studies and have not been systematically ‘recali­
brated’ (i.e. statistically adapted) to contemporary CVD rates, meaning 
they are not ideal for use in contemporary European populations. To ad­
dress these limitations, the current Guidelines recommend use of the 
SCORE2-Diabetes model, which extends the regionally recalibrated 
European SCORE2 10-year risk model to enable use in individuals with 
T2DM aged 40–69 years without ASCVD or severe TOD, and to esti­
mate an individual’s 10-year risk of fatal and non-fatal CVD events (MI, 
stroke).49
SCORE2-Diabetes integrates information on conventional CVD risk 
factors (i.e. age, smoking status, systolic blood pressure [SBP], and total 
and high-density lipoprotein [HDL]-cholesterol) with diabetes-specific 
information (e.g. age at diabetes diagnosis, HbA1c, and eGFR).50 This 
model is calibrated to four clusters of countries (low, moderate, high, 
and very high CVD risk) using the similar methodology of the 
Recommendation Table 1 — Recommendations for 
diagnosing diabetes
Recommendations
Classa
Levelb
Screening for diabetes is recommended in all 
individuals with CVD,c using fasting glucose and/or 
HbA1c.5–7,36,37,39
I
A
It is recommended that the diagnosis of diabetes is 
based on HbA1c and/or fasting plasma glucose, or on 
an OGTT if still in doubt.d,5–8,10,11
I
B
© ESC 2023
CVD, cardiovascular disease; HbA1c, glycated haemoglobin; OGTT, oral glucose tolerance 
test. 
aClass of recommendation. 
bLevel of evidence. 
cCardiovascular disease includes atherosclerotic cardiovascular disease, atrial fibrillation, 
and heart failure. 
dStress hyperglycaemia should be suspected in the presence of high glucose levels and 
normal HbA1c (see text for details).
Table 7 Cardiovascular risk categories in type 2 
diabetes
Very high CV 
risk
Patients with T2DM with: 
• Clinically established ASCVD or
• Severe TOD or
• 10-year CVD risk ≥20% using SCORE2-Diabetes
High CV risk
Patients with T2DM not fulfilling the very high-risk 
criteria and a: 
• 10-year CVD risk 10 to <20% using 
SCORE2-Diabetes
Moderate CV 
risk
Patients with T2DM not fulfilling the very high-risk 
criteria and a: 
• 10-year CVD risk 5 to <10% using 
SCORE2-Diabetes
Low CV risk
Patients with T2DM not fulfilling the very high-risk 
criteria and a: 
• 10-year CVD risk <5% using SCORE2-Diabetes
© ESC 2023
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular 
disease; eGFR, estimated glomerular filtration rate; SCORE2-Diabetes, type 2 
diabetes-specific 10-year CVD risk score; T2DM, type 2 diabetes mellitus; TOD, 
target-organ damage; UACR, urinary albumin-to-creatinine ratio. 
Severe TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR 45– 
59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria 
(UACR >300 mg/g; stage A3); or presence of microvascular disease in at least three 
different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus neuropathy].43–45


<!-- PAGE 19 -->

### Page 19

SCORE2 and SCORE2-Older Persons (SCORE2-OP) algorithms 
(Supplementary data online, Section 2; Table S3).49,51
The ESC CVD Risk Calculation App includes SCORE2-Diabetes to 
facilitate risk estimation and communication between health profes­
sionals and individuals with T2DM (Supplementary data online, Tables 
S4–6).
Additional risk scores that attempt to estimate lifetime risk in indivi­
duals with diabetes (such as the DIAL2 [DIAbetes Lifetime] model, 
which is calibrated to different European countries) can also be used 
to aid treatment decisions.52 However, estimation of lifetime risk 
should be adapted as new methods become available in the future.
Thresholds for the different risk categories are shown in Table 7 and 
Figure 3. In general, no risk threshold is universally applicable, and the 
risk thresholds suggested in these Guidelines for use with 
SCORE2-Diabetes should be used to help guide clinicians and patients 
to prompt joint decision-making conversations for considering the in­
tensity of treatment and additional interventions to prevent ASCVD 
(such as lipid-lowering therapies [Section 5.5] or SGLT2 inhibitors 
and/or GLP-1 RAs [Section 5.3]). However, 10-year risk thresholds 
are for guidance only and other patient characteristics may lead to de­
cisions to treat or not treat irrespective of such thresholds.
5. Cardiovascular risk reduction in 
patients with diabetes: targets and 
treatments
5.1. Lifestyle and diabetes
Lifestyle changes are recommended as the basic measure for preventing 
and managing T2DM.48 Advice should be addressed by a multifactorial 
approach with patient-centred communication adapted to the health 
status and health literacy of the patient (Section 5.7). In T2DM, as inves­
tigated in the Action for Health in Diabetes trial (Look AHEAD; 5145 
T2DM patients, 59% female, mean age 58 years, mean body mass index 
[BMI] 36 kg/m2), lifestyle intervention by nutritional counselling, meal 
replacement, and exercise induced an average of 8.6% weight loss, 
which was associated with a significant reduction in HbA1c and BP.56
Effects on weight and risk-factor control diminished after 5 years in 
those with low adherence to the lifestyle programme.56 After 10 years, 
CV events (i.e. a composite endpoint of CV death, non-fatal MI, non- 
fatal stroke, and hospitalization for angina) were not different to usual 
Very high risk
High risk
Moderate risk
Low risk
Scoringb
SCORE2-Diabetes
Patient with ASCVD or severe TODa
Y
≥20%
10% to <20%
5% to <10%
<5%
N
Figure 3 Cardiovascular risk categories in patients with type 2 diabetes. ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease risk; 
eGFR, estimated glomerular filtration rate; TOD, target-organ damage; UACR, urinary albumin-to-creatinine ratio. aSevere TOD defined as eGFR <45 mL/ 
min/1.73 m2 irrespective of albuminuria; or eGFR 45–59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria (UACR 
>300 mg/g; stage A3), or presence of microvascular disease in at least three different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus neur­
opathy].43–45 bThe thresholds (10-year CVD risk) suggested are not definitive but rather designed to prompt joint decision-making conversations with pa­
tients about intensity of treatment, as well as additional interventions. SCORE2-Diabetes refers to patients aged ≥40 years.
Recommendation Table 2 — Recommendations for 
assessing cardiovascular risk in patients with type 2 
diabetes
Recommendations to assess cardiovascular 
risk in patients with diabetes
Classa
Levelb
It is recommended to screen patients with diabetes 
for the presence of severe TOD.c,43,44
I
A
It is recommended to assess medical history and the 
presence of symptoms suggestive of ASCVD in 
patients with diabetes.53–55
I
B
Continued
In patients with T2DM without symptomatic ASCVD 
or severe TOD,c it is recommended to estimate 
10-year CVD risk via SCORE2-Diabetes.d,50
I
B
© ESC 2023
ASCVD, atherosclerotic cardiovascular disease; eGFR, estimated glomerular filtration rate; 
SCORE2-Diabetes, type 2 diabetes-specific 10-year ASCVD risk score; T2DM, type 2 
diabetes mellitus; TOD, target-organ damage; UACR, urinary albumin-to-creatinine ratio. 
aClass of recommendation. 
bLevel of evidence. 
cSevere TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR 
45–59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or 
proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease in at 
least three different sites (e.g. microalbuminuria (stage A2) plus retinopathy plus 
neuropathy). 
dSCORE2-Diabetes refers to patients aged ≥40 years. In patients with T2DM without 
ASCVD and/or severe TOD, with age <40 years, risk factors for ASCVD should be 
evaluated on an individual basis.
ESC Guidelines                                                                                                                                                                                          4061


<!-- PAGE 20 -->

### Page 20

care.56 However, microvascular disease complications (i.e. develop­
ment of CKD) were significantly reduced (hazard ratio [HR] 0.69; 
95% confidence interval [CI], 0.55–0.87; P = 0.002) by lifestyle interven­
tion, an effect associated with improvements in CV risk factors.57
Additional analyses 16.7 years after the start of the study (9.6 years 
of intervention and then observation) revealed that participants who 
lost ≥10% of weight at 1 year of intervention had a 21% reduced risk 
of mortality (HR 0.79; 95% CI, 0.67–0.94; P = 0.007).58 The decline in 
body fat mass was significantly associated with a lower risk of HF 
with reduced ejection fraction (HFrEF) and HF with preserved ejection 
fraction (HFpEF), while a decline in waist circumference was only signifi­
cantly associated with a lower risk of HFpEF.59 In addition, baseline 
cardio-pulmonary fitness was associated with reduced risks of mortality 
and CV events during follow-up of 9.2 years.60
The DiRECT (Diabetes Remission Clinical Trial)—an open-label, 
cluster-randomized trial in patients with T2DM—assigned practices 
to provide either a weight-management programme including exercise 
(intervention group) or best-practice care by guidelines (control 
group). At 12 months, almost half of the participants in the intervention 
group achieved remission to a non-diabetic state and were off glucose- 
lowering drugs.61 Home-based exercise intervention in patients with 
CAD and T2DM (ARTEMIS study; Finnish randomized controlled trial 
[RCT]; n = 127; 2-year controlled, home-based exercise training vs. 
usual care), however, did not significantly improve CV risk factors des­
pite significant improvements in exercise capacity (P = 0.030).62
5.1.1. Weight reduction
In patients with obesity and T2DM, reducing weight is one of the cor­
nerstones of treatment.63 Weight loss of >5% improves glycaemic con­
trol, lipid levels, and BP in overweight and obese adults with T2DM.64,65
These effects can be achieved by improving energy balance and/or 
introducing obesity medications. Orlistat, naltrexone/bupropion, and 
phentermine/topiramate are each associated with achieving >5% 
weight loss at 52 weeks compared with placebo.66 However, glucose- 
lowering agents such as GLP-1 RAs, the dual agonist tirzepatide, and 
SGLT2 inhibitors also significantly reduce body weight.67,68 Adding ex­
ercise to a GLP-1 RA (liraglutide) had a greater effect on weight reduc­
tion and maintenance.69 Comparing the effects on weight reduction 
between GLP-1 RAs and SGLT2 inhibitors, the former seems to be su­
perior. Given the additional beneficial effects of GLP-1 RAs and SGLT2 
inhibitors on CV outcomes in T2DM (Section 5.3), these agents should 
be the preferred glucose-lowering medication in overweight and obese 
patients with CVD and T2DM, as obesity medications have, to date, not 
shown to reduce CV events.70–72
If weight is not managed effectively by lifestyle interventions and 
medication, bariatric surgery should be considered in patients with 
T2DM and a BMI ≥35 kg/m2 (≥Class II; WHO classification) to achieve 
long-term weight loss, reduce blood glucose, and improve CV risk fac­
tors. Data from the Swedish Obesity Subjects (SOS) study revealed 
that after 24-year follow-up, bariatric surgery was associated with a 
prolonged life expectancy compared with lifestyle and intensive medical 
management alone.73,74 The corresponding HR was 0.70 (95% CI, 
0.57–0.85) for CV death and 0.77 (95% CI, 0.61–0.96) for death 
from cancer.75,76 This evidence has been extended to patients with 
CVD and obesity, as a large case-control study (n = 2638) revealed 
that bariatric surgery was also associated with a lower incidence of ma­
jor adverse cardiovascular events (MACE) in those patients.77 Still, po­
tential adverse events after bariatric surgery should also be 
considered.78
5.1.2. Change in diet or nutrition
In general, patients with T2DM should follow nutritional recommenda­
tions that reduce body weight and improve metabolic control and out­
comes.48 A Mediterranean-style eating pattern improves glycaemic 
control, lipids, and BP.80,81 If this diet is supplemented with olive oil or 
nuts, as in the non-randomized PREvencion con Dieta MEDiterranea 
(PREDIMED) study in individuals at high CV risk (49% T2DM), the risk 
of ASCVD was reduced by 28–31%.82 Recent data from the Coronary 
Diet Intervention With Olive Oil and Cardiovascular Prevention 
(CORDIOPREV) study confirmed the benefit of a Mediterranean diet 
by showing that male patients with established CAD benefitted more 
from a Mediterranean diet than from a low-fat diet intervention after 
7 years of follow-up. A shift from a more animal-based to a plant-based 
food pattern may also reduce ASCVD risk.83–85
Data from studies on supplementation with n–3 fatty acids do not 
support recommending n–3 fatty acid supplements for secondary pre­
vention of CVD in T2DM.86,87
The consumption of sugars, 
sugar-sweetened soft drinks, and fruit juices should be avoided.88,89
Moreover, alcohol intake should generally be moderate, as any amount 
of alcohol uniformly increases BP and BMI.90–92 A high-protein diet 
(30% protein, 40% carbohydrates, and 30% fat) seems to be superior 
to a standard-protein diet (15% protein, 55% carbohydrates, and 
30% fat) in overweight and obese (mean weight 107.8 ± 20.8 kg) pa­
tients with HF; both diets were equal in reducing body weight (3.6 vs. 
2.9 kg, respectively) and waist circumference (1.9 vs. 1.3 cm, respective­
ly), but the high-protein diet resulted in greater reductions in CV risk 
factors, e.g. HbA1c, cholesterol, triglycerides, and BP.93
People with CVD and T2DM are encouraged to reduce sodium in­
take, as this may reduce systolic BP by, on average, 5.8 mmHg in hyper­
tensive patients and 1.9 mmHg in normotensive patients.94,95 In a 
meta-analysis, in hypertensive and normotensive people, reducing salt 
intake by 2.5 g/day resulted in a 20% relative reduction of ASCVD 
events.95 In addition, salt substitution with reduced sodium levels and 
increased potassium levels has been shown to reduce stroke, CVD, 
and overall mortality in patients with high CV risk.96
Recommendation Table 3 — Recommendations for 
reducing weight in patients with type 2 diabetes with 
or without cardiovascular disease
Recommendations
Classa
Levelb
It is recommended that individuals living with 
overweight or obesity aim to reduce weight and 
increase physical exercise to improve metabolic 
control and overall CVD risk profile.56,79
I
A
Glucose-lowering medications with effects on weight 
loss (e.g. GLP-1 RAs) should be considered in 
patients with overweight or obesity to reduce 
weight.67
IIa
B
Bariatric surgery should be considered for high and 
very high risk patients with BMI ≥35 kg/m2 (≥Class 
IIc) when repetitive and structured efforts of lifestyle 
changes combined with weight-reducing medications 
do not result in maintained weight loss.73–77
IIa
B
© ESC 2023
BMI, body mass index; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 
receptor agonist. 
aClass of recommendation. 
bLevel of evidence. 
cWorld Health Organization classification.


<!-- PAGE 21 -->

### Page 21

5.1.3. Increasing physical activity and exercise
Regular moderate to vigorous PA has favourable effects on metabolic 
control and CV risk factors in T2DM.97–100 Intervention programmes 
reduce HbA1c by 0.6% in patients with T2DM, with the combination 
of endurance and resistance exercise having the most beneficial ef­
fects.101 Moreover, compared with low total PA, high total PA is asso­
ciated with a lower CV mortality risk, as well as a reduction in all-cause 
mortality (all-cause mortality: HR 0.60 [95% CI, 0.49–0.73], comparing 
high vs. low total PA).97
Structured exercise intervention is also recommended in patients with 
T2DM with established CVD (e.g. CAD, AF, HFpEF; heart failure with 
mildly reduced ejection fraction [HFmrEF]; HFrEF).102–104 Interval endur­
ance exercise training of more vigorous intensity (e.g. interval walking, al­
ternating between moderate to vigorous intensities) has superior effects 
compared with moderate-intensity continuous walking regarding body 
weight, waist circumference, and glucose control.105 Before starting a 
structured exercise programme in patients with T2DM and established 
CVD, performing a maximal exercise stress test to assess CV pathologies 
should be considered. Moreover, assessment of aerobic and anaerobic 
thresholds by spiroergometry is particularly useful to provide an indivi­
dualized endurance exercise prescription including exercise inten­
sity.106–108 Optimal intensity is determined based on an individual’s 
maximum (peak) effort during spiroergometry, e.g. percentage of cardio­
respiratory fitness (% peak oxygen consumption), percentage of 
maximum (peak) heart rate (% HRmax), or perceived exertion rate ac­
cording to the Borg scale.107–109 Exercise prescription is recommended 
to be adapted to T2DM-associated comorbidities, e.g. CAD, HF, AF, dia­
betic peripheral neuropathy, or retinopathy, as well as age and 
frailty.104,107,108 Resistance exercise is recommended to be performed 
at least twice weekly (intensity of 60–80% of the individual’s 
one-repetition maximum). For older or deconditioned adults, less vol­
ume and lower intensities are recommended, particularly during the ini­
tiation phase of 3–6 weeks.106
Interventions are based on encouraging an increase in any PA, as 
even small amounts were shown to have beneficial effects; even an ex­
tra 1000 steps of walking per day is advantageous and may be a good 
starting point for many patients.98,100 Moreover, a gradual increase in 
activity level is recommended. Structured exercise should be addition­
ally introduced at the start or after first achievements to increase activ­
ity. Patients should perform ≥2 sessions per week of endurance 
exercise and/or resistance exercise training. PA accumulated in bouts 
of even <10 min is associated with favourable outcomes, including re­
duced mortality.110,111
Interventions shown to increase PA level or reduce sedentary behav­
iour include behaviour theory-based interventions, such as goal-setting, 
re-evaluation of goals, self-monitoring, and feedback.112,113 Using a 
wearable activity tracker (e.g. smartphones) may help increase PA.114
Most important is to encourage PA that people enjoy and/or can 
include in their daily routines, as such activities are more likely to be 
feasible and sustainable.
5.1.4. Smoking cessation
Smoking cessation is a key lifestyle intervention in patients with T2DM 
with or without CVD with evidence suggesting a 36% reduction in mor­
tality in CVD patients.118–120 If advice, encouragement, and motivation 
are insufficient, then drug therapies should be considered early, includ­
ing nicotine replacement therapy (chewing gum, transdermal nicotine 
patches, nasal spray, inhaler, sublingual tablets) followed by bupro­
pion.121 In patients with ASCVD, varenicline, bupropion, telephone 
therapy, and individual counselling all increase success rates.122
Electronic cigarettes (e-cigarettes) have been addressed as a potential 
smoking cessation aid to bridge transition from smoking to abstention, 
but—if used at all—should be limited for a short period of time. A con­
sensus regarding the efficacy and safety for this approach has yet to be 
reached.123,124 Overall, smoking cessation programmes have low effi­
cacy at 12 months; nonetheless, cessation measures should be repeti­
tively addressed for smoking abstention to succeed.125
Recommendation Table 5 — Recommendations for 
physical activity/exercise in patients with type 2 diabetes 
with or without cardiovascular disease
Recommendation
Classa
Levelb
It is recommended to increase any physical activity 
(e.g. 10 min daily walking) in all patients with T2DM 
with and without CVD. Optimal is a weekly activity 
of 150 min of moderate intensity or 75 min of 
vigorous endurance intensity.97,98
I
A
It is recommended to adapt exercise interventions to 
T2DM-associated comorbidities, e.g. frailty, 
neuropathy, or retinopathy.108,115
I
B
It is recommended to introduce structured exercise 
training in patients with T2DM and established CVD, 
e.g. CAD, HFpEF, HFmrEF, HFrEF, or AF to improve 
metabolic control, exercise capacity and quality of 
life, and to reduce CV events. 108,115,116
I
B
It is recommended to perform resistance exercise in 
addition to endurance exercise at least twice a 
week.115,117
I
B
The use of behavioural theory-based interventions, 
such as goal-setting, re-evaluation of goals, 
self-monitoring, and feedback, should be considered 
to promote physical activity behaviour.112,113
IIa
B
It should be considered to perform a maximally 
tolerated exercise stress test in patients with T2DM 
and established CVD before starting a structured 
exercise programme.
IIa
C
It may be considered to use wearable activity 
trackers to increase physical activity behaviour.114
IIb
B
© ESC 2023
AF, atrial fibrillation; CAD, coronary artery disease; CV, cardiovascular; CVD, 
cardiovascular disease; HFpEF, heart failure with preserved ejection fraction; HFmrEF, 
heart failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced 
ejection fraction; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 4 — Recommendations for 
nutrition in patients with type 2 diabetes with or without 
cardiovascular disease
Recommendations
Classa
Levelb
It is recommended to adopt a Mediterranean or 
plant-based diet with high unsaturated fat content to 
lower cardiovascular risk.82,85
I
A
© ESC 2023
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4063


<!-- PAGE 22 -->

### Page 22

The assessment of lifestyle risk-factor components and stepwise life­
style recommendations in patients with CVD and diabetes is summar­
ized in more detail in Section 5.7.
5.2. Glycaemic targets
5.2.1. Role of glycated haemoglobin
Reducing HbA1c decreases microvascular complications, particularly 
when achieving near-normal levels (HbA1c <7%, <53 mmol/mol), 
but the effects on macrovascular disease are more complex.126–129
The DCCT (Diabetes Control and Complications Trial) in T1DM 
and the UKPDS (United Kindom Prospective Diabetes Study) in new­
ly diagnosed T2DM have shown that reducing HbA1c decreases long- 
term macrovascular events without having a significant effect in the 
medium term of 6.5–10.0 years.130–132 Other studies, such as 
ADVANCE (Action in Diabetes and Vascular Disease: Preterax and 
Diamicron MR Controlled Evaluation), ACCORD (Action to 
Control Cardiovascular Risk in Diabetes), and VADT (Veterans 
Affairs Diabetes Trial), including higher-risk T2DM cohorts, have simi­
larly failed to show an effect for intensive glycaemic control on short/ 
medium-term macrovascular risk (over 3.5–5.6 years). Meta-analyses 
of the UKPDS, ADVANCE, ACCORD, and VADT studies, including 
27 049 participants, have demonstrated that lowering HbA1c reduces 
MACE, driven by a reduction in MI (HF and stroke risk were unaffect­
ed), and decreases microvascular complications (renal and retinal but 
not neuropathy).133,134
Of interest, the ACCORD trial, with 35% of participants having a 
previous CV event, showed increased mortality (HR 1.22; 95% CI, 
1.01–1.46; P = 0.04) in the intensive glycaemic arm (HbA1c 6.5%, 
48 mmol/mol) compared with controls.129 Also, observational studies 
have shown a U-shaped relationship between HbA1c and clinical out­
come, suggesting that lower HbA1c is not always better.135,136
5.2.2. Additional glycaemic targets
Hypoglycaemia is associated with an increased risk of vascular events, 
explaining recent consensus advocating hypoglycaemic exposure at 
<1% (i.e. <15 min/day) in individuals at high CV risk.137,138 A causal re­
lationship between hypoglycaemia and adverse outcomes is not always 
clear as low glucose levels can be a marker of ill health.139,140
In addition to hypoglycaemia, glycaemic variability is emerging as a 
potential vascular risk factor, but studies are limited and more research 
in this area is warranted.
Post-prandial glucose has been suggested to independently 
predict vascular disease, even in individuals without a previous history 
of diabetes.141 However, manipulating prandial glucose levels failed to 
impact clinical outcome, and therefore, this remains an unresolved 
area.142,143
5.2.3. Glycaemic control following vascular events
Hyperglycaemia following ACS is associated with worse clinical out­
come.144 The DIGAMI 1 (Diabetes Mellitus Insulin-Glucose Infusion 
in Acute Myocardial Infarction) trial demonstrated reduced mortal­
ity with intensive glucose control post-ACS, but DIGAMI 2, which 
was underpowered, failed to confirm these findings.145,146
Unexpectedly, DIGAMI 2 showed a numerical increase in mortality 
in the intervention arm, particularly in insulin-treated patients, sug­
gesting an adverse role for hypoglycaemia in this population.147
Therefore, large-scale glycaemic studies are required, using continu­
ous glucose monitoring (CGM) to assess glucose levels, to establish 
whether optimizing glycaemia in patients with CVD and diabetes 
improves clinical outcome.
In summary, glucose control in individuals with diabetes at high CV 
risk is a complex area and current evidence indicates the need to ad­
dress multiple glycaemic measures, including personalizing HbA1c tar­
gets, minimizing hypoglycaemic exposure, and limiting glucose 
variability. Figure 4 provides a simple guide to glycaemic control in pa­
tients with T2DM and CVD.
Recommendation Table 6 — Recommendations for 
smoking cessation in patients with type 2 diabetes with 
or without cardiovascular disease
Recommendations
Classa
Levelb
It is recommended to stop smoking to reduce 
cardiovascular risk.118–120
I
A
Nicotine replacement therapy, varenicline, and 
bupropion, as well as individual or telephone 
counselling, should be considered to improve 
smoking cessation success rate.121
IIa
B
© ESC 2023
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 7 — Recommendations for 
glycaemic targets in patients with diabetes
Recommendations
Classa
Levelb
It is recommended to apply tight glycaemic control 
(HbA1c <7%) to reduce microvascular 
complications.126–128,133
I
A
It is recommended to avoid hypoglycaemia, 
particularly in patients with CVD.134–137,147
I
B
It is recommended to individualize HbA1c targets 
according to comorbidities, diabetes duration, and 
life expectancy.134,137
I
C
Tight glycaemic control should be considered for 
reducing CAD in the long term, preferably using 
agents with proven CV benefit.c,129–132
IIa
B
© ESC 2023
CAD, coronary artery disease; CVD, cardiovascular disease; GLP-1 RA, glucagon-like 
peptide-1 receptor agonist; HbA1c, glycated haemoglobin; s.c. subcutaneous; SGLT2, 
sodium–glucose co-transporter-2. 
aClass of recommendation. 
bLevel of evidence. 
cSGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, sotagliflozin) or GLP-1 RAs 
(liraglutide, semaglutide s.c., dulaglutide, efpeglenatide).


<!-- PAGE 23 -->

### Page 23

5.3. Atherosclerotic cardiovascular disease 
risk reduction by glucose-lowering 
medications in diabetes
T2DM is common among patients with ASCVD or at the highest risk of 
CVD. The converse is also true: ASCVD is common in patients with 
T2DM.148 Given these relationships, it is key to consider the presence 
of T2DM when deciding strategies to mitigate CV risk. It is imperative 
that the first step in this process is to screen all patients with CVD for 
T2DM. Many decisions are independent of glucose management, there­
fore, T2DM status can inform clinical decision-making for mitigating CV 
risk, as discussed for several other interventions in the current 
Guidelines.149 Capitalizing on the results of multiple dedicated CVOTs 
of glucose-lowering medications in patients with diabetes and ASCVD 
or at high CV risk, there is now a wealth of data to inform the preferential 
use of selected glucose-lowering medications to reduce CV risk, inde­
pendent of glucose management considerations. Glucose-lowering med­
ications can be prescribed with two parallel, mutually exclusive intentions: 
(i) to improve CV outcomes and safety; and (ii) to control glucose. On this 
basis, in the current Guidelines, we have separated prescribing recom­
mendations into those intended to improve CV outcomes and those in­
tended to control glucose. Underpinning these recommendations are 
results from the key CVOTs delineating the efficacy and safety of glucose- 
lowering therapies for treating T2DM and their effect on CV outcomes.
5.3.1. Glucose-lowering medications with 
cardiovascular efficacy demonstrated in dedicated 
cardiovascular outcomes trials
5.3.1.1. Sodium–glucose co-transporter-2 inhibitors
The results of six CVOTs with SGLT2 inhibitors and one trial of a dual 
SGLT1/2 inhibitor have been published, comprising the EMPA-REG 
OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in 
Type 2 Diabetes Mellitus Patients–Removing Excess Glucose) trial, 
the CANVAS (Canagliflozin Cardiovascular Assessment Study) pro­
gramme (two trials combined for analyses), the DECLARE-TIMI 58 
(Dapagliflozin Effect on Cardiovascular Events−Thrombolysis In 
Myocardial Infarction 58) trial, the CREDENCE (Canagliflozin and 
Renal Events in Diabetes with Established Nephropathy Clinical 
Evaluation) trial, the VERTIS CV (eValuation of ERTugliflozin 
effIcacy and Safety CardioVascular Outcomes) trial, and the 
SCORED (Effect of Sotagliflozin on Cardiovascular and Renal 
Events in Patients with Type 2 Diabetes and Moderate Renal 
Impairment Who Are at Cardiovascular Risk) trial (Supplementary 
data online, Table S7).71,150–154
A meta-analysis of the six SGLT2 inhibitor trials demonstrated a re­
duction in the primary ASCVD-based composite of time to first event 
of CV death, MI, or stroke (MACE). This was most apparent in patients 
with established ASCVD (Figure 5).155 Of note, neither dapagliflozin nor 
Short life expectancy
Longer life expectancy
Relax glycaemic targets
HbA1c <69 mmol/mol (<8.5%)a
Tighten glycaemic targets but AVOID hypoglycaemiab
HbA1c <53 mmol/mol (<7.0%)
Give priority to agents with
Proven CV benefitc
Low hypoglycaemic risk
Figure 4 Simple guide to glycaemic targets in patients with type 2 diabetes and cardiovascular disease. CV, cardiovascular; GLP-1 RA, glucagon-like 
peptide-1 receptor agonist; HbA1c, glycated haemoglobin, s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2. aAdjust target in the presence 
of hyperglycaemic symptoms (polyuria and polydipsia). bHypoglycaemia is usually a concern only in those on a sulphonylurea and/or insulin. cSGLT2 inhibitors 
(empagliflozin, canagliflozin, dapagliflozin, sotagliflozin) or GLP-1 RAs (liraglutide, semaglutide s.c., dulaglutide, efpeglenatide).
ESC Guidelines                                                                                                                                                                                          4065


<!-- PAGE 24 -->

### Page 24

ertugliflozin reduced the risk of MACE, but both reduced risk of HF 
hospitalization, with consistency across the class for HF benefits 
(Section 7). Based on these aggregate results, along with the GLP-1 
RAs (see below), SGLT2 inhibitors are a preferred glucose-lowering 
therapy for patients with T2DM with ASCVD, independent of glucose 
control considerations, and independent of background metformin use.
Results from the meta-analysis demonstrated no statistically signifi­
cant benefit for risk of MACE in the subsets of patients without 
ASCVD but with multiple ASCVD risk factors; yet the point estimate 
remains favourable in this subset, with no significant interaction by 
ASCVD status (P = 0.63; Figure 5). In patients with T2DM without 
ASCVD or severe TOD but with a calculated 10-year CVD risk 
≥10% in the SCORE2-Diabetes algorithm (Section 4.1), treatment 
with SGLT2 inhibitors and/or GLP-1 RAs may be considered to re­
duce CV risk, independent of glucose control considerations. This 
recommendation is a consensus within the Task Force based on the 
assumption that some level of predicted CVD risk appears to be 
equivalent to ‘severe TOD risk’, acknowledging it is a Level C recom­
mendation. Of note, it is in line with recommendations from EASD 
and ADA.1,156,157
5.3.1.2. Glucagon-like peptide-1 receptor agonists
Eight randomized, placebo-controlled CVOTs have examined the CV 
safety and efficacy of GLP-1 RAs in patients with T2DM with or at high 
risk of ASCVD. These trials comprise the ELIXA (Evaluation of 
0.25
0.5
1.0
2.0
0.25
0.5
1.0
2.0
Favours Treatment
Favours Placebo
Favours Treatment
Favours Placebo
Treatment
Rate/1000
patient-years
Placebo
37.4
26.9
22.6
38.7
40.0
43.9
31.5
24.2
48.7
40.3
Rate/1000
patient-years
Hazard ratio
(95% CI)
0.86 (0.74–0.99)
0.86 (0.75–0.97)
0.93 (0.84–1.03)
0.80 (0.67–0.95)
0.99 (0.88–1.12)
0.90 (0.85–0.95)
Pooled estimate
(Q statistic P = 0.27; I2 = 23.4%)
A
Treatment
Rate/1000
patient-years
Placebo
ASCVD
No ASCVD
37.4
34.1
36.8
55.6
40.0
43.9
41.3
41.0
65.0
40.3
Rate/1000
patient-years
Hazard ratio
(95% CI)
0.86 (0.74–0.99)
0.82 (0.72–0.95)
0.90 (0.79–1.02)
0.85 (0.69–1.06)
0.99 (0.88–1.12)
0.89 (0.84–0.95)
Pooled estimate
(Q statistic P = 0.34; I2 = 11.8%)
EMPA-REG OUTCOME
CANVAS Program
DECLARE-TIMI 58
CREDENCE
VERTIS CV
EMPA-REG OUTCOME
CANVAS Program
DECLARE-TIMI 58
CREDENCE
VERTIS CV
CANVAS Program
DECLARE-TIMI 58
CREDENCE
15.8
13.4
22.0
15.5
13.3
32.7
0.98 (0.74–1.30)
1.01 (0.66–1.20)
0.68 (0.49–0.94)
0.94 (0.83–1.07)
Pooled estimate
(Q statistic P = 0.10; I2 = 56.5%)
P interaction = 0.63
B
Figure 5 Meta-analysis of cardiovascular outcomes trial results of sodium–glucose co-transporter-2 inhibitors among patients with type 2 diabetes with or 
at high risk for atherosclerotic cardiovascular disease. (A) Overall major adverse cardiovascular events; (B) Major adverse cardiovascular events by athero­
sclerotic cardiovascular disease status. ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; Figure adapted from McGuire et al. 2021.This 
is an open access article distributed under the terms of the CC-BY-NC-ND License https://creativecommons.org/licenses/by-nc-nd/4.0/ 155


<!-- PAGE 25 -->

### Page 25

Lixisenatide in Acute Coronary Syndrome) trial, the LEADER (Liraglutide 
Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome 
Results) trial, the SUSTAIN 6 (Trial to Evaluate Cardiovascular and 
Other Long-term Outcomes With Semaglutide in Subjects With Type 
2 Diabetes) trial, the EXSCEL (Exenatide Study of Cardiovascular Event 
Lowering) trial, the HARMONY Outcomes (Effect of Albiglutide, 
When Added to Standard Blood Glucose Lowering Therapies, on 
Major Cardiovascular Events in Subjects With Type 2 Diabetes 
Mellitus) trial, the REWIND (Researching Cardiovascular Events With a 
Weekly Incretin in Diabetes) trial, the PIONEER 6 (Trial Investigating 
the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 
Diabetes) trial, and the AMPLITUDE-O (Effect of Efpeglenatide on 
Cardiovascular 
Outcomes) 
trial 
(Supplementary 
data 
online, 
Table S8).70,72,158–163
Five of the eight GLP-1 RAs tested demonstrated superior CV out­
comes on the primary composite of time to the first event of CV death, 
0.5
1
1.5
Favours GLP-1RA
Favours Placebo
GLP-1 receptor agonist n/N (%)
Placebo n/N (%)
Hazard ratio
(95% CI)
NNT
(95% CI)
0.87 (0.78–0.97)
0.74 (0.58–0.95)
0.91 (0.83–1.00)
0.78 (0.68–0.90)
0.88 (0.79–0.99)
Subtotal (I2 = 14.9%, P = 0.316)
0.79 (0.57–1.11)
0.73 (0.58–0.92)
0.85 (0.80–0.90)
61 (46–92)
P value
0.01
0.016
0.061
0.0006
0.026
0.17
0.0069
<0.0001
Three-point MACE
0.78 (0.66–0.93)
0.98 (0.65–1.48)
0.88 (0.76–1.02)
0.93 (0.73–1.19)
0.91 (0.78–1.06)
Subtotal (I2 = 12.4%, P = 0.335)
0.49 (0.27–0.92)
0.72 (0.50–1.03)
0.85 (0.78–0.93)
142 (97–305)
0.007
0.92
0.096
0.58
0.21
0.021
0.07
0.0005
Cardiovascular death
0.86 (0.73–1.00)
0.81 (0.57–1.16)
0.97 (0.85–1.10)
0.75 (0.61–0.90)
0.96 (0.79–1.15)
Subtotal (I2 = 16.2%, P = 0.306)
1.04 (0.66–1.66)
0.75 (0.54–1.05)
0.88 (0.81–0.96)
154 (97–463)
0.046
0.26
0.62
0.003
0.63
0.49
0.09
0.0048
Fatal or non-fatal myocardial infarction
0.86 (0.71–1.06)
0.65 (0.41–1.03)
0.85 (0.70–1.03)
0.86 (0.66–1.14)
0.76 (0.62–0.94)
Subtotal (I2 = 0.0%, P = 0.903)
Note:  Weights are from random effects analysis
LEADER
SUSTAIN-6
EXSCEL
Harmony Outcomes
REWIND
PIONEER 6
AMPLITUDE-O
LEADER
SUSTAIN-6
EXSCEL
Harmony Outcomes
REWIND
PIONEER 6
AMPLITUDE-O
LEADER
SUSTAIN-6
EXSCEL
Harmony Outcomes
REWIND
PIONEER 6
AMPLITUDE-O
LEADER
SUSTAIN-6
EXSCEL
Harmony Outcomes
REWIND
PIONEER 6
AMPLITUDE-O
0.76 (0.37–1.56)
0.74 (0.47–1.17)
0.81 (0.74–0.90) 171 (124–324)
0.16
0.066
0.095
0.30
0.010
0.43
0.19
<0.0001
Fatal or non-fatal stroke
TRIAL
608/
108/
839/
338/
594/
694/
146/
905/
428/
663/
61/
189/
76/
125/
219/
44/
340/
122/
317/
278/
46/
383/
130/
346/
15/
75/
30/
50/
292/
54/
483/
181/
223/
339/
67/
493/
240/
231/
37/
91/
35/
58/
173/
30/
187/
94/
158/
199/
46/
218/
108/
205/
13/
47/
17/
31/
4668
1648
7356
4731
4949
4672
1649
7396
4732
4952
1591
2717
1592
1359
4668
1648
7356
4731
4949
4672
1649
7396
4732
4952
1591
2717
1592
1359
4668
1648
7356
4731
4949
4672
1649
7396
4732
4952
1591
2717
1592
1359
4668
1648
7356
4731
4949
4672
1649
7396
4732
4952
1591
2717
1592
1359
(13%)
(7%)
(11%)
(7%)
(12%)
(15%)
(9%)
(12%)
(9%)
(13%)
(4%)
(7%)
(5%)
(9%)
(5%)
(3%)
(5%)
(3%)
(6%)
(6%)
(3%)
(5%)
(3%)
(7%)
(1%)
(3%)
(2%)
(4%)
(6%)
(3%)
(7%)
(4%)
(5%)
(7%)
(4%)
(7%)
(5%)
(5%)
(2%)
(3%)
(2%)
(4%)
(4%)
(2%)
(3%)
(2%)
(3%)
(4%)
(3%)
(3%)
(2%)
(4%)
(1%)
(2%)
(1%)
(2%)
Figure 6 Meta-analysis of cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists (sensitivity analysis removing ELIXA). Risk of major 
adverse cardiovascular events and its components. CI, confidence interval; GLP-1, glucagon-like peptide-1; MACE, major adverse cardiovascular outcomes; 
NNT, number needed to treat. Figure adapted from Sattar et al. 2021.Reprinted from the Lancet with permission from Elsevier.164
ESC Guidelines                                                                                                                                                                                          4067


<!-- PAGE 26 -->

### Page 26

MI, and stroke compared with placebo. A meta-analysis of seven of the 
eight completed GLP-1 RA trials, excluding the ELIXA trial results (due 
to a very short pharmacodynamic half-life [3 h] of once a day [o.d.] lix­
isenatide, and the very high-risk population post-ACS differentiating it 
from all others), showed that a pooled estimate for GLP-1 RA vs. pla­
cebo for the primary outcome was reduced by 15% (HR 0.85; 95% CI, 
0.80–0.90; Figure 6).164 Results from pooled analyses of the effects of 
GLP-1 RA vs. placebo on individual CV outcomes included CV death 
(HR 0.85; 95% CI, 0.78–0.93), MI (HR 0.88; 95% CI, 0.81–0.96), stroke 
(HR 0.81; 95% CI, 0.74–0.90), and hospitalization for HF (HR 0.88; 95% 
CI, 0.79–0.98). Notably, the point estimate in the seven trials was lower 
(HR = 0.85) in those with established ASCVD than in those without 
(HR = 0.94), with Pint = 0.068, suggesting but not conclusively proving 
that GLP-1 RAs may reduce risks more in those with established 
ASCVD. As absolute risks are greater in those with established CV dis­
ease, the absolute benefits are also expected to be greater.
Based on these aggregate results, along with the SGLT2 inhibitors (see 
above) GLP-1 RAs are a preferred glucose-lowering therapy for patients 
with T2DM and ASCVD, independent of glucose control considera­
tions, and independent of background metformin use. In patients with 
T2DM without ASCVD or severe TOD, but with a calculated 10-year 
CVD risk ≥10% in the SCORE2-Diabetes algorithm (Section 4), treat­
ment with GLP-1 RAs and/or SGLT2 inhibitors may be considered to re­
duce CV risk, independent of glucose control considerations. This 
recommendation is a consensus within the Task Force based on the as­
sumption that some level of predicted CVD risk appears to be equivalent 
to ‘severe TOD risk’, acknowledging it is a Level C recommendation. Of 
note, it is in line with recommendations from EASD and ADA.1,156,157
5.3.1.3. Pioglitazone
The PROactive (Prospective Pioglitazone 
Clinical Trial in 
Macrovascular Events) randomized CVOT assessed the CV effects 
of the thiazolidinedione (TZD) pioglitazone vs. placebo, independent 
of glucose control, in patients with T2DM and ASCVD. It failed to 
achieve statistical significance for its primary composite outcome of 
all-cause death, MI, stroke, unstable angina, coronary or peripheral re­
vascularization, and amputation (HR 0.90; 95% CI, 0.80–1.02).165
However, for the principal secondary outcome evaluating the gold- 
standard, three-point composite outcome of CV death, MI, and 
stroke, there was a nominally significant 16% relative risk (RR) reduc­
tion (HR 0.84; 95% CI, 0.72–0.98).165
Results from subsequent meta-analyses and observational studies 
have supported the suggested efficacy of pioglitazone in persons with 
ASCVD.166–169 Notably, the magnitude of the estimated treatment 
benefit with pioglitazone across these studies aligns with contemporary 
meta-analyses estimates of the effects of SGLT2 inhibitors and GLP-1 
RAs on the same composite MACE outcome.155,164
TZDs enhance fluid retention and the risk of peripheral oedema, es­
pecially with concomitant insulin use and in the context of kidney dys­
function. In addition, TZDs increase the risk of HF, with the incremental 
risk of HF with pioglitazone at an estimated 0.4% annualized, absolute 
increase.170 HF associated with TZDs appears to be attributable to ex­
panded plasma volume, with no evidence of myocardial toxicity.171
TZDs induce weight gain due to adipose tissue expansion, but with 
weight redistributed predominantly to less metabolically active adipose 
tissue; weight gain may be the greatest concern of patients and clinicians 
with the TZD class. Based on the data and net benefit-risk assessment, 
it is reasonable to consider using pioglitazone to mitigate ASCVD risk in 
patients with T2DM and prevalent ASCVD.
5.3.2. Glucose-lowering medications with 
cardiovascular safety but not incremental efficacy 
demonstrated in dedicated cardiovascular outcomes 
trials
5.3.2.1. Dipeptidyl peptidase-4 inhibitors
Five randomized CV safety trials in populations with T2DM with or at 
high risk of ASCVD have assessed the CV effects of dipeptidyl 
peptidase-4 (DPP-4) inhibitors (Supplementary data online, Table S9): 
saxagliptin, alogliptin, sitagliptin, and linagliptin each vs. placebo, and li­
nagliptin vs. glimepiride.172–175 All four of the placebo-controlled trials 
demonstrated statistical non-inferiority but not superiority for the 
DPP-4 inhibitors in the primary MACE endpoint. In the SAVOR-TIMI 
53 (Saxagliptin Assessment of Vascular Outcomes Recorded in 
Patients with Diabetes Mellitus—Thrombolysis in Myocardial 
Infarction 53) trial, saxagliptin statistically significantly increased the 
risk of hospitalization for HF vs. placebo.176 Numerically, more HF 
events occurred with alogliptin vs. placebo in the EXAMINE 
(Cardiovascular Outcomes Study of Alogliptin in Patients With Type 
2 Diabetes and Acute Coronary Syndrome) trial, though this difference 
was not nominally significant.177
These observations led to the development and regulatory filing of 
prospective HF analysis plans for the TECOS (Trial Evaluating 
Cardiovascular Outcomes with Sitagliptin) and CARMELINA 
(Cardiovascular and Renal Microvascular Outcome Study With 
Linagliptin in Patients With Type 2 Diabetes Mellitus) trials, each of 
which revealed no increased risk of HF with either sitagliptin or linaglip­
tin compared with placebo.178,179 In the CAROLINA (Cardiovascular 
Outcome Study of Linagliptin Versus Glimepiride in Patients With 
Type 2 Diabetes) trial, linagliptin was compared with the active com­
parator glimepiride, demonstrating no difference in any assessed CV 
or kidney outcome, though noting a higher risk of hypoglycaemia 
with glimepiride.180
5.3.2.2. Lixisenatide and exenatide
Of the eight GLP-1 RAs evaluated in CVOTs, two have demonstrated 
safety but not incremental efficacy. In the ELIXA trial, lixisenatide 10 or 
20 μg o.d. was non-inferior to placebo, but did not significantly affect a 
four-point MACE (three-point MACE plus hospitalization for unstable 
angina) in patients with T2DM post-ACS.158 In the EXSCEL trial of pa­
tients with T2DM in whom 73% had experienced a previous CV event, 
exenatide extended-release 2 mg once weekly showed non-inferiority 
but not superiority to placebo for the primary outcome of CV death, 
MI, and stroke.159
5.3.2.3. Insulin
Two basal insulins have been formally evaluated in dedicated CVOTs. In 
the ORIGIN (Outcome Reduction With Initial Glargine Intervention) 
trial, 12 537 patients (mean age 63.5 years) at high CVD risk with im­
paired fasting glucose (IFG), impaired glucose tolerance (IGT), or 
T2DM were randomized to insulin glargine titrated to a fasting blood 
glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86 After a 
median follow-up of 6.2 years, the incidence of CV outcomes did not 
differ between the two groups.


<!-- PAGE 27 -->

### Page 27

The DEVOTE (A Trial Comparing Cardiovascular Safety of Insulin 
Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes 
at High Risk of Cardiovascular Events) trial, a randomized, double-blind 
comparison of the ultra-long-acting, o.d. insulin degludec vs. insulin glar­
gine U100, enrolled 7637 patients with T2DM with ASCVD or at high 
CV risk.181 Over a median follow-up of 1.8 years, there was no signifi­
cant difference in the primary composite of CV death, non-fatal MI, or 
non-fatal stroke between groups. A significantly lower frequency of 
hypoglycaemia was observed in the degludec arm compared with the 
glargine arm.181
5.3.2.4. Glimepiride
Based on the findings of statistical non-inferiority of linagliptin vs. pla­
cebo in CARMELINA coupled with the non-inferiority of linagliptin 
vs. glimepiride demonstrated in CAROLINA, one might conclude 
that glimepiride is most likely not different from placebo with regards 
to CV safety.180 Thus, the long-lasting uncertainty about the CV safety 
of sulphonylureas may no longer be clinically relevant for glimeperide, at 
least in patients with a shorter duration of diabetes like those enrolled 
in the CAROLINA trial (median duration of T2DM ∼6 years).182
5.3.3. Cardiovascular considerations of older 
glucose-lowering medications not tested in dedicated 
cardiovascular outcomes trials
5.3.3.1. Metformin
Despite its long history as the recommended first-line treatment of 
hyperglycaemia for patients with T2DM, there have been no dedicated 
randomized trials to rigorously assess the CV safety or efficacy of met­
formin. Randomized trials that have reported CV outcomes with met­
formin are most-commonly limited by small sample sizes and few CV 
events for analysis, yielding low statistical power and substantially un­
certain statistical precision of the estimates.
The largest randomized trial with the most encouraging CV results 
for metformin was a nested randomized trial of 753 patients in the 
UKPDS who were overweight or obese at trial entry, comparing con­
ventional glucose targets with a policy of intensive glucose lowering 
with metformin.183 In overweight and obese patients with newly diag­
nosed T2DM without previous CVD, metformin reduced MI by 39%, 
coronary death by 50%, and stroke by 41% over a median period of 
10.7 years. However, with only 39 MIs and 16 coronary deaths in the 
metformin arm of the UKPDS, the precision of these efficacy estimates 
is largely uncertain. Initial randomization to metformin in the UKPDS 
was also associated with a lower incidence of MI and longer survival 
during an additional 8–10 years of passive follow-up.132
In meta-analyses of 13 randomized clinical trials evaluating the CV ef­
fects of metformin vs. placebo or active control, including the data from 
the UKPDS, none of the differences in assessed CV outcomes was stat­
istically significant.184 The pooled HRs (95% CIs) were: all-cause mortal­
ity 0.96 (0.84–1.09); CV death 0.97 (0.80–1.16); MI 0.89 (0.75–1.06); 
stroke 1.04 (0.73–1.48); and peripheral vascular disease 0.81 (0.50– 
1.31). While failing to demonstrate CV efficacy, the upper confidence 
limits of each of the outcomes analysed provide reassurance on the 
CV safety of metformin.
Given the inconclusive results regarding the CV effects of metformin 
outlined above, metformin should not be a prerequisite for considering 
SGLT2 inhibitor or GLP-1 RA treatment for CV benefits. However, most 
patients in CVOTs with SGLT2 inhibitors or GLP-1 RAs were treated 
with metformin. Therefore, in patients already prescribed metformin, 
SGLT2 inhibitors and/or GLP-1 RAs should be added, independent of 
the need for additional glucose control. In patients with T2DM and 
ASCVD not treated with metformin, an SGLT2 inhibitor and/or GLP-1 
RA should be given first line, and metformin should be considered for 
those who thereafter warrant additional glucose control. This Class IIa 
recommendation for metformin is based on the weight of opinion rather 
than the weight of evidence; results from meta-analyses of observational 
studies suggest associations with better CV outcome, but this is not sup­
ported by results from meta-analyses restricted to randomized trials in 
patients with T2DM and ASCVD, where no statistically significant effect 
of metformin has been observed for any major CV outcome.184,185
In patients without ASCVD or severe TOD at low or moderate CV 
risk, treatment with metformin should be considered based on the 
metformin data from the randomized sub-group with overweight or 
obesity from the UKPDS.183 For patients without ASCVD or severe 
TOD at high or very CV high risk, treatment with metformin may be 
considered based on expert consensus of the Task Force.
5.3.3.2. Sulphonylureas
Excepting glimepiride, which was assessed for CV safety and efficacy 
head-to-head against linagliptin in the CAROLINA trial, and gliclazide- 
modified release, which was compared with usual care (that could 
have included treatment with a sulphonylurea other than gliclazide) in 
the ADVANCE trial, dedicated CV safety assessments have not been 
conducted for the other sulphonylureas.132,173,174,184 In the UKPDS, 
which enrolled patients with newly diagnosed T2DM, the sulphonylur­
eas chlorpropamide and glibenclamide (also known as glyburide) did 
not have statistically significant effects on CV outcomes, but important­
ly, no concerning signal of CV risk was observed.127 Likewise, in the 
ADVANCE trial evaluating more intensive glucose control vs. usual tar­
gets, patients randomized to the more intensive arm were randomized 
to treatment with gliclazide-modified release.128 While the gliclazide- 
based more intensive control strategy did not significantly improve 
CV outcomes, there were no major CV safety concerns observed. 
The relative CV safety of gliclazide and glimepiride is somewhat sup­
ported by results of contemporary real-world data analyses.186
5.3.4. Special considerations
5.3.4.1. Hypoglycaemia and cardiovascular risk
Results from numerous studies have demonstrated associations between 
hypoglycaemia and CV events, with substantial uncertainty about whether 
these relationships are causal or simply associations. Results from rando­
mized trials challenge a causal relationship between hypoglycaemia and ad­
verse CV outcomes. For example, insulin degludec compared with 
glargine in the DEVOTE trial reduced the risk of hypoglycaemia, yet this 
did not translate into any difference in CV risk.181 Likewise, in the 
CAROLINA randomized trial, while glimepiride was associated with sig­
nificantly more hypoglycaemia than the DPP-4 inhibitor linagliptin, 
MACE did not differ between the two randomized groups.180 The results 
of these two trials challenge, to some degree, the premise that avoiding 
hypoglycaemia may improve CV risk. In analyses of data from the 
TECOS randomized trial, which compared sitagliptin with placebo, hypo­
glycaemia events were independently associated with subsequent CV 
events, but importantly, the converse was also true.139 A non-fatal CV 
event was independently associated with subsequent hypoglycaemia. 
Similar results were confirmed in other trials.140,187,188
ESC Guidelines                                                                                                                                                                                          4069


<!-- PAGE 28 -->

### Page 28

Therefore, the data suggest that the relationship between hypogly­
caemia events and risk of CV events (and vice versa) is most likely 
one of association rather than causation, each risk marking vulnerability 
and frailty of high CV risk patients. Still, in certain patients, hypogly­
caemia may directly contribute to CV risk. In addition, avoiding hypogly­
caemia remains important given the unpleasant patient experience and, 
for severe events, life-threatening nature if third-party assistance is not 
available.
5.3.4.2. Effects on weight
The choice of glucose-lowering therapy is often influenced by effects on 
weight, when weight loss or avoiding weight gain is a priority. The insu­
lins, sulphonylureas, and pioglitazone all cause weight gain; metformin, 
acarbose, and the DPP-4 inhibitors are weight neutral or may result 
in small amounts of weight loss; and the SGLT2 inhibitors and GLP-1 
RAs are associated with clinically meaningful weight loss, with weight 
effects of GLP-1 RAs being more pronounced than that of SGLT2 
inhibitors.
5.3.5. Implications of results from cardiovascular 
outcomes trials of glucose-lowering medications
Beginning with the EMPA-REG OUTCOME trial results in 2015, an ever- 
increasing body of evidence has accumulated from many CVOTs of 
glucose-lowering medications for patients with T2DM that indicate CV 
benefits from using selected SGLT2 inhibitors and GLP-1 RAs in patients 
with ASCVD. The combined results obtained from CVOTs using GLP-1 
RAs and SGLT2 inhibitors support the primacy of their recommendation 
for all patients with T2DM with prevalent ASCVD, with such considera­
tions made independently of decisions about glycaemic management 
(Figures 7 and 8). Just as T2DM informs prescription of statins, antithrom­
botic therapy, angiotensin-converting enzyme inhibitors (ACE-Is)/ 
angiotensin-II receptor blockers (ARBs), and other CV risk-mitigating 
therapies independent of glycaemic considerations, the same should 
now apply to prescribing SGLT2 inhibitors and/or GLP-1 RAs.
The mechanisms of CV benefits of the novel glucose-lowering 
medications with proven efficacy remain incompletely understood. 
For the GLP-1 RAs, CV efficacy is driven by reduced risk of 
Risk assessment for patients with type 2 diabetes based on the presence of
ASCVD/severe TOD and 10-year CVD risk estimation via SCORE2-Diabetes
Me tfo rm in
SG
LT
2 i nhi bit or
GL
P1 R
A
(C
la ss
 I)
Me tf or mi n
(C
la ss
 II
a 
)
No
 A
SC
V
D 
or
 s ev er e 
T
O
D
SC
O
RE
2Di ab et es
 <
1
0
%
No
 A
SC
V
D 
or
 s ev er e T
O
D
SC
O
RE
2Di ab et es
 
10
%
Lo w 
ris k
M
od er at e 
ris k
Hi gh
 ri sk
Ve ry
 h ig h 
ris k
A
S
C
V
D
(C
las s II
b) 
SG
LT
2 
in hi bi to rb
  
G
LP
-1
 R
Aa
Figure 7 Glucose-lowering treatment for patients with type 2 diabetes to reduce cardiovascular risk based on the presence of atherosclerotic cardiovas­
cular disease/severe target-organ damage and 10-year cardiovascular disease risk estimation via SCORE2-Diabetes. ASCVD, atherosclerotic cardiovascular 
disease; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2; 
T2DM, type 2 diabetes mellitus; TOD, target-organ damage. Risk categorization is based on the presence of ASCVD/severe TOD and 10-year CVD risk 
estimation via SCORE2-Diabetes. For patients with ASCVD, only the Class I recommendation is shown. Treatment recommendations for patients with 
T2DM and severe TOD are described in Section 9. Severe TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR 45–59 mL/ 
min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease 
in at least three different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus neuropathy]. aGLP-1 RAs with proven CV benefit: liraglutide, semaglu­
tide s.c., dulaglutide, efpeglenatide. bSGLT2 inhibitors with proven CV benefit: empagliflozin, canagliflozin, dapagliflozin, sotagliflozin.


<!-- PAGE 29 -->

### Page 29

To reduce CV risk independent of glucose controla
GLP-1 RAb
(Class I)
SGLT2 inhibitorc
(Class I)
Independent of HbA1c
Independent of concomitant glucose-lowering medication
For additional glucose control
Metformin
(Class IIa)
Pioglitazoned
(Class IIb)
Glucose-lowering agents with suggested CV benefit
Glucose-lowering agents with proven CV safety
DPP-4 inhibitors (sitagliptin, alogliptin, linagliptin)e
Other GLP-1 RAs (lixisenatide, exenatide ER, oral semaglutide)
Ertugliflozinf
Glucose-lowering agents without CV safety evaluation
E.g. short-acting insulins
E.g. other sulfonylureas
Sulfonylureas (glimepiride or gliclazide)
Insulin glargine or insulin degludec
Figure 8 Glucose-lowering treatment for patients with type 2 diabetes and atherosclerotic cardiovascular disease to reduce cardiovascular risk. ASCVD, 
atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration 
rate; ER, extended release; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; MACE, major adverse cardiovascular events; 
s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. aIn patients with ASCVD and T2DM, it is recommended to 
treat with a GLP-1 RA and an SGLT2 inhibitor with proven benefit to reduce CV risk, independent of HbA1c and concomitant glucose-lowering medications. 
If additional glucose control is needed, treatment with metformin should be considered and treatment with pioglitazone may be considered. bGLP-1 RAs with 
proven CV benefit: liraglutide, semaglutide s.c., dulaglutide, efpeglenatide. cSGLT2 inhibitors with proven CV benefit: empagliflozin, canagliflozin, dapagliflozin, 
sotagliflozin. dPioglitazone should not be used in patients with heart failure; the use in CKD requires caution as intravascular volume expansion and heart 
failure are common at reduced eGFR. eDPP-4 inhibitors should not be used in patients on GLP-1 RAs. fErtugliflozin in the VERTIS CV trial showed safety 
with respect to three-point MACE but no benefit.
ESC Guidelines                                                                                                                                                                                          4071


<!-- PAGE 30 -->

### Page 30

ASCVD-related events.164 While empagliflozin and canagliflozin im­
proved the composite of CV death, MI, and stroke, all of the 
SGLT2 inhibitors reduce HF-related endpoints (Section 7) and pro­
gression of kidney disease (Section 9).155,190 Thus, SGLT2 inhibitors 
are recommended to reduce HF hospitalization in patients with 
T2DM with or at risk of HF, or who have CKD. In patients with newly 
diagnosed T2DM without CVD or other major CV risk factors who 
are at low or moderate CV risk, factors other than mitigating CV and 
kidney risk may play a greater role in selecting glucose-lowering med­
ications, such as affordability, accessibility, side effects, weight bene­
fits, tolerability, and ease of use.
5.4. Blood pressure and diabetes
In the most recent ESC/EURObservational Research Programme 
(EORP) EUROASPIRE surveys, history of hypertension was present 
in 80% of men and 87% of women with known diabetes and in 74% 
of men and 81% of women with newly diagnosed diabetes with a his­
tory of coronary heart disease (CHD).191
5.4.1. Screening and diagnosis
Regular BP measurements under standardized conditions are manda­
tory in all patients with diabetes (Figure 9; Table 8). Hypertension 
should be confirmed in both arms using multiple readings, including 
measurements on separate days.48,157 In patients with CVD and values 
>180/110 mmHg, it could be reasonable to diagnose hypertension at a 
single visit.192 Details on BP measurements are comprehensively sum­
marized in the 2018 ESC/European Society of Hypertension (ESH) 
Guidelines for the management of arterial hypertension and in the 
Supplementary data online, Section 2.6.1.193
5.4.2. Treatment targets
Randomized controlled trials have shown the benefit (reduction of 
stroke, coronary events, and kidney disease) of lowering SBP to 
Recommendation Table 8 — Recommendations for 
glucose-lowering treatment for patients with type 2 
diabetes and atherosclerotic cardiovascular disease to 
reduce cardiovascular risk
Recommendations
Classa
Levelb
It is recommended to prioritize the use of 
glucose-lowering agents with proven CV benefitsc,d 
followed by agents with proven CV safetye over agents 
without proven CV benefit or proven CV safety.
I
C
Sodium–glucose co-transporter-2 inhibitors
SGLT2 inhibitors with proven CV benefitc are 
recommended in patients with T2DM and ASCVD 
to reduce CV events, independent of baseline or 
target HbA1c and independent of concomitant 
glucose-lowering medication.71,150–152,155,189
I
A
Glucagon-like peptide-1 receptor agonists
GLP-1 RAs with proven CV benefitd are 
recommended in patients with T2DM and ASCVD 
to reduce CV events, independent of baseline or 
target HbA1c and independent of concomitant 
glucose-lowering medication.70,72,161,163,164
I
A
Other glucose-lowering medications to reduce cardiovascular 
risk
If additional glucose control is needed, metformin 
should be considered in patients with T2DM and 
ASCVD.
IIa
C
If additional glucose control is needed, pioglitazone 
may be considered in patients with T2DM and 
ASCVD without HF.165
IIb
B
© ESC 2023
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular 
disease; DPP-4, dipeptidyl peptidase-4; GLP-1 RA, glucagon-like peptide-1 receptor 
agonist; HbA1c, glycated haemoglobin; HF, heart failure; s.c., subcutaneous; SGLT2, 
sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cEmpagliflozin, canagliflozin, dapagliflozin, sotagliflozin. 
dLiraglutide, semaglutide s.c., dulaglutide, efpeglenatide. 
eMetformin, pioglitazone, DPP-4 inhibitor (sitagliptin, alogliptin, linagliptin), glimepiride, 
gliclazide, insulin glargine, insulin degludec, ertugliflozin, lixisenatide, exenatide (extended 
release), oral semaglutide.
Recommendation Table 9 — Recommendation for 
glucose-lowering treatment for patients with type 2 dia­
betes without atherosclerotic cardiovascular disease or 
severe target-organ damage to reduce cardiovascular 
risk
Recommendations
Classa
Levelb
In patients with T2DM without ASCVD or severe 
TODc at low or moderate risk, treatment with 
metformin should be considered to reduce CV risk.183
IIa
C
Continued
In patients with T2DM without ASCVD or severe 
TODc at high or very high risk, treatment with 
metformin may be considered to reduce CV risk.
IIb
C
In patients with T2DM without ASCVD or severe 
TODc but with a calculated 10-year CVD riskd 
≥10%, treatment with a SGLT2 inhibitor or GLP-1 
RA may be considered to reduce CV risk.155,164
IIb
C
© ESC 2023
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular 
disease; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 
receptor agonist; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes 
mellitus; TOD, target-organ damage; UACR, urinary albumin-to-creatinine ratio. 
aClass of recommendation. 
bLevel of evidence. 
cSevere TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR 
45–59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or 
proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease in at 
least three different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus 
neuropathy]. 
dUsing SCORE2-Diabetes.


<!-- PAGE 31 -->

### Page 31

<140 mmHg and diastolic blood pressure (DBP) to <90 mmHg in pa­
tients with diabetes. However, the optimal BP target in patients with 
diabetes is still a matter of debate. The UKPDS post-trial, 10-year 
follow-up study reported no benefits persisting from the earlier period 
of tight BP control with respect to macrovascular events, death, and 
microvascular complications, while initial between-group BP differ­
ences were no longer maintained.132 RCTs evaluating the benefits 
and risks of more intense compared with standard hypertension treat­
ment strategies in patients with diabetes are summarized in 
Supplementary data online, Table S10.
In a meta-analysis of RCTs involving patients with diabetes or pre- 
diabetes, an SBP reduction to ≤135 mmHg compared with a less intensive 
control reduced the RR of all-cause mortality by 10% (odds ratio [OR] 0.90; 
95% CI, 0.83–0.98), whereas more intensive BP control (≤130 mmHg) was 
associated with a greater reduction in stroke but did not reduce other 
events.194,195 Similarly, anti-hypertensive treatment significantly reduced 
mortality in people with T2DM, CAD, HF, and stroke, with an achieved 
mean SBP of 138 mmHg, whereas only stroke was reduced significantly, 
with a mean SBP of 122 mmHg compared with higher BP values.196
Thus, reducing SBP to <130 mmHg may benefit patients with a particularly 
high risk of a cerebrovascular event, such as those with a history of 
stroke.193,194,196–200 However, SBP >140 mmHg or <120 mmHg were re­
lated to higher risk of adverse renal outcomes in patients with diabetes 
when compared with those without diabetes and with high CV risk.199–202
The 2018 ESC/ESH Guidelines for the management of arterial hyper­
tension recommend that in all patients with diabetes, office BP should 
be targeted to an SBP of 130 mmHg, and lower if tolerated but not 
<120 mmHg; DBP should be lowered to <80 mmHg but not 
<70 mmHg.193 In older patients (age ≥65 years), the SBP target range 
should be 130–140 mmHg if tolerated.193 However, more recent data 
challenge these recommendations for all patients with diabetes, and 
highlight a potential need for more individualized target levels.157,203,204
The 2021 ESC Prevention Guideline recommends office SBP treat­
ment target ranges of 120–130 mmHg in patients with diabetes, with 
lower SBP acceptable if tolerated until the age of 69 years.48 In patients 
aged ≥70 years, SBP values <140 mmHg, down to 130 mmHg if toler­
ated are recommended. DBP treatment target <80 mmHg is recom­
mended for all treated patients.
5.4.3. Management of hypertension
5.4.3.1. Effects of lifestyle intervention and weight loss
Diets rich in vegetables, fruits, and low-fat dairy products, such as the 
Mediterranean diets and Dietary Approaches to Stop Hypertension-style 
eating patterns (including reducing sodium to <100 mmol/day and increas­
ing potassium intake), improve BP control.205–207
Patient with increased BP
High normal BP
SBP 130–139 mmHg and/or DBP 85–89 mmHg
Hypertension
BP ≥140/90 mmHg
Out of office BP
measurement
(ABPM or HBPM)
Repeated visits for office BP measurements
Consider masked hypertension
To confirm diagnosis
Out of office BP
measurement
(ABPM or HBPM)
OR
Figure 9 Screening and diagnosis of hypertension in patients with diabetes. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; DBP, dia­
stolic blood pressure; HBPM, home blood pressure monitoring; SBP, systolic blood pressure. Figure adapted from Williams et al. 2018.193
Table 8 Blood pressure measurement
BP measurements at the initial and every follow-up visit (at every routine 
clinical visit).
Patients should be seated comfortably in a quiet environment for 5 min 
before beginning BP measurements. 
Three BP measurements should be recorded, 1–2 min apart, and 
additional measurements if the first two readings differ by >10 mmHg. 
BP is recorded as the average of the last two BP readings.
Measure BP 1 min and 3 min after standing from a seated position in all 
patients on initial visit to exclude orthostatic hypotension; lying and 
standing BP measurements should also be considered in subsequent 
visits.
Out-of-office BP measurement with ambulatory and/or home BP 
monitoring should be implemented when feasible. 
Masked hypertension should be considered in patients with normal and 
high-normal office BP but with HMOD or at high cardiovascular risk.193
© ESC 2023
BP, blood pressure; HMOD, hypertension-mediated organ damage.
ESC Guidelines                                                                                                                                                                                          4073


<!-- PAGE 32 -->

### Page 32

Long-term exercise training intervention modestly but significantly 
reduces SBP (by −7 mmHg) and DBP (by −5 mmHg). Ideally, an exer­
cise prescription aimed at lowering BP in individuals with normal BP 
or hypertension would include a mix of predominantly aerobic exercise 
training supplemented with dynamic resistance exercise training.208
A marked improvement in CV risk factors (hypertension, dyslipidae­
mia, diabetes), associated with marked weight loss, was observed after 
bariatric surgery.209 In the Look AHEAD trial, those who lost 5 to 
<10% of body weight had increased odds of achieving a 5 mmHg de­
crease in SBP and DBP compared with those who lost >10% or 
<5%.210 The frequency of CV complications appears to be modulated 
by ethnicity or racial identity.193,211,212
5.4.3.2. Pharmacological treatments in patients with diabetes
If office SBP is ≥140 mmHg and/or DBP is ≥90 mmHg, drug therapy is 
necessary in combination with non-pharmacological treatment. It is re­
commended to start with a combination therapy.48 All available 
BP-lowering drugs can be used, but evidence strongly supports using a 
renin–angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in 
patients with evidence of end-organ damage (albuminuria and left ven­
tricular [LV] hypertrophy).213–216 However, in a recent meta-analysis, 
RAS inhibitors were not superior to other classes of anti-hypertensive 
drugs for reducing total or CV mortality and renal events.217
Controlling BP often requires multiple drug therapy with an RAS inhibi­
tor and a calcium channel blocker (CCB) or diuretic, while the combination 
of an ACE-I with an ARB is not recommended.218 Consider beta-blockers 
at any treatment step when specifically indicated, e.g. HF, angina, post-MI, 
AF, or younger women with or planning pregnancy.193 A combination of 
two or more drugs at fixed doses in a single pill should be considered to 
improve adherence and to achieve earlier control of BP.48,219
In apparent resistant (including MRA-resistant) hypertension in pa­
tients with HFpEF (61% diabetes; post-hoc analysis of PARAGON-HF 
[Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity 
and Mortality in Heart Failure Patients With Preserved Ejection 
Fraction] trial) sacubitril/valsartan helped to better control BP com­
pared with valsartan.220
5.4.3.3. Blood pressure changes with glucose-lowering agents
Trials testing GLP-1 RAs have shown a BP decrease with these drugs, 
partly due to weight loss. A sustained decrease in BP was observed 
with semaglutide therapy (SBP dose dependent: −1.3 to −2.6 mmHg) 
with a slight increase in heart rate (+2 to 2.5 beats per minute 
[b.p.m.]).72 Similar effects were seen in other studies of GLP-1 RAs 
and derived from meta-analysis.161,221,222
SGLT2 inhibitors induced a larger BP decrease than did GLP-1 RAs 
without changing heart rate.223–225 A recent meta-analysis including seven 
RCTs demonstrated that SGLT2 inhibitors were associated with an aver­
age reduction of 3.6/1.7 mmHg (systolic/diastolic) in 24 h ambulatory BP, 
which is comparable with efficacy of low-dose hydrochlorothiazide.224–226
5.4.4. Sex-specific aspects
In general, the diagnosis and treatment of hypertension is comparable 
between sexes, except for women of child-bearing potential or during 
pregnancy, when some drugs, such as RAS blockers, can have adverse 
effects on the foetus, especially in early gestation.227 The possible effect 
of oral contraceptives on BP should also be considered.48 There is 
some evidence from RCTs that BP targets during pregnancy should 
range from 110 to 135 mmHg for SBP and 80 to 85 mmHg for 
DBP.228 This is also supported by the recent CHAP (Chronic 
Hypertension and Pregnancy) study of mild chronic hypertension in 
pregnancy, where 16% of the pregnant women had diabetes.229 The 
strategy targeting a BP of <140/90 mmHg was related with better preg­
ancy outcomes without an increase in the number of Small for 
Gestational Age babies.
Women usually show greater differences in BP and higher propor­
tions of hypertension than men already at diagnosis of T2DM com­
pared with women and men without T2DM, and worse BP control 
thereafter.191,230 Moreover sex-specific, hypertension-mediated organ 
damage was evidenced with a very high risk of HFpEF in women, espe­
cially in the presence of diabetes.231
Recommendation Table 10 — Recommendations for 
blood pressure management in patients with diabetes
Recommendations
Classa
Levelb
Screening for hypertension
Regular BP measurementsc are recommended in all 
patients with diabetes to detect and treat 
hypertension to reduce CV risk.193,232,233
I
A
Treatment targets
Anti-hypertensive drug treatment is recommended 
for people with diabetes when office BP is ≥140/ 
90 mmHg.196,202,234,235
I
A
It is recommended to treat hypertension in patients 
with diabetes in an individualized manner. The BP goal 
is to target SBP to 130 mmHg and <130 mmHg if 
tolerated, but not <120 mmHg. In older people (age 
>65 years), it is recommended to target SBP to 130– 
139 mmHg.196,236–238
I
A
An on-treatment SBP target of <130 mmHg may be 
considered in patients with diabetes at particularly 
high risk of a cerebrovascular event to further reduce 
their risk of stroke.194–198,239,240
IIb
B
Treatment and evaluation
Lifestyle changes (weight loss if overweight, physical 
activity, alcohol restriction, sodium restriction, 
increased consumption of vegetables, using low-fat 
dairy products) are recommended in patients with 
diabetes and hypertension.205–207,210
I
A
It is recommended to initiate treatment with a 
combination of a RAS inhibitor and a CCB or 
thiazide/thiazide-like diuretic.196,213–216,218,241
I
A
Home BP self-monitoring should be considered in 
patients with diabetes on anti-hypertensive treatments 
to check that BP is appropriately controlled.242
IIa
B
24 h ambulatory blood pressure monitoring should 
be considered to assess abnormal 24 h BP patterns, 
including nocturnal hypertension and reduced or 
reversed nocturnal BP dipping, and to adjust 
anti-hypertensive treatment.243
IIa
B
© ESC 2023
BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; CV, 
cardiovascular; CVD, cardiovascular disease; RAS, renin–angiotensin system; SBP, systolic 
blood pressure. 
aClass of recommendation. 
bLevel of evidence. 
cIdeally at every encounter.


<!-- PAGE 33 -->

### Page 33

5.5. Lipids and diabetes
A cluster of lipid and apolipoprotein abnormalities accompanies dia­
betes. The core components are moderately elevated plasma triglycer­
ide (TG), TG-rich lipoprotein (TRL), and TRL cholesterol levels, 
normal-to-mildly 
elevated 
low-density 
lipoprotein-cholesterol 
(LDL-C), and low high-density lipoprotein-cholesterol (HDL-C). 
Other features comprise structure and function of lipoproteins, e.g. 
small dense LDL and HDL particles. The same abnormalities are also 
reported in patients with T1DM, whose long-lasting exposure to dysli­
pidaemia might induce atherosclerosis as early as in adolescence. In 
T1DM, high LDL-C values are seen in patients with uncontrolled gly­
caemia, while high levels of HDL-C might be pro-inflammatory and 
therefore atherogenic instead of protective.244 In well-controlled 
T1DM, HDL-C levels tend to be normal (or even slightly elevated), 
as are serum TGs.245
5.5.1. Treatment targets
Epidemiological studies have shown that high levels of LDL-C and 
non-HDL-C and low levels of HDL-C are associated with an increased 
risk of CV events and mortality in patients with and without diabetes.246
Conversely, RCTs with lipid-lowering agents in patients at risk of CV 
events (including patients with T2DM) have demonstrated a log-linear 
proportional reduction of CV events and mortality for each 1 mmol re­
duction of LDL-C.247 LDL-C is the primary target of lipid-lowering 
therapies. A secondary goal of non-HDL-C should also be considered 
in patients with diabetes and combined dyslipidaemias, although there 
are limited data from interventional trials. Treatment targets differ 
among patients with diabetes based on their CV risk (Section 4; 
Figure 10).48 Due to the lack of evidence, no clear recommendations 
can be given for patients with T2DM at low CV risk.
5.5.2. Lipid-lowering agents
5.5.2.1. Statins
Statins remain the first-line therapy to reduce LDL-C levels in patients 
with diabetes and dyslipidaemia, due to their efficacy in preventing CV 
events and reducing CV mortality with no evidence for sex 
differences.248,249
High-intensity statins (rosuvastatin and atorvastatin) are indicated in 
patients with diabetes at high or very high CV risk, as they lower LDL-C 
by 40–63% and significantly reduce the incidence of major cerebral and 
coronary complications.250 This beneficial effect outweighs the poten­
tial diabetogenic effect of these drugs, estimated as a 9% increased risk 
of incident diabetes, especially in older patients and in patients already 
at risk of developing diabetes.251,252 Similar benefits were seen in both 
T1DM and T2DM.253–255
Statins are safe and generally well tolerated. Subjective adverse events 
(such as fatigue, myalgias, and nervous system symptoms) are more fre­
quent than objective adverse events due to the nocebo effect, with wo­
men experiencing adverse events more frequently than men.256 In most 
cases of myopathy or rhabdomyolysis, there are drug interactions with a 
higher-than-standard dose of statin or combination with gemfibrozil.200
Evidence indicates that 70–90% of patients who report statin intolerance 
are able to take a statin when re-challenged.257
5.5.2.2. Ezetimibe
Lowering of LDL-C can be further intensified by adding ezetimibe to a 
statin, which reduces cholesterol absorption from the ileum.258 The 
IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy 
International Trial) trial showed significantly reduced MACE (compos­
ite of CV death, non-fatal MI, unstable angina requiring re- 
hospitalization, 
coronary 
revascularization 
≥30 
days 
after 
Very high risk
High risk
Moderate risk
LDL-C <1.4 mmol/L
(<55 mg/dL)
(Class I)
LDL-C <1.8 mmol/L
(<70 mg/dL)
(Class I)
LDL-C <2.6 mmol/L
(<100 mg/dL)
(Class I)
CV risk categorization in patients with T2DM based on ASCVD, severe TOD, or SCORE2-Diabetes
Figure 10 Recommended low-density lipoprotein-cholesterol targets by cardiovascular risk categories in patients with type 2 diabetes. ASCVD, athero­
sclerotic cardiovascular disease; CV, cardiovascular; LDL-C, low-density lipoprotein-cholesterol; TOD, target-organ damage; T2DM, type 2 diabetes mellitus.
ESC Guidelines                                                                                                                                                                                          4075


<!-- PAGE 34 -->

### Page 34

randomization, or non-fatal stroke; HR 0.94; 95% CI, 0.89–0.99) in pa­
tients post-ACS receiving simvastatin plus ezetimibe, with a stronger 
benefit in the sub-group of patients with diabetes (HR 0.85; 95% CI, 
0.78–0.94; P <0.001).259,260 The combination of ezetimibe with a statin 
is therefore recommended in patients with diabetes and a recent ACS, 
especially when an LDL-C target <1.4 mmol/L (55 mg/dL) is required 
and not achieved with a statin alone. Young adults with T1DM have in­
creased cholesterol absorption, as shown in a recent study, suggesting 
greater efficacy of ezetimibe in this population, which remains to be as­
sessed with dedicated RCTs.261
5.5.2.3. Proprotein convertase subtilisin/kexin type 9 inhibitors
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 
evolocumab and alirocumab are monoclonal antibodies that strongly 
reduce plasma LDL-C, targeting the protein involved in regulating the 
LDL receptor on the hepatocyte.262 Administered alongside high- 
intensity statin therapy (with or without ezetimibe), PCSK9 inhibitors 
significantly reduced MACE in the sub-groups of patients with diabetes 
with ASCVD enrolled in the FOURIER (Further Cardiovascular 
Outcomes Research with PCSK9 Inhibition in Subjects with Elevated 
Risk) trial and in the ODYSSEY OUTCOMES (Evaluation of 
Cardiovascular Outcomes After an Acute Coronary Syndrome 
During Treatment With Alirocumab) trial, respectively.263,264 In par­
ticular, evolocumab showed a 17% RR reduction of a composite pri­
mary endpoint of CV death, MI, stroke, hospitalization for unstable 
angina, or coronary revascularization in patients with diabetes included 
in the FOURIER trial (HR 0.83; 95% CI, 0.75–0.93; P = 0.0008).263
Compared with placebo, evolocumab also significantly reduced other 
atherogenic lipids (i.e. TGs, non-HDL-C, apolipoprotein B-containing 
particles) in patients with diabetes and mixed dyslipidaemia enrolled 
in the BANTING (Evaluation of Evolocumab Efficacy in Diabetic 
Adults 
With 
Hypercholesterolemia/Mixed 
Dyslipidemia) 
and 
BERSON (Safety and Efficacy of Evolocumab in Combination With 
Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed 
Dyslipidemia) studies.265,266
Alirocumab significantly reduced the rate of a composite of CV 
death, MI, stroke, or hospitalization for unstable angina in the sub-group 
of patients with ACS with T2DM (n = 5444) of the ODYSSEY 
OUTCOMES trial.267 Alirocumab on top of the maximum tolerated 
statin dose was also more effective than ezetimibe, fenofibrate, or 
non-lipid-lowering therapy in reducing non-HDL-C and other athero­
genic lipids in patients with diabetes enrolled in the ODYSSEY 
DM-DYSLIPIDEMIA (Efficacy and Safety of Alirocumab Versus Usual 
Care on Top of Maximally Tolerated Statin Therapy in Patients With 
Type 2 Diabetes and Mixed Dyslipidemia) trial.268
A meta-analysis by Khan et al. did not show a significant association be­
tween PCSK9 inhibitors and new-onset diabetes (HR 1.00; 95% CI, 0.93– 
1.07; P = 0.96; I2 = 0%), while confirming a modest risk of incident diabetes 
with statins only (HR 1.10; 95% CI, 1.05–1.15; P < 0.001; I2 = 0%).269
5.5.2.4. Fibrates and other TG-lowering drugs
Potential use of fibrates to reduce TG levels is quite limited, due to the 
risk of myopathy if given with statins and the little benefit demonstrated 
in RCTs, aside from sub-group analysis including subjects with very high 
TG levels.200,270,271 Pemafibrate is a new selective peroxisome 
proliferator-activated receptor-α 
modulator with a superior 
benefit-risk balance compared with conventional fibrates.272 A phase 
3 trial determining the efficacy of pemafibrate in preventing MACE in 
patients with diabetes has been terminated early for futility.273
If TGs remain elevated even with a statin-based regimen, icosapent 
ethyl, a stable ester of eicosapentaenoic acid, might be preferred 
over other omega–3 fatty acids at the dose of 2 g twice a day (b.i.d.), 
due to its favourable impact on CV outcomes reported in the 
REDUCE-IT (Reduction of Cardiovascular Events with Icosapent 
Ethyl—Intervention Trial) trial, where benefit was consistent in patients 
with (58%) and without diabetes (Pint = 0.29).274 This benefit remained 
significant even considering a slight increase of LDL-C and high- 
sensitivity C-reactive protein due to the effect of mineral oil in the pla­
cebo arm.275,276
5.5.3. Novel cholesterol-lowering drugs
5.5.3.1. Inclisiran
Inclisiran inhibits hepatic synthesis of PCSK9 with a long-lasting effect.277
Patients on statins with high LDL-C levels and ASCVD or at least one 
ASCVD risk equivalent were included in the two phase 3 trials 
ORION-10 and ORION-11 (Inclisiran for Participants With 
Atherosclerotic Cardiovascular Disease and Elevated Low-density 
Lipoprotein Cholesterol), and obtained a further 50% reduction of 
LDL-C with inclisiran.278 This benefit was consistent in patients with dia­
betes in both trials, and CV outcome endpoints are currently being tested 
in a phase 3 trial enrolling patients with ASCVD (ORION-4 trial).279
5.5.3.2. Bempedoic acid
Bempedoic acid is a pro-drug that reduces cholesterol synthesis by in­
hibiting adenosine triphosphate (ATP) citrate lyase, with very limited 
musculoskeletal-related side effects.280 In the CLEAR (Cholesterol 
Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Harmony 
trial, adding bempedoic acid to statins significantly reduced LDL-C le­
vels (–16.5%) in patients with ASCVD or familial hypercholesterol­
aemia, with consistent results in the sub-group of patients with 
diabetes (–19.1%).267 Bempedoic acid did not induce new-onset dia­
betes or worsen diabetes as shown by a subsequent meta-analysis.281
High CV risk patients who were unable or unwilling to take statins 
have been included in the CLEAR Outcomes study and randomized 
to bempedoic acid or placebo. Among the 6992 patients assigned to 
the active arm of the study 45% had T2DM. Bempedoic acid was asso­
ciated with a significantly lower incidence of the four-component com­
posite primary endpoint of CV death, non-fatal MI, non-fatal stroke, or 
coronary revascularization and a higher incidence of some adverse 
events (gout and cholelithiasis) at the 40.6 month follow-up. Of note, 
the data were only released just before finalising these Guidelines and 
could thus not be included.282
Recommendation Table 11 — Recommendations for 
the management of dyslipidaemia in patients with 
diabetes
Recommendations
Classa
Levelb
Lipid targets
In patients with T2DM at moderate CV risk, an 
LDL-C target of <2.6 mmol/L (<100 mg/dL) is 
recommended.248,249
I
A
In patients with T2DM at high CV risk, an LDL-C 
target of <1.8 mmol/L (<70 mg/dL) and LDL-C 
reduction of at least 50% is recommended.248,249
I
A
Continued


<!-- PAGE 35 -->

### Page 35

5.6. Antithrombotic therapy and diabetes
Several mechanisms contribute to platelet activation and coagulation in 
diabetes (Figure 11). The pharmacology of different antithrombotic 
agents can be found in the Supplementary data online, Section 2.7 and 
Figures S1–5.
5.6.1. Patients without a history of symptomatic 
atherosclerotic cardiovascular disease or 
revascularization
The largest meta-analysis on 95 000 individual participant data (IPD) of 
patients at average CV risk (0.57% MACE/year) from six RCTs, included 
3818 (4%) patients with diabetes. In the whole cohort, low-dose acetyl­
salicylic acid (ASA) significantly reduced MACE vs. control (absolute risk 
reduction [ARR] 0.06%/year; P = 0.0001), while increasing major extra­
cranial bleed (0.10% vs. 0.07%/year; absolute risk increase 0.03%/year; 
P < 0.0001; Supplementary data online, Table S11).291 A similar 
proportional benefit-risk profile was also observed in the diabetes sub- 
group (Supplementary data online, Table S11).
The ASCEND (A Study of Cardiovascular Events iN Diabetes) trial 
was the largest, adequately powered, placebo-controlled RCT testing 
low-dose ASA in patients with T1DM or T2DM (n = 15 480) with no 
evident CVD.292 Over 7.4 years, ASA significantly reduced serious vas­
cular events vs. placebo (8.5% vs. 9.6%, respectively; RR 0.88; 95% CI, 
0.79–0.90; P = 0.01; number needed to treat [NNT] 91; 
Supplementary data online, Table S11), with a relative benefit similar 
to the previous meta-analysis.291
Bleeding Academic Research 
Consortium (BARC) type 3–5 bleeding (Supplementary data online, 
Figure S6) occurred in 4.1% vs. 3.2% of patients in the ASA and placebo 
arms, respectively (RR 1.29; 95% CI, 1.09–1.52; P = 0.003; number 
needed to harm [NNH] 111). ASA-associated major bleeding excess 
was largely gastrointestinal, without differences in fatal, intracranial, 
and ocular bleeding. The NNT/NNH ratio was 0.8. The pre-specified 
sub-group analysis based on vascular risk score at baseline was consist­
ent with the overall population (Supplementary data online, Figure S7).
The benefit of ASA in the ASCEND trial was observed on top of sta­
tins (75% of patients) and/or anti-hypertensive (∼60% of patients) 
drugs.292 Consistently, a recent IPD meta-analysis of 18 162 patients 
with multiple CV risk factors and no previous ASCVD (risk 1.7%/ 
year) showed a significant benefit of low-dose ASA, incremental to 
lipid- and BP-lowering drugs. This was also observed in a diabetes sub- 
group (Supplementary data online, Table S11).293
A 9.2-year follow-up analysis of the ASCEND trial excluded harm of 
ASA on incident dementia, with a trend towards a reduction (HR 0.89; 
95% CI, 0.75–1.06) confirmed by a meta-analysis of three large primary 
prevention RCTs (HR 0.92; 95% CI, 0.84–1.01; P = 0.09).294
Large, observational, prospective data suggest CAC as a non-invasive 
biomarker to identify asymptomatic patients at the highest risk of 
ASCVD or revascularization, with or without diabetes, who may largely 
benefit from ASA.295 Ongoing trials are testing the relevance of CAC 
score and related thresholds in improving primary prevention, including 
in asymptomatic patients with diabetes.296–298
In summary, in patients with diabetes and no history of symptomatic 
ASCVD or revascularization, ASA (75–100 mg o.d.) may be considered 
to prevent the first severe vascular event. However, in patients with 
diabetes with asymptomatic ASCVD (including documented CAD con­
firmed by imaging) and a higher CV risk, the net benefit of platelet in­
hibition by ASA may be higher and thus, therapy needs to be 
individualized.
In patients with T2DM at very high CV risk, an LDL-C 
target of <1.4 mmol/L (<55 mg/dL) and LDL-C 
reduction of at least 50% is recommended.248,249
I
B
In patients with T2DM, a secondary goal of a 
non-HDL-C target of <2.2 mmol/L (<85 mg/dL) in 
very high CV risk patients and <2.6 mmol/L 
(<100 mg/dL) in high CV risk patients is 
recommended.283–285
I
B
Lipid-lowering treatment
Statins are recommended as the first-choice 
LDL-C-lowering treatment in patients with diabetes 
and above-target LDL-C levels. Administration of 
statins is defined based on the CV risk profile of the 
patients and the recommended LDL-C (or 
non-HDL-C) target levels.247–249
I
A
A PCSK9 inhibitor is recommended in patients at 
very high CV risk, with persistently high LDL-C levels 
above target despite treatment with a maximum 
tolerated statin dose, in combination with ezetimibe, 
or in patients with statin intolerance.267,286
I
A
If the target LDL-C is not reached with statins, 
combination therapy with ezetimibe is 
recommended.259,260
I
B
If a statin-based regimen is not tolerated at any 
dosage (even after re-challenge), a PCSK9 inhibitor 
added to ezetimibe should be considered.287,288
IIa
B
If a statin-based regimen is not tolerated at any 
dosage (even after re-challenge), ezetimibe should be 
considered.259,260
IIa
C
High-dose icosapent ethyl (2 g b.i.d.) may be 
considered in combination with a statin in patients 
with hypertriglyceridaemiac.274
IIb
B
© ESC 2023
b.i.d., twice a day; CV, cardiovascular; HDL-C, high-density lipoprotein-cholesterol; LDL-C, 
low-density lipoprotein-cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; 
T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cHypertriglyceridaemia: triglycerides 150–499 mg/dL, according to the inclusion of the 
REDUCE-IT trial.
Recommendation Table 12 — Recommendations for 
patients with diabetes without a history of symptomatic 
atherosclerotic cardiovascular disease or revascularization
Recommendation
Classa
Levelb
In adults with T2DM without a history of 
symptomatic ASCVD or revascularization, ASA (75– 
100 mg o.d.) may be considered to prevent the first 
severe vascular event, in the absence of clear 
contraindications.c,292,293
IIb
A
© ESC 2023
ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; o.d., once daily; 
T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cHigh risk of bleeding due to gastrointestinal haemorrhage or peptic ulcer within the 
previous 6 months, active hepatic disease (such as cirrhosis, active hepatitis), or history 
of ASA allergy.
ESC Guidelines                                                                                                                                                                                          4077


<!-- PAGE 36 -->

### Page 36

5.6.2. Patients with atherosclerotic cardiovascular 
disease and/or revascularization without an 
indication for long-term oral anticoagulation
5.6.2.1. Chronic coronary syndromes
Patients with diabetes and documented significant CAD or with prior 
revascularization are at very high CV risk, and low-dose ASA (75– 
100 mg o.d.) is recommended, although ad hoc RCTs are lacking.48,299
Both the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial 
Assessing Benefits and Long-term) and CURRENT-OASIS 7 
(Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent 
EveNTs/Optimal Antiplatelet Strategy for InterventionS) trials showed 
comparable efficacy of a lower dose (75–100 mg o.d.) and a three- to 
four-fold higher (300–325 mg o.d.) ASA dose in both chronic coronary 
syndrome (CCS) and ACS.300,301
Clopidogrel provides an alternative in ASA-intolerant patients or can 
be combined with low-dose ASA (clopidogrel 75 mg o.d. and ASA 75– 
100 mg o.d.) as dual antiplatelet therapy (DAPT) in patients with CCS 
undergoing percutaneous coronary intervention (PCI).
The THEMIS (Effect of Ticagrelor on Health Outcomes in Diabetes 
Mellitus Patients Intervention Study) trial tested the efficacy and safety of 
adding the P2Y12 inhibitor ticagrelor (60 mg b.i.d.) or placebo to ASA 
(75–150 mg o.d.) in 19 220 patients with diabetes and a history of PCI or 
coronary artery bypass graft (CABG), or a documented stenosis (≥50%) 
in at least one coronary artery, and no previous MI or stroke 
Hyperglycaemia, insulin resistance or deficiency, metabolic imbalances
Atherothrombosis
Hypertension
Smoking
Obesity
Dyslipidaemia
Fibrin network
Activated platelets
Thrombin generation
Inflammation
ROS
Platelet turnover
Non-enzymatic protein glycation modifying function
Pro-coagulant and hypofibrinotic milieu
Endothelial dysfunction
NO synthesis
Figure 11 Mechanisms contributing to altered platelet activation and atherothrombosis in patients with diabetes. ↑, increase; ↓, decrease; NO, nitric oxide; 
ROS, reactive oxygen species.289,290 The figure depicts the major determinants contributing to platelet activation leading to atherothrombosis in patients 
with diabetes. An inflammatory environment, metabolic changes, endothelial dysfunction and altered platelet turnover result in a platelet population char­
acterized by enhanced activation, increased thrombin generation, and suppression of the fibrinolytic system. Thrombin release by platelets and de novo gen­
eration through activation of the coagulation pathway further amplify platelet activation and result in fibrin network formation, thus playing a pivotal role in 
the increased risk of thrombosis in individuals with diabetes.


<!-- PAGE 37 -->

### Page 37

(Supplementary data online, Table S11).302 Over a median 3.3 years of 
follow-up, the primary efficacy outcome of CV death, MI, or stroke showed 
a marginal 10% RR reduction by ticagrelor vs. placebo, while both 
Thrombolysis in Myocardial Infarction (TIMI) major and intracranial bleed­
ing were significantly increased. The pre-specified sub-groups of CABG or 
previous PCI showed a benefit-risk profile consistent with the entire 
trial.302,303 The NNT/NNH ratio was 1.5. Thus, an unfavourable 
benefit-risk profile is associated with adding ticagrelor to ASA in this setting.
The COMPASS (Cardiovascular Outcomes for People Using 
Anticoagulation Strategies) trial enrolled 27 395 patients with stable 
ASCVD (previous MI, symptomatic CAD, and/or PAD). Low-dose 
ASA combined with very low-dose rivaroxaban (2.5 mg b.i.d.) was su­
perior to ASA and placebo in preventing MACE (4.1% vs. 5.4%, respect­
ively; HR 0.76; 95% CI, 0.66–0.86; P < 0.001; NNT 77).304 International 
Society on Thrombosis and Haemostasis-defined major bleeding, but 
not fatal or intracranial bleeding, was increased (1.9% vs. 3.1%, respect­
ively; HR 1.70; 95% CI, 1.40–2.05; P < 0.001; NNH 83), with an NNT/ 
NNH ratio of 0.9 (Supplementary data online, Figure S7). The propor­
tional benefit-risk profile of the diabetes sub-group (38% of all patients) 
was similar to the overall population. Based on these data, adding very 
low-dose rivaroxaban to low-dose ASA for long-term prevention of 
serious vascular events should be considered in patients with diabetes 
and CCS or symptomatic PAD without high bleeding risk.304,305 Data 
are available up to 47 months of ASA plus very low-dose rivaroxaban 
exposure; beyond this time, continuation should be determined on 
an individual basis and with regular evaluation of thrombotic vs. bleeding 
risks.
5.6.2.2. Acute coronary syndrome
5.6.2.2.1. Peri-procedural management. Peri-procedural management 
of patients with ACS or undergoing PCI, which may include glycoprotein 
IIb/IIIa inhibitors, cangrelor, heparins, or bivalirudin, is detailed in the 2018 
ESC/European Association for Cardio-Thoracic Surgery (EACTS) 
Guidelines on myocardial revascularization.299,306–308
5.6.2.2.2. Post-procedural management. In patients with ACS 
undergoing PCI, 12 months’ DAPT with low-dose ASA and prasugrel 
or ticagrelor was superior to DAPT with clopidogrel in the diabetes 
sub-group of the respective RCTs, with a benefit-risk profile similar 
to the overall trial populations (Supplementary data online, Tables 
S12–13).309–312 With the limitations of a subgroup analysis, patients 
with diabetes on DAPT with low-dose ASA and prasugrel tended to 
have a more favourable benefit-risk profile.312 The open-label 
ISAR-REACT 5 (Intracoronary Stenting and Antithrombotic Regimen: 
Rapid Early Action for Coronary Treatment) trial randomized 4018 pa­
tients with ACS to prasugrel or ticagrelor added to ASA.313 Prasugrel 
was superior to ticagrelor in reducing MACE without increasing major 
bleeding, with similar effects in the sub-group of patients with diabetes 
(n = 892; 22%; Supplementary data online, Table S12).313
Thus, DAPT, i.e. low-dose ASA with prasugrel or ticagrelor are pre­
ferred to DAPT with clopidogrel in patients with diabetes and ACS 
(Supplementary data online, Table S12),309–312 unless the patient is 
deemed at very high bleeding risk. Of note, patients with T2DM 
have a reduced generation of the active metabolite of clopidogrel 
compared with patients without diabetes (Supplementary data 
online, Section 2.7).323,324 Notably, previous intracranial bleeding con­
traindicates patients to both prasugrel and ticagrelor.
In patients with diabetes and ACS who do not undergo cardiac revas­
cularization, DAPT with ASA (75–100 mg o.d.) and a P2Y12 receptor 
inhibitor, preferably ticagrelor over clopidogrel, is recommended for 
12 months.314,315
5.6.2.2.3. Prolonging DAPT post-ACS. The GLOBAL-LEADERS 
(A Clinical Study Comparing Two Forms of Antiplatelet Therapy 
After Stent Implantation) trial failed to show superior efficacy or safety 
of 24 months of ticagrelor monotherapy post-ACS vs. the standard 
12-month DAPT followed by 12-month low-dose ASA monotherapy 
in the overall and diabetes (25% of all patients) cohorts.316
The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in 
Patients With Prior Heart Attack Using Ticagrelor Compared to 
Placebo on a Background of Aspirin) trial compared prolonged ticagre­
lor therapy (60 or 90 mg b.i.d.) with placebo added to low-dose ASA in 
patients with an MI 1–3 years before study entry and additional CV risk 
factors.317 Reduced-dose ticagrelor (60 mg) decreased MACE com­
pared with placebo (7.77% vs. 9.04%, respectively; HR 0.84; 95% CI, 
0.74–0.95; P = 0.004; NNT 79), with no heterogeneity with respect 
to the diabetes sub-group, whereas it significantly increased TIMI major 
bleeding (2.3% vs. 1.06%, respectively; HR 2.32; 95% CI, 1.68–3.21; 
NNH 81), dyspnoea, serious adverse events, and drug discontinuation 
rates.317 Based on these data, DAPT prolonged beyond 12 months 
should be considered up to 3 years in patients with diabetes who 
have tolerated DAPT without major bleeding.63,317,318 The median 
follow-up across all trials on prolonging full-dose DAPT was 18 months 
(interquartile range 12–24 months), with a maximum DAPT exposure 
no longer than 36 months.318 No sufficient safety and efficacy data are 
available for DAPT with reduced-dose ticagrelor beyond 3 years, espe­
cially considering the significant TIMI major bleeding increase of the as­
sociation (Supplementary data online, Figure S6).317,319
5.6.2.2.4. Shortening or de-escalating DAPT post-ACS in diabetes.
No evidence supports shortening or de-escalating DAPT post-ACS specif­
ically in patients with diabetes, since RCTs on shorter DAPT duration fol­
lowed by ASA or a P2Y12 inhibitor monotherapy are relatively small, often 
with non-inferiority design for efficacy, relatively low power, and wide non- 
inferiority margins. In addition, these RCTs had primary endpoints combin­
ing minor bleeding with traditional efficacy outcomes, efficacy outcomes 
including not only MACE, and diabetes sub-groups that contain few pa­
tients and events, especially on the major hard endpoints 
(Supplementary data online, Table S13).320,321 Moreover, large, superiority 
RCTs have failed to show a higher efficacy of routine platelet-function test­
ing in guiding antiplatelet therapy post-PCI.322,322a Of note, the 
TROPICAL-ACS (Testing Responsiveness to Platelet Inhibition on 
Chronic Antiplatelet Treatment For Acute Coronary Syndromes) trial ‘de- 
escalating’ P2Y12 inhibition from prasugrel to clopidogrel after 2 weeks of 
DAPT based on platelet function testing showed an upper HR limit for 
MACE of 1.93 in the diabetes sub-group (HR 1.17; 95% CI, 0.71–1.93). 
Moreover, CV death was significantly increased in sub-groups with dia­
betes vs. without diabetes in the ‘de-escalating’ arm (HR 2.42; 95% CI, 
0.61–9.67; Pint = 0.04), thus suggesting harm from de-escalation compared 
with standard recommended DAPT.321 In addition, patients with diabetes 
form less of the clopidogrel active metabolite resulting in less platelet inhib­
ition (Supplementary data online, Section 2.7).323,324
Thus, shortening or de-escalating DAPT below 12 months is not recom­
mended in patients with diabetes in the 12 months post-ACS. Current evi­
dence does not support platelet function testing to adjust DAPT.
Figure 12 summarizes recommendations in patients with diabetes 
and ACS or CCS undergoing PCI or CABG.
ESC Guidelines                                                                                                                                                                                          4079


<!-- PAGE 38 -->

### Page 38

Low dose ASA
(Class I)
Revascularization (PCI, CABG) for ACS and CCS in patients with diabetes and no indication for anticoagulation
DAPT
Low dose ASA and prasugrel or ticagrelor
(Class I)
DAPT
Low dose ASA and prasugrel or ticagrelor
(Class 1)
DAPT
Low dose ASA
and clopidogrel
(Class I)
Low dose
ASA
(Class I)
Low dose
ASA
(Class I)
Low dose
ASA
(Class I)
Low dose 
ASA
(Class I)
DAPT
based on bleeding risk
(Class Ila)
PCI
CABG
ACS
PCI
CABG
CCS
0 months
6 months
12 months
24 months
36 months
Time
Figure 12 Recommendations for antiplatelet therapy in patients with diabetes with acute or chronic coronary syndrome undergoing percutaneous cor­
onary intervention or coronary artery bypass grafting without indications for long-term oral anticoagulation. ACS, acute coronary syndrome; ASA, acetyl­
salicylic acid; CABG, coronary artery bypass graft; CCS, chronic coronary syndrome; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary 
intervention.
Recommendation Table 13 — Recommendations for 
antithrombotic therapy in patients with diabetes and 
acute or chronic coronary syndrome without indications 
for long-term oral anticoagulation
Recommendations
Classa
Levelb
ASA at a dose of 75–100 mg o.d. is recommended in 
patients with diabetes and previous MI or 
revascularization (CABG or stenting).291,325,326
I
A
In patients with ACS and diabetes who undergo PCI, 
a P2Y12 receptor inhibitor (ticagrelor or prasugrel) is 
recommended in addition to ASA (75–100 mg o.d.), 
maintained over 12 months. 310–312,314
I
A
Clopidogrel 75 mg o.d. following appropriate loading 
(e.g. 600 mg or at least 5 days already on 
maintenance therapy) is recommended in addition to 
ASA for 6 months following coronary stenting in 
patients with CCS, irrespective of stent type, unless a 
shorter duration is indicated due to the risk or 
occurrence of life-threatening bleeding.327–332
I
A
Clopidogrel is recommended as an alternative in case 
of ASA intolerance.333
I
B
Continued
In patients with diabetes and ACS treated with 
DAPT who are undergoing CABG and do not 
require long-term OAC therapy, resuming a P2Y12 
receptor inhibitor as soon as deemed safe after 
surgery and continuing it up to 12 months is 
recommended.315,334,335
I
C
Prolonging DAPT beyond 12 months after ACS 
should be considered for up to 3 years in patients 
with diabetes who have tolerated DAPT without 
major bleeding complications.c,317,318,336
IIa
A
Adding very low-dose rivaroxaband to low-dose ASA 
for long-term prevention of serious vascular events 
should be considered in patients with diabetes and 
CCS or symptomatic PAD without high bleeding 
risk.304,305
IIa
B
© ESC 2023
ACS, acute coronary syndrome; ASA, acetylsalicylic acid; b.i.d., twice a day; CABG, 
coronary artery bypass graft; CCS, chronic coronary syndrome; DAPT, dual antiplatelet 
therapy; MI, myocardial infarction; OAC, oral anticoagulant; o.d., once daily; PAD, 
peripheral arterial disease; PCI, percutaneous coronary intervention. 
aClass of recommendation. 
bLevel of evidence. 
cIn case of ticagrelor, a reduced dose (60 mg b.i.d.) should be used.317
dRivaroxaban 2.5 mg b.i.d.


<!-- PAGE 39 -->

### Page 39

5.6.3. Patients with atherosclerotic cardiovascular 
disease and/or revascularization requiring long-term  
oral anticoagulation
In patients requiring long-term oral anticoagulants (OACs; e.g. those 
with AF) undergoing PCI for ACS or CCS, DAPT with clopidogrel is 
combined with full-dose OACs (triple antithrombotic therapy 
[TAT]). Combined antithrombotic drugs, while effective, increase 
major bleeding risk.337,338 RCTs have compared TAT with dual an­
tithrombotic therapy (DAT) combining an OAC mostly with clopi­
dogrel, in patients with AF and ACS or post-PCI (Supplementary 
data online, Table S14). These RCTs have some common features: 
a primary outcome of safety comprising moderate-to-major, often 
BARC-defined, bleeding (Supplementary data online, Figure S7); effi­
cacy (including CV death, MI, stroke, as well as revascularization, and/ 
or stent thrombosis) as a secondary endpoint, often with a non- 
inferiority comparison; relatively short follow-up (6–14 months); 
and limited sample size with few patients with diabetes (28–37% 
across RCTs; Supplementary data online, Table S14).339–342 Thus, 
these RCTs are underpowered to assess both the efficacy of DAT 
and the safety of major bleeding of TAT in patients with diabetes. 
Moreover, two meta-analyses suggest significantly higher MI and 
stent thrombosis rates with DAT vs. TAT (Supplementary data 
online, Table S14).343,344 The lack of high-quality evidence on efficacy, 
meta-analyses suggesting some harm, and the underlying high CV and 
stent thrombosis risk in patients with diabetes, indicate that TAT 
duration should be cautiously and systematically evaluated for 
both thrombotic and bleeding risks in the individual patient with 
diabetes.
5.6.4. Preventing gastrointestinal bleeding
Large observational studies or head-to-head RCTs show similar rates 
of gastrointestinal and non-gastrointestinal major bleeding for single 
antiplatelet therapy (SAPT) with low-dose ASA or a P2Y12 inhibitor 
(clopidogrel or ticagrelor).337,338,346–350 Thus, gastrointestinal mucosal 
bleeding appears to be due to pre-existing mucosal lesions associated 
with defective primary haemostasis secondary to platelet inhibition, 
rather than with a specific antiplatelet drug. A meta-analysis showed 
that gastroprotectant drugs significantly reduce the risk of gastro­
intestinal bleeding in patients on single or combined antithrombotic 
drugs.351 This benefit was also observed in the pre-specified sub- 
group of 6732 patients with diabetes in the COMPASS trial, consist­
ent with large population studies on proton pump inhibitors and 
OACs (either vitamin K antagonist [VKA] or non-vitamin K antagonist 
oral anticoagulant [NOACs]).352 Regarding CV safety, the composite 
of MI, stroke, CV death, CHD, and acute limb ischaemia was similar 
between pantoprazole and placebo, as was the rate of new-onset dia­
betes.337,351–355
Recommendation Table 14 — Recommendations for 
antithrombotic therapy in patients with diabetes and 
acute or chronic coronary syndrome and/or post- 
percutaneous coronary intervention requiring long- 
term oral anticoagulation
Recommendations
Classa
Levelb
In patients with AF and receiving antiplatelet therapy, 
eligible for anticoagulation, and without a 
contraindication,c NOACs are recommended in 
preference to a VKA.339,340,343
I
A
In patients with ACS or CCS and diabetes 
undergoing coronary stent implantation and having 
an indication for anticoagulation, triple therapy with 
low-dose ASA, clopidogrel, and an OAC is 
recommended for at least 1 week, followed by dual 
therapy with an OAC and a single, oral, antiplatelet 
agent.339–342,344,345
I
A
In patients with ACS or CCS and diabetes 
undergoing coronary stent implantation and having 
an indication for anticoagulation, prolonging triple 
therapy with low-dose ASA, clopidogrel, and an 
OAC should be considered up to 1 month if the 
thrombotic risk outweighs the bleeding risk in the 
individual patient.341–344
IIa
C
Continued
In patients with ACS or CCS and diabetes 
undergoing coronary stent implantation and having 
an indication for anticoagulation, prolonging triple 
therapy with low-dose ASA, clopidogrel, and an 
OAC up to 3 months may be considered if the 
thrombotic risk outweighs the bleeding risk in the 
individual patient.341–344
IIb
C
© ESC 2023
ACS, acute coronary syndrome; AF, atrial fibrillation; CCS, chronic coronary syndrome; 
NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; PCI, 
percutaneous coronary intervention; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cContraindications to NOACs are prosthetic mechanical heart valve, mitral stenosis, and 
creatinine clearance below the approved threshold for the specific NOAC.
Recommendation Table 15 — Recommendations for 
gastric protection in patients with diabetes taking an­
tithrombotic drugs
Recommendations
Classa
Levelb
When antithrombotic drugs are used in combination, 
proton pump inhibitors are recommended to 
prevent gastrointestinal bleeding.337,347,348,351–353,355
I
A
When a single antiplatelet or anticoagulant drug is 
used, proton pump inhibitors should be considered 
to prevent gastrointestinal bleeding, considering the 
bleeding risk of the individual patient.338,347,348,351,352
IIa
A
When clopidogrel is used, omeprazole and 
esomeprazole are not recommended for gastric 
protection.356
III
B
© ESC 2023
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4081


<!-- PAGE 40 -->

### Page 40

5.7. Multifactorial approach to risk-factor 
management in diabetes
Optimal risk factor and lifestyle management, as well as early identification 
and treatment of comorbidities, is a cornerstone of treatment for 
T2DM.357–359 The Swedish National Diabetes Registry revealed a clear im­
provement of clinical outcomes by each risk factor within the target range 
(HbA1c, LDL-C, albuminuria, smoking, and SBP).360 In patients with ad­
vanced disease, e.g. T2DM and established microalbuminuria, an intensive, 
target-driven, multifactorial therapy (Steno-2 study; targets: HbA1c <6.5%, 
total cholesterol <4.5 mmol/L [175 mg/dL], and BP <130/80 mmHg) re­
sulted in 50% fewer microvascular and macrovascular events after 7.8 
years of follow-up.361 Long-term follow-up (21 years from baseline) 
showed significantly reduced end-stage renal disease combined with death 
(HR 0.53; 95% CI, 0.35–0.80), and risk of HF hospitalization reduced by 
70%.362 Overall, this resulted in a 7.9 year gain of life expectancy.363
These positive effects were not observed in the clinical intervention trials 
of intensified, multifactorial treatment for T2DM in primary care and early 
in the disease trajectory. The ADDITION (Anglo-Danish-Dutch Study of 
Intensive Treatment in People with Screen Detected Diabetes in 
Primary Care) trial showed that microvascular or macrovascular events 
were not significantly reduced after 5 or 10 years (17% and 13% reduction, 
respectively), while intervention only slightly improved HbA1c.364,365 In ac­
cordance, the J-DOIT3 (Japan Diabetes Optimal Integrated Treatment 
Study for 3 Major Risk Factors of Cardiovascular Diseases) trial in patients 
with T2DM aged 45–69 years revealed a non-significant trend towards a 
reduced primary composite outcome (non-fatal MI, stroke, revasculariza­
tion, or all-cause death; HR 0.81; 95% CI, 0.63–1.04; P = 0.094) with inten­
sive vs. conventional therapy.366 Post-hoc analyses showed that only 
cerebrovascular events were reduced (HR 0.42; 95% CI, 0.24–0.74; P =  
0.002), while no differences were seen for all-cause death and coronary 
events. In addition, the Look AHEAD trial, introducing lifestyle intervention 
in patients with obesity and T2DM with 10 years’ follow-up, did not dem­
onstrate a reduction in the composite CV outcome.56
Key problems in optimally treating patients with T2DM and CVD are 
the low rate of detection of T2DM in patients with CVD, the low re­
ferral rate to diabetes specialists, and the difficulty of prolonged adher­
ence to medication or lifestyle interventions in this patient group. The 
EUROASPIRE V survey reported that many patients with CVD (29.7%) 
had known diabetes, while 41.1% of those with unknown T2DM were 
dysglycaemic.367 Of patients with known diabetes, 31% had been ad­
vised to attend a diabetes clinic, though only 24% attended. Only 
58% of dysglycaemic patients were prescribed all cardio-protective 
drugs, and use of SGLT2 inhibitors or GLP-1 RAs was limited (3% 
and 1%, respectively).367 A BP target <140/90 mmHg was achieved in 
only 61% of patients with newly detected T2DM, and in 54% of patients 
with previously known T2DM.34 An LDL-C target <1.8 mmol/L was 
only achieved in 18% and 28% of patients, respectively. This was ex­
plained by low prescription rates of the combination of all cardio- 
protective drugs (antiplatelet therapy, beta-blockers, RAS inhibitors, 
and statins) in only 55% of patients with newly detected T2DM, and 
in 60% of patients with previously known T2DM.34 The concept of a 
polypill, e.g. containing aspirin, ramipril, and atorvastatin, may even im­
prove clinical events in secondary cardiovascular prevention.368
Furthermore, adherence to lifestyle intervention fades over time, with 
continuously increasing body weight after 1 year.56 To overcome adher­
ence failures, the 2021 ESC Guidelines on cardiovascular disease preven­
tion in clinical practice outlines a stepwise approach to treating risk factors 
and intensifying treatment to help physicians and patients pursue risk- 
factor targets, taking into account patient profiles and preferences, ensur­
ing targets are a part of a shared decision-making process involving 
healthcare professionals and patients.48 This stepwise approach starts 
with assessing CVD risk in all patients with diabetes, including glycaemic 
state and lifestyle risk-factor profile (Figure 13). CVD risk stratification 
should be individually adapted according to comorbidities, e.g. CAD, 
HF, AF, or PAD, as well as age, frailty, and sex. This includes discussing in­
dividual preferences with the patient, particularly regarding lifestyle strat­
egies and potential treatment benefits. Particularly in the field of T2DM, 
studies have shown benefits of a stepwise approach to intensify treat­
ment, and it appears that attaining treatment goals is similar, side effects 
are fewer, and patient satisfaction is significantly higher with such an ap­
proach.369,370 Supporting evidence comes from the Italian Diabetes and 
Exercise Study 2, which showed that a behavioural intervention strategy 
compared with standard care resulted in a sustained increase in physical 
activity and decrease in sedentary time among patients with T2DM.371
To achieve a high adherence and optimization of target goals, clinician– 
patient communication is crucial and should include a personalized ap­
proach explaining background and targets to improve understanding and 
encourage lifestyle changes and drug-therapy adherence. Aside from the 
disease entity, including symptoms, the patient’s ability to adopt a healthy 
lifestyle depends on individual cognitive and emotional factors, educational 
level, socioeconomic factors, and mental health. Perceived susceptibility to 
illness and the anticipated severity of the consequences are also prominent 
components of patients’ motivation.372 Patients can be motivated by mo­
tivational interviewing including the Open-ended questions, Affirmation, 
Reflective listening, and Summarizing (OARS) and Specific, Measurable, 
Achievable, Realistic, Timely (SMART) principles.372–374 Multidisciplinary 
behavioural approaches that combine the knowledge and skills of different 
caregivers are recommended.104 Adding exercise intervention combined 
with psychological support to diet recommendations is more effective 
than diet education alone.375 Assessing depression and depressive symp­
toms is important in patients with CVD and T2DM, as adequate treatment 
improves adherence.376,377
Mobile phone applications may improve adherence to both medica­
tion and behavioural changes, but more evidence, particularly in pa­
tients with CVD and T2DM, is needed.378 Regarding the education 
method, individual education is more effective than face-to-face or 
web and mobile phone education.375 Whether a tailored and auto­
mated text message (SMS) support programme may improve glycaemic 
control in adults with poorly controlled diabetes is equivocal.379
Recommendation Table 16 — Recommendations for a 
multifactorial approach in patients with type 2 diabetes 
with and without cardiovascular disease
Recommendations
Classa
Levelb
Identifying and treating risk factors and comorbidities 
early is recommended.357,358
I
A
A multifactorial approach to managing T2DM with 
treatment targets is recommended.361
I
B
Multidisciplinary behavioural approaches that 
combine the knowledge and skills of different 
caregivers are recommended.104,380
I
C
Principles of motivational interviewing should be 
considered to induce behavioural changes.372–374
IIa
C
Telehealth may be considered to improve risk 
profile.378,379
IIb
B
© ESC 2023
T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 41 -->

### Page 41

### 6 Management of coronary artery

disease and diabetes
6.1. Chronic coronary syndromes and 
diabetes
6.1.1. Clinical presentation
Diabetes is a well-established risk factor for ischaemic heart disease 
(IHD), and CAD accounts for 40−80% of deaths in patients with 
T2DM.148,359,381 In patients with CCS, T2DM is also associated 
with an increased risk of the combined outcome (CV death, MI, 
or stroke) with an adjusted HR of 1.28.39 Studies show that clinical 
symptoms of CAD in patients with diabetes are often less severe 
and atypical in presentation. In the BARI 2D (Bypass Angioplasty 
Revascularization Investigation 2 Diabetes) trial in patients with 
angiographically confirmed CAD and a mean diabetes duration of 
10.4 years, typical angina, anginal equivalent, or a combination of 
both were observed in 19%, 21%, and 42% of patients, respectively, 
whereas 18% remained asymptomatic.382,383 In 510 asymptomatic 
patients with diabetes without prior CVD, computed tomography 
(CT) revealed calcifications indicating the presence of coronary ath­
erosclerosis in 46% of patients.384 An even higher prevalence of 
CAD was found in an autopsy study of asymptomatic decedents 
with diabetes.385
6.1.2. Screening and diagnosis
For details about sensitivity, specificity, and pre-test probability of each 
procedure in the assessment of CHD, we refer to the 2019 ESC 
Guideline on chronic coronary syndromes.299
Screening for asymptomatic CAD in diabetes remains controversial. 
Various RCTs evaluating the impact of routine screening for CAD in 
asymptomatic patients with diabetes and no history of CAD showed 
Global CV risk and disease assessment
Obesity
Nutritiona
Inactivity
Smoking
Assessment of lifestyle risk factor components
Body weight
Body composition
Questionnaire
Questionnaire
Exercise testing
Questionnaire
General lifestyle recommendations
Adaption of lifestyle recommendations to 
comorbidities, age, frailty, sex, patient preference
Individualized multidisciplinary lifestyle intervention programme
Step 2
Step 1
HFpEF
HFrEF
AF
CAD
PAD
Figure 13 Assessment of lifestyle risk-factor components and stepwise lifestyle recommendations in patients with diabetes. AF, atrial fibrillation; CAD, 
coronary artery disease; CV, cardiovascular; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; 
PAD, peripheral arterial diseases. aNutrition includes components on quality and quantity of nutritional components, as well as alcohol consumption.
ESC Guidelines                                                                                                                                                                                          4083


<!-- PAGE 42 -->

### Page 42

no differences in CV outcomes at follow-up in those who underwent 
routine screening compared with standard recommendations.386–388
Data from a meta-analysis of five RCTs with 3299 asymptomatic pa­
tients with diabetes showed non-invasive CAD screening significantly 
reduced the rate of any cardiac event by 27% (RR 0.73; 95% CI, 
0.55–0.97; P = 0.028), driven by a non-significant reduction in non-fatal 
MI (RR 0.65; P = 0.062) and hospitalization for HF (RR 0.61; P = 0.1). 
Still, given the limitations of this analysis (e.g. different screening modal­
ities, heterogenous patient populations), non-invasive, routine screen­
ing for CAD in asymptomatic patients is not recommended.389
Moreover, in a recently published RCT involving men aged 65–74 years, 
routine CVD screening did not significantly reduce the incidence of 
death from any cause after a median follow-up of 5.6 years, also in a 
pre-specified diabetes sub-group.296
6.1.3. Management
The comprehensive management of patients with diabetes and estab­
lished CAD should start with a healthy lifestyle and reducing or elimin­
ating modifiable risk factors such as obesity, hypertension, or 
dyslipidaemia. The goal of pharmacotherapy should be to substantially 
reduce serious CV events. Targets and pharmacotherapy for glycaemia, 
BP, and LDL-C levels are addressed in the respective sections (Section 
5.2, 5.4, and 5.5).
6.1.3.1. Pharmacotherapy
6.1.3.1.1. Glucose-lowering medication. Based on the results of vari­
ous CVOTs, SGLT2 inhibitors and/or GLP-1 RAs are recommended in 
patients with T2DM and CAD to reduce CV events (Section 5.3).
6.1.3.1.2. Other medications. Due to the diffuse nature of CAD, 
some patients with diabetes are not amenable to revascularization. 
Symptom relief might then be achieved by increasing myocardial oxy­
gen supply with long-acting nitrates or CCBs, or by decreasing oxygen 
demand with the help of beta-blockers, non-dihydropyridine CCBs, ra­
nolazine, or ivabradine. Note that none of these medications improves 
mortality or the rate of ischaemic events. Beta-blockers with a simultan­
eous vasodilatory effect (e.g. carvedilol, nebivolol, labetalol) may be pre­
ferred due to their neutral or positive metabolic impact.390–392
Ranolazine, a drug that reduces myocardial ischaemia at the cellular le­
vel, also has the unique effect of reducing HbA1c, especially in patients 
with poor metabolic control.393,394 In normotensive patients with dia­
betes and CAD, ACE-Is or ARBs are also recommended to reduce the 
risk of CV events, especially in patients with HF or CKD.395–397
6.1.3.2. Revascularization
In patients with diabetes, the indications for myocardial revasculariza­
tion are the same as those in patients without diabetes, the essential as­
pects of which are reported in the 2018 ESC/EACTS Guidelines on 
myocardial revascularization and 2019 ESC Guideline on chronic cor­
onary syndromes.299,308 A detailed description of the evidence from 
outcome trials on revascularization in patients with diabetes can be 
found in Supplementary data online, Section 3.1.1. In brief, given the cur­
rent knowledge, in patients with diabetes and multivessel disease, 
CABG with arterial grafts is preferred over complex PCI, providing 
that patient characteristics (e.g. frailty, cerebrovascular disease) are 
considered.398 PCI with newer-generation drug-eluting stents (DES), 
whenever possible, is acceptable for patients with less-extensive dis­
ease (i.e. single-vessel disease or two-vessel disease not involving the 
left anterior descending, and those with SYNTAX Score ≤22). Thus, 
the extent of CAD, lesion complexity, and the risk of major surgery 
are key points in the decision-making process. Because most of the 
trials on revascularization contained patients with T2DM, current 
Guidelines cannot easily be applied to patients with T1DM. It has 
now been demonstrated that CABG is also superior to PCI in patients 
with T1DM and multivessel CAD.399
For recommendations for revascularization according to the extent 
of CAD, see the 2018 ESC/EACTS Guidelines on myocardial revascu­
larization and the 2019 ESC Guideline on chronic coronary 
syndromes.299,308
6.2. Acute coronary syndromes and 
diabetes
6.2.1. Clinical presentation and diagnosis
Diabetes is a frequent comorbidity in patients hospitalized for ACS, 
with an increasing prevalence over the last decade and a high mortality 
rate.409 Among patients presenting with ST-elevation myocardial in­
farction (STEMI), ∼25% have a history of diabetes and more than 
40% show a previously undiagnosed T2DM or pre-diabetes.410
Patients with diabetes more often present with non-typical symptoms 
compared with those without diabetes, and this impacts prompt diag­
nosis and treatment.411 Moreover, patients with diabetes frequently 
have multivessel disease and multiple coronary lesions, with a higher 
percentage of highly vulnerable atherosclerotic plaques associated 
with impaired microvasculature vasodilation.412,413
Recommendation Table 17 — Recommendations for 
revascularization in patients with diabetes
Recommendations
Classa
Levelb
It is recommended that similar revascularization 
techniques are implemented (e.g. the use of DES and 
the radial approach for PCI, and the use of the left 
internal mammary artery as the graft for CABG) in 
patients with and without diabetes.400
I
A
Myocardial revascularization in CCS is 
recommended when angina persists despite 
treatment with anti-anginal drugs or in patients with 
a documented large area of ischaemia (>10% 
LV).382,401,402,402a
I
A
Complete revascularization is recommended in 
patients with STEMI without cardiogenic shock and 
with multivessel CAD.403–405
I
A
Complete revascularization should be considered in 
patients with NSTE-ACS without cardiogenic shock 
and with multivessel CAD.406,407
IIa
C
Routine immediate revascularization of non-culprit 
lesions in patients with MI and multivessel disease 
presenting with cardiogenic shock is not 
recommended.408
III
B
© ESC 2023
CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, chronic coronary 
syndrome; DES, drug-eluting stents; LV, left ventricle; MI, myocardial infarction; NSTE-ACS, 
non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; 
STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 43 -->

### Page 43

6.2.2. Management
6.2.2.1. Pharmacotherapy
Patients with diabetes and ACS, despite the poor prognosis and high 
prevalence of comorbidities, are less likely to receive appropriate treat­
ment such as revascularization, reperfusion, or adequate DAPT.414,415
One of the reasons may be the lack of typical symptoms.416 While few 
studies have focused exclusively on patients with diabetes, analyses of 
studies indicate that guideline-directed pharmacotherapy provides pa­
tients with diabetes similar or improved absolute benefits compared 
with patients without diabetes, yet the incidence of events remains con­
stantly higher in those with vs. without diabetes.309,312,417
6.2.2.2. Glucose control in patients with acute coronary syndrome
Patients with ACS and hyperglycaemia on admission to hospital have a high­
er risk of death than patients with ACS without hyperglycaemia, irrespect­
ive of diabetes status.418 Mortality correlates more strongly to the blood 
glucose level than to the presence of diabetes.419,420Thus, early assessment 
of blood glucose level is strongly recommended in all subjects, although 
there is insufficient evidence that intensive glycaemic control improves 
prognosis. The DIGAMI 1 trial showed that early, tight glycaemic control 
with intravenous (i.v.) insulin–glucose infusion followed by subcutaneous in­
jections significantly reduced 1-year mortality compared with conventional 
glucose-lowering treatment.421 Conversely, the DIGAMI 2 study, and later 
pooled analyses of studies on insulin–glucose infusions did not confirm this 
observation.146,422Other studies have shown that adequate glycaemic con­
trol improves the prognosis of patients with ACS, while also demonstrating 
the importance of avoiding hypoglycaemia, which is strongly associated 
with worse outcomes.423,424 A criticism of previous studies is the inad­
equate characterization of glycaemia, with most studies analysing HbA1c 
as the glycaemic marker, when both hypoglycaemia and glycaemic variability 
potentially have a role in CV pathology.
Considering all evidence, it is best to attempt moderately tight gly­
caemic control while avoiding hypoglycaemia in the early hours of 
ACS. Continuous insulin infusion should be limited to cases where the 
optimal glycaemic control cannot be achieved otherwise; blood glucose 
level should be maintained <11.1 mmol/L (<200 mg/dL) or 
<10.0 mmol/L (<180 mg/dL) according to some recommenda­
tions.425–427 Frequent blood glucose testing, preferably hourly during 
the acute ACS phase, will help to avoid hypoglycaemia. CGM provides 
comprehensive glucose data while being more convenient than blood 
glucose testing, and the LIBERATES (Improving Glucose Control in 
Patients with Diabetes Following Myocardial Infarction: The Role of a 
Novel Glycaemia Monitoring Strategy) RCT in 141 insulin- or 
sulphonylurea-treated patients with T2DM and ACS showed that 
CGM over 3 months significantly reduced hypoglycaemic exposure 
compared with traditional capillary glucose testing, while being equally 
effective at reducing HbA1c.428 In the EMMY (Impact of EMpagliflozin 
on cardiac function and biomarkers of heart failure in patients with acute 
MYocardial infarction) trial, 467 patients were randomized to empagli­
flozin 10 mg or placebo within 72 h of PCI for acute MI.429 The study 
drug was associated with a significantly greater N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) reduction over 26 weeks (primary 
outcome) and a significant improvement in echocardiographic LV para­
meters, without demonstrating any difference in adverse events of spe­
cial interest including metabolic acidosis and diabetic ketoacidosis.429
It should be noted that hyperglycaemia in the acute phase of ACS 
might reflect stress hyperglycaemia and is not enough to diagnose dia­
betes. These patients should be further evaluated after discharge 
(Section 3).
Antithrombotic medication in patients with ACS is further described 
in Section 5.6.
6.2.2.3. Reperfusion strategies in ST-elevation myocardial infarction
The therapeutic strategy in patients with diabetes presenting with 
STEMI should not differ from that for patients without diabetes. As 
for the general population, prognosis is determined by early and effect­
ive reperfusion. Since patients with diabetes are more likely to present 
with atypical symptoms, reperfusion is often undertaken late.431
Although, patients with diabetes and STEMI, compared with those 
without diabetes, are older, more often have multivessel disease and 
concomitant conditions, and are less likely to receive reperfusion ther­
apy. Diabetes is regarded as an independent risk factor of early and late 
mortality.432–436 Primary angioplasty, performed in a timely fashion, 
also provides the best clinical outcomes in patients with diabetes.437
Several recent studies indicate the clinical benefit of early, single-stage, 
complete revascularization in patients with non-ST-elevation ACS 
(NSTE-ACS) and early complete revascularization in those with 
STEMI and multivessel disease.403–407,432–435 The exception is patients 
in cardiogenic shock, where it is recommended to limit the procedure 
to the infarct-related artery.408 Adding proton pump inhibitors, limiting 
use of glycoprotein IIb/IIIa inhibitors, and avoiding heparin in patients on 
OACs if the international normalized ratio (INR) >2.5 are 
recommended.308
6.2.2.4. Optimal timing of invasive strategy in non-ST-elevation acute 
coronary syndrome
In patients with diabetes and NSTE-ACS, the indications and timing of 
revascularization should not differ from those for patients without dia­
betes.438 Multiple studies have indicated that an early invasive strategy is 
beneficial in high-risk sub-groups.439–442 Since diabetes is one of the risk 
factors of poor prognosis, patients with diabetes may benefit signifi­
cantly more from the early invasive approach than those without dia­
betes.417,443 In a meta-analysis of eight RCTs in patients with 
NSTE-ACS, which compared an early vs. a delayed invasive strategy, 
diabetes, elevated troponin, and a Global Registry of Acute Coronary 
Events (GRACE) risk score >140 predicted lower mortality in the early 
invasive arm.444
Recommendation Table 18 — Recommendations for 
glycaemic control in patients with diabetes and acute 
coronary syndrome
Recommendations
Classa
Levelb
It is recommended to assess glycaemic status at initial 
evaluation in all patients with ACS.141,367,430
I
B
It is recommended to frequently monitor blood 
glucose levels in patients with known diabetes or 
hyperglycaemia (defined as glucose levels 
≥11.1 mmol/L or ≥200 mg/dL).
I
C
Glucose-lowering therapy should be considered in 
patients with ACS with persistent hyperglycaemia, 
while episodes of hypoglycaemia should be 
avoided.423,424
IIa
C
© ESC 2023
ACS, acute coronary syndrome. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4085


<!-- PAGE 44 -->

### Page 44

According to current guidelines, an immediate invasive strategy 
(within 2 h from admission) should be applied to very high-risk patients, 
mostly with electrical or haemodynamic instability.426 These patients 
were excluded from all major randomized ACS trials. In addition, pa­
tients with severe symptoms, refractory to medical therapy, or those 
with electrocardiogram (ECG) signs suggesting the left main stem as 
a culprit vessel should be promptly referred for coronary angiography. 
An early invasive strategy (within 24 h) should be applied to high-risk 
patients, especially those with markedly elevated troponins, dynamic 
ST/T-segment changes, transient ST-segment elevation, or a GRACE 
risk score >140.
6.3. Ischaemia with no obstructive 
coronary artery disease in diabetes
Details on the role of ischaemia with no obstructive CAD are outlined 
in the Supplementary data online, Section 3.2.
7. Heart failure and diabetes
7.1. Definition and pathophysiology
Heart failure is not a single pathological disease but a clinical syndrome 
with current or prior symptoms and/or signs caused by a structural and/ 
or functional cardiac abnormality. It is corroborated by elevated natri­
uretic peptides and/or objective evidence of cardiogenic pulmonary or 
systemic congestion from diagnostic modalities, such as imaging or in­
vasive haemodynamic measurements.445
Heart failure is one of the most common initial manifestations of 
CVD in patients with T2DM, and may present as HFpEF, heart failure 
with mildly reduced ejection fraction (HFmrEF), or HFrEF (Table 9).446
Major causes of HF in diabetes are IHD (Section 6), hypertension 
(Section 5.3), direct or indirect effects of hyperglycaemia, and obesity 
and related factors on the myocardium.447,448 IHD is often accelerated, 
severe, diffuse, and silent, and increases the risk of MI and ischaemic 
myocardial dysfunction.449–452 Observational data have also identified 
that lower-extremity artery disease (LEAD), longer diabetes duration, 
ageing, increased BMI, and CKD (Section 9) are associated with HF in 
patients with diabetes (Table 10).449–452 Complex pathophysiological 
mechanisms may be responsible for the development of myocardial 
dysfunction, even in the absence of IHD or hypertension.453 For dec­
ades, the concept of diabetic cardiomyopathy has been discussed, 
with mostly experimental and smaller observational studies suggesting 
its presence; however, its existence has so far not been con­
firmed.447,454–458
7.2. Epidemiology and prognosis
Diabetes is an important risk factor for HF.459 Observational studies have 
consistently demonstrated a two- to four-fold increased risk of HF in in­
dividuals with diabetes compared with those without diabetes.460–463
The prevalence of chronic HF increases steadily with age for patients 
with and without diabetes. Patients with T2DM develop chronic HF 
more often and earlier in life than those without T2DM, with an incre­
mental risk inversely associated with age; for example, in one study, 
the incident rate ratio was 11.0 (95% CI, 5.6–21.8) for those <45 years, 
declining to 1.8 (95% CI, 1.6–2.2) for those aged 75–84 years, reflecting 
the higher absolute HF risk in elderly patients without diabetes.463
Unrecognized HF is frequent in T2DM: a cross-sectional study in patients 
aged ≥60 years with T2DM without known HF using a standardized diag­
nostic work-up, including medical history, physical examination, ECG, 
and echocardiography, indicated that HF was present in 28% of patients 
(∼25% HFrEF and ∼75% HFpEF).460–464
Vice versa, HF is associated with a diabetes incidence of 20–30 per 
1000 person-years in the first 5 years following HF hospitalization, 
which is substantially higher than for adults in the general population 
(10.1 per 1000 person-years).465,466 A large, pan-European registry 
found that ∼36% of all outpatients with stable HF had diabetes, while 
in patients hospitalized for acute HF for whom i.v. therapy (inotropes, 
vasodilators, or diuretics) was needed, diabetes was present in up to 
50%.467,468 In addition, available data from observational studies dem­
onstrate that diabetes prevalence in patients with HF is similar, irre­
spective of LVEF category.469,470
A significant association exists between diabetes and a higher risk of 
adverse outcomes in patients with HF, with the greatest incremental risk 
associated with diabetes observed in patients with HFrEF.467,471–475
However, CV mortality, including death caused by worsening HF, is 
also 50–90% higher in patients with HF and diabetes compared 
Table 9 Heart failure phenotypes according to ejection 
fraction distribution445
HF 
phenotype
HFpEF
HFmrEF
HFrEF
Criterion 1
Symptoms and/or 
signsa
Symptoms 
and/or signsa
Symptoms 
and/or signsa
Criterion 2
LVEF ≥50%
LVEF 41–49%
LVEF ≤40%
Criterion 3
Objective evidence of 
cardiac structural 
and/or functional 
abnormalities 
consistent with the 
presence of LV 
diastolic dysfunction 
or raised filling 
pressures, including 
raised natriuretic 
peptides
None
None
© ESC 2023
HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart 
failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; 
LV, left ventricular; LVEF, left ventricular ejection fraction. 
aSymptoms include, for example, breathlessness, ankle swelling, and fatigue. Signs may not 
be present at an early stage or in patients receiving diuretics.
Table 10 Risk factors for developing heart failure in 
patients with diabetes
Cardiac risk factors
Ischaemic heart disease 
Myocardial infarction 
Hypertension 
Valvular heart disease 
Arrhythmias
Non-cardiac risk factors
Age 
Chronic kidney disease 
Increased body mass index 
Longer duration of diabetes 
Smoking 
Alcohol excess
© ESC 2023


<!-- PAGE 45 -->

### Page 45

with HF patients without diabetes, regardless of HF phenotype.471,475–477
In patients with acute HF, for whom i.v. therapy (inotropes, vasodi­
lators, or diuretics) was needed, diabetes was associated with higher 
risk of in-hospital death, 1 year all-cause death, and 1 year HF 
re-hospitalization.468,478
7.3. Screening and diagnosis
Patients with diabetes are at risk of HF but not all patients with diabetes 
will develop HF.479 Given that the prognosis of patients with both co­
morbidities is worse, it is of utmost importance to screen all patients 
with diabetes for HF to allow early implementation of life-saving therapies. 
To predict the HF risk among outpatients with T2DM, the WATCH-DM 
(Weight [BMI], Age, Hypertension, Creatinine, HDL-C, Diabetes control 
[fasting plasma glucose], QRS duration, MI, and CABG) risk score has 
been developed.480 Each increment of 1 unit in the risk score is associated 
with a 24% higher HF risk within 5 years. In addition, a biomarker-based 
risk score including high-sensitivity cardiac troponin T ≥6 ng/L, 
NT-proBNP ≥125 pg/mL, high-sensitivity C-reactive protein ≥3 mg/L, 
and LV hypertrophy by ECG (with one point for each abnormal param­
eter) demonstrated good discrimination and calibration for predicting 5- 
and 10-year HF risk among patients with diabetes. The highest 5-year risk 
of HF was noted among those with scores ≥3.481 The Heart Failure 
Association of the ESC reviewed the clinical evidence and value of further 
biomarker testing and currently recommends no further testing.482
To detect transition from being at risk of HF to developing HF, the 
following regular evaluation is recommended in patients with diabetes 
(Figure 14): 
• Regularly, a systematic survey for HF symptoms (breathlessness, dys­
pnoea on exertion, orthopnoea, paroxysmal nocturnal dyspnoea, 
nocturia, fatigue, tiredness, increased time to recover following exer­
cise) or signs (weight gain, peripheral oedema, elevated jugular ven­
ous pulse, rales, hepatojugular reflux, third heart sound, or laterally 
≤40%
 (HFrEF)
Repeat evaluation
 regularly
41%–49%
 (HFmrEF)
≥50% 
(HFpEF)
Symptoms and/or 
signs for HF and/or 
abnormal ECG
Patient with diabetes (at risk for HF)
Determine aetiology and commence treatment
Y
Suspected HF
NT-proBNP ≥125 pg/mL 
or BNP ≥35 pg/mL
Y
Echocardiography with 
structural and/or 
functional cardiac abnormality
Y
HF confirmed
Define HF phenotype based on LVEF measurement
N
N
N
Figure 14 Diagnostic algorithm for heart failure in patients with diabetes. BNP, B-type natriuretic peptide; ECG, electrocardiogram; HF, heart failure; 
HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection 
fraction; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
ESC Guidelines                                                                                                                                                                                          4087


<!-- PAGE 46 -->

### Page 46

displaced apical impulse) is recommended. For more details, see the 
chronic heart failure.445
If one or more of the symptoms or signs above is present, HF can be 
suspected, and the following diagnostic tests are recommended: 
• Measurement of natriuretic peptides is recommended, if available. 
Values below the following cut-offs make the diagnosis of HF unlikely 
and other diagnoses should be considered:483–485
○B-type natriuretic peptide (BNP) <35 pg/mL (threshold in AF: 
<105 pg/mL).
○NT-proBNP <125 pg/mL (threshold in AF: <365 pg/mL).
However, natriuretic peptide concentrations may be disproportion­
ately low in patients with obesity or in women, and disproportionately 
high in patients with advanced CKD, advanced age, or AF.486,487 Still, 
elevated concentrations support the diagnosis of HF and may guide fur­
ther cardiac investigation.488
• ECG is recommended to detect abnormalities such as AF, signs of LV 
hypertrophy, Q waves, or widened QRS, each of which may be a sign 
of HF.489
• Echocardiography is recommended to assess cardiac function includ­
ing LV function, chamber size, LV hypertrophy, regional wall motion 
abnormalities (that may suggest CAD), right ventricular function, es­
timated pulmonary pressure, valvular function, and markers of diastol­
ic dysfunction. Transthoracic echocardiography may be considered to 
detect HF in patients with diabetes if other risk factors arise.
• Chest X-ray is recommended to investigate other causes of dys­
pnoea (e.g. pulmonary disease). It may provide supportive evidence 
of HF (e.g. cardiomegaly, pulmonary congestion, pleural effusion).
• Routine blood tests (including full blood count, urea, creatinine, and 
electrolytes, thyroid and liver function, lipids, and iron status (ferritin 
and transferrin saturation) are recommended to differentiate HF 
from other conditions, to obtain prognostic information, and to 
guide potential therapy. Additional diagnostic tests should be consid­
ered if other specific diagnoses are suspected (e.g. amyloidosis).
• If HF is confirmed, additional diagnostic tests are recommended as 
summarized in the 2021 ESC Guidelines for the diagnosis and treat­
ment of acute and chronic heart failure.445
7.4. Treatment of heart failure in patients 
with diabetes
7.4.1. Treatment of heart failure with reduced  
ejection fraction
Treatment of HFrEF encompasses therapeutic lifestyle modifications, as 
well as pharmacological and device therapies with benefits confirmed in 
RCTs, in which 30–40% of patients had diabetes. Treatment effects of 
medications and devices for HFrEF have been consistently demon­
strated to not differ in patients with vs. without diabetes. Importantly, 
while the RR reductions are consistently similar for those with and with­
out diabetes, given the higher absolute HFrEF clinical risk associated with 
diabetes, the ARR in patients with diabetes is typically higher, yielding a 
lower NNT for benefit among patients with diabetes.
The cornerstone of treatment for HFrEF is pharmacotherapy along­
side lifestyle interventions, which should be implemented before con­
sidering device therapy. The recent 2021 ESC Guidelines for the 
diagnosis and treatment of acute and chronic heart failure recommend 
starting quadruple therapy (angiotensin receptor–neprilysin inhibitor 
[ARNI]/ACE-I, MRA, beta-blocker, SGLT2 inhibitor).445 These four 
foundational treatments should be initiated early, as much of the ben­
efits are seen within 30 days of starting treatment, and adding new 
drugs yields greater benefits than up-titrating existing drug classes. In 
the STRONG-HF (Safety, Tolerability and Efficacy of Rapid 
Optimization, Helped by NT-proBNP testinG, of Heart Failure 
Therapies) trial, 1078 patients with acute HF, 29% of whom had dia­
betes at baseline, were assigned to either high-intensity care with up- 
titration of treatments to 100% of recommended doses within 2 weeks 
of discharge or to usual care.490 Safety and tolerability were assessed at 
weeks 1, 2, 3, and 6 by full physical examination and laboratory assess­
ments of NT-proBNP, sodium, potassium, glucose, kidney function, and 
haemoglobin measures. The study was stopped early due to a greater 
than expected between-group difference. The primary endpoint, con­
sisting of 180-day re-admission to hospital due to HF or all-cause death, 
was significantly reduced in the high-intensity group, with a RR reduc­
tion of 34% (HR 0.66; 95% CI, 0.50–0.86) with similar incidences of ser­
ious adverse events. Of note, no sub-group analysis exists on patients 
with diabetes. Based on these data, an intensive strategy of early initi­
ation of evidence-based treatment (SGLT2 inhibitors, ARNI/ACE-Is, 
beta-blockers, and MRAs), with rapid up-titration to trial-defined target 
doses and frequent follow-up visits in the first 6 weeks following dis­
charge from a HF hospitalization is recommended to reduce 
re-admissions or mortality. The sequence of therapy initiation should 
be based on the individual patient phenotype taking into account BP, 
heart rhythm, and heart rate, as well as kidney function and risk of hy­
perkalaemia. While the start dose of SGLT2 inhibitors is the same as the 
target dose, ARNI/ACE-Is, beta-blockers, and MRAs should be started 
at low dose and up-titrated to the maximum tolerated dose. For more 
details on HFrEF therapy, please refer to the 2021 ESC Guidelines for 
the diagnosis and treatment of acute and chronic heart failure.445 The 
Recommendation Table 19 — Recommendations for 
heart failure screening and diagnosis in patients with 
diabetes
Recommendations
Classa
Levelb
Evaluating for heart failure
If HF is suspected, it is recommended to measure 
BNP/NT-proBNP.485
I
B
Systematic survey for HF symptoms and/or signs of 
HF is recommended at each clinical encounter in all 
patients with diabetes.
I
C
Diagnostic tests in all patients with suspected heart failure
12-lead ECG is recommended.
I
C
Transthoracic echocardiography is recommended.
I
C
Chest radiography (X-ray) is recommended.
I
C
Continued
Routine blood tests for comorbidities are 
recommended, including full blood count, urea, 
creatinine and electrolytes, thyroid function, lipids, 
and iron status (ferritin and TSAT).
I
C
© ESC 2023
ECG, electrocardiogram; HF, heart failure; BNP, B-type natriuretic peptide; NT-proBNP, 
N-terminal pro-B-type natriuretic peptide; TSAT, transferrin saturation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 47 -->

### Page 47

specific characteristics for patients with diabetes are presented in the 
following sections.
7.4.1.1. Sodium–glucose co-transporter-2 inhibitors
Two randomized placebo-controlled trials have investigated the effect of 
an SGLT2 inhibitor compared with placebo added to optimal medical 
therapy (OMT) in patients with HFrEF with and without diabetes. The 
DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in 
Heart Failure) trial included patients if they were in New York Heart 
Association (NYHA) class II–IV, had an LVEF ≤40% despite OMT, and 
had elevated NT-proBNP (in sinus rhythm ≥600 pg/mL, in AF 
≥900 mg/mL, or ≥400 pg/mL if they had been hospitalized for HF within 
the previous 12 months). Patients with T1DM or an eGFR <30 mL/min/ 
1.73 m2 were excluded. Therapy with dapagliflozin 10 mg o.d. vs. placebo 
reduced the risk of the primary outcome, a composite of worsening 
HF (hospitalization or an urgent visit resulting in i.v. therapy for HF) or 
CV death, by 26% (HR 0.74; 95% CI, 0.65–0.85). In addition, dapagliflozin 
reduced all-cause mortality (HR 0.83; 95% CI, 0.71–0.97) and improved 
symptoms, physical function, and quality of life in patients with 
HFrEF.491,492 All of the clinical benefits observed were independent of 
baseline diabetes status and background glucose-lowering therapy, 
and consistent across the spectrum of HbA1c.491,493 The EMPEROR- 
Reduced (Empagliflozin Outcome Trial in Patients with Chronic Heart 
Failure with Reduced Ejection Fraction) trial evaluated empagliflozin vs. 
placebo and included patients with HFrEF with and without diabetes, 
with NYHA class II–IV, and LVEF ≤40% despite OMT, an eGFR 
≥20 mL/min/1.73 m2, and an elevated NT-proBNP (EF ≤30% or EF 
≤40% and HF hospitalization within 12 months: NT-proBNP ≥600 pg/ 
mL; EF 31–35%: NT-proBNP ≥1000 pg/mL; EF 36–40%: NT-proBNP 
≥2500 pg/mL). Empagliflozin 10 mg o.d. reduced the risk of the primary 
outcome, a composite of CV death or HF hospitalization, by 25% vs. pla­
cebo (HR 0.75; 95% CI, 0.65–0.86).494 This effect was consistent across 
patients with and without diabetes at baseline.495 Treatment with empa­
gliflozin improved quality of life.496 A meta-analysis of the DAPA-HF and 
EMPEROR-Reduced trials showed a consistent reduction in HF hospital­
ization or CV death, CV death, and all-cause mortality by SGLT2-inhibitor 
treatment without significant heterogeneity between trials.497
The combined SGLT1 and -2 inhibitor sotagliflozin was investigated 
in patients with T2DM who were recently hospitalized for worsening 
HF, irrespective of their LVEF (SOLOIST-WHF [Effect of Sotagliflozin 
on Cardiovascular Events in Patients with Type 2 Diabetes Post 
Worsening Heart Failure] trial). Patients with an eGFR <30 mL/min/ 
1.73 m2 were excluded. Sotagliflozin significantly reduced the RR of the 
composite primary outcome (CV death, HF hospitalization, or urgent visit 
for HF) by 33% compared with placebo (HR 0.67; 95% CI, 0.52–0.85). The 
treatment effect was consistent across the spectrum of LVEF.189
Thus, the SGLT inhibitors dapagliflozin, empagliflozin, and sotagliflo­
zin are recommended, in addition to OMT (with an ARNI/ACE-I, beta- 
blocker, and MRA), in patients with HFrEF and diabetes to reduce CV 
death and HF hospitalization.
Three studies have investigated whether SGLT2 inhibitors can be safely 
started in patients hospitalized for acute HF. The EMPA-RESPONSE-AHF 
(Effects of Empagliflozin on Clinical Outcomes in Patients With Acute 
Decompensated Heart Failure) trial randomized 80 patients with acute 
HF with (approximately one-third) and without diabetes to either empa­
gliflozin or placebo for 30 days.498 Treatment with empagliflozin did not 
affect visual analogue scale dyspnoea, diuretic response, NT-proBNP le­
vels, or duration of hospital stay, but was safe, increased urinary output, 
and reduced a combined endpoint of worsening HF, re-hospitalization 
for HF, or death at 60 days compared with placebo. In the 
SOLOIST-WHF trial mentioned above, 1222 patients with T2DM re­
ceived sotagliflozin or placebo, with a median follow-up of 9 months (trial 
stopped prematurely).189 Sotagliflozin therapy, initiated before or shortly 
after discharge, resulted in significantly fewer deaths from CV causes and 
hospitalizations and urgent visits for HF than placebo, with no increase in 
acute kidney injury. The EMPULSE (A Study to Test the Effect of 
Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure) trial 
randomized 530 hospitalized patients with and without diabetes with a pri­
mary diagnosis of acute de novo or decompensated HF, regardless of LVEF 
when clinically stable, to receive either empagliflozin or placebo. More pa­
tients treated with empagliflozin had clinical benefit (win ratio 1.36; 95% CI, 
1.09–1.68) compared with placebo. This effect was consistent for acute de 
novo and decompensated chronic HF and was observed regardless of LVEF 
or the presence of diabetes.499In these trials, very few cases of euglycaemic 
diabetic ketoacidosis were reported; still, physicians treating patients with 
diabetes with SGLT2 inhibitors in this setting should be aware of this rare 
but potentially serious complication. Of note, misinterpreting eGFR 
changes can lead to inappropriate discontinuation of disease-modifying 
agents and should be avoided.
7.4.1.2. Angiotensin receptor–neprilysin inhibitor and 
angiotensin-converting enzyme inhibitors
The ARNI sacubitril/valsartan has shown superior efficacy to enalapril in 
reducing CV death and HF hospitalization in patients with HFrEF, with 
or without diabetes.471 Patients were up-titrated to 200 mg b.i.d. sacu­
bitril/valsartan within 2–4 weeks.471 The beneficial effect of sacubitril/ 
valsartan over enalapril was consistent for patients with and without 
diabetes and across the spectrum of baseline HbA1c.
ACE-Is were the first class of drugs shown to reduce mortality and 
morbidity and improve symptoms in patients with HFrEF.500 There is 
no difference in efficacy in patients with and without diabetes.501–503
As RAS inhibitors increase the risk of hyperkalaemia and may acutely 
compromise kidney function, routine surveillance of serum creatinine 
and potassium levels is advised.504,505 However, misinterpreting eGFR 
changes often leads to inappropriate discontinuation of disease- 
modifying agents and should be avoided.504–506
7.4.1.3. Mineralocorticoid receptor antagonists
The steroidal MRAs spironolactone or eplerenone reduce death and 
HF hospitalization in patients with HFrEF, with consistent results in pa­
tients with or without diabetes.507,508 Eplerenone is more specific for 
blocking aldosterone and, therefore, causes less gynaecomastia. 
Caution should be exercised when using MRAs in patients with im­
paired renal function and in those with serum potassium concentration 
>5.0 mmol/L. The non-steroidal MRA finerenone has not been investi­
gated in patients with HFrEF (Section 9).
7.4.1.4. Beta-blockers
Beta-blockers are effective at reducing all-cause death and hospitaliza­
tion for HF in patients with HFrEF, with or without diabetes.509–512
Treatment benefits strongly support using beta-blockers in patients 
with HFrEF and diabetes.
7.4.1.5. Angiotensin-II receptor blockers
The place of ARBs in managing HFrEF has changed over the last few 
years. They are now recommended for patients who cannot tolerate 
ARNI or ACE-Is because of serious side effects. ARBs have similar treat­
ment effects in patients with HFrEF with or without diabetes.513–515
ESC Guidelines                                                                                                                                                                                          4089


<!-- PAGE 48 -->

### Page 48

7.4.1.6. Ivabradine
Ivabradine slows heart rate by inhibiting the If channel in the sinus node 
and is therefore only effective in patients in sinus rhythm. Ivabradine re­
duced the combined endpoint of CV death or HF hospitalization irre­
spective of diabetes status.516
7.4.1.7. Hydralazine and isosorbide dinitrate
There is no evidence to support the use of this fixed-dose combination ther­
apy in all patients with HFrEF, but rather limited to self-identified Black pa­
tients as per product labelling. An RCT in self-identified Black patients with 
HFrEF showed that adding the combination of hydralazine and isosorbide di­
nitrate to conventional therapy (ACE-I, beta-blocker, MRA) reduced mortal­
ity and HF hospitalization in patients in NYHA class III–IV.517 The beneficial 
effects were consistent in patients with or without diabetes.518
7.4.1.8. Digoxin
Digoxin may reduce the risk of HF hospitalization in patients with 
HFrEF treated with ACE-Is, irrespective of diabetes status.519
7.4.1.9. Diuretics
Despite a lack of evidence for the efficacy of either thiazide or loop 
diuretics in reducing CV outcomes in patients with HF, diuretics pre­
vent and treat symptoms and signs of fluid congestion in patients 
with HF.520 Importantly, a judicious use of diuretic therapy including al­
ternating dosing over time is warranted.521
7.4.1.10. Device therapy and surgery
Device therapies (implantable cardioverter defibrillator [ICD], cardiac 
resynchronization therapy [CRT], and CRT with an implantable defib­
rillator [CRT-D]) have similar efficacies and risks in patients with HFrEF 
with or without diabetes.522–525 These therapies should be considered 
according to treatment guidelines in the HFrEF population. Heart trans­
plantation could be considered in end-stage HF, but a large, prospective 
study of transplanted patients indicated a decreased likelihood of 
10-year survival in those with diabetes.526
7.4.2. Treatment of heart failure with mildly reduced 
ejection fraction
As in other forms of HF, diuretics should be used to control conges­
tion.520 Results from retrospective analyses of RCTs in patients with 
Recommendation Table 20 — Recommendations for 
heart failure treatments in patients with heart failure 
with reduced ejection fraction and diabetes
Recommendations
Classa
Levelb
Recommendations for the pharmacological treatment 
indicated in patients with HFrEF (NYHA class II–IV) and 
diabetes
SGLT2 inhibitors (dapagliflozin, empagliflozin, or 
sotagliflozinc) are recommended in all patients with 
HFrEF and T2DM to reduce the risk of HF 
hospitalization and CV death.189,491,494,497
I
A
Sacubitril/valsartan or an ACE-I is recommended in 
all patients with HFrEF and diabetes to reduce the 
risk of HF hospitalization and death.471,501,502,527
I
A
Beta-blockersd are recommended in patients with 
HFrEF and diabetes to reduce the risk of HF 
hospitalization and death.509–512,528
I
A
Continued
MRAse are recommended in patients with HFrEF and 
diabetes to reduce the risk of HF hospitalization and 
death.507,529
I
A
An intensive strategy of early initiation of 
evidence-based treatment (SGLT2 inhibitors, ARNI/ 
ACE-Is, beta-blockers, and MRAs), with rapid 
up-titration to trial-defined target doses starting before 
discharge and with frequent follow-up visits in the first 6 
weeks following a HF hospitalization is recommended 
to reduce re-admissions or mortality.490
I
B
Recommendations for other treatments indicated in selected 
patients with HFrEF (NYHA class II–IV) and diabetes
Device therapy with an ICD, CRT-P, or CRT-D is 
recommended in patients with diabetes, as in the 
general population with HFrEF.522–525
I
A
ARBs are recommended in symptomatic patients 
with HFrEF and diabetes who do not tolerate 
sacubitril/valsartan or ACE-Is, to reduce the risk of 
HF hospitalization and CV death.513–515
I
A
Diuretics are recommended in patients with HFrEF 
and diabetes with signs and/or symptoms of fluid 
congestion to improve symptoms, exercise capacity, 
and HF hospitalization.520
I
C
Ivabradine should be considered to reduce the risk of 
HF hospitalization and CV death in patients with 
HFrEF and diabetes in sinus rhythm, with a resting 
heart rate ≥70 b.p.m., who remain symptomatic 
despite treatment with beta-blockers (maximum 
tolerated dose), ACE-Is/ARBs, and MRAs.516
IIa
B
Hydralazine and isosorbide dinitrate should be 
considered in self-identified Black patients with 
diabetes and LVEF ≤ 35% or with LVEF <45% 
combined with a dilated left ventricle in NYHA class 
III–IV despite treatment with an ACE-I (or ARNI), a 
beta-blocker, and an MRA, to reduce the risk of HF 
hospitalization and death.517,518
IIa
B
Digoxin may be considered in patients with 
symptomatic HFrEF in sinus rhythm despite 
treatment with sacubitril/valsartan or an ACE-I, a 
beta-blocker, and an MRA, to reduce the risk of 
hospitalization.519
IIb
B
© ESC 2023
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; 
ARNI, angiotensin receptor–neprilysin inhibitor; CRT-D, cardiac resynchronization 
therapy with defibrillator; CRT-P, cardiac resynchronization therapy-pacemaker; CV, 
cardiovascular; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, 
implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRA, 
mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SGLT2, 
sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cSotagliflozin is a dual SGLT1/2 inhibitor. 
dSustained-released metoprolol succinate, carvedilol, bisoprolol, and nebivolol. 
eSpironolactone or eplerenone.


<!-- PAGE 49 -->

### Page 49

HFrEF or HFpEF indicate that patients with a LVEF between 40–50% 
benefitted from similar therapies to those with LVEF ≤40%.445
However, to date, no definitive RCT has evaluated therapies exclusively 
in patients with HFmrEF. The best evidence so far derives from 
SGLT2-inhibitor studies. The EMPEROR-Preserved (Empagliflozin 
Outcome Trial in Patients with Chronic Heart Failure With 
Preserved Ejection Fraction) trial included patients with NYHA class 
II–IV, an LVEF >40%, and an elevated NT-proBNP (>300 pg/mL in si­
nus rhythm; >900 pg/mL in AF).530 Patients with an eGFR <20 mL/ 
min/1.73 m2 were excluded. Compared with placebo, empagliflozin re­
duced the risk of the primary outcome, a composite of CV death or 
hospitalization for HF, by 21%, which was mainly related to a 29% lower 
risk of hospitalization for HF.530 This effect was independent of diabetes 
status, and baseline HbA1c did not modify the effects on the primary 
outcome.531 The DELIVER (Dapagliflozin Evaluation to Improve the 
Lives of Patients with Preserved Ejection Fraction Heart Failure) trial in­
cluded 6263 patients with NYHA class II–IV, an LVEF >40%, an elevated 
NT-proBNP (>300 pg/mL in sinus rhythm; >600 pg/mL in AF), and an 
eGFR ≥25 mL/min/1.73 m2. Compared with placebo, dapagliflozin re­
duced the primary outcome, a composite of worsening HF or CV 
death, by 18%, which was mainly driven by a reduction in hospitalization 
for HF. This effect was independent of diabetes status.532 A 
meta-analysis including 12 251 participants from DELIVER and 
EMPEROR-Preserved showed that SGLT2 inhibitors, compared with 
placebo, reduced a composite of CV death and first hospitalization 
for HF (HR 0.80; 95% CI, 0.73–0.87), with consistent reductions in 
both components: CV death (HR 0.88; 95% CI, 0.77–1.00) and first 
hospitalization for HF (HR 0.74; 95% CI, 0.67–0.83).533
There is no specific trial evaluating ARNI in patients with HFmrEF. 
The PARAGON-HF trial, which included patients with EF ≥45%, al­
though missing its primary endpoint overall, showed significant 
EF-by-treatment interaction. Sacubitril/valsartan, compared with valsar­
tan, reduced the likelihood of the primary composite outcome of CV 
death and total HF hospitalization by 22% in those with an LVEF below 
or equal to the median of 57%.534
7.4.3. Treatment of heart failure with preserved 
ejection fraction
Over the past decade, several large RCTs failed to achieve statistical sig­
nificance with regard to effects on the primary outcomes in patients 
with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (can­
desartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG 
Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsar­
tan).477,534–538 As presented above in section 7.4.2, the SGLT2 inhibi­
tors empagliflozin and dapagliflozin both reduced the RR of the 
primary composite outcome, CV death or hospitalization for HF, by 
21% and 18%, respectively.530,532 The treatment effect on the incidence 
of the primary outcome did not differ between LVEF sub-groups nor 
between patients with and without diabetes.531–533 The combined 
SGLT1 and -2 inhibitor sotagliflozin was investigated in patients with 
T2DM who were recently hospitalized for worsening HF, irrespective 
of their LVEF (SOLOIST-WHF trial); 20.9% of the patients had an 
LVEF ≥50%. Sotagliflozin reduced the risk of the primary composite 
outcome of CV death, HF hospitalization, and urgent visit for HF by 
33%, with a consistent effect across the spectrum of baseline LVEF. 
However, the number of events in the HFpEF group was too small 
to draw any firm conclusion.189
Diuretic therapy should be used to reduce symptoms of conges­
tion.520 Loop diuretics are preferred, but low-dose thiazide diuretics 
might be useful for managing hypertension. For treating comorbidities 
alongside HFpEF, refer to the 2021 ESC Guidelines for the diagnosis 
and treatment of acute and chronic heart failure.445
7.5. Safety profile of glucose-lowering 
agents in patients with heart failure and 
diabetes
For glycaemic targets in patients with diabetes, please refer to Section 
5.2.
7.5.1. Sodium–glucose co-transporter-2 inhibitors
Sodium–glucose co-transporter-2 inhibitors (see also Section 7.4.1.1) 
have been investigated in different populations with diabetes, ranging 
from patients with ASCVD or multiple ASCVD risk factors to patients 
recently hospitalized for worsening HF, with increasing ARR for 
HF-related outcomes according to higher patient risk (Figure 15; 
Supplementary data online, Table S15).
As outlined above, in dedicated HF trials, dapagliflozin and empagli­
flozin reduced CV death and HF hospitalization in patients with 
HFrEF with or without diabetes, and sotagliflozin reduced CV death 
and HF hospitalization in patients with T2DM and recent hospitalization 
for HF of any aetiology.189,491,494 Moreover, empagliflozin and dapagli­
flozin reduced the risk of CV death or HF hospitalization in patients 
with HFmrEF or HFpEF.530,532
While the EMPA-REG OUTCOME (empagliflozin) and VERTIS CV 
(ertugliflozin) trials investigated patients with T2DM and established 
ASCVD risk, the CANVAS Programme (canagliflozin) and 
DECLARE-TIMI 58 trial (dapagliflozin) included patients with 
established ASCVD or multiple ASCVD risk factors. In all of these 
placebo-controlled CVOTs of SGLT2 inhibitors, only a small proportion 
of patients had a baseline history of HF. Empagliflozin reduced the risk of 
HF hospitalization by 35% in patients with and without previous HF.71
Canagliflozin also significantly reduced the risk of HF hospitalization 
by 33%.151 Dapagliflozin significantly reduced the combined endpoint 
of CV death or HF hospitalization, a result driven mainly by lower rates 
of HF hospitalization.152 This effect was independent of pre-existing 
HF.540 Ertugliflozin did not reduce the combined endpoint of CV death 
or HF hospitalization, although there was a significant reduction in HF 
hospitalization and repeated hospitalizations.154,541
Recommendation Table 21 — Recommendations for 
heart failure treatments in patients with diabetes and 
left ventricular ejection fraction over 40%
Recommendations
Classa
Levelb
Empagliflozin or dapagliflozin are recommended in 
patients with T2DM and LVEF >40% (HFmrEF and 
HFpEF) to reduce the risk of HF hospitalization or 
CV death.530–533
I
A
Diuretics are recommended in patients with HFpEF 
or HFmrEF and diabetes with signs and/or symptoms 
of fluid congestion to improve symptoms, exercise 
capacity, and HF hospitalization.520
I
C
© ESC 2023
CV, cardiovascular disease; HF, heart failure; HFmrEF, heart failure with mildly reduced 
ejection fraction; HFpEF, heart failure with preserved ejection fraction; LVEF, left 
ventricular ejection fraction; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4091


<!-- PAGE 50 -->

### Page 50

In addition, four trials investigated the effect of SGLT2 inhibition in pa­
tients with CKD: CREDENCE (with canagliflozin) and SCORED (with so­
tagliflozin) in patients with T2DM; DAPA-CKD (with dapagliflozin) and 
EMPA-KIDNEY (with empagliflozin) in patients with and without diabetes. 
In these patients at high risk of HF, a consistent risk reduction of CV death 
or HF hospitalization was observed ranging from 23% to 31%.150,153,542,543
A meta-analysis of six outcome trials of four SGLT2 inhibitors in pa­
tients with T2DM (EMPA-REG OUTCOME, CANVAS Programme 
[two trials], DECLARE-TIMI-58, CREDENCE, VERTIS CV) demon­
strated a 32% reduction in HF hospitalization, with no heterogeneity 
between trials; the effect on HF hospitalization was independent of 
ASCVD.155 Thus, SGLT2 inhibitors are recommended for patients 
with T2DM and multiple ASCVD risk factors or established ASCVD 
to reduce HF hospitalization.
7.5.2. Glucagon-like peptide-1 receptor agonists
Eight CVOTs have been completed with GLP-1 RAs in patients with 
T2DM, and the prevalence of established HF in these trials ranged 
from 9% to 24%. Most GLP-1 RAs had a neutral effect on risk of HF 
hospitalization in the placebo-controlled RCTs assessing CV safety of 
glucose-lowering medications in patients with T2DM with or at high 
risk of ASCVD, despite increasing heart rate by 3–5 b.p.m.70,72,158– 
163,544 In addition, two meta-analyses including eight trials comprising 
60 080 patients found HF hospitalization to be reduced by 10–11% 
by GLP-1 RA compared with placebo.164,545
The AMPLITUDE-O trial, comparing efpeglenatide with placebo, 
showed a nominally significant benefit on hospitalization for HF. The 
trial included stratified randomization by baseline or anticipated use 
of SGLT2 inhibitors and had the highest prevalence (15.2%) of 
14
12
10
8
6
4
2
0
1
2
4
8
16
32
Absolute risk reduction with
SGLT2 inhibitors (per 100 pt-yrs)
DECLARE-TIMI-58
CANVAS
EMPA-KIDNEY
VERTIS-CV
EMPA-REG OUTCOME
CREDENCE
DELIVER
EMPEROR-Preserved
DAPA-CKD
Rate of first failure hospitalization or cardiovascular death in the placedo arm (per 100 pt-yrs)
DAPA-HF
EMPEROR-Reduced
SOLOIST-WHFa
NNT: 96–400
RRR: 12%–34%
NNT: 72–125
RRR: 29%–31%
NNT: 59
RRR: 21%
NNT: 21–36
RRR: 25%
NNT: 10
RRR: 129%
ARR: 0.25–1.04
per 100 pt-yrs
ARR: 0.80–1.39
per 100 pt-yrs
ARR: 1.8
per 100 pt-yrs
ARR: 3.9–5.2
per 100 pt-yrs
ARR: 10.4
per 100 pt-yrs
High risk T2DM
CKD
Chronic HFpEF
Chronic HFrEF
Worsening HF
Figure 15 Absolute risk reduction with sodium–glucose co-transporter-2 inhibitors in relation to patient risk based on rate of heart failure-related end­
points in the placebo arm of the respective trials. ARR, absolute risk reduction; CKD, chronic kidney disease; HF, heart failure; HFpEF, heart failure with 
preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NNT, number needed to treat; pt-yrs, patient-years; RRR, relative risk re­
duction; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. Bubble plots demonstrate the consistent reductions in time to cardio­
vascular mortality or first HF hospitalization with SGLT2 inhibitors across all trials, with a greater ARR in patients at higher risk. The size of the bubble 
represents the sample size of the trial. NNT is estimated from the ARR. aEvent rates of first HF hospitalization or cardiovascular mortality were not reported 
in SOLOIST-WHF.189 Figure adapted from Butler et al. 2021.539


<!-- PAGE 51 -->

### Page 51

SGLT2 inhibitor use among GLP-1 RA trials. Data from an exploratory 
analysis of the AMPLITUDE-O trial suggest that the efficacy and safety 
of efpeglenatide was independent of concurrent SGLT2 inhibitor use, 
including HF hospitalization.546
Only three small RCTs of GLP-1 RAs have been conducted in pa­
tients with HFrEF.547 The LIVE trial randomly assigned 241 patients 
with chronic, stable HFrEF with or without DM to placebo or liraglu­
tide.548 While no changes in LVEF, quality of life, or functional class 
were noted after 24 weeks of treatment, more serious adverse cardiac 
events (sustained ventricular tachycardia, AF requiring intervention, and 
aggravation of IHD; 12 [10%] vs. 3 [3%] for liraglutide and placebo, re­
spectively; P = 0.04) occurred in the liraglutide group. The FIGHT trial 
(Functional Impact of GLP1 for HF Treatment) randomly assigned 300 
patients with and without DM with HFrEF and a recent hospitalization 
for HF to liraglutide or placebo. Following 180 days of treatment, the 
primary outcome (time to death, time to re-hospitalization for HF, 
and time-averaged proportional change in NT-proBNP level from base­
line to 180 days) was not different between groups. In addition, there 
was a non-significant between-group difference in the number of re- 
hospitalizations for HF (63 [41%] in the liraglutide group vs. 50 [34%] 
in the placebo group; HR 1.30, 95% CI, 0.89–1.88; P = 0.17).549 The 
third trial was a small (n = 82), randomized study evaluating 12 weeks 
of albiglutide vs. placebo in patients with HFrEF. No significant differ­
ences were seen in LVEF, 6 min walk test, myocardial glucose utilization, 
or oxygen use.550 The study was too small and too short to evaluate 
clinical outcomes.
7.5.3. Dipeptidyl peptidase-4 inhibitors
Four DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin, and linagliptin) 
have been examined in dedicated placebo-controlled CV safety trials 
in patients with T2DM with or at high risk of ASCVD. Saxagliptin signifi­
cantly increased the risk of HF hospitalization172 and is not recom­
mended in patients with DM with or at increased risk of HF. 
Alogliptin was associated with a non-significant trend towards an in­
crease in HF hospitalization.173 Sitagliptin and linagliptin had a neutral 
effect.174,178–180 Vildagliptin, not tested in a CVOT, had no significant 
effect on LVEF but led to an increase in LV volumes in a small trial.551
7.5.4. Insulin
In patients with T2DM and advanced HF, insulin use is independently 
associated with a significantly worse prognosis.552 Two basal insulins 
have been formally evaluated in dedicated CV outcomes trials. In the 
ORIGIN trial, 12 537 patients (mean age 63.5 years) at high CV risk, 
with IFG, IGT, or T2DM, were randomized to insulin glargine titrated 
to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or stand­
ard care. After a median follow-up of 6.2 years, insulin glargine was 
neutral in its effect on HF hospitalizations.553 The DEVOTE rando­
mized trial, a double-blind comparison of the ultra-long-acting, once- 
daily insulin degludec vs. insulin glargine U100, enrolled 7637 patients 
with T2DM with ASCVD or at high CV risk.181 Treatment with insulin 
degludec vs. insulin glargine did not differ with respect to HF hospital­
ization; prior HF was independently associated with future HF 
hospitalization.554
7.5.5. Metformin
Metformin is suggested to be safe at all stages of HF with preserved or 
stable, moderately reduced kidney function (i.e. eGFR >30 mL/min/ 
1.73 m2). It is associated with a lower risk of death and HF hospitaliza­
tion compared with insulin and sulphonylureas in observational studies, 
though dedicated randomized, controlled, CVOTs evaluating safety and 
efficacy of metformin have not been conducted.555–557 Concerns re­
garding lactic acidosis have not been substantiated.558,559
7.5.6. Sulphonylureas
Data on the effects of sulphonylureas on HF are inconsistent. Data 
from two retrospective cohort studies, including 111 971 patients 
with diabetes, suggest an adverse safety profile showing ∼20–60% high­
er death rate and ∼20–30% higher risk of HF compared with metfor­
min.560,561 However, in the UKPDS, NAVIGATOR (Nateglinide And 
Valsartan in Impaired Glucose Tolerance Outcomes Research), and 
ADOPT trials, there were no increased HF signals.127,562–564 In add­
ition, data from the CAROLINA trial comparing linagliptin (shown to 
not increase the risk of HF hospitalization vs. placebo in the 
CARMELINA trial) vs. glimepiride did not show an elevated risk of 
HF hospitalization by this sulphonylurea.179
7.5.7. Thiazolidinediones
Thiazolidinediones increased the risk of HF hospitalization in several 
trials and are not recommended in patients with diabetes and symp­
tomatic HF.165,565–567
7.5.8. Special consideration: hypoglycaemia and risk 
of heart failure hospitalization
Although severe hypoglycaemic events were associated with higher HF 
hospitalization in some but not all studies, there is no clear evidence for 
causality.139,140,554,568Recent analyses have demonstrated bi-directional 
associations between hypoglycaemia and CV outcomes, including HF, 
suggesting that this is not causal, but rather reflects underlying frailty 
and risk of adverse outcomes.139,140
Figure 16 summarizes glucose-lowering treatment of patients with 
HF and T2DM.
ESC Guidelines                                                                                                                                                                                          4093


<!-- PAGE 52 -->

### Page 52

Recommendation Table 22 — Recommendations for glucose-lowering medications in patients with type 2 diabetes 
with and without heart failure
Recommendations
Classa
Levelb
Recommendations for glucose-lowering medications to reduce heart failure hospitalization in patients with type 2 diabetes with or 
without existing heart failure
SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, or sotagliflozinc) are recommended in patients with T2DM with 
multiple ASCVD risk factors or established ASCVD to reduce the risk of HF hospitalization.71,150–153,541
I
A
SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozinc) are recommended in patients with T2DM and HFrEF to reduce the risk of 
HF hospitalization and CV death.189,491,494,497
I
A
Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF 
hospitalization or CV death.530,532,533
I
A
Recommendations for additional glucose-lowering agents with safety demonstrated for heart failure hospitalization in patients with 
type 2 diabetes if additional glucose control is needed
GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER, dulaglutide, efpeglenatide) have a neutral effect on the risk of HF 
hospitalization, and should be considered for glucose-lowering treatment in patients with T2DM at risk of or with HF.70,158–164,545
IIa
A
DPP-4 inhibitors (sitagliptin and linagliptin) have a neutral effect on the risk of HF hospitalization, and should be considered for 
glucose-lowering treatment in patients with T2DM at risk of or with HF.174,179,180
IIa
A
Basal insulins (glargine and degludec) have a neutral effect on the risk of HF hospitalization and should be considered for glucose-lowering 
treatment in patients with T2DM at risk of or with HF.553,554
IIa
B
Metformin should be considered for glucose-lowering treatment in patients with T2DM and HF.d,555,556,558
IIa
B
Recommendations for glucose-lowering medications with an increased risk of heart failure hospitalization in patients with type 2 
diabetes
Pioglitazone is associated with an increased risk of incident HF in patients with diabetes and is not recommended for glucose-lowering 
treatment in patients at risk of HF (or with previous HF).165,566
III
A
The DPP-4 inhibitor saxagliptin is associated with an increased risk of HF hospitalization in patients with diabetes and is not recommended 
for glucose-lowering treatment in patients at risk of HF (or with previous HF).172
III
B
Recommendations for special consideration
It is recommended to switch glucose-lowering treatment from agents without proven CV benefit or proven safety to agents with proven 
CV benefit.e
I
C
© ESC 2023
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; ER, extended release; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure; 
HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular 
ejection fraction; MACE, major adverse cardiovascular events; s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cSotagliflozin is a dual SGLT1/2 inhibitor. 
dChronic and stable HF. 
eAgents with proven benefit: SGLT2 inhibitors: empagliflozin, canagliflozin, dapagliflozin, sotagliflozinc; GLP-1 RAs: liraglutide, semaglutide s.c., dulaglutide, efpeglenatide. In the VERTIS CV 
trial, ertugliflozin did not reduce the primary endpoint (three-point MACE) nor the key secondary endpoint (CV death or HF hospitalization), but reduced HF hospitalization as a secondary 
exploratory endpoint.


<!-- PAGE 53 -->

### Page 53

To reduce HF-related outcomesa in all patients with T2DM
and HF (HFpEF, HFmrEF, HFrEF)
SGLT2 inhibitorb
(Class I)
Independent of HbA1c
Independent of concomitant glucose-lowering medication
For additional glucose control
Metformin
(Class lla)
Insulin glargine
Insulin degludec
(Class lla)
Sitagliptin
Linagliptin
(Class lla)
GLP-1 RAc
(Class lla)
Other glucose-lowering agents with neutral effects on HF
in CVOTs should be considered
Pioglitazone
(Class III)
Saxagliptin
(Class Ill)
Other glucose-lowering agents with increased risk for HF
hospitalization in CVOTs are not recommended
Figure 16 Glucose-lowering treatment of patients with heart failure and type 2 diabetes. CVOT, cardiovascular outcomes trial; DPP-4, dipeptidyl 
peptidase-4; GLP-1 RA, glucagon-like peptide-1 receptor agonist; Hb1Ac, glycated haemoglobin; HF, heart failure; HFmrEF, heart failure with mildly reduced 
ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SGLT2, sodium–glucose 
co-transporter-2; T2DM, type 2 diabetes mellitus. aThis includes HF hospitalization or CV death. bEmpagliflozin, dapagliflozin, or sotagliflozin in patients 
with HFrEF, empagliflozin or dapagliflozin in patients with HFpEF and HFmrEF. cPreferred in patients with atherosclerotic cardiovascular disease and if weight 
reduction is needed; do not combine with DPP-4 inhibitors.
ESC Guidelines                                                                                                                                                                                          4095


<!-- PAGE 54 -->

### Page 54

### 8 Arrhythmias: atrial fibrillation,

ventricular arrhythmias, and 
sudden cardiac death and diabetes
Diabetes may increase the risk of cardiac arrhythmias via several fac­
tors including: associated CV risk factors (e.g. hypertension), CVD 
(i.e. CAD, prior MI, HF, or stroke), and diabetes-associated factors 
such as glucose control or diabetic neuropathy.157,569–572 The risk 
of cardiac arrhythmias or sudden cardiac death (SCD) in patients 
with diabetes is most often related to the presence and severity of 
underlying CVD, but diabetes-related factors may induce arrhyth­
mias independently of CV comorbidities.157,573–577 The risk of con­
duction disturbances and need for pacemaker therapy may also be 
higher in patients with T2DM than in controls, although the general 
management for these issues should not differ from that for other 
patients.578,579
8.1. Atrial fibrillation and diabetes
8.1.1. Epidemiology of atrial fibrillation and its 
association with diabetes
Patients with T1DM or T2DM may exhibit atrial electrical and 
structural remodelling associated with increased vulnerability for 
AF.580–583 Many epidemiological studies have reported an association 
of diabetes (mainly T2DM) with incident AF.584,585 Recent, large ana­
lyses confirmed that T1DM was also independently associated with a 
higher incidence of AF.586–588 Diabetes duration has also been asso­
ciated with AF; each year with diabetes conferred a 3% increase in 
the risk of AF.589 A meta-analysis of 11 studies with 108 703 AF cases 
in 1 686 097 patients showed a 40% greater risk of AF in the presence 
of diabetes. The effect was attenuated but still significant after adjusting 
for other risk factors (RR 1.24; 95% CI, 1.06–1.44).590 Although men 
have higher absolute rates for incidence of AF, the relative rates of in­
cident AF associated with diabetes are higher in women than in men for 
both T1DM and T2DM.586–588
Diabetes and AF frequently co-exist, and when this occurs, there is a 
substantially higher risk of all-cause death, CV death, stroke, kidney dis­
ease, and HF, regardless of diabetes type.541,577,591–596 Risk factors 
commonly associated with diabetes and AF (and not fully dissociable, 
e.g. hypertension and obesity) are also likely to worsen prognosis. In 
several observational studies, the age-adjusted association of diabetes 
with incident AF was no longer significant after multiple adjustments 
for hypertension, CV comorbidity, BMI, or obesity, thus suggesting 
that strategies for preventing AF in patients with diabetes should focus 
on controlling diabetes-associated comorbidities (especially weight, 
sleep apnoea, and BP).597–600
Intensive glucose lowering (target HbA1c <6.0%) has been asso­
ciated with similar incident AF rates than a less-stringent approach 
(HbA1c <8.0%).601 The rate of new-onset AF may, however, be af­
fected by diabetes therapy.577 The impact of anti-hyperglycaemic 
agents on the risk of AF is still debated. It has been suggested that met­
formin and pioglitazone may reduce the risk of AF.602 SGLT2 inhibitors, 
compared with placebo, were associated with more new-onset AF 
cases in EMPA-REG OUTCOME (empagliflozin vs. placebo), but fewer 
incident AF cases in CANVAS (canagliflozin vs. placebo) and 
DECLARE-TIMI 58 (dapagliflozin vs. placebo).71,151,153,603 In the 
EMPA-REG OUTCOME trial, empagliflozin, compared with placebo, 
reduced CV death or HF hospitalization consistently in patients with 
diabetes with or without AF (Pint = 0.56).604 It has recently been re­
ported that finerenone may reduce new-onset AF in patients with 
T2DM and CKD.605 This is consistent with results obtained with other 
MRAs in HF.508,606
In the ADVANCE study, patients with diabetes and AF (∼8%) had 
higher risks of all-cause death, CV death, major cerebrovascular events, 
and HF compared with patients with diabetes without AF. Lowering BP 
resulted in similar RR reduction in all-cause and CV death but, due to 
their higher risk of these events, the absolute benefits from BP control 
was much greater in patients with AF.607 In the VALUE (Valsartan 
Antihypertensive Long-term Use Evaluation) trial, hypertensive pa­
tients with new-onset diabetes had higher rates of new-onset AF com­
pared with patients without diabetes, and were at a higher risk of HF.608
Hence, AF in patients with diabetes should be viewed as a marker of 
adverse outcome, which should prompt aggressive management of all 
concomitant risk factors.609
8.1.2. Screening and managing atrial fibrillation in 
patients with diabetes
Detecting AF in patients with diabetes has clinical consequences be­
cause the risk of stroke is markedly higher in these patients. In the ab­
sence of other comorbidities, the annual risk of stroke can be 
estimated at 2.2% per year in isolated diabetes.610 Since asymptomatic 
(silent) AF is not uncommon, patients with diabetes should be oppor­
tunistically screened for AF by palpating pulse or by ECG.611 Patients 
with diabetes at high risk of AF would likely benefit from an active 
screening for AF, but more data are needed to define optimal AF 
screening strategies also including modern equipment, such as wear­
able digital devices in patients with diabetes (Supplementary data 
online, Table S16).612,613 Before starting treatment, clinical AF should


<!-- PAGE 55 -->

### Page 55

Screening results
ECG results
Systematic screening results
Consider repeated screening
No definite AF but symptoms or high risk
 of AF or high risk of ischaemic stroke
(CHA2DS2-VASc score >1 in men or >2 in women with diabetes)
Suspicion of AF
Atrial fibrillation confirmed
No atrial fibrillation
12-lead ECG
Symptomatic patient e.g. palpitations, dyspnoea
Asymptomatic patient
Opportunistic screening
 (e.g. pulse palpation, ECG)
(Class I)
Yearly opportunistic
 screening
Systematic screening:
repeated surface ECG, Holter ECG,
patient-activated or wearable device
Start treatment with OAC
(NOACs preferred over VKA)
According to CHA2DS2-VASc score
Screening and treatment of AF in patients with diabetes by healthcare professionals
Negative
Negative
Negative
Positive
Positive
Positive
Figure 17 Screening for atrial fibrillation in patients with diabetes. AF, atrial fibrillation; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 
years (2 points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), Vascular disease, Age 65–74 years, Sex category (female); ECG, electro­
cardiogram; OAC, oral anticoagulant; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.
ESC Guidelines                                                                                                                                                                                          4097


<!-- PAGE 56 -->

### Page 56

be well documented using surface-lead ECG (≥30 s showing heart 
rhythm with no discernible repeating P waves and irregular R–R inter­
vals 
when 
atrioventricular 
conduction 
is 
not 
impaired; 
Figure 17).600,614
In patients with diabetes and established AF, controlling the ventricu­
lar rate is recommended to decrease symptoms and prevent AF-related 
complications, while asymptomatic patients mainly need thrombo- 
embolic prevention. In those with persistent symptoms despite ad­
equate rate control, or in those with LV dysfunction attributable to 
poorly controlled high ventricular rate, rhythm-control strategies 
should be attempted, including cardioversion, antiarrhythmic drug use, 
and catheter ablation, which is the general management in this setting 
whether diabetes is present or not.600,615–617 For details on managing 
AF, please refer to the 2020 ESC/EACTS Guidelines for the diagnosis 
and management of atrial fibrillation and recent European Heart 
Rhythm Association scientific documents.577,600,613
8.1.3. Preventing stroke in patients with atrial 
fibrillation and diabetes
Stratifying AF stroke risk with diabetes should use the established 
CHA2DS2-VASc (Congestive HF, Hypertension, Age ≥75 years [2 
points], Diabetes mellitus, Stroke/transient ischaemic attack [2 points], 
Vascular disease, Age [65–74 years], Sex category [female]) score; fol­
lowing stratification, stroke prevention (i.e. OAC) should be started in 
patients with >1 risk factor.600,618 The score is likely higher in patients 
with diabetes due to the common association with other risk factors 
for stroke, such as arterial hypertension, age over 65 or 75 years, asso­
ciated vascular disease, or HF. Several studies found that diabetes inde­
pendently predicted stroke in patients with AF.619 However, diabetes 
may not be a significant risk factor for stroke in the elderly.620 The 
Stroke in AF Working Group attributed a RR of 1.7 (95% CI, 1.4– 
2.0) for stroke in patients with AF and diabetes, as well as an absolute 
stroke risk of 2–3.5% per year for non-anticoagulated patients in the 
same population.621 Diabetes is probably not the most potent inde­
pendent risk factor for stroke in AF compared with the other items 
in the CHA2DS2-VASc score, but it is included in this risk-stratification 
tool, giving a point alongside most other items.600,618,622–624 The in­
creased risk of stroke associated with AF and diabetes is similar in 
T1DM and T2DM except perhaps a slightly increased risk in T2DM 
compared with T1DM in patients <65 years of age. The risk of stroke 
in patients with diabetes and AF may increase with longer diabetes dur­
ation, increasing levels of HbA1c, and more diabetes-related comorbid­
ities, such as nephropathy and retinopathy.625,626
As an OAC is being initiated, a clinical bleeding risk score, such as the 
HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, 
Bleeding history or predisposition, Labile international normalized ra­
tio, Elderly [>65 years], Drugs/alcohol concomitantly) score, should 
be used to identify patients at risk of bleeding, and importantly, to ad­
dress the potentially reversible bleeding risk factors (that should be 
considered in all patients, irrespective of HAS-BLED score).600 Due 
to the increased risk of several CV adverse events in patients with dia­
betes, a similar RR reduction with OACs generally translates into great­
er ARR in the diabetes population.577 The beneficial efficacy and safety 
of NOACs compared with warfarin seem conserved in patients with 
AF and diabetes, irrespective of their baseline stroke risk or the pres­
ence of other CV risk factors.577,627–629
8.2. Ventricular arrhythmias and risk of 
sudden cardiac death and diabetes
Compared with the general population, patients with diabetes have an 
increased risk of both SCD and non-SCD.575,615,644–646 In a 
meta-analysis of 14 studies involving 346 356 participants and 5647 
SCD cases, the risk of SCD was two-fold higher in patients with dia­
betes compared with patients without diabetes (adjusted HR 2.25; 
95% CI, 1.70–2.97).647 However, patients with diabetes also exhibited 
a nearly three-fold greater risk of non-SCD than patients without 
Recommendation Table 23 — Recommendations for 
atrial fibrillation in patients with diabetes
Recommendations
Classa
Levelb
Screening
Opportunistic screening for AF by pulse taking or 
ECG is recommended in patients ≥65 years of 
age.577,611,630,631
I
B
Opportunistic screening for AF by pulse taking or 
ECG is recommended in patients with diabetes <65 
years of age (particularly when other risk factors are 
present) because patients with diabetes exhibit a 
higher AF frequency at a younger age.577,611,631,632
I
C
Systematic ECG screening should be considered to 
detect AF in patients aged ≥75 years, or those at high 
risk of stroke.577,633–635
IIa
B
Anticoagulation
Oral anticoagulation is recommended for preventing 
stroke in patients with AF and diabetes and with at 
least one additional (CHA2DS2-VASc) risk factor for 
stroke.636
I
A
For preventing stroke in AF, NOACs are 
recommended in preference to VKAs, with the 
exception of patients with mechanical valve 
prostheses or moderate to severe mitral stenosis.637
I
A
Oral anticoagulation should be considered for 
preventing stroke in patients with AF and diabetes 
but no other CHA2DS2-VASc risk factor for stroke. 
This includes patients with T1DM or T2DM <65 
years old.638–640
IIa
B
Use of a formal, structured, bleeding risk score 
(HAS-BLED score) should be considered to identify 
modifiable and non-modifiable risk factors for 
bleeding in patients with diabetes and AF, and to 
identify patients in need of closer follow-up.641–643
IIa
B
© ESC 2023
AF, atrial fibrillation; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥ 75 
years (2 points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), 
Vascular disease, Age 65–74 years, Sex category (female); ECG, electrocardiogram; 
HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or 
predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol 
concomitantly; NOAC, non-vitamin K antagonist oral anticoagulant; T1DM, type 1 
diabetes mellitus; T2DM, type 2 diabetes mellitus; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 57 -->

### Page 57

diabetes (adjusted HR 2.90; 95% CI, 1.89–4.46).646 Men at all ages have 
a higher risk of SCD than women, but in the presence of diabetes, the 
risk of SCD is higher in both men and women.575,615,644–646,648
Both hyperglycaemia and hypoglycaemia are independently asso­
ciated 
with 
increased 
risk 
of 
ventricular 
arrhythmias.649
Insulin-induced hypoglycaemia has been associated with nocturnal 
death (also called ‘dead-in-bed syndrome’) in T1DM, and arrhythmic 
deaths were reported in several T2DM trials.187,576,650–654 Diabetic kid­
ney disease might also play a role in the arrhythmia-associated mechan­
ism of sudden death in this setting.655
Hypoglycaemia-associated arrhythmias are difficult to document, but 
observational studies using CGM and Holter monitoring in small T2DM 
cohorts showed that hypoglycaemic episodes were common, often 
asymptomatic, and associated with various arrhythmias.656,657
Compared with daytime hypoglycaemia, nocturnal episodes were 
more common and associated with a greater risk of bradycardia or at­
rial ectopy, while ventricular arrhythmias were equally common.656,657
The use of antiarrhythmic drugs should follow the general principles 
and precautions related to pharmacological treatment of cardiac ar­
rhythmias.600,658 In patients with diabetes and an ICD, there is an in­
creased risk of death in those who have appropriate therapy 
compared to those who do not.659 In contrast, patients with diabetes 
may have a lower risk of inappropriate therapy or ICD shock, since 
they may be more sedentary with consequently less frequent 
exercise-induced sinus tachycardia and also lower incidence of lead 
fracture.600,658,659
Observational studies have reported significant corrected QT (QTc) 
interval prolongation possibly associated with microvascular complica­
tions, atypical patterns of microvolt T-wave alternans, altered heart 
rate variability, or heart rate turbulence in patients with diabetes, but 
none of these tests should routinely be used to stratify the risk of ven­
tricular arrhythmias or SCD in clinical practice.658,660–668 There may 
also be a direct effect of both hyper- and hypoglycaemia on QTc inter­
val.669–671 The mechanisms by which hyperglycaemia may produce ven­
tricular instability may be increased sympathetic activity, increased 
cytosolic calcium content in myocytes, or both.672 The risk of cardiac 
events is usually related to the underlying heart disease rather than ven­
tricular premature beats.669–671
There is no diabetes-specific protocol for SCD screening, but all pa­
tients diagnosed with diabetes should undergo regular evaluation for 
CV risk factors or structural heart disease.48,576,658 Patients with dia­
betes and symptoms suggestive of cardiac arrhythmias (e.g. palpitations, 
pre-syncope, or syncope) should undergo further detailed diagnostic 
assessment.576 Patients with diabetes and frequent premature ventricu­
lar beats, episodes of non-sustained ventricular tachycardia, or symp­
toms suggestive of HF should be examined for the presence of an 
underlying structural heart disease and their eligibility for an ICD should 
be assessed; this is a general principle in managing patients with HF, ir­
respective of diabetes status.658 In case of sustained ventricular arrhyth­
mias, diagnosing underlying structural heart disease with imaging 
techniques and coronary angiography is usually needed if no obvious 
trigger factors, such as electrolyte imbalance, can be identified.48,576,658
Although cardiac arrhythmias were not specifically investigated in ei­
ther the LEADER or the EMPA-REG OUTCOME trials, an antiarrhyth­
mic effect of these drugs (perhaps mediated by glucagon-release 
stimulation or increased blood ketone bodies, which may have 
sympathico-suppressive effects) has been hypothesized to contribute 
to the reduced risk of CV death.71,72 In the DAPA-HF trial, dapagliflozin 
reduced the risk of the composite outcome of serious ventricular ar­
rhythmia, resuscitated cardiac arrest, or sudden death by 21% in 
patients with HFrEF, compared with placebo.673 The benefit was mainly 
observed >9 months post-randomization, suggesting that the beneficial 
effects of dapagliflozin require time to develop and may involve cellular 
mechanisms that slow the progression of HFrEF.674 However, a recent 
meta-analysis indicated that SGLT2 inhibition was not associated with 
an overall lower risk of SCD or ventricular arrhythmias in patients 
with T2DM and/or HF and/or CKD, although the point estimates sug­
gested potential benefits.675
9. Chronic kidney disease and 
diabetes
9.1. Chronic kidney disease definitions, 
staging, and screening
Chronic kidney disease has a major effect on global morbidity and mor­
tality.676 CKD is defined as abnormalities of kidney structure or func­
tion, present for >3 months, with implications for health. It is staged 
primarily by categories of glomerular filtration rate (GFR) and albumin­
uria.677 The CKD Epidemiology Collaboration (CKD-EPI) has devel­
oped accurate eGFR equations based on creatinine ± cystatin C 
measurements.678 An eGFR ≥60 mL/min/1.73 m2 does not constitute 
CKD unless there is albuminuria or other evidence of kidney disease 
(Table 11).677 A persistent decrease in eGFR <60 mL/min/1.73 m2 
(i.e. stages G3–5), however, is sufficient to confirm CKD. This level 
of eGFR is associated with increased risk of CKD progression and 
CVD.43,679,680 The most advanced stage of CKD is characterized by 
an eGFR <15 mL/min/1.73 m2, and recently implemented nomencla­
ture refers to this as ‘kidney failure’.681 Such low levels of eGFR may 
Table 11 KDIGO staging by glomerular filtration rate 
and urinary albumin-to-creatinine ratio categories with 
colour chart for risk of initiation of maintenance kidney 
replacement therapy
Albuminuria stage eGFR stage 
(mL/min/ 
1.73 m2)
A1 <3 mg/ 
mmol 
(<30 mg/g)
A2 3–30 
mg/mmol 
(30– 
300 mg/g)
A3 
>30 mg/ 
mmol 
(>300 mg/g)
G1 (≥90)
G2 (60–89)
G3a (45–59)
G3b (30–44)
G4 (15–29)
G5 (<15)
© ESC 2023
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; KDIGO, Kidney 
Disease: Improving Global Outcomes. 
Note that this staging uses a ratio 1:10 to convert the urinary albumin-to-creatinine ratio 
from mg/mmol to mg/g, but the precise ratio is 1:8.84. 
Green is low risk (and represents no CKD if there is no structural or histological evidence 
of kidney disease). Relative to low risk (estimated at 0.04/1000 patient-years), yellow is 
moderately increased risk (at least ∼5×), orange is high risk (at least ∼20×), and red is 
very high risk (at least ∼150×). Risk of cardiovascular death approximately mirrors the 
same pattern. 
Table adapted from the KDIGO 2012 Clinical Practice Guideline for the Evaluation and 
Management of Chronic Kidney Disease. Reprinted with permission from Elsevier.677
ESC Guidelines                                                                                                                                                                                          4099


<!-- PAGE 58 -->

### Page 58

necessitate the need to start maintenance kidney replacement therapy 
(KRT).677
Albuminuria is an early marker of nephropathy and predicts both risk 
of kidney failure and CVD independently of eGFR.43,682 Nephropathy 
caused by diabetes is a leading cause of CKD globally, and screening pa­
tients with diabetes for CKD is recommended at least annually.676,677 A 
spot urine sample measuring UACR is an efficient method to identify 
and quantify albuminuria.677,683 Changes in UACR or GFR slope are 
used as surrogate trial endpoints for nephroprotection, but more de­
finitive evidence for reducing risk of kidney failure in patients with dia­
betes generally requires categorical endpoints based on a ≥40% 
sustained decline in GFR.684,685
9.2. Management of cardiovascular disease 
risk and kidney failure in patients with 
chronic kidney disease and diabetes
Risk of CVD increases progressively with lower levels of eGFR and, in 
those with advanced CKD, structural abnormalities of the heart, HF, 
and sudden death are particular features.679,680,686–688 Increased risk 
of CAD also accompanies CKD, often with calcification of atheroscler­
otic plaques.679,689 Accelerated vascular media calcification with in­
creased vascular stiffness is also a feature of CKD and attributed to 
disordered 
calcium–phosphate 
metabolism, 
referred 
to 
as 
CKD-mineral bone disorder (CKD-MBD).690,691 Managing CVD risk 
in patients with CKD and diabetes may, therefore, need to consider mul­
tiple interventions and both traditional and CKD-specific risk fac­
tors.361,692–694
All patients with diabetes and CKD should be offered standard ad­
vice on smoking, nutrition, and exercise.45 A raised BMI is independent­
ly associated with risk of CKD, and behavioural interventions to 
promote weight loss in people with T2DM reduce the risk of develop­
ing very high-risk CKD over the long-term.57,695,696 Management of 
people with diabetes and CKD is then based on sequentially initiating 
and titrating doses of pharmacological interventions with proven effi­
cacy (Figure 18).
Statin-based therapy reduces the risk of major atherosclerotic events 
(i.e. coronary death, non-fatal MI, ischaemic stroke, and coronary revascu­
larization) in patients with CKD, but does not meaningfully slow progres­
sion of CKD.248,697–699 Trials of statin-based therapy, combined in 
collaborative meta-analyses, show a trend towards smaller relative reduc­
tions per mmol/L reduction in LDL-C on major atherosclerotic events as 
eGFR declines, with uncertainty about benefits among patients on dialy­
sis.697 This diminution in RR reduction at decreased eGFR implies that 
more intensive LDL-C-lowering regimens are required to maximize ben­
efits.697 The goal in patients with CKD and diabetes should be to achieve 
the largest possible absolute reduction in LDL-C safely.697,700
Four large trials recruiting different types of patients with CKD have 
confirmed the safety of intensive LDL-C lowering with statins alone 
(atorvastatin, rosuvastatin, fluvastatin), or combining a moderate dose 
of simvastatin with ezetimibe.698,701–704 Although there is no dedicated, 
large-scale trial of a PCSK9 inhibitor in patients with CKD, sub-group 
analyses by CKD stage from the FOURIER trial of the PCSK9 inhibitor 
evolocumab found its LDL-C-lowering effect was preserved in patients 
with stage G3 CKD, and CV benefits on atherosclerotic events ap­
peared unmodified by baseline eGFR.699
Several drugs developed to manage CVD risk or hyperglycaemia 
have been shown to reduce the risk of CKD progression in large trials 
that recruited patients with T2DM and CKD (Figure 18). These in­
clude RAS inhibitors, SGLT2 inhibitors, and finerenone. There is 
increasing evidence that these interventions should be started early 
to prevent end-organ damage in at-risk patients.
Blocking RAS with an ACE-I (captopril) or ARBs (irbesartan/losar­
tan) prevented kidney failure in patients with diabetes and overt ne­
phropathy in dedicated clinical outcomes trials.705–707
ARBs 
(irbesartan/telmisartan) also slowed progression from microalbumi­
nuria (albuminuria stage A2) to overt nephropathy.708,709 These 
RAS inhibitors are therefore recommended in patients with diabetes 
as soon as CKD is clinically diagnosed. Combining an ARB with an 
ACE-I, however, is not recommended, as large trials have identified 
an increased risk of hyperkalaemia and acute kidney injury, without 
demonstrable additional benefits of such ‘dual-blockade’ on risk of 
kidney failure or CVD.710
In contrast, combining an SGLT2 inhibitor with an ACE-I or ARB has 
clear beneficial effects on risk of kidney failure and hospitalization for HF 
in patients with CKD and T2DM.153,542 The CREDENCE, DAPA-CKD, 
and EMPA-KIDNEY placebo-controlled trials were all stopped early for 
efficacy while testing canagliflozin, dapagliflozin, and empagliflozin, re­
spectively.153,543,711 All three trials found the RR reductions for kidney 
disease progression were unmodified by baseline eGFR, with 
EMPA-KIDNEY reporting clear benefits in patients with eGFR 20– 
30 mL/min/1.73 m2.153,542,543,712,713 EMPA-KIDNEY included 254 pa­
tients with an eGFR <20 mL/min/1.73 m2 at randomization, and once in­
itiated, SGLT2 inhibitors could be continued until the need of KRT. As 
patients with decreased eGFR are at the highest absolute risk of kidney 
disease progression, these trials’ results should encourage the initiation 
of SGLT2 inhibitors in patients with CKD down to at least an eGFR of 
20 mL/min/1.73 m2 with continued use until the need for KRT (despite 
low eGFR substantially attenuating their HbA1c-lowering effect). 
Meta-analysis of all the large SGLT2 inhibitor trials shows benefits of 
SGLT2 inhibitors on the risk of HF hospitalization or CV death are 
also unmodified by eGFR (at a trial level; Figure 19).714 The combined 
SGLT1/2 inhibitor sotagliflozin was analysed vs. placebo in the 
SCORED trial in patients with T2DM and CKD (eGFR 25–60 mL/min/ 
1.73 m2); sotagliflozin reduced the primary composite of the total num­
ber of CV deaths, hospitalizations for HF, and urgent visits for HF by 26% 
vs. placebo (HR 0.74; 95% CI, 0.63–0.88; P < 0.001).150 Initiating an 
SGLT2 inhibitor alongside an ACE-I or ARB is therefore recommended 
in patients with T2DM following the first clinical evidence of CKD. In pa­
tients with T1DM and CKD, the absence of large trials with sufficient 
follow-up means it is unclear whether the absolute benefits of SGLT2 
inhibitors on kidney failure and CVD outcomes are outweighed by the 
high absolute risk of ketoacidosis with SGLT2 inhibitors.715,716
MRAs reduce BP and albuminuria in patients with CKD.717 The 
placebo-controlled FIDELIO-DKD (Efficacy and Safety of Finerenone 
in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney 
Disease) and FIGARO-DKD (Efficacy and Safety of Finerenone in 
Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of 
Diabetic Kidney Disease) trials demonstrated for the non-steroidal 
MRA finerenone that these effects translate into reduced risk of kidney 
failure and a reduction of the combined CV outcome of CV death, non- 
fatal MI, non-fatal stroke, or hospitalization for HF in patients with CKD 
and T2DM who are already on maximum ACE-I or ARB.718–720
FIDELIO-DKD demonstrated reduced risk of a categorical kidney out­
come, a primary composite outcome combining kidney failure, a sus­
tained decline in eGFR of at least 40%, or death from renal causes, in 
patients with eGFR 25–60 mL/min/1.73 m2 and UACR of 34– 
567 mg/mmol (30–5000 mg/g), or eGFR 60–75 mL/min/1.73 m2 with 
UACR of 34–567 mg/mmol (300–5000 mg/g; mean eGFR 43 ±  
13 mL/min/1.73 m2; median UACR 96 mg/mmol [852 mg/g]).719


<!-- PAGE 59 -->

### Page 59

Information on the safety and efficacy of combining MRAs with 
SGLT2 inhibitors in CKD is limited as only ∼4% of FIDELIO-DKD, 
∼8% of FIGARO-DKD, ∼5% of DAPA-CKD, and no CREDENCE par­
ticipants were prescribed such a combination.153,718,719,721 Sub-group 
analyses considering those co-prescribed MRA and SGLT2 inhibitors 
suggest their combined use does not modify safety findings from the 
key trials.150,189,722–726
FIDELIO-DKD and FIGARO-DKD excluded patients with a potas­
sium of >4.8 mmol/L, as MRAs cause hyperkalaemia.718,719
Combining RAS and SGLT2 inhibitors does not appear to cause hyper­
kalaemia, and a hypothesis has been raised that SGLT2 inhibitors re­
duce the risk of severe hyperkalaemia among MRA users with 
HF.153,542,710,723,724,727,728 Finerenone is therefore recommended in 
addition to an RAS inhibitor in patients with T2DM and eGFR 
To reduce cardiovascular risk
To reduce kidney failure risk
Statin-based regimen
(Class I)
SGLT2 inhibitorb
(Class I)
BP control
(Class I)
Finerenone
(Class I)
ACE-I or ARB
(Class I)
For additional glucose control
Glucose-lowering medications with suggested cardiovascular benefit
GLP-1 RA
DPP-4 inhibitor
Insulin
Metformin (if eGFR >30 mL/min/1.73 m2)
Glucose-lowering medications with neutral or no proven cardiovascular benefit
Treatment of patients with T2DM and CKDa
To reduce cardiovascular and kidney failure risk
Figure 18 Pharmacological management to reduce cardiovascular or kidney failure risk in patients with type 2 diabetes and chronic kidney disease. ACE-I, 
angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; CV, cardiovascular; CVD, 
cardiovascular disease; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; RAS, 
renin–angiotensin system; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus; UACR, urinary albumin-to-creatinine ratio. aA statin- 
based regimen reduces CV risk in CKD while ACE-I or ARBs reduce kidney failure risk; SGLT2 inhibitors, BP control, and finerenone reduce both CV risk and 
kidney failure risk. SGLT2 inhibitors, RAS inhibitors, and finerenone are particularly effective at reducing risk of kidney failure when albuminuria is present [e.g. 
UACR ≥3 mg/mmol (30 mg/g); stage A2 and A3]. bCanagliflozin, empagliflozin, or dapagliflozin.
ESC Guidelines                                                                                                                                                                                          4101


<!-- PAGE 60 -->

### Page 60

No diabetes
High atherosclerotic cardiovascular riska
Mean eGFR: 80 mL/min/1.73m2
Kidney disease progression
Acute kidney injury
Cardiovascular death or hospitalization for heart failure
Ketoacidosis
Lower limb amputationb
-2
-1
-5
0.3
0.6
-45
4
4
4
21
0.2
-15
-10
5
-5
0
-20
-25
-30
-35
-40
Events avoided or caused per 1000
patient-years in
SGLT2i groups
Placebo population mean event rate
Events avoided or caused per 1000
patient-years in
SGLT2i groups
Placebo population mean event rate
-6
-4
0.5
1.0
-45
16
23
6
148
0.5
-15
-10
5
-5
0
-20
-25
-30
-35
-40
-34
Stable heart failure
Mean eGFR: 61 mL/min/1.73m2
7
17
1.0
104
-2
-5
c
0.0
-23
Mean eGFR: 64 mL/min/1.73m2
Events avoided or caused per 1000
patient-years in
SGLT2i groups
Placebo population mean event rate
-11
-4
1.3
1.1
-45
29
19
7
47
1.2
-15
-10
5
-5
0
-20
-25
-30
-35
-40
-11
Chronic kidney disease
Mean eGFR: 45 mL/min/1.73m2
48
16
0.6
11
-15
-5
c
0.0
-2
Mean eGFR: 40 mL/min/1.73m2
Diabetes
Figure 19 Absolute benefits and harms of sodium–glucose co-transporter-2 inhibitors in patients with and without diabetes. eGFR, estimated glomerular 
filtration rate; RR, relative risk; SE, standard error; SGLT2i, sodium–glucose co-transporter-2 inhibitor. Patient group-specific absolute effects estimated by 
applying the diabetes sub-group-specific RR to the average event rate in the placebo arms (first event only). Negative numbers indicate events avoided by 
SGLT2 inhibition per 1000 patient-years. Error bars represent SE in the numbers of events avoided or caused, estimated from uncertainty in the RRs. Mean 
eGFR values are given for combined trial populations by patient group and diabetes status. Placebo population mean event rates are the absolute numbers of 
events per 1000 patient-years in the placebo groups of all trials in the relevant subpopulation. aAdditionally, two (SE 0.5) fewer myocardial infarctions per 
1000 patient-years of SGLT2i treatment were observed in the diabetes and high atherosclerotic cardiovascular risk group. bRRs to determine absolute effects 
for lower-limb amputation included the CANVAS trial. cToo few ketoacidosis events to estimate absolute effects. Figure adapted from the Nuffield 
Department of Population Health Renal Studies Group and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. This is an open access article 
distributed under the terms of the Creative Commons CC-BY License. https://creativecommons.org/licenses/by/4.0/714


<!-- PAGE 61 -->

### Page 61

>60 mL/min/1.73 m2 with UACR ≥34 mg/mmol (≥300 mg/g), or 
eGFR 25–60 mL/min/1.73 m2 and UACR ≥3 mg/mmol (≥30 mg/g), 
with appropriate potassium monitoring.718,719
9.3. Blood pressure and glycaemic control 
in patients with diabetes and chronic 
kidney disease
In patients with T2DM, BP lowering reduces CV risk, with relative ben­
efits similar in people with and without CKD.196,693,729 RR reductions 
for CVD per 10 mmHg of lower SBP are greater in patients with a start­
ing SBP of ≥140 mmHg, but a reduced risk of stroke and albuminuria is 
evident with a further reduction in SBP in those with an SBP 
<140 mmHg.196 Whether intensively lowering moderately elevated 
SBP prevents kidney failure, however, is uncertain.
The effect of tight glycaemic control, as compared with standard con­
trol, on risk of kidney failure is also uncertain, but such an approach reduces 
risk of developing or worsening of diabetic nephropathy based on mea­
sures of albuminuria.132,133,730 Personalized HbA1c targets of 6.5−8.0% 
(48−64 mmol/mol) are suggested for people with diabetes and CKD, 
with a target <7.0% (<53 mmol/mol) still recommended to reduce micro­
vascular complications, wherever possible.132,133 Above eGFR 30 mL/min/ 
1.73 m2, metformin with appropriate dose adjustment can be used, but 
below eGFR 30 mL/min/1.73 m2, metformin should generally be stopped 
to avoid risk of lactic acidosis due to its accumulation.731,732
In CKD, HbA1c monitoring may be less reliable when eGFR is 
<30 mL/min/1.73 m2, and self-monitoring or CGM may help safely 
achieve tight glycaemic control in such patients.45
Another potential strategy to help achieve glycaemic targets in pa­
tients with CKD is use of GLP-1 RAs. Extrapolating evidence from 
trials in patients with T2DM suggest GLP-1 RAs safely improve gly­
caemic control and may reduce weight and CV risk in patients with 
CKD.164 Meta-analysis of the GLP-1 RAs trials (lixisenatide, liraglutide, 
semaglutide, exenatide, albiglutide, dulaglutide, efpeglenatide) showed 
they favourably lower levels of albuminuria in T2DM, with some 
GLP-1 RAs reducing MACE in those with prior CVD or at high CV 
risk.164 The size of RR reductions on MACE appears similar in people 
with or without reduced eGFR.164 Dulaglutide has been tested in pa­
tients with T2DM and CKD stages G3–4. It was as effective at lower­
ing HbA1c as insulin glargine, but it reduced weight, had lower rates of 
symptomatic hypoglycaemia, and slowed eGFR decline compared 
with insulin glargine.733 The benefits of GLP-1 RAs on risk of kidney 
failure have yet to be confirmed, and a definitive assessment of sema­
glutide in the FLOW (Effect of Semaglutide Versus Placebo on the 
Progression of Renal Impairment in Subjects With Type 2 Diabetes 
and Chronic Kidney Disease) trial of 3535 patients with T2DM and 
albuminuric CKD is ongoing.734
An alternative to GLP-1 RAs in CKD is a DPP-4 inhibitor. Linagliptin 
safely lowers HbA1c in patients with T2DM and CKD but does not re­
duce risk of CVD or kidney failure.180
9.4. Roles for antithrombotic therapy and 
invasive strategies in managing 
atherosclerotic cardiovascular disease in 
patients with diabetes and chronic kidney 
disease
Low-dose ASA (75–100 mg o.d.) is indicated in patients with diabetes and/ 
or CKD and ASCVD.325 In primary ASCVD prevention in T2DM and 
CKD, the benefits and risks of low-dose ASA may be finely 
counterbalanced.291,292,325,735 CKD is associated with both increased 
ASCVD and bleeding risk, and so the net effects of low-dose ASA 
(75 mg o.d.) in CKD (stages G3–G4 or G1–2 with albuminuria) without 
ASCVD is being tested in the large, open-label, ATTACK (Aspirin to 
Target Arterial Events in Chronic Kidney Disease) trial.679,736,737 The net 
benefit of low-dose rivaroxaban (2.5 mg b.i.d.) on atherothrombotic vs. 
bleeding risk is also being tested in the large, placebo-controlled, 
TRACK (Treatment of Cardiovascular Disease with Low Dose 
Rivaroxaban in Advanced Chronic Kidney Disease) trial in people with 
CKD stage G4–5 who are at high CVD risk due to diabetes, age >65 years, 
or prior ASCVD.738
Invasive vs. medical management strategies for stable moderate or se­
vere CAD in CKD have been assessed in the ISCHEMIA-CKD 
(International Study of Comparative Health Effectiveness with Medical 
and Invasive Approaches–Chronic Kidney Disease) trial, in which 57% 
(444/777) of participants had diabetes.739 The trial was conducted in 
parallel with the large ISCHEMIA trial.740 When results from both these 
trials are considered alongside one another, ISCHEMIA-CKD suggests 
that an initial conservative approach using intensive medical therapies 
to manage stable CAD is appropriate for patients with diabetes and 
an eGFR <30 mL/min/1.73 m2.739 ISCHEMIA-CKD did not replicate 
the anti-anginal benefits of an invasive strategy observed in 
ISCHEMIA, but such benefits should not be ruled out due to lower 
power.739,740 It should also be noted that patients with acute MI, un­
stable CAD, or unacceptable levels of angina were excluded from 
both trials, meaning optimal management of such conditions in patients 
with CKD may still include an intensive strategy (Section 6).
Serum phosphate may increase in advanced CKD (e.g. eGFR <30 mL/ 
min/1.73 m2) and is associated with an increased risk of CVD.694 Lowering 
phosphate, controlling parathyroid hormone, and maintaining normal cal­
cium levels is common practice in nephrology despite a lack of definitive 
evidence that it modifies risk of CVD.691,741 Some evidence suggests the 
dose of calcium-based phosphate binders should be restricted.742,743In pa­
tients with T2DM and CKD, correcting renal anaemia improves quality of 
life, but does not reduce the risk of CVD and may increase the risk of 
stroke.744 Renal specialist advice should be sought for managing a raised 
serum phosphate (>1.5 mmol/L) or other evidence of CKD-MBD, and re­
nal anaemia (e.g. haemoglobin <10 g/dL).
Recommendation Table 24 — Recommendations for 
patients with chronic kidney disease and diabetes
Recommendations
Classa
Levelb
Intensive LDL-C lowering with statins or a statin/ 
ezetimibe combination is recommended.c,697,698
I
A
A BP target of ≤130/80 mmHg is recommended to 
reduce risk of CVD and albuminuria.196
I
A
Personalized HbA1c targets 6.5–8.0% (48–64 mmol/ 
mol) are recommended, with a target <7.0% 
(<53 mmol/mol) to reduce microvascular 
complications, wherever possible.132,133
I
A
The maximum tolerated dose of an ACE-I or ARB is 
recommended.705–709
I
A
A SGLT2 inhibitor (canagliflozin, empagliflozin, or 
dapagliflozin)d is recommended in patients with 
T2DM and CKD with an eGFR ≥20 mL/min/1.73 m2 
to reduce the risk of CVD and kidney 
failure.150,153,542,543,711,714,715
I
A
Continued
ESC Guidelines                                                                                                                                                                                          4103


<!-- PAGE 62 -->

### Page 62

### 10 Aortic and peripheral arterial

diseases and diabetes
10.1. The impact of diabetes on peripheral 
atherosclerosis
Diabetes is one of the most important risk factors for the develop­
ment and progression of atherosclerosis.747–751 The number of pa­
tients with atherosclerosis associated with diabetes is steadily 
increasing alongside the increasing number of patients with diabetes 
worldwide. Peripheral atherosclerosis summarizes LEAD and carotid 
atherosclerosis.
10.1.1. Diabetes and lower-extremity artery disease
The impact of diabetes differs between vascular territories.747 The strong 
correlation between LEAD and diabetes is well established.747–749 Up to 
30% of all patients with intermittent claudication and ∼50–70% of 
patients with chronic limb-threatening ischaemia (CLTI) have dia­
betes.750,752 Patients with diabetes and LEAD show specific anatomic 
and morphologic characteristics, which are important for further man­
agement.753 In addition, patients with diabetes have occlusions of arteries 
below the knee more often than do patients without diabetes. Moreover, 
severe calcification, such as media sclerosis and development of collateral 
circulation, is typical for these patients.753
Compared with patients without diabetes, those with diabetes de­
velop LEAD at a younger age and have faster LEAD progression, 
with more patients having CLTI. Prolonged diabetes duration, sub- 
optimal glycaemic control, co-existing CV risk factors, and other 
end-organ damage (e.g. proteinuria) increase the prevalence of 
LEAD.751 Moreover, patients with microangiopathy are at increased 
risk of CLTI and major amputation.754,755 In a cohort study with 125  
674 participants, the presence of microvascular disease such as retinop­
athy, nephropathy, or neuropathy independently increased the risk of 
amputation.754
For patients with a diabetic foot ulcer (diabetic foot disease), the 
risk of death at 5 years is 2.5 times higher than for patients with dia­
betes but no foot ulcer.752,756 In patients with diabetes, pain is often 
masked because of peripheral neuropathy with decreased pain sensi­
tivity. Therefore, atherosclerosis is often advanced when diagnosed. 
CLTI is the clinical presentation of advanced disease, characterized 
by ischaemic rest pain; however, pain may be absent in patients 
with diabetes. The 2017 ESC Guidelines on the diagnosis and treat­
ment of peripheral arterial diseases and the 2019 Global Vascular 
Guidelines on the management of chronic limb-threatening ischaemia 
proposed the Wound, Ischaemia, and foot Infection (WIfI) classifica­
tion to stratify amputation risk and the potential benefits of revascu­
larization (Supplementary data online, Table S17).747,757,758 Patients 
with diabetes and critical limb ischaemia are at very high risk of lower- 
limb amputation and recurrent wounds. All of these factors increase 
the risk of limb infection.
Although 20–30% of patients with diabetes have LEAD, more than 
half of these have no clinical symptoms.760 Therefore, screening and 
early diagnosis is important to allow early treatment and prevent major 
amputation. Clinical evaluation includes medical history, assessing 
symptoms, palpating peripheral pulses, and evaluating skin colour and 
temperature. In addition, examination for neuropathy is important; 
however, the sensitivity of clinical examination is limited.761
Therefore, screening for LEAD is indicated in patients with diabetes 
and foot ulceration.747,761 There is a lack of evidence concerning the 
frequency of screening for LEAD in patients with diabetes, but it seems 
plausible to assess leg perfusion regularly.
An ankle–brachial index (ABI) ≤0.90 is diagnostic for LEAD, with 
80% sensitivity and 95% specificity in all populations.760,762 However, 
the accuracy of ABI is lower in patients with diabetes.762,763 Beyond 
LEAD, an ABI ≤0.90 (or >1.40) is associated with an increased risk 
of death and CV events.762,763 Measuring ABI can be difficult due to 
medial calcinosis (ABI >1.40), in which case, other tests are useful for 
diagnosing LEAD, including Doppler waveform analysis of the ankle ar­
teries, or the toe–brachial index (TBI), which may be helpful because 
medial calcinosis barely affects digital arteries. A TBI <0.70 is diagnostic 
for LEAD.747,763
In patients with intermittent claudication, a treadmill test is useful for 
assessing walking distance.747 Duplex scan is the first-line imaging for 
confirming LEAD and should be performed at least when revasculariza­
tion is indicated. Magnetic resonance angiography or CT angiography 
can also help to plan further treatment (Figure 20).
Finerenone is recommended in addition to an ACE-I 
or ARB in patients with T2DM and eGFR >60 mL/ 
min/1.73 m2 with a UACR ≥30 mg/mmol (≥300 mg/ 
g), or eGFR 25–60 mL/min/1.73 m2 and UACR 
≥3 mg/mmol (≥30 mg/g) to reduce CV events and 
kidney failure.718–720
I
A
A GLP-1 RA is recommended at eGFR >15 mL/min/ 
1.73 m2 to achieve adequate glycaemic control, due 
to low risk of hypoglycaemia and beneficial effects on 
weight, CV risk, and albuminuria.164
I
A
Low-dose ASA (75–100 mg o.d.) is recommended in 
patients with CKD and ASCVD.325,735
I
A
It is recommended that patients with diabetes are 
routinely screened for kidney disease by assessing 
eGFR defined by CKD-EPI and UACR.43,678,745
I
B
Treatment with intensive medical or an initial invasive 
strategy is recommended in people with CKD, 
diabetes, and stable moderate or severe CAD, due to 
similar outcomes.e,740,746
I
B
Kidney specialist advice may be considered for 
managing a raised serum phosphate, other evidence 
of CKD-MBD, and renal anaemia.
IIb
C
Combined use of an ARB with an ACE-I is not 
recommended.710
III
B
© ESC 2023
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; ASA, 
acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; 
CAD, coronary artery disease; CKD, chronic kidney disease; CKD-EPI, chronic kidney 
disease epidemiology; CKD-MBD, chronic kidney-mineral bone disorder; CV, 
cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; 
GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; 
LDL-C, low-density lipoprotein-cholesterol; o.d., once daily; SGLT2, sodium–glucose 
co-transporter-2; T2DM, type 2 diabetes mellitus; UACR, urinary albumin-to-creatinine 
ratio. 
aClass of recommendation. 
bLevel of evidence. 
cLittle evidence of benefit in patients on dialysis. 
dSotagliflozin reduces CV risk but has not demonstrated a reduction in the risk of kidney 
failure. 
eISCHEMIA-CKD trial primary and key secondary outcomes were a composite of ‘death or 
non-fatal myocardial infarction’ and ‘death, non-fatal myocardial infarction, or 
hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest’, respectively.


<!-- PAGE 63 -->

### Page 63

Ulcer or wound
Wound healing without
 revascularization likely
LEAD
LEAD
Intermittent claudication
Regular screening
Clinical examination ABI
(Additional MRA or CTAc)
Revascularization
Regular screening
Exercise trainingb
Limited daily practice despite exercise training
Regular screening / follow-up
Clinical symptoms for LEAD
Aetiology for LEAD
≤0.9 or >1.4
Wound managementb
Search for other causes
 for limited walking distance
Wound healing
Clinical examination
ABI (TBIa), TcPO2
Duplex sonography
WIfI score
Clinical examination
ABI (TBIa)
Duplex sonography
Treadmill test
TBIa 
Duplex sonography
Treadmill test
Patients with diabetes
Y
Y
Y
Y
Y
N
N
N
N
N
N
N
Y
Y
Figure 20 Screening for and managing lower-extremity artery disease in patients with diabetes. ABI, ankle–brachial index; CTA, computed tomography 
angiography; LEAD, lower-extremity artery disease; MRA, magnet resonance angiography; TBI, toe–brachial index; TcPO2, transcutaneous oxygen pressure; 
WlfI, Wound, Ischaemia, foot Infection. aTBI when ABI >1.4. bFurther information regarding wound management and exercise training can be found in the 
revascularization.
ESC Guidelines                                                                                                                                                                                          4105


<!-- PAGE 64 -->

### Page 64

Due to the high burden of comorbidities in patients with diabetes, 
interdisciplinary co-operation is crucial. The medical management of 
LEAD in patients with diabetes does not differ from that recommended 
for patients with ASCVD in general including SGLT2 inhibitors and 
GLP-1 RAs.747,757,764,765 Still, it should be noted that for the SGLT2 in­
hibitor canagliflozin, the risk of amputation was increased in the 
CANVAS study, a finding that has not been repeated in the 
CREDENCE trial comparing canagliflozin with placebo in patients 
with T2DM and CKD, nor in CVOTs with other SGLT2 inhibitors.151
Still, according to US Food and Drug Administration requirements, 
the amputation risk with canagliflozin is described in the Warnings 
and Precautions section of the prescribing information. There are 
some discussions as to whether the use of GLP-1 RAs could be prefer­
able in patients with LEAD. Ongoing studies may help to clarify this 
question in the future.
Recent data showed that the combination of low-dose ASA and riv­
aroxaban 2.5 mg b.i.d. reduces MACE and major adverse limb events 
including amputation (MALE) compared with ASA and placebo, par­
ticularly in patients with PAD.766 A sub-group analysis of patients 
with LEAD showed a significantly higher MACE and MALE rate com­
pared with patients with CAD and a higher benefit of the combination 
therapy.767 Improvement of prognosis was similar in patients with 
(44%) and without diabetes. The total number of major bleeding events 
was increased but fatal or critical organ bleeding did not.
Patients with intermittent claudication should take part in exercise 
training programmes (30–45 min, at least three times per week), as 
regular intensive exercise improves walking distance.747
In patients with CLTI, revascularization must be attempted when pos­
sible, and amputation should only be considered when revascularization 
options fail.768 With respect to the revascularization modality of choice, 
we refer to dedicated guidelines. There has not been a specific trial on 
revascularization strategies in patients with diabetes; however, a review 
of 56 studies including patients with diabetes suggested higher limb- 
salvage rates after revascularization (78–85% at 1 year) compared with 
conservative management.768 Due to disease progression, long-term 
follow-up is very important in patients with diabetes and LEAD.769
10.1.2. Diabetes and carotid artery disease
According to the results of a recent community-based study, the preva­
lence of diabetes linearly correlated with carotid plaques, and patients 
with diabetes had more advanced carotid atherosclerosis than indivi­
duals without diabetes.770 Based on a prospective cohort study with 
300 patients, which showed a high prevalence of carotid atherosclerosis 
especially in men, screening of male patients with diabetes and a history 
of CAD or ABI <0.85 has been suggested.771 Nevertheless, in patients 
with diabetes without a history of cerebrovascular disease, there is only 
limited evidence that carotid screening improves outcomes, and regular 
screening is not recommended.747,772 Asymptomatic carotid artery dis­
ease is frequently treated conservatively, and the patient is followed up 
with duplex ultrasound.
Carotid revascularization should be considered in asymptomatic pa­
tients with one or more indicators of increased stroke risk (previous 
transient ischaemic attack/stroke, ipsilateral silent infarction, stenosis 
progression, or high-risk plaques), and if the estimated peri-operative 
stroke or death rate is <3% and the patient’s life expectancy is >5 years. 
In symptomatic patients, carotid revascularization is indicated if the 
stenosis is >70%, and should be considered if the stenosis is >50%, as­
suming that the estimated peri-operative stroke or death rate is 
<6%.747
With respect to the impact of diabetes on carotid revascularization, a 
meta-analysis of 14 observational studies involving 16 264 patients 
showed that patients with diabetes had a higher risk of peri-operative 
stroke and death versus those without diabetes.773 The CREST 
(Carotid Revascularization Endarterectomy versus Stenting) trial was 
the only trial comparing carotid endarterectomy and carotid artery 
stenting to enrol enough patients with diabetes (n = 759) for sub-group 
analysis.774 Although re-stenosis rates were low at 2 years after carotid 
stenting (6.0%) and carotid endarterectomy (6.3%), diabetes predicted 
re-stenosis with both techniques.
Details on revascularization strategies can be found in the 2017 ESC 
Guidelines on the diagnosis and treatment of peripheral arterial diseases.747
10.2. Diabetes and aortic aneurysm
Current evidence shows a lower risk of developing aortic aneurysm in 
patients with diabetes compared with persons without dia­
betes.759,775,776There are different mechanisms under discussion includ­
ing effects on extracellular matrix volume, extracellular matrix glycation, 
the formation of advanced glycation end-products, inflammation, oxida­
tive stress, and intraluminal thrombus biology.777 Moreover, some med­
ications, such as metformin used to treat diabetes, seem to have 
protective effects on the development of abdominal aortic aneurysms.
Nevertheless, aortic aneurysm is associated with atherosclerosis and 
general secondary prevention is recommended based on expert 
consensus.
Recommendation Table 25 — Recommendations for 
peripheral arterial and aortic diseases in patients with 
diabetes
Recommendation
Classa
Levelb
Lower-extremity arterial disease
In patients with diabetes and symptomatic LEAD, 
antiplatelet therapy is recommended.325
I
A
In patients with diabetes and CLTI, it is 
recommended to assess the risk of amputation; the 
WIfI score is useful for this purpose.747,758
I
B
As patients with diabetes and LEAD are at very high 
CV risk, a LDL-C target of <1.4 mmol/L (<55 mg/dL) 
and a LDL-C reduction of at least 50% is 
recommended.778,779
I
B
Screening for LEAD is recommended on a regular 
basis, with clinical assessment and/or ABI 
measurement.
I
C
Patient education about foot care is recommended in 
patients with diabetes, and especially those with 
LEAD, even if asymptomatic. Early recognition of 
tissue loss and/or infection, and referral to a 
multidisciplinary team, is mandatory to improve limb 
salvage.
I
C
An ABI ≤0.90 is diagnostic of LEAD, irrespective of 
symptoms. In symptomatic cases, further assessment 
including duplex ultrasound is recommended.
I
C
When ABI is elevated (>1.40), other non-invasive 
tests, including TBI or duplex ultrasound, are 
recommended.
I
C
Continued


<!-- PAGE 65 -->

### Page 65

### 11 Type 1 diabetes and

cardiovascular disease
This section summarizes evidence-based recommendations to effect­
ively manage CV risk factors in patients with T1DM; the section does 
not address the control of glucose levels, which must follow the prin­
ciples of patient self-management under the guidance of the diabetes 
healthcare multidisciplinary team according to clinical recommenda­
tions by EASD/ADA.1
People with T1DM face a three-fold increase in mortality compared 
with the general population, which translates into an 11-year reduction 
in life expectancy; CVD mortality accounts for 30–44% of all deaths in 
patients with T1DM.780–784
The DCCT prospectively investigated not only the impact of an in­
tensified glucose-lowering treatment strategy on microvascular compli­
cations in patients with T1DM, but also the rate of macrovascular 
events at long-term follow-up. This study showed that intensified insu­
lin therapy lasting over a mean of 6.5 years halved the incidence and 
progression of microvascular sequelae, which was associated with a sig­
nificant decrease in HbA1c, compared with conventional therapy.126
After a mean follow-up of 17 years in >90% of the initially enrolled pa­
tients, CV risk was also significantly reduced by 42% in the intensified- 
treatment group, and the reduction in HbA1c over the first 6.5 years 
was significantly associated with a reduction in CV risk.785 In the 
EDIC (Epidemiology of Diabetes Interventions and Complications) 
study, patients were followed up for over 30 years and the following 
was concluded: (i) hyperglycaemia is the primary modifiable mediator 
of late complications in T1DM; (ii) near-normal glucose control reduces 
the incidence and progression of microvascular complications, such as 
retinopathy, nephropathy, and neuropathy; and (iii) intensive diabetes 
therapy reduces CV complications in T1DM.786
Recently, a mediation analysis and multi-variable models of the EDIC 
trial showed that the quality of adjustment of traditional risk factors ac­
counts for only ∼50% of the cardio-protective effect of improved 
metabolic control.787 About 40% of the cardio-protective effect re­
mains for HbA1c or elevated glucose concentrations per se. 
Accordingly, recent analyses from the Swedish National Diabetes 
Register evaluated the prognostic significance of 17 risk factors for 
death, acute MI, or stroke. Of the 32 611 patients with T1DM in this 
Swedish registry cohort, 5.5% died over the course of 10.4 years. 
The strongest predictors of death and CV endpoints were HbA1c, al­
buminuria, diabetes duration, systolic BP, and LDL-C concentration.788
Thus, reducing CV risk in patients with T1DM relates to both low­
ering HbA1c and controlling other classical CV risk factors, including 
BP and LDL-C. Therefore, glucose control target values are recom­
mended for most adults with T1DM by the joint consensus report of 
the ADA and EASD: HbA1c <53 mmol/mol or <7.0%; pre-prandial glu­
cose 4.4–7.2 mmol/L or 80–130 mg/dL; and 1–2 h post-prandial glu­
cose <10.0 mmol/L or <180 mg/dL.13 Hypoglycaemia should be 
avoided, especially in patients with CV complications.
Advances in diabetes technologies have started a new era in clinical 
practice, and the use of CGM has now become widespread. CGM can 
significantly improve glycaemic control in T1DM, providing more de­
tailed information and introducing new outcome variables including 
time-in-range and glycaemic variability.138
Management strategies should adapt new therapies and technologies 
as they become available, according to the wishes and desires of the 
person with diabetes.
11.1. Cardiovascular risk assessment in 
type 1 diabetes
With respect to treatment targets and thresholds for other CV risk fac­
tors, a critical question is predicting CV risk in patients with T1DM 
without CVD. Determining ASCVD risk in patients with T1DM is 
less well studied than in patients with T2DM.
In 2011, an observational study using the data from 3661 patients in the 
Swedish National Diabetes Register proposed a 5-year CVD risk model for 
use in patients with T1DM.789 More recently, the Steno Type 1 Risk Engine 
was externally validated at 5 years but lacks validation at 10 years.790 Age at 
the onset and duration of diabetes are two risk factors that lead the estima­
tion of CV risk. Thus, patients diagnosed with T1DM at an early age show an 
increased incidence of CVD. In addition, excess mortality in patients diag­
nosed with T1DM under the age of 10 years, compared with those aged 
26–30 years at diagnosis, has been highlighted by a Swedish study.791
This concept has been underlined by the Pittsburgh Epidemiology of 
Diabetes Complications (EDC) study, which showed duration of diabetes 
to be an independent risk factor for MACE.791,792 Several other risk factors 
related to diabetes management, including glycaemic control, insulin re­
quirements, smoking, cardiac autonomic neuropathy, dysfunctional im­
mune response, and insulin resistance, are to be taken into account.788
A recent risk tool, developed based on the Scottish/Swedish 
Diabetes Registry and validated in the Swedish National Diabetes 
Register can provide individualized risk predictions.793 This 10-year 
ASCVD risk prediction tool https://diabepi.shinyapps.io/cvdrisk/ could 
facilitate risk estimation and discussions with patients with T1DM.
11.2. Managing cardiovascular risk
Analogies of recommendations for risk-factor modifications in patients 
with T1DM derive from the fact that there is no direct evidence that 
CV risk reduction by lowering causal CV risk factors, like LDL-C or 
Duplex ultrasound is recommended as the first-line 
imaging method to assess the anatomy and 
haemodynamic status of lower-extremity arteries.
I
C
In case of CLTI, revascularization is recommended 
whenever feasible for limb salvage.747,758
I
C
In patients with chronic, symptomatic LEAD without 
high bleeding risk, a combination of low-dose 
rivaroxaban (2.5 mg b.i.d.) and ASA (100 mg o.d.) 
should be considered.766
IIa
B
Carotid artery disease
In patients with diabetes and carotid artery disease, it 
is recommended to implement the same diagnostic 
work-up and therapeutic strategies (medical, surgical, 
or endovascular) as in patients without diabetes.
I
C
Aortic aneurysm
In patients with diabetes and aortic aneurysm, it is 
recommended to implement the same diagnostic 
work-up and therapeutic strategies (medical, surgical, 
or endovascular) as in patients without diabetes.
I
C
© ESC 2023
ABI, ankle–brachial index; ASA, acetylsalicylic acid; b.i.d., twice a day; CLTI, chronic 
limb-threatening ischaemia; CV, cardiovascular; LDL-C, low-density lipoprotein-cholesterol; 
LEAD, lower-extremity artery disease; o.d., once a day; TBI, toe–brachial index; WIfI, 
Wound, Ischaemia, foot Infection. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4107


<!-- PAGE 66 -->

### Page 66

BP, differs in patients with T1DM or T2DM. However, the recommen­
dations are given in the awareness that, in most CVOTs for lipids, BP, 
antiplatelet agents, and anticoagulation, patients with T1DM were ex­
cluded or recruited in small groups. In the following, we summarize re­
commendations of the respective sections with focus on specific 
aspects or caveats that should be considered in patients with T1DM.794
11.2.1. Exercise and lifestyle
Data on the effects of exercise on T1DM are inconclusive. Aerobic fit­
ness improved HbA1c in patients with T1DM, but did not affect BMI, 
BP, and lipids.795
11.2.2. Lipid lowering
Statins remain the cornerstone of lipid-lowering treatment. In patients 
with T1DM at a younger age, starting statins early might be justified 
with long duration of disease, two additional risk factors, or microalbu­
minuria. In the Cholesterol Treatment Trialists’ Collaboration 
meta-analysis, 1466 patients with T1DM were also included.248
Increased cholesterol absorption in T1DM compared with T2DM 
may explain why ezetimibe, a drug that directly decreases cholesterol 
absorption, may reduce LDL-C more in T1DM than in T2DM.796,797
11.2.3. Blood pressure
People with T1DM may benefit from stringent BP-lowering strategies. 
A recent analysis of the EDC study in patients without known CAD 
showed that the optimal BP threshold associated with reduced CVD 
risk was 120/80 mmHg in young adults with childhood-onset 
T1DM.798 Routine ambulatory BP monitoring is recommended to iden­
tify subjects with masked hypertension, as demonstrated in a Finnish 
study in which one-quarter of patients with T1DM had underlying 
hypertension and increased arterial stiffness.799
11.2.4. Antiplatelet therapy
Antiplatelet agents may be beneficial in individuals with T1DM without 
symptomatic ASCVD who have at least one additional major CV risk 
factor.800
11.3. Glucose-lowering agents beyond 
insulin
Glucagon-like peptide-1 receptor agonists or SGLT2 inhibitors are cur­
rently not indicated for T1DM.
Although GLP-1 RAs and SGLT2 inhibitors reduce CV risk in patients 
with T2DM in large CVOTs, no such data are available for patients with 
T1DM. For GLP-1 RAs, despite showing potential in reducing HbA1c 
and weight in patients with T1DM in the ADJUNCT ONE (The Efficacy 
and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment 
of Type 1 Diabetes) Treat-To-Target trial, concerns have been raised 
about increased rates of symptomatic hypoglycaemia and hyperglycaemia 
with ketosis.801 Another RCT in patients with T1DM also showed no sig­
nificant overall reduction in HbA1c by liraglutide compared with pla­
cebo.802 Adding SGLT2 inhibitors at a lower than usual dose to insulin 
therapy in T1DM may reduce glucose variability and facilitate glucose con­
trol, thereby reducing insulin doses and hypoglycaemia.803 However, ke­
toacidosis at lower glucose levels, so called ‘euglycaemic ketoacidosis’, 
has been reported in 2–3% of patients with T1DM taking SGLT2 inhibi­
tors.804 This is a potentially lethal complication.
11.4. Renal protection in type 1 diabetes
As in patients with T2DM, patients with T1DM should be regularly 
screened for kidney disease by assessing eGFR defined by CKD-EPI 
and UACR.677 RAS blockade with an ACE-I prevents kidney failure in 
patients with T1DM and overt nephropathy (Section 9).705,805 RAS in­
hibitors are therefore recommended in patients with T1DM as soon as 
kidney damage is first clinically evident.
12. Person-centred care
A person-centred approach that encourages and empowers patients to 
actively take part in finding solutions to their problems is suggested.806
Person-centred care, including shared decision-making, goes beyond 
maintaining active person consent to decisions and the person’s partici­
pation to the development of the therapeutic plan. It shapes disease 
management to advance the life and health-related quality of life of 
the person.806,807 It helps people make better healthcare decisions 
based on their informed preferences in collaboration with their health­
care professionals (HCPs). 806 Person-centred care requires: 
• Identifying and integrating patient needs, background, and culture 
into decisions regarding health practices.808–812
• Active person participation as a key factor for successful self- 
management.808 This encompasses all kinds of preferences, as well 
as physical, psychosocial, behavioural, and financial needs in the devel­
opment of the therapeutic plan.808,813 It also refers to meal planning, 
planned physical activity, managing symptoms, blood glucose moni­
toring, medical treatments, and managing episodes of illness and of 
low and high blood glucose, as well as psychosocial, cultural, and spir­
itual consequences of health conditions.814–816
Recommendation Table 26 — Recommendations for 
patients with type 1 diabetes
Recommendation
Classa
Levelb
In patients with T1DM, it is recommended that 
adjustment of glucose-lowering medication follows 
principles of patient self-management under the 
guidance of the diabetes healthcare multidisciplinary 
team.
I
C
Avoiding hypoglycaemic episodes is recommended, 
particularly in those with established CVD.780–782
I
C
Statins should be considered for LDL-C lowering in 
adults older than 40 years with T1DM without a 
history of CVD to reduce CV risk.787
IIa
B
Statins should be considered for use in adults 
younger than 40 years with T1DM and other risk 
factors of CVD or microvascular end-organ damage 
or 10-year CVD risk ≥10% to reduce CVD 
risk.787,788
IIa
B
The use of the Scottish/Swedish risk prediction 
model may be considered to estimate 10-year CVD 
risk in patients with T1DM.793
IIb
B
© ESC 2023
CV, cardiovascular; CVD, cardiovascular disease; LDL-C, low-density lipoprotein-cholesterol; 
T1DM, type 1 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 67 -->

### Page 67

• Motivation and support of people with diabetes, such as: support to 
stop smoking; adopt a healthy diet; increase PA and exercise; man­
age other comorbidities, such as arthritis, renal failure, frailty, and 
cognitive impairment, which increase risk of drug interactions; 
and manage body weight, taking psychosocial factors into ac­
count.817–826
• Interdisciplinary teams comprising the person (including caregivers/ 
family), physicians, nurses, social workers, physiotherapists, occupa­
tional therapists, dieticians, pharmacists, physical activity specialists, 
and psychologists are effective for enhancing effective communica­
tion, collaboration, and preventing CVD.827,828 The most effective 
models of preventive care are those that adopt a total risk- 
management approach (i.e. those that address all of the risk factors 
that impact CV health) using behavioural counselling with action 
plans, education, comprehensive, goal-setting, and problem-solving 
approaches, and proven therapeutics supported by frequent follow- 
up, either face to face or by telephone and/or digital health 
interventions.820,829,830
Figure 21 summarizes the model of person-centred care approach 
for patients with diabetes with or without CVD, considering sex and 
cultural and socioeconomic factors.
Person-centred care
Family/caregivers
Cultural, gender, physical,
psychological, socioeconomic, spiritual perspectives
Physicians, nurses,
dietologists, psychologists,
physiotherapists, etc
Face-to-face meetings
Telemedicine
Persons with diabetes
Interdisciplinary team
Frequent follow-up
Communication,
relationship development,
education, empowerment,
support, holistic, comprehensive
& problem-solving care,
self-management
Figure 21 Person-centred care approach for patients with diabetes with or without cardiovascular disease.
ESC Guidelines                                                                                                                                                                                          4109


<!-- PAGE 68 -->

### Page 68

### 13 Practical guidance

New guidelines and clinical recommendations for treating T2DM are pa­
tient centred and evidence based; the clinical picture and risk of 
cardio-renal complications, rather than HbA1c alone, are the forefront 
of personalized treatment decisions. The primary therapeutic goals in pa­
tients with diabetes and ASCVD or increased risk of CV complications is 
protecting organs and improving prognosis (Figure 1). Accordingly, these 
ESC Guidelines on CVD and diabetes are based on the extensive data 
from large CVOTs of recent years. For patients with T2DM and 
ASCVD, a wealth of data exists but CV risk reduction in those without 
ASCVD is less clear. Thus, to provide recommendations for treatment 
strategies to lower CV risk in patients with T2DM but without 
ASCVD or severe TOD, an appropriate tool for stratifying risk in these 
patients is of major importance. Therefore, an extension of SCORE2 for 
T2DM, named SCORE2-Diabetes, is provided to predict 10-year risk of 
fatal and non-fatal CVD events (MI, stroke) across four European risk re­
gions in patients without ASCVD or severe TOD.63
Implementation of the current Guidelines should be fostered not only 
by using respective educational tools developed by the ESC including the 
ESC Clinical Practice Guideline, but also by integrating it into national elec­
tronic health-record systems and digital-based healthcare solutions.
The evidence-based concept of the current Guidelines, its key messages, 
and gaps of evidence as medical needs for future research must be distrib­
uted to all healthcare stakeholders, policymakers, politicians, and the gen­
eral public. Awareness should be raised, respectively, on national and 
European levels, including in European Union (EU) parliament and respon­
sible commissions.
From our point of view, the current Guidelines might provide a blue­
print for approaching multimorbid patients with common, chronic, 
non-communicable diseases such as ASCVD, HF, diabetes, and CKD. 
Non-communicable diseases are one of the greatest burdens on health­
care systems and societies in Europe and many other areas of the 
world. Therefore, we hope that the current Guidelines will contribute 
to the ultimate goal of managing CVD and CV risk in patients with dia­
betes: to improve patients’ prognosis and health-related quality of life.
14. Key messages
Diagnosis of diabetes 
• Raised fasting or random glucose, elevated HbA1c, or an abnormal 
OGTT is diagnostic of diabetes; a single abnormal test is sufficient 
with symptoms, while two abnormal tests are usually required with­
out symptoms.
• Undiagnosed diabetes is common, particularly in individuals with 
CVD. Therefore, screening for diabetes in all individuals with CVD, 
including HF, is recommended using HbA1c and/or fasting glucose.
Cardiovascular risk assessment 
• All patients with diabetes should be evaluated for the presence of 
ASCVD and severe TOD.
• In patients with T2DM without symptomatic ASCVD or severe 
TOD, 10-year CVD risk via SCORE2-Diabetes should be calculated.
Lifestyle 
• For smokers, smoking cessation is a primary target of lifestyle inter­
vention in patients with CVD and diabetes.
• Exercise should be introduced in all patients with CVD and T2DM, 
following the paradigm ‘every step counts’.
• In patients with obesity and T2DM with or without CVD, reducing 
weight combined with increasing daily PA through structured exer­
cise sessions are key lifestyle components to improve metabolic con­
trol, improve exercise capacity, and reduce clinical outcomes.
• A Mediterranean diet supplemented with olive oil and/or nuts re­
duces the incidence of major CV events in patients with CVD.
Glycaemic targets 
• Tight glycaemic control reduces short- and long-term microvascular 
disease.
• Tight glycaemic control reduces long-term macrovascular complica­
tions (over 20 years).
• Hypoglycaemia is associated with adverse CV outcomes and is best 
avoided.
Glucose-lowering therapy 
• ASCVD complications are common in patients with T2DM.
• Glycaemic status should be systematically evaluated in all patients 
with or at high risk of CVD, as diabetes status informs many clinical 
decisions in cardiology.
• Independent of baseline HbA1c or additional glucose-lowering 
agents, selected SGLT2 inhibitors and GLP-1 RAs reduce CV events 
in patients with T2DM with ASCVD and/or severe TOD.
Blood pressure 
• BP targets should be individualized for hypertensive patients.
• Optimal BP control reduces the risk of micro- and macrovascular 
complications.
• Controlling BP often requires multiple drug therapies with an RAS in­
hibitor, and a CCB or diuretic. Dual therapy is recommended as first- 
line treatment.
• All hypertensive patients with diabetes, irrespective of their anti- 
hypertensive treatments, should monitor their BP at home.
Lipids 
• Statins remain the first-line and state-of-the-art therapy to decrease 
LDL-C levels.
• Ezetimibe and PCSK9 inhibitors in addition to statins (if treatment 
targets have not been achieved)—or alone (in case of documented 
Recommendation Table 27 — Recommendations for 
person-centred care in diabetes
Recommendations
Classa
Levelb
Structured education programmes are 
recommended in patients with diabetes to improve 
diabetes knowledge, glycaemic control, disease 
management, and patient empowerment.811,812,821
I
A
Person-centred care is recommended to facilitate 
shared control and decision-making within the 
context of person priorities and goals.822–824
I
C
Providing individual empowerment strategies should 
be considered to enhance self-efficacy, self-care, and 
motivation in patients with diabetes.825,826,831–834
IIa
B
© ESC 2023
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 69 -->

### Page 69

intolerance to statins)—significantly reduce LDL-C levels, thus im­
proving CV outcomes.
Antithrombotic therapy 
• Based on the presence of ASCVD and individual CV risk, antiplatelet 
agents are a cornerstone of preventing CV events in patients with 
diabetes.
• Shortening or scaling down DAPT to clopidogrel should be 
avoided in patients with diabetes post-ACS, given their high back­
ground CV risk, the lack of efficacy data, and the poor bio-activation 
of clopidogrel.
• Platelet-function testing guided de-escalation should be avoided 
based on lack of evidence and poor bio-activation of clopidogrel.
Multifactorial approach 
• Continuous, multidisciplinary counselling is necessary to achieve 
long-term lifestyle changes.
Management of coronary artery disease 
• In patients with CAD, SGLT2 inhibitors and/or GLP-1 RAs reduce 
the risk of CV events.
• In patients with diabetes and multivessel CAD, suitable coronary 
anatomy for revascularization, and low predicted surgical mortality, 
CABG is superior to PCI.
Heart failure 
• The prognosis of patients with diabetes and HF is worse compared 
with patients with HF without diabetes.
• Beta-blockers, ARNI/ACE-Is, MRAs, and SGLT2 inhibitors are recom­
mended as cornerstone therapies for patients with HFrEF and diabetes.
• Empagliflozin and dapagliflozin reduce the combined endpoint of CV 
death or HF hospitalization in patients with HF and a LVEF >40%.
• Glucose-lowering treatment with SGLT2 inhibitors in patients with 
diabetes and HF reduces HF-related endpoints.
• Saxagliptin and pioglitazone increase the risk of HF hospitalization in 
patients with diabetes and HF.
Arrhythmias 
• AF is common in patients with diabetes, and increases mortality, risk 
of stroke, and risk of HF.
• Opportunistic screening for AF is recommended for patients with 
diabetes aged ≥65 years by palpating pulse (or using wearable de­
vices) and systematic ECG screening when age is ≥75 years. AF 
should always be confirmed by ECG.
• Opportunistic screening for AF by pulse taking or ECG is recom­
mended in patients with diabetes aged <65 years in view of their 
risk of AF and the possibly associated risk of ischaemic stroke.
Chronic kidney disease 
• CKD in patients with diabetes is associated with high risk of develop­
ing kidney failure and CVD.
• Patients with diabetes should be regularly screened for CKD, or have 
their CKD staged, by assessing eGFR and UACR.
• Certain ACE-I/ARBs, SGLT2 inhibitors, and finerenone reduce the risk 
of kidney failure and the risk of CVD in patients with T2DM and CKD.
Aortic and peripheral arterial diseases 
• LEAD is a common complication in patients with diabetes and asso­
ciated with poorer prognosis.
• Patients with diabetes are at higher risk of CLTI as the first clinical 
manifestation of LEAD, supporting regular screening with ABI meas­
urement for early diagnosis.
• The management of patients with LEAD and indications for different 
treatment strategies are similar in patients with or without diabetes, 
although the options for revascularization may be poorer in patients 
with diabetes because of diffuse and distal lesions.
Type 1 diabetes 
• Glucose-lowering therapy in T1DM should follow principles of pa­
tient self-management under the guidance of the diabetes healthcare 
multidisciplinary team.
Person-centred care 
• A person-centred approach is a key factor in successful self- 
management, resulting in greater patient satisfaction, adherence to 
therapeutic plans, and improved health outcomes.
• Important factors for self-management of diabetes and comorbidities 
are education, motivation, empowerment, and continuing supportive 
care of individuals.
15. Gaps in evidence
Diagnosis of diabetes 
• Global screening programmes for diabetes, adjusted for regional 
demographics and ethnic groups, are required to establish the 
most accurate and cost-effective screening test.
Lifestyle 
• RCTs of long-term exercise intervention to reduce CV outcomes are 
needed in different patient groups with diabetes and CVD, e.g. CAD, 
HFpEF, HFrEF, AF, or PAD.
• Large RCTs assessing the benefit of a multidisciplinary team to in­
crease adherence to lifestyle interventions and optimal medication 
are needed in patients with T2DM and CVD.
• The applicability and best practice of telehealth needs to be evaluated 
in elderly and frail patients with T2DM and CVD.
Glycaemic targets 
• The independent role of hypoglycaemia, glycaemic variability, 
time-in-range, and post-prandial hyperglycaemia in CV pathology re­
quires further research.
• Large-scale studies are required to understand the role of modern 
glucose-monitoring strategies (CGM) in improving macrovascular 
and HF outcomes.
Glucose-lowering therapy 
• It remains unclear if the combination therapy of GLP-1 RAs and 
SGLT2 inhibitors is complementary in cardio-renal outcomes in pa­
tients with T2DM.
• It needs to be examined if more intensive glycaemic control, achieved 
with novel medications, might prove to have incremental CV efficacy.
ESC Guidelines                                                                                                                                                                                          4111


<!-- PAGE 70 -->

### Page 70

Blood pressure 
• High-quality data on managing BP in T1DM are lacking.
• Optimal targets for (isolated) DBP in patients with diabetes and 
hypertension remain inconclusive.
• More information on optimizing CV protection in diabetes by man­
aging BP based on out-of-office BP levels should be provided by ran­
domized intervention trials.
Lipids 
• Optimal LDL-C target levels for patients with diabetes need to 
be established; good scientific evidence is especially missing in 
T1DM.
• Novel lipid-lowering drugs, such as inclisiran need efficacy data on CV 
endpoints both in the general population and in patients with 
diabetes.
Antithrombotic therapy 
• More data on primary CV prevention are needed for patients with 
T1DM.
• Future phase 3 RCTs testing antithrombotic drugs in CV prevention 
should share homogeneous classifications of bleeding to make the 
benefit-risk profile of mono- or combined therapy comparable 
across different studies.
• The benefit-risk profile of ASA in CV prevention in patients with dia­
betes, documented significant atherosclerotic lesions (peripheral or 
coronary), or high CAC score but without history of stroke or MI 
should be further investigated in RCTs.
• Since documented kidney and/or eye microvascular disease inde­
pendently predict future CV events, it needs to be assessed whether 
patients with diabetes with microvascular disease and no history of 
MACE would benefit from early primary prophylaxis.
• It needs to be demonstrated in adequately powered, superiority, 
efficacy-based RCTs whether 12-month DAPT post-ACS can be re­
duced to a shorter period in patients with diabetes using SAPT with 
ASA or with a P2Y12 inhibitor.
• The optimal duration of TAT post-ACS in patients with diabetes and 
AF needs to be established.
Multifactorial approach 
• An optimal intervention protocol to improve adherence remains to 
be established, particularly addressing patients with diabetes and co­
morbidities, and the elderly population.
• Sex and ethnicity differences regarding efficacy of multifactorial inter­
ventions need to be evaluated.
• Evaluation of E-health applications to improve adherence to lifestyle 
intervention and medication also assessing clinical outcomes is 
needed in patients with CVD and diabetes.
Management of coronary artery disease 
• Optimal glycaemic control and in-hospital anti-glycaemic strategies 
for the outcomes of ACS and stable CAD, as well as after coronary 
revascularization, remain to be established.
• Although newer-generation DES have improved outcomes in pa­
tients with diabetes, RCTs are needed to determine whether they 
can reduce the gap in outcomes between CABG and PCI.
• No direct comparison RCT has focused on revascularization in pa­
tients with diabetes and left main disease.
• Robust data on patients with CAD and T1DM are missing.
• The effect of anti-inflammatory strategies in patients with diabetes 
should be assessed in dedicated trials.
Heart failure 
• The effect of finerenone on cardio-renal endpoints in patients with 
diabetes and HFrEF or HFpEF needs to be examined.
• More mechanistic studies are warranted to better understand how 
SGLT2 inhibitors improve HF outcomes.
• Research is needed to guide OMT in patients with HF and T1DM.
• The prognostic benefit of HF screening with BNP/NT-proBNP in 
asymptomatic patients with diabetes needs to be determined.
Arrhythmias 
• Better evidence is needed regarding the risks of atrial and ventricular 
arrhythmias associated with T1DM and how they should be optimally 
managed.
• Optimal screening methods and treatment for patients with diabetes 
still need to be defined in RCTs.
• The role of AF in diabetes needs to be evaluated in CVOTs.
• Whether SGLT2 inhibitors reduce the risk of CV death by reducing the 
risk of ventricular tachyarrhythmias should be more precisely evaluated.
Chronic kidney disease 
• CV and renal effects of using non-steroidal MRAs in patients with CKD on 
a combined ACE-I/ARB + SGLT2-inhibitor regimen need to be explored.
• Net benefits of antiplatelet therapy in patients with diabetes and 
CKD with and without ASCVD need to be examined.
Aortic and peripheral arterial diseases 
• The frequency and mode of vascular screening in patients with dia­
betes needs to be assessed.
• Specific trials are needed to help clinicians choose different pharma­
cological strategies according to the presence of PAD.
Type 1 diabetes 
• Comprehensive cardio-protection management in patients with 
early-onset T1DM needs to be evaluated.
• The role of ameliorating insulin resistance and using adjunctive ther­
apies to reduce CV risk remains to be elucidated.
• Lifestyle intervention trials in patients with T1DM and CVD are lacking.
Person-centred care 
• Better CVD management of women with diabetes is needed.
• Effective interdisciplinary approaches to better manage glycaemic 
control and minimize the risk of complications are required.
• Data are lacking on personalization of mobile Health (mHealth) by 
assessing how individual factors, such as health literacy, culture, socio­
economic status, ageing, behaviours, and treatment plan, impact pa­
tient engagement with mHealth tools and clinical outcomes.
16. Sex differences
Epidemiological studies suggest that diabetes is a stronger risk factor for 
CVD in women compared with men. Data from large CVOTs do not sug­
gest sex differences with respect to the benefit of CV risk-reducing


<!-- PAGE 71 -->

### Page 71

strategies in T2DM, i.e. treatment with SGLT2 inhibitors or GLP-1 RAs. 
Although women are under-represented in clinical trials, there is no evi­
dence for sex-specific recommendations for managing CVD in patients 
with diabetes. However, epidemiological and real-world data suggest that 
guideline-directed therapy in women is less likely to be applied compared 
with men.835–837 This should be explored in future studies. Therefore, 
we recommend implementing sex-balanced recruitment strategies for fu­
ture CVOTs. In addition, pre-specified analyses addressing sex differences 
are needed. Most importantly, every effort should be made to ensure wo­
men receive equal healthcare opportunities in managing CVD in diabetes.
17. ‘What to do’ and ‘What not to do’ messages from the Guidelines
Table 12 ‘What to do’ and ‘What not to do’
Recommendations
Classa
Levelb
Recommendations for diagnosis of diabetes
Screening for diabetes is recommended in all individuals with CVD, using fasting glucose and/or HbA1c.
I
A
It is recommended that the diagnosis of diabetes is based on HbA1c and/or fasting plasma glucose, or on an OGTT if still in doubt.
I
B
Recommendations for assessing cardiovascular risk in patients with diabetes
It is recommended to screen patients with diabetes for the presence of severe TOD.
I
A
It is recommended to assess medical history and the presence of symptoms suggestive of ASCVD in patients with diabetes.
I
B
In patients with T2DM without symptomatic ASCVD or severe TOD, it is recommended to estimate 10-year CVD risk via 
SCORE2-Diabetes.
I
B
Recommendations for weight reduction in patients with diabetes
It is recommended that individuals living with overweight or obesity aim to reduce weight and increase physical exercise to improve 
metabolic control and overall CVD risk profile.
I
A
Recommendations for nutrition in patients with diabetes
It is recommended to adopt a Mediterranean or plant-based diet with high unsaturated fat content to lower cardiovascular risk.
I
A
Recommendation for physical activity/exercise in patients with diabetes
It is recommended to increase any physical activity (e.g. 10 min daily walking) in all patients with T2DM with and without CVD. Optimal is a 
weekly activity of 150 min of moderate intensity or 75 min of vigorous endurance intensity.
I
A
It is recommended to adapt exercise interventions to T2DM-associated comorbidities, e.g. frailty, neuropathy, or retinopathy.
I
B
It is recommended to introduce structured exercise training in patients with T2DM and established CVD, e.g. CAD, HFpEF, HFmrEF, 
HFrEF, or AF to improve metabolic control, exercise capacity and quality of life, and to reduce CV events.
I
B
It is recommended to perform resistance exercise in addition to endurance exercise at least twice a week.
I
B
Recommendation for smoking cessation in patients with diabetes
It is recommended to stop smoking to reduce cardiovascular risk.
I
A
Recommendations for glycaemic targets
It is recommended to apply tight glycaemic control (HbA1c <7%) to reduce microvascular complications.
I
A
It is recommended to avoid hypoglycaemia, particularly in patients with CVD.
I
B
It is recommended to individualize HbA1c targets according to comorbidities, diabetes duration, and life expectancy.
I
C
Recommendations for glucose-lowering treatment for patients with type 2 diabetes and atherosclerotic cardiovascular disease to 
reduce cardiovascular risk
It is recommended to prioritize the use of glucose-lowering agents with proven CV benefits followed by agents with proven CV safety over 
agents without proven CV benefit or proven CV safety.
I
C
Sodium–glucose co-transporter-2 inhibitors
SGLT2 inhibitors with proven CV benefit are recommended in patients with T2DM and ASCVD to reduce CV events, independent of 
baseline or target HbA1c and independent of concomitant glucose-lowering medication.
I
A
Glucagon-like peptide-1 receptor agonists
GLP-1 RAs with proven CV benefit are recommended in patients with T2DM and ASCVD to reduce CV events, independent of baseline or 
target HbA1c and independent of concomitant glucose-lowering medication.
I
A
Continued
ESC Guidelines                                                                                                                                                                                          4113


<!-- PAGE 72 -->

### Page 72

Recommendations for blood pressure in patients with diabetes
Screening for hypertension
Regular BP measurements are recommended in all patients with diabetes to detect and treat hypertension to reduce CV risk.
I
A
Treatment targets
Anti-hypertensive drug treatment is recommended for people with diabetes when office BP is ≥140/90 mmHg.
I
A
It is recommended to treat hypertension in patients with diabetes in an individualized manner. The BP goal is to target SBP to 130 mmHg 
and <130 mmHg if tolerated, but not <120 mmHg. In older people (age >65 years), it is recommended to target SBP to 130–139 mmHg.
I
A
Treatment and evaluation
Lifestyle changes (weight loss if overweight, physical activity, alcohol restriction, sodium restriction, increased consumption of vegetables, 
using low-fat dairy products) are recommended in patients with diabetes and hypertension.
I
A
It is recommended to initiate treatment with a combination of an RAS inhibitor and a CCB or thiazide/thiazide-like diuretic.
I
A
Recommendations for lipids and diabetes
Lipid targets in patients with diabetes
In patients with T2DM at moderate CV risk, an LDL-C target of <2.6 mmol/L (<100 mg/dL) is recommended.
I
A
In patients with T2DM at high CV risk, an LDL-C target of <1.8 mmol/L (<70 mg/dL) and LDL-C reduction of at least 50% is recommended.
I
A
In patients with T2DM at very high CV risk, an LDL-C target of <1.4 mmol/L (<55 mg/dL) and LDL-C reduction of at least 50% is 
recommended.
I
B
In patients with T2DM, a secondary goal of a non-HDL-C target of <2.2 mmol/L (<85 mg/dL) in very high CV risk patients, and <2.6 mmol/ 
L (<100 mg/dL) in high CV risk patients, is recommended.
I
B
Lipid-lowering treatment in patients with diabetes
Statins are recommended as the first-choice LDL-C-lowering treatment in patients with diabetes and above-target LDL-C levels. 
Administration of statins is defined based on the CV risk profile of the patients and the recommended LDL-C (or non-HDL-C) target levels.
I
A
A PCSK9 inhibitor is recommended in patients at very high CV risk, with persistently high LDL-C levels above target despite treatment with 
a maximum tolerated statin dose, in combination with ezetimibe, or in patients with statin intolerance.
I
A
If the target LDL-C is not reached with statins, combination therapy with ezetimibe is recommended.
I
B
Recommendations for antithrombotic therapy in patients with diabetes and acute or chronic coronary syndrome without indications 
for long-term oral anticoagulation
ASA at a dose of 75–100 mg o.d. is recommended in patients with diabetes and previous MI or revascularization (CABG or stenting).
I
A
In patients with ACS and diabetes who undergo PCI, a P2Y12 receptor inhibitor (ticagrelor or prasugrel) is recommended in addition to ASA 
(75–100 mg o.d.), maintained over 12 months.
I
A
Clopidogrel 75 mg o.d. following appropriate loading (e.g. 600 mg or at least 5 days already on maintenance therapy) is recommended in 
addition to ASA for 6 months following coronary stenting in patients with CCS, irrespective of stent type, unless a shorter duration is 
indicated due to the risk or occurrence of life-threatening bleeding.
I
A
Clopidogrel is recommended as an alternative in case of ASA intolerance.
I
B
In patients with diabetes and ACS treated with DAPT who are undergoing CABG and do not require long-term OAC therapy, resuming a 
P2Y12 receptor inhibitor as soon as deemed safe after surgery and continuing it up to 12 months is recommended.
I
C
Recommendations for antithrombotic therapy in patients with diabetes and acute or chronic coronary syndrome and/or 
post-percutaneous coronary intervention requiring long-term oral anticoagulation
In patients with AF and receiving antiplatelet therapy, eligible for anticoagulation, and without a contraindication, NOACs are 
recommended in preference to a VKA.
I
A
In patients with ACS or CCS and diabetes undergoing coronary stent implantation and having an indication for anticoagulation, triple 
therapy with low-dose ASA, clopidogrel, and an OAC is recommended for at least 1 week, followed by dual therapy with an OAC and a 
single, oral, antiplatelet agent.
I
A
Recommendations for gastric protection
When antithrombotic drugs are used in combination, proton pump inhibitors are recommended to prevent gastrointestinal bleeding.
I
A
When clopidogrel is used, omeprazole and esomeprazole are not recommended for gastric protection.
III
B
Recommendations for a multifactorial approach in patients with diabetes
Identifying and treating risk factors and comorbidities early is recommended.
I
A
A multifactorial approach to managing T2DM with treatment targets is recommended.
I
B
Multidisciplinary behavioural approaches that combine the knowledge and skills of different caregivers are recommended.
I
C
Continued


<!-- PAGE 73 -->

### Page 73

Recommendations for revascularization in patients with diabetes
It is recommended that similar revascularization techniques are implemented (e.g. the use of DES and the radial approach for PCI, and the 
use of the left internal mammary artery as the graft for CABG) in patients with and without diabetes.
I
A
Myocardial revascularization in CCS is recommended when angina persists despite treatment with anti-anginal drugs or in patients with a 
documented large area of ischaemia (>10% LV).
I
A
Complete revascularization is recommended in patients with STEMI without cardiogenic shock and with multivessel CAD.
I
A
Routine immediate revascularization of non-culprit lesions in patients with MI with multivessel disease presenting with cardiogenic shock is 
not recommended.
III
B
Recommendations for glycaemic control in patients with diabetes and acute coronary syndrome
It is recommended to assess glycaemic status at initial evaluation in all patients with ACS.
I
B
It is recommended to frequently monitor blood glucose levels in patients with known diabetes or hyperglycaemia (defined as glucose levels 
≥11.1 mmol/L or ≥200 mg/dL).
I
C
Recommendations for heart failure screening and diagnosis in patients with diabetes
Evaluation for heart failure
If HF is suspected, it is recommended to measure BNP/NT-proBNP.
I
B
Systematic survey for HF symptoms and/or signs of HF is recommended at each clinical encounter in all patients with diabetes.
I
C
Diagnostic tests in all patients with suspected heart failure
12-lead ECG is recommended.
I
C
Transthoracic echocardiography is recommended.
I
C
Chest radiography (X-ray) is recommended.
I
C
Routine blood tests for comorbidities are recommended, including full blood count, urea, creatinine and electrolytes, thyroid function, 
lipids, and iron status (ferritin and TSAT).
I
C
Recommendations for heart failure treatments in patients with heart failure with reduced ejection fraction and diabetes
Recommendations for pharmacological treatment indicated in patients with HFrEF (NYHA class II–IV) and diabetes
SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozin) are recommended in all patients with HFrEF and T2DM to reduce the risk of 
HF hospitalization and death.
I
A
Sacubitril/valsartan or an ACE-I is recommended in all patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death.
I
A
Beta-blockers are recommended in patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death.
I
A
MRAs are recommended in patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death.
I
A
An intensive strategy of early initiation of evidence-based treatment (SGLT2 inhibitors, ARNI/ACE-Is, beta-blockers, and MRAs), with rapid 
up-titration to trial-defined target doses starting before discharge and with frequent follow-up visits in the first 6 weeks following a HF 
hospitalization is recommended to reduce re-admissions or mortality.
I
B
Recommendations for other treatments indicated in selected patients with HFrEF (NYHA class II–IV) and diabetes
Device therapy with an ICD, CRT-P, or CRT-D is recommended in patients with diabetes, as in the general population with HFrEF.
I
A
ARBs are recommended in symptomatic patients with HFrEF and diabetes who do not tolerate sacubitril/valsartan or ACE-Is, to reduce the 
risk of HF hospitalization and  death.
I
A
Diuretics are recommended in patients with HFrEF and diabetes with signs and/or symptoms of fluid congestion to improve symptoms, 
exercise capacity, and HF hospitalization.
I
C
Recommendations for the treatment of heart failure patients with left ventricular ejection fraction >40% and diabetes
Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF 
hospitalization or CV death.
I
A
Diuretics are recommended in patients with HFpEF or HFmrEF and diabetes with signs and/or symptoms of fluid congestion to improve 
symptoms, exercise capacity, and HF hospitalization.
I
C
Recommendations for glucose-lowering medications in patients with type 2 diabetes with and without heart failure
Recommendations for glucose-lowering medications to reduce heart failure hospitalization in patients with type 2 diabetes with or 
without existing heart failure
SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, or sotagliflozin) are recommended in patients with T2DM with 
multiple ASCVD risk factors or established ASCVD to reduce the risk of HF hospitalization.
I
A
SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozin) are recommended in patients with T2DM and HFrEF to reduce the risk of HF 
hospitalization and death.
I
A
Continued
ESC Guidelines                                                                                                                                                                                          4115


<!-- PAGE 74 -->

### Page 74

Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF 
hospitalization or CV death.
I
A
Recommendations for glucose-lowering medications with an increased risk of heart failure hospitalization in patients with type 2 
diabetes
Pioglitazone is associated with an increased risk of incident HF in patients with diabetes and is not recommended for glucose-lowering 
treatment in patients at risk of HF (or with previous HF).
III
A
The DPP-4 inhibitor saxagliptin is associated with an increased risk of HF hospitalization in patients with diabetes and is not recommended 
for glucose-lowering treatment in patients at risk of HF (or with previous HF).
III
B
Recommendations for special consideration in patients with heart failure and diabetes
It is recommended to switch glucose-lowering treatment from agents without proven CV benefit or proven safety to agents with proven 
CV benefit.
I
C
Recommendations for atrial fibrillation in patients with diabetes
Screening for atrial fibrillation in diabetes
Opportunistic screening for AF by pulse taking or ECG is recommended in patients ≥65 years of age.
I
B
Opportunistic screening for AF by pulse taking or ECG is recommended in patients with diabetes <65 years of age (particularly when other 
risk factors are present) because patients with diabetes exhibit a higher AF frequency at a younger age.
I
C
Anticoagulation for atrial fibrillation in patients with diabetes
Oral anticoagulation is recommended for preventing stroke in patients with AF and diabetes and with at least one additional 
(CHA2DS2-VASc) risk factor for stroke.
I
A
For preventing stroke in AF, NOACs are recommended in preference to VKAs, with the exception of patients with mechanical valve 
prostheses or moderate to severe mitral stenosis.
I
A
Recommendations for patients with chronic kidney disease and diabetes
Intensive LDL-C lowering with statins or a statin/ezetimibe combination is recommended.
I
A
A BP target of ≤130/80 mmHg is recommended to reduce risk of CVD and albuminuria.
I
A
Personalized HbA1c targets 6.5–8.0% (48–64 mmol/mol) are recommended, with a target <7.0% (<53 mmol/mol) to reduce 
microvascular complications, wherever possible.
I
A
The maximum tolerated dose of an ACE-I or ARB is recommended.
I
A
A SGLT2 inhibitor (canagliflozin, empagliflozin, or dapagliflozin) is recommended in patients with T2DM and CKD with an eGFR ≥20 mL/ 
min/1.73 m2 to reduce the risk of CVD and kidney failure.
I
A
Finerenone is recommended in addition to an ACE-I or ARB in patients with T2DM and eGFR >60 mL/min/1.73 m2 with a UACR ≥30 mg/ 
mmol (≥300 mg/g), or eGFR 25–60 mL/min/1.73 m2 and UACR ≥3 mg/mmol (≥30 mg/g) to reduce CV events and kidney failure.
I
A
A GLP-1 RA is recommended at eGFR >15 mL/min/1.73 m2 to achieve adequate glycaemic control, due to low risk of hypoglycaemia and 
beneficial effects on weight, CV risk, and albuminuria.
I
A
Low-dose ASA (75–100 mg o.d.) is recommended in patients with CKD and ASCVD.
I
A
It is recommended that patients with diabetes are routinely screened for kidney disease by assessing eGFR defined by CKD-EPI and UACR.
I
B
Treatment with intensive medical or an initial invasive strategy is recommended in people with CKD, diabetes, and stable moderate or 
severe CAD, due to similar outcomes.
I
B
Combined use of an ARB with an ACE-I is not recommended.
III
B
Recommendations for aortic and peripheral arterial diseases and diabetes
Lower-extremity artery disease in patients with diabetes
In patients with diabetes and symptomatic LEAD, antiplatelet therapy is recommended.
I
A
In patients with diabetes and CLTI, it is recommended to assess the risk of amputation; the WIfI score is useful for this purpose.
I
B
As patients with diabetes and LEAD are at very high CV risk, an LDL-C target of <1.4 mmol/L (<55 mg/dL) and an LDL-C reduction of at 
least 50% is recommended.
I
B
Screening for LEAD is recommended on a regular basis, with clinical assessment and/or ABI measurement.
I
C
Patient education about foot care is recommended in patients with diabetes, and especially those with LEAD, even if asymptomatic. Early 
recognition of tissue loss and/or infection, and referral to a multidisciplinary team, is mandatory to improve limb salvage.
I
C
An ABI ≤0.90 is diagnostic of LEAD, irrespective of symptoms. In symptomatic cases, further assessment including duplex ultrasound is 
recommended.
I
C
When ABI is elevated (>1.40), other non-invasive tests, including TBI or duplex ultrasound, are recommended.
I
C
Duplex ultrasound is recommended as the first-line imaging method to assess the anatomy and haemodynamic status of lower-extremity 
arteries.
I
C
Continued


<!-- PAGE 75 -->

### Page 75

### 18 Quality indicators

Quality indicators (QIs) are tools that may be used to evaluate care qual­
ity, including structural, process, and outcomes of care.838 They may also 
serve as a mechanism for enhancing adherence to Guideline recommen­
dations, through associated quality-improvement initiatives and bench­
marking of care clinicians.839,840 As such, the role of QIs in improving 
care and outcomes for CVD is increasingly recognized by healthcare au­
thorities, professional organizations, payers, and the public.838
The ESC understands the need for measuring and reporting quality 
and outcomes of CV care and has established methods for developing 
the ESC QIs for quantifying care and outcomes for CVDs.838 To date, 
the ESC has developed QI suites for a number of CVDs in parallel with 
writing the ESC Clinical Practice Guidelines.841–844
The ESC aims to harmonize its QIs for various CV conditions and in­
tegrate them with ESC registries, providing real-world data about the 
patterns and outcomes of care for CVD across Europe.845
19. Supplementary data
Supplementary data is available at European Heart Journal online.
20. Data availability statement
No new data were generated or analysed in support of this research.
21. Author information
Author/Task Force Member Affiliations: Katharina Schütt, 
Department of Internal Medicine I Cardiology, RWTH Aachen 
University, Aachen, Germany; Dirk Müller-Wieland, Department of 
Internal Medicine I Cardiology, RWTH Aachen University, Aachen, 
Germany; Ramzi A. Ajjan, Clinical Population and Sciences 
Department, Leeds Institute of Cardiovascular and Metabolic Medicine, 
University of Leeds, Leeds, United Kingdom, Department of Diabetes 
and Endocrinology, Leeds Teaching Hospitals Trust, Leeds, United 
Kingdom; Manuel J. Antunes, Faculty of Medicine, University of 
Coimbra, Coimbra, Portugal; Ruxandra M. Christodorescu, 
Department V Internal Medicine, University of Medicine and Pharmacy 
V. Babeș, Timișoara, Romania, Research Center Institute of 
Cardiovascular Diseases, Timișoara, Romania; Carolyn Crawford 
(United Kingdom), ESC Patient Forum, Sophia Antipolis, France; 
Emanuele Di Angelantonio, Department of Public Health and 
Primary Care University of Cambridge, Cambridge, United Kingdom, 
Health Data Science Centre, Human Technopole, Milan, Italy; Björn 
Eliasson, Institute of Medicine, Sahlgrenska University Hospital, 
Gothenburg, Sweden; Christine Espinola-Klein, Department of 
Angiology, Center of Cardiology, University Medical Center of the 
Johannes Gutenberg University Mainz, Mainz, Germany; Laurent 
Fauchier, Cardiology Department Centre Hospitalier Universitaire 
Trousseau, Université de Tours, Tours, France; Martin Halle, 
Preventive Sports Medicine and Sports Cardiology, Technical University 
In case of CLTI, revascularization is recommended whenever feasible for limb salvage.
I
C
Carotid artery disease in patients with diabetes
In patients with diabetes and carotid artery disease, it is recommended to implement the same diagnostic work-up and therapeutic 
strategies (medical, surgical, or endovascular) as in patients without diabetes.
I
C
Aortic aneurysm in patients with diabetes
In patients with diabetes and aortic aneurysm, it is recommended to implement the same diagnostic work-up and therapeutic strategies 
(medical, surgical, or endovascular) as in patients without diabetes.
I
C
Recommendations for type 1 diabetes and cardiovascular disease
In patients with T1DM, it is recommended that adjustment of glucose-lowering medication follows principles of patient self-management 
under the guidance of the diabetes healthcare multidisciplinary team.
I
C
Avoiding hypoglycaemic episodes is recommended, particularly in those with established CVD.
I
C
Recommendations for person-centred care in diabetes
Structured education programmes are recommended in patients with diabetes to improve diabetes knowledge, glycaemic control, disease 
management, and patient empowerment.
I
A
Person-centred care is recommended to facilitate shared control and decision-making within the context of person priorities and goals.
I
C
© ESC 2023
ABI, ankle–brachial index; ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial fibrillation; ARB, angiotensin-II receptor blocker; ARNI, angiotensin 
receptor–neprilysin inhibitor; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; BNP, B-type natriuretic peptide; BP, blood pressure; CABG, coronary artery 
bypass graft; CAD, coronary artery disease; CCB, calcium channel blocker; CCS, chronic coronary syndrome; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 years (2 
points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), Vascular disease, Age 65–74 years, Sex category (female); CKD, chronic kidney disease; CKD-EPI, chronic 
kidney disease epidemiology; CLTI, chronic limb-threatening ischaemia; CRT-D, cardiac resynchronization therapy with an implantable defibrillator; CRT-P, cardiac resynchronization 
therapy-pacemaker; CV, cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DES, drug-eluting stents; DPP-4, dipeptidyl peptidase-4; ECG, electrocardiogram; 
eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein-cholesterol; HF, heart 
failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, 
implantable cardioverter defibrillator; LEAD, lower-extremity artery disease; LDL-C, low-density lipoprotein-cholesterol; LV, left ventricle; LVEF, left ventricular ejection fraction; MI, 
myocardial infarction; MRA, mineralocorticoid receptor antagonist; NOAC, non-vitamin K antagonist oral anticoagulant; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, 
New York Heart Association; OAC, oral anticoagulant; o.d., once daily; OGTT, oral glucose tolerance test; PCI, percutaneous coronary intervention; PCSK9, proprotein convertase 
subtilisin/kexin type 9; RAS, renin–angiotensin system; SBP, systolic blood pressure; SCORE2-Diabetes, type 2 diabetes-specific 10-year CVD risk score; SGLT2, sodium–glucose 
co-transporter-2; STEMI, ST-elevation myocardial infarction; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TBI, toe–brachial index; TOD, target-organ damage; TSAT, 
transferrin saturation; UACR, urinary albumin-to-creatinine ratio; VKA, vitamin K antagonist; WIfI, Wound, Ischaemia, foot Infection. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4117


<!-- PAGE 76 -->

### Page 76

of Munich, Muenchen, Germany; William G. Herrington, Nuffield 
Department of Population Health, University of Oxford, Oxford, 
United Kingdom; Alexandra Kautzky-Willer, Department of 
Medicine III, Medical University of Vienna, Vienna, Austria, Institute for 
Gender Medicine, La pura women’s health resort Kamptal, Gars am 
Kamp, Austria; Ekaterini Lambrinou, Department of Nursing, 
Cyprus University of Technology, Limassol, Cyprus; Maciej Lesiak, 
1st Department of Cardiology, Poznan University of Medical Sciences, 
Poznan, Poland; Maddalena Lettino, Cardiothoracic and Vascular 
Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; 
Darren K. McGuire, Department of Internal Medicine, Division of 
Cardiology, University of Texas Southwestern Medical Center, Dallas, 
United States of America, Parkland Health and Hospital System, Dallas, 
United States of America; Wilfried Mullens, Cardiology, Ziekenhuis 
Oost Limburg, Genk, Belgium, Faculty of Medicine and Life Sciences, 
University Hasselt, Hasselt, Belgium; Bianca Rocca, Section of 
Pharmacology, Catholic University School of Medicine, Rome, Italy; and 
Naveed Sattar, School of Cardiovascular and Metabolic Health, 
University of Glasgow, Glasgow, United Kingdom.
22. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Eva Prescott (CPG Review Co-ordinator) 
(Denmark), Francesco Cosentino (CPG Review Co-ordinator) 
(Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Sotiris 
Antoniou (United Kingdom), Riccardo Asteggiano (Italy), Iris 
Baumgartner (Switzerland), Sergio Buccheri (Sweden), Hector Bueno 
(Spain), Jelena Čelutkienė (Lithuania), Alaide Chieffo (Italy), Christina 
Christersson (Sweden), Andrew Coats (United Kingdom), Bernard 
Cosyns (Belgium), Martin Czerny (Germany), Christi Deaton (United 
Kingdom), 
Volkmar 
Falk 
(Germany), 
Brian 
A. 
Ference 
(United Kingdom), Gerasimos Filippatos (Greece), Miles Fisher (United 
Kingdom), Heikki Huikuri (Finland), Borja Ibanez (Spain), Tiny Jaarsma 
(Sweden), Stefan James (Sweden), Kamlesh Khunti (United Kingdom), 
Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Basil 
S. Lewis (Israel), Maja-Lisa Løchen (Norway), John William McEvoy 
(Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham 
(United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis 
Nielsen (Denmark), Gianfranco Parati (Italy), Agnes A. Pasquet 
(Belgium), Carlo Patrono (Italy), Steffen E. Petersen (United Kingdom), 
Massimo F. Piepoli (Italy), Amina Rakisheva (Kazakhstan), Xavier 
Rossello (Spain), Peter Rossing (Denmark), Lars Ryden (Sweden), 
Eberard Standl (Germany), Lale Tokgozoglu (Türkiye), Rhian M. Touyz 
(Canada/United Kingdom), Frank Visseren (Netherlands), Massimo 
Volpe (Italy), Christiaan Vrints (Belgium), and Adam Witkowski (Poland).
ESC National Cardiac Societies actively involved in the review 
process of the 2023 ESC Guidelines for the management of cardiovas­
cular disease in patients with diabetes: Armenia: Armenian 
Cardiologists Association, Lusine Hazarapetyan; Austria: Austrian 
Society of Cardiology, Andreas Zirlik; Azerbaijan: Azerbaijan 
Society of Cardiology, Yasmin Rustamova; Belgium: Belgian Society 
of Cardiology, Philippe van de Borne; Bosnia and Herzegovina: 
Association of Cardiologists of Bosnia and Herzegovina, Šekib 
Sokolović; Bulgaria: Bulgarian Society of Cardiology, Nina 
Gotcheva; Croatia: Croatian Cardiac Society, Davor Milicic; 
Cyprus: Cyprus Society of Cardiology, Petros Agathangelou; 
Czechia: Czech Society of Cardiology, Michal Vrablík; Denmark: 
Danish Society of Cardiology, Morten Schou; Egypt: Egyptian 
Society of Cardiology, Hosam Hasan-Ali; Estonia: Estonian Society 
of Cardiology, Margus Viigimaa; Finland: Finnish Cardiac Society, 
Riikka Lautamäki; France: French Society of Cardiology, Victor 
Aboyans; Georgia: Georgian Society of Cardiology, Zurab 
Klimiashvili; Germany: German Cardiac Society, Malte Kelm; 
Greece: Hellenic Society of Cardiology, Gerasimos Siasos; 
Hungary: Hungarian Society of Cardiology, Róbert Gábor Kiss; 
Iceland: Icelandic Society of Cardiology, Berglind Libungan; Ireland: 
Irish Cardiac Society, Maeve Durkan; Israel: Israel Heart Society, 
Barak Zafrir; Italy: Italian Federation of Cardiology, Furio Colivicchi; 
Kazakhstan: Association of Cardiologists of Kazakhstan, Meiramgul 
Tundybayeva; Kosovo (Republic of): Kosovo Society of 
Cardiology, Ibadete Bytyçi; Kyrgyzstan: Kyrgyz Society of 
Cardiology, 
Erkin 
Mirrakhimov; 
Latvia: 
Latvian 
Society 
of Cardiology, Karlis Trusinskis; Lebanon: Lebanese Society of 
Cardiology, Georges Saadé; Lithuania: Lithuanian Society of 
Cardiology, Jolita Badarienė; Luxembourg: Luxembourg Society 
of Cardiology, Cristiana-Astra Banu; Malta: Maltese Cardiac Society, 
Caroline Jane Magri; Montenegro: Montenegro Society of 
Cardiology, Aneta Boskovic; Morocco: Moroccan Society of 
Cardiology, Mustapha El Hattaoui; Netherlands: Netherlands 
Society of Cardiology, Fabrice Martens; North Macedonia: The 
National Society of Cardiology of North Macedonia, Marijan 
Bosevski; Norway: Norwegian Society of Cardiology, Eva Cecilie 
Knudsen; Poland: Polish Cardiac Society, Paweł Burchardt; 
Portugal: 
Portuguese 
Society 
of 
Cardiology, 
Ricardo 
Fontes-Carvalho; Romania: Romanian Society of Cardiology, 
Dragos Vinereanu; San Marino: San Marino Society of Cardiology, 
Tatiana Mancini; Serbia: Cardiology Society of Serbia, Branko 
Beleslin; Slovakia: Slovak Society of Cardiology, Emil Martinka; 
Slovenia: Slovenian Society of Cardiology, Zlatko Fras; Spain: 
Spanish Society of Cardiology, Almudena Castro Conde; Sweden: 
Swedish Society of Cardiology, Linda Mellbin; Switzerland: Swiss 
Society of Cardiology, David Carballo; Syrian Arab Republic: 
Syrian Cardiovascular Association, Walid Bsata; Tunisia: Tunisian 
Society of Cardiology and Cardiovascular Surgery, Fathia Mghaieth; 
Türkiye: Turkish Society of Cardiology, Baris Gungor; Ukraine: 
Ukrainian Association of Cardiology, Olena Mitchenko; United 
Kingdom of Great Britain and Northern Ireland: British 
Cardiovascular Society, Stephen Wheatcroft; and Uzbekistan: 
Association of Cardiologists of Uzbekistan, Raisa Trigulova.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rosselló (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
23. Acknowledgements
The Task Force Chairs thank Marlo Verket for her support in the 
co-ordination of this document.


<!-- PAGE 77 -->

### Page 77

### 24 References

1. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. 
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the 
American Diabetes Association (ADA) and the European Association for the Study 
of Diabetes (EASD). Diabetologia 2022;65:1925–1966. https://doi.org/10.1007/ 
s00125-022-05787-2
2. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF 
Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 
2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119. https://doi. 
org/10.1016/j.diabres.2021.109119
3. Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes 
in adults. Diabetes Res Clin Pract 2014;103:150–160. https://doi.org/10.1016/j.diabres. 
2013.11.001
4. International Expert Committee. International Expert Committee report on the role 
of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327–1334. 
https://doi.org/10.2337/dc09-9033
5. World Health Organization. Classification of Diabetes Mellitus 2019. Geneva, 
Switzerland, 1–36.
6. WHO Guidelines Approved by the Guidelines Review Committee. Use of glycated 
Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a 
WHO Consultation. Geneva, Switzerland, 2011.
7. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 
2021;44(Suppl 1):S15–S33. https://doi.org/10.2337/dc21-S002
8. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of 
the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes 
Care 2003;26:S5–S20. https://doi.org/10.2337/diacare.26.2007.s5
9. Pareek M, Bhatt DL, Nielsen ML, Jagannathan R, Eriksson K-F, Nilsson PM, et al. 
Enhanced predictive capability of a 1-hour oral glucose tolerance test: a prospective 
population-based cohort study. Diabetes Care 2018;41:171–177. https://doi.org/10. 
2337/dc17-1351
10. Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, et al. Prevalence of 
diabetes and high risk for diabetes using A1C criteria in the US population in 1988– 
2006. Diabetes Care 2010;33:562–568. https://doi.org/10.2337/dc09-1524
11. Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and man­
agement of youth-onset type 2 diabetes: a position statement by the American 
Diabetes Association. Diabetes Care 2018;41:2648–2668. https://doi.org/10.2337/ 
dci18-0052
12. Krhač M, Lovrenčić MV. Update on biomarkers of glycemic control. World J Diabetes 
2019;10:1–15. https://doi.org/10.4239/wjd.v10.i1.1
13. Holt RI, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, et al. The manage­
ment of type 1 diabetes in adults. A consensus report by the American Diabetes 
Association (ADA) and the European Association for the Study of Diabetes 
(EASD). Diabetes Care 2021;44:2589–2625. https://doi.org/10.2337/dci21-0043
14. Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, et al. 
Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 
2014;311:1225–1233. https://doi.org/10.1001/jama.2014.1873
15. Foteinopoulou E, Clarke CA, Pattenden RJ, Ritchie SA, McMurray EM, Reynolds RM, 
et al. Impact of routine clinic measurement of serum C-peptide in people with a 
clinician-diagnosis of type 1 diabetes. Diabet Med 2021;38:e14449. https://doi.org/10. 
1111/dme.14449
16. Kietsiriroje N, Pearson S, Campbell M, Ariëns RA, Ajjan RA. Double diabetes: a distinct 
high-risk group? Diabetes Obes Metab 2019;21:2609–2618. https://doi.org/10.1111/ 
dom.13848
17. Riddle MC, Philipson LH, Rich SS, Carlsson A, Franks PW, Greeley SAW, et al. 
Monogenic diabetes: from genetic insights to population-based precision in care. 
Reflections from a diabetes care editors’ expert forum. Diabetes Care 2020;43: 
3117–3128. https://doi.org/10.2337/dci20-0065
18. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, 
et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: 
an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97:16–38. 
https://doi.org/10.1210/jc.2011-2098
19. Bellis A, Mauro C, Barbato E, Ceriello A, Cittadini A, Morisco C. Stress-induced hyper­
glycaemia in non-diabetic patients with acute coronary syndrome: from molecular me­
chanisms to new therapeutic perspectives. Int J Mol Sci 2021;22:775. https://doi.org/10. 
3390/ijms22020775
20. Norhammar A, Tenerz Å, Nilsson G, Hamsten A, Efendíc S, Rydén L, et al. Glucose 
metabolism in patients with acute myocardial infarction and no previous diagnosis 
of diabetes mellitus: a prospective study. Lancet 2002;359:2140–2144. https://doi. 
org/10.1016/S0140-6736(02)09089-X
21. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, et al. The prevalence 
of abnormal glucose regulation in patients with coronary artery disease across Europe: 
the Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25:1880–1890. 
https://doi.org/10.1016/j.ehj.2004.07.027
22. International Association of Diabetes Pregnancy Study Groups Consensus Panel. 
International association of diabetes and pregnancy study groups recommendations 
on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 
2010;33:676–682. https://doi.org/10.2337/dc09-1848
23. Harreiter J, Fadl H, Kautzky-Willer A, Simmons D. Do women with diabetes need 
more intensive action for cardiovascular reduction than men with diabetes? Curr 
Diab Rep 2020;20:61. https://doi.org/10.1007/s11892-020-01348-2
24. Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type 
2 diabetes in women with a known history of gestational diabetes: systematic review 
and meta-analysis. BMJ 2020;369:m1361. https://doi.org/10.1136/bmj.m1361
25. Lowe WL, Scholtens DM, Lowe LP, Kuang A, Nodzenski M, Talbot O, et al. 
Association of gestational diabetes with maternal disorders of glucose metabolism 
and childhood adiposity. JAMA 2018;320:1005–1016. https://doi.org/10.1001/jama. 
2018.11628
26. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovas­
cular disease in women: a systematic review and meta-analysis. Diabetologia 2019;62: 
905–914. https://doi.org/10.1007/s00125-019-4840-2
27. Tobias DK, Stuart JJ, Li S, Chavarro J, Rimm EB, Rich-Edwards J, et al. Association of 
history of gestational diabetes with long-term cardiovascular disease risk in a large pro­
spective cohort of US women. JAMA Intern Med 2017;177:1735–1742. https://doi.org/ 
10.1001/jamainternmed.2017.2790
28. McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational 
diabetes mellitus. Nat Rev Dis Primers 2019;5:47. https://doi.org/10.1038/s41572- 
019-0098-8
29. Daly B, Toulis KA, Thomas N, Gokhale K, Martin J, Webber J, et al. Increased risk of 
ischemic heart disease, hypertension, and type 2 diabetes in women with previous ges­
tational diabetes mellitus, a target group in general practice for preventive interven­
tions: a population-based cohort study. PLoS Med 2018;15:e1002488. https://doi. 
org/10.1371/journal.pmed.1002488
30. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, et al. 2013 
ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a re­
port of the American College of Cardiology Foundation/American Heart Association 
Task Force on Practice Guidelines. J Am College Cardiol 2013;61:e78–e140. https://doi. 
org/10.1016/j.jacc.2012.11.019
31. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC 
Guidelines for the management of acute coronary syndromes in patients presenting 
without persistent ST-segment elevation: Task Force for the management of acute 
coronary syndromes in patients presenting without persistent ST-segment elevation 
of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315. https:// 
doi.org/10.1093/eurheartj/ehv320
32. Zhou M, Liu J, Hao Y, Liu J, Huo Y, Smith SC, et al. Prevalence and in-hospital outcomes 
of diabetes among patients with acute coronary syndrome in China: findings from the 
Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome 
Project. Cardiovasc Diabetol 2018;17:147. https://doi.org/10.1186/s12933-018-0793-x
33. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes 
mellitus and heart failure: a scientific statement from the American Heart Association 
and the Heart Failure Society of America: this statement does not represent an update 
of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 2019;140: 
e294–e324. https://doi.org/10.1161/CIR.0000000000000691
34. Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, et al. Patients 
with coronary artery disease and diabetes need improved management: a report from 
the EUROASPIRE IV survey: a registry from the EuroObservational Research 
Programme of the European Society of Cardiology. Cardiovasc Diabetol 2015;14: 
133. https://doi.org/10.1186/s12933-015-0296-y
35. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of 
glycemia and implications for the classification of diabetes. Arch Intern Med 2007;167: 
1545–1551. https://doi.org/10.1001/archinte.167.14.1545
36. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K, et al. Glycemic 
thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for dia­
betes. Diabetes Care 2011;34:145–150. https://doi.org/10.2337/dc10-1206
37. Preiss D, Sattar N. Diabetic microvascular complications as simple indicators of risk for 
cardiovascular outcomes and heart failure. Lancet Diabetes Endocrinol 2016;4:555–556. 
https://doi.org/10.1016/S2213-8587(16)30097-3
38. Tabák AG, Brunner EJ, Lindbohm JV, Singh-Manoux A, Shipley MJ, Sattar N, et al. Risk of 
macrovascular and microvascular disease in diabetes diagnosed using oral glucose tol­
erance test with and without confirmation by hemoglobin A1c: the Whitehall II cohort 
study. Circulation 2022;146:995–1005. https://doi.org/10.1161/CIRCULATIONAHA. 
122.059430
39. Mak K-H, Vidal-Petiot E, Young R, Sorbets E, Greenlaw N, Ford I, et al. Prevalence of 
diabetes and impact on cardiovascular events and mortality in patients with chronic 
coronary syndromes, across multiple geographical regions and ethnicities. Eur J Prev 
Cardiol 2021;28:1795–1806. https://doi.org/10.1093/eurjpc/zwab011
40. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes 
mellitus, fasting blood glucose concentration, and risk of vascular disease: a collabora­
tive meta-analysis of 102 prospective studies. Lancet 2010;375:2215–2222. https://doi. 
org/10.1016/S0140-6736(10)60484-9
ESC Guidelines                                                                                                                                                                                          4119


<!-- PAGE 78 -->

### Page 78

41. Chan JC, Lim L-L, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, et al. The Lancet 
Commission on diabetes: using data to transform diabetes care and patient lives. 
Lancet 2020;396:2019–2082. https://doi.org/10.1016/S0140-6736(20)32374-6
42. Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, et al. 
Association of cardiometabolic multimorbidity with mortality. JAMA 2015;314:52–60. 
https://doi.org/10.1001/jama.2015.7008
43. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJL, et al. 
Associations of kidney disease measures with mortality and end-stage renal disease 
in individuals with and without diabetes: a meta-analysis. Lancet 2012;380: 
1662–1673. https://doi.org/10.1016/S0140-6736(12)61350-6
44. Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ, et al. 
Microvascular disease and risk of cardiovascular events among individuals with type 2 
diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 2016;4:588–597. 
https://doi.org/10.1016/S2213-8587(16)30057-2
45. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. 
KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney dis­
ease. Kidney Int 2022;102(Suppl 5S):S1–S127. https://doi.org/10.1016/j.kint.2022.06. 
008
46. Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, et al. Contemporary mod­
el for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc 
Prevent Rehabil 2011;18:393–398. https://doi.org/10.1177/1741826710394270
47. Berkelmans GF, Gudbjörnsdottir S, Visseren FL, Wild SH, Franzen S, Chalmers J, et al. 
Prediction of individual life-years gained without cardiovascular events from lipid, 
blood pressure, glucose, and aspirin treatment based on data of more than 500 000 
patients with type 2 diabetes mellitus. Eur Heart J 2019;40:2899–2906. https://doi. 
org/10.1093/eurheartj/ehy839
48. Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC 
Guidelines on cardiovascular disease prevention in clinical practice: developed by the 
Task Force for cardiovascular disease prevention in clinical practice with representa­
tives of the European Society of Cardiology and 12 medical societies With the special 
contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart 
J 2021;42:3227–3337. https://doi.org/10.1093/eurheartj/ehab484
49. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk 
prediction algorithms: new models to estimate 10-year risk of cardiovascular dis­
ease in Europe. Eur Heart J 2021;42:2439–2454. https://doi.org/10.1093/eurheartj/ 
ehab309
50. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. 
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in 
Europe. Eur Heart J 2023;44:2544–2556. https://doi.org/10.1093/eurheartj/ehad260.
51. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP 
risk prediction algorithms: estimating incident cardiovascular event risk in older per­
sons in four geographical risk regions. Eur Heart J 2021;42:2455–2467. https://doi. 
org/10.1093/eurheartj/ehab312
52. Østergaard HB, Hageman SHJ, Read SH, Taylor O, Pennells L, Kaptoge S, et al. 
Estimating individual lifetime risk of incident cardiovascular events in adults with 
type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime per­
spective model (DIAL2). Eur J Prev Cardiol 2023;30:61–69. https://doi.org/10.1093/ 
eurjpc/zwac232
53. Ling J, Koye D, Buizen L, Khunti K, Montvida O, Paul SK. Temporal trends in co- 
morbidities and cardiometabolic risk factors at the time of type 2 diabetes diagnosis 
in the UK. Diabetes Obes Metab 2021;23:1150–1161. https://doi.org/10.1111/dom. 
14323
54. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes 
on cardiovascular disease risk and all-cause mortality in older men: influence of age at 
onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011; 
171:404–410. https://doi.org/10.1001/archinternmed.2011.2
55. Nelson AJ, Peterson ED, Pagidipati NJ. Atherosclerotic cardiovascular disease and 
heart failure: determinants of risk and outcomes in patients with diabetes. Progr 
Cardiovasc Dis 2019;62:306–314. https://doi.org/10.1016/j.pcad.2019.07.001
56. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular ef­
fects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369: 
145–154. https://doi.org/10.1056/NEJMoa1212914
57. Look AHEAD Research Group. Effect of a long-term behavioural weight loss interven­
tion on nephropathy in overweight or obese adults with type 2 diabetes: a secondary 
analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2014; 
2:801–809. https://doi.org/10.1016/S2213-8587(14)70156-1
58. Look AHEAD Research Group. Effects of intensive lifestyle intervention on all-cause 
mortality in older adults with type 2 diabetes and overweight/obesity: results from the 
Look AHEAD Study. Diabetes Care 2022;45:1252–1259. https://doi.org/10.2337/dc21- 
1805
59. Patel KV, Bahnson JL, Gaussoin SA, Johnson KC, Pi-Sunyer X, White U, et al. 
Association of baseline and longitudinal changes in body composition measures with 
risk of heart failure and myocardial infarction in type 2 diabetes: findings from the 
Look AHEAD Trial. Circulation 2020;142:2420–2430. https://doi.org/10.1161/ 
CIRCULATIONAHA.120.050941
60. Wills AC, Arreola EV, Olaiya MT, Curtis JM, Hellgren MI, Hanson RL, et al. 
Cardiorespiratory fitness, BMI, mortality, and cardiovascular disease in adults with 
overweight/obesity and type 2 diabetes. Med Sci Sports Exerc 2022;54:994–1001. 
https://doi.org/10.1249/mss.0000000000002873
61. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary 
care-led weight management for remission of type 2 diabetes (DiRECT): an open- 
label, cluster-randomised trial. Lancet 2018;391:541–551. https://doi.org/10.1016/ 
S0140-6736(17)33102-1
62. Karjalainen JJ, Kiviniemi AM, Hautala AJ, Piira O-P, Lepojärvi ES, Perkiömäki JS, et al. 
Effects of physical activity and exercise training on cardiovascular risk in coronary ar­
tery disease patients with and without type 2 diabetes. Diabetes Care 2015;38: 
706–715. https://doi.org/10.2337/dc14-2216
63. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC 
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collab­
oration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular 
diseases of the European Society of Cardiology (ESC) and the European Association 
for the Study of Diabetes (EASD). Eur Heart J 2020;41:255–323. https://doi.org/10. 
1093/eurheartj/ehz486
64. Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss interven­
tion outcomes in overweight and obese adults with type 2 diabetes: a systematic re­
view and meta-analysis of randomized clinical trials. J Acad Nutr Diet 2015;115: 
1447–1463. https://doi.org/10.1016/j.jand.2015.02.031
65. Galaviz KI, Weber MB, Straus A, Haw JS, Narayan KV, Ali MK. Global diabetes preven­
tion interventions: a systematic review and network meta-analysis of the real-world 
impact on incidence, weight, and glucose. Diabetes Care 2018;41:1526–1534. https:// 
doi.org/10.2337/dc17-2222
66. Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, et al. Effects of 
weight-loss medications on cardiometabolic risk profiles: a systematic review and net­
work meta-analysis. Gastroenterology 2018;154:1309–1319.e7. https://doi.org/10. 
1053/j.gastro.2017.12.024
67. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose co­
transporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) recep­
tor agonists for type 2 diabetes: systematic review and network meta-analysis of 
randomised controlled trials. BMJ 2021;372:m4573. https://doi.org/10.1136/bmj. 
m4573
68. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. 
Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387: 
205–216. https://doi.org/10.1056/NEJMoa2206038
69. Lundgren JR, Janus C, Jensen SB, Juhl CR, Olsen LM, Christensen RM, et al. Healthy 
weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 
2021;384:1719–1730. https://doi.org/10.1056/NEJMoa2028198
70. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. 
Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375: 
311–322. https://doi.org/10.1056/NEJMoa1603827
71. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, 
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 
2117–2128. https://doi.org/10.1056/NEJMoa1504720
72. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide 
and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 
375:1834–1844. https://doi.org/10.1056/NEJMoa1607141
73. Ikramuddin S, Korner J, Lee W-J, Thomas AJ, Connett JE, Bantle JP, et al. Lifestyle inter­
vention and medical management with vs without Roux-en-Y gastric bypass and con­
trol of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the 
diabetes surgery study. JAMA 2018;319:266–278. https://doi.org/10.1001/jama.2017. 
20813
74. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial–a 
prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273: 
219–234. https://doi.org/10.1111/joim.12012
75. Carlsson LM, Sjöholm K, Jacobson P, Andersson-Assarsson JC, Svensson P-A, Taube 
M, et al. Life expectancy after bariatric surgery in the Swedish obese subjects study. 
N Engl J Med 2020;383:1535–1543. https://doi.org/10.1056/NEJMoa2002449
76. Syn NL, Cummings DE, Wang LZ, Lin DJ, Zhao JJ, Loh M, et al. Association of meta­
bolic–bariatric surgery with long-term survival in adults with and without diabetes: a 
one-stage meta-analysis of matched cohort and prospective controlled studies with 
174 772 participants. Lancet 2021;397:1830–1841. https://doi.org/10.1016/S0140- 
6736(21)00591-2
77. Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride J-E, et al. 
Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovas­
cular disease: a population-based retrospective cohort study. Circulation 2021;143: 
1468–1480. https://doi.org/10.1161/CIRCULATIONAHA.120.052386
78. Liakopoulos V, Franzén S, Svensson A-M, Miftaraj M, Ottosson J, Näslund I, et al. Pros 
and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: na­
tionwide, matched, observational cohort study. BMJ Open 2019;9:e023882. https://doi. 
org/10.1136/bmjopen-2018-023882
79. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability 
of a primary care-led weight-management intervention for remission of type 2


<!-- PAGE 79 -->

### Page 79

diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet 
Diabetes Endocrinol 2019;7:344–355. https://doi.org/10.1016/S2213-8587(19)30068-3
80. Bloomfield HE, Koeller E, Greer N, MacDonald R, Kane R, Wilt TJ. Effects on health 
outcomes of a Mediterranean diet with no restriction on fat intake: a systematic review 
and meta-analysis. Ann Intern Med 2016;165:491–500. https://doi.org/10.7326/M16- 
0361
81. Sacks FM, Lichtenstein AH, Wu JH, Appel LJ, Creager MA, Kris-Etherton PM, et al. 
Dietary fats and cardiovascular disease: a presidential advisory from the American 
Heart 
Association. 
Circulation 
2017;136:e1–e23. 
https://doi.org/10.1161/CIR. 
0000000000000510
82. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary preven­
tion of cardiovascular disease with a Mediterranean diet supplemented with extra- 
virgin olive oil or nuts. N Engl J Med 2018;378:e34. https://doi.org/10.1056/ 
NEJMoa1800389
83. Qian F, Liu G, Hu FB, Bhupathiraju SN, Sun Q. Association between plant-based diet­
ary patterns and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 
Intern Med 2019;179:1335–1344. https://doi.org/10.1001/jamainternmed.2019.2195
84. Willett W, Rockström J, Loken B, Springmann M, Lang T, Vermeulen S, et al. Food in 
the Anthropocene: the EAT–Lancet Commission on healthy diets from sustainable 
food systems. Lancet 2019;393:447–492. https://doi.org/10.1016/S0140-6736(18) 
31788-4
85. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, Quintana-Navarro GM, Fuentes F, 
Garcia-Rios A, et al. Long-term secondary prevention of cardiovascular disease with 
a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled 
trial. Lancet 2022;399:1876–1885. https://doi.org/10.1016/S0140-6736(22)00122-2
86. Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, et al. n–3 Fatty acids and 
cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367: 
309–318. https://doi.org/10.1056/NEJMoa1203859
87. ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes 
mellitus. N Engl J Med 2018;379:1540–1550. https://doi.org/10.1056/NEJMoa1804989
88. Malik VS, Li Y, Pan A, De Koning L, Schernhammer E, Willett WC, et al. Long-term 
consumption of sugar-sweetened and artificially sweetened beverages and risk of mor­
tality in US adults. Circulation 2019;139:2113–2125. https://doi.org/10.1161/ 
CIRCULATIONAHA.118.037401
89. Mullee A, Romaguera D, Pearson-Stuttard J, Viallon V, Stepien M, Freisling H, et al. 
Association between soft drink consumption and mortality in 10 European countries. 
JAMA Intern Med 2019;179:1479–1490. https://doi.org/10.1001/jamainternmed.2019. 
2478
90. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk 
thresholds for alcohol consumption: combined analysis of individual-participant data 
for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391: 
1513–1523. https://doi.org/10.1016/S0140-6736(18)30134-X
91. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, et al. Conventional and gen­
etic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 
men and women in China. Lancet 2019;393:1831–1842. https://doi.org/10.1016/ 
S0140-6736(18)31772-0
92. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association be­
tween alcohol and cardiovascular disease: Mendelian randomisation analysis based 
on individual participant data. BMJ 2014;349:g4164. https://doi.org/10.1136/bmj.g4164
93. Evangelista LS, Jose MM, Sallam H, Serag H, Golovko G, Khanipov K, et al. High-protein 
vs. standard-protein diets in overweight and obese patients with heart failure and dia­
betes mellitus: findings of the Pro-HEART trial. ESC Heart Fail 2021;8:1342–1348. 
https://doi.org/10.1002/ehf2.13213
94. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition 
therapy recommendations for the management of adults with diabetes. Diabetes Care 
2014;37(Suppl 1):S120–S143. https://doi.org/10.2337/dc14-S120
95. He FJ, Tan M, Ma Y, MacGregor GA. Salt reduction to prevent hypertension and car­
diovascular disease: JACC state-of-the-art review. J Am College Cardiol 2020;75: 
632–647. https://doi.org/10.1016/j.jacc.2019.11.055
96. Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on car­
diovascular events and death. N Engl J Med 2021;385:1067–1077. https://doi.org/10. 
1056/NEJMoa2105675
97. Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Tj A, et al. Physical activity and 
mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. 
Arch Intern Med 2012;172:1285–1295. https://doi.org/10.1001/archinternmed.2012. 
3130
98. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, et al. Quantifying the 
association between physical activity and cardiovascular disease and diabetes: a sys­
tematic review and meta-analysis. J Am Heart Assoc 2016;5:e002495. https://doi.org/ 
10.1161/JAHA.115.002495
99. Arem H, Moore SC, Patel A, Hartge P, De Gonzalez AB, Visvanathan K, et al. Leisure time 
physical activity and mortality: a detailed pooled analysis of the dose-response relationship. 
JAMA Intern Med 2015;175:959–967. https://doi.org/10.1001/jamainternmed.2015.0533
100. Hupin D, Roche F, Gremeaux V, Chatard J-C, Oriol M, Gaspoz J-M, et al. Even a low- 
dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults 
aged≥ 60 years: a systematic review and meta-analysis. Br J Sports Med 2015;49: 
1262–1267. https://doi.org/10.1136/bjsports-2014-094306
101. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, et al. Effects of 
aerobic and resistance training on hemoglobin A1c levels in patients with type 2 dia­
betes: a randomized controlled trial. JAMA 2010;304:2253–2262. https://doi.org/10. 
1001/jama.2010.1710
102. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines 
on sports cardiology and exercise in patients with cardiovascular disease: the Task 
Force on sports cardiology and exercise in patients with cardiovascular disease of 
the European Society of Cardiology (ESC). Eur Heart J 2021;42:17–96. https://doi. 
org/10.1093/eurheartj/ehaa605
103. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical 
activity/exercise and diabetes: a position statement of the American Diabetes 
Association. Diabetes Care 2016;39:2065–2079. https://doi.org/10.2337/dc16-1728
104. Ambrosetti M, Abreu A, Corrà U, Davos CH, Hansen D, Frederix I, et al. Secondary 
prevention through comprehensive cardiovascular rehabilitation: from knowledge to 
implementation. 2020 update. A position paper from the Secondary Prevention and 
Rehabilitation Section of the European Association of Preventive Cardiology. Eur J 
Prev Cardiol 2021;28:460–495. https://doi.org/10.1177/2047487320913379
105. Karstoft K, Winding K, Knudsen SH, Nielsen JS, Thomsen C, Pedersen BK, et al. The 
effects of free-living interval-walking training on glycemic control, body composition, 
and physical fitness in type 2 diabetic patients: a randomized, controlled trial. 
Diabetes Care 2013;36:228–236. https://doi.org/10.2337/dc12-0658
106. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al. 
American College of Sports Medicine position stand. Quantity and quality of exercise 
for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor 
fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports 
Exerc 2011;43:1334–1359. https://doi.org/10.1249/mss.0b013e318213fefb
107. Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise 
intensity assessment and prescription in cardiovascular rehabilitation and beyond: why 
and how: a position statement from the Secondary Prevention and Rehabilitation 
Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 
2022;29:230–245. https://doi.org/10.1093/eurjpc/zwab007
108. Kemps H, Kränkel N, Dörr M, Moholdt T, Wilhelm M, Paneni F, et al. Exercise training 
for patients with type 2 diabetes and cardiovascular disease: what to pursue and how to 
do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). 
Eur J Prev Cardiol 2019;26:709–727. https://doi.org/10.1177/2047487318820420
109. Scherr J, Wolfarth B, Christle JW, Pressler A, Wagenpfeil S, Halle M. Associations be­
tween Borg’s rating of perceived exertion and physiological measures of exercise inten­
sity. Eur J Appl Physiol 2013;113:147–155. https://doi.org/10.1007/s00421-012-2421-x
110. Kraus WE, Powell KE, Haskell WL, Janz KF, Campbell WW, Jakicic JM, et al. Physical 
activity, all-cause and cardiovascular mortality, and cardiovascular disease. Med Sci 
Sports Exerc 2019;51:1270. https://doi.org/10.1249/MSS.0000000000001939
111. Jakicic JM, Kraus WE, Powell KE, Campbell WW, Janz KF, Troiano RP, et al. Association 
between bout duration of physical activity and health: systematic review. Med Sci Sports 
Exerc 2019;51:1213. https://doi.org/10.1249/MSS.0000000000001933
112. Cradock KA, ÓLaighin G, Finucane FM, Gainforth HL, Quinlan LR, Ginis KAM. 
Behaviour change techniques targeting both diet and physical activity in type 2 dia­
betes: a systematic review and meta-analysis. Int J Behav Nutr Phys Act 2017;14:18. 
https://doi.org/10.1186/s12966-016-0436-0
113. Howlett N, Trivedi D, Troop NA, Chater AM. Are physical activity interventions for 
healthy inactive adults effective in promoting behavior change and maintenance, and 
which behavior change techniques are effective? A systematic review and 
meta-analysis. Transl Behav Med 2019;9:147–157. https://doi.org/10.1093/tbm/iby010
114. Brickwood K-J, Watson G, O’Brien J, Williams AD. Consumer-based wearable activity 
trackers increase physical activity participation: systematic review and meta-analysis. 
JMIR mHealth uHealth 2019;7:e11819. https://doi.org/10.2196/11819
115. Mannucci E, Bonifazi A, Monami M. Comparison between different types of exercise 
training in patients with type 2 diabetes mellitus: a systematic review and network me­
tanalysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2021;31: 
1985–1992. https://doi.org/10.1016/j.numecd.2021.02.030
116. Murray EM, Whellan DJ, Chen H, Bertoni AG, Duncan P, Pastva AM, et al. Physical re­
habilitation in older patients hospitalized with acute heart failure and diabetes: insights 
from REHAB-HF. Am J Med 2022;135:82–90. https://doi.org/10.1016/j.amjmed.2021. 
08.001
117. Yang Z, Scott CA, Mao C, Tang J, Farmer AJ. Resistance exercise versus aerobic exer­
cise for type 2 diabetes: a systematic review and meta-analysis. Sports Med 2014;44: 
487–499. https://doi.org/10.1007/s40279-013-0128-8
118. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in 
patients with coronary heart disease: a systematic review. JAMA 2003;290:86–97. 
https://doi.org/10.1001/jama.290.1.86
119. Choi JW, Han E, Kim TH. Association of smoking cessation after new-onset type 2 dia­
betes with overall and cause-specific mortality among Korean men: a nationwide 
population-based cohort study. BMJ Open Diabetes Res Care 2020;8:e001249. 
https://doi.org/10.1136/bmjdrc-2020-001249
ESC Guidelines                                                                                                                                                                                          4121


<!-- PAGE 80 -->

### Page 80

120. Kim MK, Han K, Kim B, Kim J, Kwon H-S. Effects of exercise initiation and smoking ces­
sation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular 
outcomes. Sci Rep 2022;12:1–9. https://doi.org/10.1038/s41598-022-14603-1
121. Jennings C, Kotseva K, De Bacquer D, Hoes A, de Velasco J, Brusaferro S, et al. 
Effectiveness of a preventive cardiology programme for high CVD risk persistent smo­
kers: the EUROACTION PLUS varenicline trial. Eur Heart J 2014;35:1411–1420. 
https://doi.org/10.1093/eurheartj/ehu051
122. Suissa K, Larivière J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety 
of smoking cessation interventions in patients with cardiovascular disease: a network 
meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10: 
e002458. https://doi.org/10.1161/CIRCOUTCOMES.115.002458
123. Gotts JE, Jordt S-E, McConnell R, Tarran R. What are the respiratory effects of 
e-cigarettes? BMJ 2019;366:l5275. https://doi.org/10.1136/bmj.l5980
124. Skotsimara G, Antonopoulos AS, Oikonomou E, Siasos G, Ioakeimidis N, Tsalamandris 
S, et al. Cardiovascular effects of electronic cigarettes: a systematic review and 
meta-analysis. Eur J Prev Cardiol 2019;26:1219–1228. https://doi.org/10.1177/ 
2047487319832975
125. Franck C, Filion KB, Eisenberg MJ. Smoking cessation in patients with acute coronary 
syndrome. Am J Cardiol 2018;121:1105–1111. https://doi.org/10.1016/j.amjcard.2018. 
01.017
126. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of in­
tensive treatment of diabetes on the development and progression of long-term com­
plications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986. 
https://doi.org/10.1056/NEJM199309303291401
127. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulpho­
nylureas or insulin compared with conventional treatment and risk of complications in 
patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853. https://doi.org/ 
10.1016/S0140-6736(98)07019-6
128. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood 
glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 
2008;358:2560–2572. https://doi.org/10.1056/NEJMoa0802987
129. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of inten­
sive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an 
analysis of the ACCORD randomised trial. Lancet 2010;376:419–430. https://doi. 
org/10.1016/S0140-6736(10)60576-4
130. Nathan DM, DCCT/EDIC Research Group. The diabetes control and complications 
trial/epidemiology of diabetes interventions and complications study at 30 years: over­
view. Diabetes Care 2014;37:9–16. https://doi.org/10.2337/dc13-2112
131. Writing Group for the DCCT/EDIC Research Group. Coprogression of cardiovascu­
lar risk factors in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC 
study. Diabetes Care 2016;39:1621–1630. https://doi.org/10.2337/dc16-0502
132. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of in­
tensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589. 
https://doi.org/10.1056/NEJMoa0806470
133. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects 
of intensive glucose control on microvascular outcomes in patients with type 2 dia­
betes: a meta-analysis of individual participant data from randomised controlled trials. 
Lancet Diabetes Endocrinol 2017;5:431–437. https://doi.org/10.1016/S2213-8587(17) 
30104-3
134. Turnbull F, Abraira C, Anderson R, Byington R, Chalmers J, Duckworth W, et al. 
Intensive glucose control and macrovascular outcomes in type 2 diabetes. 
Diabetologia 2009;52:2288–2298. https://doi.org/10.1007/s00125-009-1470-0
135. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function 
of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 
375:481–489. https://doi.org/10.1016/S0140-6736(09)61969-3
136. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper M, Colagiuri S, et al. Association of 
HbA1c levels with vascular complications and death in patients with type 2 diabetes: 
evidence of glycaemic thresholds. Diabetologia 2012;55:636–643. https://doi.org/10. 
1007/s00125-011-2404-1
137. International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and 
mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes 
Endocrinol 2019;7:385–396. https://doi.org/10.1016/S2213-8587(18)30315-2
138. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets 
for continuous glucose monitoring data interpretation: recommendations from the 
international consensus on time in range. Diabetes Care 2019;42:1593–1603. https:// 
doi.org/10.2337/dci19-0028
139. Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JC, Green JB, et al. Increased risk of 
severe hypoglycemic events before and after cardiovascular outcomes in TECOS sug­
gests an at-risk type 2 diabetes frail patient phenotype. Diabetes Care 2018;41: 
596–603. https://doi.org/10.2337/dc17-1778
140. Standl E, Stevens SR, Lokhnygina Y, Bethel MA, Buse JB, Gustavson SM, et al. 
Confirming the bidirectional nature of the association between severe hypoglycemic 
and cardiovascular events in type 2 diabetes: insights from EXSCEL. Diabetes Care 
2020;43:643–652. https://doi.org/10.2337/dc19-1079
141. Shahim B, De Bacquer D, De Backer G, Gyberg V, Kotseva K, Mellbin L, et al. The prog­
nostic value of fasting plasma glucose, two-hour postload glucose, and HbA1c in 
patients with coronary artery disease: a report from EUROASPIRE IV: a survey 
from the European Society of Cardiology. Diabetes Care 2017;40:1233–1240. 
https://doi.org/10.2337/dc17-0245
142. Hanssen NM, Kraakman MJ, Flynn MC, Nagareddy PR, Schalkwijk CG, Murphy AJ. 
Postprandial glucose spikes, an important contributor to cardiovascular disease in dia­
betes? Front Cardiovasc Med 2020;7:570553. https://doi.org/10.3389/fcvm.2020. 
570553
143. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al. Effects of prandial 
versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D 
trial. Diabetes Care 2009;32:381–386. https://doi.org/10.2337/dc08-1671
144. Kosiborod M. Hyperglycemia in acute coronary syndromes: from mechanisms to 
prognostic implications. Endocrinol Metab Clin North Am 2018;47:185–202. https:// 
doi.org/10.1016/j.ecl.2017.11.002
145. Malmberg K, Ryden L, Hamstent A, Herlitz J, Waldenström A, Wedel H. Effects of in­
sulin treatment on cause-specific one-year mortality and morbidity in diabetic patients 
with acute myocardial infarction. Eur Heart J 1996;17:1337–1344. https://doi.org/10. 
1093/oxfordjournals.eurheartj.a015067
146. Malmberg K, Rydé n L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense 
metabolic control by means of insulin in patients with diabetes mellitus and acute myo­
cardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26: 
650–661. https://doi.org/10.1093/eurheartj/ehi199
147. Caturano A, Galiero R, Pafundi PC, Cesaro A, Vetrano E, Palmiero G, et al. Does a 
strict glycemic control during acute coronary syndrome play a cardioprotective effect? 
Pathophysiology and clinical evidence. Diabetes Res Clin Practice 2021;178:108959. 
https://doi.org/10.1016/j.diabres.2021.108959
148. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A-M, Miftaraj M, et al. 
Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 
2017;376:1407–1418. https://doi.org/10.1056/NEJMoa1608664
149. Stancoven A, McGuire DK. Preventing macrovascular complications in type 2 diabetes 
mellitus: glucose control and beyond. Am J Cardiol 2007;99:S5–S11. https://doi.org/10. 
1016/j.amjcard.2007.04.005
150. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in 
patients with diabetes and chronic kidney disease. N Engl J Med 2021;384:129–139. 
https://doi.org/10.1056/NEJMoa2030186
151. Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. 
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 
2017;377:644–657. https://doi.org/10.1056/NEJMoa1611925
152. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and 
cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357. https:// 
doi.org/10.1056/NEJMoa1812389
153. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. 
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 
2019;380:2295–2306. https://doi.org/10.1056/NEJMoa1811744
154. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. 
Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 
383:1425–1435. https://doi.org/10.1056/NEJMoa2004967
155. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack S, et al. 
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients 
with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148–158. https://doi.org/10. 
1001/jamacardio.2020.4511
156. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL, et al. 2018 ACC 
expert consensus decision pathway on novel therapies for cardiovascular risk reduc­
tion in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a re­
port of the American College of Cardiology Task Force on Expert Consensus Decision 
Pathways. J Am College Cardiol 2018;72:3200–3223. https://doi.org/10.1016/j.jacc.2018. 
09.020
157. American Diabetes Association Professional Practice Committee. 10. Cardiovascular 
Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes 
Care 2022;45(Suppl 1):S144–S174. https://doi.org/10.2337/dc22-S010
158. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide 
in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373: 
2247–2257. https://doi.org/10.1056/NEJMoa1509225
159. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects 
of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 
2017;377:1228–1239. https://doi.org/10.1056/NEJMoa1612917
160. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, 
et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and 
cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo- 
controlled 
trial. 
Lancet 
2018;392:1519–1529. 
https://doi.org/10.1016/S0140- 
6736(18)32261-X
161. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. 
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double- 
blind, randomised placebo-controlled trial. Lancet 2019;394:121–130. https://doi. 
org/10.1016/S0140-6736(19)31149-3


<!-- PAGE 81 -->

### Page 81

162. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. 
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J 
Med 2019;381:841–851. https://doi.org/10.1056/NEJMoa1901118
163. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, 
et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N 
Engl J Med 2021;385:896–907. https://doi.org/10.1056/NEJMoa2108269
164. Sattar N, Lee MM, Kristensen SL, Branch KR, Del Prato S, Khurmi NS, et al. 
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in pa­
tients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. 
Lancet Diabetes Endocrinol 2021;9:653–662. https://doi.org/10.1016/S2213-8587(21) 
00203-5
165. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, 
et al. Secondary prevention of macrovascular events in patients with type 2 diabetes 
in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular 
Events): a randomised controlled trial. Lancet 2005;366:1279–1289. https://doi.org/ 
10.1016/S0140-6736(05)67528-9
166. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular 
events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. 
JAMA 2007;298:1180–1188. https://doi.org/10.1001/jama.298.10.1180
167. Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y. Pioglitazone for the primary and sec­
ondary prevention of cardiovascular and renal outcomes in patients with or at high risk 
of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab 2020;105: 
1670–1681. https://doi.org/10.1210/clinem/dgz252
168. de Jong M, van der Worp HB, van der Graaf Y, Visseren FL, Westerink J. Pioglitazone 
and the secondary prevention of cardiovascular disease. A meta-analysis of 
randomized-controlled trials. Cardiovasc Diabetol 2017;16:134. https://doi.org/10. 
1186/s12933-017-0617-4
169. Lin M-H, Yang H-Y, Yen C-L, Wu C-Y, Jenq C-C, Kuo G, et al. Pioglitazone is associated 
with lower major adverse cardiovascular and cerebrovascular events than 
DPP4-inhibitors in diabetic patients with end-stage renal disease: a Taiwan 
Nationwide Cohort Study, 2006–2016. J Clin Med 2020;9:3578. https://doi.org/10. 
3390/jcm9113578
170. Rydén L, Thráinsdóttir I, Swedberg K. Adjudication of serious heart failure in patients 
from PROactive. Lancet 2007;369:189–190. https://doi.org/10.1016/S0140-6736(07) 
60106-8
171. McGuire DK, Abdullah SM, See R, Snell PG, McGavock J, Szczepaniak LS, et al. 
Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated 
cardiovascular performance, cardiac structure, and function. Eur Heart J 2010;31: 
2262–70. https://doi.org/10.1093/eurheartj/ehq228
172. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin 
and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 
2013;369:1317–1326. https://doi.org/10.1056/NEJMoa1307684
173. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. 
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J 
Med 2013;369:1327–1335. https://doi.org/10.1056/NEJMoa1305889
174. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin 
on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232–242. 
https://doi.org/10.1056/NEJMoa1501352
175. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of 
linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and 
high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 
2019;321:69–79. https://doi.org/10.1001/jama.2018.18269
176. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart fail­
ure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 rando­
mized 
trial. 
Circulation 
2014;130:1579–1588. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.114.010389
177. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart fail­
ure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus 
placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 
385:2067–2076. https://doi.org/10.1016/S0140-6736(14)62225-X
178. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, et al. 
Association between sitagliptin use and heart failure hospitalization and related out­
comes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. 
JAMA Cardiol 2016;1:126–135. https://doi.org/10.1001/jamacardio.2016.0103
179. McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, et al. 
Linagliptin effects on heart failure and related outcomes in individuals with type 2 dia­
betes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation 2019; 
139:351–361. https://doi.org/10.1161/CIRCULATIONAHA.118.038352
180. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect 
of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with 
type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 2019;322:1155–1166. 
https://doi.org/10.1001/jama.2019.13772
181. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy 
and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377: 
723–732. https://doi.org/10.1056/NEJMoa1615692
182. Gore MO, McGuire DK. Resolving drug effects from class effects among drugs for type 
2 diabetes mellitus: more support for cardiovascular outcome assessments. Eur Heart J 
2011;32:1832–1834. https://doi.org/10.1093/eurheartj/ehr019
183. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with 
metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). 
Lancet 1998;352:854–865. https://doi.org/10.1016/S0140-6736(98)07037-8
184. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a 
meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 
2017;60:1620–1629. https://doi.org/10.1007/s00125-017-4337-9
185. Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and car­
diovascular mortality in patients with coronary artery diseases: a systematic review and 
an updated meta-analysis. Cardiovasc Diabetol 2019;18:1–16. https://doi.org/10.1186/ 
s12933-019-0900-7
186. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality 
and cardiovascular risk associated with different insulin secretagogues compared with 
metformin in type 2 diabetes, with or without a previous myocardial infarction: a na­
tionwide study. Eur Heart J 2011;32:1900–1908. https://doi.org/10.1093/eurheartj/ 
ehr077
187. Mellbin LG, Rydén L, Riddle MC, Probstfield J, Rosenstock J, Díaz R, et al. Does hypo­
glycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. 
Eur Heart J 2013;34:3137–3144. https://doi.org/10.1093/eurheartj/eht332
188. ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during 
glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. 
Diabetes Care 2015;38:22–28. https://doi.org/10.2337/dc14-1329
189. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in 
patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384: 
117–128. https://doi.org/10.1056/NEJMoa2030183
190. Tuttle KR, Brosius FC III, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJ, et al. 
SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a 
scientific workshop sponsored by the National Kidney Foundation. Diabetes 2021; 
70:1–16. https://doi.org/10.2337/dbi20-0040
191. Ferrannini G, De Bacquer D, Vynckier P, De Backer G, Gyberg V, Kotseva K, et al. 
Gender differences in screening for glucose perturbations, cardiovascular risk factor 
management and prognosis in patients with dysglycaemia and coronary artery disease: 
results from the ESC-EORP EUROASPIRE surveys. Cardiovasc Diabetol 2021;20:1–12. 
https://doi.org/10.1186/s12933-021-01233-6
192. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 
International Society of Hypertension global hypertension practice guidelines. 
Hypertension 2020;75:1334–1357. https://doi.org/10.1161/HYPERTENSIONAHA. 
120.15026
193. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ 
ESH Guidelines for the management of arterial hypertension: the Task Force for the 
management of arterial hypertension of the European Society of Cardiology (ESC) and 
the European Society of Hypertension (ESH). Eur Heart J 2018;39:3021–3104. https:// 
doi.org/10.1093/eurheartj/ehy339
194. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with 
type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and 
Bayesian random-effects meta-analyses of randomized trials. Circulation 2011;123: 
2799–2810. https://doi.org/10.1161/CIRCULATIONAHA.110.016337
195. Grenet G, Le H, Bejan-Angoulvant T, Erpeldinger S, Boussageon R, Kassaï B, et al. 
Association between difference in blood pressure reduction and risk of cardiovascular 
events in a type 2 diabetes population: a meta-regression analysis. Diabetes Metab 
2019;45:550–556. https://doi.org/10.1016/j.diabet.2019.05.003
196. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering 
in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313:603–615. 
https://doi.org/10.1001/jama.2014.18574
197. Arima H, Anderson C, Omae T, Woodward M, MacMahon S, Mancia G, et al. Degree 
of blood pressure reduction and recurrent stroke: the PROGRESS trial. J Neurol 
Neurosurg Psychiatry 2014;85:1284–1285. https://doi.org/10.1136/jnnp-2014-307856
198. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of 
low blood pressures among patients with diabetes: subgroup analyses from the 
ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global 
Endpoint Trial). J Am College Cardiol 2012;59:74–83. https://doi.org/10.1016/j.jacc. 
2011.09.040
199. Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. 
Outcomes of combined cardiovascular risk factor management strategies in type 2 dia­
betes: the ACCORD randomized trial. Diabetes Care 2014;37:1721–1728. https://doi. 
org/10.2337/dc13-2334
200. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, et al. Effects of com­
bination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563–1574. 
https://doi.org/10.1056/NEJMoa1001282
201. Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Emrich I, et al. Renal outcomes and 
blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J 
Hypertension 2021;39:766–774. https://doi.org/10.1097/HJH.0000000000002697
202. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment 
on outcome incidence in hypertension: 10–should blood pressure management differ 
ESC Guidelines                                                                                                                                                                                          4123


<!-- PAGE 82 -->

### Page 82

in hypertensive patients with and without diabetes mellitus? Overview and 
meta-analyses of randomized trials. J Hypertension 2017;35:922–944. https://doi.org/ 
10.1097/HJH.0000000000001276
203. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, et al. The influence 
of baseline diastolic blood pressure on the effects of intensive blood pressure lowering 
on cardiovascular outcomes and all-cause mortality in type 2 diabetes. Diabetes Care 
2020;43:1878–1884. https://doi.org/10.2337/dc19-2047
204. Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and 
blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for 
the prevention of cardiovascular disease and death: an individual participant-level 
data meta-analysis. Lancet 2021;398:1053–1064. https://doi.org/10.1016/S0140- 
6736(21)01921-8
205. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on 
blood pressure of reduced dietary sodium and the Dietary Approaches to Stop 
Hypertension (DASH) diet. N Engl J Med 2001;344:3–10. https://doi.org/10.1056/ 
NEJM200101043440101
206. Kastorini C-M, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. 
The effect of Mediterranean diet on metabolic syndrome and its components: a 
meta-analysis of 50 studies and 534,906 individuals. J Am College Cardiol 2011;57: 
1299–1313. https://doi.org/10.1016/j.jacc.2010.09.073
207. Toledo E, Hu FB, Estruch R, Buil-Cosiales P, Corella D, Salas-Salvadó J, et al. Effect of 
the Mediterranean diet on blood pressure in the PREDIMED trial: results from a ran­
domized controlled trial. BMC Med 2013;11:207. https://doi.org/10.1186/1741-7015- 
11-207
208. Hansen D, Niebauer J, Cornelissen V, Barna O, Neunhäuserer D, Stettler C, et al. 
Exercise prescription in patients with different combinations of cardiovascular disease 
risk factors: a consensus statement from the EXPERT Working Group. Sports Med 
2018;48:1781–1797. https://doi.org/10.1007/s40279-018-0930-4
209. Beamish AJ, Olbers T, Kelly AS, Inge TH. Cardiovascular effects of bariatric surgery. 
Nat Rev Cardiol 2016;13:730–743. https://doi.org/10.1038/nrcardio.2016.162
210. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of 
modest weight loss in improving cardiovascular risk factors in overweight and obese 
individuals with type 2 diabetes. Diabetes Care 2011;34:1481–1486. https://doi.org/ 
10.2337/dc10-2415
211. Allhat Officers and Coordinators for the Allhat Collaborative Research Group, The 
Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major out­
comes in high-risk hypertensive patients randomized to angiotensin-converting en­
zyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 
288:2981–2997. https://doi.org/10.1001/jama.288.23.2981
212. Wright JT, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, et al. 
Clinical outcomes by race in hypertensive patients with and without the metabolic syn­
drome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT). 
Arch 
Intern 
Med 
2008;168:207–217. 
https://doi.org/10.1001/ 
archinternmed.2007.66
213. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. 
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan 
Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial 
against atenolol. Lancet 2002;359:1004–1010. https://doi.org/10.1016/S0140- 
6736(02)08090-X
214. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A; CAPPP Study Group. Reduced 
cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line 
therapy with an ACE inhibitor compared with a diuretic/β-blocker–based treatment 
regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001;24: 
2091–2096. https://doi.org/10.2337/diacare.24.12.2091
215. Östergren J, Poulter NR, Sever PS, Dahlöf B, Wedel H, Beevers G, et al. The 
Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects 
in patients with type II diabetes. J Hypertension 2008;26:2103–2111. https://doi.org/ 
10.1097/HJH.0b013e328310e0d9
216. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. 
Cardiovascular events during differing hypertension therapies in patients with dia­
betes. J Am College Cardiol 2010;56:77–85. https://doi.org/10.1016/j.jacc.2010.02.046
217. Kunimura A, Himuro N, Fujiyoshi A, Segawa H, Ohnishi H, Saitoh S. The effects of re­
nin–angiotensin system inhibitors on mortality, cardiovascular events, and renal events 
in hypertensive patients with diabetes: a systematic review and meta-analysis of rando­
mized controlled trials. Hypertension Res 2019;42:669–680. https://doi.org/10.1038/ 
s41440-019-0234-6
218. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus mono­
therapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 
trials. Am J Med 2009;122:290–300. https://doi.org/10.1016/j.amjmed.2008.09.038
219. Bahiru E, de Cates AN, Farr MR, Jarvis MC, Palla M, Rees K, et al. Fixed-dose combin­
ation therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane 
Database Syst Rev 2017;3:CD009868. https://doi.org/10.1002/14651858.CD009868. 
pub3
220. Jackson AM, Jhund PS, Anand IS, Düngen H-D, Lam CS, Lefkowitz MP, et al. Sacubitril– 
valsartan as a treatment for apparent resistant hypertension in patients with heart 
failure and preserved ejection fraction. Eur Heart J 2021;42:3741–3752. https://doi. 
org/10.1093/eurheartj/ehab499
221. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of 
GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. 
Diabetes Obes Metab 2013;15:737–749. https://doi.org/10.1111/dom.12085
222. Liakos CI, Papadopoulos DP, Sanidas EA, Markou MI, Hatziagelaki EE, Grassos CA, 
et al. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhi­
bitors, GLP-1 receptor agonists, and DPP-4 inhibitors). Am J Cardiovasc Drugs 2021;21: 
123–137. https://doi.org/10.1007/s40256-020-00423-z
223. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhi­
bitors on blood pressure in people with type 2 diabetes mellitus: a systematic review 
and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart 
Assoc 2017;6:e004007. https://doi.org/10.1161/JAHA.116.004007
224. Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJ, Agarwal R, et al. Blood pres­
sure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney 
disease: insights from the CREDENCE trial. Circulation 2021;143:1735–1749. https:// 
doi.org/10.1161/CIRCULATIONAHA.120.048740
225. Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. 24-hour blood 
pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncon­
trolled nocturnal hypertension: results from the randomized, placebo-controlled 
SACRA 
study. 
Circulation 
2019;139:2089–2097. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.118.037076
226. Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibi­
tors: dose-response meta-analysis and comparative evaluation with low-dose hydro­
chlorothiazide. Diabetes Care 2019;42:693–700. https://doi.org/10.2337/dc18-2207
227. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cifkova 
R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular dis­
eases during pregnancy: the task force for the management of cardiovascular diseases 
during pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2018;39: 
3165–3241. https://doi.org/10.1093/eurheartj/ehy340
228. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. 
Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management 
recommendations for international practice. Hypertension 2018;72:24–43. https://doi. 
org/10.1161/HYPERTENSIONAHA.117.10803
229. Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for 
mild chronic hypertension during pregnancy. N Engl J Med 2022;386:1781–1792. 
https://doi.org/10.1056/NEJMoa2201295
230. Wright AK, Welsh P, Gill JM, Kontopantelis E, Emsley R, Buchan I, et al. Age-, sex-and 
ethnicity-related differences in body weight, blood pressure, HbA1c and lipid levels at 
the diagnosis of type 2 diabetes relative to people without diabetes. Diabetologia 2020; 
63:1542–1553. https://doi.org/10.1007/s00125-020-05169-6
231. Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, et al. Sex differences in 
arterial hypertension: a scientific statement from the ESC Council on Hypertension, 
the European Association of Preventive Cardiology, Association of Cardiovascular 
Nursing and Allied Professions, the ESC Council for Cardiology Practice, and the 
ESC Working Group on Cardiovascular Pharmacotherapy. Eur Heart J 2022;43: 
4777–4788. https://doi.org/10.1093/eurheartj/ehac470
232. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, aware­
ness, treatment, and control of hypertension in rural and urban communities in high-, 
middle-, and low-income countries. JAMA 2013;310:959–968. https://doi.org/10.1001/ 
jama.2013.184182
233. Lindholt JS, Søgaard R. Population screening and intervention for vascular disease in 
Danish men (VIVA): a randomised controlled trial. Lancet 2017;390:2256–2265. 
https://doi.org/10.1016/S0140-6736(17)32250-X
234. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on out­
come incidence in hypertension: 7. Effects of more vs. less intensive blood pressure 
lowering and different achieved blood pressure levels–updated overview and 
meta-analyses of randomized trials. J Hypertension 2016;34:613–622. https://doi.org/ 
10.1097/HJH.0000000000000881
235. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on out­
come incidence in hypertension: 1. Overview, meta-analyses, and meta-regression 
analyses of randomized trials. J Hypertension 2014;32:2285–2295. https://doi.org/10. 
1097/HJH.0000000000000378
236. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al. Follow-up of blood- 
pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371: 
1392–1406. https://doi.org/10.1056/NEJMoa1407963
237. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, et al. 
Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: 
systematic review and meta-analysis. Arch Intern Med 2012;172:1296–1303. https://doi. 
org/10.1001/archinternmed.2012.3147
238. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood 
pressure lowering on cardiovascular and renal outcomes: updated systematic review 
and meta-analysis. Lancet 2016;387:435–443. https://doi.org/10.1016/S0140-6736(15) 
00805-3


<!-- PAGE 83 -->

### Page 83

239. Mancia G, Grassi G. Blood pressure targets in type 2 diabetes. Evidence against or in 
favour of an aggressive approach. Diabetologia 2018;61:517–525. https://doi.org/10. 
1007/s00125-017-4537-3
240. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. 
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 
2010;362:1575–1585. https://doi.org/10.1056/NEJMoa1001286
241. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al. Renal outcomes 
with different fixed-dose combination therapies in patients with hypertension at high 
risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a 
randomised controlled trial. Lancet 2010;375:1173–1181. https://doi.org/10.1016/ 
S0140-6736(09)62100-0
242. McManus RJ, Mant J, Franssen M, Nickless A, Schwartz C, Hodgkinson J, et al. Efficacy of 
self-monitored blood pressure, with or without telemonitoring, for titration of antihy­
pertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet 
2018;391:949–959. https://doi.org/10.1016/S0140-6736(18)30309-X
243. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated 
with selective and combined elevation in office, home, and ambulatory blood pressure. 
Hypertension 2006;47:846–853. https://doi.org/10.1161/01.HYP.0000215363.69793.bb
244. Chiesa ST, Charakida M, McLoughlin E, Nguyen HC, Georgiopoulos G, Motran L, et al. 
Elevated high-density lipoprotein in adolescents with type 1 diabetes is associated with 
endothelial dysfunction in the presence of systemic inflammation. Eur Heart J 2019;40: 
3559–3566. https://doi.org/10.1093/eurheartj/ehz114
245. Chait A, Goldberg I. Treatment of dyslipidemia in diabetes: recent advances and re­
maining questions. Curr Diab Rep 2017;17:112. https://doi.org/10.1007/s11892-017- 
0942-8
246. Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, De Boer IH, et al. Update on 
prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light 
of recent evidence: a scientific statement from the American Heart Association and 
the American Diabetes Association. Circulation 2015;132:691–718. https://doi.org/ 
10.1161/CIR.0000000000000230
247. Cholesterol Treatment Trialists’ (CTT) Collaboration. The effects of lowering LDL 
cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis 
of individual data from 27 randomised trials. Lancet 2012;380:581–590. https://doi.org/ 
10.1016/S0140-6736(12)60367-5
248. Cholesterol Treatment Trialists’ (CTT) Collaboration; Kearney P, Blackwell L, Collins 
R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18 686 people 
with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371: 
117–125. https://doi.org/10.1016/S0140-6736(08)60104-X
249. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of 
LDL-lowering therapy among men and women: meta-analysis of individual data 
from 174 000 participants in 27 randomised trials. Lancet 2015;385:1397–1405. 
https://doi.org/10.1016/S0140-6736(14)61368-4
250. Jones P, Kafonek S, Hunninghake D. Comparative dose efficacy study of atorvastatin 
versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholes­
terolemia (the CURVES study). Am J Cardiol 1998;81:582–587. https://doi.org/10.1016/ 
S0002-9149(97)00965-X
251. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk 
of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 
2010;375:735–742. https://doi.org/10.1016/S0140-6736(09)61965-6
252. Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, et al. Statin use 
and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ 
Open Diabetes Res Care 2017;5:e000438. https://doi.org/10.1136/bmjdrc-2017- 
000438
253. Hero C, Rawshani A, Svensson A-M, Franzén S, Eliasson B, Eeg-Olofsson K, et al. 
Association between use of lipid-lowering therapy and cardiovascular diseases and 
death in individuals with type 1 diabetes. Diabetes Care 2016;39:996–1003. https:// 
doi.org/10.2337/dc15-2450
254. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative 
Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 
5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 
2005–2016. https://doi.org/10.1016/S0140-6736(03)13636-7
255. Marcovecchio ML, Chiesa ST, Bond S, Daneman D, Dawson S, Donaghue KC, et al. 
ACE inhibitors and statins in adolescents with type 1 diabetes. N Engl J Med 2017; 
377:1733–1745. https://doi.org/10.1056/NEJMoa1703518
256. Moon J, Cohen Sedgh R, Jackevicius CA. Examining the nocebo effect of statins 
through statin adverse events reported in the food and drug administration adverse 
event reporting system. Circ Cardiovasc Quality Outcomes 2021;14:e007480. https:// 
doi.org/10.1161/CIRCOUTCOMES.120.007480
257. Reston JT, Buelt A, Donahue MP, Neubauer B, Vagichev E, McShea K. Interventions to 
improve statin tolerance and adherence in patients at risk for cardiovascular disease: a 
systematic review for the 2020 US Department of Veterans Affairs and US 
Department of Defense Guidelines for Management of Dyslipidemia. Ann Intern 
Med 2020;173:806–812. https://doi.org/10.7326/M20-4680
258. Ali AH, Younis N, Abdallah R, Shaer F, Dakroub A, Ayoub MA, et al. Lipid-lowering 
therapies for atherosclerosis: statins, fibrates, ezetimibe and PCSK9 monoclonal 
antibodies. 
Curr 
Med 
Chem 
2021;28:7427–7445. 
https://doi.org/10.2174/ 
0929867328666210222092628
259. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. 
Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 
2015;372:2387–2397. https://doi.org/10.1056/NEJMoa1410489
260. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, et al. Benefit of 
adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients 
with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction 
of Outcomes: Vytorin Efficacy International Trial). Circulation 2018;137:1571–1582. 
https://doi.org/10.1161/CIRCULATIONAHA.117.030950
261. Semova I, Levenson AE, Krawczyk J, Bullock K, Williams KA, Wadwa RP, et al. Type 1 
diabetes is associated with an increase in cholesterol absorption markers but a de­
crease in cholesterol synthesis markers in a young adult population. J Clin Lipidol 
2019;13:940–946. https://doi.org/10.1016/j.jacl.2019.09.008
262. Durairaj A, Sabates A, Nieves J, Moraes B, Baum S. Proprotein convertase subtilisin/ 
kexin type 9 (PCSK9) and its inhibitors: a review of physiology, biology, and clinical 
data. Curr Treat Options Cardiovasc Med 2017;19:58. https://doi.org/10.1007/s11936- 
017-0556-0
263. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. 
Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J 
Med 2017;376:1713–1722. https://doi.org/10.1056/NEJMoa1615664
264. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and 
cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379: 
2097–2107. https://doi.org/10.1056/NEJMoa1801174
265. Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, et al. 
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary 
results of the randomised controlled BANTING study. Diabetologia 2019;62:948–958. 
https://doi.org/10.1007/s00125-019-4856-7
266. Lorenzatti AJ, Monsalvo ML, López JAG, Wang H, Rosenson RS. Effects of evolocumab 
in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an ana­
lysis from BANTING and BERSON. Cardiovasc Diabetol 2021;20:94. https://doi.org/10. 
1186/s12933-021-01287-6
267. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and 
efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380: 
1022–1032. https://doi.org/10.1056/NEJMoa1803917
268. Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, et al. 
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low 
high-density lipoprotein cholesterol. Cardiovasc Diabetol 2020;19:14. https://doi.org/ 
10.1186/s12933-020-0991-1
269. Khan SU, Rahman H, Okunrintemi V, Riaz H, Khan MS, Sattur S, et al. Association of 
lowering low-density lipoprotein cholesterol with contemporary lipid-lowering ther­
apies and risk of diabetes mellitus: a systematic review and meta-analysis. J Am Heart 
Assoc 2019;8:e011581. https://doi.org/10.1161/JAHA.118.011581
270. Scott R, O’Brien R, Fulcher G, Pardy C, d’Emden M, Tse D, et al. Effects of fenofibrate 
treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and 
various components of the metabolic syndrome: the Fenofibrate Intervention and 
Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493–498. https:// 
doi.org/10.2337/dc08-1543
271. Bruckert E, Labreuche J, Deplanque D, Touboul P-J, Amarenco P. Fibrates effect on 
cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dys­
lipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011; 
57:267–272. https://doi.org/10.1097/FJC.0b013e318202709f
272. Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPARα modulator: 
drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr 
Atheroscler Rep 2020;22:5. https://doi.org/10.1007/s11883-020-0823-5
273. Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, et al. Rationale 
and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing 
Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J 2018;206: 
80–93. https://doi.org/10.1016/j.ahj.2018.09.011
274. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. 
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J 
Med 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792
275. Olshansky B, Chung MK, Budoff MJ, Philip S, Jiao L, Doyle J, et al. Mineral oil: safety and 
use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl 2020;22­
(Suppl J):J34–J48. https://doi.org/10.1093/eurheartj/suaa117
276. Steg PG, Bhatt DL. The reduction in cardiovascular risk in REDUCE-IT is due to eicosa­
pentaenoic acid in icosapent ethyl. Eur Heart J 2021;42:4865–4866. https://doi.org/10. 
1093/eurheartj/ehab760
277. Warden BA, Duell PB. Inclisiran: a novel agent for lowering apolipoprotein B–contain­
ing lipoproteins. J Cardiovasc Pharmacol 2021;78:e157–e174. https://doi.org/10.1097/ 
FJC.0000000000001053
278. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of 
inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507–1519. 
https://doi.org/10.1056/NEJMoa1912387
ESC Guidelines                                                                                                                                                                                          4125


<!-- PAGE 84 -->

### Page 84

279. ClinicalTrials.gov. A Randomized Trial Assessing the Effects of Inclisiran on Clinical 
Outcomes among People with Cardiovascular Disease (ORION-4). https://clinicaltrials. 
gov/ct2/show/NCT03705234 (19 April 2022)
280. Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific 
ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates ath­
erosclerosis. Nat Commun 2016;7:13457. https://doi.org/10.1038/ncomms13457
281. Masson W, Lobo M, Lavalle-Cobo A, Masson G, Molinero G. Effect of bempedoic acid 
on new onset or worsening diabetes: a meta-analysis. Diabetes Res Clin Practice 2020; 
168:108369. https://doi.org/10.1016/j.diabres.2020.108369
282. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJ, et al. Bempedoic acid 
and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;388: 
1353–1364. https://doi.org/10.1056/NEJMoa2215024
283. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, et al. 
Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein 
B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin 
Chem 2009;55:473–480. https://doi.org/10.1373/clinchem.2008.111401
284. Thanassoulis G, Williams K, Ye K, Brook R, Couture P, Lawler PR, et al. Relations of 
change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from sta­
tin therapy: a meta-analysis of randomized trials. J Am Heart Assoc 2014;3:e000759. 
https://doi.org/10.1161/JAHA.113.000759
285. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B 
and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin- 
treated patients. J Am College Cardiol 2021;77:1439–1450. https://doi.org/10.1016/j. 
jacc.2021.01.027
286. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, et al. Effects 
of alirocumab on cardiovascular and metabolic outcomes after acute coronary syn­
drome in patients with or without diabetes: a prespecified analysis of the ODYSSEY 
OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 2019;7: 
618–628. https://doi.org/10.1016/S2213-8587(19)30158-5
287. Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, et al. 
Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: 
design of the goal achievement after utilizing an anti-PCSK9 antibody in 
statin-intolerant subjects 3 (GAUSS-3) trial. Clin Cardiol 2016;39:137–144. https:// 
doi.org/10.1002/clc.22518
288. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy 
and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechal­
lenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015;9: 
758–769. https://doi.org/10.1016/j.jacl.2015.08.006
289. Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: a therapeutic 
target for the reduction of cardiovascular risk. Cardiovasc Diabetol 2017;16:1–17. 
https://doi.org/10.1186/s12933-017-0515-9
290. Rocca B, Patrono C. Aspirin in the primary prevention of cardiovascular disease in dia­
betes mellitus: a new perspective. Diabetes Res Clin Practice 2020;160:108008. https:// 
doi.org/10.1016/j.diabres.2020.108008
291. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the 
primary and secondary prevention of vascular disease: collaborative meta-analysis of 
individual participant data from randomised trials. Lancet 2009;373:1849–1860. 
https://doi.org/10.1016/S0140-6736(09)60503-1
292. ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in per­
sons with diabetes mellitus. N Engl J Med 2018;379:1529–1539. https://doi.org/10. 
1056/NEJMoa1804988
293. Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D, et al. Fixed-dose combination 
therapies with and without aspirin for primary prevention of cardiovascular disease: an 
individual participant data meta-analysis. Lancet 2021;398:1133–1146. https://doi.org/ 
10.1016/S0140-6736(21)01827-4
294. Parish S, Mafham M, Offer A, Barton J, Wallendszus K, Stevens W, et al. Effects of as­
pirin on dementia and cognitive function in diabetic patients: the ASCEND trial. Eur 
Heart J 2022;43:2010–2019. https://doi.org/10.1093/eurheartj/ehac179
295. Cainzos-Achirica M, Miedema MD, McEvoy JW, Al Rifai M, Greenland P, Dardari Z, 
et al. Coronary artery calcium for personalized allocation of aspirin in primary preven­
tion of cardiovascular disease in 2019: the MESA Study (Multi-Ethnic Study of 
Atherosclerosis). 
Circulation 
2020;141:1541–1553. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.119.045010
296. Lindholt JS, Søgaard R, Rasmussen LM, Mejldal A, Lambrechtsen J, Steffensen FH, et al. 
Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) trial. N 
Engl J Med 2022;387:1385–1394. https://doi.org/10.1056/NEJMoa2208681
297. Denissen SJ, Van Der Aalst CM, Vonder M, Gratama JWC, Adriaansen HJ, Kuijpers D, 
et al. Screening for coronary artery calcium in a high-risk population: the ROBINSCA 
trial. Eur J Prev Cardiol 2021;28:1155–1159. https://doi.org/10.1177/204748732093 
2263
298. Marwick TH, Whitmore K, Nicholls SJ, Stanton T, Mitchell G, Tonkin A, et al. Rationale 
and design of a trial to personalize risk assessment in familial coronary artery disease. 
Am Heart J 2018;199:22–30. https://doi.org/10.1016/j.ahj.2017.09.011
299. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 
ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the 
Task Force for the diagnosis and management of chronic coronary syndromes of the 
European Society of Cardiology (ESC). Eur Heart J 2020;41:407–477. https://doi.org/ 
10.1093/eurheartj/ehz425
300. Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, et al. Comparative 
effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med 2021;384: 
1981–1990. https://doi.org/10.1056/NEJMoa2102137
301. Current-Oasis 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute 
coronary syndromes. N Engl J Med 2010;363:930–942. https://doi.org/10.1056/ 
NEJMoa0909475
302. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in pa­
tients with stable coronary disease and diabetes. N Engl J Med 2019;381:1309–1320. 
https://doi.org/10.1056/NEJMoa1908077
303. Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, et al. Ticagrelor in patients 
with diabetes and stable coronary artery disease with a history of previous percutan­
eous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised 
trial. Lancet 2019;394:1169–1180. https://doi.org/10.1016/S0140-6736(19)31887-2
304. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. 
Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 
2017;377:1319–1330. https://doi.org/10.1056/NEJMoa1709118
305. Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, et al. Role of com­
bination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascu­
lar disease: insights from the COMPASS trial. Circulation 2020;141:1841–1854. https:// 
doi.org/10.1161/CIRCULATIONAHA.120.046448
306. Lu H, Guan W, Zhou Y, Tang Z, Bao H. Cangrelor or clopidogrel in patients with type 
2 diabetes mellitus undergoing percutaneous coronary intervention: a meta-analysis of 
randomized controlled trials. Diabetes Ther 2019;10:937–950. https://doi.org/10.1007/ 
s13300-019-0593-7
307. Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, et al. Efficacy and 
safety of cangrelor in preventing periprocedural complications in patients with stable 
angina and acute coronary syndromes undergoing percutaneous coronary interven­
tion: the CHAMPION PHOENIX trial. JACC Cardiovasc Interv 2016;9:1905–1913. 
https://doi.org/10.1016/j.jcin.2016.06.046
308. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 
2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40: 
87–165. https://doi.org/10.1093/eurheartj/ehy394
309. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, et al. Ticagrelor vs. 
clopidogrel in patients with acute coronary syndromes and diabetes: a substudy 
from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 
2010;31:3006–3016. https://doi.org/10.1093/eurheartj/ehq325
310. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. 
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J 
Med 2007;357:2001–2015. https://doi.org/10.1056/NEJMoa0706482
311. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor 
versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 
1045–1057. https://doi.org/10.1056/NEJMoa0904327
312. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et al. Greater 
clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients 
with diabetes mellitus in the trial to assess improvement in therapeutic outcomes 
by optimizing platelet inhibition with prasugrel–Thrombolysis in Myocardial 
Infarction 
38. 
Circulation 
2008;118:1626–1636. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.108.791061
313. Schüpke S, Neumann F-J, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. 
Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 
2019;381:1524–1534. https://doi.org/10.1056/NEJMoa1908973
314. Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, et al. 
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome 
with or without revascularization: results from the PLATO trial. Eur Heart J 2014;35: 
2083–2093. https://doi.org/10.1093/eurheartj/ehu160
315. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the 
combination of clopidogrel and aspirin in patients undergoing surgical revascularization 
for non–ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to 
prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202–1208. 
https://doi.org/10.1161/01.CIR.0000140675.85342.1B
316. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin 
for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopi­
dogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months 
after implantation of a drug-eluting stent: a multicentre, open-label, randomised 
superiority trial. Lancet 2018;392:940–949. https://doi.org/10.1016/S0140-6736(18) 
31858-0
317. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of 
ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372: 
1791–1800. https://doi.org/10.1056/NEJMoa1500857
318. Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, et al. Dual antiplatelet 
therapy after percutaneous coronary intervention and drug-eluting stents: a systemat­
ic review and network meta-analysis. Circulation 2020;142:1425–1436. https://doi.org/ 
10.1161/CIRCULATIONAHA.120.046308


<!-- PAGE 85 -->

### Page 85

319. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in 
ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in 
PEGASUS–TIMI 54. J Am College Cardiol 2016;67:2732–2740. https://doi.org/10.1016/j. 
jacc.2016.03.529
320. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de- 
escalation of antiplatelet treatment in patients with acute coronary syndrome under­
going percutaneous coronary intervention (TROPICAL-ACS): a randomised, open- 
label, multicentre trial. Lancet 2017;390:1747–1757. https://doi.org/10.1016/S0140- 
6736(17)32155-4
321. Hein R, Gross L, Aradi D, Rieber J, Hadamitzky M, Merkely B, et al. Diabetes and out­
comes following guided de-escalation of antiplatelet treatment in acute coronary syn­
drome patients undergoing percutaneous coronary intervention: a pre-specified 
analysis from the randomised TROPICAL-ACS trial. EuroIntervention 2019;15: 
e513–e521. https://doi.org/10.4244/EIJ-D-18-01077
322. Collet J-P, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring 
to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367: 
2100–2109. https://doi.org/10.1056/NEJMoa1209979
322a. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, et al.; 
ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet ther­
apy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an 
open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016; 
388:2015–2022. https://doi.10.1016/S0140-6736(16)31323-X
323. Erlinge D, Varenhorst C, Braun OÖ, James S, Winters KJ, Jakubowski JA, et al. Patients 
with poor responsiveness to thienopyridine treatment or with diabetes have lower le­
vels of circulating active metabolite, but their platelets respond normally to active me­
tabolite added ex vivo. J Am College Cardiol 2008;52:1968–1977. https://doi.org/10. 
1016/j.jacc.2008.07.068
324. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OÖ, Jakubowski JA, et al. 
Prasugrel achieves greater and faster P2Y 12 receptor-mediated platelet inhibition 
than clopidogrel due to more efficient generation of its active metabolite in aspirin- 
treated patients with coronary artery disease. Eur Heart J 2008;29:21–30. https:// 
doi.org/10.1093/eurheartj/ehm545
325. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised 
trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke 
in high risk patients. BMJ 2002;324:71–86. https://doi.org/10.1136/bmj.324.7329.71
326. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of 
antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by pro­
longed antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106. 
https://doi.org/10.1136/bmj.308.6943.1540
327. Gwon H-C, Hahn J-Y, Park KW, Song YB, Chae I-H, Lim D-S, et al. Six-month versus 
12-month dual antiplatelet therapy after implantation of drug-eluting stents: the 
Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting 
(EXCELLENT) randomized, multicenter study. Circulation 2012;125:505–513. 
https://doi.org/10.1161/CIRCULATIONAHA.111.059022
328. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. 
Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: 
a randomized multicenter trial. Circulation 2012;125:2015–2026. https://doi.org/10. 
1161/CIRCULATIONAHA.111.071589
329. Schulz-Schüpke S, Byrne RA, Ten Berg JM, Neumann F-J, Han Y, Adriaenssens T, et al. 
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of 
clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252–1263. https:// 
doi.org/10.1093/eurheartj/ehu523
330. Han Y, Xu B, Xu K, Guan C, Jing Q, Zheng Q, et al. Six versus 12 months of dual anti­
platelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: 
randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv 2016;9:e003145. 
https://doi.org/10.1161/CIRCINTERVENTIONS.115.003145
331. Hong S-J, Shin D-H, Kim J-S, Kim B-K, Ko Y-G, Choi D, et al. 6-month versus 12-month 
dual-antiplatelet therapy following long everolimus-eluting stent implantation: the 
IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv 2016;9:1438–1446. https:// 
doi.org/10.1016/j.jcin.2016.04.036
332. Byrne RA, Neumann F-J, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al. Paclitaxel-eluting 
balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis 
after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label 
trial. Lancet 2013;381:461–467. https://doi.org/10.1016/S0140-6736(12)61964-3
333. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin 
in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–1339. https:// 
doi.org/10.1016/S0140-6736(96)09457-3
334. Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, et al. Effect of ticagrelor plus aspirin, 
ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary 
artery bypass grafting: a randomized clinical trial. JAMA 2018;319:1677–1686. https:// 
doi.org/10.1001/jama.2018.3197
335. Held C, Åsenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, et al. Ticagrelor 
versus clopidogrel in patients with acute coronary syndromes undergoing coronary ar­
tery bypass surgery: results from the PLATO (Platelet Inhibition and Patient 
Outcomes) trial. J Am College Cardiol 2011;57:672–684. https://doi.org/10.1016/j.jacc. 
2010.10.029
336. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve 
or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 
371:2155–2166. https://doi.org/10.1056/NEJMoa1409312
337. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and 
combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: 
population based case-control study. BMJ 2006;333:726. https://doi.org/10.1136/bmj. 
38947.697558.AE
338. Han Y, Liao Z, Li Y, Zhao X, Ma S, Bao D, et al. Magnetically controlled capsule endos­
copy for assessment of antiplatelet therapy-induced gastrointestinal injury. J Am College 
Cardiol 2022;79:116–128. https://doi.org/10.1016/j.jacc.2021.10.028
339. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic 
therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 
380:1509–1524. https://doi.org/10.1056/NEJMoa1817083
340. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. 
Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J 
Med 2016;375:2423–2434. https://doi.org/10.1056/NEJMoa1611594
341. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. 
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after suc­
cessful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a ran­
domised, open-label, phase 3b trial. Lancet 2019;394:1335–1343. https://doi.org/10. 
1016/S0140-6736(19)31872-0
342. Cannon CP, Bhatt DL, Oldgren J, Lip GY, Ellis SG, Kimura T, et al. Dual antithrombotic 
therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377: 
1513–1524. https://doi.org/10.1056/NEJMoa1708454
343. Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet J-P, et al. Revisiting 
the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrilla­
tion and acute coronary syndromes or percutaneous coronary interventions: 
meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and 
AUGUSTUS trials. Europace 2020;22:33–46. https://doi.org/10.1093/europace/ 
euz259
344. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and ef­
ficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fib­
rillation following percutaneous coronary intervention: a systematic review and 
meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical 
trials. Eur Heart J 2019;40:3757–3767. https://doi.org/10.1093/eurheartj/ehz732
345. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman J-P, et al. Use 
of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and 
undergoing percutaneous coronary intervention: an open-label, randomised, con­
trolled trial. Lancet 2013;381:1107–1115. https://doi.org/10.1016/S0140-6736(12) 
62177-1
346. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al. 
Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 
2016;375:35–43. https://doi.org/10.1056/NEJMoa1603060
347. Soriano LC, Fowkes FGR, Allum AM, Johansson S, Rodriguez LAG. Predictors of 
bleeding in patients with symptomatic peripheral artery disease: a cohort study using 
the health improvement network in the United Kingdom. Thromb Haemost 2018;118: 
1101–1112. https://doi.org/10.1055/s-0038-1646923
348. Lanas A, García-Rodríguez L-A, Arroyo M-T, Gomollón F, Feu F, González-Pérez A, 
et al. Risk of upper gastrointestinal ulcer bleeding associated with selective 
cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory 
drugs, aspirin and combinations. Gut 2006;55:1731–1738. https://doi.org/10.1136/ 
gut.2005.080754
349. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable 
Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of clopidogrel 
in addition to aspirin in patients with acute coronary syndromes without ST-segment 
elevation. N Engl J Med 2001;345:494–502. https://doi.org/10.1056/NEJMoa010746
350. Gaist D, Rodríguez LAG, Hellfritzsch M, Poulsen FR, Halle B, Hallas J, et al. Association 
of antithrombotic drug use with subdural hematoma risk. JAMA 2017;317:836–846. 
https://doi.org/10.1001/jama.2017.0639
351. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastropro­
tectant drugs for the prevention and treatment of peptic ulcer disease and its compli­
cations: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3: 
231–241. https://doi.org/10.1016/S2468-1253(18)30037-2
352. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. 
Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban 
and/or 
aspirin 
in 
a 
randomized, 
double-blind, 
placebo-controlled 
trial. 
Gastroenterology 2019;157:403–412. https://doi.org/10.1053/j.gastro.2019.04.041
353. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. 
Association of proton pump inhibitors with reduced risk of warfarin-related serious 
upper gastrointestinal bleeding. Gastroenterology 2016;151:1105–1112.e10. https:// 
doi.org/10.1053/j.gastro.2016.08.054
354. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety 
of proton pump inhibitors based on a large, multi-year, randomized trial of patients 
receiving rivaroxaban or aspirin. Gastroenterology 2019;157:682–691.e2. https://doi. 
org/10.1053/j.gastro.2019.05.056
ESC Guidelines                                                                                                                                                                                          4127


<!-- PAGE 86 -->

### Page 86

355. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. 
Association of oral anticoagulants and proton pump inhibitor cotherapy with hospital­
ization for upper gastrointestinal tract bleeding. JAMA 2018;320:2221–2230. https:// 
doi.org/10.1001/jama.2018.17242
356. Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C, et al. Combination use of clopi­
dogrel and proton pump inhibitors increases major adverse cardiovascular events in 
patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Therap 
2017;22:142–152. https://doi.org/10.1177/1074248416663647
357. Yang R, Xu H, Pedersen NL, Li X, Yu J, Bao C, et al. A healthy lifestyle mitigates the risk 
of heart disease related to type 2 diabetes: a prospective nested case-control study in a 
nationwide Swedish twin cohort. Diabetologia 2021;64:530–539. https://doi.org/10. 
1007/s00125-020-05324-z
358. Mancini GJ, Maron DJ, Hartigan PM, Spertus JA, Kostuk WJ, Berman DS, et al. Lifestyle, 
glycosylated hemoglobin A1c, and survival among patients with stable ischemic heart 
disease and diabetes. J Am College Cardiol 2019;73:2049–2058. https://doi.org/10.1016/ 
j.jacc.2018.11.067
359. Magliano DJ, Chen L, Carstensen B, Gregg EW, Pavkov ME, Salim A, et al. Trends in 
all-cause mortality among people with diagnosed diabetes in high-income settings: a 
multicountry analysis of aggregate data. Lancet Diabetes Endocrinol 2022;10: 
112–119. https://doi.org/10.1016/S2213-8587(21)00327-2
360. Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson A-M, et al. Risk fac­
tors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J 
Med 2018;379:633–644. https://doi.org/10.1056/NEJMoa1800256
361. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial inter­
vention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–591. https://doi. 
org/10.1056/NEJMoa0706245
362. Oellgaard J, Gæde P, Rossing P, Rørth R, Køber L, Parving H-H, et al. Reduced risk of 
heart failure with intensified multifactorial intervention in individuals with type 2 dia­
betes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. 
Diabetologia 2018;61:1724–1733. https://doi.org/10.1007/s00125-018-4642-y
363. Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving H-H, et al. 
Years of life gained by multifactorial intervention in patients with type 2 diabetes mel­
litus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. 
Diabetologia 2016;59:2298–2307. https://doi.org/10.1007/s00125-016-4065-6
364. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, et al. Effect of 
early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals 
with type 2 diabetes detected by screening (ADDITION-Europe): a cluster- 
randomised trial. Lancet 2011;378:156–167. https://doi.org/10.1016/S0140-6736(11) 
60698-3
365. Griffin SJ, Rutten GE, Khunti K, Witte DR, Lauritzen T, Sharp SJ, et al. Long-term effects 
of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in 
primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. 
Lancet Diabetes Endocrinol 2019;7:925–937. https://doi.org/10.1016/S2213-8587(19) 
30349-3
366. Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, et al. Effect of an in­
tensified multifactorial intervention on cardiovascular outcomes and mortality in 
type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet 
Diabetes Endocrinol 2017;5:951–964. https://doi.org/10.1016/S2213-8587(17)30327-3
367. Ferrannini G, De Bacquer D, De Backer G, Kotseva K, Mellbin L, Wood D, et al. 
Screening for glucose perturbations and risk factor management in dysglycemic pa­
tients with coronary artery disease—a persistent challenge in need of substantial im­
provement: a report from ESC EORP EUROASPIRE V. Diabetes Care 2020;43: 
726–733. https://doi.org/10.2337/dc19-2165
368. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. 
Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387: 
967–977. https://doi.org/10.1056/NEJMoa2208275
369. Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly 
diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. Diabetes 
Obes Metab 2018;20:497–507. https://doi.org/10.1111/dom.13108
370. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification 
with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus 
therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes 
Endocrinol 2014;2:30–37. https://doi.org/10.1016/S2213-8587(13)70090-1
371. Balducci S, D’Errico V, Haxhi J, Sacchetti M, Orlando G, Cardelli P, et al. Effect of a be­
havioral intervention strategy on sustained change in physical activity and sedentary be­
havior in patients with type 2 diabetes: the IDES_2 randomized clinical trial. JAMA 2019; 
321:880–890. https://doi.org/0.1001/jama.2019.0922
372. Astin F, Lucock M, Jennings CS. Heart and mind: behavioural cardiology demystified for 
the clinician. Heart 2019;105:881–888. https://doi.org/10.1136/heartjnl-2016-310750
373. Zulman DM, Haverfield MC, Shaw JG, Brown-Johnson CG, Schwartz R, Tierney AA, 
et al. Practices to foster physician presence and connection with patients in the clinical 
encounter. JAMA 2020;323:70–81. https://doi.org/10.1001/jama.2019.19003
374. Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol 2009; 
64:527. https://doi.org/10.1037/a0016830
375. Kim J, Hur M-H. The effects of dietary education interventions on individuals with type 
2 diabetes: a systematic review and meta-analysis. Int J Environ Res Public Health 2021; 
18:8439. https://doi.org/10.3390/ijerph18168439
376. Hennein R, Hwang SJ, Au R, Levy D, Muntner P, Fox CS, et al. Barriers to medication 
adherence and links to cardiovascular disease risk factor control: the Framingham 
Heart Study. Intern Med J 2018;48:414–421. https://doi.org/10.1111/imj.13687
377. Goldstein CM, Gathright EC, Garcia S. Relationship between depression and medica­
tion adherence in cardiovascular disease: the perfect challenge for the integrated care 
team. Patient Prefer Adherence 2017;11:547–559. https://doi.org/10.2147/PPA. 
S127277
378. Palmer MJ, Machiyama K, Woodd S, Gubijev A, Barnard S, Russell S, et al. Mobile 
phone-based interventions for improving adherence to medication prescribed for 
the primary prevention of cardiovascular disease in adults. Cochrane Database Syst 
Rev 2021;3:CD012675. https://doi.org/10.1002/14651858.CD012675.pub3
379. Dobson R, Whittaker R, Jiang Y, Maddison R, Shepherd M, McNamara C, et al. 
Effectiveness of text message based, diabetes self management support programme 
(SMS4BG): two arm, parallel randomised controlled trial. BMJ 2018;361:k1959. 
https://doi.org/10.1136/bmj.k1959
380. Wändell PE, de Waard A-KM, Holzmann MJ, Gornitzki C, Lionis C, de Wit N, et al. 
Barriers and facilitators among health professionals in primary care to prevention of 
cardiometabolic diseases: a systematic review. Family Practice 2018;35:383–398. 
https://doi.org/10.1093/fampra/cmx137
381. Krempf M, Parhofer KG, Steg PG, Bhatt DL, Ohman EM, Röther J, et al. Cardiovascular 
event rates in diabetic and nondiabetic individuals with and without established ather­
othrombosis (from the REduction of Atherothrombosis for Continued Health 
[REACH] Registry). Am J Cardiol 2010;105:667–671. https://doi.org/10.1016/j. 
amjcard.2009.10.048
382. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coron­
ary artery disease. N Engl J Med 2009;360:2503–2515. https://doi.org/10.1056/ 
NEJMoa0805796
383. Krishnaswami A, Hardison R, Nesto RW, Sobel B, BARI 2D Investigators. Presentation 
in patients with angiographically documented coronary artery disease and type II dia­
betes mellitus (from the BARI 2D Clinical Trial). Am J Cardiol 2012;109:36–41. https:// 
doi.org/10.1016/j.amjcard.2011.08.004
384. Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, et al. Risk stratification in 
uncomplicated type 2 diabetes: prospective evaluation of the combined use of coron­
ary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 
2006;27:713–721. https://doi.org/10.1093/eurheartj/ehi808
385. Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer EA, et al. Coronary 
atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am College 
Cardiol 2002;40:946–953. https://doi.org/10.1016/s0735-1097(02)02065-x
386. Lièvre MM, Moulin P, Thivolet C, Rodier M, Rigalleau V, Penfornis A, et al. Detection of 
silent myocardial ischemia in asymptomatic patients with diabetes: results of a rando­
mized trial and meta-analysis assessing the effectiveness of systematic screening. Trials 
2011;12:23. https://doi.org/10.1186/1745-6215-12-23
387. Muhlestein JB, Lappé DL, Lima JA, Rosen BD, May HT, Knight S, et al. Effect of screen­
ing for coronary artery disease using CT angiography on mortality and cardiac events in 
high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA 2014; 
312:2234–2243. https://doi.org/10.1001/jama.2014.15825
388. Young LH, Frans JT, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac out­
comes after screening for asymptomatic coronary artery disease in patients with 
type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009;301: 
1547–1555. https://doi.org/10.1001/jama.2009.476
389. Clerc OF, Fuchs TA, Stehli J, Benz DC, Gräni C, Messerli M, et al. Non-invasive screen­
ing for coronary artery disease in asymptomatic diabetic patients: a systematic review 
and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging 2018; 
19:838–846. https://doi.org/10.1093/ehjci/jey014
390. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic 
effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hyper­
tension: a randomized controlled trial. JAMA 2004;292:2227–2236. https://doi.org/10. 
1001/jama.292.18.2227
391. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in 
hypertensive patients with type 2 diabetes mellitus. Clin Drug Invest 2007;27:841–849. 
https://doi.org/10.2165/00044011-200727120-00006
392. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients 
with hypertension treated with beta blockers to determine the risk of new-onset dia­
betes mellitus. Am J Cardiol 2007;100:1254–1262. https://doi.org/10.1016/j.amjcard. 
2007.05.057
393. Arnold SV, McGuire DK, Spertus JA, Li Y, Yue P, Ben-Yehuda O, et al. Effectiveness of 
ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according 
to baseline hemoglobin A1c. Am Heart J 2014;168:457–465.e2. https://doi.org/10. 
1016/j.ahj.2014.06.020
394. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and 
HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42–48. https:// 
doi.org/10.1093/eurheartj/ehi495


<!-- PAGE 87 -->

### Page 87

### 395 Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardio­

vascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor 
blocker telmisartan on cardiovascular events in high-risk patients intolerant to 
angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 
2008;372:1174–1183. https://doi.org/10.1016/S0140-6736(08)61242-8
396. Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indica­
tion for use of renin angiotensin system blockers: systematic review and meta-analysis 
of randomized trials. BMJ 2016;352:i438. https://doi.org/10.1136/bmj.i438
397. Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, et al. 
Clinical management of stable coronary artery disease in patients with type 2 diabetes 
mellitus: a scientific statement from the American Heart Association. Circulation 2020; 
141:e779–e806. https://doi.org/10.1161/CIR.0000000000000766
398. Taggart DP, Audisio K, Gerry S, Robinson NB, Rahouma M, Soletti G Jr, et al. Single 
versus multiple arterial grafting in diabetic patients at 10 years: the Arterial 
Revascularization Trial. Eur Heart J 2022;43:4644–4652. https://doi.org/10.1093/ 
eurheartj/ehac199
399. Nyström T, Sartipy U, Franzén S, Eliasson B, Gudbjörnsdottir S, Miftaraj M, et al. PCI 
Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease. J Am Coll 
Cardiol 2017;70:1441–1451.
400. Navarese EP, Lansky AJ, Kereiakes DJ, Kubica J, Gurbel PA, Gorog DA, et al. Cardiac 
mortality in patients randomised to elective coronary revascularisation plus medical 
therapy or medical therapy alone: a systematic review and meta-analysis. Eur Heart J 
2021;42:4638–4651. https://doi.org/10.1093/eurheartj/ehab246
401. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery 
bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364: 
1607–1616. https://doi.org/10.1056/NEJMoa1100356
402. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, et al. Percutaneous 
coronary intervention versus optimal medical therapy in stable coronary artery dis­
ease: a systematic review and meta-analysis of randomized clinical trials. Circ 
Cardiovasc Interv 2012;5:476–490. https://doi.org/10.1161/CIRCINTERVENTIONS. 
112.970954
402a. Newman JD, Anthopolos R, Mancini GJ, Bangalore S, Reynolds HR, Kunichoff DF, 
et al. Outcomes of participants with diabetes in the ISCHEMIA trials. Circulation 
2021;144:1380–1395. https://doi.org/10.1161/CIRCULATIONAHA.121.054439
403. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al. 
Randomized trial of complete versus lesion-only revascularization in patients undergo­
ing primary percutaneous coronary intervention for STEMI and multivessel disease: 
the CvLPRIT trial. J Am College Cardiol 2015;65:963–972. https://doi.org/10.1016/j. 
jacc.2014.12.038
404. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, et al. 
Complete revascularisation versus treatment of the culprit lesion only in patients 
with ST-segment elevation myocardial infarction and multivessel disease 
(DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015; 
386:665–671. https://doi.org/10.1016/S0140-6736(15)60648-1
405. Smits PC, Abdel-Wahab M, Neumann F-J, Boxma-de Klerk BM, Lunde K, Schotborgh 
CE, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarc­
tion. N Engl J Med 2017;376:1234–1244. https://doi.org/10.1056/NEJMoa1701067
406. Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, et al. Complete versus 
culprit-only lesion intervention in patients with acute coronary syndromes. J Am 
College Cardiol 2018;72:1989–1999. https://doi.org/10.1016/j.jacc.2018.07.089
407. Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, et al. Single-staged 
compared with multi-staged PCI in multivessel NSTEMI patients: the SMILE trial. J 
Am College Cardiol 2016;67:264–272. https://doi.org/10.1016/j.jacc.2015.10.082
408. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI strategies 
in patients with acute myocardial infarction and cardiogenic shock. N Eng J Med 2017; 
377:2419–2432. https://doi.org/10.1056/NEJMoa1710261
409. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 
2 diabetes: a systematic literature review of scientific evidence from across the world 
in 2007–2017. Cardiovasc Diabetol 2018;17:83. https://doi.org/10.1186/s12933-018- 
0728-6
410. Aggarwal B, Shah GK, Randhawa M, Ellis SG, Lincoff AM, Menon V. Utility of glycated 
hemoglobin for assessment of glucose metabolism in patients with ST-segment eleva­
tion myocardial infarction. Am J Cardiol 2016;117:749–753. https://doi.org/10.1016/j. 
amjcard.2015.11.060
411. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibi­
tors in the early treatment of acute myocardial infarction: systematic overview of in­
dividual data from 100 000 patients in randomized trials. Circulation 1998;97: 
2202–2212. https://doi.org/10.1161/01.cir.97.22.2202
412. Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, et al. Pathology of hu­
man coronary and carotid artery atherosclerosis and vascular calcification in diabetes 
mellitus. Arterioscler Thromb Vasc Biol 2017;37:191–204. https://doi.org/10.1161/ 
ATVBAHA.116.306256
413. Henriksen EJ. A radical concept on caveolae and endothelial dysfunction in coronary 
microvascular disease in diabetes. Diabetes 2014;63:1200–1202. https://doi.org/10. 
2337/db14-0057
414. Alabas O, Hall M, Dondo T, Rutherford MJ, Timmis A, Batin P, et al. Long-term excess 
mortality associated with diabetes following acute myocardial infarction: a population- 
based cohort study. J Epidemiol Community Health 2017;71:25–32. https://doi.org/10. 
1136/jech-2016-207402
415. Niedziela JT, Hiczkiewicz J, Kleinrok A, Pączek P, Leszek P, Lelonek M, et al. Prevalence, 
characteristics, and prognostic implications of type 2 diabetes in patients with myocar­
dial infarction: the Polish Registry of Acute Coronary Syndromes (PL-ACS) annual 
2018 report. Kardiol Pol 2020;78:243–246. https://doi.org/10.33963/KP.15189
416. Canto JG, Fincher C, Kiefe CI, Allison JJ, Li Q, Funkhouser E, et al. Atypical presenta­
tions among Medicare beneficiaries with unstable angina pectoris. Am J Cardiol 2002; 
90:248–253. https://doi.org/10.1016/S0002-9149(02)02463-3
417. O’Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, et al. An 
invasive or conservative strategy in patients with diabetes mellitus and 
non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis 
of randomized trials. J Am College Cardiol 2012;60:106–111. https://doi.org/10.1016/j. 
jacc.2012.02.059
418. Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Pinto MD, Repaci S, et al. 
New-onset hyperglycemia and acute coronary syndrome: a systematic overview and 
meta-analysis. Curr Diabetes Rev 2010;6:102–110. https://doi.org/10.2174/1573399 
10790909413
419. Goyal A, Mehta SR, Gerstein HC, Díaz R, Afzal R, Xavier D, et al. Glucose levels com­
pared with diabetes history in the risk assessment of patients with acute myocardial 
infarction. Am Heart J 2009;157:763–770. https://doi.org/10.1016/j.ahj.2008.12.007
420. Kosiborod M, Inzucchi SE, Krumholz HM, Xiao L, Jones PG, Fiske S, et al. Glucometrics 
in patients hospitalized with acute myocardial infarction: defining the optimal 
outcomes-based measure of risk. Circulation 2008;117:1018–1027. https://doi.org/ 
10.1161/CIRCULATIONAHA.107.740498
421. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized 
trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic 
patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 
year. J Am College Cardiol 1995;26:57–65. https://doi.org/10.1016/0735-1097(95) 
00126-K
422. Zhao Y-T, Weng C-L, Chen M-L, Li K-B, Ge Y-G, Lin X-M, et al. Comparison of 
glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial 
infarction: a contemporary meta-analysis of randomised controlled trials. Heart 2010; 
96:1622–1626. https://doi.org/10.1136/hrt.2010.194563
423. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, et al. 
U-shaped relationship of blood glucose with adverse outcomes among patients with 
ST-segment elevation myocardial infarction. J Am College Cardiol 2005;46:178–180. 
https://doi.org/10.1016/j.jacc.2005.03.052
424. Svensson A-M, McGuire DK, Abrahamsson P, Dellborg M. Association between 
hyper-and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with 
acute coronary events. Eur Heart J 2005;26:1255–1261. https://doi.org/10.1093/ 
eurheartj/ehi230
425. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control 
in critically ill patients. N Engl J Med 2009;360:1283–1297. https://doi.org/10.1056/ 
NEJMoa0810625
426. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC 
Guidelines for the management of acute coronary syndromes in patients presenting 
without persistent ST-segment elevation: the Task Force for the management of acute 
coronary syndromes in patients presenting without persistent ST-segment elevation 
of the European Society of Cardiology (ESC). Eur Heart J 2021;42:1289–1367. 
https://doi.org/10.1093/eurheartj/ehaa575
427. Malcolm J, Halperin I, Miller DB, Moore S, Nerenberg KA, Woo V, et al. In-hospital 
management of diabetes. Can J Diabetes 2018;42:S115–S123. https://doi.org/10. 
1016/j.jcjd.2017.10.014
428. Ajjan RA, Heller SR, Everett CC, Vargas-Palacios A, Higham R, Sharples L, et al. 
Multicenter randomized trial of intermittently scanned continuous glucose monitoring 
versus self-monitoring of blood glucose in individuals with type 2 diabetes and 
recent-onset acute myocardial infarction: results of the LIBERATES trial. Diabetes 
Care 2023;46:441–449. https://doi.org/10.2337/dc22-1219
429. von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. 
Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J 2022;43: 
4421–4432. https://doi.org/10.1093/eurheartj/ehac494
430. Ritsinger V, Tanoglidi E, Malmberg K, Näsman P, Rydén L, Tenerz Å, et al. Sustained 
prognostic implications of newly detected glucose abnormalities in patients with acute 
myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with 
Acute Myocardial Infarction cohort. Diabetes Vasc Dis Res 2015;12:23–32. https://doi. 
org/10.1177/1479164114551746
431. Timmer JR, Ottervanger JP, de Boer M-J, Boersma E, Grines CL, Westerhout CM, et al. 
Primary percutaneous coronary intervention compared with fibrinolysis for myocar­
dial infarction in diabetes mellitus: results from the primary coronary angioplasty vs 
thrombolysis–2 trial. Arch Intern Med 2007;167:1353–1359. https://doi.org/10.1001/ 
archinte.167.13.1353
ESC Guidelines                                                                                                                                                                                          4129


<!-- PAGE 88 -->

### Page 88

432. Megaly M, Schmidt CW, Dworak MW, Garberich R, Stanberry L, Sharkey S, et al. 
Diabetic patients who present with ST-elevation myocardial infarction. Cardiovasc 
Revasc Med 2022;38:89–93. https://doi.org/10.1016/j.carrev.2021.08.003
433. Burgess S, Juergens CP, Yang W, Shugman IM, Idris H, Nguyen T, et al. Cardiac mor­
tality, diabetes mellitus, and multivessel disease in ST elevation myocardial infarction. 
Int J Cardiol 2021;323:13–18. https://doi.org/10.1016/j.ijcard.2020.08.021
434. Burgess SN, Juergens CP, Nguyen T, Leung M, Robledo KP, Thomas L, et al. Diabetes 
and incomplete revascularisation in ST elevation myocardial infarction. Heart Lung Circ 
2021;30:471–480. https://doi.org/10.1016/j.hlc.2020.09.928
435. Ullah W, Saleem S, Zahid S, Sattar Y, Mukhtar M, Younas S, et al. Clinical outcomes of 
patients with diabetes mellitus and acute ST-elevation myocardial infarction following 
fibrinolytic therapy: a nationwide inpatient sample (NIS) database analysis. Expert Rev 
Cardiovasc Ther 2021;19:357–362. https://doi.org/10.1080/14779072.2021.1888716
436. Rakowski T, De Luca G, Siudak Z, Plens K, Dziewierz A, Kleczyński P, et al. 
Characteristics of patients presenting with myocardial infarction with non-obstructive 
coronary arteries (MINOCA) in Poland: data from the ORPKI national registry. J 
Thromb Thrombol 2019;47:462–466. https://doi.org/10.1007/s11239-018-1794-z
437. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC 
Guidelines for the management of acute myocardial infarction in patients presenting 
with ST-segment elevation: the Task Force for the management of acute myocardial 
infarction in patients presenting with ST-segment elevation of the European Society 
of Cardiology (ESC). Eur Heart J 2018;39:119–177. https://doi.org/10.1093/ 
eurheartj/ehx393
438. Tardif J-C, L’Allier PL, Fitchett DH. Management of acute coronary syndromes. Can J 
Diabetes 2018;42:S190–S195. https://doi.org/10.1016/j.jcjd.2017.10.029
439. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand J-P, Faxon DP, et al. Early versus 
delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009;360: 
2165–2175. https://doi.org/10.1056/NEJMoa0807986
440. Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, Kløvgaard L, et al. 
Early versus standard care invasive examination and treatment of patients with 
non-ST-segment elevation acute coronary syndrome: VERDICT randomized con­
trolled 
trial. 
Circulation 
2018;138:2741–2750. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.118.037152
441. Bonello L, Laine M, Puymirat E, Lemesle G, Thuny F, Paganelli F, et al. Timing of cor­
onary invasive strategy in non-ST-segment elevation acute coronary syndromes and 
clinical outcomes: an updated meta-analysis. JACC Cardiovasc Interv 2016;9: 
2267–2276. https://doi.org/10.1016/j.jcin.2016.09.017
442. Martinón-Martínez J, Alvarez Alvarez B, Gonzalez Ferrero T, Garcia-Rodeja Arias F, 
Otero Garcia O, Cacho Antonio C, et al. Prognostic benefit from an early invasive 
strategy in patients with non-ST elevation acute coronary syndrome (NSTEACS): 
evaluation of the new risk stratification in the NSTEACS European guidelines. Clin 
Res Cardiol 2021;110:1464–1472. https://doi.org/10.1007/s00392-021-01829-8
443. Jobs A, Mehta SR, Montalescot G, Vicaut E, Van’t Hof AW, Badings EA, et al. Optimal 
timing of an invasive strategy in patients with non-ST-elevation acute coronary syn­
drome: a meta-analysis of randomised trials. Lancet 2017;390:737–746. https://doi. 
org/10.1016/S0140-6736(17)31490-3
444. Li Y, Wang C, Nan Y, Zhao H, Cao Z, Du X, et al. Early invasive strategy for non-ST 
elevation acute coronary syndrome: a meta-analysis of randomized, controlled trials. J 
Int Med Res 2020;48:300060520966500. https://doi.org/10.1177/0300060520966500
445. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: de­
veloped by the Task Force for the diagnosis and treatment of acute and chronic heart 
failure of the European Society of Cardiology (ESC) with the special contribution of 
the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–3726. 
https://doi.org/10.1093/eurheartj/ehab368
446. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, 
et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 
million people. Lancet Diabetes Endocrinol 2015;3:105–113. https://doi.org/10.1016/ 
S2213-8587(14)70219-0
447. Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with 
restrictive and dilated phenotypes. Eur Heart J 2015;36:1718–1727. https://doi.org/ 
10.1093/eurheartj/ehv134
448. Sattar N, McGuire DK. Pathways to cardiorenal complications in type 2 diabetes mel­
litus: a need to rethink. Circulation 2018;138:7–9. https://doi.org/10.1161/ 
CIRCULATIONAHA.118.035083
449. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: 
prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614–1619. https://doi. 
org/10.2337/diacare.24.9.1614
450. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, et al. Association 
of systolic blood pressure with macrovascular and microvascular complications of type 
2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412–419. 
https://doi.org/10.1136/bmj.321.7258.412
451. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart fail­
ure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 
2004;27:699–703. https://doi.org/10.2337/diacare.27.3.699
452. Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, et al. 
Hospitalizations for new heart failure among subjects with diabetes mellitus in the 
RENAAL and LIFE studies. Am J Cardiol 2005;96:1530–1536. https://doi.org/10.1016/ 
j.amjcard.2005.07.061
453. Maack C, Lehrke M, Backs J, Heinzel FR, Hulot J-S, Marx N, et al. Heart failure and dia­
betes: metabolic alterations and therapeutic interventions: a state-of-the-art review 
from the Translational Research Committee of the Heart Failure Association– 
European Society of Cardiology. Eur Heart J 2018;39:4243–4254. https://doi.org/10. 
1093/eurheartj/ehy596
454. Pham I, Cosson E, Nguyen MT, Banu I, Genevois I, Poignard P, et al. Evidence for a spe­
cific diabetic cardiomyopathy: an observational retrospective echocardiographic study 
in 656 asymptomatic type 2 diabetic patients. Int J Endocrinol 2015;2015:743503. 
https://doi.org/10.1155/2015/743503
455. Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, et al. Serum levels 
of advanced glycation end products are associated with left ventricular diastolic func­
tion in patients with type 1 diabetes. Diabetes Care 1999;22:1186–1190. https://doi. 
org/10.2337/diacare.22.7.1186
456. Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end- 
products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart 
Fail 2007;9:1146–1155. https://doi.org/10.1016/j.ejheart.2007.09.009
457. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, et al. 
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 dia­
betes mellitus. J Am College Cardiol 2008;52:1793–1799. https://doi.org/10.1016/j.jacc. 
2008.07.062
458. Shenouda SM, Widlansky ME, Chen K, Xu G, Holbrook M, Tabit CE, et al. Altered 
mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. 
Circulation 
2011;124:444–453. 
https://doi.org/10.1161/CIRCULATIONAHA.110. 
014506
459. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, 
et al. The association between glucose abnormalities and heart failure in the 
population-based Reykjavik study. Diabetes Care 2005;28:612–616. https://doi.org/ 
10.2337/diacare.28.3.612
460. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. 
JAMA 1979;241:2035–2038. https://doi.org/10.1001/jama.1979.03290450033020
461. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al. 
Predictors of congestive heart failure in the elderly: the Cardiovascular Health 
Study. J Am College Cardiol 2000;35:1628–1637. https://doi.org/10.1016/S0735- 
1097(00)00582-9
462. van Melle JP, Bot M, De Jonge P, De Boer RA, van Veldhuisen DJ, Whooley MA. 
Diabetes, glycemic control, and new-onset heart failure in patients with stable coron­
ary artery disease: data from the heart and soul study. Diabetes Care 2010;33: 
2084–2089. https://doi.org/10.2337/dc10-0286
463. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive 
heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879–1884. https:// 
doi.org/10.2337/diacare.27.8.1879
464. Boonman-de Winter L, Rutten F, Cramer M, Landman M, Liem A, Rutten G, et al. High 
prevalence of previously unknown heart failure and left ventricular dysfunction in pa­
tients with type 2 diabetes. Diabetologia 2012;55:2154–2162. https://doi.org/10.1007/ 
s00125-012-2579-0
465. Zareini B, Rørth R, Holt A, Mogensen UM, Selmer C, Gislason G, et al. Heart failure and 
the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide 
cohort study. Cardiovasc Diabetol 2019;18:79. https://doi.org/10.1186/s12933-019- 
0883-4
466. Centers for Disease Control and Prevention. Incidence of Newly Diagnosed Diabetes. 
https://www.cdc.gov/diabetes/data/statistics-report/newly-diagnosed-diabetes.html
(21 April 2022)
467. Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, et al. Association 
between diabetes and 1-year adverse clinical outcomes in a multinational cohort of 
ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure 
long-term registry. Diabetes Care 2017;40:671–678. https://doi.org/10.2337/dc16- 
2016
468. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al. 
In-hospital and 1-year mortality associated with diabetes in patients with acute heart 
failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 
2017;19:54–65. https://doi.org/10.1002/ejhf.679
469. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. 
Epidemiology and one-year outcomes in patients with chronic heart failure and pre­
served, mid-range and reduced ejection fraction: an analysis of the ESC Heart 
Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574–1585. https://doi.org/10. 
1002/ejhf.813
470. Johansson I, Dahlström U, Edner M, Näsman P, Ryden L, Norhammar A. Type 2 dia­
betes and heart failure: characteristics and prognosis in preserved, mid-range and re­
duced ventricular function. Diab Vasc Dis Res 2018;15:494–503. https://doi.org/10. 
1177/1479164118794619


<!-- PAGE 89 -->

### Page 89

471. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin– 
neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. 
https://doi.org/10.1056/NEJMoa1409077
472. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, et al. Impact of dia­
betes mellitus on hospitalization for heart failure, cardiovascular events, and death: 
outcomes at 4 years from the Reduction of Atherothrombosis for Continued 
Health (REACH) registry. Circulation 2015;132:923–931. https://doi.org/10.1161/ 
CIRCULATIONAHA.114.014796
473. Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A. Prognostic 
implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J 
Am College Cardiol 2016;68:1404–1416. https://doi.org/10.1016/j.jacc.2016.06.061
474. Kristensen SL, Jhund PS, Lee MM, Køber L, Solomon SD, Granger CB, et al. Prevalence 
of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and asso­
ciated clinical outcomes. Cardiovasc Drugs Ther 2017;31:545–549. https://doi.org/10. 
1007/s10557-017-6754-x
475. MacDonald MR, Petrie MC, Varyani F, Östergren J, Michelson EL, Young JB, et al. 
Impact of diabetes on outcomes in patients with low and preserved ejection fraction 
heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction 
in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:1377–1385. 
https://doi.org/10.1093/eurheartj/ehn153
476. Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, et al. Clinical and 
echocardiographic characteristics and cardiovascular outcomes according to diabetes 
status in patients with heart failure and preserved ejection fraction: a report from the 
I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). 
Circulation 
2017;135:724–735. 
https://doi.org/10.1161/CIRCULATIONAHA.116. 
024593
477. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of 
candesartan in patients with chronic heart failure and preserved left-ventricular ejec­
tion fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781. https://doi.org/ 
10.1016/S0140-6736(03)14285-7
478. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. 
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 
1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016;18: 
613–625. https://doi.org/10.1002/ejhf.566
479. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. 
Universal definition and classification of heart failure: a report of the Heart Failure 
Society of America, Heart Failure Association of the European Society of 
Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal 
Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart 
Failure Association of India, Cardiac Society of Australia and New Zealand, and 
Chinese Heart Failure Association. Eur J Heart Fail 2021;23:352–380. https://doi.org/ 
10.1002/ejhf.2115
480. Segar MW, Vaduganathan M, Patel KV, McGuire DK, Butler J, Fonarow GC, et al. 
Machine learning to predict the risk of incident heart failure hospitalization among pa­
tients with diabetes: the WATCH-DM risk score. Diabetes Care 2019;42:2298–2306. 
https://doi.org/10.2337/dc19-0587
481. Pandey A, Vaduganathan M, Patel KV, Ayers C, Ballantyne CM, Kosiborod MN, et al. 
Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes. 
Heart Fail 2021;9:215–223. https://doi.org/10.1016/j.jchf.2020.10.013
482. Seferović P, Farmakis D, Bayes-Genis A, Gal TB, Böhm M, Chioncel O, et al. 
Biomarkers for the prediction of heart failure and cardiovascular events in patients 
with type 2 diabetes: a position statement from the Heart Failure Association of the 
European Society of Cardiology. Eur J Heart Fail 2022;24:1162–1170. https://doi.org/ 
10.1002/ejhf.2575
483. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, et al. State of 
the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10: 
824–839. https://doi.org/10.1016/j.ejheart.2008.07.014
484. Hildebrandt P, Collinson PO. Amino-terminal pro-B-type natriuretic peptide testing to 
assist the diagnostic evaluation of heart failure in symptomatic primary care patients. 
Am J Cardiol 2008;101:S25–S28. https://doi.org/10.1016/j.amjcard.2007.11.016
485. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, et al. The 
diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary 
care with suspected heart failure: results of the UK natriuretic peptide study. Eur J 
Heart Fail 2005;7:537–541. https://doi.org/10.1016/j.ejheart.2005.01.022
486. Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, 
BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J 
Cardiol 2014;176:611–617. https://doi.org/10.1016/j.ijcard.2014.08.007
487. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JG, Kozhuharov N, et al. Heart 
Failure Association of the European Society of Cardiology practical guidance on the 
use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–731. https:// 
doi.org/10.1002/ejhf.1494
488. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, et al. 
The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review 
and diagnostic meta-analysis in the acute care setting. BMJ 2015;350:h910. https://doi. 
org/10.1136/bmj.h910
489. Mant J, Doust J, Roalfe A, Barton P, Cowie M, Glasziou P, et al. Systematic review and 
individual patient data meta-analysis of diagnosis of heart failure, with modelling of im­
plications of different diagnostic strategies in primary care. Health Technol Assess 2009; 
13:1–207. https://doi.org/10.3310/hta13320
490. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, 
tolerability and efficacy of up-titration of guideline-directed medical therapies for acute 
heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 
2022;400:1938–1952. https://doi.org/10.1016/S0140-6736(22)02076-1
491. McMurray JJ, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. 
Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J 
Med 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
492. Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, et al. Effects of 
dapagliflozin on symptoms, function, and quality of life in patients with heart failure and 
reduced ejection fraction: results from the DAPA-HF trial. Circulation 2020;141: 
90–99. https://doi.org/10.1161/CIRCULATIONAHA.119.044138
493. Docherty KF, Jhund PS, Bengtsson O, DeMets DL, Inzucchi SE, Køber L, et al. Effect of 
dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes 
Care 2020;43:2878–2881. https://doi.org/10.2337/dc20-1402
494. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular 
and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383: 
1413–1424. https://doi.org/10.1056/NEJMoa2022190
495. Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CS, et al. Effect of empagliflozin 
on cardiovascular and renal outcomes in patients with heart failure by baseline dia­
betes status: results from the EMPEROR-reduced trial. Circulation 2021;143: 
337–349. https://doi.org/10.1161/CIRCULATIONAHA.120.051824
496. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, et al. Empagliflozin and 
health-related quality of life outcomes in patients with heart failure with reduced ejec­
tion fraction: the EMPEROR-Reduced trial. Eur Heart J 2021;42:1203–1212. https://doi. 
org/10.1093/eurheartj/ehaa1007
497. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibi­
tors in patients with heart failure with reduced ejection fraction: a meta-analysis of the 
EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819–829. https://doi.org/ 
10.1016/S0140-6736(20)31824-9
498. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TD, Elvan A, et al. 
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects 
of empagliflozin on clinical outcomes in patients with acute decompensated heart fail­
ure (EMPA-RESPONSE-AHF). Eur J Heart Fail 2020;22:713–722. https://doi.org/10. 
1002/ejhf.1713
499. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The 
SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multi­
national randomized trial. Nat Med 2022;28:568–574. https://doi.org/10.1038/s41591- 
021-01659-1
500. Garg R, Yusuf S, Bussmann W, Sleight P, Uprichard A, Massie B, et al. Overview of ran­
domized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity 
in patients with heart failure. JAMA 1995;273:1450–1456. https://doi.org/10.1001/ 
jama.1995.03520420066040
501. Gustafsson I, Torp-Pedersen C, Køber L, Gustafsson F, Hildebrandt P, Group TS. 
Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and 
morbidity in diabetic patients with left ventricular dysfunction after acute myocardial 
infarction. J Am College Cardiol 1999;34:83–89. https://doi.org/10.1016/S0735- 
1097(99)00146-1
502. Moye L, Pfeffer M, Wun C, Davis B, Geltman E, Hayes D, et al. Uniformity of captopril 
benefit in the SAVE study: subgroup analysis. Eur Heart J 1994;15(Suppl B):2–8. https:// 
doi.org/10.1093/eurheartj/15.suppl_B.2
503. Shekelle PG, Rich MW, Morton SC, Atkinson CSW, Tu W, Maglione M, et al. Efficacy 
of angiotensin-converting enzyme inhibitors and beta-blockers in the management of 
left ventricular systolic dysfunction according to race, gender, and diabetic status: a 
meta-analysis of major clinical trials. J Am College Cardiol 2003;41:1529–1538. https:// 
doi.org/10.1016/S0735-1097(03)00262-6
504. Vijayakumar S, Butler J, Bakris GL. Barriers to guideline mandated renin–angiotensin 
inhibitor use: focus on hyperkalaemia. Eur Heart J Suppl 2019;21(Suppl A):A20–A27. 
https://doi.org/10.1093/eurheartj/suy030
505. Beldhuis IE, Streng KW, Ter Maaten JM, Voors AA, van der Meer P, Rossignol P, et al. 
Renin–angiotensin system inhibition, worsening renal function, and outcome in heart 
failure patients with reduced and preserved ejection fraction: a meta-analysis of pub­
lished study data. Circ Heart Fail 2017;10:e003588. https://doi.org/10.1161/ 
CIRCHEARTFAILURE.116.003588
506. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of 
kidney function throughout the heart failure trajectory–a position statement from the 
Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 
22:584–603. https://doi.org/10.1002/ejhf.1697
507. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spir­
onolactone on morbidity and mortality in patients with severe heart failure. N Engl J 
Med 1999;341:709–717. https://doi.org/10.1056/NEJM199909023411001
508. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, et al. 
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the 
ESC Guidelines                                                                                                                                                                                          4131


<!-- PAGE 90 -->

### Page 90

EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in 
Heart Failure) study. J Am College Cardiol 2012;59:1598–1603. https://doi.org/10. 
1016/j.jacc.2011.11.063
509. Bobbio M, Ferrua S, Opasich C, Porcu M, Lucci D, Scherillo M, et al. Survival and hos­
pitalization in heart failure patients with or without diabetes treated with β-blockers. J 
Cardiac Fail 2003;9:192–202. https://doi.org/10.1054/jcaf.2003.31
510. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, et al. Efficacy, 
safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart 
failure: experiences from MERIT-HF. Am Heart J 2005;149:159–167. https://doi.org/10. 
1016/j.ahj.2004.05.056
511. Erdmann E, Philippe L, Patricia V, Hermann W. Results from post-hoc analyses of the 
CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. 
Eur J Heart Fail 2001;3:469–479. https://doi.org/10.1016/S1388-9842(01)00174-X
512. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of car­
vedilol on the morbidity of patients with severe chronic heart failure: results of the car­
vedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 
2002;106:2194–2199. https://doi.org/10.1161/01.CIR.0000035653.72855.BF
513. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of 
candesartan in patients with chronic heart failure and reduced left-ventricular systolic 
function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM- 
Alternative trial. Lancet 2003;362:772–776. https://doi.org/10.1016/S0140-6736(03) 
14284-5
514. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. 
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with 
heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374: 
1840–1848. https://doi.org/10.1016/S0140-6736(09)61913-9
515. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, et al. Effects of val­
sartan on morbidity and mortality in patients with heart failure not receiving 
angiotensin-converting enzyme inhibitors. J Am College Cardiol 2002;40:1414–1421. 
https://doi.org/10.1016/S0735-1097(02)02304-5
516. Komajda M, Tavazzi L, Francq BG, Böhm M, Borer JS, Ford I, et al. Efficacy and safety of 
ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from 
the SHIFT trial. Eur J Heart Fail 2015;17:1294–1301. https://doi.org/10.1002/ejhf.347
517. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R Jr, Ferdinand K, et al. 
African-American Heart Failure Trial Investigators. Combination of isosorbide dini­
trate and hydralazine in blacks with heart failure. N Engl J Med 2004;351: 
2049–2057. https://doi.org/10.1056/NEJMoa042934
518. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al. Early and sus­
tained benefit on event-free survival and heart failure hospitalization from fixed-dose 
combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the 
African-American Heart Failure Trial. Circulation 2007;115:1747–1753. https://doi. 
org/10.1161/CIRCULATIONAHA.106.644013
519. Abdul-Rahim AH, MacIsaac RL, Jhund PS, Petrie MC, Lees KR, McMurray JJ, et al. 
Efficacy and safety of digoxin in patients with heart failure and reduced ejection frac­
tion according to diabetes status: an analysis of the Digitalis Investigation Group (DIG) 
trial. Int J Cardiol 2016;209:310–316. https://doi.org/10.1016/j.ijcard.2016.02.074
520. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence 
supporting the role of diuretics in heart failure: a meta analysis of randomised con­
trolled trials. Int J Cardiol 2002;82:149–158. https://doi.org/10.1016/S0167-5273(01) 
00600-3
521. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. 
The use of diuretics in heart failure with congestion—a position statement from the 
Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 
2019;21:137–155. https://doi.org/10.1002/ejhf.1369
522. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. 
Cardiac-resynchronization therapy with or without an implantable defibrillator in ad­
vanced chronic heart failure. N Engl J Med 2004;350:2140–2150. https://doi.org/10. 
1056/NEJMoa032423
523. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, et al. Influence of 
diabetes on cardiac resynchronization therapy with or without defibrillator in patients 
with advanced heart failure. J Cardiac Fail 2007;13:769–773. https://doi.org/10.1016/j. 
cardfail.2007.06.723
524. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator im­
plantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 
375:1221–1230. https://doi.org/10.1056/NEJMoa1608029
525. Rørth R, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. The effect of implan­
table cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic 
heart failure. Europace 2019;21:1203–1210. https://doi.org/10.1093/europace/euz114
526. Kilic A, Weiss ES, George TJ, Arnaoutakis GJ, Yuh DD, Shah AS, et al. What predicts 
long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors. 
Ann Thorac Surg 2012;93:699–704. https://doi.org/10.1016/j.athoracsur.2011.09.037
527. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk related to 
pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection frac­
tion: insights from prospective comparison of ARNI with ACEI to determine impact 
on global mortality and morbidity in heart failure trial. Circ Heart Fail 2016;9: 
e002560. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002560
528. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, et al. 
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST 
trial. J Am College Cardiol 2003;42:914–922. https://doi.org/10.1016/s0735-1097(03) 
00856-8
529. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. 
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 
2011;364:11–21. https://doi.org/10.1056/NEJMoa1009492
530. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in 
heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461. 
https://doi.org/10.1056/NEJMoa2107038
531. Filippatos G, Butler J, Farmakis D, Zannad F, Pernille Ofstad A, Pedro Ferreira J, et al. 
Empagliflozin for heart failure with preserved left ventricular ejection fraction with and 
without 
diabetes. 
Circulation 
2022;146:676–686. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.122.059785
532. Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. 
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N 
Engl J Med 2022;387:1089–1098. https://doi.org/10.1056/NEJMoa2206286
533. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, 
et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis 
of five randomised controlled trials. Lancet 2022;400:757–767. https://doi.org/10. 
1016/S0140-6736(22)01429-5
534. Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, et al. Angiotensin– 
neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 
2019;381:1609–1620. https://doi.org/10.1056/NEJMoa1908655
535. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone 
for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392. 
https://doi.org/10.1056/NEJMoa1313731
536. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, et al. Perindopril for 
elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Fail 1999;1: 
211–217. https://doi.org/10.1016/S1388-9842(99)00039-2
537. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan 
in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359: 
2456–2467. https://doi.org/10.1056/NEJMoa0805450
538. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects of digoxin 
on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation 
group trial. Circulation 2006;114:397–403. https://doi.org/10.1161/CIRCULATIONAHA. 
106.628347
539. Butler J, Anker SD, Filippatos G, Usman MS, Ferreira JP, Zannad F, et al. Sodium glucose 
co-transporter inhibitors and heart failure outcomes across different patient popula­
tions. Eur Heart J 2021;42:4887–4890. https://doi.org/10.1093/eurheartj/ehab704
540. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RH, et al. Effect of 
dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019; 
139:2528–2536. https://doi.org/10.1161/CIRCULATIONAHA.119.040130
541. Cosentino F, Cannon CP, Cherney DZ, Masiukiewicz U, Pratley R, Dagogo-Jack S, et al. 
Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes 
mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS 
CV Trial. Circulation 2020;142:2205–2215. https://doi.org/10.1161/CIRCULATIONAHA. 
120.050255
542. Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, 
et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383: 
1436–1446. https://doi.org/10.1056/NEJMoa2024816
543. EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney 
disease. N Engl J Med 2023;388:117–127. https://doi.org/10.1056/NEJMoa2204233
544. Marso SP, Baeres FM, Bain SC, Goldman B, Husain M, Nauck MA, et al. Effects of lir­
aglutide on cardiovascular outcomes in patients with diabetes with or without heart 
failure. J Am College Cardiol 2020;75:1128–1141. https://doi.org/10.1016/j.jacc.2019. 
12.063
545. Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 
receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated 
meta-analysis of eight CVOTs. Cardiovasc Diabetol 2021;20:189. https://doi.org/10. 
1186/s12933-021-01366-8
546. Lam CS, Ramasundarahettige C, Branch KR, Sattar N, Rosenstock J, Pratley R, et al. 
Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose 
co-transporter-2 inhibition use in type 2 diabetes: exploratory analysis of the 
AMPLITUDE-O 
trial. 
Circulation 
2021;145:565–574. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.121.057934
547. Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, 
et al. Glucagon-like peptide 1 receptor agonists and heart failure: the need for further 
evidence generation and practice guidelines optimization. Circulation 2020;142: 
1205–1218. https://doi.org/10.1161/CIRCULATIONAHA.120.045888
548. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of 
liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable 
chronic heart failure patients with and without diabetes (LIVE)—a multicentre, 
double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69–77. 
https://doi.org/10.1002/ejhf.657


<!-- PAGE 91 -->

### Page 91

549. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. 
Effects of liraglutide on clinical stability among patients with advanced heart failure 
and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500–508. 
https://doi.org/10.1001/jama.2016.10260
550. Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, et al. Effects of the 
novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, 
and exercise capacity in patients with chronic heart failure and reduced ejection frac­
tion. JACC Heart Fail 2016;4:559–566. https://doi.org/10.1016/j.jchf.2016.01.008
551. McMurray JJ, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, et al. 
Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus 
and heart failure: a randomized placebo-controlled trial. JACC Heart Fail 2018;6: 
8–17. https://doi.org/10.1016/j.jchf.2017.08.004
552. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a 
marked increase in mortality in patients with advanced heart failure. Am Heart J 
2005;149:168–174. https://doi.org/10.1016/j.ahj.2004.07.005
553. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, et al. Basal insulin and 
cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–328. 
https://doi.org/10.1056/NEJMoa1203858
554. Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Saevereid HA, et al. Heart failure 
with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk 
of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol 2019;18:156. https://doi. 
org/10.1186/s12933-019-0960-8
555. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical out­
comes associated with metformin in patients with diabetes and heart failure. Diabetes 
Care 2005;28:2345–2351. https://doi.org/10.2337/diacare.28.10.2345
556. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. 
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart 
failure: an observational study. Circulation 2005;111:583–590. https://doi.org/10.1161/ 
01.CIR.0000154542.13412.B1
557. Ekström N, Schiöler L, Svensson A-M, Eeg-Olofsson K, Jonasson JM, Zethelius B, et al. 
Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and dif­
ferent levels of renal function: a cohort study from the Swedish National Diabetes 
Register. BMJ Open 2012;2:e001076. https://doi.org/10.1136/bmjopen-2012-001076
558. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. 
Comparative safety and effectiveness of metformin in patients with diabetes mellitus 
and heart failure: systematic review of observational studies involving 34000 patients. 
Circ Heart Fail 2013;6:395–402. https://doi.org/10.1161/CIRCHEARTFAILURE.112. 
000162
559. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 
2 diabetes and kidney disease: a systematic review. JAMA 2014;312:2668–2675. https:// 
doi.org/10.1001/jama.2014.15298
560. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of devel­
oping coronary artery disease or congestive heart failure, and overall mortality, in type 
2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulphonylureas: 
a retrospective analysis. Acta Diabetol 2009;46:145–154. https://doi.org/10.1007/ 
s00592-008-0090-3
561. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular 
disease and all cause mortality among patients with type 2 diabetes prescribed oral 
antidiabetes drugs: retrospective cohort study using UK general practice research 
database. BMJ 2009;339:b4731. https://doi.org/10.1136/bmj.b4731
562. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A Diabetes 
Outcome Progression Trial (ADOPT). An international multicenter study of the com­
parative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 
diabetes. Diabetes Care 2002;25:1737–1743. https://doi.org/10.2337/diacare.25.10. 
1737
563. Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, et al. Effect of 
nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 
362:1463–1476. https://doi.org/10.1056/NEJMoa1001122
564. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of 
macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 
1998;317:703–713. https://doi.org/10.1136/bmj.317.7160.703
565. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosigli­
tazone on the frequency of diabetes in patients with impaired glucose tolerance or im­
paired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–1105. 
https://doi.org/10.1016/S0140-6736(06)69420-8
566. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of 
heart failure in patients with or at high risk of type 2 diabetes mellitus. Am J Cardiovasc 
Drugs 2011;11:115–128. https://doi.org/10.2165/11587580-000000000-00000
567. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. 
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination ther­
apy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. 
Lancet 2009;373:2125–2135. https://doi.org/10.1016/S0140-6736(09)60953-3
568. Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, et al. Relationship 
between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the 
EMPA-REG OUTCOME® trial. Eur Heart J 2020;41:209–217. https://doi.org/10.1093/ 
eurheartj/ehz621
569. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes 
on long-term prognosis in patients with unstable angina and non-Q-wave myocardial 
infarction: results of the OASIS (Organization to Assess Strategies for Ischemic 
Syndromes) Registry. Circulation 2000;102:1014–1019. https://doi.org/10.1161/01. 
CIR.102.9.1014
570. Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K, et al. Prognostic implica­
tions of biomarker assessments in patients with type 2 diabetes at high cardiovascular 
risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol 2016;1:989–998. 
https://doi.org/10.1001/jamacardio.2016.3030
571. Tse G, Lai ETH, Tse V, Yeo JM. Molecular and electrophysiological mechanisms under­
lying cardiac arrhythmogenesis in diabetes mellitus. J Diabetes Res 2016;2016: 
2848759. https://doi.org/10.1155/2016/2848759
572. Koektuerk B, Aksoy M, Horlitz M, Bozdag-Turan I, Turan RG. Role of diabetes in heart 
rhythm disorders. World J Diabetes 2016;7:45. https://doi.org/10.4239/wjd.v7.i3.45
573. Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D’Agostino RB, et al. Trends in cardio­
vascular complications of diabetes. JAMA 2004;292:2495–2499. https://doi.org/10. 
1001/jama.292.20.2495
574. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and 
prior myocardial infarction on mortality from all causes and from coronary heart dis­
ease in men. J Am College Cardiol 2002;40:954–960. https://doi.org/10.1016/S0735- 
1097(02)02044-2
575. Balkau B, Jouven X, Ducimetière P, Eschwège E. Diabetes as a risk factor for sudden 
death. Lancet 1999;354:1968–1969. https://doi.org/10.1016/S0140-6736(99)04383-4
576. Gorenek B, Boriani G, Dan G-A, Fauchier L, Fenelon G, Huang H, et al. European Heart 
Rhythm Association (EHRA) position paper on arrhythmia management and device 
therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society 
(APHRS) and Latin American Heart Rhythm Society (LAHRS). Europace 2018;20: 
895–896. https://doi.org/10.1093/europace/euy051
577. Fauchier L, Boriani G, de Groot JR, Kreutz R, Rossing P, Camm AJ. Medical therapies 
for prevention of cardiovascular and renal events in patients with atrial fibrillation and 
diabetes mellitus. Europace 2021;23:1873–1891. https://doi.org/10.1093/europace/ 
euab184
578. Rautio E, Gadler F, Gudbjörnsdottir S, Franzén S, Rydén L, Svensson A-M, et al. Patients 
with type 2 diabetes have an increased demand for pacemaker treatment: a compari­
son with age-and sex-matched control subjects from the general population. Diabetes 
Care 2020;43:2853–2858. https://doi.org/10.2337/dc20-0084
579. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: developed by 
the Task Force on cardiac pacing and cardiac resynchronization therapy of the 
European Society of Cardiology (ESC) with the special contribution of the 
European Heart Rhythm Association (EHRA). Eur Heart J 2022;24:71–164. https:// 
doi.org/10.1093/eurheartj/ehab364
580. Jansen HJ, Bohne LJ, Gillis AM, Rose RA. Atrial remodeling and atrial fibrillation in ac­
quired forms of cardiovascular disease. Heart Rhythm O2 2020;1:147–159. https://doi. 
org/10.1016/j.hroo.2020.05.002
581. Reuter H, Grönke S, Adam C, Ribati M, Brabender J, Zobel C, et al. Sarcoplasmic Ca2 
+ release is prolonged in nonfailing myocardium of diabetic patients. Mol Cell Biochem 
2008;308:141–149. https://doi.org/10.1007/s11010-007-9622-3
582. Lamberts RR, Lingam SJ, Wang H-Y, Bollen IA, Hughes G, Galvin IF, et al. Impaired re­
laxation despite upregulated calcium-handling protein atrial myocardium from type 2 
diabetic patients with preserved ejection fraction. Cardiovasc Diabetol 2014;13:72. 
https://doi.org/10.1186/1475-2840-13-72
583. Sedgwick B, Riches K, Bageghni SA, O’Regan DJ, Porter KE, Turner NA. Investigating 
inherent functional differences between human cardiac fibroblasts cultured from non­
diabetic and type 2 diabetic donors. Cardiovasc Pathol 2014;23:204–210. https://doi. 
org/10.1016/j.carpath.2014.03.004
584. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, et al. A 
clinical risk score for atrial fibrillation in a biracial prospective cohort (from the 
Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011;107:85–91. 
https://doi.org/10.1016/j.amjcard.2010.08.049
585. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and pre­
disposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 
1998;82:2N–9N. https://doi.org/10.1016/S0002-9149(98)00583-9
586. Dahlqvist S, Rosengren A, Gudbjörnsdottir S, Pivodic A, Wedel H, Kosiborod M, et al. 
Risk of atrial fibrillation in people with type 1 diabetes compared with matched con­
trols from the general population: a prospective case-control study. Lancet Diabetes 
Endocrinol 2017;5:799–807. https://doi.org/10.1016/S2213-8587(17)30262-0
587. Lee Y-B, Han K, Kim B, Lee S-E, Jun JE, Ahn J, et al. Risk of early mortality and cardio­
vascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide 
study. Cardiovasc Diabetol 2019;18:157. https://doi.org/10.1186/s12933-019-0953-7
588. Bisson A, Bodin A, Fauchier G, Herbert J, Angoulvant D, Ducluzeau PH, et al. Sex, age, 
type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a 
nationwide analysis. Cardiovasc Diabetol 2021;20:1–11. https://doi.org/10.1186/ 
s12933-021-01216-7
ESC Guidelines                                                                                                                                                                                          4133


<!-- PAGE 92 -->

### Page 92

589. Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, et al. Diabetes melli­
tus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 2010;25:853–858. 
https://doi.org/10.1007/s11606-010-1340-y
590. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case–control 
studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011; 
108:56–62. https://doi.org/10.1016/j.amjcard.2011.03.004
591. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for 
stroke: the Framingham Study. Stroke 1991;22:983–988. https://doi.org/10.1161/01. 
str.22.8.983
592. Mahmoodi BK, Yatsuya H, Matsushita K, Sang Y, Gottesman RF, Astor BC, et al. 
Association of kidney disease measures with ischemic versus hemorrhagic strokes: 
pooled analyses of 4 prospective community-based cohorts. Stroke 2014;45: 
1925–1931. https://doi.org/10.1161/STROKEAHA.114.004900
593. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ 
Res 2017;120:472–495. https://doi.org/10.1161/CIRCRESAHA.116.308398
594. Patlolla SH, Lee H-C, Noseworthy PA, Wysokinski WE, Hodge DO, Greene EL, et al. 
Impact of diabetes mellitus on stroke and survival in patients with atrial fibrillation. Am J 
Cardiol 2020;131:33–39. https://doi.org/10.1016/j.amjcard.2020.06.049
595. Melduni RM, Lee H-C, Bailey KR, Miller FA Jr, Hodge DO, Seward JB, et al. Real-time 
physiologic biomarker for prediction of atrial fibrillation recurrence, stroke, and mor­
tality after electrical cardioversion: a prospective observational study. Am Heart J 2015; 
170:914–922. https://doi.org/10.1016/j.ahj.2015.07.027
596. Karayiannides S, Norhammar A, Landstedt-Hallin L, Friberg L, Lundman P. Prognostic 
impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe 
hypoglycaemia: a nationwide cohort study. Eur J Prev Cardiol 2022;29:1759–1769. 
https://doi.org/10.1093/eurjpc/zwac093
597. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial 
fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J 
Med 1995;98:476–484. https://doi.org/10.1016/S0002-9343(99)80348-9
598. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, et al. Metabolic 
syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine 
study. Circulation 2008;117:1255–1260. https://doi.org/10.1161/CIRCULATIONAHA. 
107.744466
599. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of in­
cident atrial fibrillation in women. J Am College Cardiol 2012;60:1421–1428. https://doi. 
org/10.1016/j.jacc.2012.06.030
600. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 
ESC Guidelines for the diagnosis and management of atrial fibrillation developed in col­
laboration with the European Association for Cardio-Thoracic Surgery (EACTS): the 
Task Force for the diagnosis and management of atrial fibrillation of the European 
Society of Cardiology (ESC) developed with the special contribution of the 
European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42: 
373–498. https://doi.org/10.1093/eurheartj/ehaa612
601. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of in­
tensive glycemic control on the incidence of atrial fibrillation and associated cardiovas­
cular outcomes in patients with type 2 diabetes mellitus (from the Action to Control 
Cardiovascular Risk in Diabetes Study). Am J Cardiol 2014;114:1217–1222. https://doi. 
org/10.1016/j.amjcard.2014.07.045
602. Liou Y-S, Yang F-Y, Chen H-Y, Jong G-P. Antihyperglycemic drugs use and new-onset 
atrial fibrillation: a population-based nested case control study. PLoS One 2018;13: 
e0197245. https://doi.org/10.1371/journal.pone.0197245
603. Zelniker TA, Bonaca MP, Furtado RH, Mosenzon O, Kuder JF, Murphy SA, et al. Effect 
of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights 
from the DECLARE-TIMI 58 trial. Circulation 2020;141:1227–1234. https://doi.org/ 
10.1161/CIRCULATIONAHA.119.044183
604. Böhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, et al. Efficacy of 
empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data 
from the EMPA-REG OUTCOME trial. Eur J Heart Fail 2020;22:126–135. https://doi. 
org/10.1002/ejhf.1663
605. Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, et al. Finerenone re­
duces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 
diabetes. J Am College Cardiol 2021;78:142–152. https://doi.org/10.1016/j.jacc.2021. 
04.079
606. Neefs J, Van den Berg N, Limpens J, Berger W, Boekholdt S, Sanders P, et al. 
Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and 
meta-analysis. Int J Cardiol 2017;231:155–161. https://doi.org/10.1016/j.ijcard.2016. 
12.029
607. Du X, Ninomiya T, De Galan B, Abadir E, Chalmers J, Pillai A, et al. Risks of cardiovas­
cular events and effects of routine blood pressure lowering among patients with type 2 
diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30: 
1128–1135. https://doi.org/10.1093/eurheartj/ehp055
608. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset 
diabetes mellitus on development of atrial fibrillation and heart failure in high-risk 
hypertension (from the VALUE Trial). Am J Cardiol 2008;101:634–638. https://doi. 
org/10.1016/j.amjcard.2007.10.025
609. Gallagher C, Hendriks JM, Mahajan R, Middeldorp ME, Elliott AD, Pathak RK, et al. 
Lifestyle management to prevent and treat atrial fibrillation. Expert Rev Cardiovas 
Ther 2016;14:799–809. https://doi.org/10.1080/14779072.2016.1179581
610. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation 
of risk stratification schemes for predicting stroke and thromboembolism in patients 
with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124. https://doi.org/10. 
1136/bmj.d124
611. Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased 
prevalence and incidence of atrial fibrillation. Diabetes Care 2009;32:1851–1856. 
https://doi.org/10.2337/dc09-0939
612. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, et al. Screening for 
atrial fibrillation: a report of the AF-SCREEN International Collaboration. Circulation 
2017;135:1851–1867. https://doi.org/10.1161/CIRCULATIONAHA.116.026693
613. Svennberg E, Tjong F, Goette A, Akoum N, Di Biase L, Bordachar P, et al. How to use 
digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace 
2022;24:979–1005. https://doi.org/10.1093/europace/euac038
614. Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, et al. Screening 
for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus docu­
ment endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society 
(APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia 
(SOLAECE). Europace 2017;19:1589–1623. https://doi.org/10.1093/europace/eux177
615. Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, et al. Catheter ablation 
of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized 
study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J 
Cardiovasc Electrophysiol 2009;20:22–28. https://doi.org/10.1111/j.1540-8167.2008. 
01275.x
616. Anselmino M, Matta M, D’ascenzo F, Pappone C, Santinelli V, Bunch TJ, et al. Catheter 
ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and 
meta-analysis. Europace 2015;17:1518–1525. 
https://doi.org/10.1093/europace/ 
euv214
617. Bogossian H, Frommeyer G, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, et al. 
Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus: 
who benefits and who does not? Data from the German ablation registry. Int J Cardiol 
2016;214:25–30. https://doi.org/10.1016/j.ijcard.2016.03.069
618. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification 
for predicting stroke and thromboembolism in atrial fibrillation using a novel risk 
factor-based approach: the Euro heart survey on atrial fibrillation. Chest 2010;137: 
263–272. https://doi.org/10.1378/chest.09-1584
619. Hughes M, Lip GY. Guideline Development Group for the NICE National Clinical 
Guideline for Management of Atrial Fibrillation in Primary Secondary Care. Stroke 
and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, 
risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99: 
295–304. https://doi.org/10.1160/TH07-08-0508
620. Aronow WS, Ahn C, Kronzon I, Gutstein H. Risk factors for new thromboembolic 
stroke in patients ≥62 years of age with chronic atrial fibrillation. Am J Cardiol 1998; 
82:A9. https://doi.org/10.1016/S0002-9149(98)00247-1
621. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in 
patients with atrial fibrillation: a systematic review. Neurology 2007;69:546–554. 
https://doi.org/10.1212/01.wnl.0000267275.68538.8d
622. Wang A, Green JB, Halperin JL, Piccini JP. Atrial fibrillation and diabetes mellitus: JACC 
review topic of the week. J Am College Cardiol 2019;74:1107–1115. https://doi.org/10. 
1016/j.jacc.2019.07.020
623. Proietti M, Lane DA, Boriani G, Lip GY. Stroke prevention, evaluation of bleeding risk, 
and anticoagulant treatment management in atrial fibrillation contemporary inter­
national guidelines. Can J Cardiol 2019;35:619–633. https://doi.org/10.1016/j.cjca. 
2019.02.009
624. Fauchier L, Bodin A, Bisson A. Editorial commentary: the CHA2DS2VASc score and its 
black and white items. Trends Cardiovasc Med 2019;29:392–393. https://doi.org/10. 
1016/j.tcm.2018.11.012
625. Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GY, et al. Glycemic 
status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes 
mellitus: a Danish cohort study. Circ Arrhythm Electrophysiol 2019;12:e007030. https:// 
doi.org/10.1161/CIRCEP.118.007030
626. Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic 
retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrilla­
tion: the Loire Valley Atrial Fibrillation Project. Chest 2015;147:1103–1110. https:// 
doi.org/10.1378/chest.14-2096
627. Itzhaki Ben Zadok O, Eisen A. Use of non-vitamin K oral anticoagulants in people with 
atrial fibrillation and diabetes mellitus. Diabet Med 2018;35:548–556. https://doi.org/ 
10.1111/dme.13600
628. Plitt A, McGuire DK, Giugliano RP. Atrial fibrillation, type 2 diabetes, and non–vitamin 
K antagonist oral anticoagulants: a review. JAMA Cardiol 2017;2:442–448. https://doi. 
org/10.1001/jamacardio.2016.5224
629. Plitt A, Zelniker TA, Park J-G, McGuire DK, Ruff CT, Antman EM, et al. Patients with 
diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral antic­
oagulants: meta-analysis of eight outcomes in 58634 patients across four randomized


<!-- PAGE 93 -->

### Page 93

controlled trials. Eur Heart J Cardiovasc Pharmacother 2021;7:f40–f49. https://doi.org/ 
10.1093/ehjcvp/pvaa120
630. Fitzmaurice DA, Hobbs FR, Jowett S, Mant J, Murray ET, Holder R, et al. Screening ver­
sus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster 
randomised controlled trial. BMJ 2007;335:383. https://doi.org/10.1136/bmj.39280. 
660567.55
631. Pallisgaard JL, Schjerning A-M, Lindhardt TB, Procida K, Hansen ML, Torp-Pedersen C, 
et al. Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study. Eur J Prev 
Cardiol 2016;23:621–627. https://doi.org/10.1177/2047487315599892
632. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk 
factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. 
JAMA 1994;271:840–844. https://doi.org/10.1001/jama.1994.03510350050036
633. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial 
fibrillation. Thromb Haemost 2013;110:213–222. https://doi.org/10.1160/TH13-02- 
0165
634. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibril­
lation in a 75-year-old population: implications for stroke prevention. Circulation 2013; 
127:930–937. https://doi.org/10.1161/CIRCULATIONAHA.112.126656
635. Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical out­
comes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, 
parallel group, unmasked, randomised controlled trial. Lancet 2021;398:1498–1506. 
https://doi.org/10.1016/S0140-6736(21)01637-8
636. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent 
stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 
857–867. https://doi.org/10.7326/0003-4819-146-12-200706190-00007
637. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. 
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in pa­
tients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383: 
955–962. https://doi.org/10.1016/S0140-6736(13)62343-0
638. Nielsen PB, Larsen TB, Skjøth F, Overvad TF, Lip GY. Stroke and thromboembolic 
event rates in atrial fibrillation according to different guideline treatment thresholds: 
a nationwide cohort study. Sci Rep 2016;6:27410. https://doi.org/10.1038/srep27410
639. Fauchier L, Clementy N, Bisson A, Ivanes F, Angoulvant D, Babuty D, et al. Should atrial 
fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be an­
ticoagulated? Stroke 2016;47:1831–1836. https://doi.org/10.1161/STROKEAHA.116. 
013253
640. Shin SY, Han S-J, Kim J-S, Im SI, Shim J, Ahn J, et al. Identification of markers associated 
with development of stroke in “clinically low-risk” atrial fibrillation patients. J Am Heart 
Assoc 2019;8:e012697. https://doi.org/10.1161/JAHA.119.012697
641. Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly 
score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibril­
lation: the Euro Heart Survey. Chest 2010;138:1093–1100. https://doi.org/10.1378/ 
chest.10-0134
642. Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting 
thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: 
a systematic review. Thromb Haemost 2018;118:2171–2187. https://doi.org/10.1055/s- 
0038-1675400
643. Chang G, Xie Q, Ma L, Hu K, Zhang Z, Mu G, et al. Accuracy of HAS-BLED and other 
bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: a 
network meta-analysis. J Thromb Haemost 2020;18:791–801. https://doi.org/10.1111/ 
jth.14692
644. Jouven X, Lemaître RN, Rea TD, Sotoodehnia N, Empana J-P, Siscovick DS. Diabetes, 
glucose level, and risk of sudden cardiac death. Eur Heart J 2005;26:2142–2147. https:// 
doi.org/10.1093/eurheartj/ehi376
645. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, 
et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in 
Communities study. Acta Diabetol 2010;47:161–168. https://doi.org/10.1007/s00592- 
009-0157-9
646. Eranti A, Kerola T, Aro AL, Tikkanen JT, Rissanen HA, Anttonen O, et al. Diabetes, 
glucose tolerance, and the risk of sudden cardiac death. BMC Cardiovasc Disord 
2016;16:51. https://doi.org/10.1186/s12872-016-0231-5
647. Zaccardi F, Khan H, Laukkanen JA. Diabetes mellitus and risk of sudden cardiac death: a 
systematic review and meta-analysis. Int J Cardiol 2014;177:535–537. https://doi.org/ 
10.1016/j.ijcard.2014.08.105
648. Kannel WB, Wilson PW, D’Agostino RB, Cobb J. Sudden coronary death in women. 
Am Heart J 1998;136:205–212. https://doi.org/10.1053/hj.1998.v136.90226
649. Chen-Scarabelli C, Scarabelli TM. Suboptimal glycemic control, independently of QT 
interval duration, is associated with increased risk of ventricular arrhythmias in a high- 
risk population. Pacing Clin Electrophysiol 2006;29:9–14. https://doi.org/10.1111/j.1540- 
8159.2006.00298.x
650. Secrest A, Becker D, Kelsey S, Laporte R, Orchard T. Characterizing sudden death and 
dead-in-bed syndrome in type 1 diabetes: analysis from two childhood-onset type 1 
diabetes registries. Diabet Med 2011;28:293–300. https://doi.org/10.1111/j.1464- 
5491.2010.03154.x
651. Tanenberg RJ, Newton CA, Drake AJ III. Confirmation of hypoglycemia in the 
“dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitor­
ing system. Endocr Pract 2010;16:244–248. https://doi.org/10.4158/EP09260.CR
652. NICE-Sugar Study Investigators. Hypoglycemia and risk of death in critically ill patients. 
N Engl J Med 2012;367:1108–1118. https://doi.org/10.1056/NEJMoa1204942
653. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. 
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl 
J Med 2011;364:818–828. https://doi.org/10.1056/NEJMoa1006524
654. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of 
intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559. 
https://doi.org/10.1056/NEJMoa0802743
655. Laurita KR, Khan S, McMahon T, Dennis AT, Li V, Gaivin R, et al. Ventricular arrhyth­
mias in mouse models of diabetic kidney disease. Sci Rep 2021;11:20570. https://doi. 
org/10.1038/s41598-021-99891-9
656. Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, et al. Risk of cardiac 
arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular 
risk. Diabetes 2014;63:1738–1747. https://doi.org/10.2337/db13-0468
657. Hay L, Wilmshurst E, Fulcher G. Unrecognized hypo- and hyperglycemia in well- 
controlled patients with type 2 diabetes mellitus: the results of continuous glucose 
monitoring. Diab Technol Therap 2003;5:19–26. https://doi.org/10.1089/152091503 
763816427
658. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 
the prevention of sudden cardiac death: the Task Force for the management of pa­
tients with ventricular arrhythmias and the prevention of sudden cardiac death of 
the European Society of Cardiology (ESC) endorsed by: association for European 
Paediatric and Congenital Cardiology (AEPC). Europace 2015;17:1601–1687. https:// 
doi.org/10.1093/europace/euv319
659. Ruwald MH, Zareba W, Jons C, Zhang C, Ruwald A-CH, Olshansky B, et al. Influence of 
diabetes mellitus on inappropriate and appropriate implantable cardioverter- 
defibrillator therapy and mortality in the Multicenter Automatic Defibrillator 
Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial. Circulation 
2013;128:694–701. https://doi.org/10.1161/CIRCULATIONAHA.113.002472
660. Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in 
type 2 diabetes mellitus: results of a long-term follow-up prospective study. J 
Diabetes Complications 2003;17:169–178. https://doi.org/10.1016/S1056-8727(02) 
00206-4
661. Kobayashi S, Nagao M, Asai A, Fukuda I, Oikawa S, Sugihara H. Severity and multiplicity 
of microvascular complications are associated with QT interval prolongation in pa­
tients with type 2 diabetes. J Diabetes Invest 2018;9:946–951. https://doi.org/10. 
1111/jdi.12772
662. Molon G, Costa A, Bertolini L, Zenari L, Arcaro G, Barbieri E, et al. Relationship be­
tween abnormal microvolt T-wave alternans and poor glycemic control in type 2 dia­
betic patients. Pacing Clin Electrophysiol 2007;30:1267–1272. https://doi.org/10.1111/j. 
1540-8159.2007.00849.x
663. O’Brien I, O’Hare J, Lewin I, Corrall R. The prevalence of autonomic neuropathy in 
insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. 
Q J Med 1986;61:957–967. https://doi.org/10.1093/oxfordjournals.qjmed.a068054
664. Tsuji H, Venditti Jr FJ, Manders ES, Evans JC, Larson MG, Feldman CL, et al. Reduced 
heart rate variability and mortality risk in an elderly cohort. The Framingham Heart 
Study. Circulation 1994;90:878–883. https://doi.org/10.1161/01.cir.90.2.878
665. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 
115:387–397. https://doi.org/10.1161/CIRCULATIONAHA.106.634949
666. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The ef­
fect of empagliflozin on arterial stiffness and heart rate variability in subjects with un­
complicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28. https://doi.org/ 
10.1186/1475-2840-13-28
667. Balcıoğlu S, Arslan U, Türkoğlu S, Özdemir M, Çengel A. Heart rate variability and heart 
rate turbulence in patients with type 2 diabetes mellitus with versus without cardiac 
autonomic neuropathy. Am J Cardiol 2007;100:890–893. https://doi.org/10.1016/j. 
amjcard.2007.03.106
668. Bissinger A, Ruxer J, Ahmed RB, Lubinski A. Heart rate turbulence in patients with 
poorly controlled diabetes mellitus type 2. Arch Med Sci 2014;10:1073–1077. https:// 
doi.org/10.5114/aoms.2014.47819
669. Kuppermann N, Park J, Glatter K, Marcin JP, Glaser NS. Prolonged QT interval cor­
rected for heart rate during diabetic ketoacidosis in children. Arch Pediatr Adolesc 
Med 2008;162:544–549. https://doi.org/10.1001/archpedi.162.6.544
670. Murphy N, Ford-Adams M, Ong K, Harris N, Keane S, Davies C, et al. Prolonged car­
diac repolarisation during spontaneous nocturnal hypoglycaemia in children and ado­
lescents with type 1 diabetes. Diabetologia 2004;47:1940–1947. https://doi.org/10. 
1007/s00125-004-1552-y
671. Ninkovic VM, Ninkovic SM, Miloradovic V, Stanojevic D, Babic M, Giga V, et al. 
Prevalence and risk factors for prolonged QT interval and QT dispersion in patients 
with type 2 diabetes. Acta Diabetol 2016;53:737–744. https://doi.org/10.1007/ 
s00592-016-0864-y
ESC Guidelines                                                                                                                                                                                          4135


<!-- PAGE 94 -->

### Page 94

672. Marfella R, Rossi F, Giugliano D. Hyperglycemia and QT interval: time for re-evaluation. 
Diabetes Nutr Metab 2001;14:63–65.
673. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Effect of da­
pagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in 
DAPA-HF. Eur Heart J 2021;42:3727–3738. https://doi.org/10.1093/eurheartj/ 
ehab560
674. Light PE. Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart fail­
ure. Eur Heart J 2021;42:3739–3740. https://doi.org/10.1093/eurheartj/ehab563
675. Sfairopoulos D, Zhang N, Wang Y, Chen Z, Letsas KP, Tse G, et al. Association be­
tween sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death 
or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace 
2022;24:20–30. https://doi.org/10.1093/europace/euab177
676. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of 
chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of 
Disease Study 2017. Lancet 2020;395:709–733. https://doi.org/10.1016/S0140- 
6736(20)30045-3
677. Kidney Disease: Improving Global Outcomes, CKD Work Group. KDIGO 2012 clin­
ical practice guideline for the evaluation and management of chronic kidney disease. 
Kidney Int 2013;3:1–150. https://doi.org/10.1038/kisup.2012.73
678. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- 
and cystatin C-based equations to estimate GFR without race. N Engl J Med 2021;385: 
1737–1749. https://doi.org/10.1056/NEJMoa2102953
679. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary 
events in people with chronic kidney disease compared with those with diabetes: a 
population-level cohort study. Lancet 2012;380:807–814. https://doi.org/10.1016/ 
S0140-6736(12)60572-8
680. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the 
risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351: 
1296–1305. https://doi.org/10.1056/NEJMoa041031
681. Levey AS, Eckardt K-U, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al. 
Nomenclature for kidney function and disease: report of a Kidney Disease: 
Improving Global Outcomes (KDIGO) consensus conference. Kidney Int 2020;97: 
1117–1129. https://doi.org/10.1016/j.kint.2020.02.010
682. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular 
filtration rate and albuminuria with all-cause and cardiovascular mortality in general 
population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–2081. 
https://doi.org/10.1016/S0140-6736(10)60674-5
683. Park JI, Baek H, Kim BR, Jung HH. Comparison of urine dipstick and albumin: creatinine 
ratio for chronic kidney disease screening: a population-based study. PLoS One 2017; 
12:e0171106. https://doi.org/10.1371/journal.pone.0171106
684. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change 
in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific 
workshop sponsored by the National Kidney Foundation in collaboration with the US 
Food and Drug Administration and European Medicines Agency. Am J Kidney Dis 2020; 
75:84–104. https://doi.org/10.1053/j.ajkd.2019.06.009
685. Levin A, Agarwal R, Herrington WG, Heerspink HL, Mann JF, Shahinfar S, et al. 
International consensus definitions of clinical trial outcomes for kidney failure: 2020. 
Kidney Int 2020;98:849–859. https://doi.org/10.1016/j.kint.2020.07.013
686. Park M, Hsu C-Y, Li Y, Mishra RK, Keane M, Rosas SE, et al. Associations between kid­
ney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012;23: 
1725–1734. https://doi.org/10.1681/ASN.2012020145
687. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolu­
tion of cardiomyopathy in dialysis patients. Kidney Int 1998;54:1720–1725. https://doi. 
org/10.1046/j.1523-1755.1998.00154.x
688. Suzuki T, Agarwal SK, Deo R, Sotoodehnia N, Grams ME, Selvin E, et al. Kidney func­
tion and sudden cardiac death in the community: the Atherosclerosis Risk in 
Communities (ARIC) Study. Am Heart J 2016;180:46–53. https://doi.org/10.1016/j. 
ahj.2016.07.004
689. Kono K, Fujii H, Nakai K, Goto S, Shite J, Hirata K-I, et al. Composition and plaque pat­
terns of coronary culprit lesions and clinical characteristics of patients with chronic kid­
ney disease. Kidney Int 2012;82:344–351. https://doi.org/10.1038/ki.2012.118
690. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media cal­
cification in end-stage renal disease: impact on all-cause and cardiovascular mortality. 
Nephrol Dial Transplant 2003;18:1731–1740. https://doi.org/10.1093/ndt/gfg414
691. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work 
Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, 
prevention, and treatment of chronic kidney disease–Mineral and Bone Disorder 
(CKD-MBD). Kidney Int Suppl 2017;7:1–59. https://doi.org/10.1016/j.kisu.2017.04.001
692. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular 
system. Circulation 2007;116:85–97. https://doi.org/10.1161/CIRCULATIONAHA. 
106.678342
693. Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, Cass A, et al. Blood pressure low­
ering and major cardiovascular events in people with and without chronic kidney dis­
ease: meta-analysis of randomised controlled trials. BMJ 2013;347:f5680. https://doi. 
org/10.1136/bmj.f5680
694. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of 
phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular 
disease in individuals with chronic kidney disease: a systematic review and 
meta-analysis. JAMA 2011;305:1119–1127. https://doi.org/10.1001/jama.2011.308
695. Zhu P, Herrington WG, Haynes R, Emberson J, Landray MJ, Sudlow CL, et al. 
Conventional and genetic evidence on the association between adiposity and CKD. 
J Am Soc Nephrol 2021;32:127–137. https://doi.org/10.1681/ASN.2020050679
696. Herrington WG, Smith M, Bankhead C, Matsushita K, Stevens S, Holt T, et al. 
Body-mass index and risk of advanced chronic kidney disease: prospective analyses 
from a primary care cohort of 1.4 million adults in England. PLoS One 2017;12: 
e0173515. https://doi.org/10.1371/journal.pone.0173515
697. Cholesterol Treatment Trialists’ (CTT) Collaboration. Impact of renal function on the 
effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of in­
dividual participant data from 28 randomised trials. Lancet Diab Endocrinol 2016;4: 
829–839. https://doi.org/10.1016/S2213-8587(16)30156-5
698. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects 
of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic 
kidney disease (Study of Heart and Renal Protection): a randomised placebo- 
controlled 
trial. 
Lancet 
2011;377:2181–2192. 
https://doi.org/10.1016/S0140- 
6736(11)60739-3
699. Charytan DM, Sabatine MS, Pedersen TR, Im K, Park J-G, Pineda AL, et al. Efficacy and 
safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am College 
Cardiol 2019;73:2961–2970. https://doi.org/10.1016/j.jacc.2019.03.513
700. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ 
EAS guidelines for the management of dyslipidaemias: lipid modification to reduce car­
diovascular 
risk. 
Atherosclerosis 
2019;290:140–205. 
https://doi.org/10.1016/j. 
atherosclerosis.2019.08.014
701. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. 
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J 
Med 2009;360:1395–1407. https://doi.org/10.1056/NEJMoa0810177
702. Wanner C, Krane V, März W, Olschewski M, Asmus H-G, Krämer W, et al. 
Randomized controlled trial on the efficacy and safety of atorvastatin in patients 
with type 2 diabetes on hemodialysis (4D study): demographic and baseline character­
istics. Kidney Blood Pressure Res 2004;27:259–266. https://doi.org/10.1159/000080241
703. Reith C, Staplin N, Herrington W, Stevens W, Emberson J, Haynes R, et al. Effect on 
non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney 
disease: results from the Study of Heart and Renal Protection. BMC Nephrol 2017; 
18:147. https://doi.org/10.1186/s12882-017-0545-2
704. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of flu­
vastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, 
placebo-controlled trial. Lancet 2003;361:2024–2031. https://doi.org/10.1016/S0140- 
6736(03)13638-0
705. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting- 
enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462. 
https://doi.org/10.1056/NEJM199311113292004
706. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. 
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 dia­
betes and nephropathy. N Engl J Med 2001;345:861–869. https://doi.org/10.1056/ 
NEJMoa011161
707. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective 
effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy 
due to type 2 diabetes. N Engl J Med 2001;345:851–860. https://doi.org/10.1056/ 
NEJMoa011303
708. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. 
The effect of irbesartan on the development of diabetic nephropathy in patients with 
type 2 diabetes. N Engl J Med 2001;345:870–878. https://doi.org/10.1056/NEJMoa 
011489
709. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of 
transition from incipient to overt nephropathy with telmisartan in patients with 
type 2 diabetes. Diabetes Care 2007;30:1577–1578. https://doi.org/10.2337/dc06-1998
710. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. 
Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J 
Med 2013;369:1892–1903. https://doi.org/10.1056/NEJMoa1303154
711. Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of 
dapagliflozin on major adverse kidney and cardiovascular events in patients with dia­
betic and non-diabetic chronic kidney disease: a prespecified analysis from the 
DAPA-CKD trial. Lancet Diabetes Endocrinol 2021;9:22–31. https://doi.org/10.1016/ 
S2213-8587(20)30369-7
712. Cherney DZ, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al. Pooled 
analysis of Phase III trials indicate contrasting influences of renal function on blood 
pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 2018; 
93:231–244. https://doi.org/10.1016/j.kint.2017.06.017
713. Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. 
Relative and absolute risk reductions in cardiovascular and kidney outcomes with ca­
nagliflozin across KDIGO risk categories: findings from the CANVAS program. Am J 
Kidney Dis 2021;77:23–34.e1. https://doi.org/10.1053/j.ajkd.2020.06.018


<!-- PAGE 95 -->

### Page 95

### 714 The Nuffield Department of Population Health Renal Studies Group, SGLT2 Inhibitor

Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of 
sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collabora­
tive meta-analysis of large placebo-controlled trials. Lancet 2022;400:1788–1801. 
https://doi.org/10.1016/S0140-6736(22)02074-8
715. Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of 
sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis 
of large placebo-controlled randomized trials. EClinicalMedicine 2021;41:101163. 
https://doi.org/10.1016/j.eclinm.2021.101163
716. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagli­
flozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377: 
2337–2348. https://doi.org/10.1056/NEJMoa1708337
717. Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, et al. Effect of min­
eralocorticoid receptor antagonists on proteinuria and progression of chronic kidney 
disease: a systematic review and meta-analysis. BMC Nephrol 2016;17:127. https://doi. 
org/10.1186/s12882-016-0337-0
718. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finere­
none on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383: 
2219–2229. https://doi.org/10.1056/NEJMoa2025845
719. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular 
events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 
385:2252–2263. https://doi.org/10.1056/NEJMoa2110956
720. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and 
kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney 
disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474–484. https://doi.org/10. 
1093/eurheartj/ehab777
721. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZ, Chertow GM, 
et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease 
(DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant 2020;35: 
1700–1711. https://doi.org/10.1093/ndt/gfaa234
722. Docherty KF, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Effects 
of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J 
2020;41:2379–2392. https://doi.org/10.1093/eurheartj/ehaa183
723. Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of min­
eralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR- 
Reduced. J Am College Cardiol 2021;77:1397–1407. https://doi.org/10.1016/j.jacc. 
2021.01.044
724. Shen L, Kristensen SL, Bengtsson O, Böhm M, de Boer RA, Docherty KF, et al. 
Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: 
an analysis of DAPA-HF. Heart Fail 2021;9:254–264. https://doi.org/10.1016/j.jchf. 
2020.11.009
725. Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in 
predominantly advanced CKD and type 2 diabetes with or without sodium-glucose 
cotransporter-2 inhibitor therapy. Kidney Int Rep 2022;7:36–45. https://doi.org/10. 
1016/j.ekir.2021.10.008
726. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, et al. Finerenone in 
patients with chronic kidney disease and type 2 diabetes by sodium–glucose cotran­
sporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 2022;45: 
2991–2998. https://doi.org/10.2337/dc22-0294
727. Weir MR, Slee A, Sun T, Balis D, Oh R, de Zeeuw D, et al. Effects of canagliflozin on 
serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) 
Program. Clin Kidney J 2021;14:1396–1402. https://doi.org/10.1093/ckj/sfaa133
728. Seidu S, Kunutsor SK, Topsever P, Khunti K. Benefits and harms of sodium-glucose 
co-transporter-2 inhibitors (SGLT2-I) and renin–angiotensin–aldosterone system inhi­
bitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: a systematic 
review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab 
2022;5:e00303. https://doi.org/10.1002/edm2.303
729. Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, et al. Blood 
pressure-lowering treatment for prevention of major cardiovascular diseases in peo­
ple with and without type 2 diabetes: an individual participant-level data meta-analysis. 
Lancet Diabetes Endocrinol 2022;10:645–654. https://doi.org/10.1016/S2213-8587(22) 
00172-3
730. Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-term 
benefits of intensive glucose control for preventing end-stage kidney disease: 
ADVANCE-ON. Diabetes Care 2016;39:694–700. https://doi.org/10.2337/dc15-2322
731. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong J, et al. Clinical pharmaco­
kinetics of metformin. Clin Pharmacokinet 2011;50:81–98. https://doi.org/10.2165/ 
11534750-000000000-00000
732. Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC, et al. Population 
pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes 
mellitus: simulation of doses according to renal function. Clin Pharmacokinet 2013; 
52:373–384. https://doi.org/10.1007/s40262-013-0046-9
733. Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, 
et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and 
moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, 
randomised trial. Lancet Diabetes Endocrinol 2018;6:605–617. https://doi.org/10. 
1016/S2213-8587(18)30104-9
734. ClinicalTrials.gov. FLOW: A Research Study to See How Semaglutide Works Compared to 
Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW). https:// 
clinicaltrials.gov/ct2/show/NCT03819153 (4 March 2023)
735. Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, et al. 
Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2022;2: 
CD008834. https://doi.org/10.1002/14651858.CD008834.pub4
736. Molnar AO, Bota SE, Garg AX, Harel Z, Lam N, McArthur E, et al. The risk of major 
hemorrhage with CKD. J Am Soc Nephrol 2016;27:2825–2832. https://doi.org/10.1681/ 
ASN.2015050535
737. ClinicalTrials.gov. Aspirin to Target Arterial Events in Chronic Kidney Disease (ATTACK). 
https://clinicaltrials.gov/ct2/show/NCT03796156 (19 April 2022)
738. ClinicalTrials.gov. Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in 
Advanced 
Chronic 
Kidney 
Disease 
(TRACK). 
https://clinicaltrials.gov/ct2/show/ 
NCT03969953 (19 April 2022)
739. Bangalore S, Maron DJ, O’Brien SM, Fleg JL, Kretov EI, Briguori C, et al. Management of 
coronary disease in patients with advanced kidney disease. N Engl J Med 2020;382: 
1608–1618. https://doi.org/10.1056/NEJMoa1915925
740. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, et al. Initial 
invasive or conservative strategy for stable coronary disease. N Engl J Med 2020;382: 
1395–1407. https://doi.org/10.1056/NEJMoa1915922
741. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, et al. 
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J 
Med 2012;367:2482–2494. https://doi.org/10.1056/NEJMoa1205624
742. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. 
Effect of calcium-based versus non-calcium-based phosphate binders on mortality in 
patients with chronic kidney disease: an updated systematic review and meta-analysis. 
Lancet 2013;382:1268–1277. https://doi.org/10.1016/S0140-6736(13)60897-1
743. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of 
phosphate binders in CKD: a systematic review of randomized controlled trials. Am 
J Kidney Dis 2009;54:619–637. https://doi.org/10.1053/j.ajkd.2009.06.004
744. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, De Zeeuw D, Eckardt K-U, et al. A 
trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 
2009;361:2019–2032. https://doi.org/10.1056/NEJMoa0907845
745. George C, Echouffo-Tcheugui JB, Jaar BG, Okpechi IG, Kengne AP. The need for 
screening, early diagnosis, and prediction of chronic kidney disease in people with dia­
betes in low- and middle-income countries—a review of the current literature. BMC 
Med 2022;20:1–12. https://doi.org/10.1186/s12916-022-02438-6
746. Spertus JA, Jones PG, Maron DJ, Mark DB, O’Brien SM, Fleg JL, et al. Health status after 
invasive or conservative care in coronary and advanced kidney disease. N Engl J Med 
2020;382:1619–1628. https://doi.org/10.1056/NEJMoa1916374
747. Aboyans V, Ricco J-B, Bartelink M-L, Björck M, Brodmann M, Cohner T, et al. 2017 ESC 
Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collabor­
ation with the European Society for Vascular Surgery (ESVS). Eur Heart J 2017;39: 
763–816. https://doi.org/10.1093/eurheartj/ehx095
748. Keller K, Schmitt VH, Vosseler M, Brochhausen C, Münzel T, Hobohm L, et al. Diabetes 
mellitus and its impact on patient-profile and in-hospital outcomes in peripheral artery 
disease. J Clin Med 2021;10:5033. https://doi.org/10.3390/jcm10215033
749. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. 
Comparison of global estimates of prevalence and risk factors for peripheral artery dis­
ease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382:1329–1340. 
https://doi.org/10.1016/S0140-6736(13)61249-0
750. Malyar NM, Freisinger E, Meyborg M, Lüders F, Gebauer K, Reinecke H, et al. 
Amputations and mortality in in-hospital treated patients with peripheral artery dis­
ease and diabetic foot syndrome. J Diabetes Complications 2016;30:1117–1122. 
https://doi.org/10.1016/j.jdiacomp.2016.03.033
751. American Diabetes Association. Peripheral arterial disease in people with diabetes. 
Diabetes Care 2003;26:3333–3341. https://doi.org/10.2337/diacare.26.12.3333
752. Armstrong DG, Boulton AJ, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J 
Med 2017;376:2367–2375. https://doi.org/10.1056/NEJMra1615439
753. Buso G, Aboyans V, Mazzolai L. Lower extremity artery disease in patients with type 2 
diabetes. Eur J Prev Cardiol 2019;26(2_suppl):114–124. https://doi.org/10.1177/ 
2047487319880044
754. Beckman JA, Duncan MS, Damrauer SM, Wells QS, Barnett JV, Wasserman DH, et al. 
Microvascular disease, peripheral artery disease, and amputation. Circulation 2019;140: 
449–458. https://doi.org/10.1161/CIRCULATIONAHA.119.040672
755. Behroozian A, Beckman JA. Microvascular disease increases amputation in patients 
with peripheral artery disease. Arterioscler Thromb Vasc Biol 2020;40:534–540. 
https://doi.org/10.1161/ATVBAHA.119.312859
756. Walsh J, Hoffstad O, Sullivan M, Margolis D. Association of diabetic foot ulcer and 
death in a population-based cohort from the United Kingdom. Diabet Med 2016;33: 
1493–1498. https://doi.org/10.1111/dme.13054
757. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular 
guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc 
Endovasc Surg 2019;58:S1–S109.e33. https://doi.org/10.1016/j.ejvs.2019.05.006
ESC Guidelines                                                                                                                                                                                          4137


<!-- PAGE 96 -->

### Page 96

758. Mills JL Sr, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, et al. 
The society for vascular surgery lower extremity threatened limb classification system: 
risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014; 
59:220–234. https://doi.org/10.1016/j.jvs.2013.08.003
759. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 
ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering 
acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The 
Task Force for the Diagnosis and Treatment of Aortic Diseases of the European 
Society of Cardiology (ESC). Eur Heart J 2014;35:2873–2926. https://doi.org/10. 
1093/eurheartj/ehu281
760. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116: 
1509–1526. https://doi.org/10.1161/CIRCRESAHA.116.303849
761. Hinchliffe RJ, Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP, et al. Guidelines 
on diagnosis, prognosis, and management of peripheral artery disease in patients with 
foot ulcers and diabetes (IWGDF 2019 update). Diabetes/Metab Res Rev 2020;36: 
e3276. https://doi.org/10.1002/dmrr.3276
762. Tehan PE, Barwick AL, Sebastian M, Chuter VH. Diagnostic accuracy of the postexer­
cise ankle–brachial index for detecting peripheral artery disease in suspected claudi­
cants with and without diabetes. Vasc Med 2018;23:116–125. https://doi.org/10. 
1177/1358863X17751259
763. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. 
Measurement and interpretation of the ankle-brachial index: a scientific statement 
from the American Heart Association. Circulation 2012;126:2890–2909. https://doi. 
org/10.1161/CIR.0b013e318276fbcb
764. Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, et al. 
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and 
peripheral artery disease. Diabetes Obes Metab 2022;24:1288–1299. https://doi.org/ 
10.1111/dom.14700
765. Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al. 
Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes 
mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. 
Circulation 
2018;137:405–407. 
https://doi.org/10.1161/CIRCULATIONAHA.117. 
032031
766. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban 
with or without aspirin in patients with stable peripheral or carotid artery disease: an 
international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391: 
219–229. https://doi.org/10.1016/S0140-6736(17)32409-1
767. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, et al. Major adverse limb 
events and mortality in patients with peripheral artery disease: the COMPASS trial. J 
Am College Cardiol 2018;71:2306–2315. https://doi.org/10.1016/j.jacc.2018.03.008
768. Hinchliffe RJ, Brownrigg J, Andros G, Apelqvist J, Boyko EJ, Fitridge R, et al. Effectiveness 
of revascularization of the ulcerated foot in patients with diabetes and peripheral ar­
tery disease: a systematic review. Diabetes Metab Res Rev 2016;32:136–144. https://doi. 
org/10.1002/dmrr.2705
769. Venermo M, Sprynger M, Desormais I, Björck M, Brodmann M, Cohnert T, et al. 
Follow-up of patients after revascularisation for peripheral arterial diseases: a consen­
sus document from the European Society of Cardiology Working Group on Aorta and 
Peripheral Vascular Diseases and the European Society for Vascular Surgery. Eur J Prev 
Cardiol 2019;26:1971–1984. https://doi.org/10.1177/2047487319846999
770. Wu T-W, Chou C-L, Cheng C-F, Lu S-X, Wang L-Y. Prevalences of diabetes mellitus 
and carotid atherosclerosis and their relationships in middle-aged adults and elders: a 
community-based study. J Formosan Med Assoc 2021;121:1133–1140. https://doi.org/ 
10.1016/j.jfma.2021.10.005
771. Lacroix P, Aboyans V, Criqui M, Bertin F, Bouhamed T, Archambeaud F, et al. Type-2 
diabetes and carotid stenosis: a proposal for a screening strategy in asymptomatic pa­
tients. Vasc Med 2006;11:93–99. https://doi.org/10.1191/1358863(06vm677oa
772. Weyer GW, Davis AM. Screening for asymptomatic carotid artery stenosis. JAMA 
2015;313:192–194. https://doi.org/10.1001/jama.2014.16804
773. Hussain MA, Bin-Ayeed SA, Saeed OQ, Verma S, Al-Omran M. Impact of diabetes on 
carotid artery revascularization. J Vasc Surg 2016;63:1099–1107. https://doi.org/10. 
1016/j.jvs.2015.12.041
774. Lal BK, Beach KW, Roubin GS, Lutsep HL, Moore WS, Malas MB, et al. Restenosis after 
carotid artery stenting and endarterectomy: a secondary analysis of CREST, a rando­
mised controlled trial. Lancet Neurol 2012;11:755–763. https://doi.org/10.1016/S1474- 
4422(12)70159-X
775. Pafili K, Gouni-Berthold I, Papanas N, Mikhailidis DP. Abdominal aortic aneurysms and 
diabetes mellitus. J Diabetes Complications 2015;29:1330–1336. https://doi.org/10. 
1016/j.jdiacomp.2015.08.011
776. Nikol S, Mathias K, Olinic DM, Blinc A, Espinola-Klein C. Aneurysms and dissections – 
what is new in the literature of 2019/2020 – a European Society of Vascular Medicine 
annual review. Vasa 2020;49:1–36. https://doi.org/10.1024/0301-1526/a000865
777. Dattani N, Sayers RD, Bown MJ. Diabetes mellitus and abdominal aortic aneurysms: a 
review of the mechanisms underlying the negative relationship. Diab Vasc Dis Res 2018; 
15:367–374. https://doi.org/10.1177/1479164118780799
778. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. 
Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in 
patients with peripheral artery disease: insights from the FOURIER trial (Further 
Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With 
Elevated 
Risk). 
Circulation 
2018;137:338–350. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.117.032235
779. Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in 
patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY 
OUTCOMES trial. J Am College Cardiol 2019;74:1167–1176. https://doi.org/10.1016/ 
j.jacc.2019.03.013
780. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and 
risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 
1 and type 2 diabetes: a cohort study. Diabetes Care 2015;38:316–322. https://doi.org/ 
10.2337/dc14-0920
781. Vergès B. Cardiovascular disease in type 1 diabetes: a review of epidemiological data 
and underlying mechanisms. Diabetes Metab 2020;46:442–449. https://doi.org/10. 
1016/j.diabet.2020.09.001
782. Jørgensen ME, Almdal TP, Carstensen B. Time trends in mortality rates in type 1 dia­
betes from 2002 to 2011. Diabetologia 2013;56:2401–2404. https://doi.org/10.1007/ 
s00125-013-3025-7
783. Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, et al. Risk of 
cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish regis­
try linkage study. PLoS One 2012;9:e1001321. https://doi.org/10.1371/journal.pmed. 
1001321
784. Lind M, Svensson A-M, Rosengren A. Glycemic control and excess mortality in type 1 
diabetes. N Engl J Med 2015;372:880–881. https://doi.org/10.1056/nejmc1415677
785. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive 
diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J 
Med 2005;353:2643–2653. https://doi.org/10.1056/NEJMoa052187
786. Zinman B, Genuth S, Nathan DM. The diabetes control and complications trial/epi­
demiology of diabetes interventions and complications study: 30th anniversary presen­
tations. Diabetes Care 2014;37:8. https://doi.org/10.2337/dc13-2111
787. Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM, DCCT/EDIC Research Group. 
Mediation of the effect of glycemia on the risk of CVD outcomes in type 1 diabetes: the 
DCCT/EDIC study. Diabetes Care 2019;42:1284–1289. https://doi.org/10.2337/dc18- 
1613
788. Rawshani A, Rawshani A, Sattar N, Franzén S, McGuire DK, Eliasson B, et al. Relative 
prognostic importance and optimal levels of risk factors for mortality and cardiovas­
cular outcomes in type 1 diabetes mellitus. Circulation 2019;139:1900–1912. https:// 
doi.org/10.1161/CIRCULATIONAHA.118.037454
789. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjörnsdottir S; Swedish 
National Diabetes Register. A new model for 5-year risk of cardiovascular disease in 
Type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med 
2011;28:1213–1220. https://doi.org/10.1111/j.1464-5491.2011.03342.x
790. Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. 
Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the Steno 
Type 1 Risk Engine. Circulation 2016;133:1058–1066. https://doi.org/10.1161/ 
CIRCULATIONAHA.115.018844
791. Rawshani A, Sattar N, Franzén S, Rawshani A, Hattersley AT, Svensson A-M, et al. 
Excess mortality and cardiovascular disease in young adults with type 1 diabetes in re­
lation to age at onset: a nationwide, register-based cohort study. Lancet 2018;392: 
477–486. https://doi.org/10.1016/S0140-6736(18)31506-X
792. Miller RG, Costacou T, Orchard TJ. Risk factor modeling for cardiovascular disease in 
type 1 diabetes in the Pittsburgh epidemiology of diabetes complications (EDC) study: 
a comparison with the diabetes control and complications trial/epidemiology of dia­
betes interventions and complications study (DCCT/EDIC). Diabetes 2019;68: 
409–419. https://doi.org/10.2337/db18-0515
793. McGurnaghan SJ, McKeigue PM, Read SH, Franzen S, Svensson A-M, Colombo M, et al. 
Development and validation of a cardiovascular risk prediction model in type 1 dia­
betes. Diabetologia 2021;64:2001–2011. https://doi.org/10.1007/s00125-021-05478-4
794. Teoh I, Elisaus P, Schofield J. Cardiovascular risk management in type 1 diabetes. Curr 
Diabetes Rep 2021;21:29. https://doi.org/10.1007/s11892-021-01400-9
795. Wu N, Bredin SS, Guan Y, Dickinson K, Kim DD, Chua Z, et al. Cardiovascular health 
benefits of exercise training in persons living with type 1 diabetes: a systematic review 
and meta-analysis. J Clin Med 2019;8:253. https://doi.org/10.3390/jcm8020253
796. Ciriacks K, Coly G, Krishnaswami S, Patel SB, Kidambi S. Effects of simvastatin and eze­
timibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 
2 diabetes mellitus. Metab Syndr Relat Disord 2015;13:84–90. https://doi.org/10.1089/ 
met.2014.0114
797. Tell S, Nadeau KJ, Eckel RH. Lipid management for cardiovascular risk reduction in type 
1 diabetes. Curr Opin Endocrinol Diabetes Obes 2020;27:207. https://doi.org/10.1097/ 
MED.0000000000000551
798. Guo J, Brooks MM, Muldoon MF, Naimi AI, Orchard TJ, Costacou T. Optimal blood 
pressure thresholds for minimal coronary artery disease risk in type 1 diabetes. 
Diabetes Care 2019;42:1692–1699. https://doi.org/10.2337/dc19-0480
799. Lithovius R, Gordin D, Forsblom C, Saraheimo M, Harjutsalo V, Groop P-H; FinnDiane 
Study Group. Ambulatory blood pressure and arterial stiffness in individuals with type


<!-- PAGE 97 -->

### Page 97

1 diabetes. Diabetologia 2018;61:1935–1945. https://doi.org/10.1007/s00125-018- 
4648-5
800. Kalyani RR, Cannon CP, Cherrington AL, Coustan DR, De Boer IH, Feldman H, et al. 
Professional practice committee: standards of medical care in Diabetes-2018. Diabetes 
Care 2018;41:S3. https://doi.org/10.2337/dc18-SPPC01
801. Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, et al. 
Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the 
ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 2016;39: 
1702–1710. https://doi.org/10.2337/dc16-0691
802. Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S. 
Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients 
with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double- 
blind parallel study. Diabetes Care 2015;38:2250–2257. https://doi.org/10.2337/dc15- 
1037
803. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium-glucose 
co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: 
systematic review and meta-analysis of randomized controlled trials. Diabetes Obes 
Metab 2018;20:1755–1761. https://doi.org/10.1111/dom.13260
804. Fattah H, Vallon V. The potential role of SGLT2 inhibitors in the treatment of type 1 
diabetes mellitus. Drugs 2018;78:717–726. https://doi.org/10.1007/s40265-018-0901-y
805. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 
diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibi­
tors? A meta-analysis of individual patient data. Ann Intern Med 2001;134:370–379. 
https://doi.org/10.7326/0003-4819-134-5-200103060-00009
806. Lambrinou E, Hansen TB, Beulens JW. Lifestyle factors, self-management and patient 
empowerment in diabetes care. Eur J Prev Cardiol 2019;26(2_suppl):55–63. https://doi. 
org/10.1177/2047487319885455
807. Lambrinou E, Kyriakou M, Lakatamitou I, Angus N, Khatib R, Vellone E, et al. An inte­
grative review on facilitators and barriers in delivering and managing injectable therap­
ies in chronic conditions: a part of the ACNAP project ‘injectable medicines among 
patients with cardiovascular conditions’. Eur J Cardiovasc Nursing 2020;19:663–680. 
https://doi.org/10.1177/1474515120939007
808. Jennings C, Astin F. A multidisciplinary approach to prevention. Eur J Prev Cardiol 2017; 
24(3_suppl):77–87. https://doi.org/10.1177/2047487317709118
809. Chen Y, Tian Y, Sun X, Wang B, Huang X. Effectiveness of empowerment-based inter­
vention on HbA1c and self-efficacy among cases with type 2 diabetes mellitus: a 
meta-analysis of randomized controlled trials. Medicine (Baltimore) 2021;100: 
e27353. https://doi.org/10.1097/MD.0000000000027353
810. Galati G, Sabouret P, Germanova O, Bhatt DL. Women and diabetes: preventing heart 
disease in a new era of therapies. Eur Cardiol 2021;16:e40. https://doi.org/10.15420/ecr. 
2021.22
811. Deakin TA, McShane CE, Cade JE, Williams R. Group based training for self- 
management strategies in people with type 2 diabetes mellitus. Cochrane Database 
Syst Rev 2005;2:CD003417. https://doi.org/10.1002/14651858.CD003417.pub2
812. Steinsbekk A, Rygg L, Lisulo M, Rise MB, Fretheim A. Group based diabetes self- 
management education compared to routine treatment for people with type 2 dia­
betes mellitus. A systematic review with meta-analysis. BMC Health Services Res 
2012;12:213. https://doi.org/10.1186/1472-6963-12-213
813. Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, et al. Insulin and glucose-lowering 
agents for treating people with diabetes and chronic kidney disease. Cochrane Database 
Syst Rev 2018;9:CD011798. https://doi.org/10.1002/14651858.CD011798.pub2
814. Tan SM, Han E, Quek RYC, Singh SR, Gea-Sánchez M, Legido-Quigley H. A systematic 
review of community nursing interventions focusing on improving outcomes for indi­
viduals exhibiting risk factors of cardiovascular disease. J Adv Nursing 2020;76:47–61. 
https://doi.org/10.1111/jan.14218
815. Snaterse M, Dobber J, Jepma P, Peters RJ, Ter Riet G, Boekholdt SM, et al. Effective 
components of nurse-coordinated care to prevent recurrent coronary events: a sys­
tematic review and meta-analysis. Heart 2016;102:50–56. https://doi.org/10.1136/ 
heartjnl-2015-308050
816. Carrington MJ, Zimmet PZ. Nurse co-ordinated health and lifestyle modification for 
reducing multiple cardio-metabolic risk factors in regional adults: outcomes from 
the MODERN randomized controlled trial. Eur J Cardiovasc Nursing 2022;21:26–35. 
https://doi.org/10.1093/eurjcn/zvab042
817. Seidu S, Cos X, Brunton S, Harris S, Jansson SP, Mata-Cases M, et al. A disease state 
approach to the pharmacological management of type 2 diabetes in primary care: a 
position statement by Primary Care Diabetes Europe. Primary Care Diabetes 2021; 
15:31–51. https://doi.org/10.1016/j.pcd.2020.05.004
818. Goldwater D, Wenger NK. Patient-centered care in geriatric cardiology. Trends 
Cardiovasc Med 2023;33:13–20. doi:10.1016/j.tcm.2021.11.001
819. Ekman I, Wolf A, Olsson L-E, Taft C, Dudas K, Schaufelberger M, et al. Effects of 
person-centred care in patients with chronic heart failure: the PCC-HF study. Eur 
Heart J 2012;33:1112–1119. https://doi.org/10.1093/eurheartj/ehr306
820. Elissen AM, Hertroijs DF, Schaper NC, Bosma H, Dagnelie PC, Henry RM, et al. 
Differences in biopsychosocial profiles of diabetes patients by level of glycaemic con­
trol and health-related quality of life: the Maastricht Study. PLoS One 2017;12: 
e0182053. https://doi.org/10.1371/journal.pone.0182053
821. Odgers-Jewell K, Ball L, Kelly J, Isenring E, Reidlinger D, Thomas R. Effectiveness of 
group-based self-management education for individuals with type 2 diabetes: a system­
atic review with meta-analyses and meta-regression. Diabet Med 2017;34:1027–1039. 
https://doi.org/10.1111/dme.13340
822. Coulter A, Entwistle VA, Eccles A, Ryan S, Shepperd S, Perera R. Personalised care 
planning for adults with chronic or long-term health conditions. Cochrane Database 
Syst Rev 2015;2015:CD010523. https://doi.org/10.1002/14651858.CD010523.pub2
823. Lewin S, Skea Z, Entwistle VA, Zwarenstein M, Dick J. Interventions for providers to 
promote a patient-centred approach in clinical consultations. Cochrane Database Syst 
Rev 2001;4:CD003267. https://doi.org/10.1002/14651858.CD003267
824. Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, et al. Person-centered 
care—ready for prime time. Eur J Cardiovasc Nursing 2011;10:248–251. https://doi.org/ 
10.1016/j.ejcnurse.2011.06.008
825. Aquino JA, Baldoni NR, Flôr CR, Sanches C, Oliveira CDL, Alves GCS, et al. 
Effectiveness of individual strategies for the empowerment of patients with diabetes 
mellitus: a systematic review with meta-analysis. Primary Care Diabetes 2018;12: 
97–110. https://doi.org/10.1016/j.pcd.2017.10.004
826. Cox DJ, Taylor AG, Singh H, Moncrief M, Diamond A, Yancy WS Jr, et al. Glycemic 
load, exercise, and monitoring blood glucose (GEM): a paradigm shift in the treatment 
of type 2 diabetes mellitus. Diabetes Res Clin Pract 2016;111:28–35. https://doi.org/10. 
1016/j.diabres.2015.10.021
827. Schulman-Green D, Jaser SS, Park C, Whittemore R. A metasynthesis of factors affect­
ing self-management of chronic illness. J Adv Nursing 2016;72:1469–1489. https://doi. 
org/10.1111/jan.12902
828. Dunn JA, Chokron Garneau H, Filipowicz H, Mahoney M, Seay-Morrison T, Dent K, 
et al. What are patient preferences for integrated behavioral health in primary care? 
J Primary Care Community Health 2021;12:21501327211049053. https://doi.org/10. 
1177/21501327211049053
829. Piepoli MF, Villani GQ. Lifestyle modification in secondary prevention. Eur J Prev Cardiol 
2017;24(3_suppl):101–107. https://doi.org/10.1177/2047487317703828
830. Kyriakou M, Samara A, Philippou K, Lakatamitou I, Lambrinou E. A qualitative meta- 
synthesis of patients with heart failure perceived needs. Rev Cardiovasc Med 2021; 
22:853–864. https://doi.org/10.31083/j.rcm2203091
831. Greenwood DA, Blozis SA, Young HM, Nesbitt TS, Quinn CC. Overcoming clinical 
inertia: a randomized clinical trial of a telehealth remote monitoring intervention using 
paired glucose testing in adults with type 2 diabetes. J Med Internet Res 2015;17:e4112. 
https://doi.org/10.2196/jmir.4112
832. McCarrier KP, Ralston JD, Hirsch IB, Lewis G, Martin DP, Zimmerman FJ, et al. 
Web-based collaborative care for type 1 diabetes: a pilot randomized trial. Diabetes 
Technol Ther 2009;11:211–217. https://doi.org/10.1089/dia.2008.0063
833. Sigurdardottir AK, Benediktsson R, Jonsdottir H. Instruments to tailor care of people 
with type 2 diabetes. J Adv Nursing 2009;65:2118–2130. https://doi.org/10.1111/j.1365- 
2648.2009.05040.x
834. Wu H-C, Tan S, Yeh C, Wu S. A study on efficacy of empowerment training among 
diabetes patients. Life Sci J 2011;8:215–219. https://doi.org/10.7537/marslsj080311.39
835. Clayton JA, Gaugh MD. Sex as a biological variable in cardiovascular diseases: JACC 
focus seminar 1/7. J Am College Cardiol 2022;79:1388–1397. https://doi.org/10.1016/j. 
jacc.2021.10.050
836. Nussbaum SS, Henry S, Yong CM, Daugherty SL, Mehran R, Poppas A. Sex-specific 
considerations in the presentation, diagnosis, and management of ischemic heart dis­
ease: JACC focus seminar 2/7. J Am College Cardiol 2022;79:1398–1406. https://doi.org/ 
10.1016/j.jacc.2021.11.065
837. Gaudino M, Di Franco A, Cao D, Giustino G, Bairey Merz CN, Fremes SE, et al. 
Sex-related outcomes of medical, percutaneous, and surgical interventions for coron­
ary artery disease: JACC focus seminar 3/7. J Am College Cardiol 2022;79:1407–1425. 
https://doi.org/10.1016/j.jacc.2021.07.066
838. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European Society of 
Cardiology methodology for the development of quality indicators for the quantifica­
tion of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes 2022;8: 
4–13. https://doi.org/10.1093/ehjqcco/qcaa069
839. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the United 
Kingdom after removal of financial incentives. N Engl J Med 2018;379:948–957. https:// 
doi.org/10.1056/NEJMsa1801495
840. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality 8 
years into global payment. N Engl J Med 2019;381:252–263. https://doi.org/10.1056/ 
NEJMsa1813621
841. Arbelo EC, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indica­
tors for the care and outcomes of adults with atrial fibrillation: Task Force for the de­
velopment of quality indicators in atrial fibrillation of the European Heart Rhythm 
Association (EHRA) of the European Society of Cardiology (ESC): developed in collab­
oration with the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society 
(APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace 2021;23: 
494–495. https://doi.org/10.1093/europace/euaa253
842. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet J-P, et al. 2020 update of the 
quality indicators for acute myocardial infarction: a position paper of the Association 
for Acute Cardiovascular Care: the study group for quality indicators from the ACVC 
ESC Guidelines                                                                                                                                                                                          4139


<!-- PAGE 98 -->

### Page 98

and the NSTE-ACS guideline group. Eur Heart J Acute Cardiovasc Care 2021;10: 
224–233. https://doi.org/10.1093/ehjacc/zuaa037
843. Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomström-Lundqvist C, et al. 
European Society of Cardiology Quality Indicators for the care and outcomes of car­
diac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in 
collaboration with the European Heart Rhythm Association of the European Society 
of Cardiology. Europace 2022;24:165–172. https://doi.org/10.1093/europace/euab193
844. Aktaa S, Gencer B, Arbelo E, Davos CH, Désormais I, Hollander M, et al. European 
Society of Cardiology Quality Indicators for cardiovascular disease prevention: 
developed by the working group for cardiovascular disease prevention quality indica­
tors in collaboration with the European Association for Preventive Cardiology of the 
European Society of Cardiology. Eur J Prev Cardiol 2022;29:1060–1071. https://doi.org/ 
10.1093/eurjpc/zwab160
845. Aktaa S, Yadegarfar ME, Wu J, Rashid M, de Belder M, Deanfield J, et al. Quality of acute 
myocardial infarction care in England and Wales during the COVID-19 pandemic: 
linked nationwide cohort study. BMJ Qual Saf 2022;31:116–122. https://doi.org/10. 
1136/bmjqs-2021-013040

<!-- 2023_Cardiomyopathies.md -->

# ESC Guidelines: Cardiomyopathies (2023)

**Source**: `2023_Cardiomyopathies.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 124

---

## Table of Contents

- [2023 ESC Guidelines for the management of cardiomyopathies](#2023-esc-guidelines-for-the-management-of-cardiomy) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 9)*
  - [3. Phenotypic approach to cardiomyopathies](#3-phenotypic-approach-to-cardiomyopathies) *(p. 9)*
    - [3.1. Definitions](#31-definitions) *(p. 12)*
    - [3.2. Cardiomyopathy phenotypes](#32-cardiomyopathy-phenotypes) *(p. 12)*
      - [3.2.1. Hypertrophic cardiomyopathy](#321-hypertrophic-cardiomyopathy) *(p. 12)*
      - [3.2.2. Dilated cardiomyopathy](#322-dilated-cardiomyopathy) *(p. 12)*
      - [3.2.3. Non-dilated left ventricular cardiomyopathy](#323-non-dilated-left-ventricular-cardiomyopathy) *(p. 12)*
      - [3.2.4. Arrhythmogenic right ventricular cardiomyopathy](#324-arrhythmogenic-right-ventricular-cardiomyopath) *(p. 14)*
      - [3.2.5. Restrictive cardiomyopathy](#325-restrictive-cardiomyopathy) *(p. 15)*
    - [3.3. Other traits and syndromes associated with cardiomyopathy phenotypes](#33-other-traits-and-syndromes-associated-with-card) *(p. 15)*
      - [3.3.1. Left ventricular hypertrabeculation (left ventricular non-compaction)](#331-left-ventricular-hypertrabeculation-(left-vent) *(p. 15)*
      - [3.3.2. Takotsubo syndrome](#332-takotsubo-syndrome) *(p. 15)*
  - [4. Epidemiology](#4-epidemiology) *(p. 15)*
    - [4.1. Special populations](#41-special-populations) *(p. 16)*
  - [5. Integrated patient management](#5-integrated-patient-management) *(p. 16)*
    - [5.1. Multidisciplinary cardiomyopathy teams](#51-multidisciplinary-cardiomyopathy-teams) *(p. 16)*
    - [5.2. Co-ordination between different levels of care](#52-co-ordination-between-different-levels-of-care) *(p. 16)*
  - [6. The patient pathway](#6-the-patient-pathway) *(p. 17)*
    - [6.1. Clinical presentation](#61-clinical-presentation) *(p. 18)*
    - [6.2. Initial work-up](#62-initial-work-up) *(p. 18)*
    - [6.3. Systematic approach to diagnosis of cardiomyopathy](#63-systematic-approach-to-diagnosis-of-cardiomyopa) *(p. 18)*
    - [6.4. History and physical examination](#64-history-and-physical-examination) *(p. 18)*
    - [6.5. Resting and ambulatory electrocardiography](#65-resting-and-ambulatory-electrocardiography) *(p. 19)*
    - [6.6. Laboratory tests](#66-laboratory-tests) *(p. 22)*
    - [6.7. Multimodality imaging](#67-multimodality-imaging) *(p. 22)*
      - [6.7.1. General considerations](#671-general-considerations) *(p. 22)*
      - [6.7.2. Echocardiography](#672-echocardiography) *(p. 22)*
      - [6.7.3. Cardiac magnetic resonance](#673-cardiac-magnetic-resonance) *(p. 23)*
        - [6.7.3.1. Special considerations](#6731-special-considerations) *(p. 23)*
      - [6.7.4. Computed tomography and nuclear medicine techniques](#674-computed-tomography-and-nuclear-medicine-techn) *(p. 26)*
      - [6.7.5. Endomyocardial biopsy](#675-endomyocardial-biopsy) *(p. 26)*
    - [6.8. Genetic testing and counselling](#68-genetic-testing-and-counselling) *(p. 27)*
      - [6.8.1. Genetic architecture](#681-genetic-architecture) *(p. 27)*
      - [6.8.2. Genetic testing](#682-genetic-testing) *(p. 27)*
        - [6.8.2.1. Non-Mendelian cardiomyopathies and implications for genetic testing](#6821-non-mendelian-cardiomyopathies-and-implicatio) *(p. 32)*
        - [6.8.2.2. Genetic test reports and variant interpretation](#6822-genetic-test-reports-and-variant-interpretati) *(p. 32)*
      - [6.8.3. Genetic counselling](#683-genetic-counselling) *(p. 32)*
        - [6.8.3.1. Genetic counselling in children](#6831-genetic-counselling-in-children) *(p. 32)*
        - [6.8.3.2. Pre- and post-test genetic counselling (proband)](#6832-pre--and-post-test-genetic-counselling-(proba) *(p. 33)*
        - [6.8.3.3. Genetic counselling for cascade testing](#6833-genetic-counselling-for-cascade-testing) *(p. 33)*
        - [6.8.3.4. Pre-natal or pre-implantation genetic diagnosis](#6834-pre-natal-or-pre-implantation-genetic-diagnos) *(p. 34)*
    - [6.9. Diagnostic approach to paediatric patients](#69-diagnostic-approach-to-paediatric-patients) *(p. 35)*
      - [6.9.1. Infantile and early childhood-onset cardiomyopathy](#691-infantile-and-early-childhood-onset-cardiomyop) *(p. 36)*
    - [6.10. General principles in the management of patients with cardiomyopathy](#610-general-principles-in-the-management-of-patien) *(p. 37)*
      - [6.10.1. Assessment of symptoms](#6101-assessment-of-symptoms) *(p. 37)*
      - [6.10.2. Heart failure management](#6102-heart-failure-management) *(p. 37)*
        - [6.10.2.1. Preventive heart failure medical therapy of asymptomatic carriers/early disease expression](#61021-preventive-heart-failure-medical-therapy-of-) *(p. 38)*
        - [6.10.2.2. Cardiac transplantation](#61022-cardiac-transplantation) *(p. 38)*
        - [6.10.2.3. Left ventricular assist devices](#61023-left-ventricular-assist-devices) *(p. 38)*
      - [6.10.3. Management of atrial arrhythmias](#6103-management-of-atrial-arrhythmias) *(p. 39)*
        - [6.10.3.1. Anticoagulation](#61031-anticoagulation) *(p. 39)*
        - [6.10.3.2. Rate control](#61032-rate-control) *(p. 39)*
        - [6.10.3.3. Rhythm control](#61033-rhythm-control) *(p. 41)*
        - [6.10.3.4. Comorbidities and risk factor management](#61034-comorbidities-and-risk-factor-management) *(p. 41)*
      - [6.10.4. Management of ventricular arrhythmias](#6104-management-of-ventricular-arrhythmias) *(p. 42)*
      - [6.10.5. Device therapy: implantable cardioverter defibrillator](#6105-device-therapy:-implantable-cardioverter-defi) *(p. 42)*
      - [6.10.6. Routine follow-up of patients with cardiomyopathy](#6106-routine-follow-up-of-patients-with-cardiomyop) *(p. 44)*
    - [6.11. Family screening and follow-up evaluation of relatives](#611-family-screening-and-follow-up-evaluation-of-r) *(p. 44)*
      - [6.11.1. Special considerations in family screening](#6111-special-considerations-in-family-screening) *(p. 45)*
    - [6.12. Psychological support in cardiomyopathy patients and family members](#612-psychological-support-in-cardiomyopathy-patien) *(p. 46)*
    - [6.13. The patient pathway](#613-the-patient-pathway) *(p. 47)*
  - [7. Specific cardiomyopathy phenotypes](#7-specific-cardiomyopathy-phenotypes) *(p. 47)*
    - [7.1. Hypertrophic cardiomyopathy](#71-hypertrophic-cardiomyopathy) *(p. 47)*
      - [7.1.1. Diagnosis](#711-diagnosis) *(p. 47)*
        - [7.1.1.1. Diagnostic criteria](#7111-diagnostic-criteria) *(p. 47)*
        - [7.1.1.2. Diagnostic work-up](#7112-diagnostic-work-up) *(p. 47)*
        - [7.1.1.3. Echocardiography](#7113-echocardiography) *(p. 47)*
        - [7.1.1.4. Cardiac magnetic resonance](#7114-cardiac-magnetic-resonance) *(p. 48)*
        - [7.1.1.5. Nuclear imaging](#7115-nuclear-imaging) *(p. 49)*
      - [7.1.2. Genetic testing and family screening](#712-genetic-testing-and-family-screening) *(p. 49)*
      - [7.1.3. Assessment of symptoms](#713-assessment-of-symptoms) *(p. 50)*
      - [7.1.4. Management of symptoms and complications](#714-management-of-symptoms-and-complications) *(p. 50)*
        - [7.1.4.1. Management of left ventricular outflow tract obstruction](#7141-management-of-left-ventricular-outflow-tract-) *(p. 51)*
          - [7.1.4.1.1. General measures](#71411-general-measures) *(p. 51)*
          - [7.1.4.1.2. Drug therapy](#71412-drug-therapy) *(p. 51)*
          - [7.1.4.1.3. Invasive treatment of left ventricular outflow tract (septal reduction therapy)](#71413-invasive-treatment-of-left-ventricular-outfl) *(p. 53)*
        - [7.1.4.2. Management of symptoms in patients without left ventricular outflow tract obstruction](#7142-management-of-symptoms-in-patients-without-le) *(p. 55)*
          - [7.1.4.2.1. Heart failure and chest pain](#71421-heart-failure-and-chest-pain) *(p. 55)*
          - [7.1.4.2.2. Cardiac resynchronization therapy](#71422-cardiac-resynchronization-therapy) *(p. 55)*
      - [7.1.5. Sudden cardiac death prevention in hypertrophic cardiomyopathy](#715-sudden-cardiac-death-prevention-in-hypertrophi) *(p. 56)*
        - [7.1.5.1. Left ventricular apical aneurysms](#7151-left-ventricular-apical-aneurysms) *(p. 57)*
        - [7.1.5.2. Left ventricular systolic dysfunction](#7152-left-ventricular-systolic-dysfunction) *(p. 57)*
        - [7.1.5.3. Late gadolinium enhancement on cardiac magnetic resonance imaging](#7153-late-gadolinium-enhancement-on-cardiac-magnet) *(p. 57)*
        - [7.1.5.4. Abnormal exercise blood pressure response](#7154-abnormal-exercise-blood-pressure-response) *(p. 57)*
        - [7.1.5.5. Sarcomeric variants](#7155-sarcomeric-variants) *(p. 58)*
        - [7.1.5.6. Prevention of sudden cardiac death](#7156-prevention-of-sudden-cardiac-death) *(p. 58)*
    - [7.2. Dilated cardiomyopathy](#72-dilated-cardiomyopathy) *(p. 60)*
      - [7.2.1. Diagnosis](#721-diagnosis) *(p. 60)*
        - [7.2.1.1. Index case](#7211-index-case) *(p. 60)*
        - [7.2.1.2. Relatives](#7212-relatives) *(p. 60)*
        - [7.2.1.3. Diagnostic work-up](#7213-diagnostic-work-up) *(p. 60)*
        - [7.2.1.4. Echocardiography](#7214-echocardiography) *(p. 60)*
        - [7.2.1.5. Cardiac magnetic resonance](#7215-cardiac-magnetic-resonance) *(p. 61)*
        - [7.2.1.6. Nuclear medicine](#7216-nuclear-medicine) *(p. 61)*
      - [7.2.2. Genetic testing and family screening](#722-genetic-testing-and-family-screening) *(p. 61)*
        - [7.2.2.1. Genetic testing](#7221-genetic-testing) *(p. 61)*
      - [7.2.3. Assessment of symptoms](#723-assessment-of-symptoms) *(p. 62)*
      - [7.2.4. Management](#724-management) *(p. 62)*
      - [7.2.5. Sudden cardiac death prevention in dilated cardiomyopathy](#725-sudden-cardiac-death-prevention-in-dilated-car) *(p. 62)*
        - [7.2.5.1. Secondary prevention of sudden cardiac death](#7251-secondary-prevention-of-sudden-cardiac-death) *(p. 62)*
        - [7.2.5.2. Primary prevention of sudden cardiac death](#7252-primary-prevention-of-sudden-cardiac-death) *(p. 62)*
    - [7.3. Non-dilated left ventricular cardiomyopathy](#73-non-dilated-left-ventricular-cardiomyopathy) *(p. 64)*
      - [7.3.1. Diagnosis](#731-diagnosis) *(p. 64)*
        - [7.3.1.1. Index case](#7311-index-case) *(p. 64)*
        - [7.3.1.2. Relatives](#7312-relatives) *(p. 64)*
        - [7.3.1.3. Diagnostic work-up](#7313-diagnostic-work-up) *(p. 64)*
        - [7.3.1.4. Electrocardiographic features](#7314-electrocardiographic-features) *(p. 65)*
        - [7.3.1.5. Echocardiography](#7315-echocardiography) *(p. 65)*
        - [7.3.1.6. Cardiac magnetic resonance](#7316-cardiac-magnetic-resonance) *(p. 65)*
        - [7.3.1.7. Nuclear medicine](#7317-nuclear-medicine) *(p. 65)*
        - [7.3.1.8. Endomyocardial biopsy](#7318-endomyocardial-biopsy) *(p. 65)*
      - [7.3.2. Genetic testing](#732-genetic-testing) *(p. 65)*
      - [7.3.3. Assessment of symptoms](#733-assessment-of-symptoms) *(p. 65)*
      - [7.3.4. Management](#734-management) *(p. 65)*
      - [7.3.5. Sudden cardiac death prevention in non-dilated left ventricular cardiomyopathy](#735-sudden-cardiac-death-prevention-in-non-dilated) *(p. 66)*
        - [7.3.5.1. Secondary prevention of sudden cardiac death](#7351-secondary-prevention-of-sudden-cardiac-death) *(p. 66)*
        - [7.3.5.2. Primary prevention of sudden cardiac death](#7352-primary-prevention-of-sudden-cardiac-death) *(p. 66)*
    - [7.4. Arrhythmogenic right ventricular cardiomyopathy](#74-arrhythmogenic-right-ventricular-cardiomyopathy) *(p. 67)*
      - [7.4.1. Diagnosis](#741-diagnosis) *(p. 67)*
        - [7.4.1.1. Index case](#7411-index-case) *(p. 67)*
        - [7.4.1.2. Relatives](#7412-relatives) *(p. 67)*
        - [7.4.1.3. Diagnostic work-up](#7413-diagnostic-work-up) *(p. 67)*
        - [7.4.1.4. Electrocardiography and Holter monitoring](#7414-electrocardiography-and-holter-monitoring) *(p. 67)*
        - [7.4.1.5. Echocardiography and cardiac magnetic resonance](#7415-echocardiography-and-cardiac-magnetic-resonan) *(p. 67)*
        - [7.4.1.6. Endomyocardial biopsy](#7416-endomyocardial-biopsy) *(p. 67)*
        - [7.4.1.7. Nuclear medicine](#7417-nuclear-medicine) *(p. 67)*
        - [7.4.1.8. Arrhythmogenic right ventricular cardiomyopathy phenocopies](#7418-arrhythmogenic-right-ventricular-cardiomyopat) *(p. 68)*
      - [7.4.2. Genetic testing and family screening](#742-genetic-testing-and-family-screening) *(p. 68)*
      - [7.4.3. Assessment of symptoms](#743-assessment-of-symptoms) *(p. 68)*
      - [7.4.4. Management](#744-management) *(p. 68)*
        - [7.4.4.1. Antiarrhythmic therapy](#7441-antiarrhythmic-therapy) *(p. 68)*
      - [7.4.5. Sudden cardiac death prevention in arrhythmogenic right ventricular cardiomyopathy](#745-sudden-cardiac-death-prevention-in-arrhythmoge) *(p. 68)*
        - [7.4.5.1. Secondary prevention of sudden cardiac death](#7451-secondary-prevention-of-sudden-cardiac-death) *(p. 69)*
        - [7.4.5.2. Primary prevention of sudden cardiac death](#7452-primary-prevention-of-sudden-cardiac-death) *(p. 69)*
    - [7.5. Restrictive cardiomyopathy](#75-restrictive-cardiomyopathy) *(p. 70)*
      - [7.5.1. Diagnosis](#751-diagnosis) *(p. 70)*
      - [7.5.2. Genetic testing](#752-genetic-testing) *(p. 70)*
      - [7.5.3. Assessment of symptoms](#753-assessment-of-symptoms) *(p. 71)*
      - [7.5.4. Management](#754-management) *(p. 71)*
    - [7.6. Syndromic and metabolic cardiomyopathies](#76-syndromic-and-metabolic-cardiomyopathies) *(p. 72)*
      - [7.6.1. Anderson–Fabry disease](#761-anderson–fabry-disease) *(p. 72)*
        - [7.6.1.1. Definition](#7611-definition) *(p. 72)*
        - [7.6.1.2. Diagnosis, clinical work-up, and differential diagnosis](#7612-diagnosis,-clinical-work-up,-and-differential) *(p. 72)*
        - [7.6.1.3. Clinical course, outcome, and risk stratification](#7613-clinical-course,-outcome,-and-risk-stratifica) *(p. 72)*
        - [7.6.1.4. Management](#7614-management) *(p. 75)*
      - [7.6.2. RASopathies](#762-rasopathies) *(p. 75)*
        - [7.6.2.1. Definition](#7621-definition) *(p. 75)*
        - [7.6.2.2. Diagnosis, clinical work-up, and differential diagnosis](#7622-diagnosis,-clinical-work-up,-and-differential) *(p. 75)*
        - [7.6.2.3. Clinical course, management, and sudden death risk stratification](#7623-clinical-course,-management,-and-sudden-death) *(p. 75)*
        - [7.6.2.4. Management](#7624-management) *(p. 75)*
      - [7.6.3. Friedreich ataxia](#763-friedreich-ataxia) *(p. 76)*
        - [7.6.3.1. Definition](#7631-definition) *(p. 76)*
        - [7.6.3.2. Diagnosis, clinical work-up, and differential diagnosis](#7632-diagnosis,-clinical-work-up,-and-differential) *(p. 76)*
        - [7.6.3.3. Clinical course, management, and risk stratification](#7633-clinical-course,-management,-and-risk-stratif) *(p. 77)*
        - [7.6.3.4. Management](#7634-management) *(p. 77)*
      - [7.6.4. Glycogen storage disorders](#764-glycogen-storage-disorders) *(p. 77)*
        - [7.6.4.1. Definition](#7641-definition) *(p. 77)*
        - [7.6.4.2. Diagnosis, clinical work-up, and differential diagnosis](#7642-diagnosis,-clinical-work-up,-and-differential) *(p. 77)*
        - [7.6.4.3. Clinical course, management, and risk stratification](#7643-clinical-course,-management,-and-risk-stratif) *(p. 77)*
        - [7.6.4.4. Management](#7644-management) *(p. 77)*
    - [7.7. Amyloidosis](#77-amyloidosis) *(p. 77)*
      - [7.7.1. Definition](#771-definition) *(p. 77)*
      - [7.7.2. Diagnosis, clinical work-up, and differential diagnosis](#772-diagnosis,-clinical-work-up,-and-differential-) *(p. 77)*
      - [7.7.3. Clinical course and risk stratification](#773-clinical-course-and-risk-stratification) *(p. 78)*
      - [7.7.4. Management](#774-management) *(p. 78)*
        - [7.7.4.1. Specific therapies](#7741-specific-therapies) *(p. 79)*
  - [8. Other recommendations](#8-other-recommendations) *(p. 79)*
    - [8.1. Sports](#81-sports) *(p. 79)*
      - [8.1.1. Cardiovascular benefits of exercise](#811-cardiovascular-benefits-of-exercise) *(p. 79)*
      - [8.1.2. Exercise-related sudden cardiac death and historical exercise recommendations for patients with cardiomyopathy](#812-exercise-related-sudden-cardiac-death-and-hist) *(p. 80)*
      - [8.1.3. Exercise recommendations in hypertrophic cardiomyopathy](#813-exercise-recommendations-in-hypertrophic-cardi) *(p. 80)*
      - [8.1.4. Exercise recommendations in arrhythmogenic right ventricular cardiomyopathy](#814-exercise-recommendations-in-arrhythmogenic-rig) *(p. 80)*
      - [8.1.5. Exercise recommendations in dilated cardiomyopathy and non-dilated left ventricular cardiomyopathy](#815-exercise-recommendations-in-dilated-cardiomyop) *(p. 80)*
    - [8.2. Reproductive issues](#82-reproductive-issues) *(p. 81)*
      - [8.2.1. Contraception, in vitro fertilization, and hormonal treatment](#821-contraception,-in-vitro-fertilization,-and-hor) *(p. 81)*
      - [8.2.2. Pregnancy management](#822-pregnancy-management) *(p. 81)*
        - [8.2.2.1. Pre-pregnancy](#8221-pre-pregnancy) *(p. 81)*
        - [8.2.2.2. Pregnancy](#8222-pregnancy) *(p. 81)*
        - [8.2.2.3. Timing and mode of delivery](#8223-timing-and-mode-of-delivery) *(p. 82)*
        - [8.2.2.4. Post-partum](#8224-post-partum) *(p. 82)*
        - [8.2.2.5. Pharmacological treatment: general aspects](#8225-pharmacological-treatment:-general-aspects) *(p. 82)*
        - [8.2.2.6. Specific cardiomyopathies](#8226-specific-cardiomyopathies) *(p. 82)*
        - [8.2.2.7. Peripartum cardiomyopathy](#8227-peripartum-cardiomyopathy) *(p. 83)*
    - [8.3. Recommendations for non-cardiac surgery](#83-recommendations-for-non-cardiac-surgery) *(p. 83)*
  - [9. Requirements for specialized cardiomyopathy units](#9-requirements-for-specialized-cardiomyopathy-unit) *(p. 84)*
  - [10. Living with cardiomyopathy: advice for patients](#10-living-with-cardiomyopathy:-advice-for-patients) *(p. 84)*
  - [11. Sex differences in cardiomyopathies](#11-sex-differences-in-cardiomyopathies) *(p. 85)*
  - [12. Comorbidities and cardiovascular risk factors in cardiomyopathies](#12-comorbidities-and-cardiovascular-risk-factors-i) *(p. 85)*
    - [12.1. Cardiovascular risk factors](#121-cardiovascular-risk-factors) *(p. 85)*
    - [12.2. Dilated cardiomyopathy](#122-dilated-cardiomyopathy) *(p. 86)*
    - [12.3. Hypertrophic cardiomyopathy](#123-hypertrophic-cardiomyopathy) *(p. 86)*
    - [12.4. Arrhythmogenic right ventricular cardiomyopathy](#124-arrhythmogenic-right-ventricular-cardiomyopath) *(p. 86)*
  - [13. Coronavirus disease (COVID-19) and cardiomyopathies](#13-coronavirus-disease-(covid-19)-and-cardiomyopat) *(p. 86)*
  - [14. Key messages](#14-key-messages) *(p. 86)*
  - [15. Gaps in evidence](#15-gaps-in-evidence) *(p. 87)*
  - [16. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#16-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 89)*
  - [17. Supplementary data](#17-supplementary-data) *(p. 93)*
  - [18. Data availability statement](#18-data-availability-statement) *(p. 93)*
  - [19. Author information](#19-author-information) *(p. 93)*
  - [Appendix](#appendix) *(p. 94)*
  - [21. Acknowledgements](#21-acknowledgements) *(p. 95)*
  - [22. References](#22-references) *(p. 95)*
  - [22. References](#22-references) *(p. 95)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2023 ESC Guidelines for the management 
of cardiomyopathies
Developed by the task force on the management of 
cardiomyopathies of the European Society of Cardiology (ESC)
Authors/Task Force Members: Elena Arbelo  *†, (Chairperson) (Spain), 
Alexandros Protonotarios  
‡, (Task Force Co-ordinator) (United Kingdom), 
Juan R. Gimeno  
‡, (Task Force Co-ordinator) (Spain), Eloisa Arbustini  
(Italy), 
Roberto Barriales-Villa  
(Spain), Cristina Basso  
(Italy), Connie R. Bezzina  
(Netherlands), Elena Biagini  
(Italy), Nico A. Blom1 (Netherlands), 
Rudolf A. de Boer  
(Netherlands), Tim De Winter (Belgium), Perry M. Elliott  
(United Kingdom), Marcus Flather  
(United Kingdom), Pablo Garcia-Pavia  
(Spain), Kristina H. Haugaa  
(Sweden), Jodie Ingles  
(Australia), 
Ruxandra Oana Jurcut  
(Romania), Sabine Klaassen  
(Germany), 
Giuseppe Limongelli  
(Italy), Bart Loeys  
2 (Belgium), Jens Mogensen  
(Denmark), Iacopo Olivotto  
(Italy), Antonis Pantazis  
(United Kingdom), 
Sanjay Sharma  
(United Kingdom), J. Peter Van Tintelen  
(Netherlands), 
James S. Ware  
(United Kingdom), Juan Pablo Kaski  *†, (Chairperson) 
(United Kingdom), and ESC Scientific Document Group
* Corresponding authors: Elena Arbelo, Arrhythmia Section, Cardiology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain, IDIBAPS, Institut d’Investigació August Pi i 
Sunyer (IDIBAPS), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, and European Reference Network for Rare, Low 
Prevalence and Complex Diseases of the Heart, ERN GUARD-Heart, Barcelona, Spain. Tel: +34 93 22 75 55 11, E-mail: elenaarbelo@secardiologia.es; and Juan Pablo Kaski, Centre for 
Paediatric Inherited and Rare Cardiovascular Disease, University College London, Institute of Cardiovascular Science, London, United Kingdom and Centre for Inherited Cardiovascular 
Diseases, Great Ormond Street Hospital, London, United Kingdom. Tel: +44 78 29 88 39, E-mail: j.kaski@ucl.ac.uk
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the Association for European Paediatric and Congenital Cardiology (AEPC)
2 Representing the European Society of Human Genetics (ESHG)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive 
Cardiology (EAPC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council on Cardiovascular Genomics.
Working Groups: Development Anatomy and Pathology, Myocardial and Pericardial Diseases.
Patient Forum  
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC 
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the 
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; 
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from 
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case 
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices at the time of prescription.
© The European Society of Cardiology 2023. All rights reserved. For permissions please email: journals.permissions@oup.com.
https://doi.org/10.1093/eurheartj/ehad194
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Philippe Charron, (CPG Review Co-ordinator) (France), Massimo Imazio, (CPG Review 
Co-ordinator) (Italy), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Michael Arad (Israel), Folkert 
W. Asselbergs (Netherlands), Riccardo Asteggiano (Italy), Zofia Bilinska (Poland), Damien Bonnet (France), 
Henning Bundgaard (Denmark), Nuno Miguel Cardim (Portugal), Jelena Čelutkienė (Lithuania), Maja Cikes 
(Croatia), Gaetano Maria De Ferrari (Italy), Veronica Dusi (Italy), Volkmar Falk (Germany), Laurent Fauchier 
(France), Estelle Gandjbakhch (France), Tiina Heliö (Finland), Konstantinos Koskinas (Switzerland), Dipak Kotecha 
(United Kingdom), Ulf Landmesser (Germany), George Lazaros (Greece), Basil S. Lewis (Israel), Ales Linhart 
(Czechia), Maja-Lisa Løchen (Norway), Benjamin Meder (Germany), Richard Mindham (United Kingdom), 
James Moon (United Kingdom), Jens Cosedis Nielsen (Denmark), Steffen Petersen (United Kingdom), Eva Prescott 
(Denmark), Mary N. Sheppard (United Kingdom), Gianfranco Sinagra (Italy), Marta Sitges (Spain), 
Jacob Tfelt-Hansen (Denmark), Rhian Touyz (Canada), Rogier Veltrop (Netherlands), Josef Veselka (Czechia), 
Karim Wahbi (France), Arthur Wilde (Netherlands), and Katja Zeppenfeld (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest. These have 
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The 
report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary documents that include background information and 
evidence tables.
Keywords 
Guidelines • Arrhythmia • Arrhythmogenic right ventricular cardiomyopathy • Cardiomyopathies • Diagnosis • 
Dilated cardiomyopathy • Genetics • Genetic counselling • Genetic testing • Hypertrophic cardiomyopathy • 
Implantable cardioverter defibrillator • Management • Multimodality imaging • Non-dilated left ventricular 
cardiomyopathy • Pregnancy • Restrictive cardiomyopathy • Risk stratification • Screening • Sports • 
Sudden cardiac death
Table of contents 
1. Preamble .............................................................................................................. 3509 
2. Introduction ....................................................................................................... 3511 
3. Phenotypic approach to cardiomyopathies .......................................... 3511 
3.1. Definitions .................................................................................................
3514 
3.2. Cardiomyopathy phenotypes ............................................................
3514 
3.2.1. Hypertrophic cardiomyopathy ................................................. 3514 
3.2.2. Dilated cardiomyopathy .............................................................. 3514 
3.2.3. Non-dilated left ventricular cardiomyopathy ..................... 3514 
3.2.4. Arrhythmogenic right ventricular cardiomyopathy ......... 3516 
3.2.5. Restrictive cardiomyopathy ........................................................ 3517 
3.3. Other traits and syndromes associated with cardiomyopathy 
phenotypes ........................................................................................................
3517 
3.3.1. Left ventricular hypertrabeculation (left ventricular non- 
compaction) .................................................................................................. 3517 
3.3.2. Takotsubo syndrome .................................................................... 3517 
4. Epidemiology ...................................................................................................... 3517 
4.1. Special populations ................................................................................
3518 
5. Integrated patient management ................................................................. 3518 
5.1. Multidisciplinary cardiomyopathy teams ......................................
3518 
5.2. Co-ordination between different levels of care ........................
3518 
6. The patient pathway ....................................................................................... 3519 
6.1. Clinical presentation .............................................................................
3520 
6.2. Initial work-up ..........................................................................................
3520 
6.3. Systematic approach to diagnosis of cardiomyopathy ...........
3520 
6.4. History and physical examination ...................................................
3520 
6.5. Resting and ambulatory electrocardiography ............................
3521 
6.6. Laboratory tests ......................................................................................
3524 
6.7. Multimodality imaging ...........................................................................
3524 
6.7.1. General considerations ................................................................ 3524 
6.7.2. Echocardiography ........................................................................... 3524 
6.7.3. Cardiac magnetic resonance ...................................................... 3525 
6.7.3.1. Special considerations ..........................................................
3525 
6.7.4. Computed tomography and nuclear medicine 
techniques ...................................................................................................... 3528 
6.7.5. Endomyocardial biopsy ................................................................ 3528 
6.8. Genetic testing and counselling ........................................................
3529 
6.8.1. Genetic architecture ..................................................................... 3529 
6.8.2. Genetic testing ................................................................................. 3529 
6.8.2.1. Non-Mendelian cardiomyopathies and implications 
for genetic testing ..................................................................................
3534 
6.8.2.2. Genetic test reports and variant interpretation .......
3534 
6.8.3. Genetic counselling ........................................................................ 3534


<!-- PAGE 3 -->

### Page 3

6.8.3.1. Genetic counselling in children ........................................
3534 
6.8.3.2. Pre- and post-test genetic counselling (proband) ....
3535 
6.8.3.3. Genetic counselling for cascade testing ........................
3535 
6.8.3.4. Pre-natal or pre-implantation genetic diagnosis .......
3536 
6.9. Diagnostic approach to paediatric patients ................................
3537 
6.9.1. Infantile and early childhood-onset cardiomyopathy ...... 3538 
6.10. General principles in the management of patients with 
cardiomyopathy ...............................................................................................
3539 
6.10.1. Assessment of symptoms ......................................................... 3539 
6.10.2. Heart failure management ........................................................ 3539 
6.10.2.1. Preventive heart failure medical therapy of 
asymptomatic carriers/early disease expression .......................
3540 
6.10.2.2. Cardiac transplantation .....................................................
3540 
6.10.2.3. Left ventricular assist devices .........................................
3540 
6.10.3. Management of atrial arrhythmias ........................................ 3541 
6.10.3.1. Anticoagulation .....................................................................
3541 
6.10.3.2. Rate control ...........................................................................
3541 
6.10.3.3. Rhythm control ....................................................................
3543 
6.10.3.4. Comorbidities and risk factor management ............
3543 
6.10.4. Management of ventricular arrhythmias ............................ 3544 
6.10.5. Device therapy: implantable cardioverter defibrillator
3544 
6.10.6. Routine follow-up of patients with cardiomyopathy ... 3546 
6.11. Family screening and follow-up evaluation of relatives .......
3546 
6.11.1. Special considerations in family screening ......................... 3547 
6.12. Psychological support in cardiomyopathy patients and family 
members .............................................................................................................
3548 
6.13. The patient pathway ..........................................................................
3549 
7. Specific cardiomyopathy phenotypes ...................................................... 3549 
7.1. Hypertrophic cardiomyopathy .........................................................
3549 
7.1.1. Diagnosis ............................................................................................ 3549 
7.1.1.1. Diagnostic criteria ..................................................................
3549 
7.1.1.2. Diagnostic work-up ...............................................................
3549 
7.1.1.3. Echocardiography ...................................................................
3549 
7.1.1.4. Cardiac magnetic resonance .............................................
3550 
7.1.1.5. Nuclear imaging ......................................................................
3551 
7.1.2. Genetic testing and family screening ...................................... 3551 
7.1.3. Assessment of symptoms ........................................................... 3552 
7.1.4. Management of symptoms and complications ................... 3552 
7.1.4.1. Management of left ventricular outflow tract 
obstruction ...............................................................................................
3553 
7.1.4.1.1. General measures ..........................................................
3553 
7.1.4.1.2. Drug therapy ...................................................................
3553 
7.1.4.1.3. Invasive treatment of left ventricular outflow 
tract (septal reduction therapy) .................................................
3555 
7.1.4.2. Management of symptoms in patients without left 
ventricular outflow tract obstruction ...........................................
3557 
7.1.4.2.1. Heart failure and chest pain ......................................
3557 
7.1.4.2.2. Cardiac resynchronization therapy ........................
3557 
7.1.5. Sudden cardiac death prevention in hypertrophic 
cardiomyopathy ........................................................................................... 3558 
7.1.5.1. Left ventricular apical aneurysms ....................................
3559 
7.1.5.2. Left ventricular systolic dysfunction ...............................
3559 
7.1.5.3. Late gadolinium enhancement on cardiac magnetic 
resonance imaging .................................................................................
3559 
7.1.5.4. Abnormal exercise blood pressure response ............
3559 
7.1.5.5. Sarcomeric variants ...............................................................
3560 
7.1.5.6. Prevention of sudden cardiac death ..............................
3560 
7.2. Dilated cardiomyopathy ......................................................................
3562 
7.2.1. Diagnosis ............................................................................................ 3562 
7.2.1.1. Index case ..................................................................................
3562 
7.2.1.2. Relatives .....................................................................................
3562 
7.2.1.3. Diagnostic work-up ...............................................................
3562 
7.2.1.4. Echocardiography ...................................................................
3562 
7.2.1.5. Cardiac magnetic resonance .............................................
3563 
7.2.1.6. Nuclear medicine ...................................................................
3563 
7.2.2. Genetic testing and family screening ...................................... 3563 
7.2.2.1. Genetic testing ........................................................................
3563 
7.2.3. Assessment of symptoms ........................................................... 3564 
7.2.4. Management ...................................................................................... 3564 
7.2.5. Sudden cardiac death prevention in dilated 
cardiomyopathy ........................................................................................... 3564 
7.2.5.1. Secondary prevention of sudden cardiac death .......
3564 
7.2.5.2. Primary prevention of sudden cardiac death .............
3564 
7.3. Non-dilated left ventricular cardiomyopathy .............................
3566 
7.3.1. Diagnosis ............................................................................................ 3566 
7.3.1.1. Index case ..................................................................................
3566 
7.3.1.2. Relatives .....................................................................................
3566 
7.3.1.3. Diagnostic work-up ...............................................................
3566 
7.3.1.4. Electrocardiographic features ...........................................
3567 
7.3.1.5. Echocardiography ...................................................................
3567 
7.3.1.6. Cardiac magnetic resonance .............................................
3567 
7.3.1.7. Nuclear medicine ...................................................................
3567 
7.3.1.8. Endomyocardial biopsy ........................................................
3567 
7.3.2. Genetic testing ................................................................................. 3567 
7.3.3. Assessment of symptoms ........................................................... 3567 
7.3.4. Management ...................................................................................... 3567 
7.3.5. Sudden cardiac death prevention in non-dilated left 
ventricular cardiomyopathy .................................................................... 3568 
7.3.5.1. Secondary prevention of sudden cardiac death .......
3568 
7.3.5.2. Primary prevention of sudden cardiac death .............
3568 
7.4. Arrhythmogenic right ventricular cardiomyopathy .................
3569 
7.4.1. Diagnosis ............................................................................................ 3569 
7.4.1.1. Index case ..................................................................................
3569 
7.4.1.2. Relatives .....................................................................................
3569 
7.4.1.3. Diagnostic work-up ...............................................................
3569 
7.4.1.4. Electrocardiography and Holter monitoring ..............
3569 
7.4.1.5. Echocardiography and cardiac magnetic resonance
3569 
7.4.1.6. Endomyocardial biopsy ........................................................
3569 
7.4.1.7. Nuclear medicine ...................................................................
3569 
7.4.1.8. Arrhythmogenic right ventricular cardiomyopathy 
phenocopies .............................................................................................
3570 
7.4.2. Genetic testing and family screening ...................................... 3570 
7.4.3. Assessment of symptoms ........................................................... 3570 
7.4.4. Management ...................................................................................... 3570 
7.4.4.1. Antiarrhythmic therapy .......................................................
3570 
7.4.5. Sudden cardiac death prevention in arrhythmogenic right 
ventricular cardiomyopathy .................................................................... 3570 
7.4.5.1. Secondary prevention of sudden cardiac death .......
3571 
7.4.5.2. Primary prevention of sudden cardiac death .............
3571 
7.5. Restrictive cardiomyopathy ...............................................................
3572 
7.5.1. Diagnosis ............................................................................................ 3572 
7.5.2. Genetic testing ................................................................................. 3572 
ESC Guidelines                                                                                                                                                                                          3505


<!-- PAGE 4 -->

### Page 4

7.5.3. Assessment of symptoms ........................................................... 3573 
7.5.4. Management ...................................................................................... 3573 
7.6. Syndromic and metabolic cardiomyopathies .............................
3574 
7.6.1. Anderson–Fabry disease .............................................................. 3574 
7.6.1.1. Definition ...................................................................................
3574 
7.6.1.2. Diagnosis, clinical work-up, and differential diagnosis
3574 
7.6.1.3. Clinical course, outcome, and risk stratification .......
3574 
7.6.1.4. Management .............................................................................
3577 
7.6.2. RASopathies ...................................................................................... 3577 
7.6.2.1. Definition ...................................................................................
3577 
7.6.2.2. Diagnosis, clinical work-up, and differential diagnosis
3577 
7.6.2.3. Clinical course, management, and sudden death risk 
stratification ..............................................................................................
3577 
7.6.2.4. Management .............................................................................
3577 
7.6.3. Friedreich ataxia .............................................................................. 3578 
7.6.3.1. Definition ...................................................................................
3578 
7.6.3.2. Diagnosis, clinical work-up, and differential diagnosis
3578 
7.6.3.3. Clinical course, management, and risk stratification
3579 
7.6.3.4. Management .............................................................................
3579 
7.6.4. Glycogen storage disorders ....................................................... 3579 
7.6.4.1. Definition ...................................................................................
3579 
7.6.4.2. Diagnosis, clinical work-up, and differential diagnosis
3579 
7.6.4.3. Clinical course, management, and risk stratification
3579 
7.6.4.4. Management .............................................................................
3579 
7.7. Amyloidosis ...............................................................................................
3579 
7.7.1. Definition ........................................................................................... 3579 
7.7.2. Diagnosis, clinical work-up, and differential diagnosis ..... 3579 
7.7.3. Clinical course and risk stratification ..................................... 3580 
7.7.4. Management ...................................................................................... 3580 
7.7.4.1. Specific therapies ....................................................................
3581 
8. Other recommendations .............................................................................. 3581 
8.1. Sports ..........................................................................................................
3581 
8.1.1. Cardiovascular benefits of exercise ........................................ 3581 
8.1.2. Exercise-related sudden cardiac death and historical 
exercise recommendations for patients with cardiomyopathy
3582 
8.1.3. Exercise recommendations in hypertrophic 
cardiomyopathy ........................................................................................... 3582 
8.1.4. Exercise recommendations in arrhythmogenic right 
ventricular cardiomyopathy .................................................................... 3582 
8.1.5. Exercise recommendations in dilated cardiomyopathy 
and non-dilated left ventricular cardiomyopathy .......................... 3582 
8.2. Reproductive issues ...............................................................................
3583 
8.2.1. Contraception, in vitro fertilization, and hormonal 
treatment ........................................................................................................ 3583 
8.2.2. Pregnancy management ............................................................... 3583 
8.2.2.1. Pre-pregnancy ..........................................................................
3583 
8.2.2.2. Pregnancy ..................................................................................
3583 
8.2.2.3. Timing and mode of delivery ............................................
3584 
8.2.2.4. Post-partum ..............................................................................
3584 
8.2.2.5. Pharmacological treatment: general aspects ..............
3584 
8.2.2.6. Specific cardiomyopathies ..................................................
3584 
8.2.2.7. Peripartum cardiomyopathy .............................................
3585 
8.3. Recommendations for non-cardiac surgery ...............................
3585 
9. Requirements for specialized cardiomyopathy units ........................ 3586 
10. Living with cardiomyopathy: advice for patients ............................. 3586 
11. Sex differences in cardiomyopathies ..................................................... 3587 
12. Comorbidities and cardiovascular risk factors in 
cardiomyopathies .................................................................................................. 3587 
12.1. Cardiovascular risk factors ..............................................................
3587 
12.2. Dilated cardiomyopathy ...................................................................
3588 
12.3. Hypertrophic cardiomyopathy ......................................................
3588 
12.4. Arrhythmogenic right ventricular cardiomyopathy ..............
3588 
13. Coronavirus disease (COVID-19) and cardiomyopathies ........... 3588 
14. Key messages .................................................................................................. 3588 
15. Gaps in evidence ............................................................................................ 3589 
16. ‘What to do’ and ‘What not to do’ messages from the 
Guidelines ................................................................................................................. 3591 
17. Supplementary data ...................................................................................... 3595 
18. Data availability statement ......................................................................... 3595 
19. Author information ...................................................................................... 3595 
20. Appendix ........................................................................................................... 3596 
21. Acknowledgements ...................................................................................... 3597 
22. References ........................................................................................................ 3597
Tables of Recommendations 
Recommendation Table 1 — Recommendations for the provision of 
service of multidisciplinary cardiomyopathy teams ................................ 3519 
Recommendation Table 2 — Recommendations for diagnostic 
work-up in cardiomyopathies .......................................................................... 3520 
Recommendation Table 3 — Recommendations for laboratory 
tests in the diagnosis of cardiomyopathies ................................................ 3524 
Recommendation Table 4 — Recommendation for 
echocardiographic evaluation in patients with cardiomyopathy ...... 3524 
Recommendation Table 5 — Recommendations for cardiac 
magnetic resonance indication in patients with cardiomyopathy .... 3526 
Recommendation Table 6 — Recommendations for computed 
tomography and nuclear imaging ................................................................... 3528 
Recommendation Table 7 — Recommendation for endomyocardial 
biopsy in patients with cardiomyopathy ..................................................... 3528 
Recommendation Table 8 — Recommendations for genetic 
counselling and testing in cardiomyopathies ............................................. 3537 
Recommendation Table 9 — Recommendations for cardiac 
transplantation in patients with cardiomyopathy ................................... 3540 
Recommendation Table 10 — Recommendation for left ventricular 
assist device therapy in patients with cardiomyopathy ........................ 3540 
Recommendation Table 11 — Recommendations for management of 
atrial fibrillation and atrial flutter in patients with cardiomyopathy ....
3543 
Recommendation Table 12 — Recommendations for implantable 
cardioverter defibrillator in patients with cardiomyopathy ................ 3545 
Recommendation Table 13 — Recommendations for routine 
follow-up of patients with cardiomyopathy .............................................. 3546 
Recommendation Table 14 — Recommendations for family 
screening and follow-up evaluation of relatives ....................................... 3546 
Recommendation Table 15 — Recommendations for psychological 
support in patients and family members with cardiomyopathies .... 3549 
Recommendation Table 16 — Recommendation for evaluation of 
left ventricular outflow tract obstruction .................................................. 3549 
Recommendation Table 17 — Additional recommendation for 
cardiovascular magnetic resonance evaluation in hypertrophic 
cardiomyopathy ..................................................................................................... 3550 
Recommendation Table 18 — Recommendations for treatment of 
left ventricular outflow tract obstruction (general measures) .......... 3553 
Recommendation Table 19 — Recommendations for medical 
treatment of left ventricular outflow tract obstruction ....................... 3554 
Recommendation Table 20 — Recommendations for septal 
reduction therapy ................................................................................................. 3556


<!-- PAGE 5 -->

### Page 5

Recommendation Table 21 — Recommendations for indications for 
cardiac pacing in patients with obstruction ............................................... 3557 
Recommendation Table 22 — Recommendations for chest pain on 
exertion in patients without left ventricular outflow tract 
obstruction .............................................................................................................. 3557 
Recommendation Table 23 — Additional recommendations for 
prevention of sudden cardiac death in patients with hypertrophic 
cardiomyopathy ..................................................................................................... 3561 
Recommendation Table 24 — Recommendations for an implantable 
cardioverter defibrillator in patients with dilated cardiomyopathy
3566 
Recommendation Table 25 — Recommendation for resting and 
ambulatory electrocardiogram monitoring in patients with 
non-dilated left ventricular cardiomyopathy ............................................. 3567 
Recommendation Table 26 — Recommendations for an implantable 
cardioverter defibrillator in patients with non-dilated left ventricular 
cardiomyopathy ..................................................................................................... 3568 
Recommendation Table 27 — Recommendation for resting and 
ambulatory electrocardiogram monitoring in patients with 
arrhythmogenic right ventricular cardiomyopathy ................................. 3569 
Recommendation Table 28 — Recommendations for the 
antiarrhythmic management of patients with arrhythmogenic right 
ventricular cardiomyopathy .............................................................................. 3570 
Recommendation Table 29 — Recommendations for sudden 
cardiac death prevention in patients with arrhythmogenic right 
ventricular cardiomyopathy .............................................................................. 3571 
Recommendation Table 30 — Recommendations for the 
management of patients with restrictive cardiomyopathy ................. 3574 
Recommendation Table 31 — Exercise recommendations for 
patients with cardiomyopathy ......................................................................... 3582 
Recommendation Table 32 — Recommendations for reproductive 
issues in patients with cardiomyopathy ...................................................... 3585 
Recommendation Table 33 — Recommendations for non-cardiac 
surgery in patients with cardiomyopathy ................................................... 3585 
Recommendation Table 34 — Recommendation for management 
of cardiovascular risk factors in patients with cardiomyopathy ....... 3588
List of tables 
Table 1 Classes for recommendations ........................................................ 3510 
Table 2 Levels of evidence ................................................................................ 3510 
Table 3 Morphological and functional traits used to describe 
cardiomyopathy phenotypes ............................................................................ 3514 
Table 4 Key epidemiological metrics in adults and children for the 
different cardiomyopathy phenotypes ......................................................... 3517 
Table 5 Examples of inheritance patterns that should raise the 
suspicion of specific genetic aetiologies, grouped according to 
cardiomyopathy phenotype ............................................................................. 3521 
Table 6 Examples of signs and symptoms that should raise the 
suspicion of specific aetiologies, grouped according to 
cardiomyopathy phenotype ............................................................................. 3522 
Table 7 Examples of electrocardiographic features that should raise 
the suspicion of specific aetiologies, grouped according to 
cardiomyopathy phenotype ............................................................................. 3523 
Table 8 First-level (to be performed in each patient) and 
second-level (to be performed in selected patients following 
specialist evaluation to identify specific aetiologies) laboratory tests, 
grouped by cardiomyopathy phenotype .................................................... 3525 
Table 9 Frequently encountered actionable results on multimodality 
imaging ....................................................................................................................... 3528 
Table 10 Overview of genes associated with monogenic, 
non-syndromic cardiomyopathies, and their relative contributions 
to different cardiomyopathic phenotypes .................................................. 3530 
Table 11 Utility of genetic testing in cardiomyopathies ....................... 3533 
Table 12 Specific issues to consider when counselling children ....... 3534 
Table 13 Key discussion points of pre- and post-test genetic 
counselling ................................................................................................................ 3536 
Table 14 Pre-natal and pre-implantation options and implications
3536 
Table 15 Atrial fibrillation burden and management in 
cardiomyopathies .................................................................................................. 3542 
Table 16 Psychological considerations ......................................................... 3548 
Table 17 Imaging evaluation in hypertrophic cardiomyopathy ......... 3550 
Table 18 Echocardiographic features that suggest specific aetiologies 
in hypertrophic cardiomyopathy .................................................................... 3551 
Table 19 Major clinical features associated with an increased risk of 
sudden cardiac death ........................................................................................... 3558 
Table 20 Non-genetic causes of dilated cardiomyopathy .......................
3563 
Table 21 High-risk genotypes and associated predictors of sudden 
cardiac death ........................................................................................................... 3566 
Table 22 Clinical features and management of syndromic and 
metabolic cardiomyopathies ............................................................................ 3575 
Table 23 Anderson–Fabry disease red flags .............................................. 3577 
Table 24 General guidance for daily activity for patients with 
cardiomyopathies .................................................................................................. 3586 
Table 25 Modulators of the phenotypic expression of 
cardiomyopathies .................................................................................................. 3588
List of figures 
Figure 1 Central illustration .............................................................................. 3512 
Figure 2 Clinical diagnostic workflow of cardiomyopathy .................. 3513 
Figure 3 Examples of non-dilated left ventricular cardiomyopathy 
phenotypes and their aetiological correlates ............................................ 3515 
Figure 4 Worked example of the non-dilated left ventricular 
cardiomyopathy phenotype ............................................................................. 3516 
Figure 5 Multidisciplinary care of cardiomyopathies .............................. 3519 
Figure 6 Multimodality imaging process in cardiomyopathies ........... 3526 
Figure 7 Examples of cardiac magnetic resonance imaging tissue 
characterization features that should raise the suspicion of specific 
aetiologies, grouped according to cardiomyopathy phenotype ....... 3527 
Figure 8 The genetic architecture of the cardiomyopathies .............. 3533 
Figure 9 A patient-centred approach to cascade genetic testing of 
children ...................................................................................................................... 3535 
Figure 10 Clinical approach to infantile and childhood 
cardiomyopathy ..................................................................................................... 3538 
Figure 11 Algorithm for the approach to family screening and 
follow-up of family members ........................................................................... 3547 
Figure 12 Protocol for the assessment and treatment of left 
ventricular outflow tract obstruction .......................................................... 3551 
Figure 13 Algorithm for the treatment of heart failure in 
hypertrophic cardiomyopathy ......................................................................... 3552 
Figure 14 Flow chart on the management of left ventricular outflow 
tract obstruction ................................................................................................... 3554 
Figure 15 Pre-assessment checklist for patients being considered for 
invasive septal reduction therapies ................................................................ 3555 
Figure 16 Flow chart for implantation of an implantable cardioverter 
defibrillator in patients with hypertrophic cardiomyopathy .............. 3561 
Figure 17 Implantation of implantable cardioverter defibrillators in 
patients with dilated cardiomyopathy or non-dilated left ventricular 
cardiomyopathy flowchart ................................................................................ 3565 
ESC Guidelines                                                                                                                                                                                          3507


<!-- PAGE 6 -->

### Page 6

Figure 18 Algorithm to approach implantable cardioverter 
defibrillator decision-making in patients with arrhythmogenic right 
ventricular cardiomyopathy .............................................................................. 3572 
Figure 19 Spectrum of restrictive heart diseases .................................... 3573 
Figure 20 Anderson–Fabry disease diagnostic algorithm ..................... 3578 
Figure 21 Screening for cardiac amyloidosis ............................................. 3580 
Figure 22 Diagnosis of cardiac amyloidosis ............................................... 3581
Abbreviations and acronyms
18F-FDG
18F-fluorodeoxyglucose
2D
Two-dimensional
3D
Three-dimensional
99mTc
99mTechnetium
AAD
Antiarrhythmic drug
ABC
Atrial Fibrillation Better Care approach
ACE
Angiotensin-converting enzyme
ACE-I
Angiotensin-converting enzyme inhibitor
ACM
Arrhythmogenic cardiomyopathy
AD
Autosomal dominant
AED
Automated external defibrillator
AF
Atrial fibrillation
AFD
Anderson–Fabry disease
AHA/ACC
American Heart Association/American College of 
Cardiology
AL
Monoclonal immunoglobulin light chain amyloidosis
ALCAPA
Anomalous left coronary artery from the pulmonary 
artery
ALT
Alanine aminotransferase
ALVC
Arrhythmogenic left ventricular cardiomyopathy
APHRS
Asia Pacific Heart Rhythm Society
AR
Autosomal recessive
ARB
Angiotensin receptor blocker
ARNI
Angiotensin receptor neprilysin inhibitor
ARVC
Arrhythmogenic right ventricular cardiomyopathy
ASA
Alcohol septal ablation
AST
Aspartate transaminase
ATPase
Adenosine triphosphatase
ATTR
Transthyretin amyloidosis
ATTR-CA
Transthyretin cardiac amyloidosis
ATTR-CM
Transthyretin amyloid cardiomyopathy
ATTRv
Hereditary transthyretin amyloidosis
ATTRwt
Wild-type OR Acquired transthyretin amyloidosis
AV
Atrioventricular b.p.m.
Beats per minute
BAG3
BAG cochaperone-3
BNP
Brain natriuretic peptide
CAD
Coronary artery disease
CCB
Calcium channel blocker
CHA2DS2-VASc
Congestive heart failure or left ventricular 
dysfunction, hypertension, age ≥75 (doubled), 
diabetes, stroke (doubled)-vascular disease, age 65– 
74, sex category (female) (score)
CHD
Congenital heart disease
CK
Creatinine kinase
CMR
Cardiac magnetic resonance
COVID-19
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection
CPET
Cardio-pulmonary exercise testing
CPR
Cardio-pulmonary resuscitation
CRT
Cardiac resynchronization therapy
CrCl
Creatinine clearance
CT
Computed tomography
CTCA
Computed tomography coronary angiography
DBS
Deep brain stimulation
DCM
Dilated cardiomyopathy
DES
Desmin
DMD
Duchenne muscular dystrophy
DOAC
Direct-acting oral anticoagulant
DPD
3,3-diphosphono-1,2-propanodicarboxylic acid
DSP
Desmoplakin
EAST-AFNET
Early Treatment of Atrial Fibrillation for Stroke 
Prevention Trial
ECG
Electrocardiogram
ECHO
Echocardiogram
ECV
Extracellular volume
EF
Ejection fraction
EHRA
European Heart Rhythm Association
EMB
Endomyocardial biopsy
EMF
Endomyocardial fibrosis
EORP
EURObservational Research Programme
ERN
European Reference Network
ERT
Enzyme replacement therapy
FLNC
Filamin C
FRA
Friedreich ataxia
FTX
Frataxin
Gb3
Globotriaosylceramide
GDMT
Guideline-directed medical therapy
GSD
Glycogen storage disorder
GWAS
Genome-wide association study
HbA1c
Haemoglobin A1C
HBP
His-Bundle pacing
HCM
Hypertrophic cardiomyopathy
HCMR
Hypertrophic Cardiomyopathy Registry
HF
Heart failure
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HMDP
Hydroxymethylene diphosphonate
HR
Hazard ratio
HRS
Heart Rhythm Society hs-cTnT
High-sensitivity cardiac troponin T
ICD
Implantable cardioverter defibrillator
INR
International normalized ratio
ITFC
International Task Force Consensus statement
IVF
In vitro fertilization
LA
Left atrium
LAHRS
Latin American Heart Rhythm Society
LBBB
Left bundle branch block
LGE
Late gadolinium enhancement
LMNA
Lamin A/C
LMWH
Low-molecular-weight heparin
LSD
Lysosomal storage disease
LV
Left ventricular
LVAD
LV assist device
LVEDV
Left ventricular end-diastolic volume
LVEF
Left ventricular ejection fraction
LVH
Left ventricular hypertrophy


<!-- PAGE 7 -->

### Page 7

LVNC
Left ventricular non-compaction
LVOT
Left ventricular outflow tract
LVSD
Left ventricular systolic dysfunction
LVOTO
Left ventricular outflow tract obstruction
MCS
Mechanical circulatory support
MELAS
Mitochondrial encephalomyopathy, lactic acidosis, 
and stroke-like episodes (syndrome)
MERRF
Mitochondrial epilepsy with ragged-red fibres
MGUS
Monoclonal gammopathy of undetermined 
significance
MICONOS
Mitochondrial Protection with Idebenone in Cardiac 
or Neurological Outcome (study group)
MLVWT
Maximum left ventricular wall thickness
MRA
Mineralocorticoid receptor antagonist
MRI
Magnetic resonance imaging
MV
Mitral valve mWHO
Modified World Health Organization  
(classification)
NCS
Non-cardiac surgery
NDLVC
Non-dilated left ventricular cardiomyopathy
NGS
Next-generation sequencing
NSML
Noonan syndrome with multiple lentigines
NSVT
Non-sustained ventricular tachycardia
NT-proBNP
N-terminal pro-brain natriuretic peptide
NYHA
New York Heart Association
OMT
Optimal medical therapy
P/LP
Pathogenic/likely pathogenic
PES
Programmed electrical stimulation
PET
Positron emission tomography
PKP2
Plakophilin 2
PLN
Phospholamban
PPCM
Peripartum cardiomyopathy
PRKAG2
Protein kinase AMP-activated non-catalytic subunit 
gamma 2
PRS
Polygenic risk scores
PTH
Parathyroid hormone
PVR
Pulmonary vascular resistance
PYP
Pyrophosphate
QoL
Quality of life
QRS
Q, R, and S waves of an ECG
RAS-HCM
RASopathy-associated HCM
RBBB
Right bundle branch block
RBM20
RNA binding motif protein
RCM
Restrictive cardiomyopathy
RCT
Randomized controlled trial
RV
Right ventricular
RVEF
Right ventricular ejection fraction
RVOTO
Right ventricular outflow tract obstruction
RWMA
Regional wall motion abnormality
SAECG
Signal-averaged electrocardiogram
SAM
Systolic anterior motion
SCD
Sudden cardiac death
SGLT2i
Sodium–glucose co-transporter 2 inhibitor
SMVT
Sustained monomorphic ventricular tachycardia
SPECT
Single-photon emission computed tomography
SRT
Septal reduction therapy
TIA
Transient ischaemic attack
TMEM43
transmembrane protein 43
TRED-HF
Therapy withdrawal in REcovered Dilated 
cardiomyopathy—Heart Failure
TTE
Transthoracic echocardiography
TTN
Titin
TTNtv
Titin gene truncating variants
TTR
Transthyretin
TWI
T wave inversion
UFH
Unfractionated heparin
VALOR-HCM
A Study to Evaluate Mavacamten in Adults With 
Symptomatic Obstructive HCM Who Are Eligible 
for Septal Reduction Therapy
VE
Ventricular extrasystole
VF
Ventricular fibrillation
VKA
Vitamin K antagonist
VT
Ventricular tachycardia
VUS
Variant of unknown significance
WHO
World Health Organization
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of 
assisting health professionals in proposing the best diagnostic or thera­
peutic approach for an individual patient with a given condition. 
Guidelines are intended for use by health professionals and the 
European Society of Cardiology (ESC) makes its Guidelines freely 
available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription, and, where appropriate, to respect the ethical rules of 
their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated. ESC Policies and Procedures for for­
mulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines).
The Members of this Task Force were selected by the ESC to re­
present professionals involved with the medical care of patients with 
this pathology. The selection procedure aimed to include members 
from across the whole of the ESC region and from relevant ESC 
Subspecialty Communities. Consideration was given to diversity and in­
clusion, notably with respect to gender and country of origin. The Task 
Force performed a critical evaluation of diagnostic and therapeutic ap­
proaches, including assessment of the risk-benefit ratio. The strength of 
every recommendation and the level of evidence supporting them were 
weighed and scored according to predefined scales as outlined below. 
The Task Force followed ESC voting procedures, and all approved re­
commendations were subject to a vote and achieved at least 75% 
agreement among voting members.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules and 
can be found on the ESC website (http://www.escardio.org/ 
Guidelines) and have been compiled in a report published in a supple­
mentary document with the guidelines. The Task Force received its
ESC Guidelines                                                                                                                                                                                          3509


<!-- PAGE 8 -->

### Page 8

Table 1 Classes for recommendations
©ESC 2023
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2023
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2023
© ESC 2023


<!-- PAGE 9 -->

### Page 9

entire financial support from the ESC without any involvement from 
the healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible 
for the approval process. ESC Guidelines undergo extensive review 
by the CPG Committee and external experts, including members 
from across the whole of the ESC region and from relevant ESC 
Subspecialty Communities and National Cardiac Societies. After appro­
priate revisions, the guidelines are signed off by all the experts involved 
in the Task Force. The finalized document is signed off by the CPG 
Committee for publication in the European Heart Journal. The guidelines 
were developed after careful consideration of the scientific and medical 
knowledge and the evidence available at the time of their writing. Tables 
of evidence summarizing the findings of studies informing development 
of the guidelines are included. The ESC warns readers that the technical 
language may be misinterpreted and declines any responsibility in this 
respect.
Off-label use of medication may be presented in this guideline if a suf­
ficient level of evidence shows that it can be considered medically ap­
propriate for a given condition.
However, the final decisions concerning an individual patient must be 
made by the responsible health professional giving special consideration 
to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest, with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
The objective of this European Society of Cardiology (ESC) Guideline is 
to help healthcare professionals diagnose and manage patients with car­
diomyopathies according to the best available evidence. Uniquely for 
relatively common cardiovascular diseases, there are very few rando­
mized controlled clinical trials in patients with cardiomyopathies. For 
this reason, the majority of the recommendations in this guideline are 
based on observational cohort studies and expert consensus opinion. 
The aim is to provide healthcare professionals with a practical diagnos­
tic and treatment framework for patients of all ages and, as an increasing 
number of patients have a known genetic basis for their disease, the 
guideline also considers the implications of a diagnosis for families 
and provides advice on reproduction and contraception. As cardio­
myopathies can present at any age and can affect individuals and families 
across the entire life course, this guideline follows the principle of con­
sidering cardiomyopathies in all age groups as single disease entities, 
with recommendations applicable to children and adults with cardio­
myopathy throughout, while accepting that the evidence base for 
many of the recommendations is significantly more limited for children. 
Age-related differences are specifically highlighted.
This is a new guideline, not an update of existing guidelines, with the 
exception of the section on hypertrophic cardiomyopathy (HCM), in 
which we have provided a focused update to the 2014 ESC Guidelines 
on diagnosis and management of hypertrophic cardiomyopathy.1 As such, 
most of the recommendations in this guideline are new. It is beyond 
the scope of this guideline to provide detailed descriptions and 
recommendations for each individual cardiomyopathy phenotype; in­
stead, the aim is to provide a guide to the diagnostic approach to car­
diomyopathies, highlight general evaluation and management issues, 
and signpost the reader to the relevant evidence base for the 
recommendations.
Adoption of morphological and functional disease definitions means 
that the number of possible aetiologies is considerable, particularly in 
young children. As it is impractical to provide an exhaustive compen­
dium of all possible causes of cardiomyopathy, the guideline focuses 
on the most common disease phenotypes, but additional references 
for less common disorders are also provided. Similarly, treatment re­
commendations focus largely on generic management issues but refer 
to specific rare diseases when appropriate. The central illustration 
(Figure 1) highlights key aspects in the evaluation and management of 
cardiomyopathies addressed in this guideline.
This is the first major international guideline to address cardiomyop­
athies other than HCM. Other major innovations include: 
• A new phenotypic description of cardiomyopathies, including up­
dated descriptions of dilated and non-dilated left ventricular (LV) car­
diomyopathy phenotypes, and highlighting the key role of ventricular 
myocardial scar assessment using cardiac magnetic resonance (CMR) 
imaging.
• A focus on the patient pathway, from presentation, through initial as­
sessment and diagnosis, to management, highlighting the importance 
of considering cardiomyopathy as a cause of common clinical presen­
tations (e.g. heart failure, arrhythmia) and the importance of utilizing a 
multiparametric approach following the identification of the present­
ing phenotype to arrive at an aetiological diagnosis.
• Updated recommendations for clinical and genetic cascade screening 
for relatives of individuals with cardiomyopathies.
• A focus on cardiomyopathies across the life course, from paediatric 
to adult age (including transition), and considering the different clin­
ical phases (e.g. concealed, overt, end stage).
• New recommendations on sudden cardiac death (SCD) risk stratifi­
cation for different cardiomyopathy phenotypes, including in child­
hood, and highlighting the important role of genotype in the 
assessment of sudden death risk.
• Updated recommendations for the management of left ventricular 
outflow tract obstruction (LVOTO) in HCM.
• A multidisciplinary approach to cardiomyopathies that has the pa­
tient and their family at its heart.
3. Phenotypic approach to 
cardiomyopathies
In medicine, classification systems are used to standardize disease no­
menclature by grouping disorders according to shared characteristics. 
In 2008, the ESC promoted a pragmatic system for the clinical descrip­
tion of cardiomyopathies in which a historical focus on ventricular 
morphology and function was maintained, while signposting aetiological 
diversity through subdivision into genetic and non-genetic subtypes.2
Since then, knowledge of cardiomyopathies has increased substantially 
through the application of new imaging and molecular technologies.
In this guideline, the Task Force took a number of considerations into 
account when deciding its approach to disease description. These in­
cluded: (i) a historical legacy which, while still useful, has led to contra­
dictory and confusing terminology in many situations; (ii) the evolving 
nature of cardiomyopathies over a lifetime; (iii) aetiological complexity 
with multiple disease processes contributing to disease phenotypes;
ESC Guidelines                                                                                                                                                                                          3511


<!-- PAGE 10 -->

### Page 10

Symptoms
Ventricular morphology/
function
Ventricular scar and tissue characterization
Pedigree analysis
Genetic testing
HCM
DCM
NDLVC
ARVC
RCM
Extracardiac involvement
Laboratory markers
Pathology
Incidental findings
Family screening
Phenotypespecific management
General management principles
LVOTO management
SCD risk prediction
GDMT for HF symptoms
Aetiology-specific SCD
risk prediction
Antiarrhythmic therapy
SCD risk prediction
GDMT for HF symptoms
PVR study to guide timing of transplantation
Drug therapy
Mechanical circulatory 
support/transplantation
Symptom management
Genetic testing and counselling
Family screening and monitoring
Family screening and genetic risk to relatives
Exercise recommendations
Pregnancy
School, employment,
psychological support
Lifestyle
Prevention of diseaserelated complications
SCD
Stroke thromboembolic prophylaxis
ICD
Clinical scenario
Morphological/functional characterization
Phenotype
Additional traits
4
5
6
1
2
3
GDMT for HF symptoms
Aetiology-specific SCD
risk prediction
Arrhythmias/conduction disease
Arrhythmias/conduction disease
Figure 1 Central illustration. Key aspects in the evaluation and management of cardiomyopathies. ARVC, arrhythmogenic right ventricular cardiomyop­
athy; CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; GDMT, guideline-directed medical therapy; HCM, hypertrophic cardiomyopathy; HF, 
heart failure ICD, implantable cardioverter defibrillator; LVOTO, left ventricular outflow tract obstruction; MCS, mechanical circulatory support; NDLVC, 
non-dilated left ventricular cardiomyopathy; PVR, pulmonary vascular resistance; RCM, restrictive cardiomyopathy; SCD, sudden cardiac death.Image %:


<!-- PAGE 11 -->

### Page 11

(iv) differential disease expression in families; and (v) emerging 
aetiology-focused therapies.
The Task Force concluded that a single classification system that em­
braces all possible causes of disease and every clinical scenario remains 
an aspiration that is outside the scope of this clinical guideline. Instead, 
the Task Force updated the existing clinical classification to include new 
phenotypic descriptions and to simplify terminology, while simultan­
eously providing a conceptual framework for diagnosis and treatment. 
This nomenclature prompts clinicians to consider cardiomyopathy as 
the cause of several clinical presentations (e.g. arrhythmia, heart failure), 
and focuses on morphological and functional characteristics of the 
myocardium (Figure 2). It is important to recognize that different 
Suspected cardiomyopathy
Ventricular morphology/function
Hypertrophy
Dilatation
Systolic/diastolic function
Ventricular scar/fatty replacement
Non-ischaemic ventricular scar on
CMR/pathological examination
Other tissue characterization parameters on CMR
Symptoms
Incidental findings
Family screening
Dyspnoea
Chest pain
Palpitation
Syncope/presyncope
Cardiac arrest
1st degree relative with CMP
Family history of sudden death
Abnormal ECG
Murmur
Arrhythmia
Clinical scenario
Arrhythmias/conduction disease
(atrial, ventricular, atrioventricular block)
Pedigree analysis
Laboratory markers
Pathology
Genetic testing
Extracardiac involvement
Phenotype-based integrated aetiological diagnosis
Phenotype
HCM
DCM
ARVC
RCM
NDLVC
Morphological/
functional characterization
Additional traits
Figure 2 Clinical diagnostic workflow of cardiomyopathy. ARVC, arrhythmogenic right ventricular cardiomyopathy; CMP, cardiomyopathy; CMR, cardiac 
magnetic resonance; DCM, dilated cardiomyopathy; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; NDLVC, non-dilated left ventricular car­
diomyopathy; RCM, restrictive cardiomyopathy.
ESC Guidelines                                                                                                                                                                                          3513


<!-- PAGE 12 -->

### Page 12

cardiomyopathy phenotypes may coexist in the same family, and that 
disease progression in an individual patient can include evolution 
from one cardiomyopathy phenotype to another. Nevertheless, the 
Task Force recommends an approach to disease nomenclature and 
diagnosis that is based on the predominant cardiac phenotype at 
presentation.
While recognizing the fact that genes encoding cardiac ion channels 
may be implicated in some patients with dilated cardiomyopathy 
(DCM), conduction disorders, and arrhythmias, the Task Force was 
not persuaded that there is sufficient evidence to consider cardiac chan­
nelopathies as cardiomyopathies, in keeping with the approach taken by 
other recent ESC Guidelines.3
The most important changes in this guideline relate to the group of 
conditions variously included under the umbrella term ‘arrhythmogenic 
cardiomyopathies’. This term refers to a group of conditions that fea­
ture structural and functional abnormalities of the myocardium (identi­
fied by cardiac imaging and/or macroscopic and microscopic 
pathological investigation) and ventricular arrhythmia. This nosology 
has evolved in response to the recognition of the clinical and genetic 
overlap between right ventricular (RV) and LV cardiomyopathies, but 
a lack of a generally accepted definition has meant that the term encom­
passes a broad range of diverse pathologies and has introduced a num­
ber of inconsistencies and contradictions when applied in a clinical 
setting.4 The term ‘arrhythmogenic right ventricular (dysplasia/) cardio­
myopathy’ (ARVC) was originally used by physicians who first discov­
ered the disease, in the pre-genetic and pre-CMR era, to describe a 
new heart muscle disease predominantly affecting the right ventricle, 
whose cardinal clinical manifestation was the occurrence of malignant 
ventricular arrhythmias. Subsequently, autopsy investigations, geno­
type–phenotype correlation studies and the increasing use of 
contrast-enhancement CMR led to the identification of fibro-fatty re­
placement of the myocardium as a key phenotypic feature of the dis­
ease that affects the myocardium of both ventricles, with LV 
involvement which may even exceed the severity of RV involvement. 
This has led to the catch-all term of arrhythmogenic cardiomyopathy 
(ACM), which represents the evolution of the original term of 
ARVC.5 Consistent with its general approach, the Task Force agreed 
to highlight the vital importance of arrhythmia as a diagnostic red flag 
and prognostic marker across a range of clinical phenotypes, but did 
not recommend the use of the term ACM as a distinct cardiomyopathy 
subtype as it lacks a morphological or functional definition consistent 
with the existing classification scheme. While acknowledging that 
‘ACM’ as an umbrella term that encompasses diverse clinical pheno­
types has been previously used, this decision will, it is hoped, help to re­
solve many of the circular arguments that currently bedevil the field. 
The fundamental tenet throughout this guideline is that aetiology is vital 
to the management of patients with heart muscle disease and that a 
careful and consistent description of the morphological and functional 
phenotype is a crucial first step in the diagnostic pathway, while the final 
diagnosis will ideally describe aetiology alongside the phenotype.6,7
3.1. Definitions
A cardiomyopathy is defined as ‘a myocardial disorder in which the 
heart muscle is structurally and functionally abnormal, in the absence 
of coronary artery disease (CAD), hypertension, valvular disease, and 
congenital heart disease (CHD) sufficient to cause the observed myo­
cardial abnormality’.2 This definition applies to both children and 
adults and makes no a priori assumptions about aetiology (which 
can be familial/genetic or acquired) or myocardial pathology. While 
the focus of this guideline is on genetic cardiomyopathies, the system­
atic approach to diagnosis starting from the phenotype at presenta­
tion described in this guideline enables clinicians to reach precise 
diagnoses that may also include non-genetic (e.g. inflammatory, toxic, 
and multisystem diseases) causes. It is important to note that cardio­
myopathies can coexist with ischaemic, valvular, and hypertensive dis­
ease and that the presence of one does not exclude the possibility of 
the other.
The morphological and functional traits used to describe the cardio­
myopathy phenotypes are shown in Table 3. The major innovation is 
the specific inclusion of myocardial tissue characterization traits, includ­
ing non-ischaemic ventricular scarring or fatty replacement, which can 
occur with and without ventricular dilatation, wall motion abnormal­
ities, or global systolic or diastolic dysfunction. This phenotype is im­
portant to recognize, as it may be the sole clue to the diagnosis of a 
cardiomyopathy and has prognostic significance that varies with the 
underlying aetiology.
Atrial dilatation (left and/or right) is an important additional clinical 
finding in the phenotypic description of cardiomyopathies. Ultra-rare, 
usually autosomal recessive, cases of pure dilated atrial cardiomyopathy 
are reported,8 but these are outside the scope of this guideline.
3.2. Cardiomyopathy phenotypes
3.2.1. Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is defined as the presence of in­
creased LV wall thickness (with or without RV hypertrophy) or mass 
that is not solely explained by abnormal loading conditions.2
3.2.2. Dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is defined as the presence of LV dilata­
tion and global or regional systolic dysfunction unexplained solely by ab­
normal loading conditions (e.g. hypertension, valve disease, CHD) or 
CAD.2 Very rarely, LV dilatation can occur with normal ejection frac­
tion (EF) in the absence of athletic remodelling or other environmental 
factors; this is not in itself a cardiomyopathy, but may represent an early 
manifestation of DCM. The preferred term for this is isolated left ven­
tricular dilatation.
Right ventricular dilatation and dysfunction may be present but are 
not necessary for the diagnosis. When dilatation or wall motion abnor­
malities are confined or predominant to the right ventricle, the possibil­
ity of ARVC should be considered (see Section 3.2.4).
3.2.3. Non-dilated left ventricular cardiomyopathy
Hitherto, the definition of DCM had a number of important limita­
tions, most notably the exclusion of genetic and acquired disorders
Table 3 Morphological and functional traits used to de­
scribe cardiomyopathy phenotypes
Morphological traits
Ventricular hypertrophy: left and/or right
Ventricular dilatation: left and/or right
Non-ischaemic ventricular scar and other myocardial tissue 
characterization features on cardiac magnetic resonance
Functional traits
Ventricular systolic dysfunction (global, regional)
Ventricular diastolic dysfunction (restrictive physiology)
© ESC 2023


<!-- PAGE 13 -->

### Page 13

that manifest as intermediate phenotypes that do not meet standard 
disease definitions in spite of the presence of myocardial disease on 
cardiac imaging or tissue analysis. In a previous ESC statement, this 
phenomenon inspired the creation of a new disease category, hypo­
kinetic non-dilated cardiomyopathy.9 In this guideline, we propose 
replacement of this term with non-dilated left ventricular cardiomy­
opathy (NDLVC), which can be further characterized by the pres­
ence or absence of systolic dysfunction (regional or global). 
Isolated LV dysfunction (regional or global) without scarring should 
also be considered under this diagnostic category. The NDLVC 
phenotype is defined as the presence of non-ischaemic LV scarring 
or fatty replacement regardless of the presence of global or regional 
wall motion abnormalities (RWMAs), or isolated global LV hypokine­
sia without scarring.
The NDLVC phenotype will include individuals that up until now may 
have variably been described as having DCM (but without LV dilata­
tion), arrhythmogenic left ventricular cardiomyopathy (ALVC), left- 
dominant ARVC, or arrhythmogenic DCM (but often without fulfilling 
diagnostic criteria for ARVC) (Figure 3). The simple worked example 
(Figure 4) shows how the identification of an NDLVC phenotype should 
trigger a multiparametric approach that leads to a specific aetiological 
diagnosis, with implications for clinical treatment.
DSP
LMNA
PLN
BAG3
FLNC
LMNA
TTN
BAG3 (no LGE)
RBM20
LMNA (no LGE)
Myocarditis
DMD
Figure 3 Examples of non-dilated left ventricular cardiomyopathy phenotypes and their aetiological correlates. BAG3, BAG cochaperone-3; DMD, 
Duchenne muscular dystrophy; DSP, desmoplakin; FLNC, filamin C; LGE, late gadolinium enhancement; LMNA, lamin A/C; NDLVC, non-dilated left ven­
tricular cardiomyopathy; PLN, phospholamban; RBM20, RNA binding motif protein 20; TTN, titin. Distribution of LGE (arrowheads) in NDLVC and aetio­
logical correlates. Desmoplakin (DSP), filamin C (FLNC) and phospholamban (PLN) genotypes show a characteristic subepicardial, ring-like LGE pattern, 
whereas titin (TTN), BAG3 (BAG3), lamin A/C (LMNA), DMD, RBM20 genotypes and myocarditis are more heterogeneous, but with overall less scar (some­
times without) and lower left ventricular ejection fraction.
ESC Guidelines                                                                                                                                                                                          3515


<!-- PAGE 14 -->

### Page 14

3.2.4. Arrhythmogenic right ventricular 
cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is 
defined as the presence of predominantly RV dilatation and/or dys­
function in the presence of histological involvement and/or 
electrocardiographic abnormalities in accordance with published 
criteria.10
For decades, ARVC has been one of the principal cardiomyopathy 
subtypes. It has been defined in accordance with published consensus 
criteria that comprise RV dysfunction (global or regional), histological 
abnormalities in the form of fibro-fatty replacement of cardiomyocytes, 
electrocardiographic characteristics, ventricular arrhythmia of RV ori­
gin, and the presence of familial disease and/or pathogenic variants in 
desmosomal protein genes.
Over time, the clinical paradigm of ARVC has moved from a focus on 
severe RV disease and malignant ventricular arrhythmia to a broader 
concept that includes concealed or subclinical phenotypes and biventri­
cular or even left-dominant disease. This has led to a plethora of new 
terms, including ‘arrhythmogenic left ventricular cardiomyopathy 
(ALVC)’, ‘left and right dominant cardiomyopathy’, ‘arrhythmogenic di­
lated cardiomyopathy’, and most recently, the catch-all term ‘arrhyth­
mogenic cardiomyopathy’. The term ARVC can be used to describe 
the original variant in which ventricular dilatation or wall motion abnor­
malities are predominantly confined to the right ventricle, with or with­
out LV involvement, and the 2010 modified Task Force criteria for the 
diagnosis of ARVC can be applied.10 Predominant LV disease can also 
occur in the same family;5 see Section 7.3 for recommendations on as­
sessment and management of this phenotype.
Previous classification
17 y/o male; palpitation
Family history SCD
Normal physical examination
DCM
ALVC
ACM
DSP Trp180*
Non-dilated LV
EF 55%
Subepicardial scar
Sinus rhythm, minor intraventricular conduction delay 
200 VEs, few couplets
Clinical presentation
Cardiac morphology/
function
ECG/
arrhythmia
Genetics
Diagnostic pathway
Proposed phenotypebased integrated approach
Autosomal dominant 
DSP-related non-dilated LV 
cardiomyopathy phenotype 
with subepicardial scar and low-normal EF
Figure 4 Worked example of the non-dilated left ventricular cardiomyopathy phenotype. ACM, arrhythmogenic cardiomyopathy; ALVC, arrhythmogenic 
left ventricular cardiomyopathy; DCM, dilated cardiomyopathy; DSP, desmoplakin; ECG, electrocardiogram; EF, ejection fraction; LV, left ventricular; 
NDLVC, non-dilated left ventricular cardiomyopathy; SCD, sudden cardiac death; VE, ventricular extrasystole. Worked example of the NDLVC phenotype 
showing how a systematic multiparametric approach to clinical phenotyping, starting from the recognition of a clinical phenotype and integrating extended 
phenotypic information and targeted diagnostics, including genetic testing, can be used to arrive at highly specific phenotypic descriptions that can result in 
personalized treatment plans. In this worked example, the diagnosis transforms from a simplistic categorization to a complex genetic disorder characterized 
by myocardial scar and a propensity to ventricular arrhythmia.


<!-- PAGE 15 -->

### Page 15

3.2.5. Restrictive cardiomyopathy
Restrictive cardiomyopathy (RCM) is defined as restrictive left and/or 
RV pathophysiology in the presence of normal or reduced diastolic vo­
lumes (of one or both ventricles), normal or reduced systolic volumes, 
and normal ventricular wall thickness.2
Restrictive cardiomyopathy commonly presents as biatrial enlarge­
ment. Left ventricular systolic function can be preserved, but it is rare 
for contractility to be completely normal. Restrictive pathophysiology 
may not be present throughout the natural history, but only at an initial 
stage (with an evolution towards a hypokinetic-dilated phase).11
Restrictive physiology can also occur in patients with end-stage hyper­
trophic and dilated cardiomyopathy; the preferred terms are ‘hyper­
trophic’ or ‘dilated cardiomyopathy with restrictive physiology’. 
Restrictive ventricular physiology can also be caused by endocardial 
pathology (fibrosis, fibroelastosis, and thrombosis) that impairs diastolic 
function.
3.3. Other traits and syndromes associated 
with cardiomyopathy phenotypes
3.3.1. Left ventricular hypertrabeculation (left 
ventricular non-compaction)
The term ‘left ventricular non-compaction’ (LVNC) has been used to 
describe a ventricular phenotype characterized by prominent LV tra­
beculae and deep intertrabecular recesses. The myocardial wall is often 
thickened with a thin, compacted epicardial layer and a thicker endocar­
dial layer. In some patients, this abnormal trabecular architecture is as­
sociated with LV dilatation and systolic dysfunction. Left ventricular 
non-compaction is frequently a familial trait and is associated with var­
iants in a range of genes, including those encoding proteins of the sarco­
mere, Z-disc, cytoskeleton, and nuclear envelope.12–16
Left ventricular non-compaction has also been used to describe an 
acquired and sometimes transient phenomenon of excessive LV trabe­
culation (e.g. in athletes, during pregnancy, or following vigorous activ­
ity)17–19 that must reflect increased prominence of an otherwise 
normal myocardial architecture, given that cardiomyocytes are termin­
ally differentiated and the formation of new cardiac structures is 
impossible.20
The Task Force does not consider LVNC to be a cardiomyopathy in 
the general sense. Instead, it is seen as a phenotypic trait that can occur 
either in isolation or in association with other developmental abnormal­
ities, ventricular hypertrophy, dilatation, and/or systolic dysfunction. 
Given the lack of morphometric evidence for ventricular compaction 
in humans,21,22 the term ‘hypertrabeculation’, rather than LVNC, is re­
commended, particularly when the phenomenon is transient or clearly 
of adult onset.
3.3.2. Takotsubo syndrome
Transient LV apical ballooning syndrome, or takotsubo syndrome, is 
characterized, in its most typical variant, by transient regional systolic 
dysfunction, dilatation, and oedema involving the LV apex and/or mid- 
ventricle in the absence of obstructive coronary disease on coronary 
angiography.23 Patients present with an abrupt onset of angina-like 
chest pain and have diffuse T wave inversion (TWI), sometimes pre­
ceded by ST-segment elevation and mild cardiac enzyme elevation. 
Most reported cases occur in post-menopausal women. Symptoms 
are often preceded by emotional or physical stress. Norepinephrine 
concentration is elevated in most patients and a transient, dynamic out­
flow tract pressure gradient is reported in some cases. Left ventricular 
function usually normalizes over a period of days to weeks, and recur­
rence is rare. The same kind of reversible myocardial dysfunction is oc­
casionally encountered in patients with intracranial haemorrhage or 
other acute cerebral accidents (neurogenic myocardial stunning).
Takotsubo syndrome is sometimes referred to as takotsubo or 
stress cardiomyopathy. Given the transient nature of the phenomenon, 
the Task Force does not recommend its classification as a 
cardiomyopathy.
4. Epidemiology
Cardiomyopathies have a variable expression throughout life.24
Geographical distribution of genetic variants influences estimated 
prevalence in different populations, ethnicities, regions, and countries. 
The complexity of diagnostic criteria for some conditions, such as 
ARVC, limits the evaluation of the true prevalence of the disease in 
the general population. Moreover, epidemiological data are often not 
collected systematically at population level. For example, the preva­
lence of idiopathic DCM has been recently estimated to be almost 
10 times higher based on several population-based estimates and indir­
ect assumptions of the prevalence of genetic variants associated with 
the disease in general populations,25 and with less stringent diagnostic 
criteria.9
There are no specific data on the epidemiology of the NDLVC 
phenotype, but patients affected by it have previously been included 
in DCM or ARVC cohorts, from which extrapolations may be pos­
sible. Contemporary epidemiological metrics for the main cardiomy­
opathies are shown in Table 4. Further details on the epidemiology of 
cardiomyopathies can be found in the Supplementary data online, 
Section 1.
Table 4 Key epidemiological metrics in adults and 
children for the different cardiomyopathy phenotypes
Cardiomyopathy 
phenotype
Adults
Children
HCM
Prevalence: 
0.2%26–33
Childhood incidence: 
0.002–0.005%34–36
Childhood prevalence: 
0.029%36
DCM
Prevalence:  
0.036–0.400%25,37
Childhood incidence: 
0.003–0.006% 
Childhood prevalence: 
0.026%36
Infantile incidence: 
0.038–0.046%34–36,38
NDLVC
To be determined
To be determined
ARVC
Prevalence: 
0.078%39–41
Very rare in infancy and 
early childhood; to be 
determined in older 
children and adolescents
RCM
Rare
Childhood incidence: 
0.0003%34
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; 
HCM, 
hypertrophic 
cardiomyopathy; 
NDLVC, 
non-dilated 
left 
ventricular 
cardiomyopathy; RCM, restrictive cardiomyopathy.
ESC Guidelines                                                                                                                                                                                          3517


<!-- PAGE 16 -->

### Page 16

4.1. Special populations
Several forms of cardiomyopathy previously considered secondary to 
external factors were recently proved to have genetic contributors, 
leading to the ‘second hit theory’, and a genetic aetiology should be 
kept in mind for family history taking and genetic testing. 
• Titin gene truncating variants (TTNtv) represent a prevalent genetic 
predisposition for alcoholic cardiomyopathy (present in 13.5% of pa­
tients vs. 2.9% in controls), as they are associated with a worse left 
ventricular ejection fraction (LVEF) in DCM patients who consume 
alcohol above recommended levels.42
• Unrecognized rare variants in cardiomyopathy-associated genes, par­
ticularly TTNtv (in 7.5% of cases), appear to be associated with an in­
creased risk of cancer therapy-induced cardiomyopathy in children 
and adults.43
• Rare truncating variants in eight genes are found in 15% of women 
with peripartum cardiomyopathy (PPCM), and two-thirds are 
TTNtv (10% of patients vs. 1.4% of the reference population).44,45
Additionally, other truncating variants are identified in the DSP 
(1%), FLNC (1%), and BAG3 (0.2%) genes.45
• Anderson–Fabry disease is found in 0.94% of males and 0.90% of fe­
males in cardiac screening programmes for left ventricular hyper­
trophy (LVH) in selected populations and HCM.46
• Screening with bone scintigraphy found a high prevalence of trans­
thyretin cardiac amyloidosis (ATTR-CA) in specific populations: 8% 
in severe aortic stenosis, 12% in heart failure with preserved ejection 
fraction (HFpEF) with LVH, 7% in LVH/HCM depending on the age, 
and 7% in carpal tunnel syndrome undergoing surgery (a higher 
prevalence if it is bilateral), mainly for the wild-type form.47,48
• Disease-causing variants in genes implicated in DCM, NDLVC, and 
ARVC have been identified in 8–22% of adults and children present­
ing with acute myocarditis.49–51 Individuals with an acute myocarditis 
presentation and desmosomal protein gene variants were shown to 
have a higher rate of myocarditis recurrence and ventricular arrhyth­
mia compared with myocarditis patients without a desmosomal vari­
ant identified.52
5. Integrated patient management
The diagnosis, assessment, and management of patients with cardiomy­
opathy requires a co-ordinated, systematic, and individualized pathway 
that delivers optimized care by a multidisciplinary and expert team. 
Central to this approach is not only the individual patient, but also 
the family as a whole; clinical findings in relatives are essential for under­
standing what happens to the patient, and vice versa.53,54
5.1. Multidisciplinary cardiomyopathy 
teams
Healthcare professionals encounter diseases affecting the myocardium 
in many and varied clinical settings. Some may manifest for the first time 
with an acute event, including sudden unexplained death, whereas 
others present with progressive symptoms or are detected incidentally. 
Patients with cardiomyopathy can also have extracardiac manifesta­
tions (e.g. neurological, neuromuscular, ophthalmological, nephrologic­
al). Patient care requires the collaboration of different specialties.55 The 
composition of the multidisciplinary team will depend on the patient’s 
and family’s needs and the local availability of services (Figure 5). Patients 
with complex needs benefit from a multidisciplinary team, including 
relevant specialties as well as the general cardiologist, general practi­
tioner, and the family/carer. In addition, the integration of genetics 
into mainstream cardiology services requires expertise from different 
specialties: 
• Adult and paediatric cardiologists subspecialized in cardiogenetic 
conditions.
• Cardiac imaging specialists (technicians, cardiologists, radiologists), in­
cluding CMR experts.
• Specialist nurses and/or genetic counsellors with skills in family his­
tory taking, drawing pedigrees, and patient/family management, par­
ticularly when the number of disciplines or the complexity implicated 
in a patient’s/family’s care increases.
• Clinical psychologists to support patients and their relatives.
• Geneticists and bioinformaticians to interpret results of genetic 
investigations.
• Expert pathologists to interpret findings by endomyocardial biopsy 
(EMB) and autopsy of individuals dying from a suspected inherited 
cardiac condition. Specialist cardiovascular pathology centres play a 
crucial role in the autopsy diagnosis of cardiomyopathy when local 
expertise is not available.56,57
Finally, patients’ associations should be promoted and integrated into 
the healthcare process for rare and very rare cardiac conditions.
One particularly important aspect of the multidisciplinary approach 
to patient care in cardiomyopathies is the need for appropriate transi­
tion of care from paediatric to adult services. Children with a genetic 
cardiomyopathy generally need lifelong cardiac follow-up. The transi­
tion to adulthood, including the transfer of care to adult cardiomyop­
athy services, can be challenging for both the child and the parents. 
The process of transition should include adequate and timely prepar­
ation and joint consultations, taking into consideration the child’s 
wishes, and level of understanding and independence at different life 
stages. Evidence from the field of CHD highlights the importance of 
specific interventions that can help the process of transition of clinical 
care, including adequate and timely preparation for transition and joint 
consultations.58,59
5.2. Co-ordination between different 
levels of care
A shared care approach between cardiomyopathy specialists and gen­
eral adult and paediatric cardiology centres is strongly recommended. 
While referral cardiomyopathy units are essential for complex cases 
with diagnostic and/or treatment difficulties that require expertise 
that may only be available in high-volume centres, general adult and 
paediatric cardiologists have a key role to play in the diagnosis, manage­
ment, and follow-up of patients with cardiomyopathy (see Section 9). A 
shared approach between cardiomyopathy units and between general 
cardiologist/paediatric cardiologist is strongly recommended. This ap­
proach can be facilitated by the implementation of telemedical contact 
between units and the use of remote monitoring with patients.60 The 
creation of local/regional/national/international networks, such as the 
European Reference Network for Rare and Low Prevalence 
Complex Diseases of the Heart (ERN GUARD-Heart) (https:// 
guardheart.ern-net.eu) allows clinicians and health professionals to 
share information about these pathologies, for the benefit of cardiomy­
opathy patients.61


<!-- PAGE 17 -->

### Page 17

### 6 The patient pathway

The diagnosis of cardiomyopathy rests on the identification of struc­
tural and/or functional myocardial abnormalities, including myocardial 
fibrosis, that are not explained solely by abnormal loading conditions 
or CAD. However, disease phenotypes can also include arrhythmic 
and electrocardiographic manifestations, morphological abnormalities 
of the cardiac valves, and abnormal coronary microcirculatory function. 
As a key theme throughout this guideline, the Task Force highlights the 
importance of using a systematic approach to the identification and as­
sessment of patients with a suspected cardiomyopathy. Central to this 
is the need for clinicians to consider a diagnosis of cardiomyopathy as 
the cause of several common adult and paediatric clinical presentations. 
The identification of a cardiomyopathy phenotype is only the beginning 
of the diagnostic process and should prompt a systematic search for the 
underlying aetiology, which may be genetic or acquired.
Cardiologist with cardiomyopathy expertise
Paediatric cardiologist with cardiomyopathy expertise
Specialist nurse
Cardiac genetic counsellor
Heart failure team
Arrhythmia team
Cardiac imaging team
Interventional cardiologist team
Cardiologist with expertise in sports cardiology
Geneticist
Family/carer(s)
Psychologist
Patient associations
Patient support
Cardiomyopathy specialists
Other related specialtiesa
Other related cardiology experts
Pathologist
Other: cardiac surgeon, primary care physician, paediatrician, internist,
nephrologist, neurologist,
dermatologist, endocrinologist,
ophthalmologist, pharmacist,
rheumatologist etc.
Figure 5 Multidisciplinary care of cardiomyopathies. aThe list presented is not exhaustive and represents examples of specialties that often interact in the 
care of cardiomyopathy patients.Image %:   
Recommendation Table 1 — Recommendations for the 
provision of service of multidisciplinary cardiomyopathy 
teams
Recommendations
Classa
Levelb
It is recommended that all patients with 
cardiomyopathy and their relatives have access to 
multidisciplinary teams with expertise in the 
diagnosis and management of cardiomyopathies.
I
C
Timely and adequate preparation for transition of 
care from paediatric to adult services, including joint 
consultations, is recommended in all adolescents 
with cardiomyopathy.58,59
I
C
© ESC 2023
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3519


<!-- PAGE 18 -->

### Page 18

6.1. Clinical presentation
Patients with cardiomyopathy may access health services through sev­
eral pathways. Referral from primary care (e.g. general practitioners 
and general paediatricians) may be triggered by symptoms (most 
commonly dyspnoea, chest pain, palpitation, syncope) or incidental 
findings (e.g. an abnormal electrocardiogram [ECG] in the context of 
community, school, work-related medical check-ups, or sports pre- 
participation screening; the incidental detection of a murmur; or, in­
creasingly, genotype-first identification as a result of secondary findings 
during research or clinical sequencing for other indications). In second­
ary and tertiary care (general cardiology and paediatric cardiology), pa­
tients with cardiomyopathy may present to the heart failure clinic with 
symptoms of heart failure with reduced ejection fraction (HFrEF), mild­
ly reduced ejection fraction (HFmrEF), or preserved ejection fraction 
(HFpEF); to the arrhythmia clinic with early-onset conduction disease, 
atrial arrhythmia, or ventricular arrhythmia; or to the emergency de­
partment with suspected myocarditis. Frequently, patients enter the 
cardiomyopathy pathway in primary, secondary, or tertiary care as a re­
sult of family screening following the diagnosis of cardiomyopathy or a 
sudden death in a relative, and may also be identified as part of the 
work-up for multiorgan disease known to be associated with cardiovas­
cular involvement. Clinicians in all these settings therefore need to con­
sider the possibility of cardiomyopathy as a cause and use a systematic, 
cardiomyopathy-oriented approach to clinical evaluation.
6.2. Initial work-up
The cardiomyopathy-oriented approach is based on interpreting clinic­
al and instrumental findings to suspect and ultimately generate a 
phenotype-based aetiological diagnosis to guide disease-specific man­
agement.62 This approach requires deliberate analysis of multipara­
metric investigations in the individual and their relatives and an 
integrated probabilistic analysis of clinical investigations. Re-analysis of 
clinical data is required as new information emerges, and family infor­
mation can provide important clues to the diagnosis, given the variable 
expression and incomplete penetrance of most cardiomyopathies, and 
can result in differences in diagnostic criteria between probands and re­
latives. In this context, relatives of individuals with cardiomyopathy can 
have non-diagnostic morphological and electrocardiographic abnor­
malities that can indicate mild and early phenotypic expression of dis­
ease and can increase diagnostic accuracy for predicting disease in 
genotyped populations. The identification of diagnostic clues, or red 
flags, is a crucial aspect of the initial work-up.
6.3. Systematic approach to diagnosis of 
cardiomyopathy
A multiparametric approach to the evaluation of patients with sus­
pected cardiomyopathy is recommended, with the aims of: (i) establish­
ing and characterizing the presence of a cardiomyopathy phenotype; 
and (ii) identifying the underlying aetiological diagnosis.62 Clinicians 
should approach a patient with suspected cardiomyopathy using a ‘car­
diomyopathy mindset’ (Figure 2): 
• Use multimodality imaging to characterize the phenotype and iden­
tify abnormal ventricular morphology (e.g. hypertrophy, dilatation) 
and function (systolic/diastolic, global/regional), and detect abnormal­
ities of tissue characterization (e.g. non-ischaemic myocardial scar 
and fatty replacement).
• Use a combination of personal and family history, clinical examin­
ation, electrocardiography, and laboratory investigations to achieve 
an aetiological diagnosis, looking for specific signs and symptoms 
and laboratory markers suggestive of a specific diagnosis; the pres­
ence of ventricular and atrial arrhythmia and conduction disease to 
aid diagnosis, suggest specific causes, and monitor disease progres­
sion and risk stratification; and clues from the pedigree to suggest 
specific inheritance patterns and identify at-risk relatives. This ap­
proach should result in a timely and accurate diagnosis to enable early 
treatment of symptoms and prevention of disease-related 
complications.
6.4. History and physical examination
Age is one of the most important factors to take into account when 
considering the possible causes of cardiomyopathy. For example, inher­
ited metabolic disorders and congenital dysmorphic syndromes are 
more common in neonates and infants (see Section 6.9.1) than in older 
children or adults, whereas wild-type transthyretin amyloidosis 
(ATTRwt) is a disease mostly of adults over the age of 65 years (see 
Section 7.6).
Construction of a three- to four-generation family pedigree helps to 
identify Mendelian forms of inheritance and identifies other family 
members who may be at risk of disease development.62 Specific fea­
tures to note in the family history include premature deaths (taking 
into account that SCDs may sometimes be reported as accidental 
deaths, e.g. drowning, unexplained traffic accident, and, rarely, as still­
birth or sudden infant death syndromes), unexplained heart failure, car­
diac transplantation, pacemaker and defibrillator implants, and evidence 
for systemic disease (e.g. stroke at a young age, skeletal muscle weak­
ness, renal dysfunction, diabetes, deafness). Most Mendelian forms of 
cardiomyopathy are autosomal dominant and are therefore character­
ized by the presence of affected individuals across generations, with 
transmission from parents of either sex (including male-to-male) and 
a 50% risk of allele transmission to offspring (although, due to incom­
plete penetrance, the proportion of affected individuals in an individual 
pedigree will be lower). X-linked inheritance should be suspected if 
males are the most severely affected individuals and there is no 
male-to-male transmission. Autosomal recessive inheritance, the least 
common pattern, is likely when both parents of the proband are
Recommendation Table 2 — Recommendations for 
diagnostic work-up in cardiomyopathies
Recommendations
Classa
Levelb
It is recommended that all patients with suspected or 
established cardiomyopathy undergo systematic 
evaluation using a multiparametric approach that 
includes clinical evaluation, pedigree analysis, ECG, 
Holter monitoring, laboratory tests, and 
multimodality imaging.63
I
C
It is recommended that all patients with suspected 
cardiomyopathy undergo evaluation of family history 
and that a three- to four-generation family tree is 
created to aid in diagnosis, provide clues to 
underlying aetiology, determine inheritance pattern, 
and identify at-risk relatives.64–66
I
C
© ESC 2023
ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 19 -->

### Page 19

unaffected and consanguineous, although severe autosomal recessive 
cardiomyopathies can also occur in the absence of familial consanguin­
ity.67,68 When women—but not men—transmit the disease to children 
of either sex, mitochondrial DNA variants should be considered 
(Table 5). It is important to note that the absence of familial disease 
does not exclude a genetic origin (see Section 6.8).
Patients with cardiomyopathy may experience dyspnoea, chest pain, 
palpitation, and syncope and/or pre-syncope, although many individuals 
complain of few, if any, symptoms (see Section 6.4 for assessment of 
symptoms in specific cardiomyopathy subtypes). A number of non- 
cardiac symptoms act as pointers for specific diagnoses (Table 6). 
Similarly, general physical examination can provide diagnostic clues in 
patients with syndromic or metabolic causes of cardiomyopathy.62
6.5. Resting and ambulatory 
electrocardiography
The resting 12-lead ECG is often the first test that suggests the possi­
bility of cardiomyopathy. Although the ECG can be normal in a small 
proportion of individuals with cardiomyopathy, standard ECG abnor­
malities are common in all cardiomyopathy subtypes and can precede 
the development of an overt morphological or functional phenotype 
by many years; for example, in genotype-positive individuals identified 
during family screening. When interpreted in conjunction with findings 
on echocardiography and CMR imaging, features that would normally 
indicate other conditions, such as myocardial ischaemia or infarction, 
can—with age at diagnosis, inheritance pattern, and associated clinical 
features—suggest an underlying diagnosis or provide clues to the
Table 5 Examples of inheritance patterns that should raise the suspicion of specific genetic aetiologies, grouped ac­
cording to cardiomyopathy phenotype
Cardiomyopathy phenotype
AD
AR
X-linked
Matrilineal
HCM
Sarcomeric
X
Anderson–Fabry
X
Danon
X
TTR amyloidosis
X
RASopathy
X
(X)
Friedreich ataxia
X
Mitochondrial
Mitochondrial DNA
X
Nuclear DNA
X
X
X
DCM
LMNA
X
RBM20
X
Sarcomeric
X
Dystrophin
X
Emerin
X
Barth syndrome
X
Mitochondrial
Mitochondrial DNA
X
Nuclear DNA
X
X
X
NDLVC
LMNA
X
DES
X
X
FLNC
X
PLN
X
TMEM43
X
RBM20
X
ARVC
PLN
X
Desmosomal
X
X
TMEM43
X
RCM
Sarcomeric
X
DES
X
X
FLNC
X
BAG3
X
RASopathy
X
(X)
© ESC 2023
AD, autosomal dominant; AR, autosomal recessive; ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; NDLVC, 
non-dilated left ventricular cardiomyopathy; RCM, restrictive cardiomyopathy; TTR, transthyretin; DNA, deoxyribonucleic acid; RASopathies, Ras/mitogen-activated protein kinase pathway 
dysregulation. 
(X) indicates the presence of a correlation between a cardiomyopathy and a pattern of inheritance.
ESC Guidelines                                                                                                                                                                                          3521


<!-- PAGE 20 -->

### Page 20

Table 6 Examples of signs and symptoms that should raise the suspicion of specific aetiologies, grouped according to 
cardiomyopathy phenotype
Finding
Cardiomyopathy phenotype
HCM
DCM
NDLVC
ARVC
RCM
Learning difficulties, developmental 
delay
Mitochondrial 
diseases
Dystrophinopathies
Noonan 
syndrome
Noonan syndrome
Mitochondrial diseases
Danon disease
Myotonic dystrophy
FKTN variants
Sensorineural deafness
Mitochondrial 
diseases
Epicardin variants
NSML
Mitochondrial diseases
Visual impairment
Mitochondrial 
diseases
CRYAB
ATTRv or hereditary 
ATTR
Type 2 myotonic 
dystrophy
Danon disease
Anderson–Fabry 
diseasea
Gait disturbance
Friedreich ataxia
Dystrophinopathies
Myofibrillar 
myopathies
Sarcoglycanopathies
Myofibrillar myopathies
Myotonia
Myotonic dystrophy
Paraesthesia/sensory 
abnormalities/neuropathic pain
Amyloidosis
Amyloidosis
Anderson–Fabry 
disease
Carpal tunnel syndrome
TTR-related 
amyloidosis
Muscle weakness
Mitochondrial 
diseases
Dystrophinopathies
Laminopathies
Desminopathies
Glycogenoses
Sarcoglycanopathies
Desminopathies
FHL1 variants
Laminopathies
Myotonic dystrophy
Desminopathies
Palpebral ptosis
Mitochondrial 
diseases
Mitochondrial diseases
Myotonic dystrophy
Lentigines
NSML
Angiokeratomata
Anderson–Fabry 
disease
Pigmentation of skin and scars
Haemochromatosis
Palmoplantar keratoderma and 
woolly hair
Carvajal syndrome
Naxos and Carvajal 
syndromes
DSP variants
DSP variants
DSP variants
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; ATTR, transthyretin amyloidosis; ATTRv, hereditary transthyretin amyloidosis; DCM, dilated cardiomyopathy; DSP, desmoplakin; 
HCM, hypertrophic cardiomyopathy; NDLVC, non-dilated left ventricular cardiomyopathy; NSML, Noonan syndrome with multiple lentigines; RCM, restrictive cardiomyopathy; TTR, 
transthyretin. 
aCornea verticillata, characteristic of Anderson–Fabry disease, does not cause visual impairment per se.


<!-- PAGE 21 -->

### Page 21

underlying diagnosis. For this reason, the ECG is recommended at the 
first clinic visit in all individuals with known or suspected cardiomyop­
athy and should be repeated whenever there is a change in symptoms 
in patients with an established diagnosis. Although the ECG is often 
non-specific, there are particular features that can suggest a certain aeti­
ology or morphological diagnosis, including atrioventricular (AV) block, 
ventricular pre-excitation pattern, distribution of repolarization abnor­
malities, and high or low QRS voltages (Table 7).
Patients with cardiomyopathy may seek cardiology evaluation due 
to arrhythmia-related symptoms or documented arrhythmia, 
including bradyarrhythmias and tachyarrhythmias, ranging from symp­
tomatic atrial/ventricular premature beats to life-threating ventricular 
arrhythmias. The frequency of arrhythmias detected during ambula­
tory electrocardiographic monitoring is age related and variable 
across different cardiomyopathy subtypes. Some arrhythmias are 
relatively common in the context of cardiomyopathy (e.g. atrial fibril­
lation [AF] or ventricular premature beats), while others may suggest 
a specific diagnosis. ECG monitoring is therefore useful at the initial 
clinical assessment and at regular intervals to assess the risk of SCD 
and stroke.
Table 7 Examples of electrocardiographic features that should raise the suspicion of specific aetiologies, grouped 
according to cardiomyopathy phenotype
Cardiomyopathy phenotype
Finding
Specific diseases to be considered
HCM
Short PR interval/pre-excitation
Glycogenosis 
Danon disease 
PRKAG2 cardiomyopathy 
Anderson–Fabry disease 
Mitochondrial disease
AV block
Amyloidosis 
Anderson–Fabry disease (late stage) 
Danon disease 
Sarcoidosis 
PRKAG2 cardiomyopathy
Extreme LVH
Danon disease 
Glycogenosis (e.g. Pompe disease) 
PRKAG2 cardiomyopathy
Low QRS voltagea
Amyloidosis 
Friedreich ataxia
Superior QRS axis (‘northwest axis’)
Noonan syndrome
Q waves/pseudoinfarction pattern
Amyloidosis
DCM
AV block
Laminopathy 
Emery–Dreifuss 1 
Myocarditis (esp. Chagas disease, Lyme disease, diphtheria) 
Sarcoidosis 
Desminopathy 
Myotonic dystrophy
Low P wave amplitude
Emery–Dreifuss 1 and 2
Atrial standstill
Emery–Dreifuss 1 and 2
Posterolateral infarction pattern
Dystrophinopathy 
Limb-girdle muscular dystrophy 
Sarcoidosis
Extremely low QRS amplitude
PLN variant
NDLVC
AV block
Laminopathy 
Desminopathy
Extremely low QRS amplitude
PLN variant
Low QRS voltage + atypical RBBB
Desmosomal variants
ARVC
T wave inversion V1-V3 + terminal activation delay  
+/− low right ventricular voltages +/− atypical RBBB
RCM
AV block
Desminopathy 
Amyloidosis
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; AV, atrioventricular; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; 
NDLVC, non-dilated left ventricular cardiomyopathy; PKP2, plakophilin 2; PLN, phospholamban; PRKAG2, protein kinase AMP-activated non-catalytic subunit gamma 2; QRS, Q, R, and S 
waves of an ECG; RBBB, right bundle branch block; RCM, restrictive cardiomyopathy. 
aIn the absence of obesity, pericardial effusion, chronic obstructive pulmonary disease, abnormalities of the chest, or other reasons that may cause low voltage. 
Adapted from Rapezzi et al.62
ESC Guidelines                                                                                                                                                                                          3523


<!-- PAGE 22 -->

### Page 22

6.6. Laboratory tests
Routine laboratory testing aids the detection of extracardiac conditions 
that cause or exacerbate ventricular dysfunction (e.g. thyroid disease, 
renal dysfunction, and diabetes mellitus) and secondary organ dysfunc­
tion in patients with severe heart failure. High levels of brain natriuretic 
peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-proBNP), 
and high-sensitivity cardiac troponin T (hs-cTnT) are associated with 
cardiovascular events, heart failure, and death, and may have diagnostic, 
prognostic, and therapeutic monitoring value.69 Routine blood tests for 
comorbidities, including full blood count, renal and liver function para­
meters and electrolytes, thyroid function, fasting glucose, and 
Haemoglobin A1C (HbA1c) are recommended in all patients with 
heart failure symptoms.69 Persistently elevated serum creatinine kinase 
(CK) levels can be suggestive of myopathies or neuromuscular disor­
ders including dystrophinopathies (e.g. Becker muscular dystrophy or 
X-linked DCM), laminopathies, desminopathies, or less often, a myofi­
brillar myopathy.62 Elevated C-reactive protein levels may be present in 
patients with ARVC and NDLVC, particularly in the context of recur­
rent myocarditis-like episodes.70 Elevated serum levels of iron and fer­
ritin and high transferrin saturation can suggest a diagnosis of 
haemochromatosis and should trigger further aetiological refinement 
(primary vs. secondary) based on genetic testing. Lactic acidosis, myo­
globinuria, and leucocytopaenia can be suggestive of mitochondrial dis­
eases. A list of recommended laboratory tests in adults and children is 
shown in Table 8. Following specialist evaluation, additional tests to de­
tect rare metabolic causes are often required in children, including 
measurement of lactate, pyruvate, pH, uric acid, ammonia, ketones, 
free fatty acids, carnitine profile, urine organic acids, and amino acids 
(see Section 6.9).
6.7. Multimodality imaging
6.7.1. General considerations
Non-invasive imaging modalities represent the backbone of diagnosis 
and follow-up in patients with cardiomyopathies, including ultrasound- 
based techniques, CMR imaging, computed tomography (CT), and nu­
clear techniques, such as positron emission tomography (PET) and scin­
tigraphy (Figure 6).1,71,72 Physicians should always consider the yield of 
actionable results vs. the costs, advantages, and limitations of each tech­
nique, as well as patient safety and patient exposure to ionizing radi­
ation and contrast media. Standardized algorithms should be in place 
to move hierarchically from simpler and cheaper to more complex 
and expensive tests. A bi-directional flow of information between the 
clinician and the imager is key to maximizing appropriateness: clinicians 
should formulate and share clear pre-test hypotheses, based on avail­
able information, to aid the interpretation of novel findings. The imager 
should respond in a similarly focused fashion, assessing the likelihood of 
alternative diagnoses and refraining from diagnoses that are not com­
patible/plausible based on the overall clinical context.
6.7.2. Echocardiography
The non-invasive nature and widespread availability of echocardiography 
make it the main imaging tool, from initial diagnosis to follow-up. 
Transthoracic echocardiography (TTE) provides relevant information 
on global and regional RV and LV anatomy and function as well as valve 
function and the presence of dynamic obstruction, pulmonary hyperten­
sion, or pericardial effusions.71–73 Myocardial deformation imaging 
(speckle tracking or tissue Doppler) with global longitudinal strain is a 
more sensitive marker than EF to detect subtle ventricular dysfunction 
(e.g. in genotype-positive HCM, DCM, and ARVC family mem­
bers72,74,75), and may help discriminate between different aetiologies of 
hypertrophy76 (e.g. amyloidosis, HCM, and athlete’s heart). Mechanical 
dispersion is a marker of contraction inhomogeneity and highlights fine 
structural changes that may be missed by other modalities.77–80
Three-dimensional echocardiography reliably assesses volumes of car­
diac chambers but needs an adequate acoustic window. Contrast agents 
can be considered for better endocardial delineation to depict the pres­
ence of hypertrabeculation, apical HCM, or apical aneurysms, and to ex­
clude thrombus. Stress echocardiography can be helpful in selected 
patients to evaluate myocardial ischaemia and exercise echocardiography 
is useful to identify provocable LVOTO in symptomatic patients with 
HCM (see Section 7.1.1.3). Transoesophageal echocardiography is limited 
to selected indications, such as the exclusion of atrial thrombi related to 
AF, elucidating the mechanism of mitral regurgitation, or in planning inva­
sive interventions (e.g. septal myectomy in HCM).
When measuring cardiac dimensions and wall thickness in children, it 
is important to correct for body size, using z-scores (defined as the 
number of standard deviations from the population mean). Of note, 
there are inherent limitations with the use of z-scores in the diagnosis 
of cardiomyopathies, including the fact that there are many different 
normative data published resulting in significant variation in z-scores 
for the same patient.81 In addition, there are no normative data for 
wall thickness other than at the basal interventricular septum or poster­
ior wall. The Task Force recommends using the normative data from 
the Paediatric Heart Network consortium.82
Recommendation Table 3 — Recommendations for 
laboratory tests in the diagnosis of cardiomyopathies
Recommendations
Classa
Levelb
Routine (first-level) laboratory testsc are 
recommended in all patients with suspected or 
confirmed cardiomyopathy to evaluate aetiology, 
assess disease severity, and aid in detection of 
extracardiac manifestations and assessment of 
secondary organ dysfunction.
I
C
Additional (second-level) testsc should be considered 
in patients with cardiomyopathy and extracardiac 
features to aid in detection of metabolic and 
syndromic causes, following specialist evaluation.
IIa
C
© ESC 2023
aClass of recommendation. 
bLevel of evidence. 
cSee Table 8.
Recommendation Table 4 — Recommendation for 
echocardiographic 
evaluation 
in 
patients 
with 
cardiomyopathy
Recommendation
Classa
Levelb
A comprehensive evaluation of cardiac dimensions 
and LV and RV systolic (global and regional) and LV 
diastolic function is recommended in all patients with 
cardiomyopathy at initial evaluation, and during 
follow-up, to monitor disease progression and aid 
risk stratification and management.78,83–102
I
B
© ESC 2023
LV, left ventricular; RV, right ventricular. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 23 -->

### Page 23

6.7.3. Cardiac magnetic resonance
Cardiac magnetic resonance imaging (MRI) combines the advantages of 
non-invasiveness and independence of acoustic window with the ability 
for tissue characterization. The latter advantage is particularly import­
ant in the diagnosis of NDLVC, ARVC, myocarditis, amyloidosis, sar­
coidosis and other forms of inflammatory disease, and iron overload/ 
haemochromatosis. Cardiac magnetic resonance is particularly useful 
if echocardiography provides poor image quality. Initial evaluation 
should routinely include cine imaging sequences, T2-weighted se­
quences, pre- and post-contrast T1 mapping, and late gadolinium en­
hancement (LGE). When suspecting haemochromatosis, T2* 
mapping should be employed. Cardiac magnetic resonance findings 
can provide important aetiological clues (Figure 7), with potential thera­
peutic implications (Table 9) and should be assessed collectively with 
genetic results and other clinical features by experienced operators 
in cardiac imaging and the evaluation of heart muscle disease. Serial 
follow-up CMR, every 2–5 years depending on initial severity and clin­
ical course, can assist in evaluating disease progression as well as the 
benefits of therapy (e.g. evaluation of extracellular volume [ECV] in 
amyloidosis, or of iron deposition in haemochromatosis), and should 
be considered in all patients with cardiomyopathy.
6.7.3.1. Special considerations
• Recently developed rapid CMR techniques allow scans to be performed 
without general anaesthesia even in very young children.103 In children 
(and adults) unable to undergo CMR without general anaesthesia, the 
relative risks and benefits of the procedure should be considered.
• Imaging artefacts caused by cardiac implantable electronic devices 
have posed limitations for CMR imaging in the past.104–110 A number 
of solutions are available to reduce artefacts, including reducing in­
homogeneity, technical adjustments, and the use of special sequences, 
which reduce the rate of uninterpretable studies to one in five.111,112
Cardiac magnetic resonance can therefore be considered in patients 
with conditional devices and nearly all non-conditional devices pro­
vided appropriate protocols are put in place.113
• Nephrogenic systemic fibrosis is a rare complication reported in pa­
tients with first-generation linear unstable gadolinium chelates and
Table 8 First-level (to be performed in each patient) and second-level (to be performed in selected patients following 
specialist evaluation to identify specific aetiologies) laboratory tests, grouped by cardiomyopathy phenotype
Level
HCM
DCM
NDLVC
ARVC
RCM
First
• CK
• Liver function
• NT-proBNPa
• Proteinuria
• Renal function
• Troponin
• Calcium
• CK
• Ferritin
• Full blood count
• Liver function
• NT-proBNPa
• Phosphate
• Proteinuria
• Renal function
• Serum iron
• Thyroid function
• Troponin
• Vitamin D (children)
• Calcium
• CK
• C-reactive protein
• Full blood count
• Liver function
• NT-proBNPa
• Phosphate
• Proteinuria
• Renal function
• Troponin
• C-reactive 
protein
• Liver function
• NT-proBNPa
• Renal function
• Troponin
• CK
• Ferritin
• Full blood count
• Liver function
• NT-proBNPa
• Proteinuria
• Renal function
• Serum 
angiotensin-converting 
enzyme
• Serum iron
• Troponin
• Urine and plasma protein 
immunofixation, free light 
chains
Second
• Alpha-galactosidase A 
levels (males) and 
lyso-Gb3
• Carnitine profile
• Free fatty acids
• Immunofixation and free 
light chains
• Lactic acid
• Myoglobinuria
• Pyruvate
• PTH
• Urine and plasma protein
• Urine organic acids and 
plasma amino acids
• Carnitine profile
• Free fatty acids
• Lactic acid
• Organ- and non– 
organ-specific serum 
autoantibodies
• Serum 
angiotensin-converting 
enzyme
• Thiamine
• Viral serology
• Urine organic acids and 
plasma amino acids
• Organ- and 
non-organ-specific 
serum autoantibodies
• Viral serology
• Organ- and non– 
organ-specific 
autoantibodies
• Serum 
angiotensin-converting 
enzyme
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; BNP, brain natriuretic peptide; CK, creatinine kinase; DCM, dilated cardiomyopathy; Gb3, globotriaosylceramide; HCM, 
hypertrophic cardiomyopathy; NDLVC, non-dilated left ventricular cardiomyopathy; NT-proBNP, N-terminal pro-brain natriuretic peptide; PTH, parathyroid hormone; RCM, restrictive 
cardiomyopathy. 
aAlternatively, BNP can be considered depending on the local availability.
ESC Guidelines                                                                                                                                                                                          3525


<!-- PAGE 24 -->

### Page 24

severe renal disease.114 However, gadolinium-based contrast agents 
can be safely administered for patients with an estimated glomerular fil­
tration rate >30 mL/min/1.73 m2, and nephrogenic systemic fibrosis is 
virtually unreported with the use of newer linear or macrocyclic gado­
linium contrasts. For patients with severe renal impairment, new CMR 
modalities and mapping procedures, which are very informative and do 
not require the use of contrast, are particularly valuable when assessing 
Anderson–Fabry disease and cardiac amyloidosis.115–117
• The use of gadolinium contrast is generally not advised in pregnancy 
due to the potential for adverse outcomes in the foetus and 
neonate.118
Multimodality imaging
LV functional and structural abnormalities
Ventricular function
Hypertrophy
Dilatation
Echocardiography and CMR
Tissue characterization (T1/T2/T2* /LGE)
CMR
Amyloidosis
Bone scintigraphy
Myocardial inflammation
PET-CT
Targeted studies
Valvular and dynamic gradients
Stress echocardiography
Myocardial ischaemia
CTCA/stress tests
Functional abnormalities
Clinical suspicion of cardiomyopathy
Risk stratification and disease prognostication
Disease progression
(follow-up)
Cardiomyopathy diagnosis
Phenotype identification
Rule out phenocopies
Figure 6 Multimodality imaging process in cardiomyopathies. CMR, cardiac magnetic resonance; CTCA, computed tomography coronary angiography; 
LGE, late gadolinium enhancement; LV, left ventricular; PET, positron emission tomography.
Recommendation Table 5 — Recommendations for 
cardiac magnetic resonance indication in patients with 
cardiomyopathy
Recommendations
Classa
Levelb
Contrast-enhanced CMR is recommended in 
patients with cardiomyopathy at initial 
evaluation.10,90,116,119–143
I
B
Continued 
Contrast-enhanced CMR should be considered in 
patients with cardiomyopathy during follow-up to 
monitor disease progression and aid risk stratification 
and management.89,90,120–122,127,129,136–147
IIa
C
Contrast-enhanced CMR should be considered for 
the serial follow-up and assessment of therapeutic 
response in patients with cardiac amyloidosis, 
Anderson–Fabry disease, sarcoidosis, inflammatory 
cardiomyopathies, and haemochromatosis with 
cardiac involvement.148–152
IIa
C
In families with cardiomyopathy in which a 
disease-causing variant has been identified, 
contrast-enhanced CMR should be considered in 
genotype-positive/phenotype-negative family 
members to aid diagnosis and detect early 
disease.10,122,126,128,129,135–143,145,153–159
IIa
B
In cases of familial cardiomyopathy without a genetic 
diagnosis, contrast-enhanced CMR may be 
considered in phenotype-negative family members to 
aid diagnosis and detect early disease.10,128
IIb
C
© ESC 2023
CMR, cardiac magnetic resonance. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 25 -->

### Page 25

Finding
Cardiomyopathy phenotype
Cardiac CMR examples
Specific diseases to be considered
Posterolateral LGE and concentric LVH
Low native T1
Anderson–Fabry disease
Amyloidosis
Sarcomeric HCM
Haemochromatosis
Post-myocarditis
Dystrophinopathy
Sarcoidosis
Chagas disease
DSP variants
FLNC variants
DES variants
Laminopathy
Desmosomal variants
EMF/hypereosinophilia
Diffuse subendocardial LGE,
high native T1
Patchy mid-wall in hypertrophied areas
Short T2*
Subepicardial LGE
Lateral wall epicardial LGE
Subepicardial and midwall LGE at basal septum +/- extension into inferolateral wall and RV insertion points
Apical transmural LGE
Ring-like and/or subepicardial
LGE pattern
Septal mid-wall LGE
Fat and LGE (transmural RV plus sub-epicardial-midmural LV free wall)
Partial LV or RV apical obliteration +
LGE at endocardial level
HCM
DCM
NDLVC
ARVC
RCM
Figure 7 Examples of cardiac magnetic resonance imaging tissue characterization features that should raise the suspicion of specific aetiologies, grouped 
according to cardiomyopathy phenotype. ARVC, arrhythmogenic right ventricular cardiomyopathy; CMR, cardiac magnetic resonance; DCM, dilated cardio­
myopathy; DES, desmin; DSP, desmoplakin; EMF, endomyocardial fibrosis; FLNC, filamin C; HCM, hypertrophic cardiomyopathy; LGE, late gadolinium en­
hancement; LV, left ventricular; LVH, left ventricular hypertrophy; NDLVC, non-dilated left ventricular cardiomyopathy; RCM, restrictive 
cardiomyopathy; RV, right ventricular. Examples of CMR tissue characterization features that should raise the suspicion of specific aetiologies (column 
4), grouped according to cardiomyopathy phenotype (column 1). CMR images features (column 3) correspond to the listed findings (column 2).Image %:   
ESC Guidelines                                                                                                                                                                                          3527


<!-- PAGE 26 -->

### Page 26

6.7.4. Computed tomography and nuclear medicine 
techniques
Other imaging modalities, including nuclear medicine-based techniques 
and CT, are indicated in selected subsets of patients with cardiomyop­
athy.160,161 Indications and the risk-benefit ratio should be evaluated on 
an individual patient basis, always taking into account radioprotection 
issues, which are particularly relevant in the young. Nuclear medicine 
is particularly helpful in the aetiological diagnosis of cardiac amyloidosis 
(see Section 7.7). 18FDG-PET is useful in the identification of myocardial 
inflammation associated with active sarcoidosis and, potentially, in 
other atypical forms of myocarditis.162–164 However, a negative scan 
does not exclude sarcoidosis in its inactive form. In patients with 
HCM, DCM, and Anderson–Fabry disease, H2
15O or 13NH3 dipyrid­
amole or regadenoson PET has been used to evaluate microvascular 
dysfunction, an important predictor of adverse outcome.165
However, this test does not currently have a role in aetiological diagno­
sis (e.g. in distinguishing phenocopies) and is largely confined to re­
search purposes.
Computed tomography-based imaging is primarily used in patients 
with a suspicion of cardiomyopathy to rule out CAD, either as an alter­
native diagnosis (e.g. in individuals with DCM, NDLVC, or ARVC phe­
notypes) or as a comorbidity affecting clinical manifestations and 
course. In children and adolescents, CT angiography can be useful to ex­
clude congenital vascular malformations (e.g. anomalous left coronary 
artery from the pulmonary artery [ALCAPA] or anomalous pulmonary 
venous return). Standard CT imaging provides additional information 
regarding concomitant pulmonary disease (e.g. sarcoidosis), pericardial 
disease, and chest wall deformities affecting the heart.
6.7.5. Endomyocardial biopsy
Endomyocardial biopsy (EMB) with immunohistochemical quantifica­
tion of inflammatory cells and identification of viral genomes remains 
the gold standard for the identification of cardiac inflammation. It 
may confirm the diagnosis of autoimmune disease in patients with un­
explained heart failure and suspected giant cell myocarditis, eosinophilic 
myocarditis, vasculitis, and sarcoidosis. Electron microscopy should be 
employed when storage or mitochondrial cardiomyopathies are sus­
pected. Endomyocardial biopsy should be reserved for specific situa­
tions where its results may affect treatment after careful evaluation 
of the risk-benefit ratio. Importantly, EMB is not completely risk-free 
and should be performed by experienced teams. Likewise, the diagnos­
tic work-up of a biopsy should be performed by pathologists with ex­
pertise in cardiomyopathies.
Table 9 Frequently encountered actionable results on 
multimodality imaging
Parameter/finding
Action
RWMAs on echocardiography or 
CMR
Raise suspicion of concomitant CAD, 
myocarditis, ARVC, NDLVC, or 
sarcoidosis
Systolic impairment on 
echocardiography or CMR
Assessment of risk in DCM, NDLVC, 
and ARVC; evaluation of treatment 
efficacy
Measurement of the wall 
thickness on echocardiography or 
CMR
Diagnosis of HCM (when 
echocardiography is inconclusive); risk 
stratification in HCM
Diastolic dysfunction on 
echocardiography
Explain symptoms; evaluation of 
treatment efficacy
Left atrial size on 
echocardiography
SCD risk prediction in HCM; 
systematic screening for AF in case of 
left atrial enlargement
LVOTO in HCM on resting/ 
exercise echocardiography
Explain symptoms; guide management
Non-invasive evaluation of 
pulmonary pressures
Explain symptoms; guide management
Tissue characterization on CMR
Diagnosis; risk assessment
Inflammation on CMR or 
18F-FDG-PET
Diagnosis; evaluation of treatment 
efficacy in inflammatory 
cardiomyopathies
© ESC 2023
18F-FDG-PET, fluorodeoxyglucose positron emission tomography; AF, atrial fibrillation; 
ARVC, arrhythmogenic right ventricular cardiomyopathy; AF, atrial fibrillation; CAD, 
coronary artery disease; CMR, cardiac magnetic resonance; DCM, dilated 
cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVOTO, left ventricular outflow 
tract obstruction; NDLVC, non-dilated left ventricular cardiomyopathy; RWMA, regional 
wall motion abnormality; SCD, sudden cardiac death.
Recommendation Table 6 — Recommendations for 
computed tomography and nuclear imaging
Recommendations
Classa
Levelb
DPD/PYP/HMDP bone-tracer scintigraphy is 
recommended in patients with suspected 
ATTR-related cardiac amyloidosis to aid 
diagnosis.166–168
I
B
Contrast-enhanced cardiac CT should be considered 
in patients with suspected cardiomyopathy who have 
inadequate echocardiographic imaging and 
contraindications to CMR.169,170
IIa
C
In patients with suspected cardiomyopathy, 
CT-based imaging should be considered to exclude 
congenital or acquired coronary artery disease as a 
cause of the observed myocardial abnormality.171
IIa
C
18F-FDG-PET scanning should be considered for the 
diagnostic work-up in patients with cardiomyopathy 
in whom cardiac sarcoidosis is suspected.164,172,173
IIa
C
© ESC 2023
18F-FDG-PET, 
18F-fluorodeoxyglucose 
positron 
emission 
tomography; 
ATTR, 
transthyretin amyloidosis; CMR, cardiac magnetic resonance; CT, computed 
tomography; 
DPD, 
3,3-diphosphono-1,2-propanodicarboxylic 
acid; 
HMDP, 
hydroxymethylene diphosphonate; PYP, pyrophosphate. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 7 — Recommendation for 
endomyocardial biopsy in patients with cardiomyopathy
Recommendation
Classa
Levelb
In patients with suspected cardiomyopathy, EMB 
should be considered to aid in diagnosis and 
management when the results of other clinical 
investigations suggest myocardial inflammation, 
infiltration, or storage that cannot be identified by 
other means.174–177
IIa
C
© ESC 2023
EMB, endomyocardial biopsy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 27 -->

### Page 27

6.8. Genetic testing and counselling
6.8.1. Genetic architecture
Familial forms of cardiomyopathies show diverse modes of inheritance. 
Gene identification has, over the last three decades, primarily focused 
on the identification of Mendelian (monogenic) disease genes that most 
commonly display autosomal dominant inheritance, although other inher­
itance patterns including autosomal recessive, X-linked, and mitochondrial 
(matrilineal) are also observed (Table 5). Major genes currently associated 
with different types of cardiomyopathies are listed in Table 10. 
Cardiomyopathies are characterized by a marked genetic and allelic het­
erogeneity, that is, many different variants in many different genes can 
cause the same phenotype. Rare pathogenic variants associated with car­
diomyopathies often exhibit the phenomena of incomplete and 
age-related penetrance, and variable expressivity.178,179 That is, not all in­
dividuals carrying a causative variant manifest the disease and, among those 
who do, there is broad variability in age of onset and disease severity. Thus, 
while some individuals may have severe disease necessitating cardiac trans­
plantation at a young age, others may remain unaffected throughout their 
lives or are only mildly affected. This variability could be due to heterogen­
eity among causative variants, the additional contribution of non-genetic 
(clinical, environmental) factors (e.g. hypertension in HCM,180 exercise 
in ARVC181), and the co-inheritance of additional genetic factors, which 
act to exacerbate or attenuate the effect of the principal Mendelian genetic 
variant on the phenotype. This is an active area of research, and recent 
genome-wide association studies conducted in patients with HCM have 
provided strong evidence for the modulatory role of common genetic var­
iants of individually small effect that collectively modulate the effects of 
Mendelian variants (Figure 8).182,183
Across the different cardiomyopathies, the proportion of cases with a 
confident genetic diagnosis (that is with identification of a likely causal 
Mendelian genetic variant) is relatively low (e.g. as low as ∼40% in 
HCM124 and ∼30% in DCM184–186). Genome-wide association studies 
of common variants in HCM and DCM have provided empirical evi­
dence for substantial polygenic inheritance in these cardiomyop­
athies.182,183,187 Contrary to Mendelian inheritance, where a single, 
large-effect variant primarily determines susceptibility to the disorder, 
complex inheritance rests on the co-inheritance of multiple susceptibil­
ity variants. Although not yet studied systematically, besides common 
variants of small effect, intermediate-effect variants with effect sizes 
and frequencies between common and Mendelian variants are also ex­
pected to contribute to such complex inheritance.188 It is likely that car­
diomyopathies span a continuum of genetic complexity, with Mendelian 
forms at one end, determined primarily by the inheritance of an ultra- 
rare large-effect genetic variant, and highly polygenic forms at the other 
(see Figure 8). Variants that contribute to disease susceptibility in the set­
ting of complex inheritance likely overlap with those that modulate dis­
ease penetrance and expressivity in the Mendelian form of the 
disease.182,183
6.8.2. Genetic testing
Genetic testing of Mendelian cardiomyopathy genes has become a 
standard aspect of clinical management in affected families.3 First-line 
testing should be focused on genes robustly associated with the pre­
senting phenotype. If initial testing does not reveal a cause, but suspicion 
of a monogenic cause remains high, then more extended sequencing or 
analysis may be indicated, depending on the family structure and other 
factors. Once a genetic cause is established in one family member, then 
other family members may undergo testing for only the causative 
variant.
Genetic testing in an individual with cardiomyopathy (known as con­
firmatory testing or diagnostic testing) is recommended for their direct 
benefit: (i) to confirm the diagnosis; (ii) where it may inform prognosis; 
(iii) where it may inform treatment selection; or (iv) where it may in­
form their reproductive management. Genetic testing of an affected in­
dividual may be indicated, even if it is unlikely to alter their management, 
if there are relatives who may benefit from testing, particularly if there 
are relatives who will be enrolled in longitudinal surveillance if the gen­
etic aetiology is not established and who may be spared this burden if a 
genetic diagnosis is made in the family (Table 11). Testing may also be 
helpful in broader contexts, even when not obviously informative for 
immediate management; for example, a genetic diagnosis may provide 
psychological benefit in a patient struggling to understand their disease.
Genetic testing in a clinically unaffected relative of an individual with 
cardiomyopathy may be indicated irrespective of age, even in very 
young children, if a genetic diagnosis has been established with confi­
dence in the affected individual (known as cascade testing, predictive 
testing, or pre-symptomatic testing). Once a pathogenic/likely patho­
genic (P/LP) variant has been identified within an index patient following 
investigations of relevant disease genes associated with the specific 
phenotype, it is possible to offer cascade genetic testing of first-degree 
at-risk relatives, including pre-test genetic counselling (see Section 
6.8.3). In a scenario where a first-degree relative has died, evaluation 
of close relatives of the deceased individual (i.e. second-degree relatives 
of the index patient) should also be considered.
Individuals who are found not to harbour the familial variant can usu­
ally be discharged from clinical follow-up; those who do carry the famil­
ial variant are recommended to undergo clinical evaluation and usually 
ongoing surveillance. Cascade testing is not indicated when a variant of 
uncertain significance is identified in the proband.
Sequencing may also be indicated for segregation analysis (rather 
than as a diagnostic test) to inform interpretation of a variant of uncer­
tain significance found in an affected individual. This is usually limited to 
individuals who are clearly affected, or to testing of the parents to iden­
tify a de novo variant. Genetic counselling in this circumstance would in­
volve clear communication to family members that this is not a 
diagnostic test, but rather is contributing to clarifying the pathogenicity 
of the uncertain variant.
Finally, the evaluation of cardiac genes for secondary findings where data 
are generated in the setting of genetic testing for another clinical indication 
(also referred to as opportunistic screening) may be reasonable where the 
balance of benefits and harm is known, and if the cost is acceptable. 
Broader population screening might also prove reasonable if the balance 
of benefits and harm proves favourable. At present there is insufficient 
data to evaluate the balance of benefits and harm in either context, and 
this should currently only be performed in a research context in order 
to obtain such data. Careful genetic counselling to fully explain benefits 
and risks in this setting is critical. At present, there are very little data to 
evaluate this balance and this is an important evidence gap. In the United 
States of America, the American College of Medical Genetics and 
Genomics has recommended that cardiomyopathy-associated genes be 
evaluated for secondary findings whenever broad clinical sequencing is 
undertaken, regardless of the initial indication for testing.192,193 There is 
currently no international consensus around this recommendation.
ESC Guidelines                                                                                                                                                                                          3529


<!-- PAGE 28 -->

### Page 28

Table 10 Overview of genes associated with monogenic, non-syndromic cardiomyopathies, and their relative contribu­
tions to different cardiomyopathic phenotypes
Gene
Cardiomyopathy phenotype
Associated phenotype
HCM
DCM
NDLVC
ARVC
RCM
ABCC9
a a Cantu syndrome
ACTA1
ACTC1
ACTN2b
ALPK3
ANKRD1
BAG3
a a Myofibrillar myopathy
CACNA1C
c c Timothy syndrome
CACNB2
CALR3
CASQ2
CAV3
a a Caveolinopathy
CDH2
COX15
a a Leigh syndrome
CRYAB
a a Alpha-B crystallinopathy
CSRP3
CTF1
CTNNA3
DES
c c Desminopathy
DMD
c c X-linked progressive MD
DMPK
DSC2
DSG2
DSP
DTNA
EYA4
FHL1
c c Emery–Dreifuss MD
FLNC
c c Myofibrillar myopathy
FHOD3
FXN
a a Friedreich ataxia
GAA
a a Pompe disease
Continued


<!-- PAGE 29 -->

### Page 29

GATA4
GATAD1
GLA
c c Anderson–Fabry disease
HCN4
ILK
JPH2
JUP
a
Naxos disease (cardiocutaneous syndrome)
KCNQ1
KLF10
LAMA4
LAMP2
c c Danon disease
LDB3
a a Myofibrillar myopathy
LMNA
LRRC10
MIB1
MYBPC3
MYH6
MYH7
MYL2
MYL3
MYLK2
MYOM1
MYOZ2
MYPN
NEBL
NEXN
NKX2–5
NNT
NONO
NPPA
OBSCN
PDLIM3
PKP2
PLEKHM2
PLN b
Continued 
ESC Guidelines                                                                                                                                                                                          3531


<!-- PAGE 30 -->

### Page 30

PRDM16
PRKAG2
c c PRKAG2 cardiomyopathy
PSEN1
PSEN2
PTPN11
c c Noonan syndrome
RAF1
c c Noonan syndrome
RBM20
RIT1
c c Noonan syndrome
RYR2
SCN5A
SGCD
SLC25A4
a a Mitochondrial disease
TAZ
TBX5
TBX20
TCAP
TGFB3
TJP1
TMEM43
a
TMEM70
TMPO
TNNC1
TNNI3
TNNI3K
TNNT2
TPM1
TRIM63
TTN
TTR
c c Transthyretin amyloidosis
VCL
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; MD, muscular dystrophy; 
NDLVC, non-dilated left ventricular cardiomyopathy; RCM, restrictive cardiomyopathy. 
Based on ClinGen gene validation efforts;189–191a ooo: very common (>10% of tested cases); oo: common (1–10% of tested cases); o: less common (<1% of tested cases); blue circle: 
definitive/strong evidence; light blue circle: moderate evidence; white circle: limited, no association or refuted/dispute evidence; blank cells: not classified; grey circle: has been described 
(generally rare, sporadic cases), yet not classified/evaluated by ClinGen. The yield may be higher in subgroups with more specific phenotypes, e.g. the yield of testing LMNA is higher in 
groups with DCM and conduction disease. As NDLVC is a new phenotypic description, genes have not been formally curated for associations with this phenotype. Values shown are 
based on curations for related cardiomyopathies where the phenotypic spectrum is understood to include NDLVC. 
a indicates genes associated with syndromic presentations that can include cardiomyopathy as a feature, but where cardiomyopathy is not expected to occur as the only or presenting feature 
of the syndrome. 
bACTN2 and PLN can present a mixed phenotypic picture that may not fit into classical cardiomyopathy descriptions. 
cindicates genes associated with syndromic presentations that can include cardiomyopathy as a feature, and where cardiomyopathy may be the only or presenting feature of the syndrome.  These 
are sometimes referred to as genocopies. E.g. GLA is shown as definitive for HCM, because it causes Anderson–Fabry disease which can present with LVH fulfilling diagnostic criteria for HCM.


<!-- PAGE 31 -->

### Page 31

+
+
+
-
-
+
-
-
+
+
+
-
+
+
-
+
+
-
+
+
+
+
-
+
-
+
Severity
Disease susceptibility
Disease threshold
Severity
Disease susceptibility
Disease threshold
Rare pathogenic variant
Intermediate effect variant
Small effect common variant
Non-genetic factors
Panel A
Panel B
Panel C
Severity
Disease susceptibility
Disease threshold
Low familial aggregation
Autosomal dominant with incomplete penetrance and variable severity/expressivity
Sporadic presentation
(negative family history)
Autosomal dominant with complete penetrance
Rare Mendelian variant
Population MAF <0.01%
Intermediate effect variant
Population MAF <1–2%
Common variants (GWAS)
Population MAF >1–5%
Figure 8 The genetic architecture of the cardiomyopathies. GWAS, genome-wide association studies; MAF, minor allele frequency. Cardiomyopathy can be 
Mendelian, caused by genetic variants that are ultra-rare in the general population and have large effect sizes. Such variants can display complete penetrance; i.e. all 
individuals with the variant in the family manifest the disease (panel A). However, individual variants are often insufficient to yield a disease phenotype in isolation, and 
their effect is modulated by the co-inheritance of modulatory genetic factors and by non-genetic factors (panel B). Besides increasing disease penetrance, such mod­
ulatory variants also affect the severity of the disease (panel B). Modulatory genetic factors are thought to comprise common variants with individually small-effect 
sizes and intermediate-effect variants that have population frequencies and effect sizes between rare and common variants. Some patients have a more complex 
aetiology (non-Mendelian/polygenic inheritance) in which a substantial number of non-Mendelian genetic factors and non-genetic factors are required to reach the 
threshold for disease (panel C). Such patients typically have a sporadic presentation or present with a less pronounced familial clustering of the disease. Family trees 
demonstrate the male (square) and female (circle) family members that are affected (black filled), with incomplete phenotype (grey filled) or unaffected (white filled). 
The presence or absence of the variant of interest is noted with “+” or “-”, respectively.
Table 11 Utility of genetic testing in cardiomyopathies
For the patient
• Diagnosis: for the affected individual, the diagnosis of cardiomyopathy is primarily made on the basis of a phenotypic definition of disease, without reference to 
genetic aetiology. However, with appropriate genetic counselling and acknowledging the caveat that the finding will only be clinically actionable when a P/LP 
variant is found, genetic testing may be of value in clarifying borderline cases (e.g. where LVH is observed in the context of mild or controlled hypertension, but 
the clinician is not able to confidently distinguish between early sarcomeric HCM and a hypertensive phenocopy). Genetic testing can also identify genocopies: 
distinct genetic conditions that mimic a particular cardiomyopathy.
• Prognosis: for an increasing number of conditions, a genetic diagnosis can provide prognostic information. For example, DCM due to variants in LMNA has an 
adverse prognosis requiring more frequent surveillance and shifting therapeutic decision thresholds with a lower threshold for primary prevention ICD 
implantation.
• Therapy: a genetic diagnosis may directly stratify choice of therapy. In addition to decisions on primary prevention ICD implantation, an increasing number of 
treatments are either established or under trial for a specific molecular subtype of cardiomyopathy. In addition, with an increasingly sophisticated toolbox for                    
Continued 
ESC Guidelines                                                                                                                                                                                          3533


<!-- PAGE 32 -->

### Page 32

6.8.2.1. Non-Mendelian cardiomyopathies and implications for 
genetic testing
The preceding discussion has focused on genetic testing to identify 
monogenic forms of cardiomyopathy. The recognition that an import­
ant proportion of cardiomyopathies have a more complex genetic 
architecture has important implications for the use of genetic tests.
The absence of a monogenic disease-causing variant on conventional 
genetic testing (i.e. sequencing for rare variants of large effect) leaves 
three possibilities: (i) either there is a monogenic cause that has not 
been identified (i.e. not detected or recognized as causative by current 
testing); (ii) the cardiomyopathy does not have a genetic aetiology; or 
(iii) the cardiomyopathy is attributable to the effects of multiple variants 
of individually smaller effect (Figure 8). Recent data suggest that for many 
cardiomyopathies, the absence of a rare causative variant on comprehen­
sive testing indicates that the disease is unlikely to have a monogenic aeti­
ology.182,183,194 This, in turn, implies a different inheritance pattern, with a 
lower risk to first-degree relatives, such that ongoing surveillance may 
not be indicated if an initial clinical evaluation is reassuring. The use of gen­
etic testing to identify families in whom the disease is unlikely to be 
monogenic represents a likely new application of conventional testing, 
which is gathering evidence but not yet established.
Polygenic risk scores (PRS) (sometimes known as genomic risk 
scores) are another form of genetic test that may, in the future, have 
relevance in the management of cardiomyopathies. Instead of trying 
to identify a single genetic variant that is responsible for disease, 
many variants across the genome are evaluated, each associated with 
a small effect on disease risk, and a score representing the aggregate 
risk is calculated.182,183,195–197 To date, the value of a PRS in the clinical 
management of cardiomyopathies has not yet been demonstrated, and 
access to genetic counselling will be even more important in conveying 
risks and uncertainties to patients and families.
6.8.2.2. Genetic test reports and variant interpretation
Many genetic diagnostic laboratories use a standardized framework to 
interpret and report diagnostic genetic test results.3,198–200 A negative 
genetic test result in a proband indicates that no causative variant has 
been found in a known disease-associated gene. This does not necessar­
ily mean the patient does not have a genetic disease, but reflects our 
limited knowledge of the genetic architecture of inherited cardiomyop­
athies at this point in time. Aspects concerning the genetic testing ap­
proach, genetic testing methods, and variant interpretation are 
further elaborated in the Supplementary data online, Section 2, and in 
the European Heart Rhythm Association (EHRA)/Heart Rhythm 
Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin 
American Heart Rhythm Society (LAHRS) Expert Consensus 
Statement on the state of genetic testing for cardiac diseases.3
6.8.3. Genetic counselling
Genetic counselling is a process that aims to support patients and their 
families to understand and adapt to the medical, psychosocial, and familial 
impact of genetic diseases.201,202 It should be performed by healthcare 
professionals with specific training, such as genetic counsellors, genetic 
nurses, or clinical/medical geneticists, regardless of whether genetic testing 
is being considered. Genetic counselling can include a discussion of inher­
itance risks, provide education including the need for clinical evaluation, 
perform pre- and post-genetic test counselling, review variant classifica­
tions, obtain a three-generation family history, and provide psychosocial 
support.203–205For patients with a new diagnosis of cardiomyopathy, there 
can be difficulty adjusting to life with an inherited cardiomyopathy, chal­
lenges living with an implantable cardioverter defibrillator (ICD), and on­
going trauma and grief for those who have experienced a young SCD in 
their family. Attention to the psychological support needs of patients is 
therefore critical (see Section 6.12). Indeed, in the general setting, genetic 
counselling can improve knowledge, recall, and patient empowerment; in­
crease satisfaction with decision-making; and reduce anxiety.206–209
6.8.3.1. Genetic counselling in children
There are specific issues to be considered when counselling children 
and their families and considering clinical screening and cascade genetic 
testing,75,210,211 (Table 12) and a patient-centred approach that takes in manipulation of the genome, further waves of therapies aiming to replace, alter, or remove abnormal genes and transcripts responsible for cardiomyopathies are 
anticipated once a precise molecular aetiology is established in a patient.
• Reproductive advice: a genetic diagnosis informs reproductive advice and management for an affected adult and/or the parents of an affected child, enabling 
tailored advice on inheritance patterns and the risk of transmission to future children, and opening the door to management of risk; e.g. through pre-natal 
diagnostics or pre-implantation genetic diagnosis.
For relatives
• Cardiomyopathies display incomplete and age-related penetrance, with great variability, therefore it is very difficult to identify clinically those relatives who are 
not at risk of developing cardiomyopathy. A normal one-off assessment is of limited value, and relatives without cardiomyopathy on initial evaluation may require 
long-term longitudinal surveillance. Genetic testing can eliminate this uncertainty: an individual who does not carry the genetic variant proved to be responsible 
for disease in their family can be confidently reassured and discharged without surveillance, while an individual who carries a disease-causing variant can be 
followed closely, and potentially treated early.
© ESC 2023
DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LMNA, lamin A/C; LVH, left ventricular hypertrophy; P/LP, pathogenic/likely pathogenic.
Table 12 Specific issues to consider when counselling 
children
Issue
Implications
Autonomy
Competence of child to decide on testing
Informed consent
Appropriate to understanding of child
Right to know/not to know 
the result
Consider wishes of child and family
Confidentiality
Context of family history
Incomplete and age-related 
penetrance
Symptoms/features of disease may not 
become apparent for many years
Lifestyle
School, sports, employment
Life stages and transition
Moving from primary to secondary 
education; transition to adult medical 
services
© ESC 2023


<!-- PAGE 33 -->

### Page 33

to account the experiences and values of the family is needed (Figure 9). 
The guiding principle remains that any testing, clinical or genetic, should 
be in the best interests of the child and have an impact on management, 
lifestyle, and/or ongoing clinical testing.75 With appropriate multidiscip­
linary support in a paediatric setting, psychosocial outcomes in children 
undergoing clinical screening and cascade genetic testing are no differ­
ent than those of the general population.212
6.8.3.2. Pre- and post-test genetic counselling (proband)
One critical role for genetic counselling is that it should be done along­
side genetic testing (see Section 6.8.2).3 This includes a discussion prior 
to a decision to undertake genetic testing (pre-test), and at the time of 
the return of the results (post-test). Key discussion points during pre- 
and post-test counselling are summarized in Table 13.
6.8.3.3. Genetic counselling for cascade testing
Once a P/LP variant has been identified within an index patient follow­
ing investigations of relevant disease genes associated with the specific 
phenotype, it is possible to offer cascade genetic testing of first-degree 
at-risk relatives, including pre-test genetic counselling (see Section 6.8). 
In a scenario where a first-degree relative has died, evaluation of close 
relatives of the deceased individual (i.e. second-degree relatives of the 
index patient) should also be considered.
Undergo cascade genetic testing
Genotype-positive
Genotype-negative
Continue clinical screening
Release from further clinical screening
Risk of developing disease
Continue clinical screening
Risk of developing disease
Remove unnecessary worry
Decline cascade genetic testing
Understand motivations for testing
Minimize healthcare burden of unnecessary clinical screening
Tolerance to uncertainty
Willingness to undergo periodic clinical screening
Age of the child
Family experience with disease
Life stage
Explore worry and fear
Genetic counselling
Access to information and resources
Preferences of the parents
Wish to include children in decisionmaking when older
Respectful discussion
Potential impact on lifestyle, sport,
wellbeing
Family values and beliefs
Cascade genetic testing in children: a patient-centred approach
Figure 9 A patient-centred approach to cascade genetic testing of children. Factors to consider when supporting families to decide whether to pursue 
cascade genetic testing in children.
ESC Guidelines                                                                                                                                                                                          3535


<!-- PAGE 34 -->

### Page 34

The right assignment of the level of pathogenicity of a variant is cru­
cial for cascade genetic testing. Inappropriate use of genetic testing in a 
family has the potential to introduce unnecessary worry and fear, as 
well as potential harm related to the misinterpretation of genetic var­
iants. Variants should therefore be classified by a specialized multidiscip­
linary cardiac genetic team with an appropriate level of expertise. 
Systematic reclassification of identified variants and communication 
to families is crucial. Conveying information on the importance of clin­
ical and genetic testing of at-risk relatives is typically reliant on the pro­
band in the family understanding the information and passing it on to 
the appropriate relatives. Common barriers to communication can in­
clude poor family relationships, guilt regarding passing a causative vari­
ant on to children, psychosocial factors including distress, and 
comprehension of the result.214,215 A patient will often selectively com­
municate genetic information to relatives, assessing their ability to 
understand and cope with the information, their life stage, and their 
risk status.216 Poor health literacy is an important barrier to effectively 
communicating genetic risk information to relatives, highlighting the 
need for targeted resources and mechanisms for support.217
6.8.3.4. Pre-natal or pre-implantation genetic diagnosis
Pre-natal or pre-implantation genetic testing can be offered to par­
ents who have had a previous affected child with an inherited cardio­
myopathy due to a single or multiple pathogenic variant(s), or to 
couples where one or both partners carries a known pathogenic (fa­
milial) variant. The decision to pursue pre-natal or pre-implantation 
genetic testing should consider a spectrum of disease- and 
parent-related aspects, including cultural, religious, legal, and avail­
ability issues.218 Options for pre-natal or pre-implantation genetic 
diagnosis should be discussed as part of the genetic counselling pro­
cess and in a timely manner. If pre-natal diagnostics are performed, it 
should be done early enough in pregnancy to give the patient options 
regarding pregnancy continuation, or co-ordination of pregnancy, de­
livery, and neonatal care.219
Options for pre-natal and pre-implantation genetic diagnosis are 
summarized in Table 14. Most reproductive diagnostic testing op­
tions are for established pregnancies, except pre-implantation genet­
ic diagnosis which allows for selective implantation of unaffected 
embryos.
Table 13 Key discussion points of pre- and post-test 
genetic counselling
Pre-test genetic 
counselling
Detailed family history
Genetic education
Process and logistics of genetic testing and 
return of the result
Explanation of all possible outcomes
Implications for clinical care
Lifestyle implications including sport, exercise, 
and employment
Implications for the family
Risk of reclassification
Secondary genetic findings
Potential insurance implications (country 
dependent)
Exploration of feelings and understanding
Psychosocial support
Post-test genetic 
counselling
Re-cap on key points of pre-test session
Result disclosure
Specific implications for clinical care
Specific implications for the family and how to 
approach relatives
Risk of reclassification, plan for resolving 
uncertain variant status if applicable
Exploration of feelings and understanding
Provision of details about how family members 
can access genetic counselling
Offer information about reproductive genetic 
testing options for those with a genetic 
diagnosis
Psychosocial support
© ESC 2023
Modified from Ingles et al.213
Table 14 Pre-natal and pre-implantation options and 
implications
Issue
Implications
Chorionic villus sampling
• Transcervical or transabdominal sampling of 
the placenta at 10–14 weeks of gestation. 
The procedure-related foetal loss rate is 
∼0.2%.220
• Performed at early gestational age; short 
testing turnaround time.
Amniocentesis
• Direct sampling of amniotic fluid is 
performed after 15 weeks of gestation The 
loss rate is ∼0.1%.220
Non-invasive pre-natal 
testing
• Performed for a single gene disorder.
• Cell-free foetal DNA isolated from maternal 
plasma sample.
• Offered in early pregnancy (approximately 
week 9); miscarriage risk not increased.
• Not widely available (method still largely 
under development and therefore not 
readily available).
Pre-implantation genetic 
diagnosis
• IVF procedure with a success rate of 25–30% 
per embryo transfer though dependent on 
the mother’s age and fertility, followed by 
biopsy and genetic testing of a single cell of 
the embryo.
• Risks to mother and offspring of IVF, such as 
multiple birth, premature labour and low 
birth weight, as well as emotional health 
effects for those undergoing the procedure.
• Availability and methods differ across 
countries.
© ESC 2023
IVF, in vitro fertilization.


<!-- PAGE 35 -->

### Page 35

6.9. Diagnostic approach to paediatric 
patients
Traditionally, cardiomyopathies in children have been considered to be 
distinct entities from adolescent and adult cardiomyopathies, with dif­
ferent aetiologies, natural history, and management. Although substan­
tially rarer than in adults, contemporary data have shown that, beyond 
the first year of life, in most cases, paediatric cardiomyopathies re­
present part of the spectrum of the same diseases that are seen in ado­
lescents and adults.245 Given their rarity, data on clinical management 
and outcomes are more limited than in adults, but large population- 
based or international consortium data have provided important 
information on clinical presentation, natural history, and outcomes of 
cardiomyopathies in children.245 Paediatric-onset cardiomyopathies of­
ten represent two opposite ends of the spectrum of heart muscle dis­
ease: (i) severe, early-onset disease, with rapid disease progression and 
poor prognosis, in keeping with the most severe presentations in adults; 
or (ii) early phenotypic expression of adult cardiomyopathy 
phenotypes, increasingly identified as a result of family screening. For 
this reason, the Task Force highlights the principle of considering car­
diomyopathies in all age groups as single disease entities, with recom­
mendations applicable to paediatric and adult populations throughout 
this guideline, accepting that the evidence base for many of the recom­
mendations is significantly more limited for children. Where there are 
age-related differences, these are specifically highlighted.
Recommendation Table 8 — Recommendations for 
genetic counselling and testing in cardiomyopathies
Recommendations
Classa
Levelb
Genetic counselling
Genetic counselling, provided by an appropriately 
trained healthcare professional and including genetic 
education to inform decision-making and 
psychosocial support, is recommended for families 
with an inherited or suspected inherited 
cardiomyopathy, regardless of whether genetic 
testing is being considered.204,206,208,209,221–224
I
B
It is recommended that genetic testing for 
cardiomyopathy is performed with access to a 
multidisciplinary team, including those with expertise 
in genetic testing methodology, sequence variant 
interpretation, and clinical application of genetic 
testing, typically in a specialized cardiomyopathy 
service or in a network model with access to 
equivalent expertise.222,224–226
I
B
Pre- and post-test genetic counselling is 
recommended in all individuals undergoing genetic 
testing for cardiomyopathy.204,208,227–236
I
B
If pre-natal diagnostic testing is to be pursued by the 
family, it is recommended that this is performed early 
in pregnancy, to allow decisions regarding 
continuation or co-ordination of pregnancy to be 
made.
I
C
A discussion about reproductive genetic testing 
options with an appropriately trained healthcare 
professional should be considered for all families with 
a genetic diagnosis.
IIa
C
Index patients
Genetic testing is recommended in patients fulfilling 
diagnostic criteria for cardiomyopathy in cases where 
it enables diagnosis, prognostication, therapeutic 
stratification, or reproductive management of the 
patient, or where it enables cascade genetic 
evaluation of their relatives who would otherwise be 
enrolled into long-term surveillance.227–231,237,238
I
B
Genetic testing is recommended for a deceased 
individual identified to have cardiomyopathy at 
post-mortem if a genetic diagnosis would facilitate 
management of surviving relatives.239–243
I
C
Genetic testing may be considered in patients 
fulfilling diagnostic criteria for cardiomyopathy when 
it will have a net benefit to the patient, considering 
the psychological impact and preference, even if it 
does not enable diagnosis, prognostication, or 
therapeutic stratification, or cascade genetic 
screening of their relatives.
IIb
C
Genetic testing in patients with a borderline 
phenotype not fulfilling diagnostic criteria for a 
cardiomyopathy may be considered only after 
detailed assessment by specialist teams.
IIb
C
Continued 
Family members
It is recommended that cascade genetic testing, with 
pre- and post-test counselling, is offered to adult 
at-risk relatives if a confident genetic diagnosis (i.e. a 
P/LP variant) has been established in an individual 
with cardiomyopathy in the family (starting with 
first-degree relatives if available, and cascading out 
sequentially).204,227–232
I
B
Cascade genetic testing with pre- and post-test 
counselling should be considered in paediatric at-risk 
relatives if a confident genetic diagnosis (i.e. a P/LP 
variant) has been established in an individual with 
cardiomyopathy in the family (starting with 
first-degree relatives, if available, and cascading out 
sequentially), considering the underlying 
cardiomyopathy, expected age of onset, 
presentation in the family, and clinical/legal 
consequences.233–236,244
IIa
B
Testing for the presence of a familial variant of 
unknown significance, typically in parents and/or 
affected relatives, to determine if the variant 
segregates with the cardiomyopathy phenotype 
should be considered if this might allow the variant to 
be interpreted with confidence.
IIa
C
Diagnostic genetic testing is not recommended in a 
phenotype-negative relative of a patient with 
cardiomyopathy in the absence of a confident genetic 
diagnosis (i.e. a P/LP variant) in the family.
III
C
© ESC 2023
P/LP, pathogenic/likely pathogenic. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3537


<!-- PAGE 36 -->

### Page 36

The general approach to paediatric and adult cardiomyopathies is 
based on age of onset, clinical presentation, and cardiac and systemic 
phenotype.246 When a syndromic or metabolic disease is suspected, 
a step-by-step approach taking into consideration age of onset, consan­
guinity and family history, cardiac and systemic involvement, ECG and 
imaging, and laboratory work-up is recommended to define phenotype, 
aetiology, and tailored management.247 As in adults, clinical presenta­
tion varies, from an absence of symptoms to SCD as the first and un­
ique manifestation.35,81,248,249
6.9.1. Infantile and early childhood-onset 
cardiomyopathy
In contrast, the aetiology, natural history, and outcomes of 
infant-onset (<1 year of age) cardiomyopathies can be substantially 
different than those seen in older children, adolescents, and adults. 
In infantile and early childhood-onset cardiomyopathies, clinical 
presentation, cardiac phenotype, and aetiology are the main determi­
nants of management.2 Severe clinical onset of infantile cardiomyop­
athies is generally managed in intensive or subintensive care units by 
neonatologists and paediatric cardiologists, for respiratory distress 
and/or metabolic acidosis, and/or hypoglycaemia, and/or hypo­
tonia.247,250–252 A comprehensive clinical approach, taking into con­
sideration both the cardiac and systemic phenotype (consanguinity; 
dysmorphisms or skeletal anomalies; mental retardation; muscle 
hypotonia and weakness; hypoglycaemia with or without metabolic 
acidosis; increased CK and transaminases; presence of urine ketones, 
organic aciduria, acylcarnitine, and free fatty acid profiles; and calcium 
and vitamin D metabolism), and involving a multidisciplinary team 
(geneticist and experts in metabolic and neurological diseases), is 
mandatory to guide management when reversible or specific diseases 
are present (Figure 10).
Clinical approach to infantile and childhood cardiomyopathy
Friedreich
GSD
Danon
Concentric LVH
Danon
Danon
GSD
Extreme LVH
Global hypokinesia
Posterolateralakinesia
Pulmonary stenosis/CHD
Barth
Dysmorphia,
skeletal abnormalities
Skin abnormalities
Metabolic acidosis
Encephalopathy
GSD
LSD
MYH7
Ataxia
Muscle weakness
Deafness
Learning difficulties,
intellectual disability
Hypoglycaemia, 
   AST/ALT
Friedreich
Friedreich
GSD
Mitochondrial
Desmosomal
Dystrophin
RASopathy
RASopathy
RASopathy
Mitochondrial
Mitochondrial
Mitochondrial
RASopathy
Friedreich
Dystrophin/
NMD
Dystrophin/
NMD
Mitochondrial
Mitochondrial
NSML
Epicardin
Mitochondrial
Inheritance patterna
Echocardiogram
Systemic phenotype
ECGb
HCM
DCM
RCM
ARVC
NDLVC
Desmosomal
Figure 10 Clinical approach to infantile and childhood cardiomyopathy. ALT, alanine aminotransferase; ARVC, arrhythmogenic right ventricular cardio­
myopathy; AST, aspartate transaminase; CHD, congenital heart disease; DCM, dilated cardiomyopathy; ECG, electrocardiogram; GSD, glycogen storage dis­
order; HCM, hypertrophic cardiomyopathy; LSD, lysosomal storage disease; LVH, left ventricular hypertrophy; MYH7, myosin heavy chain 7; NDLVC, 
non-dilated left ventricular cardiomyopathy; NSML, Noonan syndrome with multiple lentigines; RCM, restrictive cardiomyopathy. aSee Table 5. bSee 
Table 7.Image %:


<!-- PAGE 37 -->

### Page 37

In infants with HCM, after exclusion of reversible causes (maternal dia­
betes,253 twin–twin syndrome, corticosteroid use254,255), it is important to 
define, along with the pattern of hypertrophy (asymmetric, concentric, bi­
ventricular), the presence of LVOTO, diastolic and/or systolic dysfunc­
tion,1,256 and RV involvement. Early-onset sarcomeric disease (including 
double/compound variants) should be excluded even in the absence of a 
family history for HCM and SCD; these infants present with severe heart 
failure symptoms, and survival beyond the first year of life is uncommon.257
In contrast, clinical presentation with heart failure is rare in infants with het­
erozygous sarcomeric disease compared with malformation syndromes or 
metabolic disorders, in whom survival rates are <90% and <70% at 1 year, 
respectively.248,258,259 In infants with HCM, in the presence of biventricular 
outflow tract obstruction and ≥1 red flag for a neurocardiofaciocutaneous 
syndrome (dysmorphisms, cutaneous abnormalities, skeletal anomalies, 
etc.), a diagnosis of RASopathies should be strongly suspected.260–263
Severe LVOTO in RASopathy-related HCM often requires high-dose 
beta blockade and, in some cases, consideration of septal myectomy.264– 
267 In infants with HCM, biventricular hypertrophy, often presenting 
with signs of heart failure and systolic dysfunction, and ≥1 red flag for meta­
bolic disease (muscle hypotonia, increased CK, and transaminases, consan­
guinity or matrilineal pattern of inheritance), it is mandatory to exclude 
inborn errors of metabolism, including glycogenosis type II (Pompe dis­
ease), fatty acid oxidation defects, and mitochondrial disorders.268–272 In 
infants with Pompe disease, enzyme replacement therapy (ERT) has 
been shown to result in reversal of LVH.269,273–275
In infants with DCM, reversible causes (i.e. hypocalcaemic vitamin 
D-dependent rickets) and CHD (aortic coarctation and ALCAPA, re­
quiring immediate surgical management) should be ruled out.249,276,277
Viral myocarditis should also be excluded by non-invasive (i.e. laboratory) 
and invasive (EMB) investigations, in selected cases.278,279 Neuromuscular 
(dystrophin- and sarcoglycan-related cardiomyopathies) should be ex­
cluded in patients presenting with muscle hypotonia and increased CK, 
and a multidisciplinary approach involving a neurologist and experts in 
metabolic disease is required.280–282 When a DCM phenotype is asso­
ciated with LV hypertrabeculation, other mitochondrial/metabolic dis­
eases, including Barth syndrome, should be considered.283–285
Isolated RCM is rare in infants, but a mixed RCM/HCM phenotype is 
more frequently encountered. Familial cases are frequent, particularly 
in patients with an RCM/HCM phenotype.286–289 Independently of 
the phenotype, it is generally associated with poor prognosis, though 
the RCM/HCM phenotype has significantly better transplant-free sur­
vival than isolated RCM.286
Arrhythmogenic RV cardiomyopathy and non-dilated LV cardiomy­
opathy phenotypes are very rare in infants, and are most commonly 
autosomal recessive forms associated with cutaneous manifestations 
(e.g. Naxos disease and Carvajal syndrome),290–292 although this may 
reflect a lack of systematic clinical screening for these conditions in early 
childhood. Recent data suggest that ∼15% of ARVC patients present 
with paediatric-onset disease and paediatric ARVC patients more often 
present with severe phenotype and higher risk of SCD.293 Increasingly, 
children with ARVC and NDLVC phenotypes presenting with acute 
myocarditic presentations are recognized.294–297
6.10. General principles in the 
management of patients with 
cardiomyopathy
6.10.1. Assessment of symptoms
Some people with subtle structural abnormalities with cardiomyopathy 
remain asymptomatic and have a normal lifespan; however, others may 
develop symptoms, often many years after the appearance of ECG or 
imaging evidence of disease. In infants, symptoms and signs of heart fail­
ure include tachypnoea, poor feeding, excessive sweating, and failure to 
thrive. Older children, adolescents, and adults complain of fatigue and 
dyspnoea as well as chest pain, palpitations, and syncope. Because the 
New York Heart Association (NYHA) classification to grade heart fail­
ure is not applicable to children under the age of 5 years, the Ross 
Heart Failure classification has been adopted in children <5 years of 
age but has not been validated against outcomes.298 Systematic 
two-dimensional (2D) and Doppler echocardiography, resting and am­
bulatory ECG monitoring, and exercise testing are usually sufficient to 
determine the most likely cause of symptoms. Additional investigations 
(e.g. coronary CT scanning or coronary angiography, cardio-pulmonary 
exercise testing [CPET], electrophysiological study, loop recorder im­
plantation) should be considered to investigate specific symptoms of 
chest pain, syncope, and palpitation, according to established clinical 
practice and guidelines.1,4,69,299–301 Cardiac catheterization to evaluate 
right and left heart function and pulmonary arterial resistance, and 
CPET with simultaneous measurement of respiratory gases, is not a 
standard part of the work-up, but remains recommended in severely 
symptomatic patients with systolic and/or diastolic LV dysfunction 
when uncertainty about filling status exists, or for those being consid­
ered for heart transplantation or mechanical circulatory support.69
6.10.2. Heart failure management
The clinical management of heart failure has been described in the 2021 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure.69In 
that document, recommendations are generally independent from the aeti­
ology of heart failure and include current medical therapy, devices, and LV 
assist device (LVAD)/transplantation. As such, the treatment recommenda­
tions must be regarded as generic and not specific to the different forms of 
cardiomyopathy. Medical therapies for HFrEF based on randomized con­
trolled trials (RCTs) from large cohorts, including angiotensin-converting 
enzyme inhibitors (ACE-I)/angiotensin receptor neprilysin inhibitors 
(ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRA), 
and sodium–glucose co-transporter 2 inhibitors (SGLT2i), would be mostly 
applicable to genetic DCM, NDLVC, and other phenotypes associated with 
LV dysfunction (e.g. end-stage HCM, RCM, and ARVC). Indications for a 
cardiac resynchronization therapy (CRT) device and heart transplant 
would also be generally applicable accordingly. Recommendations for man­
agement of HFpEF would be mainly applicable to non-obstructive HCM, 
RCM, and cardiac amyloidosis. A Focused Update is due to be published 
in 2023.69a
Individual response to heart failure therapies may not be the same 
for different specific genetic causes, as has been demonstrated in sev­
eral observational studies.302,303 Further management considerations 
applicable to specific cardiomyopathy subtypes in adults and children, 
and in particular contexts, such as pregnancy and rare metabolic geno­
copies, are rapidly developing304 and are discussed in the specific car­
diomyopathy sections (see Sections 7.6 and 8.2.2).
Cardiac amyloidosis and some forms of RCM deserve special consid­
eration regarding heart failure management. Fluid control and mainten­
ance of euvolaemia are central. If heart failure symptoms are present, 
loop diuretics should be given, although orthostatic hypotension may 
cause intolerance, and excessive fluid loss may worsen symptoms 
due to restriction (e.g. in HCM or amyloidosis). The role of beta- 
blockers, ACE-Is, angiotensin receptor blockers (ARBs), or ARNIs in 
the treatment of these patients has not been determined and they 
may not be well tolerated because of hypotension.305 Moreover, 
ESC Guidelines                                                                                                                                                                                          3539


<!-- PAGE 38 -->

### Page 38

withdrawal of these drugs frequently leads to improvement in symp­
toms and should be considered.
Heart failure with an LVEF >40–50% recovered from HFrEF or 
HFmrEF (improved LVEF306) is not separately considered in the 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart 
failure, but is particularly important for genetic DCM, as a substantial 
proportion of patients with HFrEF or HFmrEF will improve their 
LVEF with guideline-directed medical therapy (GDMT).69 Patients 
and physicians are faced with the dilemma of whether to continue life­
long pharmacotherapy or wean at some point. The TRED-HF (Therapy 
withdrawal in REcovered Dilated cardiomyopathy—Heart Failure) trial 
is the only RCT that evaluated if weaning GDMT is safe. The results 
showed that a large proportion of the patients had recurrent LV dys­
function or heart failure, so current recommendations caution against 
weaning.307
6.10.2.1. Preventive heart failure medical therapy of asymptomatic 
carriers/early disease expression
Heart failure therapy should be guided according to the 2021 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure 
for HFrEF, HFmrEF, and HFpEF in patients with cardiomyopathy and 
heart failure symptoms.69,69a Evidence for treatment recommendations 
in asymptomatic LV dysfunction is scarce, which presents a challenge 
for genetic cardiomyopathies, where a sizeable proportion of the pa­
tients are young with no or only mild symptoms, and where asymptom­
atic patients are frequently discovered through cascade screening. 
Because heart failure medication has proved to affect LV remodelling 
in symptomatic patients with LV dysfunction, first-line heart failure 
therapy may be considered in patients with early forms of DCM/ 
NDLVC to prevent progression of LV dilatation and dysfunction (e.g. 
ACE-I, ARBs, beta-blockers and MRAs, Class IIb Level C). Biomarkers 
may help to identify pre-symptomatic patients who might benefit 
from early neuro-hormonal blockade.308 The effect of heart failure 
drugs to prevent progression into overt disease in genetic carriers of 
DCM-/NDLVC-causing variants is currently unsettled. A placebo- 
controlled trial (EARLY-Gene trial) is under way to test the utility of 
candesartan to prevent LV dysfunction/dilatation in this scenario 
(EudraCT: 2021-004577-30).
Management in other asymptomatic affected patients with diagnoses 
of HCM, ARVC, and RCM should be decided individually, as medication 
has not been proved to affect disease expression.
There is no evidence to support the use of current pharmacological 
agents for the prevention of disease development in non-affected car­
riers. Randomized controlled trials are warranted in order to address 
the value of new pharmacologic agents in this scenario.309
Heart failure therapies are given to children with cardiomyopathies, 
applying the evidence from adults to children or based on a limited 
number of clinical studies.310 Heart failure therapies routinely used in 
children with LV dysfunction are ACE-Is, beta-blockers, diuretics, and 
aldosterone antagonists. Angiotensin receptor blockers are an alterna­
tive for ACE-Is. Early results of the multicentric randomized control 
PANORAMA-HF Trial and the subsequent Food and Drug 
Administration (FDA) approval for ARNI in children have paved the 
way for this newer class of drugs for paediatric patients with symptom­
atic heart failure with systemic left ventricle systolic dysfunction, 1 year 
of age and older. Dosing recommendations in younger children are cur­
rently pending,311 but for children <40 kg a starting dose of 1.6 mg/kg 
titrated to a maximum of 3.1 mg/kg has been suggested.312 There are 
currently no clinical trial or efficacy data available for SGLT-2 inhibitors 
in children.
6.10.2.2. Cardiac transplantation
Orthotopic cardiac transplantation should be considered in patients 
with moderate-to-severe drug-refractory symptoms (NYHA function­
al class III–IV) who meet standard eligibility criteria (see the 2021 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart fail­
ure).69 This may include patients with RCM and HCM with normal LVEF 
but severe drug-refractory symptoms (NYHA functional class III–IV) 
caused by diastolic dysfunction.313–316 In patients with refractory ven­
tricular arrhythmias that cannot be solely attributed to an acute decom­
pensation in the setting of end-stage heart failure, a comprehensive 
evaluation of all potential therapeutic options (e.g. pharmacotherapy; 
ventricular tachycardia [VT] ablation including epicardial access if indi­
cated and feasible; cardiac sympathetic denervation in patients with 
electrical storm and/or refractory polymorphic VT or rapid mono­
morphic VT) should be undertaken before recommending cardiac 
transplantation (see Section 6.10.4).
6.10.2.3. Left ventricular assist devices
As there are increasing numbers of patients with end-stage heart fail­
ure, and the organ donor pool remains limited, mechanical circulatory 
support (MCS) with an LVAD or biventricular assist device is
Recommendation Table 9 — Recommendations for 
cardiac transplantation in patients with cardiomyopathy
Recommendations
Classa
Levelb
Orthotopic cardiac transplantation is recommended 
for eligible cardiomyopathy patients with advanced 
heart failure (NYHA class III–IV) or intractable 
ventricular arrhythmia refractory to medical/invasive/ 
device therapy, and who do not have absolute 
contraindications.317–319
I
C
© ESC 2023
NYHA, New York Heart Association. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 10 — Recommendation for 
left ventricular assist device therapy in patients with 
cardiomyopathy
Recommendation
Classa
Levelb
Mechanical circulatory support therapy should be 
considered in selected cardiomyopathy patients with 
advanced heart failure (NYHA class III–IV) despite 
optimal pharmacological and device treatment, who 
are otherwise suitable for heart transplantation, to 
improve symptoms and reduce the risk of heart failure 
hospitalization from worsening heart failure and 
premature death while awaiting a transplant.320–324
IIa
B
Mechanical circulatory support therapy should be 
considered in selected cardiomyopathy patients with 
advanced heart failure (NYHA class III–IV) despite 
optimal pharmacological and device therapy, who are 
not eligible for cardiac transplantation or other 
surgical options, and without severe right ventricular 
dysfunction, to reduce the risk of death and improve 
symptoms.321,325–330
IIa
B
© ESC 2023
NYHA, New York Heart Association. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 39 -->

### Page 39

increasingly used as a bridge to transplant. Long-term MCS should also 
be considered as destination therapy for cardiomyopathy patients with 
advanced heart failure despite optimal medical therapy who are not eli­
gible for transplantation.69
6.10.3. Management of atrial arrhythmias
Atrial fibrillation is the most common arrhythmia in all subtypes of 
cardiomyopathies and is associated with an increased risk of 
cardio-embolic events, heart failure, and death.331–333 Data from 
3208 consecutive adult patients in the EURObservational 
Research Programme (EORP) Cardiomyopathy Registry showed 
an AF prevalence of 28.2% at baseline and 31.1% during follow- 
up,331–333 although it differed among cardiomyopathy types (see 
Table 15). Overall, annual incidence in this registry was 
3.0%.332,333 In patients with cardiomyopathies, the presence of AF 
is associated with more severe symptoms, an increased prevalence 
of cardiovascular risk factors and comorbidities, and an increased 
incidence of stroke and death (from any cause and from heart 
failure).332,334–336
Both the 2020 ESC Guidelines for the diagnosis and management of at­
rial fibrillation and the 2021 ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure recommend an integrated and struc­
tured approach to facilitate guideline-adherent management. The 
Atrial Fibrillation Better Care (ABC) approach has been shown to re­
duce the risk of stroke and systemic embolism, myocardial infarction, 
and mortality in the general population.337–361 Although this approach 
has not been specifically assessed in patients with cardiomyopathies, 
heart failure was present in ∼20% of the individuals of these studies 
and, where specified, cardiomyopathy in ∼5.5–6.5%. In particular, 
two RCTs support integrated care.347,361 The RACE 3, combining 
the components of the ABC pathway into structured care, resulted 
in reduced AF burden and better rhythm control among 245 patients 
with early persistent AF and stable heart failure (119 randomized to tar­
geted and 126 to conventional therapy).347 The mobile Atrial 
Fibrillation App Trial (mAFA-II), which included 714 patients with heart 
failure (21.5%), 54 with HCM (1.6%), and 105 with DCM (3.2%), 
showed the superiority of integrated care supported by mobile tech­
nology in the composite outcome of ‘ischaemic stroke/systemic 
thrombo-embolism, death, and re-hospitalization’ (1.9% vs. 6.0%; haz­
ard ratio [HR] 0.39; 95% confidence interval [CI], 0.22 to 0.67; P <  
0.001) and re-hospitalization rates (1.2% vs. 4.5%; HR 0.32; 95% CI, 
0.17 to 0.60; P < 0.001).361 Adherence to the mobile health technology 
beyond 1 year was good, and was associated with a reduction in ad­
verse clinical outcomes.362
6.10.3.1. Anticoagulation
Thrombo-embolic risk varies in different cardiomyopathy phenotypes 
(see Section 7).332,363–367 Cardiac amyloidosis, HCM, and RCM368 are 
associated with a particularly increased risk of stroke.332,365,369,370
The EORP registry indicated a worse prognosis for the population 
with cardiomyopathy and concurrent AF with an annual incidence of 
stroke/transient ischaemic attack (TIA) about three times higher in 
the cardiomyopathy group with AF.332,334 Hence, considering anticoa­
gulation is key in patients with any type of AF or atrial flutter.
Importantly, patients with cardiomyopathy and AF have more 
cardio-embolic risk factors, including greater age, more advanced 
NYHA class and more frequent history of stroke/TIA, hypertension, 
and diabetes mellitus, among others.332,333 The CHA2DS2-VASc (con­
gestive heart failure or left ventricular dysfunction, hypertension, age 
≥75 [doubled], diabetes, stroke [doubled]-vascular disease, age 65– 
74, sex category [female]) score has not been specifically tested in pa­
tients with cardiomyopathies,369 and retrospective evidence suggests 
that it may perform suboptimally with respect to stroke prediction in 
HCM and ATTR amyloidosis.334,365,371–374 For this reason, although 
there are no RCTs evaluating the role of anticoagulation among pa­
tients with HCM, given the high incidence of stroke, prophylactic antic­
oagulation is recommended in all patients with HCM and 
AF.334,371,372,374 A similar recommendation is given in patients with 
AF and RCM or cardiac amyloidosis.375 In patients with DCM, 
NDLVC, or ARVC and AF, chronic oral anticoagulation should be con­
sidered on an individual basis, taking into consideration the 
CHA2DS2-VASc score, as proposed by the 2020 ESC Guidelines for 
the diagnosis and management of atrial fibrillation.336 Atrial fibrillation is 
a rare finding in children with genetic cardiomyopathies and no data 
are available regarding the performance of CHA2DS2-VASc or any 
other risk stratification score, nor the risk and benefit of prescribing 
oral anticoagulation. There are no data on long-term prophylactic antic­
oagulation in children with DCM in sinus rhythm.
In the general population, direct-acting oral anticoagulants (DOACs) 
are preferred for the prevention of thrombo-embolic events in patients 
with AF and without severe mitral stenosis and/or mechanical valve 
prosthesis, as they have similar efficacy to vitamin K antagonists 
(VKAs) but a lower risk of intracranial haemorrhage.376 There are no 
randomized data comparing direct oral anticoagulants with VKAs in pa­
tients with cardiomyopathy, although data suggest that they may be 
used in a similar manner as the general population.373,374,377–380
6.10.3.2. Rate control
Rate control should be considered in any patient with cardiomyopathy 
presenting with AF.336 A strict rate control (resting heart rate 
<80 beats per minute [b.p.m.] and heart rate during moderate exercise 
<110 b.p.m.) did not show any benefit over lenient rate control (resting 
heart rate <110 b.p.m.) in RACE II381 and a pooled analysis of RACE II 
and AFFIRM.382 However, only 8–12% of patients had a history of car­
diomyopathy (type unspecified) in the RACE II trial, and only 10% of the 
patients in RACE II and 17% of those in the pooled analysis had a history 
of heart failure hospitalization or NYHA class II or III, respectively.381,382
No data are available for the different cardiomyopathy subtypes, but 
observational studies suggest that higher heart rates are associated 
with worse outcomes in patients with heart failure.383,384
Accordingly, the 2021 ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure consider lenient rate control to be ac­
ceptable as an initial approach but to target a lower heart rate in case of 
persistent symptoms or suspicion of associated tachycardia-induced 
cardiac dysfunction.69
Very little data are available regarding the choice of pharmacological 
treatment for rate control in patients with cardiomyopathies. 
Beta-blockers are the preferred choice in patients with cardiomyop­
athies given their long-established safety in the presence of LV dysfunc­
tion.385,386 Digoxin is an alternative, particularly in patients with 
contraindication or intolerance to beta-blockers and among patients 
with AF and heart failure symptoms (RATE-AF trial), having shown 
no difference in quality of life (QoL) at 6 months compared with biso­
prolol.387 When administering digoxin, close monitoring of plasma drug 
ESC Guidelines                                                                                                                                                                                          3541


<!-- PAGE 40 -->

### Page 40

Table 15 Atrial fibrillation burden and management in cardiomyopathies
Condition
AF epidemiology
AF management
Prevalence
Annual 
incidence
Anticoagulation
Long-term rate control
Long-term rhythm control
HCM
17–39%331–334,365,413,421–428
2.8– 
4.8%332,333,365
Always (if no 
contraindication)371,429
Beta-blockers (preferred) 
Verapamil or diltiazem (only if 
preserved LVEF) 
Digoxin 
AV node ablation + CRT or 
physiological pacing388–390
Rhythm control is preferred
Amiodarone, dofetilide 
disopyramide, sotalol,a 
dronedaroneb
Ablation397,412,415,416,418,430– 
435
DCM
25–49%331–333,426,436,437
LMNA related438–441
3.8–5.5%332,333
According to cardio-embolic 
risk 
(always if HF or reduced 
LVEF)c
Beta-blockers (preferred) 
Digoxin 
AV node ablation + CRT or 
physiological pacing388–390
Rhythm control preferred in case of symptoms or/and heart failure or 
LV dysfunction
Amiodarone, sotalola
Ablation
NDLVC
39.2–43.1%d 442–444
4.4–12%d 
442,444,445
According to cardio-embolic 
risk 
(always if HF or reduced 
LVEF)
Beta-blockers (preferred) 
Digoxin 
Verapamil or diltiazem (only if 
LVEF ≥40%) 
AV node ablation + CRT or 
physiological pacing388–390
Rhythm control preferred in case of symptoms or/and heart failure or 
LV dysfunction
Flecainidee, amiodarone, sotalola
Ablation446
ARVC
9–30%331–333,437,447–451
2.1–2.8%332,333
According to cardio-embolic 
risk 
(always if HF or reduced 
LVEF)
Beta-blockers (preferred) 
Verapamil or diltiazem (only if 
LVEF ≥40%) 
AV node ablation + CRT or 
physiological pacing388–390
Rhythm control preferred in case of symptoms or/and heart failure or 
LV dysfunction
Flecainidee (associated with 
beta-blockers) 
Amiodarone, sotalola
Ablation
RCM
45–51%331–333
4.5–10.3%332,333
Always (if no 
contraindication)
Beta-blockersd (preferred) 
Digoxinf 
Verapamil or diltiazem (only if 
≥40%) 
AV node ablation + CRT or 
physiological pacing388–390
Rhythm control is preferred
Amiodarone
No data
© ESC 2023
AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; AV, atrioventricular; CrCl, creatinine clearance; CRT, cardiac magnetic resonance; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HF, heart failure; 
HFpEF, heart failure with preserved ejection fraction; LMNA, lamin A/C; LV, left ventricular; LVEF, left ventricular ejection fraction; NDLVC, non-dilated left ventricular cardiomyopathy; QRS, Q, R, and S waves of an ECG; RCM, restrictive 
cardiomyopathy. 
aUse with caution as evidence suggests that it may be associated with increased all-cause mortality.452
bDronedarone is not contraindicated in LV hypertrophy but has no significant studies in HCM. 
cLMNA-related DCM: increased risk of stroke (8–22%).368,440
dExtrapolated from studies reporting prevalent and incident AF in HFpEF. 
eContraindicated in patients with ischaemic heart disease or reduced LVEF. Should not be used in patients with CrCl <35 mL/min/1.73 m2 and significant liver disease. Should be discontinued in case of QRS widening >25% above baseline and patients 
with left bundle branch block or any other conduction block >120 ms. Caution when sinoatrial/atrioventricular conduction disturbances. 
fIn cardiac amyloidosis, beta-blockers in low dosage and digoxin with caution.453,454 Non-dihydropyridine calcium channel blockers may worsen LV systolic function and heart failure.455


<!-- PAGE 41 -->

### Page 41

levels is needed, as observational data suggest higher mortality in pa­
tients with AF, regardless of heart failure; the risk of death was related 
to serum digoxin concentration and was highest in patients with con­
centrations ≥1.2 ng/mL. On the contrary, a lower mortality with beta- 
blocker therapy in AF patients with concomitant heart failure has been 
observed. Non-dihydropyridine calcium channel blockers (CCBs) (ver­
apamil or diltiazem) may only be used in patients with LVEF ≥40%.336
Atrioventricular node ablation is also an alternative in patients with 
poor ventricular rate control despite medical treatment not eligible 
for rhythm control by catheter ablation or in patients with biventricular 
pacing.336 In patients with symptomatic persistent AF (>6 months) un­
suitable for AF ablation or in which AF ablation had failed, narrow QRS 
and at least one admission for heart failure, AV node ablation in asso­
ciation with CRT has been shown to be superior to rate control with 
pharmacological therapy, reducing the composite outcome of death 
due to heart failure, or hospitalization due to heart failure, or worsening 
heart failure,388 and all-cause mortality,389 irrespective of baseline EF 
(APAF-CRT Trial). Whether conduction system-pacing is a (better) al­
ternative to CRT needs to be further explored with only one small 
crossover trial (ALTERNATIVE-AF) comparing His-Bundle pacing 
(HBP) and biventricular pacing in 50 patients with LVEF ≤40% with per­
sistent AF undergoing AV node ablation.390 In this study, both arms sig­
nificantly improved LVEF at 9 months, with a small, but statistically 
significant superiority with HBP.69,336
6.10.3.3. Rhythm control
Atrial fibrillation can result in haemodynamic and clinical decompensa­
tion due to shortening of the diastolic filling time with rapid heart rates 
and dependence on atrial contraction for LV filling. Therefore, mainten­
ance of sinus rhythm is highly desirable and a rhythm control strategy is 
preferred, particularly in the presence of symptoms.
Regarding long-term pharmacological treatment,336 antiarrhythmic 
drugs (AADs) have shown limited success in maintaining sinus rhythm 
over time both in the general population and in patients with cardiomy­
opathies,391–393 show high rates of withdrawal due to intolerance,394
and, most importantly, are associated with significant side effects, includ­
ing proarrhythmia and extracardiac side effects, and, in some cases (so­
talol and class IA drugs, such as quinidine and disopyramide), increased 
mortality.394 As a consequence, a degree of caution is recommended 
when using antiarrhythmic drugs in this population. Data on antiarrhyth­
mic therapy for the specific management of AF in the context of genetic 
cardiomyopathies other than HCM are scarce. It is important to note the 
potential for proarrhythmia of class I antiarrhythmics, particularly in the 
presence of significant structural heart disease; these should therefore be 
used with caution. Antiarrhythmic drug–drug treatment has mostly been 
limited to amiodarone or sotalol, as there are no available data regarding 
other antiarrhythmics such as dofetilide or dronedarone. Importantly, 
sotalol should not be used in patients with HFrEF, significant LVH, pro­
longed QT, asthma, hypokalaemia, or creatinine clearance (CrCl) 
<30 ml/min. Likewise, dronedarone should be avoided in patients with 
recent decompensated heart failure or permanent AF as it has been 
shown to increase mortality.395,396
Catheter ablation of AF is a safe and superior alternative to AAD ther­
apy for maintenance of sinus rhythm, reducing AF-related symptoms, and 
improving QoL, and can be considered an alternative to AAD therapy in 
practically any type and context of AF.336,397 In patients with AF and nor­
mal LVEF, catheter ablation has not been shown to reduce total mortality 
or stroke.398 In selected patients with HFrEF,399–401 ablation has shown a 
reduction in all-cause mortality and hospitalizations, and should be con­
sidered as a first-line option. In the general AF population, the Early 
Treatment of Atrial Fibrillation for Stroke Prevention Trial 
(EAST-AFNET 4) randomized 2789 patients with early AF and associated 
cardiovascular comorbidities to an early rhythm control strategy or usual 
care (28.6% with heart failure).402 The trial was stopped early after a me­
dian follow-up of 5.1 years for a lower occurrence of the primary out­
come of death, stroke, or hospitalization for worsening heart failure or 
acute coronary syndrome in the patients in the early rhythm control 
group vs. those assigned to usual care. A pre-specified analysis evaluated 
the effects in patients with heart failure, showing the benefit of early 
rhythm control in this subgroup of patients,403 findings which corrobo­
rated those of the CABANA trial.400 In patients with AF and heart failure, 
several RCTs have demonstrated an improvement in outcomes with 
catheter ablation when compared with medical therapy.399–401,404–409
Some observational studies in patients with HFpEF have also suggested 
better results in terms of freedom from AF and all-cause mortality,410
but proper RCTs are warranted.
The role of catheter ablation in patients with cardiomyopathies has 
been reported in several registries, mainly in HCM patients.397,411–420
Overall, maintenance is achieved in up to two-thirds of patients, although 
repeat procedures or continuation of antiarrhythmic medications are of­
ten necessary.397,411,415–419 Patients with cardiomyopathies may have a 
higher risk of AF recurrence, particularly in the presence of atrial remod­
elling/dilatation.397
6.10.3.4. Comorbidities and risk factor management
Cardiovascular risk factors and comorbidities are also more frequent 
in patients with cardiomyopathies and AF. These include smoking, 
alcohol consumption, hypertension, diabetes mellitus type 2, hyperlip­
idaemia, renal impairment, chronic obstructive pulmonary disease, 
valvular 
and 
ischaemic 
heart 
disease, 
and 
anaemia.332,334
Furthermore, these patients have a larger body mass index and report 
less physical activity than those without AF.332,334 These risk factors 
and comorbidities are associated with the risk of AF and its 
complications and should therefore be appropriately identified and 
managed to prevent AF progression and the occurrence of adverse 
outcomes.336
Recommendation Table 11 — Recommendations for 
management of atrial fibrillation and atrial flutter in 
patients with cardiomyopathy
Recommendations
Classa
Levelb
Anticoagulation
Oral anticoagulation in order to reduce the risk of 
stroke and thrombo-embolic events is recommended 
in all patients with HCM or cardiac amyloidosis and AF 
or atrial flutter (unless 
contraindicated).332,365,369,371,373,378,413,427,428,456–464
I
B
Oral anticoagulation to reduce the risk of stroke and 
thrombo-embolic events is recommended in patients 
with DCM, NDLVC, or ARVC, and AF or atrial 
flutter with a CHA2DS2-VASc score ≥2 in men or 
≥3 in women.465–469
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3543


<!-- PAGE 42 -->

### Page 42

6.10.4. Management of ventricular arrhythmias
Ventricular arrhythmias, particularly in the form of electrical storm and/ 
or repetitive appropriate ICD interventions, contribute to a significant­
ly increased risk of morbidity and mortality in patients with 
cardiomyopathies.299
The 2022 ESC Guidelines for the management of patients with ventricu­
lar arrhythmias and the prevention of sudden cardiac death provide de­
tailed recommendations on acute and long-term management of 
ventricular arrhythmias in patients with cardiomyopathies.299 Limited 
data exist addressing ventricular arrhythmia management in patients 
with specific genetic cardiomyopathies. Nonetheless, some general 
concepts can be highlighted: 
• Any reversible cause and/or precipitating factor, such as electrolyte 
imbalances, ischaemia, hypoxaemia, or drugs, should be identified 
and corrected when possible.
• Extensive efforts should be made in the attempt to understand the 
aetiology (i.e. underlying mechanism and substrate, and their relation­
ship with the underlying cardiomyopathy) as this will influence the 
choice of treatment.
• Acute termination of sustained ventricular arrhythmias can be 
achieved with electrical cardioversion, AADs, or pacing. The initial 
choice of treatment will depend on the haemodynamic tolerance, 
the underlying aetiology, and the patient profile.
• In patients presenting with electrical storm, mild-to-moderate sed­
ation is recommended to alleviate psychological distress and reduce 
sympathetic tone. If the electrical storm remains intractable despite 
antiarrhythmic therapies, deep sedation/intubation should be 
considered.
• In case of incessant ventricular arrhythmias and electrical storm not 
responding to antiarrhythmic medication, catheter ablation is recom­
mended. In refractory cases or whenever VT ablation is either not in­
dicated or not immediately available, autonomic modulation (i.e. 
stellate ganglion block or cardiac sympathetic denervation, depending 
on the setting) and/or MCS may be considered.
• In patients with cardiomyopathies and scar-related ventricular ar­
rhythmias, the therapeutic arsenal for long-term prevention of recur­
rent ventricular arrhythmias includes antiarrhythmic medications 
(mostly limited to beta-blockers, sotalol, and amiodarone) and cath­
eter ablation (particularly in the case of sustained monomorphic VT 
or in the case of polymorphic VT triggered by a premature ventricu­
lar complex of similar morphology). Additional strategies, performed 
by experienced centres, may be considered, depending on the char­
acteristics of the patient and the ventricular arrhythmia, including 
acute neuromodulation strategies (stellate ganglion block and thor­
acic epidural anaesthesia), chronic neuromodulation strategies (car­
diac sympathetic denervation), and stereotactic non-invasive VT 
ablation.514–520 Limited data are available at present concerning the 
long-term cardiac and extracardiac safety of stereotactic non-invasive 
VT ablation, as well as the dose–response relationship, therefore its 
usage should be limited to compassionate cases or within prospective 
clinical studies.
• The acute as well as the chronic management of patients with cardio­
myopathies and refractory ventricular arrhythmias, particularly in 
case of concomitant moderate-to-severe ventricular dysfunction, 
should involve an integrated evaluation by a heart team including car­
diomyopathy specialists, electrophysiologists with specific experi­
ence in catheter ablation of ventricular arrhythmias and 
neuromodulation, anaesthesiologists, and cardiac surgeons.
6.10.5. Device therapy: implantable cardioverter 
defibrillator
Implantable cardioverter defibrillators are effective at correcting poten­
tially lethal ventricular arrhythmias and preventing SCD, but are also as­
sociated with complications, particularly in young patients who will 
Oral anticoagulation to reduce the risk of stroke and 
thrombo-embolic events should be considered in 
patients with RCM and AF or atrial flutter (unless 
contraindicated).
IIa
C
Oral anticoagulation to reduce the risk of stroke and 
thrombo-embolic events should be considered in 
patients with DCM, NDLVC, or ARVC, and AF or 
atrial flutter with a CHA2DS2-VASc score of 1 in men 
or of 2 in women.470–472
IIa
B
Control of symptoms and heart failure
Atrial fibrillation catheter ablation is recommended 
for rhythm control after one failed or intolerant class 
I or III AAD to improve symptoms of AF recurrences 
in patients with paroxysmal or persistent AF and 
cardiomyopathy.335,397–399,412,415–420,430– 
435,447,451,473–498
I
B
Atrial fibrillation catheter ablation is recommended 
to reverse LV dysfunction in AF patients with 
cardiomyopathy when tachycardia-induced 
component is highly probable, independent of their 
symptom status.405,407,408,499–501
I
B
Maintenance of sinus rhythm rather than rate control 
should be considered at an early stage for patients 
with a cardiomyopathy and AF without major risk 
factors for recurrence, regardless of symptoms.402
IIa
C
Atrial fibrillation catheter ablation should be 
considered as first-line rhythm control therapy to 
improve symptoms in selected patients with 
cardiomyopathy and paroxysmal or persistent AF 
without major risk factors for recurrences as an 
alternative to class I or III AADs, considering patient 
choice, benefit, and risk.392,393,480,502–506
IIa
C
Atrial fibrillation catheter ablation should be 
considered in selected patients with cardiomyopathy, 
AF, and heart failure and/or reduced LVEF to prevent 
AF recurrences and improve QoL, LVEF, and survival 
and reduce heart failure hospitalization.399–401,403– 
408,499–501,507
IIa
B
Comorbidities and associated risk factors management
Modification of unhealthy lifestyle and targeted 
therapy of intercurrent conditions is recommended 
to reduce AF burden and symptom severity in 
patients with cardiomyopathy.347,508–513
I
B
© ESC 2023
AAD, antiarrhythmic drug; AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular 
cardiomyopathy; CHA2DS2-VASc, congestive heart failure or left ventricular dysfunction, 
hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74, 
sex category (female) (score); DCM, dilated cardiomyopathy; HCM, hypertrophic 
cardiomyopathy; LV, left ventricular; LVEF, left ventricular ejection fraction; NDLVC, 
non-dilated left ventricular cardiomyopathy; QoL, quality of life; RCM, restrictive 
cardiomyopathy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 43 -->

### Page 43

require several replacements during their lifetimes. Implantable cardio­
verter defibrillators reduce mortality in survivors of cardiac arrest and 
in patients who have experienced haemodynamically compromising 
sustained ventricular arrhythmias.521–523 An ICD is recommended in 
such patients when the intent is to increase survival; the decision to im­
plant should consider the patient’s view and their QoL, as well as the 
absence of other diseases likely to cause death within the following 
year.
Arrhythmic risk calculators may be useful tools to predict the risk of 
SCD and, where available, they may provide a clinical benefit compared 
with a risk factor approach.524–526 The issue of the threshold for ICD 
implantation may be a reasonable concern as every cut-off point comes 
with a trade-off between unnecessary ICDs with their potential compli­
cations vs. the potential for unprotected SCD. The relative weight of 
these opposing undesirable events varies significantly from one person 
to another and should be part of the individualized decision-making 
process. Risk stratification strategies in each cardiomyopathy and the 
role of ICDs for primary prevention are discussed in Section 7.
The 2022 ESC Guidelines for the management of patients with ventricu­
lar arrhythmias and the prevention of sudden cardiac death provide de­
tailed recommendations regarding optimal device programming and 
prevention/treatment of inappropriate therapy. The implantation of 
conditional devices is reasonable taking into account the expected 
need for CMR during follow-up. In children, simpler ICD devices (e.g. 
single chamber/single coil or subcutaneous) should be considered, bear­
ing in mind specific issues of body size/shape and growth. The wearable 
cardioverter defibrillator has been shown to detect and treat ventricu­
lar arrhythmias successfully.527 However, data on its benefit for primary 
prevention other than the early phase of myocardial infarction (e.g. 
myocarditis, PPCM etc.) are scarce and no recommendation can be 
made at present.
Recommendation Table 12 — Recommendations for 
implantable cardioverter defibrillator in patients with 
cardiomyopathy
Recommendations
Classa
Levelb
General recommendations
Implantation of a cardioverter defibrillator is only 
recommended in patients who have an expectation 
of good quality survival >1 year.
I
C
It is recommended that ICD implantation be guided 
by shared decision-making that: 
• is evidence-based;
• considers a person’s individual preferences, beliefs, 
circumstances, and values; and
• ensures that the person understands the benefits, 
harms, and possible consequences of different 
treatment options.c
I
C
It is recommended that prior to ICD implantation, 
patients are counselled on the risk of inappropriate 
shocks, implant complications, and the social, 
occupational, and driving implications of the device.
I
C
It is not recommended to implant an ICD in patients 
with incessant ventricular arrhythmias until the 
ventricular arrhythmia is controlled.
III
C
Continued 
Secondary prevention
Implantation of an ICD is recommended:d
• in patients with HCM, DCM, and ARVC who have 
survived a cardiac arrest due to VT or VF, or who 
have spontaneous sustained ventricular arrhythmia 
causing syncope or haemodynamic compromise in 
the absence of reversible causes.528–534
I
B
• in patients with NDLVC and RCM who have 
survived a cardiac arrest due to VT or VF, or who 
have spontaneous sustained ventricular arrhythmia 
causing syncope or haemodynamic compromise in 
the absence of reversible causes.
I
C
ICD implantation should be considered in patients with 
cardiomyopathy presenting with haemodynamically 
tolerated VT, in the absence of reversible causes.
IIa
C
Primary prevention
Comprehensive SCD risk stratification is 
recommended in all cardiomyopathy patients who 
have not suffered a previous cardiac arrest/sustained 
ventricular arrhythmia at initial evaluation and at 1–2 
year intervals, or whenever there is a change in 
clinical status.
I
C
The use of validated SCD algorithms/scores as aids to the shared 
decision-making when offering ICD implantation, where available:e
• is recommended in patients with HCM.81,525,535
I
B
• should be considered in patients with DCM, 
NDLVC, and ARVC.185,186,524,526,536–542
IIa
B
If a patient with cardiomyopathy requires pacemaker 
implantation, comprehensive SCD risk stratification 
to evaluate the need for ICD implantation should be 
considered.
IIa
C
Choice of ICD
When an ICD is indicated, it is recommended to 
evaluate whether the patient could benefit from 
CRT.533
I
A
Subcutaneous defibrillators should be considered as 
an alternative to transvenous defibrillators in patients 
with an indication for an ICD when pacing therapy 
for bradycardia, cardiac resynchronization, or 
antitachycardia pacing is not anticipated.543
IIa
B
The wearable cardioverter defibrillator should be 
considered for adult patients with a secondary 
prevention ICD indication who are temporarily not 
candidates for ICD implantation.
IIa
C
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; CRT, cardiac resynchronization 
therapy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICD, 
implantable 
cardioverter 
defibrillator; 
NDLVC, 
non-dilated 
left 
ventricular 
cardiomyopathy; RCM, restrictive cardiomyopathy; SCD, sudden cardiac death; VF, 
ventricular fibrillation; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence. 
cShared decision-making is greatly enhanced by patient decision aids tailored specifically to 
receivers of care as well as more traditional decision-support tools for healthcare 
practitioners. 
dThe difference in level of evidence reflects the different levels of evidence available for the 
various cardiomyopathy phenotypes. 
eThe difference in class of recommendation reflects different performance of available 
models for different cardiomyopathy phenotypes.
ESC Guidelines                                                                                                                                                                                          3545


<!-- PAGE 44 -->

### Page 44

6.10.6. Routine follow-up of patients with 
cardiomyopathy
In general, patients with cardiomyopathy require lifelong follow-up to 
detect changes in symptoms, risk of adverse events, ventricular func­
tion, and cardiac rhythm.
The frequency of monitoring is determined by the severity of disease, 
age, and symptoms. A clinical examination, including 12-lead ECG and 
TTE, should be performed every 1–2 years, or sooner should patients 
complain of new symptoms. Ambulatory electrocardiography is re­
commended every 1–2 years in most patients to detect asymptomatic 
atrial and ventricular arrhythmia, and is indicated whenever patients 
experience syncope or palpitations. Cardiac magnetic resonance evalu­
ation should be considered every 2–5 years or more frequently in pa­
tients with progressive disease (see Section 6.7.3). Cardio-pulmonary 
exercise testing can provide objective evidence for worsening disease 
but need only be performed every 2–3 years unless there is a change 
in symptoms. Ergometry and treadmill exercise testing may also pro­
vide valuable functional information in patients unable to perform 
CPET.
6.11. Family screening and follow-up 
evaluation of relatives
All first-degree relatives of patients with cardiomyopathy should be of­
fered clinical screening with ECG and cardiac imaging (echocardiogram 
[ECHO] and/or CMR). In families in whom a disease-causing genetic 
variant has been identified, cascade genetic testing should be offered 
(see Section 6.8.3). Individuals found not to carry the familial variant 
and who do not have a clinical phenotype can usually be discharged, 
with advice to seek re-assessment if they develop symptoms or when 
new clinically relevant data emerge in the family. Those relatives har­
bouring the familial genetic variant(s) should undergo regular clinical 
evaluation with ECG, multimodality cardiac imaging, and additional in­
vestigations (e.g. Holter monitoring) guided by age, family phenotype, 
and genotype (Figure 11). Similarly, if a genetic cause of the disease 
has not been identified, either because P/LP variants are absent in the 
proband or because genetic testing has not been performed, clinical 
follow-up of all first-degree relatives is recommended; in families with­
out a known disease-causing variant, children should be offered ongoing 
clinical surveillance, due to age-related penetrance, and ongoing surveil­
lance should also be offered to adult relatives dependent on family 
history and other factors. In families where there is only one affected 
individual and where no genetic variant has been identified, the fre­
quency and duration of clinical follow-up may be reduced (see 
Figure 11).
Generally, the frequency of the clinical cardiac evaluation in relatives 
will be based on the inheritance pattern, the risk of events in the af­
fected individual(s), and the quality-adjusted life-year. It would also de­
pend on age, type of cardiomyopathy, and family history (penetrance, 
phenotype expression, and risk of complications in affected relatives).
Disease-penetrance studies have demonstrated a similar sigmoid 
shape pattern of phenotypic expression throughout life in families 
with confirmed genetic cardiomyopathies. The penetrance during child­
hood is ∼5% during the first decade of life, increasing to 10–20% per 
decade from the second to the seventh decades, after which the slope 
flattens to 5–10% in the last decades, although up to 25% of diagnoses 
can be made in individuals older than 65 years in some populations.544
The slope in childhood and early adulthood can be steeper (20% per 
decade) and similar to that in middle age for HCM, where male sex, sub­
tle ECG abnormalities, and particular genes are predictors of disease 
expression during follow-up.178
Penetrance in most cardiomyopathies is incomplete, reaching 
70–90% by the age of 70 years in families with cardiomyopathy.178
Recommendation Table 13 — Recommendations for 
routine follow-up of patients with cardiomyopathy
Recommendations
Classa
Levelb
It is recommended that all clinically stable patients 
with cardiomyopathy undergo routine follow-up 
using a multiparametric approach that includes ECG 
and echocardiography every 1 to 2 years.
I
C
Clinical evaluation with ECG and multimodality 
imaging is recommended in patients with 
cardiomyopathy whenever there is a substantial or 
unexpected change in symptoms.
I
C
© ESC 2023
ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 14 — Recommendations for 
family screening and follow-up evaluation of relatives
Recommendations
Classa
Levelb
Following cascade genetic testing, clinical evaluation 
using a multiparametric approach that includes ECG 
and cardiac imaging and long-term follow-up is 
recommended in first-degree relatives who have the 
same disease-causing variant as the 
proband.178,544,547
I
B
Following cascade genetic testing, it is recommended 
that first-degree relatives without a phenotype who 
do not have the same disease-causing variant as the 
proband are discharged from further follow-up but 
advised to seek re-assessment if they develop 
symptoms or when new clinically relevant data 
emerge in the family.
I
C
It is recommended that when no P/LP variant is 
identified in the proband or genetic testing is not 
performed, an initial clinical evaluation using a 
multiparametric approach that includes ECG and 
cardiac imaging is performed in first-degree relatives.
I
C
When no P/LP variant is identified in the proband or 
genetic testing is not performed, regular, long-term 
clinical evaluation using a multiparametric approach 
that includes ECG and cardiac imaging should be 
considered in first-degree relatives.
IIa
C
During cascade screening, where a first-degree 
relative has died, clinical evaluation of close relatives 
of the deceased individual (i.e. second-degree 
relatives of the index patient) should be considered.
IIa
C
© ESC 2023
ECG, electrocardiogram, P/LP, pathogenic/likely pathogenic. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 45 -->

### Page 45

With some exceptions using the current diagnostic criteria, the pene­
trance of the disease in women has been shown to be delayed (shifted) 
by 10 years compared with men.178,545–548
Cardiac screening in: (i) carriers of genetic P/LP variants associated 
with cardiomyopathies; or (ii) in those with demonstration of a familial 
disease should be offered from childhood to old age. The proposed fre­
quency of screening is every 1–3 years with ECG and ECHO (plus add­
itional tests where this is considered appropriate) before the age of 60 
years, and then every 3–5 years thereafter.
These recommendations apply to families affected by cardiomyop­
athy. The penetrance of similar variants identified outside this context 
is likely to be much lower, and the benefits and harm of screening and 
surveillance remain under evaluation.549–551
6.11.1. Special considerations in family screening
If the comprehensive study of the index cardiomyopathy patient (includ­
ing negative genetic testing) and first-degree relatives from informative 
families (i.e. with a large enough pedigree) leads to the conclusion that 
the cardiomyopathy presents in isolation (i.e. the index patient is the 
only individual affected), termination of periodic surveillance could be 
considered in first-degree relatives ≥50 years of age with normal cardiac 
investigations.
When the pattern of inheritance is likely to be, or is definitively, other 
than autosomal dominant, consideration for periodic evaluation of re­
latives should be individualized, e.g. (i) heterozygous carriers from clear 
recessive forms of cardiomyopathy could be discharged; (ii) heterozy­
gous carriers of X-linked disease may delay cardiac evaluation, as
Genetic testing results
Variant status
Phenotype
Genetic testing in proband
P/LP variant
Variant positive
+/- clinical phenotype
Variant negative
Long-term follow-up
(Class I)
Discharge
(Class I)
Cardiomyopathy phenotype
Normal
Long-term follow-up
(Class I)
Repeat screening at regular intervalsa
(Class IIa)
VUS
No variant/genetic testing not performed
Reconsider other causes
Segregation analysis/functional studies where possible
Cascade clinical and genetic testing
(Class I)
Cascade clinical screening
(Class I)
Figure 11 Algorithm for the approach to family screening and follow-up of family members. P/LP, pathogenic/likely pathogenic, VUS, variant of unknown 
significance. aIf no additional affected relatives and no variant identified on genetic testing, consider earlier termination of clinical screening.
ESC Guidelines                                                                                                                                                                                          3547


<!-- PAGE 46 -->

### Page 46

phenotype may express later in life; and (iii) follow-up in families with 
more than one likely or definitively pathogenic variant (oligo- 
polygenicity) should be discussed in the cardiomyopathy team.
6.12. Psychological support in 
cardiomyopathy patients and family 
members
Adjusting to a diagnosis of an inherited cardiomyopathy can pose a psy­
chosocial challenge. This includes coming to terms with a new diagnosis, 
exclusion from competitive sports, or living with the small risk of 
SCD.205 While studies show patients with inherited cardiomyopathies 
adjust well following an ICD, there is an important subgroup who do 
require additional support.552–556 The decision to have an ICD, and liv­
ing with the device, can also pose psychological challenges, especially in 
those who are young or who have experienced multiple shocks and/or 
have poor baseline psychosocial functioning.553,554,557 The SCD of a 
young relative not only leads to profound grief, but one in two relatives 
report post-traumatic stress or prolonged grief on average 6 years after 
the death.558 Clinical psychological support for patients and their fam­
ilies affected by inherited cardiomyopathies is an important aspect of 
the multidisciplinary team’s care approach and should be available as re­
quired.559 Clinicians should be aware of the potential for poor psycho­
logical outcomes and should have a low threshold for referral.
Psychological challenges for patients and their family members are 
summarized in Table 16. While many patients and family members 
will benefit from psychosocial counselling provided by any number of 
healthcare professionals, it is important to highlight that for some, 
treatment by a trained professional such as a clinical psychologist is 
required.
Table 16 Psychological considerations
Patient group
Psychological considerations 
New diagnosis
• Stigma associated with cardiovascular disease and misconception that it only affects older people.
• Fear of sudden cardiac death can shake confidence and create anxiety around exercise.
• Fear of inheritance risk to other relatives, especially children.
• Confidence and self-efficacy to manage their disease.
• Direct experience with the disease will affect perceptions about prognosis.211
ICD
• Most patients will adjust well following ICD insertion, although there might be an initial decline in health-related quality of life and 
psychological well-being, this often returns to normal.552,560,561
• Up to 30% will develop anxiety and/or symptoms of post-traumatic stress and need additional support.562
• Those who are young, who experience multiple ICD shocks, and/or have poor baseline psychological functioning are at greater risk 
of poor psychological outcomes.553–555,561,563
• In young people, especially women, body image concerns can be a major consideration.554
• Decision-making for those recommended to have an ICD should be patient-centred and include balanced discussion of benefits 
and risks and careful attention to questions and concerns.564
Exercise restrictions
• Physical inactivity is a major determinant of poor health outcomes.
• Can reduce health-related quality of life for those who become fearful of performing even low-intensity exercise.
• Athletes who are recommended to reduce their activity levels can experience a profound grief and difficulty adjusting to this 
advice.565
• Patient-centred discussions and careful attention to concerns is critical in helping to support people make drastic lifestyle 
changes.566–568
Family history of young 
SCD
• Relatives who experience the SCD of a young relative have significant risk of poor psychological functioning, including 
post-traumatic stress and prolonged grief.558
• Grief is a normal response to a loss. Prolonged grief occurs when the grieving process becomes ‘stuck’.569
• Those who witness the death or discover the decedents body have a greater risk of psychological difficulties.558
• Mothers of the decedent have greater anxiety.558
• Psychological support for family members is an important and often unmet need following a young SCD.570,571
Children and adolescents
• Diagnosis during childhood can raise anxiety especially among parents. Access to resources to support practical issues like 
information for schools is important.
• Navigating transition from paediatric to adult care can be challenging for children and their families.
• Decision-making regarding genetic testing of asymptomatic children can often benefit from the inclusion of a clinical psychologist to 
support adjustment to the result.
Symptomatic disease
• Those managing symptoms will likely perceive a greater impact on their health-related quality of life. Factors influencing self-efficacy 
will impact on a patient’s ability to manage their disease, including medication adherence.572
• Need for major intervention such as cardiac transplantation can raise significant psychological challenges and clinical psychological 
support is very important.573
Genetic testing
• Despite potential adjustment issues, most patients who undertake genetic testing do not report distress.574
• Genetic counselling should cover any psychosocial concerns or needs.204
• Additional support to patients to convey the genetic risk information to at-risk family members should be provided as necessary.575
© ESC 2023
ICD, implantable cardioverter defibrillator; SCD, sudden cardiac death.


<!-- PAGE 47 -->

### Page 47

6.13. The patient pathway
The systematic, multiparametric approach to diagnosis and evaluation 
of patients with suspected cardiomyopathy described in this section al­
lows clinicians to establish the presence of a cardiomyopathy and iden­
tify its aetiology and guides the management of symptoms and 
prevention of disease-related complications. While many of the aspects 
of clinical care and the accompanying recommendations are common 
to all cardiomyopathy phenotypes, achieving an aetiological diagnosis 
is key to delivering disease-specific management; this is discussed in de­
tail in the subsequent sections of this guideline (see Section 7).
7. Specific cardiomyopathy 
phenotypes
7.1. Hypertrophic cardiomyopathy
The 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy provide detailed recommendations on the assessment 
and management of patients with HCM.1 The aim in this guideline is 
to provide a focused update to the 2014 document, highlighting novel 
aspects and signposting the reader to the assessment and management 
of HCM in adults and children. Further details to support the recom­
mendations are available in Supplementary data online, Table S1.
7.1.1. Diagnosis
7.1.1.1. Diagnostic criteria
Adults: in an adult, HCM is defined by an LV wall thickness ≥15 mm in 
any myocardial segment that is not explained solely by loading condi­
tions. Lesser degrees of wall thickening (13–14 mm) require evaluation 
of other features including family history, genetic findings, and ECG 
abnormalities.
Children: the diagnosis of HCM requires an LV wall thickness more than 
2 standard deviations greater than the predicted mean (z-score >2).578
Relatives: the clinical diagnosis of HCM in adult first-degree relatives 
of patients with unequivocal disease is based on the presence of LV wall 
thickness ≥13 mm. In child first-degree relatives with LV wall thickness 
z-scores of <2, the presence of associated morphological or ECG ab­
normalities should raise the suspicion but are not on their own diagnos­
tic for HCM.
7.1.1.2. Diagnostic work-up
The initial work-up for HCM includes personal and family history, phys­
ical examination, electrocardiography, cardiac imaging, and first-line la­
boratory tests, as described in Section 6.
7.1.1.3. Echocardiography
As increased ventricular wall thickness can be found at any location (in­
cluding the right ventricle), the presence, distribution, and severity of 
hypertrophy should be documented using a standardized protocol 
for cross-sectional imaging from several projections.579 Table 17 sum­
marizes the key imaging features to assess in patients with suspected 
or confirmed HCM. Several imaging features can point to a specific diag­
nosis (Table 18 and Section 6).62
Identification of LVOTO is important in the management of 
symptoms and assessment of SCD risk (see Section 7.1.5). 
Two-dimensional and Doppler echocardiography during a Valsalva 
manoeuvre in the sitting and semi-supine position—and then on 
standing if no gradient is provoked—is recommended in all patients 
(Figure 12).587,588 Exercise stress echocardiography is recom­
mended in symptomatic patients if bedside manoeuvres fail to in­
duce LVOTO ≥50 mmHg. Pharmacological provocation with 
dobutamine is not advised, as it is not physiological and can be 
poorly tolerated.
Recommendation Table 15 — Recommendations for 
psychological support in patients and family members 
with cardiomyopathies
Recommendations
Classa
Levelb
It is recommended that psychological support by an 
appropriately trained health professional be offered 
to all individuals who have experienced the 
premature sudden cardiac death of a family member 
with cardiomyopathy.558,570,571,576,577
I
B
It is recommended that psychological support by an 
appropriately trained health professional be offered 
to all individuals with an inherited cardiomyopathy 
who receive an implantable cardioverter 
defibrillator.552–556,561,563
I
B
Psychological support by an appropriately trained 
health professional should be considered in all 
patients and families with an inherited 
cardiomyopathy and in particular for those issues 
described in the text.c
IIa
C
© ESC 2023
aClass of recommendation. 
bLevel of evidence. 
cSee Table 16.
Recommendation Table 16 — Recommendation for 
evaluation of left ventricular outflow tract obstruction
Recommendations
Classa
Levelb
In all patients with HCM, at initial evaluation, 
transthoracic 2D and Doppler echocardiography are 
recommended, at rest and during Valsalva 
manoeuvre in the sitting and semi-supine positions— 
and then on standing if no gradient is provoked—to 
detect LVOTO.84,86,365,525,584,587,589–594
I
B
In symptomatic patients with HCM and a resting or 
provokedc peak instantaneous LV outflow tract 
gradient <50 mmHg, 2D and Doppler 
echocardiography during exercise in the standing, 
sitting (when possible), or semi-supine position are 
recommended to detect provocable LVOTO and 
exercise-induced mitral regurgitation.588,595–598
I
B
Transoesophageal echocardiography should be 
considered in patients with HCM and LVOTO if the 
mechanism of obstruction is unclear or when 
assessing the mitral valve apparatus before a septal 
reduction procedure, or when severe mitral 
regurgitation caused by intrinsic valve abnormalities 
is suspected.599–602
IIa
C
Continued 
ESC Guidelines                                                                                                                                                                                          3549


<!-- PAGE 48 -->

### Page 48

7.1.1.4. Cardiac magnetic resonance
Cardiac magnetic resonance is recommended in patients with HCM at 
their baseline assessment (general recommendations are described in 
Section 6.7.3 and Recommendation Table 5). CMR imaging can be par­
ticularly helpful in patients with suspected apical or lateral wall hyper­
trophy or LV apical aneurysm. Table 17 summarizes the main 
features to be assessed.
Late gadolinium enhancement is present in 65% of patients (range 
33–84%), typically in a patchy mid-wall pattern in areas of hypertrophy 
and at the anterior and posterior RV insertion points.604 Late gadolin­
ium enhancement is unusual in non-hypertrophied segments except in 
advanced stages of disease, when full-thickness LGE in association with 
wall thinning is common.604 Late gadolinium enhancement may be as­
sociated with increased myocardial stiffness and adverse LV
remodelling and the extent of LGE is associated with a higher incidence 
of RWMAs. Late gadolinium enhancement varies substantially with the 
quantification method used but the 2-standard deviation technique is 
the only one validated against necropsy.605
Although CMR rarely distinguishes the causes of HCM by their 
magnetic properties alone, the distribution and severity of intersti­
tial expansion can, in context, suggest specific diagnoses (see Section 
6). The absence of fibrosis may be helpful in differentiating HCM 
from physiological adaptation in athletes, but LGE may be absent 
in people with HCM, particularly young people and those with 
mild disease.
Table 17 Imaging evaluation in hypertrophic cardiomyopathy
Item to assess
Primary imaging 
modality
Comments
LV wall thickness
ECHO/CMR
• All LV segments from base to apex examined in end-diastole, preferably in the 2D short-axis view, 
ensuring that the wall thickness is recorded at mitral, mid-LV, and apical levels.
• CMR is superior in the detection of LV apical and anterolateral hypertrophy, aneurysms,580 and 
thrombi,581 and is more sensitive in the detection of subtle markers of disease in patients with 
sarcomeric protein gene variants (e.g. myocardial crypts, papillary muscle abnormalities).159,582,583
Systolic function (global 
and regional)
ECHO/CMR
• Ejection fraction is a suboptimal measure of LV systolic performance when hypertrophy is present.
• Doppler myocardial velocities and deformation parameters (strain and strain rate) are typically reduced 
at the site of hypertrophy despite a normal EF and may be abnormal before the development of 
increased wall thickness in genetically affected patients.
Diastolic function
ECHO
• Routine examination should include mitral inflow assessment, tissue Doppler imaging, pulmonary vein 
flow velocities, pulmonary artery systolic pressure, and LA size/volume.
Mitral valve
ECHO
• Assess presence and degree of SAM and mitral regurgitation. The presence of a central- or anteriorly 
directed jet of mitral regurgitation should raise suspicion of an intrinsic/primary mitral valve abnormality 
and prompt further assessment.
LVOT
ECHO
• See Figure 12.
LA dimensions
ECHO/CMR
• Provides important prognostic information.365,525,584
• Most common mechanisms of LA enlargement are SAM-related mitral regurgitation and elevated LV 
filling pressures.
Myocardial fibrosis/LGE
CMR
• The distribution and severity of interstitial expansion can suggest specific diagnoses. Anderson–Fabry 
disease is characterized by a reduction in non-contrast T1 signal and the presence of posterolateral 
LGE.134,155 In cardiac amyloidosis, there is often global, subendocardial or segmental LGE and a highly 
specific pattern of myocardial and blood-pool gadolinium kinetics caused by similar myocardial and 
blood T1 signals.585,586
© ESC 2023
2D, two-dimensional; CMR, cardiac magnetic resonance; ECHO, echocardiogram; EF, ejection fraction; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricular; LVOT, left 
ventricular outflow tract; SAM, systolic anterior motion; SCD, sudden cardiac death.
In symptomatic patients with HCM and inconclusive 
non-invasive cardiac imaging, left and right heart 
catheterization may be considered to assess the 
severity of LVOTO and to measure LV filling 
pressures.603
IIb
C
© ESC 2023
2D, two-dimensional; HCM, hypertrophic cardiomyopathy; LV, left ventricular; LVOTO, 
left ventricular outflow tract obstruction. 
aClass of recommendation. 
bLevel of evidence. 
cProvocation with Valsalva, standing, or oral nitrate.
Recommendation Table 17 — Additional recommen­
dation for cardiovascular magnetic resonance evaluation 
in hypertrophic cardiomyopathy
Recommendation
Classa
Levelb
Contrast-enhanced CMR may be considered before 
ASA or myectomy to assess the extent and 
distribution of hypertrophy and myocardial 
fibrosis.606,607
IIb
C
© ESC 2023
ASA, alcohol septal ablation; CMR, cardiac magnetic resonance. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 49 -->

### Page 49

7.1.1.5. Nuclear imaging
The major clinical contribution of nuclear imaging in HCM is the detec­
tion of TTR-related cardiac amyloidosis (see Section 7.7). 
Recommendations on the utility of bone scintigraphy and cardiac CT 
are described in Section 6.7.4.
7.1.2. Genetic testing and family screening
In about half of cases, HCM is inherited as a Mendelian genetic trait. In 
such cases, the inheritance is primarily autosomal dominant, i.e. with a 
50% risk of transmission to offspring.608 Apparently sporadic cases can 
have a monogenic cause, either because of incomplete penetrance of a 
Table 18 Echocardiographic features that suggest specific aetiologies in hypertrophic cardiomyopathy
Finding
Specific diseases to be considered
Increased interatrial septum thickness
Amyloidosis
Increased AV valve thickness
Amyloidosis; Anderson–Fabry disease
Increased RV free wall thickness
Amyloidosis, myocarditis, Anderson–Fabry disease, Noonan syndrome, and related disorders
Mild-to-moderate pericardial effusion
Amyloidosis, myocarditis/myopericarditis
Ground-glass appearance of ventricular myocardium 
on 2D echocardiography
Amyloidosis
Concentric LVH
Glycogen storage disease, Anderson–Fabry disease, PRKAG2 variants, Friedreich ataxia
Extreme concentric LVH (wall thickness ≥30 mm)
Danon disease, Pompe disease
Global LV hypokinesia (with or without LV dilatation)
Mitochondrial disease, TTR-related amyloidosis, PRKAG2 variants, Danon disease, myocarditis, advanced 
sarcomeric HCM, Anderson–Fabry disease, Friedreich ataxia
RVOTO
Noonan syndrome and associated disorders
Apical sparing pattern on longitudinal strain imaging
Amyloidosis
© ESC 2023
2D, two-dimensional; AV, atrioventricular; HCM, hypertrophic cardiomyopathy; LV, left ventricular; LVH, left ventricular hypertrophy; PRKAG2, protein kinase AMP-activated non-catalytic 
subunit gamma 2; RV, right ventricular; RVOTO, right ventricular outflow tract obstruction; TTR, transthyretin. 
Modified from Rapezzi et al.62
N
N
2D and Doppler echocardiography at rest,  Valsalva manoeuvre, and standing
Maximum provoked peak
LVOTO ≥50 mmHg
Maximum provoked peak
LVOTO ≥50 mmHg
Symptoms
Exercise stress echocardiogram
(Class I)
Repeat echocardiogram at 1 year see LVOTO management
Medical therapy
Y
Y
Asymptomatica
Symptomatic
Figure 12 Protocol for the assessment and treatment of left ventricular outflow tract obstruction. 2D, two-dimensional; LVOTO, left ventricular outflow 
tract obstruction. aExercise echocardiography may be considered in individual patients when the presence of an left ventricular outflow tract gradient is 
relevant to lifestyle advice and decisions on medical treatment.
ESC Guidelines                                                                                                                                                                                          3551


<!-- PAGE 50 -->

### Page 50

variant inherited from a parent or due to de novo variants that were not 
carried by the parents or, less commonly, due to autosomal recessive 
inheritance. In those who undergo genetic testing, ∼40–60% will have 
a single variant identified as the cause of their disease, although this is 
influenced by the cohort studied.124 The likelihood of finding a causal 
variant is highest in young patients with familial disease and lowest 
in older patients and individuals with non-classical features. 
Phenotype-based scores to predict genetic yield in HCM have been de­
veloped and may be used to prioritize genetic testing where resources 
are limited.609,610 Genes with definitive evidence for gene–disease asso­
ciation with HCM are summarized in Table 10. An important subgroup 
characterized by no identifiable monogenic variant, no family history of 
disease and often being older, more likely to be male and with a history 
of hypertension, and less risk of major cardiovascular events is likely to 
be underlied by complex aetiology.238,611,612
Less than 5% of adult patients, but up to 25% of children, with HCM, 
will have a causative variant in a gene that is known to mimic the HCM 
phenotype. Such genocopies can have clinically important differences 
such as altered inheritance risks, and management and therapy options. 
The aetiology of HCM in childhood is more heterogeneous than that 
seen in adult populations, and includes inborn errors of metabolism, 
malformation syndromes, and neuromuscular disorders.613–615 Most 
cases of HCM in childhood, however, are caused by variants in the car­
diac sarcomere protein genes, inherited as autosomal dominant 
traits.616,617 The relative prevalence of different HCM aetiologies varies 
according to age: HCM related to inborn errors of metabolism and mal­
formation syndromes is most commonly diagnosed in the first 2 years 
of life, whereas HCM due to neuromuscular disorders (e.g. Friedreich 
ataxia) most commonly presents in adolescence.613–615 Outside of 
infancy, sarcomere protein gene variants account for 55–75% of cases 
of childhood-onset HCM,616–619 and even in infancy, sarcomeric dis­
ease is present in up to 40% of cases.616,620 Although rarer, inborn er­
rors of metabolism and malformation syndromes can also present for 
the first time in older children and adolescents (see Section 7.6).614
A thorough and comprehensive diagnostic work-up is essential in the 
diagnosis of childhood-onset HCM in order to confirm the diagnosis, 
identify the underlying aetiology, and guide treatment (see Section 6).
Recommendations for clinical screening, genetic counselling, and 
testing are described in Sections 6.8.3 and 6.11, respectively.
7.1.3. Assessment of symptoms
Most people with HCM are asymptomatic and have a normal lifespan, 
but some develop symptoms, often many years after the appearance of 
ECG or echocardiographic evidence of LVH. Assessment of symptoms 
in patients with cardiomyopathies is described in Section 6.4. 
Assessment of LVOTO, as outlined in Figure 12, should be part of 
the routine evaluation of all symptomatic patients.
7.1.4. Management of symptoms and complications
In the absence of many randomized trials,621–623 pharmacological ther­
apy is mostly administered on an empirical basis to improve functional 
capacity and reduce symptoms. In symptomatic patients with LVOTO, 
the aim is to improve symptoms by using drugs, surgery, or alcohol sep­
tal ablation. Therapy in symptomatic patients without LVOTO focuses 
on management of arrhythmia, reduction of LV filling pressures, and 
treatment of angina. Patients with progressive LV systolic or diastolic 
dysfunction refractory to medical therapy may be candidates for car­
diac transplantation (Figure 13).
N
N
Patient with heart failure  NYHA II–IV
Atrial fibrillation
LVEF value
LVOTO management
Rate/rhythm control
Anticoagulation
Still symptomatic
Consider MCS/cardiac transplantation
Beta-blockers, ACEi, ARB
MRA, ARNI, SGLT2i
Low-dose diuretics
Beta-blockers,
verapamil, diltiazem
Low-dose diuretics
Resting/provocable
LVOTO ≥50 mmHg?
Y
Y
≥50%
<50%
Figure 13 Algorithm for the treatment of heart failure in hypertrophic cardiomyopathy. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; 
MCS, mechanical circulatory support; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SGLT2i, sodium–glucose co- 
transporter 2 inhibitor.Image %:


<!-- PAGE 51 -->

### Page 51

7.1.4.1. Management of left ventricular outflow tract obstruction
By convention, LVOTO is defined as a peak instantaneous Doppler LV 
outflow tract gradient of ≥30 mmHg, but the threshold for invasive 
treatment is usually considered to be ≥50 mmHg (the threshold at 
which theoretical models examining the relationship between the gra­
dient and stroke volume predict that this becomes haemodynamically 
significant).587,624,625 Most patients with a maximum resting or pro­
voked LV outflow tract gradient <50 mmHg should be managed in ac­
cordance with the recommendations for non-obstructive HCM but, in 
a very small number of selected cases with LV outflow tract gradients 
between 30 and 50 mmHg and no other obvious cause of symptoms, 
invasive gradient reduction may be considered, acknowledging that 
data covering this group are lacking. Most asymptomatic patients 
with LVOTO do not require treatment but, in a very small number 
of selected cases, pharmacological treatment to reduced LV pressures 
may be considered.626,627
7.1.4.1.1. General measures. All patients with LVOTO should avoid 
dehydration and excess alcohol consumption, and weight loss should 
be encouraged. Arterial and venous dilators, including nitrates and 
phosphodiesterase type 5 inhibitors, can exacerbate LVOTO and 
should be avoided if possible (see Section 12.2).626 New-onset or 
poorly controlled AF can exacerbate symptoms caused by LVOTO 
and should be managed by prompt restoration of sinus rhythm or ven­
tricular rate control.628
7.1.4.1.2. Drug therapy. Figure 14 describes the management of 
LVOTO in patients with HCM. By consensus, patients with symptom­
atic LVOTO have been treated initially with non-vasodilating beta- 
blockers titrated to the maximum tolerated dose, but there are very 
few studies comparing individual beta-blockers. A recent small, rando­
mized placebo-controlled trial showed reduction of resting and exer­
tional LVOTO, and improvement in symptoms and QoL with 
metoprolol therapy.631
If beta-blockers alone are ineffective, disopyramide, titrated up to a 
maximum tolerated dose (usually 400–600 mg/day), may be 
added.632–634 This class IA AAD can abolish basal LV outflow pressure 
gradients and improve exercise tolerance and functional capacity with a 
low risk of proarrhythmic effects and without an increased risk of 
SCD.632,633 Dose-limiting anticholinergic side effects include dry eyes 
and mouth, urinary hesitancy or retention, and constipation.632,633,635
The QTc interval should be monitored during dose up-titration and 
the dose reduced if it exceeds 500 ms. Disopyramide should be avoided 
in patients with glaucoma, in men with prostatism, and in patients taking 
other drugs that prolong the QT interval, such as amiodarone and so­
talol. Disopyramide may be used in combination with verapamil.633
Verapamil (starting dose 40 mg three times daily to maximum 
480 mg daily) can be used when beta-blockers are contraindicated or 
ineffective but, based on limited data, should be used cautiously in pa­
tients with severe obstruction (≥100 mmHg) or elevated pulmonary 
artery systolic pressures, as it may provoke pulmonary oedema.636
Short-term oral administration may increase exercise capacity, improve 
symptoms, and normalize or improve LV diastolic filling without altering 
systolic function.637–640 Similar findings have been demonstrated for dil­
tiazem (starting dose 60 mg three times daily to maximum 360 mg dai­
ly),641 and it should be considered in patients who are intolerant or 
have contraindications to beta-blockers and verapamil.
Low-dose loop or thiazide diuretics may be used cautiously to im­
prove dyspnoea associated with LVOTO, but it is important to avoid 
hypovolaemia.
Cardiac myosin ATPase inhibitors. Mavacamten is a first-in-class cardiac 
myosin adenosine triphosphatase (ATPase) inhibitor that acts by redu­
cing actin–myosin cross-bridge formation, thereby reducing contractil­
ity and improving myocardial energetics. In the recently published 
Clinical Study to Evaluate Mavacamten in Adults with Symptomatic 
Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM) trial, 
mavacamten reduced the left ventricular outflow tract (LVOT) gradient 
and improved exercise capacity compared with placebo in patients with 
HCM and symptomatic LVOTO (NYHA II–III and EF >55%); 27% of 
patients on mavacamten had an LVOT gradient reduction to 
<30 mmHg and improved to NYHA class I.622 The drug was well tol­
erated and has a good safety profile; only a small subset of patients de­
veloped transient LV systolic dysfunction, which resolved after 
temporary discontinuation of the drug. A second study (A Study to 
Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM 
Who Are Eligible for Septal Reduction Therapy [VALOR-HCM]) in 
adult patients with obstructive HCM referred for septal reduction ther­
apy (SRT) due to intractable symptoms showed that mavacamten sig­
nificantly reduced the proportion of patients meeting criteria for SRT 
at 16 and 32 weeks.642,643 Small CMR and ECHO substudies suggest 
that mavacamten may also lead to positive myocardial remodelling, 
with reduction in myocardial mass, LV wall thickness, and left atrial vol­
ume.644–646 Aficamten, a next-in-class cardiac myosin inhibitor, was 
also recently shown in a Phase II randomized placebo-controlled study 
(Randomized Evaluation of Dosing With CK-3773274 in Obstructive 
Outflow Disease in HCM [REDWOOD-HCM]) to significantly reduce 
LVOT gradients and NT-proBNP levels in adult patients with symp­
tomatic obstructive HCM.647
In the absence of a direct head-to-head comparison, the Task Force 
was unable to recommend the use of cardiac myosin ATPase inhibitors 
as first-line medical therapy, but did consider the evidence sufficiently 
robust to support the recommendation that their use as second-line 
therapy should be considered when optimal medical therapy with beta- 
blockers, calcium antagonists, and/or disopyramide is ineffective or 
poorly tolerated. In the absence of evidence to the contrary, cardiac 
myosin ATPase inhibitors should not be used with disopyramide, but 
may be coadministered with beta-blockers or calcium antagonists. 
Up-titration of medication to a maximum dose of 15 mg should be 
monitored in accordance with licensed recommendations using echo­
cardiography. In patients with contraindications or known sensitivity 
to beta-blockers, calcium antagonists, and disopyramide, cardiac my­
osin ATPase inhibitors may be considered as monotherapy.
Recommendation Table 18 — Recommendations for 
treatment of left ventricular outflow tract obstruction 
(general measures)
Recommendations
Classa
Levelb
Avoidance of digoxin and arterial and venous dilators, 
including nitrates and phosphodiesterase inhibitors, 
should be considered, if possible, in patients with 
resting or provocable LVOTO.626,627
IIa
C
Restoration of sinus rhythm or appropriate rate 
control should be considered before invasive 
management of LVOTO in patients with new-onset 
or poorly controlled AF.629,630
IIa
C
© ESC 2023
AF, atrial fibrillation; LVOTO, left ventricular outflow tract obstruction. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3553


<!-- PAGE 52 -->

### Page 52

Recommendation Table 19 — Recommendations for 
medical treatment of left ventricular outflow tract 
obstruction
Recommendations
Classa
Levelb
Non-vasodilating beta-blockers, titrated to 
maximum tolerated dose, are recommended as 
first-line therapy to improve symptoms in patients 
with resting or provokedc LVOTO.631–633,648–650
I
B
Verapamil or diltiazem, titrated to maximum 
tolerated dose, are recommended to improve 
symptoms in symptomatic patients with resting or 
provokedc LVOTO who are intolerant or have 
contraindications to beta-blockers.633,637–641
I
B
Disopyramide,d titrated to maximum tolerated dose, 
is recommended in addition to a beta-blocker (or, if 
this is not possible, with verapamil or diltiazem) to 
improve symptoms in patients with resting or 
provokedc LVOTO.632–634
I
B
Cardiac myosin ATPase inhibitor (mavacamten), 
titrated to maximum tolerated dose with 
echocardiographic surveillance of LVEF, should be 
considered in addition to a beta-blocker (or, if this is 
not possible, with verapamil or diltiazem) to improve 
symptoms in adult patients with resting or provokedc 
LVOTO.622,642–646
IIa
A
Continued 
N
Resting/provocable LVOTO ≥50 mmHg
Symptoms
Beta-blockers or verapamil may be considered
(Class IIb)
Beta-blockers
(Class I)
Verapamil
(Class I)
 Diltiazem
(Class I)
Septal reduction therapies
(Class I)
OR
Y
Still symptomatic or intolerant/contraindication to beta-blockers
Disopyramide
(Class I)
 Mavacamten
(Class IIa)
OR
Still symptomatic
Still symptomatic
Figure 14 Flow chart on the management of left ventricular outflow tract obstruction. LVOTO, left ventricular outflow tract obstruction.Image %:   
Cardiac myosin ATPase inhibitor (mavacamten), 
titrated to maximum tolerated dose with 
echocardiographic surveillance of LVEF, should be 
considered as monotherapy in symptomatic adult 
patients with resting or provokedc LVOTO (exercise 
or Valsalva manoeuvre) who are intolerant or have 
contraindications to beta-blockers, verapamil/ 
diltiazem, or disopyramide.622,644–646
IIa
B
Oral or i.v. beta-blockers and vasoconstrictors 
should be considered in patients with severe 
provocablec LVOTO presenting with hypotension 
and acute pulmonary oedema who do not respond 
to fluid administration.627
IIa
C
Disopyramide, titrated to maximum tolerated dose, 
may be considered as monotherapy in patients who 
are intolerant to or have contraindications to 
beta-blockers and verapamil/diltiazem to improve 
symptoms in patients with resting or provokedc 
LVOTO.632
IIb
C
Beta-blockers or verapamil may be considered in 
selected cases in asymptomatic patients with resting 
or provokedc LVOTO to reduce LV pressures.623,639
IIb
C
The cautious use of low-dose diuretics may be 
considered in symptomatic LVOTO to improve 
exertional dyspnoea.
IIb
C
© ESC 2023
ATPase, adenosine triphosphatase; i.v., intravenous; LV, left ventricular; LVEF, left 
ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction. 
aClass of recommendation. 
bLevel of evidence. 
cProvocation with Valsalva manoeuvre, upright exercise, or oral nitrates if unable to 
exercise. 
dQTc interval should be monitored during up-titration of disopyramide and the dose 
reduced if it exceeds 500 ms.


<!-- PAGE 53 -->

### Page 53

7.1.4.1.3. Invasive treatment of left ventricular outflow tract (septal 
reduction therapy). There are no data to support the use of invasive 
procedures to reduce LVOTO in asymptomatic patients, regardless 
of its severity. However, some retrospective data suggest that indivi­
duals with high LVOT gradients, even if minimally symptomatic, have 
a higher mortality than those without markedly elevated gradients.651
Delay in SRT may have an impact on long-term outcomes, particularly 
when >5 years from first detection of gradient, even when successful 
relief of symptoms and gradient is achieved. Earlier interventions may 
be associated with lower complication rates and better prognosis.652
Invasive treatment (SRT) to reduce LVOTO should be considered in 
patients with a LVOTO gradient ≥50 mmHg, severe symptoms 
(NYHA functional class III–IV), and/or exertional or unexplained recur­
rent syncope in spite of maximally tolerated drug therapy. Invasive ther­
apy may also be considered in patients with mild symptoms (NYHA 
class II) refractory to medical therapy who have a resting or maximum 
provoked gradient of ≥50 mmHg (exercise or Valsalva) and 
moderate-to-severe systolic anterior motion-related mitral regurgita­
tion, AF, or moderate-to-severe left atrial dilatation in expert centres 
with demonstrable low procedural complication rates.653
Surgery. The most commonly performed surgical procedure to treat 
LVOTO is ventricular septal myectomy, in which a rectangular trough 
that extends distally to beyond the point of the mitral leaflet–septal 
contact is created in the basal septum below the aortic valve.654 This
Assess alternative/additional explanations
Assess the mechanism of obstruction
Assess MV anatomy/function
Assess distribution and severity of hypertrophy
Obesity
Respiratory disease
Coronary artery disease
Anaemia
Thyroid disease
Arrhythmia (e.g.  AF)
Drug side effects
Systemic disease (e.g. amyloid)
RVOTO
Mid-cavity
Sub-aortic membrane
Aortic stenosis
Anomalous papillary muscle insertion
Accessory MV tissue
SAM related
MV prolapse
Other intrinsic MV abnormalities
Minimum anterior septal thickness 15 mm
1
2
3
4
Figure 15 Pre-assessment checklist for patients being considered for invasive septal reduction therapies. AF, atrial fibrillation; MV, mitral valve; RVOTO, 
right ventricular outflow tract obstruction; SAM, systolic anterior motion.
ESC Guidelines                                                                                                                                                                                          3555


<!-- PAGE 54 -->

### Page 54

abolishes or substantially reduces LV outflow tract gradients in over 
90% of cases, reduces systolic anterior motion-related mitral regurgita­
tion, and improves exercise capacity and symptoms. Long-term symp­
tomatic benefit is achieved in >80% of patients with a long-term survival 
comparable to that of the general population.655–665 Pre-operative de­
terminants of a good long-term outcome are age <50 years, left atrial 
size <46 mm, absence of AF, and male sex.663
The main surgical complications are AV nodal block, left bundle 
branch block (LBBB), ventricular septal defect, and aortic regurgitation, 
but these are uncommon (except LBBB) in experienced centres using 
intra-operative transoesophageal echocardiography guidance.662,666,667
When there is coexisting mid-cavity obstruction, the standard myect­
omy can be extended distally into the mid-ventricle around the base 
of the papillary muscles; however, data on the efficacy and long-term 
outcomes of this approach are limited.668
In patients with intrinsic/primary mitral valve disease or marked mi­
tral leaflet elongation and/or moderate-to-severe mitral regurgitation, 
septal myectomy can be combined with mitral valve repair or replace­
ment.669–675 In patients with AF, concomitant ablation using the Cox– 
Maze procedure can also be performed.676 In infants and very young 
children, the modified Konno procedure may be an alternative to 
myectomy when the aortic annulus is too small.677
Alcohol septal ablation (ASA). In experienced centres, selective injection 
of alcohol into a septal perforator artery to create a localized septal scar 
has outcomes similar to surgery in terms of gradient reduction, symptom 
improvement, and exercise capacity, including in younger adults.678–685 In 
many centres, ASA has become the primary SRT modality. The main non- 
fatal complication is AV block in 7–20% of patients, and the procedural 
mortality is lower than isolated myectomy.679–683,686,687
Due to the variability of the septal blood supply, myocardial contrast 
echocardiography is essential prior to alcohol injection. Injection of 
large volumes of alcohol in multiple septal branches—with the aim of 
gradient reduction—in the catheter laboratory is generally not recom­
mended, as it can be associated with a high risk of complications and 
arrhythmic events.688
Alternative methods have been reported in small numbers of pa­
tients, including non-ASA techniques (coils,689,690 polyvinyl alcohol 
foam particles,691 cyanoacrylate692) and direct endocavitary and intra­
muscular ablation (radiofrequency, cryotherapy).693,694 These alterna­
tive methods have not been directly compared with other septal 
reduction therapies and long-term outcome/safety data are not avail­
able. Alcohol septal ablation and alternative methods should not be 
used in children with HCM outside experimental settings, due to a 
lack of medium- to long-term safety and efficacy data.
Surgery vs. alcohol septal ablation. Because of specific anatomic fea­
tures of the LVOT and the mitral valve, some patients with HCM will 
be more suitable candidates for septal myectomy than ASA. 
Experienced multidisciplinary teams should assess all patients before 
intervention, as morbidity and mortality are highly dependent on the 
available level of expertise (see Section 9).687,695,696 A summary of the 
key points in pre-operative assessment is shown in Figure 15.
There are no randomized trials comparing surgery and ASA, but sev­
eral meta-analyses have shown that both procedures improve functional 
status with a similar procedural mortality.697–703 Alcohol septal ablation 
is associated with a higher risk of AV block, requiring permanent pace­
maker implantation, and larger residual LV outflow tract gradients.697– 
702 The risk of AV block following surgery and ASA is highest in patients 
with pre-existing conduction disease, and prophylactic permanent pacing 
before intervention has been advocated,704 although recent data suggest 
that the long-term outcome of patients after ASA with implanted per­
manent pacemaker is similar to those without pacemaker.705 Repeat 
ASA or myectomy procedure is reported in 7–20% of patients after 
ASA, which is higher than reported following surgical myectomy.702
Septal ablation may be less effective in patients with very severe hyper­
trophy (≥30 mm), but systematic data are limited.706 In general, the 
risk of ventricular septal defect following septal myectomy is very small 
and could be higher in patients with mild hypertrophy (≤16 mm) at 
the point of the mitral leaflet–septal contact. This risk is exceedingly 
rare with ASA, but alternatives such as dual-chamber pacing or mitral 
valve repair/replacement may also be considered in such cases.707
Recommendation Table 20 — Recommendations for 
septal reduction therapy
Recommendations
Classa
Levelb
It is recommended that SRT be performed by 
experienced operators working as part of a 
multidisciplinary team expert in the management of 
HCM.664,665,687,695,696,708–710
I
C
SRT to improve symptoms is recommended in 
patients with a resting or maximum provoked LVOT 
gradient of ≥50 mmHg who are in NYHA/Ross 
functional class III–IV, despite maximum tolerated 
medical therapy.697–702
I
B
Septal myectomy, rather than ASA, is recommended 
in children with an indication for SRT, as well as in 
adult patients with an indication for SRT and other 
lesions requiring surgical intervention (e.g. mitral 
valve abnormalities).673
I
C
SRT should be considered in patients with recurrent 
exertional syncope caused by a resting or maximum 
provoked LVOTO gradient ≥50 mmHg despite 
optimal medical therapy.686,711–713
IIa
C
Mitral valve repair or replacement should be 
considered in symptomatic patients with a resting or 
maximum provoked LVOTO gradient ≥50 mmHg 
and moderate-to-severe mitral regurgitation that 
cannot be corrected by SRT alone.661,669–672,714
IIa
C
Mitral valve repair should be considered in patients 
with a resting or maximum provoked LVOTO 
gradient ≥50 mmHg when there is 
moderate-to-severe mitral regurgitation following 
isolated myectomy.
IIa
C
SRT may be considered in expert centres with 
demonstrable low procedural complication rates in 
patients with mild symptoms (NYHA class II) 
refractory to medical therapy who have a resting or 
maximum provoked (exercise or Valsalva) gradient 
of ≥50 mmHg and: 
• moderate-to-severe SAM-related mitral 
regurgitation; or
• AF; or
• moderate-to-severe left atrial dilatation.653,715
IIb
C
Continued


<!-- PAGE 55 -->

### Page 55

Dual-chamber pacing. Three small, randomized, placebo-controlled 
studies of dual-chamber pacing and several long-term observational 
studies have reported reductions in LV outflow tract gradients and vari­
able improvement in symptoms and QoL, including one paediatric 
study.719–724 A Cochrane review concluded that the data on the ben­
efits of pacing are based on physiological measures and lack information 
on clinically relevant endpoints.725
Left ventricular mid-cavity obstruction and apical aneurysms. Left ventricu­
lar mid-cavity obstruction occurs in ∼10% of patients with HCM.727,728
Patients with mid-cavity obstruction tend to be very symptomatic and, 
in a number of studies, have shown an increased risk of progressive heart 
failure and SCD.727–729 Approximately 25% of patients also have an LV 
apical aneurysm (see Section 7.1.5).580,727,728,730 Patients with LV mid- 
cavity obstruction should be treated with high-dose beta-blockers, ver­
apamil, or diltiazem, but the response is often suboptimal. Limited experi­
ence, mostly from single centres, suggests that mid-ventricular 
obstruction can be relieved by transaortic myectomy, a transapical ap­
proach, or combined transaortic and transapical incisions, with good 
short-term outcomes but uncertain long-term survival.731,732
Left ventricular apical aneurysms by themselves rarely need treatment. 
A few patients develop monomorphic ventricular tachycardia related to 
adjacent apical scarring, which may be amenable to mapping and ablation 
(see Section 7.1.5).730,733 Rarely, thrombi are present within the aneur­
ysm and should be treated with long-term oral anticoagulation.734,735
Anticoagulation may also be considered in patients with HCM and apical 
aneurysms in the absence of documented thrombi.736,737
7.1.4.2. Management of symptoms in patients without left 
ventricular outflow tract obstruction
7.1.4.2.1. Heart failure and chest pain. Management of heart failure 
in patients without LVOTO should follow the recommendations of 
the 2021 ESC Guidelines for the diagnosis and treatment of acute and 
chronic heart failure, summarized in Section 6.10.2. The aim of drug 
therapy is to reduce LV diastolic pressures and improve LV filling by 
slowing the heart rate with beta-blockers, verapamil, or diltiazem 
(ideally monitored by ambulatory ECG recording), and cautious use 
of loop diuretics. Beta-blockers or calcium antagonists should be con­
sidered in patients with exertional or prolonged episodes of angina- 
like pain even in the absence of resting or provocable LVOTO or ob­
structive CAD. In the absence of LVOTO, cautious use of oral nitrates 
may be considered. Ranolazine may also be considered to improve 
symptoms in patients with angina-like chest pain and no evidence 
for LVOTO.738,739
7.1.4.2.2. Cardiac resynchronization therapy. Regional heterogen­
eity of LV contraction and relaxation can be seen in patients with 
HCM, and LV dyssynchrony may be a marker of poor prognosis.745
Data on the impact of CRT on symptoms, LV function, and prognosis 
in patients with non-obstructive HCM remain limited, but new evi­
dence has emerged since the 2014 ESC Guidelines on diagnosis and man­
agement of hypertrophic cardiomyopathy.746,747 There is one small study 
using a blinded crossover design of biventricular and sham pacing and a 
pre-specified analysis stratified by changes in LV end-diastolic volume 
(LVEDV) with exercise at baseline.748 Biventricular pacing was asso­
ciated with significant increases in LVEDV and stroke volume in patients 
Recommendation Table 21 — Recommendations for 
indications 
for 
cardiac 
pacing 
in 
patients 
with 
obstruction
Recommendations
Classa
Levelb
Sequential AV pacing, with optimal AV interval to 
reduce the LV outflow tract gradient or to facilitate 
medical treatment with beta-blockers and/or 
verapamil, may be considered in selected patients 
with resting or provocable LVOTO ≥50 mmHg, 
sinus rhythm, and drug-refractory symptoms, who 
have contraindications for ASA or septal myectomy 
or are at high risk of developing heart block following 
ASA or septal myectomy.633,719–724
IIb
C
In patients with resting or provocable LVOTO 
≥50 mmHg, sinus rhythm, and drug-refractory 
symptoms, in whom there is an indication for an ICD, 
a dual-chamber ICD (instead of a single-lead device) 
may be considered, to reduce the LV outflow tract 
gradient or to facilitate medical treatment with 
beta-blockers and/or verapamil.633,719–724,726
IIb
C
© ESC 2023
ASA, alcohol septal ablation; AV, atrioventricular; ICD, implantable cardioverter 
defibrillator; LV, left ventricular; LVOTO, left ventricular outflow tract obstruction. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 22 — Recommendations for 
chest pain on exertion in patients without left ventricu­
lar outflow tract obstruction
Recommendations
Classa
Levelb
Beta-blockers and calcium antagonists (verapamil or 
diltiazem) should be considered to improve symptoms 
in patients with angina-like chest pain even in the 
absence of LVOTO or obstructive CAD.740–744
IIa
C
Oral nitrates may be considered to improve 
symptoms in patients with angina-like chest pain, 
even in the absence of obstructive CAD, if there is no 
LVOTO.
IIb
C
Ranolazine may be considered to improve symptoms 
in patients with angina-like chest pain even in the 
absence of LVOTO or obstructive CAD. 738,739
IIb
C
© ESC 2023
CAD, coronary artery disease; LVOTO, left ventricular outflow tract obstruction. 
aClass of recommendation. 
bLevel of evidence.
Mitral valve replacement may be considered in 
patients with a resting or maximum provoked 
LVOTO gradient ≥50 mmHg when there is 
moderate-to-severe mitral regurgitation following 
isolated myectomy.661,674,714,716
IIb
C
Surgical AF ablation and/or left atrial appendage 
occlusion procedures during septal myectomy may 
be considered in patients with HCM and 
symptomatic AF.717,718
IIb
C
© ESC 2023
AF, atrial fibrillation; ASA, alcohol septal ablation; HCM, hypertrophic cardiomyopathy; 
LVOT, left ventricular outflow tract; LVOTO, left ventricular outflow tract obstruction; 
NYHA, New York Heart Association; SAM, systolic anterior motion; SRT, septal 
reduction therapy. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3557


<!-- PAGE 56 -->

### Page 56

who had a reduction in exercise LVEDV pre-pacing (consistent with the 
relief of diastolic ventricular interaction). This translated into improve­
ments in peak maximum oxygen consumption (VO2) (1.4 mL/kg/min) 
and QoL scores.748 Together, they suggest that symptomatic responses 
to CRT may occur in individual patients, but that these are not asso­
ciated with consistent changes in LVEF or evidence for a reduction in 
progression to end-stage heart failure.
The 2021 ESC Guidelines on cardiac pacing and cardiac resynchroniza­
tion therapy recommend that standard criteria for CRT are used in pa­
tients with HCM.724 The Task Force considered these of limited utility 
in HCM, as the unique pathology of this disease means that patients 
with contractile impairment rarely have an LVEF ≤35%. While ac­
knowledging this as an area of unmet research need, the Task Force 
suggests a more pragmatic approach in which CRT might be consid­
ered in individual symptomatic patients with LV impairment (LVEF 
<50%) that meet current ESC ECG criteria (LBBB, QRS 130– 
149 ms). Cardiac resynchronization therapy might also be considered 
in patients with HCM and impaired systolic function who require per­
manent ventricular pacing.746 In keeping with the 2021 ESC Guidelines 
on cardiac pacing and cardiac resynchronization therapy, the Task Force 
did not include these as specific recommendations, given the limited 
evidence base.
7.1.5. Sudden cardiac death prevention in 
hypertrophic cardiomyopathy
Most contemporary series of adult patients with HCM report an annual 
incidence for cardiovascular death of 1–2%, with SCD, heart failure, and 
thrombo-embolism being the main causes of death.749 The most com­
monly recorded fatal arrhythmic event is spontaneous ventricular fibril­
lation (VF), but asystole, AV block, and pulseless electrical activity are 
described.532,750–754 In children with HCM, although initial studies, usu­
ally from small, highly selected cohorts, reported SCD rates of up to 
10% per year,755–757 more recent, larger, population-based studies 
have shown SCD rates in the region of 1.2–1.5% per year.81,535,758
While much lower than previously thought, this is still >50% higher 
than reported in adult HCM populations. Sudden cardiac death appears 
to be very rare below the age of 6 years.81,759
Estimation of SCD risk is an integral part of clinical management. Clinical 
features that are associated with an increased SCD risk and that have been 
used in previous guidelines to estimate risk are shown in Table 19.
Table 19 Major clinical features associated with an increased risk of sudden cardiac death
Risk factor
Comment
Age
• The effect of age on SCD has been examined in a number of studies86,525,584,760–764 and two have shown a significant 
association, with an increased risk of SCD in younger patients.525,584
• Some risk factors appear to be more important in younger patients, most notably NSVT,765 severe LVH,766 and 
unexplained syncope.584
• Sudden cardiac death is very rare below the age of 6 years,535,767 and there are some data to suggest a peak of SCD in 
childhood HCM between 9 and 15 years;757 however, the association between age at diagnosis and SCD risk in 
childhood HCM remains unclear.
NSVT
• NSVT (defined as ≥3 consecutive ventricular beats at ≥120 b.p.m. lasting <30 s) occurs in 20–30% of patients during 
ambulatory ECG monitoring and is an independent predictor of SCD.81,525,535,590,764,765,768–773
• There is no evidence that the frequency, duration, or rate of NSVT influences the risk of SCD.765,774
• NSVT occurring during or immediately following exercise is very rare, but may be associated with a high risk of SCD.768
Maximum LV wall thickness
• The severity and extent of LVH measured by TTE are associated with the risk of SCD.81,535,592,593,763,765,770–772,775–780
• Several studies have shown the greatest risk of SCD in patients with a maximum wall thickness of ≥30 mm; however, 
there are few data in patients with extreme hypertrophy (≥35 mm).525,592,763,765,769,781–784
Family history of sudden cardiac death 
at a young age
• While definitions vary,525,592,762,782 a family history of SCD is usually considered clinically significant when one or 
more first-degree relatives have died suddenly aged <40 years with or without a diagnosis of HCM, or when SCD has 
occurred in a first-degree relative at any age with an established diagnosis of HCM.
• Family history of SCD does not appear to be an independent risk factor for SCD in childhood HCM.81,535 This may be 
due to a higher prevalence of de novo variants in childhood HCM, the inclusion of non-sarcomeric disease, and/or 
under-reporting of family history in paediatric cohorts.
Syncope
• Syncope is common in patients with HCM but is challenging to assess, as it has multiple causes.785
• Non-neurocardiogenic syncope for which there is no explanation after investigation is associated with an increased 
risk of SCD.81,525,535,584,590,755,761,768,769,781,786–788
• Episodes within 6 months of evaluation may be more predictive of SCD.584
Left atrial diameter
• Several studies have reported a positive association between LA size and SCD.81,525,535,584,772,789 There are no data 
on the association between SCD and LA area or volume. Measurement of LA size is also important in assessing the 
risk of AF (see Section 6.10.3).
LV outflow tract obstruction
• A number of studies have reported a significant association between LVOTO and SCD risk.86,525,590,762,768,790 Several 
unanswered questions remain, including the prognostic importance of provocable LVOTO and the impact of 
treatment (medical or invasive) on SCD.
• In childhood HCM, there are conflicting data on the association between LVOTO and SCD risk.81,535,772,777
© ESC 2023
AF, atrial fibrillation; b.p.m., beats per minute; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; LA, left atrium; LV, left ventricular; LVH, left ventricular hypertrophy; LVOTO, 
left ventricular outflow tract obstruction; NSVT, non-sustained ventricular tachycardia; SCD, sudden cardiac death; TTE, transthoracic echocardiogram.


<!-- PAGE 57 -->

### Page 57

7.1.5.1. Left ventricular apical aneurysms
Left ventricular apical aneurysms are defined as a discrete thin-walled 
dyskinetic or akinetic segment of the most distal portion of the left 
ventricle and are often associated with a mid-cavity gradient. Their 
prevalence in unselected patients is uncertain but they were re­
ported in 3% of individuals in the prospective Hypertrophic 
Cardiomyopathy Registry (HCMR).124 The first descriptions of LV 
apical aneurysms in HCM suggested an association with sustained 
monomorphic ventricular tachycardia (SMVT)730—a relatively rare 
occurrence in HCM—and a number of studies have suggested that 
they are a useful marker of SCD risk.580,728,736,737,791,792 Based on 
these data, LV aneurysms were included in the recent 2020 
American Heart Association/American College of Cardiology 
(AHA/ACC) HCM guideline as a major independent SCD risk factor 
and were considered a reasonable sole indication for an ICD.793 In a 
review for this guideline, the data from two published studies and a 
meta-analysis were evaluated (see Supplementary data online, 
Table S2). All these studies were retrospective and the absolute num­
ber of events is too small to assess the independent predictive value 
of apical aneurysms. In two small series that described a selected sub­
group of HCM patients with mid-ventricular obstruction, there was 
no increase in incidence of SCD events. In the only series that pro­
vides a detailed analysis of SCD events, the majority were appropri­
ate ICD interventions for monomorphic VT, suggesting significant 
inclusion bias.737 Finally, a large proportion of individuals with events 
had other important risk markers including prior sustained ventricu­
lar arrhythmia. Based on the current data, the Task Force recom­
mends that individualized ICD decisions should be based using 
well-established risk factors and not solely on the presence of an 
LV apical aneurysm.
7.1.5.2. Left ventricular systolic dysfunction
A small number of retrospective studies and two larger registries 
have examined the relation between prognosis in patients with 
HCM and LV systolic dysfunction (most frequently defined by a 
LVEF <50%) (see Supplementary data online, Table S3). All studies 
consistently show an increased rate of SCD events in patients with 
left ventricular systolic dysfunction (LVSD) ranging from 7 to 20% 
compared with that of patients with normal LV systolic function. 
However, the independent and additional value of LVSD compared 
with current risk stratification tools has not been investigated. 
There is only one multivariable model that investigates the independ­
ent relation of LVSD to the risk of SCD events but the covariables 
examined were limited (age, sex, and follow-up time).315 As with 
other recently proposed risk markers in HCM, the Task Force main­
tains its recommendation to first estimate SCD risk using the 
HCM-SCD Risk and HCM Risk-Kids tools, and then to use the pres­
ence of an LVEF <50% in shared decision-making about prophylactic 
ICD implantation, with full disclosure of the lack of robust data on its 
impact on prognosis.
7.1.5.3. Late gadolinium enhancement on cardiac magnetic 
resonance imaging
In the 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy, the extent of LGE on CMR was considered helpful in 
predicting cardiovascular mortality, but data at that time were felt insuf­
ficient to support the use of LGE in prediction of SCD risk. Since then, 
more studies have been published (see Supplementary data online, 
Table S1). In aggregate, the data show that LGE is common and, that 
when extensive (expressed as a percentage of LV mass), is associated 
with an increase in SCD risk and other events, particularly in the pres­
ence of other markers of disease severity including LV systolic impair­
ment. A meta-analysis of nearly 3000 patients from several studies 
suggests that the presence of LGE is associated with a 2.32-fold in­
creased risk of SCD/aborted SCD/appropriate ICD discharge, and a 
2.1-fold increase in all-cause mortality.794 It has been suggested that 
the addition of LGE to the current AHA/ACC sudden death algorithm 
or the HCM-SCD risk model improves stratification of patients who 
are otherwise considered low or intermediate risk.793
As in 2014, a number of uncertainties persist. These include the in­
evitable confounders in the retrospective studies that bias towards 
high-risk patients or patients referred specifically for septal myectomy. 
There also remains some debate about the methods used to quantify 
LGE with the 2-standard deviation technique; the only one that is vali­
dated against necropsy.605 Retrospective CMR series also report rela­
tively high event rates suggesting that they are not representative of the 
broad spectrum of disease. In HCMR, a prospective CMR study of 2755 
patients, LGE was present in 50% of patients based on visual criteria and 
in 60% based on >6 SCD signal criteria, but only 2% of patients had LGE 
>15% of LV mass.124 In the most recent report from the registry, there 
have been 24 deaths from any cause after a mean follow-up of 33.5 ±  
12.4 months (median: 36 months and range 1–64 months); the relation 
with LGE is not reported.795 There are very limited data on the role of 
CMR over and above validated risk algorithms in SCD risk prediction in 
children with HCM.796,797
On balance, the Task Force maintains the recommendation to first 
estimate SCD risk using the HCM-SCD Risk calculators. For patients 
who are in the low to intermediate risk category, the presence of ex­
tensive LGE (≥15%) may be used in shared decision-making with pa­
tients about prophylactic ICD implantation, acknowledging the lack of 
robust data on the impact of scar quantification on the personalized 
risk estimates generated by the HCM-SCD Risk calculators.
7.1.5.4. Abnormal exercise blood pressure response
Approximately one-third of adult patients with HCM have an abnormal 
systolic blood pressure response to exercise characterized by progres­
sive hypotension or a failure to augment the systolic blood pressure 
that is caused by an inappropriate drop in systemic vascular resistance 
and a low cardiac output reserve.798,799 Various definitions for abnor­
mal blood pressure response in patients with HCM have been re­
ported;590,765,768,782 for the purposes of this guideline, an abnormal 
blood pressure response is defined as a failure to increase systolic pres­
sure by at least 20 mmHg from rest to peak exercise or a fall of 
>20 mmHg from peak pressure.590,765,768,782,800
Abnormal exercise blood pressure response may be associated 
with a higher risk of SCD in adult patients aged ≤40 years, but it 
has a low positive predictive accuracy and its prognostic significance 
in patients >40 years of age is unknown, and recent data have sug­
gested that, although it may be associated with increased overall mor­
tality largely related to heart failure, it is not consistently associated 
with an increased risk of ventricular arrhythmia or SCD.800,801
There is no evidence to suggest that abnormal blood pressure re­
sponse to exercise is associated with a higher risk of SCD in children 
with HCM.802 The Task Force, therefore, does not recommend the 
use of abnormal blood pressure response to exercise as an indication 
ESC Guidelines                                                                                                                                                                                          3559


<!-- PAGE 58 -->

### Page 58

for primary prevention ICD implantation in patients with a low or 
intermediate risk category.
7.1.5.5. Sarcomeric variants
A small number of studies have explored the prognostic value of sarco­
meric variants in HCM. Despite initial attempts to classify variants as 
‘malignant’ or ‘benign’,803–807 no studies have shown an independent 
role for specific sarcomeric variants in SCD risk prediction. Variants ini­
tially classified as ‘malignant’ or ‘benign’ can have very different pheno­
typic expression, even in members of the same family,808–810 and, as 
variants are often found in individual families, evaluation of their prog­
nostic implications is problematic. Similarly, while the presence of mul­
tiple sarcomeric variants in an individual has been suggested to be 
associated with a worse prognosis,608,811–813 other cohorts have not 
consistently reported this association.807,814–816 Recent studies have 
evaluated the potential prognostic role of the presence of any sarco­
meric variant. The largest of these, comprising 2763 patients, showed 
a statistically significant impact on overall prognosis in those with vs. 
without a sarcomeric variant, but did not assess its association specific­
ally with SCD.238 A smaller study of 512 probands and 114 relatives, of 
whom 327 had a disease-causing sarcomeric variant, suggested that the 
presence of a pathogenic variant was independently associated with all- 
cause, cardiovascular, and heart failure mortality as well as SCD/ 
aborted SCD (HR 2.88; 95% CI, 1.23–6.71).817 Patients with a sarco­
meric variant were younger and were more likely to have NSVT, syn­
cope, and LVOTO and the association with SCD lost statistical 
significance (HR 2.44; 95% CI, 0.99–6.01; P = 0.052) after adjusting 
for ≥2 major clinical risk factors. The role of sarcomeric variants as a 
predictor of SCD independent of SCD risk-prediction models (e.g. 
HCM Risk-SCD and HCM Risk-Kids) remains to be demonstrated. 
Based on the available data, the Task Force does not recommend the 
use of the presence of sarcomeric variant(s) to guide decisions around 
ICD implantation for primary prevention in individuals with a low or 
intermediate SCD risk score.
7.1.5.6. Prevention of sudden cardiac death
There are no randomized, controlled data to support the use of AADs 
for the prevention of SCD in HCM. Amiodarone was associated with a 
lower incidence of SCD in one small observational study of patients 
with non-sustained ventricular tachycardia (NSVT) on Holter monitor­
ing, but observational data suggest that amiodarone often fails to pre­
vent SCD.818,819 Disopyramide does not appear to have a significant 
impact on the risk of SCD.632 However, beta-blockers and/or amiodar­
one are recommended in patients with an ICD who continue to have 
symptomatic ventricular arrhythmias, paroxysmal AF, or recurrent 
shocks despite optimal treatment and device re-programming.820
There are no randomized trials or statistically validated prospective 
prediction models that can be used to guide ICD implantation in pa­
tients with HCM. Recommendations are instead based on observation­
al, retrospective cohort studies that have determined the relationship 
between clinical characteristics and prognosis. The 2014 ESC 
Guidelines on diagnosis and management of hypertrophic cardiomyopathy 
recommended a risk-prediction model—HCM Risk-SCD (https:// 
qxmd.com/calculate/calculator_303/hcm-risk-scd)—that provides indi­
vidualized, quantitative risk estimates using an enhanced phenotypic ap­
proach.525 This approach has since been validated in independent 
cohorts and a meta-analysis of available published data, relevant to 
the 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy performance, for SCD prevention has shown that 
pooled estimates are concordant with the observed SCD risk in pa­
tients designated as high or low risk.821–824 In children, risk stratification 
for SCD has traditionally been based on risk factors extrapolated from 
adults with HCM, but this approach does not identify the children most 
at risk of SCD. In 2019, the first validated paediatric-specific risk model 
for SCD was developed (HCM Risk-Kids; https://hcmriskkids.org), using 
a similar approach to HCM Risk-SCD,81,825 and has since been inde­
pendently externally validated.535,797,826 A similar paediatric risk- 
prediction model (PRIMaCY Childhood HCM Sudden Cardiac Death 
Risk Prediction tool) has also been developed, using similar clinical para­
meters and with similar reported accuracy to HCM Risk-Kids (https:// 
primacy.shinyapps.io/calculator/).535
In this update, the Task Force maintains the principle of risk esti­
mation using the validated HCM Risk-SCD tool as the first step in 
sudden death prevention in patients aged 16 years or more, and re­
commends the use of a validated risk score (e.g. HCM Risk-Kids tool) 
for children and adolescents <16 years. This is in contrast to the 
2020 AHA/ACC Guideline for the diagnosis and treatment of patients 
with hypertrophic cardiomyopathy,793 in which the tool is considered 
an aid to a shared decision-making process for ICD placement in pa­
tients with clinical risk markers. This approach by the AHA/ACC, in 
part, reflected concerns that reliance on a risk tool does not account 
for individual patient perception and acceptance of pre-determined 
thresholds for medical intervention, as well as the omission of clinical 
risk markers such as LV systolic impairment from the HCM Risk-SCD 
model.
The Task Force acknowledges the challenges associated with defining 
universal thresholds for acceptable risk, but feels that reliance on an un­
quantified estimate of risk does nothing to resolve this dilemma. 
Instead, the Task Force recommends more overt shared decision- 
making based on real-world data as well as individual preferences, be­
liefs, circumstances, and values. Gaps in evidence are acknowledged 
and should be shared with patients. Similarly, competing risks related 
to the disease (heart failure, stroke) and to age and comorbidity, as 
well as device-related complications, should be discussed.726,827,828
Critically, the Task Force calls for development of enhanced patient de­
cision aids tailored specifically to receivers of care as well as more trad­
itional decision-support tools for healthcare practitioners.
Figure 16 summarizes the recommendations for primary preven­
tion ICD implantation in HCM in each risk category. These take 
into account not only the absolute statistical risk, but also the age 
and general health of the patient, socioeconomic factors, and the psy­
chological impact of therapy. The recommendations are meant to be 
sufficiently flexible to account for scenarios that are not encompassed 
by the HCM Risk-SCD or HCM Risk-Kids models. These models 
should not be used in elite athletes or in individuals with metabolic/in­
filtrative diseases (e.g. Anderson–Fabry disease) and syndromes (e.g. 
Noonan syndrome). The models do not use exercise-induced LV out­
flow tract gradients and have not been validated before and after 
myectomy. The HCM Risk-SCD model has been validated in one 
study of adult patients following ASA,829 and a recent study has 
suggested that severe LVH and residual LVOTO are associated with 
an increased risk of SCD following ASA, with a modest C-statistic 
of 0.68.830


<!-- PAGE 59 -->

### Page 59

shared decision making
Secondary prevention
Primary prevention
HCM-risk scores
≥1 clinical risk factorsa
ICD
(Class IIb)
ICD
(Class IIb)
ICD
(Class IIa)
ICD
(Class I)
Low risk
5-year risk <4%
Intermediate risk
5-year risk ≥4 to <6%
High risk
5-year risk ≥6%
History
2D and Doppler echocardiogram
Ambulatory ECG
Symptom limited exercise test
Age 
Unexplained syncope
 LV outflow gradient 
Maximum LV wall thickness 
Left atrial diameter
 NSVT
Family history of SCD
LV systolic function
 Extent of myocardial scar
Cardiac arrest due to VT or VF 
Spontaneous sustained VT 
causing syncope or 
haemodynamic compromise
AND
Life expectancy ≥1 year
Figure 16 Flow chart for implantation of an implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy. 2D, two-dimensional; 
CMR, cardiac magnetic resonance; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LGE, late gado­
linium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; SCD, sudden cardiac death; VF, 
ventricular fibrillation; VT, ventricular tachycardia. aClinical risk factors: extensive LGE (>15%) on CMR; LVEF <50%.
Recommendation Table 23 — Additional recommen­
dations for prevention of sudden cardiac death in 
patients with hypertrophic cardiomyopathy
Recommendations
Classa
Levelb
Secondary prevention
Implantation of an ICD is recommended in patients 
who have survived a cardiac arrest due to VT or VF, 
or who have spontaneous sustained VT with 
haemodynamic compromise.532,534,726,831,832
I
B
Continued 
Primary prevention
The HCM Risk-SCD calculator is recommended as a 
method of estimating risk of sudden death at 5 years 
in patients aged ≥16 years for primary 
prevention.525,821–824
I
B
Validated paediatric-specific risk prediction models 
(e.g. HCM Risk-Kids) are recommended as a method 
of estimating risk of sudden death at 5 years in 
patients aged <16 years for primary prevention.81,833
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3561


<!-- PAGE 60 -->

### Page 60

7.2. Dilated cardiomyopathy
7.2.1. Diagnosis
7.2.1.1. Index case
Dilated cardiomyopathy is defined by the presence of LV dilatation and 
systolic dysfunction unexplained solely by abnormal loading conditions 
or CAD. Left ventricular dilatation is defined by LV end-diastolic dimen­
sions or volumes >2 z-scores above population mean values corrected 
for body size, sex, and/or age. For adults this represents an LV end- 
diastolic diameter >58 mm in males and >52 in females and an 
LVEDV index of ≥75 mL/m2 in males and ≥62 mL/m2 in females by 
ECHO.9,845,846 Left ventricular global systolic dysfunction is defined 
by LVEF <50%.9
7.2.1.2. Relatives
Clinical testing in relatives often reveals mild non-diagnostic abnormal­
ities that overlap with normal variation or mimic changes seen in other 
more common diseases such as hypertension and obesity. In this con­
text, the presence of isolated LV dilatation with preserved systolic func­
tion or in the presence of a familial causative variant is sufficient for a 
diagnosis of DCM in a relative. Additional electrocardiographic or im­
aging abnormalities in the context of a family history of DCM are sug­
gestive of disease and warrant close follow-up.9,75,817 In the absence of 
conclusive genetic information in a family, DCM is considered familial if: 
(i) one or more first- or second-degree relatives have DCM; or (ii) 
when an otherwise unexplained SCD has occurred in a first-degree 
relative at any age with an established diagnosis of DCM.
7.2.1.3. Diagnostic work-up
The key elements of the diagnostic work-up for all patients with DCM 
are described in Section 6 and include clinical and family history, labora­
tory tests, ECG, Holter monitoring, cardiac imaging, and genetic testing. 
Echocardiography is central for the diagnosis and CMR provides more 
detailed morphological and prognostic information. Additional labora­
tory tests, exercise testing, EMB, cardiac CT, and cardiac catheteriza­
tion should also be considered, as detailed in Section 6.
7.2.1.4. Echocardiography
Comprehensive TTE is recommended for all DCM patients as it pro­
vides all the relevant information on the global and regional LV anat­
omy, function and haemodynamics, valvular heart disease, right heart 
function, pulmonary pressure, atrial geometry, and associated fea­
tures.71 Advanced echocardiographic techniques (tissue Doppler and 
speckle tracking deformation imaging) can allow the early detection 
of subclinical myocardial dysfunction in specific situations (e.g. genetic 
DCM carriers, recipients of known cardiotoxic chemotherapy).71,74
Contrast agents may be considered for better endocardial delinea­
tion, to better depict the presence of hypertrabeculation, or to exclude 
intraventricular thrombus. Transoesophageal echocardiography is rare­
ly necessary except for when atrial thrombi are present in patients with 
AF, or for assessing valvular function and guiding transcatheter therapy 
in patients with concomitant secondary mitral or tricuspid 
regurgitation.
It is recommended that the 5-year risk of SCD be 
assessed at first evaluation and re-evaluated at 1–2 
year intervals or whenever there is a change in clinical 
status.525
I
B
Implantation of an ICD should be considered in 
patients with an estimated 5-year risk of sudden 
death of ≥6%, following detailed clinical assessment 
that considers: 
(i) the lifelong risk of complications;
(ii) competing mortality risk from the disease and 
comorbidities;
AND 
(iii) the impact of an ICD on lifestyle, 
socio-economic status, and psychological 
health.81,521,525,726,832,833
IIa
B
In patients with LV apical aneurysms, decisions about 
primary prevention ICD based on an assessment of 
risk using the HCM Risk-SCD or a validated 
paediatric risk-prediction (e.g. HCM Risk-Kids) tool 
and not solely on the presence of the aneurysm 
should be considered.580,728,737,791,792
IIa
B
Implantation of an ICD may be considered in 
individual patients with an estimated 5-year risk of 
SCD of between ≥4% and <6%, following detailed 
clinical assessment that takes into account the 
lifelong risk of complications and the impact of an 
ICD on lifestyle, socio-economic status, and 
psychological health.81,521,525,726,832,833
IIb
B
For patients who are in the low-risk category (<4% 
estimated 5-year risk of SCD), the presence of 
extensive LGE (≥15%) on CMR may be considered in 
shared decision-making with patients about 
prophylactic ICD implantation, acknowledging the 
lack of robust data on the impact of scar 
quantification on the personalized risk estimates 
generated by HCM Risk-SCD or a validated 
paediatric model (e.g. HCM Risk-Kids).141,796,797,834– 
841
IIb
B
For patients who are in the low-risk category (<4% 
estimated 5-year risk of SCD), the presence of LVEF 
<50% may be considered in shared decision-making 
with patients about prophylactic ICD implantation, 
acknowledging the lack of robust data on the impact 
of systolic dysfunction on the personalized risk 
estimates generated by HCM Risk-SCD or a 
validated paediatric model (e.g. HCM 
Risk-Kids).89,315,841–844
IIb
B
© ESC 2023
CMR, cardiac magnetic resonance; HCM, hypertrophic cardiomyopathy; ICD, implantable 
cardioverter defibrillator; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left 
ventricular ejection fraction; SCD, sudden cardiac death; VF, ventricular fibrillation; VT, 
ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 61 -->

### Page 61

7.2.1.5. Cardiac magnetic resonance
Cardiac magnetic resonance provides additional information on tissue 
characterization in patients with DCM, including the presence of myo­
cardial oedema, which may suggest a myocarditic or inflammatory 
cause, and LGE, to determine the presence and extent of fibrosis, as 
well as its distribution, which may allow exclusion of myocardial infarc­
tion and also point towards specific aetiologies (e.g. subepicardial distri­
bution in post-myocarditis forms, patchy in sarcoidosis, extensive 
inferolateral in dystrophinopathies, septal mid-wall in LMNA carriers, 
and ring-like in DSP and FLNC-truncating variant carriers) (see Section 
7.3).71,847 Late gadolinium enhancement distribution and extent hold 
prognostic value both for arrhythmia and heart failure severity.137,848
Dedicated T2* sequences describe myocardial iron deposition, which 
is useful for the diagnosis of haemochromatosis.71
7.2.1.6. Nuclear medicine
There is a limited role for radionuclide imaging in DCM. Measurement 
of 18F-fluorodeoxyglucose (18F-FDG) uptake using PET, with focal or 
focal-on-diffuse FDG uptake patterns especially if there is concomitant 
abnormal 18F-FDG-PET uptake in extracardiac tissues, can be useful in 
suspected cardiac sarcoidosis.849
7.2.2. Genetic testing and family screening
The aetiology of DCM is highly heterogeneous and includes inherited 
(genetic/familial) and acquired causes.9,545,850,851 Direct causes of 
DCM include pathogenic gene variants, toxins, auto-immunity, infec­
tions, storage diseases, and tachyarrhythmias. Monogenic gene variants 
causing DCM are highly heterogeneous, implicating many genes and di­
verse pathways. Moreover, only 30–40% of DCM cases are attributable 
to pathogenic rare variants, with a substantial polygenic/common vari­
ant contribution in this population. Furthermore, disease modifiers can 
play a role in the acceleration of the DCM phenotype.7,9,850 This in­
cludes conditions that may aggravate or trigger DCM, including epigen­
etic factors and acquired modifiers, such as pregnancy, hypertension, 
excessive alcohol use, and other toxins.42–44 It is important to consider 
the interplay between genetic and acquired causes during the diagnostic 
work-up. Identification of an acquired cause does not exclude an under­
lying causative gene variant, whereas the latter may require an addition­
al acquired cause and/or disease modifier to manifest. Within the genes 
that can cause DCM, there are genes robustly associated with classical 
DCM that have been recently curated,189 and also others classically as­
sociated with ARVC but that very commonly can present with LV dila­
tation and predominantly LV dysfunction. Moreover, genes described in 
the context of hypertrabeculation/LVNC (e.g. NKX2.5 and PRDM16), 
or that can cause DCM with or without skeletal involvement (such as 
DMD or EMD), should also be considered DCM-associated genes and 
examined, particularly if phenotype is concordant. The most common 
genetic and acquired causes of DCM are shown in Table 10 and 
Table 20. Detailed lists of causes of DCM have been previously 
published.9,852
7.2.2.1. Genetic testing
Causative gene variants occur in up to 40% of DCM patients in contem­
porary cohorts,185,186,853,854
and between 10 and 15% in 
chemotherapy-induced, alcoholic, or peripartum DCM.42–44 Although 
the prevalence of genetic variants is higher in familial DCM, causative 
genetic variants are also identified in over 20% of non-familial DCM 
cases.185,854,855 Finding a causative gene variant in a patient with 
DCM allows better prediction of the disease outcome and progression,
Table 20 Non-genetic causes of dilated cardiomyopathy
Infection (post-myocarditis)
Viral (enteroviruses, adenoviruses, echoviruses, herpes viruses, parvovirus B19, 
HIV, SARS-CoV-2, etc.)
Bacterial (Lyme disease)
Mycobacterial
Fungal
Parasitic (Chagas disease)
Toxic and overload
Alcohol (ethanol)
Cocaine, amphetamines, ecstasy
Cobalt
Anabolic/androgenic steroids
Haemochromatosis and other causes of iron overload
Endocrinology
Hypo- and hyperthyroidism
Cushing/Addison disease
Phaeochromocytoma
Acromegaly
Diabetes mellitus
Nutritional deficiency
Selenium deficiency
Thiamine deficiency (Beri-Beri)
Zinc and copper deficiency
Carnitine deficiency
Electrolyte disturbance
Hypocalcaemia
Hypophosphataemia
Peripartum
Autoimmune diseases
Giant cell myocarditis
Inflammatory (biopsy-proven, non-infectious myocarditis)
Eosinophilic granulomatosis with polyangiitis
Systemic lupus erythematosus
Sarcoidosis
Rheumatoid arthritis
Coeliac disease
Primary biliary cirrhosis
Myasthenia gravis
Pemphigus pemphigoid
Crohn disease
Ulcerative colitis
Polymyositis/dermatomyositis
Reactive arthritis
Drugs
Antineoplastic 
drugs
Anthracyclines; antimetabolites; alkylating agents; Taxol; 
hypomethylating agent; monoclonal antibodies; tyrosine 
kinase inhibitors; immunomodulating agents
Psychiatric drugs
Clozapine, olanzapine; chlorpromazine, risperidone, 
lithium; methylphenidate; tricyclic antidepressants
Other drugs
All-trans retinoic acid; antiretroviral agents; phenothiazines
© ESC 2023
HIV, human immunodeficiency virus; SARS-CoV-2, severe acute respiratory syndrome 
coronavirus 2.
ESC Guidelines                                                                                                                                                                                          3563


<!-- PAGE 62 -->

### Page 62

may contribute to the indications for device implantation, informs gen­
etic counselling, and allows familial screening for relatives. Moreover, 
genetic testing in DCM has long-term implications in terms of cost- 
effectiveness by identifying at-risk family members with positive geno­
types, and thus reducing the number of family members requiring serial 
clinical follow-up.229 Genetic testing can therefore be beneficial in all 
patients with DCM, including children856,857 and those with alcohol-/ 
chemotherapy-induced and peripartum DCM. Where resources are 
limited, scores designed to identify DCM patients with a high probabil­
ity of a positive genotype (e.g. the Madrid DCM Genotype Score 
[https://madridDCMscore.com]) may be considered to prioritize gen­
etic testing.858 Of note, age should not be a limiting factor when decid­
ing which DCM patients should undergo genetic testing.185,858,859
Recommendations for clinical screening, genetic counselling, and 
testing are described in Sections 6.8.3 and 6.11. More detailed evalu­
ation of conduction defects or arrhythmia, which may be an early pres­
entation of certain genetic DCM subtypes, should be considered in the 
context of certain gene variants (e.g. LMNA, EMD, DES). Cardiac MRI 
should also be considered in relatives with normal cardiac function 
who carry causative genetic variants associated with increased risk of 
SCD (e.g. FLNC, DES, DSP, PLN, LMNA, TMEM43, RMB20). If there 
are no additional family members with DCM, other than the proband, 
periodic evaluation of first-degree relatives should follow the same in­
tervals according to age (see Section 6.11), but termination of periodic 
surveillance in families in whom a genetic variant has not been identified 
could be considered in first-degree relatives ≥50 years of age with nor­
mal ECG and normal cardiac imaging tests.
7.2.3. Assessment of symptoms
Patients with DCM often develop symptoms of heart failure, although 
this can occur many years after the appearance of ECG or echocardio­
graphic abnormalities. Assessment of symptoms in patients with cardio­
myopathies is described in Section 6.10.1.
7.2.4. Management
The clinical management of heart failure and other manifestations of 
DCM has been described in the 2021 ESC Guidelines for the diagnosis 
and treatment of acute and chronic heart failure, the 2020 ESC 
Guidelines for the diagnosis and management of atrial fibrillation, and the 
apy.69,336,724 In these guidelines, recommendations are generally inde­
pendent of the aetiology of heart failure, AF, and other clinical 
presentations. As such, although they summarize large and robust da­
tasets and trials, the treatment recommendations must be regarded 
as generic and not specific to the different forms of genetic DCM. 
However, as large cohorts of genetic DCMs with uniform genetic fea­
tures are relatively rare, adequately powered RCTs in cardiomyop­
athies are scarce. The Task Force therefore recommends applying 
the 2021 ESC Guidelines for the diagnosis and treatment of acute and 
chronic heart failure, which contain treatment guidelines for patients 
with signs and symptoms of heart failure, for symptom management 
of patients with DCM.69 Treatment recommendations for asymptom­
atic LV dysfunction or dilatation are scarce, which presents a challenge 
for genetic DCM, where a sizeable proportion of the patients are young 
with no or mild symptoms, and where asymptomatic patients are fre­
quently discovered through cascade screening. Recommendations for 
the pharmacological management of heart failure symptoms in patients 
with cardiomyopathies are described in Section 6.10.2.
7.2.5. Sudden cardiac death prevention in dilated 
cardiomyopathy
Predicting SCD is a challenging aspect of the clinical care of patients 
with DCM. Implantable cardioverter defibrillators are effective at treat­
ing potentially lethal ventricular arrhythmias and preventing SCD, but 
are also associated with complications, particularly in young patients, 
who will require several replacements during their lifetimes (see 
Section 6.10.5).
7.2.5.1. Secondary prevention of sudden cardiac death
Implantable cardioverter defibrillators reduce mortality in survivors of 
cardiac arrest and in patients who have experienced sustained symp­
tomatic ventricular arrhythmias with haemodynamic compromise.531
An ICD is recommended in such patients when the intent is to increase 
survival; the decision to implant should consider the patient’s view and 
their QoL, as well as the absence of other diseases likely to cause death 
within the following year.
7.2.5.2. Primary prevention of sudden cardiac death
Available RCTs examining the usefulness of ICDs to prevent SCD and 
improve survival have included only patients with LVEF ≤35%, with 
conflicting results. While a trial including both ischaemic and non- 
ischaemic symptomatic heart failure patients showed reduction in 
mortality,860 trials including only patients without CAD did not signifi­
cantly improve the overall risk of mortality despite the fact that there 
was an absolute reduction in SCD with ICDs, and subgroup analysis 
suggested that there was a survival benefit in patients ≤70 years.861,862
Nevertheless, in a recent meta-analysis of studies that examined the 
effect of ICDs in DCM, a survival benefit was observed, although 
the effect was modest compared with LVEF ≤35% patients with 
CAD.863
Although LVEF ≤35% has been reported as an independent risk 
marker of all-cause and cardiac death in DCM, it has also shown only 
modest ability in identifying DCM patients with higher risk of SCD, sug­
gesting that additional factors should be taken into consideration when 
deciding on ICD implantation in a disease with significant aetiological 
heterogeneity. Recent natural history studies suggest that phenotype 
plays a role a role in SCD risk, with patients harbouring disease-causing 
variants in PLN, DSP, LMNA, FLNC, TMEM43, and RBM20 having a sub­
stantially higher rate of major arrhythmic events than other causes of 
DCM regardless of LVEF.440,542,864–870 A recent retrospective study 
of 1161 individuals with DCM has shown that DCM patients with P/ 
LP DCM-causing genetic variants have a worse clinical evolution and 
higher rate of major arrhythmic events than genotype-negative DCM 
patients and particularly in DCM patients with LVEF ≤35%.185 The 
study also observed a higher risk of major arrhythmic events in DCM 
patients affected by DCM-causing variants in certain genotypes regard­
less of LVEF. Genes associated with higher arrhythmic risk included 
genes coding for nuclear envelope (LMNA, EMD, TMEM43), desmo­
somal (DSP, DSG2, DSC2, PKP2), and certain cytoskeletal proteins.185
Together, these data suggest that DCM patients harbouring 
DCM-causing variants in high-risk genes (LMNA, EMD, TMEM43, DSP, 
RBM20, PLN, FLNC-truncating variants) should be considered as pa­
tients with a high-risk genetic background for SCD and primary preven­
tion ICD implantation should be considered with LVEF thresholds 
higher than 35%, particularly in the presence of additional risk factors 
(e.g. NSVT, increased ventricular ectopic beats, male sex, significant 
LGE, specific gene variant). For some high-risk genotypes (e.g. LMNA 
[https://lmna-risk-vta.fr]541), gene-specific (or, in the case of the PLN


<!-- PAGE 63 -->

### Page 63

p.Arg14del variant, variant-specific [https://plnriskcalculator.shinyapps. 
io/final_shiny])542 risk-prediction scores have been developed that con­
sider genotype characteristics and additional phenotypic features. 
Where such scores are available, they should be used to guide primary 
prevention ICD implantation (Figure 17). As discussed in Section 7.1.5, 
the Task Force acknowledges the challenges associated with defining 
universal thresholds for acceptable risk across different cardiomyop­
athy phenotypes, but is of the opinion that a similar approach to that 
taken in risk stratification for HCM is reasonable. Although the 2022 
ESC Guidelines for the management of patients with ventricular arrhythmias 
and the prevention of sudden cardiac death have suggested a higher 
threshold of 10% risk at 5 years to guide primary prevention ICD im­
plantation in patients with DCM and LMNA variants,3 this Task Force 
recommends shared decision-making based on real-world data as 
well as individual preferences, beliefs, circumstances, and values. Gaps 
in evidence should be shared with patients, and competing risks related 
to the disease (heart failure, stroke), and to age and comorbidity, as well 
as device-related complications, should be discussed. In support of this, 
a recent study validating the LMNA-risk VTA calculator overestimated 
arrhythmic risk when using ≥7% predicted 5-year risk as threshold 
(specificity 26%, C-statistic 0.85), despite a high sensitivity.871
Importantly, there are also data to suggest that other genotypes (e.g. 
TTN truncating variants) are associated with recovery of LVEF with 
standard heart failure criteria from the 2021 ESC Guidelines for the diag­
nosis and treatment of acute and chronic heart failure.185,867,872
In patients without a high-risk genotype and LVEF >35%, the pres­
ence and extent of myocardial scarring determined by LGE on CMR im­
aging can be helpful in risk stratification in patients with DCM.873,874
Late gadolinium enhancement is observed in 25–35% of patients with 
DCM and its presence is a strong risk marker for all-cause mortality 
and ventricular arrhythmias, both in retrospective and prospective 
studies. A recent prospective study of 1020 DCM patients with a me­
dian follow-up of 5.2 years showed that myocardial scar had a strong 
and incremental prognostic value for predicting SCD, while LVEF 
≤35% was not associated with SCD.138 In another study, a risk calcula­
tor was developed that among others, incorporated the presence of 
LGE on CMR imaging540, although this has not yet been externally va­
lidated. There are at least two ongoing trials of ICD therapy according 
to the presence of scar on CMR imaging, including DCM patients 
(NCT04558723 and NCT03993730), but the Task Force’s opinion is 
that the existing level of evidence can support using LGE to guide 
ICD implantation in subgroups of patients with DCM (Figure 17). 
Additional risk factors, such as syncope or the presence of NSVT and 
burden of ventricular ectopy (VE), may also help guide ICD implant­
ation. There are no data currently to support a specific threshold for 
VE burden, and this will depend on the underlying genotype and other 
Cardiac arrest or VT with haemodynamic compromise
LVEF <35%
Gene specific risk assessmenta
High risk
ICD
(Class I)
ICD
(Class IIa)
ICD
(Class IIa/IIb)b
N
Additional risk factorsc
N
N
High-risk gene
N
Patients with DCM/NDLVC
Y
Y
Y
Y
ICD
(Class IIb)
Figure 17 Implantation of implantable cardioverter defibrillators in patients with dilated cardiomyopathy or non-dilated left ventricular cardiomyopathy 
flowchart. CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; ICD, implantable cardioverter defibrillator; LGE, late gadolinium enhancement; 
LVEF, left ventricular ejection fraction; NDLVC, non-dilated left ventricular cardiomyopathy; VE, ventricular ectopic beats; VT, ventricular fibrillation. aSee 
Table 21. bStrength of recommendation depends on gene and context. cAdditional risk factors include syncope, LGE presence on CMR.
ESC Guidelines                                                                                                                                                                                          3565


<!-- PAGE 64 -->

### Page 64

clinical factors.542,867,872 In patients with unexplained syncope, pro­
grammed electrical stimulation (PES) may provide additional informa­
tion on the underlying cause.875 There are no definitive data 
supporting the routine use of PES for primary prevention risk stratifica­
tion in patients with DCM, but this may be beneficial in patients with 
DCM and myotonic dystrophy with an independent indication to elec­
trophysiological study to assess conduction disturbances,876 although 
the clinical value of this approach has not been consistently 
demonstrated.877
7.3. Non-dilated left ventricular 
cardiomyopathy
7.3.1. Diagnosis
7.3.1.1. Index case
The non-dilated LV cardiomyopathy phenotype is defined by the pres­
ence of non-ischaemic LV scarring or fatty replacement in the absence 
of LV dilatation, with or without global or regional wall motion abnor­
malities, or isolated global LV hypokinesia without scarring (as assessed by the presence of LGE on CMR) that is unexplained solely by abnormal 
loading conditions (hypertension, valve disease) or CAD. Global LV sys­
tolic dysfunction is defined by abnormal LVEF (i.e. <50%).9
7.3.1.2. Relatives
Clinical testing in relatives may reveal non-diagnostic abnormalities. In 
this context, the presence of LV systolic global or regional dysfunction, 
or additional electrocardiographic abnormalities (e.g. repolarization ab­
normalities, low QRS voltages, frequent ventricular extrasystoles 
[>500 per 24 h] or NSVT) in a first-degree relative of an individual 
with NDLVC (or a first-degree relative with autopsy-proven 
NDLVC) is highly suggestive of NDLVC and warrants close follow-up.
In the absence of conclusive genetic information in the family, 
NDLVC should be considered familial if one or more first- or second- 
degree relatives have NDLVC, or when SCD has occurred in a first- 
degree relative at any age with an established diagnosis of NDLVC. 
Familial disease should also be suspected if a first-degree relative has 
sudden death at <50 years of age and autopsy findings suggestive of 
the NDLVC phenotype.
7.3.1.3. Diagnostic work-up
The key elements of the diagnostic work-up for all patients with 
NDLVC are described in Section 6 and include clinical history, labora­
tory tests, Holter monitoring and cardiac imaging, and genetic testing.
Recommendation Table 24 — Recommendations for 
an implantable cardioverter defibrillator in patients 
with dilated cardiomyopathy
Recommendations
Classa
Levelb
Secondary prevention
An ICD is recommended to reduce the risk of 
sudden death and all-cause mortality in patients with 
DCM who have survived a cardiac arrest or have 
recovered from a ventricular arrhythmia causing 
haemodynamic instability.530,531,884
I
B
Primary prevention
An ICD should be considered to reduce the risk of 
sudden death and all-cause mortality in patients with 
DCM, symptomatic heart failure, and LVEF ≤35% 
despite >3 months of OMT.861,885
IIa
A
The patient’s genotype should be considered in the 
estimation of SCD risk in DCM.185,186,869,886
IIa
B
An ICD should be considered in patients with DCM 
with a genotype associated with high SCD risk and 
LVEF >35% in the presence of additional risk factors 
(see Table 21).541,542,867,869,873,878,881,886
IIa
C
An ICD may be considered in selected patients with 
DCM with a genotype associated with high SCD risk 
and LVEF >35% without additional risk factors (see 
Table 21).869,873,881,886
IIb
C
An ICD may be considered in patients with DCM 
without a genotype associated with high SCD risk 
and LVEF >35% in the presence of additional risk 
factors.c,138,873,874
IIb
C
© ESC 2023
CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; ICD, implantable 
cardioverter defibrillator; LGE, late gadolinium enhancement; LVEF, left ventricular 
ejection fraction; OMT, optimal medical therapy; SCD, sudden cardiac death. 
aClass of recommendation. 
bLevel of evidence. 
cAdditional risk factors include syncope, LGE presence on CMR.
Table 21 High-risk genotypes and associated predic­
tors of sudden cardiac death
Gene
Annual 
SCD rate
Predictors of SCD
LMNA185,186,438,541,865,878,879
5–10%
Estimated 5-year risk of 
life-threatening arrhythmia 
using LMNA risk score 
(https://lmna-risk-vta.fr)
FLNC-truncating 
variants866,867,880
5–10%
LGE on CMR 
LVEF < 45%
TMEM43868,881
5–10%
Male 
Female and any of the 
following: LVEF <45%, 
NSVT, LGE on CMR, >200 
VE on 24h Holter ECG
PLN542,882,883
3–5%
Estimated 5-year risk of 
life-threatening arrhythmia 
using PLN risk score 
(https://plnriskcalculator. 
shinyapps.io/final_shiny) 
LVEF < 45% 
LGE on CMR 
NSVT
DSP185,186
3–5%
LGE on CMR 
LVEF < 45%
RBM20869
3–5%
LGE on CMR 
LVEF < 45%
© ESC 2023
CMR, cardiac magnetic resonance; DSP, desmoplakin; ECG, electrocardiogram; FLNC, 
filamin C; LGE, late gadolinium enhancement; LMNA, lamin A/C; LVEF, left ventricular 
ejection fraction; NSVT, non-sustained ventricular tachycardia; PLN, phospholamban; 
RMB, RNA binding motif protein; SCD, sudden cardiac death; VE, ventricular ectopic beats.


<!-- PAGE 65 -->

### Page 65

Echocardiography and CMR are both central to the diagnosis. 
Additional laboratory tests, exercise testing, EMB, and cardiac catheter­
ization may also be considered (see Section 6).
7.3.1.4. Electrocardiographic features
Recommendations on resting and ambulatory ECG testing are de­
scribed in Section 6.5 and are of particular importance in patients 
with NDLVC, as specific features can indicate the underlying genetic 
cause. Prolonged PR interval or AV block is frequent in neuromuscular 
causes of NDLVC and in sarcoidosis. Laminopathies are characterized 
by prolonged PR interval, AF, and ventricular ectopics (VEs), and fre­
quently show low voltage in pre-cordial leads.887 Depolarization abnor­
malities such as low QRS voltage are also a common finding in NDLVC 
caused by DSP and PLN variants.542 Ambulatory ECG monitoring is use­
ful in NDLVC patients to reveal supraventricular and ventricular ar­
rhythmias or bradycardias due to AV conduction block and is 
recommended at least yearly, or when there is a change in clinical sta­
tus. In some patients with NDLVC at high risk of developing conduction 
disease and/or arrhythmias (including laminopathies, neuromuscular 
disease, PLN, and FLNC-truncating variants), Holter monitoring may 
be considered more frequently.
7.3.1.5. Echocardiography
Comprehensive TTE is recommended for all patients with NDLVC as it 
provides all relevant information on the global and regional LV anatomy, 
function, and haemodynamics; valvular heart disease; right heart func­
tion; pulmonary pressure; atrial geometry; and other features.71,73
Advanced echocardiographic techniques (including deformation im­
aging using tissue Doppler and speckle tracking) can allow the early de­
tection of subclinical myocardial dysfunction in specific situations (e.g. 
genetic NDLVC carriers).71,74
7.3.1.6. Cardiac magnetic resonance
Cardiac magnetic resonance with LGE is the foremost imaging modality 
in NDLVC as it provides confirmation of the presence of non-ischaemic 
myocardial fibrosis that is essential for the diagnosis in most cases. 
Cardiac magnetic resonance can also be useful to detect the presence 
of myocardial oedema, which may suggest an inflammatory or myocar­
ditic aetiology, and to describe the extent and pattern of fibrosis 
distribution. This can provide clues to the underlying aetiology (e.g. sub­
epicardial distribution in post-myocarditis forms, patchy in sarcoidosis, 
extensive inferolateral in dystrophinopathies, septal mid-wall in LMNA 
carriers, and ring-like in DSP and FLNC variant carriers),71 and may pro­
vide additional prognostic value both for arrhythmia and heart failure 
severity.137,848
7.3.1.7. Nuclear medicine
The role of radionuclide imaging in NDLVC is limited. Measurement of 
18F-FDG uptake using PET, with focal or focal-on-diffuse FDG uptake 
patterns, especially if concomitant abnormal 18F-FDG-PET uptake in 
extracardiac tissues, can be useful in suspected cardiac sarcoidosis.849
Isolated cardiac uptake has also been described in patients with 
NDLVC caused by DSP variants.888
7.3.1.8. Endomyocardial biopsy
Endomyocardial biopsy (EMB) with immunohistochemical quantifi­
cation of inflammatory cells remains the gold standard investigation 
for the identification of cardiac inflammation. It may confirm the 
diagnosis of autoimmune disease in patients with unexplained heart 
failure and suspected giant cell myocarditis, eosinophilic myocardi­
tis, vasculitis, and sarcoidosis. In experienced centres, electroanato­
mical voltage mapping-guided EMB may improve the yield of 
diagnosis of NDLVC.889 The risks and benefits of EMB should be 
evaluated and this procedure should be reserved for specific situa­
tions where its results may affect diagnosis or treatment (see 
Section 6.7.5).
7.3.2. Genetic testing
The genes most commonly implicated in NDLVC are DSP, FLNC (trun­
cating variants), DES, LMNA, or PLN, but there is substantial overlap 
with the genetic background of both DCM and ARVC (Table 10). 
Desmoplakin (DSP) variants, in particular, cause a unique form of car­
diomyopathy with a high prevalence of LV fibrosis and myocardial in­
flammatory episodes.864
The identification of a P/LP gene variant in a patient with NDLVC al­
lows better prediction of the disease outcome and progression, may 
contribute to the indications for device implantation, informs genetic 
counselling, and allows familial screening for relatives (see Section 
6.8.3). Therefore, genetic testing is recommended in all patients with 
NDLVC.
Recommendations for clinical screening, genetic counselling, and 
testing are described in Sections 6.8.3 and 6.11. Evaluation of conduc­
tion disease, and atrial and ventricular arrhythmia, is of particular im­
portance in patients with NDLVC, as these may often be early 
phenotypic features. There are very few data on the natural history 
of phenotype-negative variant carriers or on the clinical yield of familial 
cascade screening in NDLVC, but cross-sectional studies suggest 
age-related increases in penetrance.9 Precautionary long-term evalu­
ation of first-degree relatives is therefore recommended.
7.3.3. Assessment of symptoms
Most patients with NDLVC are asymptomatic, but some develop 
symptoms related to arrhythmia or conduction disease (e.g. syncope, 
palpitation) or diastolic heart failure (e.g. dyspnoea). Sustained ventricu­
lar arrhythmia, cardiac arrest, or SCD can be the initial presentation in a 
proportion of patients. Assessment of symptoms in patients with car­
diomyopathies is described in Section 6.10.1.
7.3.4. Management
The clinical management of heart failure and other manifestations of 
NDLVC (atrial tachyarrhythmia, conduction disease) has been de­
scribed in the 2021 ESC Guidelines for the diagnosis and treatment of 
acute and chronic heart failure, the 2020 ESC Guidelines for the diagnosis 
and management of atrial fibrillation, the 2021 ESC Guidelines on cardiac 
Recommendation Table 25 — Recommendation for 
resting and ambulatory electrocardiogram monitoring 
in 
patients 
with 
non-dilated 
left 
ventricular 
cardiomyopathy
Recommendation
Classa
Levelb
Ambulatory ECG monitoring is recommended in 
patients with NDLVC annually or when there is a 
change in clinical status, to aid in management and 
risk stratification.
I
C
© ESC 2023
ECG, electrocardiogram; NDLVC, non-dilated left ventricular cardiomyopathy. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3567


<!-- PAGE 66 -->

### Page 66

pacing and cardiac resynchronization therapy, and the 2022 ESC Guidelines 
for the management of patients with ventricular arrhythmias and the pre­
vention of sudden cardiac death,69,299,336,724 and are discussed in 
Section 6.10.2.
7.3.5. Sudden cardiac death prevention in non-dilated 
left ventricular cardiomyopathy
The prediction and prevention of SCD is the cornerstone of the clinical 
care of patients with NDLVC.
7.3.5.1. Secondary prevention of sudden cardiac death
As in other cardiomyopathy subtypes, ICD implantation is recom­
mended in survivors of cardiac arrest and in patients who have experi­
enced sustained ventricular arrhythmias with haemodynamic 
compromise;531 the decision to implant should consider the patient’s 
view and their QoL, as well as the absence of other diseases likely to 
cause death within 1 year.
7.3.5.2. Primary prevention of sudden cardiac death
There are no available RCTs examining the usefulness of ICDs to 
prevent SCD in patients with mild or moderate LV dysfunction. 
Recommendations for ICD implantation in DCM individuals with 
LVEF <35% are discussed in Section 6.10.2 and also apply to pa­
tients with NDLVC and LVEF <35%. Most patients with NDLVC, 
however, have either normal or mildly impaired LV systolic func­
tion. Much of the data on the natural history and risk prediction 
in NDLVC are derived from cohorts that include either patients 
with DCM or with ARVC (see Sections 7.2 and 7.4), and data on 
patients with NDLVC are therefore necessarily very limited. 
However, the available data suggest that genotype is a major deter­
minant of SCD risk, with patients harbouring variants in PLN, 
TMEM43, DES, DSP, LMNA, FLNC (truncating variants), and 
RBM20 having a substantially higher rate of major arrhythmic events 
than other causes regardless of LVEF.440,542,864–869 For some 
high-risk 
genotypes 
(e.g. 
LMNA 
[https://lmna-risk-vta.fr]541), 
gene-specific (or, in the case of the PLN p.Arg14del variant, variant- 
specific [https://plnriskcalculator.shinyapps.io/final_shiny])542
risk- 
prediction scores have been developed that consider genotype 
characteristics and additional phenotypic features. Where such 
scores are available, they should be used to guide primary preven­
tion ICD implantation (Figure 12). As discussed in Sections 7.1.5 and 
7.2.5, the Task Force acknowledges the challenges associated with 
defining universal thresholds for acceptable risk across different car­
diomyopathy phenotypes, but is of the opinion that a similar ap­
proach to that taken in risk stratification for HCM is reasonable, 
although the 2022 ESC Guidelines for the management of patients 
with ventricular arrhythmias and the prevention of sudden cardiac death 
have suggested a higher threshold of 10% risk at 5 years to guide 
primary prevention ICD implantation in patients with NDLVC 
and LMNA variants.3 This Task Force recommends more overt 
shared decision-making based on real-world data as well as individ­
ual preferences, beliefs, circumstances, and values. Gaps in evidence 
are acknowledged and should be shared with patients, and compet­
ing risks related to the disease (heart failure, stroke) and to age and 
comorbidity, as well as device-related complications, should be 
discussed.
There are very few data to guide risk stratification in patients with 
NDLVC without a known causative gene variant, but on the basis of 
the existing literature, the Task Force suggests that it may be reasonable 
to consider primary prevention ICD implantation in patients with 
NSVT, a family history of SCD, or significant LGE. Additional risk fac­
tors, such as the burden of VE, may also help guide ICD implantation, 
but there are no data currently to support a specific threshold for 
VE burden, and this will depend on the underlying genotype and other 
clinical factors.542,867,872 In patients with unexplained syncope, PES may 
provide additional information on the underlying cause.875 There are no 
definitive data supporting the regular use of PES for primary prevention 
risk stratification in patients with NDLVC, but may be beneficial in pa­
tients with NDLVC and myotonic dystrophy with an independent indi­
cation to EP study to assess conduction disturbances,876 although the 
clinical value of this approach has not been consistently demon­
strated.877 Given the overlap with DCM and available data, and in keep­
ing with the 2022 ESC Guidelines for the management of patients with 
ventricular arrhythmias and the prevention of sudden cardiac death, the 
Task Force agreed that the recommendations for primary prevention 
ICD implantation in NDLVC should be the same as those for DCM 
(Figure 17), but the level of evidence is necessarily lower.
Recommendation Table 26 — Recommendations for 
an implantable cardioverter defibrillator in patients 
with non-dilated left ventricular cardiomyopathy
Recommendations
Classa
Levelb
Secondary prevention
An ICD is recommended to reduce the risk of 
sudden death and all-cause mortality in patients with 
NDLVC who have survived a cardiac arrest or have 
recovered from a ventricular arrhythmia causing 
haemodynamic instability.
I
C
Primary prevention
An ICD should be considered to reduce the risk of 
sudden death and all-cause mortality in patients with 
NDLVC, heart failure symptoms, and LVEF ≤35% 
despite >3 months of OMT.861,885
IIa
A
The patient’s genotype should be considered in the 
estimation of SCD risk in NDLVC.
IIa
C
An ICD should be considered in patients with 
NDLVC with a genotype associated with high SCD 
risk and LVEF >35% in the presence of additional risk 
factors (see Table 21).185,186,438,541,542,865–869,878–883
IIa
C
An ICD may be considered in selected patients with 
NDLVC with a genotype associated with high SCD 
risk and LVEF >35% without additional risk factors 
(see Table 21).
IIb
C
An ICD may be considered in patients with NDLVC 
without a genotype associated with high SCD risk 
and LVEF >35% in the presence of additional risk 
factors.c
IIb
C
© ESC 2023
ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NDLVC, 
non-dilated left ventricular cardiomyopathy; OMT, optimal medical therapy; SCD, sudden 
cardiac death. 
aClass of recommendation. 
bLevel of evidence. 
cAdditional risk factors include syncope, LGE presence on CMR.


<!-- PAGE 67 -->

### Page 67

7.4. Arrhythmogenic right ventricular 
cardiomyopathy
7.4.1. Diagnosis
7.4.1.1. Index case
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is charac­
terized structurally by a progressive myocardial atrophy with fibro-fatty 
replacement of the RV myocardium.890 Lesions can also be present in 
the LV myocardium; predominant LV disease can coexist in the same 
family. Arrhythmogenic right ventricular cardiomyopathy usually mani­
fests in the second to fourth decade of life.891 Men are affected more 
frequently than women and an age-related penetrance has been de­
monstrated, with high clinical and genetic variability.
An ARVC diagnosis should be suspected in adolescents or young 
adults with palpitations, syncope, or aborted sudden death. Frequent 
VEs or VT of LBBB morphology are among the most common clinical 
presentation. The presence of right pre-cordial TWI (V1–V3) in routine 
ECG testing should also be suspected for ARVC.10,892 Less common 
ECG changes include low QRS voltages in the peripheral leads and ter­
minal activation delay in the right pre-cordial leads.893 Right ventricular 
dilatation on 2D echocardiography is also a frequent reason for patient 
referral. Less common presentations are RV or biventricular heart fail­
ure that can mimic DCM or NDLVC.894 Patients with multiple variants 
are thought to develop a more severe phenotype, and patients with a 
DSP or DSG2 variant are more prone to develop heart failure.895,896
In children and young adults, syncope, palpitations, and ventricular 
arrhythmias are also the usual presenting symptoms.897 However, 
chest pain, dynamic ST-T wave changes on basal 12-lead ECG, and myo­
cardial enzymes release in the setting of normal coronary arteries are 
often reported, requiring differential diagnosis with myocarditis or 
acute myocardial infarction.898
7.4.1.2. Relatives
Clinical testing in relatives often reveals non-diagnostic abnormalities. In 
this context, the presence of RV systolic global or regional dysfunction, 
or additional electrocardiographic abnormalities (e.g. repolarization ab­
normalities, prolonged terminal activation duration, low QRS voltages, 
frequent ventricular extrasystoles [>500 per 24 h], or NSVT) in a first- 
degree relative of an individual with ARVC (or a first-degree relative 
with autopsy-proven ARVC) is highly suggestive of ARVC and warrants 
close follow-up.
7.4.1.3. Diagnostic work-up
The key elements of the diagnostic work-up for all patients with ARVC 
are defined by the diagnostic criteria used for the identification of af­
fected individuals. The revised Task Force criteria for the diagnosis of 
ARVC published by Marcus et al. in 2010 have been used for the diag­
nosis of ARVC for more than a decade.10 More recently, the Padua cri­
teria have offered an updated iteration to include LV involvement but 
are yet to be externally validated.5 Key elements of the diagnostic work- 
up include ECG, Holter monitoring, cardiac imaging, genetic testing, 
and, in specific circumstances, EMB.4,10,892 Additional laboratory tests, 
exercise testing, and cardiac catheterization should also be considered, 
as detailed in Section 6.
7.4.1.4. Electrocardiography and Holter monitoring
Abnormalities of the repolarization and depolarization as well as ar­
rhythmias are key to the diagnosis of ARVC.5 The diagnostic utility 
of late potentials on signal-averaged electrocardiogram (SAECG) 
has been challenged in patients with ARVC for showing poor sensitiv­
ity and specificity.5,899 It has been noted that epsilon waves are fre­
quently overdiagnosed and that there is poor agreement even 
between experts regarding their presence.900 Furthermore, it has 
been demonstrated that they occur in the presence of severe struc­
tural disease and thus add little to the diagnosis.900,901 Therefore, ep­
silon waves and SAECG should be utilized for diagnostic purposes 
with caution.
7.4.1.5. Echocardiography and cardiac magnetic resonance
A comprehensive cardiac imaging assessment is recommended for all 
ARVC patients.71,73 Structural and functional alterations assessed by 
echocardiography and CMR are key to ARVC diagnosis.10 The key fea­
ture is the presence of wall motional abnormalities such as RV akinesia, 
dyskinesia, or bulging, and the determinant of the diagnostic perform­
ance is the level of RV dilatation or dysfunction (major and minor cri­
teria). Cardiac magnetic resonance should be considered the first-line 
test for assessment of the RV functional structural abnormalities criter­
ion as it has demonstrated superior sensitivity.10 Contrast-enhanced 
CMR is the only tool allowing the detection of LV involvement which 
remains otherwise underestimated by applying the 2010 Task Force 
Criteria. Tissue characterization by CMR or indirectly by electroanato­
mical voltage mapping may show signs of fibro-fatty replacement that 
can be present in either ventricle.889,903,904
7.4.1.6. Endomyocardial biopsy
Differential diagnosis in patients with suspected ARVC includes inflam­
matory processes affecting the right ventricle such as myocarditis and 
sarcoidosis. In some instances, especially when dealing with probands 
with a sporadic form, EMB may be helpful to rule out myocarditis 
and sarcoidosis.72,892,905 Endomyocardial biopsy can also be useful in 
selected patients in whom non-invasive assessment is inconclusive.4,72
Electroanatomic voltage mapping-guided EMB may be considered in se­
lected cases, particularly in case of negative CMR.906
7.4.1.7. Nuclear medicine
Measurement of 18F-FDG uptake using PET, with focal or 
focal-on-diffuse FDG uptake patterns, can be useful in suspected car­
diac sarcoidosis.849 However, it has been demonstrated that patients 
with ARVC can also show myocardial 18F-FDG-PET uptake.888,907
Therefore, there is a limited role for radionuclide imaging in ARVC un­
less there is concomitant abnormal 18F-FDG-PET uptake in extracar­
diac tissues, or other clinical features suggestive of cardiac 
sarcoidosis.904,908
Recommendation Table 27 — Recommendation for 
resting and ambulatory electrocardiogram monitoring 
in patients with arrhythmogenic right ventricular 
cardiomyopathy
Recommendation
Classa
Levelb
Annual ambulatory ECG monitoring is 
recommended in patients with ARVC to aid in 
diagnosis, management, and risk stratification.902
I
C
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3569


<!-- PAGE 68 -->

### Page 68

7.4.1.8. Arrhythmogenic right ventricular cardiomyopathy 
phenocopies
In suspicion of ARVC, a systematic approach to investigation of pheno­
copies should be undertaken. Differential diagnosis in patients with sus­
pected ARVC includes myocarditis, sarcoidosis, RV infarction, DCM, 
Chagas disease, pulmonary hypertension, and CHD with volume over­
load (such as Ebstein anomaly, atrial septal defect, and partial anomal­
ous venous return, left-to-right shunt, and pericardial agenesis).909,910
Disease phenocopies also include non-structural diseases. In fact, one 
of the main diagnostic dilemmas is to distinguish ARVC from idiopathic 
RV outflow tract VT, since the latter is usually benign.4 The idiopathic 
nature of VT is supported by the absence of family history, a normal 
basal 12-lead ECG, a normal ventricular structure by cardiac imaging 
and electroanatomic mapping, a single VT morphology, and the non- 
inducibility at programmed ventricular stimulation.
In highly trained competitive athletes, differential diagnosis with 
physiological adaptation to training needs to be considered.911 Right 
ventricular enlargement, ECG abnormalities, and arrhythmias reflect 
the increased haemodynamic load during exercise. While global RV sys­
tolic dysfunction and/or RWMAs, such as bulgings or aneurysms, are 
more in keeping with ARVC, the absence of overt structural changes 
of the right ventricle, frequent VEs, or inverted T waves in pre-cordial 
leads all support a benign nature (so-called athlete’s heart).72,912,913
7.4.2. Genetic testing and family screening
The genes underlying ARVC mainly encode proteins of the cardiac 
desmosome: plakophilin-2 (PKP2), desmoplakin (DSP), desmoglein-2 
(DSG2), desmocollin-2 (DSC2), and plakoglobin (JUP). In addition to 
desmosomal genes, P/LP variants have also been described in other 
genes, including DES,914 TMEM43,915 and PLN.190,882 Pathogenic or like­
ly pathogenic variants can be identified in up to 60% of patients with a 
diagnosis of ARVC.230 Given the diagnostic importance of genetic test­
ing in ARVC, it is important that genetic variants are frequently re- 
appraised in terms of their pathogenicity.916 The pattern of inheritance 
in the majority of ARVC families is autosomal dominant. The pene­
trance of the disease in genetic carriers is age, gender, and physical ac­
tivity dependent.892,917
Recommendations for clinical screening, genetic counselling, and 
testing are described in Sections 6.8.3 and 6.11. Cardiac evaluation 
should be adapted to the particular risk of complications in the family. 
Evaluation every 1–2 years including ECG, ECHO, and Holter/ECG 
monitoring is generally recommended for relatives at risk of developing 
the disease. Cardiac magnetic resonance should be considered at the 
baseline evaluation.
7.4.3. Assessment of symptoms
Patients with ARVC commonly experience palpitations and can de­
velop symptoms of heart failure, although this may occur many years 
after the appearance of the initial abnormalities. Assessment of symp­
toms in patients with cardiomyopathies is described in Section 6.10.1.
7.4.4. Management
The aim of the clinical management of ARVC relies on the improve­
ment of symptoms, the reduction of the pace of disease progression, 
and the prevention of complications. Recommendations for the 
pharmacological management of atrial arrhythmias and heart failure 
symptoms in patients with cardiomyopathies are described in Sections 
6.10.2 and 6.10.3.
7.4.4.1. Antiarrhythmic therapy
Beta-blockers constitute the first option to reduce arrhythmic burden 
via a reduction in adrenergic tone, particularly on exercise. Titration to 
the maximal tolerated dose has been associated with an improvement 
in survival from major ventricular arrhythmias in retrospective observa­
tional studies.918
Amiodarone is often used when other beta-blockers fail to control 
arrhythmias.917,919,920 It should, however, be used with caution for 
the long-term management of ventricular arrhythmias, especially in 
young patients. Sotalol has been used for many years, but evidence re­
garding its efficacy remain limited and conflicting.921,922 Flecainide 
should be considered when single agent treatment has failed to control 
arrhythmia-related symptoms in patients with ARVC or when auto­
nomic side effects limit the use of beta-blockers.923,924 Experience 
with other antiarrhythmics (dofetilide, ranolazine) is limited to very 
small case series.919,923
A proportion of patients require invasive arrhythmic procedures 
and/or ICD implantation. Complex endocardial and/or epicardial ap­
proach guided by three-dimensional (3D) electroanatomical mapping 
can be recommended but with a high recurrence rate (30–50% in ex­
perienced centres).919,925–927 Sympathetic denervation has also been 
used.928 Such procedures do not confer adequate protection against 
SCD, but may be very useful in reducing the VT burden and the risk 
of electrical storm.917 Discontinuation of intense physical exercise 
has shown a potential to slow the pace of disease progression and re­
duce the ventricular arrhythmia burden.917,919
7.4.5. Sudden cardiac death prevention in 
arrhythmogenic right ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy is characterized by its 
high propensity for ventricular arrhythmias and SCD.919 Although esti­
mated to be a rare disease, it has been consistently reported as one of 
Recommendation Table 28 — Recommendations for 
the antiarrhythmic management of patients with 
arrhythmogenic right ventricular cardiomyopathy
Recommendations
Classa
Levelb
Beta-blocker therapy is recommended in ARVC 
patients with VE, NSVT, and VT.920–922
I
C
Amiodarone should be considered when regular 
beta-blocker therapy fails to control 
arrhythmia-related symptoms in patients with 
ARVC.921,922
IIa
C
Flecainide in addition to beta-blockers should be 
considered when single agent treatment has failed to 
control arrhythmia-related symptoms in patients 
with ARVC.923,924
IIa
C
Catheter ablation with availability for epicardial 
approach guided by 3D electroanatomical mapping 
of VT should be considered in ARVC patients with 
incessant VT or frequent appropriate ICD 
interventions for VT despite pharmacological 
therapy with beta-blockers.925,929–934
IIa
C
© ESC 2023
3D, three-dimensional; ARVC, arrhythmogenic right ventricular cardiomyopathy; ICD, 
implantable cardioverter defibrillator; NSVT, non-sustained ventricular tachycardia; VE, 
ventricular ectopic beats; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 69 -->

### Page 69

the most common causes of SCD in registries around the world.935–937
Sudden cardiac death seems to be more prevalent in young athletic in­
dividuals affected by the disease.935,938
7.4.5.1. Secondary prevention of sudden cardiac death
Implantable cardioverter defibrillators reduce mortality in survivors of 
cardiac arrest and in patients who have experienced sustained symp­
tomatic ventricular arrhythmias.531 An ICD is recommended in such 
patients when the intent is to increase survival; the decision to implant 
should consider the patient’s view and their QoL, as well as the absence 
of other diseases likely to cause death within the following year.
7.4.5.2. Primary prevention of sudden cardiac death
Most of the current evidence on the outcomes of patients with ARVC 
and their predictors is limited to observational retrospective cohort 
studies that are typically of small size.939 Thus, the number of clinical pre­
dictors that can be studied using multivariate models is very limited, and 
most studies cannot be compared with one another. A systematic review 
and meta-analysis (n = 18 studies) has shown that the average risk of ven­
tricular arrhythmia ranges from 3.7 to 10.6% per year and that male sex, 
RV dysfunction, and prior non-sustained or sustained VT/VF consistently 
predict ventricular arrhythmias in populations with ARVC.939
The first comprehensive effort to offer an approach to risk stratifica­
tion in the context of decision-making for ICD implantation was made 
in the 2015 International Task Force consensus statement (ITFC) on 
the treatment of ARVC/dysplasia, where recommendations were 
made according to the presence of risk factors that would characterize 
the risk level of each patient.919 A follow-up study (n = 365) offered a 
modification on the International Task Force approach that resulted in 
better discrimination.940 The 2017 AHA/ACC/HRS guideline for manage­
ment of patients with ventricular arrhythmias and the prevention of sudden 
cardiac death941 and the 2019 HRS expert consensus statement on evalu­
ation, risk stratification, and management of arrhythmogenic cardiomyop­
athy4 have also offered alternative approaches to this issue. A 
risk-prediction model was developed from a multicentre collaboration 
(n = 528); it utilizes sex, age, recent syncope, NSVT, VE count, number 
of leads with TWI, and right ventricular ejection fraction (RVEF) as pre­
dictors to provide an individualized estimate of sustained ventricular ar­
rhythmias in patients with ARVC (arvcrisk.com).539
A study (n = 617) comparing the previous approaches to risk stratify 
patients has revealed that the modified ITFC approach provides the 
highest net benefit, up to an estimated 5-year risk of 25%, whereas 
AHA and HRS perform best in patients with an estimated 5-year risk 
>25%.538 In the same study, an estimated 5-year risk of 12.5% seems 
to be the optimal threshold, beyond which the risk-prediction model 
has the best performance. An external comparison (n = 140) of the dif­
ferent ARVC risk levels showed that the highest net benefit was seen 
with a 10% cut-off, using the 2019 ARVC risk calculator.536 In the 
same study, the 10% cut-off was superior to the HRS and ITFC ap­
proaches.536 Another external validation study (n = 128) of the 2019 
ARVC risk model showed that although discriminative ability is excel­
lent (c-index 0.84), the model seems to significantly overestimate the 
risk of patients below the 50% 5-year risk threshold.537 Recently, a cor­
rection to the 2019 ARVC risk calculator was issued.539 Two large ex­
ternal validation studies of the updated 2019 ARVC risk calculator have 
been published, suggesting a good discriminative performance, but the 
latter study revealed overestimation of risk.524,526 This raises concerns 
regarding the accuracy of the model in offering an individualized predic­
tion that can help inform patients during decision-making; however, it 
can remain informative due to its excellent discriminative performance. 
Furthermore, one study suggested that the updated 2019 ARVC risk 
calculator performs best in PKP2 patients, but its performance is 
more limited in gene-negative individuals.524
Therefore, a combination of these approaches is recommended to 
individualize risk quantification that can aid clinicians in balancing the 
risks and benefits of ICD implantation. The final decision should be 
made together with the patient, considering other competing risks 
and the patient’s risk tolerance. As discussed in Section 7.1.5, the 
Task Force acknowledges the challenges associated with defining uni­
versal thresholds for acceptable risk across different cardiomyopathy 
phenotypes, but is of the opinion that a similar approach to that taken 
in risk stratification for HCM, DCM, and NDLVC is reasonable. In this 
context, the Task Force recommends shared decision-making based on 
real-world data as well as individual preferences, beliefs, circumstances, 
and values. Gaps in evidence should be shared with patients, and com­
peting risks related to the disease (heart failure, stroke) and to age and 
comorbidity, as well as device-related complications, should be dis­
cussed. The suggested approach is summarized in Figure 18.
Patients with ARVC are known to suffer from sustained VTs that can 
be well tolerated without leading to SCD. Using appropriate ICD inter­
ventions as surrogate for SCD outcome has been shown to overesti­
mate SCD.942 Considering that, in most centres, a high ratio of ARVC 
patients will be implanted with an ICD, it is conceivable why this may 
hamper risk stratification for SCD in patients with ARVC. Efforts to ad­
dress this have been made within several studies,522,523,943–947 where
Recommendation Table 29 — Recommendations for 
sudden cardiac death prevention in patients with 
arrhythmogenic right ventricular cardiomyopathy
Recommendations
Classa
Levelb
Secondary prevention
An ICD is recommended to reduce the risk of 
sudden death and all-cause mortality in patients with 
ARVC who have survived a cardiac arrest or have 
recovered from a ventricular arrhythmia causing 
haemodynamic instability.939,943,944,948,949
I
A
An ICD should be considered in ARVC patients who 
have suffered a haemodynamically tolerated 
VT.522,939,943–945,948–950
IIa
B
Primary prevention
High-risk featuresc should be considered to aid 
individualized decision-making for ICD implantation 
in patients with ARVC.538,939
IIa
B
The updated 2019 ARVC risk calculator should be 
considered to aid individualized decision-making for 
ICD implantation in patients with ARVC.d,524,526,536– 
539
IIa
B
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; ICD, implantable cardioverter 
defibrillator; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular 
tachycardia; PES, programmed electrical stimulation; RVEF, right ventricular ejection 
fraction; SMVT, sustained monomorphic ventricular tachycardia; VT, ventricular 
tachycardia. 
aClass of recommendation. 
bLevel of evidence. 
cHigh-risk features: arrhythmic syncope, NSVT, RVEF <40%, LVEF <45%, SMVT at PES. 
dSee text for discussion of gene-specific differences in the performance of the updated 
2019 ARVC risk calculator.
ESC Guidelines                                                                                                                                                                                          3571


<!-- PAGE 70 -->

### Page 70

the outcome of interest is fast VT (>250 b.p.m.) rather than any sus­
tained VT. The largest of these studies (n = 864) has led to the develop­
ment of a separate score for the prediction of unstable VT/VF.945 Due to 
the lack of any external validation studies, there is insufficient informa­
tion to support the applicability of this risk score outside of its develop­
ment cohorts. Furthermore, a specific rate cut-off is also not well 
evidence-based and its performance to predict SCD remains unclear. 
Although it is likely that slower sustained VTs per se are not life- 
threatening, it remains unknown how frequently they would degenerate 
to faster VTs or VF. It is therefore reasonable to suggest that all patients 
at risk of any sustained ventricular arrhythmia should be offered primary 
prevention ICDs.
The role of PES in risk stratification of ARVC patients is not well de­
fined, particularly in those who are asymptomatic.523,939 However, cur­
rent practice suggests that inducibility of SMVT at PES might add value 
in patients with symptoms consistent with sustained ventricular ar­
rhythmia and this is further supported in this guideline3
7.5. Restrictive cardiomyopathy
7.5.1. Diagnosis
Patients with overt RCM manifest signs and symptoms typical of 
HFpEF.306 The systematic approach to diagnosis should include clinical 
examination, ECG, echocardiography, and CMR.951 Physical examin­
ation may show a prominent jugular venous pulse. In the advanced 
phases, the pulse volume is low, the stroke volume declines, and the 
heart rate may increase. Hepatomegaly, ascites, and peripheral oedema 
are common in decompensated patients. Echocardiography is the gold 
standard diagnostic tool; criteria for diagnosing and grading diastolic 
dysfunction have been previously described.951,952 Importantly, the de­
gree of diastolic dysfunction in patients with RCM is often only truly re­
strictive in advanced stages and most patients show milder grades of 
diastolic impairment at diagnosis.951 Cardiac catheterization should 
be performed in cases where the diagnosis is in doubt and to aid in 
the assessment for and timing of cardiac transplantation.953 Cardiac 
MRI distinguishes RCM from constrictive pericarditis, provides informa­
tion on the presence and extent of myocardial fibrosis, and contributes 
to distinguishing metabolic from inflammatory diseases.951,954
Endomyocardial biopsy is a precision diagnostic tool in restrictive 
cardio-desminopathies;955 iron myocardial overload, both intramyo­
cyte in haemochromatosis956 and mitochondrial in Friedreich ataxia 
cardiomyopathy;957 cystinosis;958 generalized arterial calcification of in­
fancy;955,959 and lysosomal storage diseases (LSDs).960,961 Deep pheno­
typing in probands should go beyond cardiac traits and explore 
extracardiac manifestations in syndromic diseases and in RCM asso­
ciated with neuromuscular disorders (see Section 6).962
7.5.2. Genetic testing
When inherited, RCM most commonly presents as an autosomal 
dominant disorder and, less commonly, autosomal recessive or spor­
adic. Genes associated with RCM encode sarcomeric structural and 
regulatory 
proteins 
and 
cytoskeletal 
intermediate 
filaments 
(Table 10). Although all major sarcomeric genes may cause RCM,963
the most common disease gene is TNNI3, which encodes the thin fila­
ment troponin I.964 Other less commonly involved genes include 
TNNT2, ACTC1, MYH7, MYBPC3, TTN, TPM1, MYPN, MYL3, and 
MYL2. Restrictive cardiomyopathy can be associated with intramyocyte 
accumulation of unfolded defective proteins, a feature that is increas­
ingly demonstrated in carriers of defects in DES, FLNC, and BAG3. 
These diseases have significant implications for prognosis and timely 
decision-making, both in children and adults. Restrictive cardiomyop­
athy may also occur in individuals with a family history of HCM289 or 
DCM.965 The observation of different cardiomyopathy phenotypes 
within families suggests a variable response to the variant, and
Cardiac arrest or syncopal VT
Non-syncopal sustained VT
ICDa
(Class I)
ICDa
(Class IIa)
N
N
Patients with ARVC
Y
Y
High risk featuresb
ICD
(Class IIa)
Figure 18 Algorithm to approach implantable cardioverter defibrillator decision-making in patients with arrhythmogenic right ventricular cardiomyopathy. 
ARVC, arrhythmogenic right ventricular cardiomyopathy; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NSVT, non- 
sustained ventricular tachycardia; PES, programmed electrical stimulation; RVEF, right ventricular ejection fraction; SMVT, sustained monomorphic ventricu­
lar tachycardia; VT, ventricular tachycardia. aClinicians should aim to control ventricular arrhythmia with pharmacological or invasive antiarrhythmic therapies 
in addition to offering an ICD. bHigh-risk features are defined as either cardiac syncope, NSVT, RVEF <40%, LVEF <45%, SMVT at PES or as per the updated 
2019 ARVC risk calculator.539


<!-- PAGE 71 -->

### Page 71

implicates factors beyond the specific variant in the determination of 
ultimate clinical manifestation of disease.966 Hereditary infiltrative dis­
eases can also cause RCM, the most common of which is amyloidosis 
caused by pathogenic variants in the TTR gene, although this is usually in 
the presence of LVH (see Section 7.7).
7.5.3. Assessment of symptoms
Patients with RCM often develop symptoms of heart failure, although 
this can occur some years after the appearance of the initial abnormal­
ities. Assessment of symptoms in patients with cardiomyopathies is de­
scribed in Section 6.10.1.
7.5.4. Management
The administration of heart failure medications and device implantation, 
including ventricular assist device as a bridge-to-candidacy is guided by 
symptoms and heart failure phenotype and severity,967 and is described 
in Section 6.10.2. Precision diagnosis (phenotype and cause) is key to time­
ly planning of heart transplantation as it guarantees the exclusion of all 
genetic and acquired phenocopies that may be amenable to alternative 
treatment. Prevention of heart transplantation in all RCM patients with 
alternative treatments is a major goal for all adult and paediatric RCM.
Precise diagnosis is also essential for genetic phenocopies with avail­
able target treatments: ERT for Anderson–Fabry disease or glycogeno­
sis 
such 
as 
Pompe 
disease; 
therapeutic 
phlebotomy 
for 
haemochromatosis; immunosuppressive therapeutics for sarcoidosis; 
new biological drugs for systemic diseases (e.g. autoimmune diseases 
with cardiac involvement that can reverse or stabilize by treating the 
disease itself); and removal of the toxic causes (see Figure 19 and 
Supplementary data online, Table S4). Precision diagnosis today is es­
sential due to the increasing availability of disease-specific treatments 
and diagnostic tools to exclude geno/phenocopies.
Restrictive heart diseases
Intrinsic myocyte dysfunction
Genetic
Primary RCM
Variants in sarcomeric,
cytoskeletal, nuclear envelope, filamin, titin genes
Storage
AFD
Desmin
Danon
Glycogenoses
PRKAG2 variants
Iron overload/storage disorders
Non-genetic
Myocardial extracellular matrix disorders
Infiltrative
Fibrosis
Amyloidosis
Sarcoidosis
Diabetic heart disease
Drugs (e.g. chloroquine)
Hyperoxaluria
Radiation
Chemotherapy
Systemic sclerosis
Inflammatory/granulomatous
Endomyocardial disorders
Endomyocardial fibrosis
Hypereosinophilia
Carcinoid
Endocardial fibroelastosis
Endocardial neoplasms
Iatrogenic/drug toxicity
RCM
Myocardial diseases with occasional restrictive physiology, often in the context of LVH
Figure 19 Spectrum of restrictive heart diseases. AFD, Anderson–Fabry disease; LVH, left ventricular hypertrophy; PRKAG2, Protein kinase 
AMP-activated non-catalytic subunit gamma 2; RCM, restrictive cardiomyopathy. For a more detailed spectrum of restrictive heart disease, please refer 
to Supplementary data online, Table S4.Image %:   
ESC Guidelines                                                                                                                                                                                          3573


<!-- PAGE 72 -->

### Page 72

Restrictive cardiomyopathy is associated with the worst prognosis of 
all the cardiomyopathy phenotypes. Survival data are limited to small 
windows of observation. The prognosis of RCM largely depends on 
the restrictive physiology, regardless of the underlying cause.968–971
More than 50% of children with RCM are at risk of death (including 
SCD) or transplantation shortly after diagnosis; clinical features puta­
tively associated with increased risk of death or transplantation include: 
heart failure symptoms; reduced LV systolic function; increased left at­
rial size; syncope; ischaemia; and impaired LV diastolic function on 
echocardiography.286,969,972,973 Up to 75% of surviving patients demon­
strate heart failure, and the outcome is either death or heart transplant­
ation within a few years of diagnosis.968,969 Elevated pulmonary vascular 
resistance (PVR) is present in up to 40% of children with RCM, and can 
rise quickly even in the absence of other clinical changes, which has an 
impact on suitability for and timing of cardiac transplantation.953
Cardiac catheterization with an assessment of PVR is therefore recom­
mended in all children at diagnosis and every 6 to 12 months.953 In adult 
patients with genetic RCM, the main cause of death is heart failure 
(more than 40%), with a 5-year survival rate of ∼50% in cohorts that 
include patients with HCM and restrictive physiology.616
7.6. Syndromic and metabolic 
cardiomyopathies
It is beyond the scope of these guidelines to provide a detailed review 
and recommendations on specific cardiomyopathy genocopies and 
phenocopies. Instead, the Task Force refers the reader to detailed pos­
ition statements and consensus documents published on behalf of the 
ESC Working Group on Myocardial and Pericardial Diseases (e.g. on 
Anderson–Fabry Disease and amyloidosis ).370,375,974 This section high­
lights only the key diagnostic and management issues. Table 22 sum­
marizes the clinical features and management of syndromic and 
metabolic cardiomyopathies.
7.6.1. Anderson–Fabry disease
7.6.1.1. Definition
Anderson–Fabry disease is an inborn error of metabolism where a de­
ficient or absent enzyme, alpha-galactosidase A (α-Gal A), due to a 
pathogenic genetic variant in the GLA gene, causes the storage of 
some degradation cell products, mainly globotriaosylceramide (Gb3) 
in a patient’s lysosomes.975 This storage causes cell dysfunction in its 
own right and activates cellular hypertrophy pathways, common to 
other causes of HCM, as well as inflammation and immune activa­
tion.976 It is a multisystem disorder affecting particularly the heart, kid­
ney, and brain. 975 It is inherited in an X-linked manner; males are 
therefore always affected, while females’ organ involvement usually de­
velops later in life but can become similar to males due to the lyoniza­
tion phenomena.977,978
Two Anderson–Fabry phenotypes can be distinguished, depending 
on the gender, lyonization phenomena, and pathogenic genetic 
variant:976,979
• A severe clinical phenotype, known as ‘classic’ Anderson–Fabry char­
acterized by absent or severely reduced (<1% of mean normal) α-Gal 
A activity, marked Gb3 accumulation, and childhood or adolescent 
onset of symptoms followed by progressive multiorgan failure, is 
most often seen in males (but not exclusively) without residual en­
zyme activity.
• A ‘non-classical’ Anderson–Fabry phenotype or later-onset pheno­
type with incomplete systemic involvement, which is seen in both 
males and females, with some level of residual enzyme activity, and 
in most cases manifesting as isolated cardiac involvement.
7.6.1.2. Diagnosis, clinical work-up, and differential diagnosis
Anderson–Fabry disease should be suspected in patients with LVH and 
additional cardiac and extracardiac red flags (see Table 23) sought 
(Figure 20). The diagnosis is established by assessment of α-GalA activity 
and lyso-Gb3 measurement in male patients; in females, genetic testing 
is usually required to confirm the diagnosis. Severe LVH (>15 mm) is 
unlikely to be seen in patients <20 years of age.980 In children and ado­
lescents, diagnosis is made by family history or based on other extracar­
diac symptoms, but overt LVH is usually not present.981
7.6.1.3. Clinical course, outcome, and risk stratification
Cardiovascular involvement usually manifests as LVH, myocardial fibro­
sis, inflammation, heart failure, and arrhythmias, which limit QoL and 
are the most common cause of death. Clinical monitoring is essential 
to assess disease progression and requires a multidisciplinary 
approach.980
Recommendation Table 30 — Recommendations for 
the 
management 
of 
patients 
with 
restrictive 
cardiomyopathy
Recommendations
Classa
Levelb
It is recommended that multimodality imaging be 
used to differentiate RCM from HCM or DCM with 
restrictive physiology.
I
C
It is recommended that baseline cardiac and 
non-cardiac investigations are performed to assess 
involvement of the neuromuscular system or other 
syndromic disorders.
I
C
Cardiac catheterization is recommended in all 
children with RCM to measure pulmonary artery 
pressures and PVR at diagnosis and at 6–12 monthly 
intervals to assess change in PVR.953
I
B
ICD implantation is recommended to reduce the risk 
of sudden death and all-cause mortality in patients 
with RCM who have survived a cardiac arrest or have 
recovered from a ventricular arrhythmia causing 
haemodynamic instability.
I
C
Endomyocardial biopsy should be considered in 
patients with RCM to exclude specific diagnoses 
(including iron overload, storage disorders, 
mitochondrial cytopathies, amyloidosis, and 
granulomatous myocardial diseases) and to diagnose 
restrictive myofibrillar disease caused by desmin 
variants.
IIa
C
ICD implantation may be considered in children with 
RCM who have evidence of myocardial ischaemia and 
syncope.969
IIb
C
© ESC 2023
DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICD, implantable 
cardioverter defibrillator; PVR, pulmonary vascular resistance; RCM, restrictive 
cardiomyopathy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 73 -->

### Page 73

Table 22 Clinical features and management of syndromic and metabolic cardiomyopathies
Clinical red flags
Diagnosis
Specific cause
Multidisciplinary 
team
Management
Abnormal facial features 
Cryptorchidism 
Pulmonary valve stenosis 
Congenital heart disease 
Extreme right-axis 
deviation at ECG 
Lymphangectasis 
Bleeding diathesis 
Café au lait spots 
Lentigines 
Growth retardation 
Sensorineural deafness
NGS panel testing for RASopathy
Noonan syndrome 
Costello syndrome 
Cardiofaciocutaneous 
syndrome 
Noonan syndrome with 
multiple lentigines
Cardiologist 
Geneticist 
Endocrinologist 
Paediatrician 
Dermatologist 
Radiologist
Beta-blockers/CCBs 
Selective management of RVOTO/ 
pulmonary valvuloplasty 
SCD risk stratification
Short PR interval 
End-stage, hypokynetic 
HCM 
AV block (Kearns–Sayre 
syndrome) 
Lactic acidosis 
Sensorineural deafness 
Neutropenia (Barth 
syndrome) 
Diabetes 
Stroke-like lesions at 
brain MRI
NGS panel for mtDNA and 
nuclear DNA 
Skeletal muscle biopsy/ 
endomyocardial biopsy
MELAS syndrome 
MERRF syndrome 
Leigh syndrome 
Other mitochondrial 
disease 
Beta-oxidation disorders
Cardiologist 
Neurologist 
Endocrinologist 
Paediatrician 
Metabolism expert 
Radiologist
Avoiding drugs or situational 
stressors 
Beta-oxidation disorders: 
nutritional management, avoidance 
of fasting, aggressive treatment 
during increased metabolic stress 
Carnitine supplementation 
(selected cases)
Hepatomegaly 
Increased 
aminotransferase 
enzymes 
Delayed motor 
milestones 
Hypotonia 
Short PR interval 
ECG criteria for extreme 
LVH
Screening: GAA activity in DBS or 
leucocytes/Glc4 dosing 
Diagnostic confirmation: acid 
alpha-glucosidase assay performed 
on skin fibroblasts (preferred 
method) or muscle biopsy
Type II glycogen storage 
disease (Pompe disease)
Cardiologist 
General Paediatrician/ 
neonatologist 
Gastroenterologist 
Neuromuscular 
disease specialist
Enzyme replacement therapy
Short PR interval 
Massive LVH 
Skeletal myopathy 
Increased serum CK 
enzyme 
Intellectual disability 
X-linked inheritance
NGS or target testing for LAMP-2 
variants
Danon disease
Cardiologist 
Neuromuscular 
disease specialist 
Pneumologist 
Advanced heart failure 
specialist
No treatment
Short PR interval 
Early-onset atrial 
fibrillation 
AV block 
Increased serum CK 
enzyme 
Autosomal dominant 
inheritance pattern
NGS or target testing for PRKAG2
PRKAG2 syndrome
Cardiologist 
Neuromuscular 
disease expert
No treatment
Continued 
ESC Guidelines                                                                                                                                                                                          3575


<!-- PAGE 74 -->

### Page 74

Progressive limb ataxia 
Diabetes mellitus 
Pes cavus 
Reduced native T1 at 
CMR imaging
NGS testing for bi-allelic expansion 
of GAA repeats in the FXN gene
Friedreich ataxia
Cardiologist 
Neurologist 
Endocrinologist 
Orthopaedic surgeon 
Neuromuscular 
disease expert
No specific treatment
Bilateral carpal tunnel 
syndrome 
Lumbar spinal stenosis 
Autonomic dysfunction 
Peripheral neuropathy 
Relative apical sparing 
pattern 
Ejection fraction/strain 
ratio >5 
Pseudonecrosis Q waves 
Low ECG voltages 
OR 
Positive serum or urine 
monoclonal chain at 
immunofixation
DPD/HMDP Tc99 scintigraphy 
Free light chain/serum and urine 
immunofixation 
Endomyocardial biopsy
Cardiac amyloidosis (AL 
or ATTR) (see Section 7.7)
Cardiologist 
Neurologist 
Nephrologist 
Haematologist (AL 
amyloidosis) 
Ophthalmologist
Tafamidis 
Patisirana 
Inotersena 
(ATTR-CA) 
OR 
Specific chemotherapy 
(AL amyloidosis)
Gastrointestinal 
symptoms 
Angiokeratoma 
Cornea verticillata 
Chronic kidney disease 
Proteinuria 
Sensorineural hypoacusia 
Stroke/TIA 
Neuropathic pain 
X-linked inheritance 
pattern 
Short PR interval 
Low native T1 at cardiac 
CMR
Screening in males: lyso-Gb3 
dosing 
Screening in females/diagnostic 
confirmation: genetic testing for 
GLA variants
Anderson–Fabry disease
Cardiologist 
Nephrologist 
Neurologist 
Ophthalmologist 
Audiologist 
Gastroenterologist 
Dermatologist
Enzyme replacement therapy 
(agalsidase alfa/beta) 
Migalastat
Skeletal myopathy 
Posterolateral 
pseudonecrosis pattern 
Posterolateral or 
inferolateral akinesia
Genetic testing for 
dystrophinopathies
DMD
Neurologist 
Cardiologist 
Pneumologist 
Neuromuscular 
disease expert
Steroids (prednisone or 
deflazacort)
Skeletal myopathy 
AV block 
Premature atrial 
fibrillation 
Malignant ventricular 
arrhythmias
NGS testing
LMNA cardiomyopathy 
Emery–Dreifuss muscular 
dystrophy
Cardiologist 
Neurologist
SCD risk prevention 
Pacing if indicated
Bilateral hilar 
lymphadenopathy 
Pulmonary infiltrates 
Uveitis 
Gastrointestinal 
involvement 
High-degree AV block 
Frequent VEs 
Thinned basal 
interventricular septum 
Extended LGE at CMR 
imaging
18F-FDG-PET 
Endomyocardial biopsy 
Lung biopsy
Sarcoidosis
Cardiologist 
Pneumologist 
Neurologist 
Gastroenterologist
Steroids 
Steroid-sparing 
immunosuppressant drugs
Continued


<!-- PAGE 75 -->

### Page 75

7.6.1.4. Management
Specific treatment strategies, including enzyme replacement or 
pharmacological chaperone, have limited efficacy in advanced cases 
with irreversible organ damage, so early initiation appears to be import­
ant. Enzyme replacement therapy is indicated in all symptomatic 
patients with classical disease, including children, at the earliest signs 
of organ involvement.974 Therapeutic strategies currently in develop­
ment include second-generation ERTs, substrate-reduction therapies, 
and gene and mRNA therapies.980
7.6.2. RASopathies
7.6.2.1. Definition
The RASopathies constitute a group of multisystemic syndromes caused 
by variants in the RAS-mitogen-activated kinase (RAS-MAPK) cas­
cade,984–986 including Noonan syndrome,987–989 Noonan syndrome 
with multiple lentigines;990,991 Costello syndrome,992,993 and cardiofa­
ciocutaneous syndrome.994–996
7.6.2.2. Diagnosis, clinical work-up, and differential diagnosis
The suspicion of an underlying RASopathy should be raised in infant- 
and childhood-onset HCM with coexisting CHD262,263,991,997–1000 or 
extracardiac abnormalities (see Table 22). Gene testing is recom­
mended for diagnosis when phenotypic features are present. 
Compared with sarcomeric HCM, RASopathy-associated HCM 
(RAS-HCM) shows earlier age at diagnosis,261,999 increased prevalence 
and severity of left or biventricular obstruction,258,262,1001 and higher 
rates of early hospitalizations for heart failure or need for interventional 
procedures or surgery.258
Pulmonary stenosis is the most 
commonly associated CHD, with a prevalence ranging between 25% 
and 70%, and unfavourable outcomes for pulmonary valvulo­
plasty.256,1002–1004
7.6.2.3. Clinical course, management, and sudden death risk 
stratification
Data from the North American Pediatric Cardiomyopathy Registry1005
cohort show poorer survival rates among patients with RAS-HCM 
compared with non-syndromic HCM, particularly in patients who 
have been diagnosed before 1 year of age. Disease-specific risk factors 
for SCD are currently an area of debate, and may include the degree of 
LV hypertrophy, prolonged QTc interval, ECG risk score for HCM,771
and the HCM Risk-Kids score >6%.81,826
7.6.2.4. Management
Non-vasodilating beta-blockers should be titrated to maximum toler­
ated dose in patients with RAS-HCM, particularly in cases of severe
Previous transfusions 
Chronic liver disease 
Skin pigmentation 
Diabetes 
Hypogonadotropic 
hypogonadism 
Elevated ferritin 
AV block
Iron status 
Complete blood count 
Increased T2* values at CMR 
imaging 
Genetic test for HFE, HJV, hepcidin 
receptor, ferroportin, HAMP gene 
Peripheral blood smear 
Haemoglobin electrophoresis 
Genetic testing for hereditary 
haemoglobinopathies
Iron overload 
cardiomyopathy
Cardiologist 
Haematologist 
Endocrinologist 
Paediatrician 
Gastroenterologist
Iron-chelating drugs 
Phlebotomy
© ESC 2023
18F-FDG-PET, 18F-fluorodeoxyglucose positron emission tomography; AL, amyloid light chain; ATTR, transthyretin amyloidosis; ATTR-CA: transthyretin cardiac amyloidosis; AV, 
atrioventricular; CCB, calcium channel blocker; CK, creatinine kinase; CMR, cardiac magnetic resonance; DBS, deep brain stimulation; DMD, Duchenne muscular dystrophy; DPD, 
3,3-diphosphono-1,2-propanodicarboxylic acid; ECG, electrocardiogram; Gb3, globotriaosylceramide; HCM, hypertrophic cardiomyopathy; HMDP, hydroxymethylene diphosphonate; 
LGE, late gadolinium enhancement; LMNA, lamin A/C; LVH, left ventricular hypertrophy; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
(syndrome); MERRF, mitochondrial epilepsy with ragged-red fibres; MRI, magnetic resonance; mtDNA, mitochondrial DNA; NGS, next-generation sequencing; PRKAG2, protein kinase 
AMP-activated non-catalytic subunit gamma 2; RVOTO, right ventricular outflow tract obstruction; SCD, sudden cardiac death; TIA, transient ischaemic attack; VE, ventricular ectopic beats. 
aPatisiran and inotersen approved for treatment of familial polyneuropathy with/without cardiomyopathy.
Table 23 Anderson–Fabry disease red flags
Extracardiac red flags
No male-to-male transmission in pedigree
Renal involvement (dialysis, renal transplantation) or LVH in relatives
Neuropathic pain
Angiokeratomas
Albuminuria
Cornea verticillata
Hypohidrosis, heat/cold and exercise intolerance
Gastrointestinal symptoms (nausea, vomiting, non-specific abdominal pain, 
constipation, diarrhoea)
Hearing loss (either progressive or sudden), tinnitus, vertigo
Cardiac red flags
ECG
Short PQ interval in young patients
Atrioventricular blocks in adult patients
Bradycardia
Chronotropic incompetence
LVH
Echocardiogram
LVH with normal systolic function
Hypertrophy of papillary muscles
Mitral and aortic valve thickening with 
mild-to-moderate regurgitation
Reduced global longitudinal strain
CMR
Basal-inferolateral late gadolinium enhancement
Low native T1 (caution with ‘pseudonormalization’ in 
areas affected by fibrosis)
High focal/global T2
Laboratory
Elevated high-sensitivity troponin 
Elevated NT-proBNP
© ESC 2023
CMR, cardiac magnetic resonance; ECG, electrocardiogram; LVH, left ventricular 
hypertrophy; NT-proBNP, N-terminal pro-brain natriuretic peptide.
ESC Guidelines                                                                                                                                                                                          3577


<!-- PAGE 76 -->

### Page 76

biventricular obstruction.248,1002,1006–1008 Calcium channel blockers 
may be considered as a second-line option in patients >6 months of 
age when beta-blocker therapy is ineffective or not tolerated.267,639
Surgical myectomy and orthotopic heart transplantation may be con­
sidered in high-volume centres after multidisciplinary assessment by 
the heart team.265,266,1009–1011 Pulmonary valvuloplasty may be consid­
ered in children and infants with severe RV outflow tract obstruction 
(RVOTO).1012–1015
7.6.3. Friedreich ataxia
7.6.3.1. Definition
Friedreich ataxia is an autosomal recessive disorder caused by a 
homozygous GAA triplet repeat expansion in the frataxin (FTX) 
gene,1016–1019 leading to HCM, progressive neuromuscular symptoms, 
and extracardiac manifestations, including diabetes mellitus.1016,1020,1021
7.6.3.2. Diagnosis, clinical work-up, and differential diagnosis
Although several diagnostic criteria have been proposed to suspect 
Friedreich ataxia,1022,1023
genetic testing with identification of 
bi-co-allelic GAA expansion in the first intron of the FTX gene or com­
pound heterozygosis is required for diagnosis.1024,1025
Cardiovascular involvement usually manifests as hypertrophic non- 
obstructive cardiomyopathy, with hypokinetic end-stage disease pro­
gression and impaired perfusion reserve,1026 leading to advanced heart 
failure and death.248,1005,1027–1029 There appears to be no specific rela­
tionship between the extent of neurological involvement and cardiac 
If genetic study, include
GLA in HCM panel
N
Patient with suspected AFD
Red flags of AFDa
Results
VUS
Benign variant
P/LP variant
GLA genetic analysisb
Cardiac CMRc Lyso Gb3d Biopsye
Gender
Enzymatic activity
AFD unlikely
Diagnosis of AFD
Low index of suspicion
Female
Reduced
Normal
Normal
Abnormal
Y
Male
Figure 20 Anderson–Fabry disease diagnostic algorithm. α-Gal A, alpha-galactosidase A; AFD, Anderson–Fabry disease; CMR, cardiac magnetic resonance; 
Gb3, globotriaosylceramide; HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; lyso Gb3, globotriaosylsphingosine; P/LP, pathogenic/ 
likely pathogenic; VUS, variant of unknown significance. aSee Table 23. bGenetic analysis must include the study of possible large deletions or a copy number 
variation not detected by the Sanger method. cThe finding of increased plasma and/or urinary Gb3, or plasma lyso Gb3 and its analogues in the evaluation of 
male or female patients with a VUS and normal (in female patients) or lowered α-Gal A activity provides additional diagnostic information, but the role of 
biomarkers in such patients still requires validation. dLow native T1 values reinforce or generate suspicion of Fabry disease. Normal native T1 values do not 
exclude Fabry disease, as they are rarely observed in untreated patients with mild LVH (mostly females), or in advanced disease due to pseudonormalization. 
eAn endomyocardial biopsy is recommended, but could be done in other affected organs such as the kidneys and skin. It should be evaluated by expert 
pathologists and always include electron microscopy studies to detect lamellar bodies and intracellular inclusions. Of note, some drugs may produce 
drug-induced phospholipidosis with an intracellular accumulation of phospholipids in different organs that can mimic zebra bodies on electron 
microscopy.982,983


<!-- PAGE 77 -->

### Page 77

phenotype.248,1005,1027–1029,1005,1027–1030,1030 Mitochondrial iron stor­
age is the pathologic hallmark of the disease.1031
7.6.3.3. Clinical course, management, and risk stratification
Supraventricular arrhythmias, particularly AF, are commonly de­
tected.1027 Despite the lack of long-term follow-up longitudinal studies, 
the risk of ventricular arrhythmias and SCD seems low compared with 
sarcomeric HCM.1027,1032,1033 The Mitochondrial Protection with 
Idebenone in Cardiac or Neurological Outcome (MICONOS) study 
group1034 has proposed a staging of cardiac involvement based on 
LVEF and end-diastolic wall thickness. The extent of TWI at ECG, 
LVEF, LV end-diastolic posterior wall thickness, fibrosis on CMR, and 
hs-TnT have been proposed as negative prognostic factors.1035
7.6.3.4. Management
No specific treatment is currently available for Friedreich ataxia. 
Treatment with idebenone, a coenzyme Q10 analogue, showed the po­
tential to improve LV mass and cardiac outcomes in open-label stud­
ies;1036 nevertheless, four RCTs1037–1040 showed no significant 
benefit on cardiac or neurologic outcomes.
7.6.4. Glycogen storage disorders
7.6.4.1. Definition
Glycogen storage disorders (GSDs) represent a heterogeneous group 
of metabolic diseases, including infantile-onset Pompe disease (GSD, 
type IIa), Danon disease (GSD, type IIb), and PRKAG2 disease.272
7.6.4.2. Diagnosis, clinical work-up, and differential diagnosis
Despite wide clinical heterogeneity, a presentation within the first few 
months of life, hypotonia, failure to thrive, generalized muscle weak­
ness, and severe non-obstructive HCM with concentric pattern fol­
lowed by hypokinetic end-stage cardiomyopathy, usually within the 
first year of life, are typical of GSD IIa.259,268,1041,1042 Short PR interval 
and increased ECG voltages may represent useful diagnostic clues for 
GSDs.1042,1043 PRKAG2 syndrome should be suspected in the setting 
of autosomal dominant transmission and association with conduction 
system disease including ventricular pre-excitation, sick sinus syn­
drome, AF, AV block, intraventricular conduction delays or sinoatrial 
blocks.1043–1047 An X-linked pattern of inheritance is typical of 
Danon disease (GSD IIb). Skeletal myopathy, in association with learn­
ing disability, retinal involvement and ventricular pre-excitation, has 
been detected in males affected by Danon disease, while the cardiac 
phenotype can be isolated in affected females.1048–1052
7.6.4.3. Clinical course, management, and risk stratification
In the absence of therapeutic intervention, Pompe disease has a poor 
prognosis, mainly due to end-stage heart failure.268,1041 Recently, data 
from a large multicentre European registry have shown that Danon dis­
ease runs a malignant phenotype, but there are insufficient data to iden­
tify candidate risk factors for sudden death.1049 Sudden cardiac death 
occurs in almost 10% of patients with PRKAG2 syndrome, mainly as 
a consequence of advanced AV block, supraventricular tachycardia de­
generated to VF, or massive hypertrophy.1044,1053,1054
7.6.4.4. Management
Enzyme replacement therapy is recommended in patients with GSD 
IIa.269,274,275,1055,1056 To date, there are no approved aetiological ther­
apies for PRKAG2 syndrome and Danon disease. Heart failure therapy, 
antiarrhythmic therapy, and indications for the implantation of devices 
are included in Section 6.10.
7.7. Amyloidosis
It is beyond the scope of this document to provide specific recommen­
dations for the assessment and management of cardiac amyloidosis. 
Instead, the Task Force refers the reader to the 2021 position state­
ment of the ESC Working Group on Myocardial and Pericardial 
Diseases on Diagnosis and Treatment of Cardiac Amyloidosis.375
This section highlights only the key diagnostic and management issues.
7.7.1. Definition
Cardiac amyloidosis is characterized by the extracellular deposition of 
misfolded proteins in the ventricular myocardium with the pathogno­
monic histological property of green birefringence when viewed under 
cross-polarized light after staining with Congo Red.375
Although once considered a rare disease, data obtained in the last 
decade suggest that cardiac amyloidosis is underappreciated as a cause 
of common cardiac diseases or syndromes such as HFpEF, aortic sten­
osis, or unexplained LVH, particularly in the elderly.1057–1059 Although 
nine different types of cardiac amyloidosis have been described, most 
cases correspond to monoclonal immunoglobulin light chain amyloid­
osis (AL) or transthyretin amyloidosis (ATTR), either in its hereditary 
(ATTRv) or acquired (ATTRwt) form.375 The ATTRwt form, which 
is associated with ageing, is currently considered the most frequent 
form of cardiac amyloidosis worldwide.
7.7.2. Diagnosis, clinical work-up, and differential 
diagnosis
Cardiac amyloidosis should be suspected in patients with increased LV 
wall thickness in the presence of cardiac or extracardiac red flags and/or 
in specific clinical situations, as detailed in Figure 21, particularly in pa­
tients >65 years of age.375
Cardiac amyloidosis can be diagnosed using both invasive and non- 
invasive diagnostic criteria.375 Invasive diagnostic criteria apply to all 
forms of cardiac amyloidosis, whereas non-invasive criteria are ac­
cepted only for ATTR. Invasive criteria include demonstration of amyl­
oid fibrils within cardiac tissue or, alternatively, demonstration of 
amyloid deposits in an extracardiac biopsy accompanied either by char­
acteristic features of cardiac amyloidosis on echocardiography or 
CMR.375 Non-invasive criteria include typical echocardiographic/CMR 
findings combined with planar and single-photon emission computed 
tomography (SPECT) grade 2 or 3 myocardial radiotracer uptake in 
99mtechnetium-pyrophosphate (99mTc-PYP) or 3,3-diphosphono-1,2- 
propanodicarboxylic acid (DPD) or hydroxymethylene diphosphonate 
(HMDP) scintigraphy and exclusion of a clonal dyscrasia by all the fol­
lowing tests: serum free light chain assay, serum and urine protein elec­
trophoresis with immunofixation.168 Tomographic scintigraphy should 
be considered in order to reduce the number of misclassifications.1060
False negative scans may rarely occur in certain ATTRv genotypes; false 
positives may be due to AL, recent myocardial infarction, or long-term 
chloroquine use.370 Therefore, planar and SPECT scintigraphy coupled 
with assessment for monoclonal proteins followed by CMR and/or car­
diac/extracardiac biopsy if necessary allows appropriate diagnosis in pa­
tients with suggestive signs/symptoms, as described in Figure 22.375
However, the DPD/PYP/HMDP scan cannot distinguish between wild- 
type and mutated ATTR, and therefore TTR genetic testing is required. 
Of note, TTR genetic testing is recommended in all transthyretin amyl­
oid cardiomyopathy (ATTR-CM) patients regardless of age, as 5% of
ESC Guidelines                                                                                                                                                                                          3579


<!-- PAGE 78 -->

### Page 78

ATTR-CM patients ≥70 years (and 10% among females) have 
ATTRv.375,1061
7.7.3. Clinical course and risk stratification
Cardiac amyloidosis is a progressive disease with poor outcomes if left 
untreated. Amyloid light chain cardiac amyloidosis is associated with 
more rapid progression of heart failure and worse prognosis than 
ATTR.1058,1062,1063 Fortunately, the prognosis of AL amyloidosis has 
significantly improved with the introduction of very effective therapies 
capable of dramatically reducing the production of the cardiotoxic light 
chains.1064 Prognosis in ATTR depends on the variant, degree of cardiac 
involvement, and neurologic phenotype.1065–1068 Several multipara­
metric biomarker-based staging systems have been developed for 
AL1069,1070
and 
ATTR 
cardiac 
amyloidosis1066–1068
(see 
Supplementary data online, Table S5).
7.7.4. Management
The treatment of cardiac amyloidosis includes treating and preventing 
complications and stopping or delaying amyloid deposition by specific 
treatment.375,1071 There is no evidence to support the use of standard
Heart failure in 65 years
Aortic stenosis in 65 years
Hypotension or normotensive if previously hypertensive
Sensory involvement, autonomic dysfunction
Peripheral polyneuropathy
Proteinuria
Skin bruising
Bilateral carpal tunnel syndrome
Ruptured biceps tendon
Subendocardial/transmural LGE or increased ECV
Reduced longitudinal strain with apical sparing
Decreased QRS voltage to mass ratio
Pseudo Q waves on ECG
AV conduction disease
Possible family history of ATTR
Chronically increased troponin levels
Known multiple myeloma or MGUS
Left ventricular wall thickness 12 mm
1 of
Figure 21 Screening for cardiac amyloidosis. ATTR, transthyretin amyloidosis; AV, atrioventricular; ECG, electrocardiogram; ECV, extracellular volume; 
LGE, late gadolinium enhancement; MGUS, monoclonal gammopathy of undetermined significance.


<!-- PAGE 79 -->

### Page 79

heart failure therapy, which often is not well tolerated, apart from 
diuretics (see Section 6.10.2).1072,1073
The natural history of cardiac amyloidosis associates electrical con­
duction disease of the heart with symptomatic bradycardia and ad­
vanced AV block.375,1074,1075 The clinical threshold for pacemaker 
indication should be low, as the disease progresses and implantation 
of the device allows rate response to exercise and medication adjust­
ment.375,1074 The role of ICD in cardiac amyloidosis for SCD preven­
tion is not clearly known, but available data do not support their use 
in primary prevention.1076,1077
7.7.4.1. Specific therapies
Therapy for AL cardiac amyloidosis is based on treatment of the under­
lying haematological problem with chemotherapy or autologous stem- 
cell transplant.1064
Transthyretin stabilization and reduction of its production are the 
basis of TTR cardiac amyloidosis treatment. Tafamidis reduced all-cause 
mortality and cardiovascular hospitalizations in ATTR, with the largest 
effect achieved in patients at NYHA functional class I and II.1078
Additional studies are being conducted with other stabilizing agents 
and other molecules that reduce TTR production.1078a
8. Other recommendations
8.1. Sports
8.1.1. Cardiovascular benefits of exercise
Regular physical activity and systematic exercise confer several cardio­
vascular, psychological, and QoL benefits. Through curbing risk factors 
for atherosclerosis, such as obesity and insulin resistance,1079 hyperten­
sion,1080 and hyperlipidaemia,1081 regular physical activity is associated 
with an up to 50% risk reduction in an adverse event from CAD in 
middle-aged and older individuals.1082,1083 Individuals who exercise 
regularly live 5–7 years longer than their sedentary counterparts,1084
Scintigraphy grade
Haematologic tests
AL/ATTR cardiac amyloidosis unlikely
If suspicion 
persists consider repeat
CMR followed by biopsy
Scintigraphy grade
Haematologic tests
Grade
Cardiac ATTR
amyloidosis
TTR genetic testing
ATTRwt/ATTRv
Grade
Histological confirmation
(cardiac/
extracardiac)
to diagnose
Scintigraphy grade
Haematologic tests
Histological confirmation
(usually cardiac)
to subtype 
Scintigraphy grade
Haematologic tests
AL amyloidosis?
CMR
Amyloidosis unlikely
Histological confirmation
(cardiac/
extracardiac)
to diagnose
CMR       or inconclusive
Signs and symptoms, ECG, ECHO, or CMR suggestive of cardiac amyloidosis
99mTc-DPD/PYP/HMDP
scintigraphy with SPECT
Haematologic tests
(serum free light chain quantification and serum and urine immunofixation) 
0
-
1–3
-
0
+
1–3
+
I
2–3
-
+
Figure 22 Diagnosis of cardiac amyloidosis. AL, amyloid light chain; ATTR, transthyretin amyloidosis; ATTRv, variant transthyretin amyloidosis; ATTRwt, 
wild-type transthyretin amyloidosis; CMR, cardiac magnetic resonance; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; ECG, electrocardiogram; 
ECHO, echocardiogram; HMDP, hydroxymethylene diphosphonate; PYP, pyrophosphate; TTR, transthyretin.
ESC Guidelines                                                                                                                                                                                          3581


<!-- PAGE 80 -->

### Page 80

and have a lower risk of cerebrovascular accidents1085 and certain ma­
lignancies.1085–1087 These benefits that can be derived later in life also 
apply to individuals with established cardiovascular disease. For a defin­
ition of exercise intensity levels, please refer to Supplementary data 
online, Table S6.
8.1.2. Exercise-related sudden cardiac death and 
historical exercise recommendations for patients 
with cardiomyopathy
Rigorous exercise may trigger myocardial infarction and fatal arrhyth­
mias among individuals with an underlying cardiovascular disease.1088– 
1091 Superimposed on the pathological substrate of the disease entity 
itself, exercise may induce sudden cardiac arrest through mechanical 
shearing forces within the coronary arteries, effects of high concentra­
tions of circulating catecholamines, increased cardiac loading condi­
tions, raised core temperature, electrolyte shifts, and acid-base 
disturbance.
Cardiomyopathies are the leading cause of exercise-related SCD in 
young people in the Western world.40,1092–1095 The established link be­
tween exercise and SCD from cardiomyopathy, and the finding that, in 
some cardiomyopathy phenotypes, exercise may accelerate progres­
sion of the underlying cardiomyopathic disease process, has historically 
resulted in restrictive exercise recommendations in all affected patients 
regardless of pathology, disease severity, symptomatic status, general 
risk profile, or prior therapeutic interventions, including an ICD.1096– 
1098 As a result, individuals with cardiomyopathy often confine them­
selves to a relatively sedentary lifestyle through fear of potential SCD 
and accrue risk factors for atherosclerotic CAD, which confer a worse 
prognosis.1099–1102,1096,1097
8.1.3. Exercise recommendations in hypertrophic 
cardiomyopathy
Recent pre-clinical1103 and clinical data suggest that moderate exercise 
may be beneficial and safe in patients with HCM.1098–1102 Information 
on a safe dose of vigorous exercise is still limited, but the heteroge­
neous morphology and pathophysiology of HCM means that some in­
dividuals are capable of participating in vigorous exercise, including 
high-intensity competitive sports.760 Most athletes capable of exercis­
ing intensively have mild LV hypertrophy, normal-sized or enlarged 
LV, normal diastolic function, and no evidence of LVOTO.1104,1105
Currently available data indicate that participation in vigorous exercise 
and competitive sport may be considered in a select group of predom­
inantly adult patients who have mild morphology and a low-risk pro­
file.1106–1108 However, studies examining the effect of vigorous 
exercise or moderate-to-high-intensity competitive sport on the nat­
ural history of HCM were not designed or powered adequately to ad­
dress the question and there are potential issues of selection bias. 
Nevertheless, based on emerging evidence, the Task Force agreed to 
adopt a comparatively liberal approach, advocating that, after appropri­
ate selection, some individuals with a low-risk profile may participate in 
high-intensity exercise and competitive sport after comprehensive ex­
pert evaluation and shared discussion, which highlights the unpredict­
able nature of exercise-related SCD in HCM. Sporting disciplines in 
which syncope may result in fatal accidental injury or danger to others 
are not recommended.
Genotype-positive/phenotype-negative patients may engage in all 
competitive sport; however, annual assessment is recommended to 
check for developing phenotypic features of disease.1109
8.1.4. Exercise recommendations in arrhythmogenic 
right ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy is a recognized cause of 
exercise-related SCD in young asymptomatic individuals,40,890 postulated 
to result from ventricular stretch leading to myocyte detachment with 
subsequent inflammation and fibro-fatty replacement of the ventricular 
myocardium. Fatal arrhythmias may occur during the inflammatory pro­
cess or because of myocardial scar. In addition, there are data to suggest 
that high-intensity exercise is associated with acceleration of disease 
phenotype in individuals with ARVC, including those who are genotype 
positive/phenotype negative, and particularly those with PKP2 var­
iants.181,1110–1114 Furthermore, exercise restriction has been shown to 
improve clinical outcomes in patients with ARVC.40,1111,1115–1117 Based 
on these data, the Task Force recommends against intensive exercise 
or competitive sports in individuals with ARVC as part of a shared 
decision-making process. The evidence on the impact of exercise in 
genotype-positive/phenotype-negative individuals is more limited. In these 
cases, the Task Force recommends a cautious approach in the context of 
shared decision-making when discussing competitive sports participation. 
Mild-to-moderate physical activity for up to 150 min per week is consid­
ered safe and is recommended in able phenotype-negative individuals.1118
8.1.5. Exercise recommendations in dilated 
cardiomyopathy and non-dilated left ventricular 
cardiomyopathy
There is evidence that moderate exercise in optimally treated patients 
with DCM improves functional capacity, ventricular function, and 
QoL;1119 however, intensive exercise and competitive sports may 
also trigger fatal arrhythmias in DCM and NDLVC.1093,1120–1122
In general, symptomatic individuals with DCM and NDLVC should 
abstain from most competitive and leisure sports, or recreational exer­
cise associated with moderate or high exercise intensity. A select group 
of asymptomatic individuals with DCM and NDLVC who have mildly 
impaired LV function without exercise-induced arrhythmias or signifi­
cant myocardial fibrosis may participate in most competitive sports.
Although the natural history of most pathogenic variants capable of 
causing DCM and NDLVC is unknown, it would be reasonable to permit 
intensive exercise and competitive sports in most individuals with patho­
genic variants in the absence of overt features of DCM or NDLVC. 
Special consideration, however, should be given to individuals with 
pathogenic variants in genes that are associated with an increased risk 
of life-threatening arrhythmias, such as lamin A/C181,1123 or TMEM43 
variants, for which there is emerging evidence that exercise may have 
an adverse effect on cardiac function and risk of potentially fatal arrhyth­
mias. The impact of vigorous exercise in patients with pathogenic variants 
in other high-risk genes, such as filamin C variants1112 exhibiting DCM or 
NDLVC phenotypes, is not fully understood; however, extrapolating our 
understanding of the effect of exercise on some ARVC and DCM phe­
notypes necessitates a cautious approach.
Recommendation Table 31 — Exercise recommenda­
tions for patients with cardiomyopathy
Recommendations
Classa
Levelb
All cardiomyopathies
Regular low- to moderate-intensity exercise is 
recommended in all able individuals with 
cardiomyopathy.
I
C
Continued


<!-- PAGE 81 -->

### Page 81

8.2. Reproductive issues
Pregnancy and the post-partum period constitute periods of increased 
risk of cardiovascular complications in women with cardiomyop­
athy.1127–1130 Cardiomyopathy can also be first diagnosed in pregnancy 
or arise during pregnancy as PPCM.1131
The risk associated with pregnancy in a patient with a cardiomyop­
athy is estimated using the modified World Health Organization 
(mWHO) classification.1130 Pregnancy is contraindicated in women 
with WHO class IV, including patients with EF <30% or NYHA 
class III–IV or previous PPCM with persisting impairment of the LV 
function.
8.2.1. Contraception, in vitro fertilization, and 
hormonal treatment
Counselling on safe and effective contraception is indicated in all wo­
men of fertile age. Ethinyloestradiol-containing contraceptives have 
the greatest risk of thrombosis1132 and are not advised in women 
with a high risk of thrombo-embolic disease. Progestin-only contracep­
tives are an alternative, as they have little or no effect on coagulation 
factors, blood pressure, and lipid levels. Levonorgestrel-based long- 
acting reversible contraception implants or intrauterine devices are 
the safest and most effective contraceptives and have few side effects 
affecting cardiomyopathies.
Medically assisted procreation adds risks beyond those of pregnancy 
alone; superovulation is pro-thrombotic and can be complicated by 
ovarian hyperstimulation syndrome, with marked fluid shifts and an 
even greater risk of thrombosis. Hormonal stimulation should be care­
fully considered in women who have WHO class III disease (VT or 
HCM) or who are anticoagulated.
8.2.2. Pregnancy management
8.2.2.1. Pre-pregnancy
Patients with a known cardiomyopathy and at risk of developing cardio­
myopathy should receive pre-pregnancy counselling by a multidisciplin­
ary team: the pregnancy heart team. The individual risk of the woman 
by pregnancy should be discussed using the WHO classification, in add­
ition to discussing the likelihood of transmission of the disease to the 
offspring and how to reduce the transgenerational risk of transmitting 
the disorder.
For individual risk estimation, at a minimum, an ECG, echocardiog­
raphy, and exercise test should be performed. Several aspects must 
be discussed with the woman, including long-term prognosis, drug ther­
apy, estimated maternal risk and outcome, and plans for pregnancy care 
and delivery.
8.2.2.2. Pregnancy
In women with mWHO class II–III, III, and IV (including women with 
HCM, VTs, and EF <35%), management during pregnancy and around 
delivery should be conducted in an expert centre by a multidisciplinary 
team: the pregnancy heart team, including cardiologists with expertise 
in cardiomyopathies and arrhythmias; obstetricians; and anaesthetists. 
Depending on the individual case, other specialists may be included 
(geneticist, cardio-thoracic surgeon, paediatric cardiologist, foetal medi­
cine specialist, neonatologist, etc.). A delivery plan should be created 
that includes the details of induction; the management of labour and de­
livery; and post-partum surveillance.
An individualized risk assessment for exercise 
prescription is recommended in all patients with 
cardiomyopathy.
I
C
HCM
High-intensity exercise and competitive sport should 
be considered in genotype-positive/ 
phenotype-negative individuals who seek to do 
so.1124
IIa
C
High-intensity exercise and competitive sport may be 
considered in asymptomatic low-riskc individuals 
with morphologically mild hypertrophic 
cardiomyopathy in the absence of resting or 
inducible left ventricular outflow obstruction and 
exercise-induced complex ventricular 
arrhythmias.1107,1113,1125,1126
IIb
B
High-intensity exercise, including competitive sport, 
is not recommended in high-risk individuals and in 
individuals with left ventricular outflow tract 
obstruction and exercise-induced complex 
ventricular arrhythmias.
III
C
ARVC
Avoidance of high-intensity exercise, including 
competitive sport, may be considered in 
genotype-positive/phenotype-negative individuals in 
families with ARVC.1111,1116,1117
IIb
C
Moderate- and/or high-intensity exercise, including 
competitive sport, is not recommended in individuals 
with ARVC.181,1111–1114
III
B
DCM and NDLVC
Moderate- and high-intensity exercise should be 
considered in individuals who are gene positive and 
phenotype negative (with the exception of 
pathogenic variants in LMNA and TMEM43) who seek 
to do so.1123
IIa
C
High-intensity exercise and competitive sport may be 
considered in a select group of asymptomatic and 
optimally treated individuals with a left ventricular 
ejection fraction ≥50% in the absence of 
exercise-induced complex arrhythmias.
IIb
C
Moderate-intensity exercise may be considered 
in asymptomatic and optimally treated individuals 
with a left ventricular ejection fraction of 40–49% in 
the absence of exercise-induced complex 
arrhythmias.
IIb
C
High-intensity exercise, including competitive sport, 
is not recommended in symptomatic individuals, 
those with a left ventricular ejection fraction ≤40%, 
exercise-induced arrhythmias or pathogenic variants 
in LMNA or TMEM43.
III
C
© ESC 2023
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; 
HCM, hypertrophic cardiomyopathy; LMNA, lamin A/C; NDLVC, non-dilated left 
ventricular cardiomyopathy; TMEM43, transmembrane protein 43. 
aClass of recommendation. 
bLevel of evidence. 
cSee Section 7.1.5 for risk assessment in HCM.
ESC Guidelines                                                                                                                                                                                          3583


<!-- PAGE 82 -->

### Page 82

8.2.2.3. Timing and mode of delivery
The timing and mode of delivery should be personalized according to 
the type of cardiomyopathy, ventricular function, NYHA class, arrhyth­
mic risk, and thrombo-embolic risk. Vaginal delivery is associated with 
less blood loss and lower risk of infection, venous thrombosis, and em­
bolism than caesarean section and should be advised for most women. 
Caesarean section should be considered for obstetric indications, pa­
tients with severe outflow tract obstruction, or in cases of severe 
acute/intractable heart failure, or in cases at high risk of threatening ar­
rhythmia and for patients presenting in labour on oral anticoagu­
lants.1130 During delivery, patients with cardiomyopathy should be 
circulatory and heart rhythm monitored on an individualized basis.
8.2.2.4. Post-partum
The post-partum period is associated with significant haemodynamic 
changes and fluid shifts, particularly in the first 24–48 h after delivery, 
which may precipitate heart failure. Haemodynamic monitoring should 
therefore be continued for at least 24–48 h in patients at risk. Most 
drugs enter the milk and could thus contraindicate breastfeeding (see 
Section 8.2.2.5).
8.2.2.5. Pharmacological treatment: general aspects
Pharmacological treatment in pregnant women should be the same as 
in non-pregnant patients, with an avoidance of drugs contraindicated in 
pregnancy, such as ACE-Is, ARBs, and renin inhibitors.1130 The first tri­
mester is associated with the greatest teratogenic risk. Pharmacologic 
therapy is advised to begin as late as possible in pregnancy and at the 
lowest effective dose. Drug exposure later in pregnancy may confer ad­
verse effects on foetal growth and development. It is recommended to 
check drug and safety data before initiation of a new drug in pregnancy; 
see Table 7 in the 2018 ESC Guidelines for the management of cardiovas­
cular diseases during pregnancy.1130 From this list, antiarrhythmics can be 
summarized as follows: 
• Well tolerated: sotalol, oral verapamil.
• While the benefits and risks should be evaluated in each case, the fol­
lowing drugs can often be continued if there is a clear indication for 
use during pregnancy: bisoprolol, carvedilol, digoxin, diltiazem (pos­
sible teratogenic effects), disopyramide (uterine contractions), flecai­
nide, lidocaine, metoprolol, nadolol, propranolol, verapamil, 
quinidine.
• Insufficient data: ivabradine, mexiletine, propafenone, vernakalant.
• Contraindicated: amiodarone, atenolol, dronedarone, ACE-Is, ARBs, 
renin inhibitors, and spironolactone.1130
Ongoing beta-blocker treatment in cardiomyopathies should be con­
tinued during pregnancy, with close monitoring of foetal growth. After 
delivery, it is advised to heart rhythm monitor the infant for 48 h. The 
use of beta-blockers and anticoagulation during pregnancy is described 
in the 2018 ESC Guidelines for the management of cardiovascular diseases 
during pregnancy.1130
Vitamin K antagonist use in the first trimester results in embryopathy 
(limb defects, nasal hypoplasia) in 0.6–10% of cases.1133,1134 In contrast, 
unfractionated heparin (UFH) and low-molecular-weight heparin 
(LMWH) do not cross the placenta; therefore, substitution of VKA 
with UFH or LMWH in weeks 6–12 almost eliminates the risk of em­
bryopathy. This risk is also dose dependent (0.45–0.9% with low-dose 
warfarin). Vaginal delivery while the mother is on VKAs is 
contraindicated because of the risk of foetal intracranial bleeding. 
Haemorrhagic complications in the mother occur with all regimens, 
but the incidence is lower with VKA than with LMWH/UFH through­
out pregnancy.1130
VKA should be continued until pregnancy is achieved. Continuation 
of VKAs throughout pregnancy should be considered when the dose is 
low (see Table 7 in the 2018 ESC Guidelines for the management of car­
diovascular diseases during pregnancy1130). The target international nor­
malized ratio (INR) should be chosen according to current guidelines, 
with INR monitoring weekly or every 2 weeks. Self-monitoring of 
INR in suitable patients is recommended. Alternatively, depending on 
the indication, a switch to LMWH from weeks 6–12 under strict mon­
itoring may be considered in patients with a low dose requirement. 
When a higher dose of VKAs is required, discontinuation of VKAs be­
tween weeks 6 and 12 and replacement with adjusted-dose i.v. UFH or 
LMWH twice daily with dose adjustment according to peak anti-Xa (for 
LMWH) levels should be considered.
In case of delivery in anticoagulated women (not including mechan­
ical valves) with a planned caesarean section, therapeutic LMWH dosing 
can be simply omitted for 24 h prior to surgery. If delivery has to be 
performed earlier, anti-Xa activity can guide the timing of the 
procedure.
Antiarrhythmic therapy in pregnancy other than medication. 
Implantation of an ICD and catheter ablation should ideally be consid­
ered prior to pregnancy in patients with a high risk of ventricular ar­
rhythmias 
to 
avoid implantations 
and 
interventions during 
pregnancy.1135 If an ICD is indicated in pregnancy, ICD implantation 
should be performed beyond 8 weeks of gestation with radiation pro­
tection1136 and the indication should be weighed against the limited ex­
perience available. In pregnant patients with existing ICD, routine ICD 
interrogation and advice are recommended prior to delivery.
8.2.2.6. Specific cardiomyopathies
Most women with HCM tolerate pregnancy well.1137 Complications 
during pregnancy most often occur in women who have symptoms, ar­
rhythmias, or impaired LV function before pregnancy. Left ventricular 
outflow tract gradients may increase slightly during pregnancy and 
high gradients before pregnancy are associated with more complica­
tions.1137 Women should be assessed according to WHO risk class, in­
dicating at trimester for low-risk patients (class II) and monthly or 
bi-monthly for higher-risk patients (class III). Therapeutic anticoagula­
tion with LMWH or VKAs according to the stage of pregnancy is re­
commended for patients with AF. Cardioversion in pregnancy should 
be considered for poorly tolerated persistent AF. Hypovolaemia is 
poorly tolerated. Caesarean section should be considered in patients 
with severe LVOTO, pre-term labour while on oral anticoagulants, 
or severe heart failure.1130 Epidural and spinal anaesthesia must be ap­
plied cautiously, especially with severe LVOTO, due to potential hypo­
volaemia, and single-shot spinal anaesthesia should be avoided.
Pregnancy in ARVC seems to be relatively tolerable, as shown in sev­
eral studies, with no excess mortality and no clear negative long-term 
outcome.1138–1141 Previous VTs represent a WHO risk class III, indicat­
ing bi-monthly or monthly follow-up at an expert centre.
Women with DCM are at risk of further deterioration of LV function 
in pregnancy. Data suggest that pregnancy might not be associated with 
long-term adverse disease progression or event-free survival in LMNA 
genotype-positive women.1142 Predictors of maternal mortality are 
NYHA class III/IV and EF <40%. Highly adverse risk factors include


<!-- PAGE 83 -->

### Page 83

EF <20%, severe mitral regurgitation, RV failure, AF, and/or 
hypotension.1143
8.2.2.7. Peripartum cardiomyopathy
Genetic studies in patients with PPCM have revealed genetic similarity 
between PPCM and DCM. Specifically, an overrepresentation of trun­
cating variants has been demonstrated in TTN, FLNC, BAG3, and DSP, 
with TTN truncating variants most commonly involved (found in 
∼10% of patients).44,45 It has been suggested that approaches to genetic 
testing in PPCM should mirror those taken in DCM.45 Medications used 
to treat heart failure during pregnancy require special considerations as 
discussed above. In the presence of persistant cardiac dysfunction, 
medication should be continued. Use of bromocriptine as disease- 
specific therapy in patients with PPCM as an addition to standard heart 
failure therapy has shown promising results in two clinical trials.1144,1145
In severe cases of PPCM, temporary MCS has been used successfully 
and should be considered in patients with haemodynamic instability 
despite inotropic support.1146 In patients with PPCM, thresholds for 
early ICD implantations should be higher than in other conditions be­
cause of a high rate of spontaneous recovery after delivery.1147
8.3. Recommendations for non-cardiac 
surgery
Cardiomyopathies, in general, are associated with an increased inci­
dence of peri-operative heart failure and arrhythmias, although the sig­
nificant variability in the phenotypic expression of cardiomyopathies 
must be considered. Special attention should be given to the clinical sta­
tus, LVEF, volume overload, and increased levels of natriuretic peptides. 
In the period after non-cardiac surgery (NCS), fluids given during the 
operation may be mobilized, causing hypervolaemia and pulmonary 
congestion. Careful attention to fluid balance is therefore essen­
tial.1148,1149 Obstructive HCM deserves specific consideration due to 
its peculiar pathophysiology, with adequate intra-operative vigilance, 
avoiding factors and medication that may increase LVOTO and prompt 
pharmacological treatment and intravascular fluid therapy if needed 
(see Supplementary data online, Table S7).1150,1151
Natriuretic peptide concentrations are quantitative plasma biomar­
kers for the presence and severity of haemodynamic cardiac stress 
and heart failure, and elevated NT-proBNP concentrations may facili­
tate detection of heart failure, optimal intra-operative monitoring, 
and initiation or optimization of heart failure therapy after surgery.1152
Moreover, in cardiomyopathy patients elevated NT-proBNP values are 
strong predictors of overall prognosis.1153–1156
Patients with a first-degree relative with a genetic cardiomyopathy 
should be evaluated with an ECG and an echocardiographic examination 
to rule out the presence of the disease, irrespective of age (see Section 
6.11). There are no specific data on risks of NCS in phenotype-negative 
family members; however, they are at risk of developing the disease, which 
may be subclinical at the time of the NCS.1157 Data in children with HCM 
undergoing general anaesthesia for cardiac and non-cardiac procedures 
show that, in a specialist setting with multidisciplinary involvement, peri- 
operative morbidity and mortality are extremely low.1158
Recommendation Table 32 — Recommendations for 
reproductive issues in patients with cardiomyopathy
Recommendations
Classa
Levelb
Pre-pregnancy risk assessment and counselling are 
recommended in all women using the mWHO 
classification of maternal risk.
I
C
Counselling on safe and effective contraception is 
recommended in all women of fertile age and their 
partners.
I
C
Counselling on the risk of disease inheritance is 
recommended for all men and women before 
conception.
I
C
Vaginal delivery is recommended in most women 
with cardiomyopathies, unless there are obstetric 
indications for caesarean section, severe heart failure 
(EF <30% or NYHA class III–IV), or severe outflow 
tract obstructions, or in women presenting in labour 
on oral anticoagulants.
I
C
It is recommended that medication be carefully 
reviewed for safety in advance of pregnancy and 
adjusted according to tolerability in pregnancy.
I
C
Therapeutic anticoagulation with LMWH or VKAs 
according to the stage of pregnancy is recommended 
for patients with AF.
I
C
Continuation of beta-blockers should be considered 
during pregnancy in women with cardiomyopathies, 
with close follow-up of foetal growth and of the 
condition of the neonate, and if benefits outweigh 
risks.
IIa
C
Genetic counselling and testing should be considered 
in patients with peripartum cardiomyopathy.
IIa
C
© ESC 2023
AF, atrial fibrillation; EF, ejection fraction; LMWH, low-molecular-weight heparin; mWHO, 
modified World Health Organization; NYHA, New York Heart Association; VKA, vitamin 
K antagonist. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 33 — Recommendations for 
non-cardiac surgery in patients with cardiomyopathy
Recommendations
Classa
Levelb
Peri-operative ECG monitoring is recommended for 
all patients with cardiomyopathy undergoing surgery.
I
C
In patients with cardiomyopathy and suspected or 
known HF scheduled for intermediate or high-risk 
NCS, it is recommended to re-evaluate LV function 
with echocardiography (assessing LVOTO in HCM 
patients) and measurement of NT-proBNP/BNP 
levels, unless this has recently been 
performed.1151,1153–1156,1158–1165
I
B
It is recommended that cardiomyopathy patients 
with high-risk genotypes or associated factors for 
arrhythmic or heart failure complications or severe 
LVOTO be referred for additional specialized 
investigations to a cardiomyopathy unit before 
undergoing elective NCS.
I
C
In patients aged <65 years with a first-degree relative 
with a cardiomyopathy, it is recommended to perform 
an ECG and TTE before NCS, regardless of symptoms.
I
C
© ESC 2023
ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; HF, heart failure; LV, left 
ventricular; LVOTO, left ventricular outflow tract obstruction; NCS, non-cardiac 
surgery; NT-proBNP, N-terminal pro-brain natriuretic peptide; TTE, transthoracic 
echocardiography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3585


<!-- PAGE 84 -->

### Page 84

### 9 Requirements for specialized

cardiomyopathy units
As genomic tests and information are incorporated into strategies for 
the routine diagnosis and management of cardiomyopathies and the es­
timation of disease risk, cardiologists need to familiarize themselves 
with the general principles underlying the interpretation of test results 
and must be able to convey the implications to patients. They also need 
to be able to make informed judgments about which tests are appropri­
ate for different patients and clinical situations. The risk of SCD and the 
possibility that family members could inherit the condition makes multi­
disciplinary expertise, including genetic counselling, psychological care, 
and patient support associations, a critical aspect of care.1166 As a re­
sult, there is a growing need for clinicians to develop their understand­
ing of the basic principles of clinical genetics and the diverse clinical 
manifestations of individual genetic disorders.54,964,1166,1167
Cardiomyopathies have a highly heterogeneous clinical presentation 
and an evolution that sometimes is difficult to predict. Disease phenotype 
can be the result of various acquired factors or genetic backgrounds. 
Mixed phenotypes or two conditions within the same patient or among 
a family can coexist. Genetic diagnosis raises common logistical and eth­
ical problems in its execution, as well as in the interpretation and com­
munication of the results.1166 Diagnostic process, the management of 
symptoms, and risk stratification often require comprehensive evaluation 
of the patient and their family, with the participation of multidisciplinary 
teams. On the other hand, interventional procedures (septal ablation, 
myectomies, etc.) require an expertise that only centres that treat 
many patients can achieve. Specialization in this area also requires per­
manent updating to accurately characterize the disease prognosis, ensure 
the choice of the best therapeutic option in each case, and guarantee the 
implementation of that choice by a team with experience in the field.
These characteristics imply that the adequate management of these 
diseases requires specific tools, extensive experience, and a multidiscip­
linary basic-clinical approach that are difficult to achieve.
The cardiomyopathy unit is usually integrated into a general cardioge­
netic (or inherited cardiac conditions) unit, where other professionals in­
volved in hereditary cardiac and vascular conditions, such as 
channelopathies, genetic aortopathies, familial dyslipidaemias, and a num­
ber of genetic metabolic and syndromic diseases with cardiac involve­
ment, are co-ordinated. They represent an organizational model aimed 
at providing comprehensive cardiovascular and genetic assessment and 
personalized management in patients with inherited cardiovascular dis­
eases. Specialized multidisciplinary clinics have long been advocated as 
the ideal model for the management of patients and families with inher­
ited cardiac conditions.4,53,559,1166 Such a model of care supports the hol­
istic care of patients and their at-risk family members, taking a 
patient-centred approach and valuing clinical, genetic, and psychosocial 
outcomes. The benefit of a specialized clinic for management of HCM 
has been previously reported, with patients showing better adjustment 
and less worry than those who did not attend.53,224 Besides expertise 
in the field of inherited cardiac conditions, the presence of a multidiscip­
linary team, access to good technical resources, participation in dedicated 
research projects, availability of genetic counselling, and family screening 
are all pre-requisites for organizing a cardiogenetic clinic. The ability to 
provide education and training for medical professionals and collabor­
ation with patients’ associations is of utmost importance.
Supplementary data online, Table S8 synthesizes the requirements 
and skills and recommendations for professional education/training 
needed for a cardiogenetic clinic as proposed by international expert 
associations.
10. Living with cardiomyopathy: 
advice for patients
Most people with cardiomyopathy lead normal and productive 
lives, but a small number experience significant symptoms and are at 
risk of disease-related complications. Regardless of the severity of their 
disease, it is important that individuals receive support and accurate 
advice from cardiomyopathy specialists and other healthcare 
professionals, and that they are encouraged to understand and 
manage the disease themselves (see the Supplemental Data online, 
Table S9, for a description of the patient education process).
Table 24 General guidance for daily activity for pa­
tients with cardiomyopathies
Topic
General guidance
Exercise
• See earlier section on exercise 
recommendations.
Diet, alcohol use, and 
weight
• Patients should be encouraged to maintain a 
recommended body mass index.
• Avoid dehydration, excess alcohol intake, and 
drugs consumption.
Smoking
• There are no data that show an interaction 
between tobacco smoking and 
cardiomyopathy, but patients should be 
provided with general advice on the health risks 
associated with smoking, including 
pro-arrhythmic and pro-inflammatory effects 
and, when available, information on smoking 
cessation.1168–1171
Reproductive issues
• Patients should be given the opportunity to 
discuss their concerns about reproductive 
issues. Anxiety and depression following a 
diagnosis are frequent, and some patients may 
express guilt or fear about their genetic 
diagnosis and the risk of transmission to 
offspring.
Sexual activity
• Patients should be counselled on the potential 
effect of their medication on sexual 
performance.
• Most people with cardiomyopathy will be able 
to undertake normal sexual activity. 
Individualized advice should be provided 
regarding its safety and the possible impact of 
sexual activity on the risk of disease 
progression, ventricular arrhythmias, and/or 
ICD shocks.
Medication
• Patients should be provided with information 
about their medication, including potential side 
and teratogenic effects and interactions with 
prescribed medications, over-the-counter 
remedies, and other complementary therapies.
Vaccination
• In the absence of contraindications, patients 
should be advised to have regular 
recommended vaccinations (e.g. yearly 
influenza and SARS-CoV-2 vaccination).
Continued


<!-- PAGE 85 -->

### Page 85

Table 24 summarizes some of the key issues that should be discussed 
with patients, relatives, and carers. When appropriate (e.g. when con­
sidering pregnancy, see Section 8.2), patients should be referred to 
other specialist services.
11. Sex differences in 
cardiomyopathies
Sex differences in phenotypic expression and outcomes are well docu­
mented across cardiovascular medicine. Differences in clinical presenta­
tion, progression, and outcome in cardiomyopathies between females 
and males can be attributable to genetic and hormonal differences, 
but also to variations in management, access to healthcare, or response 
to specific therapies.546,1173 Eliminating these variations represents a 
major unmet need in the care of cardiomyopathies.
Cardiomyopathies are typically inherited as an autosomal dominant 
trait. Therefore, the prevalence would be expected to be equal among 
the sexes. Women are consistently less represented than men in clinical 
studies across different cardiomyopathies (30–40%). Despite this, the 
difference may be explained by bias in interaction with healthcare facil­
ities or by diagnosis criteria based on unadjusted cardiac imaging mea­
surements; data from large pedigrees seem to support the hypothesis 
that there is a real delay in the age of phenotypic expression in female 
carriers (at least for HCM).178,1174–1176
Females with HCM are diagnosed later than males (8–13 years later), 
are more severely affected, more often have LVOTO, have more severe 
symptoms at baseline, and more commonly develop advanced heart failure 
during follow-up.1177,1178Women with LVOTO and indication for invasive 
procedures are often older and more symptomatic than males.1179–1181
Females and males appear to show similar survival benefit from invasive 
SRT.705,1181 Cardiomyopathy-related death has shown to be increased 
in middle-aged females with HCM compared with men and the general 
population; this is due to a higher rate of death from heart failure. No dif­
ference in SCD has been demonstrated in HCM regarding sex.1182,1183
Females with DCM may have a better response to therapy and seem 
to have a more favourable clinical course than males.186,1184 Male sex 
has been reported to be consistently associated with an increased 
SCD rate in DCM (general cohorts and particular genotypes ser­
ies),186,541,872,878,1185–1187 and death from heart failure or transplant 
in general DCM cohorts.1188,1189
Male sex and sports have been traditionally identified as variables as­
sociated with an earlier phenotypic penetrance and a more severe dis­
ease expression in genetic carriers, and are independent predictors of 
malignant ventricular arrhythmic events in ARVC.522,950,1190–1195 As in 
HCM, females with ARVC may have an increased risk of developing 
heart failure.1193
Reports on sex differences in familial or genetic RCM are 
scarce.331,546 Compared with other types of cardiomyopathies, females 
seem to be as equally represented as males in RCM series.331
12. Comorbidities and 
cardiovascular risk factors in 
cardiomyopathies
12.1. Cardiovascular risk factors
The 
penetrance 
of 
the 
disease 
in 
genetic 
carriers 
of 
cardiomyopathy-associated variants is incomplete. Gene–environment 
Driving
• Most patients should be eligible for an ordinary 
driving licence and can continue driving unless 
they experience distracting or disabling 
symptoms.
• Advice on driving licences for heavy goods or 
passenger-carrying vehicles should be in line 
with local legislation.
• For further information on driving with ICDs, 
see local rules.
Occupation
• Most people with cardiomyopathy will be able 
to accomplish their normal jobs. The 
implications of heavily manual jobs that involve 
strenuous activity should be discussed with the 
appropriate specialist.
• For some occupations, such as pilots, military 
personnel, and emergency services personnel, 
there are strict guidelines or rules on eligibility.
• The social and financial implications of a 
diagnosis of cardiomyopathy should be included 
in the counselling of relatives before clinical or 
genetic screening.
Holidays and travel 
insurance
• Most asymptomatic or mildly symptomatic 
patients can fly safely. For further information 
on flying with ICD, see ‘Fitness to fly for 
passengers with cardiovascular disease’.1172
• Insurance companies may charge more for 
travel insurance. In some countries, patient 
support organizations can provide advice about 
obtaining reasonable insurance.
Life insurance
• The diagnosis of cardiomyopathy will result in 
difficulty obtaining life insurance or mortgages. 
Advice on the rules that apply in different 
countries should be provided to patients at 
diagnosis.
Pregnancy and 
childbirth
See Section 8.2
Education/schooling
• Teachers and other carers should be provided 
with advice and written information relevant to 
the care of children with cardiomyopathy.
• In the absence of symptoms and risk factors, 
children should be allowed to perform low- to 
moderate-level aerobic physical activity, in 
accordance with advice from their paediatric 
cardiologist. Advice on high-intensity exercise in 
children should be guided by cardiomyopathy 
phenotype and the presence of symptoms and 
risk factors within a specialist paediatric 
cardiomyopathy setting.
• Provision should be made for children with 
learning difficulties and other special needs.
• Parents, teachers, and staff at sports facilities 
should be trained in CPR and in the use of 
AEDs.
© ESC 2023
AED, automated external defibrillator; CPR, cardio-pulmonary resuscitation; ICD, 
implantable cardioverter defibrillator; SARS-CoV-2, severe acute respiratory syndrome 
coronavirus 2.
ESC Guidelines                                                                                                                                                                                          3587


<!-- PAGE 86 -->

### Page 86

interactions can explain part of the heterogeneity of the phenotypic 
expression of all cardiomyopathy phenotypes, although published 
data focus primarily on HCM, DCM, and ARVC.
12.2. Dilated cardiomyopathy
Individual genetic predisposition favours a dilated phenotype in the 
presence of trigger factors, such as inflammation, infection, toxic insults 
from alcohol or drugs, and tachyarrhythmias.
12.3. Hypertrophic cardiomyopathy
Hypertension and obesity have been associated with penetrance and 
phenotypic expression of HCM.1196
Results from the EORP 
Cardiomyopathy/Mycarditis Registry showed that patients with HCM 
had a high prevalence of cardiovascular risk factors, comparable with 
data from the general population.1196 Hypertension, diabetes, and 
obesity were associated with older age at presentation, a lower preva­
lence of family history of HCM and SCD, more symptoms, frequent AF, 
and worse LV diastolic function.1197 Hypertension and obesity were 
also associated with higher provocable LVOT gradients and LVH.1198
12.4. Arrhythmogenic right ventricular 
cardiomyopathy
The role of intense exercise in disease expression and outcomes has 
been studied in HCM and DCM, but the impact has shown to be par­
ticularly relevant in ARVC (Table 25). Despite significant research, the 
pathophysiology of ARVC is complex and not well understood. The 
search for genetic or environmental triggers, such as viruses and im­
mune response, has failed to identify actionable factors. The role of in­
flammation on the pathophysiology is thought to be key.1199
13. Coronavirus disease 
(COVID-19) and cardiomyopathies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infec­
tion, known as COVID-19, is characterized by a high variability of clin­
ical presentation and outcomes with an adverse association between 
underlying 
cardiac 
disease, 
including 
heart 
failure, 
and 
SARS-CoV-2-related mortality.1200–1202 However, examination of 
SARS-CoV-2 infection in underlying causes of heart failure, particularly 
cardiomyopathies, has been limited.
Analyses of international registries on cardiomyopathies and 
SARS-CoV-2 from the pre-vaccine period have identified several mar­
kers of adverse outcomes.1203 Prior history of heart failure and particu­
lar phenotypes (amyloidosis and DCM) were significantly associated 
with intensive care unit admission and death compared with HCM, 
ARVC, and the general population. For HCM, age, baseline functional 
class, LVOTO, and systolic impairment were independent predictors 
of death.1204
SARS-CoV-2 vaccination has been demonstrated to be safe in large 
population studies and reports on complications related to the vaccin­
ation in patients with cardiomyopathy are anecdotal. Given this, and the 
potential for worse outcomes in cardiomyopathy patients who con­
tract COVID-19, vaccination is encouraged in all cardiomyopathy pa­
tients and, in particular, in those with signs or symptoms of heart failure.
14. Key messages
(1) Cardiomyopathies are more common than previously thought 
and they typically require nuanced management that may differ 
from the conventional approach to patients with arrhythmia or 
heart failure.
(2) Aetiology is fundamental to the management of patients with 
heart muscle disease and careful and systematic description of 
the morphological and functional phenotype is a crucial first 
step in the diagnostic pathway.
(3) An approach to nomenclature and diagnosis of cardiomyopathies 
that is based on the predominant phenotype at presentation is 
recommended.
(4) Patients with cardiomyopathy may seek medical attention due to 
symptoms onset (HF or arrhythmia related), incidental abnormal 
findings, or as a result of family screening following the diagnosis in 
a relative.
Recommendation Table 34 — Recommendation for 
management of cardiovascular risk factors in patients 
with cardiomyopathy
Recommendation
Classa
Levelb
Identification and management of risk factors and 
concomitant diseases is recommended as an integral 
part of the management of cardiomyopathy patients.
I
C
© ESC 2023
aClass of recommendation. 
bLevel of evidence.
Table 25 Modulators of the phenotypic expression of cardiomyopathies
Condition
HCM
DCM
ARVC
Expression
Hypertension
+++
++
?
Hypertrophy, dilatation, dysfunction, AF
Diabetes
++
+
?
Hypertrophy, dysfunction, AF
Obesity
++
+
?
Hypertrophy, LVOTO, AF
Toxic
−
+++
?
Dilatation, dysfunction
Sports
+
+
+++
Dilatation, dysfunction, ventricular arrhythmia
Virus
−
++
+
Dilatation, dysfunction, ventricular arrhythmia
Pregnancy
−
++
−
Dilatation, dysfunction
© ESC 2023
AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVOTO, left ventricular outflow tract 
obstruction. 
+, degree of positive association; −, absence of definitive association; ?, unknown association.


<!-- PAGE 87 -->

### Page 87

(5) Multimodality imaging to characterize the cardiac phenotype 
(morphology and function)—including tissue characterization 
for non-ischaemic myocardial scar detection—is necessary, 
in combination with a detailed personal and family history, 
clinical examination, electrocardiography, and laboratory 
investigations.
(6) Imaging results should always be interpreted in the overall clinical 
context, including genetic testing results, rather than in isolation.
(7) Tissue characterization by CMR is of value in diagnosis, monitor­
ing of disease progression and risk stratification in each of the 
main cardiomyopathy phenotypes.
(8) DPD/PYP/HMDP bone-tracer scintigraphy or SPECT represent 
the gold standard for the diagnosis of ATTR-related cardiac 
amyloidosis.
(9) The presence of non-ischaemic ventricular scar or fatty replace­
ment on cardiac CMR and/or pathological examination, which 
can occur with or without ventricular dilatation and/or systolic 
dysfunction, can be the sole clue to the diagnosis of a cardiomy­
opathy and can have prognostic significance that varies with 
aetiology.
(10) The aim of this multiparametric and systemic approach is to gen­
erate a phenotype-based aetiological diagnosis, interpreting avail­
able data with a cardiomyopathy-oriented mindset that combines 
cardiological assessment with non-cardiac parameters.
(11) A multidisciplinary approach to patient care and appropriate tran­
sition of care from paediatric to adult cardiomyopathy services is 
needed.
(12) Genetic testing should be performed in patients with cardiomy­
opathy and may influence risk stratification and management.
(13) Genetic counselling, including pre- and post-test counselling, and 
psychological support are an essential aspect of the multidisciplin­
ary care of patients with cardiomyopathy and their relatives.
(14) Paediatric cardiomyopathies largely represent part of the same 
clinical spectrum as those seen in older adolescents and adults, 
but infant-onset (in the first year of life) cardiomyopathies are of­
ten associated with severe phenotypes and a high rate of heart 
failure-related morbidity and mortality.
(15) Beyond the first year of life, genetic causes of childhood-onset 
cardiomyopathies are similar to those in adults.
(16) Symptom management, identification, and prevention of 
disease-related complications (including SCD, heart failure, and 
stroke) 
are 
the 
cornerstone 
of 
management 
of 
all 
cardiomyopathies.
(17) Cardiac myosin inhibitors (Mavacamten) should be considered in 
patients with HCM and LVOTO who remain symptomatic des­
pite optimal medical therapy.
(18) Validated SCD risk-prediction tools (HCM Risk-SCD and HCM 
Risk-Kids) are the first step in sudden death prevention in patients 
with HCM.
(19) Additional risk markers may be of use in patients with low or 
intermediate risk, but there is a lack of robust data on the impact 
of these parameters on the personalized risk estimates generated 
by the risk-prediction tools.
(20) Pharmacological treatment of DCM patients does not differ from 
those recommended in chronic heart failure.
(21) SCD risk of DCM and NDLVC patients varies depending on the 
underlying cause and genetic subtype.
(22) CMR findings play an important role in guiding ICD implantation 
for patients with DCM and NDLVC.
(23) In DCM and NDLVC patients, ICD should be considered for cer­
tain genetic forms even if LVEF is >35%.
(24) It is of importance to define aetiology for a tailored management 
in patients with syndromic and metabolic cardiomyopathies (i.e. 
ERT/chaperone in lysosomal storage disease; tafamidis in 
ATTRwt, etc.).
(25) Pregnancy and the post-partum period are associated with in­
creased cardiovascular risk in women with known cardiomyopathy.
(26) A multidisciplinary team should evaluate the patient with cardio­
myopathy to assess the risk associated with pregnancy.
(27) Beta-blocker therapy on arrhythmic indication can safely be con­
tinued during pregnancy; safety data should be checked before ini­
tiation of new drugs in pregnancy.
(28) Healthy adults of all ages and individuals with known cardiac dis­
ease should exercise with moderate intensity, totalling at least 
150 min per week.
(29) All patients with cardiomyopathy should have an individualized 
risk assessment for exercise prescription. Evaluation should be 
guided by three principles: (i) preventing life-threatening arrhyth­
mias during exercise; (ii) symptom management to allow sports; 
and (iii) preventing sports-induced progression of the arrhythmo­
genic condition.
(30) Individuals who are genotype positive/phenotype negative or have 
a mild cardiomyopathy phenotype and absence of symptoms or 
any risk factors, may be able to participate in competitive sports. 
In some high-risk patients with HCM, ARVC, and NDLVC, high- 
intensity exercise and competitive sports should be discouraged.
(31) Patients with high-risk genotypes or associated factors for ar­
rhythmic or heart failure complications or severe LVOTO should 
be referred for specialized investigations before undergoing elect­
ive NCS.
(32) Identification and management of risk factors and concomitant 
diseases is recommended as an integral part of the management 
of cardiomyopathy patients.
15. Gaps in evidence
Although there have been major advances in the genetics, diagnosis, and 
treatments of patients with cardiomyopathy over the last few years, 
there are a number of areas where robust evidence is still lacking and 
deserve to be addressed in future clinical research. 
(1) Cardiomyopathy phenotypes.
(2) Epidemiology: 
(a) Prevalence of NDLVC phenotype (children and adults).
(b) Systematic assessment of prevalence of cardiomyopathy phe­
notypes in childhood.
(3) Integrated patient management: 
(a) Embedding of telemedicine into cardiomyopathy networks.
(4) Patient pathway: 
(a) Laboratory tests: 
(i) Studies on novel ‘omic’ biomarkers (proteomics, metabo­
lomics, and transcriptomics) are needed to assess their 
potential value for diagnostic and prognostic purposes in 
cardiomyopathies.
(b) Multimodality imaging: 
(i) Advanced echocardiographic techniques, including speckle 
tracking deformation imaging, are promising but lack ro­
bust validation in the setting of cardiomyopathies.
ESC Guidelines                                                                                                                                                                                          3589


<!-- PAGE 88 -->

### Page 88

(ii) A universally accepted, standardized method for the 
quantification of myocardial fibrosis by CMR is lacking.
(iii) CMR scans may be performed in patients with compat­
ible implantable devices, but the quality is limited by 
artefacts.
(iv) Artificial intelligence enhanced electrocardiography and 
imaging for cardiomyopathy evaluation has been proving 
a novel tool to dramatically improve diagnosis and prog­
nosis; further studies are needed for routine introduction 
in clinical practice.
(v) Impact of CMR on screening in genotype-positive rela­
tives of individuals with cardiomyopathy and in 
gene-elusive families.
(c) Genetics: 
(i) Penetrance is poorly characterized for most pathogenic 
variants. This is true both for variants found through cas­
cade screening of relatives of a patient with cardiomyop­
athy, and also for variants found in the wider population 
who may have clinical sequencing for another indication 
or may choose to have genome sequencing as a screening 
test.
(ii) The benefits, harm, and costs of screening of 
cardiomyopathy-associated genes in individuals without 
a personal or family history of cardiomyopathy is not 
known.
(d) General principles in management: 
(i) Management 
of 
RV 
failure 
remains 
largely 
non-evidence-based.
(ii) Large-scale studies are required to guide ventricular ar­
rhythmia management in patients with genetic 
cardiomyopathies.
(iii) Optimal rate control and AADs per subtype of 
cardiomyopathy.
(iv) The role of ICDs in patients with well tolerated VT.
(v) All risk calculators are developed using baseline data. 
Therefore, the utility of their application during follow- 
up visits of patients remains unclear and needs to be 
studied.
(vi) Risk prediction in childhood cardiomyopathies other 
than HCM remains empirical—multicentre approach 
required to understand and develop SCD risk models 
in childhood.
(vii) Lack of controlled studies on the effect of ablation in pa­
tients with AF and cardiomyopathy.
(viii) Models to predict AF recurrence have not been vali­
dated in cardiomyopathy patients.
(ix) Lack of randomized studies assessing the efficacy of car­
diac sympathetic denervation for the prevention of VT/ 
VF recurrences.
(e) Approach to paediatric cardiomyopathies: 
(i) Lack of randomized studies or large registries addressing 
the benefit and optimal dosing of drug therapy in paediat­
ric population.
(5) Hypertrophic cardiomyopathy: 
(a) Epidemiology: 
(i) Imaging and genotype studies suggest a population preva­
lence of up to 1 in 200 of the population. However, 
HER-based studies suggest a much lower number of 3– 
4/10 000. Further studies into the prevalence of clinically 
important diseases are necessary.
(b) Aetiology: 
(i) Aetiology of gene-elusive disease.
(ii) The role of polygenic risk.
(iii) Interaction between comorbidity and disease outcomes.
(iv) Genetic and environmental determinants of disease ex­
pression in variant carriers.
(c) Symptom management: 
(i) Optimal timing of LVOTO management and its impact on 
disease progression.
(ii) Prevention of AF and heart failure.
(d) Sudden death prevention: 
(i) Impact of genetics (Mendelian and complex) on risk of 
disease-related outcomes.
(ii) Improved prediction models that reduce residual risk and 
prevent unnecessary ICD implantation.
(iii) Refinement of risk-prediction models to include serial 
data.
(iv) Role of LVOTO in risk prediction in children (apparent 
discrepancy compared with adults).
(e) New therapies: 
(i) Clinical utility of myosin inhibitors, other small molecules, 
and emerging genetic therapies.
(6) Dilated cardiomyopathy: 
(a) Genetic basis of familial DCM is still unknown in a high num­
ber of cases.
(b) Detailed data about the specific clinical course in diverse gen­
etic and non-genetic DCM forms are not available.
(c) It is unknown if patients with DCM respond differently to 
pharmacological treatment according to underlying aetiology.
(d) Optimized SCD prevention strategy remains unsolved. There 
are not data from prospective clinical trials in modern 
cohorts with contemporary medical treatment. This gap is 
knowledge is particularly relevant for DCM patients with 
LVEF > 35%.
(e) Sport recommendations and utility of prophylactic pharma­
cological therapy to prevent DCM onset in genetic carriers.
(7) Non-dilated left ventricular cardiomyopathy: 
(a) Prevalence of disease.
(b) Natural history and response to treatment.
(c) SCD prevention.
(d) Sports recommendations.
(8) Arrhythmogenic right ventricular cardiomyopathy: 
(a) RCTs for therapies for the management of arrhythmias and 
heart failure are lacking.
(b) Studies on the effect of exercise remain largely retrospective.
(c) Studies on the incidence and prognostication of heart failure 
remain limited.
(d) Studies on the frequency and mode of clinical screening for 
asymptomatic family members are lacking.
(9) Restrictive cardiomyopathy: 
(a) SCD prevention.
(10) Syndromic and metabolic cardiomyopathies: 
(a) Lack of randomized trials or large observational cohort stud­
ies assessing the role of new target therapies addressing the 
RAS/MAPK pathway (i.e trametinib).
(b) There are few long-term outcome studies addressing ven­
tricular remodelling in RAS-HCM.
(c) HCM Risk-Kids has not been validated in paediatric patients 
with RAS-HCM. Data regarding SCD risk stratification are 
lacking, although candidate risk factors have been identified.


<!-- PAGE 89 -->

### Page 89

(d) Lack of studies addressing the optimal timing to start ERT in 
adolescents and adults with late-onset Pompe disease.
(e) Lack of standardized protocols to treat cross-reactive im­
munologic material-negative patients.
(f) Lack of standardization of clinical endpoints in ERT/chaper­
one therapy trials.
(g) Lack of head-to-head comparisons between agalsidase alpha 
and beta.
(h) Optimal time to begin treatment in asymptomatic female pa­
tients with non-classic disease.
(11) Amyloid: 
(a) Further studies are needed to assess the efficacy and safety of 
tafamidis in NYHA class III patients.
(b) SCD risk stratification and indications for ICD implantation 
should be carefully defined, taking into account the estimated 
life expectancy, competitive non-cardiovascular mortality, 
and the high rate of pulseless electrical activity.
(c) The need for drug therapy in patients with cardiac amyloid­
osis and subclinical cardiac involvement (i.e asymptomatic pa­
tients, positive scintigraphy with negative ECHO) has not 
been clearly defined.
(12) Sports: 
(a) ‘Return to play’ for patients with low-risk cardiomyopathies 
(and how to define low risk in relation to exercise).
(b) SCD risk and exercise recommendations in phenotype- 
negative gene carriers.
(c) Role of exercise in disease expression and progression.
(d) Large, adequately powered randomized prospective studies are 
necessary to provide evidence-based recommendations for op­
timal exercise prescription without compromising safety.
(13) Reproductive issues: 
(a) Several cardiomyopathies lack specific outcome data regard­
ing pregnancy.
(b) There is a lack of randomized trials on the use of AADs, heart 
failure drugs, and interventions during pregnancy.
(14) Non-cardiac interventions: 
(a) There is a lack specific outcome data regarding risks of non- 
cardiac interventions.
(15) Management of cardiovascular risk factors in patients with 
cardiomyopathies: 
(a) There is a lack of data on the impact of comorbidities on 
penetrance, severity, and outcome of cardiomyopathies.
16. ‘What to do’ and ‘What not to do’ messages from the Guidelines
Recommendations
Classa
Levelb
Recommendations for the provision of service of multidisciplinary cardiomyopathy teams
It is recommended that all patients with cardiomyopathy and their relatives have access to multidisciplinary teams with expertise in the 
diagnosis and management of cardiomyopathies.
I
C
Timely and adequate preparation for transition of care from paediatric to adult services, including joint consultations, is recommended in all 
adolescents with cardiomyopathy.
I
C
Recommendations for diagnostic work-up in cardiomyopathies
It is recommended that all patients with suspected or established cardiomyopathy undergo systematic evaluation using a multiparametric 
approach that includes clinical evaluation, pedigree analysis, ECG, Holter monitoring, laboratory tests, and multimodality imaging.
I
C
It is recommended that all patients with suspected cardiomyopathy undergo evaluation of family history and that a three- to four-generation 
family tree is created to aid in diagnosis, provide clues to underlying aetiology, determine inheritance pattern, and identify at-risk relatives.
I
C
Recommendations for laboratory tests in the diagnosis of cardiomyopathies
Routine (first-level) laboratory tests are recommended in all patients with suspected or confirmed cardiomyopathy to evaluate aetiology, 
assess disease severity, and aid in detection of extracardiac manifestations and assessment of secondary organ dysfunction.
I
C
Recommendation for echocardiographic evaluation in patients with cardiomyopathy
A comprehensive evaluation of cardiac dimensions and LV and RV systolic (global and regional) and LV diastolic function is recommended in all 
patients with cardiomyopathy at initial evaluation, and during follow-up, to monitor disease progression and aid risk stratification and management.
I
B
Recommendations for cardiac magnetic resonance indication in patients with cardiomyopathy
Contrast-enhanced CMR is recommended in patients with cardiomyopathy at initial evaluation.
I
B
Recommendations for computed tomography and nuclear imaging
DPD/PYP/HMDP bone-tracer scintigraphy is recommended in patients with suspected ATTR-related cardiac amyloidosis to aid diagnosis.
I
B
Recommendations for genetic counselling and testing in cardiomyopathies
Genetic counselling
Genetic counselling, provided by an appropriately trained healthcare professional and including genetic education to inform decision-making 
and psychosocial support, is recommended for families with an inherited or suspected inherited cardiomyopathy, regardless of whether 
genetic testing is being considered.
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3591


<!-- PAGE 90 -->

### Page 90

It is recommended that genetic testing for cardiomyopathy is performed with access to a multidisciplinary team, including those with 
expertise in genetic testing methodology, sequence variant interpretation, and clinical application of genetic testing, typically in a specialized 
cardiomyopathy service or in a network model with access to equivalent expertise.
I
B
Pre- and post-test genetic counselling is recommended in all individuals undergoing genetic testing for cardiomyopathy.
I
B
If pre-natal diagnostic testing is to be pursued by the family, it is recommended that this is performed early in pregnancy, to allow decisions 
regarding continuation or co-ordination of pregnancy to be made.
I
C
Index patients
Genetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, 
prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of 
their relatives who would otherwise be enrolled into long-term surveillance.
I
B
Genetic testing is recommended for a deceased individual identified to have cardiomyopathy at post-mortem if a genetic diagnosis would 
facilitate management of surviving relatives.
I
C
Family members
It is recommended that cascade genetic testing, with pre- and post-test counselling, is offered to adult at-risk relatives if a confident genetic 
diagnosis (i.e. a P/LP variant) has been established in an individual with cardiomyopathy in the family (starting with first-degree relatives if available, 
and cascading out sequentially).
I
B
Diagnostic genetic testing is not recommended in a phenotype-negative relative of a patient with cardiomyopathy in the absence of a 
confident genetic diagnosis (i.e. a P/LP variant) in the family.
III
C
Recommendations for cardiac transplantation in patients with cardiomyopathy
Orthotopic cardiac transplantation is recommended for eligible cardiomyopathy patients with advanced heart failure (NYHA class III–IV) or 
intractable ventricular arrhythmia refractory to medical/invasive/device therapy, and who do not have absolute contraindications.
I
C
Recommendations for management of atrial fibrillation and atrial flutter in patients with cardiomyopathy
Anticoagulation
Oral anticoagulation in order to reduce the risk of stroke and thromboembolic events is recommended in all patients with HCM or cardiac 
amyloidosis and AF or atrial flutter (unless contraindicated).
I
B
Oral anticoagulation to reduce the risk of stroke and thrombo-embolic events is recommended in patients with DCM, NDLVC, or ARVC, 
and AF or atrial flutter with a CHA2DS2-VASc score ≥2 in men or ≥3 in women.
I
B
Control of symptoms and heart failure
Atrial fibrillation catheter ablation is recommended for rhythm control after one failed or intolerant class I or III AAD to improve symptoms 
of AF recurrences in patients with paroxysmal or persistent AF and cardiomyopathy.
I
B
Atrial fibrillation catheter ablation is recommended to reverse LV dysfunction in AF patients with cardiomyopathy when a 
tachycardia-induced component is highly probable, independent of their symptom status.
I
B
Comorbidities and associated risk factor management
Modification of an unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom 
severity in patients with cardiomyopathy.
I
B
Recommendations for implantable cardioverter defibrillator in patients with cardiomyopathy
General recommendations
Implantation of a cardioverter defibrillator is only recommended in patients who have an expectation of good quality survival >1 year.
I
C
It is recommended that ICD implantation be guided by shared decision-making that: 
• is evidence-based;
• considers a person’s individual preferences, beliefs, circumstances, and values; and
• ensures that the person understands the benefits, harm, and possible consequences of different treatment options.
I
C
It is recommended that prior to ICD implantation, patients are counselled on the risk of inappropriate shocks, implant complications, and 
the social, occupational, and driving implications of the device.
I
C
It is not recommended to implant an ICD in patients with incessant ventricular arrhythmias until the ventricular arrhythmia is controlled.
III
C
Secondary prevention
Implantation of an ICD is recommended:
• in patients with HCM, DCM, and ARVC who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained 
ventricular arrhythmia causing syncope or haemodynamic compromise in the absence of reversible causes.
I
B
• in patients with NDLVC and RCM who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained ventricular 
arrhythmia causing syncope or haemodynamic compromise in the absence of reversible causes.
I
C
Continued


<!-- PAGE 91 -->

### Page 91

Primary prevention
Comprehensive SCD risk stratification is recommended in all cardiomyopathy patients who have not suffered a previous cardiac arrest/ 
sustained ventricular arrhythmia at initial evaluation and at 1–2 year intervals, or whenever there is a change in clinical status.
I
C
The use of validated SCD algorithms/scores as aids to the shared decision-making when offering ICD implantation, where available is 
recommended in patients with HCM.
I
B
Choice of ICD
When an ICD is indicated, it is recommended to evaluate whether the patient could benefit from CRT.
I
A
Recommendations for routine follow-up of patients with cardiomyopathy
It is recommended that all clinically stable patients with cardiomyopathy undergo routine follow-up using a multiparametric approach that 
includes ECG and echocardiography every 1–2 years.
I
C
Clinical evaluation with ECG and multimodality imaging is recommended in patients with cardiomyopathy whenever there is a substantial or 
unexpected change in symptoms.
I
C
Recommendations for family screening and follow-up evaluation of relatives
Following cascade genetic testing, clinical evaluation using a multiparametric approach that includes ECG and cardiac imaging and long-term 
follow-up is recommended in first-degree relatives who have the same disease-causing variant as the proband.
I
B
Following cascade genetic testing, it is recommended that first-degree relatives without a phenotype who do not have the same 
disease-causing variant as the proband are discharged from further follow-up but advised to seek re-assessment if they develop symptoms 
or when new clinically relevant data emerge in the family.
I
C
It is recommended that when no P/LP variant is identified in the proband or genetic testing is not performed, an initial clinical evaluation 
using a multiparametric approach that includes ECG and cardiac imaging is performed in first-degree relatives.
I
C
Recommendations for psychological support in patients and family members with cardiomyopathies
It is recommended that psychological support by an appropriately trained health professional be offered to all individuals who have 
experienced the premature sudden cardiac death of a family member with cardiomyopathy.
I
B
It is recommended that psychological support by an appropriately trained health professional be offered to all individuals with an inherited 
cardiomyopathy who receive an implantable cardioverter defibrillator.
I
B
Recommendation for evaluation of left ventricular outflow tract obstruction
In all patients with HCM, at initial evaluation, transthoracic 2D and Doppler echocardiography are recommended, at rest and during Valsalva 
manoeuvre in the sitting and semi-supine positions—and then on standing if no gradient is provoked—to detect LVOTO.
I
B
In symptomatic patients with HCM and a resting or provoked peak instantaneous LV outflow tract gradient <50 mmHg, 2D and Doppler 
echocardiography during exercise in the standing, sitting (when possible), or semi-supine position are recommended to detect provocable 
LVOTO and exercise-induced mitral regurgitation.
I
B
Recommendations for medical treatment of left ventricular outflow tract obstruction
Non-vasodilating beta-blockers, titrated to maximum tolerated dose, are recommended as first-line therapy to improve symptoms in 
patients with resting or provoked LVOTO.
I
B
Verapamil or diltiazem, titrated to maximum tolerated dose, are recommended to improve symptoms in symptomatic patients with resting 
or provoked LVOTO who are intolerant or have contraindications to beta-blockers.
I
B
Disopyramide, titrated to maximum tolerated dose, is recommended in addition to a beta-blocker (or, if this is not possible, with verapamil 
or diltiazem) to improve symptoms in patients with resting or provoked LVOTO.
I
B
Recommendations for septal reduction therapy
It is recommended that SRT be performed by experienced operators working as part of a multidisciplinary team expert in the management 
of HCM.
I
C
SRT to improve symptoms is recommended in patients with a resting or maximum provoked LVOT gradient of ≥50 mmHg who are in 
NYHA/Ross functional class III–IV, despite maximum tolerated medical therapy.
I
B
Septal myectomy, rather than ASA, is recommended in children with an indication for SRT, as well as in adult patients with an indication for 
SRT and other lesions requiring surgical intervention (e.g. mitral valve abnormalities).
I
C
Additional recommendations for prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy
Secondary prevention
Implantation of an ICD is recommended in patients who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained 
VT with haemodynamic compromise.
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3593


<!-- PAGE 92 -->

### Page 92

Primary prevention
The HCM Risk-SCD calculator is recommended as a method of estimating risk of sudden death at 5 years in patients aged ≥16 years for 
primary prevention.
I
B
Validated paediatric-specific risk-prediction models (e.g. HCM Risk-Kids) are recommended as a method of estimating risk of sudden death 
at 5 years in patients aged <16 years for primary prevention.
I
B
It is recommended that the 5-year risk of SCD be assessed at first evaluation and re-evaluated at 1–2 year intervals or whenever there is a 
change in clinical status.
I
B
Recommendations for an implantable cardioverter defibrillator in patients with dilated cardiomyopathy
Secondary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with DCM who have survived a cardiac arrest 
or have recovered from a ventricular arrhythmia causing haemodynamic instability.
I
B
Recommendation for resting and ambulatory electrocardiogram monitoring in patients with non-dilated left ventricular 
cardiomyopathy
Ambulatory ECG monitoring is recommended in patients with NDLVC annually or when there is a change in clinical status, to aid in 
management and risk stratification.
I
C
Recommendations for an implantable cardioverter defibrillator in patients with non-dilated left ventricular cardiomyopathy
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with NDLVC who have survived a cardiac 
arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.
I
C
Recommendation for resting and ambulatory electrocardiogram monitoring in patients with arrhythmogenic right ventricular 
cardiomyopathy
Annual ambulatory ECG monitoring is recommended in patients with ARVC to aid in diagnosis, management, and risk stratification.
I
C
Recommendations for the antiarrhythmic management of patients with arrhythmogenic right ventricular cardiomyopathy
Beta-blocker therapy is recommended in ARVC patients with VE, NSVT, and VT.
I
C
Recommendations for sudden cardiac death prevention in patients with arrhythmogenic right ventricular cardiomyopathy
Secondary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with ARVC who have survived a cardiac 
arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.
I
A
Recommendations for the management of patients with restrictive cardiomyopathy
It is recommended that multimodality imaging be used to differentiate RCM from HCM or DCM with restrictive physiology.
I
C
It is recommended that baseline cardiac and non-cardiac investigations are performed to assess involvement of the neuromuscular system 
or other syndromic disorders.
I
C
Cardiac catheterization is recommended in all children with RCM to measure pulmonary artery pressures and PVR at diagnosis and at 6–12 
monthly intervals to assess change in PVR.
I
B
ICD implantation is recommended to reduce the risk of sudden death and all-cause mortality in patients with RCM who have survived a 
cardiac arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability.
I
C
Exercise recommendations for cardiomyopathy patients
All cardiomyopathies
Regular low- to moderate-intensity exercise is recommended in all able individuals with cardiomyopathy.
I
C
An individualized risk assessment for exercise prescription is recommended in all patients with cardiomyopathy.
I
C
HCM
High-intensity exercise, including competitive sport, is not recommended in high-risk individuals and in individuals with left ventricular 
outflow tract obstruction and exercise-induced complex ventricular arrhythmias.
III
C
ARVC
Moderate- and/or high-intensity exercise, including competitive sport, is not recommended in individuals with ARVC.
III
B
DCM and NDLVC
High-intensity exercise, including competitive sport, is not recommended in symptomatic individuals, those with a left ventricular ejection 
fraction ≤40%, exercise-induced arrhythmias, or pathogenic variants in LMNA or TMEM43.
III
C
Recommendations for reproductive issues in patients with cardiomyopathy
Pre-pregnancy risk assessment and counselling are recommended in all women using the mWHO classification of maternal risk.
I
C
Continued


<!-- PAGE 93 -->

### Page 93

### 17 Supplementary data

Supplementary material is available at European Heart Journal online.
18. Data availability statement
No new data were generated or analysed in support of this research.
19. Author information
Author/Task Force Member Affiliations: Alexandros 
Protonotarios, Centre for Heart Muscle Disease, UCL Institute of 
Cardiovascular 
Science, 
London, 
United 
Kingdom, 
Inherited 
Cardiovascular Disease Unit, St Bartholomew’s Hospital, London, 
United Kingdom; Juan R. Gimeno, Inherited Heart Diseases Unit 
(CSUR /ERN), Hospital Universitario Virgen de la Arrixaca- IMIB- 
Universidad de Murcia, Murcia, Spain, European Reference Networks 
for rare, low prevalence and complex diseases of the heart, ERN 
GUARD-Heart, European Commission 6, Amsterdam, Netherlands; 
Eloisa Arbustini, Centre For Inherited Cardiovascular Diseases, 
IRCCS Foundation Policlinico San Matteo, Piazzale Golgi, 27100 
Pavia, Italy; Roberto Barriales-Villa, Inherited Cardiovascular 
Diseases 
Unit, 
Cardiology 
Service, 
Complexo 
Hospitalario 
Universitario A Coruña (CHUAC), A Coruña, Spain, Instituto de 
Investigación Biomédica de A Coruña (INIBIC), Servizo Galego de 
Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain, Centro 
de 
Investigación 
Biomédica 
en 
Red 
de 
Enfermedades 
Cardiovasculares, Instituto de Salud Carlos III, A Coruña, Spain; 
Cristina Basso, Department of Cardiac, Thoracic, Vascular 
Sciences and Public Health-University of Padua, Cardiovascular 
Pathology 
Unit-Azienda 
Ospedaliera, 
Padua, 
Italy; 
Connie 
R. Bezzina, Amsterdam UMC location University of Amsterdam, 
Department of experimental cardiology, Heart centre, Meibergdreef 
9, Amsterdam, Netherlands, Amsterdam cardiovascular sciences, 
Heart failure and arrhythmias, Amsterdam, Netherlands, European 
Reference Networks for rare, low prevalence and complex diseases 
of the heart, ERN GUARD-Heart; Elena Biagini, Cardiology, 
IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, 
Cardiology, Centro di riferimento europeo delle malattie cardiovasco­
lari, ERN GUARD-Heart, Bologna, Italy; Nico A. Blom, Paediatric 
Cardiology, Leiden University Medical Center, Leiden, Netherlands, 
Paediatric Cardiology, Amsterdam University Medical Center, 
Amsterdam, Netherlands; Rudolf A. de Boer, Erasmus Medical 
Counselling on safe and effective contraception is recommended in all women of fertile age and their partners.
I
C
Counselling on the risk of disease inheritance is recommended for all men and women before conception.
I
C
Vaginal delivery is recommended in most women with cardiomyopathies, unless there are obstetric indications for caesarean section, severe 
heart failure (EF <30% or NYHA class III–IV), or severe outflow tract obstructions, or in women presenting in labour on oral anticoagulants.
I
C
It is recommended that medication be carefully reviewed for safety in advance of pregnancy and adjusted according to tolerability in 
pregnancy.
I
C
Therapeutic anticoagulation with LMWH or VKAs according to the stage of pregnancy is recommended for patients with AF.
I
C
Recommendations for non-cardiac surgery in patients with cardiomyopathy
Peri-operative ECG monitoring is recommended for all patients with cardiomyopathy undergoing surgery.
I
C
In patients with cardiomyopathy and suspected or known HF scheduled for intermediate or high-risk NCS, it is recommended to 
re-evaluate LV function with echocardiography (assessing LVOTO in HCM patients) and measurement of NT-proBNP/BNP levels, unless 
this has recently been performed.
I
B
It is recommended that cardiomyopathy patients with high-risk genotypes or associated factors for arrhythmic or heart failure 
complications or severe LVOTO be referred for additional specialized investigations to a cardiomyopathy unit before undergoing elective 
NCS.
I
C
In patients aged <65 years with a first-degree relative with a cardiomyopathy, it is recommended to perform an ECG and TTE before NCS, 
regardless of symptoms.
I
C
Recommendation for management of cardiovascular risk factors in patients with cardiomyopathy
Identification and management of risk factors and concomitant diseases is recommended as an integral part of the management of 
cardiomyopathy patients.
I
C
© ESC 2023
2D, two-dimensional; AAD, antiarrhythmic drug; AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; ASA, alcohol septal ablation; ATTR, transthyretin amyloidosis; 
BNP, brain natriuretic peptide; CHA2DS2-VASc, congestive heart failure or left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65– 
74, 
sex 
category 
(female) 
(score); 
CMR, 
cardiac 
magnetic 
resonance; 
CRT, 
cardiac 
resynchronization 
therapy; 
DCM, 
dilated 
cardiomyopathy; 
DPD, 
3,3-diphosphono-1,2-propanodicarboxylic acid; ECG, electrocardiogram; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HMDP, hydroxymethylene diphosphonate; ICD, 
implantable cardioverter defibrillator; LMWH, low-molecular-weight heparin; LV, left ventricular; LVOT, left ventricular outflow tract; LVOTO, left ventricular outflow tract obstruction; 
mWHO, modified World Health Organization; NCS, non-cardiac surgery; NDLVC, non-dilated left ventricular cardiomyopathy; NSVT, non-sustained ventricular tachycardia; 
NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; P/LP, pathogenic/likely pathogenic; PVR, pulmonary vascular resistance; PYP, 
pyrophosphate; RCM, restrictive cardiomyopathy; RV, right ventricular; SCD, sudden cardiac death; SRT, septal reduction therapy; TTE, transthorasic echocardiogram; VE, ventricular 
ectopic beats; VF, ventricular fibrillation; VKA, vitamin K antagonist; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3595


<!-- PAGE 94 -->

### Page 94

Center, Department of Cardiology, Rotterdam, Netherlands; Tim De 
Winter (Belgium), ESC Patient Forum, Sophia Antipolis, France; 
Perry M. Elliott, UCL Institute of Cardiovascular Science 
University 
College 
London, 
London, 
United 
Kingdom, 
St. Bartholomew’s Hospital, London, United Kingdom; Marcus 
Flather, Norwich Medical School, University of East Anglia, 
Norwich, United Kingdom, Department of Cardiology, Norfolk and 
Norwich University Hospital, Norwich, United Kingdom; Pablo 
Garcia-Pavia, Department of cardiology, Hospital Universitario 
Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain, 
Centro Nacional de Invstigaciones Cardiovasculares (CNIC), Madrid, 
Spain, European Reference Networks for rare, low prevalence and 
complex diseases of the heart, ERN GUARD-Heart, Madrid, Spain; 
Kristina H. Haugaa, Cardiology, Karolinska University Hospital, 
Stockholm, Sweden, Cardiology, Oslo University Hospital, Oslo, 
Norway; Jodie Ingles, Centre for Population Genomics, Garvan 
Institute of Medical Research, and UNSW Sydney, Sydney, Australia; 
Ruxandra Oana Jurcut, Expert Center for Rare Genetic 
Cardiovascular Diseases, Department of Cardiology, Emergency 
Institute of Cardiovascular Diseases “Prof.dr.C.C.Iliescu”, Bucharest, 
Romania, Cardiology, University of Medicine and Pharmacy “Carol 
Davila”, Bucharest, Romania; Sabine Klaassen, Experimental and 
Clinical Research Center, A Cooperation Between the Max Delbrück 
Center and Charité - Universitätsmedizin Berlin, Charité - 
Universitätsmedizin Berlin, Corporate Member of Freie Universität 
Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 
Congenital Heart Disease - Pediatric Cardiology, Deutsches 
Herzzentrum der Charité (DHZC), Berlin, Germany, DZHK 
(German Centre for Cardiovascular Research) partner site Berlin, 
Berlin, Germany; Giuseppe Limongelli, Translational Medical 
Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy, 
Cardiology, Monaldi Hospital - AORN Colli, Naples, Italy, European 
Reference Network for Rare, Low Prevalence, or Complex Diseases 
of the Heart (ERN GUARD-Heart); Bart Loeys, Center for medical 
genetics, Antwerp university hospital/university of Antwerp, 
Antwerp, Belgium, Department of human genetics, Radboud university 
medical 
center, 
Nijmegen, 
Netherlands; 
Jens 
Mogensen, 
Department of Cardiology, Aalborg University Hospital, Aalborg, 
Denmark; Iacopo Olivotto, Meyer Children’s Hospital IRCCS, 
University of Florence, Florence, Italy; Antonis Pantazis, Royal 
Brompton, and Harefield Hospitals, London, United Kingdom; 
Sanjay Sharma, St George’s, University of London, London, United 
Kingdom, St George’s University Hospital NHS Foundation Trust, 
London, United Kingdom; J. Peter van Tintelen, Department of 
Genetics, University Medical Center Utrecht, Utrecht, Netherlands; 
and James S. Ware, National Heart & Lung Institute, Imperial 
College London, London, United Kingdom, MRC London Institute of 
Medical Sciences, Imperial College London, London, United Kingdom, 
Royal Brompton & Harefield Hospitals, Guy’s and St. Thomas’ NHS 
Foundation Trust, London, United Kingdom.
20. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Philippe Charron (CPG Review 
Co-ordinator) (France), Massimo Imazio (CPG Review Co-ordinator) 
(Italy), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Michael 
Arad (Israel), Folkert W. Asselbergs (Netherlands), Riccardo 
Asteggiano (Italy), Zofia Bilinska (Poland), Damien Bonnet (France), 
Henning Bundgaard (Denmark), Nuno Miguel Cardim (Portugal), 
Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), Gaetano Maria 
De Ferrari (Italy), Veronica Dusi (Italy), Volkmar Falk (Germany), 
Laurent Fauchier (France), Estelle Gandjbakhch (France), Tiina Heliö 
(Finland), Konstantinos Koskinas (Switzerland), Dipak Kotecha 
(United Kingdom), Ulf Landmesser (Germany), George Lazaros 
(Greece), Basil S. Lewis (Israel), Ales Linhart (Czechia), Maja-Lisa 
Løchen (Norway), Benjamin Meder (Germany), Richard Mindham 
(United Kingdom), James Moon (United Kingdom), Jens Cosedis 
Nielsen (Denmark), Steffen Petersen (United Kingdom), Eva Prescott 
(Denmark), Mary N. Sheppard (United Kingdom), Gianfranco Sinagra 
(Italy), Marta Sitges (Spain), Jacob Tfelt-Hansen (Denmark), Rhian 
Touyz (Canada), Rogier Veltrop (Netherlands), Josef Veselka 
(Czechia), Karim Wahbi (France), Arthur Wilde (Netherlands), and 
Katja Zeppenfeld (Netherlands).
ESC National Cardiac Societies actively involved in the review 
process of the 2023 ESC Guidelines for the management of 
cardiomyopathies:
Algeria: Algerian Society of Cardiology, Brahim Kichou; Armenia: 
Armenian Cardiologists Association, Hamayak Sisakian; Austria: 
Austrian Society of Cardiology, Daniel Scherr; Belgium: Belgian 
Society 
of 
Cardiology, 
Bernhard 
Gerber; 
Bosnia 
and 
Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Alen Džubur; Bulgaria: Bulgarian Society of 
Cardiology, Mariana Gospodinova; Croatia: Croatian Cardiac 
Society, Ivo Planinc; Cyprus: Cyprus Society of Cardiology, Hera 
Heracleous Moustra; Czechia: Czech Society of Cardiology, David 
Zemánek; Denmark: Danish Society of Cardiology, Morten Steen 
Kvistholm Jensen; Egypt: Egyptian Society of Cardiology, Ahmad 
Samir; Estonia: Estonian Society of Cardiology, Kairit Palm; 
Finland: Finnish Cardiac Society, Tiina Heliö; France: French 
Society of Cardiology, Karim,Wahbi; Germany: German Cardiac 
Society, Eric Schulze-Bahr; Greece: Hellenic Society of Cardiology, 
Vlachopoulos Haralambos; Hungary: Hungarian 
Society of 
Cardiology Róbert Sepp; Iceland: Icelandic Society of Cardiology, 
Berglind Aðalsteinsdóttir; Ireland: Irish Cardiac Society, Deirdre 
Ward; Israel: Israel Heart Society, Miry Blich; Italy: Italian 
Federation of Cardiology, Gianfranco Sinagra; Kosovo (Republic 
of): Kosovo Society of Cardiology, Afrim Poniku; Kyrgyzstan: 
Kyrgyz Society of Cardiology, Olga Lunegova, Latvia: Latvian Society 
of Cardiology, Ainars Rudzitis; Lebanon: Lebanese Society 
of Cardiology, Roland Kassab; Lithuania: Lithuanian Society of 
Cardiology, Jūratė Barysienė; Luxembourg: Luxembourg Society of 
Cardiology, Steve Huijnen; Malta: Maltese Cardiac Society, Tiziana 
Felice; Moldova (Republic of): Moldavian Society of Cardiology, 
Eleonora 
Vataman; 
Montenegro: 
Montenegro 
Society 
of 
Cardiology, 
Nikola 
Pavlovic; 
Morocco: 
Moroccan 
Society 
of Cardiology, Nawal Doghmi; Netherlands: Netherlands Society 
of Cardiology, Folkert W. Asselbergs; North Macedonia: The 
National Society of Cardiology of North Macedonia, Elizabeta 
Srbinovska Kostovska; Norway: Norwegian Society of Cardiology, 
Vibeke Marie Almaas; Poland: Polish Cardiac Society, Elżbieta 
Katarzyna Biernacka; Portugal: Portuguese Society of Cardiology, 
Dulce Brito; Romania: Romanian Society of Cardiology, Monica 
Rosca; San Marino: San Marino Society of Cardiology, Marco 
Zavatta; Serbia: Cardiology Society of Serbia, Arsen Ristic; 
Slovakia: Slovak Society of Cardiology, Eva Goncalvesová; 
Slovenia: Slovenian Society of Cardiology, Matjaž Šinkovec; Spain: 
Spanish Society of Cardiology, Victoria Cañadas-Godoy; Sweden:


<!-- PAGE 95 -->

### Page 95

Swedish Society of Cardiology, Pyotr G. Platonov; Switzerland: Swiss 
Society of Cardiology, Ardan M. Saguner; Syrian Arab Republic: 
Syrian Cardiovascular Association, Ahmad Rasheed Al Saadi; 
Tunisia: Tunisian Society of Cardiology and Cardiovascular Surgery, 
Ikram Kammoun; Türkiye: Turkish Society of Cardiology, Ahmet 
Celik; Ukraine: Ukrainian Association of Cardiology, Elena Nesukay; 
and Uzbekistan: Association of Cardiologists of Uzbekistan, Timur 
Abdullaev.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes Pasquet 
(Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier 
Rossello (Spain), Ilonca Vaartjes (Netherlands), Christiaan Vrints 
(Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld 
(Netherlands).
21. Acknowledgements
The Task Force Chairs thank Sebastian Onciul for providing cardiac 
magnetic resonance images in Figure 7.
22. References
1. Authors/Task Force Members; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, 
Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy: the Task Force for the Diagnosis and Management of 
Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur 
Heart J 2014;35:2733–2779. https://doi.org/10.1093/eurheartj/ehu284
2. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification 
of the cardiomyopathies: a position statement from the European Society of 
Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 
2008;29:270–276. https://doi.org/10.1093/eurheartj/ehm342
3. Wilde AAM, Semsarian C, Marquez MF, Shamloo AS, Ackerman MJ, Ashley EA, et al. 
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia 
Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society 
(LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac dis­
eases. Europace 2022;24:1307–1367. https://doi.org/10.1093/europace/euac030
4. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al. 
2019 HRS expert consensus statement on evaluation, risk stratification, and manage­
ment of arrhythmogenic cardiomyopathy. Heart Rhythm 2019;16:e301–e372. https:// 
doi.org/10.1016/j.hrthm.2019.05.007
5. Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari M, et al. 
Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol 2020; 
319:106–114. https://doi.org/10.1016/j.ijcard.2020.06.005
6. Biesecker LG, Adam MP, Alkuraya FS, Amemiya AR, Bamshad MJ, Beck AE, et al. A 
dyadic approach to the delineation of diagnostic entities in clinical genomics. Am J 
Hum Genet 2021;108:8–15. https://doi.org/10.1016/j.ajhg.2020.11.013
7. Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, et al. The 
MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: 
endorsed by the World Heart Federation. J Am Coll Cardiol 2013;62:2046–2072. 
https://doi.org/10.1016/j.jacc.2013.08.1644
8. Disertori M, Quintarelli S, Grasso M, Pilotto A, Narula N, Favalli V, et al. Autosomal 
recessive atrial dilated cardiomyopathy with standstill evolution associated with muta­
tion of Natriuretic Peptide Precursor A. Circ Cardiovasc Genet 2013;6:27–36. https:// 
doi.org/10.1161/CIRCGENETICS.112.963520
9. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Bohm M, et al. Proposal for a 
revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, 
and its implications for clinical practice: a position statement of the ESC working group 
on myocardial and pericardial diseases. Eur Heart J 2016;37:1850–1858. https://doi.org/ 
10.1093/eurheartj/ehv727
10. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of 
arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of 
the Task Force Criteria. Eur Heart J 2010;31:806–14. https://doi.org/10.1093/ 
eurheartj/ehq025
11. Rapezzi C, Aimo A, Barison A, Emdin M, Porcari A, Linhart A, et al. Restrictive cardio­
myopathy: definition and diagnosis. Eur Heart J 2022;43:4679–4693. https://doi.org/10. 
1093/eurheartj/ehac543
12. van Waning JI, Caliskan K, Michels M, Schinkel AFL, Hirsch A, Dalinghaus M, et al. 
Cardiac phenotypes, genetics, and risks in familial noncompaction cardiomyopathy. J 
Am Coll Cardiol 2019;73:1601–1611. https://doi.org/10.1016/j.jacc.2018.12.085
13. Sedaghat-Hamedani F, Haas J, Zhu F, Geier C, Kayvanpour E, Liss M, et al. Clinical gen­
etics and outcome of left ventricular non-compaction cardiomyopathy. Eur Heart J 
2017;38:3449–3460. https://doi.org/10.1093/eurheartj/ehx545
14. Klaassen S, Probst S, Oechslin E, Gerull B, Krings G, Schuler P, et al. Mutations in sarco­
mere protein genes in left ventricular noncompaction. Circulation 2008;117: 
2893–2901. https://doi.org/10.1161/CIRCULATIONAHA.107.746164
15. Probst S, Oechslin E, Schuler P, Greutmann M, Boye P, Knirsch W, et al. Sarcomere 
gene mutations in isolated left ventricular noncompaction cardiomyopathy do not pre­
dict clinical phenotype. Circ Cardiovasc Genet 2011;4:367–374. https://doi.org/10.1161/ 
CIRCGENETICS.110.959270
16. Hoedemaekers YM, Caliskan K, Michels M, Frohn-Mulder I, van der Smagt JJ, 
Phefferkorn JE. The importance of genetic counseling, DNA diagnostics, and cardiolo­
gic family screening in left ventricular noncompaction cardiomyopathy. Circ Cardiovasc 
Genet 2010;3:232–239. https://doi.org/10.1161/CIRCGENETICS.109.903898
17. Gati S, Papadakis M, Papamichael ND, Zaidi A, Sheikh N, Reed M, et al. Reversible de 
novo left ventricular trabeculations in pregnant women: implications for the diagnosis 
of left ventricular noncompaction in low-risk populations. Circulation 2014;130: 
475–483. https://doi.org/10.1161/CIRCULATIONAHA.114.008554
18. Gati S, Chandra N, Bennett RL, Reed M, Kervio G, Panoulas VF, et al. Increased left 
ventricular trabeculation in highly trained athletes: do we need more stringent criteria 
for the diagnosis of left ventricular non-compaction in athletes? Heart 2013;99: 
401–408. https://doi.org/10.1136/heartjnl-2012-303418
19. de la Chica JA, Gomez-Talavera S, Garcia-Ruiz JM, Garcia-Lunar I, Oliva B, 
Fernandez-Alvira JM, et al. Association between left ventricular noncompaction and 
vigorous physical activity. J Am Coll Cardiol 2020;76:1723–1733. https://doi.org/10. 
1016/j.jacc.2020.08.030
20. Jensen B, van der Wal AC, Moorman AFM, Christoffels VM. Excessive trabeculations in 
noncompaction do not have the embryonic identity. Int J Cardiol 2017;227:325–330. 
https://doi.org/10.1016/j.ijcard.2016.11.089
21. Faber JW, D’Silva A, Christoffels VM, Jensen B. Lack of morphometric evidence for 
ventricular compaction in humans. J Cardiol 2021;78:397–405. https://doi.org/10. 
1016/j.jjcc.2021.03.006
22. Anderson RH, Jensen B, Mohun TJ, Petersen SE, Aung N, Zemrak F, et al. Key ques­
tions relating to left ventricular noncompaction cardiomyopathy: is the emperor still 
wearing any clothes? Can J Cardiol 2017;33:747–757. https://doi.org/10.1016/j.cjca. 
2017.01.017
23. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al. Current 
state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce 
on Takotsubo Syndrome of the Heart Failure Association of the European Society of 
Cardiology. Eur J Heart Fail 2016;18:8–27. https://doi.org/10.1002/ejhf.424
24. McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden of 
cardiomyopathies. 
Circ 
Res 
2017;121:722–730. 
https://doi.org/10.1161/ 
CIRCRESAHA.117.309711
25. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a 
diverse genetic architecture. Nat Rev Cardiol 2013;10:531–547. https://doi.org/10. 
1038/nrcardio.2013.105
26. Hada Y, Sakamoto T, Amano K, Yamaguchi T, Takenaka K, Takahashi H, et al. 
Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers 
as detected by echocardiographic screening. Am J Cardiol 1987;59:183–184. https://doi. 
org/10.1016/S0002-9149(87)80107-8
27. Agnarsson UT, Hardarson T, Hallgrimsson J, Sigfusson N. The prevalence of hyper­
trophic cardiomyopathy in men: an echocardiographic population screening study 
with a review of death records. J Intern Med 1992;232:499–506. https://doi.org/10. 
1111/j.1365-2796.1992.tb00623.x
28. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hyper­
trophic cardiomyopathy in a general population of young adults. Echocardiographic 
analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development 
in (Young) Adults. Circulation 1995;92:785–789. https://doi.org/10.1161/01.CIR.92.4. 
785
29. Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic 
cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 1999;33: 
1590–1595. https://doi.org/10.1016/S0735-1097(99)00039-X
30. Maron BJ, Spirito P, Roman MJ, Paranicas M, Okin PM, Best LG, et al. Prevalence of 
hypertrophic cardiomyopathy in a population-based sample of American Indians 
aged 51 to 77 years (the Strong Heart Study). Am J Cardiol 2004;93:1510–1514. 
https://doi.org/10.1016/j.amjcard.2004.03.007
31. Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, et al. Prevalence of idiopathic hypertrophic 
cardiomyopathy in China: a population-based echocardiographic analysis of 8080 
adults. Am J Med 2004;116:14–18. https://doi.org/10.1016/j.amjmed.2003.05.009
ESC Guidelines                                                                                                                                                                                          3597


<!-- PAGE 96 -->

### Page 96

32. Maro EE, Janabi M, Kaushik R. Clinical and echocardiographic study of hypertrophic 
cardiomyopathy in Tanzania. Trop Doct 2006;36:225–227. https://doi.org/10.1258/ 
004947506778604904
33. Basavarajaiah S, Wilson M, Whyte G, Shah A, McKenna W, Sharma S. Prevalence of 
hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation 
screening. J Am Coll Cardiol 2008;51:1033–1039. https://doi.org/10.1016/j.jacc.2007.10. 
055
34. Nugent AW, Daubeney PE, Chondros P, Carlin JB, Cheung M, Wilkinson LC, et al. The 
epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003;348: 
1639–1646. https://doi.org/10.1056/NEJMoa021737
35. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of 
pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003;348: 
1647–1655. https://doi.org/10.1056/NEJMoa021715
36. Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela AL, et al. 
Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nation­
wide study in Finland. Am J Epidemiol 1997;146:385–393. https://doi.org/10.1093/ 
oxfordjournals.aje.a009291
37. Codd MB, Sugrue DD, Gersh BJ, Melton LJ III. Epidemiology of idiopathic dilated and hyper­
trophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975– 
1984. Circulation 1989;80:564–572. https://doi.org/10.1161/01.CIR.80.3.564
38. Andrews RE, Fenton MJ, Ridout DA, Burch M. New-onset heart failure due to heart 
muscle disease in childhood: a prospective study in the United Kingdom and Ireland. 
Circulation 2008;117:79–84. https://doi.org/10.1161/CIRCULATIONAHA.106.671735
39. Peters S, Trümmel M, Meyners W. Prevalence of right ventricular dysplasia- 
cardiomyopathy in a non-referral hospital. Int J Cardiol 2004;97:499–501. https://doi. 
org/10.1016/j.ijcard.2003.10.037
40. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden car­
diovascular death in young competitive athletes after implementation of a prepartici­
pation screening program. JAMA 2006;296:1593–1601. https://doi.org/10.1001/jama. 
296.13.1593
41. Migliore F, Zorzi A, Michieli P, Perazzolo Marra M, Siciliano M, Rigato I, et al. Prevalence 
of cardiomyopathy in Italian asymptomatic children with electrocardiographic T-wave 
inversion at preparticipation screening. Circulation 2012;125:529–538. https://doi.org/ 
10.1161/CIRCULATIONAHA.111.055673
42. Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguchia J, et al. 
Genetic etiology for alcohol-induced cardiac toxicity. J Am Coll Cardiol 2018;71: 
2293–2302. https://doi.org/10.1016/j.jacc.2018.03.462
43. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, 
et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. 
Circulation 
2019;140:31–41. 
https://doi.org/10.1161/CIRCULATIONAHA.118. 
037934
44. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic pre­
disposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016;374: 
233–241. https://doi.org/10.1056/NEJMoa1505517
45. Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, et al. Genetic and phenotypic 
landscape of peripartum cardiomyopathy. Circulation 2021;143:1852–1862. https:// 
doi.org/10.1161/CIRCULATIONAHA.120.052395
46. Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry disease: preva­
lence of affected males and heterozygotes with pathogenic GLA mutations identified 
by screening renal, cardiac and stroke clinics, 1995–2017. J Med Genet 2018;55: 
261–268. https://doi.org/10.1136/jmedgenet-2017-105080
47. Tini G, Sessarego E, Benenati S, Vianello PF, Musumeci B, Autore C, et al. Yield of bone 
scintigraphy screening for transthyretin-related cardiac amyloidosis in different condi­
tions: methodological issues and clinical implications. Eur J Clin Invest 2021;51:e13665. 
https://doi.org/10.1111/eci.13665
48. Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining 
the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of 
screening studies. Eur J Heart Fail 2022;24:2342–2351. https://doi.org/10.1002/ejhf. 
2532
49. Lota AS, Hazebroek MR, Theotokis P, Wassall R, Salmi S, Halliday BP, et al. Genetic 
architecture of acute myocarditis and the overlap with inherited cardiomyopathy. 
Circulation 2022;146:1123–1134. https://doi.org/10.1161/CIRCULATIONAHA.121. 
058457
50. Tiron C, Campuzano O, Fernandez-Falgueras A, Alcalde M, Loma-Osorio P, Zamora 
E, et al. Prevalence of pathogenic variants in cardiomyopathy-associated genes in myo­
carditis. Circ Genom Precis Med 2022;15:e003408. https://doi.org/10.1161/CIRCGEN. 
121.003408
51. Seidel F, Holtgrewe M, Al-Wakeel-Marquard N, Opgen-Rhein B, Dartsch J, Herbst C, 
et al. Pathogenic variants associated with dilated cardiomyopathy predict outcome in 
pediatric myocarditis. Circ Genom Precis Med 2021;14:e003250. https://doi.org/10. 
1161/CIRCGEN.120.003250
52. Ammirati E, Raimondi F, Piriou N, Sardo Infirri L, Mohiddin SA, Mazzanti A, et al. Acute 
myocarditis associated with desmosomal gene variants. JACC Heart Fail 2022;10: 
714–727. https://doi.org/10.1016/j.jchf.2022.06.013
53. Cardim N, Freitas A, Brito D. From hypertrophic cardiomyopathy centers to inherited 
cardiovascular disease centers in Europe. A small or a major step? A position paper 
from the Nucleus of the Working Group on Myocardial and Pericardial Diseases of 
the Portuguese Society of Cardiology. Rev Port Cardiol 2011;30:829–835. https://doi. 
org/10.1016/j.repc.2011.09.005
54. Barriales-Villa R, Gimeno-Blanes JR, Zorio-Grima E, Ripoll-Vera T, Evangelista-Masip A, 
Moya-Mitjans A, et al. Plan of action for inherited cardiovascular diseases: synthesis of 
recommendations and action algorithms. Rev Esp Cardiol 2016;69:300–309. https://doi. 
org/10.1016/j.recesp.2015.11.031
55. Vriz O, AlSergani H, Elshaer AN, Shaik A, Mushtaq AH, Lioncino M, et al. A complex 
unit for a complex disease: the HCM-Family Unit. Monaldi Arch Chest Dis 2021;92. 
https://doi.org/10.4081/monaldi.2021.2147
56. Basso C, Aguilera B, Banner J, Cohle S, d’Amati G, de Gouveia RH, et al. Guidelines for 
autopsy investigation of sudden cardiac death: 2017 update from the Association for 
European Cardiovascular Pathology. Virchows Arch 2017;471:691–705. https://doi.org/ 
10.1007/s00428-017-2221-0
57. Fellmann F, van El CG, Charron P, Michaud K, Howard HC, Boers SN, et al. European 
recommendations integrating genetic testing into multidisciplinary management of 
sudden cardiac death. Eur J Hum Genet 2019;27:1763–1773. https://doi.org/10.1038/ 
s41431-019-0445-y
58. de Hosson M, Goossens PJJ, De Backer J, De Wolf D, Van Hecke A. Needs and experi­
ences of adolescents with congenital heart disease and parents in the transitional pro­
cess: a qualitative study. J Pediatr Nurs 2021;61:90–95. https://doi.org/10.1016/j.pedn. 
2021.03.016
59. de Hosson M, De Backer J, De Wolf D, De Groote K, Demulier L, Mels S, et al. 
Development of a transition program for adolescents with congenital heart disease. 
Eur J Pediatr 2020;179:339–348. https://doi.org/10.1007/s00431-019-03515-4
60. Tini G, Vianello PF, Rizzola G, La Malfa G, Porto I, Canepa M. Telehealth monitoring for 
hypertrophic cardiomyopathy and amyloid cardiomyopathy patients: lessons from the 
coronavirus disease 2019 lockdown in Italy. J Cardiovasc Med 2020;21:622–623. https:// 
doi.org/10.2459/JCM.0000000000001024
61. Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011. 
In: The European Parliament and the Council of the European Union, (ed); 2011. 
https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:52022DC0210
(5 April 2023 date last accessed).
62. Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Helio T, et al. 
Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes 
and final diagnosis. A position statement from the ESC Working Group on Myocardial 
and Pericardial Diseases. Eur Heart J 2013;34:1448–1458. https://doi.org/10.1093/ 
eurheartj/ehs397
63. Elliott P, Charron P, Blanes JR, Tavazzi L, Tendera M, Konte M, et al. European cardio­
myopathy pilot registry: EURObservational research programme of the European 
Society of Cardiology. Eur Heart J 2016;37:164–173. https://doi.org/10.1093/ 
eurheartj/ehv497
64. van Velzen HG, Schinkel AFL, Baart SJ, Oldenburg RA, Frohn-Mulder IME, van 
Slegtenhorst MA, et al. Outcomes of contemporary family screening in hypertrophic 
cardiomyopathy. Circ Genom Precis Med 2018;11:e001896. https://doi.org/10.1161/ 
CIRCGEN.117.001896
65. Ranthe MF, Carstensen L, Oyen N, Jensen MK, Axelsson A, Wohlfahrt J, et al. Risk of 
cardiomyopathy in younger persons with a family history of death from cardiomyop­
athy: a nationwide family study in a cohort of 3.9 million persons. Circulation 2015;132: 
1013–1019. https://doi.org/10.1161/CIRCULATIONAHA.114.013478
66. Gimeno JR, Lacunza J, Garcia-Alberola A, Cerdan MC, Oliva MJ, Garcia-Molina E, et al. 
Penetrance and risk profile in inherited cardiac diseases studied in a dedicated screen­
ing clinic. Am J Cardiol 2009;104:406–410. https://doi.org/10.1016/j.amjcard.2009.03. 
055
67. Ploski R, Rydzanicz M, Ksiazczyk TM, Franaszczyk M, Pollak A, Kosinska J, et al. Evidence 
for troponin C (TNNC1) as a gene for autosomal recessive restrictive cardiomyop­
athy with fatal outcome in infancy. Am J Med Genet A 2016;170:3241–3248. https:// 
doi.org/10.1002/ajmg.a.37860
68. Surmacz R, Franaszczyk M, Pyda M, Ploski R, Bilinska ZT, Bobkowski W. Autosomal 
recessive transmission of familial nonsyndromic dilated cardiomyopathy due to com­
pound desmoplakin gene mutations. Pol Arch Intern Med 2018;128:785–787. https:// 
doi.org/10.20452/pamw.4365
69. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 
Eur Heart J 2021;42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368
69a. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 
Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute 
and chronic heart failure. Eur Heart J 2023;44:3627–3639. https://doi.org/10.1093/ 
eurheartj/ehad195. In press.
70. Bonny A, Lellouche N, Ditah I, Hidden-Lucet F, Yitemben MT, Granger B, et al. 
C-reactive protein in arrhythmogenic right ventricular dysplasia/cardiomyopathy and 
relationship with ventricular tachycardia. Cardiol Res Pract 2010;2010:919783. 
https://doi.org/10.4061/2010/919783
71. Donal E, Delgado V, Bucciarelli-Ducci C, Galli E, Haugaa KH, Charron P, et al. 
Multimodality imaging in the diagnosis, risk stratification, and management of patients 
with dilated cardiomyopathies: an expert consensus document from the European


<!-- PAGE 97 -->

### Page 97

Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2019;20: 
1075–1093. https://doi.org/10.1093/ehjci/jez178
72. Haugaa KH, Basso C, Badano LP, Bucciarelli-Ducci C, Cardim N, Gaemperli O, et al. 
Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyop­
athy–an expert consensus document of the European Association of Cardiovascular 
Imaging. Eur Heart J Cardiovasc Imaging 2017;18:237–253. https://doi.org/10.1093/ 
ehjci/jew229
73. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. 
Recommendations for cardiac chamber quantification by echocardiography in adults: 
an update from the American Society of Echocardiography and the European 
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16: 
233–270. https://doi.org/10.1093/ehjci/jev014
74. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert 
consensus for multi-modality imaging evaluation of cardiovascular complications of 
radiotherapy in adults: a report from the European Association of Cardiovascular 
Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc 
Imaging 2013;14:721–740. https://doi.org/10.1093/ehjci/jet123
75. Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P, et al. Genetic counselling 
and testing in cardiomyopathies: a position statement of the European Society of 
Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 
2010;31:2715–2726. https://doi.org/10.1093/eurheartj/ehq271
76. Liu D, Hu K, Nordbeck P, Ertl G, Störk S, Weidemann F. Longitudinal strain bull’s eye 
plot patterns in patients with cardiomyopathy and concentric left ventricular hyper­
trophy. Eur J Med Res 2016;21:21. https://doi.org/10.1186/s40001-016-0216-y
77. Haugaa KH, Hasselberg NE, Edvardsen T. Mechanical dispersion by strain echocardi­
ography: a predictor of ventricular arrhythmias in subjects with lamin A/C mutations. 
JACC Cardiovasc Imaging 2015;8:104–106. https://doi.org/10.1016/j.jcmg.2014.04.029
78. Haugaa KH, Goebel B, Dahlslett T, Meyer K, Jung C, Lauten A, et al. Risk assessment of 
ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy by strain 
echocardiography. J Am Soc Echocardiogr 2012;25:667–673. https://doi.org/10.1016/j. 
echo.2012.02.004
79. Leren IS, Saberniak J, Haland TF, Edvardsen T, Haugaa KH. Combination of ECG and 
echocardiography for identification of arrhythmic events in early ARVC. JACC 
Cardiovasc Imaging 2017;10:503–513. https://doi.org/10.1016/j.jcmg.2016.06.011
80. Haland TF, Almaas VM, Hasselberg NE, Saberniak J, Leren IS, Hopp E, et al. Strain echo­
cardiography is related to fibrosis and ventricular arrhythmias in hypertrophic cardio­
myopathy. Eur Heart J Cardiovasc Imaging 2016;17:613–621. https://doi.org/10.1093/ 
ehjci/jew005
81. Norrish G, Ding T, Field E, Ziolkowska L, Olivotto I, Limongelli G, et al. Development 
of a novel risk prediction model for sudden cardiac death in childhood hypertrophic 
cardiomyopathy (HCM Risk-Kids). JAMA Cardiol 2019;4:918–927. https://doi.org/10. 
1001/jamacardio.2019.2861
82. Lopez L, Frommelt PC, Colan SD, Trachtenberg FL, Gongwer R, Stylianou M, et al. 
Pediatric heart network echocardiographic Z scores: comparison with other published 
models. J Am Soc Echocardiogr 2021;34:185–192. https://doi.org/10.1016/j.echo.2020. 
09.019
83. Adabag AS, Kuskowski MA, Maron BJ. Determinants for clinical diagnosis of hyper­
trophic cardiomyopathy. Am J Cardiol 2006;98:1507–1511. https://doi.org/10.1016/j. 
amjcard.2006.07.029
84. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular 
hypertrophy in hypertrophic cardiomyopathy: morphologic observations and signifi­
cance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll 
Cardiol 1995;26:1699–1708. https://doi.org/10.1016/0735-1097(95)00390-8
85. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic 
cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol 1983;2: 
437–444. https://doi.org/10.1016/S0735-1097(83)80269-1
86. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ven­
tricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyop­
athy. N Engl J Med 2003;348:295–303. https://doi.org/10.1056/NEJMoa021332
87. Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, et al. Prognostic sig­
nificance of left atrial size in patients with hypertrophic cardiomyopathy (from the 
Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol 2006;98:960–965. 
https://doi.org/10.1016/j.amjcard.2006.05.013
88. Debonnaire P, Joyce E, Hiemstra Y, Mertens BJ, Atsma DE, Schalij MJ, et al. Left atrial 
size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial 
fibrillation. Circ Arrhythm Electrophysiol 2017;10:e004052. https://doi.org/10.1161/ 
CIRCEP.116.004052
89. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, et al. 
Prevalence, clinical profile, and significance of left ventricular remodeling in the end- 
stage phase of hypertrophic cardiomyopathy. Circulation 2006;114:216–225. https:// 
doi.org/10.1161/CIRCULATIONAHA.105.583500
90. Alba AC, Gaztanaga J, Foroutan F, Thavendiranathan P, Merlo M, Alonso-Rodriguez D, 
et al. Prognostic value of late gadolinium enhancement for the prediction of cardiovas­
cular outcomes in dilated cardiomyopathy: an international, multi-institutional study of 
the MINICOR group. Circ Cardiovasc Imaging 2020;13:e010105. https://doi.org/10. 
1161/CIRCIMAGING.119.010105
91. Leong DP, Chakrabarty A, Shipp N, Molaee P, Madsen PL, Joerg L, et al. Effects of myo­
cardial fibrosis and ventricular dyssynchrony on response to therapy in new- 
presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic 
resonance and echocardiography. Eur Heart J 2012;33:640–648. https://doi.org/10. 
1093/eurheartj/ehr391
92. Yoerger DM, Marcus F, Sherrill D, Calkins H, Towbin JA, Zareba W, et al. 
Echocardiographic findings in patients meeting task force criteria for arrhythmogenic 
right ventricular dysplasia: new insights from the multidisciplinary study of right ven­
tricular dysplasia. J Am Coll Cardiol 2005;45:860–865. https://doi.org/10.1016/j.jacc. 
2004.10.070
93. Pieles GE, Grosse-Wortmann L, Hader M, Fatah M, Chungsomprasong P, Slorach C, 
et al. Association of echocardiographic parameters of right ventricular remodeling and 
myocardial performance with modified task force criteria in adolescents with arrhyth­
mogenic right ventricular cardiomyopathy. Circ Cardiovasc Imaging 2019;12:e007693. 
https://doi.org/10.1161/CIRCIMAGING.118.007693
94. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, et al. Cardiac 
involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient 
testing. Chest 2008;133:1426–1435. https://doi.org/10.1378/chest.07-2784
95. Skold CM, Larsen FF, Rasmussen E, Pehrsson SK, Eklund AG. Determination of cardiac 
involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiog­
raphy. J Intern Med 2002;252:465–471. https://doi.org/10.1046/j.1365-2796.2002. 
01058.x
96. Joyce E, Ninaber MK, Katsanos S, Debonnaire P, Kamperidis V, Bax JJ, et al. Subclinical 
left ventricular dysfunction by echocardiographic speckle–tracking strain analysis re­
lates to outcome in sarcoidosis. Eur J Heart Fail 2015;17:51–62. https://doi.org/10. 
1002/ejhf.205
97. Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, et al. 
Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head com­
parison of deformation and nondeformation parameters. Circ Cardiovasc Imaging 2017; 
10:e005588. https://doi.org/10.1161/CIRCIMAGING.116.005588
98. Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, et al. Relative 
apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardi­
ography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 
2012;98:1442–1448. https://doi.org/10.1136/heartjnl-2012-302353
99. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. 
Cardiac manifestations of Anderson–Fabry disease: results from the international 
Fabry outcome survey. Eur Heart J 2007;28:1228–1235. https://doi.org/10.1093/ 
eurheartj/ehm153
100. Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A, 
et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloid­
osis. JACC Cardiovasc Imaging 2020;13:909–920. https://doi.org/10.1016/j.jcmg.2019. 
10.011
101. Pieroni M, Chimenti C, De Cobelli F, Morgante E, Del Maschio A, Gaudio C, et al. 
Fabry’s disease cardiomyopathy: echocardiographic detection of endomyocardial gly­
cosphingolipid compartmentalization. J Am Coll Cardiol 2006;47:1663–1671. https:// 
doi.org/10.1016/j.jacc.2005.11.070
102. Zemrak F, Ahlman MA, Captur G, Mohiddin SA, Kawel-Boehm N, Prince MR, et al. The 
relationship of left ventricular trabeculation to ventricular function and structure over 
a 9.5-year follow-up: the MESA study. J Am Coll Cardiol 2014;64:1971–1980. https://doi. 
org/10.1016/j.jacc.2014.08.035
103. Steeden JA, Quail M, Gotschy A, Mortensen KH, Hauptmann A, Arridge S, et al. Rapid 
whole-heart CMR with single volume super-resolution. J Cardiovasc Magn Reson 2020; 
22:56. https://doi.org/10.1186/s12968-020-00651-x
104. Kiblboeck D, Reiter C, Kammler J, Schmit P, Blessberger H, Kellermair J, et al. Artefacts 
in 1.5 Tesla and 3 Tesla cardiovascular magnetic resonance imaging in patients with 
leadless cardiac pacemakers. J Cardiovasc Magn Reson 2018;20:47. https://doi.org/10. 
1186/s12968-018-0469-4
105. Rajiah P, Kay F, Bolen M, Patel AR, Landeras L. Cardiac magnetic resonance in patients 
with cardiac implantable electronic devices: challenges and solutions. J Thorac Imaging 
2020;35:W1–W17. https://doi.org/10.1097/RTI.0000000000000462
106. Gandjbakhch E, Dacher JN, Taieb J, Chauvin M, Anselme F, Bartoli A, et al. Joint 
Position Paper of the Working Group of Pacing and Electrophysiology of the 
French Society of Cardiology and the French Society of Diagnostic and 
Interventional Cardiac and Vascular Imaging on magnetic resonance imaging in patients 
with cardiac electronic implantable devices. Arch Cardiovasc Dis 2020;113:473–484.
107. Nazarian S, Hansford R, Rahsepar AA, Weltin V, McVeigh D, Gucuk Ipek E, et al. Safety 
of magnetic resonance imaging in patients with cardiac devices. N Engl J Med 2017;377: 
2555–2564. https://doi.org/10.1056/NEJMoa1604267
108. Russo RJ, Costa HS, Silva PD, Anderson JL, Arshad A, Biederman RW, et al. Assessing 
the risks associated with MRI in patients with a pacemaker or defibrillator. N Engl J Med 
2017;376:755–764. https://doi.org/10.1056/NEJMoa1603265
109. Gakenheimer-Smith L, Etheridge SP, Niu MC, Ou Z, Presson AP, Whitaker P, et al. MRI 
in pediatric and congenital heart disease patients with CIEDs and epicardial or aban­
doned leads. Pacing Clin Electrophysiol 2020;43:797–804. https://doi.org/10.1111/ 
pace.13984
ESC Guidelines                                                                                                                                                                                          3599


<!-- PAGE 98 -->

### Page 98

110. Vigen KK, Reeder SB, Hood MN, Steckner M, Leiner T, Dombroski DA, et al. 
Recommendations for imaging patients with cardiac implantable electronic devices 
(CIEDs). J Magn Reson Imaging 2021;53:1311–1317. https://doi.org/10.1002/jmri. 
27320
111. Bhuva AN, Feuchter P, Hawkins A, Cash L, Boubertakh R, Evanson J, et al. MRI for pa­
tients with cardiac implantable electronic devices: simplifying complexity with a ‘one- 
stop’ service model. BMJ Qual Saf 2019;28:853–858. https://doi.org/10.1136/bmjqs- 
2018-009079
112. Seewoster T, Lobe S, Hilbert S, Bollmann A, Sommer P, Lindemann F, et al. 
Cardiovascular magnetic resonance imaging in patients with cardiac implantable elec­
tronic devices: best practice and real-world experience. Europace 2019;21:1220–1228. 
https://doi.org/10.1093/europace/euz112
113. Stühlinger M, Burri H, Vernooy K, Garcia R, Lenarczyk R, Sultan A, et al. EHRA con­
sensus on prevention and management of interference due to medical procedures 
in patients with cardiac implantable electronic devices. Europace 2022;24: 
1512–1537. https://doi.org/10.1093/europace/euac040
114. Primary P, Ian Paterson D, White JA, Butler CR, Connelly KA, Guerra PG, et al. 2021 
Update on safety of magnetic resonance imaging: joint statement from Canadian 
Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/ 
Canadian Heart Rhythm Society. Can J Cardiol 2021;37:835–847. https://doi.org/10. 
1016/j.cjca.2021.02.012
115. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. 
Clinical recommendations for cardiovascular magnetic resonance mapping of T1, 
T2, T2* and extracellular volume: a consensus statement by the Society for 
Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association 
for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017;19:75. https://doi. 
org/10.1186/s12968-017-0389-8
116. Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al. 
Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC 
Cardiovasc Imaging 2020;13:69–80. https://doi.org/10.1016/j.jcmg.2019.03.026
117. Nordin S, Kozor R, Vijapurapu R, Augusto JB, Knott KD, Captur G, et al. Myocardial 
storage, inflammation, and cardiac phenotype in Fabry disease after one year of en­
zyme replacement therapy. Circ Cardiovasc Imaging 2019;12:e009430. https://doi.org/ 
10.1161/CIRCIMAGING.119.009430
118. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI 
exposure during pregnancy and fetal and childhood outcomes. JAMA 2016;316: 
952–961. https://doi.org/10.1001/jama.2016.12126
119. Andreini D, Dello Russo A, Pontone G, Mushtaq S, Conte E, Perchinunno M, et al. 
CMR for identifying the substrate of ventricular arrhythmia in patients with normal 
echocardiography. JACC Cardiovasc Imaging 2020;13:410–421. https://doi.org/10. 
1016/j.jcmg.2019.04.023
120. Halliday BP, Baksi AJ, Gulati A, Ali A, Newsome S, Izgi C, et al. Outcome in dilated car­
diomyopathy related to the extent, location, and pattern of late gadolinium enhance­
ment. JACC Cardiovasc Imaging 2019;12:1645–1655. https://doi.org/10.1016/j.jcmg. 
2018.07.015
121. Barison A, Aimo A, Ortalda A, Todiere G, Grigoratos C, Passino C, et al. Late gado­
linium enhancement as a predictor of functional recovery, need for defibrillator im­
plantation and prognosis in non-ischemic dilated cardiomyopathy. Int J Cardiol 2018; 
250:195–200. https://doi.org/10.1016/j.ijcard.2017.10.043
122. Holmstrom M, Kivisto S, Helio T, Jurkko R, Kaartinen M, Antila M, et al. Late gadolinium 
enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related di­
lated cardiomyopathy. J Cardiovasc Magn Reson 2011;13:30. https://doi.org/10.1186/ 
1532-429X-13-30
123. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and 
significance of left ventricular mass by cardiovascular magnetic resonance in hyper­
trophic cardiomyopathy. J Am Coll Cardiol 2008;52:559–566. https://doi.org/10.1016/ 
j.jacc.2008.04.047
124. Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF, et al. Distinct sub­
groups in hypertrophic cardiomyopathy in the NHLBI HCM registry. J Am Coll 
Cardiol 2019;74:2333–2345. https://doi.org/10.1016/j.jacc.2019.08.1057
125. Miller RJH, Heidary S, Pavlovic A, Schlachter A, Dash R, Fleischmann D, et al. Defining 
genotype-phenotype relationships in patients with hypertrophic cardiomyopathy 
using cardiovascular magnetic resonance imaging. PLoS One 2019;14:e0217612. 
https://doi.org/10.1371/journal.pone.0217612
126. Quarta G, Husain SI, Flett AS, Sado DM, Chao CY, Tome Esteban MT, et al. 
Arrhythmogenic right ventricular cardiomyopathy mimics: role of cardiovascular mag­
netic resonance. J Cardiovasc Magn Reson 2013;15:16. https://doi.org/10.1186/1532- 
429X-15-16
127. Menghetti L, Basso C, Nava A, Angelini A, Thiene G. Spin-echo nuclear magnetic res­
onance for tissue characterisation in arrhythmogenic right ventricular cardiomyop­
athy. Heart 1996;76:467–470. https://doi.org/10.1136/hrt.76.6.467
128. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and 
genetic characterization of families with arrhythmogenic right ventricular dysplasia/car­
diomyopathy provides novel insights into patterns of disease expression. Circulation 
2007;115:1710–1720. https://doi.org/10.1161/CIRCULATIONAHA.106.660241
129. Aquaro GD, Barison A, Todiere G, Grigoratos C, Ait Ali L, Di Bella G, et al. Usefulness 
of combined functional assessment by cardiac magnetic resonance and tissue charac­
terization versus task force criteria for diagnosis of arrhythmogenic right ventricular 
cardiomyopathy. Am J Cardiol 2016;118:1730–1736. https://doi.org/10.1016/j. 
amjcard.2016.08.056
130. Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH, 
et al. Left ventricular non-compaction: insights from cardiovascular magnetic reson­
ance imaging. J Am Coll Cardiol 2005;46:101–105. https://doi.org/10.1016/j.jacc.2005. 
03.045
131. Masso AH, Uribe C, Willerson JT, Cheong BY, Davis BR. Left ventricular noncompac­
tion detected by cardiac magnetic resonance screening: a reexamination of diagnostic 
criteria. Tex Heart Inst J 2020;47:183–193. https://doi.org/10.14503/THIJ-19-7157
132. Grothoff M, Pachowsky M, Hoffmann J, Posch M, Klaassen S, Lehmkuhl L, et al. Value of 
cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and 
in discriminating between other cardiomyopathies. Eur Radiol 2012;22:2699–2709. 
https://doi.org/10.1007/s00330-012-2554-7
133. Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert JY, et al. Measurement of tra­
beculated left ventricular mass using cardiac magnetic resonance imaging in the diag­
nosis of left ventricular non-compaction. Eur Heart J 2010;31:1098–1104. https://doi. 
org/10.1093/eurheartj/ehp595
134. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. 
Identification and assessment of Anderson–Fabry disease by cardiovascular magnetic 
resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6: 
392–398. https://doi.org/10.1161/CIRCIMAGING.112.000070
135. Deva DP, Hanneman K, Li Q, Ng MY, Wasim S, Morel C, et al. Cardiovascular magnetic 
resonance demonstration of the spectrum of morphological phenotypes and patterns 
of myocardial scarring in Anderson–Fabry disease. J Cardiovasc Magn Reson 2016;18: 
14. https://doi.org/10.1186/s12968-016-0233-6
136. Francone M. Role of cardiac magnetic resonance in the evaluation of dilated cardiomy­
opathy: diagnostic contribution and prognostic significance. ISRN Radiol 2014;2014: 
365404. https://doi.org/10.1155/2014/365404
137. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late gadolinium 
enhancement and the risk for ventricular arrhythmias or sudden death in dilated car­
diomyopathy: systematic review and meta-analysis. JACC Heart Fail 2017;5:28–38. 
https://doi.org/10.1016/j.jchf.2016.09.017
138. Klem I, Klein M, Khan M, Yang EY, Nabi F, Ivanov A, et al. Relationship of LVEF and 
myocardial scar to long-term mortality risk and mode of death in patients with non­
ischemic cardiomyopathy. Circulation 2021;143:1343–1358. https://doi.org/10.1161/ 
CIRCULATIONAHA.120.048477
139. Rastegar N, Te Riele ASJM, James CA, Bhonsale A, Murray B, Tichnell C, et al. 
Fibrofatty changes: incidence at cardiac MR imaging in patients with arrhythmogenic 
right ventricular dysplasia/cardiomyopathy. Radiology 2016;280:405–412. https://doi. 
org/10.1148/radiol.2016150988
140. te Riele ASJM, Bhonsale A, James CA, Rastegar N, Murray B, Burt JR, et al. Incremental 
value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhyth­
mogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation 
carriers. J Am Coll Cardiol 2013;62:1761–1769. https://doi.org/10.1016/j.jacc.2012.11. 
087
141. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value 
of quantitative contrast-enhanced cardiovascular magnetic resonance for the evalu­
ation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 
2014;130:484–495. https://doi.org/10.1161/CIRCULATIONAHA.113.007094
142. He D, Ye M, Zhang L, Jiang B. Prognostic significance of late gadolinium enhancement 
on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. Heart 
Lung 2018;47:122–126. https://doi.org/10.1016/j.hrtlng.2017.10.008
143. Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D. Primary prevention implan­
table cardioverter-defibrillators in hypertrophic cardiomyopathy–are there predictors 
of appropriate therapy? Heart Rhythm 2021;18:63–70. https://doi.org/10.1016/j.hrthm. 
2020.08.009
144. Raman B, Ariga R, Spartera M, Sivalokanathan S, Chan K, Dass S, et al. Progression of 
myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implica­
tions. Eur Heart J Cardiovasc Imaging 2019;20:157–167. https://doi.org/10.1093/ehjci/ 
jey135
145. Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B, et al. T1 measurements 
identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere 
mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc 
Imaging 2013;6:415–422. https://doi.org/10.1161/CIRCIMAGING.112.000333
146. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic car­
diomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic 
echocardiography. Heart 2004;90:645–649. https://doi.org/10.1136/hrt.2003.014969
147. Aquaro GD, De Luca A, Cappelletto C, Raimondi F, Bianco F, Botto N, et al. Prognostic 
value of magnetic resonance phenotype in patients with arrhythmogenic right ven­
tricular cardiomyopathy. J Am Coll Cardiol 2020;75:2753–2765. https://doi.org/10. 
1016/j.jacc.2020.04.023


<!-- PAGE 99 -->

### Page 99

### 148 Martinez-Naharro A, Abdel-Gadir A, Treibel TA, Zumbo G, Knight DS, Rosmini S,

et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC 
Cardiovasc Imaging 2018;11:152–154. https://doi.org/10.1016/j.jcmg.2017.02.012
149. Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, 
et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac 
amyloid regression. JACC Cardiovasc Imaging 2021;14:189–199. https://doi.org/10. 
1016/j.jcmg.2020.07.043
150. Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, et al. 
Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc 
Imaging 2019;12:810–819. https://doi.org/10.1016/j.jcmg.2018.02.006
151. Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 mapping 
in recognition of early cardiac involvement in systemic sarcoidosis. Radiology 2017;285: 
63–72. https://doi.org/10.1148/radiol.2017162732
152. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. 
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in 
patients with beta-thalassemia major. Haematologica 2012;97:842–848. https://doi. 
org/10.3324/haematol.2011.049957
153. Dalal D, Tandri H, Judge DP, Amat N, Macedo R, Jain R, et al. Morphologic variants of 
familial arrhythmogenic right ventricular dysplasia/cardiomyopathy a genetics–magnet­
ic resonance imaging correlation study. J Am Coll Cardiol 2009;53:1289–1299. https:// 
doi.org/10.1016/j.jacc.2008.12.045
154. Stokke MK, Castrini AI, Aneq MA, Jensen HK, Madsen T, Hansen J, et al. Absence of 
ECG Task Force Criteria does not rule out structural changes in genotype positive 
ARVC patients. Int J Cardiol 2020;317:152–158. https://doi.org/10.1016/j.ijcard.2020. 
05.095
155. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. 
Gadolinium enhanced cardiovascular magnetic resonance in Anderson–Fabry disease. 
Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 
2003;24:2151–2155. https://doi.org/10.1016/j.ehj.2003.09.017
156. Huurman R, van der Velde N, Schinkel AFL, Hassing HC, Budde RPJ, van Slegtenhorst 
MA, et al. Contemporary family screening in hypertrophic cardiomyopathy: the role of 
cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging 2022;23: 
1144–1154. https://doi.org/10.1093/ehjci/jeac099
157. Valente AM, Lakdawala NK, Powell AJ, Evans SP, Cirino AL, Orav EJ, et al. Comparison 
of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardio­
myopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ 
Cardiovasc Genet 2013;6:230–237. https://doi.org/10.1161/CIRCGENETICS.113. 
000037
158. Germans T, Russel IK, Gotte MJ, Spreeuwenberg MD, Doevendans PA, Pinto YM, et al. 
How do hypertrophic cardiomyopathy mutations affect myocardial function in car­
riers with normal wall thickness? Assessment with cardiovascular magnetic resonance. 
J Cardiovasc Magn Reson 2010;12:13. https://doi.org/10.1186/1532-429X-12-13
159. Germans T, Wilde AA, Dijkmans PA, Chai W, Kamp O, Pinto YM, et al. Structural ab­
normalities of the inferoseptal left ventricular wall detected by cardiac magnetic res­
onance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll 
Cardiol 2006;48:2518–2523. https://doi.org/10.1016/j.jacc.2006.08.036
160. Aziz W, Claridge S, Ntalas I, Gould J, de Vecchi A, Razeghi O, et al. Emerging role of 
cardiac computed tomography in heart failure. ESC Heart Fail 2019;6:909–920. 
https://doi.org/10.1002/ehf2.12479
161. Galand V, Ghoshhajra B, Szymonifka J, Das S, Leclercq C, Martins RP, et al. Utility of 
computed tomography to predict ventricular arrhythmias in patients with nonischemic 
cardiomyopathy receiving cardiac resynchronization therapy. Am J Cardiol 2020;125: 
607–612. https://doi.org/10.1016/j.amjcard.2019.11.003
162. Palmisano A, Vignale D, Peretto G, Busnardo E, Calcagno C, Campochiaro C, et al. 
Hybrid FDG-PET/MR or FDG-PET/CT to detect disease activity in patients with per­
sisting arrhythmias after myocarditis. JACC Cardiovasc Imaging 2021;14:288–292. 
https://doi.org/10.1016/j.jcmg.2020.03.009
163. Wicks EC, Menezes LJ, Barnes A, Mohiddin SA, Sekhri N, Porter JC, et al. Diagnostic 
accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose posi­
tron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. Eur 
Heart J Cardiovasc Imaging 2018;19:757–767. https://doi.org/10.1093/ehjci/jex340
164. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 
18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaa­
nalysis including the Ontario experience. J Nucl Med 2012;53:241–248. https://doi.org/ 
10.2967/jnumed.111.090662
165. Bravo PE, Di Carli MF, Dorbala S. Role of PET to evaluate coronary microvascular dys­
function in non-ischemic cardiomyopathies. Heart Fail Rev 2017;22:455–464. https:// 
doi.org/10.1007/s10741-017-9628-1
166. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive 
etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2- 
propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076–1084. https:// 
doi.org/10.1016/j.jacc.2005.05.073
167. Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, et al. Prognostic util­
ity of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyl­
oidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J 
Cardiovasc Imaging 2017;18:1344–1350. https://doi.org/10.1093/ehjci/jew325
168. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy 
diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404–2412. 
https://doi.org/10.1161/CIRCULATIONAHA.116.021612
169. Langer C, Lutz M, Eden M, Ludde M, Hohnhorst M, Gierloff C, et al. Hypertrophic car­
diomyopathy in cardiac CT: a validation study on the detection of intramyocardial fi­
brosis in consecutive patients. Int J Cardiovasc Imaging 2014;30:659–667. https://doi. 
org/10.1007/s10554-013-0358-8
170. Asferg C, Usinger L, Kristensen TS, Abdulla J. Accuracy of multi-slice computed tom­
ography for measurement of left ventricular ejection fraction compared with cardiac 
magnetic resonance imaging and two-dimensional transthoracic echocardiography: a 
systematic review and meta-analysis. Eur J Radiol 2012;81:e757–e762. https://doi.org/ 
10.1016/j.ejrad.2012.02.002
171. Premaratne M, Shamsaei M, Chow JD, Haddad T, Erthal F, Curran H, et al. Using cor­
onary calcification to exclude an ischemic etiology for cardiomyopathy: a validation 
study and systematic review. Int J Cardiol 2017;230:518–522. https://doi.org/10. 
1016/j.ijcard.2016.12.068
172. Dweck MR, Abgral R, Trivieri MG, Robson PM, Karakatsanis N, Mani V, et al. Hybrid 
magnetic resonance imaging and positron emission tomography with fluorodeoxyglu­
cose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging 2018;11:94–107. 
https://doi.org/10.1016/j.jcmg.2017.02.021
173. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 
18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989–1998.
174. Besler C, Urban D, Watzka S, Lang D, Rommel KP, Kandolf R, et al. Endomyocardial 
miR-133a levels correlate with myocardial inflammation, improved left ventricular 
function, and clinical outcome in patients with inflammatory cardiomyopathy. Eur J 
Heart Fail 2016;18:1442–1451. https://doi.org/10.1002/ejhf.579
175. Ardehali H, Qasim A, Cappola T, Howard D, Hruban R, Hare JM, et al. Endomyocardial 
biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 
2004;147:919–923. https://doi.org/10.1016/j.ahj.2003.09.020
176. Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, et al. A positive 
endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients 
with initially unexplained cardiomyopathy. Am Heart J 2005;150:459–463. https://doi. 
org/10.1016/j.ahj.2004.10.006
177. Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, et al. Endomyocardial bi­
opsy characterization of heart failure with preserved ejection fraction and prevalence 
of cardiac amyloidosis. JACC Heart Fail 2020; 8:712–724. https://doi.org/10.1016/j.jchf. 
2020.04.007
178. Lorenzini M, Norrish G, Field E, Ochoa JP, Cicerchia M, Akhtar MM, et al. Penetrance 
of hypertrophic cardiomyopathy in sarcomere protein mutation carriers. J Am Coll 
Cardiol 2020;76:550–559. https://doi.org/10.1016/j.jacc.2020.06.011
179. Dalal D, James C, Devanagondi R, Tichnell C, Tucker A, Prakasa K, et al. Penetrance of 
mutations in plakophilin-2 among families with arrhythmogenic right ventricular dys­
plasia/cardiomyopathy. J Am Coll Cardiol 2006;48:1416–1424. https://doi.org/10. 
1016/j.jacc.2006.06.045
180. Claes GR, van Tienen FH, Lindsey P, Krapels IP, Helderman-van den Enden AT, Hoos 
MB, et al. Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) 
founder mutation carriers. Eur Heart J 2016;37:1815–1822. https://doi.org/10.1093/ 
eurheartj/ehv522
181. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise in­
creases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular 
dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 
2013;62:1290–1297. https://doi.org/10.1016/j.jacc.2013.06.033
182. Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, et al. Shared gen­
etic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with 
opposite directions of effect. Nat Genet 2021;53:128–134. https://doi.org/10.1038/ 
s41588-020-00762-2
183. Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, et al. Common genetic 
variants and modifiable risk factors underpin hypertrophic cardiomyopathy suscepti­
bility and expressivity. Nat Genet 2021;53:135–142. https://doi.org/10.1038/s41588- 
020-00764-0
184. Pugh TJ, Kelly MA, Gowrisankar S, Hynes E, Seidman MA, Baxter SM, et al. The land­
scape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA se­
quencing. Genet Med 2014;16:601–608. https://doi.org/10.1038/gim.2013.204
185. Escobar-Lopez L, Ochoa JP, Mirelis JG, Espinosa MA, Navarro M, Gallego-Delgado M, 
et al. Association of genetic variants with outcomes in patients with nonischemic di­
lated cardiomyopathy. J Am Coll Cardiol 2021;78:1682–1699. https://doi.org/10.1016/ 
j.jacc.2021.08.039
186. Gigli M, Merlo M, Graw SL, Barbati G, Rowland TJ, Slavov DB, et al. Genetic risk of ar­
rhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol 2019; 
74:1480–1490. https://doi.org/10.1016/j.jacc.2019.06.072
187. Garnier S, Harakalova M, Weiss S, Mokry M, Regitz-Zagrosek V, Hengstenberg C, et al. 
Genome-wide association analysis in dilated cardiomyopathy reveals two new players 
in systolic heart failure on chromosomes 3p25.1 and 22q11.23. Eur Heart J 2021;42: 
2000–2011. https://doi.org/10.1093/eurheartj/ehab030
188. Pua CJ, Tham N, Chin CWL, Walsh R, Khor CC, Toepfer CN, et al. Genetic studies of 
hypertrophic cardiomyopathy in Singaporeans identify variants in TNNI3 and TNNT2 
ESC Guidelines                                                                                                                                                                                          3601


<!-- PAGE 100 -->

### Page 100

that are common in Chinese patients. Circ Genom Precis Med 2020;13:424–434. https:// 
doi.org/10.1161/CIRCGEN.119.002823
189. Jordan E, Peterson L, Ai T, Asatryan B, Bronicki L, Brown E, et al. Evidence-based as­
sessment of genes in dilated cardiomyopathy. Circulation 2021;144:7–19. https://doi. 
org/10.1161/CIRCULATIONAHA.120.053033
190. James CA, Jongbloed JDH, Hershberger RE, Morales A, Judge DP, Syrris P, et al. 
International evidence based reappraisal of genes associated with arrhythmogenic right 
ventricular cardiomyopathy using the clinical genome resource framework. Circ Genom 
Precis Med 2021;14:e003273. https://doi.org/10.1161/CIRCGEN.120.003273
191. Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, et al. Evaluating the 
clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med 2019;12: 
e002460. https://doi.org/10.1161/CIRCGEN.119.002460
191a. ClinGen Clinical Genome Resource. https://search.clinicalgenome.org/kb/gene- 
validity (12 July 2023 date last accessed).
192. Miller DT, Lee K, Chung WK, Gordon AS, Herman GE, Klein TE, et al. ACMG SF v3.0 
list for reporting of secondary findings in clinical exome and genome sequencing: a pol­
icy statement of the American College of Medical Genetics and Genomics (ACMG). 
Genet Med 2021;23:1381–1390. https://doi.org/10.1038/s41436-021-01172-3
193. Miller DT, Lee K, Gordon AS, Amendola LM, Adelman K, Bale SJ, et al. 
Recommendations for reporting of secondary findings in clinical exome and genome 
sequencing, 2021 update: a policy statement of the American College of Medical 
Genetics and Genomics (ACMG). Genet Med 2021;23:1391–1398. https://doi.org/ 
10.1038/s41436-021-01171-4
194. Watkins H. Time to think differently about sarcomere-negative hypertrophic cardio­
myopathy. 
Circulation 
2021;143:2415–2417. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.121.053527
195. Kumuthini J, Zick B, Balasopoulou A, Chalikiopoulou C, Dandara C, El-Kamah G, et al. 
The clinical utility of polygenic risk scores in genomic medicine practices: a systematic 
review. Hum Genet 2022;141:1697–1704. https://doi.org/10.1007/s00439-022- 
02452-x
196. Pirruccello JP, Bick A, Wang M, Chaffin M, Friedman S, Yao J, et al. Analysis of cardiac 
magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated car­
diomyopathy. Nat Commun 2020;11:2254. https://doi.org/10.1038/s41467-020- 
15823-7
197. Biddinger KJ, Jurgens SJ, Maamari D, Gaziano L, Choi SH, Morrill VN, et al. Rare and 
common genetic variation underlying the risk of hypertrophic cardiomyopathy in a 
National Biobank. JAMA Cardiol 2022;7:715–722. https://doi.org/10.1001/jamacardio. 
2022.1061
198. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines 
for the interpretation of sequence variants: a joint consensus recommendation of the 
American College of Medical Genetics and Genomics and the Association for 
Molecular Pathology. Genet Med 2015;17:405–424. https://doi.org/10.1038/gim. 
2015.30
199. Kelly MA, Caleshu C, Morales A, Buchan J, Wolf Z, Harrison SM, et al. Adaptation and 
validation of the ACMG/AMP variant classification framework for MYH7-associated 
inherited 
cardiomyopathies: 
recommendations 
by 
ClinGen’s 
Inherited 
Cardiomyopathy Expert Panel. Genet Med 2018;20:351–359. https://doi.org/10. 
1038/gim.2017.218
200. Arbustini E, Behr ER, Carrier L, van Duijn C, Evans P, Favalli V, et al. Interpretation and 
actionability of genetic variants in cardiomyopathies: a position statement from the 
European Society of Cardiology Council on cardiovascular genomics. Eur Heart J 
2022;43:1901–1916. https://doi.org/10.1093/eurheartj/ehab895
201. National Society of Genetic Counselors Definition Task Force; Resta R, Biesecker BB, 
Bennett RL, Blum S, Hahn SE. A new definition of genetic counseling: National Society 
of Genetic Counselors’ Task Force report. J Genet Couns 2006;15:77–83. https://doi. 
org/10.1007/s10897-005-9014-3
202. Biesecker BB. Goals of genetic counseling. Clin Genet 2001;60:323–330. https://doi.org/ 
10.1034/j.1399-0004.2001.600501.x
203. Ingles J, Yeates L, Semsarian C. The emerging role of the cardiac genetic counselor. 
Heart Rhythm 2011;8:1958–1962. https://doi.org/10.1016/j.hrthm.2011.07.017
204. Bordet C, Brice S, Maupain C, Gandjbakhch E, Isidor B, Palmyre A, et al. Psychosocial 
impact of predictive genetic testing in hereditary heart diseases: the PREDICT study. J 
Clin Med 2020;9:1365. https://doi.org/10.3390/jcm9051365
205. Ingles J. Psychological issues in managing families with inherited cardiovascular diseases. 
Cold Spring Harb Perspect Med 2020;10:a036558. https://doi.org/10.1101/cshperspect. 
a036558
206. Edwards A, Gray J, Clarke A, Dundon J, Elwyn G, Gaff C, et al. Interventions to improve 
risk communication in clinical genetics: systematic review. Patient Educ Couns 2008;71: 
4–25. https://doi.org/10.1016/j.pec.2007.11.026
207. Austin J, Semaka A, Hadjipavlou G. Conceptualizing genetic counseling as psychother­
apy in the era of genomic medicine. J Genet Couns 2014;23:903–909. https://doi.org/10. 
1007/s10897-014-9728-1
208. Michie S, Marteau TM, Bobrow M. Genetic counselling: the psychological impact of 
meeting patients’ expectations. J Med Genet 1997;34:237–241. https://doi.org/10. 
1136/jmg.34.3.237
209. Ison HE, Ware SM, Schwantes-An TH, Freeze S, Elmore L, Spoonamore KG. The im­
pact of cardiovascular genetic counseling on patient empowerment. J Genet Couns 
2019;28:570–577. https://doi.org/10.1002/jgc4.1050
210. Borry P, Evers-Kiebooms G, Cornel MC, Clarke A, Dierickx K. Public Professional 
Policy Committee (PPPC) of the European Society of Human Genetics (ESHG). 
Genetic testing in asymptomatic minors: background considerations towards ESHG 
recommendations. Eur J Hum Genet 2009;17:711–719. https://doi.org/10.1038/ejhg. 
2009.25
211. Ormondroyd E, Oates S, Parker M, Blair E, Watkins H. Pre-symptomatic genetic test­
ing for inherited cardiac conditions: a qualitative exploration of psychosocial and eth­
ical implications. Eur J Hum Genet 2014;22:88–93. https://doi.org/10.1038/ejhg.2013.81
212. Spanaki A, O’Curry S, Winter-Beatty J, Mead-Regan S, Hawkins K, English J, et al. 
Psychosocial adjustment and quality of life in children undergoing screening in a spe­
cialist paediatric hypertrophic cardiomyopathy clinic. Cardiol Young 2016;26: 
961–967. https://doi.org/10.1017/S1047951115001717
213. Ingles J, Semsarian C. Conveying a probabilistic genetic test result to families with an 
inherited heart disease. Heart Rhythm 2014;11:1073–1078. https://doi.org/10.1016/j. 
hrthm.2014.03.017
214. Whyte S, Green A, McAllister M, Shipman H. Family communication in inherited car­
diovascular conditions in Ireland. J Genet Couns 2016;25:1317–1326. https://doi.org/10. 
1007/s10897-016-9974-5
215. Daly MB, Montgomery S, Bingler R, Ruth K. Communicating genetic test results within 
the family: is it lost in translation? A survey of relatives in the randomized six-step study. 
Fam Cancer 2016;15:697–706. https://doi.org/10.1007/s10689-016-9889-1
216. Burns C, McGaughran J, Davis A, Semsarian C, Ingles J. Factors influencing uptake of 
familial long QT syndrome genetic testing. Am J Med Genet A 2016;170A:418–425. 
https://doi.org/10.1002/ajmg.a.37455
217. Kaphingst KA, Blanchard M, Milam L, Pokharel M, Elrick A, Goodman MS. Relationships 
between health literacy and genomics-related knowledge, self-efficacy, perceived im­
portance, and communication in a medically underserved population. J Health 
Commun 2016;21:58–68. https://doi.org/10.1080/10810730.2016.1144661
218. Yeates L, McDonald K, Burns C, Semsarian C, Carter S, Ingles J. Decision-making and 
experiences of preimplantation genetic diagnosis in inherited heart diseases: a qualita­
tive study. Eur J Hum Genet 2022;30:187–193. https://doi.org/10.1038/s41431-021- 
00963-1
219. Landstrom AP, Kim JJ, Gelb BD, Helm BM, Kannankeril PJ, Semsarian C, et al. Genetic 
testing for heritable cardiovascular diseases in pediatric patients: a scientific statement 
from the American Heart Association. Circ Genom Precis Med 2021;14:e000086. 
https://doi.org/10.1161/HCG.0000000000000086
220. Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F. Procedure-related risk of mis­
carriage following amniocentesis and chorionic villus sampling: a systematic review and 
meta-analysis. Ultrasound Obstet Gynecol 2015;45:16–26. https://doi.org/10.1002/uog. 
14636
221. Meiser B, Irle J, Lobb E, Barlow-Stewart K. Assessment of the content and process of 
genetic counseling: a critical review of empirical studies. J Genet Couns 2008;17: 
434–451. https://doi.org/10.1007/s10897-008-9173-0
222. Waddell-Smith KE, Donoghue T, Oates S, Graham A, Crawford J, Stiles MK, et al. 
Inpatient detection of cardiac-inherited disease: the impact of improving family history 
taking. Open Heart 2016;3:e000329. https://doi.org/10.1136/openhrt-2015-000329
223. Murray B, Tichnell C, Burch AE, Calkins H, James CA. Strength of the genetic counsel­
or: patient relationship is associated with extent of increased empowerment in pa­
tients with arrhythmogenic cardiomyopathy. J Genet Couns 2022;31:388–397. 
https://doi.org/10.1002/jgc4.1499
224. Ingles J, Lind JM, Phongsavan P, Semsarian C. Psychosocial impact of specialized cardiac 
genetic clinics for hypertrophic cardiomyopathy. Genet Med 2008;10:117–120. https:// 
doi.org/10.1097/GIM.0b013e3181612cc7
225. Furqan A, Arscott P, Girolami F, Cirino AL, Michels M, Day SM, et al. Care in specialized 
centers and data sharing increase agreement in hypertrophic cardiomyopathy genetic 
test interpretation. Circ Cardiovasc Genet 2017;10:e001700. https://doi.org/10.1161/ 
CIRCGENETICS.116.001700
226. Reuter C, Grove ME, Orland K, Spoonamore K, Caleshu C. Clinical cardiovascular gen­
etic counselors take a leading role in team-based variant classification. J Genet Couns 
2018;27:751–760. https://doi.org/10.1007/s10897-017-0175-7
227. Ingles J, McGaughran J, Scuffham PA, Atherton J, Semsarian C. A cost-effectiveness 
model of genetic testing for the evaluation of families with hypertrophic cardiomyop­
athy. Heart 2012;98:625–630. https://doi.org/10.1136/heartjnl-2011-300368
228. Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A, et al. DNA testing for 
hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J 2010;31: 
926–935. https://doi.org/10.1093/eurheartj/ehq067
229. Catchpool M, Ramchand J, Martyn M, Hare DL, James PA, Trainer AH, et al. A cost- 
effectiveness model of genetic testing and periodical clinical screening for the evalu­
ation of families with dilated cardiomyopathy. Genet Med 2019;21:2815–2822. 
https://doi.org/10.1038/s41436-019-0582-2
230. Groeneweg JA, Bhonsale A, James CA, te Riele AS, Dooijes D, Tichnell C, et al. Clinical 
presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right


<!-- PAGE 101 -->

### Page 101

ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc 
Genet 2015;8:437–446. https://doi.org/10.1161/CIRCGENETICS.114.001003
231. Alfares AA, Kelly MA, McDermott G, Funke BH, Lebo MS, Baxter SB, et al. Results of 
clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: ex­
panded panels offer limited additional sensitivity. Genet Med 2015;17:880–888. 
https://doi.org/10.1038/gim.2014.205
232. Ingles J, Yeates L, O’Brien L, McGaughran J, Scuffham PA, Atherton J, et al. Genetic test­
ing for inherited heart diseases: longitudinal impact on health-related quality of life. 
Genet Med 2012;14:749–752. https://doi.org/10.1038/gim.2012.47
233. Friess MR, Marino BS, Cassedy A, Wilmot I, Jefferies JL, Lorts A. Health-related quality 
of life assessment in children followed in a cardiomyopathy clinic. Pediatr Cardiol 2015; 
36:516–523. https://doi.org/10.1007/s00246-014-1042-z
234. Wakefield CE, Hanlon LV, Tucker KM, Patenaude AF, Signorelli C, McLoone JK, et al. 
The psychological impact of genetic information on children: a systematic review. 
Genet Med 2016;18:755–762. https://doi.org/10.1038/gim.2015.181
235. Christian S, Somerville M, Taylor S, Atallah J. When to offer predictive genetic testing 
to children at risk of an inherited arrhythmia or cardiomyopathy. Circ Genom Precis 
Med 2018;11:e002300. https://doi.org/10.1161/CIRCGEN.118.002300
236. MacLeod R, Beach A, Henriques S, Knopp J, Nelson K, Kerzin-Storrar L. Experiences of 
predictive testing in young people at risk of Huntington’s disease, familial cardiomyop­
athy or hereditary breast and ovarian cancer. Eur J Hum Genet 2014;22:396–401. 
https://doi.org/10.1038/ejhg.2013.143
237. Knight LM, Miller E, Kovach J, Arscott P, von Alvensleben JC, Bradley D, et al. Genetic 
testing and cascade screening in pediatric long QT syndrome and hypertrophic cardio­
myopathy. Heart Rhythm 2020;17:106–112. https://doi.org/10.1016/j.hrthm.2019.06. 
015
238. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and life­
time burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric 
Human Cardiomyopathy Registry (SHaRe). Circulation 2018;138:1387–1398. https:// 
doi.org/10.1161/CIRCULATIONAHA.117.033200
239. Marey I, Fressart V, Rambaud C, Fornes P, Martin L, Grotto S, et al. Clinical impact of 
post-mortem genetic testing in cardiac death and cardiomyopathy. Open Med (Wars) 
2020;15:435–446. https://doi.org/10.1515/med-2020-0150
240. Isbister JC, Nowak N, Butters A, Yeates L, Gray B, Sy RW, et al. “Concealed cardio­
myopathy” as a cause of previously unexplained sudden cardiac arrest. Int J Cardiol 
2021;324:96–101. https://doi.org/10.1016/j.ijcard.2020.09.031
241. Dellefave-Castillo LM, Cirino AL, Callis TE, Esplin ED, Garcia J, Hatchell KE, et al. 
Assessment of the diagnostic yield of combined cardiomyopathy and arrhythmia gen­
etic testing. JAMA Cardiol 2022;7:966–974. https://doi.org/10.1001/jamacardio.2022. 
2455
242. Williams N, Manderski E, Stewart S, Bao R, Tang Y. Lessons learned from testing car­
diac channelopathy and cardiomyopathy genes in individuals who died suddenly: a two- 
year prospective study in a large medical examiner’s office with an in-house molecular 
genetics laboratory and genetic counseling services. J Genet Couns 2020;29:293–302. 
https://doi.org/10.1002/jgc4.1157
243. Isbister JC, Nowak N, Yeates L, Singer ES, Sy RW, Ingles J, et al. Concealed cardiomy­
opathy in autopsy-inconclusive cases of sudden cardiac death and implications for fam­
ilies. J Am Coll Cardiol 2022;80:2057–2068. https://doi.org/10.1016/j.jacc.2022.09.029
244. Michie S, Bobrow M, Marteau TM. Predictive genetic testing in children and adults: a 
study of emotional impact. J Med Genet 2001;38:519–526. https://doi.org/10.1136/ 
jmg.38.8.519
245. Rath A, Weintraub R. Overview of cardiomyopathies in childhood. Front Pediatr 2021; 
9:708732. https://doi.org/10.3389/fped.2021.708732
246. Lipshultz SE, Law YM, Asante-Korang A, Austin ED, Dipchand AI, Everitt MD, et al. 
Cardiomyopathy in children: classification and diagnosis: a scientific statement from 
the American Heart Association. Circulation 2019;140:e9–e68. https://doi.org/10. 
1161/CIR.0000000000000682
247. Kindel SJ, Miller EM, Gupta R, Cripe LH, Hinton RB, Spicer RL, et al. Pediatric cardio­
myopathy: importance of genetic and metabolic evaluation. J Card Fail 2012;18: 
396–403. https://doi.org/10.1016/j.cardfail.2012.01.017
248. Norrish G, Field E, McLeod K, Ilina M, Stuart G, Bhole V, et al. Clinical presentation and 
survival of childhood hypertrophic cardiomyopathy: a retrospective study in United 
Kingdom. Eur Heart J 2019;40:986–993. https://doi.org/10.1093/eurheartj/ehy798
249. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, 
and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:1867–1876. 
https://doi.org/10.1001/jama.296.15.1867
250. Shamszad P, Hall M, Rossano JW, Denfield SW, Knudson JD, Penny DJ, et al. 
Characteristics and outcomes of heart failure-related intensive care unit admissions 
in children with cardiomyopathy. J Card Fail 2013;19:672–677. https://doi.org/10. 
1016/j.cardfail.2013.08.006
251. Pelliccia F, Alfieri O, Calabro P, Cecchi F, Ferrazzi P, Gragnano F, et al. Multidisciplinary 
evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: to­
wards the HCM Heart Team. Int J Cardiol 2020;304:86–92. https://doi.org/10.1016/j. 
ijcard.2020.01.021
252. Law SP, Oron AP, Kemna MS, Albers EL, McMullan DM, Chen JM, et al. Comparison of 
transplant waitlist outcomes for pediatric candidates supported by ventricular assist 
devices versus medical therapy. Pediatr Crit Care Med 2018;19:442–450. https://doi. 
org/10.1097/PCC.0000000000001503
253. Ullmo S, Vial Y, Di Bernardo S, Roth-Kleiner M, Mivelaz Y, Sekarski N, et al. Pathologic 
ventricular hypertrophy in the offspring of diabetic mothers: a retrospective study. Eur 
Heart J 2007;28:1319–1325. https://doi.org/10.1093/eurheartj/ehl416
254. Yunis KA, Bitar FF, Hayek P, Mroueh SM, Mikati M. Transient hypertrophic cardiomy­
opathy in the newborn following multiple doses of antenatal corticosteroids. Am J 
Perinatol 1999;16:17–21. https://doi.org/10.1055/s-2007-993830
255. Brickman WJ, Silverman BL. Cardiovascular effects of growth hormone. Endocrine 
2000;12:153–161. https://doi.org/10.1385/ENDO:12:2:153
256. Monda E, Rubino M, Lioncino M, Di Fraia F, Pacileo R, Verrillo F, et al. Hypertrophic 
cardiomyopathy in children: pathophysiology, diagnosis, and treatment of non- 
sarcomeric causes. Front Pediatr 2021;9:632293. https://doi.org/10.3389/fped.2021. 
632293
257. Fourey D, Care M, Siminovitch KA, Weissler-Snir A, Hindieh W, Chan RH, et al. 
Prevalence and clinical implication of double mutations in hypertrophic cardiomyop­
athy: revisiting the gene-dose effect. Circ Cardiovasc Genet 2017;10:e001685. https:// 
doi.org/10.1161/CIRCGENETICS.116.001685
258. Kaltenecker E, Schleihauf J, Meierhofer C, Shehu N, Mkrtchyan N, Hager A, et al. 
Long-term outcomes of childhood onset Noonan compared to sarcomere hyper­
trophic cardiomyopathy. Cardiovasc Diagn Ther 2019;9:S299–S309. https://doi.org/10. 
21037/cdt.2019.05.01
259. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, et al. A retrospective, 
multinational, multicenter study on the natural history of infantile-onset Pompe dis­
ease. J Pediatr 2006;148:671–676.e2. https://doi.org/10.1016/j.jpeds.2005.11.033
260. Linglart L, Gelb BD. Congenital heart defects in Noonan syndrome: diagnosis, manage­
ment, and treatment. Am J Med Genet C Semin Med Genet 2020;184:73–80. https://doi. 
org/10.1002/ajmg.c.31765
261. Gelb BD, Roberts AE, Tartaglia M. Cardiomyopathies in Noonan syndrome and the 
other RASopathies. Prog Pediatr Cardiol 2015;39:13–19. https://doi.org/10.1016/j. 
ppedcard.2015.01.002
262. Calcagni G, Limongelli G, D’Ambrosio A, Gesualdo F, Digilio MC, Baban A, et al. 
Cardiac defects, morbidity and mortality in patients affected by RASopathies. 
CARNET study results. Int J Cardiol 2017;245:92–98. https://doi.org/10.1016/j.ijcard. 
2017.07.068
263. Lioncino M, Monda E, Verrillo F, Moscarella E, Calcagni G, Drago F, et al. Hypertrophic 
cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implica­
tions, and management. Heart Fail Clin 2022;18:19–29. https://doi.org/10.1016/j.hfc. 
2021.07.004
264. Calcagni G, Adorisio R, Martinelli S, Grutter G, Baban A, Versacci P, et al. Clinical pres­
entation and natural history of hypertrophic cardiomyopathy in RASopathies. Heart 
Fail Clin 2018;14:225–235. https://doi.org/10.1016/j.hfc.2017.12.005
265. Poterucha JT, Johnson JN, O’Leary PW, Connolly HM, Niaz T, Maleszewski JJ, et al. 
Surgical ventricular septal myectomy for patients with Noonan syndrome and symp­
tomatic left ventricular outflow tract obstruction. Am J Cardiol 2015;116:1116–1121. 
https://doi.org/10.1016/j.amjcard.2015.06.037
266. Hemmati P, Dearani JA, Daly RC, King KS, Ammash NM, Cetta F, et al. Early outcomes 
of cardiac surgery in patients with Noonan syndrome. Semin Thorac Cardiovasc Surg 
2019;31:507–513. https://doi.org/10.1053/j.semtcvs.2018.12.004
267. Moran AM, Colan SD. Verapamil therapy in infants with hypertrophic cardiomyop­
athy. Cardiol Young 1998;8:310–319. https://doi.org/10.1017/S1047951100006818
268. van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet 2008;372:1342–1353. https:// 
doi.org/10.1016/S0140-6736(08)61555-X
269. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant 
human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe dis­
ease. Neurology 2007;68:99–109. https://doi.org/10.1212/01.wnl.0000251268.41188. 
04
270. Tanaka M, Ino H, Ohno K, Hattori K, Sato W, Ozawa T, et al. Mitochondrial mutation 
in fatal infantile cardiomyopathy. Lancet 1990;336:1452. https://doi.org/10.1016/0140- 
6736(90)93162-I
271. Holmgren D, Wahlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M. 
Cardiomyopathy in children with mitochondrial disease; clinical course and cardio­
logical findings. Eur Heart J 2003;24:280–288. https://doi.org/10.1016/S0195- 
668X(02)00387-1
272. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, et al. 
Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 
2005;352:362–372. https://doi.org/10.1056/NEJMoa033349
273. Ansong AK, Li JS, Nozik-Grayck E, Ing R, Kravitz RM, Idriss SF, et al. 
Electrocardiographic response to enzyme replacement therapy for Pompe disease. 
Genet Med 2006;8:297–301. https://doi.org/10.1097/01.gim.0000195896.04069.5f
274. Schoser B, Attarian S, Borges J, Bouhour F, Chien Y, Choi Y, et al. Efficacy and safety 
results of the avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease 
patients. Eur J Neurol 2021;28:68–68.
275. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. 
A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 
2010;362:1396–1406. https://doi.org/10.1056/NEJMoa0909859
ESC Guidelines                                                                                                                                                                                          3603


<!-- PAGE 102 -->

### Page 102

276. Lee TM, Hsu DT, Kantor P, Towbin JA, Ware SM, Colan SD, et al. Pediatric cardiomy­
opathies. Circ Res 2017;121:855–873. https://doi.org/10.1161/CIRCRESAHA.116. 
309386
277. Chang RR, Allada V. Electrocardiographic and echocardiographic features that distin­
guish anomalous origin of the left coronary artery from pulmonary artery from idio­
pathic dilated cardiomyopathy. Pediatr Cardiol 2001;22:3–10. https://doi.org/10.1007/ 
s002460010142
278. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of 
endomyocardial biopsy in the management of cardiovascular disease: a scientific state­
ment from the American Heart Association, the American College of Cardiology, and 
the European Society of Cardiology. Endorsed by the Heart Failure Society of America 
and the Heart Failure Association of the European Society of Cardiology. J Am Coll 
Cardiol 2007;50:1914–1931. https://doi.org/10.1093/eurheartj/ehm456
279. Law YM, Lal AK, Chen S, Cihakova D, Cooper LT Jr, Deshpande S, et al. Diagnosis and 
management of myocarditis in children: a scientific statement from the American 
Heart Association. Circulation 2021;144:e123–e135. https://doi.org/10.1161/CIR. 
0000000000001001
280. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. Missense muta­
tions in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and 
conduction-system disease. N Engl J Med 1999;341:1715–1724. https://doi.org/10. 
1056/NEJM199912023412302
281. Towbin JA, Hejtmancik JF, Brink P, Gelb B, Zhu XM, Chamberlain JS, et al. X-linked di­
lated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscu­
lar dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993;87:1854–1865. 
https://doi.org/10.1161/01.CIR.87.6.1854
282. D’Amario D, Amodeo A, Adorisio R, Tiziano FD, Leone AM, Perri G, et al. A current 
approach to heart failure in Duchenne muscular dystrophy. Heart 2017;103: 
1770–1779. https://doi.org/10.1136/heartjnl-2017-311269
283. Towbin JA. Left ventricular noncompaction: a new form of heart failure. Heart Fail Clin 
2010;6:453–469. https://doi.org/10.1016/j.hfc.2010.06.005
284. Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. 
Lancet 2015;386:813–825. https://doi.org/10.1016/S0140-6736(14)61282-4
285. Pignatelli RH, McMahon CJ, Dreyer WJ, Denfield SW, Price J, Belmont JW, et al. 
Clinical characterization of left ventricular noncompaction in children: a relatively com­
mon form of cardiomyopathy. Circulation 2003;108:2672–2678. https://doi.org/10. 
1161/01.CIR.0000100664.10777.B8
286. Webber SA, Lipshultz SE, Sleeper LA, Lu M, Wilkinson JD, Addonizio LJ, et al. 
Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: 
a report from the Pediatric Cardiomyopathy Registry. Circulation 2012;126: 
1237–1244. https://doi.org/10.1161/CIRCULATIONAHA.112.104638
287. Pinto JR, Parvatiyar MS, Jones MA, Liang J, Potter JD. A troponin T mutation that causes 
infantile restrictive cardiomyopathy increases Ca2+ sensitivity of force development 
and impairs the inhibitory properties of troponin. J Biol Chem 2008;283:2156–2166. 
https://doi.org/10.1074/jbc.M707066200
288. Peled Y, Gramlich M, Yoskovitz G, Feinberg MS, Afek A, Polak-Charcon S, et al. Titin 
mutation in familial restrictive cardiomyopathy. Int J Cardiol 2014;171:24–30. https:// 
doi.org/10.1016/j.ijcard.2013.11.037
289. Mogensen J, Kubo T, Duque M, Uribe W, Shaw A, Murphy R, et al. Idiopathic restrictive 
cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin 
Invest 2003;111:209–216. https://doi.org/10.1172/JCI200316336
290. Protonotarios N, Tsatsopoulou A. Naxos disease and Carvajal syndrome: cardiocuta­
neous disorders that highlight the pathogenesis and broaden the spectrum of arrhyth­
mogenic right ventricular cardiomyopathy. Cardiovasc Pathol 2004;13:185–194. https:// 
doi.org/10.1016/j.carpath.2004.03.609
291. McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, et al. 
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomy­
opathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000; 
355:2119–2124. https://doi.org/10.1016/S0140-6736(00)02379-5
292. Carvajal-Huerta L. Epidermolytic palmoplantar keratoderma with woolly hair and di­
lated cardiomyopathy. J Am Acad Dermatol 1998;39:418–421. https://doi.org/10.1016/ 
S0190-9622(98)70317-2
293. Smedsrud MK, Chivulescu M, Forsa MI, Castrini I, Aabel EW, Rootwelt-Norberg C, 
et al. Highly malignant disease in childhood-onset arrhythmogenic right ventricular car­
diomyopathy. Eur Heart J 2022;43:4694–4703. https://doi.org/10.1093/eurheartj/ 
ehac485
294. Kontorovich AR, Patel N, Moscati A, Richter F, Peter I, Purevjav E, et al. Myopathic car­
diac genotypes increase risk for myocarditis. JACC Basic Transl Sci 2021;6:584–592. 
https://doi.org/10.1016/j.jacbts.2021.06.001
295. Poller W, Haas J, Klingel K, Kuhnisch J, Gast M, Kaya Z, et al. Familial recurrent myo­
carditis triggered by exercise in patients with a truncating variant of the desmoplakin 
gene. J Am Heart Assoc 2020;9:e015289. https://doi.org/10.1161/JAHA.119.015289
296. Martins D, Ovaert C, Khraiche D, Boddaert N, Bonnet D, Raimondi F. Myocardial in­
flammation detected by cardiac MRI in arrhythmogenic right ventricular cardiomyop­
athy: a paediatric case series. Int J Cardiol 2018;271:81–86. https://doi.org/10.1016/j. 
ijcard.2018.05.116
297. Bariani R, Cipriani A, Rizzo S, Celeghin R, Bueno Marinas M, Giorgi B, et al. ‘Hot phase’ 
clinical presentation in arrhythmogenic cardiomyopathy. Europace 2021;23:907–917. 
https://doi.org/10.1093/europace/euaa343
298. Ross RD. The Ross classification for heart failure in children after 25 years: a review 
and an age-stratified revision. Pediatr Cardiol 2012;33:1295–1300. https://doi.org/10. 
1007/s00246-012-0306-8
299. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 
ESC Guidelines for the management of patients with ventricular arrhythmias and 
the prevention of sudden cardiac death. Eur Heart J 2022;43:3997–4126. https://doi. 
org/10.1093/eurheartj/ehac262
300. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 
ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur 
Heart J 2020;41:407–477. https://doi.org/10.1093/eurheartj/ehz425
301. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. 2018 ESC 
Guidelines for the diagnosis and management of syncope. Eur Heart J 2018; 39: 
1883–1948. https://doi.org/10.1093/eurheartj/ehy037
302. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev 
Genomics Hum Genet 2005;6:185–216. https://doi.org/10.1146/annurev.genom.6. 
080604.162132
303. Ferro MD, Stolfo D, Altinier A, Gigli M, Perrieri M, Ramani F, et al. Association between 
mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. 
Heart 2017;103:1704–1710. https://doi.org/10.1136/heartjnl-2016-311017
304. de Boer RA, Heymans S, Backs J, Carrier L, Coats AJS, Dimmeler S, et al. Targeted ther­
apies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechan­
isms to therapeutic targets. A position paper from the Heart Failure Association (HFA) 
and the Working Group on Myocardial Function of the European Society of 
Cardiology (ESC). Eur J Heart Fail 2022;24:406–420.
305. Oghina S, Bougouin W, Bezard M, Kharoubi M, Komajda M, Cohen-Solal A, et al. The 
impact of patients with cardiac amyloidosis in HFpEF trials. JACC Heart Fail 2021;9: 
169–178. https://doi.org/10.1016/j.jchf.2020.12.005
306. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. 
Universal definition and classification of heart failure: a report of the Heart Failure 
Society of America, Heart Failure Association of the European Society of 
Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal 
Definition of Heart Failure. J Card Fail 2021;3:S1071-9164(21)00050-6. https://doi. 
org/10.1016/j.cardfail.2021.01.022
307. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal 
of pharmacological treatment for heart failure in patients with recovered dilated car­
diomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393: 
61–73. https://doi.org/10.1016/S0140-6736(18)32484-X
308. Mureddu GF, Tarantini L, Agabiti N, Faggiano P, Masson S, Latini R, et al. Evaluation of 
different strategies for identifying asymptomatic left ventricular dysfunction and pre- 
clinical (stage B) heart failure in the elderly. Results from ‘PREDICTOR’, a population 
based-study in central Italy. Eur J Heart Fail 2013;15:1102–1112. https://doi.org/10. 
1093/eurjhf/hft098
309. Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al. A 
small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardio­
myopathy in mice. Science 2016;351:617–621. https://doi.org/10.1126/science. 
aad3456
310. Masarone D, Valente F, Rubino M, Vastarella R, Gravino R, Rea A, et al. Pediatric heart 
failure: a practical guide to diagnosis and management. Pediatr Neonatol 2017;58: 
303–312. https://doi.org/10.1016/j.pedneo.2017.01.001
311. Loss KL, Shaddy RE, Kantor PF. Recent and upcoming drug therapies for pediatric 
heart failure. Front Pediatr 2021;9:681224. https://doi.org/10.3389/fped.2021.681224
312. Arya A, Azad S, Sitaraman R. Angiotensin receptor and neprylisin inhibitor: a new drug 
in pediatric cardiologist’s armamentarium. Ann Pediatr Cardiol 2020;13:334–336. 
https://doi.org/10.4103/apc.APC_9_20
313. Biagini E, Spirito P, Leone O, Picchio FM, Coccolo F, Ragni L, et al. Heart transplant­
ation in hypertrophic cardiomyopathy. Am J Cardiol 2008;101:387–392. https://doi. 
org/10.1016/j.amjcard.2007.09.085
314. Bograd AJ, Mital S, Schwarzenberger JC, Mosca RS, Quaegebeur JM, Addonizio LJ, et al. 
Twenty-year experience with heart transplantation for infants and children with re­
strictive cardiomyopathy: 1986–2006. Am J Transplant 2008;8:201–207. https://doi. 
org/10.1111/j.1600-6143.2007.02027.x
315. Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M, et al. Hypertrophic car­
diomyopathy with left ventricular systolic dysfunction: insights from the SHaRe regis­
try. Circulation 2020;141:1371–1383. https://doi.org/10.1161/CIRCULATIONAHA. 
119.044366
316. DePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyop­
athy after heart transplantation. J Heart Lung Transplant 2012;31:1269–1275. https:// 
doi.org/10.1016/j.healun.2012.09.018
317. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D Jr, Hsich E, et al. The 
international thoracic organ transplant registry of the International Society for 
Heart and Lung Transplantation: thirty-sixth adult heart transplantation report – 
2019; focus theme: donor and recipient size match. J Heart Lung Transplant 2019;38: 
1056–1066. https://doi.org/10.1016/j.healun.2019.08.004


<!-- PAGE 103 -->

### Page 103

318. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. 
The Registry of the International Society for Heart and Lung Transplantation: 
Thirtieth Official Adult Heart Transplant Report–2013; focus theme: age. J Heart 
Lung Transplant 2013;32:951–964. https://doi.org/10.1016/j.healun.2013.08.006
319. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 
International Society for Heart Lung Transplantation listing criteria for heart trans­
plantation: a 10-year update. J Heart Lung Transplant 2016;35:1–23. https://doi.org/ 
10.1016/j.healun.2015.10.023
320. Bansal A, Akhtar F, Desai S, Velasco-Gonzalez C, Bansal A, Teagle A, et al. Six-month 
outcomes in postapproval HeartMate3 patients: a single-center US experience. J Card 
Surg 2022;37:1907–1914. https://doi.org/10.1111/jocs.16452
321. Mehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, Salerno CT, et al. A fully 
magnetically levitated left ventricular assist device – final report. N Engl J Med 2019; 
380:1618–1627. https://doi.org/10.1056/NEJMoa1900486
322. Mehra MR, Goldstein DJ, Uriel N, Cleveland JC Jr, Yuzefpolskaya M, Salerno C, et al. 
Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N 
Engl J Med 2018;378:1386–1395. https://doi.org/10.1056/NEJMoa1800866
323. Zimpfer D, Gustafsson F, Potapov E, Pya Y, Schmitto J, Berchtold-Herz M, et al. 
Two-year outcome after implantation of a full magnetically levitated left ventricular as­
sist device: results from the ELEVATE Registry. Eur Heart J 2020;41:3801–3809. 
https://doi.org/10.1093/eurheartj/ehaa639
324. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh 
INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 
2015;34:1495–1504. https://doi.org/10.1016/j.healun.2015.10.003
325. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. 
Randomized evaluation of mechanical assistance for the treatment of Congestive 
Heart Failure Study Group. Long-term use of a left ventricular assist device for end- 
stage heart failure. N Engl J Med 2001;345:1435–1443. https://doi.org/10.1056/ 
NEJMoa012175
326. Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, et al. Chronic mech­
anical circulatory support for inotrope-dependent heart failure patients who are not 
transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 2007;50: 
741–747. https://doi.org/10.1016/j.jacc.2007.03.063
327. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced 
heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 
2009;361:2241–2251. https://doi.org/10.1056/NEJMoa0909938
328. Goldstein DJ, Naka Y, Horstmanshof D, Ravichandran AK, Schroder J, Ransom J, et al. 
Association of clinical outcomes with left ventricular assist device use by bridge to 
transplant or destination therapy intent: the multicenter study of MagLev technology 
in patients undergoing mechanical circulatory support therapy with HeartMate 3 
(MOMENTUM 3) randomized clinical trial. JAMA Cardiol 2020;5:411–419. https://doi. 
org/10.1001/jamacardio.2019.5323
329. Theochari CA, Michalopoulos G, Oikonomou EK, Giannopoulos S, Doulamis IP, Villela 
MA, et al. Heart transplantation versus left ventricular assist devices as destination 
therapy or bridge to transplantation for 1-year mortality: a systematic review and 
meta-analysis. Ann Cardiothorac Surg 2018;7:3–11. https://doi.org/10.21037/acs.2017. 
09.18
330. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, et al. Results of the 
destination therapy post-food and drug administration approval study with a continu­
ous flow left ventricular assist device: a prospective study using the INTERMACS regis­
try (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll 
Cardiol 2014;63:1751–1757. https://doi.org/10.1016/j.jacc.2014.01.053
331. Charron P, Elliott PM, Gimeno JR, Caforio ALP, Kaski JP, Tavazzi L, et al. The 
Cardiomyopathy registry of the EURObservational Research Programme of the 
European Society of Cardiology: baseline data and contemporary management of 
adult patients with cardiomyopathies. Eur Heart J 2018;39:1784–1793. https://doi. 
org/10.1093/eurheartj/ehx819
332. Mizia-Stec K, Caforio ALP, Charron P, Gimeno JR, Elliott P, Kaski JP, et al. Atrial fibril­
lation, anticoagulation management and risk of stroke in the Cardiomyopathy/ 
Myocarditis registry of the EURObservational Research Programme of the 
European Society of Cardiology. ESC Heart Fail 2020;7:3601–3609. https://doi.org/ 
10.1002/ehf2.12854
333. Gimeno JR, Elliott PM, Tavazzi L, Tendera M, Kaski JP, Laroche C, et al. Prospective 
follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP 
Cardiomyopathy Registry. Eur Heart J Qual Care Clin Outcomes 2021;7:134–142. 
https://doi.org/10.1093/ehjqcco/qcaa075
334. Fauchier L, Bisson A, Bodin A, Herbert J, Spiesser P, Pierre B, et al. Ischemic stroke in 
patients with hypertrophic cardiomyopathy according to presence or absence of atrial 
fibrillation. Stroke 2022;53:497–504. https://doi.org/10.1161/STROKEAHA.121. 
034213
335. Buckley BJR, Harrison SL, Gupta D, Fazio-Eynullayeva E, Underhill P, Lip GYH. Atrial 
fibrillation in patients with cardiomyopathy: prevalence and clinical outcomes from 
real-world data. J Am Heart Assoc 2021;10:e021970. https://doi.org/10.1161/JAHA. 
121.021970
336. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 
ESC Guidelines for the diagnosis and management of atrial fibrillation developed in 
collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): 
the Task Force for the diagnosis and management of atrial fibrillation of the 
European Society of Cardiology (ESC) developed with the special contribution of 
the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42: 
373–498. https://doi.org/10.1093/eurheartj/ehaa612
337. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat 
Rev Cardiol 2017;14:627–628. https://doi.org/10.1038/nrcardio.2017.153
338. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved outcomes by inte­
grated care of anticoagulated patients with atrial fibrillation using the simple ABC 
(Atrial Fibrillation Better Care) pathway. Am J Med 2018;131:1359–1366.e6. https:// 
doi.org/10.1016/j.amjmed.2018.06.012
339. Yoon M, Yang P-S, Jang E, Yu HT, Kim T-H, Uhm J-S, et al. Improved population-based 
clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC 
(Atrial Fibrillation Better Care) pathway for integrated care management: a nationwide 
cohort study. Thromb Haemost 2019;119:1695–1703. https://doi.org/10.1055/s-0039- 
1693516
340. Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GYH. ABC (Atrial Fibrillation Better 
Care) pathway and healthcare costs in atrial fibrillation: the ATHERO-AF study. Am 
J Med 2019;132:856–861. https://doi.org/10.1016/j.amjmed.2019.01.003
341. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated care management of 
patients with atrial fibrillation and risk of cardiovascular events: the ABC (Atrial 
Fibrillation Better Care) pathway in the ATHERO-AF study cohort. Mayo Clin Proc 
2019;94:1261–1267. https://doi.org/10.1016/j.mayocp.2018.10.022
342. Proietti M, Lip GYH, Laroche C, Fauchier L, Marin F, Nabauer M, et al. Relation of out­
comes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European pa­
tients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation 
General Long-Term (AFGen LT) Registry. Europace 2021;23:174–183. https://doi. 
org/10.1093/europace/euaa274
343. Pastori D, Menichelli D, Violi F, Pignatelli P, Lip GYH; ATHERO-AF study group. The 
Atrial Fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibril­
lation: a potential sex-based difference. The ATHERO-AF study. Eur J Intern Med 2021; 
85:80–85. https://doi.org/10.1016/j.ejim.2020.12.011
344. Stevens D, Harrison SL, Kolamunnage-Dona R, Lip GYH, Lane DA. The Atrial 
Fibrillation Better Care pathway for managing atrial fibrillation: a review. Europace 
2021;23:1511–1527. https://doi.org/10.1093/europace/euab092
345. Yao Y, Guo Y, Lip GYH; mAF-App II Trial investigators. The effects of implementing a 
mobile health-technology supported pathway on atrial fibrillation-related adverse 
events among patients with multimorbidity: the mAFA-II randomized clinical trial. 
JAMA Netw Open 2021;4:e2140071. https://doi.org/10.1001/jamanetworkopen.2021. 
40071
346. Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, et al. 
Adherence to the ‘Atrial Fibrillation Better Care’ Pathway in patients with atrial fibril­
lation: impact on clinical outcomes–a systematic review and meta-analysis of 285,000 
patients. Thromb Haemost 2022;122:406–414. https://doi.org/10.1055/a-1515-9630
347. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J, et al. Targeted 
therapy of underlying conditions improves sinus rhythm maintenance in patients with 
persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J 2018;39:2987–2996. 
https://doi.org/10.1093/eurheartj/ehx739
348. Wang YF, Jiang C, He L, Du X, Sang CH, Long DY, et al. Integrated care of atrial fib­
rillation using the ABC (Atrial fibrillation Better Care) pathway improves clinical out­
comes in Chinese population: an analysis from the Chinese atrial fibrillation registry. 
Front Cardiovasc Med 2021;8:762245. https://doi.org/10.3389/fcvm.2021.762245
349. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Comprehensive management 
with the ABC (Atrial fibrillation Better Care) pathway in clinically complex patients 
with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. J Am Heart 
Assoc 2020;9:e014932. https://doi.org/10.1161/JAHA.119.014932
350. Gumprecht J, Domek M, Proietti M, Li YG, Asaad N, Rashed W, et al. Compliance of 
atrial fibrillation treatment with the Atrial fibrillation Better Care (ABC) pathway im­
proves the clinical outcomes in the Middle East population: a report from the Gulf 
Survey of Atrial Fibrillation Events (SAFE) registry. J Clin Med 2020;9:1286. https:// 
doi.org/10.3390/jcm9051286
351. Proietti M, Vitolo M, Lip GYH. Integrated care and outcomes in patients with atrial fib­
rillation and comorbidities. Eur J Clin Invest 2021;51:e13498. https://doi.org/10.1111/ 
eci.13498
352. Rivera-Caravaca JM, Roldan V, Martinez-Montesinos L, Vicente V, Lip GYH, Marin F. 
The Atrial Fibrillation Better Care (ABC) pathway and clinical outcomes in patients 
with atrial fibrillation: the prospective Murcia AF Project Phase II Cohort. J Gen 
Intern Med 2023;38:315–323. https://doi.org/10.1007/s11606-022-07567-5
353. Vitolo M, Proietti M, Malavasi VL, Bonini N, Romiti GF, Imberti JF, et al. Adherence to 
the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and 
cancer: a report from the ESC-EHRA EURObservational Research Programme in at­
rial fibrillation (EORP-AF) General Long-Term Registry. Eur J Intern Med 2022;105: 
54–62. https://doi.org/10.1016/j.ejim.2022.08.004
354. Patel SM, Palazzolo MG, Murphy SA, Antman EM, Braunwald E, Lanz HJ, et al. 
Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 
trial. Europace 2022;24:1730–1738. https://doi.org/10.1093/europace/euac082
ESC Guidelines                                                                                                                                                                                          3605


<!-- PAGE 104 -->

### Page 104

355. Yang PS, Sung JH, Jang E, Yu HT, Kim TH, Lip GYH, et al. Application of the simple atrial 
fibrillation better care pathway for integrated care management in frail patients with 
atrial fibrillation: a nationwide cohort study. J Arrhythm 2020;36:668–677. https://doi. 
org/10.1002/joa3.12364
356. Romiti GF, Proietti M, Vitolo M, Bonini N, Fawzy AM, Ding WY, et al. Clinical complex­
ity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with at­
rial fibrillation: a report from the ESC-EHRA EURObservational Research Programme 
in AF General Long-Term Registry. BMC Med 2022;20:326. https://doi.org/10.1186/ 
s12916-022-02526-7
357. Yang PS, Sung JH, Jang E, Yu HT, Kim TH, Uhm JS, et al. The effect of integrated care 
management on dementia in atrial fibrillation. J Clin Med 2020;9:1696. https://doi.org/ 
10.3390/jcm9061696
358. Kotalczyk A, Guo Y, Stefil M, Wang Y, Lip GYH, Chi ORI. Effects of the atrial fibrillation 
better care pathway on outcomes among clinically complex Chinese patients with at­
rial fibrillation with multimorbidity and polypharmacy: a report from the ChiOTEAF 
registry. J Am Heart Assoc 2022;11:e024319. https://doi.org/10.1161/JAHA.121.024319
359. Esteve-Pastor MA, Ruiz-Ortiz M, Muniz J, Roldan-Rabadan I, Otero D, Cequier A, et al. 
Impact of integrated care management on clinical outcomes in atrial fibrillation pa­
tients: a report from the FANTASIIA registry. Front Cardiovasc Med 2022;9:856222. 
https://doi.org/10.3389/fcvm.2022.856222
360. Guo Y, Imberti JF, Kotalczyk A, Wang Y, Lip GYH, Chi ORI. 4S-AF scheme and ABC 
pathway guided management improves outcomes in atrial fibrillation patients. Eur J Clin 
Invest 2022;52:e13751. https://doi.org/10.1111/eci.13751
361. Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, et al. Mobile health technology 
to improve care for patients with atrial fibrillation. J Am Coll Cardiol 2020;75: 
1523–1534. https://doi.org/10.1016/j.jacc.2020.01.052
362. Guo Y, Guo J, Shi X, Yao Y, Sun Y, Xia Y, et al. Mobile health technology-supported 
atrial fibrillation screening and integrated care: a report from the mAFA-II trial long- 
term extension cohort. Eur J Intern Med 2020;82:105–111. https://doi.org/10.1016/j. 
ejim.2020.09.024
363. Koniaris LS, Goldhaber SZ. Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol 
1998;31:745–748. https://doi.org/10.1016/S0735-1097(98)00003-5
364. Eapen ZJ, Mi X, Fonarow GC, Setoguchi S, Piccini JP, Mills RM, et al. Anticoagulation 
and clinical outcomes in heart failure patients with atrial fibrillation: findings from 
the ADHERE registry. J Atr Fibrillation 2013;6:953.
365. Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation 
and thromboembolism in patients with hypertrophic cardiomyopathy: systematic re­
view. Heart 2014;100:465–472. https://doi.org/10.1136/heartjnl-2013-304276
366. Camm CF, Camm AJ. Atrial fibrillation and anticoagulation in hypertrophic 
cardiomyopathy. Arrhythm Electrophysiol Rev 2017;6:63–68. https://doi.org/10.15420/ 
aer.2017:4:2
367. Nasser MF, Gandhi S, Siegel RJ, Rader F. Anticoagulation for stroke prevention in pa­
tients with hypertrophic cardiomyopathy and atrial fibrillation: a review. Heart Rhythm 
2021;18:297–302. https://doi.org/10.1016/j.hrthm.2020.09.018
368. van Rijsingen IAW, Bakker A, Azim D, Hermans-van Ast JF, van der Kooi AJ, van 
Tintelen JP, et al. Lamin A/C mutation is independently associated with an increased 
risk of arterial and venous thromboembolic complications. Int J Cardiol 2013;168: 
472–477. https://doi.org/10.1016/j.ijcard.2012.09.118
369. Guttmann OP, Pavlou M, O’Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al. 
Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy 
(HCM Risk-CVA). Eur J Heart Fail 2015;17:837–845. https://doi.org/10.1002/ejhf.316
370. Garcia-Pavia P, Bengel F, Brito D, Damy T, Duca F, Dorbala S, et al. Expert consensus 
on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail 2021;23: 
895–905. https://doi.org/10.1002/ejhf.2198
371. Jung H, Yang P-S, Sung J-H, Jang E, Yu HT, Kim T-H, et al. Hypertrophic cardiomyop­
athy in patients with atrial fibrillation: prevalence and associated stroke risks in a na­
tionwide cohort study. Thromb Haemost 2019;119:285–293. https://doi.org/10.1055/ 
s-0038-1676818
372. Jung H, Sung J-H, Yang P-S, Jang E, Yu HT, Kim T-H, et al. Stroke risk stratification for 
atrial fibrillation patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2018;72: 
2409–2411. https://doi.org/10.1016/j.jacc.2018.07.098
373. Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, et al. Systemic 
embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail 2022;24: 
1387–1396. https://doi.org/10.1002/ejhf.2566
374. Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Effectiveness and safety of non- 
vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hyper­
trophic cardiomyopathy: a nationwide cohort study. Chest 2019;155:354–363. 
https://doi.org/10.1016/j.chest.2018.11.009
375. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and 
treatment of cardiac amyloidosis: a position statement of the ESC Working Group 
on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554–1568. https://doi. 
org/10.1093/eurheartj/ehab072
376. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. 
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in pa­
tients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383: 
955–962. https://doi.org/10.1016/S0140-6736(13)62343-0
377. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH. Non-vitamin K antagonist oral 
anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart fail­
ure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015;17: 
1192–1200. https://doi.org/10.1002/ejhf.343
378. Noseworthy PA, Yao X, Shah ND, Gersh BJ. Stroke and bleeding risks in NOAC- and 
warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation. J Am 
Coll Cardiol 2016;67:3020–3021. https://doi.org/10.1016/j.jacc.2016.04.026
379. Lee HJ, Kim HK, Jung JH, Han KD, Lee H, Park JB, et al. Novel oral anticoagulants for 
primary stroke prevention in hypertrophic cardiomyopathy patients with atrial fibril­
lation. Stroke 2019;50:2582–2586. https://doi.org/10.1161/STROKEAHA.119.026048
380. Lin Y, Xiong H, Su J, Lin J, Zhou Q, Lin M, et al. Effectiveness and safety of non-vitamin K 
antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non- 
valvular atrial fibrillation. Heart Vessels 2022;37:1224–1231. https://doi.org/10.1007/ 
s00380-022-02021-2
381. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. 
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 
2010;362:1363–1373. https://doi.org/10.1056/NEJMoa1001337
382. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, et al. 
Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of 
pooled data from the RACE and AFFIRM studies. Europace 2006;8:935–942. https:// 
doi.org/10.1093/europace/eul106
383. Sartipy U, Savarese G, Dahlstrom U, Fu M, Lund LH. Association of heart rate with 
mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection 
fraction. Eur J Heart Fail 2019;21:471–479. https://doi.org/10.1002/ejhf.1389
384. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, et al. Strict 
versus lenient versus poor rate control among patients with atrial fibrillation and heart 
failure (from the Get With The Guidelines – Heart Failure Program). Am J Cardiol 2020; 
125:894–900. https://doi.org/10.1016/j.amjcard.2019.12.025
385. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. 
Lancet 2016;388:818–828. https://doi.org/10.1016/S0140-6736(16)31258-2
386. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, et al. Heart rate 
and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll 
Cardiol 2017;69:2885–2896. https://doi.org/10.1016/j.jacc.2017.04.001
387. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of digoxin vs 
bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: 
the RATE-AF randomized clinical trial. JAMA 2020;324:2497–2508. https://doi.org/10. 
1001/jama.2020.23138
388. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, et al. A ran­
domized controlled trial of atrioventricular junction ablation and cardiac resynchroni­
zation therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart 
J 2018;39:3999–4008. https://doi.org/10.1093/eurheartj/ehy555
389. Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV 
junction ablation and cardiac resynchronization for patients with permanent atrial fib­
rillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J 2021;42: 
4731–4739. https://doi.org/10.1093/eurheartj/ehab569
390. Huang W, Wang S, Su L, Fu G, Su Y, Chen K, et al. His-bundle pacing vs biventricular 
pacing following atrioventricular nodal ablation in patients with atrial fibrillation and 
reduced ejection fraction: a multicenter, randomized, crossover study–The 
ALTERNATIVE-AF trial. Heart Rhythm 2022;19:1948–1955. https://doi.org/10.1016/ 
j.hrthm.2022.07.009
391. Guttmann OP, Pavlou M, O’Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al. 
Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart 2017;103: 
672–678. https://doi.org/10.1136/heartjnl-2016-309672
392. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al. 
Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 
2021;384:305–315. https://doi.org/10.1056/NEJMoa2029980
393. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Cryoballoon ab­
lation as initial therapy for atrial fibrillation. N Engl J Med 2021;384:316–324. https:// 
doi.org/10.1056/NEJMoa2029554
394. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment 
comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the 
management of atrial fibrillation. Europace 2011;13:329–345. https://doi.org/10.1093/ 
europace/euq450
395. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al. Increased 
mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358: 
2678–2687. https://doi.org/10.1056/NEJMoa0800456
396. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone 
in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268–2276. https://doi. 
org/10.1056/NEJMoa1109867
397. Providencia R, Elliott P, Patel K, McCready J, Babu G, Srinivasan N, et al. Catheter ab­
lation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and 
meta-analysis. Heart 2016;102:1533–1543. https://doi.org/10.1136/heartjnl-2016- 
309406
398. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of 
catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and


<!-- PAGE 105 -->

### Page 105

cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical 
trial. JAMA 2019;321:1261–1274. https://doi.org/10.1001/jama.2019.0693
399. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation 
versus amiodarone for treatment of persistent atrial fibrillation in patients with con­
gestive heart failure and an implanted device. Results from the AATAC multicenter 
randomized 
trial. 
Circulation 
2016;133:1637–1644. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.115.019406
400. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, 
et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from 
the CABANA trial. Circulation 2021;143:1377–1390. https://doi.org/10.1161/ 
CIRCULATIONAHA.120.050991
401. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. 
Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378: 
417–427. https://doi.org/10.1056/NEJMoa1707855
402. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm- 
control therapy in patients with atrial fibrillation. N Engl J Med 2020;383: 
1305–1316. https://doi.org/10.1056/NEJMoa2019422
403. Rillig A, Magnussen C, Ozga AK, Suling A, Brandes A, Breithardt G, et al. Early rhythm 
control therapy in patients with atrial fibrillation and heart failure. Circulation 2021; 
144:845–858. https://doi.org/10.1161/CIRCULATIONAHA.121.056323
404. Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, et al. Pulmonary-vein 
isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008;359: 
1778–1785. https://doi.org/10.1056/NEJMoa0708234
405. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, et al. 
Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart 
failure and severe left ventricular systolic dysfunction: a randomised controlled trial. 
Heart 2011;97:740–747. https://doi.org/10.1136/hrt.2010.207340
406. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, et al. A ran­
domized trial to assess catheter ablation versus rate control in the management of per­
sistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013;61:1894–1903. https:// 
doi.org/10.1016/j.jacc.2013.01.069
407. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, et al. A randomized 
controlled trial of catheter ablation versus medical treatment of atrial fibrillation in 
heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014;7:31–38. https:// 
doi.org/10.1161/CIRCEP.113.000806
408. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A, et al. 
Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunc­
tion: the CAMERA-MRI study. J Am Coll Cardiol 2017;70:1949–1961. https://doi.org/10. 
1016/j.jacc.2017.08.041
409. Romero J, Gabr M, Alviz I, Briceno D, Diaz JC, Rodriguez D, et al. Improved survival in 
patients with atrial fibrillation and heart failure undergoing catheter ablation compared 
to medical treatment: a systematic review and meta-analysis of randomized controlled 
trials. J Cardiovasc Electrophysiol 2022;33:2356–2366. https://doi.org/10.1111/jce.15622
410. Androulakis E, Sohrabi C, Briasoulis A, Bakogiannis C, Saberwal B, Siasos G, et al. 
Catheter ablation for atrial fibrillation in patients with heart failure with preserved 
ejection fraction: a systematic review and meta-analysis. J Clin Med 2022;11:288. 
https://doi.org/10.3390/jcm11020288
411. Bunch TJ, Munger TM, Friedman PA, Asirvatham SJ, Brady PA, Cha YM, et al. Substrate 
and procedural predictors of outcomes after catheter ablation for atrial fibrillation in 
patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2008;19: 
1009–1014. https://doi.org/10.1111/j.1540-8167.2008.01192.x
412. Bassiouny M, Lindsay BD, Lever H, Saliba W, Klein A, Banna M, et al. Outcomes of non­
pharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomy­
opathy. Heart Rhythm 2015;12:1438–1447. https://doi.org/10.1016/j.hrthm.2015.03. 
042
413. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, et al. Clinical profile 
and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 
2017;136:2420–2436. https://doi.org/10.1161/CIRCULATIONAHA.117.029267
414. Chen X, Dong JZ, Du X, Wu JH, Yu RH, Long DY, et al. Long-term outcome of cath­
eter ablation for atrial fibrillation in patients with apical hypertrophic cardiomyopathy. J 
Cardiovasc Electrophysiol 2018;29:951–957. https://doi.org/10.1111/jce.13645
415. Di Donna P, Olivotto I, Delcre SDL, Caponi D, Scaglione M, Nault I, et al. Efficacy of 
catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, 
atrial remodelling, and disease progression. Europace 2010;12:347–355. https://doi. 
org/10.1093/europace/euq013
416. Santangeli P, Di Biase L, Themistoclakis S, Raviele A, Schweikert RA, Lakkireddy D, et al. 
Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term out­
comes and mechanisms of arrhythmia recurrence. Circ Arrhythm Electrophysiol 2013;6: 
1089–1094. https://doi.org/10.1161/CIRCEP.113.000339
417. Ha HS, Wang N, Wong S, Phan S, Liao J, Kumar N, et al. Catheter ablation for atrial 
fibrillation in hypertrophic cardiomyopathy patients: a systematic review. J Interv 
Card Electrophysiol 2015;44:161–170. https://doi.org/10.1007/s10840-015-0047-8
418. Zhao DS, Shen Y, Zhang Q, Lin G, Lu YH, Chen BT, et al. Outcomes of catheter ab­
lation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic 
review and meta-analysis. Europace 2016;18:508–520. https://doi.org/10.1093/ 
europace/euv339
419. Lapenna E, Pozzoli A, De Bonis M, La Canna G, Nisi T, Nascimbene S, et al. Mid-term 
outcomes of concomitant surgical ablation of atrial fibrillation in patients undergoing 
cardiac surgery for hypertrophic cardiomyopathy. Eur J Cardiothorac Surg 2017;51: 
1112–1118. https://doi.org/10.1093/ejcts/ezx017
420. Gasperetti A, James CA, Chen L, Schenker N, Casella M, Kany S, et al. Efficacy of cath­
eter ablation for atrial arrhythmias in patients with arrhythmogenic right ventricular 
cardiomyopathy–a multicenter study. J Clin Med 2021;10:4962. https://doi.org/10. 
3390/jcm10214962
421. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, et al. Clinical profile 
of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39: 
301–307. https://doi.org/10.1016/S0735-1097(01)01727-2
422. Losi M-A, Betocchi S, Aversa M, Lombardi R, Miranda M, D’Alessandro G, et al. 
Determinants of atrial fibrillation development in patients with hypertrophic cardio­
myopathy. Am J Cardiol 2004;94:895–900. https://doi.org/10.1016/j.amjcard.2004.06. 
024
423. Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ. Atrial fibrillation in 
hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large 
high-risk population. J Am Heart Assoc 2014;3:e001002. https://doi.org/10.1161/JAHA. 
114.001002
424. Klopotowski M, Kwapiszewska A, Kukula K, Jamiolkowski J, Dabrowski M, Derejko P, 
et al. Clinical and echocardiographic parameters as risk factors for atrial fibrillation in 
patients with hypertrophic cardiomyopathy. Clin Cardiol 2018;41:1336–1340. https:// 
doi.org/10.1002/clc.23050
425. Choi Y-J, Choi E-K, Han K-D, Jung J-H, Park J, Lee E, et al. Temporal trends of the 
prevalence and incidence of atrial fibrillation and stroke among Asian patients with 
hypertrophic cardiomyopathy: a nationwide population-based study. Int J Cardiol 
2018;273:130–135. https://doi.org/10.1016/j.ijcard.2018.08.038
426. Yeung C, Enriquez A, Suarez-Fuster L, Baranchuk A. Atrial fibrillation in patients with 
inherited cardiomyopathies. Europace 2019;21:22–32. https://doi.org/10.1093/ 
europace/euy064
427. Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, et al. Occurrence and 
natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomy­
opathy. Am J Cardiol 2017;119:1862–1865. https://doi.org/10.1016/j.amjcard.2017.02. 
040
428. van Velzen HG, Theuns DA, Yap SC, Michels M, Schinkel AF. Incidence of device- 
detected atrial fibrillation and long-term outcomes in patients with hypertrophic car­
diomyopathy. Am J Cardiol 2017;119:100–105. https://doi.org/10.1016/j.amjcard.2016. 
08.092
429. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. 
Atrial fibrillation in hypertrophie cardiomyopathy: a longitudinal study. J Am Coll 
Cardiol 1990;15:1279–1285. https://doi.org/10.1016/S0735-1097(10)80014-2
430. Gaita F, Di Donna P, Olivotto I, Scaglione M, Ferrero I, Montefusco A, et al. Usefulness 
and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic 
cardiomyopathy. Am J Cardiol 2007;99:1575–1581. https://doi.org/10.1016/j.amjcard. 
2006.12.087
431. Zheng S, Jiang W, Dai J, Li K, Shi H, Wu W, et al. Five-year outcomes after catheter 
ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J 
Cardiovasc Electrophysiol 2020;31:621–628. https://doi.org/10.1111/jce.14349
432. Cao ZJ, Guo XG, Sun Q, Yang JD, Wei HQ, Zhang S, et al. Pulmonary vein isolation 
implemented by second-generation cryoballoon for treating hypertrophic cardiomy­
opathy patients with symptomatic atrial fibrillation: a case-control study. J Geriatr 
Cardiol 2020;17:476–485.
433. Castagno D, Di Donna P, Olivotto I, Frontera A, Calo L, Scaglione M, et al. 
Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyop­
athy: long-term results and clinical outcomes. J Cardiovasc Electrophysiol 2021;32: 
657–666. https://doi.org/10.1111/jce.14880
434. Dinshaw L, Munkler P, Schaffer B, Klatt N, Jungen C, Dickow J, et al. Ablation of atrial 
fibrillation in patients with hypertrophic cardiomyopathy: treatment strategy, charac­
teristics of consecutive atrial tachycardia and long-term outcome. J Am Heart Assoc 
2021;10:e017451. https://doi.org/10.1161/JAHA.120.017451
435. Creta A, Elliott P, Earley MJ, Dhinoja M, Finlay M, Sporton S, et al. Catheter ablation of 
atrial fibrillation in patients with hypertrophic cardiomyopathy: a European observa­
tional multicentre study. Europace 2021;23:1409–1417. https://doi.org/10.1093/ 
europace/euab022
436. Grünig E, Tasman JA, Kücherer H, Franz W, Kübler W, Katus HA. Frequency and phe­
notypes of familial dilated cardiomyopathy. J Am Coll Cardiol 1998;31:186–194. https:// 
doi.org/10.1016/S0735-1097(97)00434-8
437. Bourfiss M, Riele ASJMT, Mast TP, Cramer MJ, Heijden JF, Veen TABV, et al. Influence 
of genotype on structural atrial abnormalities and atrial fibrillation or flutter in arrhyth­
mogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol 2016; 
27:1420–1428. https://doi.org/10.1111/jce.13094
438. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, et al. Long-term out­
come and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008;52: 
1250–1260. https://doi.org/10.1016/j.jacc.2008.06.044
439. Van Rijsingen IAW, Nannenberg EA, Arbustini E, Elliott PM, Mogensen J, Hermans-van 
Ast JF, et al. Gender-specific differences in major cardiac events and mortality in lamin 
ESC Guidelines                                                                                                                                                                                          3607


<!-- PAGE 106 -->

### Page 106

A/C mutation carriers. Eur J Heart Fail 2013;15:376–384. https://doi.org/10.1093/ 
eurjhf/hfs191
440. Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF, et al. 
Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. 
J Am Coll Cardiol 2016;68:2299–2307. https://doi.org/10.1016/j.jacc.2016.08.058
441. Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP, et al. Lamin A/ 
C cardiomyopathy: young onset, high penetrance, and frequent need for heart trans­
plantation. Eur Heart J 2017;39:853–860. https://doi.org/10.1093/eurheartj/ehx596
442. Cikes M, Claggett B, Shah AM, Desai AS, Lewis EF, Shah SJ, et al. Atrial fibrillation in 
heart failure with preserved ejection fraction: the TOPCAT trial. JACC Heart Fail 
2018;6:689–697. https://doi.org/10.1016/j.jchf.2018.05.005
443. Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS, et al. 
Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, 
and preserved ejection fraction: a report from 14 964 patients in the European 
Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J 2018;39: 
4277–4284. https://doi.org/10.1093/eurheartj/ehy626
444. Cikes M, Planinc I, Claggett B, Cunningham J, Milicic D, Sweitzer N, et al. Atrial fibril­
lation in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC 
Heart Fail 2022;10:336–346. https://doi.org/10.1016/j.jchf.2022.01.018
445. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. 
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by 
candesartan in the Candesartan in Heart failure: Assessment of Reduction in 
Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86–92. https:// 
doi.org/10.1016/j.ahj.2005.06.036
446. Aldaas OM, Lupercio F, Darden D, Mylavarapu PS, Malladi CL, Han FT, et al. 
Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients 
with heart failure with preserved ejection fraction. Am J Cardiol 2021;142:66–73. 
https://doi.org/10.1016/j.amjcard.2020.11.039
447. Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with arrhythmogenic 
right ventricular cardiomyopathy/dysplasia and ventricular tachycardia. Am J Cardiol 
2010;106:720–722. https://doi.org/10.1016/j.amjcard.2010.04.031
448. Camm CF, James CA, Tichnell C, Murray B, Bhonsale A, Te Riele ASJM, et al. 
Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardio­
myopathy. Heart Rhythm 2013;10:1661–1668. https://doi.org/10.1016/j.hrthm.2013. 
08.032
449. Saguner AM, Brunckhorst C, Duru F. Atrial arrhythmias in arrhythmogenic cardiomy­
opathy: at the beginning or at the end of the disease story? Reply. Circ J 2015;79:447. 
https://doi.org/10.1253/circj.CJ-14-1234
450. Müssigbrodt A, Knopp H, Efimova E, Weber A, Bertagnolli L, Hilbert S, et al. 
Supraventricular arrhythmias in patients with arrhythmogenic right ventricular dyspla­
sia/cardiomyopathy associate with long-term outcome after catheter ablation of ven­
tricular tachycardias. Europace 2018;20:1182–1187. https://doi.org/10.1093/europace/ 
eux179
451. Saguner AM, Ganahl S, Kraus A, Baldinger SH, Medeiros-Domingo A, Saguner AR, et al. 
Clinical role of atrial arrhythmias in patients with arrhythmogenic right ventricular dys­
plasia. Circ J 2014;78:2854–2861. https://doi.org/10.1253/circj.CJ-14-0474
452. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. 
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. 
Cochrane Database Syst Rev 2019;9:CD005049. https://doi.org/10.1002/14651858. 
CD005049.pub4
453. Muchtar E, Gertz MA, Kumar SK, Lin G, Boilson B, Clavell A, et al. Digoxin use in sys­
temic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid 2018;25: 
86–92. https://doi.org/10.1080/13506129.2018.1449744
454. Donnelly JP, Sperry BW, Gabrovsek A, Ikram A, Tang WHW, Estep J, et al. Digoxin use 
in cardiac amyloidosis. Am J Cardiol 2020;133:134–138. https://doi.org/10.1016/j. 
amjcard.2020.07.034
455. Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in car­
diac amyloidosis. Chest 1993;104:618–620. https://doi.org/10.1378/chest.104.2.618
456. Yang YJ, Yuan JQ, Fan CM, Pu JL, Fang PH, Ma J, et al. Incidence of ischemic stroke and 
systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial 
fibrillation, CHA2DS2-VASc score of 1 and without anticoagulant therapy. Heart 
Vessels 2016;31:1148–1153. https://doi.org/10.1007/s00380-015-0718-5
457. Lee SE, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Impact of atrial fibrillation on 
the clinical course of apical hypertrophic cardiomyopathy. Heart 2017;103: 
1496–1501. https://doi.org/10.1136/heartjnl-2016-310720
458. Hirota T, Kubo T, Baba Y, Ochi Y, Takahashi A, Yamasaki N, et al. Clinical profile of 
thromboembolic events in patients with hypertrophic cardiomyopathy in a regional 
Japanese cohort – results from Kochi RYOMA study. Circ J 2019;83:1747–1754. 
https://doi.org/10.1253/circj.CJ-19-0186
459. Tsuda T, Hayashi K, Fujino N, Konno T, Tada H, Nomura A, et al. Effect of hypertroph­
ic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular 
atrial fibrillation. Heart Rhythm 2019;16:829–837. https://doi.org/10.1016/j.hrthm. 
2018.11.029
460. Lozier MR, Sanchez AM, Lee JJ, Donath EM, Font VE, Escolar E. Thromboembolic out­
comes of different anticoagulation strategies for patients with atrial fibrillation in the 
setting of hypertrophic cardiomyopathy: a systematic review. J Atr Fibrillation 2019; 
12:2207. https://doi.org/10.4022/jafib.2207
461. Hsu JC, Huang YT, Lin LY. Stroke risk in hypertrophic cardiomyopathy patients with 
atrial fibrillation: a nationwide database study. Aging (Albany NY) 2020;12:24219–­
24227. https://doi.org/10.18632/aging.104133
462. Komatsu J, Imai RI, Nakaoka Y, Nishida K, Seki SI, Kubo T, et al. Importance of parox­
ysmal atrial fibrillation and sex differences in the prevention of embolic stroke in hyper­
trophic cardiomyopathy. Circ Rep 2021;3:273–278. https://doi.org/10.1253/circrep. 
CR-20-0101
463. Donnellan E, Elshazly MB, Vakamudi S, Wazni OM, Cohen JA, Kanj M, et al. No asso­
ciation between CHADS-VASc score and left atrial appendage thrombus in patients 
with transthyretin amyloidosis. JACC Clin Electrophysiol 2019;5:1473–1474. https:// 
doi.org/10.1016/j.jacep.2019.10.013
464. El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al. 
Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. 
J Am Coll Cardiol 2019;73:589–597. https://doi.org/10.1016/j.jacc.2018.10.079
465. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non- 
valvular atrial fibrillation and no previous history of stroke or transient ischemic at­
tacks. Cochrane Database Syst Rev 2005;3:CD001927. https://doi.org/10.1002/ 
14651858.CD001927
466. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent 
stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 
857–867. https://doi.org/10.7326/0003-4819-146-12-200706190-00007
467. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for pre­
venting stroke in patients with non-valvular atrial fibrillation and no history of stroke or 
transient ischemic attacks. Cochrane Database Syst Rev 2007;3:CD006186. https://doi. 
org/10.1002/14651858.CD006186.pub2
468. Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L. 
Warfarin for the prevention of systemic embolism in patients with non-valvular atrial 
fibrillation: a meta-analysis. Heart 2008;94:1607–1613. https://doi.org/10.1136/hrt. 
2007.135657
469. Dogliotti A, Paolasso E, Giugliano RP. Current and new oral antithrombotics in non- 
valvular atrial fibrillation: a network meta-analysis of 79 808 patients. Heart 2014;100: 
396–405. https://doi.org/10.1136/heartjnl-2013-304347
470. Joundi RA, Cipriano LE, Sposato LA, Saposnik G; Stroke Outcomes Research Working 
Group. Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc 
score of 1: systematic review and meta-analysis. Stroke 2016;47:1364–1367. https:// 
doi.org/10.1161/STROKEAHA.115.012609
471. Nielsen PB, Larsen TB, Skjoth F, Overvad TF, Lip GY. Stroke and thromboembolic 
event rates in atrial fibrillation according to different guideline treatment thresholds: 
a nationwide cohort study. Sci Rep 2016;6:27410. https://doi.org/10.1038/srep27410
472. Shin SY, Han SJ, Kim JS, Im SI, Shim J, Ahn J, et al. Identification of markers associated 
with development of stroke in “clinically low-risk” atrial fibrillation patients. J Am Heart 
Assoc 2019;8:e012697. https://doi.org/10.1161/JAHA.119.012697
473. Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, Sriratanasathavorn C, 
Pooranawattanakul S, Punlee K, et al. A randomized clinical trial of the efficacy of radio­
frequency catheter ablation and amiodarone in the treatment of symptomatic atrial 
fibrillation. J Med Assoc Thai 2003;86:S8–16.
474. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, et al. Catheter 
ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, 
multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of 
Atrial Fibrillation Study). Eur Heart J 2006;27:216–221. https://doi.org/10.1093/ 
eurheartj/ehi583
475. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, et al. A randomized 
trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in 
paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 2006;48:2340–2347. 
https://doi.org/10.1016/j.jacc.2006.08.037
476. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr, et al. Circumferential 
pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006;354: 
934–941. https://doi.org/10.1056/NEJMoa050955
477. Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation 
versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118: 
2498–2505. https://doi.org/10.1161/CIRCULATIONAHA.108.772582
478. Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, et al. Catheter ablation 
of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized 
study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J 
Cardiovasc Electrophysiol 2009;20:22–28. https://doi.org/10.1111/j.1540-8167.2008. 
01275.x
479. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison 
of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with 
paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;303:333–340. 
https://doi.org/10.1001/jama.2009.2029
480. Pappone C, Vicedomini G, Augello G, Manguso F, Saviano M, Baldi M, et al. 
Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, ran­
domized, 4-year follow-up trial: the APAF study. Circ Arrhythm Electrophysiol 2011;4: 
808–814. https://doi.org/10.1161/CIRCEP.111.966408


<!-- PAGE 107 -->

### Page 107

481. Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG, et al. 
Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results 
of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 2013;61: 
1713–1723. https://doi.org/10.1016/j.jacc.2012.11.064
482. Blandino A, Toso E, Scaglione M, Anselmino M, Ferraris F, Sardi D, et al. Long-term 
efficacy and safety of two different rhythm control strategies in elderly patients with 
symptomatic persistent atrial fibrillation. J Cardiovasc Electrophysiol 2013;24: 
731–738. https://doi.org/10.1111/jce.12126
483. Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X, Arenal A, et al. 
Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a 
multicentre, randomized, controlled trial (SARA study). Eur Heart J 2014;35: 
501–507. https://doi.org/10.1093/eurheartj/eht457
484. Hummel J, Michaud G, Hoyt R, DeLurgio D, Rasekh A, Kusumoto F, et al. Phased RF 
ablation in persistent atrial fibrillation. Heart Rhythm 2014;11:202–209. https://doi.org/ 
10.1016/j.hrthm.2013.11.009
485. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to 
catheter ablation for persistent atrial fibrillation. N Engl J Med 2015;372:1812–1822. 
https://doi.org/10.1056/NEJMoa1408288
486. Reddy VY, Dukkipati SR, Neuzil P, Natale A, Albenque JP, Kautzner J, et al. 
Randomized, controlled trial of the safety and effectiveness of a contact force-sensing 
irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath 
Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) study. 
Circulation 
2015;132:907–915. 
https://doi.org/10.1161/CIRCULATIONAHA.114. 
014092
487. Dukkipati SR, Cuoco F, Kutinsky I, Aryana A, Bahnson TD, Lakkireddy D, et al. 
Pulmonary vein isolation using the visually guided laser balloon: a prospective, multi­
center, and randomized comparison to standard radiofrequency ablation. J Am Coll 
Cardiol 2015;66:1350–1360. https://doi.org/10.1016/j.jacc.2015.07.036
488. Sohara H, Ohe T, Okumura K, Naito S, Hirao K, Shoda M, et al. Hot balloon ablation of 
the pulmonary veins for paroxysmal AF: a multicenter randomized trial in Japan. J Am 
Coll Cardiol 2016;68:2747–2757. https://doi.org/10.1016/j.jacc.2016.10.037
489. Bertaglia E, Senatore G, De Michieli L, De Simone A, Amellone C, Ferretto S, et al. 
Twelve-year follow-up of catheter ablation for atrial fibrillation: a prospective, multi­
center, randomized study. Heart Rhythm 2017;14:486–492. https://doi.org/10.1016/j. 
hrthm.2016.12.023
490. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, et al. Effect of cath­
eter ablation vs medical therapy on quality of life among patients with atrial fibrillation: 
the CABANA randomized clinical trial. JAMA 2019;321:1275–1285. https://doi.org/10. 
1001/jama.2019.0692
491. Contreras-Valdes FM, Buxton AE, Josephson ME, Anter E. Atrial fibrillation ablation in 
patients with hypertrophic cardiomyopathy: long-term outcomes and clinical predic­
tors. J Am Coll Cardiol 2015;65:1485–1487. https://doi.org/10.1016/j.jacc.2014.12.063
492. Rozen G, Elbaz-Greener G, Marai I, Andria N, Hosseini SM, Biton Y, et al. Utilization 
and complications of catheter ablation for atrial fibrillation in patients with hyper­
trophic cardiomyopathy. J Am Heart Assoc 2020;9:e015721. https://doi.org/10.1161/ 
JAHA.119.015721
493. Hodges K, Tang A, Rivas CG, Umana-Pizano J, Chemtob R, Desai MY, et al. Surgical 
ablation of atrial fibrillation in hypertrophic obstructive cardiomyopathy: outcomes 
of a tailored surgical approach. J Card Surg 2020;35:2957–2964. https://doi.org/10. 
1111/jocs.14946
494. Meng Y, Zhang Y, Liu P, Zhu C, Lu T, Hu E, et al. Clinical efficacy and safety of 
Cox-Maze IV procedure for atrial fibrillation in patients with hypertrophic obstructive 
cardiomyopathy. Front Cardiovasc Med 2021;8:720950. https://doi.org/10.3389/fcvm. 
2021.720950
495. Zhang HD, Ding L, Weng SX, Zhou B, Ding XT, Hu LX, et al. Characteristics and long- 
term ablation outcomes of supraventricular arrhythmias in hypertrophic cardiomyop­
athy: a 10-year, single-center experience. Front Cardiovasc Med 2021;8:766571. https:// 
doi.org/10.3389/fcvm.2021.766571
496. Cardona-Guarache R, Astrom-Aneq M, Oesterle A, Asirvatham R, Svetlichnaya J, 
Marcus GM, et al. Atrial arrhythmias in patients with arrhythmogenic right ventricular 
cardiomyopathy: prevalence, echocardiographic predictors, and treatment. J 
Cardiovasc Electrophysiol 2019;30:1801–1810. https://doi.org/10.1111/jce.14069
497. Zhao L, Xu K, Jiang W, Zhou L, Wang Y, Zhang X, et al. Long-term outcomes of cath­
eter ablation of atrial fibrillation in dilated cardiomyopathy. Int J Cardiol 2015;190: 
227–232. https://doi.org/10.1016/j.ijcard.2015.04.186
498. Stollberger C, Gatterer E, Finsterer J, Kuck KH, Tilz RR. Repeated radiofrequency ab­
lation of atrial tachycardia in restrictive cardiomyopathy secondary to myofibrillar my­
opathy. J Cardiovasc Electrophysiol 2014;25:905–907. https://doi.org/10.1111/jce.12436
499. Briceno DF, Markman TM, Lupercio F, Romero J, Liang JJ, Villablanca PA, et al. Catheter 
ablation versus conventional treatment of atrial fibrillation in patients with heart failure 
with reduced ejection fraction: a systematic review and meta-analysis of randomized 
controlled trials. J Interv Card Electrophysiol 2018;53:19–29. https://doi.org/10.1007/ 
s10840-018-0425-0
500. Prabhu S, Costello BT, Taylor AJ, Gutman SJ, Voskoboinik A, McLellan AJA, et al. 
Regression of diffuse ventricular fibrosis following restoration of sinus rhythm with 
catheter ablation in patients with atrial fibrillation and systolic dysfunction: a substudy 
of the CAMERA MRI trial. JACC Clin Electrophysiol 2018;4:999–1007. https://doi.org/10. 
1016/j.jacep.2018.04.013
501. Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schluter M, et al. Catheter ablation 
versus best medical therapy in patients with persistent atrial fibrillation and congestive 
heart failure: the randomized AMICA trial. Circ Arrhythm Electrophysiol 2019;12: 
e007731. https://doi.org/10.1161/CIRCEP.119.007731
502. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al. 
Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomat­
ic atrial fibrillation: a randomized trial. JAMA 2005;293:2634–2640. https://doi.org/10. 
1001/jama.293.21.2634
503. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad 
O, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N 
Engl J Med 2012;367:1587–1595. https://doi.org/10.1056/NEJMoa1113566
504. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, et al. 
Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal 
atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014;311:692–700. https://doi. 
org/10.1001/jama.2014.467
505. Nielsen JC, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Pehrson SM, 
et al. Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial 
fibrillation: 5-year outcome in a randomised clinical trial. Heart 2017;103:368–376. 
https://doi.org/10.1136/heartjnl-2016-309781
506. Kuniss M, Pavlovic N, Velagic V, Hermida JS, Healey S, Arena G, et al. Cryoballoon ab­
lation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fib­
rillation. Europace 2021;23:1033–1041. https://doi.org/10.1093/europace/euab029
507. Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A, et al. Randomized 
ablation-based rhythm-control versus rate-control trial in patients with heart failure 
and atrial fibrillation: results from the RAFT-AF trial. Circulation 2022;145: 
1693–1704. https://doi.org/10.1161/CIRCULATIONAHA.121.057095
508. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. 
Aggressive risk factor reduction study for atrial fibrillation and implications for the out­
come of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 2014;64:2222–2231. 
https://doi.org/10.1016/j.jacc.2014.09.028
509. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al. 
Long-term effect of goal-directed weight management in an atrial fibrillation cohort: 
a long-term follow-up study (LEGACY). J Am Coll Cardiol 2015;65:2159–2169. 
https://doi.org/10.1016/j.jacc.2015.03.002
510. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, et al. Impact of 
CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial 
fibrillation: the CARDIO-FIT study. J Am Coll Cardiol 2015;66:985–996. https://doi.org/ 
10.1016/j.jacc.2015.06.488
511. Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M, et al. Obesity and 
the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis 
of 626,603 individuals in 51 studies. JACC Clin Electrophysiol 2015;1:139–152. https:// 
doi.org/10.1016/j.jacep.2015.04.004
512. Trines SA, Stabile G, Arbelo E, Dagres N, Brugada J, Kautzner J, et al. Influence of risk 
factors in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. Pacing Clin 
Electrophysiol 2019;42:1365–1373. https://doi.org/10.1111/pace.13763
513. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, et al. 
Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med 2020;382:20–28. 
https://doi.org/10.1056/NEJMoa1817591
514. Meng L, Tseng CH, Shivkumar K, Ajijola O. Efficacy of stellate ganglion blockade in 
managing electrical storm: a systematic review. JACC Clin Electrophysiol 2017;3: 
942–949. https://doi.org/10.1016/j.jacep.2017.06.006
515. Do DH, Bradfield J, Ajijola OA, Vaseghi M, Le J, Rahman S, et al. Thoracic epidural an­
esthesia can be effective for the short-term management of ventricular tachycardia 
storm. J Am Heart Assoc 2017;6:e007080. https://doi.org/10.1161/JAHA.117.007080
516. Richardson T, Lugo R, Saavedra P, Crossley G, Clair W, Shen S, et al. Cardiac sympath­
ectomy for the management of ventricular arrhythmias refractory to catheter ablation. 
Heart Rhythm 2018;15:56–62. https://doi.org/10.1016/j.hrthm.2017.09.006
517. Price J, Mah DY, Fynn-Thompson FL, Tsirka AE. Successful bilateral thoracoscopic 
sympathectomy for recurrent ventricular arrhythmia in a pediatric patient with hyper­
trophic cardiomyopathy. HeartRhythm Case Rep 2020;6:23–26. https://doi.org/10. 
1016/j.hrcr.2019.10.003
518. Vaseghi M, Barwad P, Malavassi Corrales FJ, Tandri H, Mathuria N, Shah R, et al. 
Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll 
Cardiol 2017;69:3070–3080. https://doi.org/10.1016/j.jacc.2017.04.035
519. Dusi V, Gornbein J, Do DH, Sorg JM, Khakpour H, Krokhaleva Y, et al. Arrhythmic risk 
profile and outcomes of patients undergoing cardiac sympathetic denervation for re­
current monomorphic ventricular tachycardia after ablation. J Am Heart Assoc 2021;10: 
e018371. https://doi.org/10.1161/JAHA.120.018371
520. Krug D, Blanck O, Andratschke N, Guckenberger M, Jumeau R, Mehrhof F, et al. 
Recommendations regarding cardiac stereotactic body radiotherapy for treatment re­
fractory ventricular tachycardia. Heart Rhythm 2021;18:2137–2145. https://doi.org/10. 
1016/j.hrthm.2021.08.004
521. Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, et al. Device com­
plications and inappropriate implantable cardioverter defibrillator shocks in patients 
ESC Guidelines                                                                                                                                                                                          3609


<!-- PAGE 108 -->

### Page 108

with hypertrophic cardiomyopathy. Heart 2009;95:709–714. https://doi.org/10.1136/ 
hrt.2008.150656
522. Orgeron GM, James CA, Te Riele A, Tichnell C, Murray B, Bhonsale A, et al. 
Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular dys­
plasia/cardiomyopathy: predictors of appropriate therapy, outcomes, and complica­
tions. J Am Heart Assoc 2017;6:e006242. https://doi.org/10.1161/JAHA.117.006242
523. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, et al. Prophylactic im­
plantable defibrillator in patients with arrhythmogenic right ventricular cardiomyop­
athy/dysplasia and no prior ventricular fibrillation or sustained ventricular 
tachycardia. 
Circulation 
2010;122:1144–1152. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.109.913871
524. Protonotarios A, Bariani R, Cappelletto C, Pavlou M, Garcia-Garcia A, Cipriani A, et al. 
Importance of genotype for risk stratification in arrhythmogenic right ventricular car­
diomyopathy using the 2019 ARVC risk calculator. Eur Heart J 2022;43:3053–3067. 
https://doi.org/10.1093/eurheartj/ehac235
525. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. 
Hypertrophic cardiomyopathy outcomes I. A novel clinical risk prediction model for 
sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 
2014;35:2010–2020. https://doi.org/10.1093/eurheartj/eht439
526. Jorda P, Bosman LP, Gasperetti A, Mazzanti A, Gourraud JB, Davies B, et al. Arrhythmic 
risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation 
of the arrhythmogenic right ventricular cardiomyopathy risk calculator. Eur Heart J 
2022;43:3041–3052. https://doi.org/10.1093/eurheartj/ehac289
527. Masri A, Altibi AM, Erqou S, Zmaili MA, Saleh A, Al-Adham R, et al. Wearable 
cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a sys­
tematic review and meta-analysis. JACC Clin Electrophysiol 2019;5:152–161. https:// 
doi.org/10.1016/j.jacep.2018.11.011
528. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implan­
table defibrillator study (CIDS): a randomized trial of the implantable cardioverter de­
fibrillator against amiodarone. Circulation 2000;101:1297–1302. https://doi.org/10. 
1161/01.CIR.101.11.1297
529. Antiarrhythmics versus Implantable Defibrillators Investigators. A comparison of 
antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated 
from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–1583. https:// 
doi.org/10.1056/NEJM199711273372202
530. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic 
drug therapy with implantable defibrillators in patients resuscitated from cardiac ar­
rest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748–754. 
https://doi.org/10.1161/01.CIR.102.7.748
531. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. 
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. 
Eur Heart J 2000;21:2071–2078. https://doi.org/10.1053/euhj.2000.2476
532. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after 
cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic car­
diomyopathy. J Am Coll Cardiol 1999;33:1596–1601. https://doi.org/10.1016/S0735- 
1097(99)00056-X
533. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The 
effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J 
Med 2005;352:1539–1549. https://doi.org/10.1056/NEJMoa050496
534. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic car­
diomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989;13: 
1283–1288. https://doi.org/10.1016/0735-1097(89)90302-1
535. Miron A, Lafreniere-Roula M, Steve Fan CP, Armstrong KR, Dragulescu A, Papaz T, 
et al. A validated model for sudden cardiac death risk prediction in pediatric hyper­
trophic cardiomyopathy. Circulation 2020;142:217–229. https://doi.org/10.1161/ 
CIRCULATIONAHA.120.047235
536. Aquaro GD, De Luca A, Cappelletto C, Raimondi F, Bianco F, Botto N, et al. 
Comparison of different prediction models for the indication of implanted cardiover­
ter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy. ESC 
Heart Fail 2020;7:4080–4088. https://doi.org/10.1002/ehf2.13019
537. Baudinaud P, Laredo M, Badenco N, Rouanet S, Waintraub X, Duthoit G, et al. 
External validation of a risk prediction model for ventricular arrhythmias in arrhythmo­
genic right ventricular cardiomyopathy. Can J Cardiol 2021;37:1263–1266. https://doi. 
org/10.1016/j.cjca.2021.02.018
538. Bosman LP, Nielsen Gerlach CL, Cadrin-Tourigny J, Orgeron G, Tichnell C, Murray B, 
et al. Comparing clinical performance of current implantable cardioverter-defibrillator 
implantation recommendations in arrhythmogenic right ventricular cardiomyopathy. 
Europace 2022;24:296–305. https://doi.org/10.1093/europace/euab162
539. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, et al. A new 
prediction model for ventricular arrhythmias in arrhythmogenic right ventricular car­
diomyopathy. Eur Heart J 2022;43:e1–e9. https://doi.org/10.1093/eurheartj/ehac180
540. Kayvanpour E, Sammani A, Sedaghat-Hamedani F, Lehmann DH, Broezel A, 
Koelemenoglu J, et al. A novel risk model for predicting potentially life-threatening ar­
rhythmias in non-ischemic dilated cardiomyopathy (DCM-SVA risk). Int J Cardiol 2021; 
339:75–82. https://doi.org/10.1016/j.ijcard.2021.07.002
541. Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, et al. 
Development and validation of a new risk prediction score for life-threatening ven­
tricular tachyarrhythmias in laminopathies. Circulation 2019;140:293–302. https://doi. 
org/10.1161/CIRCULATIONAHA.118.039410
542. Verstraelen TE, van Lint FHM, Bosman LP, de Brouwer R, Proost VM, Abeln BGS, et al. 
Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers- 
reaching the frontiers of individual risk prediction. Eur Heart J 2021;42:2842–2850. 
https://doi.org/10.1093/eurheartj/ehab294
543. Knops RE, Olde Nordkamp LRA, Delnoy PHM, Boersma LVA, Kuschyk J, El-Chami MF, 
et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med 2020;383: 
526–536. https://doi.org/10.1056/NEJMoa1915932
544. Cardim N, Brito D, Rocha Lopes L, Freitas A, Araujo C, Belo A, et al. The Portuguese 
registry of hypertrophic cardiomyopathy: overall results. Rev Port Cardiol (Engl Ed) 
2018;37:1–10. https://doi.org/10.1016/j.repc.2017.08.005
545. McKenna WJ, Judge DP. Epidemiology of the inherited cardiomyopathies. Nat Rev 
Cardiol 2021;18:22–36. https://doi.org/10.1038/s41569-020-0428-2
546. Pelliccia F, Limongelli G, Autore C, Gimeno-Blanes JR, Basso C, Elliott P. Sex-related 
differences in cardiomyopathies. Int J Cardiol 2019;286:239–243. https://doi.org/10. 
1016/j.ijcard.2018.10.091
547. Perez-Sanchez I, Romero-Puche AJ, Garcia-Molina Saez E, Sabater-Molina M, 
Lopez-Ayala JM, Munoz-Esparza C, et al. Factors influencing the phenotypic expression 
of hypertrophic cardiomyopathy in genetic carriers. Rev Esp Cardiol (Engl Ed) 2018;71: 
146–154. https://doi.org/10.1016/j.rec.2017.06.002
548. Argiro A, Ho C, Day SM, van der Velden J, Cerbai E, Saberi S, et al. Sex-related differ­
ences in genetic cardiomyopathies. J Am Heart Assoc 2022;11:e024947. https://doi.org/ 
10.1161/JAHA.121.024947
549. Shah RA, Asatryan B, Sharaf Dabbagh G, Aung N, Khanji MY, Lopes LR, et al. 
Genotype-first approach I. Frequency, penetrance, and variable expressivity of dilated 
cardiomyopathy-associated putative pathogenic gene variants in UK Biobank partici­
pants. Circulation 2022;146:110–124. https://doi.org/10.1161/CIRCULATIONAHA. 
121.058143
550. de Marvao A, McGurk KA, Zheng SL, Thanaj M, Bai W, Duan J, et al. Phenotypic ex­
pression and outcomes in individuals with rare genetic variants of hypertrophic cardio­
myopathy. J Am Coll Cardiol 2021;78:1097–1110. https://doi.org/10.1016/j.jacc.2021. 
07.017
551. McGurk KA, Zheng SL, Henry A, Josephs K, Edwards M, de Marvao A, et al. 
Correspondence on “ACMG SF v3.0 list for reporting of secondary findings in clinical 
exome and genome sequencing: a policy statement of the American College of Medical 
Genetics and Genomics (ACMG)” by Miller et al. Genet Med 2022;24:744–746. https:// 
doi.org/10.1016/j.gim.2021.10.020
552. Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, et al. Clinical 
course and quality of life in high-risk patients with hypertrophic cardiomyopathy 
and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 2018;11: 
e005820. https://doi.org/10.1161/CIRCEP.117.005820
553. Ingles J, Sarina T, Kasparian N, Semsarian C. Psychological wellbeing and posttraumatic 
stress associated with implantable cardioverter defibrillator therapy in young adults 
with genetic heart disease. Int J Cardiol 2013;168:3779–3784. https://doi.org/10. 
1016/j.ijcard.2013.06.006
554. James CA, Tichnell C, Murray B, Daly A, Sears SF, Calkins H. General and disease- 
specific psychosocial adjustment in patients with arrhythmogenic right ventricular dys­
plasia/cardiomyopathy with implantable cardioverter defibrillators: a large cohort 
study. Circ Cardiovasc Genet 2012;5:18–24. https://doi.org/10.1161/CIRCGENETICS. 
111.960898
555. Rhodes AC, Murray B, Tichnell C, James CA, Calkins H, Sears SF. Quality of life metrics 
in arrhythmogenic right ventricular cardiomyopathy patients: the impact of age, shock 
and sex. Int J Cardiol 2017;248:216–220. https://doi.org/10.1016/j.ijcard.2017.08.026
556. Sweeting J, Ball K, McGaughran J, Atherton J, Semsarian C, Ingles J. Impact of the im­
plantable cardioverter defibrillator on confidence to undertake physical activity in in­
herited heart disease: a cross-sectional study. Eur J Cardiovasc Nurs 2017;16:742–752. 
https://doi.org/10.1177/1474515117715760
557. Sears SF Jr, Conti JB. Quality of life and psychological functioning of icd patients. Heart 
2002;87:488–493. https://doi.org/10.1136/heart.87.5.488
558. Ingles J, Spinks C, Yeates L, McGeechan K, Kasparian N, Semsarian C. Posttraumatic 
stress and prolonged grief after the sudden cardiac death of a young relative. JAMA 
Intern Med 2016;176:402–405. https://doi.org/10.1001/jamainternmed.2015.7808
559. Stiles MK, Wilde AAM, Abrams DJ, Ackerman MJ, Albert CM, Behr ER, et al. 2020 
APHRS/HRS expert consensus statement on the investigation of decedents with sud­
den unexplained death and patients with sudden cardiac arrest, and of their families. 
Heart Rhythm 2021;18:e1–e50. https://doi.org/10.1016/j.hrthm.2020.10.010
560. van den Heuvel LM, Sarina T, Sweeting J, Yeates L, Bates K, Spinks C, et al. A prospect­
ive longitudinal study of health-related quality of life and psychological wellbeing after 
an implantable cardioverter-defibrillator in patients with genetic heart diseases. Heart 
Rhythm O2 2022;3:143–151. https://doi.org/10.1016/j.hroo.2022.02.003
561. Passman R, Subacius H, Ruo B, Schaechter A, Howard A, Sears SF, et al. Implantable 
cardioverter defibrillators and quality of life: results from the defibrillators in


<!-- PAGE 109 -->

### Page 109

nonischemic cardiomyopathy treatment evaluation study. Arch Intern Med 2007;167: 
2226–2232. https://doi.org/10.1001/archinte.167.20.2226
562. Ni SQ, Ni J, Yang N, Wang J. Effect of magnetic nanoparticles on the performance of 
activated sludge treatment system. Bioresour Technol 2013;143:555–561. https://doi. 
org/10.1016/j.biortech.2013.06.041
563. von Kanel R, Baumert J, Kolb C, Cho E-Y, Ladwig K-H. Chronic posttraumatic stress 
and its predictors in patients living with an implantable cardioverter defibrillator. J 
Affect Disord 2011;131:344–352. https://doi.org/10.1016/j.jad.2010.12.002
564. Lewis KB, Carroll SL, Birnie D, Stacey D, Matlock DD. Incorporating patients’ prefer­
ence diagnosis in implantable cardioverter defibrillator decision-making: a review of re­
cent literature. Curr Opin Cardiol 2018;33:42–49. https://doi.org/10.1097/HCO. 
0000000000000464
565. Luiten RC, Ormond K, Post L, Asif IM, Wheeler MT, Caleshu C. Exercise restrictions 
trigger psychological difficulty in active and athletic adults with hypertrophic cardiomy­
opathy. Open Heart 2016;3:e000488. https://doi.org/10.1136/openhrt-2016-000488
566. Subas T, Luiten R, Hanson-Kahn A, Wheeler M, Caleshu C. Evolving decisions: per­
spectives of active and athletic individuals with inherited heart disease who exercise 
against recommendations. J Genet Couns 2019;28:119–129. https://doi.org/10.1007/ 
s10897-018-0297-6
567. Alpert C, Day SM, Saberi S. Sports and exercise in athletes with hypertrophic cardio­
myopathy. Clin Sports Med 2015;34:489–505. https://doi.org/10.1016/j.csm.2015.03. 
005
568. Day SM. Exercise in hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2009;2: 
407–414. https://doi.org/10.1007/s12265-009-9134-5
569. Simon NM. Treating complicated grief. JAMA 2013;310:416–423. https://doi.org/10. 
1001/jama.2013.8614
570. McDonald K, Sharpe L, Yeates L, Semsarian C, Ingles J. Needs analysis of parents fol­
lowing sudden cardiac death in the young. Open Heart 2020;7:e001120. https://doi.org/ 
10.1136/openhrt-2019-001120
571. Wisten A, Zingmark K. Supportive needs of parents confronted with sudden cardiac 
death–a qualitative study. Resuscitation 2007;74:68–74. https://doi.org/10.1016/j. 
resuscitation.2006.11.014
572. O’Donovan CE, Waddell-Smith KE, Skinner JR, Broadbent E. Predictors of β-blocker 
adherence in cardiac inherited disease. Open Heart 2018;5:e000877. https://doi.org/10. 
1136/openhrt-2018-000877
573. Cupples S, Dew MA, Grady KL, De Geest S, Dobbels F, Lanuza D, et al. Report of the 
Psychosocial Outcomes Workgroup of the Nursing and Social Sciences Council of the 
International Society for Heart and Lung Transplantation: present status of research 
on psychosocial outcomes in cardiothoracic transplantation: review and recommenda­
tions for the field. J Heart Lung Transplant 2006;25:716–725. https://doi.org/10.1016/j. 
healun.2006.02.005
574. Aatre RD, Day SM. Psychological issues in genetic testing for inherited cardiovascular 
diseases. 
Circ 
Cardiovasc 
Genet 
2011;4:81–90. 
https://doi.org/10.1161/ 
CIRCGENETICS.110.957365
575. Burns C, James C, Ingles J. Communication of genetic information to families with in­
herited rhythm disorders. Heart Rhythm 2018;15:780–786. https://doi.org/10.1016/j. 
hrthm.2017.11.024
576. Yeates L, Hunt L, Saleh M, Semsarian C, Ingles J. Poor psychological wellbeing particu­
larly in mothers following sudden cardiac death in the young. Eur J Cardiovasc Nurs 
2013;12:484–491. https://doi.org/10.1177/1474515113485510
577. Karam N, Jabre P, Narayanan K, Sharifzadehgan A, Perier MC, Tennenbaum J, et al. 
Psychological support and medical screening of first-degree relatives of sudden cardiac 
arrest victims. JACC Clin Electrophysiol 2020;6:586–587. https://doi.org/10.1016/j.jacep. 
2020.02.002
578. Kampmann C, Wiethoff CM, Wenzel A, Stolz G, Betancor M, Wippermann CF, et al. 
Normal values of M mode echocardiographic measurements of more than 2000 
healthy infants and children in central Europe. Heart 2000;83:667–672. https://doi. 
org/10.1136/heart.83.6.667
579. Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D’Andrea A, et al. Role of 
multimodality cardiac imaging in the management of patients with hypertrophic car­
diomyopathy: an expert consensus of the European Association of Cardiovascular 
Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 
2015;16:280. https://doi.org/10.1093/ehjci/jeu291
580. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, et al. Prevalence, clinical 
significance, and natural history of left ventricular apical aneurysms in hypertrophic car­
diomyopathy. 
Circulation 
2008;118:1541–1549. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.108.781401
581. Weinsaft JW, Kim HW, Crowley AL, Klem I, Shenoy C, Van Assche L, et al. LV throm­
bus detection by routine echocardiography: insights into performance characteristics 
using delayed enhancement CMR. JACC Cardiovasc Imaging 2011;4:702–712. https://doi. 
org/10.1016/j.jcmg.2011.03.017
582. Brouwer WP, Germans T, Head MC, van der Velden J, Heymans MW, Christiaans I, 
et al. Multiple myocardial crypts on modified long-axis view are a specific finding in pre- 
hypertrophic HCM mutation carriers. Eur Heart J Cardiovasc Imaging 2012;13: 
292–297. https://doi.org/10.1093/ehjci/jes005
583. Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson CM, et al. Prevalence and 
clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc 
Imaging 2012;5:441–447. https://doi.org/10.1161/CIRCIMAGING.112.972760
584. Spirito P, Autore C, Rapezzi C, Bernabo P, Badagliacca R, Maron MS, et al. Syncope and 
risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009;119: 
1703–1710. https://doi.org/10.1161/CIRCULATIONAHA.108.798314
585. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, et al. 
Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: non­
invasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51: 
1022–1030. https://doi.org/10.1016/j.jacc.2007.10.049
586. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of 
cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC 
Cardiovasc Imaging 2010;3:155–164. https://doi.org/10.1016/j.jcmg.2009.09.023
587. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, et al. 
Hypertrophic cardiomyopathy. The importance of the site and the extent of hyper­
trophy. A review. Prog Cardiovasc Dis 1985;28:1–83. https://doi.org/10.1016/0033- 
0620(85)90024-6
588. Dimitrow PP, Bober M, Michalowska J, Sorysz D. Left ventricular outflow tract gradi­
ent provoked by upright position or exercise in treated patients with hypertrophic 
cardiomyopathy without obstruction at rest. Echocardiography 2009;26:513–520. 
https://doi.org/10.1111/j.1540-8175.2008.00851.x
589. Maron BJ, Gottdiener JS, Bonow RO, Epstein SE. Hypertrophic cardiomyopathy with 
unusual locations of left ventricular hypertrophy undetectable by M-mode echocardi­
ography. Identification by wide-angle two-dimensional echocardiography. Circulation 
1981;63:409–418. https://doi.org/10.1161/01.CIR.63.2.409
590. Elliott P, Gimeno J, Tome M, McKenna W. Left ventricular outflow tract obstruction 
and sudden death in hypertrophic cardiomyopathy. Eur Heart J 2006;27:3073; author 
reply 3073-4. https://doi.org/10.1093/eurheartj/ehl383
591. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. 
Clinical spectrum and treatment. Circulation 1995;92:1680–1692. https://doi.org/10. 
1161/01.CIR.92.7.1680
592. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ven­
tricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl 
J Med 2000;342:1778–1785. https://doi.org/10.1056/NEJM200006153422403
593. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation be­
tween severity of left-ventricular hypertrophy and prognosis in patients with hyper­
trophic cardiomyopathy. Lancet 2001;357:420–424. https://doi.org/10.1016/S0140- 
6736(00)04005-8
594. Kumar S, Van Ness G, Bender A, Yadava M, Minnier J, Ravi S, et al. Standardized goal- 
directed valsalva maneuver for assessment of inducible left ventricular outflow tract 
obstruction in hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2018;31: 
791–798. https://doi.org/10.1016/j.echo.2018.01.022
595. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. 
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow 
tract 
obstruction. 
Circulation 
2006;114:2232–2239. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.106.644682
596. Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, et al. Prevalence of 
exercise-induced left ventricular outflow tract obstruction in symptomatic patients 
with non-obstructive hypertrophic cardiomyopathy. Heart 2008;94:1288–1294. 
https://doi.org/10.1136/hrt.2007.126003
597. Marwick TH, Nakatani S, Haluska B, Thomas JD, Lever HM. Provocation of latent left 
ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic car­
diomyopathy. Am J Cardiol 1995;75:805–809. https://doi.org/10.1016/S0002-9149(99) 
80416-0
598. Reant P, Dufour M, Peyrou J, Reynaud A, Rooryck C, Dijos M, et al. Upright treadmill 
vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symp­
tomatic hypertrophic cardiomyopathy: a pilot study. Eur Heart J Cardiovasc Imaging 
2018;19:31–38. https://doi.org/10.1093/ehjci/jew313
599. Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation 
in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief 
with myectomy. J Am Coll Cardiol 2000;36:2219–2225. https://doi.org/10.1016/ 
S0735-1097(00)01019-6
600. Oki T, Fukuda N, Iuchi A, Tabata T, Tanimoto M, Manabe K, et al. Transesophageal 
echocardiographic evaluation of mitral regurgitation in hypertrophic cardiomyopathy: 
contributions of eccentric left ventricular hypertrophy and related abnormalities of the 
mitral complex. J Am Soc Echocardiogr 1995;8:503–510. https://doi.org/10.1016/S0894- 
7317(05)80338-4
601. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler 
echocardiography in obstructive hypertrophic cardiomyopathy: clarification of patho­
physiology and importance in intraoperative decision making. J Am Coll Cardiol 1992;20: 
42–52. https://doi.org/10.1016/0735-1097(92)90135-A
602. Marwick TH, Stewart WJ, Lever HM, Lytle BW, Rosenkranz ER, Duffy CI, et al. Benefits 
of intraoperative echocardiography in the surgical management of hypertrophic car­
diomyopathy. J Am Coll Cardiol 1992;20:1066–1072. https://doi.org/10.1016/0735- 
1097(92)90359-U
ESC Guidelines                                                                                                                                                                                          3611


<!-- PAGE 110 -->

### Page 110

603. Geske JB, Cullen MW, Sorajja P, Ommen SR, Nishimura RA. Assessment of left ven­
tricular outflow gradient: hypertrophic cardiomyopathy versus aortic valvular stenosis. 
JACC Cardiovasc Interv 2012;5:675–681. https://doi.org/10.1016/j.jcin.2012.01.026
604. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, et al. Noninvasive de­
tection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different 
forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009;53: 
284–291. https://doi.org/10.1016/j.jacc.2008.08.064
605. Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic 
basis of late gadolinium enhancement cardiovascular magnetic resonance in hyper­
trophic cardiomyopathy. J Am Coll Cardiol 2004;43:2260–2264. https://doi.org/10. 
1016/j.jacc.2004.03.035
606. Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, et al. Cardiac 
magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: 
correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll 
Cardiol 2009;54:242–249. https://doi.org/10.1016/j.jacc.2009.04.026
607. White RD, Obuchowski NA, Gunawardena S, Lipchik EO, Lever HM, Van Dyke CW, 
et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: pre­
surgical and postsurgical evaluation by computed tomography magnetic resonance im­
aging. Am J Card Imaging 1996;10:1–13.
608. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, et al. Hypertrophic 
cardiomyopathy: distribution of disease genes, spectrum of mutations, and implica­
tions for a molecular diagnosis strategy. Circulation 2003;107:2227–2232. https://doi. 
org/10.1161/01.CIR.0000066323.15244.54
609. Murphy SL, Anderson JH, Kapplinger JD, Kruisselbrink TM, Gersh BJ, Ommen SR, et al. 
Evaluation of the Mayo Clinic phenotype-based genotype predictor score in patients 
with clinically diagnosed hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2016;9: 
153–161. https://doi.org/10.1007/s12265-016-9681-5
610. Gruner C, Ivanov J, Care M, Williams L, Moravsky G, Yang H, et al. Toronto hyper­
trophic cardiomyopathy genotype score for prediction of a positive genotype in 
hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2013;6:19–26. https://doi.org/ 
10.1161/CIRCGENETICS.112.963363
611. Ingles J, Burns C, Bagnall RD, Lam L, Yeates L, Sarina T, et al. Nonfamilial hypertrophic 
cardiomyopathy: prevalence, natural history, and clinical implications. Circ Cardiovasc 
Genet 2017;10:e001620. https://doi.org/10.1161/CIRCGENETICS.116.001620
612. Ko C, Arscott P, Concannon M, Saberi S, Day SM, Yashar BM, et al. Genetic testing 
impacts the utility of prospective familial screening in hypertrophic cardiomyopathy 
through identification of a nonfamilial subgroup. Genet Med 2018;20:69–75. https:// 
doi.org/10.1038/gim.2017.79
613. Anan R, Shono H, Kisanuki A, Arima S, Nakao S, Tanaka H. Patients with familial hyper­
trophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac 
troponin T gene have variable cardiac morphologies and a favorable prognosis. 
Circulation 1998;98:391–397. https://doi.org/10.1161/01.CIR.98.5.391
614. Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB, et al. Prevalence of 
Anderson–Fabry disease in patients with hypertrophic cardiomyopathy: the 
European Anderson–Fabry Disease survey. Heart 2011;97:1957–1960. https://doi. 
org/10.1136/heartjnl-2011-300364
615. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. 
Recommendations for the evaluation of left ventricular diastolic function by echocar­
diography. Eur J Echocardiogr 2009;10:165–193. https://doi.org/10.1093/ejechocard/ 
jep007
616. Kubo T, Gimeno JR, Bahl A, Steffensen U, Steffensen M, Osman E, et al. Prevalence, 
clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive 
phenotype. J Am Coll Cardiol 2007;49:2419–2426. https://doi.org/10.1016/j.jacc.2007. 
02.061
617. Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F, et al. Prognostic implications of 
the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol 
2009;104:1727–1731. https://doi.org/10.1016/j.amjcard.2009.07.057
618. Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling 
pressures by Doppler echocardiography in patients with hypertrophic cardiomyop­
athy: correlation with direct left atrial pressure measurement at cardiac catheteriza­
tion. Circulation 2007;116:2702–2708. https://doi.org/10.1161/CIRCULATIONAHA. 
107.698985
619. Kitaoka H, Kubo T, Okawa M, Takenaka N, Sakamoto C, Baba Y, et al. Tissue doppler 
imaging and plasma BNP levels to assess the prognosis in patients with hypertrophic 
cardiomyopathy. J Am Soc Echocardiogr 2011;24:1020–1025. https://doi.org/10.1016/ 
j.echo.2011.05.009
620. Ha J-W, Cho J-R, Kim J-M, Ahn J-A, Choi E-Y, Kang S-M, et al. Tissue Doppler-derived 
indices predict exercise capacity in patients with apical hypertrophic cardiomyopathy. 
Chest 2005;128:3428–3433. https://doi.org/10.1378/chest.128.5.3428
621. Spoladore R, Maron MS, D’Amato R, Camici PG, Olivotto I. Pharmacological treat­
ment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J 
2012;33:1724–1733. https://doi.org/10.1093/eurheartj/ehs150
622. Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. 
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy 
(EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. 
Lancet 2020;396:759–769. https://doi.org/10.1016/S0140-6736(20)31792-X
623. Dybro AM, Rasmussen TB, Nielsen RR, Ladefoged BT, Andersen MJ, Jensen MK, et al. 
Effects of metoprolol on exercise hemodynamics in patients with obstructive hyper­
trophic cardiomyopathy. J Am Coll Cardiol 2022;79:1565–1575. https://doi.org/10. 
1016/j.jacc.2022.02.024
624. Wigle ED, Auger P, Marquis Y. Muscular subaortic stenosis. The direct relation be­
tween the intraventricular pressure difference and the left ventricular ejection time. 
Circulation 1967;36:36–44. https://doi.org/10.1161/01.CIR.36.1.36
625. Wigle ED, Henderson M, Rakowski H, Wilansky S. Muscular (hypertrophic) subaortic 
stenosis (hypertrophic obstructive cardiomyopathy): the evidence for true obstruc­
tion to left ventricular outflow. Postgrad Med J 1986;62:531–536. https://doi.org/10. 
1136/pgmj.62.728.531
626. Stauffer JC, Ruiz V, Morard JD. Subaortic obstruction after sildenafil in a patient with 
hypertrophic cardiomyopathy. N Engl J Med 1999;341:700–701. https://doi.org/10. 
1056/NEJM199908263410916
627. Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertroph­
ic subaortic stenosis. I. A description of the disease based upon an analysis of 64 pa­
tients. Circulation 1964;30(Suppl 4):3–119. https://doi.org/10.1161/01.cir.29.5s4.iv-3
628. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fib­
rillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104: 
2517–2524. https://doi.org/10.1161/hc4601.097997
629. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 fo­
cused update of the ESC Guidelines for the management of atrial fibrillation: an update 
of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with 
the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 
33:2719–2747. https://doi.org/10.1093/eurheartj/ehs253
630. European Heart Rhythm Association, European Association for Cardio-Thoracic 
Surgery; Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, et al. Guidelines 
for the management of atrial fibrillation: the Task Force for the management of atrial 
fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31: 
2369–2429. https://doi.org/10.1093/eurheartj/ehq278
631. Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. 
Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomy­
opathy. J Am Coll Cardiol 2021;78:2505–2517. https://doi.org/10.1016/j.jacc.2021.07. 
065
632. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter 
study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomy­
opathy. J Am Coll Cardiol 2005;45:1251–1258. https://doi.org/10.1016/j.jacc.2005.01. 
012
633. Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL, et al. Treatment of ob­
structive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line 
therapy with beta-blockade or verapamil. Circ Heart Fail 2013;6:694–702. https://doi. 
org/10.1161/CIRCHEARTFAILURE.112.000122
634. O’Connor MJ, Miller K, Shaddy RE, Lin KY, Hanna BD, Ravishankar C, et al. 
Disopyramide use in infants and children with hypertrophic cardiomyopathy. Cardiol 
Young 2018;28:530–535. https://doi.org/10.1017/S1047951117002384
635. Adler A, Fourey D, Weissler-Snir A, Hindieh W, Chan RH, Gollob MH, et al. Safety of 
outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy pa­
tients. J Am Heart Assoc 2017;6:e005152. https://doi.org/10.1161/JAHA.116.005152
636. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in pa­
tients with hypertrophic cardiomyopathy. Circulation 1981;64:437–441. https://doi. 
org/10.1161/01.CIR.64.3.437
637. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the 
pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise cap­
acity and symptomatic status. Circulation 1979;60:1208–1213. https://doi.org/10.1161/ 
01.CIR.60.6.1208
638. Bonow RO, Rosing DR, Epstein SE. The acute and chronic effects of verapamil on left 
ventricular function in patients with hypertrophic cardiomyopathy. Eur Heart J 1983; 
4(Suppl F):57–65. https://doi.org/10.1093/eurheartj/4.suppl_F.57
639. Spicer RL, Rocchini AP, Crowley DC, Vasiliades J, Rosenthal A. Hemodynamic effects 
of verapamil in children and adolescents with hypertrophic cardiomyopathy. 
Circulation 1983;67:413–420. https://doi.org/10.1161/01.CIR.67.2.413
640. Rosing DR, Idanpaan-Heikkila U, Maron BJ, Bonow RO, Epstein SE. Use of calcium- 
channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol 1985;55: 
185B–195B. https://doi.org/10.1016/0002-9149(85)90630-7
641. Toshima H, Koga Y, Nagata H, Toyomasu K, Itaya K, Matoba T. Comparable effects of 
oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. 
Double-blind crossover study. Jpn Heart J 1986;27:701–715. https://doi.org/10.1536/ 
ihj.27.701
642. Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhib­
ition in patients with obstructive hypertrophic cardiomyopathy referred for septal re­
duction therapy. J Am Coll Cardiol 2022;80:95–108. https://doi.org/10.1016/j.jacc.2022. 
04.048
643. Desai MY, Owens A, Geske JB, Wolski K, Saberi S, Wang A, et al. Dose-blinded myosin 
inhibition in patients with obstructive hypertrophic cardiomyopathy referred for sep­
tal reduction therapy: outcomes through 32 weeks. Circulation 2023;147:850–863. 
https://doi.org/10.1161/CIRCULATIONAHA.122.062534


<!-- PAGE 111 -->

### Page 111

644. Spertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S, et al. Mavacamten for treat­
ment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): 
health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 
Lancet 2021;397:2467–2475. https://doi.org/10.1016/S0140-6736(21)00763-7
645. Saberi S, Cardim N, Yamani M, Schulz-Menger J, Li W, Florea V, et al. Mavacamten fa­
vorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: 
EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation 2021; 
143:606–608. https://doi.org/10.1161/CIRCULATIONAHA.120.052359
646. Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, et al. Discovery of 
Aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of 
hypertrophic cardiomyopathy. J Med Chem 2021;64:14142–14152. https://doi.org/10. 
1021/acs.jmedchem.1c01290
647. Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, et al. Phase 2 study of 
aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 
2023;81:34–45. https://doi.org/10.1016/j.jacc.2022.10.020
648. Adelman AG, Shah PM, Gramiak R, Wigle ED. Long-term propranolol therapy in mus­
cular subaortic stenosis. Br Heart J 1970;32:804–811. https://doi.org/10.1136/hrt.32.6. 
804
649. Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis. Prevention of 
outflow obstruction with propranolol. Circulation 1968;38:846–858. https://doi.org/ 
10.1161/01.CIR.38.5.846
650. Monda E, Lioncino M, Palmiero G, Franco F, Rubino M, Cirillo A, et al. Bisoprolol for 
treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. 
The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study. Int J 
Cardiol 2022;354:22–28. https://doi.org/10.1016/j.ijcard.2022.03.013
651. Sorajja P, Nishimura RA, Gersh BJ, Dearani JA, Hodge DO, Wiste HJ, et al. Outcome of 
mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a 
long-term follow-up study. J Am Coll Cardiol 2009;54:234–241. https://doi.org/10. 
1016/j.jacc.2009.01.079
652. Cavigli L, Fumagalli C, Maurizi N, Rossi A, Arretini A, Targetti M, et al. Timing of invasive 
septal reduction therapies and outcome of patients with obstructive hypertrophic car­
diomyopathy. Int J Cardiol 2018;273:155–161. https://doi.org/10.1016/j.ijcard.2018.09. 
004
653. Menon SC, Ackerman MJ, Ommen SR, Cabalka AK, Hagler DJ, O’Leary PW, et al. 
Impact of septal myectomy on left atrial volume and left ventricular diastolic filling pat­
terns: an echocardiographic study of young patients with obstructive hypertrophic car­
diomyopathy. J Am Soc Echocardiogr 2008;21:684–688. https://doi.org/10.1016/j.echo. 
2007.11.006
654. Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, et al. Operative 
treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and 
postoperative assessments in 83 patients. Circulation 1975;52:88–102. https://doi. 
org/10.1161/01.CIR.52.1.88
655. Krajcer Z, Leachman RD, Cooley DA, Coronado R. Septal myotomy-myomectomy 
versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up 
in 185 patients. Circulation 1989;80:I57–I64.
656. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical man­
agement of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac 
Cardiovasc Surg 1995;110:195–206;discussion 206-8. https://doi.org/10.1016/S0022- 
5223(05)80026-1
657. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy 
for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996;111: 
586–594. https://doi.org/10.1016/S0022-5223(96)70310-0
658. Schonbeck MH, Brunner-La Rocca HP, Vogt PR, Lachat ML, Jenni R, Hess OM, et al. 
Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myect­
omy. Ann Thorac Surg 1998;65:1207–1214. https://doi.org/10.1016/S0003-4975(98) 
00187-8
659. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B. 
Management of symptomatic hypertrophic obstructive cardiomyopathy–long-term 
results after surgical therapy. Thorac Cardiovasc Surg 1999;47:213–218. https://doi. 
org/10.1055/s-2007-1013146
660. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term 
effects of surgical septal myectomy on survival in patients with obstructive hyper­
trophic cardiomyopathy. J Am Coll Cardiol 2005;46:470–476. https://doi.org/10.1016/ 
j.jacc.2005.02.090
661. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, et al. Clinical and 
echocardiographic determinants of long-term survival after surgical myectomy in ob­
structive hypertrophic cardiomyopathy. Circulation 2005;111:2033–2041. https://doi. 
org/10.1161/01.CIR.0000162460.36735.71
662. Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, et al. 
Current effectiveness and risks of isolated septal myectomy for hypertrophic ob­
structive cardiomyopathy. Ann Thorac Surg 2008;85:127–133. https://doi.org/10. 
1016/j.athoracsur.2007.07.063
663. Desai MY, Bhonsale A, Smedira NG, Naji P, Thamilarasan M, Lytle BW, et al. Predictors 
of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy pa­
tients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation 
2013;128:209–216. https://doi.org/10.1161/CIRCULATIONAHA.112.000849
664. Hodges K, Rivas CG, Aguilera J, Borden R, Alashi A, Blackstone EH, et al. Surgical man­
agement of left ventricular outflow tract obstruction in a specialized hypertrophic ob­
structive cardiomyopathy center. J Thorac Cardiovasc Surg 2019;157:2289–2299. 
https://doi.org/10.1016/j.jtcvs.2018.11.148
665. Nguyen A, Schaff HV, Nishimura RA, Dearani JA, Geske JB, Lahr BD, et al. Does septal 
thickness influence outcome of myectomy for hypertrophic obstructive cardiomyop­
athy? Eur J Cardiothorac Surg 2018;53:582–589. https://doi.org/10.1093/ejcts/ezx398
666. Altarabsheh SE, Dearani JA, Burkhart HM, Schaff HV, Deo SV, Eidem BW, et al. 
Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in chil­
dren and young adults. Ann Thorac Surg 2013;95:663–669;discussion 669. https://doi. 
org/10.1016/j.athoracsur.2012.08.011
667. Iacovoni A, Spirito P, Simon C, Iascone M, Di Dedda G, De Filippo P, et al. A contem­
porary European experience with surgical septal myectomy in hypertrophic cardiomy­
opathy. Eur Heart J 2012;33:2080–2087. https://doi.org/10.1093/eurheartj/ehs064
668. Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK. Surgery insight: septal 
myectomy for obstructive hypertrophic cardiomyopathy–the Mayo Clinic experience. 
Nat Clin Pract Cardiovasc Med 2007;4:503–512. https://doi.org/10.1038/ncpcardio0965
669. Kofflard MJ, van Herwerden LA, Waldstein DJ, Ruygrok P, Boersma E, Taams MA, et al. 
Initial results of combined anterior mitral leaflet extension and myectomy in patients 
with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 1996;28:197–202. 
https://doi.org/10.1016/0735-1097(96)00103-9
670. McIntosh CL, Maron BJ, Cannon RO III, Klues HG. Initial results of combined anterior 
mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ven­
tricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. 
Circulation 1992;86(5 Suppl):II60–II7.
671. Reis RL, Bolton MR, King JF, Pugh DM, Dunn MI, Mason DT. Anterion-superior dis­
placement of papillary muscles producing obstruction and mitral regurgitation in idio­
pathic hypertrophic subaortic stenosis. Operative relief by posterior-superior 
realignment of papillary muscles following ventricular septal myectomy. Circulation 
1974;50(2 Suppl):II181–II188.
672. Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ. 
Long-term clinical and echocardiographic follow-up after surgical correction of hyper­
trophic obstructive cardiomyopathy with extended myectomy and reconstruction of 
the subvalvular mitral apparatus. Circulation 1995;92(9 Suppl):II122–II127. https://doi. 
org/10.1161/01.CIR.92.9.122
673. Kaple RK, Murphy RT, DiPaola LM, Houghtaling PL, Lever HM, Lytle BW, et al. Mitral 
valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and 
surgical outcomes. Ann Thorac Surg 2008;85:1527–1535,1535.e1-2. https://doi.org/ 
10.1016/j.athoracsur.2008.01.061
674. Stassano P, Di Tommaso L, Triggiani D, Contaldo A, Gagliardi C, Spampinato N. Mitral 
valve replacement and limited myectomy for hypertrophic obstructive cardiomyop­
athy: a 25-year follow-up. Tex Heart Inst J 2004;31:137–142.
675. Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK. Extended septal 
myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral pap­
illary muscles or chordae. J Thorac Cardiovasc Surg 2004;127:481–489. https://doi.org/ 
10.1016/j.jtcvs.2003.09.040
676. Boll G, Rowin EJ, Maron BJ, Wang W, Rastegar H, Maron MS. Efficacy of combined 
Cox-Maze IV and ventricular septal myectomy for treatment of atrial fibrillation in pa­
tients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 2020;125:120–126. 
https://doi.org/10.1016/j.amjcard.2019.09.029
677. Laredo M, Khraiche D, Raisky O, Gaudin R, Bajolle F, Maltret A, et al. Long-term results 
of the modified Konno procedure in high-risk children with obstructive hypertrophic 
cardiomyopathy. J Thorac Cardiovasc Surg 2018;156:2285–2294.e2. https://doi.org/10. 
1016/j.jtcvs.2018.06.040
678. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomy­
opathy. Lancet 1995;346:211–214. https://doi.org/10.1016/S0140-6736(95)91267-3
679. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. One-year 
follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive 
cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin 
Res Cardiol 2007;96:864–873. https://doi.org/10.1007/s00392-007-0578-9
680. Fernandes VL, Nielsen C, Nagueh SF, Herrin AE, Slifka C, Franklin J, et al. Follow-up of 
alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the 
Baylor and Medical University of South Carolina experience 1996 to 2007. JACC 
Cardiovasc Interv 2008;1:561–570. https://doi.org/10.1016/j.jcin.2008.07.005
681. Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, et al. Survival 
after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardio­
myopathy (TASH): a 10 year experience. Clin Res Cardiol 2008;97:234–243. https://doi. 
org/10.1007/s00392-007-0616-7
682. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of 
alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008; 
118:131–139. https://doi.org/10.1161/CIRCULATIONAHA.107.738740
683. Sorajja P, Ommen SR, Holmes DR Jr, Dearani JA, Rihal CS, Gersh BJ, et al. Survival after 
alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2012; 
126:2374–2380. https://doi.org/10.1161/CIRCULATIONAHA.111.076257
ESC Guidelines                                                                                                                                                                                          3613


<!-- PAGE 112 -->

### Page 112

684. Veselka J, Krejci J, Tomasov P, Zemanek D. Long-term survival after alcohol septal ab­
lation for hypertrophic obstructive cardiomyopathy: a comparison with general popu­
lation. Eur Heart J 2014;35:2040–2045. https://doi.org/10.1093/eurheartj/eht495
685. Liebregts M, Faber L, Jensen MK, Vriesendorp PA, Januska J, Krejci J, et al. Outcomes of 
alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyop­
athy. JACC Cardiovasc Interv 2017;10:1134–1143. https://doi.org/10.1016/j.jcin.2017.03. 
030
686. Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, et al. Long-term clinical 
outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: 
results from the Euro-ASA registry. Eur Heart J 2016;37:1517–1523. https://doi.org/ 
10.1093/eurheartj/ehv693
687. Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. 
Hospital volume outcomes after septal myectomy and alcohol septal ablation for 
treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient 
Database, 2003–2011. JAMA Cardiol 2016;1:324–332. https://doi.org/10.1001/ 
jamacardio.2016.0252
688. ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, et al. 
Long-term outcome of alcohol septal ablation in patients with obstructive hypertroph­
ic cardiomyopathy: a word of caution. Circ Heart Fail 2010;3:362–369. https://doi.org/ 
10.1161/CIRCHEARTFAILURE.109.862359
689. Durand E, Mousseaux E, Coste P, Pilliere R, Dubourg O, Trinquart L, et al. 
Non-surgical septal myocardial reduction by coil embolization for hypertrophic ob­
structive cardiomyopathy: early and 6 months follow-up. Eur Heart J 2008;29: 
348–355. https://doi.org/10.1093/eurheartj/ehm632
690. Iacob M, Pinte F, Tintoiu I, Cotuna L, Caroescu M, Popa A, et al. Microcoil embolisation 
for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Kardiol 
Pol 2004;61:350–355.
691. Gross CM, Schulz-Menger J, Kramer J, Siegel I, Pilz B, Waigand J, et al. Percutaneous 
transluminal septal artery ablation using polyvinyl alcohol foam particles for septal 
hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 
3-year outcomes. J Endovasc Ther 2004;11:705–711. https://doi.org/10.1583/03- 
1171MR.1
692. Oto A, Aytemir K, Okutucu S, Kaya EB, Deniz A, Cil B, et al. Cyanoacrylate for septal 
ablation in hypertrophic cardiomyopathy. J Interv Cardiol 2011;24:77–84. https://doi. 
org/10.1111/j.1540-8183.2010.00605.x
693. Lawrenz T, Borchert B, Leuner C, Bartelsmeier M, Reinhardt J, Strunk-Mueller C. 
Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: 
acute results and 6 months’ follow-up in 19 patients. J Am Coll Cardiol 2011;57: 
572–576. https://doi.org/10.1016/j.jacc.2010.07.055
694. Keane D, Hynes B, King G, Shiels P, Brown A. Feasibility study of percutaneous trans­
valvular endomyocardial cryoablation for the treatment of hypertrophic obstructive 
cardiomyopathy. J Invasive Cardiol 2007;19:247–251.
695. Panaich SS, Badheka AO, Chothani A, Mehta K, Patel NJ, Deshmukh A, et al. Results of 
ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide 
Inpatient Sample [1998–2010]). Am J Cardiol 2014;114:1390–1395. https://doi.org/ 
10.1016/j.amjcard.2014.07.075
696. Bourque C, Reant P, Bernard A, Leroux L, Bonnet G, Pernot M, et al. Comparison of 
surgical ventricular septal reduction to alcohol septal ablation therapy in patients with 
hypertrophic cardiomyopathy. Am J Cardiol 2022;172:109–114. https://doi.org/10. 
1016/j.amjcard.2022.02.033
697. Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, et al. Updated 
meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomy­
opathy. J Am Coll Cardiol 2010;55:823–834. https://doi.org/10.1016/j.jacc.2009.09.047
698. Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy–alcohol 
septal ablation vs. myectomy: a meta-analysis. Eur Heart J 2009;30:1080–1087. https:// 
doi.org/10.1093/eurheartj/ehp016
699. Zeng Z, Wang F, Dou X, Zhang S, Pu J. Comparison of percutaneous transluminal sep­
tal myocardial ablation versus septal myectomy for the treatment of patients with 
hypertrophic obstructive cardiomyopathy–a meta analysis. Int J Cardiol 2006;112: 
80–84. https://doi.org/10.1016/j.ijcard.2005.10.009
700. Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction ther­
apies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mor­
tality and sudden cardiac death after treatment. Circ Cardiovasc Interv 2010;3:97–104. 
https://doi.org/10.1161/CIRCINTERVENTIONS.109.916676
701. Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H. Survival after al­
cohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. J Am 
Coll Cardiol 2018;72:3087–3094. https://doi.org/10.1016/j.jacc.2018.09.064
702. Nguyen A, Schaff HV, Hang D, Nishimura RA, Geske JB, Dearani JA, et al. Surgical 
myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyop­
athy: a propensity score-matched cohort. J Thorac Cardiovasc Surg 2019;157:306–­
315.e3. https://doi.org/10.1016/j.jtcvs.2018.08.062
703. Bytyci I, Nistri S, Morner S, Henein MY. Alcohol septal ablation versus septal myect­
omy treatment of obstructive hypertrophic cardiomyopathy: a systematic review 
and meta-analysis. J Clin Med 2020;9:3062. https://doi.org/10.3390/jcm9103062
704. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. 
Percutaneous 
septal 
ablation 
for 
symptomatic 
hypertrophic 
obstructive 
cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. 
Int J Cardiol 2007;119:163–167. https://doi.org/10.1016/j.ijcard.2006.07.179
705. Veselka J, Liebregts M, Cooper R, Faber L, Januska J, Kashtanov M, et al. Outcomes of 
patients with hypertrophic obstructive cardiomyopathy and pacemaker implanted 
after alcohol septal ablation. JACC Cardiovasc Interv 2022;15:1910–1917. https://doi. 
org/10.1016/j.jcin.2022.06.034
706. Veselka J, Jensen M, Liebregts M, Cooper RM, Januska J, Kashtanov M, et al. Alcohol 
septal ablation in patients with severe septal hypertrophy. Heart 2020;106:462–466. 
https://doi.org/10.1136/heartjnl-2019-315422
707. Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Kashtanov M, et al. Short- and 
long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomy­
opathy in patients with mild left ventricular hypertrophy: a propensity score matching 
analysis. Eur Heart J 2019;40:1681–1687. https://doi.org/10.1093/eurheartj/ehz110
708. Tumiene B, Graessner H, Mathijssen IM, Pereira AM, Schaefer F, Scarpa M, et al. 
European reference networks: challenges and opportunities. J Community Genet 
2021;12:217–229. https://doi.org/10.1007/s12687-021-00521-8
709. Veselka J, Faber L, Jensen MK, Cooper R, Januska J, Krejci J, et al. Effect of institutional 
experience on outcomes of alcohol septal ablation for hypertrophic obstructive car­
diomyopathy. Can J Cardiol 2018;34:16–22. https://doi.org/10.1016/j.cjca.2017.10.020
710. Cui H, Schaff HV, Wang S, Lahr BD, Rowin EJ, Rastegar H, et al. Survival following al­
cohol septal ablation or septal myectomy for patients with obstructive hypertrophic 
cardiomyopathy. J Am Coll Cardiol 2022;79:1647–1655. https://doi.org/10.1016/j.jacc. 
2022.02.032
711. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical im­
provement after surgical treatment of hypertrophic obstructive cardiomyopathy. 
Circulation 1996;94:467–471. https://doi.org/10.1161/01.CIR.94.3.467
712. Orme NM, Sorajja P, Dearani JA, Schaff HV, Gersh BJ, Ommen SR. Comparison of sur­
gical septal myectomy to medical therapy alone in patients with hypertrophic cardio­
myopathy and syncope. Am J Cardiol 2013;111:388–392. https://doi.org/10.1016/j. 
amjcard.2012.10.014
713. Geske JB, Driver CN, Yogeswaran V, Ommen SR, Schaff HV. Comparison of expected 
and observed outcomes for septal myectomy in hypertrophic obstructive cardiomy­
opathy. Am Heart J 2020;221:159–164. https://doi.org/10.1016/j.ahj.2019.11.020
714. Ferrazzi P, Spirito P, Iacovoni A, Calabrese A, Migliorati K, Simon C, et al. Transaortic 
chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with 
mild septal hypertrophy. J Am Coll Cardiol 2015;66:1687–1696. https://doi.org/10.1016/ 
j.jacc.2015.07.069
715. Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Krejci J, et al. Outcome of alcohol 
septal ablation in mildly symptomatic patients with hypertrophic obstructive cardio­
myopathy: a long-term follow-up study based on the Euro-alcohol septal ablation 
registry. J Am Heart Assoc 2017;6:e005735. https://doi.org/10.1161/JAHA.117.005735
716. Cooley DA, Wukasch DC, Leachman RD. Mitral valve replacement for idiopathic 
hypertrophic subaortic stenosis. Results in 27 patients. J Cardiovasc Surg (Torino) 
1976;17:380–387.
717. Chen MS, McCarthy PM, Lever HM, Smedira NG, Lytle BL. Effectiveness of atrial fib­
rillation surgery in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004;93: 
373–375. https://doi.org/10.1016/j.amjcard.2003.10.025
718. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left at­
rial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021; 
384:2081–2091. https://doi.org/10.1056/NEJMoa2101897
719. Slade AK, Sadoul N, Shapiro L, Chojnowska L, Simon JP, Saumarez RC, et al. DDD pa­
cing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart 1996;75: 
44–49. https://doi.org/10.1136/hrt.75.1.44
720. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, et al. 
Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, 
crossover trial. J Am Coll Cardiol 1997;29:435–441. https://doi.org/10.1016/S0735- 
1097(96)00473-1
721. Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, et al. Pacing in 
hypertrophic obstructive cardiomyopathy. A randomized crossover study. Eur Heart J 
1997;18:1249–1256. https://doi.org/10.1093/oxfordjournals.eurheartj.a015435
722. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. 
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory 
symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, 
double-blind, crossover study (M-PATHY). Circulation 1999;99:2927–2933. https://doi. 
org/10.1161/01.CIR.99.22.2927
723. Mickelsen S, Bathina M, Hsu P, Holmes J, Kusumoto FM. Doppler evaluation of the des­
cending aorta in patients with hypertrophic cardiomyopathy: potential for assessing 
the functional significance of outflow tract gradients and for optimizing pacemaker 
function. J Interv Card Electrophysiol 2004;11:47–53. https://doi.org/10.1023/B:JICE. 
0000035929.84238.2f
724. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 
ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 
2021;42:3427–3520. https://doi.org/10.1093/eurheartj/ehab364
725. Qintar M, Morad A, Alhawasli H, Shorbaji K, Firwana B, Essali A, et al. Pacing for 
drug-refractory or drug-intolerant hypertrophic cardiomyopathy. Cochrane Database 
Syst Rev 2012;2012:CD008523. https://doi.org/10.1002/14651858.CD008523.pub2


<!-- PAGE 113 -->

### Page 113

726. O’Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, et al. 
The long-term survival and the risks and benefits of implantable cardioverter defibril­
lators in patients with hypertrophic cardiomyopathy. Heart 2012;98:116–125. https:// 
doi.org/10.1136/hrt.2010.217182
727. Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, et al. Clinical im­
plications of midventricular obstruction in patients with hypertrophic cardiomyopathy. 
J Am Coll Cardiol 2011;57:2346–2355. https://doi.org/10.1016/j.jacc.2011.02.033
728. Efthimiadis GK, Pagourelias ED, Parcharidou D, Gossios T, Kamperidis V, 
Theofilogiannakos EK, et al. Clinical characteristics and natural history of hypertrophic 
cardiomyopathy with midventricular obstruction. Circ J 2013;77:2366–2374. https:// 
doi.org/10.1253/circj.CJ-12-1561
729. Shah A, Duncan K, Winson G, Chaudhry FA, Sherrid MV. Severe symptoms in mid and 
apical hypertrophic cardiomyopathy. Echocardiography 2009;26:922–933. https://doi. 
org/10.1111/j.1540-8175.2009.00905.x
730. Alfonso F, Frenneaux MP, McKenna WJ. Clinical sustained uniform ventricular tachy­
cardia in hypertrophic cardiomyopathy: association with left ventricular apical aneur­
ysm. Br Heart J 1989;61:178–181. https://doi.org/10.1136/hrt.61.2.178
731. Said SM, Schaff HV, Abel MD, Dearani JA. Transapical approach for apical myectomy 
and relief of midventricular obstruction in hypertrophic cardiomyopathy. J Card Surg 
2012;27:443–448. https://doi.org/10.1111/j.1540-8191.2012.01475.x
732. Kunkala MR, Schaff HV, Nishimura RA, Abel MD, Sorajja P, Dearani JA, et al. 
Transapical approach to myectomy for midventricular obstruction in hypertrophic 
cardiomyopathy. Ann Thorac Surg 2013;96:564–570. https://doi.org/10.1016/j. 
athoracsur.2013.04.073
733. Gao X-J, Kang L-M, Zhang J, Dou K-F, Yuan J-S, Yang Y-J. Mid-ventricular obstructive 
hypertrophic cardiomyopathy with apical aneurysm and sustained ventricular tachy­
cardia: a case report and literature review. Chin Med J (Engl) 2011;124:1754–1757.
734. Takeda I, Sekine M, Matsushima H, Hosomi N, Nakamura T, Ohtsuki T, et al. Two 
cases of cerebral embolism caused by apical thrombi in midventricular obstructive car­
diomyopathy. 
Intern 
Med 
2011;50:1059–1060. 
https://doi.org/10.2169/ 
internalmedicine.50.5079
735. Sato Y, Matsumoto N, Matsuo S, Yoda S, Tani S, Kasamaki Y, et al. Mid-ventricular ob­
structive hypertrophic cardiomyopathy associated with an apical aneurysm: evaluation 
of possible causes of aneurysm formation. Yonsei Med J 2007;48:879–882. https://doi. 
org/10.3349/ymj.2007.48.5.879
736. Papanastasiou CA, Zegkos T, Kokkinidis DG, Parcharidou D, Karamitsos TD, 
Efthimiadis GK. Prognostic role of left ventricular apical aneurysm in hypertrophic car­
diomyopathy: a systematic review and meta-analysis. Int J Cardiol 2021;339:108. https:// 
doi.org/10.1016/j.ijcard.2021.07.025
737. Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic 
cardiomyopathy with left ventricular apical aneurysm: implications for risk stratifica­
tion and management. J Am Coll Cardiol 2017;69:761–773. https://doi.org/10.1016/j. 
jacc.2016.11.063
738. Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivotto I. Pharmacological 
treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. 
Eur J Heart Fail 2016;18:1106–1118. https://doi.org/10.1002/ejhf.541
739. Olivotto I, Camici PG, Merlini PA, Rapezzi C, Patten M, Climent V, et al. Efficacy of ra­
nolazine in patients with symptomatic hypertrophic cardiomyopathy: the 
RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail 
2018;11:e004124. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004124
740. Bourmayan C, Razavi A, Fournier C, Dussaule JC, Baragan J, Gerbaux A, et al. Effect of 
propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echo­
graphic study. Am Heart J 1985;109:1311–1316. https://doi.org/10.1016/0002- 
8703(85)90357-6
741. Alvares RF, Goodwin JF. Non-invasive assessment of diastolic function in hypertrophic 
cardiomyopathy on and off beta adrenergic blocking drugs. Br Heart J 1982;48: 
204–212. https://doi.org/10.1136/hrt.48.3.204
742. Wilmshurst PT, Thompson DS, Juul SM, Jenkins BS, Webb-Peploe MM. Effects of ver­
apamil on haemodynamic function and myocardial metabolism in patients with hyper­
trophic cardiomyopathy. Br Heart J 1986;56:544–553. https://doi.org/10.1136/hrt.56.6. 
544
743. Udelson JE, Bonow RO, O’Gara PT, Maron BJ, Van Lingen A, Bacharach SL, et al. 
Verapamil prevents silent myocardial perfusion abnormalities during exercise in 
asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989;79: 
1052–1060. https://doi.org/10.1161/01.CIR.79.5.1052
744. Pacileo G, De Cristofaro M, Russo MG, Sarubbi B, Pisacane C, Calabro R. 
Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional 
and global left ventricular diastolic function. Can J Cardiol 2000;16:146–152.
745. Cappelli F, Morini S, Pieragnoli P, Targetti M, Stefano P, Marchionni N, et al. Cardiac 
resynchronization therapy for end-stage hypertrophic cardiomyopathy: the need for 
disease-specific criteria. J Am Coll Cardiol 2018;71:464–466. https://doi.org/10.1016/j. 
jacc.2017.11.040
746. Killu AM, Park J-Y, Sara JD, Hodge DO, Gersh BJ, Nishimura RA, et al. Cardiac resyn­
chronization therapy in patients with end-stage hypertrophic cardiomyopathy. 
Europace 2018;20:82–88. https://doi.org/10.1093/europace/euw327
747. Gu M, Jin H, Hua W, Fan X-H, Niu H-X, Tian T, et al. Clinical outcome of cardiac re­
synchronization therapy in dilated-phase hypertrophic cardiomyopathy. J Geriatr 
Cardiol 2017;14:238–244. https://doi.org/10.11909/j.issn.1671-5411.2017.04.002
748. Ahmed I, Loudon BL, Abozguia K, Cameron D, Shivu GN, Phan TT, et al. Biventricular 
pacemaker therapy improves exercise capacity in patients with non-obstructive hyper­
trophic cardiomyopathy via augmented diastolic filling on exercise. Eur J Heart Fail 
2020;22:1263–1272. https://doi.org/10.1002/ejhf.1722
749. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in 
reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006;92: 
785–791. https://doi.org/10.1136/hrt.2005.068577
750. Barriales-Villa R, Centurion-Inda R, Fernandez-Fernandez X, Ortiz MF, Perez-Alvarez 
L, Rodriguez Garcia I, et al. Severe cardiac conduction disturbances and pacemaker im­
plantation in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol 2010;63: 
985–988. https://doi.org/10.1016/S0300-8932(10)70210-4
751. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. N 
Engl J Med 1988;318:1255–1257. https://doi.org/10.1056/NEJM198805123181907
752. Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ. Cardiac 
arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J 
Am Coll Cardiol 1986;7:701–704. https://doi.org/10.1016/S0735-1097(86)80484-3
753. Krikler DM, Davies MJ, Rowland E, Goodwin JF, Evans RC, Shaw DB. Sudden death in 
hypertrophic cardiomyopathy: associated accessory atrioventricular pathways. Br 
Heart J 1980;43:245–251. https://doi.org/10.1136/hrt.43.3.245
754. Joseph S, Balcon R, McDonald L. Syncope in hypertrophic obstructive cardiomyopathy 
due to asystole. Br Heart J 1972;34:974–976. https://doi.org/10.1136/hrt.34.9.974
755. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sud­
den death. Arch Dis Child 1984;59:971–975. https://doi.org/10.1136/adc.59.10.971
756. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. 
Arrhythmia and prognosis in infants, children and adolescents with hypertrophic car­
diomyopathy. J Am Coll Cardiol 1988;11:147–153. https://doi.org/10.1016/0735- 
1097(88)90181-7
757. Ostman-Smith I, Wettrell G, Keeton B, Holmgren D, Ergander U, Gould S, et al. Age- 
and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur 
Heart J 2008;29:1160–1167. https://doi.org/10.1093/eurheartj/ehn122
758. Lipshultz SE, Orav EJ, Wilkinson JD, Towbin JA, Messere JE, Lowe AM, et al. Risk strati­
fication at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data 
from the Pediatric Cardiomyopathy Registry. Lancet 2013;382:1889–1897. https://doi. 
org/10.1016/S0140-6736(13)61685-2
759. Marston NA, Han L, Olivotto I, Day SM, Ashley EA, Michels M, et al. Clinical charac­
teristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J 
2021;42:1988–1996. https://doi.org/10.1093/eurheartj/ehab148
760. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis 
of patients with hypertrophic cardiomyopathy who have epicardial coronary artery 
disease. 
Circulation 
2003;108:2342–2348. 
https://doi.org/10.1161/01.CIR. 
0000097110.55312.BF
761. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyop­
athy in a large community-based population: clinical outcome and identification of risk 
factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003;41: 
987–993. https://doi.org/10.1016/S0735-1097(02)03004-8
762. Maki S, Ikeda H, Muro A, Yoshida N, Shibata A, Koga Y, et al. Predictors of sudden car­
diac death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774–778. https://doi. 
org/10.1016/S0002-9149(98)00455-X
763. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left 
ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to 
the severity of symptoms. J Am Coll Cardiol 2005;45:1076–1080. https://doi.org/10. 
1016/j.jacc.2004.12.067
764. D’Andrea A, Caso P, Severino S, Cuomo S, Capozzi G, Calabro P, et al. Prognostic va­
lue of intra-left ventricular electromechanical asynchrony in patients with hypertrophic 
cardiomyopathy. Eur Heart J 2006;27:1311–1318. https://doi.org/10.1093/eurheartj/ 
ehi688
765. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. 
Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independ­
ent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873–879. 
https://doi.org/10.1016/S0735-1097(03)00827-1
766. Maron BJ, Casey SA, Hurrell DG, Aeppli DM. Relation of left ventricular thickness to 
age and gender in hypertrophic cardiomyopathy. Am J Cardiol 2003;91:1195–1198. 
https://doi.org/10.1016/S0002-9149(03)00266-2
767. Norrish G, Cleary A, Field E, Cervi E, Boleti O, Ziolkowska L, et al. Clinical features and 
natural history of preadolescent nonsyndromic hypertrophic cardiomyopathy. J Am 
Coll Cardiol 2022;79:1986–1997. https://doi.org/10.1016/j.jacc.2022.03.347
768. Gimeno JR, Tome-Esteban M, Lofiego C, Hurtado J, Pantazis A, Mist B, et al. 
Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients 
with hypertrophic cardiomyopathy. Eur Heart J 2009;30:2599–2605. https://doi.org/ 
10.1093/eurheartj/ehp327
769. Dimitrow PP, Chojnowska L, Rudzinski T, Piotrowski W, Ziolkowska L, Wojtarowicz 
A, et al. Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a 
ESC Guidelines                                                                                                                                                                                          3615


<!-- PAGE 114 -->

### Page 114

new model of maximalized follow-up. Eur Heart J 2010;31:3084–3093. https://doi.org/ 
10.1093/eurheartj/ehq308
770. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA III, et al. 
Prevention of sudden cardiac death with implantable cardioverter-defibrillators in chil­
dren and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 2013;61: 
1527–1535. https://doi.org/10.1016/j.jacc.2013.01.037
771. Ostman-Smith I, Sjoberg G, Rydberg A, Larsson P, Fernlund E. Predictors of risk for 
sudden death in childhood hypertrophic cardiomyopathy: the importance of the 
ECG risk score. Open Heart 2017;4:e000658. https://doi.org/10.1136/openhrt-2017- 
000658
772. Ziolkowska L, Turska-Kmiec A, Petryka J, Kawalec W. Predictors of long-term out­
come in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2016;37: 
448–458. https://doi.org/10.1007/s00246-015-1298-y
773. Yetman AT, Hamilton RM, Benson LN, McCrindle BW. Long-term outcome and prog­
nostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 
1998;32:1943–1950. https://doi.org/10.1016/S0735-1097(98)00493-8
774. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value 
of non-sustained ventricular tachycardia and the potential role of amiodarone treat­
ment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based 
patient population. Heart 1998;79:331–336. https://doi.org/10.1136/hrt.79.4.331
775. Jensen MK, Jacobsson L, Almaas V, van Buuren F, Hansen PR, Hansen TF, et al. Influence 
of septal thickness on the clinical outcome after alcohol septal alation in hypertrophic 
cardiomyopathy. Circ Cardiovasc Interv 2016;9:e003214. https://doi.org/10.1161/ 
CIRCINTERVENTIONS.115.003214
776. Nakajima S, Morioka S. [Effects of plasminogen activator on epidermal cell migration]. 
Nihon Hifuka Gakkai Zasshi 1990;100:1199–1201.
777. Balaji S, DiLorenzo MP, Fish FA, Etheridge SP, Aziz PF, Russell MW, et al. Risk factors 
for lethal arrhythmic events in children and adolescents with hypertrophic cardiomy­
opathy and an implantable defibrillator: an international multicenter study. Heart 
Rhythm 2019;16:1462–1467. https://doi.org/10.1016/j.hrthm.2019.04.040
778. Bharucha T, Lee KJ, Daubeney PE, Nugent AW, Turner C, Sholler GF, et al. Sudden 
death in childhood cardiomyopathy: results from a long-term national population- 
based study. J Am Coll Cardiol 2015;65:2302–2310. https://doi.org/10.1016/j.jacc. 
2015.03.552
779. McMahon CJ, Nagueh SF, Pignatelli RH, Denfield SW, Dreyer WJ, Price JF, et al. 
Characterization of left ventricular diastolic function by tissue Doppler imaging and 
clinical status in children with hypertrophic cardiomyopathy. Circulation 2004;109: 
1756–1762. https://doi.org/10.1161/01.CIR.0000124723.16433.31
780. Ostman-Smith I, Wettrell G, Keeton B, Riesenfeld T, Holmgren D, Ergander U. 
Echocardiographic and electrocardiographic identification of those children with 
hypertrophic cardiomyopathy who should be considered at high-risk of dying sudden­
ly. Cardiol Young 2005;15:632–642. https://doi.org/10.1017/S1047951105001824
781. Efthimiadis GK, Parcharidou DG, Giannakoulas G, Pagourelias ED, Charalampidis P, 
Savvopoulos G, et al. Left ventricular outflow tract obstruction as a risk factor for sud­
den cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 2009;104:695–699. 
https://doi.org/10.1016/j.amjcard.2009.04.039
782. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death 
in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 
2000;36:2212–2218. https://doi.org/10.1016/S0735-1097(00)01003-2
783. Louie EK, Maron BJ. Hypertrophic cardiomyopathy with extreme increase in left ven­
tricular wall thickness: functional and morphologic features and clinical significance. J 
Am Coll Cardiol 1986;8:57–65. https://doi.org/10.1016/S0735-1097(86)80092-4
784. Norrish G, Ding T, Field E, Cervi E, Ziolkowska L, Olivotto I, et al. Relationship be­
tween maximal left ventricular wall thickness and sudden cardiac death in childhood 
onset hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 2022;15:e010075. 
https://doi.org/10.1161/CIRCEP.121.010075
785. Williams L, Frenneaux M. Syncope in hypertrophic cardiomyopathy: mechanisms and 
consequences for treatment. Europace 2007;9:817–822. https://doi.org/10.1093/ 
europace/eum093
786. Sediva H, Hnat T, Bonaventura J, Slesarenko J, Veselka J. Head-up tilt test in risk strati­
fication of patients with hypertrophic cardiomyopathy. Int J Angiol 2019;28:245–248. 
https://doi.org/10.1055/s-0039-1688983
787. Moak JP, Leifer ES, Tripodi D, Mohiddin SA, Fananapazir L. Long-term follow-up of 
children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors 
for adverse arrhythmic events. Pediatr Cardiol 2011;32:1096–1105. https://doi.org/ 
10.1007/s00246-011-9967-y
788. Romeo F, Cianfrocca C, Pelliccia F, Colloridi V, Cristofani R, Reale A. Long-term prog­
nosis in children with hypertrophic cardiomyopathy: an analysis of 37 patients aged less 
than or equal to 14 years at diagnosis. Clin Cardiol 1990;13:101–107. https://doi.org/10. 
1002/clc.4960130208
789. Maskatia SA, Decker JA, Spinner JA, Kim JJ, Price JF, Jefferies JL, et al. Restrictive physi­
ology is associated with poor outcomes in children with hypertrophic cardiomyop­
athy. Pediatr Cardiol 2012;33:141–149. https://doi.org/10.1007/s00246-011-0106-6
790. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-related 
differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J 
Am Coll Cardiol 2005;46:480–487. https://doi.org/10.1016/j.jacc.2005.04.043
791. Yan L-R, Zhao S-H, Wang H-Y, Duan F-J, Wang Z-M, Yang Y-J, et al. Clinical charac­
teristics and prognosis of 60 patients with midventricular obstructive hypertrophic 
cardiomyopathy. J Cardiovasc Med (Hagerstown) 2015;16:751–760. https://doi.org/10. 
2459/JCM.0000000000000163
792. Minami Y, Haruki S, Hagiwara N. Phenotypic overlap in hypertrophic cardiomyopathy: 
apical hypertrophy, midventricular obstruction, and apical aneurysm. J Cardiol 2014;64: 
463–469. https://doi.org/10.1016/j.jjcc.2014.03.003
793. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC 
Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyop­
athy: a report of the American College of Cardiology/American Heart Association 
Joint Committee on Clinical Practice Guidelines. Circulation 2020;142:e558–e631. 
https://doi.org/10.1161/CIR.0000000000000937
794. Kamp NJ, Chery G, Kosinski AS, Desai MY, Wazni O, Schmidler GS, et al. Risk strati­
fication using late gadolinium enhancement on cardiac magnetic resonance imaging in 
patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. 
Prog Cardiovasc Dis 2021;66:10–16. https://doi.org/10.1016/j.pcad.2020.11.001
795. Kramer CM, DiMarco JP, Kolm P, Ho CY, Desai MY, Kwong RY, et al. Predictors of 
major atrial fibrillation endpoints in the National Heart, Lung, and Blood Institute 
HCMR. JACC Clin Electrophysiol 2021;7:1376–1386. https://doi.org/10.1016/j.jacep. 
2021.04.004
796. Raja AA, Farhad H, Valente AM, Couce JP, Jefferies JL, Bundgaard H, et al. Prevalence 
and progression of late gadolinium enhancement in children and adolescents with 
hypertrophic cardiomyopathy. Circulation 2018;138:782–792. https://doi.org/10. 
1161/CIRCULATIONAHA.117.032966
797. Petryka-Mazurkiewicz J, Ziolkowska L, Kowalczyk-Domagala M, Mazurkiewicz L, 
Boruc A, Spiewak M, et al. LGE for risk stratification in primary prevention in children 
with HCM. JACC Cardiovasc Imaging 2020;13:2684–2686. https://doi.org/10.1016/j. 
jcmg.2020.06.009
798. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood 
pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990; 
82:1995–2002. https://doi.org/10.1161/01.CIR.82.6.1995
799. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal vascular responses to 
supine exercise in hypertrophic cardiomyopathy. Circulation 1991;84:686–696. https:// 
doi.org/10.1161/01.CIR.84.2.686
800. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective 
prognostic assessment of blood pressure response during exercise in patients with 
hypertrophic cardiomyopathy. Circulation 1997;96:2987–2991. https://doi.org/10. 
1161/01.CIR.96.9.2987
801. Smith ED, Tome J, McGrath R, Kumar S, Concannon M, Day SM, et al. Exercise hemo­
dynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not 
ventricular arrhythmias or sudden cardiac death. Int J Cardiol 2019;274:226–231. 
https://doi.org/10.1016/j.ijcard.2018.07.110
802. Norrish G, Cantarutti N, Pissaridou E, Ridout DA, Limongelli G, Elliott PM, et al. Risk 
factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a system­
atic review and meta-analysis. Eur J Prev Cardiol 2017;24:1220–1230. https://doi.org/10. 
1177/2047487317702519
803. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, et al. 
Characteristics and prognostic implications of myosin missense mutations in familial 
hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108–1114. https://doi.org/ 
10.1056/NEJM199204233261703
804. Anan R, Greve G, Thierfelder L, Watkins H, McKenna WJ, Solomon S, et al. Prognostic 
implications of novel beta cardiac myosin heavy chain gene mutations that cause famil­
ial hypertrophic cardiomyopathy. J Clin Invest 1994;93:280–285. https://doi.org/10. 
1172/JCI116957
805. Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, Brink PA, et al. Sudden 
death due to troponin T mutations. J Am Coll Cardiol 1997;29:549–555. https://doi.org/ 
10.1016/S0735-1097(96)00530-X
806. Ackerman MJ, VanDriest SL, Ommen SR, Will ML, Nishimura RA, Tajik AJ, et al. 
Prevalence and age-dependence of malignant mutations in the beta-myosin heavy 
chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive out­
patient perspective. J Am Coll Cardiol 2002;39:2042–2048. https://doi.org/10.1016/ 
S0735-1097(02)01900-9
807. Garcia-Giustiniani D, Arad M, Ortiz-Genga M, Barriales-Villa R, Fernandez X, 
Rodriguez-Garcia I, et al. Phenotype and prognostic correlations of the converter re­
gion mutations affecting the beta myosin heavy chain. Heart 2015;101:1047–1053. 
https://doi.org/10.1136/heartjnl-2014-307205
808. Van Driest SL, Maron BJ, Ackerman MJ. From malignant mutations to malignant do­
mains: the continuing search for prognostic significance in the mutant genes causing 
hypertrophic cardiomyopathy. Heart 2004;90:7–8. https://doi.org/10.1136/heart.90. 
1.7
809. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardio­
myopathy. Insights provided by comparisons of kindreds with distinct and identical 
beta-myosin heavy chain gene mutations. Circulation 1994;89:22–32. https://doi.org/ 
10.1161/01.CIR.89.1.22


<!-- PAGE 115 -->

### Page 115

810. Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prog­
nosis in hypertrophic cardiomyopathy. Circulation 2010;122:2441–2449;discussion 
2450. https://doi.org/10.1161/CIRCULATIONAHA.110.954446
811. Richard P, Charron P, Leclercq C, Ledeuil C, Carrier L, Dubourg O, et al. 
Homozygotes for a R869G mutation in the beta-myosin heavy chain gene have a se­
vere form of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000;32: 
1575–1583. https://doi.org/10.1006/jmcc.2000.1193
812. Richard P, Isnard R, Carrier L, Dubourg O, Donatien Y, Mathieu B, et al. Double het­
erozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin 
binding protein C genes in a family with hypertrophic cardiomyopathy. J Med Genet 
1999;36:542–545. https://doi.org/10.1136/jmg.36.7.542
813. Jeschke B, Uhl K, Weist B, Schroder D, Meitinger T, Dohlemann C, et al. A high risk 
phenotype of hypertrophic cardiomyopathy associated with a compound genotype 
of two mutated beta-myosin heavy chain genes. Hum Genet 1998;102:299–304. 
https://doi.org/10.1007/s004390050695
814. Kaski JP, Syrris P, Esteban MT, Jenkins S, Pantazis A, Deanfield JE, et al. Prevalence of 
sarcomere protein gene mutations in preadolescent children with hypertrophic car­
diomyopathy. Circ Cardiovasc Genet 2009;2:436–441. https://doi.org/10.1161/ 
CIRCGENETICS.108.821314
815. Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati R, et al. 
Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 
2008;358:1899–1908. https://doi.org/10.1056/NEJMoa075463
816. Lopes LR, Syrris P, Guttmann OP, O’Mahony C, Tang HC, Dalageorgou C, et al. Novel 
genotype-phenotype associations demonstrated by high-throughput sequencing in pa­
tients with hypertrophic cardiomyopathy. Heart 2015;101:294–301. https://doi.org/ 
10.1136/heartjnl-2014-306387
817. van Velzen HG, Vriesendorp PA, Oldenburg RA, van Slegtenhorst MA, van der Velden 
J, Schinkel AFL, et al. Value of genetic testing for the prediction of long-term outcome 
in patients with hypertrophic cardiomyopathy. Am J Cardiol 2016;118:881–887. https:// 
doi.org/10.1016/j.amjcard.2016.06.038
818. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodar­
one in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br 
Heart J 1985;53:412–416. https://doi.org/10.1136/hrt.53.4.412
819. Melacini P, Maron BJ, Bobbo F, Basso C, Tokajuk B, Zucchetto M, et al. Evidence that 
pharmacological strategies lack efficacy for the prevention of sudden death in hyper­
trophic cardiomyopathy. Heart 2007;93:708–710. https://doi.org/10.1136/hrt.2006. 
099416
820. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/ 
AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias 
and the prevention of sudden cardiac death: a report of the American College of 
Cardiology/American Heart Association Task Force and the European Society of 
Cardiology Committee for Practice Guidelines (Writing Committee to Develop 
guidelines for management of patients with ventricular arrhythmias and the prevention 
of sudden cardiac death) developed in collaboration with the European Heart Rhythm 
Association and the Heart Rhythm Society. Europace 2006;8:746–837. https://doi.org/ 
10.1093/europace/eul108
821. Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, Ten Cate FJ, 
et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction 
model for the primary prevention of sudden cardiac death in hypertrophic cardiomy­
opathy. Circ Arrhythm Electrophysiol 2015;8:829–835. https://doi.org/10.1161/CIRCEP. 
114.002553
822. Choi Y-J, Kim H-K, Lee SC, Park J-B, Moon I, Park J, et al. Validation of the hypertrophic 
cardiomyopathy risk-sudden cardiac death calculator in Asians. Heart 2019;105: 
1892–1897. https://doi.org/10.1136/heartjnl-2019-315160
823. O’Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. 
International external validation study of the 2014 European Society of Cardiology 
Guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy 
(EVIDENCE-HCM). 
Circulation 
2018;137:1015–1023. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.117.030437
824. Fernandez A, Quiroga A, Ochoa JP, Mysuta M, Casabe JH, Biagetti M, et al. Validation of 
the 2014 European Society of Cardiology sudden cardiac death risk prediction model 
in hypertrophic cardiomyopathy in a reference center in South America. Am J Cardiol 
2016;118:121–126. https://doi.org/10.1016/j.amjcard.2016.04.021
825. Norrish G, Ding T, Field E, McLeod K, Ilina M, Stuart G, et al. A validation study of the 
European Society of Cardiology guidelines for risk stratification of sudden cardiac 
death in childhood hypertrophic cardiomyopathy. Europace 2019;21:1559–1565. 
https://doi.org/10.1093/europace/euz118
826. Ostman-Smith I, Sjoberg G, Alenius Dahlqvist J, Larsson P, Fernlund E. Sudden cardiac 
death in childhood hypertrophic cardiomyopathy is best predicted by a combination of 
electrocardiogram risk-score and HCMRisk-Kids score. Acta Paediatr 2021;110: 
3105–3115. https://doi.org/10.1111/apa.16045
827. Magnusson P, Gadler F, Liv P, Morner S. Hypertrophic cardiomyopathy and implanta­
ble defibrillators in Sweden: inappropriate shocks and complications requiring surgery. 
J Cardiovasc Electrophysiol 2015;26:1088–1094. https://doi.org/10.1111/jce.12750
828. Norrish G, Chubb H, Field E, McLeod K, Ilina M, Spentzou G, et al. Clinical outcomes 
and programming strategies of implantable cardioverter-defibrillator devices in 
paediatric hypertrophic cardiomyopathy: a UK National Cohort Study. Europace 
2021;23:400–408. https://doi.org/10.1093/europace/euaa307
829. Liebregts M, Faber L, Jensen MK, Vriesendorp PA, Hansen PR, Seggewiss H, et al. 
Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy 
following alcohol septal ablation. Europace 2018;20:f198–f203. https://doi.org/10.1093/ 
europace/eux251
830. Veselka J, Liebregts M, Cooper R, Faber L, Januska J, Kashtanov M, et al. Prediction of 
sudden cardiac arrest after alcohol septal ablation for hypertrophic obstructive cardio­
myopathy: ASA-SCARRE risk score. Am J Cardiol 2022;184:120–126. https://doi.org/ 
10.1016/j.amjcard.2022.08.028
831. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. Implantable 
cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic 
cardiomyopathy. JAMA 2007;298:405–412. https://doi.org/10.1001/jama.298.4.405
832. Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterlinski M, Maciag A, et al. 
Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: 
efficacy and complications of the therapy in long-term follow-up. J Cardiovasc 
Electrophysiol 2010;21:883–889. https://doi.org/10.1111/j.1540-8167.2009.01716.x
833. Norrish G, Qu C, Field E, Cervi E, Khraiche D, Klaassen S, et al. External validation of 
the HCM Risk-Kids model for predicting sudden cardiac death in childhood hyper­
trophic cardiomyopathy. Eur J Prev Cardiol 2022;29:678–686. https://doi.org/10.1093/ 
eurjpc/zwab181
834. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical pro­
file and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ 
Heart 
Fail 
2008;1:184–191. 
https://doi.org/10.1161/CIRCHEARTFAILURE.108. 
768119
835. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar 
visualized by cardiovascular magnetic resonance imaging predicts major adverse events 
in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875–887. 
https://doi.org/10.1016/j.jacc.2010.05.007
836. O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic sig­
nificance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010; 
56:867–874. https://doi.org/10.1016/j.jacc.2010.05.010
837. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium en­
hancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc 
Imaging 2012;5:370–377. https://doi.org/10.1016/j.jcmg.2011.11.021
838. Ismail TF, Jabbour A, Gulati A, Mallorie A, Raza S, Cowling TE, et al. Role of late gado­
linium enhancement cardiovascular magnetic resonance in the risk stratification of 
hypertrophic cardiomyopathy. Heart 2014;100:1851–1858. https://doi.org/10.1136/ 
heartjnl-2013-305471
839. Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial fibrosis on car­
diac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a 
meta-analysis. Heart 2015;101:1406–1411. https://doi.org/10.1136/heartjnl-2015- 
307682
840. Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, et al. Late gadolin­
ium enhancement in patients with hypertrophic cardiomyopathy and preserved systol­
ic function. J Am Coll Cardiol 2018;72:857–870. https://doi.org/10.1016/j.jacc.2018.05. 
060
841. Rowin EJ, Maron MS, Adler A, Albano AJ, Varnava AM, Spears D, et al. Importance of 
newer cardiac magnetic resonance-based risk markers for sudden death prevention in 
hypertrophic cardiomyopathy: an international multicenter study. Heart Rhythm 2022; 
19:782–789. https://doi.org/10.1016/j.hrthm.2021.12.017
842. Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S, et al. Outcomes in pa­
tients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. J 
Am Coll Cardiol 2020;75:3033–3043. https://doi.org/10.1016/j.jacc.2020.04.045
843. Thaman R, Gimeno JR, Murphy RT, Kubo T, Sachdev B, Mogensen J, et al. Prevalence 
and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 
2005;91:920–925. https://doi.org/10.1136/hrt.2003.031161
844. Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H. Risk of sudden death in 
end-stage hypertrophic cardiomyopathy. J Card Fail 2011;17:459–464. https://doi. 
org/10.1016/j.cardfail.2011.01.015
845. Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for calculation of z 
scores of cardiac structures in a large cohort of healthy infants, children, and adoles­
cents: an echocardiographic study. J Am Soc Echocardiogr 2008;21:922–934. https:// 
doi.org/10.1016/j.echo.2008.02.006
846. Chubb H, Simpson JM. The use of Z-scores in paediatric cardiology. Ann Pediatr Cardiol 
2012;5:179–184. https://doi.org/10.4103/0974-2069.99622
847. Sepehrkhouy S, Gho J, van Es R, Harakalova M, de Jonge N, Dooijes D, et al. Distinct 
fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary 
cardiomyopathies. Heart Rhythm 2017;14:1024–1032. https://doi.org/10.1016/j. 
hrthm.2017.03.034
848. Chen W, Qian W, Zhang X, Li D, Qian Z, Xu H, et al. Ring-like late gadolinium en­
hancement for predicting ventricular tachyarrhythmias in non-ischaemic dilated car­
diomyopathy. Eur Heart J Cardiovasc Imaging 2021;22:1130–1138. https://doi.org/10. 
1093/ehjci/jeab117
849. Writing Group, Document Reading Group, EACVI Reviewers: this document was re­
viewed by members of the EACVI Scientific Documents Committee for 2014–2016 
ESC Guidelines                                                                                                                                                                                          3617


<!-- PAGE 116 -->

### Page 116

and 2016–2018. A joint procedural position statement on imaging in cardiac sarcoid­
osis: from the Cardiovascular and Inflammation & Infection Committees of the 
European Association of Nuclear Medicine, the European Association of 
Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Eur Heart 
J Cardiovasc Imaging 2017;18:1073–1089. https://doi.org/10.1093/ehjci/jex146
850. Fatkin D, Huttner IG, Kovacic JC, Seidman JG, Seidman CE. Precision medicine in the 
management of dilated cardiomyopathy: JACC state-of-the-art review. J Am Coll 
Cardiol 2019;74:2921–2938. https://doi.org/10.1016/j.jacc.2019.10.011
851. Merlo M, Cannata A, Sinagra G. Dilated cardiomyopathy: a paradigm of revolution in 
medicine. J Clin Med 2020;9:3385. https://doi.org/10.3390/jcm9113385
852. Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, et al. Heart failure in 
cardiomyopathies: a position paper from the Heart Failure Association of the 
European Society of Cardiology. Eur J Heart Fail 2019;21:553–576. https://doi.org/ 
10.1002/ejhf.1461
853. Verdonschot JAJ, Hazebroek MR, Krapels IPC, Henkens M, Raafs A, Wang P, et al. 
Implications of genetic testing in dilated cardiomyopathy. Circ Genom Precis Med 
2020;13:476–487. https://doi.org/10.1161/CIRCGEN.120.003031
854. Hey TM, Rasmussen TB, Madsen T, Aagaard MM, Harbo M, Molgaard H, et al. Clinical 
and genetic investigations of 109 index patients with dilated cardiomyopathy and 445 
of their relatives. Circ Heart Fail 2020;13:e006701. https://doi.org/10.1161/ 
CIRCHEARTFAILURE.119.006701
855. Cuenca S, Ruiz-Cano MJ, Gimeno-Blanes JR, Jurado A, Salas C, Gomez-Diaz I, et al. 
Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplant­
ation. J Heart Lung Transplant 2016;35:625–635. https://doi.org/10.1016/j.healun.2015. 
12.014
856. van der Meulen MH, Herkert JC, den Boer SL, du Marchie Sarvaas GJ, Blom N, Ten 
Harkel ADJ, et al. Genetic evaluation of a nation-wide Dutch pediatric DCM cohort: 
the use of genetic testing in risk stratification. Circ Genom Precis Med 2022;15: 
e002981. https://doi.org/10.1161/CIRCGEN.120.002981
857. Ware SM, Wilkinson JD, Tariq M, Schubert JA, Sridhar A, Colan SD, et al. Genetic 
causes of cardiomyopathy in children: first results from the pediatric cardiomyopathy 
genes study. J Am Heart Assoc 2021;10:e017731. https://doi.org/10.1161/JAHA.120. 
017731
858. Escobar-Lopez L, Ochoa JP, Royuela A, Verdonschot JAJ, Dal Ferro M, Espinosa MA, 
et al. Clinical risk score to predict pathogenic genotypes in patients with dilated cardio­
myopathy. J Am Coll Cardiol 2022;80:1115–1126. https://doi.org/10.1016/j.jacc.2022. 
06.040
859. Cannata A, Merlo M, Dal Ferro M, Barbati G, Manca P, Paldino A, et al. Association of 
titin variations with late-onset dilated cardiomyopathy. JAMA Cardiol 2022;7:371–377. 
https://doi.org/10.1001/jamacardio.2021.5890
860. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an 
implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 
352:225–237. https://doi.org/10.1056/NEJMoa043399
861. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al. Defibrillator im­
plantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 
375:1221–1230. https://doi.org/10.1056/NEJMoa1608029
862. Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, et al. Age and 
outcomes of primary prevention implantable cardioverter-defibrillators in patients 
with nonischemic systolic heart failure. Circulation 2017;136:1772–1780. https://doi. 
org/10.1161/CIRCULATIONAHA.117.028829
863. Alba AC, Foroutan F, Duero Posada J, Battioni L, Schofield T, Alhussein M, et al. 
Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an 
updated meta-analysis. Heart 2018;104:230–236. https://doi.org/10.1136/heartjnl- 
2017-311430
864. Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, et al. 
Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy 
distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. 
Circulation 2020;141:1872–1884. https://doi.org/10.1161/CIRCULATIONAHA.119. 
044934
865. Barriales-Villa R, Ochoa JP, Larranaga-Moreira JM, Salazar-Mendiguchia J, Diez-Lopez 
C, Restrepo-Cordoba MA, et al. Risk predictors in a Spanish cohort with cardiac lami­
nopathies. The REDLAMINA registry. Rev Esp Cardiol (Engl Ed) 2021;74:216–224. 
https://doi.org/10.1016/j.recesp.2020.03.002
866. Gigli M, Stolfo D, Graw SL, Merlo M, Gregorio C, Nee Chen S, et al. Phenotypic ex­
pression, natural history, and risk stratification of cardiomyopathy caused by filamin 
C truncating variants. Circulation 2021;144:1600–1611. https://doi.org/10.1161/ 
CIRCULATIONAHA.121.053521
867. Akhtar MM, Lorenzini M, Pavlou M, Ochoa JP, O’Mahony C, Restrepo-Cordoba MA, 
et al. Association of left ventricular systolic dysfunction among carriers of truncating 
variants in filamin C with frequent ventricular arrhythmia and end-stage heart failure. 
JAMA Cardiol 2021;6:891–901. https://doi.org/10.1001/jamacardio.2021.1106
868. Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young T-L, et al. Long-term 
clinical outcome of arrhythmogenic right ventricular cardiomyopathy in individuals 
with a p.S358L mutation in TMEM43 following implantable cardioverter defibrillator 
therapy. Circ Arrhythm Electrophysiol 2016;9:e003589. https://doi.org/10.1161/ 
CIRCEP.115.003589
869. Hey TM, Rasmussen TB, Madsen T, Aagaard MM, Harbo M, Molgaard H, et al. 
Pathogenic RBM20-variants are associated with a severe disease expression in male 
patients with dilated cardiomyopathy. Circ Heart Fail 2019;12:e005700. https://doi. 
org/10.1161/CIRCHEARTFAILURE.118.005700
870. Ebert M, Wijnmaalen AP, de Riva M, Trines SA, Androulakis AFA, Glashan CA, et al. 
Prevalence and prognostic impact of pathogenic variants in patients with dilated car­
diomyopathy referred for ventricular tachycardia ablation. JACC Clin Electrophysiol 
2020;6:1103–1114. https://doi.org/10.1016/j.jacep.2020.04.025
871. Rootwelt-Norberg C, Christensen AH, Skjolsvik ET, Chivulescu M, Vissing CR, 
Bundgaard H, et al. Timing of cardioverter-defibrillator implantation in patients with 
cardiac laminopathies–external validation of the LMNA-risk ventricular tachyarrhyth­
mia calculator. Heart Rhythm 2023;20:423–429. https://doi.org/10.1016/j.hrthm.2022. 
11.024
872. Akhtar MM, Lorenzini M, Cicerchia M, Ochoa JP, Hey TM, Sabater Molina M, et al. 
Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating var­
iants in the TTN gene. Circ Heart Fail 2020;13:e006832. https://doi.org/10.1161/ 
CIRCHEARTFAILURE.119.006832
873. Mirelis JG, Escobar-Lopez L, Ochoa JP, Espinosa MA, Villacorta E, Navarro M, et al. 
Combination of late gadolinium enhancement and genotype improves prediction of 
prognosis in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 2022;24: 
1183–1196. https://doi.org/10.1002/ejhf.2514
874. Di Marco A, Brown PF, Bradley J, Nucifora G, Claver E, de Frutos F, et al. Improved risk 
stratification for ventricular arrhythmias and sudden death in patients with nonis­
chemic dilated cardiomyopathy. J Am Coll Cardiol 2021;77:2890–2905. https://doi. 
org/10.1016/j.jacc.2021.04.030
875. Brilakis ES, Shen WK, Hammill SC, Hodge DO, Rea RF, Lexvold NY, et al. Role of pro­
grammed ventricular stimulation and implantable cardioverter defibrillators in patients 
with idiopathic dilated cardiomyopathy and syncope. Pacing Clin Electrophysiol 2001;24: 
1623–1630. https://doi.org/10.1046/j.1460-9592.2001.01623.x
876. Merino JL, Carmona JR, Fernandez-Lozano I, Peinado R, Basterra N, Sobrino JA. 
Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications 
for catheter ablation. Circulation 1998;98:541–546. https://doi.org/10.1161/01.CIR. 
98.6.541
877. Russo V, Papa AA, Rago A, Ciardiello C, Martino AM, Stazi A, et al. Arrhythmic 
CArdiac DEath in MYotonic dystrophy type 1 patients (ACADEMY 1) study: the pre­
dictive role of programmed ventricular stimulation. Europace 2022;24:1148–1155. 
https://doi.org/10.1093/europace/euab282
878. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi 
AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation car­
riers a European cohort study. J Am Coll Cardiol 2012;59:493–500. https://doi.org/10. 
1016/j.jacc.2011.08.078
879. Thuillot M, Maupain C, Gandjbakhch E, Waintraub X, Hidden-Lucet F, Isnard R, et al. 
External validation of risk factors for malignant ventricular arrhythmias in lamin A/C 
mutation carriers. Eur J Heart Fail 2019;21:253–254. https://doi.org/10.1002/ejhf.1384
880. Ader F, De Groote P, Reant P, Rooryck-Thambo C, Dupin-Deguine D, Rambaud C, 
et al. FLNC pathogenic variants in patients with cardiomyopathies: prevalence and 
genotype-phenotype correlations. Clin Genet 2019;96:317–329. https://doi.org/10. 
1111/cge.13594
881. Hodgkinson KA, Connors SP, Merner N, Haywood A, Young T-L, McKenna WJ, et al. 
The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomy­
opathy caused by a p.S358L mutation in TMEM43. Clin Genet 2013;83:321–331. 
https://doi.org/10.1111/j.1399-0004.2012.01919.x
882. van der Zwaag PA, van Rijsingen IA, Asimaki A, Jongbloed JD, van Veldhuisen DJ, 
Wiesfeld AC, et al. Phospholamban R14del mutation in patients diagnosed with dilated 
cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence sup­
porting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 2012;14: 
1199–1207. https://doi.org/10.1093/eurjhf/hfs119
883. van Rijsingen IA, van der Zwaag PA, Groeneweg JA, Nannenberg EA, Jongbloed JD, 
Zwinderman AH, et al. Outcome in phospholamban R14del carriers: results of a large 
multicentre cohort study. Circ Cardiovasc Genet 2014;7:455–465. https://doi.org/10. 
1161/CIRCGENETICS.113.000374
884. Hallstrom AP, Greene HL, Wyse DG, Zipes D, Epstein AE, Domanski MJ, et al. 
Antiarrhythmics Versus Implantable Defibrillators (AVID)–rationale, design, and 
methods. Am J Cardiol 1995;75:470–475. https://doi.org/10.1016/S0002-9149(99) 
80583-9
885. Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non-ischaemic cardio­
myopathy, sudden death and implantable defibrillators: a review and meta-analysis. 
Heart 2018;104:144–150. https://doi.org/10.1136/heartjnl-2016-310850
886. Jorda P, Toro R, Diez C, Salazar-Mendiguchia J, Fernandez-Falgueras A, Perez-Serra A, 
et al. Malignant arrhythmogenic role associated with RBM20: a comprehensive inter­
pretation focused on a personalized approach. J Pers Med 2021;11:130. https://doi. 
org/10.3390/jpm11020130
887. Hasselberg NE, Edvardsen T, Petri H, Berge KE, Leren TP, Bundgaard H, et al. Risk pre­
diction of ventricular arrhythmias and myocardial function in Lamin A/C mutation 
positive subjects. Europace 2014;16:563–571. https://doi.org/10.1093/europace/ 
eut291


<!-- PAGE 117 -->

### Page 117

888. Protonotarios A, Wicks E, Ashworth M, Stephenson E, Guttmann O, Savvatis K, et al. 
Prevalence of (18)F-fluorodeoxyglucose positron emission tomography abnormalities 
in patients with arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol 2019; 
284:99–104. https://doi.org/10.1016/j.ijcard.2018.10.083
889. Casella M, Gasperetti A, Sicuso R, Conte E, Catto V, Sommariva E, et al. Characteristics 
of patients with arrhythmogenic left ventricular cardiomyopathy: combining genetic 
and histopathologic findings. Circ Arrhythm Electrophysiol 2020;13:e009005. https:// 
doi.org/10.1161/CIRCEP.120.009005
890. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy 
and sudden death in young people. N Engl J Med 1988;318:129–133. https://doi.org/10. 
1056/NEJM198801213180301
891. Protonotarios A, Anastasakis A, Panagiotakos DB, Antoniades L, Syrris P, Vouliotis A, 
et al. Arrhythmic risk assessment in genotyped families with arrhythmogenic right ven­
tricular cardiomyopathy. Europace 2016;18:610–616. https://doi.org/10.1093/ 
europace/euv061
892. Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A, Asimaki A, 
et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diag­
nostic criteria and differential diagnosis. Eur Heart J 2020;41:1414–1429. https://doi. 
org/10.1093/eurheartj/ehz669
893. Cipriani A, Bauce B, De Lazzari M, Rigato I, Bariani R, Meneghin S, et al. 
Arrhythmogenic right ventricular cardiomyopathy: characterization of left ventricular 
phenotype and differential diagnosis with dilated cardiomyopathy. J Am Heart Assoc 
2020;9:e014628. https://doi.org/10.1161/JAHA.119.014628
894. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, et al. 
Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. 
J Am Coll Cardiol 2008;52:2175–2187. https://doi.org/10.1016/j.jacc.2008.09.019
895. Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JD, et al. 
Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/ 
cardiomyopathy-associated mutation carriers. Eur Heart J 2015;36:847–855. https:// 
doi.org/10.1093/eurheartj/ehu509
896. Hermida A, Fressart V, Hidden-Lucet F, Donal E, Probst V, Deharo JC, et al. High risk of 
heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mu­
tations in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Heart Fail 
2019;21:792–800. https://doi.org/10.1002/ejhf.1423
897. DeWitt ES, Chandler SF, Hylind RJ, Beausejour Ladouceur V, Blume ED, VanderPluym 
C, et al. Phenotypic manifestations of arrhythmogenic cardiomyopathy in children and 
adolescents. J Am Coll Cardiol 2019;74:346–358. https://doi.org/10.1016/j.jacc.2019.05. 
022
898. Protonotarios A, Elliott PM. Arrhythmogenic right ventricular cardiomyopathy as a 
hidden cause of paediatric myocarditis presentation. Int J Cardiol 2018;271:113–114. 
https://doi.org/10.1016/j.ijcard.2018.06.117
899. Bosman LP, Cadrin-Tourigny J, Bourfiss M, Aliyari Ghasabeh M, Sharma A, Tichnell C, 
et al. Diagnosing arrhythmogenic right ventricular cardiomyopathy by 2010 Task Force 
Criteria: clinical performance and simplified practical implementation. Europace 2020; 
22:787–796. https://doi.org/10.1093/europace/euaa039
900. Platonov PG, Calkins H, Hauer RN, Corrado D, Svendsen JH, Wichter T, et al. High 
interobserver variability in the assessment of epsilon waves: implications for diagnosis 
of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2016;13: 
208–216. https://doi.org/10.1016/j.hrthm.2015.08.031
901. Protonotarios A, Anastasakis A, Tsatsopoulou A, Antoniades L, Prappa E, Syrris P, et al. 
Clinical significance of epsilon waves in arrhythmogenic cardiomyopathy. J Cardiovasc 
Electrophysiol 2015;26:1204–1210. https://doi.org/10.1111/jce.12755
902. Gasperetti A, Cappelletto C, Carrick R, Targetti M, Tichnell C, Martino A, et al. 
Association of premature ventricular contraction burden on serial Holter monitoring 
with arrhythmic risk in patients with arrhythmogenic right ventricular cardiomyopathy. 
JAMA Cardiol 2022;7:378–385. https://doi.org/10.1001/jamacardio.2021.6016
903. Corrado D, Basso C, Leoni L, Tokajuk B, Bauce B, Frigo G, et al. Three-dimensional 
electroanatomic voltage mapping increases accuracy of diagnosing arrhythmogenic 
right ventricular cardiomyopathy/dysplasia. Circulation 2005;111:3042–3050. https:// 
doi.org/10.1161/CIRCULATIONAHA.104.486977
904. Hoogendoorn JC, Sramko M, Venlet J, Siontis KC, Kumar S, Singh R, et al. 
Electroanatomical voltage mapping to distinguish right-sided cardiac sarcoidosis 
from arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol 
2020;6:696–707. https://doi.org/10.1016/j.jacep.2020.02.008
905. Avella A, d’Amati G, Pappalardo A, Re F, Silenzi PF, Laurenzi F, et al. Diagnostic value of 
endomyocardial biopsy guided by electroanatomic voltage mapping in arrhythmogenic 
right ventricular cardiomyopathy/dysplasia. J Cardiovasc Electrophysiol 2008;19: 
1127–1134. https://doi.org/10.1111/j.1540-8167.2008.01228.x
906. Casella M, Dello Russo A, Bergonti M, Catto V, Conte E, Sommariva E, et al. Diagnostic 
yield of electroanatomic voltage mapping in guiding endomyocardial biopsies. 
Circulation 2020;142:1249–1260. https://doi.org/10.1161/CIRCULATIONAHA.120. 
046900
907. Tessier R, Marteau L, Vivien M, Guyomarch B, Thollet A, Fellah I, et al. 
18F-Fluorodeoxyglucose positron emission tomography for the detection of myocar­
dial inflammation in arrhythmogenic left ventricular cardiomyopathy. Circ Cardiovasc 
Imaging 2022;15:e014065. https://doi.org/10.1161/CIRCIMAGING.122.014065
908. Gasperetti A, Rossi VA, Chiodini A, Casella M, Costa S, Akdis D, et al. Differentiating 
hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis 
fulfilling 2010 ARVC Task Force Criteria. Heart Rhythm 2021;18:231–238. https://doi. 
org/10.1016/j.hrthm.2020.09.015
909. Laredo M, Duthoit G, Gandjbakhch E, Redheuil A, Hebert J-L. Total pericardium agen­
esis mistaken for arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 
Cardiovasc Imaging 2018;19:120. https://doi.org/10.1093/ehjci/jex251
910. Castelletti S, Crotti L, Dagradi F, Rella V, Salerno S, Parati G, et al. Partial pericardial 
agenesis mimicking arrhythmogenic right ventricular cardiomyopathy. Clin J Sport 
Med 2020;30:e159–e162. https://doi.org/10.1097/JSM.0000000000000733
911. Brosnan MJ, Te Riele A, Bosman LP, Hoorntje ET, van den Berg MP, Hauer RNW, et al. 
Electrocardiographic features differentiating arrhythmogenic right ventricular cardio­
myopathy from an athlete’s heart. JACC Clin Electrophysiol 2018;4:1613–1625. 
https://doi.org/10.1016/j.jacep.2018.09.008
912. D’Ascenzi F, Solari M, Corrado D, Zorzi A, Mondillo S. Diagnostic differentiation be­
tween arrhythmogenic cardiomyopathy and athlete’s heart by using imaging. JACC 
Cardiovasc Imaging 2018;11:1327–1339. https://doi.org/10.1016/j.jcmg.2018.04.031
913. Rossi VA, Niederseer D, Sokolska JM, Kovacs B, Costa S, Gasperetti A, et al. A novel 
diagnostic score integrating atrial dimensions to differentiate between the athlete’s 
heart and arrhythmogenic right ventricular cardiomyopathy. J Clin Med 2021;10: 
4094. https://doi.org/10.3390/jcm10184094
914. van Tintelen JP, Van Gelder IC, Asimaki A, Suurmeijer AJH, Wiesfeld ACP, Jongbloed 
JDH, et al. Severe cardiac phenotype with right ventricular predominance in a large co­
hort of patients with a single missense mutation in the DES gene. Heart Rhythm 2009;6: 
1574–1583. https://doi.org/10.1016/j.hrthm.2009.07.041
915. Merner ND, Hodgkinson KA, Haywood AFM, Connors S, French VM, Drenckhahn JD, 
et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, le­
thal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J 
Hum Genet 2008;82:809–821. https://doi.org/10.1016/j.ajhg.2008.01.010
916. Costa S, Medeiros-Domingo A, Gasperetti A, Akdis D, Berger W, James CA, et al. 
Impact of genetic variant reassessment on the diagnosis of arrhythmogenic right ven­
tricular cardiomyopathy based on the 2010 Task Force Criteria. Circ Genom Precis Med 
2021;14:e003047. https://doi.org/10.1161/CIRCGEN.120.003047
917. Elliott PM, Anastasakis A, Asimaki A, Basso C, Bauce B, Brooke MA, et al. Definition and 
treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. Eur J 
Heart Fail 2019;21:955–964. https://doi.org/10.1002/ejhf.1534
918. Gasperetti A, Targetti M, Olivotto I. Anti-arrhythmic drugs in arrhythmogenic right 
ventricular cardiomyopathy: the importance of optimal beta-blocker dose titration. 
Int J Cardiol 2021;338:150–151. https://doi.org/10.1016/j.ijcard.2021.06.009
919. Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, et al. 
Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an inter­
national task force consensus statement. Eur Heart J 2015;36:3227–3237. https://doi. 
org/10.1093/eurheartj/ehv162
920. Cappelletto C, Gregorio C, Barbati G, Romani S, De Luca A, Merlo M, et al. 
Antiarrhythmic therapy and risk of cumulative ventricular arrhythmias in arrhythmo­
genic right ventricle cardiomyopathy. Int J Cardiol 2021;334:58–64. https://doi.org/ 
10.1016/j.ijcard.2021.04.069
921. Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, et al. Efficacy 
of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report 
from the North American ARVC Registry. J Am Coll Cardiol 2009;54:609–615. https:// 
doi.org/10.1016/j.jacc.2009.04.052
922. Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efficacy of antiarrhyth­
mic drugs in patients with arrhythmogenic right ventricular disease. Results in patients 
with inducible and noninducible ventricular tachycardia. Circulation 1992;86:29–37. 
https://doi.org/10.1161/01.CIR.86.1.29
923. Ermakov S, Gerstenfeld EP, Svetlichnaya Y, Scheinman MM. Use of flecainide in com­
bination antiarrhythmic therapy in patients with arrhythmogenic right ventricular car­
diomyopathy. Heart Rhythm 2017;14:564–569. https://doi.org/10.1016/j.hrthm.2016. 
12.010
924. Rolland T, Badenco N, Maupain C, Duthoit G, Waintraub X, Laredo M, et al. Safety and 
efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular 
cardiomyopathy. Europace 2022;24:278–284. https://doi.org/10.1093/europace/ 
euab182
925. Daimee UA, Assis FR, Murray B, Tichnell C, James CA, Calkins H, et al. Clinical out­
comes of catheter ablation of ventricular tachycardia in patients with arrhythmogenic 
right ventricular cardiomyopathy: insights from the Johns Hopkins ARVC Program. 
Heart Rhythm 2021;18:1369–1376. https://doi.org/10.1016/j.hrthm.2021.04.028
926. Mathew S, Saguner AM, Schenker N, Kaiser L, Zhang P, Yashuiro Y, et al. Catheter ab­
lation of ventricular tachycardia in patients with arrhythmogenic right ventricular car­
diomyopathy/dysplasia: a sequential approach. J Am Heart Assoc 2019;8:e010365. 
https://doi.org/10.1161/JAHA.118.010365
927. Gandjbakhch E, Laredo M, Berruezo A, Gourraud JB, Sellal JM, Martins R, et al. 
Outcomes after catheter ablation of ventricular tachycardia without implantable 
cardioverter-defibrillator in selected patients with arrhythmogenic right ventricular 
cardiomyopathy. Europace 2021;23:1428–1436. https://doi.org/10.1093/europace/ 
euab172
ESC Guidelines                                                                                                                                                                                          3619


<!-- PAGE 118 -->

### Page 118

928. Assis FR, Krishnan A, Zhou X, James CA, Murray B, Tichnell C, et al. Cardiac sympath­
ectomy for refractory ventricular tachycardia in arrhythmogenic right ventricular car­
diomyopathy. Heart Rhythm 2019;16:1003–1010. https://doi.org/10.1016/j.hrthm. 
2019.01.019
929. Shen L-S, Liu L-M, Zheng L-H, Hu F, Hu Z-C, Liu S-Y, et al. Ablation strategies for ar­
rhythmogenic right ventricular cardiomyopathy: a systematic review and 
meta-analysis. J Geriatr Cardiol 2020;17:694–703. https://doi.org/10.11909/j.issn.1671- 
5411.2020.11.001
930. Romero J, Patel K, Briceno D, Alviz I, Gabr M, Diaz JC, et al. Endo-epicardial ablation vs 
endocardial ablation for the management of ventricular tachycardia in arrhythmogenic 
right ventricular cardiomyopathy: a systematic review and meta-analysis. J Cardiovasc 
Electrophysiol 2020;31:2022–2031. https://doi.org/10.1111/jce.14593
931. Christiansen MK, Haugaa KH, Svensson A, Gilljam T, Madsen T, Hansen J, et al. 
Incidence, predictors, and success of ventricular tachycardia catheter ablation in ar­
rhythmogenic right ventricular cardiomyopathy (from the Nordic ARVC Registry). 
Am J Cardiol 2020;125:803–811. https://doi.org/10.1016/j.amjcard.2019.11.026
932. Briceno DF, Liang JJ, Shirai Y, Markman TM, Chahal A, Tschabrunn C, et al. 
Characterization of structural changes in arrhythmogenic right ventricular cardiomy­
opathy with recurrent ventricular tachycardia after ablation: insights from repeat elec­
troanatomic voltage mapping. Circ Arrhythm Electrophysiol 2020;13:e007611. https:// 
doi.org/10.1161/CIRCEP.119.007611
933. Laredo M, Da Silva L, Extramiana F, Lellouche N, Varlet E, Amet D, et al. Catheter ab­
lation of electrical storm in patients with arrhythmogenic right ventricular cardiomy­
opathy. Heart Rhythm 2020;17:41–48. https://doi.org/10.1016/j.hrthm.2019.06.022
934. Berruezo A, Acosta J, Fernandez-Armenta J, Pedrote A, Barrera A, Arana-Rueda E, 
et al. Safety, long-term outcomes and predictors of recurrence after first-line com­
bined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic car­
diomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective 
multicentre study. Europace 2017;19:607–616. https://doi.org/10.1093/europace/ 
euw212
935. Finocchiaro G, Papadakis M, Robertus JL, Dhutia H, Steriotis AK, Tome M, et al. 
Etiology of sudden death in sports: insights from a United Kingdom regional registry. 
J Am Coll Cardiol 2016;67:2108–2115. https://doi.org/10.1016/j.jacc.2016.02.062
936. de Noronha SV, Sharma S, Papadakis M, Desai S, Whyte G, Sheppard MN. Aetiology of 
sudden cardiac death in athletes in the United Kingdom: a pathological study. Heart 
2009;95:1409–1414. https://doi.org/10.1136/hrt.2009.168369
937. D’Silva A, Papadakis M. Sudden cardiac death in athletes. Eur Cardiol 2015;10:48–53. 
https://doi.org/10.15420/ecr.2015.10.01.48
938. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the 
risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003;42: 
1959–63. https://doi.org/10.1016/j.jacc.2003.03.002
939. Bosman LP, Sammani A, James CA, Cadrin-Tourigny J, Calkins H, van Tintelen JP, et al. 
Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: a sys­
tematic review and meta-analysis. Heart Rhythm 2018;15:1097–1107. https://doi.org/ 
10.1016/j.hrthm.2018.01.031
940. Orgeron GM, Te Riele A, Tichnell C, Wang W, Murray B, Bhonsale A, et al. 
Performance of the 2015 International Task Force Consensus Statement risk stratifi­
cation algorithm for implantable cardioverter-defibrillator placement in arrhythmo­
genic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol 2018; 
11:e005593. https://doi.org/10.1161/CIRCEP.117.005593
941. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 
2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhyth­
mias and the prevention of sudden cardiac death: a report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines 
and the Heart Rhythm Society. J Am Coll Cardiol 2018;72:e91–e220. https://doi.org/ 
10.1016/j.jacc.2017.10.054
942. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, et al. Are 
implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in 
patients with nonischemic cardiomyopathy? Circulation 2006;113:776–782. https:// 
doi.org/10.1161/CIRCULATIONAHA.105.561571
943. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable 
cardioverter-defibrillator therapy for prevention of sudden death in patients with ar­
rhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003;108: 
3084–3091. https://doi.org/10.1161/01.CIR.0000103130.33451.D2
944. Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, et al. Ventricular arrhyth­
mias in the North American multidisciplinary study of ARVC: predictors, characteris­
tics, and treatment. J Am Coll Cardiol 2014;64:119–125. https://doi.org/10.1016/j.jacc. 
2014.04.035
945. Cadrin-Tourigny J, Bosman LP, Wang W, Tadros R, Bhonsale A, Bourfiss M, et al. 
Sudden cardiac death prediction in arrhythmogenic right ventricular cardiomyopathy: 
a multinational collaboration. Circ Arrhythm Electrophysiol 2021;14:e008509. https://doi. 
org/10.1161/CIRCEP.120.008509
946. Platonov PG, Haugaa KH, Bundgaard H, Svensson A, Gilljam T, Hansen J, et al. Primary 
prevention of sudden cardiac death with implantable cardioverter-defibrillator therapy 
in patients with arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2019; 
123:1156–1162. https://doi.org/10.1016/j.amjcard.2018.12.049
947. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, et al. Incidence and 
predictors of implantable cardioverter-defibrillator therapy in patients with arrhyth­
mogenic right ventricular dysplasia/cardiomyopathy undergoing implantable 
cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 
2011;58:1485–1496. https://doi.org/10.1016/j.jacc.2011.06.043
948. Watkins DA, Hendricks N, Shaboodien G, Mbele M, Parker M, Vezi BZ, et al. Clinical 
features, survival experience, and profile of plakophylin-2 gene mutations in partici­
pants of the arrhythmogenic right ventricular cardiomyopathy registry of South 
Africa. Heart Rhythm 2009;6(11 Suppl):S10–S17. https://doi.org/10.1016/j.hrthm. 
2009.08.018
949. Hulot J-S, Jouven X, Empana J-P, Frank R, Fontaine G. Natural history and risk strati­
fication of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 
2004;110:1879–1884. https://doi.org/10.1161/01.CIR.0000143375.93288.82
950. Mazzanti A, Ng K, Faragli A, Maragna R, Chiodaroli E, Orphanou N, et al. 
Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of ar­
rhythmic risk. J Am Coll Cardiol 2016;68:2540–2550. https://doi.org/10.1016/j.jacc.2016. 
09.951
951. Habib G, Bucciarelli-Ducci C, Caforio ALP, Cardim N, Charron P, Cosyns B, et al. 
Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus 
document in collaboration with the “Working Group on myocardial and pericardial 
diseases” of the European Society of Cardiology Endorsed by The Indian Academy 
of Echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:1090–1121. https://doi. 
org/10.1093/ehjci/jex034
952. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T, et al. 
Recommendations for the evaluation of left ventricular diastolic function by echocar­
diography: an update from the American Society of Echocardiography and the 
European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29: 
277–314. https://doi.org/10.1016/j.echo.2016.01.011
953. Fenton MJ, Chubb H, McMahon AM, Rees P, Elliott MJ, Burch M. Heart and heart-lung 
transplantation for idiopathic restrictive cardiomyopathy in children. Heart 2006;92: 
85–89. https://doi.org/10.1136/hrt.2004.049502
954. Saeed M, Liu H, Liang C-H, Wilson MW. Magnetic resonance imaging for characteriz­
ing myocardial diseases. Int J Cardiovasc Imaging 2017;33:1395–1414. https://doi.org/10. 
1007/s10554-017-1127-x
955. Arbustini E, Morbini P, Grasso M, Fasani R, Verga L, Bellini O, et al. Restrictive cardio­
myopathy, atrioventricular block and mild to subclinical myopathy in patients with 
desmin-immunoreactive material deposits. J Am Coll Cardiol 1998;31:645–653. 
https://doi.org/10.1016/S0735-1097(98)00026-6
956. Arbustini E, Grasso M, Rindi G, Arosio P, Gavazzi A, Diegoli M, et al. H and L ferritins in 
myocardium in iron overload. Am J Cardiol 1991;68:1233–1236. https://doi.org/10. 
1016/0002-9149(91)90202-V
957. Koeppen AH, Ramirez RL, Becker AB, Bjork ST, Levi S, Santambrogio P, et al. The 
pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS One 2015;10:e0116396. 
https://doi.org/10.1371/journal.pone.0116396
958. Dixit MP, Greifer I. Nephropathic cystinosis associated with cardiomyopathy: a 
27-year clinical follow-up. BMC Nephrol 2002;3:8. https://doi.org/10.1186/1471- 
2369-3-8
959. Giovannoni I, Callea F, Travaglini L, Amodeo A, Cogo P, Secinaro A, et al. Heart trans­
plant and 2-year follow up in a child with generalized arterial calcification of infancy. Eur 
J Pediatr 2014;173:1735–1740. https://doi.org/10.1007/s00431-014-2447-7
960. Gambarin FI, Disabella E, Narula J, Diegoli M, Grasso M, Serio A, et al. When should 
cardiologists suspect Anderson–Fabry disease? Am J Cardiol 2010;106:1492–1499. 
https://doi.org/10.1016/j.amjcard.2010.07.016
961. Ben-Ami R, Puglisi J, Haider T, Mehta D. The Mount Sinai Hospital clinicalpathological 
conference: a 45-year-old man with Pompe’s disease and dilated cardiomyopathy. Mt 
Sinai J Med 2001;68:205–212.
962. Kawano H, Kawamura K, Kanda M, Ishijima M, Abe K, Hayashi T, et al. 
Histopathological changes of myocytes in restrictive cardiomyopathy. Med Mol 
Morphol 2021;54:289–295. https://doi.org/10.1007/s00795-021-00293-7
963. Kaski JP, Syrris P, Burch M, Tome-Esteban MT, Fenton M, Christiansen M, et al. 
Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac 
sarcomere protein genes. Heart 2008;94:1478–1484. https://doi.org/10.1136/hrt. 
2007.134684
964. Mogensen J, van Tintelen JP, Fokstuen S, Elliott P, van Langen IM, Meder B, et al. The 
current role of next-generation DNA sequencing in routine care of patients with her­
editary cardiovascular conditions: a viewpoint paper of the European Society of 
Cardiology working group on myocardial and pericardial diseases and members of 
the European Society of Human Genetics. Eur Heart J 2015;36:1367–1370. https:// 
doi.org/10.1093/eurheartj/ehv122
965. Menon SC, Michels VV, Pellikka PA, Ballew JD, Karst ML, Herron KJ, et al. Cardiac 
troponin T mutation in familial cardiomyopathy with variable remodeling and restrict­
ive physiology. Clin Genet 2008;74:445–454. https://doi.org/10.1111/j.1399-0004.2008. 
01062.x
966. Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into 
the genetics of cardiomyopathy. J Am Coll Cardiol 2016;68:2871–2886. https://doi. 
org/10.1016/j.jacc.2016.08.079


<!-- PAGE 119 -->

### Page 119

967. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, 
clinical manifestations, diagnosis, and therapy. Circ Res 2017;121:819–837. https://doi. 
org/10.1161/CIRCRESAHA.117.310982
968. Mori H, Kogaki S, Ishida H, Yoshikawa T, Shindo T, Inuzuka R, et al. Outcomes of re­
strictive cardiomyopathy in Japanese children–a retrospective cohort study. Circ J 
2022;86:1943–1949. https://doi.org/10.1253/circj.CJ-21-0706
969. Rivenes SM, Kearney DL, Smith EO, Towbin JA, Denfield SW. Sudden death and car­
diovascular collapse in children with restrictive cardiomyopathy. Circulation 2000;102: 
876–882. https://doi.org/10.1161/01.CIR.102.8.876
970. Mogensen J, Arbustini E. Restrictive cardiomyopathy. Curr Opin Cardiol 2009;24: 
214–220. https://doi.org/10.1097/HCO.0b013e32832a1d2e
971. Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and out­
come of idiopathic restrictive cardiomyopathy. Circulation 2000;101:2490–2496. 
https://doi.org/10.1161/01.CIR.101.21.2490
972. Anderson HN, Cetta F, Driscoll DJ, Olson TM, Ackerman MJ, Johnson JN. Idiopathic 
restrictive cardiomyopathy in children and young adults. Am J Cardiol 2018;121: 
1266–1270. https://doi.org/10.1016/j.amjcard.2018.01.045
973. Walsh MA, Grenier MA, Jefferies JL, Towbin JA, Lorts A, Czosek RJ. Conduction ab­
normalities in pediatric patients with restrictive cardiomyopathy. Circ Heart Fail 
2012;5:267–273. https://doi.org/10.1161/CIRCHEARTFAILURE.111.964395
974. Linhart A, Germain DP, Olivotto I, Akhtar MM, Anastasakis A, Hughes D, et al. An ex­
pert consensus document on the management of cardiovascular manifestations of 
Fabry disease. Eur J Heart Fail 2020;22:1076–1096. https://doi.org/10.1002/ejhf.1960
975. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. 
Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 
2008;105:2812–2817. https://doi.org/10.1073/pnas.0712309105
976. Germain DP. Fabry disease. Orphanet J Rare Dis 2010;5:30. https://doi.org/10.1186/ 
1750-1172-5-30
977. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease re­
visited: management and treatment recommendations for adult patients. Mol Genet 
Metab 2018;123:416–427. https://doi.org/10.1016/j.ymgme.2018.02.014
978. Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. 
X-chromosome inactivation in female patients with Fabry disease. Clin Genet 2016; 
89:44–54. https://doi.org/10.1111/cge.12613
979. Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, et al. 
Screening, diagnosis, and management of patients with Fabry disease: conclusions 
from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies 
Conference. Kidney Int 2017;91:284–293. https://doi.org/10.1016/j.kint.2016.10.004
980. Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, et al. 
Cardiac involvement in Fabry disease: JACC review topic of the week. J Am Coll Cardiol 
2021;77:922–936. https://doi.org/10.1016/j.jacc.2020.12.024
981. Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M, et al. Consensus 
recommendations for diagnosis, management and treatment of Fabry disease in paedi­
atric patients. Clin Genet 2019;96:107–117. https://doi.org/10.1111/cge.13546
982. Bracamonte ER, Kowalewska J, Starr J, Gitomer J, Alpers CE. Iatrogenic phospholipi­
dosis mimicking Fabry disease. Am J Kidney Dis 2006;48:844–850. https://doi.org/10. 
1053/j.ajkd.2006.05.034
983. Politei J, Frabasil J, Durand C, Di Pietrantonio S, Fernandez A, Alberton V, et al. 
Incidental finding of cornea verticillata or lamellar inclusions in kidney biopsy: measure­
ment of lyso-Gb3 in plasma defines between Fabry disease and drug-induced phospho­
lipidosis. Biochim Biophys Acta Mol Basis Dis 2021;1867:165985. https://doi.org/10. 
1016/j.bbadis.2020.165985
984. Mendez HM, Opitz JM. Noonan syndrome: a review. Am J Med Genet 1985;21: 
493–506. https://doi.org/10.1002/ajmg.1320210312
985. Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. 
Best Pract Res Clin Endocrinol Metab 2011;25:161–179. https://doi.org/10.1016/j. 
beem.2010.09.002
986. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet 2013;381: 
333–342. https://doi.org/10.1016/S0140-6736(12)61023-X
987. Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAPK 
pathway: phenotypic spectrum and molecular mechanisms. Ann NY Acad Sci 2010; 
1214:99–121. https://doi.org/10.1111/j.1749-6632.2010.05790.x
988. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. Noonan syn­
drome: clinical features, diagnosis, and management guidelines. Pediatrics 2010;126: 
746–759. https://doi.org/10.1542/peds.2009-3207
989. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. 
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause 
Noonan syndrome. Nat Genet 2001;29:465–468. https://doi.org/10.1038/ng772
990. Limongelli G, Pacileo G, Marino B, Digilio MC, Sarkozy A, Elliott P, et al. Prevalence and 
clinical significance of cardiovascular abnormalities in patients with the LEOPARD syn­
drome. Am J Cardiol 2007;100:736–741. https://doi.org/10.1016/j.amjcard.2007.03.093
991. Limongelli G, Sarkozy A, Pacileo G, Calabro P, Digilio MC, Maddaloni V, et al. 
Genotype-phenotype analysis and natural history of left ventricular hypertrophy in 
LEOPARD syndrome. Am J Med Genet A 2008;146A:620–628. https://doi.org/10. 
1002/ajmg.a.32206
992. Gripp KW, Morse LA, Axelrad M, Chatfield KC, Chidekel A, Dobyns W, et al. Costello 
syndrome: clinical phenotype, genotype, and management guidelines. Am J Med Genet A 
2019;179:1725–1744. https://doi.org/10.1002/ajmg.a.61270
993. Gripp KW, Hopkins E, Sol-Church K, Stabley DL, Axelrad ME, Doyle D, et al. 
Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C. 
Am J Med Genet A 2011;155A:706–716. https://doi.org/10.1002/ajmg.a.33884
994. Pierpont ME, Magoulas PL, Adi S, Kavamura MI, Neri G, Noonan J, et al. 
Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guide­
lines. Pediatrics 2014;134:e1149–e1162. https://doi.org/10.1542/peds.2013-3189
995. Allanson JE, Anneren G, Aoki Y, Armour CM, Bondeson ML, Cave H, et al. 
Cardio-facio-cutaneous syndrome: does genotype predict phenotype? Am J Med 
Genet C Semin Med Genet 2011;157C:129–135. https://doi.org/10.1002/ajmg.c.30295
996. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, et al. Germline KRAS and 
BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 2006;38:294–296. 
https://doi.org/10.1038/ng1749
997. Calcagni G, Gagliostro G, Limongelli G, Unolt M, De Luca E, Digilio MC, et al. Atypical 
cardiac defects in patients with RASopathies: updated data on CARNET study. Birth 
Defects Res 2020;112:725–731. https://doi.org/10.1002/bdr2.1670
998. Hickey EJ, Mehta R, Elmi M, Asoh K, McCrindle BW, Williams WG, et al. Survival im­
plications: hypertrophic cardiomyopathy in Noonan syndrome. Congenit Heart Dis 
2011;6:41–47. https://doi.org/10.1111/j.1747-0803.2010.00465.x
999. Wilkinson JD, Lowe AM, Salbert BA, Sleeper LA, Colan SD, Cox GF, et al. Outcomes in 
children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the 
Pediatric Cardiomyopathy Registry. Am Heart J 2012;164:442–448. https://doi.org/10. 
1016/j.ahj.2012.04.018
1000. Prendiville TW, Gauvreau K, Tworog-Dube E, Patkin L, Kucherlapati RS, Roberts AE, 
et al. Cardiovascular disease in Noonan syndrome. Arch Dis Child 2014;99:629–634. 
https://doi.org/10.1136/archdischild-2013-305047
1001. Cerrato F, Pacileo G, Limongelli G, Gagliardi MG, Santoro G, Digilio MC, et al. A 
standard echocardiographic and tissue Doppler study of morphological and function­
al findings in children with hypertrophic cardiomyopathy compared to those with left 
ventricular hypertrophy in the setting of Noonan and LEOPARD syndromes. Cardiol 
Young 2008;18:575–580. https://doi.org/10.1017/S104795110800320X
1002. Colquitt JL, Noonan JA. Cardiac findings in Noonan syndrome on long-term follow- 
up. Congenit Heart Dis 2014;9:144–150. https://doi.org/10.1111/chd.12102
1003. Ishizawa A, Oho S, Dodo H, Katori T, Homma SI. Cardiovascular abnormalities in 
Noonan syndrome: the clinical findings and treatments. Acta Paediatr Jpn 1996;38: 
84–90. https://doi.org/10.1111/j.1442-200X.1996.tb03444.x
1004. Bertola DR, Castro MAA, Yamamoto GL, Honjo RS, Ceroni JR, Buscarilli MM, et al. 
Phenotype-genotype analysis of 242 individuals with RASopathies: 18-year experi­
ence of a tertiary center in Brazil. Am J Med Genet C Semin Med Genet 2020;184: 
896–911. https://doi.org/10.1002/ajmg.c.31851
1005. Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, et al. Epidemiology 
and cause-specific outcome of hypertrophic cardiomyopathy in children: findings 
from the Pediatric Cardiomyopathy Registry. Circulation 2007;115:773–781. 
https://doi.org/10.1161/CIRCULATIONAHA.106.621185
1006. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic 
cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagon­
ist treatment. J Am Coll Cardiol 1999;34:1813–1822. https://doi.org/10.1016/S0735- 
1097(99)00421-0
1007. Jackson G, Anand IS, Oram S. Asymmetric septal hypertrophy and propranolol treat­
ment in a case of Ullrich–Noonan syndrome. Br Heart J 1979;42:611–614. https://doi. 
org/10.1136/hrt.42.5.611
1008. Chen H, Li X, Liu X, Wang J, Zhang Z, Wu J, et al. Clinical and mutation profile of 
pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results 
from a Chinese cohort. Orphanet J Rare Dis 2019;14:29. https://doi.org/10.1186/ 
s13023-019-1010-z
1009. McCallen LM, Ameduri RK, Denfield SW, Dodd DA, Everitt MD, Johnson JN, et al. 
Cardiac transplantation in children with Noonan syndrome. Pediatr Transplant 
2019;23:e13535. https://doi.org/10.1111/petr.13535
1010. Chen S, Chen L, Jiang Y, Xu H, Sun Y, Shi H, et al. Early outcomes of septal myectomy 
for obstructive hypertrophic cardiomyopathy in children with Noonan syndrome. 
Semin Thorac Cardiovasc Surg 2022;34:655–665. https://doi.org/10.1053/j.semtcvs. 
2021.07.027
1011. Schleihauf J, Cleuziou J, Pabst von Ohain J, Meierhofer C, Stern H, Shehu N, et al. 
Clinical long-term outcome of septal myectomy for obstructive hypertrophic cardio­
myopathy in infants. Eur J Cardiothorac Surg 2018;53:538–544. https://doi.org/10. 
1093/ejcts/ezx369
1012. Holzmann J, Tibby SM, Rosenthal E, Qureshi S, Morgan G, Krasemann T. Results of 
balloon pulmonary valvoplasty in children with Noonan’s syndrome. Cardiol Young 
2018;28:647–652. https://doi.org/10.1017/S1047951117002827
1013. Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA. The natural history of Noonan 
syndrome: a long-term follow-up study. Arch Dis Child 2007;92:128–132. https://doi. 
org/10.1136/adc.2006.104547
ESC Guidelines                                                                                                                                                                                          3621


<!-- PAGE 120 -->

### Page 120

1014. Anderson K, Cnota J, James J, Miller EM, Parrott A, Pilipenko V, et al. Prevalence of 
Noonan spectrum disorders in a pediatric population with valvar pulmonary stenosis. 
Congenit Heart Dis 2019;14:264–273. https://doi.org/10.1111/chd.12721
1015. Ko S, Komuro J, Katsumata Y, Shiraishi Y, Kawakami T, Yamada Y, et al. Peripheral 
pulmonary stenosis with Noonan syndrome treated by balloon pulmonary angio­
plasty. Pulm Circ 2020;10:2045894020954310. https://doi.org/10.1177/2045894020 
954310
1016. Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, et al. Clinical and gen­
etic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 1996;335: 
1169–1175. https://doi.org/10.1056/NEJM199610173351601
1017. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, et al. 
Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet re­
peat expansion. Science 1996;271:1423–1427. https://doi.org/10.1126/science.271. 
5254.1423
1018. Cai K, Frederick RO, Tonelli M, Markley JL. Interactions of iron-bound frataxin with 
ISCU and ferredoxin on the cysteine desulfurase complex leading to Fe-S cluster as­
sembly. J Inorg Biochem 2018;183:107–116. https://doi.org/10.1016/j.jinorgbio.2018. 
03.007
1019. Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G, et al. The 
relationship between trinucleotide (GAA) repeat length and clinical features in 
Friedreich ataxia. Am J Hum Genet 1996;59:554–560.
1020. Delatycki MB, Paris DB, Gardner RJ, Nicholson GA, Nassif N, Storey E, et al. Clinical 
and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet 
1999;87:168–174.https://doi.org/10.1002/(sici)1096-8628(19991119)87:2<168:: 
AID-AJMG8>3.0.CO;2-2
1021. Ackroyd RS, Finnegan JA, Green SH. Friedreich’s ataxia. A clinical review with neuro­
physiological and echocardiographic findings. Arch Dis Child 1984;59:217–221. https:// 
doi.org/10.1136/adc.59.3.217
1022. Harding AE. Friedreich’s ataxia: a clinical and genetic study of 90 families with an ana­
lysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 
1981;104:589–620. https://doi.org/10.1093/brain/104.3.589
1023. Geoffroy G, Barbeau A, Breton G, Lemieux B, Aube M, Leger C, et al. Clinical descrip­
tion and roentgenologic evaluation of patients with Friedreich’s ataxia. Can J Neurol Sci 
1976;3:279–286. https://doi.org/10.1017/S0317167100025464
1024. Hoffman-Zacharska D, Mazurczak T, Zajkowski T, Tataj R, Gorka-Skoczylas P, 
Polatynska K, et al. Friedreich ataxia is not only a GAA repeats expansion disorder: 
implications for molecular testing and counselling. J Appl Genet 2016;57:349–355. 
https://doi.org/10.1007/s13353-015-0331-4
1025. de Silva R, Greenfield J, Cook A, Bonney H, Vallortigara J, Hunt B, et al. Guidelines on 
the diagnosis and management of the progressive ataxias. Orphanet J Rare Dis 2019; 
14:51. https://doi.org/10.1186/s13023-019-1013-9
1026. Raman SV, Phatak K, Hoyle JC, Pennell ML, McCarthy B, Tran T, et al. Impaired myo­
cardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomy­
opathy with metabolic syndrome. Eur Heart J 2011;32:561–567. https://doi.org/10. 
1093/eurheartj/ehq443
1027. Pousset F, Legrand L, Monin ML, Ewenczyk C, Charles P, Komajda M, et al. A 22-year 
follow-up study of long-term cardiac outcome and predictors of survival in Friedreich 
ataxia. JAMA Neurol 2015;72:1334–1341. https://doi.org/10.1001/jamaneurol.2015. 
1855
1028. Meyer C, Schmid G, Gorlitz S, Ernst M, Wilkens C, Wilhelms I, et al. Cardiomyopathy 
in Friedreich’s ataxia–assessment by cardiac MRI. Mov Disord 2007;22:1615–1622. 
https://doi.org/10.1002/mds.21590
1029. Casazza F, Morpurgo M. The varying evolution of Friedreich’s ataxia cardiomyopathy. 
Am J Cardiol 1996;77:895–898. https://doi.org/10.1016/S0002-9149(97)89194-1
1030. Child JS, Perloff JK, Bach PM, Wolfe AD, Perlman S, Kark RA. Cardiac involvement in 
Friedreich’s ataxia: a clinical study of 75 patients. J Am Coll Cardiol 1986;7:1370–1378. 
https://doi.org/10.1016/S0735-1097(86)80159-0
1031. Koeppen AH. Friedreich’s ataxia: pathology, pathogenesis, and molecular genetics. J 
Neurol Sci 2011;303:1–12. https://doi.org/10.1016/j.jns.2011.01.010
1032. Payne RM, Peverill RE. Cardiomyopathy of Friedreich’s ataxia (FRDA). Ir J Med Sci 
2012;181:569–570. https://doi.org/10.1007/s11845-012-0808-7
1033. Payne RM, Wagner GR. Cardiomyopathy in Friedreich ataxia: clinical findings and re­
search. J Child Neurol 2012;27:1179–1186. https://doi.org/10.1177/088307381244 
8535
1034. Weidemann F, Rummey C, Bijnens B, Stork S, Jasaityte R, Dhooge J, et al. The heart in 
Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with 
neurological symptoms. Circulation 2012;125:1626–1634. https://doi.org/10.1161/ 
CIRCULATIONAHA.111.059477
1035. Weidemann F, Liu D, Hu K, Florescu C, Niemann M, Herrmann S, et al. The cardio­
myopathy in Friedreich’s ataxia – new biomarker for staging cardiac involvement. Int J 
Cardiol 2015;194:50–57. https://doi.org/10.1016/j.ijcard.2015.05.074
1036. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A. 
Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: a preliminary study. 
Lancet 1999;354:477–479. https://doi.org/10.1016/S0140-6736(99)01341-0
1037. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose 
idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. 
Lancet Neurol 2007;6:878–886. https://doi.org/10.1016/S1474-4422(07)70220-X
1038. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of 
idebenone in Friedreich ataxia. Arch Neurol 2010;67:941–947. https://doi.org/10. 
1001/archneurol.2010.168
1039. Lagedrost SJ, Sutton MS, Cohen MS, Satou GM, Kaufman BD, Perlman SL, et al. 
Idebenone in Friedreich ataxia cardiomyopathy–results from a 6-month phase III 
study (IONIA). Am Heart J 2011;161:639–645.e1. https://doi.org/10.1016/j.ahj. 
2010.10.038
1040. Cook A, Boesch S, Heck S, Brunt E, Klockgether T, Schols L, et al. Patient-reported 
outcomes in Friedreich’s ataxia after withdrawal from idebenone. Acta Neurol Scand 
2019;139:533–539. https://doi.org/10.1111/ane.13088
1041. van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. 
The natural course of infantile Pompe’s disease: 20 original cases compared with 133 
cases from the literature. Pediatrics 2003;112:332–340. https://doi.org/10.1542/peds. 
112.2.332
1042. Gillette PC, Nihill MR, Singer DB. Electrophysiological mechanism of the short PR 
interval in Pompe disease. Am J Dis Child 1974;128:622–6. https://doi.org/10.1001/ 
archpedi.1974.02110300032005
1043. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan A-S, et al. 
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. 
N Engl J Med 2001;344:1823–1831. https://doi.org/10.1056/NEJM200106143442403
1044. Sternick EB, Oliva A, Magalhaes LP, Gerken LM, Hong K, Santana O, et al. Familial 
pseudo-Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol 2006;17: 
724–732. https://doi.org/10.1111/j.1540-8167.2006.00485.x
1045. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, et al. 
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking 
hypertrophic cardiomyopathy. J Clin Invest 2002;109:357–362. https://doi.org/10. 
1172/JCI0214571
1046. Porto AG, Brun F, Severini GM, Losurdo P, Fabris E, Taylor MRG, et al. Clinical spec­
trum of PRKAG2 syndrome. Circ Arrhythm Electrophysiol 2016;9:e003121. https://doi. 
org/10.1161/CIRCEP.115.003121
1047. Lopez-Sainz A, Dominguez F, Lopes LR, Ochoa JP, Barriales-Villa R, Climent V, et al. 
Clinical features and natural history of PRKAG2 variant cardiac glycogenosis. J Am Coll 
Cardiol 2020;76:186–197. https://doi.org/10.1016/j.jacc.2020.05.029
1048. Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB, et al. Clinical out­
come and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009;301: 
1253–1259. https://doi.org/10.1001/jama.2009.371
1049. Lotan D, Salazar-Mendiguchia J, Mogensen J, Rathore F, Anastasakis A, Kaski J, et al. 
Clinical profile of cardiac involvement in Danon disease: a multicenter European 
registry. Circ Genom Precis Med 2020;13:e003117. https://doi.org/10.1161/ 
CIRCGEN.120.003117
1050. Stevens-Lapsley JE, Kramer LR, Balter JE, Jirikowic J, Boucek D, Taylor M. Functional 
performance and muscle strength phenotypes in men and women with Danon dis­
ease. Muscle Nerve 2010;42:908–914. https://doi.org/10.1002/mus.21811
1051. D’Souza RS, Levandowski C, Slavov D, Graw SL, Allen LA, Adler E, et al. Danon dis­
ease: clinical features, evaluation, and management. Circ Heart Fail 2014;7:843–849. 
https://doi.org/10.1161/CIRCHEARTFAILURE.114.001105
1052. Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Koori T, et al. Primary LAMP-2 defi­
ciency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). 
Nature 2000;406:906–910. https://doi.org/10.1038/35022604
1053. Sternick EB, Oliva A, Gerken LM, Magalhaes L, Scarpelli R, Correia FS, et al. Clinical, 
electrocardiographic, and electrophysiologic characteristics of patients with a fascicu­
loventricular pathway: the role of PRKAG2 mutation. Heart Rhythm 2011;8:58–64. 
https://doi.org/10.1016/j.hrthm.2010.09.081
1054. Murphy RT, Mogensen J, McGarry K, Bahl A, Evans A, Osman E, et al. Adenosine 
monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyop­
athy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 2005; 
45:922–930. https://doi.org/10.1016/j.jacc.2004.11.053
1055. Hahn SH, Kronn D, Leslie ND, Pena LDM, Tanpaiboon P, Gambello MJ, et al. Efficacy, 
safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter 
scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, 
open-label, prospective study. Genet Med 2018;20:1284–1294. https://doi.org/10. 
1038/gim.2018.2
1056. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, et al. Clinical out­
comes after long-term treatment with alglucosidase alfa in infants and children 
with advanced Pompe disease. Genet Med 2009;11:210–219. https://doi.org/10. 
1097/GIM.0b013e31819d0996
1057. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, 
Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of 
heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585–2594. 
https://doi.org/10.1093/eurheartj/ehv338
1058. Damy T, Costes B, Hagege AA, Donal E, Eicher J-C, Slama M, et al. Prevalence and 
clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients


<!-- PAGE 121 -->

### Page 121

with increased left ventricular wall thickness. Eur Heart J 2016;37:1826–1834. https:// 
doi.org/10.1093/eurheartj/ehv583
1059. Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. 
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients 
with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur 
Heart J 2017;38:2879–2887. https://doi.org/10.1093/eurheartj/ehx350
1060. Asif T, Gomez J, Singh V, Doukky R, Nedeltcheva A, Malhotra S. Comparison of pla­
nar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloid­
osis: perils and pitfalls. J Nucl Cardiol 2021;28:104–111. https://doi.org/10.1007/ 
s12350-020-02328-5
1061. Maestro-Benedicto A, Vela P, de Frutos F, Mora N, Pomares A, Gonzalez-Vioque E, 
et al. Frequency of hereditary transthyretin amyloidosis among elderly patients with 
transthyretin cardiomyopathy. Eur J Heart Fail 2022;24:2367–2373. https://doi.org/ 
10.1002/ejhf.2658
1062. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac 
amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009; 
120:1203–1212. https://doi.org/10.1161/CIRCULATIONAHA.108.843334
1063. Lopez-Sainz A, Hernandez-Hernandez A, Gonzalez-Lopez E, Dominguez F, 
Restrepo-Cordoba MA, Cobo-Marcos M, et al. Clinical profile and outcome of car­
diac amyloidosis in a Spanish referral center. Rev Esp Cardiol (Engl Ed) 2021;74: 
149–158. https://doi.org/10.1016/j.rec.2019.12.020
1064. Bianchi G, Zhang Y, Comenzo RL. AL amyloidosis: current chemotherapy and im­
mune therapy treatment strategies: JACC: CardioOncology State-of-the-Art 
Review. JACC CardioOncol 2021;3:467–487. https://doi.org/10.1016/j.jaccao.2021.09. 
003
1065. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective 
evaluation of the morbidity and mortality of wild-type and V122I mutant transthyr­
etin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study 
(TRACS). Am Heart J 2012;164:222–228.e1. https://doi.org/10.1016/j.ahj.2012.04. 
015
1066. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history 
of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel sta­
ging system. J Am Coll Cardiol 2016;68:1014–1020. https://doi.org/10.1016/j.jacc.2016. 
06.033
1067. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, 
et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39: 
2799–2806. https://doi.org/10.1093/eurheartj/ehx589
1068. Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los Santos J, Leedy D, et al. Diuretic 
dose and NYHA functional class are independent predictors of mortality in patients 
with transthyretin cardiac amyloidosis. JACC CardioOncol 2020;2:414–424. https://doi. 
org/10.1016/j.jaccao.2020.06.007
1069. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prog­
nostic staging system for light chain amyloidosis incorporating cardiac biomarkers and 
serum free light chain measurements. J Clin Oncol 2012;30:989–995. https://doi.org/ 
10.1200/JCO.2011.38.5724
1070. Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and val­
idation of a survival staging system incorporating BNP in patients with light chain 
amyloidosis. Blood 2019;133:215–223. https://doi.org/10.1182/blood-2018-06- 
858951
1071. Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloid­
osis: current and emerging management strategies: JACC: CardioOncology 
State-of-the-Art Review. JACC CardioOncol 2021;3:488–505. https://doi.org/10. 
1016/j.jaccao.2021.06.006
1072. Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M. Safety and tolerability of neu­
rohormonal antagonism in cardiac amyloidosis. Eur J Intern Med 2020;80:66–72. 
https://doi.org/10.1016/j.ejim.2020.05.015
1073. Mitrani LR, De Los Santos J, Driggin E, Kogan R, Helmke S, Goldsmith J, et al. 
Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibril­
lation in adults with transthyretin cardiac amyloidosis: comparison of thrombo­
embolic events and major bleeding. Amyloid 2021;28:30–34. https://doi.org/10. 
1080/13506129.2020.1810010
1074. Rehorn MR, Loungani RS, Black-Maier E, Coniglio AC, Karra R, Pokorney SD, et al. 
Cardiac implantable electronic devices: a window into the evolution of conduction 
disease in cardiac amyloidosis. JACC Clin Electrophysiol 2020;6:1144–1154. https:// 
doi.org/10.1016/j.jacep.2020.04.020
1075. Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, et al. Cardiac 
amyloidosis: the great pretender. Heart Fail Rev 2015;20:117–124. https://doi.org/10. 
1007/s10741-015-9480-0
1076. Higgins AY, Annapureddy AR, Wang Y, Minges KE, Lampert R, Rosenfeld LE, et al. 
Survival following implantable cardioverter-defibrillator implantation in patients 
with amyloid cardiomyopathy. J Am Heart Assoc 2020;9:e016038. https://doi.org/10. 
1161/JAHA.120.016038
1077. Kim EJ, Holmes BB, Huang S, Lugo R, Al Aboud A, Goodman S, et al. Outcomes in 
patients with cardiac amyloidosis and implantable cardioverter-defibrillator. 
Europace 2020;22:1216–1223. https://doi.org/10.1093/europace/euaa094
1078. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, 
et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N 
Engl J Med 2018;379:1007–1016. https://doi.org/10.1056/NEJMoa1805689
1078a. Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, 
et al. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin 
Amyloid. N Engl J Med 2023. https://doi.org/10.1056/NEJMoa2303765. Online ahead 
of print.
1079. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic 
control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clin­
ical trials. JAMA 2001;286:1218–1227. https://doi.org/10.1001/jama.286.10.1218
1080. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA, et al. Exercise 
and hypertension. Med Sci Sports Exerc 2004;36:533–553. https://doi.org/10.1249/01. 
MSS.0000115224.88514.3A
1081. Kelley GA, Kelley KS, Tran ZV. Walking, lipids, and lipoproteins: a meta-analysis of 
randomized controlled trials. Prev Med 2004;38:651–661. https://doi.org/10.1016/j. 
ypmed.2003.12.012
1082. Morris JN, Heady JA, Raffle PA, Roberts CG, Parks JW. Coronary heart-disease and 
physical activity of work. Lancet 1953;262:1053–1057. https://doi.org/10.1016/ 
S0140-6736(53)90665-5
1083. Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Exercise 
type and intensity in relation to coronary heart disease in men. JAMA 2002;288: 
1994–2000. https://doi.org/10.1001/jama.288.16.1994
1084. Clausen JSR, Marott JL, Holtermann A, Gyntelberg F, Jensen MT. Midlife cardio­
respiratory fitness and the long-term risk of mortality: 46 years of follow-up. J Am 
Coll Cardiol 2018;72:987–995. https://doi.org/10.1016/j.jacc.2018.06.045
1085. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, et al. Physical 
activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, 
and ischemic stroke events: systematic review and dose-response meta-analysis for 
the Global Burden of Disease Study 2013. BMJ 2016;354:i3857. https://doi.org/10. 
1136/bmj.i3857
1086. Kim K, Choi S, Hwang SE, Son JS, Lee J-K, Oh J, et al. Changes in exercise frequency 
and cardiovascular outcomes in older adults. Eur Heart J 2020;41:1490–1499. https:// 
doi.org/10.1093/eurheartj/ehz768
1087. Lee IM. Physical activity and cancer prevention–data from epidemiologic studies. Med 
Sci Sports Exerc 2003;35:1823–1827. https://doi.org/10.1249/01.MSS.0000093620. 
27893.23
1088. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac arrest 
during vigorous exercise. N Engl J Med 1984;311:874–877. https://doi.org/10.1056/ 
NEJM198410043111402
1089. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. 
Triggering of acute myocardial infarction by heavy physical exertion. Protection 
against triggering by regular exertion. Determinants of Myocardial Infarction Onset 
Study Investigators. N Engl J Med 1993;329:1677–1683. https://doi.org/10.1056/ 
NEJM199312023292301
1090. Marijon E, Tafflet M, Celermajer DS, Dumas F, Perier M-C, Mustafic H, et al. 
Sports-related sudden death in the general population. Circulation 2011;124: 
672–681. https://doi.org/10.1161/CIRCULATIONAHA.110.008979
1091. Kim JH, Malhotra R, Chiampas G, d’Hemecourt P, Troyanos C, Cianca J, et al. Cardiac 
arrest during long-distance running races. N Engl J Med 2012;366:130–140. https:// 
doi.org/10.1056/NEJMoa1106468
1092. Maron BJ, Rowin EJ, Maron MS. Letter by Maron et al. regarding article, “Genotype 
and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the 
Sarcomeric Human Cardiomyopathy Registry (SHaRe)”. Circulation 2019;139: 
1557–1558. https://doi.org/10.1161/CIRCULATIONAHA.118.038189
1093. Peterson DF, Siebert DM, Kucera KL, Thomas LC, Maleszewski JJ, Lopez-Anderson 
M, et al. Etiology of sudden cardiac arrest and death in US competitive athletes: a 
2-year prospective surveillance study. Clin J Sport Med 2020;30:305–314. https:// 
doi.org/10.1097/JSM.0000000000000598
1094. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyop­
athy in young athletes. N Engl J Med 1998;339:364–369. https://doi.org/10.1056/ 
NEJM199808063390602
1095. Holst AG, Winkel BG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al. 
Incidence and etiology of sports-related sudden cardiac death in Denmark–implica­
tions for preparticipation screening. Heart Rhythm 2010;7:1365–1371. https://doi. 
org/10.1016/j.hrthm.2010.05.021
1096. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for 
determining eligibility for competition in athletes with cardiovascular abnormalities. 
Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial 
diseases and mitral valve prolapse. J Am Coll Cardiol 1994;24:880–885. https://doi. 
org/10.1016/0735-1097(94)90844-3
1097. Maron BJ, Zipes DP. Introduction: eligibility recommendations for competitive ath­
letes with cardiovascular abnormalities–general considerations. J Am Coll Cardiol 
2005;45:1318–1321. https://doi.org/10.1016/j.jacc.2005.02.006
1098. Maron BJ, Harris KM, Thompson PD, Eichner ER, Steinberg MH. Eligibility and dis­
qualification recommendations for competitive athletes with cardiovascular abnor­
malities: Task Force 14: Sickle Cell Trait: A Scientific Statement From the 
ESC Guidelines                                                                                                                                                                                          3623


<!-- PAGE 122 -->

### Page 122

American Heart Association and American College of Cardiology. J Am Coll Cardiol 
2015;66:2444–2446. https://doi.org/10.1016/j.jacc.2015.09.046
1099. Reineck E, Rolston B, Bragg-Gresham JL, Salberg L, Baty L, Kumar S, et al. Physical ac­
tivity and other health behaviors in adults with hypertrophic cardiomyopathy. Am J 
Cardiol 2013;111:1034–1039. https://doi.org/10.1016/j.amjcard.2012.12.018
1100. Sweeting J, Ingles J, Timperio A, Patterson J, Ball K, Semsarian C. Physical activity in 
hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers. 
Open Heart 2016;3:e000484. https://doi.org/10.1136/openhrt-2016-000484
1101. Olivotto I, Maron BJ, Tomberli B, Appelbaum E, Salton C, Haas TS, et al. Obesity and 
its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am 
Coll Cardiol 2013;62:449–457. https://doi.org/10.1016/j.jacc.2013.03.062
1102. Fumagalli C, Maurizi N, Day SM, Ashley EA, Michels M, Colan SD, et al. Association of 
obesity with adverse long-term outcomes in hypertrophic cardiomyopathy. JAMA 
Cardiol 2020;5:65–72. https://doi.org/10.1001/jamacardio.2019.4268
1103. Pelliccia A, Fagard R, Bjornstad HH, Anastassakis A, Arbustini E, Assanelli D, et al. 
Recommendations for competitive sports participation in athletes with cardiovascu­
lar disease: a consensus document from the Study Group of Sports Cardiology of the 
Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working 
Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. 
Eur Heart J 2005;26:1422–1445. https://doi.org/10.1093/eurheartj/ehi325
1104. Sorajja P, Allison T, Hayes C, Nishimura RA, Lam CS, Ommen SR. Prognostic utility of 
metabolic exercise testing in minimally symptomatic patients with obstructive hyper­
trophic cardiomyopathy. Am J Cardiol 2012;109:1494–1498. https://doi.org/10.1016/j. 
amjcard.2012.01.363
1105. Desai MY, Bhonsale A, Patel P, Naji P, Smedira NG, Thamilarasan M, et al. Exercise 
echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract 
gradient predicts long-term outcomes. JACC Cardiovasc Imaging 2014;7:26–36. https:// 
doi.org/10.1016/j.jcmg.2013.08.010
1106. Konhilas JP, Watson PA, Maass A, Boucek DM, Horn T, Stauffer BL, et al. Exercise can 
prevent and reverse the severity of hypertrophic cardiomyopathy. Circ Res 2006;98: 
540–548. https://doi.org/10.1161/01.RES.0000205766.97556.00
1107. Pelliccia A, Borrazzo C, Caselli S, Lemme E, Musumeci MB, Maestrini V, et al. Neither 
athletic training nor detraining affects LV hypertrophy in adult, low-risk patients with 
HCM. JACC Cardiovasc Imaging 2022;15:170–171. https://doi.org/10.1016/j.jcmg. 
2021.08.012
1108. Klempfner R, Kamerman T, Schwammenthal E, Nahshon A, Hay I, Goldenberg I, et al. 
Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyop­
athy: results of a structured exercise training program in a cardiac rehabilitation cen­
ter. Eur J Prev Cardiol 2015;22:13–19. https://doi.org/10.1177/2047487313501277
1109. Kwon S, Lee H-J, Han K-D, Kim DH, Lee S-P, Hwang I-C, et al. Association of physical 
activity with all-cause and cardiovascular mortality in 7666 adults with hypertrophic 
cardiomyopathy (HCM): more physical activity is better. Br J Sports Med 2021;55: 
1034–1040. https://doi.org/10.1136/bjsports-2020-101987
1110. Benito B, Gay-Jordi G, Serrano-Mollar A, Guasch E, Shi Y, Tardif J-C, et al. Cardiac 
arrhythmogenic remodeling in a rat model of long-term intensive exercise training. 
Circulation 
2011;123:13–22. 
https://doi.org/10.1161/CIRCULATIONAHA.110. 
938282
1111. Saberniak J, Hasselberg NE, Borgquist R, Platonov PG, Sarvari SI, Smith H-J, et al. 
Vigorous physical activity impairs myocardial function in patients with arrhythmo­
genic right ventricular cardiomyopathy and in mutation positive family members. 
Eur J Heart Fail 2014;16:1337–1344. https://doi.org/10.1002/ejhf.181
1112. Ruwald AC, Marcus F, Estes NA, Link M, McNitt S, Polonsky B, et al. Association of 
competitive and recreational sport participation with cardiac events in patients with 
arrhythmogenic right ventricular cardiomyopathy: results from the North American 
multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart 
J 2015;36:1735–1743. https://doi.org/10.1093/eurheartj/ehv110
1113. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M, et al. Safety 
of sports for athletes with implantable cardioverter-defibrillators: long-term results 
of a prospective multinational registry. Circulation 2017;135:2310–2312. https://doi. 
org/10.1161/CIRCULATIONAHA.117.027828
1114. Lie OH, Rootwelt-Norberg C, Dejgaard LA, Leren IS, Stokke MK, Edvardsen T, et al. 
Prediction of life-threatening ventricular arrhythmia in patients with arrhythmogenic 
cardiomyopathy: a primary prevention cohort study. JACC Cardiovasc Imaging 2018; 
11:1377–1386. https://doi.org/10.1016/j.jcmg.2018.05.017
1115. Costa S, Koch K, Gasperetti A, Akdis D, Brunckhorst C, Fu G, et al. Changes in ex­
ercise capacity and ventricular function in arrhythmogenic right ventricular cardiomy­
opathy: the impact of sports restriction during follow-up. J Clin Med 2022;11:1150. 
https://doi.org/10.3390/jcm11051150
1116. Sawant AC, Te Riele AS, Tichnell C, Murray B, Bhonsale A, Tandri H, et al. Safety of 
American Heart Association-recommended minimum exercise for desmosomal mu­
tation carriers. Heart Rhythm 2016;13:199–207. https://doi.org/10.1016/j.hrthm. 
2015.08.035
1117. Lie OH, Dejgaard LA, Saberniak J, Rootwelt C, Stokke MK, Edvardsen T, et al. 
Harmful effects of exercise intensity and exercise duration in patients with arrhyth­
mogenic cardiomyopathy. JACC Clin Electrophysiol 2018;4:744–753. https://doi.org/10. 
1016/j.jacep.2018.01.010
1118. Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, et al. 2020 ESC Guidelines 
on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 
2021;42:17–96. https://doi.org/10.1093/eurheartj/ehaa605
1119. Cruz FM, Sanz-Rosa D, Roche-Molina M, Garcia-Prieto J, Garcia-Ruiz JM, Pizarro G, 
et al. Exercise triggers ARVC phenotype in mice expressing a disease-causing mutated 
version of human plakophilin-2. J Am Coll Cardiol 2015;65:1438–1450. https://doi.org/ 
10.1016/j.jacc.2015.01.045
1120. Maron BJ, Haas TS, Murphy CJ, Ahluwalia A, Rutten-Ramos S. Incidence and causes of 
sudden death in U.S. college athletes. J Am Coll Cardiol 2014;63:1636–1643. https:// 
doi.org/10.1016/j.jacc.2014.01.041
1121. Malhotra A, Dhutia H, Finocchiaro G, Gati S, Beasley I, Clift P, et al. Outcomes of car­
diac screening in adolescent soccer players. N Engl J Med 2018;379:524–534. https:// 
doi.org/10.1056/NEJMoa1714719
1122. Harmon KG, Drezner JA, Maleszewski JJ, Lopez-Anderson M, Owens D, Prutkin JM, 
et al. Pathogeneses of sudden cardiac death in national collegiate athletic association 
athletes. Circ Arrhythm Electrophysiol 2014;7:198–204. https://doi.org/10.1161/ 
CIRCEP.113.001376
1123. Skjolsvik ET, Hasselberg NE, Dejgaard LA, Lie OH, Andersen K, Holm T, et al. 
Exercise is associated with impaired left ventricular systolic function in patients 
with lamin A/C genotype. J Am Heart Assoc 2020;9:e012937. https://doi.org/10. 
1161/JAHA.119.012937
1124. Dejgaard LA, Haland TF, Lie OH, Ribe M, Bjune T, Leren IS, et al. Vigorous exercise in 
patients with hypertrophic cardiomyopathy. Int J Cardiol 2018;250:157–163. https:// 
doi.org/10.1016/j.ijcard.2017.07.015
1125. Pelliccia A, Caselli S, Pelliccia M, Musumeci MB, Lemme E, Di Paolo FM, et al. Clinical 
outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up 
study. Br J Sports Med 2020;54:1008–1012. https://doi.org/10.1136/bjsports-2019- 
100890
1126. Saarel EV, Law I, Berul CI, Ackerman MJ, Kanter RJ, Sanatani S, et al. Safety of sports 
for young patients with implantable cardioverter-defibrillators: long-term results of 
the multinational ICD sports registry. Circ Arrhythm Electrophysiol 2018;11: 
e006305. https://doi.org/10.1161/CIRCEP.118.006305
1127. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, et al. Prospective 
multicenter study of pregnancy outcomes in women with heart disease. Circulation 
2001;104:515–521. https://doi.org/10.1161/hc3001.093437
1128. Roos-Hesselink JW, Ruys TP, Stein JI, Thilén U, Webb GD, Niwa K, et al. Outcome of 
pregnancy in patients with structural or ischaemic heart disease: results of a registry 
of the European Society of Cardiology. Eur Heart J 2013;34:657–665. https://doi.org/ 
10.1093/eurheartj/ehs270
1129. Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I, Furokawa 
T, et al. Sex differences in cardiac arrhythmia: a consensus document of the European 
Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific 
Heart Rhythm Society. Europace 2018;20:1565–1565ao. https://doi.org/10.1093/ 
europace/euy067
1130. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, 
Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovas­
cular diseases during pregnancy. Eur Heart J 2018;39:3165–3241. https://doi.org/10. 
1093/eurheartj/ehy340
1131. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C, et al. 
Clinical characteristics of patients from the worldwide registry on peripartum cardio­
myopathy (PPCM): EURObservational Research Programme in conjunction with the 
Heart Failure Association of the European Society of Cardiology Study Group on 
PPCM. Eur J Heart Fail 2017;19:1131–1141. https://doi.org/10.1002/ejhf.780
1132. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke 
and myocardial infarction with hormonal contraception. N Engl J Med 2012;366: 
2257–2266. https://doi.org/10.1056/NEJMoa1111840
1133. D’Souza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, et al. 
Anticoagulation for pregnant women with mechanical heart valves: a systematic re­
view and meta-analysis. Eur Heart J 2017;38:1509–1516. https://doi.org/10.1093/ 
eurheartj/ehx032
1134. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical 
heart valves: a systematic review of the literature. Arch Intern Med 2000;160: 
191–196. https://doi.org/10.1001/archinte.160.2.191
1135. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 
and the prevention of sudden cardiac death: The Task Force for the Management 
of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac 
Death of the European Society of Cardiology (ESC). Endorsed by: Association for 
European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36: 
2793–2867. https://doi.org/10.1093/eurheartj/ehv316
1136. Miyoshi T, Kamiya CA, Katsuragi S, Ueda H, Kobayashi Y, Horiuchi C, et al. Safety and 
efficacy of implantable cardioverter-defibrillator during pregnancy and after delivery. 
Circ J 2013;77:1166–1170. https://doi.org/10.1253/circj.CJ-12-1275
1137. Krul SP, van der Smagt JJ, van den Berg MP, Sollie KM, Pieper PG, van 
Spaendonck-Zwarts KY. Systematic review of pregnancy in women with inherited


<!-- PAGE 123 -->

### Page 123

cardiomyopathies. Eur J Heart Fail 2011;13:584–594. https://doi.org/10.1093/eurjhf/ 
hfr040
1138. Castrini AI, Lie OH, Leren IS, Estensen ME, Stokke MK, Klaeboe LG, et al. Number of 
pregnancies and subsequent phenotype in a cross-sectional cohort of women with 
arrhythmogenic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2019;20:192–198. 
https://doi.org/10.1093/ehjci/jey061
1139. Platonov PG, Castrini AI, Svensson A, Christiansen MK, Gilljam T, Bundgaard H, et al. 
Pregnancies, ventricular arrhythmias, and substrate progression in women with ar­
rhythmogenic right ventricular cardiomyopathy in the Nordic ARVC Registry. 
Europace 2020;22:1873–1879. https://doi.org/10.1093/europace/euaa136
1140. Gandjbakhch E, Varlet E, Duthoit G, Fressart V, Charron P, Himbert C, et al. 
Pregnancy and newborn outcomes in arrhythmogenic right ventricular cardiomyop­
athy/dysplasia. Int J Cardiol 2018;258:172–178. https://doi.org/10.1016/j.ijcard.2017. 
11.067
1141. Wu L, Liang E, Fan S, Zheng L, Hu F, Liu S, et al. Effect of pregnancy in arrhythmogenic 
right ventricular cardiomyopathy. Am J Cardiol 2020;125:613–617. https://doi.org/10. 
1016/j.amjcard.2019.11.008
1142. Castrini AI, Skjolsvik E, Estensen ME, Almaas VM, Skulstad H, Lyseggen E, et al. 
Pregnancy and progression of cardiomyopathy in women with LMNA genotypepo­
sitive. J Am Heart Assoc 2022;11:e024960. https://doi.org/10.1161/JAHA.121.024960
1143. Grewal J, Siu SC, Ross HJ, Mason J, Balint OH, Sermer M, et al. Pregnancy outcomes in 
women with dilated cardiomyopathy. J Am Coll Cardiol 2009;55:45–52. https://doi.org/ 
10.1016/j.jacc.2009.08.036
1144. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation 
of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a 
proof-of-concept pilot study. Circulation 2010;121:1465–1473. https://doi.org/10. 
1161/CIRCULATIONAHA.109.901496
1145. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. 
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre ran­
domized study. Eur Heart J 2017;38:2671–2679. https://doi.org/10.1093/eurheartj/ 
ehx355
1146. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyop­
athy: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:207–221. https://doi. 
org/10.1016/j.jacc.2019.11.014
1147. Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, 
et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: 
a position statement from the Heart Failure Association of the European Society 
of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019; 
21:827–843. https://doi.org/10.1002/ejhf.1493
1148. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, et al. ACC/ 
AHA guideline update for perioperative cardiovascular evaluation for noncardiac sur­
gery—executive summary a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines (Committee to Update the 
1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac 
Surgery). Circulation 2002;105:1257–1267. https://doi.org/10.1161/circ.105.10.1257
1149. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, et al. 2014 ESC/ESA 
Guidelines on non-cardiac surgery: cardiovascular assessment and management: the 
Joint Task Force on non-cardiac surgery: cardiovascular assessment and management 
of the European Society of Cardiology (ESC) and the European Society of 
Anaesthesiology (ESA). Eur Heart J 2014;35:2383–2431. https://doi.org/10.1093/ 
eurheartj/ehu282
1150. Sahoo RK, Dash SK, Raut PS, Badole UR, Upasani CB. Perioperative anesthetic man­
agement of patients with hypertrophic cardiomyopathy for noncardiac surgery: a 
case series. Ann Card Anaesth 2010;13:253–256. https://doi.org/10.4103/0971-9784. 
69049
1151. Dhillon A, Khanna A, Randhawa MS, Cywinski J, Saager L, Thamilarasan M, et al. 
Perioperative outcomes of patients with hypertrophic cardiomyopathy undergoing 
non-cardiac surgery. Heart 2016;102:1627–1632. https://doi.org/10.1136/heartjnl- 
2016-309442
1152. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. 
Heart Failure Association of the European Society of Cardiology practical guidance 
on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–731. 
https://doi.org/10.1002/ejhf.1494
1153. Coats CJ, Gallagher MJ, Foley M, O’Mahony C, Critoph C, Gimeno J, et al. Relation 
between serum N-terminal pro-brain natriuretic peptide and prognosis in patients 
with hypertrophic cardiomyopathy. Eur Heart J 2013;34:2529–2537. https://doi. 
org/10.1093/eurheartj/eht070
1154. D’Amato R, Tomberli B, Castelli G, Spoladore R, Girolami F, Fornaro A, et al. 
Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with 
hypertrophic cardiomyopathy. Am J Cardiol 2013;112:1190–1196. https://doi.org/ 
10.1016/j.amjcard.2013.06.018
1155. van der Meulen M, den Boer S, du Marchie Sarvaas GJ, Blom N, Ten Harkel ADJ, Breur 
H, et al. Predicting outcome in children with dilated cardiomyopathy: the use of re­
peated measurements of risk factors for outcome. ESC Heart Fail 2021;8:1472–1481. 
https://doi.org/10.1002/ehf2.13233
1156. Cheng H, Lu M, Hou C, Chen X, Wang J, Yin G, et al. Relation between N-terminal 
pro-brain natriuretic peptide and cardiac remodeling and function assessed by cardio­
vascular magnetic resonance imaging in patients with arrhythmogenic right ventricu­
lar cardiomyopathy. Am J Cardiol 2015;115:341–347. https://doi.org/10.1016/j. 
amjcard.2014.10.040
1157. Chivulescu M, Lie OH, Popescu BA, Skulstad H, Edvardsen T, Jurcut RO, et al. High 
penetrance and similar disease progression in probands and in family members with 
arrhythmogenic cardiomyopathy. Eur Heart J 2020;41:1401–1410. https://doi.org/10. 
1093/eurheartj/ehz570
1158. Norrish G, Forshaw N, Woo C, Avanis MC, Field E, Cervi E, et al. Outcomes follow­
ing general anaesthesia in children with hypertrophic cardiomyopathy. Arch Dis Child 
2019;104:471–475. https://doi.org/10.1136/archdischild-2018-315366
1159. Kazmers A, Cerqueira MD, Zierler RE. Perioperative and late outcome in patients 
with left ventricular ejection fraction of 35% or less who require major vascular sur­
gery. J Vasc Surg 1988;8:307–315. https://doi.org/10.1016/0741-5214(88)90283-2
1160. Healy KO, Waksmonski CA, Altman RK, Stetson PD, Reyentovich A, Maurer MS. 
Perioperative outcome and long-term mortality for heart failure patients undergoing 
intermediate- and high-risk noncardiac surgery: impact of left ventricular ejection 
fraction. Congest Heart Fail 2010;16:45–49. https://doi.org/10.1111/j.1751-7133. 
2009.00130.x
1161. Barbara DW, Hyder JA, Behrend TL, Abel MD, Schaff HV, Mauermann WJ. Safety of 
noncardiac surgery in patients with hypertrophic obstructive cardiomyopathy at a 
tertiary care center. J Cardiothorac Vasc Anesth 2016;30:659–664. https://doi.org/10. 
1053/j.jvca.2015.08.017
1162. Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, et al. PONTIAC 
(NT-proBNP selected prevention of cardiac events in a population of diabetic pa­
tients without a history of cardiac disease): a prospective randomized controlled trial. 
J Am Coll Cardiol. 2013;62:1365–1372. https://doi.org/10.1016/j.jacc.2013.05.069
1163. Ledwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I, et al. Natriuretic 
peptide-based screening and collaborative care for heart failure: the STOP-HF rando­
mized trial. JAMA 2013;310:66–74. https://doi.org/10.1001/jama.2013.7588
1164. Rodseth RN, Biccard BM, Le Manach Y, Sessler DI, Lurati Buse GA, Thabane L, et al. 
The prognostic value of pre-operative and post-operative B-type natriuretic peptides 
in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal 
fragment of pro-B-type natriuretic peptide: a systematic review and individual patient 
data meta-analysis. J Am Coll Cardiol 2014;63:170–180. https://doi.org/10.1016/j.jacc. 
2013.08.1630
1165. Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MT, Alonso-Coello P, 
et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic 
peptide measurement an independent predictor of adverse cardiovascular outcomes 
within 30 days of noncardiac surgery? A systematic review and meta-analysis of ob­
servational studies. J Am Coll Cardiol 2009;54:1599–1606. https://doi.org/10.1016/j. 
jacc.2009.06.028
1166. Ahmad F, McNally EM, Ackerman MJ, Baty LC, Day SM, Kullo IJ, et al. Establishment of 
specialized clinical cardiovascular genetics programs: recognizing the need and meet­
ing standards: a scientific statement from the American Heart Association. Circ 
Genom Precis Med 2019;12:e000054. https://doi.org/10.1161/HCG.000000000000 
0054
1167. Burton H, Alberg C, Stewart A. Heart to Heart: Inherited Cardiovascular Conditions 
Services. Cambridge, UK: PHG Foundation, 2009.
1168. Chamberlain AM, Agarwal SK, Folsom AR, Duval S, Soliman EZ, Ambrose M, et al. 
Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in 
Communities (ARIC) study. Heart Rhythm 2011;8:1160–1166. https://doi.org/10. 
1016/j.hrthm.2011.03.038
1169. Kamimura D, Cain LR, Mentz RJ, White WB, Blaha MJ, DeFilippis AP, et al. Cigarette 
smoking and incident heart failure: insights from the Jackson Heart Study. Circulation 
2018;137:2572–2582. https://doi.org/10.1161/CIRCULATIONAHA.117.031912
1170. Gottdiener JS, Buzkova P, Kahn PA, DeFilippi C, Shah S, Barasch E, et al. Relation of 
cigarette smoking and heart failure in adults >/=65 years of age (from the 
Cardiovascular Health Study). Am J Cardiol 2022;168:90–98. https://doi.org/10. 
1016/j.amjcard.2021.12.021
1171. Park J, Lee H-J, Kim SK, Yi J-E, Shin DG, Lee JM, et al. Smoking aggravates ventricular 
arrhythmic events in non-ischemic dilated cardiomyopathy associated with a late 
gadolinium enhancement in cardiac MRI. Sci Rep 2018;8:15609. https://doi.org/10. 
1038/s41598-018-34145-9
1172. Smith D, Toff W, Joy M, Dowdall N, Johnston R, Clark L, et al. Fitness to fly for pas­
sengers with cardiovascular disease. Heart 2010;96(Suppl 2):ii1–ii16. https://doi.org/ 
10.1136/hrt.2010.203091
1173. Fumagalli C, Olivotto I. The importance of sex differences in patients with hyper­
trophic cardiomyopathy – tailoring management and future perspectives. Am J Med 
Sci 2020;360:433–434. https://doi.org/10.1016/j.amjms.2020.07.004
1174. Terauchi Y, Kubo T, Baba Y, Hirota T, Tanioka K, Yamasaki N, et al. Gender differ­
ences in the clinical features of hypertrophic cardiomyopathy caused by cardiac 
myosin-binding protein C gene mutations. J Cardiol 2015;65:423–428. https://doi. 
org/10.1016/j.jjcc.2014.07.010
ESC Guidelines                                                                                                                                                                                          3625


<!-- PAGE 124 -->

### Page 124

### 1175 Sabater-Molina M, Saura D, Garcia-Molina Saez E, Gonzalez-Carrillo J, Polo L,

Perez-Sanchez I, et al. A novel founder mutation in MYBPC3: phenotypic comparison 
with the most prevalent MYBPC3 mutation in Spain. Rev Esp Cardiol (Engl Ed) 2017; 
70:105–114. https://doi.org/10.1016/j.recesp.2016.06.025
1176. Adalsteinsdottir B, Burke M, Maron BJ, Danielsen R, Lopez B, Diez J, et al. 
Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic 
founder mutation carriers. Open Heart 2020;7:e001220. https://doi.org/10.1136/ 
openhrt-2019-001220
1177. Lakdawala NK, Olivotto I, Day SM, Han L, Ashley EA, Michels M, et al. Associations 
between female sex, sarcomere variants, and clinical outcomes in hypertrophic car­
diomyopathy. Circ Genom Precis Med 2021;14:e003062. https://doi.org/10.1161/ 
CIRCGEN.120.003062
1178. Lorenzini M, Anastasiou Z, O’Mahony C, Guttman OP, Gimeno JR, Monserrat L, et al. 
Mortality among referral patients with hypertrophic cardiomyopathy vs the general 
European population. JAMA Cardiol 2020;5:73–80. https://doi.org/10.1001/ 
jamacardio.2019.4534
1179. Batzner A, Aicha D, Pfeiffer B, Neugebauer A, Seggewiss H. Sex-related differences in 
symptomatic patients with hypertrophic obstructive cardiomyopathy – time for a 
new definition? Int J Cardiol 2021;328:117–121. https://doi.org/10.1016/j.ijcard. 
2020.12.039
1180. Sreenivasan J, Khan MS, Kaul R, Bandyopadhyay D, Hooda U, Aronow WS, et al. Sex 
differences in the outcomes of septal reduction therapies for obstructive hyper­
trophic cardiomyopathy. JACC Cardiovasc Interv 2021;14:930–932. https://doi.org/ 
10.1016/j.jcin.2020.10.002
1181. Meghji Z, Nguyen A, Fatima B, Geske JB, Nishimura RA, Ommen SR, et al. Survival 
differences in women and men after septal myectomy for obstructive hypertrophic 
cardiomyopathy. JAMA Cardiol 2019;4:237–245. https://doi.org/10.1001/jamacardio. 
2019.0084
1182. Butters A, Lakdawala NK, Ingles J. Sex differences in hypertrophic cardiomyopathy: 
interaction with genetics and environment. Curr Heart Fail Rep 2021;18:264–273. 
https://doi.org/10.1007/s11897-021-00526-x
1183. Rowin EJ, Maron MS, Wells S, Patel PP, Koethe BC, Maron BJ. Impact of sex on clinical 
course and survival in the contemporary treatment era for hypertrophic cardiomy­
opathy. J Am Heart Assoc 2019;8:e012041. https://doi.org/10.1161/JAHA.119.012041
1184. D’Amario D, Camilli M, Migliaro S, Canonico F, Galli M, Arcudi A, et al. Sex-related 
differences in dilated cardiomyopathy with a focus on cardiac dysfunction in oncol­
ogy. Curr Cardiol Rep 2020;22:102. https://doi.org/10.1007/s11886-020-01377-z
1185. Vissing CR, Rasmussen TB, Dybro AM, Olesen MS, Pedersen LN, Jensen M, et al. 
Dilated cardiomyopathy caused by truncating titin variants: long-term outcomes, ar­
rhythmias, response to treatment and sex differences. J Med Genet 2021;58:832–841. 
https://doi.org/10.1136/jmedgenet-2020-107178
1186. Dominguez F, Cuenca S, Bilinska Z, Toro R, Villard E, Barriales-Villa R, et al. Dilated 
cardiomyopathy due to BLC2-associated athanogene 3 (BAG3) mutations. J Am Coll 
Cardiol 2018;72:2471–2481. https://doi.org/10.1016/j.jacc.2018.08.2181
1187. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic 
defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N 
Engl J Med 2004;350:2151–2158. https://doi.org/10.1056/NEJMoa033088
1188. Halliday BP, Gulati A, Ali A, Newsome S, Lota A, Tayal U, et al. Sex- and age-based 
differences in the natural history and outcome of dilated cardiomyopathy. Eur J 
Heart Fail 2018;20:1392–1400. https://doi.org/10.1002/ejhf.1216
1189. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, et al. 
Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012;366: 
619–628. https://doi.org/10.1056/NEJMoa1110186
1190. Calkins H, Corrado D, Marcus F. Risk stratification in arrhythmogenic right ventricu­
lar cardiomyopathy. Circulation 2017;136:2068–2082. https://doi.org/10.1161/ 
CIRCULATIONAHA.117.030792
1191. Choudhary N, Tompkins C, Polonsky B, McNitt S, Calkins H, Mark Estes NA, et al. 
Clinical presentation and outcomes by sex in arrhythmogenic right ventricular cardio­
myopathy: findings from the North American ARVC registry. J Cardiovasc 
Electrophysiol 2016;27:555–562. https://doi.org/10.1111/jce.12947
1192. Akdis D, Saguner AM, Shah K, Wei C, Medeiros-Domingo A, von Eckardstein A, et al. 
Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/ 
dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers 
of disease outcome. Eur Heart J 2017;38:1498–1508. https://doi.org/10.1093/ 
eurheartj/ehx011
1193. Kimura Y, Noda T, Otsuka Y, Wada M, Nakajima I, Ishibashi K, et al. Potentially lethal 
ventricular arrhythmias and heart failure in arrhythmogenic right ventricular cardio­
myopathy: what are the differences between men and women? JACC Clin 
Electrophysiol 2016;2:546–555. https://doi.org/10.1016/j.jacep.2016.02.019
1194. Hoorntje ET, Te Rijdt WP, James CA, Pilichou K, Basso C, Judge DP, et al. 
Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. 
Cardiovasc Res 2017;113:1521–1531. https://doi.org/10.1093/cvr/cvx150
1195. Rootwelt-Norberg C, Lie OH, Chivulescu M, Castrini AI, Sarvari SI, Lyseggen E, et al. 
Sex differences in disease progression and arrhythmic risk in patients with arrhyth­
mogenic cardiomyopathy. Europace 2021;23:1084–1091. https://doi.org/10.1093/ 
europace/euab077
1196. Lopes LR, Losi MA, Sheikh N, Laroche C, Charron P, Gimeno J, et al. Association be­
tween common cardiovascular risk factors and clinical phenotype in patients with 
hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) 
EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis regis­
try. Eur Heart J Qual Care Clin Outcomes 2022;9:42–53. https://doi.org/10.1093/ 
ehjqcco/qcac006
1197. Wasserstrum Y, Barriales-Villa R, Fernandez-Fernandez X, Adler Y, Lotan D, Peled Y, 
et al. The impact of diabetes mellitus on the clinical phenotype of hypertrophic car­
diomyopathy. Eur Heart J 2019;40:1671–1677. https://doi.org/10.1093/eurheartj/ 
ehy625
1198. Limongelli G, Monda E, D’Aponte A, Caiazza M, Rubino M, Esposito A, et al. 
Combined effect of Mediterranean diet and aerobic exercise on weight loss and clin­
ical status in obese symptomatic patients with hypertrophic cardiomyopathy. Heart 
Fail Clin 2021;17:303–313. https://doi.org/10.1016/j.hfc.2021.01.003
1199. Asatryan B, Asimaki A, Landstrom AP, Khanji MY, Odening KE, Cooper LT, et al. 
Inflammation and immune response in arrhythmogenic cardiomyopathy: 
state-of-the-art review. Circulation 2021;144:1646–1655. https://doi.org/10.1161/ 
CIRCULATIONAHA.121.055890
1200. Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and 
its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir 
J 2020;55:2000547. https://doi.org/10.1183/13993003.00547-2020
1201. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of 
coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720. https://doi. 
org/10.1056/NEJMoa2002032
1202. Capacity-Covid Collaborative Consortium, Leoss Study Group. Clinical presentation, 
disease course, and outcome of COVID-19 in hospitalized patients with and without 
pre-existing cardiac disease: a cohort study across 18 countries. Eur Heart J 2022;43: 
1104–1120. https://doi.org/10.1093/eurheartj/ehab656
1203. Omidi F, Hajikhani B, Kazemi SN, Tajbakhsh A, Riazi S, Mirsaeidi M, et al. COVID-19 
and cardiomyopathy: a systematic review. Front Cardiovasc Med 2021;8:695206. 
https://doi.org/10.3389/fcvm.2021.695206
1204. Gimeno JR, Olivotto I, Rodriguez AI, Ho CY, Fernandez A, Quiroga A, et al. Impact of 
SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an 
international multicentre registry. ESC Heart Fail 2022;9:2189–2198. https://doi.org/ 
10.1002/ehf2.13964

<!-- 2023_Cardiomyopathies_Supplementary.md -->

# ESC Guidelines: Cardiomyopathies Supplementary (2023)

**Source**: `2023_Cardiomyopathies_Supplementary.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 22

---

## Table of Contents

- [2023 ESC Guidelines for the management of cardiomyopathies Supplementary data](#2023-esc-guidelines-for-the-management-of-cardiomy) *(p. 1)*
  - [1. Epidemiology](#1-epidemiology) *(p. 3)*
    - [1.1. General epidemiological data](#11-general-epidemiological-data) *(p. 3)*
    - [1.2. Paediatric cardiomyopathies](#12-paediatric-cardiomyopathies) *(p. 4)*
    - [1.3. Special populations](#13-special-populations) *(p. 4)*
  - [2. The patient pathway](#2-the-patient-pathway) *(p. 4)*
    - [2.1. Genetic testing](#21-genetic-testing) *(p. 4)*
      - [2.1.1. Variant interpretation](#211-variant-interpretation) *(p. 4)*
    - [2.2. Genetic counselling](#22-genetic-counselling) *(p. 4)*
      - [2.2.1. What is genetic counselling?](#221-what-is-genetic-counselling?) *(p. 4)*
      - [2.2.2. Who performs genetic counselling?](#222-who-performs-genetic-counselling?) *(p. 5)*
      - [2.2.3. Genetic counselling in paediatrics](#223-genetic-counselling-in-paediatrics) *(p. 5)*
      - [2.2.4. Pre- and post-test genetic counselling (proband)](#224-pre--and-post-test-genetic-counselling-(proban) *(p. 5)*
      - [2.2.5. Cascade genetic testing](#225-cascade-genetic-testing) *(p. 5)*
      - [2.2.6. Uptake of genetic counselling and testing](#226-uptake-of-genetic-counselling-and-testing) *(p. 5)*
      - [2.2.7. Approaching relatives of the index patient](#227-approaching-relatives-of-the-index-patient) *(p. 5)*
      - [2.2.8. Inheritance and family communication](#228-inheritance-and-family-communication) *(p. 6)*
      - [2.2.9. Psychological support](#229-psychological-support) *(p. 6)*
  - [3. Specific entities](#3-specific-entities) *(p. 6)*
    - [3.1. Hypertrophic cardiomyopathy](#31-hypertrophic-cardiomyopathy) *(p. 6)*
      - [3.1.1. Cardiac magnetic resonance imaging and sudden cardiac death risk in hypertrophic cardiomyopathy](#311-cardiac-magnetic-resonance-imaging-and-sudden-) *(p. 6)*
    - [3.2. Restrictive cardiomyopathy](#32-restrictive-cardiomyopathy) *(p. 14)*
    - [3.3. Amyloid](#33-amyloid) *(p. 15)*
  - [4. Sports](#4-sports) *(p. 15)*
  - [5. Recommendations for non-cardiac interventions](#5-recommendations-for-non-cardiac-interventions) *(p. 16)*
  - [6. Requirements for specialized cardiomyopathy units](#6-requirements-for-specialized-cardiomyopathy-unit) *(p. 16)*
    - [6.1. Requirements and skills](#61-requirements-and-skills) *(p. 16)*
  - [7. Living with cardiomyopathy: patient and family education](#7-living-with-cardiomyopathy:-patient-and-family-e) *(p. 16)*
  - [8. References](#8-references) *(p. 19)*
  - [8. References](#8-references) *(p. 19)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2023 ESC Guidelines for the management 
of cardiomyopathies Supplementary data 
Developed by the task force on the management of 
cardiomyopathies of the European Society of Cardiology (ESC) 
Authors/Task Force Members: Elena Arbelo  *†, (Chairperson) (Spain), 
Alexandros Protonotarios  
‡, (Task Force Co-ordinator) (United Kingdom), 
Juan R. Gimeno  
‡, (Task Force Co-ordinator) (Spain), Eloisa Arbustini  
(Italy), 
Roberto Barriales-Villa  
(Spain), Cristina Basso  
(Italy), Connie R. Bezzina  
(Netherlands), Elena Biagini  
(Italy), Nico A. Blom1 (Netherlands), 
Rudolf A. de Boer  
(Netherlands), Tim De Winter (Belgium), Perry M. Elliott  
(United Kingdom), Marcus Flather  
(United Kingdom), Pablo Garcia-Pavia  
(Spain), Kristina H. Haugaa  
(Sweden), Jodie Ingles  
(Australia), 
Ruxandra Oana Jurcut  
(Romania), Sabine Klaassen  
(Germany), 
Giuseppe Limongelli  
(Italy), Bart Loeys  
2 (Belgium), Jens Mogensen  
(Denmark), Iacopo Olivotto  
(Italy), Antonis Pantazis  
(United Kingdom), 
Sanjay Sharma  
(United Kingdom), J. Peter Van Tintelen  
(Netherlands), 
James S. Ware  
(United Kingdom), Juan Pablo Kaski  *†, (Chairperson) 
(United Kingdom), and ESC Scientific Document Group 
* Corresponding authors: Elena Arbelo, Arrhythmia Section, Cardiology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain, IDIBAPS, Institut d’Investigació August Pi i 
Sunyer (IDIBAPS), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, and European Reference Network for rare, low 
prevalence and complex diseases of the heart, ERN GUARD-Heart, Barcelona, Spain. Tel: +34 93 22 75 55 11, E-mail: elenaarbelo@secardiologia.es; and Juan Pablo Kaski, Centre for Paediatric 
Inherited and Rare Cardiovascular Disease, University College London, Institute of Cardiovascular Science, London, United Kingdom and Centre for Inherited Cardiovascular Diseases, Great 
Ormond Street Hospital, London, United Kingdom. Tel: +44 78 29 88 39, E-mail: j.kaski@ucl.ac.uk 
† The two Chairpersons contributed equally to the document and are joint corresponding authors. 
‡ The two Task Force Co-ordinators contributed equally to the document. 
Author/Task Force Member affiliations are listed in author information in the full text. 
1 Representing the Association for European Paediatric and Congenital Cardiology (AEPC) 
2 Representing the European Society of Human Genetics (ESHG) 
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix in the full text. 
ESC subspecialty communities having participated in the development of this document: 
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive 
Cardiology (EAPC), European Heart Rhythm Association (EHRA), and Heart Failure Association (HFA). 
Councils: Council on Cardiovascular Genomics. 
Working Groups: Development Anatomy and Pathology, Myocardial and Pericardial Diseases. 
Patient Forum  
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC 
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com). 
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the 
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; 
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from 
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case 
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices at the time of prescription. 
© The European Society of Cardiology 2023. All rights reserved. For permissions please email: journals.permissions@oup.com.  
https://doi.org/10.1093/eurheartj/ehad194 
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Philippe Charron, (CPG Review Co-ordinator) (France), Massimo Imazio, (CPG Review 
Co-ordinator) (Italy), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Michael Arad (Israel), Folkert 
W. Asselbergs (Netherlands), Riccardo Asteggiano (Italy), Zofia Bilinska (Poland), Damien Bonnet (France), 
Henning Bundgaard (Denmark), Nuno Miguel Cardim (Portugal), Jelena Čelutkienė (Lithuania), Maja Cikes 
(Croatia), Gaetano Maria De Ferrari (Italy), Veronica Dusi (Italy), Volkmar Falk (Germany), Laurent Fauchier 
(France), Estelle Gandjbakhch (France), Tiina Heliö (Finland), Konstantinos Koskinas (Switzerland), Dipak Kotecha 
(United Kingdom), Ulf Landmesser (Germany), George Lazaros (Greece), Basil S. Lewis (Israel), Ales Linhart 
(Czechia), Maja-Lisa Løchen (Norway), Benjamin Meder (Germany), Richard Mindham (United Kingdom), 
James Moon (United Kingdom), Jens Cosedis Nielsen (Denmark), Steffen Petersen (United Kingdom), Eva Prescott 
(Denmark), Mary N. Sheppard (United Kingdom), Gianfranco Sinagra (Italy), Marta Sitges (Spain), Jacob Tfelt- 
Hansen (Denmark), Rhian Touyz (Canada), Rogier Veltrop (Netherlands), Josef Veselka (Czechia), Karim Wahbi 
(France), Arthur Wilde (Netherlands), and Katja Zeppenfeld (Netherlands) 
All experts involved in the development of these guidelines have submitted declarations of interest. These have 
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The 
report is also available on the ESC website www.escardio.org/Guidelines   
Keywords 
Guidelines • Arrhythmia • Arrhythmogenic right ventricular cardiomyopathy • Cardiomyopathies • Diagnosis • 
Dilated cardiomyopathy • Genetics • Genetic counselling • Genetic testing • Hypertrophic cardiomyopathy • 
Implantable cardioverter defibrillator • Management • Multimodality imaging • Non-dilated left ventricular 
cardiomyopathy • Pregnancy • Restrictive cardiomyopathy • Risk stratification • Screening • Sports • 
Sudden cardiac death  
Table of contents 
1. Epidemiology .............................................................................................................. 3 
1.1. General epidemiological data ....................................................................
3 
1.2. Paediatric cardiomyopathies ......................................................................
4 
1.3. Special populations ........................................................................................
4 
2. The patient pathway ............................................................................................... 4 
2.1. Genetic testing ................................................................................................
4 
2.1.1. Variant interpretation ........................................................................... 4 
2.2. Genetic counselling ........................................................................................
4 
2.2.1. What is genetic counselling? .............................................................. 4 
2.2.2. Who performs genetic counselling? ............................................... 5 
2.2.3. Genetic counselling in paediatrics .................................................... 5 
2.2.4. Pre- and post-test genetic counselling (proband) .................... 5 
2.2.5. Cascade genetic testing ........................................................................ 5 
2.2.6. Uptake of genetic counselling and testing .................................... 5 
2.2.7. Approaching relatives of the index patient ................................. 5 
2.2.8. Inheritance and family communication .......................................... 6 
2.2.9. Psychological support ........................................................................... 6 
3. Specific entities .......................................................................................................... 6 
3.1. Hypertrophic cardiomyopathy .................................................................
6 
3.1.1. Cardiac magnetic resonance imaging and sudden cardiac 
death risk in hypertrophic cardiomyopathy ............................................ 6 
3.2. Restrictive cardiomyopathy ..................................................................... 14 
3.3. Amyloid ............................................................................................................ 15 
4. Sports ......................................................................................................................... 15 
5. Recommendations for non-cardiac interventions .................................. 16 
6. Requirements for specialized cardiomyopathy units ............................. 16 
6.1. Requirements and skills ............................................................................. 16 
7. Living with cardiomyopathy: patient and family education ................. 16 
8. References ............................................................................................................... 19   
List of tables 
Table S1 Studies on the role of late gadolinium enhancement in 
predicting sudden cardiac death in patients with hypertrophic 
cardiomyopathy ............................................................................................................. 7 
Table S2 Apical aneurysms and sudden death in hypertrophic 
cardiomyopathy .......................................................................................................... 12 
Table S3 Studies on the prevalence of and predictors for left 
ventricular systolic dysfunction in patients with hypertrophic 
cardiomyopathy .......................................................................................................... 13 
Table S4 Spectrum of restrictive heart disease ............................................ 14 
Table S5 Prognostic staging scores in light chain amyloidosis and 
transthyretin amyloidosis ........................................................................................ 15 
Table S6 Indices for exercise intensity during sport .................................. 15


<!-- PAGE 3 -->

### Page 3

Table S7 Management of a patient with hypertrophic 
cardiomyopathy and left ventricular outflow tract obstruction for 
non-cardiac interventions ....................................................................................... 16 
Table S8 Cardiomyopathy units: requirements and skills ........................ 17 
Table S9 Educational steps .................................................................................... 18  
Abbreviations and acronyms 
3D 
Three-dimensional 
AFD 
Anderson–Fabry disease 
AlcCM 
Alcoholic cardiomyopathy 
AR 
Autosomal recessive 
ARVC 
Arrhythmogenic right ventricular cardiomyopathy 
ASA 
Alcohol septal ablation 
ATTR 
Transthyretin amyloidosis 
ATTRv 
Hereditary transthyretin amyloidosis 
ATTRwt 
Wild-type OR Acquired transthyretin amyloidosis 
AV 
Atrioventricular 
BNP 
Brain natriuretic peptide 
CCM 
Cancer therapy-induced cardiomyopathy 
CGU 
Cardiogenetic unit 
CMP 
Cardiomyopathy 
CMR 
Cardiac magnetic resonance 
CMU 
Cardiomyopathy unit 
CT 
Computed tomography 
CV 
Cardiovascular 
DCM 
Dilated cardiomyopathy 
DIP 
Drug-induced phospholipidosis 
ECG 
Electrocardiogram 
ECV 
Extracellular volume 
EF 
Ejection fraction 
eGFR 
Estimated glomerular filtration rate 
EORP 
EURObservational Research Programme 
EU 
European Union 
FLC 
Free light chain 
HCM 
Hypertrophic cardiomyopathy 
HF 
Heart failure 
HH 
Hereditary haemochromatosis 
HRR 
Heart rate reserve 
ICC 
Inherited cardiac condition 
ICD 
Implantable cardioverter defibrillator 
LAD 
Left anterior descending 
LGE 
Late gadolinium enhancement 
LV 
Left ventricular 
LVEF 
Left ventricular ejection fraction 
LVH 
Left ventricular hypertrophy 
LVOT 
Left ventricular outflow tract 
LVOTO 
Left ventricular outflow tract obstruction 
LVSD 
Left ventricular systolic dysfunction 
MRI 
Magnetic resonance imaging 
NAC 
National amyloid centre 
NCS 
Non-cardiac surgery 
NSVT 
Non-sustained ventricular tachycardia 
NT-proBNP 
N-terminal pro-brain natriuretic peptide 
NYHA 
New York Heart Association 
PET 
Positron emission tomography 
PMCR 
Paediatric Cardiomyopathy Registry 
PPCM 
Peripartum cardiomyopathy  
RCM 
Restrictive cardiomyopathy 
RPE 
Rate of perceived exertion 
SCD 
Sudden cardiac death 
SRT 
Septal reduction therapy 
SVD 
Small vessel disease 
TTNtv 
Titin gene truncating variants 
VF 
Ventricular fibrillation 
VO2max 
Maximum oxygen consumption 
VT 
Ventricular tachycardia 
VUS 
Variant of uncertain significance 
1. Epidemiology 
1.1. General epidemiological data 
Cardiomyopathies are in many cases inherited cardiac diseases with an 
identifiable or suspected genetic cause, with variable and often incomplete penetrance throughout life.1 Geographical differences in the distribution of genetic variants may influence the estimated prevalence of 
different cardiomyopathy phenotypes in different populations, ethnicities, regions, and countries. The complexity of diagnostic criteria for 
some conditions, such as arrhythmogenic right ventricular cardiomyopathy (ARVC), limits the evaluation of the true prevalence of the disease 
in the general population. Moreover, epidemiological data are often not 
collected systematically at the population level, particularly in children. 
Hypertrophic cardiomyopathy (HCM) is the most common cardiomyopathy, with an estimated prevalence taken from a pooled analysis 
of eight studies of 0.2% (95% confidence interval [CI], 1.44–2.71) or 
1/460 population.2–9 Data from cardiac magnetic resonance (CMR) 
analysis of a large adult cohort (>45 years of age) suggested that the 
prevalence may be higher than those derived from early 
echocardiography-based studies, with up to 1.4% prevalence, or 1/76 
population.10 In contrast, data from the UK Biobank reported a prevalence of 0.11% of left ventricular hypertrophy (LVH) above 15 mm in a 
population where arterial hypertension and aortic stenosis were excluded (0.22% in men and 0.04% in women).11 Of note, (likely and definite) pathogenic gene variants have been detected in up to 60% of 
HCM.12 
The prevalence of dilated cardiomyopathy (DCM) has been traditionally estimated at 0.036% (95% CI, 0.023–0.050) or 1/2740 based 
on one large population study.13 More recent data suggest that the 
prevalence of DCM may be almost 10 times higher, based on indirect 
assumptions of the prevalence of genetic variants associated with the 
disease in general populations14 and with less stringent diagnostic criteria.15 Likely and/or definitely pathogenic gene variants occur in up 
to 40% of DCM,16 and the prevalence of (likely) pathogenic genetic variants is also over 10% in non-familial DCM. 
The true prevalence of ARVC based on the pooled analysis of three 
relatively large series is estimated at 0.078% (95% CI, 0.077–0.078) or 
1/1290.17–19 However, substantial geographical differences in the estimated population prevalence have been reported. 
Data from the EURObservational Research Programme (EORP) 
Cardiomyopathy and Myocarditis registry with consecutive inclusion 
of cardiomyopathy cases provide information on the relative burden 
of cardiomyopathies seen in specialized clinics across Europe.20 
Hypertrophic cardiomyopathy burden in inherited cardiac disease units 
is 1.4 times higher than DCM, 12.2 times higher than classical ARVC, 
and 26.3 times higher than restrictive cardiomyopathy (RCM).  
ESC Guidelines                                                                                                                                                                                                 3


<!-- PAGE 4 -->

### Page 4

1.2. Paediatric cardiomyopathies 
Overall, the annual incidence of paediatric cardiomyopathies is estimated to be about 1 per 100 000 children, with the highest incidence 
in the first year of life, based on population studies in Finland, the 
United States of America, and Australia.21–23 
Paediatric cardiomyopathies form a diverse group of uncommon diseases, including genetic causes, metabolic or neuromuscular diseases, 
toxic causes, and infections. Dilated cardiomyopathy and HCM make 
up ∼50% and 25% of all children with cardiomyopathy, respectively, 
whereas ARVC rarely presents in the first decade of life.21,23 
Restrictive cardiomyopathy is rare in childhood. The annual incidence 
of DCM is 0.34–0.58 per 100 000 children, with the highest incidence 
in infants (<1 year of age) of 3.80–4.58 per 100 000.21–24 The annual 
incidence is higher in boys than in girls (0.66 vs. 0.47) and in Blacks 
than in Whites (0.98 vs. 0.46).25 Data from the Paediatric 
Cardiomyopathy Registry (PMCR) suggest that 66% of children have 
idiopathic disease. Of known causes, myocarditis was the most common (46%), followed by neuromuscular disease (26%), familial DCM 
(14%), metabolic disease (11%), and malformation syndrome (3%).25 
In the current era, clinical genetic testing detects a genetic cause in 
about one-third of paediatric DCM cases, including a relatively high percentage of de novo mutations.26,27 The overall annual incidence of HCM 
is 0.24–0.47 per 100 000 children.21–23 A large peak in incidence in the 
first year of life is mainly caused by HCM due to metabolic disorders 
and malformation syndromes. Another smaller peak in the second decade is mainly due to sarcomeric diseases.28 Arrhythmogenic right ventricular cardiomyopathy is very rare in early childhood; however, large 
ARVC registry data show that ∼15% of ARVC patients present with 
paediatric onset disease with mean 15.3 ± 2.4 years of age. Paediatric 
ARVC patients more often present with sudden cardiac death 
(SCD).29,30 Restrictive cardiomyopathy is very rare, with an annual incidence of 0.03–0.04 per 100 000 children.21,23 Age at diagnosis ranges 
from infancy to adolescence; however, in contrast with other paediatric 
cardiomyopathies, RCM shows no peak in infancy and the incidence increases with age.31 
1.3. Special populations 
Direct causes of cardiomyopathies include pathogenic gene variants, 
toxins (e.g. alcohol, chemotherapy), autoimmunity, storage diseases 
(e.g. Fabry disease), infiltrative diseases (e.g. amyloidosis), various stressors (e.g. pregnancy, tachyarrhythmias), or infections. 
Several forms of DCM previously considered secondary to external 
factors were recently proved to have genetic contributors, including alcoholic cardiomyopathy (AlcCM), cancer therapy-induced cardiomyopathy (CCM), and peripartum cardiomyopathy (PPCM). Titin gene 
truncating variants (TTNtv) represent a prevalent genetic predisposition 
for AlcCM (present in 13.5% vs. 2.9% in controls), as they are associated 
with a worse left ventricular ejection fraction (LVEF) in DCM patients 
who consume alcohol above recommended levels.32 Unrecognized 
rare variants in cardiomyopathy-associated genes, particularly TTNtv 
(in 7.5% of cases), appeared to be associated with an increased risk 
of CCM in children and adults, and adverse cardiac events in adults.33 
Rare truncating variants in eight genes were found in 15% of women 
with PPCM, and two-thirds were TTNtv (10% of patients vs. 1.4% of 
the reference population).34,35 Additionally, other truncating variants 
were identified in the genes DSP (1%), FLNC (1%), and BAG3 (0.2%).35 
Hypertrophic cardiomyopathy can represent the common phenotype for several phenocopies and genocopies.12 Anderson–Fabry disease was found in 0.94% of males and 0.90% of females in cardiac 
screening programmes for LVH and HCM.36 Screening with bone scintigraphy found a high prevalence of transthyretin cardiac amyloidosis in 
specific populations: 11.4% in aortic stenosis, 4.8% in heart failure with 
preserved ejection fraction, 12.9% in LVH/HCM, and 2.6% in carpal tunnel syndrome (more if it is bilateral).37 
The concept that cardiomyopathies are more prevalent than initially 
thought has generally been accepted by the scientific community, but 
more work needs to be done to ensure that the classification and detection of these rarer cardiac conditions are carried out in a systematic 
manner. 
2. The patient pathway 
2.1. Genetic testing 
2.1.1. Variant interpretation 
If a variant is identified in a gene known to be associated with the presenting phenotype, the laboratory will classify it according to a 5-tier 
system. Where there is sufficient evidence to support causation, the 
variant will be classified as pathogenic or likely pathogenic (P/LP). 
Conversely, where there is sufficient evidence to support a variant as 
not being the cause of disease, it is classified as benign or likely benign. 
Where there is conflicting or insufficient evidence, this will be considered a variant of uncertain significance (VUS). Benign/likely benign variants may not be included in the report. Pathogenic and benign 
classifications convey high confidence regarding the causal significance 
of a variant. ‘Likely’ represents >90% likelihood that a variant is pathogenic or benign, usually sufficient confidence to act on a result. Often 
there are insufficient data to achieve 90% confidence for or against 
pathogenicity, and variants are reported as uncertain. There are 
many rare variants in the genomes of healthy individuals, and many of 
these, even in well-known disease-associated genes, are innocent bystanders and not causative for the observed disease. VUS should therefore not be used for cascade testing and are seldom actionable in the 
proband. 
It is important for the clinician to recognize when they can contribute 
additional information that might allow a VUS to be re-interpreted with 
more confidence, and the laboratory will often flag in the report if extra 
information might be sufficient to reclassify. For example, if a variant is 
not inherited from either parent, then it has likely arisen de novo in the 
affected individual and is more likely to be pathogenic. Segregation analysis may reveal that the variant is shared by several affected relatives, 
providing additional evidence for a role in disease rather than a bystander role. Reclassification of variants can be challenging for patients and 
families,38,39 but should be part of pre-test genetic counselling 
discussions. 
2.2. Genetic counselling 
2.2.1. What is genetic counselling? 
Genetic counselling is a process that aims to support patients and their 
families to understand and adapt to the medical, psychosocial, and familial impact of genetic diseases.40,41 Genetic counselling can include 
discussion of inheritance risks, provide education, perform pre- and 
post-genetic test counselling and variant interpretation, obtain a three- 
generation family history, and provide psychosocial support.42 The 
unique psychosocial needs of the inherited cardiomyopathy patient 
population have shaped the field of cardiac genetic counselling.43 For 
those with a new diagnosis, there can be difficulty adjusting to life 
with an inherited cardiomyopathy, challenges living with an implantable


<!-- PAGE 5 -->

### Page 5

cardioverter defibrillator (ICD), and ongoing trauma and grief for those 
who have experienced a young SCD in their family. Attention to the 
psychological support needs of patients is therefore critical. Indeed, 
in the general setting, genetic counselling can improve knowledge, recall, and patient empowerment; increase satisfaction with decision- 
making; and reduce anxiety.44–47 
2.2.2. Who performs genetic counselling? 
Genetic counselling is a process that is preferably performed by healthcare professionals with specific training, such as genetic counsellors, 
genetic nurses, or clinical/medical geneticists. Regardless of who takes 
on this role, it involves more than simply the provision of information: 
it requires careful attention to psychosocial needs. A systematic review 
of genetic counselling communication showed that higher levels of empathic responses, less verbal dominance (ratio of counsellor to patient 
talk), and the provision of a summary letter were associated with more 
positive outcomes.48 
2.2.3. Genetic counselling in paediatrics 
Genetic counselling performed by trained healthcare professionals 
working within a multidisciplinary team is recommended for all children 
with all types of cardiomyopathies, regardless of whether genetic testing is being considered. 
There are specific issues to consider when counselling children and 
their families and considering clinical screening and predictive genetic 
testing.49–51 The guiding principle remains that any testing, clinical or 
genetic, should be in the best interests of the child and have an impact 
on management, lifestyle, and/or ongoing clinical testing.50 The psychosocial impact should be considered and counselling should take place in 
the context of a multidisciplinary setting involving the child and their 
family.42,52–54 With appropriate multidisciplinary support in a paediatric 
setting, psychosocial outcomes in children undergoing clinical screening 
and predictive genetic testing are no different than those of the general 
population.54 Pre- and post-test counselling should be performed,42,53 
and the wishes of the child in terms of testing and disclosure of results 
should be at the forefront. Although the Task Force acknowledges that 
different healthcare systems may not allow for this, psychological support should be made available to all children and families with cardiomyopathy or undergoing clinical and/or genetic testing, with a particular 
focus on those with a recent diagnosis, a family history of SCD, and 
who are at important points during childhood, such as moving from primary to secondary education and transitioning from paediatric to adult 
services.52,54–56 
2.2.4. Pre- and post-test genetic counselling 
(proband) 
One critical role for genetic counselling is alongside genetic testing. This 
includes a discussion prior to a decision to undertake genetic testing 
(pre-test) and when the results are returned (post-test). Pre-test genetic counselling focuses on the collection of a detailed family history, 
providing genetic education about inheritance risks, the process and logistics of genetic testing and options for return of the results, an explanation of all possible outcomes, clinical and family implications, the risk of 
reclassification and identification of secondary genetic findings, insurance implications, and an exploration of feelings and understanding of 
the information provided. Post-test discussions include a review 
of the key points previously discussed in the pre-test session, return 
of the result, discussion of the implications of this result to the patient’s 
care, and implications for the family. It can be helpful to provide tailored 
information from the family history, explicitly noting every family member’s inheritance risk, and clinical and genetic testing options. Where a 
suspicious VUS has been identified, specific explanation of what this 
means is important, including whether there is a plan for resolving it, 
such as segregation to other affected relatives in the family, and how 
often the classification will be reviewed. There should be ample opportunity for questions or clarification at all points in the process. 
2.2.5. Cascade genetic testing 
Once a P/LP variant has been identified within an index patient following investigations of relevant disease genes associated with the specific 
phenotype, it is possible to offer cascade genetic testing of first-degree 
at-risk relatives, including pre-test genetic counselling. In a scenario 
where a first-degree relative has died, evaluation of close relatives of 
the deceased individual (i.e. second-degree relatives of the index patient) should also be considered. Genetic cascade screening should continue for all offspring of relatives who are shown to carry a P/LP variant. 
Relatives who do not carry the variant can be dismissed from follow- 
up, while genotype-positive relatives should continue regular clinical 
evaluation. 
The right assignment of the level of pathogenicity of a variant is crucial for cascade genetic testing. Inappropriate use of genetic testing in a 
family has the potential to introduce unnecessary worry and fear, as 
well as potential harm related to the misinterpretation of genetic variants. Therefore, it is advised that variants should be classified by a specialized multidisciplinary cardiac genetic team with an appropriate level 
of expertise. In this context, it is important to understand that up to 
50% of published variants are wrongly classified. In addition, systematic 
reclassification of identified variants is crucial, including its communication to families, emphasizing the need for these specialized multidisciplinary cardiogenetic teams. 
2.2.6. Uptake of genetic counselling and testing 
Several studies have evaluated the uptake of genetic testing and counselling and/or cardiological screening in inherited cardiomyopathies in 
first-degree relatives of index patients. Roughly 39–45% of at-risk relatives for an inherited cardiomyopathy come for screening within 1–2 
years after the identification of the pathogenic variant in the family.57–60 After a longer follow-up (median 16 years) this increased to 
60%.60 A first-intervention study (more intensive discussion of informing relatives at risk with the index patient, followed by a family letter 
sent directly to the relatives) did not increase the uptake.60 This suboptimal uptake leaves room for improvement, and future studies will 
give guidance on how to do this. Currently, it is recommended to discuss with the index patient how they will reach out to first-degree relatives and how the healthcare provider can help and provide support. 
2.2.7. Approaching relatives of the index patient 
At-risk relatives are generally informed by the index patient, who is supported with a family letter about the condition, the content of the family screening programme, and links to relevant websites with further 
information. However, the approach to relatives varies between countries due to differences in tradition and legislation. 
The discussion of how to approach family members is an important 
part of the genetic counselling process with the index patient. 
For a variety of reasons, the index patient may refuse to inform at- 
risk relatives of having inherited the condition and about the offer of 
family screening. This is a cause for concern, since most inherited cardiac conditions (ICCs) are associated with adverse complications and  
ESC Guidelines                                                                                                                                                                                                 5


<!-- PAGE 6 -->

### Page 6

SCD, which may be prevented if diagnosed in due time. Depending on 
the legislation of each country, it may be possible to bypass the index 
patient and approach at-risk relatives directly. This may be done 
through a letter informing each relative that a hereditary condition is 
suspected in the family and that they should contact the ICC unit and 
obtain more information if they wish. Sometimes, affected relatives 
may refuse to have their minor children investigated; an issue which 
may be difficult to solve unless there is legislation in place that outlines 
how to deal with this issue. 
When these kinds of difficult situations occur, it is important to be 
patient and try to understand the reasons of the affected individuals 
for withholding information from at-risk relatives. Offering repeated 
counselling sessions or suggesting a phone call with relatives at a later 
stage are two possible solutions. Usually, however, the problem resolves once the affected individual has had sufficient time to consider 
the implications. 
2.2.8. Inheritance and family communication 
Knowing that one’s family is at increased risk of inheriting a genetic condition can create uncertainty and worry for many index patients. 
Because most inherited cardiomyopathies follow an autosomal dominant inheritance pattern, there is a need to communicate the importance 
of both clinical and genetic testing of relatives. Conveying this information to at-risk relatives is typically reliant on the proband in the family 
understanding the information and passing it on to the appropriate relatives. Numerous studies show that effective family communication is 
an important challenge, and interventions to support communication 
have so far not yielded favourable results, highlighting the multidimensional nature of the issue.52,60,61 Common barriers to communication 
may include poor family relationships; guilt about passing a causative 
variant on to children; psychosocial factors, including distress; and comprehension of the result.62,63 A patient will often selectively communicate genetic information to relatives, assessing their ability to 
understand and cope with the information, their life stage, and risk status.61 Health literacy is an important barrier to effectively communicating genetic risk information to relatives, highlighting the need for 
targeted resources and mechanisms for support.64 
2.2.9. Psychological support 
Coming to terms with a diagnosis of an inherited cardiomyopathy can 
be difficult and have a significant impact on psychological well- 
being.43,65–70 
As a patient, being at risk of hereditary cardiomyopathy is not only a 
matter of facts and test results, but also of perception: while one affected family member can have only mild symptoms that can be treated 
with medication, others may have a different outcome with a greater 
impact in terms of the treatment needed (e.g. ICD or transplant). 
This fact should be considered when treating a family with a hereditary 
cause of cardiomyopathy, in aspects such as the communication of test 
results and targeting psychological needs. Not every patient within a 
family has the same burden of symptoms and/or disease outcome. 
The ‘estimate of risk’ is not only a matter for the professional caretaker in terms of how to treat the patient: the impact on the patient 
themselves and the consequences of that treatment may necessitate 
a very thorough and professional need for psychological assistance. 
The psychological well-being of a patient with cardiomyopathy has a 
broad range of aspects to consider, from the very personal to specific 
and practical needs: 
• Self-care should be clearly emphasized: from day-to-day blood pressure testing to the importance of a strict medication schedule. This 
contributes to a patient’s feeling of self-control. 
• The aspects of treatment (medication, ICD, transplant) that have an 
effect on daily life should be clearly communicated (e.g. medication 
schedule, side effects of medication, diet restrictions, exercise restrictions, etc.). 
• The significance of the hereditary component of the condition should 
be made clear, as the possibility of having children with the defect (or 
the decision not to have children at all) can be a difficult burden to 
bear for many patients. 
• Practical issues should be emphasized (these may vary according to 
local legislation); e.g. seeking a mortgage, getting a driver’s licence, 
career planning, etc.  
Psychological assistance should support and encourage the patient as 
well as the family, but also give guidance to the patient to try to find answers to the very specific challenges they will face. 
3. Specific entities 
3.1. Hypertrophic cardiomyopathy 
3.1.1. Cardiac magnetic resonance imaging and 
sudden cardiac death risk in hypertrophic 
cardiomyopathy 
Although current data suggest that the extent of late gadolinium enhancement (LGE) on CMR may be of use in predicting cardiovascular 
mortality, data in regards to the use of LGE in the prediction of SCD 
risk are conflicting (Table S1). Similarly, the roles of the presence of 
LV apical aneurysms (Table S2) and LV systolic dysfunction 
(Table S3) as additional independent predictors of SCD risk in HCM remain to be determined.


<!-- PAGE 7 -->

### Page 7

Table S1 Studies on the role of late gadolinium enhancement in predicting sudden cardiac death in patients with hypertrophic cardiomyopathy 
Study name 
or first 
author 
Details and quality of evidence 
Summary of key findings 
Study type 
Number of 
patients and 
follow-up 
duration 
Key inclusion and exclusion 
criteria 
Relevant aims and 
outcome(s) 
Key findings 
Conclusions and limitations  
Maron et al., 
200871 
Observational, 
prospective 
n = 202 
Two centres 
FU: 681 ± 249 days 
Inclusion: consecutive HCM pts 
Aim: describe clinical profile 
and relation of LGE to CV 
outcomes 
Adverse cardiovascular events in 
11/202 pts. 
Among 7/11 with LGE: 
• 2 died suddenly; 
• 2 had appropriate ICD discharge; 
and 
• 3 with progressive HF symptoms 
vs. 4/11 pts without LGE: 
• 3 with sudden death; and 
• 1 with progressive HF. 
Annual cardiovascular event rate in 
HCM pts with LGE exceeded that 
of pts without LGE (5.5% vs. 3.3%), 
but not statistically significant (HR 
1.45; 95% CI, 0.43–4.97; P = 0.5) 
Conclusions: 
LGE was an independent 
predictor of systolic dysfunction. 
Data insufficient to consider LGE 
as an independent risk factor for 
adverse prognosis 
Bruder et al., 
201072 
Observational, 
prospective 
n = 243; 220 in 
analysis 
Single centre 
Mean FU: 1090 days 
Inclusion: 
consecutive HCM pts 
Exclusion: 
Hx of previous septal ablation or 
myectomy, known coronary artery 
disease, aortic stenosis, amyloidosis, 
systemic hypertension, or 
contraindications to CMR 
Primary endpoints:  
(i) all-cause death; and  
(ii) cardiac 
death 
(death 
from all cardiac causes, 
including SCD, heart 
failure, and aborted 
SCD)  
All-cause mortality: 20/220 
SCD: 11/220 among which 2 with 
ICD discharged 
Univariate analysis for SCD: 
Presence of LGE: OR 5.14; 95% CI, 
0.65–41.0; P = 0.10 (non-significant) 
Multivariable Cox regression 
analysis, (presence of LGE, 
LVEF, and LV mass): 
LGE independent predictor of 
cardiac death (HR 4.81; P = 0.035) 
Not performed in the subgroup of 
SCD patients (n = 11, limited 
number of events) 
Conclusions: 
LGE is a predictor of all-cause and 
cardiac mortality. Unable to 
demonstrate statistically 
significant relation to SCD 
Limitations: 
single centre, small size, limited 
number of events                                                     
Continued  
ESC Guidelines                                                                                                                                                                                                 7


<!-- PAGE 8 -->

### Page 8

O’Hanlon 
et al., 201073 
Observational, 
prospective 
n = 217 
Single centre 
Mean FU: 3.1 ± 1.7 
years 
Inclusion: consecutive HCM pts 
Exclusion: significant coronary 
artery disease, or prior SRT 
Combined primary endpoint:  
(i) CV death;  
(ii) unplanned CV  
admission;  
(iii)  sustained VT/VF, or  
(iv)  appropriate ICD  
discharge 
Secondary outcomes:  
(i) HF;  
(ii) arrhythmic  
Primary endpoint: 40/217 
(18.4%) pts 
• 34/136 (25%) in the LGE group 
• 6/81 (7.4%) in the non-LGE group 
(HR 3.4; 95% CI, 1.4–8.1; P = 0.006) 
CV deaths: 9 
LGE group: 8 
Multivariable analysis: 
presence and amount of LGE 
remained independent predictors 
of the primary endpoint (HR 2.7; 
95% CI, 1.01–7.1; P = 0.046) 
Arrhythmic endpoint: 12/217 
overall 
• LGE group: 10/136 (7.3%), and 
• non-LGE group: 2/81 (2.5%) 
(HR 3.15; 95% CI, 0.69–14.4; P =  
0.138) 
Univariate analysis: 
the amount of LGE was significantly 
associated with the outcome (HR 
1.30; 95% CI, 1.05–1.61; P = 0.014), 
but in the multivariable analysis: 
NSVT was the strongest predictor. 
No other variables were added to 
the model (low event rate) 
Conclusion: 
LGE is an independent predictor 
of adverse outcomes. Longer 
follow-up in a larger cohort will 
clarify the role of LGE as a risk 
factor in SCD prediction 
Limitations: single referral 
centre, small cohort, 
underpowered, low event rate, 
selection bias (pts with ICDs 
excluded at baseline) 
Rubinshtein 
et al., 201074 
Observational, 
retrospective 
n = 424 
Single centre 
Mean FU: 43 ± 14 
months 
Inclusion: consecutive HCM pts 
Exclusion: ICD in situ, previous hx 
of SRT 
Aims:  
(i) evaluate 
the 
relation 
between LGE and HCM 
genes status, severity of 
symptoms, and the 
degree of ventricular 
ectopy on Holter ECG;  
(ii) Outcomes of SCD and 
appropriate ICD 
therapies were recorded  
Outcome occurred in 8/424 pts 
• SCD 4 pts; and 
• ICD discharge: 4 pts 
All 8 pts had LGE 
In addition to LGE, the presence of 
NSVT was another univariate 
associate of events (HR 6.9; 95% CI, 
1.14–52.4; P = 0.04) 
No multivariable Cox model 
analysis performed (low event rate). 
On bivariate analysis LGE remained 
associated with events after 
controlling for all other parameters 
Conclusion: 
LGE remained a significant 
associate of subsequent SCD or 
appropriate ICD therapies after 
controlling for other factors 
Limitations: 
single centre, selection bias, low 
event rate, lack of multivariate 
Cox model, high number of SRT 
in FU                                                                       
Continued


<!-- PAGE 9 -->

### Page 9

Green et al., 
201275 
Systematic 
review and 
meta-analysis 
n = 1063 
Pooled HCM pts 
from 4 studies (1–4) 
Mean FU: 3.1 years 
Inclusion: 
studies of LGE in HCM that 
reported outcomes of 
cardiovascular mortality, SCD, 
aborted SCD, and HF death 
Aim: 
association of LGE with CV 
mortality, SCD, aborted 
SCD, and HF death 
LGE correlated with: 
• cardiac death (OR 2.92; 95% CI, 
1.01–8.42; P = 0.047) 
• HF death (OR 5.68; 95% CI, 1.04– 
31.07; P = 0.045); and 
• all-cause mortality (OR 4.46; 95% 
CI, 1.53–13.01; P = 0.006), 
but was not significant for SCD/ 
aborted SCD (OR 2.39; 95% CI, 
0.87–6.58; P = 0.091) 
Conclusion: 
there are significant relationships 
between LGE and cardiovascular 
mortality, heart failure death, and 
all-cause mortality in HCM. 
Additionally, LGE and SCD/ 
aborted SCD displayed a trend 
toward significance 
Chan et al., 
201476 
Observational, 
prospective 
n = 1293 
7 HCM centres 
Mean FU: 3.3 years 
Inclusion: consecutive HCM 
patients with CMR at first evaluation 
Exclusion: 
prior ICD implantation or history of 
sustained VT/ VF, claustrophobia, 
obstructive coronary artery disease, 
septal myectomy or alcohol ablation 
(before CMR), and incomplete 
follow-up 
SCD composite endpoint: 
HCM-related sudden death, 
aborted arrest, ICD 
discharge 
Cumulative SCD events incidence: 
0.9%/year 
SCD events in 37/1293 patients 
(3%): 
• 14/1293 died suddenly; 
• 6/1293 aborted cardiac arrest; 
• 17/1293 appropriate ICD therapy 
LGE present in 548/1293 pts (42%): 
• ≤10% of the LV mass (n = 381, 
29%); 
• 11–19% (n = 94, 7%); 
• ≥20% (n = 73, 6%) 
Among 37 pts with SCD events, 
LGE was present in 26 (70%), 
occupying 13 ± 14% of the LV 
myocardium 
Each 10% increase in LGE was 
associated with 40% increase in 
relative SCD events risk (adjusted 
HR 1.46 for 10% increase in LGE; 
95% CI, 1.12–1.92; P = 0.002) 
Compared with patients without 
LGE, the adjusted (for conventional 
risk factors and EF) HR of SCD 
events related to %LGE: 
• 10%, 1.46; 
• 15%, 1.77; 
• 20%, 2.14 
In low-risk pts SCD event risk 
increased in direct proportion to 
extent of LGE (HR 1.66/10% LGE; 
95% CI, 1.24–2.23; P = 0.0007) 
The absence of LGE was associated 
with lower risk of SCD events 
(adjusted HR 0.39; 95% CI, 0.18– 
0.84; P = 0.02) 
Conclusions: 
extensive LGE provides additional 
information for assessing SCD 
event risk among HCM patients, 
particularly patients otherwise 
judged to be at low risk 
Limitations: selection bias, 
exclusion of high-risk pts with 
ICDs, low event rate in HCM. 17 
out of 37 ICD shocks potentially 
non-fatal arrhythmias                                                
Continued  
ESC Guidelines                                                                                                                                                                                                 9


<!-- PAGE 10 -->

### Page 10

Ismail et al., 
201477 
Observational, 
prospective 
Size: 711 
Median FU: 
3.5 years 
Single HCM centre 
Inclusion: consecutive HCM pts 
Exclusion: 
previous myectomy or alcohol 
septal ablation; previous myocardial 
infarction; or contraindications to 
CMR (including prior device 
implantation) and gadolinium-based 
contrast agents 
Primary endpoint: SCD or 
aborted SCD 
SCD composite endpoint 22/711 
pts (3.1%), in detail: 
• 18 (3.8%) pts with LGE and 4 
(1.7%) with no LGE (HR LGE, 
2.69; 95% CI, 0.91–7.97, P =  
0.073) 
Patients with LGE were more likely 
to have extreme hypertrophy (LV 
wall thickness ≥30 mm) and 
non-sustained VT at baseline. 
On univariable analysis, the amount 
of fibrosis was a significant predictor 
of outcome: (HR per 5% LGE 1.24; 
95% CI, 1.06–1.45, P = 0.007) 
On multivariable analysis, only LVEF 
was an independent predictor (HR 
0.92; 95% CI, 0.89–0.95, P ≤ 0.001) 
Increasing %LGE was associated 
with increased risk. However, not 
statistically significant after adjusting 
for EF 
Conclusions: 
the amount of myocardial fibrosis 
is an important predictor of 
outcome in HCM but may not 
provide information incremental 
to EF. 
Limitations: single centre. Small 
size. Low event rate. Selection 
bias. High-risk pts with ICDs 
excluded. Methodology of LGE 
quantification 
Briasoulis 
et al., 201478 
Meta-analysis 
n = 3067 
Pooled pts from 6 
HCM studies. 
Mean FU: 3.05 years 
Inclusion: 
prospective HCM studies reporting 
the effects of LGE on clinical 
outcomes (SCD/aborted SCD, 
all-cause mortality, cardiac and heart 
failure death) 
Aim: 
assess the utility of CMR on 
LGE as a prognostic factor of 
SCD in HCM 
SCD/aborted SCD in HCM pts with 
LGE was significantly increased as 
compared with pts without LGE 
(OR 2.52; 95% CI, 1.44–4.4; P =  
0.001) 
The extent of LGE was not 
significantly related to the risk of 
SCD 
Conclusion: 
LGE is significantly associated with 
SCD risk, cardiac mortality, and 
all-cause mortality in patients with 
non-high-risk HCM according to 
conventional risk factors                                           
Continued


<!-- PAGE 11 -->

### Page 11

Mentias et al., 
201879 
Observational, 
retrospective 
n = 1423 (458 
non-obstructive, 
965 obstructive) 
Single HCM centre 
Median FU: 
4.5 years 
Inclusion: consecutive low-/ 
intermediate-risk HCM pts with 
preserved LVEF undergoing CMR. 
Exclusion: 
prior device implantation; 
claustrophobia; high SCD risk pts; 
≥moderate aortic/mitral stenosis; 
subaortic membrane; LGE pattern 
consistent with ischaemic 
myocardial damage; LVEF <50%; 
prior history of alcohol septal 
ablation or surgical myectomy; and 
prior mitral and/or aortic valve 
replacement 
Primary composite endpoint: 
actual SCD, successful 
resuscitation from cardiac 
arrest or appropriate ICD 
shocks 
60/1423 (4%) composite primary 
events: 
• 40 actual SCD; 
• 20 appropriate ICD discharges 
Any LGE on CMR: 717 (50%) pts 
Risk of primary events increased 
when %LGE increased ≥15% 
Entire cohort: 32 pts with primary 
event of 342 (9%) with %LGE ≥15% 
vs. 28 pts of 1081 (3%) with %LGE  
< 15%; P < 0.001 
%LGE on univariable analysis: 
• >0 to <15% (HR 1.41; 95% CI, 
0.87–2.39; P = 0.39) 
• ≥15% (HR 2.34; 95% CI, 1.29– 
3.31; P ≤ 0.001) 
%LGE on multivariable 
competing risk regression 
analysis (Fine Gray method, 
ESC risk score in the model) 
for primary composite 
events: 
obstructive group: 
• >0 to <15% (HR 1.52; 95% CI, 
0.91–5.39; P = 0.21) 
• ≥15% (HR 3.04; 95% CI, 1.48– 
6.10; P = 0.003) 
Non-obstructive group: 
• >0 to <15% (HR 1.43; 95% CI, 
0.87–7.16; P = 0.32) 
• ≥15% (HR 2.84; 95% CI, 1.27– 
6.34; P = 0.01)  
Conclusions: 
%LGE ≥15% was associated with 
increased risk of primary 
composite events in patients with 
low/ intermediate SCD risk and 
preserved EF. 
Limitations: 
retrospective single centre study. 
Selection bias, exclusion of 
high-risk pts, SRT referral centre 
(high volume of myectomy pts) 
© ESC 2023
CI, confidence interval; CMR, cardiac magnetic resonance; CV, cardiovascular; ECG, electrocardiogram; EF, ejection fraction; ESC, European Society of Cardiology; FU, follow-up; HCM, hypertrophic cardiomyopathy; HF, heart failure; HR, hazard ratio; 
Hx, history; ICD, implantable cardioverter defibrillator; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; OR, odds ratio; pts, patients; SCD, sudden cardiac death; 
SRT, septal reduction therapy; VF, ventricular fibrillation; VT, ventricular tachycardia.   
ESC Guidelines                                                                                                                                                                                               11


<!-- PAGE 12 -->

### Page 12

Table S2 Apical aneurysms and sudden death in hypertrophic cardiomyopathy 
Study 
name or 
first 
author 
Details and quality of evidence 
Summary of key findings 
Study type 
Number of patients 
and intervention(s) 
Key inclusion and 
exclusion criteria 
Relevant outcome(s) 
Key findings 
Conclusion(s)  
Rowin 
et al., 
201780 
Retrospective 
observational 
93 pts from 2 centres 
Inclusion: 
diagnosis of HCM and 
apical aneurysm on 
cardiac MRI and/or echo 
Exclusion: 
known obstructive 
coronary artery disease 
SCD composite endpoint 
(actual SCD + resuscitated 
cardiac arrest + appropriate 
ICD therapy) 
Composite endpoint event rate 
4.7%/year vs. 0.9%/year in 
remaining HCM cohort. 
SCD composite endpoint 21/93 
pts (22.6%), in detail: 
• Actual SCD: 1.1% (1/93 pts) 
• Aborted SCD: 2.2% (2/93 pts) 
• Appropriate ICD therapy 
19.4% (18/93 pts). Rhythm 
was monomorphic VT in 89% 
(16/18 pts)  
Conclusion: 
HCM patients with LV apical aneurysms are at 
high risk of arrhythmic sudden death 
Limitations: 
selection bias, high prevalence of confounders 
in patients with events (previous VT/VF and LV 
systolic function) 
Lee et al., 
2022 81 
Retrospective 
observational 
160 pts from a single 
centre 
Inclusion: diagnosis of 
HCM and apical aneurysm 
on cardiac MRI and/or 
echo 
Exclusion: history of 
anterior infarction or 
significant LAD stenosis 
SCD composite endpoint 
(actual SCD + resuscitated 
cardiac arrest + appropriate 
ICD therapy) 
Composite endpoint event rate 
1.8%/year 
SCD composite endpoint 14/ 
160 pts (8.8%), in detail: 
• actual SCD: none 
• aborted SCD: 4.4% (7/160 
pts) 
• appropriate ICD therapy 
4.4% (7/160 pts). Rhythm not 
specified  
Conclusion: 
LV apical aneurysms in HCM are a high-risk 
phenotype, associated with increased risk of 
adverse cardiovascular events, including 
malignant ventricular arrhythmias 
Limitations: 
selection bias, high prevalence of confounders 
in patients with events (previous VT/VF and LV 
systolic function) 
© ESC 2023
HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LAD, left anterior descending; LV, left ventricular; MRI, magnetic resonance imaging; pts, patients; SCD, sudden cardiac death; VT, ventricular tachycardia; VF, ventricular 
fibrillation.


<!-- PAGE 13 -->

### Page 13

Table S3 Studies on the prevalence of and predictors for left ventricular systolic dysfunction in patients with hypertrophic cardiomyopathy 
Study name or 
first author 
Number 
Specific subset 
LVSD 
prevalence 
Annual incidence 
of HCM-LVSD 
Main endpoints 
Multivariable analysis for prediction of SCD 
events  
Wasserstrum 
et al.82  
1328 
None 
2.8% 
0.39% 
All-cause mortality or ventricular assist 
device or transplant 
Not available 
Biagini et al.83  
222 
Both paediatric and adult 
patients 
4.9% 
0.53% 
Cardiovascular death (SCD, HF-related 
death, stroke-related death) 
LV wall thickness (HR 1.07; 95% CI, 1.01–1.14; P =  
0.03) and LV end-diastolic diameter (HR 1.08; 95% CI, 
1.04–1.11; P = 0.0001)a 
Thaman et al.84  
1080 
Serial echocardiography 
substudy (n = 462) 
2.4% 
0.87% 
Composite of SCD and ICD firing; 
composite of all-cause death, ICD firing, 
and heart transplantation 
Not available 
Harris et al.85  
44 
None 
3.5% 
1.12% 
Death, SCD, ICD firing, heart 
transplantation 
Not available 
Kawarai et al.86  
43 
Incident HCM-LVSD 
8.7% 
0.73% 
Sudden death including also non-fatal 
cardiac arrest and appropriate ICD 
intervention 
Among HCM-LVSD the presence of syncope resulted 
as an independent predictor of sudden death (HR 6.15; 
95% CI, 2.40–15.75; P < 0.001)b 
Rowin et al.87  
2447 
None 
4.8% 
na 
SCD events, heart transplant listing, 
HCM-related death, all-cause death 
Not available 
SHaRe 
Consortium88  
6793 
None 
8.1% 
na 
All-cause death, heart transplantation, 
sudden death, ICD activation 
Adjustedc HCM-LVSD HR for SCD, 3.9; 95% CI, 2.6– 
6.3; P < 0.001; adjusted HCM-LVSD HR for ICD 
activation, 1.6; 95% CI, 1.4–1.8; P < 0.001 
© ESC 2023
CI, confidence interval; HCM, hypertrophic cardiomyopathy; HF, heart failure; HR, hazard ratio; ICD, implantable cardioverter defibrillator; LV, left ventricular; LVSD, left ventricular systolic dysfunction; na, not available; pts, patients; SCD, sudden cardiac 
death; VT, ventricular tachycardia. 
aGender, age at first evaluation, family history of sudden death, New York Heart Association (NYHA) functional class I to II or III to IV, medical treatment at first evaluation, non-sustained ventricular tachycardia, LV outflow obstruction, maximum LV wall 
thickness, posterior wall thickness, LV end-diastolic diameter, end-systolic left atrial diameter, and (as a time-dependant covariate) dilated-hypokinetic evolution. 
bMultivariable Cox regression including: positive family history, maximum LV wall thickness >30 mm at the initial diagnosis of HCM, non-sustained VT at the diagnosis of end-stage HCM, and unexplained syncope at the diagnosis of end-stage HCM. 
cBased on a Cox proportional hazards model following patients from initial SHaRe evaluation, adjusted for age, sex, and follow-up time. HR >1 represents an increased risk observed in patients with HCM with LVSD.   
ESC Guidelines                                                                                                                                                                                               13


<!-- PAGE 14 -->

### Page 14

3.2. Restrictive cardiomyopathy 
The systematic approach to the diagnosis of RCM should include clinical examination, ECG, advance cardiac imaging and genetic testing. Table S4 summarizes the spectrum of restrictive heart 
disease.  
Table S4 Spectrum of restrictive heart disease 
Myocardium 
Endocardium 
Pericardium 
Myocytes 
ECV 
RCM, primary, genetic 
Genocopies 
Phenocopies, non-genetic 
Infiltration 
Fibrosis/ECV 
remodelling  
With or without 
intramyocyte 
aggregates of 
misfolded, mutated 
proteins: 
• troponinopathies (1 
most common; T; C) 
• Myosinopathies (MYH7) 
• Desminopathies (DES) 
• BAG30pathies (BAG3) 
• Myotilinopathies 
(MYOT) Filaminopathies 
(FLNC) 
• Ab-crystallinopathies 
(CRYAB) 
• Titinopathies (TTN) 
(rare) 
• Less common: ACTCI, 
MYBPC3, MYL3, TPMI, 
MYL3, MYL2  
Storage diseases with 
intramyocyte 
accumulation: 
Lysosomal diseasesa 
• glycogenoses (pompe, 
Mcardle, Danon, etc.) 
• Glycosphingolipidoses 
(AFD) 
Iron storage diseases, genetic 
forms: 
• HH (myocytes) 
• Friedreich ataxia 
(mitochondria) 
Heritable 
haemoglobinopaties and 
other haematologic diseases 
may cause myocardial iron 
storage 
Toxicity: 
intramyocyte accumulation in acquired 
lysosomal diseases: 
• DIP by cationic amphiphilic drugs: 
e.g. 
chloroquine-hydroxychloroquine 
(other cationic amphiphilic drugs) 
• Less common: 
• serotonin 
• methysergide 
• ergotamine 
• mercurial agents, busulfan 
• heavy metals 
• potentially reversible  
Extramyocyte 
deposition/ 
infiltration: 
• amyloidosis, genetic 
and non-genetica (+ 
myocyte toxicity in 
primary 
amyloidosis) 
• cystinosis, genetic, 
AR (CTNS gene) 
• hyperoxaluria: 
primary, genetic: 
AGXT and GRHPR 
genes; secondary 
(jejunoileal bypass, 
oxalate poisoning, 
drug toxicity)  
Non-specific 
features: 
• diabetic heart 
disease (SVD, 
fibrosis and 
myocyte damage) 
• autoimmune 
diseases (fibrosis, 
large and small 
vessel 
involvement) e.g. 
scleroderma 
• inflammatory, 
granulomatous 
(e.g. sarcoidosis: 
sporadic; rare 
genetic early-onset 
sarcoidosis: 
CARD15/NOD2 
gene  
Diseases affecting 
endomyocardial 
layers: 
• endomyocardial 
fibrosis 
• eosinophilic: tropical 
and non-tropical forms 
(myeloproliferative, 
with hypereosinophilia, 
Löffler endocarditis, 
endocardial 
thrombosis) 
• Endinger syndrome 
(carcinoid heart 
disease) 
• iatrogenic/drug toxicity 
• radiation therapy 
• endocardial neoplasmsa  
Pericardium diseases 
affecting 
pericardium and 
epicardial fat tissue: 
• constrictive pericarditis 
(panpericardial or 
segmental; rare, 
post-pericardiotomy) 
• pericardial tumours,a 
benign (cysts and 
lipomas); malignant 
(primary 
mesothelioma, most 
common) 
• radiation therapy 
• epicardial 
steatonecrosis in heart 
transplantation  
© ESC 2023
AFD, Anderson–Fabry disease; AR, autosomal recessive; DIP, drug-induced phospholipidosis; ECV, extracellular volume; HH, hereditary haemochromatosis; RCM, restrictive cardiomyopathy; SVD, small vessel disease. 
aTumours: rhabdomyomas isolated or in tuberous sclerosis 1 and 2, fibromas; angiosarcomas, fibrosarcomas, rhabdomyosarcomas, liposarcomas, fibrosarcomas, rhabdomyosarcomas, liposarcomas, lymphomas.


<!-- PAGE 15 -->

### Page 15

3.3. Amyloid 
Prognosis in cardiac amyloidosis was originally considered poor but this can be further stratified (Table S5). Several multiparametric biomarker- 
based staging systems have been developed for AL89,90 and ATTR cardiac amyloidosis.91–93 
4. Sports 
Exercise recommendations for the different cardiomyopathies are referred to intensity levels that are provided in Table S6. 
Table S5 Prognostic staging scores in light chain amyloidosis and transthyretin amyloidosis 
Kumar et al.89  
AL 
Lillenes et al.90 
AL 
Grogan et al.93 
ATTRwt 
Gillmore et al.92 
ATTRv and ATTRwt 
Cheng et al.91 
ATTRv and ATTRwt  
Staging parameters: 
FLC-diff >18 mg/dL 
Troponin T > 0.025 ng/mL 
NT-proBNP > 1800 pg/mL 
Staging parameters: 
troponin I > 0.1 ng/mL 
BNP > 81 pg/mL 
Staging parameters: 
troponin T > 0.5 ng/mL 
NT-proBNP > 3000 pg/mL 
Staging parameters: 
eGFR <45 mL/min 
NT-proBNP > 3000 pg/mL 
Scoring parameters: 
Mayo or NAC Score  
(0–2 points) 
Daily dose of furosemide or  
equivalent: 0 mg/kg (0 points),  
>0–0.5 mg/kg (1 point),  
>0.5–1 mg/kg (2 points),  
and >1 mg/kg (3 points) 
NYHA class I–IV (1–4 points)  
Stage 
5-year  
survival 
Stage 
Median 
survival 
Stage 
4-year 
survival/ 
median 
survival 
Stage 
Median 
survival 
Score 
Median survival  
Stage I 
(0 parameters) 
68% 
Stage I 
(0 parameters) 
Not 
reached 
Stage I 
(0 parameters) 
57% 
66 
months 
Stage I 
(0 parameters) 
69.2 
months 
Score 
1–3 
90.5 months 
Stage II 
(1 parameter) 
60% 
Stage II 
(1 parameter) 
112.8 
months 
Stage II 
(1 parameter) 
42% 
40 
months 
Stage II 
(1 parameter) 
46.7 
months 
Score 
4–6 
38.5 months (Mayo) 
36 months (NAC) 
Stage III 
(2 parameters) 
28% 
Stage III 
(2 parameters) 
51.6 
months 
Stage III 
(2 parameters) 
18% 
20 
months 
Stage III 
(2 parameters) 
24.1 
months 
Score 
7–9 
20.3 months (Mayo) 
19.8 months (NAC) 
Stage IV 
(3 parameters) 
14% 
Stage IIIb 
(2 parameters  
and BNP  
>700 pg/mL) 
12 
months       
© ESC 2023
AL, Monoclonal immunoglobulin light chains amyloidosis; ATTRv, Hereditary transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis; BNP, brain natriuretic peptide; eGFR, 
estimated glomerular filtration rate; FLC, free light chain; NAC, national amyloid centre; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association.  
Table S6 Indices for exercise intensity during sport 
Intensity 
VO2max (%) 
HRmax (%) 
HRR (%) 
RPE scale 
Training zone  
Low-intensity, light exercise  
<40  
<55  
<40  
10–11 
Aerobic 
Moderate-intensity exercise  
40–69  
55–74  
40–69  
12–13 
Aerobic 
High-intensity exercise  
70–85  
75–90  
70–85  
14–16 
Aerobic + lactate 
Very high-intensity exercise  
>85  
>90  
>85  
17–19 
Aerobic + lactate + anaerobic 
© ESC 2023
HRmax, maximum heart rate; HRR, heart rate reserve; RPE, rate of perceived exertion; VO2max, maximum oxygen consumption. 
Adapted from Vanhees et al.94   
ESC Guidelines                                                                                                                                                                                               15


<!-- PAGE 16 -->

### Page 16

### 5 Recommendations for

non-cardiac interventions 
Management of patients with HCM and LVOTO deserves careful evaluation. Objectives and specific actions are summarized in Table S7. 
6. Requirements for specialized 
cardiomyopathy units 
6.1. Requirements and skills 
A cardiogenetic unit/cardiomyopathy unit (CGU/CMU) should have access to both outpatient and inpatient facilities within a healthcare provider structure.98–101 The activity of a CGU/CMU is based on the 
availability of multimodality cardiac imaging facilities (echocardiography 
with advanced analysis, CMR, nuclear medicine), electrocardiographic 
(including Holter monitoring), and functional evaluation (cardio- 
pulmonary test, electrocardiogram [ECG] exercise testing). Close collaboration with interventional cardiology, electrophysiology, and cardiac surgery departments is necessary. A genetic team with expertise 
in cardiomyopathies and links to a clinical genetic testing laboratory is 
also required. These units should also provide a framework for discussing the diagnosis, therapeutic options, and prognosis. Clinical psychologists and genetic counsellors assist with the integration of information 
by the patients and their families. These units should also collaborate in 
the management of relatives across different geographic areas. These 
requirements are summarized in Table S8. 
7. Living with cardiomyopathy: 
patient and family education 
Our knowledge of both the clinical and genetic basis of cardiomyopathies has been a rapidly evolving area of cardiology over the last 30 
years. This poses significant challenges to healthcare professionals 
who seek to stay abreast of new knowledge and ensure that their patients are receiving the highest standard of care. This can also be difficult 
for patients who seek to better understand the condition they are being 
assessed or managed for. For a patient and their at-risk family members, 
resources to enable understanding and make sense of the tangible impact a diagnosis will have on them should be made available. Patient support groups may also play an important role in supporting patient and 
family education. 
Patient education has been defined as a ‘process of assisting consumers of healthcare to learn how to incorporate health-related behaviours (knowledge, skill, attitude) into everyday life with the purpose 
of achieving the goal of optimal health’.103 Incorporating patient education into the design and development of healthcare services, as well as 
clinical guideline documents, can enable greater awareness and appreciation of the need for clear and understandable patient education 
resources. 
Patient education reduces the uncertainty regarding symptoms, management, and prognosis; provides appropriate risk information; and promotes patient empowerment and self-efficacy, whereby the patient plays 
a leading role in their own health management. This is particularly relevant in the case of paediatric cardiomyopathy patients in which the parent’s and child’s environment should be appropriately addressed. 
The process of patient education can be classified into four components: assessment, planning, implementation, and evaluation.104 
Assessment of the patient, including literacy levels, concerns, priorities, 
learning preferences, and potential barriers to learning, is crucial to personalizing education. The planning of patient education strategies 
Table S7 Management of a patient with hypertrophic 
cardiomyopathy and left ventricular outflow tract 
obstruction for non-cardiac interventions 
Objectives 
• To maintain normal to high cardiac pre-load. 
• Afterload control. 
• To maintain sinus rhythm/AV synchrony at low 
heart rates (60–65 b.p.m.). 
• Medication to treat LVOTO should remain on 
board during NCS.  
To avoid 
Diuretics and inotropic agents. 
If hypotension appears 
• Pre-load should be corrected (fluids, 
Trendelenburg position to favour venous 
return). 
• Use drugs that increase systemic vascular 
resistance without causing greater ventricular 
obstruction and without increasing 
contractility and heart rate as phenylephrine or 
vasopressin.  
If LVOTO appears 
Consider use of intravenous beta-blockers such 
as short-acting esmolol, metoprolol, or labetalol. 
If rapid atrial 
fibrillation appears 
Rate control with beta-blockers or calcium 
blockers or electric cardioversion if 
haemodynamic instability. 
© ESC 2023
AV, atrioventricular; b.p.m., beats per minute; LVOTO, left ventricular outflow tract 
obstruction; NCS, non-cardiac surgery. 
Adapted from Sahoo et al., Dhillon, et al., and Hensley et al.95–97


<!-- PAGE 17 -->

### Page 17

involves setting mutual goals for the healthcare provider and the patient, and developing an education plan that uses evidence-based teaching strategies with a focus on patient’s needs and priorities. 
Implementation of the plan should be adjusted according to how the 
patient responds and their changing learning needs. Finally, the plan 
should be evaluated to determine where learning has been achieved. 
The patient education process should be repeated accordingly. A comprehensive approach is shown in Table S9. 
Table S8 Cardiomyopathy units: requirements and skills 
Requirements 
Skills  
Integrated cardiology/paediatric cardiology unit (should include adult 
and paediatric cardiovascular specialists with expertise in cardiac genetics and 
cardiomyopathies) 
Ability to perform a family history and draw and interpret a family pedigree 
Ability to perform or interpret appropriate diagnostic tests and examine 
diagnostic clues to define the nature of the cardiomyopathy and its underlying 
aetiology 
Clinical Nurse Specialists and clinic co-ordinators to facilitate scheduling of new 
patients and families and arrange appropriate follow-up 
Dedicated outpatient clinic 
Capacity to see and follow-up cardiomyopathy patients and their families in a 
dedicated outpatient clinic 
Family screening 
Ability to carry out a complete clinical screening of relatives (adults and 
children) 
Diagnostic imaging unit (with experience in and capacity to carry out 
studies on cardiomyopathies, including basal, stress, and transoesophageal 
echocardiography; CMR; and cardiac CT [whether integrated or not into the 
cardiology unit]) 
Performance and interpretation of echocardiography with focus on the 
evaluation of myocardial morphology, outflow geometry, septum morphology, 
valve apparatus anatomy, presence of LVOTO, mitral valve and/or papillary 
muscle anomalies, right ventricle myocardium, Doppler and strain studies, etc. 
Performance and/or interpretation of CMR with special focus on the 
characterization of myocardial tissue with parametric mapping methods 
(quantification of T1, T2, and extracellular volume fraction), LGE, etc. 
Performance and/or interpretation of cardiac CT scans 
Nuclear imaging unit (with experience in cardiac involvement of systemic 
diseases [amyloidosis, sarcoidosis, etc.]; may not be co-located) 
Ability to interpret cardiac scintigraphy studies and PET scans 
Genetics unit (with experience in cardiomyopathies and links to a clinical 
genetic testing laboratory, with access to genetic counselling) 
Ability to discuss genetic testing options with patients and their families, as well 
as the impact on the patient and/or family 
Access to clinical genetic testing encompassing genes with definitive gene– 
disease association with the condition tested for 
Ability to interpret the genetic result and differentiate the clinical implications 
of different variant classification for the patient and their family 
Ability to perform cascade genetic testing of at-risk relatives 
Access to genetic counselling for the patient and all families seen with an 
inherited cardiomyopathy 
Access to pre- and post-test genetic counselling for all patients undergoing 
genetic testing 
Catheterization and interventional cardiology unit (diagnostic and 
therapeutic procedures including structural procedures, with experience in 
ASA and an adequate number of procedures according to guidelines) 
Ability to perform and interpret invasive haemodynamic studies to assess 
cardiac performance and intracardiac pressures in cardiomyopathies and valve 
disease as well as coronary angiography to detect haemodynamically significant 
epicardial coronary disease as contributors to myocardial ischaemia or heart 
failure 
Performance and/or interpretation of coronary angiograms of HCM patients 
that allow for correct identification of a septal perforator branch with 
compatible anatomy for ASA 
Ability to contextualize the clinical condition of patients, determine the need 
for interventions, and the likelihood of safe and effective septal reduction with 
ASA 
Electrophysiology and arrhythmia unit (with experience in 
electrophysiological studies, ventricular tachycardia and atrial fibrillation 
ablation, and device implantation [pacemakers, resynchronization devices, and 
ICDs]) 
Ability to interpret other arrhythmia screening tools (e.g. implantable loop 
recorders), perform basic device troubleshooting, and deactivate defibrillator 
therapy and pacemaker functions 
Accurate selection of suitable patients for defibrillator therapy/ 
resynchronization based on guidelines                                                                            
Continued  
ESC Guidelines                                                                                                                                                                                               17


<!-- PAGE 18 -->

### Page 18

Cardiac surgery unit (with experience in myectomies and mitral valve repair 
for the management of obstructive HCM with an adequate number of 
procedures according to guidelines; may be in another reference centre) 
Active heart transplant and ventricular assist device programme 
that allows for a response to and continuity for needs derived from the 
treatment of patients with cardiomyopathies (may be in another reference 
centre) 
Ability to determine the need for effective septal reduction with myectomy and 
or mitral valve repair 
Ability to detect patient deterioration and offer referral for heart 
transplantation when necessary 
Ability to offer ventricular assist device therapy or access to such a centre 
Pathological anatomy unit (with experience in cardiomyopathies) 
Forensic pathologist unit (directly involved in the study of SCDs in the 
community) 
Ability to understand the microscopic study of patient tissue samples in order 
to arrive at a diagnosis of the disease 
Ability to develop protocols between forensics and the cardiomyopathy unit 
for study of SCDs that occur in the community in an out-of-hospital setting 
Clinical psychological support (from healthcare professionals with 
appropriate qualifications in the psychotherapeutic treatment of emotional and 
behavioural disorders caused by inherited conditions and SCD in relatives) 
Psychological support should be offered to the patient or the family, with 
referral to an appropriately qualified healthcare professional 
Access to clinical psychological expertise for families with psychological 
difficulties, e.g. following a young SCD in the family; and patients adjusting to a 
new diagnosis, ICD therapy, possible medical restrictions on their daily routine, 
and the psychological aspects of living with a condition for the foreseeable 
future (aided by medication, ICD, transplant, etc.) 
Research, teaching, and educational capacity 
Research capacity, and demonstrated research experience in the field of 
cardiomyopathies, at national and international levels 
Capacity to carry out teaching and educational activities related to the area of 
cardiomyopathies, aimed at improving the knowledge and technical capacity of 
healthcare providers involved in the same chain of care within and outside of 
the provider facility, such as continuing medical education and distance learning 
Telemedicine and other e-health tools 
Ability to exchange expertise with other healthcare providers and support 
them 
Established procedures and a framework for ensuring the management, 
safeguarding, and exchange of medical data, including established outcomes, 
process indicators, and patient registers for the specific area of expertise in 
accordance with EU data protection legislation 
Ability to foster the use of telemedicine and other e-health tools within and 
outside their facilities, by fulfilling the minimum interoperability requirements 
and, when possible, using agreed standards and recommendations102 
© ESC 2023
ASA, alcohol septal ablation; CMR, cardiac magnetic resonance; CT, computed tomography; EU, European Union; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter 
defibrillator; LGE, late gadolinium enhancement; LVOTO, left ventricular outflow tract obstruction; PET, positron emission tomography; SCD, sudden cardiac death.  
Table S9 Educational steps 
Step 
Examples  
Assessment 
Demographic data 
• Enquire about the patient’s level of education, and cultural and religious beliefs and values.  
Patient’s concerns and 
priorities 
• Enquire what the patient is most concerned about. 
• Enquire what knowledge the patient has regarding the cardiomyopathy they are being assessed for or affected by. 
• Ask the patient about level of knowledge of the condition in their close social environment.  
Patient’s interests 
• What does the patient want to understand?  
Learning preferences 
• Enquire about the patient’s preferred mode of learning (e.g. reading, video, verbal, demonstration, app).  
Assessment tools 
• Questionnaires or other assessment tools can be used to establish the level of knowledge pre- and post-patient education 
activity.  
Planning 
Set mutual goals 
• Set goals according to the context. For example, educate the patient so that they are able to inform family members about the 
condition. 
• Aim to address individual health literacy needs and consider disabilities that might affect this. 
• Offer education according to the patient’s interests and learning preferences.                                                                                      
Continued


<!-- PAGE 19 -->

### Page 19

### 8 References

1. McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden 
of 
cardiomyopathies. 
Circ 
Res 
2017;121:722–730. 
https://doi.org/10.1161/ 
CIRCRESAHA.117.309711 
2. Hada Y, Sakamoto T, Amano K, Yamaguchi T, Takenaka K, Takahashi H, et al. 
Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers 
as detected by echocardiographic screening. Am J Cardiol 1987;59:183–184. https://doi. 
org/10.1016/S0002-9149(87)80107-8 
3. Agnarsson UT, Hardarson T, Hallgrimsson J, Sigfusson N. The prevalence of hypertrophic cardiomyopathy in men: an echocardiographic population screening study 
with a review of death records. J Intern Med 1992;232:499–506. https://doi.org/10. 
1111/j.1365-2796.1992.tb00623.x 
4. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic 
analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development 
in (Young) Adults. Circulation 1995;92:785–789. https://doi.org/10.1161/01.CIR.92.4. 
785 
5. Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic 
cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 1999;33: 
1590–1595. https://doi.org/10.1016/S0735-1097(99)00039-X 
6. Maron BJ, Spirito P, Roman MJ, Paranicas M, Okin PM, Best LG, et al. Prevalence of 
hypertrophic cardiomyopathy in a population-based sample of American Indians 
aged 51 to 77 years (the Strong Heart Study). Am J Cardiol 2004;93:1510–1514.  
https://doi.org/10.1016/j.amjcard.2004.03.007 
7. Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, et al. Prevalence of idiopathic hypertrophic 
cardiomyopathy in China: a population-based echocardiographic analysis of 8080 
adults. Am J Med 2004;116:14–18. https://doi.org/10.1016/j.amjmed.2003.05.009 
8. Maro EE, Janabi M, Kaushik R. Clinical and echocardiographic study of hypertrophic 
cardiomyopathy in Tanzania. Trop Doct 2006;36:225–227. https://doi.org/10.1258/ 
004947506778604904 
9. Basavarajaiah S, Wilson M, Whyte G, Shah A, McKenna W, Sharma S. Prevalence of 
hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation 
screening. J Am Coll Cardiol 2008;51:1033–1039. https://doi.org/10.1016/j.jacc.2007.10. 
055 
10. Massera D, McClelland RL, Ambale-Venkatesh B, Gomes AS, Hundley WG, 
Kawel-Boehm N, et al. Prevalence of unexplained left ventricular hypertrophy by cardiac magnetic resonance imaging in MESA. J Am Heart Assoc 2019;8:e012250. https:// 
doi.org/10.1161/JAHA.119.012250 
11. Lopes LR, Aung N, van Duijvenboden S, Munroe PB, Elliott PM, Petersen SE. 
Prevalence of hypertrophic cardiomyopathy in the UK biobank population. JAMA 
Cardiol 2021;6:852–854. https://doi.org/10.1001/jamacardio.2021.0689 
12. Authors/Task Force members; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, 
Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35: 
2733–2779. https://doi.org/10.1093/eurheartj/ehu284 
13. Codd MB, Sugrue DD, Gersh BJ, Melton LJ 3rd. Epidemiology of idiopathic dilated and 
hypertrophic cardiomyopathy. A population-based study in Olmsted County, 
Minnesota, 1975–1984. Circulation 1989;80:564–572. https://doi.org/10.1161/01.CIR. 
80.3.564 
Develop an educational plan 
• Avoid medical jargon. 
• Use simple, direct messaging. 
• Create objectives and a step-wise approach. 
• Create communities that promote patient education. 
• Provide both written material and videos, but also engagement events that allow faster feedback in learning.  
Create resources 
• Documents. 
• Videos to watch asynchronously. 
• Creation of mobile apps, if relevant. 
• Decision aids to be used in shared decision-making (e.g. decision on genetic testing or ICD implantation). 
• Illustrations, 3D models. 
• Accommodate patients who are visually or hearing impaired. 
• Make available in languages other than English, depending on the location.  
Implementation 
Focus on the patient 
• Plain language. 
• Active listening. 
• Allow for interactive learning (e.g. encourage patients to ask questions). 
• Be respectful and empathetic.  
Follow key educational 
principles 
• Frame the objectives to be clear from the beginning. 
• Create small educational snippets/segments that are easily understood and digestible. 
• Create clear summaries and review key points.  
Adjust teaching 
• Use analogies that make sense in terms of the context and the patient’s profile. 
• Allow enough time to reiterate information on more challenging topics. 
• Allow for hands-on practice (e.g. have a model of an ICD to demonstrate, and allow the patient to manipulate when 
discussing ICDs). 
• Use multiple teaching methods depending on the context.  
Evaluation 
Direct patient input 
• Have direct conversation with patients to get feedback for any educational activity.  
Patient outcomes 
• Measure adherence to therapy plans. 
• Assess re-admission rates. 
• Assess engagement with genetic counselling. 
• Assess adherence to lifestyle changes.  
© ESC 2023
3D, three-dimensional; ICD, implantable cardioverter defibrillator.   
ESC Guidelines                                                                                                                                                                                               19


<!-- PAGE 20 -->

### Page 20

14. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a 
diverse genetic architecture. Nat Rev Cardiol 2013;10:531–547. https://doi.org/10. 
1038/nrcardio.2013.105 
15. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Bohm M, et al. Proposal for a 
revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, 
and its implications for clinical practice: a position statement of the ESC working group 
on myocardial and pericardial diseases. Eur Heart J 2016;37:1850–1858. https://doi.org/ 
10.1093/eurheartj/ehv727 
16. Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, et al. Heart failure in 
cardiomyopathies: a position paper from the Heart Failure Association of the 
European Society of Cardiology. Eur J Heart Fail 2019;21:553–576. https://doi.org/ 
10.1002/ejhf.1461 
17. Peters S, Trummel M, Meyners W. Prevalence of right ventricular dysplasia- 
cardiomyopathy in a non-referral hospital. Int J Cardiol 2004;97:499–501. https://doi. 
org/10.1016/j.ijcard.2003.10.037 
18. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006;296:1593–1601. https://doi.org/10.1001/jama. 
296.13.1593 
19. Migliore F, Zorzi A, Michieli P, Perazzolo Marra M, Siciliano M, Rigato I, et al. Prevalence 
of cardiomyopathy in Italian asymptomatic children with electrocardiographic T-wave 
inversion at preparticipation screening. Circulation 2012;125:529–538. https://doi.org/ 
10.1161/CIRCULATIONAHA.111.055673 
20. Charron P, Elliott PM, Gimeno JR, Caforio ALP, Kaski JP, Tavazzi L, et al. The cardiomyopathy registry of the EURObservational research programme of the European 
Society of Cardiology: baseline data and contemporary management of adult patients 
with cardiomyopathies. Eur Heart J 2018;39:1784–1793. https://doi.org/10.1093/ 
eurheartj/ehx819 
21. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of 
pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003;348: 
1647–1655. https://doi.org/10.1056/NEJMoa021715 
22. Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela AL, et al. 
Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. Am J Epidemiol 1997;146:385–393. https://doi.org/10.1093/ 
oxfordjournals.aje.a009291 
23. Nugent AW, Daubeney PE, Chondros P, Carlin JB, Cheung M, Wilkinson LC, et al. The 
epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003;348: 
1639–1646. https://doi.org/10.1056/NEJMoa021737 
24. Andrews RE, Fenton MJ, Ridout DA, Burch M. New-onset heart failure due to heart 
muscle disease in childhood: a prospective study in the United Kingdom and Ireland. 
Circulation 
2008;117:79–84. 
https://doi.org/10.1161/CIRCULATIONAHA.106. 
671735 
25. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, 
and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:1867–1876.  
https://doi.org/10.1001/jama.296.15.1867 
26. Herkert JC, Abbott KM, Birnie E, Meems-Veldhuis MT, Boven LG, Benjamins M, et al. 
Toward an effective exome-based genetic testing strategy in pediatric dilated cardiomyopathy. Genet Med 2018;20:1374–1386. https://doi.org/10.1038/gim.2018.9 
27. Quiat D, Witkowski L, Zouk H, Daly KP, Roberts AE. Retrospective analysis of clinical 
genetic testing in pediatric primary dilated cardiomyopathy: testing outcomes and the 
effects of variant reclassification. J Am Heart Assoc 2020;9:e016195. https://doi.org/10. 
1161/JAHA.120.016195 
28. Norrish G, Field E, McLeod K, Ilina M, Stuart G, Bhole V, et al. Clinical presentation and 
survival of childhood hypertrophic cardiomyopathy: a retrospective study in United 
Kingdom. Eur Heart J 2019;40:986–993. https://doi.org/10.1093/eurheartj/ehy798 
29. Te Riele A, James CA, Sawant AC, Bhonsale A, Groeneweg JA, Mast TP, et al. 
Arrhythmogenic right ventricular dysplasia/cardiomyopathy in the pediatric population: clinical characterization and comparison with adult-onset disease. JACC Clin 
Electrophysiol 2015;1:551–560. https://doi.org/10.1016/j.jacep.2015.08.004 
30. Surget E, Maltret A, Raimondi F, Fressart V, Bonnet D, Gandjbakhch E, et al. Clinical 
presentation and heart failure in children with arrhythmogenic cardiomyopathy. Circ 
Arrhythm 
Electrophysiol 
2022;15:e010346. 
https://doi.org/10.1161/CIRCEP.121. 
010346 
31. Webber SA, Lipshultz SE, Sleeper LA, Lu M, Wilkinson JD, Addonizio LJ, et al. 
Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: 
a report from the pediatric cardiomyopathy registry. Circulation 2012;126:1237–1244.  
https://doi.org/10.1161/CIRCULATIONAHA.112.104638 
32. Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguchia J, et al. 
Genetic etiology for alcohol-induced cardiac toxicity. J Am Coll Cardiol 2018;71: 
2293–2302. https://doi.org/10.1016/j.jacc.2018.03.462 
33. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, 
et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. 
Circulation 
2019;140:31–41. 
https://doi.org/10.1161/CIRCULATIONAHA.118. 
037934 
34. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016;374: 
233–241. https://doi.org/10.1056/NEJMoa1505517 
35. Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, et al. Genetic and phenotypic 
landscape of peripartum cardiomyopathy. Circulation 2021;143:1852–1862. https:// 
doi.org/10.1161/CIRCULATIONAHA.120.052395 
36. Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified 
by screening renal, cardiac and stroke clinics, 1995–2017. J Med Genet 2018;55: 
261–268. https://doi.org/10.1136/jmedgenet-2017-105080 
37. Tini G, Sessarego E, Benenati S, Vianello PF, Musumeci B, Autore C, et al. Yield of bone 
scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: methodological issues and clinical implications. Eur J Clin Invest 2021;51:e13665.  
https://doi.org/10.1111/eci.13665 
38. Wong EK, Bartels K, Hathaway J, Burns C, Yeates L, Semsarian C, et al. Perceptions of 
genetic variant reclassification in patients with inherited cardiac disease. Eur J Hum 
Genet 2019;27:1134–1142. https://doi.org/10.1038/s41431-019-0377-6 
39. Costa S, Medeiros-Domingo A, Gasperetti A, Akdis D, Berger W, James CA, et al. 
Impact of genetic variant reassessment on the diagnosis of arrhythmogenic right ventricular cardiomyopathy based on the 2010 task force criteria. Circ Genom Precis Med 
2021;14:e003047. https://doi.org/10.1161/CIRCGEN.120.003047 
40. National Society of Genetic Counselors’ Definition Task Force; Resta R, Biesecker BB, 
Bennett RL, Blum S, Hahn SE, et al. A new definition of genetic counseling: national society of genetic counselors’ task force report. J Genet Couns 2006;15:77–83. https://doi. 
org/10.1007/s10897-005-9014-3 
41. Biesecker BB. Goals of genetic counseling. Clin Genet 2001;60:323–330. https://doi.org/ 
10.1034/j.1399-0004.2001.600501.x 
42. Ingles J, Yeates L, Semsarian C. The emerging role of the cardiac genetic counselor. 
Heart Rhythm 2011;8:1958–1962. https://doi.org/10.1016/j.hrthm.2011.07.017 
43. Ingles J. Psychological issues in managing families with inherited cardiovascular diseases. 
Cold Spring Harb Perspect Med 2020;10:a036558. https://doi.org/10.1101/cshperspect. 
a036558 
44. Edwards A, Gray J, Clarke A, Dundon J, Elwyn G, Gaff C, et al. Interventions to improve 
risk communication in clinical genetics: systematic review. Patient Educ Couns 2008;71: 
4–25. https://doi.org/10.1016/j.pec.2007.11.026 
45. Austin J, Semaka A, Hadjipavlou G. Conceptualizing genetic counseling as psychotherapy in the era of genomic medicine. J Genet Couns 2014;23:903–909. https://doi.org/10. 
1007/s10897-014-9728-1 
46. Michie S, Marteau TM, Bobrow M. Genetic counselling: the psychological impact of 
meeting patients’ expectations. J Med Genet 1997;34:237–241. https://doi.org/10. 
1136/jmg.34.3.237 
47. Ison HE, Ware SM, Schwantes-An TH, Freeze S, Elmore L, Spoonamore KG. The impact of cardiovascular genetic counseling on patient empowerment. J Genet Couns 
2019;28:570–577. https://doi.org/10.1002/jgc4.1050 
48. Meiser B, Irle J, Lobb E, Barlow-Stewart K. Assessment of the content and process of 
genetic counseling: a critical review of empirical studies. J Genet Couns 2008;17: 
434–451. https://doi.org/10.1007/s10897-008-9173-0 
49. Borry P, Evers-Kiebooms G, Cornel MC, Clarke A, Dierickx K. Public Professional 
Policy Committee (PPPC) of the European Society of Human Genetics (ESHG). 
Genetic testing in asymptomatic minors: background considerations towards ESHG 
recommendations. Eur J Hum Genet 2009;17:711–719. https://doi.org/10.1038/ejhg. 
2009.25 
50. Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P, et al. Genetic counselling 
and testing in cardiomyopathies: a position statement of the European Society of 
Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 
2010;31:2715–2726. https://doi.org/10.1093/eurheartj/ehq271 
51. Ormondroyd E, Oates S, Parker M, Blair E, Watkins H. Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implications. Eur J Hum Genet 2014;22:88–93. https://doi.org/10.1038/ejhg.2013.81 
52. Burns C, James C, Ingles J. Communication of genetic information to families with inherited rhythm disorders. Heart Rhythm 2018;15:780–786. https://doi.org/10.1016/j. 
hrthm.2017.11.024 
53. Rhodes A, Rosman L, Cahill J, Ingles J, Murray B, Tichnell C, et al. Minding the genes: a 
multidisciplinary approach towards genetic assessment of cardiovascular disease. J 
Genet Couns 2017;26:224–231. https://doi.org/10.1007/s10897-016-0017-z 
54. Spanaki A, O’Curry S, Winter-Beatty J, Mead-Regan S, Hawkins K, English J, et al. 
Psychosocial adjustment and quality of life in children undergoing screening in a specialist paediatric hypertrophic cardiomyopathy clinic. Cardiol Young 2016;26: 
961–967. https://doi.org/10.1017/S1047951115001717 
55. Last AN, English J, Pote H, Shafran R, Owen T, Kaski JP. Anxiety in children attending a 
specialist inherited cardiac arrhythmia clinic: a questionnaire study. BMJ Paediatr Open 
2018;2:e000271. https://doi.org/10.1136/bmjpo-2018-000271 
56. Meulenkamp TM, Tibben A, Mollema ED, van Langen IM, Wiegman A, de Wert GM, 
et al. Predictive genetic testing for cardiovascular diseases: impact on carrier children. 
Am J Med Genet A 2008;146A:3136–3146. https://doi.org/10.1002/ajmg.a.32592


<!-- PAGE 21 -->

### Page 21

57. Christiaans I, Birnie E, Bonsel GJ, Wilde AA, van Langen IM. Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy. Eur J Hum 
Genet 2008;16:1201–1207. https://doi.org/10.1038/ejhg.2008.92 
58. Charron P, Heron D, Gargiulo M, Richard P, Dubourg O, Desnos M, et al. Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience. J 
Med Genet 2002;39:741–746. https://doi.org/10.1136/jmg.39.10.741 
59. van der Roest WP, Pennings JM, Bakker M, van den Berg MP, van Tintelen JP. Family 
letters are an effective way to inform relatives about inherited cardiac disease. Am J 
Med Genet A 2009;149A:357–363. https://doi.org/10.1002/ajmg.a.32672 
60. van den Heuvel LM, van Teijlingen MO, van der Roest W, van Langen IM, Smets EMA, 
van Tintelen JP, et al. Long-term follow-up study on the uptake of genetic counseling 
and predictive DNA testing in inherited cardiac conditions. Circ Genom Precis Med 
2020;13:524–530. https://doi.org/10.1161/CIRCGEN.119.002803 
61. Burns C, McGaughran J, Davis A, Semsarian C, Ingles J. Factors influencing uptake of 
familial long QT syndrome genetic testing. Am J Med Genet A 2016;170A:418–425.  
https://doi.org/10.1002/ajmg.a.37455 
62. Whyte S, Green A, McAllister M, Shipman H. Family communication in inherited cardiovascular conditions in Ireland. J Genet Couns 2016;25:1317–1326. https://doi.org/10. 
1007/s10897-016-9974-5 
63. Daly MB, Montgomery S, Bingler R, Ruth K. Communicating genetic test results within 
the family: is it lost in translation? A survey of relatives in the randomized six-step 
study. Fam Cancer 2016;15:697–706. https://doi.org/10.1007/s10689-016-9889-1 
64. Kaphingst KA, Blanchard M, Milam L, Pokharel M, Elrick A, Goodman MS. Relationships 
between health literacy and genomics-related knowledge, self-efficacy, perceived importance, and communication in a medically underserved population. J Health 
Commun 2016;21:58–68. https://doi.org/10.1080/10810730.2016.1144661 
65. O’Donovan C, Ingles J, Broadbent E, Skinner JR, Kasparian NA. How patient perceptions shape responses and outcomes in inherited cardiac conditions. Heart Lung Circ 
2020;29:641–652. https://doi.org/10.1016/j.hlc.2019.11.003 
66. Caleshu C, Kasparian NA, Edwards KS, Yeates L, Semsarian C, Perez M, et al. 
Interdisciplinary psychosocial care for families with inherited cardiovascular diseases. 
Trends Cardiovasc Med 2016;26:647–653. https://doi.org/10.1016/j.tcm.2016.04.010 
67. Ingles J, Spinks C, Yeates L, McGeechan K, Kasparian N, Semsarian C. Posttraumatic 
stress and prolonged grief after the sudden cardiac death of a young relative. JAMA 
Intern Med 2016;176:402–405. https://doi.org/10.1001/jamainternmed.2015.7808 
68. Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, et al. Clinical 
course and quality of life in high-risk patients with hypertrophic cardiomyopathy 
and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 2018;11: 
e005820. https://doi.org/10.1161/CIRCEP.117.005820 
69. Wynn J, Holland DT, Duong J, Ahimaz P, Chung WK. Examining the psychosocial impact of genetic testing for cardiomyopathies. J Genet Couns 2018;27:927–934. https:// 
doi.org/10.1007/s10897-017-0186-4 
70. Christiaans I, van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Quality of life 
and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross- 
sectional cohort study. Am J Med Genet A 2009;149A:602–612. https://doi.org/10. 
1002/ajmg.a.32710 
71. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ 
Heart 
Fail 
2008;1:184–191. 
https://doi.org/10.1161/CIRCHEARTFAILURE.108. 
768119 
72. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar 
visualized by cardiovascular magnetic resonance imaging predicts major adverse events 
in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875–887.  
https://doi.org/10.1016/j.jacc.2010.05.007 
73. O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010; 
56:867–874. https://doi.org/10.1016/j.jacc.2010.05.010 
74. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. 
Characteristics and clinical significance of late gadolinium enhancement by 
contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. 
Circ 
Heart 
Fail 
2010;3:51–58. 
https://doi.org/10.1161/ 
CIRCHEARTFAILURE.109.854026 
75. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc 
Imaging 2012;5:370–377. https://doi.org/10.1016/j.jcmg.2011.11.021 
76. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value 
of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 
2014;130:484–495. https://doi.org/10.1161/CIRCULATIONAHA.113.007094 
77. Ismail TF, Jabbour A, Gulati A, Mallorie A, Raza S, Cowling TE, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of 
hypertrophic cardiomyopathy. Heart 2014;100:1851–1858. https://doi.org/10.1136/ 
heartjnl-2013-305471 
78. Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a 
meta-analysis. Heart 2015;101:1406–1411. https://doi.org/10.1136/heartjnl-2015- 
307682 
79. Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, et al. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol 2018;72:857–870. https://doi.org/10.1016/j.jacc.2018.05. 
060 
80. Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic 
cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol 2017;69:761–773. https://doi.org/10.1016/j. 
jacc.2016.11.063 
81. Lee DZJ, Montazeri M, Bataiosu R, Hoss S, Adler A, Nguyen ET, et al. Clinical characteristics and prognostic importance of left ventricular apical aneurysms in hypertrophic 
cardiomyopathy. JACC Cardiovasc Imaging 2022;15:1696–1711. https://doi.org/10. 
1016/j.jcmg.2022.03.029 
82. Wasserstrum Y, Larranaga-Moreira JM, Martinez-Veira C, Itelman E, Lotan D, Sabbag 
A, et al. Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and 
prognosis. ESC Heart Fail 2022;9:2301–2312. https://doi.org/10.1002/ehf2.13914 
83. Biagini E, Coccolo F, Ferlito M, Perugini E, Rocchi G, Bacchi-Reggiani L, et al. 
Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, 
risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 
2005;46:1543–1550. https://doi.org/10.1016/j.jacc.2005.04.062 
84. Thaman R, Gimeno JR, Murphy RT, Kubo T, Sachdev B, Mogensen J, et al. Prevalence 
and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 
2005;91:920–925. https://doi.org/10.1136/hrt.2003.031161 
85. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, et al. 
Prevalence, clinical profile, and significance of left ventricular remodeling in the end- 
stage phase of hypertrophic cardiomyopathy. Circulation 2006;114:216–225. https:// 
doi.org/10.1161/CIRCULATIONAHA.105.583500 
86. Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H. Risk of sudden death in 
end-stage hypertrophic cardiomyopathy. J Card Fail 2011;17:459–464. https://doi. 
org/10.1016/j.cardfail.2011.01.015 
87. Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S, et al. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. J 
Am Coll Cardiol 2020;75:3033–3043. https://doi.org/10.1016/j.jacc.2020.04.045 
88. Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M, et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry. Circulation 2020;141:1371–1383. https://doi.org/10.1161/CIRCULATIONAHA. 
119.044366 
89. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and 
serum free light chain measurements. J Clin Oncol 2012;30:989–995. https://doi.org/10. 
1200/JCO.2011.38.5724 
90. Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 2019;133:215–223. https://doi.org/10.1182/blood-2018-06-858951 
91. Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los Santos J, Leedy D, et al. Diuretic 
dose and NYHA functional class are independent predictors of mortality in patients 
with transthyretin cardiac amyloidosis. JACC CardioOncol 2020;2:414–424. https://doi. 
org/10.1016/j.jaccao.2020.06.007 
92. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, 
et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39: 
2799–2806. https://doi.org/10.1093/eurheartj/ehx589 
93. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of 
wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging 
system. J Am Coll Cardiol 2016;68:1014–1020. https://doi.org/10.1016/j.jacc.2016.06. 
033 
94. Vanhees L, Geladas N, Hansen D, Kouidi E, Niebauer J, Reiner Z, et al. Importance of 
characteristics and modalities of physical activity and exercise in the management of 
cardiovascular health in individuals with cardiovascular risk factors: recommendations 
from the EACPR. Part II. Eur J Prev Cardiol 2012;19:1005–1033. https://doi.org/10. 
1177/1741826711430926 
95. Sahoo RK, Dash SK, Raut PS, Badole UR, Upasani CB. Perioperative anesthetic management of patients with hypertrophic cardiomyopathy for noncardiac surgery: a case 
series. Ann Card Anaesth 2010;13:253–256. https://doi.org/10.4103/0971-9784.69049 
96. Dhillon A, Khanna A, Randhawa MS, Cywinski J, Saager L, Thamilarasan M, et al. 
Perioperative outcomes of patients with hypertrophic cardiomyopathy undergoing 
non-cardiac surgery. Heart 2016;102:1627–1632. https://doi.org/10.1136/heartjnl- 
2016-309442 
97. Hensley N, Dietrich J, Nyhan D, Mitter N, Yee MS, Brady M. Hypertrophic cardiomyopathy: a review. Anesth Analg 2015;120:554–569. https://doi.org/10.1213/ANE. 
0000000000000538 
98. Cardim N, Freitas A, Brito D. From hypertrophic cardiomyopathy centers to inherited 
cardiovascular disease centers in Europe. A small or a major step? A position paper 
from the Nucleus of the Working Group on Myocardial and Pericardial Diseases of 
the Portuguese Society of Cardiology. Rev Port Cardiol 2011;30:829–835. https://doi. 
org/10.1016/j.repc.2011.09.005  
ESC Guidelines                                                                                                                                                                                               21


<!-- PAGE 22 -->

### Page 22

99. McDonagh TA, Gardner RS, Lainscak M, Nielsen OW, Parissis J, Filippatos G, et al. 
Heart failure association of the European Society of Cardiology specialist heart failure 
curriculum. Eur J Heart Fail 2014;16:151–162. https://doi.org/10.1002/ejhf.41 
100. Barriales-Villa R, Gimeno-Blanes JR, Zorio-Grima E, Ripoll-Vera T, Evangelista-Masip A, 
Moya-Mitjans A, et al. Plan of action for inherited cardiovascular diseases: synthesis of 
recommendations and action algorithms. Rev Esp Cardiol (Engl Ed) 2016;69:300–309.  
https://doi.org/10.1016/j.recesp.2015.11.031 
101. Ahmad F, McNally EM, Ackerman MJ, Baty LC, Day SM, Kullo IJ, et al. Establishment of 
specialized clinical cardiovascular genetics programs: recognizing the need and meeting 
standards: a scientific statement from the American Heart Association. Circ Genom 
Precis Med 2019;12:e000054. https://doi.org/10.1161/HCG.0000000000000054 
102. Tini G, Vianello PF, Rizzola G, La Malfa G, Porto I, Canepa M. Telehealth monitoring for 
hypertrophic cardiomyopathy and amyloid cardiomyopathy patients: lessons from the 
coronavirus disease 2019 lockdown in Italy. J Cardiovasc Med (Hagerstown) 2020;21: 
622–623. https://doi.org/10.2459/JCM.0000000000001024 
103. Bastable SB. Nurse as Educator: Principles of Teaching and Learning for Nursing Practice: 
Principles of Teaching and Learning for Nursing Practice. Jones & Bartlett Learning; 2017. 
104. Health Care Education Association. https://www.hcea-info.org (25 January 2021, date 
last accessed).

<!-- 2023_Endocarditis.md -->

# ESC Guidelines: Endocarditis (2023)

**Source**: `2023_Endocarditis.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 95

---

## Table of Contents

- [2023 ESC Guidelines for the management of endocarditis](#2023-esc-guidelines-for-the-management-of-endocard) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 6)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 8)*
  - [3. Prevention](#3-prevention) *(p. 12)*
    - [3.1. Rationale](#31-rationale) *(p. 12)*
    - [3.2. Populations at risk of infective endocarditis](#32-populations-at-risk-of-infective-endocarditis) *(p. 13)*
    - [3.3. Situations and procedures at risk](#33-situations-and-procedures-at-risk) *(p. 14)*
      - [3.3.1. Dental procedures](#331-dental-procedures) *(p. 14)*
      - [3.3.2. Non-dental procedures](#332-non-dental-procedures) *(p. 14)*
      - [3.3.3. Cardiac or vascular interventions](#333-cardiac-or-vascular-interventions) *(p. 15)*
    - [3.4. Patient education](#34-patient-education) *(p. 15)*
  - [4. The Endocarditis Team](#4-the-endocarditis-team) *(p. 16)*
  - [5. Diagnosis](#5-diagnosis) *(p. 18)*
    - [5.1. Clinical features](#51-clinical-features) *(p. 18)*
    - [5.2. Laboratory findings](#52-laboratory-findings) *(p. 19)*
    - [5.3. Microbiological diagnosis](#53-microbiological-diagnosis) *(p. 19)*
      - [5.3.1. Blood culture-positive infective endocarditis](#531-blood-culture-positive-infective-endocarditis) *(p. 19)*
      - [5.3.2. Blood culture-negative infective endocarditis](#532-blood-culture-negative-infective-endocarditis) *(p. 19)*
      - [5.3.3. Proposed strategy for a microbiological diagnostic algorithm in suspected infective endocarditis](#533-proposed-strategy-for-a-microbiological-diagno) *(p. 20)*
    - [5.4. Imaging techniques](#54-imaging-techniques) *(p. 20)*
      - [5.4.1. Echocardiography](#541-echocardiography) *(p. 20)*
      - [5.4.2. Computed tomography](#542-computed-tomography) *(p. 22)*
      - [5.4.3. Magnetic resonance imaging](#543-magnetic-resonance-imaging) *(p. 22)*
      - [5.4.4. Nuclear imaging positron emission tomography/computed tomography (angiography) and single photon emission tomography/computed tomography](#544-nuclear-imaging-positron-emission-tomography/c) *(p. 23)*
    - [5.5. Diagnostic criteria](#55-diagnostic-criteria) *(p. 24)*
      - [5.5.1. Modifications for the diagnosis of infective endocarditis](#551-modifications-for-the-diagnosis-of-infective-e) *(p. 24)*
        - [5.5.1.1. Major criteria – microbiology](#5511-major-criteria-–-microbiology) *(p. 26)*
        - [5.5.1.2. Major criteria – imaging](#5512-major-criteria-–-imaging) *(p. 26)*
        - [5.5.1.3. Minor criteria](#5513-minor-criteria) *(p. 27)*
        - [5.5.1.4. Microbiological criteria](#5514-microbiological-criteria) *(p. 27)*
        - [5.5.1.5. Infective endocarditis classification](#5515-infective-endocarditis-classification) *(p. 28)*
      - [5.5.2. The new 2023 European Society of Cardiology diagnostic algorithms](#552-the-new-2023-european-society-of-cardiology-di) *(p. 28)*
  - [6. Prognostic assessment at admission](#6-prognostic-assessment-at-admission) *(p. 28)*
  - [7. Antimicrobial therapy: principles and methods](#7-antimicrobial-therapy:-principles-and-methods) *(p. 28)*
    - [7.1. General principles](#71-general-principles) *(p. 28)*
    - [7.2. Penicillin-susceptible oral streptococci and Streptococcus gallolyticus group](#72-penicillin-susceptible-oral-streptococci-and-st) *(p. 30)*
    - [7.3. Oral streptococci and Streptococcus gallolyticus group susceptible, increased exposure or resistant to penicillin](#73-oral-streptococci-and-streptococcus-gallolyticu) *(p. 30)*
    - [7.4. Streptococcus pneumoniae, β-haemolytic streptococci (groups A, B, C, and G)](#74-streptococcus-pneumoniae,-β-haemolytic-streptoc) *(p. 32)*
    - [7.5. Granulicatella and Abiotrophia (formerly nutritionally variant streptococci)](#75-granulicatella-and-abiotrophia-(formerly-nutrit) *(p. 32)*
    - [7.6. Staphylococcus aureus and coagulase-negative staphylococci](#76-staphylococcus-aureus-and-coagulase-negative-st) *(p. 32)*
    - [7.7. Methicillin-resistant staphylococci](#77-methicillin-resistant-staphylococci) *(p. 32)*
    - [7.8. Enterococcus spp.](#78-enterococcus-spp) *(p. 35)*
    - [7.9. Gram-negative bacteria](#79-gram-negative-bacteria) *(p. 36)*
      - [7.9.1. Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, and Kingella-related species](#791-haemophilus,-aggregatibacter,-cardiobacterium,) *(p. 36)*
      - [7.9.2. Non-Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, and Kingella species](#792-non-haemophilus,-aggregatibacter,-cardiobacter) *(p. 37)*
    - [7.10. Blood culture-negative infective endocarditis](#710-blood-culture-negative-infective-endocarditis) *(p. 37)*
    - [7.11. Fungi](#711-fungi) *(p. 37)*
    - [7.12. Empirical therapy](#712-empirical-therapy) *(p. 37)*
    - [7.13. Outpatient parenteral or oral antibiotic therapy for infective endocarditis](#713-outpatient-parenteral-or-oral-antibiotic-thera) *(p. 38)*
      - [7.13.1. Parenteral and oral step-down antibiotic treatment](#7131-parenteral-and-oral-step-down-antibiotic-trea) *(p. 39)*
      - [7.13.2. Other considerations for outpatient oral or parenteral antimicrobial therapy](#7132-other-considerations-for-outpatient-oral-or-p) *(p. 39)*
  - [8. Indications for surgery and management of main infective endocarditis complications](#8-indications-for-surgery-and-management-of-main-i) *(p. 40)*
    - [8.1. Pre-operative risk assessment](#81-pre-operative-risk-assessment) *(p. 40)*
    - [8.2. Heart failure](#82-heart-failure) *(p. 40)*
      - [8.2.1. Heart failure in infective endocarditis](#821-heart-failure-in-infective-endocarditis) *(p. 40)*
      - [8.2.2. Indications and timing of surgery in the presence of heart failure in infective endocarditis](#822-indications-and-timing-of-surgery-in-the-prese) *(p. 42)*
    - [8.3. Uncontrolled infection](#83-uncontrolled-infection) *(p. 42)*
      - [8.3.1. Septic shock and persistent infection](#831-septic-shock-and-persistent-infection) *(p. 42)*
      - [8.3.2. Locally uncontrolled infection](#832-locally-uncontrolled-infection) *(p. 42)*
      - [8.3.3 Indications and timing of surgery in the presence of uncontrolled infection](#833-indications-and-timing-of-surgery-in-the-prese) *(p. 43)*
        - [8.3.3.1. Persistent infection](#8331-persistent-infection) *(p. 43)*
        - [8.3.3.2. Locally uncontrolled infection](#8332-locally-uncontrolled-infection) *(p. 43)*
        - [8.3.3.3. Infection with resistant or virulent organisms](#8333-infection-with-resistant-or-virulent-organism) *(p. 43)*
    - [8.4. Prevention of systemic embolism](#84-prevention-of-systemic-embolism) *(p. 43)*
      - [8.4.1. Incidence of embolic events in infective endocarditis](#841-incidence-of-embolic-events-in-infective-endoc) *(p. 43)*
      - [8.4.2. Predicting the risk of embolism](#842-predicting-the-risk-of-embolism) *(p. 43)*
      - [8.4.3. Indications and timing of surgery to prevent embolism in infective endocarditis](#843-indications-and-timing-of-surgery-to-prevent-e) *(p. 43)*
  - [9. Other complications of infective endocarditis](#9-other-complications-of-infective-endocarditis) *(p. 44)*
    - [9.1. Neurological complications](#91-neurological-complications) *(p. 44)*
      - [9.1.1. The role of cerebral imaging in infective endocarditis](#911-the-role-of-cerebral-imaging-in-infective-endo) *(p. 45)*
    - [9.2. Infective aneurysms](#92-infective-aneurysms) *(p. 45)*
    - [9.3. Splenic complications](#93-splenic-complications) *(p. 45)*
    - [9.4. Myocarditis and pericarditis](#94-myocarditis-and-pericarditis) *(p. 46)*
    - [9.5. Heart rhythm and conduction disturbances](#95-heart-rhythm-and-conduction-disturbances) *(p. 46)*
    - [9.6. Musculoskeletal manifestations](#96-musculoskeletal-manifestations) *(p. 46)*
      - [9.6.1. Osteoarticular infective endocarditis-related infections](#961-osteoarticular-infective-endocarditis-related-) *(p. 46)*
      - [9.6.2. Rheumatological manifestations](#962-rheumatological-manifestations) *(p. 47)*
    - [9.7. Acute renal failure](#97-acute-renal-failure) *(p. 47)*
  - [10. Surgical therapy: principles and methods](#10-surgical-therapy:-principles-and-methods) *(p. 47)*
    - [10.1. Pre-operative and peri-operative management](#101-pre-operative-and-peri-operative-management) *(p. 47)*
      - [10.1.1. Coronary angiography](#1011-coronary-angiography) *(p. 47)*
      - [10.1.2. Extracardiac infection](#1012-extracardiac-infection) *(p. 48)*
      - [10.1.3. Intra-operative echocardiography](#1013-intra-operative-echocardiography) *(p. 48)*
    - [10.2. Other intra-operative considerations](#102-other-intra-operative-considerations) *(p. 48)*
    - [10.3. Surgical approach and techniques](#103-surgical-approach-and-techniques) *(p. 48)*
      - [10.3.1. Choice of valve prosthesis](#1031-choice-of-valve-prosthesis) *(p. 49)*
    - [10.4. Timing of surgery after ischaemic and haemorrhagic stroke](#104-timing-of-surgery-after-ischaemic-and-haemorrh) *(p. 50)*
    - [10.5. Post-operative complications](#105-post-operative-complications) *(p. 50)*
    - [10.6. Management of antithrombotic therapy after surgery](#106-management-of-antithrombotic-therapy-after-sur) *(p. 51)*
  - [11. Outcome after discharge: follow-up and long-term prognosis](#11-outcome-after-discharge:-follow-up-and-long-ter) *(p. 51)*
    - [11.1. Recurrences: relapses and reinfections](#111-recurrences:-relapses-and-reinfections) *(p. 51)*
    - [11.2. First year follow-up](#112-first-year-follow-up) *(p. 52)*
    - [11.3. Long-term prognosis](#113-long-term-prognosis) *(p. 52)*
  - [12. Management of specific situations](#12-management-of-specific-situations) *(p. 52)*
    - [12.1. Prosthetic valve endocarditis](#121-prosthetic-valve-endocarditis) *(p. 52)*
      - [12.1.1. Definition and pathophysiology](#1211-definition-and-pathophysiology) *(p. 53)*
      - [12.1.2. Diagnosis](#1212-diagnosis) *(p. 53)*
      - [12.1.3. Prognosis and treatment](#1213-prognosis-and-treatment) *(p. 53)*
    - [12.2. Endocarditis in the elderly](#122-endocarditis-in-the-elderly) *(p. 53)*
    - [12.3. Transcatheter prosthetic valve endocarditis](#123-transcatheter-prosthetic-valve-endocarditis) *(p. 54)*
      - [12.3.1. Endocarditis following transcatheter aortic valve implantation](#1231-endocarditis-following-transcatheter-aortic-v) *(p. 54)*
        - [12.3.1.1. Diagnosis](#12311-diagnosis) *(p. 54)*
        - [12.3.1.2. Prognosis and treatment](#12312-prognosis-and-treatment) *(p. 54)*
      - [12.3.2. Endocarditis following transcatheter pulmonary valve implantation](#1232-endocarditis-following-transcatheter-pulmonar) *(p. 54)*
        - [12.3.2.1. Diagnosis](#12321-diagnosis) *(p. 55)*
        - [12.3.2.2. Prognosis and treatment](#12322-prognosis-and-treatment) *(p. 55)*
    - [12.4. Infective endocarditis affecting cardiac implantable electronic devices](#124-infective-endocarditis-affecting-cardiac-impla) *(p. 55)*
      - [12.4.1. Definitions of cardiac device infections](#1241-definitions-of-cardiac-device-infections) *(p. 55)*
      - [12.4.2. Pathophysiology and microbiology](#1242-pathophysiology-and-microbiology) *(p. 55)*
      - [12.4.3. Risk factors](#1243-risk-factors) *(p. 55)*
      - [12.4.4. Prophylaxis](#1244-prophylaxis) *(p. 55)*
      - [12.4.5. Diagnosis](#1245-diagnosis) *(p. 55)*
      - [12.4.6. Antimicrobial therapy](#1246-antimicrobial-therapy) *(p. 57)*
      - [12.4.7. Device extraction](#1247-device-extraction) *(p. 57)*
      - [12.4.8. Device reimplantation](#1248-device-reimplantation) *(p. 57)*
    - [12.5. Infective endocarditis in patients admitted to intensive care units](#125-infective-endocarditis-in-patients-admitted-to) *(p. 58)*
      - [12.5.1. Causative microorganisms](#1251-causative-microorganisms) *(p. 58)*
      - [12.5.2. Diagnosis](#1252-diagnosis) *(p. 58)*
      - [12.5.3. Management](#1253-management) *(p. 58)*
    - [12.6. Right-sided infective endocarditis](#126-right-sided-infective-endocarditis) *(p. 58)*
      - [12.6.1. Diagnosis and complications](#1261-diagnosis-and-complications) *(p. 59)*
      - [12.6.2. Endocarditis in people who inject drugs](#1262-endocarditis-in-people-who-inject-drugs) *(p. 59)*
      - [12.6.3. Prognosis and treatment](#1263-prognosis-and-treatment) *(p. 59)*
        - [12.6.3.1. Antimicrobial therapy](#12631-antimicrobial-therapy) *(p. 59)*
        - [12.6.3.2. Surgery](#12632-surgery) *(p. 59)*
    - [12.7. Infective endocarditis in congenital heart disease](#127-infective-endocarditis-in-congenital-heart-dis) *(p. 60)*
    - [12.8. Infective endocarditis in rheumatic heart disease](#128-infective-endocarditis-in-rheumatic-heart-dise) *(p. 61)*
    - [12.9. Infective endocarditis during pregnancy](#129-infective-endocarditis-during-pregnancy) *(p. 61)*
    - [12.10. Infective endocarditis in immunocompromised patients](#1210-infective-endocarditis-in-immunocompromised-p) *(p. 61)*
      - [12.10.1. Solid organ transplant recipients](#12101-solid-organ-transplant-recipients) *(p. 61)*
      - [12.10.2. Patients with human immunodeficiency virus](#12102-patients-with-human-immunodeficiency-virus) *(p. 61)*
      - [12.10.3. Patients with neutropaenia](#12103-patients-with-neutropaenia) *(p. 62)*
    - [12.11. Antithrombotic and anticoagulant therapy in infective endocarditis](#1211-antithrombotic-and-anticoagulant-therapy-in-i) *(p. 62)*
    - [12.12. Non-bacterial thrombotic endocarditis](#1212-non-bacterial-thrombotic-endocarditis) *(p. 62)*
    - [12.13. Infective endocarditis and malignancy](#1213-infective-endocarditis-and-malignancy) *(p. 63)*
  - [13. Patient-centred care and shared decision-making in infective endocarditis](#13-patient-centred-care-and-shared-decision-making) *(p. 63)*
    - [13.1. What is patient-centred care and shared decision-making and why is it important?](#131-what-is-patient-centred-care-and-shared-decisi) *(p. 63)*
    - [13.2. Patient-centred care and shared decision-making in infective endocarditis](#132-patient-centred-care-and-shared-decision-makin) *(p. 63)*
  - [14. Sex differences](#14-sex-differences) *(p. 64)*
  - [15. Key messages](#15-key-messages) *(p. 65)*
  - [16. Gaps in evidence](#16-gaps-in-evidence) *(p. 66)*
  - [17. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#17-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 67)*
  - [18. Supplementary data](#18-supplementary-data) *(p. 73)*
  - [19. Data availability](#19-data-availability) *(p. 73)*
  - [20. Author information](#20-author-information) *(p. 73)*
  - [Appendix](#appendix) *(p. 74)*
  - [22. References](#22-references) *(p. 74)*
  - [22. References](#22-references) *(p. 74)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2023 ESC Guidelines for the management 
of endocarditis
Developed by the task force on the management of endocarditis 
of the European Society of Cardiology (ESC)
Endorsed by the European Association for Cardio-Thoracic Surgery 
(EACTS) and the European Association of Nuclear Medicine (EANM)
Authors/Task Force Members: Victoria Delgado  *†, (Chairperson) (Spain),  
Nina Ajmone Marsan  
‡, (Task Force Co-ordinator) (Netherlands),  
Suzanne de Waha‡, (Task Force Co-ordinator) (Germany), Nikolaos Bonaros  
(Austria), Margarita Brida  
(Croatia), Haran Burri  
(Switzerland), 
Stefano Caselli  
(Switzerland), Torsten Doenst  
(Germany), 
Stephane Ederhy  
(France), Paola Anna Erba  
1 (Italy), Dan Foldager (Denmark), 
Emil L. Fosbøl  
(Denmark), Jan Kovac (United Kingdom), Carlos A. Mestres  
(South Africa), Owen I. Miller  
(United Kingdom), Jose M. Miro  
2 (Spain), 
Michal Pazdernik  
(Czech Republic), Maria Nazarena Pizzi  
(Spain), 
Eduard Quintana  
3 (Spain), Trine Bernholdt Rasmussen  
(Denmark),  
Arsen D. Ristić  
(Serbia), Josep Rodés-Cabau (Canada), Alessandro Sionis  
(Spain), Liesl Joanna Zühlke  
(South Africa), Michael A. Borger  *†, 
(Chairperson) (Germany), and ESC Scientific Document Group
© The European Society of Cardiology 2023. All rights reserved. For permissions please e-mail: journals.permissions@oup.com.
* Corresponding authors: Victoria Delgado, Cardiology, Hospital University Germans Trias i Pujol, Badalona, Spain, and Institute for Health Science Research Germans Trias i Pujol (IGTP), 
Badalona, Spain. Tel: +34 934 65 12 00, E-mail: videlga@gmail.com; and Michael A. Borger, University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. Tel: +49-341- 
865-0, E-mail: Michael.Borger@helios-gesundheit.de
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the European Association of Nuclear Medicine (EANM)
2 Representing the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
3 Representing the European Association for Cardio-Thoracic Surgery (EACTS)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
and Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Stroke.
Working Groups: Adult Congenital Heart Disease, Cardiovascular Surgery.
Patient Forum  
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC 
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
https://doi.org/10.1093/eurheartj/ehad193
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Bernard Iung, (CPG Review Co-ordinator) (France), Bernard Prendergast, (CPG Review  
Co-ordinator) (United Kingdom), Magdy Abdelhamid (Egypt), Marianna Adamo (Italy), Riccardo Asteggiano 
(Italy), Larry M. Baddour (Unites States of America), Jelena Čelutkienė (Lithuania), John Chambers  
(United Kingdom), Jean-Claude Deharo (France), Wolfram Doehner (Germany), Laura Dos Subira (Spain), 
Xavier Duval (France), Volkmar Falk (Germany), Laurent Fauchier (France), Nuria Fernandez-Hidalgo (Spain), 
Christian Giske2 (Sweden), Anežka Gombošová (Czechia), Gilbert Habib (France), Borja Ibanez (Spain), 
Tiny Jaarsma (Sweden), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha  
(United Kingdom), Ulf Landmesser (Germany), Sandra B. Lauck (Canada), Basil S. Lewis (Israel), Maja-Lisa Løchen 
(Norway), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom),  
Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark),  
Jean-François Obadia (France), Agnes A. Pasquet (Belgium), Steffen Petersen (United Kingdom), Eva Prescott 
(Denmark), Susanna Price (United Kingdom), Amina Rakisheva (Kazakhstan), Archana Rao (United Kingdom),  
François Rouzet (France), Jonathan Sandoe (United Kingdom), Renate B. Schnabel (Germany),  
Christine Selton-Suty (France), Lars Sondergaard (Denmark), Martin Thornhill (United Kingdom), 
Konstantinos Toutouzas (Greece), Nico Van de Veire (Belgium), Isidre Vilacosta (Spain),  
Christiaan Vrints (Belgium), and Olaf Wendler (United Kingdom)
All experts involved in the development of these guidelines have submitted declarations of interest. These have 
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The 
report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary documents that include background information and 
evidence tables.
Keywords 
Guidelines • Antibiotics • Cardiac imaging • Cardiac implantable electronic device • Cardiac surgery • Complications 
• Computed tomography • Congenital heart disease • Diagnosis • Echocardiography • Endocarditis • Infection • 
Nuclear imaging • Positron emission tomography • Prevention • Prognosis • Prosthetic heart valve • Valve disease
Table of contents
1. Preamble .............................................................................................................. 3953
2. Introduction ....................................................................................................... 3955
2.1. What is new .............................................................................................
3955
3. Prevention ........................................................................................................... 3959
3.1. Rationale .....................................................................................................
3959
3.2. Populations at risk of infective endocarditis ...............................
3960
3.3. Situations and procedures at risk ....................................................
3961
3.3.1. Dental procedures ......................................................................... 3961
3.3.2. Non-dental procedures ............................................................... 3961
3.3.3. Cardiac or vascular interventions ............................................ 3962
3.4. Patient education ....................................................................................
3962
4. The Endocarditis Team ................................................................................. 3963
5. Diagnosis .............................................................................................................. 3965
5.1. Clinical features .......................................................................................
3965
5.2. Laboratory findings ................................................................................
3966
5.3. Microbiological diagnosis .....................................................................
3966
5.3.1. Blood culture-positive infective endocarditis ..................... 3966
5.3.2. Blood culture-negative infective endocarditis .................... 3966
5.3.3. Proposed strategy for a microbiological diagnostic 
algorithm in suspected infective endocarditis ................................. 3967
5.4. Imaging techniques .................................................................................
3967
5.4.1. Echocardiography ........................................................................... 3967
5.4.2. Computed tomography ............................................................... 3969
5.4.3. Magnetic resonance imaging ...................................................... 3969
5.4.4. Nuclear imaging positron emission tomography/ 
computed tomography (angiography) and single photon 
emission tomography/computed tomography ............................... 3970
5.5. Diagnostic criteria ..................................................................................
3971
5.5.1. Modifications for the diagnosis of infective endocarditis
3971
5.5.1.1. Major criteria – microbiology ...........................................
3973
5.5.1.2. Major criteria – imaging .......................................................
3973
5.5.1.3. Minor criteria ...........................................................................
3974
5.5.1.4. Microbiological criteria ........................................................
3974
5.5.1.5. Infective endocarditis classification .................................
3975
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular, in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the 
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; 
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from 
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case 
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices at the time of prescription.
ESC Guidelines                                                                                                                                                                                          3949


<!-- PAGE 3 -->

### Page 3

5.5.2. The new 2023 European Society of Cardiology diagnostic 
algorithms ....................................................................................................... 3975
6. Prognostic assessment at admission ........................................................ 3975
7. Antimicrobial therapy: principles and methods .................................. 3975
7.1. General principles ..................................................................................
3975
7.2. Penicillin-susceptible oral streptococci and 
Streptococcus gallolyticus group ..................................................................
3977
7.3. Oral streptococci and Streptococcus gallolyticus group 
susceptible, increased exposure or resistant to penicillin .............
3977
7.4. Streptococcus pneumoniae, β-haemolytic streptococci  
(groups A, B, C, and G) ................................................................................
3979
7.5. Granulicatella and Abiotrophia (formerly nutritionally variant 
streptococci) .....................................................................................................
3979
7.6. Staphylococcus aureus and coagulase-negative staphylococci
3979
7.7. Methicillin-resistant staphylococci ...................................................
3979
7.8. Enterococcus spp. .....................................................................................
3982
7.9. Gram-negative bacteria ........................................................................
3983
7.9.1. Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, 
and Kingella-related species .................................................................... 3983
7.9.2. Non-Haemophilus, Aggregatibacter, Cardiobacterium, 
Eikenella, and Kingella species ................................................................. 3984
7.10. Blood culture-negative infective endocarditis .........................
3984
7.11. Fungi ..........................................................................................................
3984
7.12. Empirical therapy .................................................................................
3984
7.13. Outpatient parenteral or oral antibiotic therapy for infective 
endocarditis .......................................................................................................
3985
7.13.1. Parenteral and oral step-down antibiotic treatment .... 3986
7.13.2. Other considerations for outpatient oral or parenteral 
antimicrobial therapy ................................................................................. 3986
8. Indications for surgery and management of main infective 
endocarditis complications ............................................................................... 3987
8.1. Pre-operative risk assessment ..........................................................
3987
8.2. Heart failure ..............................................................................................
3987
8.2.1. Heart failure in infective endocarditis .................................... 3987
8.2.2. Indications and timing of surgery in the presence of heart 
failure in infective endocarditis .............................................................. 3989
8.3. Uncontrolled infection .........................................................................
3989
8.3.1. Septic shock and persistent infection .................................... 3989
8.3.2. Locally uncontrolled infection ................................................... 3989
8.3.3 Indications and timing of surgery in the presence of 
uncontrolled infection ............................................................................... 3990
8.3.3.1. Persistent infection ................................................................
3990
8.3.3.2. Locally uncontrolled infection ..........................................
3990
8.3.3.3. Infection with resistant or virulent organisms ...........
3990
8.4. Prevention of systemic embolism ...................................................
3990
8.4.1. Incidence of embolic events in infective endocarditis ..... 3990
8.4.2. Predicting the risk of embolism ................................................ 3990
8.4.3. Indications and timing of surgery to prevent embolism in 
infective endocarditis ................................................................................. 3990
9. Other complications of infective endocarditis .................................... 3991
9.1. Neurological complications ................................................................
3991
9.1.1. The role of cerebral imaging in infective endocarditis .... 3992
9.2. Infective aneurysms ...............................................................................
3992
9.3. Splenic complications ............................................................................
3992
9.4. Myocarditis and pericarditis ...............................................................
3993
9.5. Heart rhythm and conduction disturbances ..............................
3993
9.6. Musculoskeletal manifestations ........................................................
3993
9.6.1. Osteoarticular infective endocarditis-related infections
3993
9.6.2. Rheumatological manifestations ............................................... 3994
9.7. Acute renal failure ..................................................................................
3994
10. Surgical therapy: principles and methods ........................................... 3994
10.1. Pre-operative and peri-operative management ......................
3994
10.1.1. Coronary angiography ............................................................... 3994
10.1.2. Extracardiac infection ................................................................. 3995
10.1.3. Intra-operative echocardiography ......................................... 3995
10.2. Other intra-operative considerations .........................................
3995
10.3. Surgical approach and techniques ................................................
3995
10.3.1. Choice of valve prosthesis ....................................................... 3996
10.4. Timing of surgery after ischaemic and haemorrhagic stroke
3997
10.5. Post-operative complications .........................................................
3997
10.6. Management of antithrombotic therapy after surgery ........
3998
11. Outcome after discharge: follow-up and long-term prognosis . 3998
11.1. Recurrences: relapses and reinfections ......................................
3998
11.2. First year follow-up .............................................................................
3999
11.3. Long-term prognosis ..........................................................................
3999
12. Management of specific situations ......................................................... 3999
12.1. Prosthetic valve endocarditis ..........................................................
3999
12.1.1. Definition and pathophysiology ............................................. 4000
12.1.2. Diagnosis .......................................................................................... 4000
12.1.3. Prognosis and treatment .......................................................... 4000
12.2. Endocarditis in the elderly ...............................................................
4000
12.3. Transcatheter prosthetic valve endocarditis ............................
4001
12.3.1. Endocarditis following transcatheter aortic valve 
implantation ................................................................................................... 4001
12.3.1.1. Diagnosis .................................................................................
4001
12.3.1.2. Prognosis and treatment ..................................................
4001
12.3.2. Endocarditis following transcatheter pulmonary valve 
implantation ................................................................................................... 4001
12.3.2.1. Diagnosis .................................................................................
4002
12.3.2.2. Prognosis and treatment ..................................................
4002
12.4. Infective endocarditis affecting cardiac implantable 
electronic devices ............................................................................................
4002
12.4.1. Definitions of cardiac device infections .............................. 4002
12.4.2. Pathophysiology and microbiology ....................................... 4002
12.4.3. Risk factors ..................................................................................... 4002
12.4.4. Prophylaxis ...................................................................................... 4002
12.4.5. Diagnosis .......................................................................................... 4002
12.4.6. Antimicrobial therapy ................................................................. 4004
12.4.7. Device extraction ......................................................................... 4004
12.4.8. Device reimplantation ................................................................ 4004
12.5. Infective endocarditis in patients admitted to intensive care 
units ......................................................................................................................
4005
12.5.1. Causative microorganisms ....................................................... 4005
12.5.2. Diagnosis .......................................................................................... 4005
12.5.3. Management ................................................................................... 4005
12.6. Right-sided infective endocarditis .................................................
4005
12.6.1. Diagnosis and complications ................................................... 4006
12.6.2. Endocarditis in people who inject drugs ............................ 4006
12.6.3. Prognosis and treatment .......................................................... 4006
12.6.3.1. Antimicrobial therapy ........................................................
4006


<!-- PAGE 4 -->

### Page 4

12.6.3.2. Surgery .....................................................................................
4006
12.7. Infective endocarditis in congenital heart disease ..................
4007
12.8. Infective endocarditis in rheumatic heart disease ..................
4008
12.9. Infective endocarditis during pregnancy ....................................
4008
12.10. Infective endocarditis in immunocompromised patients .
4008
12.10.1. Solid organ transplant recipients ........................................ 4008
12.10.2. Patients with human immunodeficiency virus ............... 4008
12.10.3. Patients with neutropaenia ................................................... 4009
12.11. Antithrombotic and anticoagulant therapy in infective 
endocarditis .......................................................................................................
4009
12.12. Non-bacterial thrombotic endocarditis ..................................
4009
12.13. Infective endocarditis and malignancy ......................................
4010
13. Patient-centred care and shared decision-making in infective 
endocarditis ............................................................................................................. 4010
13.1. What is patient-centred care and shared decision-making 
and why is it important? ...............................................................................
4010
13.2. Patient-centred care and shared decision-making in infective 
endocarditis .......................................................................................................
4010
14. Sex differences ............................................................................................... 4011
15. Key messages .................................................................................................. 4012
16. Gaps in evidence ............................................................................................ 4013
17. ‘What to do’ and ‘What not to do’ messages from the 
Guidelines ................................................................................................................. 4014
18. Supplementary data ...................................................................................... 4020
19. Data availability ............................................................................................... 4020
20. Author information ...................................................................................... 4020
21. Appendix ........................................................................................................... 4021
22. References ........................................................................................................ 4021
Tables of Recommendations
Recommendation Table 1 — Recommendations for antibiotic 
prophylaxis in patients with cardiovascular diseases undergoing 
oro-dental procedures at increased risk for infective endocarditis
3961
Recommendation Table 2 — Recommendations for infective 
endocarditis prevention in high-risk patients ............................................ 3963
Recommendation Table 3 — Recommendations for infective 
endocarditis prevention in cardiac procedures ....................................... 3963
Recommendation Table 4 — Recommendations for the 
Endocarditis Team ................................................................................................ 3965
Recommendation Table 5 — Recommendations for the role of 
echocardiography in infective endocarditis ................................................ 3969
Recommendation Table 6 — Recommendations for the role of 
computed tomography, nuclear imaging, and magnetic resonance in 
infective endocarditis ........................................................................................... 3970
Recommendation Table 7 — Recommendations for antibiotic 
treatment of infective endocarditis due to oral streptococci and 
Streptococcus gallolyticus group ........................................................................ 3977
Recommendation Table 8 — Recommendations for antibiotic 
treatment of infective endocarditis due to Staphylococcus spp. ........ 3980
Recommendation Table 9 — Recommendations for antibiotic 
treatment of infective endocarditis due to Enterococcus spp. ..................
3982
Recommendation Table 10 — Recommendations for antibiotic 
regimens for initial empirical treatment of infective endocarditis 
(before pathogen identification) ..................................................................... 3985
Recommendation Table 11 — Recommendations for outpatient 
antibiotic treatment of infective endocarditis ........................................... 3987
Recommendation Table 12 — Recommendations for the main 
indications of surgery in infective endocarditis (native valve 
endocarditis and prosthetic valve endocarditis) ....................................... 3991
Recommendation Table 13 — Recommendations for the treatment 
of neurological complications of infective endocarditis ....................... 3992
Recommendation Table 14 — Recommendations for pacemaker 
implantation in patients with complete atrioventricular block and 
infective endocarditis ........................................................................................... 3993
Recommendation Table 15 — Recommendations for patients with 
musculoskeletal manifestations of infective endocarditis .................... 3994
Recommendation Table 16 — Recommendations for pre-operative 
coronary anatomy assessment in patients requiring surgery for 
infective endocarditis ........................................................................................... 3995
Recommendation Table 17 — Indications and timing of cardiac 
surgery after neurological complications in active infective 
endocarditis ............................................................................................................. 3997
Recommendation Table 18 — Recommendations for 
post-discharge follow-up ................................................................................... 3999
Recommendation Table 19 — Recommendations for prosthetic 
valve endocarditis .................................................................................................. 4000
Recommendation Table 20 — Recommendations for cardiovascular 
implanted electronic device-related infective endocarditis ................. 4004
Recommendation Table 21 — Recommendations for the surgical 
treatment of right-sided infective endocarditis ........................................ 4007
Recommendation Table 22 — Recommendations for the use of 
antithrombotic therapy in infective endocarditis .................................... 4009
List of tables
Table 1 Classes of recommendations .......................................................... 3953
Table 2 Levels of evidence ................................................................................ 3953
Table 3 New recommendations .................................................................... 3955
Table 4 Revised recommendations ............................................................... 3957
Table 5 General prevention measures to be followed in patients at 
high and intermediate risk of infective endocarditis .............................. 3960
Table 6 Prophylactic antibiotic regime for high-risk dental 
procedures ............................................................................................................... 3961
Table 7 Members of the Endocarditis Team ............................................ 3963
Table 8 Cardiac and non-cardiac risk factors ........................................... 3965
Table 9 Investigation of rare causes of blood culture-negative 
infective endocarditis ........................................................................................... 3967
Table 10 Definitions of the 2023 European Society of Cardiology 
modified diagnostic criteria of infective endocarditis ............................. 3971
Table 11 Antibiotic treatment of blood culture-negative infective 
endocarditis ............................................................................................................. 3984
Table 12 Features favouring a non-mechanical valve substitute in the 
setting of surgery for acute infective endocarditis ................................. 3997
Table 13 Factors associated with an increased rate of relapse of 
infective endocarditis ........................................................................................... 3999
Table 14 ‘What to do’ and ‘What not to do’ .......................................... 4014
List of figures
Figure 1 Management of patients with infective endocarditis ........... 3954
Figure 2 Education of high-risk patients to prevent infective 
endocarditis ............................................................................................................. 3962
Figure 3 Management of patients with infective endocarditis: 
positioning of the Endocarditis Team .......................................................... 3964
ESC Guidelines                                                                                                                                                                                          3951


<!-- PAGE 5 -->

### Page 5

Figure 4 Microbiological diagnostic algorithm in culture-positive and 
culture-negative infective endocarditis ........................................................ 3968
Figure 5 European Society of Cardiology 2023 algorithm for 
diagnosis of native valve infective endocarditis ........................................ 3972
Figure 6 European Society of Cardiology 2023 algorithm for diagnosis 
of prosthetic valve infective endocarditis ...........................................................
3973
Figure 7 European Society of Cardiology 2023 algorithm for 
diagnosis of cardiac device-related infective endocarditis ................... 3974
Figure 8 Phases of antibiotic treatment for infective endocarditis in 
relation to outpatient parenteral antibiotic therapy and partial oral 
endocarditis treatment ....................................................................................... 3976
Figure 9 Flowchart to assess clinical stability based on the Partial Oral 
Treatment of Endocarditis trial ...................................................................... 3986
Figure 10 Proposed surgical timing for infective endocarditis ........... 3988
Figure 11 Surgery for infective endocarditis following stroke ........... 3996
Figure 12 Algorithm differentiating relapse from reinfection ............ 3998
Figure 13 Management of cardiovascular implanted electronic 
device-related infective endocarditis ............................................................ 4003
Figure 14 Concept of patient-centred care in infective endocarditis
4011
Abbreviations and acronyms
[18F]FDG
18F-fluorodeoxyglucose
99mTc-HMPAO
99mTechnetium-hexamethylpropyleneamine 
oxime
AIDS
Acquired immune deficiency syndrome
AEPEI
Association for the Study and Prevention of 
Infective Endocarditis Study
ANCLA
Anaemia, NYHA class IV, critical state, large 
intracardiac destruction, surgery of thoracic aorta
APLs
Antiphospholipid syndrome
AUC
Area under the curve
AVB
Atrioventricular block
AVN
Atrioventricular node
BCNIE
Blood culture-negative infective endocarditis
BMI
Body mass index
CAD
Coronary artery disease
CHD
Congenital heart disease
CI
Confidence interval
CIED
Cardiovascular implanted electronic device
CNS
Central nervous system
CoNS
Coagulase-negative staphylococci
CPB
Cardio-pulmonary bypass
CRT
Cardiac resynchronization therapy
CT
Computed tomography
CTA
Computed tomography angiography
DIC
Disseminated intravascular coagulation
DNA
Deoxyribonucleic acid
DSA
Digital subtraction angiography
ECG
Electrocardiogram
EHRA
European Heart Rhythm Association
ESC
European Society of Cardiology
EUCAST
European Committee on Antimicrobial 
Susceptibility Testing
EURO-ENDO
European Infective Endocarditis Registry
HACEK
Haemophilus, Aggregatibacter, Cardiobacterium, 
Eikenella, and Kingella
HF
Heart failure
HIV
Human immunodeficiency virus
HLAR
High-level aminoglycoside resistance i.m.
Intramuscular i.v.
Intravenous
ICD
Implantable cardioverter defibrillator
ICE-PCS
International Collaboration on 
Endocarditis-Prospective Cohort Study
ICU
Intensive care unit
IE
Infective endocarditis
Ig
Immunoglobulin
MALDI-TOF MS
Matrix-assisted laser desorption ionization 
time-of-flight mass spectrometry
MIC
Minimum inhibitory concentration
MRA
Magnetic resonance angiography
MRI
Magnetic resonance imaging
MRSA
Methicillin-resistant Staphylococcus aureus
MSSA
Methicillin-susceptible Staphylococcus aureus
NBTE
Non-bacterial thrombotic endocarditis
NIHSS
National Institutes of Health Stroke Scale Score
NVE
Native valve endocarditis
NYHA
New York Heart Association
OPAT
Outpatient parenteral antibiotic therapy
PADIT
Previous procedure on same pocket; Age; 
Depressed renal function; Immunocompromised; 
Type of procedure
PALSUSE
Prosthetic valve, age ≥70, large intracardiac 
destruction, Staphylococcus spp., urgent surgery, 
sex (female), EuroSCORE ≥10
PBP
Penicillin-binding protein
PCR
Polymerase chain reaction
PET/CT
Positron emission tomography/computed 
tomography
POET
Partial Oral Treatment of Endocarditis (trial)
PPV
Positive predictive value
PVE
Prosthetic valve endocarditis
PWID
People who inject drugs
RCT
Randomized clinical trial
RHD
Rheumatic heart disease rRNA
Ribosomal ribonucleic acid
SAPS
Simplified Acute Physiology Score
SLE
Systemic lupus erythematous
SOT
Solid organ transplantation
SPECT/CT
Single photon emission tomography/computed 
tomography
STS
Society of Thoracic Surgeons
TAVI
Transcatheter aortic valve implantation
TOE
Transoesophageal echocardiography
TPVI
Transcatheter pulmonary valve implantation
TTE
Transthoracic echocardiography
WBC
White blood cell
WRAP-IT
Worldwide Randomized Antibiotic Envelope 
Infection Prevention Trial


<!-- PAGE 6 -->

### Page 6

### 1 Preamble

Guidelines evaluate and summarize available evidence, with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeutic 
approach for an individual patient with a given condition. Guidelines are in­
tended for use by health professionals and the European Society of 
Cardiology (ESC) makes its Guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consideration 
of each patient’s health condition and in consultation with that patient or 
the patient’s caregiver where appropriate and/or necessary. It is also the 
health professional’s responsibility to verify the rules and regulations ap­
plicable in each country to drugs and devices at the time of prescription, 
and, where appropriate, to respect the ethical rules of their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated. ESC Policies and Procedures for for­
mulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines).
The Members of this Task Force were selected by the ESC to represent 
professionals involved with the medical care of patients with this 
Table 1 Classes of recommendations
©ESC 2023
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2023
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2023
© ESC 2023
ESC Guidelines                                                                                                                                                                                          3953


<!-- PAGE 7 -->

### Page 7

Yes
No
Yes
No
Emergency
Urgent
Non-urgent
Patient with infective endocarditis
Imaging
Blood culture
Adjust antibiotic according to results of blood cultures
Endocarditis Team
Empiric antibiotic therapy i.v.
Continue appropriate antibiotic therapy
Complications
Complications
Cardiac surgery
Antibiotic therapy i.v. in hospital or OPAT
Patient-centred care
Recovery plan
Patient education - oral and general hygiene
Continue appropriate antibiotic therapy
Continue appropriate antibiotic therapy
Endocarditis Team
Figure 1 Management of patients with infective endocarditis. i.v., intravenous; OPAT, outpatient parenteral antibiotic therapy.


<!-- PAGE 8 -->

### Page 8

pathology. The selection procedure aimed to include members from 
across the whole of the ESC region and from relevant ESC Subspecialty 
Communities. Consideration was given to diversity and inclusion, notably 
with respect to gender and country of origin. The Task Force performed a 
critical evaluation of diagnostic and therapeutic approaches, including as­
sessment of the risk-benefit ratio. The strength of every recommendation 
and the level of evidence supporting them were weighed and scored ac­
cording to predefined scales as outlined below. The Task Force followed 
ESC voting procedures, and all approved recommendations were subject 
to a vote and achieved at least 75% agreement among voting members.
The experts of the writing and reviewing panels provided declaration of 
interest forms for all relationships that might be perceived as real or po­
tential sources of conflicts of interest. Their declarations of interest were 
reviewed according to the ESC declaration of interest rules and can be 
found on the ESC website (http://www.escardio.org/Guidelines) and 
have been compiled in a report published in a supplementary document 
with the guidelines. The Task Force received its entire financial support 
from the ESC without any involvement from the healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises and 
co-ordinates the preparation of new guidelines and is responsible for the 
approval process. ESC Guidelines undergo extensive review by the CPG 
Committee and external experts, including members from across the 
whole of the ESC region and from relevant ESC Subspecialty 
Communities and National Cardiac Societies. After appropriate revisions, 
the guidelines are signed off by all the experts involved in the Task Force. 
The finalized document is signed off by the CPG Committee for publica­
tion in the European Heart Journal. The guidelines were developed after 
careful consideration of the scientific and medical knowledge and the evi­
dence available at the time of their writing. Tables of evidence summariz­
ing the findings of studies informing development of the guidelines are 
included. The ESC warns readers that the technical language may be mis­
interpreted and declines any responsibility in this respect.
Off-label use of medication may be presented in this guideline if a suf­
ficient level of evidence shows that it can be considered medically ap­
propriate for a given condition. However, the final decisions 
concerning an individual patient must be made by the responsible health 
professional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
Infective endocarditis (IE) is a major public health challenge.1 In 2019, the 
estimated incidence of IE was 13.8 cases per 100 000 subjects per year, 
and IE accounted for 66 300 deaths worldwide.2 Due to the associated 
high morbidity and mortality (1723.59 disability-adjusted life years and 
0.87 death cases per 100 000 population, respectively), identification of 
the best preventive strategies has been the focus of research.2,3 Since the 
publication of the 2015 ESC Guidelines for the management of infective endo­
carditis,4 important new data have been published mandating an update of 
recommendations. First, the population at risk of IE has increased and new 
data on IE in different clinical scenarios have arisen.5–11 Furthermore, the 
emerging and increasing antibiotic resistance among oral streptococci is 
of concern. The rate of resistance to azythromycin and clarithromycin is 
higher than that to penicillin.12 Whether changes in national guidelines on 
the use of antibiotic prophylaxis have resulted in an increase in the incidence 
of IE remains unclear.13–18 It is likely that the increased use of diagnostic 
tools to diagnose IE is an important contributor to the increase in the inci­
dence of IE. The use of echocardiography has probably increased in patients 
with positive blood cultures for Enteroccus faecalis, Staphylococcus aureus, or 
streptococci due to the associated increased risk of IE.19 In addition, com­
puted tomography (CT) and nuclear imaging techniques have increased the 
number of definite IE cases particularly among patients with prosthetic 
valves and implantable cardiac devices.20–22
Data on the contemporary characterization of patients with IE have 
been taken into consideration to update the recommendations on the 
diagnosis and management of patients with IE.5,19,23–41 Furthermore, 
the recommendations on antibiotic therapy have been updated based 
on the susceptibility of various microorganisms defined by the 
European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) clinical breakpoints.42 Recommendations on outpatient par­
enteral antibiotic therapy (OPAT) or oral antibiotic treatment have 
been included based on the results of the Partial Oral Treatment of 
Endocarditis (POET) randomized trial and other trials.43–46
The main objective of the current Task Force was to provide clear 
and simple recommendations, assisting healthcare providers in their 
clinical decision-making. These recommendations were obtained by ex­
pert consensus after thorough review of the available literature (see 
Supplementary data, evidence tables online). An evidence-based scor­
ing system was used, based on a classification of the strength of recom­
mendations and the levels of evidence.
2.1. What is new
Table 3 New recommendations
Recommendation
Class
Level
Section 3. Recommendation Table 1 — Recommendations for 
antibiotic prophylaxis in patients with cardiovascular diseases 
undergoing oro-dental procedures at increased risk of infective 
endocarditis
General prevention measures are recommended in 
individuals at high and intermediate risk of IE.
I
C
Antibiotic prophylaxis is recommended in patients with 
ventricular assist devices.
I
C
Antibiotic prophylaxis may be considered in recipients 
of heart transplant.
IIb
C
Section 3. Recommendation Table 2 — Recommendations for 
infective endocarditis prevention in high-risk patients
Systemic antibiotic prophylaxis may be considered for 
high-risk patients undergoing an invasive diagnostic or 
therapeutic procedure of the respiratory, 
gastrointestinal, genitourinary tract, skin, or 
musculoskeletal systems.
IIb
C
Section 3. Recommendation Table 3 — Recommendations for 
infective endocarditis prevention in cardiac procedures
Optimal pre-procedural aseptic measures of the site of 
implantation is recommended to prevent CIED 
infections.
I
B
Continued
ESC Guidelines                                                                                                                                                                                          3955


<!-- PAGE 9 -->

### Page 9

Surgical standard aseptic measures are recommended 
during the insertion and manipulation of catheters in 
the catheterization laboratory environment.
I
C
Antibiotic prophylaxis covering for common skin flora 
including Enterococcus spp. and S. aureus should be 
considered before TAVI and other transcatheter 
valvular procedures.
IIa
C
Section 5. Recommendation Table 5 — Recommendations for 
the role of echocardiography in infective endocarditis
TOE is recommended when the patient is stable before 
switching from intravenous to oral antibiotic therapy.
I
B
Section 5. Recommendation Table 6 — Recommendations for 
the role of computed tomography, nuclear imaging, and 
magnetic resonance in infective endocarditis
Cardiac CTA is recommended in patients with possible 
NVE to detect valvular lesions and confirm the 
diagnosis of IE.
I
B
[18F]FDG-PET/CT(A) and cardiac CTA are 
recommended in possible PVE to detect valvular 
lesions and confirm the diagnosis of IE.
I
B
[18F]FDG-PET/CT(A) may be considered in possible 
CIED-related IE to confirm the diagnosis of IE.
IIb
B
Cardiac CTA is recommended in NVE and PVE to 
diagnose paravalvular or periprosthetic complications if 
echocardiography is inconclusive.
I
B
Brain and whole-body imaging (CT, [18F]FDG-PET/ 
CT, and/or MRI) are recommended in symptomatic 
patients with NVE and PVE to detect peripheral lesions 
or add minor diagnostic criteria.
I
B
WBC SPECT/CT should be considered in patients with 
high clinical suspicion of PVE when echocardiography is 
negative or inconclusive and when PET/CT is 
unavailable.
IIa
C
Brain and whole-body imaging (CT, [18F]FDG-PET/ 
CT, and MRI) in NVE and PVE may be considered for 
screening of peripheral lesions in asymptomatic 
patients.
IIb
B
Section 7. Recommendation Table 11 — Recommendations for 
outpatient antibiotic treatment of infective endocarditis
Outpatient parenteral antibiotic treatment should be 
considered in patients with left-sided IE caused by 
Streptococcus spp., E. faecalis, S. aureus, or CoNS who 
were receiving appropriate i.v. antibiotic treatment for 
at least 10 days (or at least 7 days after cardiac surgery), 
are clinically stable, and who do not show signs of 
abscess formation or valve abnormalities requiring 
surgery on TOE.
IIa
A
Outpatient parenteral antibiotic treatment is not 
recommended in patients with IE caused by highly 
difficult-to-treat microorganisms, liver cirrhosis (Child– 
Pugh B or C), severe cerebral nervous system emboli, 
untreated large extracardiac abscesses, heart valve 
complications, or other severe conditions requiring 
surgery, severe post-surgical complications, and in 
PWID-related IE.
III
C
Continued
Section 9. Recommendation Table 13 — Recommendations for 
the treatment of neurological complications of infective 
endocarditis
In embolic stroke, mechanical thrombectomy may be 
considered if the expertise is available in a timely manner.
IIb
C
Thrombolytic therapy is not recommended in embolic 
stroke due to IE.
III
C
Section 9. Recommendation Table 14 — Recommendations for 
pacemaker implantation in patients with complete 
atrioventricular block and infective endocarditis
Immediate epicardial pacemaker implantation should be 
considered in patients undergoing surgery for valvular IE 
and complete AVB if one of the following predictors of 
persistent AVB is present: pre-operative conduction 
abnormality, S. aureus infection, aortic root abscess, 
tricuspid valve involvement, or previous valvular surgery.
IIa
C
Section 9. Recommendation Table 15 — Recommendations for 
patients with musculoskeletal manifestations of infective 
endocarditis
MRI or PET/CT is recommended in patients with 
suspected spondylodiscitis and vertebral osteomyelitis 
complicating IE.
I
C
TTE/TOE is recommended to rule out IE in patients 
with spondylodiscitis and/or septic arthritis with 
positive blood cultures for typical IE microorganisms.
I
C
More than 6-week antibiotic therapy should be 
considered in patients with osteoarticular IE-related 
lesions caused by difficult-to-treat microorganisms, 
such as S. aureus or Candida spp., and/or complicated 
with severe vertebral destruction or abscesses.
IIa
C
Section 10. Recommendation Table 16 — Recommendations for 
pre-operative coronary anatomy assessment in patients 
requiring surgery for infective endocarditis
In haemodynamically stable patients with aortic valve 
vegetations who require cardiac surgery and are high 
risk of CAD, a high-resolution multislice coronary CTA 
is recommended.
I
B
Invasive coronary angiography is recommended in 
patients requiring heart surgery who are high risk of 
CAD, in the absence of aortic valve vegetations.
I
C
In emergency situations, valvular surgery without 
pre-operative coronary anatomy assessment 
regardless of CAD risk should be considered.
IIa
C
Invasive coronary angiography may be considered 
despite the presence of aortic valve vegetations in 
selected patients with known CAD or at high risk of 
significant obstructive CAD.
IIb
C
Section 10. Recommendation Table 17 — Indications and timing 
of cardiac surgery after neurological complications in active 
infective endocarditis
In patients with intracranial haemorrhage and unstable 
clinical status due to HF, uncontrolled infection, or 
persistent high embolic risk, urgent or emergency 
surgery should be considered weighing the likelihood of 
a meaningful neurological outcome.
IIa
C
Continued


<!-- PAGE 10 -->

### Page 10

Section 11. Recommendation Table 18 — Recommendations for 
post-discharge follow-up
Patient education on the risk of recurrence and 
preventive measures, with emphasis on dental health, 
and based on the individual risk profile, is 
recommended during follow-up.
I
C
Addiction treatment for patients following 
PWID-related IE is recommended.
I
C
Cardiac rehabilitation including physical exercise 
training should be considered in clinically stable patients 
based on an individual assessment.
IIa
C
Psychosocial support may be considered to be 
integrated in follow-up care, including screening for 
anxiety and depression, and referral to relevant 
psychological treatment.
IIb
C
Section 12. Recommendation Table 19 — Recommendations for 
prosthetic valve endocarditis
Surgery is recommended for early PVE (within 6 
months of valve surgery) with new valve replacement 
and complete debridement.
I
C
Section 12. Recommendation Table 20 — Recommendations for 
cardiovascular implanted electronic device-related infective 
endocarditis
Complete system extraction without delay is 
recommended in patients with definite CIED-related IE 
under initial empirical antibiotic therapy.
I
B
Extension of antibiotic treatment of CIED-related 
endocarditis to (4–)6 weeks following device 
extraction should be considered in the presence of 
septic emboli or prosthetic valves.
IIa
C
Use of an antibiotic envelope may be considered in 
select high-risk patients undergoing CIED 
reimplantation to reduce risk of infection.
IIb
B
Continued
Table 4 Revised recommendations
Recommendations in 2015 version
Class
Level
Recommendations in 2023 version
Class
Level
Section 3. Recommendation Table 1 — Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing 
oro-dental procedures at increased risk of infective endocarditis
Antibiotic prophylaxis should be considered for patients 
at highest risk of IE: 
(1) Patients with any prosthetic valve, including a 
transcatheter valve, or those in whom any 
prosthetic material was used for cardiac valve repair.
(2) Patients with a previous episode of IE.
(3) Patients with CHD: 
(a) Any type of cyanotic CHD.
(b) Any type of CHD repaired with a prosthetic 
material, whether placed surgically or by 
percutaneous techniques, up to 6 months after 
the procedure or lifelong if residual shunt.
IIa
C
Antibiotic prophylaxis is recommended in patients with 
previous IE.
I
B
Antibiotic prophylaxis is recommended in patients with 
surgically implanted prosthetic valves and with any 
material used for surgical cardiac valve repair.
I
C
Antibiotic prophylaxis is recommended in patients with 
transcatheter implanted aortic and pulmonary valvular 
prostheses.
I
C
Antibiotic prophylaxis should be considered in patients 
with transcatheter mitral and tricuspid valve repair.
IIa
C
Continued
In non-S. aureus CIED-related endocarditis without 
valve involvement or lead vegetations, and if follow-up 
blood cultures are negative without septic emboli, 2 
weeks of antibiotic treatment may be considered 
following device extraction.
IIb
C
Removal of CIED after a single positive blood culture, 
with no other clinical evidence of infection, is not 
recommended.
III
C
Section 12. Recommendation Table 21 — Recommendations for 
the surgical treatment of right-sided infective endocarditis
Tricuspid valve repair should be considered instead of 
valve replacement, when possible.
IIa
B
Surgery should be considered in patients with 
right-sided IE who are receiving appropriate antibiotic 
therapy and present persistent bacteraemia/sepsis after 
at least 1 week of appropriate antibiotic therapy.
IIa
C
Prophylactic placement of an epicardial pacing lead 
should be considered at the time of tricuspid valve 
surgical procedures.
IIa
C
Debulking of right intra-atrial septic masses by 
aspiration may be considered in select patients who are 
high risk of surgery.
IIb
C
© ESC 2023
[18F]FDG-PET, 
18F-fluorodeoxyglucose 
positron 
emission 
tomography; 
AVB, 
atrioventricular block; CAD, coronary artery disease; CIED, cardiovascular implanted 
electronic device; CoNS, coagulase-negative staphylococci; CT, computed tomography; 
CTA, computed tomography angiography; HF, heart failure; IE, infective endocarditis; i.v., 
intravenous; MRI, magnetic resonance imaging; NVE, native valve endocarditis; PET, 
positron emission tomography; PVE, prosthetic valve endocarditis; PWID, people who 
inject drugs; TAVI, transcatheter aortic valve implantation; TOE, transoesophageal 
echocardiography; TTE, transthoracic echocardiography; WBC SPECT/CT, white blood 
cell single photon emission tomography/computed tomography.
ESC Guidelines                                                                                                                                                                                          3957


<!-- PAGE 11 -->

### Page 11

Antibiotic prophylaxis is recommended in patients with 
untreated cyanotic CHD, and patients treated with 
surgery or transcatheter procedures with post-operative 
palliative shunts, conduits, or other prostheses. After 
surgical repair, in the absence of residual defects or valve 
prostheses, antibiotic prophylaxis is recommended only 
for the first 6 months after the procedure.
I
C
Section 4. Recommendation Table 4 — Recommendations for the Endocarditis Team
Patients with complicated IE should be evaluated and 
managed at an early stage in a reference centre, with 
immediate surgical facilities and the presence of a 
multidisciplinary ‘Endocarditis Team’, including an 
infectious disease specialist, a microbiologist, a 
cardiologist, imaging specialists, a cardiac surgeon and, if 
needed, a specialist in CHD.
IIa
B
Diagnosis and management of patients with complicated 
IE are recommended to be performed at an early stage in 
a Heart Valve Centre, with immediate surgical facilities 
and an ‘Endocarditis Team’ to improve the outcomes.
I
B
For patients with uncomplicated IE managed in a 
non-reference centre, early and regular communication 
with the reference centre and, when needed, visits to the 
reference centre should be made.
IIa
B
For patients with uncomplicated IE managed in a Referring 
Centre, early and regular communication between the 
local and the Heart Valve Centre Endocarditis Teams is 
recommended to improve the outcomes of the patients.
I
B
Section 5. Recommendation Table 5 — Recommendations for the role of echocardiography in infective endocarditis
TOE should be considered in patients with suspected IE, 
even in cases with positive TTE, except in isolated 
right-sided native valve IE with good quality TTE 
examination and unequivocal echocardiographic finding.
IIa
C
TOE is recommended in patients with suspected IE, even 
in cases with positive TTE, except in isolated right-sided 
native valve IE with good quality TTE examination and 
unequivocal echocardiographic findings.
I
C
Section 8. Recommendation Table 12 — Recommendations for the main indications of surgery in infective endocarditis (native valve 
endocarditis and prosthetic valve endocarditis)
Aortic or mitral NVE with vegetations >10 mm, 
associated with severe valve stenosis or regurgitation, and 
low operative risk (urgent surgery should be considered).
IIa
B
Urgent surgery is recommended in IE with vegetation 
≥10 mm and other indications for surgery.
I
C
Aortic or mitral NVE or PVE with isolated large 
vegetations (>15 mm) and no other indication for surgery 
(urgent surgery may be considered).
IIb
C
Urgent surgery may be considered in aortic or mitral IE 
with vegetation ≥10 mm and without severe valve 
dysfunction or without clinical evidence of embolism and 
low surgical risk.
IIb
B
Section 9. Recommendation Table 13 — Recommendations for the treatment of neurological complications of infective endocarditis
Intracranial infectious aneurysms should be looked for in 
patients with IE and neurological symptoms. CT or MRA 
should be considered for diagnosis. If non-invasive 
techniques are negative and the suspicion of intracranial 
aneurysm remains, conventional angiography should be 
considered.
IIa
B
Brain CT or MRA is recommended in patients with IE and 
suspected infective cerebral aneurysms.
I
B
If non-invasive techniques are negative and the suspicion 
of infective aneurysm remains, invasive angiography 
should be considered.
IIa
B
Section 12. Recommendation Table 20 — Recommendations for cardiovascular implanted electronic device-related infective 
endocarditis
Routine antibiotic prophylaxis is recommended before 
device implantation.
I
B
Antibiotic prophylaxis covering S. aureus is recommended 
for CIED implantation.
I
A
TOE is recommended in patients with suspected cardiac 
device-related infective endocarditis with positive or 
negative blood cultures, independent of the results of 
TTE, to evaluate lead-related endocarditis and heart valve 
infection.
I
C
TTE and TOE are both recommended in case of 
suspected CIED-related IE to identify vegetations.
I
B
In patients with NVE or PVE and an intracardiac device 
with no evidence of associated device infection, complete 
hardware extraction may be considered.
IIb
C
Complete CIED extraction should be considered in case 
of valvular IE, even without definite lead involvement, 
taking into account the identified pathogen and 
requirement for valve surgery.
IIa
C
Continued


<!-- PAGE 12 -->

### Page 12

### 3 Prevention

3.1. Rationale
The development of IE usually requires several conditions, including the 
presence of predisposing risk factors (i.e. a surface/structure that could 
be colonized by bacteria), pathogens entering the bloodstream, and the 
competence of the host’s immune response. The role of predisposing 
risk factors has been recently underscored by Thornhill et al.47
Predisposing risk factors conveying a moderate and high risk of IE 
had an incidence of 280 and 497 cases per 100 000 subjects per year, 
respectively.47
The portals of entry of bacteria/fungi are variable and include: (i) in­
fections of the skin, oral cavity, gastrointestinal, or genitourinary system; 
(ii) direct inoculation in people who inject drugs (PWID), or by any un­
safe or unprotected vascular puncture; (iii) healthcare exposure (in­
cluding a variety of invasive diagnostic or therapeutic procedures, 
such as transcatheter or surgical techniques).6,11,48–50
The oral cavity is colonized by relevant commensal flora, including 
oral group streptococci, and represents an important entry port. 
Oral surgery procedures (including all extractions, periodontal surgery, 
implant surgery, and oral biopsies) and dental procedures that involve 
manipulation of the gingival or periapical region of the teeth are consid­
ered at high risk of causing bacteraemia.11,48,49,51
Successful antibiotic prophylaxis assumes that reducing the bacter­
aemia associated with medical procedures will lead to a reduced risk 
of IE. This concept was supported by a few animal models and obser­
vational studies that led to the recommendation for antibiotic prophy­
laxis in a large number of patients with predisposing cardiac conditions 
undergoing a wide range of procedures.4,14,52–60
However, systematic use of antibiotic prophylaxis has been ques­
tioned based on several considerations, the most important being the 
lack of randomized clinical trials (RCTs) demonstrating the efficacy of 
antibiotic prophylaxis prior to medical procedures in preventing IE. 
Such trials would entail enrolment of a very large number of individuals 
and prolonged follow-up, making the feasibility of such studies improb­
able. Furthermore, since the standard of care for high-risk individuals is 
antibiotic prophylaxis (to date, mostly before invasive oro-dental pro­
cedures), there may not be sufficient equipoise to perform such RCTs. 
Finally, the costs of performing such trials have been considered un­
acceptable.61 To overcome these limitations, population-based studies 
Complete hardware removal should be considered on the 
basis of occult infection without another apparent source 
of infection.
IIa
C
In cases of possible CIED-related IE or occult 
Gram-positive bacteraemia or fungaemia, complete 
system removal should be considered in case 
bacteraemia/fungaemia persists after a course of 
antimicrobial therapy.
IIa
C
In cases of possible CIED-related IE with occult 
Gram-negative bacteraemia, complete system removal 
may be considered in case of persistent/relapsing 
bacteraemia after a course of antimicrobial therapy.
IIb
C
When indicated, definite reimplantation should be 
postponed if possible, to allow a few days or weeks of 
antibiotic therapy.
IIa
C
If CIED reimplantation is indicated after extraction for 
CIED-related IE, it is recommended to be performed at a 
site distant from the previous generator, as late as 
possible, once signs and symptoms of infection have 
abated and until blood cultures are negative for at least 
72 h in the absence of vegetations, and negative for at 
least 2 weeks if vegetations were visualized.
I
C
Section 12. Recommendation Table 21 — Recommendations for the surgical treatment of right-sided infective endocarditis
Surgical treatment should be considered in the following scenarios:
Surgery is recommended in patients with right-sided IE who are receiving 
appropriate antibiotic therapy for the following scenarios:
• Microorganisms difficult to eradicate (e.g. persistent 
fungi) or bacteraemia for >7 days (e.g. S. aureus, P. 
aeruginosa) despite adequate antimicrobial therapy; or
• Persistent tricuspid valve vegetations >20 mm after 
recurrent pulmonary emboli with or without 
concomitant right HF; or
• Right HF secondary to severe tricuspid regurgitation 
with poor response to diuretic therapy.
IIa
C
Right ventricular dysfunction secondary to acute severe 
tricuspid regurgitation non-responsive to diuretics.
I
B
Persistent vegetation with respiratory insufficiency 
requiring ventilatory support after recurrent pulmonary 
emboli.
I
B
Large residual tricuspid vegetations (>20 mm) after 
recurrent septic pulmonary emboli.
I
C
Patients with simultaneous involvement of left-heart 
structures.
I
C
Section 12. Recommendation Table 22 — Recommendations for the use of antithrombotic therapy in infective endocarditis
Interruption of antiplatelet therapy is recommended in 
the presence of major bleeding.
I
B
Interruption of antiplatelet or anticoagulant therapy is 
recommended in the presence of major bleeding 
(including intracranial haemorrhage).
I
C
© ESC 2023
CHD, congenital heart disease; CIED, cardiovascular implanted electronic device; CT, computed tomography; HF, heart failure; IE, infective endocarditis; MRA, magnetic resonance 
angiography; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.
ESC Guidelines                                                                                                                                                                                          3959


<!-- PAGE 13 -->

### Page 13

have evaluated the efficacy of antibiotic prophylaxis using bacteraemia 
as a surrogate of IE.16–18,52,62 However, the relationship between bac­
teraemia and IE is not straightforward. Bacteraemia may be caused by 
daily activities such as tooth brushing, flossing, and chewing, and al­
though these constitute low-level bacteraemia, they occur repetitively 
and may therefore outweigh the risk of bacteraemia associated with 
dental procedures.48,49 A meta-analysis of 36 studies, including 21 trials 
that investigated the effect of antibiotic prophylaxis on the incidence of 
bacteraemia following dental procedures, demonstrated that antibiotic 
prophylaxis is effective in reducing the incidence of bacteraemia, but did 
not lead to a statistically significant protective effect against IE in case- 
control studies.52 Additionally, the potential risk of anaphylaxis,63 or 
other adverse side effects in a small minority of patients, and the fact 
that a widespread use of antibiotics may be associated with antibiotic 
resistance, are areas of concern.57,58,64–67 While some studies did not 
demonstrate significant increases in IE-related hospitalizations and 
death rates after scaling down antibiotic prophylaxis indications,68–77
others showed an increase in the incidence of IE among individuals at 
moderate and high risk of IE.13,26,59,78–81 A meta-analysis including 16 
studies reporting over 1.3 million cases of IE has shown that restricting 
antibiotic prophylaxis to only high-risk individuals has not resulted in an 
increase in the incidence of streptococcal IE in a North American popu­
lation (despite the fact that it was unable to draw that conclusion for 
other populations).18 In contrast, a systematic review including multiple 
nationwide population-based studies in Europe has shown a 4% per 
year rise in the incidence of IE.82 These contrasting results may be ex­
plained by differences in the methodology of the studies (retrospective, 
population- or health-system-based studies that relied on claims data or 
epidemiological observations to estimate the incidence of IE), greater 
disease diagnosis with the use of newer imaging technologies, lack of 
microbiological data, and the lack of specific International 
Classification of Diseases codes for oral streptococci.83 Recently, it 
has been shown that antibiotic prophylaxis in high-risk individuals was 
associated with a significant reduction of IE after invasive dental proce­
dures (particularly extractions and oral surgical procedures).11,51 After 
careful consideration of all the new studies published after 2015, the 
present Task Force decided to revise and update the risk categories 
for IE, strengthening the recommendation of antibiotic prophylaxis, 
clarifying the definition of the population at risk, and considering the ad­
vances in transcatheter valve interventions.
3.2. Populations at risk of infective 
endocarditis
The groups of individuals at high risk of IE in whom antibiotic prophy­
laxis is recommended or should be considered include the following: 
(i) Patients with previous IE: the highest risk of IE is observed in pa­
tients with previous history of IE who have an ominous prognosis 
during IE-related hospitalization. Patients with recurrent IE more 
frequently have prosthetic valves or prosthetic material, are 
more commonly PWID, or have staphylococcal IE.47,84–86
(ii) Patients with surgically implanted prosthetic valves, with transcath­
eter implanted prosthetic valves, and with any material used for 
cardiac valve repair: the increased risk of IE in these patients, com­
bined with the ominous outcomes as compared with patients with 
native IE (NVE), make antibiotic prophylaxis advisable in this pa­
tient group. Patients with prosthetic valve endocarditis (PVE) 
have an in-hospital mortality rate that is twice as high with more 
complications (e.g. heart failure [HF], conduction disturbances) 
as compared with patients with NVE, regardless of the 
pathogen.87,88 Furthermore, mitral and aortic bioprostheses may 
be associated with increased risk of IE as compared with mechan­
ical prostheses,89,90 and bioprostheses are being implanted in an 
ever-increasing proportion of patients requiring valve replacement 
therapy. The indication for prophylaxis also expands to transcath­
eter aortic and pulmonic prosthetic valves, since IE is also asso­
ciated with a high risk of morbidity and mortality in these 
patients.91–94 In terms of transcatheter mitral and tricuspid valve 
interventions, the data on the risk of IE are limited.95 Patients 
with septal defect closure devices, left atrial appendage closure de­
vices, vascular grafts, vena cava filters, and central venous system 
ventriculo-atrial shunts are considered within this risk category in 
the first 6 months after implantation.96
(iii) Patients with congenital heart disease (CHD) (not including iso­
lated congenital valve abnormalities) are at increased risk of 
IE.8,47,97–99 The cumulative incidence over time is influenced 
strongly by the improved long-term survival of children with 
CHD into adulthood.98 Indeed, there are now more adults living 
with CHD than children with CHD.100 The overall incidence 
rate of IE among adult patients with CHD is 27–44 times that re­
ported for contemporary adults of the general population (1.33 
cases per 1000 persons per year)8 while in children with CHD 
the incidence of IE is 0.41 cases per 1000 persons per year.101
CHD groups at increased risk include those with untreated cyan­
otic CHD, and those whose surgery includes prosthetic material, 
including valved conduits or systemic to pulmonary shunts.8,47,97
The risk of post-operative IE for CHD patients undergoing trans­
catheter atrial or ventricular septal defect closure with devices or 
surgery with non-valve-related prosthetic material is also in­
creased, but predominantly for the first 6 months after surgery.8
(iv) Patients with ventricular assist devices as destination therapy are 
also considered at high risk because of associated morbidity and 
mortality, and prophylaxis is also recommended in such patients.102
Patients at intermediate risk of IE include those with: (i) rheumatic 
heart disease (RHD); (ii) non-rheumatic degenerative valve disease; 
(iii) congenital valve abnormalities including bicuspid aortic valve dis­
ease; (iv) cardiovascular implanted electronic devices (CIEDs); and (v) 
hypertrophic cardiomyopathy.47,103,104 Some epidemiological data sug­
gest that certain conditions stratified as intermediate risk are associated 
Table 5 General prevention measures to be followed in 
patients at high and intermediate risk of infective 
endocarditis
Patients should be encouraged to maintain twice daily tooth cleaning and 
to seek professional dental cleaning and follow-up at least twice yearly 
for high-risk patients and yearly for others.
Strict cutaneous hygiene, including optimized treatment of chronic skin 
conditions.
Disinfection of wounds.
Curative antibiotics for any focus of bacterial infection.
No self-medication with antibiotics.
Strict infection control measures for any at-risk procedure.
Discouragement of piercing and tattooing.
Limitation of infusion catheters and invasive procedures. when possible. 
Strict adherence to care bundles for central and peripheral cannulae 
should be performed.
© ESC 2023


<!-- PAGE 14 -->

### Page 14

with a higher risk of IE compared with the background popula­
tion,47,90,103 but further studies are required. In patients at intermediate 
risk of IE, antibiotic prophylaxis is not routinely recommended and may 
be considered on an individual basis. However, prevention measures 
(Table 5) are strongly encouraged in these patients.7
Most of the IE in recipients of solid organ transplant is nosocomial. A 
recent systematic review of patient-level data including 57 heart trans­
plant patients has shown that IE occurs frequently during the first year 
post-transplant, and the most common pathogen is S. aureus followed 
by Aspergillus fumigatus.105 Oral streptococci are a very infrequent 
cause of IE, making the value of antibiotic prophylaxis after invasive oro- 
dental procedures questionable. However, IE in this group of patients is 
associated with very high mortality, particularly in patients with fungal 
IE. In contrast, other series that include a larger proportion of non- 
cardiac solid organ transplant patients have shown that the pathogens 
are more frequently from the Staphylococcus spp. and the mortality 
seems to be similar to that of patients without solid organ 
transplant.106,107
3.3. Situations and procedures at risk
3.3.1. Dental procedures
Antibiotic prophylaxis is recommended in patients at high risk of IE under­
going at-risk dental procedures and is not currently recommended in other 
situations. At-risk dental procedures include dental extractions, oral sur­
gery procedures (including periodontal surgery, implant surgery, and oral 
biopsies), and dental procedures involving manipulation of the gingival or 
periapical region of the teeth (including scaling and root canal proce­
dures).49,108 The use of dental implants raises concerns about potential 
risk due to foreign material at the interface between the buccal cavity 
and blood, but available data remain very limited.109 So far there is no evi­
dence to contraindicate implants in all patients at risk and the indication 
should be discussed on an individual basis. Implant placement procedures, 
and invasive dental procedures on established implants, however, should 
be covered by antibiotic prophylaxis in those at high risk of IE. Once dental 
implants are placed in high-risk patients, professional dental hygiene and 
follow-up should be performed at least twice yearly under antibiotic cover, 
when indicated.
The main target for antibiotic prophylaxis is oral streptococci. 
Table 6 summarizes the main regimens of antibiotic prophylaxis recom­
mended before dental procedures. The risk of adverse fatal/non-fatal 
events appear to be extremely low for amoxicillin but high for clinda­
mycin (mainly related to Clostridioides difficile infections).63,110–112
Accordingly, this Task Force does not recommend the use of clindamy­
cin for antibiotic prophylaxis.
3.3.2. Non-dental procedures
No convincing evidence has been brought forward on the relationship 
between bacteraemia resulting from a non-dental procedure and risk of 
subsequent IE. However, observational studies reported that, com­
pared with patients with IE not undergoing an invasive procedure, 
Recommendation Table 1 — Recommendations for 
antibiotic prophylaxis in patients with cardiovascular 
diseases undergoing oro-dental procedures at increased 
risk for infective endocarditis
Recommendations
Classa
Levelb
General prevention measures are recommended in 
individuals at high and intermediate risk for IE.
I
C
Antibiotic prophylaxis is recommended in patients 
with previous IE.47,84,86
I
B
Antibiotic prophylaxis is recommended in patients 
with surgically implanted prosthetic valves and with 
any material used for surgical cardiac valve 
repair.47,87–89
I
C
Antibiotic prophylaxis is recommended in patients 
with transcatheter implanted aortic and pulmonary 
valvular prostheses.91–94
I
C
Antibiotic prophylaxis is recommended in patients 
with untreated cyanotic CHD, and patients treated 
with surgery or transcatheter procedures with 
post-operative palliative shunts, conduits, or other 
prostheses. After surgical repair, in the absence of 
residual defects or valve prostheses, antibiotic 
prophylaxis is recommended only for the first 6 
months after the procedure.8,47,97,101
I
C
Antibiotic prophylaxis is recommended in patients 
with ventricular assist devices.102
I
C
Antibiotic prophylaxis should be considered in 
patients with transcatheter mitral and tricuspid valve 
repair.95
IIa
C
Antibiotic prophylaxis may be considered in 
recipients of heart transplant.105–107
IIb
C
Antibiotic prophylaxis is not recommended in other 
patients at low risk for IE.11,51
III
C
© ESC 2023
CHD, congenital heart disease; IE, infective endocarditis. 
aClass of recommendation. 
bLevel of evidence.
Table 6 Prophylactic antibiotic regime for high-risk 
dental procedures
Situation
Antibiotic
Single-dose 30–60 min before 
procedure
Adults
Children
No allergy to 
penicillin or 
ampicillin
Amoxicillin
2 g orally
50 mg/kg orally up to 
maximum of 2 g
Ampicillin
2 g i.m. 
or i.v.
50 mg/kg i.m. or i.v. up 
to maximum of 2 g
Cefazolin or 
ceftriaxone
1 g i.m. 
or i.v.
50 mg/kg i.v. or i.m. up 
to maximum of 1 g
Allergy to 
penicillin or 
ampicillin
Cephalexina,b
2 g orally
50 mg/kg orally up to 
maximum of 2 g
Azithromycin or 
clarithromycin
500 mg 
orally
15 mg/kg orally up to 
maximum of 500 mg
Doxycycline
100 mg 
orally
<45 kg, 2.2 mg/kg orally 
>45 kg, 100 mg orally
Cefazolin or 
ceftriaxoneb
1 g i.m. 
or i.v.
50 mg/kg i.v. or i.m. up 
to maximum of 1 g
© ESC 2023
i.m., intramuscular; i.v., intravenous. 
aOr other first- or second-generation oral cephalosporin in equivalent adult or paediatric 
dosing. 
bCephalosporins should not be used in an individual with a history of anaphylaxis, 
angioedema, or urticarial with penicillin or ampicillin.
ESC Guidelines                                                                                                                                                                                          3961


<!-- PAGE 15 -->

### Page 15

several invasive non-dental medical procedures were associated with 
increased risk of IE, including cardiovascular interventions, skin proce­
dures and wound management, transfusion, dialysis, bone marrow 
puncture, and endoscopic procedures.6,11,51 For this reason, an aseptic 
operational environment should be ensured during all these proce­
dures to minimize the risk of IE. As previously indicated, it is very unlike­
ly that an RCT on antibiotic prophylaxis for IE will be performed in the 
foreseeable future. However, at-risk patients have longer survival due 
to the advent of newer medical and device-based medical therapies. 
In addition, the ageing general population with their accumulating num­
ber of co-morbidities has an increased risk of surgical therapy, if IE oc­
curs. For these reasons, this Task Force no longer felt that a class III 
recommendation for antibiotic prophylaxis in high-risk patients under­
going non-dental medical procedures (see Recommendation Table 2) 
was appropriate, despite the limitations of observational data used to 
support this class IIb recommendation.
3.3.3. Cardiac or vascular interventions
In all patients undergoing implantation of a prosthetic valve, any type of 
prosthetic graft/occluder device or CIED, peri-operative antibiotic 
prophylaxis is recommended due to the increased risk and adverse out­
come of an infection.6 The most frequent microorganisms underlying 
early (1 year after surgery) surgical PVE are coagulase-negative 
staphylococci (CoNS) and S. aureus. Pre-operative screening of nasal 
carriage for S. aureus is recommended before elective cardiac surgery 
or transcatheter valve implantation to treat carriers using local mupir­
ocin and chlorhexidine.113,114 Rapid identification techniques using gene 
amplification are useful to avoid delaying urgent surgery. Systematic lo­
cal treatment without screening is not recommended. It is strongly re­
commended that potential sources of dental sepsis should be 
eliminated at least 2 weeks before implantation of a prosthetic valve 
or other intracardiac or intravascular foreign material unless the latter 
procedure is urgent. For specific prophylactic measures in other cardiac 
and vascular interventions (i.e. CIED, transcatheter aortic valve implant­
ation [TAVI]), please see the Supplementary data online, Section S1.1.
3.4. Patient education
Preventing IE also depends on preventive measures other than antibiot­
ic prophylaxis. People at risk should be educated to maintain good den­
tal and skin hygiene, to look out for signs of infection and, when 
Education of high-risk patients to prevent infective endocarditis
Use dental floss daily
Brush teeth morning and evening
See your dentist for regular check-ups
Maintain good dental hygiene
If experiencing fever for no obvious reason,
contact your doctor, and discuss appropriate action based on your risk of endocarditis
Minimize risk of skin lesions
In case of lesions, observe for signs of infection (redness, swelling, tenderness, puss)
Avoid tattoos and piercings
Maintain good skin hygiene
Be mindful of infections
Do not self prescribe antibiotics
Show this card to your doctors before any interventions
Figure 2 Education of high-risk patients to prevent infective endocarditis.


<!-- PAGE 16 -->

### Page 16

experiencing fever of unknown origin, report to their physician that 
they are at risk, in which case clinicians should consider screening for 
IE before initiating antibiotics.
Use of non-medical language, visual aids, digital tools, repetition, and 
teach back methods all aid the patients’ comprehension and is encour­
aged.115 National cardiology societies should be encouraged to develop 
specific IE cards for patient awareness (Figure 2).
4. The Endocarditis Team
The importance of an Endocarditis Team in the diagnosis, management, 
and clinical outcomes of patients with IE has been demonstrated in sev­
eral observational studies.36–41,122–126 Establishing multidisciplinary 
endocarditis teams according to the European Society of Cardiology 
(ESC) and the American College of Cardiology/American Heart 
Association Guidelines4,127,128 has resulted in earlier and more accurate 
diagnosis of the primary disease and its complications,5,22,31,40,129 uni­
form antibiotic treatment,36,40,123 and optimized timing for surgical 
intervention.36,37,40,123 A variety of scenarios of patients presenting 
with 
IE 
justifies 
a 
multidisciplinary 
approach.5,25,27,28,130–135
Furthermore, the clinical presentation may vary significantly depending 
on the characteristics of the host and virulence of the microorganism. 
Accordingly, the concept of the Endocarditis Team needs to embrace a 
multidisciplinary approach that must adapt according to the patient’s 
clinical needs and the local epidemiology to ensure prompt diagnosis 
and treatment.
The members of the Endocarditis Team should include the specialists 
with direct involvement in the diagnostic and therapeutic processes 
(Table 7), and may vary depending on the type of centre. In the 
Recommendation Table 2 — Recommendations for 
infective endocarditis prevention in high-risk patients
Recommendations
Classa
Levelb
Antibiotic prophylaxis is recommended in dental 
extractions, oral surgery procedures, and 
procedures requiring manipulation of the gingival or 
periapical region of the teeth.11,49,51,108
I
B
Systemic antibiotic prophylaxis may be considered 
for high-riskc patients undergoing an invasive 
diagnostic or therapeutic procedure of the 
respiratory, gastrointestinal, genitourinary tract, skin, 
or musculoskeletal systems.6,11
IIb
C
© ESC 2023
aClass of recommendation. 
bLevel of evidence. 
cThis recommendation does not apply to patients with intermediate risk for IE or to the 
general population.
Recommendation Table 3 — Recommendations for 
infective endocarditis prevention in cardiac procedures
Recommendations
Classa
Levelb
Pre-operative screening for nasal carriage of S. aureus 
is recommended before elective cardiac surgery or 
transcatheter valve implantation to treat 
carriers.113,114
I
A
Peri-operative antibiotic prophylaxis is 
recommended before placement of a CIED.116–118
I
A
Optimal pre-procedural aseptic measures of the site 
of implantation is recommended to prevent CIED 
infections.119
I
B
Periprocedural antibiotic prophylaxis is 
recommended in patients undergoing surgical or 
transcatheter implantation of a prosthetic valve, 
intravascular prosthetic, or other foreign material.120
I
B
Surgical standard aseptic measures are 
recommended during the insertion and manipulation 
of catheters in the catheterization laboratory 
environment.
I
C
Elimination of potential sources of sepsis (including of 
dental origin) should be considered ≥2 weeks before 
implantation of a prosthetic valve or other 
intracardiac or intravascular foreign material, except 
in urgent procedures.
IIa
C
Continued
Antibiotic prophylaxis covering for common skin 
flora including Enterococcus spp. and S. aureus should 
be considered before TAVI and other transcatheter 
valvular procedures.121
IIa
C
Systematic skin or nasal decolonization without 
screening for S. aureus is not recommended.
III
C
© ESC 2023
CIED, cardiac implantable electronic device; TAVI, transcatheter aortic valve implantation. 
aClass of recommendation. 
bLevel of evidence.
Table 7 Members of the Endocarditis Team
Heart Valve Centre
Core members
• Cardiologists.
• Cardiac imaging experts.
• Cardiovascular surgeons.
• Infectious disease specialist (or internal medicine 
specialist with expertise in infectious diseases).
• Microbiologist.
• Specialist in outpatient parenteral antibiotic 
treatment.
Adjunct 
specialities
• Radiologist and nuclear medicine specialist.
• Pharmacologist.
• Neurologist and neurosurgeon.
• Nephrologist.
• Anaesthesiologists.
• Critical care.
• Multidisciplinary addiction medicine teams.
• Geriatricians.
• Social worker.
• Nurses.
• Pathologist.
© ESC 2023
ESC Guidelines                                                                                                                                                                                          3963


<!-- PAGE 17 -->

### Page 17

Heart Valve Centre, a centre having all diagnostic and therapeutic re­
sources to treat IE, the core members of the Endocarditis Team should 
include cardiologists, cardiovascular surgeons, infectious disease specia­
lists (or internal medicine specialists with expertise in infectious dis­
eases), and microbiologists. Furthermore, for specific clinical 
questions, cardiologists/surgeons with expertise in CIED extraction, 
HF, and CHD; pathologists; critical care specialists; cardiac anaesthesiol­
ogists; interventional cardiologists; neurologists and neurosurgeons; 
pharmacologists; radiologists and nuclear medicine specialists; 
nephrologists; geriatricians; and multidisciplinary addiction medicine 
teams (psychiatrists, nurses, and social work specialists providing coun­
selling) are crucial adjuncts that should be available onsite for consult­
ation. Specific subgroups of complex and high-risk patients are 
frequently assessed by the Endocarditis Team. The decision-making 
process may involve difficult decisions regarding continuation of ther­
apy, and legal counsel may therefore be required.
Cardiovascular imaging has achieved such an advanced sophistication 
in the diagnosis of IE that the cardiologists with expertise in 
N
Start empirical antibiotic treatment
Admission to a Heart Valve Centre
Admission to a Referring Centre
Adjust antibiotic treatment according to blood culture results
Patient with deﬁnite infective endocarditis 2023 ESC diagnostic criteria
Y
Endocarditis Team
Cardiologists
Cardiovascular surgeons
Infecious disease specialists
Microbiologists
Adjunct specialities
Radiologists/nuclear medicine specialists
Neurologists/
neurosurgeons
Intensive care specialists
Geriatricians
Nephrologists
Nurses
Addiction medicine teams
Establish indication and timing of cardiac surgery
Consultation with outpatient antibiotic therapy team
Frequent communication
Clinical, microbiological,
and imaging data sharing
Endocarditis Team
Cardiologists
Infectious disease specialists
Complicated clinical evolution
Unstable haemodynamic condition under pharmacological and/or respiratory support
Severe valvular regurgitation (clinical and echocardiographic criteria)
Prosthetic valve endocarditis with or without prosthetic valve dysfunction
Stroke (ischaemic or haemorrhagic) with definite or possible IE
Extravalvular complications (abscesses, fistulae, etc.)
Positive blood cultures >7 days under appropriate antibiotic therapy
Embolism
CIED-related infective endocarditis
Aggressive or difficult-to-treat microorganisms (S. aureus,
Gram-negative bacilli, fungi)
Figure 3 Management of patients with infective endocarditis: positioning of the Endocarditis Team. CIED, cardiovascular implanted electronic device; ESC, 
European Society of Cardiology.


<!-- PAGE 18 -->

### Page 18

multimodality imaging are key in the Endocarditis Team. In addition, 
radiology and nuclear medicine specialists with expertise on clinical car­
diovascular imaging should be available whenever indicated.22,31,129 The 
Endocarditis Team must meet on a frequent basis and work with stand­
ard operating procedures and the clinical governance arrangements de­
fined locally.128,136 Although the decision of timing is left to the 
discretion of the local team, a weekly meeting is to be considered.
In Referring Centres, i.e. those without a cardiovascular surgical 
team, the treating physician diagnosing IE should consult with a special­
ist in infectious diseases (or an internal medicine specialist with expert­
ise in infectious diseases) and the microbiologist.136 In addition, a 
cardiologist with expertise in valvular heart disease and cardiac imaging 
should be present to provide the initial and subsequent evaluations with 
echocardiography. Information of the strains of the isolated microor­
ganisms, usually kept for 7–15 days, should be provided to the Heart 
Valve Centre if requested.
Communication between Referring Centres and the Heart Valve 
Centres should be facilitated with digital solutions that enable reliable 
data sharing. Early referral to the Heart Valve Centre for further diag­
nostic testing and clinical management should be available when 
deemed necessary (Figure 3). When there is evidence of failure to re­
spond to the antibiotic therapy or there are complications related to 
valvular tissue destruction, the Referring Centre should consult the 
Heart Valve Centre. The Endocarditis Team of the Heart Valve 
Centre should share protocols with the physicians from the referring 
hospitals and should facilitate their continuing education.136
A critical aspect of the Endocarditis Team decision-making process is 
defining when a patient must be transferred to a Heart Valve Centre to 
expedite advanced diagnostics and therapy. The indications for transfer 
are comprehensive, to facilitate interhospital communication and avoid 
delaying therapy to improve prognosis.
5. Diagnosis
The diagnosis of IE is based on a clinical suspicion supported by consist­
ent microbiological data and the documentation of IE-related cardiac 
lesions by imaging techniques. Evidence of involvement of cardiac valves 
(native or prosthetic) or prosthetic intracardiac material is a major diag­
nostic criterion of IE. Echocardiography is the first-line diagnostic 
imaging technique. Other imaging modalities such as CT, nuclear im­
aging, and magnetic resonance imaging (MRI) are currently part of the 
diagnostic strategy of suspected IE, given their ability to provide key in­
formation to confirm IE diagnosis, to assess local IE complications as 
well as IE-related distant lesions, and to identify the original source of 
bacteraemia in patients who develop secondary IE.137 Beyond diagnosis 
of IE, imaging findings also have prognostic implications.
5.1. Clinical features
Infective endocarditis remains a diagnostic challenge due to its variable 
clinical presentation. In general, a diagnosis of IE should be considered in 
all patients with sepsis or fever of unknown origin in the presence of risk 
factors. Infective endocarditis may present as an acute, rapidly progres­
sive infection, but also as a subacute or chronic disease with low-grade, 
or even no fever, and non-specific symptoms that may mislead or con­
fuse initial assessment. Infective endocarditis can also present with a 
complication mimicking a wide range of medical conditions that may 
prompt evaluation of other diseases, such as rheumatological, neuro­
logical, and autoimmune disorders, or even malignancy, before reaching 
a diagnosis of IE. Therefore, high suspicion for IE is generally driven by 
fever and positive blood cultures in the absence of an alternative focus 
of infection, especially in patients with one or more risk factors. Early 
involvement of the Endocarditis Team to guide management is highly 
recommended.
The initial clinical assessment should include evaluation of cardiac and 
non-cardiac risk factors (Table 8), supportive clinical context, and phys­
ical examination findings including potential portals of entry. Physical 
examination may reveal a variety of clinical signs. However, the absence 
of clinical signs alone should not exclude IE since the overall sensitivity 
and specificity of the clinical signs are low.
In the European Infective Endocarditis Registry (EURO-ENDO), fe­
ver (77.7%), cardiac murmur (64.5%), and congestive HF (27.2%) were 
the most frequent clinical presentations.5 Embolic complications were 
detected in 25.3% of patients and cardiac conduction abnormalities 
were found in 11.5%. Some classical signs, such as peripheral stigmata, 
are less frequently observed, but may still be observed in severe infec­
tions caused by S. aureus and in cases of subacute endocarditis (mainly 
caused by Streptococcis spp.). However, vascular and immunological 
phenomena, such as splinter haemorrhages,138 Roth spots, and 
Recommendation Table 4 — Recommendations for the 
Endocarditis Team
Recommendations
Classa
Levelb
Diagnosis and management of patients with 
complicated IE are recommended to be performed 
at an early stage in a Heart Valve Centre, with 
immediate surgical facilities and an ‘Endocarditis 
Team’ to improve the outcomes.36–41,122,123,125,126
I
B
For patients with uncomplicated IE managed in a 
Referring Centre, early and regular communication 
between the local and the Heart Valve Centre 
endocarditis teams is recommended to improve the 
outcomes of the patients.36–41,122,123,125,126
I
B
© ESC 2023
IE, infective endocarditis. 
aClass of recommendation. 
bLevel of evidence.
Table 8 Cardiac and non-cardiac risk factors
Cardiac risk factors
Previous infective endocarditis
Valvular heart disease
Prosthetic heart valve
Central venous or arterial catheter
Transvenous cardiac implantable electronic device
Congenital heart disease
Non-cardiac risk factors
Central venous catheter
People who inject drugs
Immunosuppression
Recent dental or surgical procedures
Recent hospitalization
Haemodialysis
© ESC 2023
ESC Guidelines                                                                                                                                                                                          3965


<!-- PAGE 19 -->

### Page 19

glomerulonephritis, remain common. The main symptoms and signs 
observed in the EURO-ENDO registry are shown in the 
Supplementary data online, Table S1. Atypical presentation is common 
in elderly or immunocompromised patients.139–141 A high index of sus­
picion and low threshold for investigation are therefore essential to ex­
clude IE or avoid delays in diagnosis in these and other high-risk groups, 
such as those with CHD or prosthetic valves.142 It is important to in­
form those patients about the risk of IE who should be aware of com­
patible symptoms to ask for advice in referral centres.
5.2. Laboratory findings
Laboratory investigations and biomarkers typically yield non-specific re­
sults. A large number of potential biomarkers have been proposed, re­
flecting the complex pathophysiology of the pro- and anti-inflammatory 
processes, humoral and cellular reactions, and both circulatory and 
end-organ abnormalities involved in IE.143 The degree of anaemia, 
leucocytosis/leucopaenia, the number of immature white cell forms, 
concentrations of C-reactive protein and procalcitonin, erythrocyte 
sedimentation rate, and markers of end-organ dysfunction (serum lac­
tate, serum creatinine, bilirubin, thrombocytopaenia, cardiac troponin, 
and natriuretic brain peptides) can be used to estimate the severity of 
sepsis, but none is diagnostic of IE. C-reactive protein and procalcitonin 
are the most widely evaluated biomarkers in RCTs of antibiotic stew­
ardship. Furthermore, several of these biomarkers are included in 
scores used for risk stratification in critically ill patients. 
Unfortunately, no biomarker has sufficient accuracy for the diagnosis 
of sepsis or specificity for IE.144 Therefore, the main role of biomarkers 
is to facilitate initial risk stratification and monitor the response to anti­
biotic therapy.
5.3. Microbiological diagnosis
The aetiology of IE is described in the EURO-ENDO registry5 and the 
International Collaboration on Endocarditis-Prospective Cohort Study 
(ICE-PCS).145 In 2009, the ICE-PCS showed that the most frequent mi­
croorganisms causing IE were S. aureus (31%), followed by oral strepto­
cocci (17%), and CoNS (11%).145 Similar results were reported in the 
EURO-ENDO registry.5,145 Other registries have highlighted the 
increasing incidence of IE caused by E. faecalis and CoNS, particularly 
in the elderly.146–149 However, the results of these registries 
should be carefully interpreted due to inherent biases (type of partici­
pating centres, geographical differences, lack of complete granular data, 
etc.).
5.3.1. Blood culture-positive infective endocarditis
Positive blood cultures remain the cornerstone of IE diagnosis and pro­
vide live bacteria for both identification and susceptibility testing. At 
least three sets of blood cultures should be obtained at 30-minute in­
tervals prior to antibiotic therapy, each containing 10 mL of blood, 
and should be incubated in both aerobic and anaerobic atmo­
spheres.150,151 Sampling should be obtained from a peripheral vein ra­
ther than from a central venous catheter (because of the risk of 
contamination and misleading interpretation), using a meticulous sterile 
technique. In the absence of previous antimicrobial therapy, this is vir­
tually always sufficient to identify the usual causative microorganisms. 
The need for culture before antibiotic administration is self-evident. 
In IE, bacteraemia is almost constant and has two implications: (i) there 
is no rationale for delaying blood sampling to coincide with peaks of 
fever; and (ii) nearly all blood cultures are positive during bacteraemia. 
As a result, a single positive blood culture should be regarded cautiously 
for establishing IE diagnosis. The microbiology laboratory should be 
aware of the clinical suspicion of IE. Automated machines perform con­
tinuous monitoring of bacterial growth, which ensures quick provision 
of reports to physicians. When a positive blood culture is identified, 
presumptive identification is based on Gram staining. This information 
is immediately given to clinicians in order to adapt empirical antibiotic 
therapy. Complete identification is routinely achieved the same day 
or the following day with current methodology (e.g. matrix-assisted la­
ser 
desorption 
ionization 
time-of-flight 
mass 
spectrometry 
[MALDI-TOF MS]), but may require a longer time for fastidious or 
atypical organisms. Since there is a long delay between blood culture 
sampling and definitive identification of the organism responsible for 
the bacteraemia and antibiotic susceptibility testing, many improve­
ments have been proposed to speed up the process of detection and 
identification. One of the most recent procedures for rapid bacterial 
identification is based on peptide spectra obtained by MALDI-TOF 
MS.152 However, despite technical developments and the progress to­
ward rapid susceptibility testing using MALDI-TOF MS, the gold stand­
ard for susceptibility testing is still the determination of the minimal 
inhibitory concentrations (MICs) to select appropriate antibiotic ther­
apy, which needs to be performed following validated, standardized 
methodology.153
5.3.2. Blood culture-negative infective endocarditis
Blood culture-negative infective endocarditis (BCNIE) refers to IE in 
which no causative microorganism can be grown using the usual blood 
culture methods. The frequency of BCNIE as the cause of IE is highly 
variable and often poses considerable diagnostic and therapeutic dilem­
mas.154,155 Blood culture-negative IE most commonly arises as a conse­
quence of previous antibiotic administration, underlying the importance 
of performing blood cultures prior to antibiotic therapy, particularly in 
patients with known risk factors for IE. Withdrawal of antibiotics and 
repeating blood cultures may be required in stable patients with sub­
acute symptoms, no evidence of local or distant complications, and re­
ceiving a very short course of antibiotics. Blood culture-negative IE can 
also be caused by fungi or fastidious bacteria, notably obligatory intra­
cellular bacteria. Isolation of these microorganisms requires culturing 
on specialized media, and their growth is relatively slow. Depending 
on local epidemiology,156 systematic serological testing for Coxiella bur­
netii, Bartonella spp., Aspergillus spp., Mycoplasma pneumoniae, Brucella 
spp., and Legionella pneumophila should be proposed,157 followed by 
specific polymerase chain reaction (PCR) assays for Tropheryma whip­
plei, Bartonella spp., and fungi (Candida spp., Aspergillus spp.) from blood 
and the tissue (Table 9).158
In addition, 16S and 18S ribosomal ribonucleic acid (rRNA) sequen­
cing from tissue is routinely performed in most laboratories and may 
provide a microorganism diagnosis in BCNIE. For patients with pros­
thetic valve BCNIE, molecular imaging technique fluorescence in situ hy­
bridization combined with 16S rRNA-gene PCR and sequencing 
improved the conventional cultural diagnostic methods in 30% of 
cases.159 Next-generation sequencing of plasma microbial cell-free de­
oxyribonucleic acid (DNA) may facilitate a rapid diagnosis of IE in the 
future.160
When all microbiological assays are negative, the diagnosis of non- 
bacterial endocarditis should systematically be considered and assays


<!-- PAGE 20 -->

### Page 20

for antinuclear antibodies as well as antiphospholipid syndrome (APLs) 
(anticardiolipin 
antibodies 
[immunoglobulin 
(Ig)G] 
and 
anti-β2-glycoprotein 1 antibodies [IgG and IgM]) should be performed 
(although these antibodies may also be present in patients with proven 
IE).161,162 Pathological examination of resected tissue or embolic frag­
ments remains the gold standard for IE diagnosis. All tissue samples 
that are excised during surgical valve debridement/resection must be 
collected in a sterile container without fixative or culture medium. 
Samples should be sent to the pathology department and the micro­
biology laboratory for the identification of microorganisms. On histo­
logical examination of excised valve tissue, patterns, and degrees of 
inflammation will vary depending on the infecting organism. Stains for 
bacteria, mycobacteria, and fungi may identify the microorganisms, 
and organism-specific immunohistochemical stains can be very useful 
for the final diagnosis. Importantly, histopathological analysis may facili­
tate the diagnosis of non-infectious causes of endocarditis, such as neo­
plastic and autoimmune causes.160
5.3.3. Proposed strategy for a microbiological 
diagnostic algorithm in suspected infective 
endocarditis
A proposed diagnostic scheme is provided in Figure 4. When there is 
clinical suspicion of IE and blood cultures remain negative at 48 h, con­
sultation with the microbiologist is necessary.156,160 A suggested strat­
egy is the use of a diagnostic kit including blood cultures for the 
suspected microorganism and when negative, systematic serological 
testing for C. burnetii, Bartonella spp., Aspergillus spp., L. pneumophila, 
Brucella spp., and M. pneumoniae, as well as rheumatoid factor, sero­
logical tests for APLs (anticardiolipin [IgG] and anti-β2-glycoprotein 1 
[IgG and IgM]), antinuclear antibodies, and anti-pork antibodies. 
Serological testing should be performed taking into consideration the 
clinical characteristics of the patients (i.e. Aspergillus spp. in severe im­
munocompromised patients), the local epidemiology, and being aware 
of the specificity of the tests. In addition, tissue or prosthetic material 
obtained at surgery must be subjected to systematic culture, histologic­
al examination, and 16S or 18S rRNA sequencing aimed at document­
ing the presence of organisms.
5.4. Imaging techniques
Evidence of lesions characteristic of IE are major diagnostic criterion. 
Echocardiography is the first-line imaging technique to diagnose IE 
and to assess the structural and functional damage of cardiac struc­
tures. Echocardiographic findings have prognostic implications, and 
help to guide decision-making and patient follow-up while receiving 
antibiotic therapy and during the peri-operative and post-operative 
periods.163 In some clinical scenarios, other imaging modalities, such 
as CT, nuclear imaging, and MRI, are needed to confirm or exclude 
the diagnosis of IE, to characterize the extent of the cardiac lesions, 
and to diagnose extracardiac complications. They can also provide 
additional useful information for patient management.137 Each of 
these techniques has its diagnostic strengths and weaknesses (see 
Supplementary data online, Table S2). The use of an optimal imaging 
strategy depends on the availability of, and expertise in, each tech­
nique, but when indicated a multimodality imaging approach is essen­
tial for patients with suspected IE and should be strongly encouraged 
by the Endocarditis Team.21
5.4.1. Echocardiography
Transthoracic echocardiography (TTE) and transoesophageal echocar­
diography (TOE) are the first and key imaging techniques used to diag­
nose IE. Although echocardiography is widely accessible, significant 
variation in the use of TOE still exists.164 Three-dimensional TOE 
and intracardiac echocardiography have also been shown to be useful 
for the diagnosis of IE and its complications.165 However, the availability 
of intracardiac echocardiography is limited. Vegetation characteristics 
and size, perivalvular complications (abscess, pseudoaneurysm, new 
partial dehiscence of prosthetic valve), intracardiac fistula, and leaflet 
perforation are the main echocardiographic findings for the diagnosis 
and evaluation of local complications of IE (see Supplementary data 
online, Table S3). Importantly, vegetation size is a key metric that guides 
surgical indication, and vegetation size is defined as the maximal length 
of the vegetation.166 When evaluating IE on native or prosthetic valves, 
TTE had low sensitivity but good specificity as compared with TOE.166
TOE is helpful in a wide range of clinical scenarios, due to limitations of 
TTE to diagnose perivalvular complications, small vegetations, PVE, and 
vegetations associated with CIED. TOE is strongly recommended in pa­
tients with an inconclusive TTE, in patients with a negative TTE and a 
high suspicion of IE, as well as in patients with a positive TTE, in order 
to document local complications. Repeating TTE and/or TOE should be 
considered during follow-up of uncomplicated IE, in order to detect 
new silent complications and monitor vegetation size. The timing and 
mode (TTE or TOE) of repeated examination depend on the initial 
findings, type of microorganism, and initial response to therapy.
Table 9 Investigation of rare causes of blood culture- 
negative infective endocarditis
Pathogen
Diagnostic procedures
Brucella spp.
Serology, blood cultures, tissue culture, 
immunohistology, and 16S rRNA 
sequencing of tissue
C. burnetii
Serology (IgG phase l >1:800), tissue 
culture, immunohistology, and 16S rRNA 
sequencing of tissue
Bartonella spp.
Serology (IgG phase I >1:800), blood 
cultures, tissue culture, immunohistology, 
and 16S rRNA sequencing of tissue
T. whipplei
Histology and 16S rRNA sequencing of 
tissue
Mycoplasma spp.
Serology, tissue culture, immunohistology, 
and 16S rRNA sequencing of tissue
Legionella spp.
Serology, blood cultures, tissue culture, 
immunohistology, and 16S rRNA 
sequencing of tissue
Fungi
Serology, blood cultures, 18S rRNA 
sequencing of tissue
Mycobacteria (including 
Mycobacterium chimaera)
Specific blood cultures, 16S rRNA 
sequencing of tissue
© ESC 2023
Ig, immunoglobulin; rRNA, ribosomal ribonucleic acid.
ESC Guidelines                                                                                                                                                                                          3967


<!-- PAGE 21 -->

### Page 21

Echocardiographic imaging should be performed as soon as the IE 
diagnosis is suspected. The degree of valvular damage, the rate of 
peripheral embolic events, and the need for valve surgery increase 
with increasing time to initial echocardiographic assessment.167
Echocardiography should be repeated 5–7 days after an initial 
normal or inconclusive echocardiography, if the suspicion of IE re­
mains high, and in patients with diagnosed IE at high risk of compli­
cations 
(e.g. 
aggressive 
microorganisms, 
prosthetic 
valves).22,165,168,169
There is uncertainty regarding whether echocardiography should be 
systematically performed in patients with bloodstream infections due 
to different bacterial species, or if there are strategies (microbiological 
or imaging) that allow the identification of patients at higher risk of IE. 
Scoring systems have been developed to help in the appropriate 
indication to perform echocardiography when bacteraemia of different 
microorganisms 
occurs 
(see 
Supplementary 
data 
online, 
Table S4).60,170–173 The combination of microbiological parameters 
(type of microorganism and number of positive blood culture bottles) 
and cardiac-related risk factors (native valve disease, previous IE, pros­
thetic valve, and cardiac devices) may help identify the patients in whom 
echocardiography (TTE+TOE) is needed.19,174 Three risk scores were 
recently developed to identify patients at high risk of IE caused by S. aur­
eus, and those who should be evaluated with echocardiography (see 
Supplementary data online, Section S2.2.1).170–173,175–178 The cut-off 
values of the various scores are provided in Supplementary data 
online, Table S4.
N
N
N
N
N
Suspected IE
Y
Y
Y
Y
Blood cultures
Culture
Serologies
BCNIE
Identification by
MALDI-TOF MS
Microbiological identification
Antimicrobial susceptibility testing
Gram-positive and negative bacteria, fungi,
Mycobacterium spp.
Blood and vegetations PCRa
Antinuclear antibodiesb
Antiphospholipid antibodiesb
Anti-pork antibodiesb
Specific PCR
Antibiotic resistance and culture
C. burnetii
Bartonella spp.
Aspergillus spp.
L. pneumophila
Brucella spp.
M. pneumoniae
Y
Figure 4 Microbiological diagnostic algorithm in culture-positive and culture-negative infective endocarditis. BCNIE, blood cultures negative endocarditis; 
IE, infective endocarditis; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectrometry; PCR, polymerase chain reaction. 
aQualified microbiological laboratory. bImmunological laboratory.


<!-- PAGE 22 -->

### Page 22

5.4.2. Computed tomography
The indications for CT in patients with suspected or diagnosed IE 
include: 
(i) Diagnosis of IE and cardiac complications. Cardiac CT is more ac­
curate than TOE for diagnosing perivalvular and periprosthetic 
complications of IE (abscesses, pseudoaneurysms, and fistulae) 
and is recommended in both NVE and PVE if TOE is not conclusive 
or not feasible.33,168,169 In addition, cardiac CT can significantly 
influence 
subsequent 
surgical 
decision-making.20,185,186
Echocardiography continues to be superior for detecting valvular 
lesions, particularly small vegetations (<10 mm) which remain un­
derdiagnosed by CT, but also leaflet perforations and fistulae (see 
Supplementary data online, Table S3).35,168,169 Cardiac CT should 
be acquired according to the recommendations of cardiac CT 
guidelines to ensure high diagnostic accuracy, and can be per­
formed alone or in combination with PET.187
(ii) Detection of distant lesions and sources of bacteraemia. Whole-body 
and brain CT are useful for assessing IE systemic complications, includ­
ing septic emboli. The detection of distant lesions adds a minor diag­
nostic criterion leading to a more conclusive diagnosis of definite or 
rejected IE, and can be relevant for decision-making.188 CT angiog­
raphy can detect mycotic arterial aneurysms complicating IE in almost 
any site of the vascular tree,189,190 including the central nervous sys­
tem (CNS). Although MRI is superior to CT for diagnosing neuro­
logical complications,191 CT may be more feasible in an emergency 
setting and is an acceptable alternative for the detection of neurologic­
al complications, with a sensitivity of 90% and specificity of 86% in the 
detection of ischaemic and haemorrhagic lesions.192 Finally, CT can 
also detect the extracardiac sources of the bacteraemia, including 
early neoplastic lesions, that may be important for patient manage­
ment, and which need to be ideally addressed prior to undergoing 
heart valve surgery. However, CT does not replace the specific test 
indicated for the diagnosis of the extracardiac source of bacteraemia 
(i.e. colonoscopy in colon neoplasms).
(iii) Pre-operative assessment. Cardiac CT is a valuable alternative for 
non-invasive assessment of coronary artery disease (CAD) before 
cardiac surgery in patients with IE.193
(iv) Alternative diagnosis. In patients in whom IE is ruled out, or even in 
doubtful patients with possible IE, an alternative diagnosis can be 
reached by whole-body CT, as it can help to detect alternative in­
fectious foci. However, in these circumstances, an [18]FDG posi­
tron emission tomography/computed tomography (PET/CT) is 
the preferred imaging technique.194
5.4.3. Magnetic resonance imaging
The roles of MRI in the diagnostic work-up of IE include: 
(i) Diagnosis of IE and cardiac complications. The role of cardiac MRI to 
diagnose IE is limited by the low spatial resolution (as compared 
with cardiac CT) and the signal void generated by some prostheses 
impairing the assessment of prosthetic valve anatomy and 
function.195,196
(ii) Diagnosis of neurological IE-related complications. MRI has higher 
sensitivity than CT for the diagnosis of neurological lesions and, 
hence, increases the likelihood of detecting neurological complica­
tions in patients with IE. Patients with IE might present CNS lesions 
in up to 60–80% of cases,197 most of them corresponding to is­
chaemic lesions (50–80% of patients) that are often small and 
asymptomatic and do not impact on the decision-making.198
Other lesions that may influence the decision-making, such as par­
enchymal or subarachnoid haemorrhages, abscesses, or mycotic 
aneurysms, are found in <10% of patients.198–201 The systematic 
performance of brain MRI has shown to directly impact the 
Recommendation Table 5 — Recommendations for the 
role of echocardiography in infective endocarditis
Recommendations
Classa
Levelb
A. Diagnosis
TTE is recommended as the first-line imaging 
modality in suspected IE.166,179
I
B
TOE is recommended in all patients with clinical 
suspicion of IE and a negative or non-diagnostic 
TTE.166,178,179
I
B
TOE is recommended in patients with clinical 
suspicion of IE, when a prosthetic heart valve or an 
intracardiac device is present.166,178,179
I
B
Repeating TTE and/or TOE within 5–7 days is 
recommended in cases of initially negative or 
inconclusive examination when clinical suspicion of IE 
remains high.178
I
C
TOE is recommended in patients with suspected IE, 
even in cases with positive TTE, except in isolated 
right-sided native valve IE with good quality TTE 
examination and unequivocal echocardiographic 
findings.165,166,179
I
C
Performing an echocardiography should be 
considered in S. aureus, E. faecalis, and some 
Streptococcus spp. bacteraemia.19,149,174
IIa
B
B. Follow-up under medical therapy
Repeating TTE and/or TOE is recommended as soon 
as a new complication of IE is suspected (new 
murmur, embolism, persisting fever and bacteraemia, 
HF, abscess, AVB).165,166,179
I
B
TOE is recommended when patient is stable before 
switching from intravenous to oral antibiotic 
therapy.43,180
I
B
During follow-up of uncomplicated IE, repeat TTE and/ 
or TOE should be considered to detect new silent 
complications. The timing of repeat TTE and/or TOE 
depends on the initial findings, type of microorganism, 
and initial response to therapy.165,166,179
IIa
B
C. Intra-operative echocardiography
Intra-operative echocardiography is recommended 
in all cases of IE requiring surgery.181
I
C
D. Following completion of therapy
TTE and/or TOE are recommended at completion of 
antibiotic therapy for evaluation of cardiac and valve 
morphology and function in patients with IE who did 
not undergo heart valve surgery.182–184
I
C
© ESC 2023
AVB, atrioventricular block; HF, heart failure; IE, infective endocarditis; PVE, prosthetic 
valve endocarditis; TOE, transoesophageal echocardiography; TTE, transthoracic 
echocardiography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3969


<!-- PAGE 23 -->

### Page 23

diagnosis of IE, as it can add a minor diagnostic criterion in patients 
without neurological symptoms with non-definitive IE diagnosis. 
Brain MRI can reclassify 25% of patients with an initially inconclu­
sive diagnosis for IE to a more conclusive diagnosis, thereby leading 
to an earlier diagnosis.151 Cerebral microbleeds, found in 50–60% 
of patients with IE, are detected at gradient echo T2* se­
quences.200,202 Cerebral microbleeds should not be considered a 
minor criterion because there is no concordance with ischaemic 
lesions.203–205
(iii) Diagnosis of spine lesions. MRI is the diagnostic modality of choice 
of spondylodiscitis and vertebral osteomyelitis with a diagnostic ac­
curacy of 89–94%. MRI findings include vertebrae and disc oedema, 
paravertebral/epidural inflammation or abscess, bone erosion, and 
gadolinium enhancement of vertebrae and discs.32,206 It should be 
acknowledged that when MRI is performed too early, the rate of 
false-negative increases.207
5.4.4. Nuclear imaging positron emission 
tomography/computed tomography (angiography) 
and single photon emission tomography/computed 
tomography
Technical specifications of these imaging techniques are in the 
Supplementary data online, Section S2.2.2. The roles of nuclear imaging 
techniques in the diagnostic work-up of IE include: 
(i) Diagnosis of IE and cardiac complications. [18F]FDG-PET/CT and white 
blood cell (WBC) single photon emission computed tomography 
(SPECT)/CT are recommended in suspected PVE in cases of inconclu­
sive echocardiography. The most recent meta-analysis showed 86% 
sensitivity and 84% specificity for [18F]FDG-PET/CT in PVE.129
Additional evidence demonstrating the incremental diagnostic value 
of [18F]FDG-PET/CT and WBC SPECT/CT is summarized in the 
Supplementary data online, Section S2.2.2; Table S5.22,208–212
White blood cell SPECT/CT is an alternative nuclear imaging tech­
nique for the diagnosis of IE, when PET/CT is unavailable and in­
experienced centres. The sensitivity of WBC SPECT/CT has been 
reported as 64–90% and the specificity as 36–100%; diagnostic 
ability significantly increases with the presence of periprosthetic 
abscesses.213–215
99mTechnetium-hexamethylpropyleneamine oxime 
(99mTc-HMPAO)-SPECT/CT helped to reduce the number of misdiag­
nosed IE cases classified in the ‘possible IE’ category by the modified 
Duke criteria by 27%.216
In cases of NVE, the sensitivity of PET/CT and SPECT/CT is low 
(about 31%) but with a higher specificity (around 98%).211 In NVE, 
the diagnosis of IE cannot be excluded in the absence of abnormal 
[18F]FDG uptake.217 The more frequent presence of valve vegetations 
in comparison with paravalvular involvement in NVE compared with 
PVE leads to reduced inflammatory response and subsequently lower 
[18F]FDG and WBC uptake. The lower sensitivity of [18F]FDG-PET/ 
CT is offset by other strengths of the technique, such as its ability to 
identify septic emboli when suspected.211,218–220 Electrocardiogram 
(ECG)-gated PET may further improve the diagnostic accuracy.221
Combining PET/CT acquisition with a CT angiography (PET/CTA) al­
lows the detection of metabolic findings ([18F]FDG uptake distribution 
and intensity) and anatomical findings (IE-related lesions) within a single 
imaging procedure, resulting in the clinical clarification of indeterminate 
findings and change in the management of the patients.22,211 Such inves­
tigations may be particularly helpful in complex settings, such as patients 
with CHD222,223 and/or aortic grafts.22,224
(ii) Detection of distant lesions and sources of bacteraemia. 
Whole-body [18F]FDG-PET/CT imaging is particularly useful in 
patients with a suspicion or proven IE to identify distant lesions, 
mycotic aneurysms, and the portal of entry of the infection.225,226
Septic emboli are typically located in the spleen, lungs (in right- 
sided IE), and kidneys, and metastatic infections in the interverte­
bral discs and/or the vertebral bone (spondylodiscitis) as well as 
in muscles and joints (septic arthritis) and liver.211,227,228 [18F] 
FDG-PET/CT is less suited to detect cerebral septic embolism 
and mycotic aneurysms of intracerebral arteries due to the high 
physiological uptake of [18F]FDG in the brain.
(iii) Monitoring response to antimicrobial treatment with [18F] 
FDG-PET/CT in patients with established IE and indication for sur­
gery but who cannot be operated on due to unacceptable high risk 
and remain with long-term suppressive antibiotic treat­
ment.137,184,229–236
Recommendation Table 6 — Recommendations for the 
role of computed tomography, nuclear imaging, and 
magnetic resonance in infective endocarditis
Recommendations
Classa
Levelb
Cardiac CTA is recommended in patients with 
possible NVE to detect valvular lesions and confirm 
the diagnosis of IE.33,168,169
I
B
[18F]FDG-PET/CT(A) and cardiac CTA are 
recommended in possible PVE to detect valvular 
lesions and confirm the diagnosis of 
IE.22,129,209,210,237–239
I
B
Cardiac CTA is recommended in NVE and PVE to 
diagnose paravalvular or periprosthetic 
complications if echocardiography is 
inconclusive.20,168,169,185,186
I
B
Brain and whole-body imaging (CT, [18F]FDG-PET/ 
CT, and/or MRI) are recommended in symptomaticc 
patients with NVE and PVE to detect peripheral 
lesions or add minor diagnostic criteria.22,197– 
200,210,213,240,241
I
B
WBC SPECT/CT should be considered in patients 
with high clinical suspicion of PVE when 
echocardiography is negative or inconclusive and 
when PET/CT is unavailable.213–216
IIa
C
[18F]FDG-PET/CT(A) may be considered in possible 
CIED-related IE to confirm the diagnosis of 
IE.22,129,209,210,237,238
IIb
B
Brain and whole-body imaging (CT, [18F]FDG-PET/ 
CT, and MRI) in NVE and PVE may be considered for 
screening of peripheral lesions in asymptomatic 
patients.188,197–201
IIb
B
© ESC 2023
[18F]FDG-PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed 
tomography; CAD, coronary artery disease; CT, computed tomography; CTA, 
computed tomography angiography; IE, infective endocarditis; MRI, magnetic resonance 
imaging; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; WBC 
SPECT/CT, white blood cell single photon emission tomography/computed tomography. 
aClass of recommendation. 
bLevel of evidence. 
cSymptomatic: symptoms suggesting septic embolic complications.


<!-- PAGE 24 -->

### Page 24

5.5. Diagnostic criteria
Since 2000, clinical, microbiological, and imaging findings have been inte­
grated in the modified Duke criteria (see Supplementary data online, 
Table S6), which have demonstrated an overall sensitivity of 80% for 
IE.151 However, the clinical presentation of IE can be highly variable 
and some major limitations of the modified Duke criteria have become 
clear, particularly when prosthetic material is present (PVE, aortic grafts, 
cardiac devices, CHD). In these situations, echocardiography can be 
normal or inconclusive in up to 30% of cases despite the presence of 
IE.242–244 Therefore, the 2015 ESC diagnostic criteria introduced a 
multimodality 
imaging 
approach 
(echocardiography, 
cardiac/ 
whole-body CT, cerebral MRI, [18F]FDG-PET/CT, and WBC SPECT/ 
CT) to improve the diagnostic yield. This new approach has shown to 
be superior over the traditional diagnostic criteria.36–41,122,123,125,126,212
5.5.1. Modifications for the diagnosis of infective 
endocarditis
The current 2023 ESC Guidelines for the management of endocarditis 
introduce the following modifications for IE diagnosis: 
(i) Changes to the major and minor diagnostic criteria (Table 10).
Table 10 Definitions of the 2023 European Society of Cardiology modified diagnostic criteria of infective endocarditis
Major criteria
(i) Blood cultures positive for IE 
(a) Typical microorganisms consistent with IE from two separate blood cultures: 
Oral streptococci, Streptococcus gallolyticus (formerly S. bovis), HACEK group, S. aureus, E. faecalis
(b) Microorganisms consistent with IE from continuously positive blood cultures: 
• ≥2 positive blood cultures of blood samples drawn >12 h apart.
• All of 3 or a majority of ≥4 separate cultures of blood (with first and last samples drawn ≥1 h apart).
(c) Single positive blood culture for C. burnetii or phase I IgG antibody titre >1:800.
(ii) Imaging positive for IE: 
Valvular, perivalvular/periprosthetic and foreign material anatomic and metabolic lesions characteristic of IE detected by any of the following imaging techniques: 
• Echocardiography (TTE and TOE).
• Cardiac CT.
• [18F]-FDG-PET/CT(A).
• WBC SPECT/CT.
Minor criteria
(i) Predisposing conditions (i.e. predisposing heart condition at high or intermediate risk of IE or PWIDs)a
(ii) Fever defined as temperature >38°C
(iii) Embolic vascular dissemination (including those asymptomatic detected by imaging only): 
• Major systemic and pulmonary emboli/infarcts and abscesses.
• Haematogenous osteoarticular septic complications (i.e. spondylodiscitis).
• Mycotic aneurysms.
• Intracranial ischaemic/haemorrhagic lesions.
• Conjunctival haemorrhages.
• Janeway’s lesions.
(IV) Immunological phenomena: 
• Glomerulonephritis.
• Osler nodes and Roth spots.
• Rheumatoid factor.
(V) Microbiological evidence: 
• Positive blood culture but does not meet a major criterion as noted above.
• Serological evidence of active infection with organism consistent with IE.
IE Classification (at admission and during follow-up)
Definite: 
• 2 major criteria.
• 1 major criterion and at least 3 minor criteria.
• 5 minor criteria.
Possible: 
• 1 major criterion and 1 or 2 minor criteria.
• 3–4 minor criteria.
Rejected: 
• Does not meet criteria for definite or possible at admission with or without a firm alternative diagnosis.
© ESC 2023
[18F]-FDG-PET/CT, 18F-fluorodeoxyglucose positron emission tomography; CT(A), computed tomography (angiography); HACEK, Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, 
and Kingella; IE, infective endocarditis; Ig, immunoglobulin; PWID, people who inject drugs; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT/CT, 
white blood cell single photon emission tomography/computed tomography. 
aFor detailed explanation of predisposing conditions, please see Section 3.
ESC Guidelines                                                                                                                                                                                          3971


<!-- PAGE 25 -->

### Page 25

(ii) Specific diagnostic algorithms to support decision-making, especially 
in the recommended sequence of imaging techniques (Figures 5–7).
(iii) CIED-related IE is considered a right-sided endocarditis for diag­
nostic purposes and is included in the diagnostic algorithms, but 
its definitions and recommendations for management can be 
found in Section 12 and are in accordance with the specific 
European Heart Rhythm Association (EHRA) consensus on 
CIED infections.130
Repeat blood cultures if negative or doubtful
Repeat TTE/TOE within 5–7  days
Cardiac CTA to diagnose valvular lesions
Add minor criteria:  brain or whole-body imaging (MRI, CT, PET/CT,  WBC SPECT)
to detect distant lesions
Suspected paravalvular complications and TOE inconclusive
Cardiac CTA
(Class I)
No symptoms suggesting extracardiac complications
Brain and whole-body imaging
(CT, [18F]FDG-PET/CT, and/or MRI)
(Class IIb)
Symptoms suggesting extracardiac complications
Brain and whole-body imaging
(CT, [18F]FDG-PET/CT, and/or MRI)
(Class I)
Suspected native valve IE
ESC 2023 DIAGNOSTIC CRITERIA after IE
Baseline assessment and initial classification:
clinical presentation + blood cultures + TTE + TOEa
(Class I)
POSSIBLE
REJECTED
DEFINITE
(Class I)
(Class IIa)
Figure 5 European Society of Cardiology 2023 algorithm for diagnosis of native valve infective endocarditis. [18F]FDG, 18F-fluorodeoxyglucose; CT, com­
puted tomography; CTA, computed tomography angiography; ESC, European Society of Cardiology; IE, infective endocarditis; MRI, magnetic resonance im­
aging; NVE, native valve endocarditis; PET, photon emission tomography; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; 
WBC SPECT, white blood cell single photon emission tomography. aTOE for diagnosis and to detect perivalvular complications in all cases (unless right-sided 
NVE when TTE is good quality and conclusive).


<!-- PAGE 26 -->

### Page 26

The reasons to justify the changes in the diagnostic criteria include:
5.5.1.1. Major criteria – microbiology
Enteroccus faecalis should be acknowledged as a typical endocarditis 
bacterium, regardless of the place of acquisition or the source of 
infection. Currently, the modified Duke criteria fail to identify 30% of 
E. faecalis definite IE. Using data from a prospective study of 344 pa­
tients with E. faecalis bacteraemia evaluated with echocardiography, 
Dahl et al. demonstrated that designating E. faecalis as a ‘typical’ endo­
carditis pathogen significantly improved the sensitivity to correctly iden­
tify definite IE, from 70% to 96%.245
5.5.1.2. Major criteria – imaging
(i) Diagnosis based on the presence of lesions characteristics of IE. 
Anatomic lesions and increased [18F]FDG uptake or WBC accu­
mulation can be depicted by nuclear imaging techniques and add 
Repeat blood cultures if negative or doubtful
Repeat TTE/TOE within 5–7  days
Cardiac CTA or [18]FDG-PET/CT(A) to diagnose valvular lesions
WBC SPECT
Add minor criteria:  brain or whole-body imaging (MRI, CT, PET/CT,  WBC SPECT)
to detect distant lesions
Suspected paravalvular complications and TOE inconclusive
Cardiac CTA
(Class I)
No symptoms suggesting extracardiac complications
Brain and whole-body imaging
(CT, [18F]FDG-PET/CT, and/or MRI)
(Class IIb)
Symptoms suggesting extracardiac complications
Brain and whole-body imaging
(CT, [18F]FDG-PET/CT, and/or MRI)
(Class I)
Suspected prosthetic valve IE
ESC 2023 DIAGNOSTIC CRITERIA after IE
Baseline assessment and initial classification:
clinical presentation + blood cultures + TTE + TOEa
(Class I)
POSSIBLE
REJECTED
DEFINITE
(Class I)
(Class IIa)
Figure 6 European Society of Cardiology 2023 algorithm for diagnosis of prosthetic valve infective endocarditis. [18F]FDG, 18F-fluorodeoxyglucose; CT, com­
puted tomography; CTA, computed tomography angiography; ESC, European Society of Cardiology; IE, infective endocarditis; MRI, magnetic resonance imaging; 
PET, positron emission tomography; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT, white blood cell single photon 
emission tomography. aTOE for diagnosis and to detect perivalvular complications in all cases (unless right-sided NVE when TTE is good quality and conclusive).
ESC Guidelines                                                                                                                                                                                          3973


<!-- PAGE 27 -->

### Page 27

a major diagnostic criterion. Definitions of the anatomic and meta­
bolic features of the infective lesions can be found in the 
Supplementary data online, Table S5.
(ii) Abnormal prosthetic or periprosthetic uptake (intense focal or 
heterogeneous) detected by [18F]FDG-PET/CT or WBC 
SPECT/CT should be considered a major criterion for PVE, irre­
spective of the interval from surgery (see Supplementary data 
online, Figure S1). Published data support that intense focal or 
heterogeneous patterns is associated with a final diagnosis of in­
fection, while post-operative inflammatory changes can be per­
sistent more than 3 months after surgery, as noted in the 
previous guidelines. However, these inflammatory changes can 
be differentiated from infection even after recent valve implant­
ation.246 Therefore, a consensus of experts has concluded that 
the need for a time interval prior to investigation is questionable, 
but accurate imaging interpretation by proper interpretation cri­
teria is mandatory.233,236
5.5.1.3. Minor criteria
Distant IE-related lesions include all lesions that can result from embolic 
events and from haematogenous seeding of bacteria. These lesions can 
be suspected due to specific symptoms or can be incidentally detected 
on imaging techniques. Spondylodiscitis is the most frequent osteoarti­
cular infective complication in patients with IE.247,248
5.5.1.4. Microbiological criteria
Molecular biology (16S/18S rRNA PCR sequencing) in cardiac tissue or 
embolic material has increased the diagnostic performance of IE with 
negative blood culture. The sensitivity ranges between 41% and 96% 
and the specificity is very high, ranging between 90% and 100%.249
Repeat blood cultures if negative or doubtful
Repeat TTE/TOE within 5–7 days
PET/CT(A) to detect pocket infection +/-
pulmonary embolism
Add minor criteria: thoracic CT to detect septic pulmonary embolism/infarction
PET/CT(A) to detect lead infection
(Class IIa)
(Class IIb)
(Class I)
Suspected CIED-associated IE
ESC 2023 DIAGNOSTIC CRITERIA after IE
Baseline assessment and initial classification:
clinical presentation + blood cultures + TTE + TOE
(Class I)
POSSIBLE
REJECTED
DEFINITE
Figure 7 European Society of Cardiology 2023 algorithm for diagnosis of cardiac device-related infective endocarditis. CIED, cardiovascular implanted 
electronic device; CT, computed tomography; CTA, computed tomography angiography; ESC, European Society of Cardiology; IE, infective endocarditis; 
PET, positron emission tomography; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT, white blood cell single 
photon emission tomography.


<!-- PAGE 28 -->

### Page 28

5.5.1.5. Infective endocarditis classification
Infective endocarditis classification has been added to the 2023 ESC cri­
teria. Possible IE cases include the combination of 1 major and 1 or 2 
minor criteria. Infective endocarditis classification should be applied 
by the Endocarditis Team at admission and later at follow-up, taking 
into account the complete clinical, microbiology, imaging, and surgical 
information to establish the final diagnosis.
It is important to acknowledge that these new criteria should be pro­
spectively validated.
5.5.2. The new 2023 European Society of Cardiology 
diagnostic algorithms
The diagnosis of IE is based on clinical suspicion, blood cultures, and im­
aging findings. Echocardiography is usually the first imaging technique to 
diagnose IE, although the use of other techniques, either for the diagno­
sis of cardiac involvement (cardiac CT, [18F]FDG-PET/CT, or WBC 
SPECT/CT), or for the diagnosis of distant lesions (cerebral MRI, whole- 
body CT, and/or PET/CT), is encouraged. In the presence of prosthetic 
valves and CIED, echocardiography is particularly limited and the afore­
mentioned imaging techniques are strongly recommended. Adapted 
diagnostic algorithms for suspected IE in NVE, PVE, and CIED are dis­
played in Figures 5–7, respectively.
6. Prognostic assessment at 
admission
The in-hospital mortality rate of patients with IE has remained largely 
unchanged over the past two decades, ranging from 15% to 
30%.5,145,250,251 Several patient characteristics, often occurring simul­
taneously, have been shown to confer an increased risk of death in 
IE. The rapid identification of patients at the highest risk may offer 
the opportunity to change the course of the disease (i.e. with urgent 
or emergency surgery) and improve prognosis. Predictors of poor out­
come on admission of patients with IE are specified in the 
Supplementary data online, Section S3.1; Table S7.
7. Antimicrobial therapy: principles 
and methods
7.1. General principles
Successful treatment of IE relies on microbial eradication by antimicro­
bial drugs. Surgery contributes by removing infected material. 
Bactericidal regimens are more effective than bacteriostatic therapy, 
both in animal experiments and in humans.252–254 Aminoglycosides sy­
nergize with cell wall inhibitors (i.e. beta-lactams and glycopeptides) for 
bactericidal activity and are useful for shortening the duration of ther­
apy (e.g. oral streptococci) and eradicating problematic organisms. 
However, the side effects of aminoglycosides should be taken into con­
sideration and currently the combination of ampicillin with ceftriaxone 
has demonstrated effective in treating IE caused by E. faecalis irrespect­
ive of the presence of high-level aminoglycoside resistance (HLAR) and 
minimizing the risk of nephrotoxicity.255,256
One major hindrance to drug-induced killing is bacterial antibiotic 
tolerance. Tolerant microbes are not resistant (i.e. they are still suscep­
tible to growth inhibition by the drug) but escape drug-induced killing 
and 
may 
resume 
growth 
after 
treatment 
discontinuation. 
Slow-growing and dormant microbes display phenotypic tolerance 
towards most antimicrobials (except rifampin to some extent). They 
are present in vegetations and biofilms (complex communities of bac­
teria residing within an exopolysaccharide matrix that adheres to a sur­
face, e.g. in PVE),257 and justify the need for prolonged therapy to fully 
sterilize infected heart valves. Some bacteria carry mutations rendering 
them tolerant during both active growth and stationary (dormant) 
phases.258,259 Bactericidal drug combinations are preferred to mono­
therapy against tolerant organisms (e.g. the combination of ampicillin 
and ceftriaxone in IE caused by E. faecalis).
Drug treatment of PVE should last longer (≥6 weeks) than that of 
NVE (2–6 weeks) but is otherwise similar. In staphylococcal PVE, the 
regimen should include rifampin whenever the strain is susceptible, 
even if some recent data have shown no differences in outcomes be­
tween patients with PVE treated with rifampin vs. those treated 
without.260,261
In NVE needing valve replacement by a prosthesis during antibiotic 
therapy, the post-operative antibiotic regimen should be that recom­
mended for NVE, not for PVE. In both NVE and PVE, the duration of 
treatment is based on the first day of effective antibiotic therapy (nega­
tive blood culture in the case of initial positive blood culture), not on the 
day of surgery. A new full course of treatment should only start if valve 
cultures are positive.
Finally, 
there 
are 
important 
considerations 
in 
these 
recommendations: 
(i) Only published antibiotic efficacy data from clinical trials and cohort 
studies in patients with IE (or bacteraemia if there are no IE data) 
have been considered in these guidelines. Data from experimental 
IE models have not been taken into account. A recent systematic 
review evaluating the existing evidence about clinical benefits and 
harms of different antibiotic regimens used to treat patients with 
IE has shown that there is limited and low- to very low-quality evi­
dence to make strong conclusions on the comparative effects of dif­
ferent antibiotic regimens on cure rates or other relevant clinical 
outcomes and, therefore, there is not enough evidence to support 
or reject any regimen of antibiotic therapy for the treatment of 
IE.262,263
(ii) These guidelines have adopted the MIC breakpoints included in the 
2022 EUCAST clinical breakpoint tables.42 The EUCAST break­
points are used to categorize results into three susceptibility 
categories: 
• Susceptible, standard dosing regimen: a microorganism is cate­
gorized as such, when there is a high likelihood of therapeutic 
success using a standard dosing regimen of the agent.
• Susceptible, increased exposure: a microorganism is categorized 
as such when there is a high likelihood of therapeutic success be­
cause exposure to the agent is increased by adjusting the dosing 
regimen or by its concentration at the site of infection.
• Resistant: a microorganism is categorized as such when there is a 
high likelihood of therapeutic failure even when there is in­
creased exposure.
The term exposure is defined as a function of how the mode of ad­
ministration, dose, dosing interval, infusion time, as well as distribution 
and excretion of the antimicrobial agent, will influence the infecting or­
ganism at the site of infection. The local laboratories are responsible for 
the use of appropriate methods and interpretative criteria and quality 
control of the test results (MIC) while the clinicians are responsible 
for adjusting the level of exposure by modifying the dosing strategy 
ESC Guidelines                                                                                                                                                                                          3975


<!-- PAGE 29 -->

### Page 29

(individual dose, frequency of dosing, mode of administration [oral or 
intravenous (i.v.)]).42
(iii) Oral antimicrobial therapy. The POET trial has changed the para­
digm of i.v. antibiotic treatment for IE.43 For more than 60 years it 
had been considered that antibiotics should always be given intra­
venously. The POET trial has shown that after an initial phase of 
i.v. treatment, up to 20% of patients could complete the treatment 
by oral antibiotic therapy (see Section 7.13.1).43 Therefore, as indi­
cated in Figure 8, the antibiotic treatment of IE has two phases. 
The first phase can last up to 2 weeks of hospital i.v. treatment using 
combinations of rapidly bactericidal antibiotics to destroy planktonic 
bacteria.257 In this initial phase, cardiac surgery should be performed 
if indicated, infected foreign bodies should be removed, and cardiac 
as well as extracardiac abscesses should be drained. After this peri­
od, clinically stable patients can end the antibiotic treatment at home 
with i.v. (OPAT) or oral antibiotic regimens for up to 6 weeks in or­
der to eliminate the dormant (resting) bacteria and prevent relapses.
(iv) Aminoglycosides are not recommended in staphylococcal NVE be­
cause their clinical benefits have not been demonstrated, but they 
can increase renal toxicity.255,264 When they are indicated in other 
conditions (e.g. resistant oral streptococci),265 aminoglycosides should 
be given for no longer than 2 weeks to reduce nephrotoxicity.266
(v) Rifampin should be used only in foreign body infections such as PVE after 
3–5 days of effective antibiotic therapy, once the bacteraemia has been 
cleared. The rationale supporting this recommendation is based on the 
likely antagonistic effect of the antibiotic combinations with rifampin 
against planktonic/replicating bacteria,267 and the synergy seen against 
dormant bacteria within the biofilms and prevention of rifampin- 
resistant variants.268New evidence based on a small, retrospective study 
has questioned this approach and needs further validation.260
(vi) Daptomycin has been recommended for treating staphylococcal 
and enterococcal endocarditis.269 When daptomycin is indicated, 
it must be given at high doses (10 mg/kg once daily)270 and 
combined with a second antibiotic (beta-lactams or fosfomycin in 
beta-lactam allergic patients) to increase activity and avoid the de­
velopment of resistance.271 It should be noted the use of fosfomycin 
is associated with increased risk of acute HF and renal failure due to 
the high load of sodium while the use of daptomycin has been asso­
ciated with eosinophilic syndromes in up to 15% of patients.272,273
Phases of antibiotic treatment of infective endocarditis
Complicated cases: continue inpatient i.v. treatmenta
From Day 10 post-treatment initiation and/or 7 days post-surgery:
consider OPAT or oral antibiotic treatment in stable patients
Inpatient treatment i.v. rapid bactericidal combinations
Removal of infected cardiac devices
0
Week
Early critical phase
Continuation phase with resting bacteria
1
2
4-6
+
+
Cardiac surgery, if 
indicated
Draining of abscesses
10
Day
Perform TOE before therapy switch
(Class I)
Figure 8 Phases of antibiotic treatment for infective endocarditis in relation to outpatient parenteral antibiotic therapy and partial oral endocarditis treat­
ment. i.v., intravenous: OPAT, outpatient parenteral antibiotic treatment; TOE, transoesophageal echocardiography. aCriteria for switching to OPAT or par­
tial oral treatment of endocarditis are given in the Supplementary data online, Table S8.


<!-- PAGE 30 -->

### Page 30

(vii) The antibiotic regimens need to adapt to the local circumstances 
and the availability of antibiotics.
(viii) Data on the efficacy of long-term antibiotic suppressive therapy in pa­
tients with IE who do not undergo cardiac surgery are limited to small 
and heterogeneous series with various antibiotic regimens.184,274 In a 
small series of Gram-positive bloodstream infections and IE, dalba­
vancin (500 mg weekly or 1000 mg biweekly regimens) has been 
shown effective.274,275 Relapses are not infrequent.184
7.2. Penicillin-susceptible oral streptococci 
and Streptococcus gallolyticus group
Oral streptococci include the groups mitis, sanguinis, anginosus, salivar­
ius, downei, and mutans (see Supplementary data online, Figure S2).276
The remaining streptococci isolated outside of the oral cavity are clas­
sified into either the Streptococcus gallolyticus (former bovis) or pyogen­
ic groups. Recommended regimens against susceptible (susceptible 
standard dosing regimen and increased exposure) streptococci are 
summarized in Recommendation Table 7.4,277–279 The cure rate is ex­
pected to be >95%. In uncomplicated cases of NVE, short-term 2-week 
therapy can be administered by combining penicillin or ceftriaxone with 
gentamicin or netilmicin.280,281 Gentamicin and netilmicin can be given 
once daily in patients with IE due to susceptible streptococci and nor­
mal renal function. When outpatient antibiotic therapy is feasible, cef­
triaxone alone or combined with gentamicin or netilmicin given once a 
day is particularly convenient.280–282 In patients with documented al­
lergy to penicillin, desensitization is recommended. If desensitization 
cannot be performed, patients allergic to beta-lactam should receive 
cephalosporins (in non-anaphylactic reaction) or vancomycin, keeping 
in mind that a beta-lactam is superior to glycopeptides. Teicoplanin 
has been proposed as an alternative,4 starting with loading doses 
(6 mg/kg/12 h for 3 days) and followed by 6–10 mg/kg/day. Loading is 
critical because the drug is highly bound (≥98%) to serum proteins 
and penetrates slowly into vegetations.283 However, only limited retro­
spective studies have assessed its efficacy in streptococcal IE.284 After 
10–14 days of therapy, OPAT or outpatient oral antibiotic therapy 
should be considered.
7.3. Oral streptococci and 
Streptococcus gallolyticus group 
susceptible, increased exposure or 
resistant to penicillin
The incidence of these resistant streptococci is increasing. Large strain 
collections have reported >30% of resistant S. mitis and Streptococcus 
oralis.285
Retrospective series provide the evidence for the recommendations 
on antibiotic treatment of IE caused by penicillin-resistant oral strepto­
cocci and S. gallolyticus. Compiling four of them, 47 of 60 patients (78%) 
were treated with penicillin or ceftriaxone, mostly combined with ami­
noglycosides.285–290 In penicillin-resistant cases, aminoglycoside treat­
ment must be given for ≥2 weeks and short-term therapy regimens 
are not recommended. There is very limited experience with daptomy­
cin in IE caused by resistant isolates.265,291 After 10–14 days of therapy, 
OPAT or outpatient oral antibiotic therapy should be considered if clin­
ically stable (see Section 7.13).
Recommendation Table 7 — Recommendations for antibiotic treatment of infective endocarditis due to oral strepto­
cocci and Streptococcus gallolyticus group
Recommendations
Classa
Levelb
Penicillin-susceptible oral streptococci and Streptococcus gallolyticus group
Standard treatment: 4-week duration in NVE or 6-week duration in PVE
In patients with IE due to oral streptococci and S. gallolyticus group, penicillin G, amoxicillin, or ceftriaxone are recommended for 4 
(in NVE) or 6 weeks (in PVE), using the following doses:277,278
I
B
Adult antibiotic dosage and route
Penicillin G
12–18 millionc U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Paediatric antibiotic dosage and route
Penicillin G
200 000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg/day i.v. in 1 dose
Standard treatment: 2-week duration (not applicable to PVE)
2-week treatment with penicillin G, amoxicillin, ceftriaxone combined with gentamicin is recommended only for the treatment of 
non-complicated NVE due to oral streptococci and S. gallolyticus in patients with normal renal function using the following 
doses:277,278
I
B
Adult antibiotic dosage and route
Penicillin G
12–18 millionc U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dosed
Continued
ESC Guidelines                                                                                                                                                                                          3977


<!-- PAGE 31 -->

### Page 31

Paediatric antibiotic dosage and route
Penicillin G
200 000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. in 1 dose
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dose or 3 equally divided dosesd
Allergy to beta-lactams
In patients allergic to beta-lactams and with IE due to oral streptococci and S. gallolyticus, vancomycin for 4 weeks in NVE or for 6 
weeks in PVE is recommended using the following doses:292
I
C
Adult antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 dosese
Paediatric antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 or 3 equally divided dosese
Oral streptococci and Streptococcus gallolyticus group susceptible, increased exposure or resistant to penicillin
In patients with NVE due to oral streptococci and S. gallolyticus, penicillin G, amoxicillin, or ceftriaxone for 4 weeks in combination 
with gentamicin for 2 weeks is recommended using the following doses:285–290
I
B
Adult antibiotic dosage and route
Penicillin G
24 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dosed
In patients with PVE due to oral streptococci and S. gallolyticus, penicillin G, amoxicillin, or ceftriaxone for 6 weeks combined with 
gentamicin for 2 weeks is recommended using the following doses:285–290
I
B
Adult antibiotic dosage and route
Penicillin G
24 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dosed
Allergy to beta-lactams
In patients with NVE due to oral streptococci and S. gallolyticus and who are allergic to beta-lactams, vancomycin for 4 weeks is 
recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 dosese
Paediatric antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 dosese
In patients with PVE due to oral streptococci and S. gallolyticus and who are allergic to beta-lactams, vancomycin for 6 weeks 
combined with gentamicin for 2 weeks is recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 dosese
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dosed
Paediatric antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 dosese
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dosed
© ESC 2023
IE, infective endocarditis; i.m., intramuscular; i.v., intravenous; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; U, units. 
aClass of recommendation. 
bLevel of evidence. 
cThe starting recommended doses are the lower doses which can be scalable to the highest doses. 
dMaximum doses 240 mg/day. High doses are associated with increased risk of nephrotoxicity. Renal function and serum gentamicin concentrations should be monitored once a week. When 
given in a single daily dose, pre-dose (trough) concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum concentrations should be ∼10–12 mg/L. 
eSerum vancomycin concentrations should achieve 10–15 mg/L at pre-dose (trough) level, although some experts recommend to increase the dose of vancomycin to 45–60 mg/kg/day i.v. in 2 
or 3 divided doses to reach serum trough vancomycin levels (Cmin) of 15–20 mg/L as in staphylococcal endocarditis. However, vancomycin dose should not exceed 2 g/day unless serum levels 
are monitored and can be adjusted to obtain a peak plasma concentration of 30–45 μg/mL 1 h after completion of the i.v. infusion of the antibiotic.


<!-- PAGE 32 -->

### Page 32

7.4. Streptococcus pneumoniae, 
β-haemolytic streptococci  
(groups A, B, C, and G)
Infective endocarditis due to Streptococcus pneumoniae has become 
rare. It is associated with meningitis and pneumonia in up to 30% of 
cases,293–296 which requires special consideration in cases with penicil­
lin resistance. Treatment of penicillin-susceptible strains is similar to 
that of oral streptococci (see Recommendation Table 7), except for 
the use of short-term 2-week therapy, which has not been thoroughly 
investigated. The same holds true for penicillin-susceptible increased 
exposure or resistant strains without meningitis, although for resistant 
strains some authors recommend high doses of cephalosporins (e.g. 
cefotaxime or ceftriaxone) or vancomycin.295 In cases with meningitis, 
penicillin must be avoided because of its poor penetration into the 
cerebrospinal fluid, and should be replaced with ceftriaxone or cefotax­
ime alone, or in association with vancomycin according to the antibiotic 
susceptibility pattern.297,298 After 10–14 days of therapy and when 
meningitis is not associated, OPAT or outpatient oral antibiotic therapy 
should be considered if clinically stable (see Section 7.13).
Infective endocarditis due to group A, B, C, or G streptococci, includ­
ing the Streptococcus anginosus group (S. constellatus, S. anginosus, and S. 
intermedius) is relatively rare.299,300 Group A streptococci are uniformly 
susceptible to beta-lactams, whereas other serogroups may display 
some degree of resistance. Infective endocarditis due to group B 
streptococci was once associated with the peripartum period, but it 
now occurs in all adults, especially the elderly. Groups B, C, and G 
streptococci and S. anginosus induce abscesses that require adjunctive 
surgery.300 Mortality from group B PVE is very high and cardiac surgery 
is recommended.301 Antibiotic treatment is similar to that of oral 
streptococci (see Recommendation Table 7), except that short-term 
(2 weeks) therapy is not recommended and gentamicin should be given 
for 2 weeks.
7.5. Granulicatella and Abiotrophia 
(formerly nutritionally variant 
streptococci)
Granulicatella and Abiotrophia induce IE with a prolonged course and are 
associated with large vegetations (>10 mm), and consequently with 
high rates of complications and valve replacement (around 
50%).302,303 This is possibly due to delayed diagnosis and treatment. 
Antibiotic recommendations include penicillin G, ceftriaxone, or vanco­
mycin for 6 weeks, combined with an aminoglycoside for at least the 
first 2 weeks in case of PVE (for doses, please see Recommendation 
Table 7).302–304
7.6. Staphylococcus aureus and 
coagulase-negative staphylococci
Staphylococcus aureus is usually responsible for acute and destructive 
IE,305 whereas CoNS can induce more protracted valve infec­
tions.306,307 Of note, the addition of an aminoglycoside in staphylococ­
cal NVE is no longer recommended because it increases renal 
toxicity.264,308 Short-term (2-week) and oral treatments have been 
proposed for uncomplicated right-sided native valve methicillin- 
susceptible S. aureus (MSSA) IE (see also Section 12.4.2), but these regi­
mens cannot be applied to left-sided IE. For penicillin-allergic patients 
with MSSA IE, penicillin desensitization can be attempted in stable pa­
tients or cefazolin can be used since vancomycin is inferior to beta- 
lactams.309 If beta-lactams cannot be given, where available, daptomycin 
should be chosen and given in combination with another effective anti­
staphylococcal drug to increase activity and avoid the development of 
resistance.310
Staphylococcus lugdunensis is mostly methicillin- 
susceptible and can be treated with cloxacillin.
Staphylococcus aureus PVE carries a very high risk of mortality 
(>45%),305,312,313 and often requires early valve replacement. Other 
differences in comparison with NVE include the overall duration of ther­
apy, the use of aminoglycosides, and the addition of rifampin after 3–5 
days of effective antibiotic therapy once the bacteraemia has been 
cleared.264,314–318 The rationale supporting this recommendation is based 
on the antagonistic effect of the antibiotic combinations with rifampin 
against planktonic/replicating bacteria as has been demonstrated in foreign 
body infection models and clinically in prosthetic orthopaedic and vascular 
infections.319 However, a recent study has shown that the addition of ami­
noglycosides to a regimen containing vancomycin or cloxacillin plus rifam­
picin in S. aureus PVE was not associated with a better outcome.320 In 
addition, the risk of nephrotoxicity associated with the use of aminoglyco­
sides should be taken into consideration. Adding rifampin to the treatment 
of staphylococcal PVE is standard practice despite the weak evi­
dence.261,321 The potential side effects and drug interactions of rifampin 
should also be considered. In patients with PVE who are allergic to penicil­
lin, daptomycin can be given combined with ceftaroline or fosfomycin or 
with gentamicin (for 2 weeks) plus rifampin for at least 6 weeks. After 
10–14 days of therapy, OPAT or outpatient oral antibiotic therapy should 
be considered if clinically stable (see Section 7.13).
7.7. Methicillin-resistant staphylococci
Methicillin-resistant S. aureus (MRSA) produces low-affinity penicillin- 
binding proteins (PBPs), which confer cross-resistance to most beta- 
lactams. Methicillin-resistant S. aureus is usually resistant to multiple 
antibiotics, leaving vancomycin, daptomycin, ceftaroline, and dalbavan­
cin to treat severe infections.322–324 However, it should be noted 
that subpopulations susceptible with increased exposure and resistant 
to vancomycin have emerged worldwide and are associated with IE 
treatment failures.325–328 The prevalence of MRSA causing IE that is 
susceptible with increased exposure or resistant to vancomycin ranges 
between 19% and 34%. In addition, among patients with IE caused by 
MRSA, those isolates with a population analysis profile MIC ≥4 mg/L 
were associated with treatment failure defined by persistent bacteriae­
mia for ≥7 days or MRSA-attributable mortality.325 Nephrotoxicity is 
of concern when using trough monitoring of levels of vancomycin as 
a surrogate marker of the area under the curve relative to the MIC 
(AUC/MIC). Therefore, it is recommended to use a target of AUC/ 
MIC between 400 and 600 mg*h/L (assuming an MIC of 1 mg/L) that 
should be achieved with 48 h of therapy.329 When the MIC is >1 mg/ 
L, the probability of achieving an AUC/MIC ≥400 is unlikely. In that clin­
ical scenario, changing therapy should be considered due to the high risk 
of nephrotoxicity with higher doses of vancomycin. Daptomycin is a li­
popeptide antibiotic approved for S. aureus bacteraemia and right-sided 
IE.330 Cohort studies of S. aureus and CoNS IE have shown that dapto­
mycin is at least as effective as vancomycin,327,328 and, in two cohort 
studies of MRSA bacteraemia with high vancomycin MICs (>1 mg/ 
L),331,332 daptomycin was associated with better outcomes (including 
survival) compared with vancomycin. Importantly, daptomycin needs 
to be administered in appropriate doses and combined with other anti­
biotics to avoid further resistance in patients with IE.330,333 Therefore, 
daptomycin should be given at high doses (10 mg/kg), and most experts 
recommend its combination with beta-lactams334 or fosfomycin335
(beta-lactams [and probably fosfomycin] increase membrane 
ESC Guidelines                                                                                                                                                                                          3979


<!-- PAGE 33 -->

### Page 33

daptomycin binding by decreasing the positive surface charge) for NVE, 
and with gentamicin and rifampin for PVE.326–328 However, in a rando­
mized trial including 352 patients with MRSA bacteraemia, daptomycin 
or vancomycin combined with i.v. flucloxacillin, cloxacillin, or cefazolin 
did not result in a significant reduction of the primary composite end­
point of mortality, persistent bacteraemia, relapse, or treatment failure 
as compared with daptomycin or vancomycin alone.328 The study was 
stopped prematurely before recruiting the target number of patients 
(n = 440) due to increased incidence of acute kidney injury in the 
combination therapy arm and, therefore, the results should be inter­
preted with caution.
Other alternatives include fosfomycin plus imipenem,336 ceftaroline,337
quinupristin–dalfopristin with or without beta-lactams,338,339 beta-lactams 
plus oxazolidinones (linezolid),340 beta-lactams plus vancomycin,341 and 
high doses of trimethoprim/sulfamethoxazole and clindamycin.342,343
These clinical and therapeutic scenarios warrant collaborative manage­
ment with the Endocarditis Team including an infectious disease specialist, 
since the evidence is based on very small populations.
Recommendation Table 8 — Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus 
spp.
Recommendations
Classa
Levelb
IE caused by methicillin-susceptible staphylococci
In patients with NVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin is recommended for 4–6 weeks using 
the following doses:264,314,316–318
I
B
Adult antibiotic dosage and route
(Flu)cloxacillinc
12 g/day i.v. in 4–6 doses
Cefazoline
6 g/day i.v. in 3 doses
Paediatric antibiotic dosage and route
(Flu)cloxacillinc
200–300 mg/kg/day i.v. in 4–6 equally divided doses
Cefazoline
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
In patients with PVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin with rifampin for at least 6 weeks and 
gentamicin for 2 weeks is recommended using the following doses:264,314,316–318,320
I
B
Adult antibiotic dosage and route
(Flu)cloxacillinc
12 g/day i.v. in 4–6 doses
Cefazolin
6 g/day i.v. in 3 doses
Rifampin
900 mg/day i.v. or orally in 3 equally divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
(Flu)cloxacillinc
200–300 mg/kg/day i.v. in 4–6 equally divided doses
Cefazolin
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Allergy to beta-lactams
In patients with NVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin for 4–6 weeks is 
recommended using the following doses:322–327
I
B
Adult antibiotic dosage and route
Cefazoline
6 g/day i.v. in 3 doses
Paediatric antibiotic dosage and route
Cefazoline
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
In patients with PVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin combined with rifampin for 
at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:344
I
B
Adult antibiotic dosage and route
Cefazoline
6 g/day i.v. in 3 doses
Rifampin
900 mg/day i.v. or orally in 3 equally divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
Cefazoline
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Continued


<!-- PAGE 34 -->

### Page 34

In patients with NVE due to methicillin-susceptible staphylococci who are allergic to penicillin, daptomycin combined with 
ceftaroline or fosfomycin may be considered.322–327
IIb
C
Adult antibiotic dosage and route
Daptomycin
10 mg/kg/day i.v. in 1 dose
Ceftarolinef 
OR 
Fosfomycing
1800 mg/day i.v. in 3 doses 
OR 
8–12 g/day i.v. in 4 doses
In patients with PVE due to methicillin-susceptible staphylococci who are allergic to penicillin, daptomycin combined with 
ceftaroline or fosfomycin or gentamicin with rifampin for at least 6 weeks and gentamicin for 2 weeks may be considered using the 
following doses:344
IIb
C
Adult antibiotic dosage and route
Daptomycin
10 mg/kg/day i.v. in 1 dose
Ceftarolinef 
OR 
Fosfomycing
1800 mg/day i.v. in 3 doses 
OR 
8–12 g/day i.v. in 4 doses
Rifampin
900 mg/day i.v. or orally in 3 equally divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
IE caused by methicillin-resistant staphylococci
In patients with NVE due to methicillin-resistant staphylococci, vancomycin is recommended for 4–6 weeks using the following 
doses:345
I
B
Adult antibiotic dosage and route
Vancomycinh
30–60 mg/kg/day i.v. in 2–3 doses
Paediatric antibiotic dosage and route
Vancomycinh
30 mg/kg/day i.v. in 2–3 equally divided doses
In patients with PVE due to methicillin-resistant staphylococci, vancomycin with rifampin for at least 6 weeks and gentamicin for 
2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Vancomycinh
30–60 mg/kg/day i.v. in 2–3 doses
Rifampin
900–1200 mg/day i.v. or orally in 2 or 3 divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
Vancomycinh
30 mg/kg/day i.v. in 2–3 equally divided doses
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
In patients with NVE due to methicillin-resistant staphylococci, daptomycin combined with cloxacillin, ceftaroline or fosfomycin may 
be considered using the following doses:335,345–349
IIb
C
Adult antibiotic dosage and route
Daptomycin
10 mg/kg/day i.v. in 1 dose
Cloxacillinc 
OR 
Ceftarolinef 
OR 
Fosfomycing
12 g/day i.v. in 6 doses 
OR 
1800 mg/day i.v. in 3 doses 
OR 
8–12 g/day i.v. in 4 doses
© ESC 2023
IE, infective endocarditis; i.m., intramuscular; i.v., intravenous; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; U, units. 
aClass of recommendation. 
bLevel of evidence. 
cCloxacillin is not recommended if the patient has penicillin allergy. 
dMaximum doses 240 mg/day. High doses are associated with increased risk of nephrotoxicity. Renal function and serum gentamicin concentrations should be monitored once a week. When 
given in a single daily dose, pre-dose (trough) concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum concentrations should be ∼10–12 mg/L. 
eCefazolin can replace cloxacillin only in patients with non–immediate-type hypersensitivity reactions to penicillin. 
fHigh doses of ceftaroline may be associated with risk of leucopaenia after 2 weeks. Ceftaroline can replace cloxacillin only in patients with non–immediate-type hypersensitivity reactions to 
penicillin. 
gIn patients with heart failure, the high load of sodium associated with the use of fosfomycin can lead to acute heart failure. 
hSerum vancomycin concentrations should achieve 10–15 mg/L at pre-dose (trough) level, although some experts recommend to increase the dose of vancomycin to 45–60 mg/kg/day i.v. in 2 
or 3 divided doses to reach serum trough vancomycin levels (Cmin) of 15–20 mg/L as in staphylococcal endocarditis. However, vancomycin dose should not exceed 2 g/d unless serum levels 
are monitored and can be adjusted to obtain a peak plasma concentration of 30–45 μg/mL 1 h after completion of the i.v. infusion of the antibiotic.
ESC Guidelines                                                                                                                                                                                          3981


<!-- PAGE 35 -->

### Page 35

7.8. Enterococcus spp.
Enterococcal IE is primarily caused by E. faecalis (90% of cases) and less 
often by Enterococcus faecium (5% of cases), or other species.350
Enterococcal IE poses two major problems. First, enterococci are highly 
resistant to antibiotic-induced killing, and eradication requires pro­
longed administration (up to 6 weeks) of synergistic bactericidal com­
binations of two cell wall inhibitors (ampicillin plus ceftriaxone, which 
synergize by inhibiting complementary PBPs), or one cell wall inhibitor 
with aminoglycosides.351–353 Second, they may be resistant to multiple 
drugs, including aminoglycosides (HLAR), beta-lactams (via PBP 5 modi­
fication and sometimes beta-lactamases), and vancomycin.351–357
Penicillin-susceptible strains are treated with penicillin G or ampicillin 
(or amoxicillin) combined with gentamicin. However, ampicillin (or 
amoxicillin) is preferred since the MIC is two to four times lower than 
that of penicillin G. Gentamicin resistance is frequent in both E. faecalis 
and E. faecium (up to 75%).358,359 An aminoglycoside MIC >128 mg/L 
(HLAR) is associated with the loss of bactericidal synergism with cell 
wall inhibitors, and aminoglycosides should not be used in such conditions.
There have been two important advances in recent years. First, in sev­
eral cohort studies of E. faecalis IE including hundreds of cases, it was ob­
served that ampicillin plus ceftriaxone is as effective as ampicillin plus 
gentamicin for non-HLAR E. faecalis IE. The combination of ampicillin 
plus ceftriaxone was also associated with a beneficial safety profile, 
due to the lack of nephrotoxicity.355,360,361 Therefore, this is the com­
bination of choice for treating NVE and PVE caused by HLAR E. faecalis. 
This double beta-lactam therapy is not effective against E. faecium and 
the experience in the treatment of other enterococcal species is very 
limited. Second, the total daily dose of gentamicin can be given in a single 
daily dose instead of the 2 or 3 divided doses previously recommended, 
and the length of the treatment with gentamicin for non-HLAR E. faeca­
lis IE may be safely shortened from 4–6 weeks to 2 weeks, reducing the 
rates of nephrotoxicity to very low levels.266,362,363 After 10–14 days of 
therapy, OPAT or outpatient oral antibiotic therapy should be consid­
ered if the patient is clinically stable (see Section 7.13).364–367
Beta-lactam or vancomycin resistance is mainly observed in E. fae­
cium. Since dual resistance is rare, beta-lactam might be used against 
vancomycin-resistant strains and vice versa. Varying results have been 
reported with quinupristin–dalfopristin (not active against E. faecalis), 
linezolid, 
daptomycin, 
teicoplanin, 
and 
tigecycline.353,365,368
Daptomycin 10–12 mg/kg/24 h, always combined with beta-lactams 
(ampicillin, ertapenem, or ceftaroline) or fosfomycin in order to 
prevent the development of daptomycin resistance, is the best 
option for treating multidrug- and vancomycin-resistant enterococcal 
IE.369
Recommendation Table 9 — Recommendations for antibiotic treatment of infective endocarditis due to Enterococcus spp.
Recommendations
Classa
Levelb
Beta-lactam and gentamicin-susceptible strains
In patients with NVE due to non-HLAR Enterococcus spp., the combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks 
or with gentamicin for 2 weeks is recommended using the following doses:355,360,361
I
B
Adult antibiotic dosage and route
Amoxicillin
12 g/day i.v. in 4–6 doses
Ampicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. in 2 doses
Gentamicinc
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. in 2 doses
Gentamicinc
3 mg/kg/day i.v. or i.m. in 3 equally divided doses
In patients with PVE and patients with complicated NVE or >3 months of symptoms due to non-HLAR Enterococcus spp., the 
combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks or with gentamicin for 2 weeks is recommended using the 
following doses:355,360,361
I
B
Adult antibiotic dosage and route
Amoxicillin
12 g/day i.v. in 4–6 doses
Ampicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. in 2 doses
Gentamicinc
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg/day i.v. in 2 doses
Gentamicinc
3 mg/kg/day i.v. or i.m. in 3 equally divided doses
Continued


<!-- PAGE 36 -->

### Page 36

7.9. Gram-negative bacteria
7.9.1. Haemophilus, Aggregatibacter, Cardiobacterium, 
Eikenella, and Kingella-related species
Haemophilus, Aggregatibacter (previously Actinobacillus), Cardiobacterium, 
Eikenella, and Kingella (HACEK) Gram-negative bacilli are fastidious organ­
isms that require special investigations when they are the suspected cause 
of IE (see also Section 5). Because they grow slowly, standard MIC tests may 
be difficult to interpret. Some HACEK group bacilli produce beta- 
lactamases, and therefore ampicillin is no longer the first-line option. 
Conversely, they are susceptible to ceftriaxone, other third-generation ce­
phalosporins, and fluoroquinolones. The standard treatment is ceftriaxone 
2 g/day for 4 weeks in NVE and for 6 weeks in PVE. If they do not produce 
beta-lactamase, ampicillin (12 g/day i.v. in 4 or 6 doses) for 4–6 weeks plus 
gentamicin (3 mg/kg/day divided into 2 or 3 doses) for 2 weeks is an 
High-level aminoglycoside resistanced
In patients with NVE or PVE due to HLAR Enterococcus spp., the combination of ampicillin or amoxicillin and ceftriaxone for 6 weeks 
is recommended using the following doses:355,360,361
I
B
Adult antibiotic dosage and route
Ampicillin
12 g/day i.v. in 4–6 doses
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. or i.m. in 2 doses
Paediatric antibiotic dosage and route
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. or i.m. in 2 doses
Beta-lactam resistant Enterococcus spp. (E. faecium)e
In patients with IE due to beta-lactam resistant Enterococcus spp. (E. faecium), vancomycin for 6 weeks combined with gentamicin for 
2 weeks is recommended using the following doses:358,359,369
I
C
Adult antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2–3 equally divided doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Vancomycin-resistant Enterococcus spp.f
In patients with IE due to vancomycin-resistant Enterococcus spp., daptomycin combined with beta-lactams (ampicillin, ertapenem, or 
ceftaroline) or fosfomycin is recommended using the following doses:369
I
C
Adult antibiotic dosage and route
Daptomycin
10–12 mg/kg/day i.v. in 1 dose
Ampicillin
12 g/day i.v. in 4–6 doses
Fosfomycin
12 g/day i.v. in 4 doses
Ceftaroline
1800 mg/day i.v. in 3 doses
Ertapenemg
2 g/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Daptomycin
10–12 mg/kg/day i.v. in 1 dose (age-adjusted)
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to a maximum of 12 g/day
Fosfomycin
2–3 g/day i.v. in 1 dose
Ceftaroline
24–36 mg/kg/day in 3 doses
Ertapenemg
1 g/day i.v. or i.m. in 1 dose [if younger than 12 years, 15 mg/kg/dose (to a maximum of 500 mg) twice daily]
© ESC 2023
HLAR, high-level aminoglycoside resistance; IE, Infective endocarditis; i.m., intramuscular; i.v., intravenous; NVE, native valve endocarditis; PBP, Penicillin-binding protein; PVE, prosthetic valve endocarditis. 
aClass of recommendation. 
bLevel of evidence. 
cMaximum doses 240 mg/day. High doses are associated with increased risk of nephrotoxicity. Renal function and serum gentamicin concentrations should be monitored once a week. When given in a single 
daily dose, pre-dose (trough) concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum concentrations should be ∼10–12 mg/L. 
dHigh-level resistance to gentamicin: if susceptible to streptomycin, replace gentamicin with streptomycin 15 mg/kg/day in two equally divided doses. 
eBeta-lactam resistance: (i) if due to beta-lactamase production, replace ampicillin with ampicillin–sulbactam or amoxicillin with amoxicillin–clavulanate; (ii) if due to PBP5 alteration, use vancomycin-based 
regimens. 
fMultiresistance to aminoglycosides, beta-lactams and vancomycin: suggested alternatives are (i) daptomycin 10 mg/kg/day plus either ampicillin 200 mg/kg/day i.v. in four to six doses, ertapenem (2 g/day i.v.), 
ceftaroline (600 mg/8 h i.v.), or fosfomycin (3 g/6 h i.v.); (ii) linezolid 2 × 600 mg/day i.v. or orally for ≥8 weeks (monitor haematological toxicity); (iii) quinupristin–dalfopristin 3 × 7.5 mg/kg/day for ≥8 weeks. 
Quinupristin–dalfopristin is not active against E. faecalis; (iv) for other combinations (daptomycin plus ertapenem or ceftaroline or fosfomycin), consult infectious disease specialists. 
gHigh doses of ertapenem are associated with seizures.
ESC Guidelines                                                                                                                                                                                          3983


<!-- PAGE 37 -->

### Page 37

option.370 Ciprofloxacin (400 mg every 8–12 h i.v. or 750 mg every 12 h 
orally) is a less well-validated alternative.370–373
7.9.2. Non-Haemophilus, Aggregatibacter, 
Cardiobacterium, Eikenella, and Kingella species
The ICE cohort reported non-HACEK Gram-negative bacteria in 49 of 
2761 (1.8%) IE cases.279,374 Recommended treatment is early surgery 
plus prolonged (6 weeks) therapy with bactericidal combinations of 
beta-lactams and aminoglycosides, sometimes with additional quino­
lones or cotrimoxazole.375,376 In vitro bactericidal tests and monitoring 
of serum antibiotic concentrations may be helpful. Because of their rar­
ity and severity, these conditions should be discussed by the 
Endocarditis Team.
7.10. Blood culture-negative infective 
endocarditis
The main causes of BCNIE are summarized in Section 5.3.2.377,378
Treatment options are summarized in Table 11.379–383 Treatment of 
Whipple’s IE remains highly empirical. Successes have been reported 
with long-term therapy (>1 year).384 In cases of CNS involvement, 
sulfadiazine 1.5 g/6 h orally must be added to doxycycline. An alterna­
tive therapy is ceftriaxone (2 g/24 h i.v.) for 2–4 weeks or penicillin G (2 
million U/4 h) and streptomycin (1 g/24 h) i.v. for 2–4 weeks followed 
by cotrimoxazole (800 mg/12 h) orally. Trimethoprim is not active 
against T. whipplei. Consultation with the Endocarditis Team, including 
an infectious disease specialist, is recommended.
7.11. Fungi
Fungi are most frequently observed in PVE and in IE affecting PWID or 
immunocompromised patients.386 Candida and Aspergillus spp. predom­
inate, the latter resulting in BCNIE.387,388 Mortality is very high (>50%), 
and treatment necessitates combined antifungal administration and with a 
low threshold for surgery.278,387,388 Antifungal therapy for Candida IE in­
cludes an echinocandin at high doses or liposomal amphotericin B (or other 
lipid formulations) with or without flucytosine. for Aspergillus IE, voricon­
azole is the drug of choice. Some experts recommend the addition of an 
echinocandin or amphotericin B.278,387–390 Suppressive long-term treat­
ment with oral azoles (fluconazole and voriconazole) is recommended, 
sometimes lifelong.278,388,389 Consultation with the Endocarditis Team in­
cluding an infectious disease specialist is recommended.
7.12. Empirical therapy
Treatment of IE should be started promptly. Three sets of blood cultures 
should be drawn at 30-minute intervals before initiation of antibiotics.391
The initial choice of empirical treatment depends on several 
considerations: 
(i) Previous antibiotic therapy.
(ii) IE in a native valve or a prosthesis (and if so, when surgery was per­
formed [early vs. late PVE]).
(iii) The place of the infection (community, nosocomial, or non- 
nosocomial healthcare-associated IE) and knowledge of the local 
epidemiology, especially for antibiotic resistance and specific genu­
ine culture-negative pathogens.
(iv) Cloxacillin/cefazolin administration is associated with lower mortality 
rates than other beta-lactams, including amoxicillin/clavulanic acid or 
ampicillin/sulbactam,392 and vancomycin for empirically treating 
MSSA bacteraemia/endocarditis.309,393 However, recently amoxicil­
lin/clavulanic acid or ampicillin/sulbactam might be an effective empir­
ical treatment for MSSA bacteraemia when de-escalated to cloxacillin 
or cefazolin within 96 h from the index blood culture.394
Native valve endocarditis and late PVE regimens should cover 
staphylococci, streptococci, and enterococci. If the patient was receiv­
ing antibiotic therapy, the empirical therapy should include different 
antibiotics. CoNS should be empirically covered in PVE but not in 
NVE. Early PVE or healthcare-associated IE regimens should cover 
methicillin-resistant 
staphylococci, 
enterococci 
and, 
ideally, 
non-HACEK Gram-negative pathogens. Once the pathogen is identi­
fied (usually within 24 h), the antibiotic treatment must be adapted 
to its antimicrobial susceptibility pattern. It should be emphasized 
that the empirical treatment should be changed to targeted therapy 
once the organism is identified within 24–48 h.
Table 11 Antibiotic treatment of blood culture- 
negative infective endocarditis
Pathogens
Proposed therapya
Treatment 
outcome
Brucella spp.
Doxycycline (200 mg/24 h) 
plus cotrimoxazole (960 mg/ 
12 h) plus rifampin (300– 
600 mg/24 h) for ≥3–6 
monthsb orally
Treatment success defined 
as an antibody titre <1:60. 
Some authors recommend 
adding gentamicin for the 
first 3 weeks
C. burnetii (Q 
fever agent)
Doxycycline (200 mg/24 h) 
plus hydroxychloroquine (200– 
600 mg/24 h)c orally (>18 
months of treatment)
Treatment success defined 
as anti-phase I IgG titre 
<1:400, and IgA and IgM 
titres <1:50
Bartonella spp.d
Doxycycline 100 mg/12 h 
orally for 4 weeks plus 
gentamicin (3 mg/24 h) i.v. for 2 
weeks
Treatment success 
expected in ≥90%
Legionella spp.
Levofloxacin (500 mg/12 h) i.v. 
or orally for ≥6 weeks or 
clarithromycin (500 mg/12 h) 
i.v. for 2 weeks, then orally for 4 
weeks plus rifampin (300– 
1200 mg/24 h)
Optimal treatment 
unknown
Mycoplasma spp.
Levofloxacin (500 mg/12 h) i.v. 
or orally for ≥6 monthse
Optimal treatment 
unknown
T. whipplei 
(Whipple’s 
disease agent)f
Doxycycline (200 mg/24 h) 
plus hydroxychloroquine (200– 
600 mg/24 h)c orally for ≥18 
months
Long-term treatment, 
optimal duration unknown
© ESC 2023
IE, infective endocarditis; Ig, immunoglobulin; i.v., intravenous. 
Adapted from Brouqui et al.383
aOwing to the lack of large series, the optimal duration of treatment of IE due to these 
pathogens is unknown. The presented durations are based on selected case reports. 
Consultation with an infectious disease specialist is recommended. 
bAddition of streptomycin (15 mg/kg/24 h in 2 doses) for the first few weeks is optional. 
cDoxycycline plus hydroxychloroquine (with monitoring of serum hydroxychloroquine 
levels) is significantly superior to doxycycline.385
dSeveral therapeutic regimens have been reported, including ampicillin or amoxicillin, (12 g/ 
24 h i.v.) or cephalosporins (ceftriaxone 2 g/24 h i.v.) combined with aminoglycosides 
(gentamicin or netilmicin).381 Dosages are as for streptococcal and enterococcal IE.379,380
eNewer fluoroquinolones (levofloxacin, moxifloxacin) are more potent than ciprofloxacin 
against intracellular pathogens such as Mycoplasma spp., Legionella spp., and Chlamydia spp. 
fTreatment of Whipple’s IE remains highly empirical. In the case of central nervous system 
involvement, sulfadiazine 1.5 g/6 h orally must be added to doxycycline. An alternative 
therapy is ceftriaxone (2 g/24 h i.v.) for 2–4 weeks or penicillin G (2 million U/4 h) and 
streptomycin (1 g/24 h) i.v. for 2–4 weeks followed by cotrimoxazole (800 mg/12 h) 
orally. Trimethoprim is not active against T. whipplei. Successes have been reported with 
long-term therapy (1 year).


<!-- PAGE 38 -->

### Page 38

7.13. Outpatient parenteral or oral 
antibiotic therapy for infective 
endocarditis
Outpatient parenteral antibiotic treatment or step-down outpatient oral 
antibiotic treatment is used to consolidate antimicrobial therapy once crit­
ical infection-related complications are under control (e.g. perivalvular ab­
scesses, acute HF, septic emboli, and stroke) and the patient is clinically 
stable.43,396–399 When feasible, early hospital discharge and OPAT helps 
to alleviate the effects of infection and prolonged hospitalization especially 
in the elderly.400 In the initial phase of IE treatment, standard i.v. treatment 
is administered according to recommendations for specific microorgan­
isms. Once the clinical condition of the patient is stable, OPAT or step- 
down outpatient oral antibiotic treatment is a safe alternative to in-hospital 
i.v. treatment in selected patients.43,399 Patients may reach such stability at 
various points in their disease course but, when criteria for stability are 
reached, the patient may then be switched to OPAT or alternatively to 
an oral therapy at hospital discharge. The OPAT regime consists of the 
same antibiotic combinations administered in the acute phase if possible. 
The 5-year outcomes from the POET trial showed continued effectiveness 
of oral antibiotic therapy as compared with i.v. antibiotic therapy for IE in 
selected patients.401 Hence, clinical stability will then differentiate IE 
courses into two phases: 
(i) Critical phase where at least 10 days of i.v. treatment is required: at 
this time point, OPAT has a restricted indication.
(ii) Continuation phase (beyond 10 days of therapy and 7 days 
post-surgery), where OPAT/step-down oral therapy may be feasible.
Supplementary data online, Table S8 summarizes the salient ques­
tions to address when considering OPAT/step-down oral therapy for IE.
Recommendation Table 10 — Recommendations for 
antibiotic regimens for initial empirical treatment of 
infective endocarditis (before pathogen identification)a
Recommendations
Classb
Levelc
In patients with community-acquired NVE or late 
PVE (≥12 months post-surgery), ampicillin in 
combination with ceftriaxone or with (flu)cloxacillin 
and gentamicin should be considered using the 
following doses:255
IIa
C
Adult antibiotic dosage and route
Ampicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. or i.m. in 2 doses
(Flu)cloxacillin
12 g/day i.v. in 4–6 doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Ampicillin
200–300 mg/kg/day i.v. in 4–6 
doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. or i.m. in 1 dose
(Flu)cloxacillin
200–300 mg/kg/day i.v. in 4–6 
equally divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 3 equally 
divided doses
In patients with early PVE (<12 months 
post-surgery) or nosocomial and non-nosocomial 
healthcare-associated IE, vancomycin or daptomycin 
combined with gentamicin and rifampin may be 
considered using the following doses:395
IIb
C
Adult antibiotic dosage and route
Vancomycine
30 mg/kg/day i.v. in 2 doses
Daptomycin
10 mg/kg/day i.v. in 1 dose
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dose
Rifampin
900–1200 mg i.v. or orally in 2 or 
3 doses
Paediatric antibiotic dosage and route
Vancomycine
40 mg/kg/day i.v. in 2–3 equally 
divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 3 equally 
divided doses
Rifampin
20 mg/kg/day i.v. or orally in 3 
equally divided doses up to 
maximum of 900 mg/day
Allergy to beta-lactams
In patients with community-acquired NVE or late 
PVE (≥12 months post-surgery) who are allergic to 
penicillin, cefazolin, or vancomycin in combination 
with gentamicin may be considered using the 
following doses:
IIb
C
Adult antibiotic dosage and route
Cefazolin
6 g/day i.v. in 3 doses
Vancomycine
30 mg/kg/day i.v. in 2 doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 1 dose
Continued
Paediatric antibiotic dosage and route
Cefazolin
100 mg/kg/d i.v. in 3–4 doses, up 
to maximum of 6 g/day
Vancomycine
40 mg/kg/day i.v. in 2–3 equally 
divided doses
Gentamicind
3 mg/kg/day i.v. or i.m. in 3 equally 
divided doses
© ESC 2023
BCNIE, blood culture-negative infective endocarditis; IE, infective endocarditis; i.m., 
intramuscular; i.v., intravenous; NVE, native valve endocarditis; PVE, prosthetic valve 
endocarditis. 
aIf initial blood cultures are negative and there is no clinical response, BCNIE aetiology (see 
Section 7.10) and the extension of the antibiotic spectrum to blood culture-negative 
pathogens should be considered. If cardiac surgery is indicated, molecular diagnosis can 
be performed. 
bClass of recommendation. 
cLevel of evidence. 
dMaximum doses 240 mg/day. High doses are associated with increased risk of 
nephrotoxicity. Renal function and serum gentamicin concentrations should be 
monitored once a week. When given in a single daily dose, pre-dose (trough) 
concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum 
concentrations should be ∼10–12 mg/L. 
eSerum vancomycin concentrations should achieve 10–15 mg/L at pre-dose (trough) 
level, although some experts recommend to increase the dose of vancomycin to 
45–60 mg/kg/day i.v. in 2 or 3 divided doses to reach serum trough vancomycin levels 
(Cmin) of 15–20 mg/L as in staphylococcal endocarditis. However, vancomycin dose 
should not exceed 2 g/d unless serum levels are monitored and can be adjusted to 
obtain a peak plasma concentration of 30–45 μg/mL 1 h after completion of the i.v. 
infusion of the antibiotic.
ESC Guidelines                                                                                                                                                                                          3985


<!-- PAGE 39 -->

### Page 39

In addition to the patient being medically stable, general considerations 
for suitability for OPAT include assessment of the patient’s home environ­
ment and self-care capabilities. Adherence to treatment and follow-up vis­
its are also crucial for a beneficial outcome of outpatient treatment and the 
healthcare provider–patient relationship is important for ensuring proper 
and continued treatment and maintenance of infection control.
7.13.1. Parenteral and oral step-down antibiotic 
treatment
Stability criteria are essential and timing in the clinical planning the pa­
tient’s course, especially TOE, becomes key (Figure 9). Stability criteria 
include blood samples, clinical parameters, and TOE.43
OPAT has been shown to be a safe treatment in IE for stable patients 
who are suitable for home treatment.
The patient, and preferably also a caregiver, should be educated care­
fully in the disease and how to monitor/observe for signs of infection, 
including daily temperature and other signs of disease progression or 
complications. In addition, regular post-discharge evaluation is required 
(nurse once per day, responsible physician 1–3 times per week). For pa­
tients receiving OPAT, regular i.v. catheter inspection and care by a 
healthcare professional should be provided. If the patient is not suffi­
ciently able to self-monitor, and has no close caregivers, added surveil­
lance is required by involved staff and home treatment should generally 
be carefully considered in such cases.
Certain combinations of two oral antibiotics should be used for oral 
step-down treatment (see Supplementary data online, Table S9).
7.13.2. Other considerations for outpatient oral or 
parenteral antimicrobial therapy
In the OPAT programme, patients continue with the same antibiotics 
that are administered in the acute phase in once-daily regimens, or 
with infusion pumps if antibiotics should be administered intermittently, 
N
N
N
N
Definite infective endocarditis
Y
Y
Y
Y
Patient not suitable for oral antibiotic treatment
The patient may be shifted from i.v. to oral antibiotics (two-drug strategy)
Blood cultures with either
S. aureus, streptococci, CoNS, or E. faecalis
Other indication for continued i.v. antibiotics?
or BMI >40 or faulty gastrointestinal uptake
Perform TOE:
New surgical indication?
Infection control?
Satisfying response to treatment: no fever >2 days,
CRP <25% of max measured value or <20 mg/L
and leukocytes <15 x 109/L
Treated with relevant i.v. antibiotics ≥10 days and ≥7 days after valve surgery
Continue i.v. antibiotics
Figure 9 Flowchart to assess clinical stability based on the Partial Oral Treatment of Endocarditis trial. BMI, body mass index; CoNS, coagulase-negative 
staphylococci; CRP, C-reactive protein; i.v., intravenous; TOE, transoesophageal echocardiography. Adapted with permission from Iversen et al.43


<!-- PAGE 40 -->

### Page 40

or in continuous infusion. Dalbavancin is a glycopeptide antibiotic with a 
very long half-life that can be administered weekly. There is previous 
positive experience in sensitive Gram-positive IE, although the most ef­
fective administration schedule is not clear.274,402 The recommended 
prescription is 1.5 g as a loading dose followed by 0.5–1 g weekly until 
completing 6 weeks of antibiotic treatment.
Although the evidence is weak, another option (in addition to the 
combinations listed in the Supplementary data online, Table S9) for 
staphylococcal IE is the combination of i.v. cotrimoxazole (sulfameth­
oxazole 4800 mg/day and trimethoprim 960 mg/day in 4–6 doses) 
plus i.v. clindamycin (1800 mg/day in 3 doses) during the first week fol­
lowed by only oral cotrimoxazole for 5 weeks.343
8. Indications for surgery and 
management of main infective 
endocarditis complications
Infective endocarditis is associated with certain risks and complications 
that can only be controlled with surgical intervention. Despite the risks 
of surgery in these patients, current evidence suggests that surgical 
treatment may generate a survival advantage of up to 20% in the first 
year.403,404 There are three main reasons to undergo surgery in the set­
ting of acute IE: HF, uncontrolled infection, and prevention of septic 
embolization (in particular, to the CNS) (Figure 10).
A significant proportion of surgical procedures for IE are performed 
on an urgent basis. The Task Force has defined urgent surgery as that 
requiring intervention within 3–5 days, although unnecessary delays 
should be avoided once the indication for urgent surgery is established. 
Some cases require emergency surgery (within 24 h), irrespective of 
the pre-operative duration of antibiotic treatment. A third group re­
quires surgery non-urgently, i.e. within the same hospital admission. 
In cases where the infective component can be completely healed 
with antibiotic treatment alone, both timing and indications for treat­
ment of residual valve dysfunction follow the conventional guidelines 
for valve treatment.128
8.1. Pre-operative risk assessment
The risk of surgical therapy during the active phase of IE can be signifi­
cant. It is heavily influenced by pre-existing co-morbidities and current 
organ function, but should not be limited by one risk factor alone (e.g. 
age or liver function).405,406 The decision to operate should therefore 
be made by the Endocarditis Team (see Section 4),167 considering ur­
gency of the patient’s clinical condition, peri-operative risk, the poten­
tial to recover from the infection, and the patient’s associated 
long-term prognosis.403,404
There are several scoring systems that predict mortality after general 
(i.e. non-IE) cardiac surgery and which are in routine clinical use.407,408
Other scoring systems were designed specifically for the setting of IE in­
cluding the AEPEI (Association for the Study and Prevention of Infective 
Endocarditis Study) score, the STS (Society of Thoracic Surgeons) IE score, 
the PALSUSE (prosthetic valve, age ≥70, large intracardiac destruction, 
Staphylococcus spp., urgent surgery, sex [female], EuroSCORE ≥10) score, 
the de Feo score, and the ANCLA (anaemia, NYHA [New York Heart 
Association] class IV, critical state, large intracardiac destruction, surgery 
of thoracic aorta) score, among others.256,409–414 Some of these scoring 
systems are web-based and free of charge (e.g. the AEPEI risk calculator 
https://www.endocardite.org/index.php/calculateurs/score-de- 
mortalite-post-chirurgie-aepei). Such scoring systems have been devel­
oped based on retrospective data and their performance is vari­
able.250,256,415–417 In addition, none of these scoring systems are used in 
daily clinical routine. Therefore, prospective surgical scoring systems 
with better precision need to be developed, particularly for determining 
operative futility in prohibitively high-risk patients.
A significant proportion of patients with clear indications for surgery 
for IE may have multiple risk factors or other reasons that lead to sur­
gery not being performed, and these patients have the worst progno­
sis.184,403 Conversely, high-risk but salvageable patients may not be 
offered life-saving operations on the basis of perceived unacceptable 
risk, and this is especially true in the elderly (see Section 12.2). The com­
plex decision of not offering surgery when indicated should therefore 
be made in the setting of an Endocarditis Team with experienced sur­
gical input.418 Determining when operative management for a specific 
patient is futile requires compassionate multidisciplinary insight along 
with consideration of the patient’s and family’s wills (see Section 13.2).
8.2. Heart failure
8.2.1. Heart failure in infective endocarditis
Heart failure is the most frequent complication of IE and the main indi­
cation for urgent and emergency surgery for IE.419 The prevalence of 
HF with left-sided IE is variable and inconsistently defined between re­
ported series, ranging between 19% and 73%.420–425 Clinical symptoms 
Recommendation Table 11 — Recommendations for 
outpatient antibiotic treatment of infective endocarditis
Recommendations
Classa
Levelb
Outpatient parenteral or oral antibiotic treatment 
should be considered in patients with left-sided IE 
caused by Streptococcus spp., E. faecalis, S. aureus, or 
CoNS who were receiving appropriate i.v. antibiotic 
treatment for at least 10 days (or at least 7 days after 
cardiac surgery), are clinically stable, and who do not 
show signs of abscess formation or valve 
abnormalities requiring surgery on TOE.43,401
IIa
A
Outpatient parenteral antibiotic treatment is not 
recommended in patients with IE caused by highly 
difficult-to-treat microorganisms,c liver cirrhosis 
(Child-Pugh B or C), severe cerebral nervous system 
emboli, untreated large extracardiac abscesses, heart 
valve complications, or other severe conditions 
requiring surgery, severe post-surgical complications, 
and PWID-related IE.
III
C
© ESC 2023
CoNS, coagulase-negative staphylococci; IE, infective endocarditis; i.v., intravenous; TOE, 
transoesophageal echocardiography; PWID, people who inject drugs. 
aClass of recommendation. 
bLevel of evidence. 
cHighly difficult-to-treat microorganism: microorganisms requiring i.v. antibiotic 
combinations that cannot be administered by means of outpatient parenteral antibiotic 
treatment or that require strict monitoring of drug levels either in blood or in other 
fluids owing to their potential toxicity or narrow therapeutic index (e.g. MRSA or 
vancomycin-resistant enterococci also resistant to alternative drugs such as daptomycin 
and linezolid, multidrug- or extensively drug-resistant Gram-negative rods, highly 
penicillin-resistant oral streptococci, fungi other than Candida).
ESC Guidelines                                                                                                                                                                                          3987


<!-- PAGE 41 -->

### Page 41

Heart failure
Emergency surgery
(Class I)
Uncontrolled infection
High risk of embolism or established embolism
Cardiogenic shock or pulmonary oedema
Local complications
(abscess, false aneurysm,
fistula, enlarging vegetation)
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Poor haemodynamic tolerance
Persistent positive blood culturesa
Vegetation ≥10 mm and other reason for surgeryb
N
Non-urgent surgery
(Class I)
N
N
Resistant bacteriac or fungi
N
N
Vegetation ≥10 mm and no evidence of embolus
N
Antibiotic therapy and continued observation
N
Surgical timing for patient with left-sided infective endocarditis
Y
Urgent surgery
(Class I)
Y
Urgent surgery
(Class I)
Y
Urgent surgery
(Class I)
Y
Urgent surgery
(Class IIa)
Y
Urgent or non-urgent surgery
(Class I)d
Y
PVE caused by S. aureus or non-HACEK
Gram-negative bacilli
N
Non-urgent surgery
(Class I)
N
Urgent surgery
(Class IIa)
Y
Urgent surgery
(Class I)
Y
Urgent surgery
(Class IIb)
Y
Figure 10 Proposed surgical timing for infective endocarditis. HACEK, Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, and Kingella; PVE, prosthet­
ic valve endocarditis. Surgery timing: emergency, within 24 h. Urgent, within 3–5 days. Non-urgent, within same hospital admission. aDespite appropriate 
antibiotic therapy for >1 week and control of septic embolic foci. bE.g. patients with significant valvular dysfunction that is, or is not, a direct result of endo­
carditis process. cS. aureus (methicillin resistant and non-methicillin resistant), vancomycin-resistant enterococci, non-HACEK Gram-negative bacteria and 
fungi. dUrgent for S. aureus, non-urgent for others.


<!-- PAGE 42 -->

### Page 42

are mainly caused by congestion and may vary from mild dyspnoea to 
severe and rapidly worsening dyspnoea, orthopnoea, pulmonary oe­
dema, and cardiogenic shock. Factors associated with increased risk 
of HF complicating the course of IE include older age, presence of 
NVE with aortic valve involvement, and high comorbidity.420–425
Leaflet perforation and rupture, as well as mitral chordal rupture, 
lead to new severe valvular regurgitation or worsening of pre-existent 
valvular regurgitation and subsequent acute HF. Other less common 
causes of HF include intracardiac fistulae, interference of the vegetation 
mass with leaflet opening and closure, or myocardial infarction from ve­
getations embolizing into the coronary arteries. Patients with right- 
sided IE complicated by HF present with symptoms of right heart con­
gestion, as discussed in Section 12.6.
New-onset HF is the predominant clinical presentation in IE patients, 
whereas worsening of pre-existing HF is less frequent. Cardiogenic 
shock can be the first presentation in up to 5% of cases, of which half 
of such patients develop cardiogenic shock within 72 h of admission 
for IE.424 On imaging tests, patients with IE complicated by HF present 
more frequently with lower left ventricular ejection fraction, larger 
vegetation size, perivalvular abscesses, pseudoaneurysms, and valvular 
regurgitation secondary to leaflet perforation or rupture.420–425
Heart failure complicating IE is independently associated with poor 
in-hospital and 1-year survival, and surgical treatment is the only effect­
ive treatment that is associated with improved survival.420,421,424,426–430
Even though in-hospital mortality rates increase with the severity of HF 
presentation, the survival benefit of surgical treatment vs. medical ther­
apy is more pronounced among patients with NYHA functional class 
III–IV symptoms.420 TTE provides important information on the sever­
ity of the haemodynamic consequences of valve dysfunction. New on­
set of elevated filling pressures, pulmonary hypertension, and/or 
pericardial effusion may lead to urgent or emergency recommendation 
for surgery.163 Biomarkers such as B-type natriuretic peptide and 
troponin have been associated with poor prognosis in IE.431,432
Patients who are discharged after treatment of IE require subsequent 
follow-up (see Section 11). Heart failure is more likely to develop during 
follow-up in IE patients who are discharged with valvular regurgitation 
than in those without regurgitation, particularly if mitral regurgitation is 
present.433
8.2.2. Indications and timing of surgery in the 
presence of heart failure in infective endocarditis
Timing of surgical intervention in patients with IE (Figure 10) compli­
cated by HF should be decided by the Endocarditis Team, although sur­
gery should not be delayed by Endocarditis Team discussions in patients 
requiring emergency operations. The presence of HF leads to recom­
mendation for surgery in the majority of patients and is the principal in­
dication for urgent surgery in IE patients.429,434 Emergency surgery 
should be performed in patients with new-onset NYHA class IV HF 
symptoms, pulmonary oedema, and/or cardiogenic shock, irrespective 
of the status of infection or length of antibiotic treatment and when 
considered non-futile intervention. Urgent surgery is indicated in pa­
tients with milder forms of HF (NYHA class II–III) and severe valve re­
gurgitation or echocardiographic signs of haemodynamic compromise 
(elevated end-diastolic left ventricular pressure, high left atrial pressure, 
or moderate and severe pulmonary hypertension), or large vegetations. 
In patients without haemodynamic compromise, i.v. antibiotic therapy 
and strict clinical and echocardiographic observation are first indicated, 
and surgery can be temporarily delayed. However, it should be 
emphasized that early surgery is a good option for patients with surgical 
indications and low risk of surgery.403,404
8.3. Uncontrolled infection
Uncontrolled infection is one of the most common complications of IE 
and is the second most frequent indication for surgery.5 Uncontrolled 
infection is considered to be present when there is: (i) persistent infec­
tion or sepsis despite antibiotic therapy; (ii) signs of local infection that 
do not respond to antibiotic therapy; or (iii) infection with resistant or 
very virulent organisms.
8.3.1. Septic shock and persistent infection
Septic shock, defined as vasopressor requirement to maintain a mean 
arterial pressure of 65 mmHg or greater and serum lactate level greater 
than 2 mmol/L in the absence of hypovolaemia,435 is a highly lethal com­
plication of IE and occurs in ∼5–10% of patients.425,436 Risk factors for 
septic shock include S. aureus and Gram-negative bacteria, persistent 
bacteraemia, nosocomial acquisition, acute renal failure, diabetes melli­
tus, CNS emboli, and large vegetations.147,436 Surgery is associated with 
a significant reduction in early and 1-year mortality for patients with IE 
and septic shock.425,436 Urgent surgery is therefore recommended in 
patients with IE and persistent sepsis or septic shock despite adequate 
antibiotic therapy, in which surgery is non-futile.
The definition of persistent infection is somewhat arbitrary and con­
sists of fever and persistent positive cultures after 7 days of appropriate 
antibiotic treatment. It has been demonstrated that persistent blood 
cultures 48–72 h after initiation of antibiotics are an independent risk 
factor for hospital mortality.437 In many cases of persistent infection, 
antibiotics alone are insufficient to eradicate the infection. Surgery is 
therefore indicated for persistent infection when extracardiac ab­
scesses (splenic, vertebral, cerebral, or renal) and other potential causes 
of positive cultures and fever (infected lines and embolic complications) 
have been excluded. Persistent fever may also be caused as an adverse 
reaction to antibiotics.438
8.3.2. Locally uncontrolled infection
Signs of locally uncontrolled infection include increasing vegetation size, 
abscess formation, the creation of pseudoaneurysms and/or fistulae, 
and new atrioventricular block (AVB). The incidence of perivalvular ex­
tension ranges from 10% to 30% in NVE with higher incidences found in 
patients with PVE.5,439 Perivalvular complications and abscess forma­
tion are more frequent in aortic valve than mitral valve IE, and may 
be higher in patients with bicuspid vs. tricuspid aortic valves.440 In aortic 
valve IE, perivalvular extension occurs most frequently in the 
mitral-aortic intervalvular fibrosa,441 whereas perivalvular abscesses 
are usually located posteriorly or laterally in mitral valve IE.442
Persistent fever and infection, new AVB, chest pain, new heart murmur, 
recurrent embolism, or HF may indicate perivalvular extension. The 
diagnosis should be confirmed by TOE, which is more sensitive and spe­
cific than TTE.443 However, mitral annular calcification may obscure 
small regions of mitral perivalvular extension, particularly in the poster­
ior aspects of the mitral annulus. Cardiac CT has been shown to be an 
accurate alternative imaging procedure for the evaluation of perivalvu­
lar extension of infection, and PET/CT imaging may be particularly help­
ful in cases of PVE (see Section 5.4.4.
ESC Guidelines                                                                                                                                                                                          3989


<!-- PAGE 43 -->

### Page 43

##### 8.3.3 Indications and timing of surgery in the presence

of uncontrolled infection
Surgery should be considered for uncontrolled infection when antibiot­
ic therapy is ineffective and extracardiac sources are ruled out. Reports 
in the literature demonstrate that surgery for uncontrolled infection in 
IE has the potential to improve 1-year survival by 15–20%.403,429,444
8.3.3.1. Persistent infection
Uncontrolled infection is present in the form of persistent infection 
when blood cultures remain positive for >1 week or persistent sepsis 
despite appropriate antimicrobial therapy and when other causes of 
bacteraemia have been excluded. Not performing surgery for uncon­
trolled infection is associated with significantly increased mortality.444
8.3.3.2. Locally uncontrolled infection
Uncontrolled infection is also present if signs of local progression, i.e. 
increasing vegetation size or perivalvular involvement, are observed 
during follow-up imaging.5,420,421,445,446 Surgery should be performed 
urgently (within 3–5 days) in such cases. Rarely, when there are no 
other reasons for surgery and fever is easily controlled with antibiotics, 
small abscesses or pseudoaneurysms can be treated conservatively un­
der close clinical and echocardiographic follow-up.429,444
8.3.3.3. Infection with resistant or virulent organisms
Microorganisms causing endocarditis that are unlikely to be controlled 
with current antimicrobial therapy include fungi,447,448 multiresistant 
bacteria (e.g. MRSA or vancomycin-resistant enterococci) and, in rare 
cases, non-HACEK Gram-negative bacteria. S. aureus should also be in­
cluded in this group due to its fast progression and ability to cause local 
tissue destruction and abscess formation,5,449 specifically, if a favourable 
early response to antibiotics is not achieved.305,312,449 The presence of 
these organisms should lead to discussions within the Endocarditis 
Team and urgent surgery.385,450
8.4. Prevention of systemic embolism
8.4.1. Incidence of embolic events in infective 
endocarditis
Embolic events are frequent and potentially life-threatening complica­
tions of IE related to the migration of cardiac vegetations.451,452 The 
brain and spleen are the most frequent sites of embolism for left-sided 
IE, while pulmonary embolism is frequent in right-sided and pacemaker 
lead IE (see Section 12). Stroke may be the first clinical manifestation of 
IE, and is a severe complication that is associated with increased mor­
bidity and mortality.451,453,454 Embolic events may be clinically silent in 
up to 50% of patients with IE.198 Emboli affecting the splenic or cerebral 
circulation are frequently asymptomatic, and are diagnosed by non- 
invasive imaging.197,200 Although whole-body CT imaging (i.e. chest, 
abdomen, and pelvis) is frequently performed during the work-up for 
surgery, diagnosis and management of patients is infrequently altered 
as a result of these investigations.194 However, cerebral CT may affect 
clinical decision-making and outcomes when surgery is considered.452
Embolic risk in IE is high, with 20–50% of patients being af­
fected.452,455 The highest incidence of embolic strokes can be observed 
in the days around the initial diagnosis of IE,456 and embolic events are 
often what leads to the initial diagnosis of IE. Embolic risk is highest the 
day after therapy initiation, and is 10–20 times higher on the day before 
and after the start of antibiotic treatment compared with 2 weeks be­
fore and after.456 Thus, embolic events occurring after the initiation of 
antibiotic therapy continuously drop in incidence within the first 2 
weeks of antibiotic treatment.429,455–457 The benefits of surgery to pre­
vent embolism may therefore be greatest during the early stages of 
therapy, when embolic risk is at its highest.
8.4.2. Predicting the risk of embolism
Predicting the risks of embolization is important for decision-making in 
IE. Echocardiography plays a key role in identifying potentially embolic 
structures in the heart,429,455,456,458 although predicting the time point 
of embolization remains difficult. Several factors are associated with in­
creased risk of embolism including the size and mobility of vegeta­
tions,455,456,458–460 the location of the vegetation on the mitral 
valve,455 the increasing or decreasing size of the vegetation under anti­
biotic therapy,455 particular microorganisms (especially S. aureus,455
S. gallolyticus,461 and Candida spp.450), previous embolism,455 multivalv­
ular involvement,458 and biological markers.462 Among these, the size 
and mobility of the vegetations are the most important independent 
predictors of new embolic events.459,460,463 A recent study, however, 
demonstrated that vegetation size was predictive of worse outcomes 
only when present with other indications for surgery (i.e. HF or uncon­
trolled infection).464 Staphylococcal endocarditis is also a risk factor for 
embolization,465–468 which is particularly important because the inci­
dence of S. aureus IE is increasing.78,469 Risk of neurological complica­
tions is particularly high in patients with very large vegetations 
(>30 mm in length).451
Additional factors may need to be taken into account and it may be 
helpful to use an embolic risk calculator.470 S. aureus infection, previous 
embolism, vegetation length, age, diabetes, and the presence of atrial 
fibrillation have been identified as specific risk factors for embolism.470
8.4.3. Indications and timing of surgery to prevent 
embolism in infective endocarditis
Surgical removal of potentially embolic material from the heart may 
prevent new or additional embolic events. Given the imminent risk 
and high rates of embolization in patients with mobile and large vegeta­
tions,5,451,455–457,460,471 surgery should be considered urgently (within 
3–5 days) in such patients. A prospective randomized trial in young, 
low-risk patients assessed the effects of early surgery in patients with 
large vegetations and streptococcal IE.471 Although there was no differ­
ence in all-cause mortality at 6 months between the early surgery and 
conventional treatment groups, the risk of embolization was significant­
ly reduced with early surgery. Non-randomized observational analyses 
including patients at higher risk also suggest that early surgery may be 
beneficial in patients with a high likelihood of embolization,428,459,472,473
and that initial conservative treatment is associated with increased mor­
tality.474,475 However, prosthetic dehiscence has also been associated 
with early surgery in patients with S. aureus IE.429 Individualized 
decision-making is required to balance the risk of surgery, which is 
also influenced by pre-operative neurological events or other 
co-morbidities.5,453
The main indications and the timing of surgery to prevent embolism 
based on the currently available literature are given in Recommendation 
Table 12 and Figure 10.


<!-- PAGE 44 -->

### Page 44

### 9 Other complications of infective

endocarditis
9.1. Neurological complications
Neurological manifestations may occur before or after the diagnosis of 
IE is established and recurrent events can also take place later in the 
course of IE.451 The possibility of IE should be considered in patients 
who present with stroke, meningitis, or brain abscess. Unexplained fe­
ver accompanying a stroke in a patient with valvular disease should trig­
ger the suspicion of IE with blood cultures taken prior to empirical 
antibiotic therapy.
Symptomatic cerebrovascular complications occur in up to 35% of pa­
tients with IE,145,198,451,452 whereas silent cerebrovascular complications 
(including ischaemia and microhaemorrhage) occur in up to 80% of pa­
tients.200,204,403 Clinical presentation is variable, but ischaemic stroke and 
transient ischaemic attack are the most common presentations.479
Other manifestations include haemorrhage (intracerebral, subarachnoid), 
meningitis, brain abscess, encephalopathy, and infectious aneurysms. Focal 
neurological symptoms are present in ∼40% of affected patients, and non- 
focal presentations occur in approximately one-third.
S. aureus IE is more frequently associated with neurological compli­
cations compared with IE caused by other microorganisms. 
Vegetation size and mobility also correlate with embolic risk.
Neurological complications are associated with excess mortality, as 
well as long-term morbidity, particularly in the case of stroke.480
Prompt diagnosis of IE and early initiation of the antibiotic therapy are 
pivotal to preventing neurological complications. Early cardiac surgery 
in high-risk patients is key to preventing embolization of vegeta­
tions.471,481 In contrast, antithrombotic/thrombolytic medical therapies 
are not beneficial.481–483
Mechanical thrombectomy may be considered within time limits in 
selected cases.484 If mechanical thrombectomy is performed, the re­
trieved embolic material must be sent off for pathological and microbio­
logical 
analyses. 
Neurosurgery 
or 
endovascular 
therapy 
is 
recommended for large infective aneurysms, especially when a continu­
ous growth, despite optimal antibiotic therapy or ruptured intracranial 
infective aneurysms, is observed.485
The use of anticoagulation in patients with left-sided IE does not 
seem to have an effect on the risk of stroke, cerebrovascular haemor­
rhage, or mortality at 10 weeks and, therefore, continuation of 
anticoagulation in patients with left-sided IE and with a pre-existing in­
dication for the use of anticoagulants is recommended in the absence of 
other contraindications.486 Substitution from oral anticoagulation to 
heparin in such patients is generally preferred in case of cerebral bleed­
ing or indication for early surgery.
Following a neurological event, the indication for cardiac surgery must 
be balanced against the peri-operative risk and post-operative prognosis 
of the patient. Randomized studies are impractical and cohort studies suf­
fer from bias that can only be partially compensated for by statistical meth­
ods. The majority of publications demonstrate lower risk of secondary 
haemorrhagic conversion of uncomplicated ischaemic lesions than the 
risk of recurrent embolism under antibiotic treatment. Therefore, the 
available evidence supports early surgery in such patients (see Section 10.4).
Recommendation Table 13 summarizes the recommended manage­
ment of neurological complications in IE; considerations for cardiac sur­
gery after neurological complications are discussed in Section 10.4.
Recommendation Table 12 — Recommendations for 
the main indications of surgery in infective endocarditis 
(native 
valve 
endocarditis 
and 
prosthetic 
valve 
endocarditis)a
Recommendations
Classb
Levelc
(i) Heart failure
Emergencyd surgery is recommended in aortic or 
mitral NVE or PVE with severe acute regurgitation, 
obstruction, or fistula causing refractory pulmonary 
oedema or cardiogenic shock.420,423,424,429,476,477
I
B
Urgentd surgery is recommended in aortic or mitral 
NVE or PVE with severe acute regurgitation or 
obstruction causing symptoms of HF or 
echocardiographic signs of poor haemodynamic 
tolerance.5,420–422,429
I
B
(ii) Uncontrolled infection
Urgentd surgery is recommended in locally 
uncontrolled infection (abscess, false aneurysm, 
fistula, enlarging vegetation, prosthetic dehiscence, 
new AVB).5,420,421,429,445
I
B
Urgentd or non-urgent surgery is recommended in IE 
caused by fungi or multiresistant organisms according 
to the haemodynamic condition of the patient.420
I
C
Urgentd surgery should be considered in IE with 
persistently positive blood cultures >1 week or 
persistent sepsis despite appropriate antibiotic 
therapy and adequate control of metastatic 
foci.436,437
IIa
B
Urgentd surgery should be considered in PVE caused 
by S. aureus or non-HACEK Gram-negative 
bacteria5,385,449
IIa
C
(iii) Prevention of embolism
Urgentd surgery is recommended in aortic or mitral 
NVE or PVE with persistent vegetations ≥10 mm 
after one or more embolic episodes despite 
appropriate antibiotic therapy.451,455,457,471,478
I
B
Urgentd surgery is recommended in IE with 
vegetation ≥10 mm and other indications for 
surgery.5,460,465,466,471,478
I
C
Urgentd surgery may be considered in aortic or 
mitral IE with vegetation ≥10 mm and without 
severe valve dysfunction or without clinical evidence 
of embolism and low surgical risk.460,463,465,473,478
IIb
B
© ESC 2023
AVB, atrioventricular block; HACEK, Haemophilus, Aggregatibacter, Cardiobacterium, 
Eikenella, Kingella; HF, heart failure; IE, infective endocarditis; NVE, native valve 
endocarditis; PVE, prosthetic valve endocarditis. 
aFor right-sided endocarditis, please refer to Section 12. 
bClass of recommendation. 
cLevel of evidence. 
dEmergency, within 24 h. Urgent, within 3–5 days. Non-urgent, within same hospital 
admission.
ESC Guidelines                                                                                                                                                                                          3991


<!-- PAGE 45 -->

### Page 45

9.1.1. The role of cerebral imaging in infective 
endocarditis
Cerebral imaging is mandatory when neurological complications of IE 
are suspected. Evaluation should include MRI with and without gadolin­
ium, or CT with and without contrast if MRI is not possible.487 Vascular 
imaging should not be performed routinely, and CTA or magnetic res­
onance angiography (MRA) is probably sufficient for screening when in­
fective aneurysm is suspected. Catheter angiography should be 
performed in patients in whom an infective aneurysm was diagnosed 
on CTA or MRA, in patients with an acute brain haemorrhage, or if 
the suspicion of aneurysm remains despite negative non-invasive tech­
niques, and if mechanical thrombectomy is considered.488
In patients without neurological symptoms, cerebral MRI often de­
tects ‘silent’ lesions such as microbleeds.204 The lack of association 
with parenchymal haemorrhage and the absence of post-operative 
neurological complications in patients with microbleeds suggest that 
microbleeds should not postpone surgery when indicated.489
9.2. Infective aneurysms
An infective (mycotic) aneurysm is a rare but potentially devastating com­
plication of IE. Infective cerebral aneurysms may be asymptomatic, cause 
headaches, seizures, or focal symptoms, and may progress to a potentially 
lethal rupture. They are associated with subarachnoid, intracerebral, and 
intracranial haemorrhage,201
particularly when the patient is 
anticoagulated. The true incidence of infective cerebral aneurysms may 
be underdiagnosed as vascular imaging modalities are not systematically 
performed in asymptomatic patients. In 168 patients who underwent 
cerebral angiography with a diagnosis of IE or infected left ventricular assist 
device were retrospectively reviewed and infective aneurysms were pre­
sent in 9% of patients.488 Another series using CTA identified infective an­
eurysms in up to 32% of patients with left-sided IE.492
Digital subtraction angiography (DSA) remains the gold standard 
diagnostic test for the detection of infective aneurysms.487 The sensitiv­
ity of CTA and MRA progressively increases with the size of the aneur­
ysm. In a large study including 142 patients, the sensitivity for detection 
of infective aneurysms smaller than 5 mm was 57% for CTA and 35% 
for MRA, compared with respective 94% and 86% sensitivities for the 
detection of aneurysms of 5 mm or larger.493 Compared with the sen­
sitivity of DSA, the sensitivities of CTA and MRA for detecting infective 
aneurysms are inferior.488,490 Therefore, in patients with IE and high 
suspicion of infective aneurysms in whom CTA or MRA are negative, 
DSA may be considered.490,494
Treatment options of infective cerebral aneurysms consist of anti­
biotic treatment with or without endovascular or surgical therapy, al­
though evidence is limited to case reports and retrospective 
studies.495–498 Therefore, management should be discussed among 
the members of the Endocarditis Team and tailored to individual clinical 
situations. Shi et al.496 reported that in patients with unruptured infect­
ive cerebral aneurysms, antibiotic treatment may have similar outcomes 
to invasive treatment. However, interventional treatment should be 
considered in cases of ruptured infective aneurysms or unruptured in­
fective aneurysms that do not respond to antibiotic therapy.485,495
Endovascular therapy is highly successful and associated with low 
morbidity compared with microsurgical and medical manage­
ment.487,499 A systematic review including 499 patients with infective 
cerebral aneurysms reported a 36% rate of aneurysm rupture.495
Endovascular surgical and conservative therapies were performed in 
an approximately equal number of patients. Among patients undergo­
ing valve surgery in this series, only 15% underwent cardiac surgery be­
fore aneurysm treatment whereas 85% underwent cardiac surgery 
after aneurysm treatment.495
Urgency of cardiac surgery plays a pivotal role in decision-making re­
garding the type of invasive treatment. Compared with neurosurgical 
clipping that requires a craniotomy and often at least 2-week delay 
prior to procedure, cardiovascular surgery can be performed on the 
same day as endovascular treatment.485,487,496,499 Finally, endovascular 
treatment of infective cerebral aneurysms prior to heart valve surgery 
may be considered, even if no rupture is documented.499
9.3. Splenic complications
Splenic complications associated with IE range from asymptomatic in­
farction500 and abscess formation501 through to splenic rupture and 
cardiovascular collapse.502 Splenic infarcts are common (∼20% of pa­
tients in the EURO-ENDO registry) and very often asymptomatic.5
Up to 5% of splenic infarcts can progress to abscess formation.503
Persistent or recurrent fever, abdominal pain, and persistent bacter­
aemia are suggestive for the presence of such complications. Patients 
with suspected splenic complications should be evaluated with ultra­
sound, abdominal CT, MRI, or PET/CT.504
Treatment of splenic complications includes conservative medical 
therapy with appropriate antibiotics for splenic infarction or for 
antibiotic-responsive abscesses, although antibiotic penetration may 
be poor in these circumstances. When an abscess is large, splenectomy 
may be considered, but the timing of splenectomy in relation to heart 
valve surgery needs careful assessment.505 Splenectomy and heart valve 
surgery are seldom performed in the same operative episode.506
Splenectomy is usually performed prior to valve surgery due to con­
cerns of dissemination and reinfection of the heart valve. 
Recommendation Table 13 — Recommendations for 
the treatment of neurological complications of infective 
endocarditis
Recommendations
Classa
Levelb
Brain CT or MRA is recommended in patients with IE 
and suspected infective cerebral aneurysms.490
I
B
Neurosurgery or endovascular therapy is 
recommended for large aneurysms, those with 
continuous growth despite optimal antibiotic 
therapy, and ruptured intracranial infective cerebral 
aneurysms.485
I
C
If non-invasive techniques are negative and the 
suspicion of infective aneurysm remains, invasive 
angiography should be considered.488
IIa
B
In embolic stroke, mechanical thrombectomy may be 
considered if the expertise is available in a timely 
manner.484
IIb
C
Thrombolytic therapy is not recommended in 
embolic stroke due to IE.481,491
III
C
© ESC 2023
CT, computed tomography; IE, infective endocarditis; MRA, magnetic resonance 
angiography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 46 -->

### Page 46

Nevertheless, one case series reported that it is safe to address the 
splenic abscess with splenectomy after valve repair.502 Alternatives to 
open splenectomy, i.e. percutaneous drainage507 and/or laparoscopic 
surgery,508 may be considered in patients with high surgical risk. 
After splenectomy, vaccination against encapsulated microorganisms 
(S. pneumoniae, N. meningitis, and Haemophilus spp.) is recommended.
9.4. Myocarditis and pericarditis
The actual prevalence of acute myocarditis in the setting of IE is un­
known. Myocarditis will usually present in the form of acute HF and/ 
or ventricular arrhythmias indicating myocardial involvement in the in­
flammatory process most likely mediated by an immune mechanism. 
Differential diagnosis and exclusion of other potential complications 
are best assessed using echocardiography and cardiac MRI.509–511
Pericarditis is an infrequent complication of IE. In one retrospective 
series of 95 patients with aortic valve IE, 19% developed pericarditis 
usually related to ring abscess formation. The same authors also de­
scribed a 12% rate of pericarditis associated with mitral valve 
IE.512,513 The pathophysiological mechanisms most commonly involved 
in IE-related pericarditis are the extension of inflammation from an in­
fective aneurysm of the aortic root or valve ring abscess, an embolus in 
an extramural coronary artery, or the rupture of an infective aneurysm. 
In a recent large series of NVE, pericardial effusion was observed in 
7.8% of patients and was associated with a higher risk of HF during ad­
mission. After adjusting for possible confounders, patients did not have 
a higher rate of surgery, and the presence of pericardial effusion was not 
associated with a higher in-hospital or 1-year mortality.513
9.5. Heart rhythm and conduction 
disturbances
Due to the critical anatomical relationship between heart valves and the 
conduction system, AVB may complicate the clinical presentation of IE. 
The atrioventricular node (AVN) and His bundle lie in close proximity 
to the insertion of the septal leaflet of the tricuspid valve, the aortic 
root (below the non-coronary and right coronary cusps), and the mitral 
annulus.514 A paravalvular abscess of these valves, especially of the aor­
tic valve, may lead to AVB, and new electrocardiographic AVN conduc­
tion abnormalities are indicative of a paravalvular extension of the 
infection. In the EURO-ENDO registry, conduction abnormalities 
were observed at diagnosis in 11.5% of patients, including first-degree 
AVB in 8.1%, second-degree AVB in 0.6%, and third-degree AVB in 
2.8% of cases.5 New-onset AVB caused by local extension of IE (i.e. ab­
scess) is an indication for urgent cardiac surgery.
Atrioventricular block may not only occur as a complication of para­
valvular extension of the infection, but it may also develop as a conse­
quence of valve surgery. In a series of 444 patients who survived cardiac 
surgery for IE,515 12.8% of patients required pacemaker implantation 
for AVB. Multivariable analysis identified that prolonged pre-operative 
PR and QRS intervals, S. aureus infection, presence of aortic root ab­
scess, tricuspid valve involvement, and prior valvular surgery were inde­
pendently associated with the need for post-operative pacemaker 
implantation.
Pacemaker implantation should be considered in patients with sur­
gery for valvular endocarditis and complete AVB if one or more of 
these risk factors is present.515
9.6. Musculoskeletal manifestations
9.6.1. Osteoarticular infective endocarditis-related 
infections
Metastatic bone or joint IE-related lesions are relatively frequent due to 
the spread of the pathogen through the bloodstream and its subse­
quent tissue implantation. Although these lesions are considered an 
IE-related distal lesion or complication because infected valves are a 
continuous source of bacteraemia, it is often impossible to determine 
whether the primary infection is the valve or the osteoarticular infec­
tion. Overall, the incidence of osteoarticular infection among patients 
with IE is 6–8%, including bones, joints, and vertebral discs.5,145,247,516
The prevalence of spondylodiscitis ranges from 2% to 10% in patients 
with IE, including symptomatic and asymptomatic cases,248,517 while 
series of spontaneous spondylodiscitis have reported co-existing IE in 
up to 20–30% of patients.518–520 In general, the rate of IE is 10 times 
higher in patients with known spondylodiscitis. Therefore, in patients 
with a definite diagnosis of pyogenic spondylodiscitis and positive blood 
cultures, TTE/TOE is recommended to rule out IE.521
The most frequent microorganisms associated with spondylodiscitis 
are S. aureus, followed by Streptococcus spp., CoNS, and Enterococcus 
spp.247,248,305,517–523
The most common symptom of spondylodiscitis is back pain, al­
though only 4% of patients with IE and back pain have spondylodisci­
tis.32,522 An MRI should be performed to accurately diagnose 
spondylodiscitis. Computed tomography can detect indirect signs of 
spondylodiscitis: loss of disc height, erosion/destruction of the end­
plates and vertebral bodies, and paravertebral soft tissue phlegmonous 
changes or abscess.206 Whole-body [18F]FDG-PET/CT can also iden­
tify spondylodiscitis.30,32,524 Indeed, spondylodiscitis is frequently de­
tected as an incidental finding when PET/CT is performed for the 
diagnosis of PVE. Imaging techniques can also be helpful in guiding biop­
sies to obtain material for cultures in cases of suspected IE with negative 
blood cultures.206
Antibiotic treatment adapted to the antimicrobial susceptibility pat­
tern is appropriate for most cases of spondylodiscitis. The outcome is 
usually favourable with the 4- to 6-week IE treatment course. 
Prolonged therapy is necessary in patients with IE caused by 
difficult-to-treat microorganisms, such as S. aureus or Candida spp., or 
in those with epidural or perivertebral abscesses.523,525 In patients 
with neurological deficits or severe spinal instability, the indication for 
Recommendation Table 14 — Recommendations for 
pacemaker implantation in patients with complete 
atrioventricular block and infective endocarditis
Recommendations
Classa
Levelb
Immediate epicardial pacemaker implantation should 
be considered in patients undergoing surgery for 
valvular IE and complete AVB if one of the following 
predictors of persistent AVB is present: 
pre-operative conduction abnormality, S. aureus 
infection, aortic root abscess, tricuspid valve 
involvement, or previous valvular surgery.515
IIa
C
© ESC 2023
AVB, atrioventricular block; IE, infective endocarditis. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3993


<!-- PAGE 47 -->

### Page 47

surgical spinal treatment should be considered.526 In patients with ur­
gent indication for cardiac surgery, the presence of these lesions 
does not contraindicate the cardiac intervention. Spondylodiscitis 
does not appear to worsen the prognosis of patients with IE but delay­
ing the diagnosis of IE in patients with spondylodiscitis is associated with 
poor prognosis.248,517–520
9.6.2. Rheumatological manifestations
The pathogenesis of rheumatological manifestations and musculoskeletal 
symptoms in IE is not well established. The probable immunological- 
inflammatory aetiology of this clinical presentation is supported by a var­
iety of antibodies and laboratory markers, the sterility of the synovial fluid, 
and the rapid resolution without sequelae.527 Myalgia and back pain are re­
ported in 12–15% of cases. Arthralgia occurs in ∼10% of patients, some­
times sequentially affecting several joints. Slightly less often are symptoms 
of peripheral arthritis preferentially involving the major and proximal joints 
at the lower extremities.5,145,182,516
Sacroiliitis is less frequently observed (1% of cases) as well as poly­
myalgia rheumatic-like syndrome with pain and morning stiffness of 
the shoulders and hips, proximal muscle weakness (0.9% of cases), 
and cutaneous leucocytoclastic vasculitis (purpuric skin lesions, 3.6% 
of cases).182,527,528 Rheumatological manifestations and musculoskel­
etal symptoms show rapid and complete resolution with antibiotics 
and their presence does not impact on the prognosis of IE.182,529
9.7. Acute renal failure
Acute renal failure is a common complication of IE and is associated 
with increased morbidity and mortality as well as significant increase 
in length and cost of hospitalization.5,531–534 Additionally, renal failure 
is an independent predictor of poor outcome after cardiac surgery.417
However, acute renal failure should not be a reason to delay cardiac 
surgery. The EURO-ENDO registry reported that in patients with IE, 
acute renal failure was the second most common complication with 
an incidence of almost 18%.5 Some single-centre studies that specifically 
reported on the incidence of acute renal failure (using standardized cri­
teria) in patients with IE reported that any degree of acute renal failure 
from mild to severe might be observed in 40–69% of cases.532,535,536
Severe renal failure requiring haemodialysis has been reported in 6% 
of patients with IE and it is associated with a very high risk of mortality 
(40%).537
Several factors may be responsible for the onset or worsening of re­
nal dysfunction: (i) immune complex and vasculitic glomerulonephritis; 
(ii) renal infarction due to septic emboli;538,539 (iii) haemodynamic im­
pairment in patients with HF; (iv) antibiotic and other drug toxicity 
(notably related to aminoglycosides, vancomycin, nafcillin, amoxicillin, 
oxacillin, concomitant use of non-steroidal anti-inflammatories, and/ 
or high dose loop diuretics); and (v) nephrotoxicity of contrast agents 
used for diagnostic imaging techniques.417,531,534,535,537,540
To reduce the incidence of acute renal failure, nephrotoxic antibio­
tics should be avoided if possible or, if not possible, serum levels (ami­
noglycosides and vancomycin) as well as creatinine should be closely 
monitored, and the optimal dose of medication should be periodically 
re-evaluated and discussed with the Endocarditis Team and a pharma­
cologist.536 Loop diuretics should also be used cautiously and other po­
tentially nephrotoxic drugs, such as non-steroidal anti-inflammatories, 
should be avoided.536 Similarly, the use of nephrotoxic contrast agents 
for diagnostic imaging techniques should be carefully evaluated and 
avoided when possible.
In patients with IE and a reduced glomerular filtration rate, contrast 
enhanced abdominal ultrasound or MRI are reasonable tests to diag­
nose embolization as cause of renal function impairment.541
10. Surgical therapy: principles and 
methods
Surgery has been demonstrated to be an independent predictor of sur­
vival in many retrospective studies of IE patients under various clinical 
conditions and offers a potential curative therapy to select patient 
groups.5,250,403,404,421,436 Optimal management of such patients may 
lead to lower peri-operative complication rates and further potential 
benefits of surgical therapy.
10.1. Pre-operative and peri-operative 
management
10.1.1. Coronary angiography
When cardiac surgery becomes necessary in IE, assessment of coronary 
anatomy is recommended (see Recommendation Table 16). Classically, 
pre-operative coronary angiography is recommended for men >40 
years, post-menopausal women, and in those with one or more cardio­
vascular risk factors or history of CAD.128 The presence of aortic valve 
vegetations may preclude invasive coronary angiography due to the risk 
of iatrogenic embolization.542,543 However, some studies have demon­
strated the safety of performing invasive coronary angiography in the 
presence of aortic valve vegetations, particularly in patients without 
very large and mobile vegetations.193,544 Alternatively, coronary CTA 
can be used to rule out significant coronary obstructions. 
Furthermore, surgery may need to be conducted without detailed in­
formation on coronary anatomy in certain clinical conditions, particu­
larly emergencies. Of note, a recent study questioned the need for 
coronary artery bypass grafting of non-critical lesions at the time of sur­
gery for IE and suggested that such concomitant intervention may have 
a negative impact on peri-operative outcomes.545
Recommendation Table 15 — Recommendations for 
patients with musculoskeletal manifestations of infect­
ive endocarditis
Recommendations
Classa
Levelb
MRI or PET/CT is recommended in patients with 
suspected spondylodiscitis and vertebral 
osteomyelitis complicating IE.30,32,206,524
I
C
TTE/TOE is recommended to rule out IE in patients 
with spondylodiscitis and/or septic arthritis with 
positive blood cultures for typical IE 
microorganisms.247,248,517–521,523
I
C
More than 6-week antibiotic therapy should be 
considered in patients with osteoarticular IE-related 
lesions caused by difficult-to-treat microorganisms, 
such as S. aureus or Candida spp., and/or complicated 
with severe vertebral destruction or 
abscesses.523,525,530
IIa
C
© ESC 2023
IE, infective endocarditis; MRI, magnetic resonance imaging; PET/CT, positron emission 
tomography/computed tomography, TOE, transoesophageal echocardiography; TTE, 
transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 48 -->

### Page 48

10.1.2. Extracardiac infection
Extracardiac foci may be treated prior to valve surgery, during the valve 
operation, or post-operatively, dependent on the urgency of cardiac 
surgery. Regardless of the timing of intervention, infective foci need 
to be eradicated before completion of antibiotic therapy in order to 
avoid cardiac valve reinfection.
10.1.3. Intra-operative echocardiography
Intra-operative TOE provides contemporaneous assessment of the ex­
tent of infection prior to valve repair/replacement. Extent of infection, 
stability of known vegetations, re-assessment of previously uninvolved 
heart valves, and biventricular function are routinely performed with 
intra-operative TOE. Intra-operative TOE post-surgical repair is man­
datory to determine the immediate result and establish a baseline for 
follow-up comparisons.547
10.2. Other intra-operative considerations
Specific peri-operative management considerations are necessary in all 
IE patients undergoing valve surgery, particularly in those following 
stroke (see Section 10.3). Pre-operative antibiotic therapy must be con­
tinued intra-operatively, and doses may need to be repeated in case of 
prolonged operations or major bleeding. Although the pharmacokinet­
ics of antibiotic therapy is altered during cardio-pulmonary bypass 
(CPB), adjustment of doses is rarely required.548 In general, ongoing 
IE antibiotic treatment offers appropriate surgical site infection prophy­
laxis. However, when the antibiotic treatment for IE does not fully cov­
er normal surgical prophylactic treatment, conventional prophylaxis 
should be added. Intra-operative bleeding management is often compli­
cated by marked coagulopathy in patients with IE, particularly those 
undergoing surgery during persistent sepsis. The management of hypo­
tension and vasoplaegia is particularly challenging in patients presenting 
with septic shock, and accompanying vasoplaegia tends to worsen sig­
nificantly during CPB. Norepinephrine is frequently used as first-line 
therapy for septic shock, followed by vasopressin or terlipressin in cases 
of resistant vasoplaegia.549 Methylene blue may be used as a rescue 
agent in patients who are unresponsive to these measures, but mortal­
ity rates are high for such patients.550
Retrospective studies have suggested that the use of haemoadsor­
bent filters during CPB may decrease the negative effects associated 
with cytokine cascade activation.551 A recent RCT of haemoadsorption 
during cardiac surgery in IE patients, however, failed to demonstrate 
any beneficial effects with regards to adverse events or end-organ 
function.552
10.3. Surgical approach and techniques
Surgery for IE aims to remove infected structures followed by re- 
establishment of anatomy and haemodynamic function. With regards 
to the involved heart valve(s), repair or replacement is carried out 
based on the extent of destruction, acuity of disease, and patient char­
acteristics.553 Appropriate collection and labelling of tissue samples for 
pathological, microbiological, and molecular biological analyses are ne­
cessary to help guide antibiotic treatment.
Aortic valve replacement is usually required for aortic IE. Aortic valve 
repair is very uncommon in the acute situation but may be performed 
for isolated aortic regurgitation after healed endocarditis. In mitral IE, leaf­
let perforations with preserved free margin and chordae tendinae may be 
treated with patch repair, particularly in the setting of subacute or healed 
IE. Although mitral valve repair is feasible in more complex mitral IE involv­
ing the annuli, the leaflet free edge, and/or chordae, evidence showing the 
feasibility and durability of such repair techniques is scarce.554,555 A large 
registry on mitral repair vs. replacement in IE was limited by the lack of in­
formation on severity of IE, different patient group profiles, and significantly 
higher incidence of staphylococcal endocarditis in the mitral valve replace­
ment group.556Therefore, it cannot be concluded that mitral valve repair is 
superior to replacement due to the high probability of selection bias. Valve 
preservation in acute IE should only be attempted if a durable repair is an­
ticipated and complete eradication of infected tissue can be achieved. 
However, valve repair may be necessary in children, where valve replace­
ment options are more limited.
Invasion of the aortic annuli may create shallow defects (very limited 
abscess or small pseudoaneurysms) that are still amenable to conven­
tional valve replacement surgery. When disease progresses into an ex­
tensive aortic root abscess or periannular destruction, aortic root 
replacement is usually required. In experienced centres, the use of allo­
grafts has been preferred as they have the advantage of adapting to ir­
regular surfaces and provide haemostatic advantages with very good 
haemodynamic function and low thrombo-embolic risk, and can be 
used to repair concomitant lesions of the anterior mitral valve leaf­
let.557,558 Additionally, allografts and stentless bioprostheses can be 
beneficial in small aortic roots and are associated with low reinfection 
rates. However, experience is generally limited to single-centre case 
series and there is no clear evidence of superiority of one valve substi­
tute over the other.559 In very selected patients and children in particu­
lar, the Ross operation (pulmonary valve autotransplantation) may be 
considered for aortic root IE.128
The use of patches to cover abscess cavities and prevent extensive 
resection and reconstruction is discouraged in aortic root IE as it 
may be associated with recurrences, periprosthetic leaks, and pseudoa­
neurysm formation. After exclusion from the circulation, abscess and 
pseudoaneurysm cavities are left to drain into the pericardial cavity.
When periannular infection of the aortic root extends into the inter­
valvular fibrosa body, complex surgical reconstructions are required and 
are frequently the only option to achieve patient survival. The reported 
Recommendation Table 16 — Recommendations for 
pre-operative coronary anatomy assessment in patients 
requiring surgery for infective endocarditis
Recommendations
Classa
Levelb
In haemodynamically stable patients with aortic valve 
vegetations who require cardiac surgery and are high 
risk for CAD, a high-resolution multislice coronary 
CTA is recommended.185,546
I
B
Invasive coronary angiography is recommended in 
patients requiring heart surgery who are high risk for 
CAD, in the absence of aortic valve vegetations.
I
C
In emergency situations, valvular surgery without 
pre-operative coronary anatomy assessment 
regardless of CAD risk should be considered.543,545
IIa
C
Invasive coronary angiography may be considered 
despite the presence of aortic valve vegetations in 
selected patients with known CAD or at high risk of 
significant obstructive CAD.193,543,544
IIb
C
© ESC 2023
CAD, coronary artery disease, CTA, computed tomography angiography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3995


<!-- PAGE 49 -->

### Page 49

pooled peri-operative survival rate of such surgical technique is 84%.560
Even more extensive repairs may be required for cases involving the in­
tervalvular fibrosa, central fibrous body, and mitral valve, with or without 
fistulation to the right-side chambers. These operations are technically 
complex and require a surgeon who is very experienced in IE, which 
may not be available in every cardiovascular surgery department.
Exceptionally, heart transplantation has been utilized for carefully se­
lected patients without other surgical options.561
10.3.1. Choice of valve prosthesis
Many patient characteristics are taken into account when deciding the 
type of valve prosthesis to implant in a given patient with IE. The studies 
published to date evaluating various valve prostheses in the setting of IE, 
however, suffer from numerous biases.90,559,562–566
Beyond the patient characteristics that apply in the non-IE setting,128
valve selection in IE is influenced by the presence of recent stroke, risk 
of new-onset bleeding, complexity of expected post-operative course, 
Haemorrhagic
Ischaemic
Meaningful recovery possible with acceptable residual quality of life
Severely decreased level of consciousnessa
Neurology and/or neurosurgery assessment and discussion with the Endocarditis Team
(Class I)
N
Cardiogenic shock
Type of stroke
N
N
Infective endocarditis with stroke
Y
Y
Uncontrolled infection, heart failure or high-risk of recurrent embolization
N
Frequent follow-up and assessment,
delay surgery 4 weeks, if possible
Y
Y
Favourable brain bleed featuresb
Conservative or palliative care
N
Continued non-surgical management
Urgent surgery
(Class I)
Y
Emergency surgery
(Class I)
Figure 11 Surgery for infective endocarditis following stroke. NIHSS, National Institutes of Health Stroke Scale Score. Surgery timing: emergency, within 
24 h. Urgent, within 48–72 h. Non-urgent, within same hospital admission. aGlasgow Coma Scale ≤4 or NIHSS >18. bIntracranial haemorrhage volume 
<30 mL or NIHSS <12.


<!-- PAGE 50 -->

### Page 50

and the ability of the patient to participate in decision-making, especially 
for emergency surgery (Table 12). In the absence of specific 
contraindications for a particular valve substitute, patient preferences 
should determine the final decision.
10.4. Timing of surgery after ischaemic and 
haemorrhagic stroke
There is a general trend of offering early surgery in IE in light of the im­
proved operative outcomes and survival benefits observed with operative 
management.451,567 For patients who have suffered a neurological injury, 
however, the optimal timing of surgery remains to be defined.568 There 
are no RCTs specifically assessing this clinically relevant issue and contem­
porary evidence arises from observational studies.415,454,473,569,570
Neurological exacerbation may occur during surgery or early post- 
operatively due to the altered physiology conditions during and imme­
diately after cardiac repair.571 Several peri-operative variables should be 
addressed in order to lower the risk of neurological deterioration and 
haemorrhagic transformation post-stroke (see Supplementary data 
online, Table S10).
The risk of neurological exacerbation during surgery needs to be ba­
lanced against that of delaying a cardiac operation. When haemo­
dynamic disturbances are present, surgery should be pursued 
without 
delay 
(see 
Figure 
11
and 
Recommendation 
Table 17).451,468,473,567,568,570–578 A more common situation occurs 
when surgery is considered for the prevention of recurrent embolism 
after stroke, due to the presence of large vegetations (>10 mm). In pa­
tients that have suffered a transient ischaemic attack, the risk of surgery 
is usually low and surgery should be performed without delay. For 
patients with ischaemic stroke, multiple observational data exist sup­
porting a non-delayed (urgent) intervention, unless the neurological 
status is poor (i.e. coma or extensive damage leading to poor functional 
prognosis).573,578 Involvement of an expert neurology/neurosurgical 
specialist will help in risk assessment discussions.
The risk of post-operative haemorrhagic conversion after pre- 
operative stroke is reported in the range of 2–7%.453,579 Remarkably, 
bleeding transformation after cardiac surgery can also occur in patients 
with silent pre-operative cerebral embolisms, with similar frequency as 
in patients with overt neurological deficits. Unfortunately, these events 
cannot currently be accurately predicted prior to surgery. When haem­
orrhagic transformation occurs, it is associated with high mortality 
(40%) and may require rescue neurointerventional or neurosurgical 
treatment to control bleeding or allow cerebral decompression by 
means of craniectomy.577,580
Several retrospective studies report benefits of early surgery (with­
in 2 weeks) after haemorrhagic stroke without further compromising 
neurological outcomes.574,581,582 Decisions should be taken on a 
case-by-case basis by the Endocarditis Team, including a neurologist, 
and should be adapted to the mechanism of intracranial haemorrhage 
and its severity including intracranial haemorrhage volume measure­
ment and National Institutes of Health Stroke Scale Score (NIHSS) 
score (see Figure 11).495 In patients in whom surgery is delayed, re­
peat CT or MRI imaging should be performed 1–2 weeks following 
intracranial haemorrhage (or earlier in the case of clinical deterior­
ation) in order to assess stability of the cerebral finding and potential­
ly re-assess timing of surgery. The timing of surgery after intracranial 
haemorrhage is controversial and an area where further evidence is 
urgently required.
10.5. Post-operative complications
Post-operative management of patients with IE may be challenging due 
to pre-operative multiorgan involvement and often complex surgical 
procedures. The risk of in-hospital mortality associated with IE surgery 
remains high (10–20%), particularly in patients >75 years of age, usually 
due to co-morbidities and complications of IE. Further research should 
focus on methods to lower surgical mortality.
The most frequent serious post-operative complications are coagu­
lopathy requiring extensive use of blood products and clotting factors, 
re-exploration of the thorax due to bleeding/tamponade, haemodialy­
sis, stroke, or cerebral haemorrhagic transformation of prior cerebro­
vascular lesions, low cardiac output syndrome, respiratory 
complications and tracheostomy, prolonged hospital stay, and need 
for a permanent pacemaker.515,585,586 When mortality occurs, the 
cause of death is often multifactorial. Post-mortem examination is help­
ful for determining the cause of death, further understanding of disease 
process, teaching purposes at academic environments, and quality 
control.
Recommendation Table 17 — Indications and timing of 
cardiac surgery after neurological complications in active 
infective endocarditis
Recommendations
Classa
Levelb
After a transient ischaemic attack, cardiac surgery, if 
indicated, is recommended without delay.454,468
I
B
After a stroke, surgery is recommended without any 
delay in the presence of HF, uncontrolled infection, 
abscess, or persistent high embolic risk, as long as 
coma is absent and the presence of cerebral 
haemorrhage has been excluded by cranial CT or 
MRI.451,468,473,567,568,570–578
I
B
Following intracranial haemorrhage, delaying cardiac 
surgery >1 month, if possible, with frequent 
re-assessment of the patient’s clinical condition and 
imaging should be considered.571
IIa
C
In patients with intracranial haemorrhage and 
unstable clinical status due to HF, uncontrolled 
infection or persistent high embolic risk, urgent or 
emergency surgery should be considered weighing 
the likelihood of a meaningful neurological 
outcome.199,581–584
IIa
C
© ESC 2023
CT, computed tomography; HF, heart failure; MRI, magnetic resonance imaging. 
aClass of recommendation. 
bLevel of evidence.
Table 12 Features favouring a non-mechanical valve 
substitute in the setting of surgery for acute infective 
endocarditis
Early surgery after a recent ischaemic stroke
Evidence of intracranial bleeding
Woman of childbearing age
High likelihood of prolonged mechanical circulatory support
Advanced age or frailty
Poor or unknown medical compliance
Expected complicated and prolonged post-operative course
Patient preference
© ESC 2023
ESC Guidelines                                                                                                                                                                                          3997


<!-- PAGE 51 -->

### Page 51

10.6. Management of antithrombotic 
therapy after surgery
The management of antithrombotic therapy early after surgery for IE 
may need to be altered when compared with non-IE clinical scenarios 
(see also Section 12.10).128 This is mainly due to known increased risk of 
intracranial haemorrhage after cerebral embolism. Restrictive or tai­
lored use of antiplatelet and antithrombotic agents after surgery are 
key to avoid further complications,203,587 which is more feasible in pa­
tients who received bioprosthetic valve prostheses or valve repair op­
erations than after mechanical valve replacement surgery.
11. Outcome after discharge: 
follow-up and long-term prognosis
Following in-hospital treatment, patients should be followed-up for the 
occurrence of main post-discharge complications, including recurrence 
of infection, HF, need for valve surgery or additional intervention, 
stroke, need for renal replacement therapy, psychological complica­
tions, and death.86,588,589
11.1. Recurrences: relapses and 
reinfections
The risk of recurrence (which includes relapses and reinfections) among 
survivors of IE varies significantly between studies, ranging from 2% to 
9% in more contemporary analyses.86,589–595 However, it has been shown 
that reinfections have worse outcomes as compared with relapses.592
Figure 12 illustrates the diagnostic paths to differentiate relapse from 
reinfection.596
Conceptually, relapse refers to a repeat episode of IE caused by the 
same microorganism and represents a failure of treatment due to insuf­
ficient duration of initial treatment, sub-optimal choice of initial antibio­
tics, or a persistent focus of infection.592 Conversely, reinfection is 
related to patients’ clinical and immunological profiles, describes an in­
fection caused by a different microorganism usually more than 6 
months after the initial episode,4,596 and is associated with worse out­
come.592 The differentiation between relapse and reinfection needs to 
be interpreted with caution, however, as a long time period from initial 
infection suggests reinfection even in the presence of the same strain. 
Contemporary data report low rates of relapse,86 most probably re­
flecting improved management of these patients. Relapse should be 
treated with i.v. antibiotics for an additional 4–6 weeks, depending on 
the causative microorganism and its antibiotic susceptibility, and cardiac 
surgery should be considered. It is also important to consider that anti­
biotic resistance may develop over time. Factors associated with an in­
creased rate of relapse are listed in Table 13.588,595,597
In surgically managed NVE, the risk of IE recurrence is no different 
when comparing valve replacement and valve repair.84,598 Several pre­
vious studies have also reported no difference regarding the risk of re­
current IE between types of valve implanted.599–601 However, the most 
recent Danish registry study reports increased risk of IE recurrence as­
sociated with biological vs. mechanical prostheses.84
Partial oral vs. i.v. antibiotic treatment of IE, as well as OPAT vs. 
hospital-based antibiotic treatment in select stable patients, is not asso­
ciated with an increased risk of recurrent IE.43,396,399,602 Notably, re­
sidual vegetation after treatment for IE also did not show increased 
association with recurrence of IE,602 although this result should be in­
terpreted with caution. Patients with relapse or reinfection IE should 
be managed as indicated in Sections 7 and 8 (if complicated IE).
Same species isolated
Reinfection
Relapse
Same strain
Stored isolate from prior infective endocarditis
Use molecular methods/
strain typing
New episode <6 months from prior infective endocarditis
N
N
N
N
Storage of isolates following infective endocarditis episode
New episode of infective endocarditis
Y
Y
Y
Y
Figure 12 Algorithm differentiating relapse from reinfection. Reproduced with permission from Chu et al.596


<!-- PAGE 52 -->

### Page 52

11.2. First year follow-up
Patients discharged after the first episode of IE should remain under 
close surveillance for potential long-term complications. A partnership 
between cardiologists, infectious disease specialists, cardiac surgeons, 
general practitioners, and dentists is encouraged to improve patient 
care and reinforce prophylaxis measures. In medically treated patients, 
residual valve dysfunction may worsen, or structural valve deterioration 
may progress, despite bacteriological cure. To monitor the risk of de­
velopment of secondary HF, an initial clinical evaluation and baseline 
TTE should be performed at the completion of antimicrobial therapy 
and repeated if a change in the clinical condition occurs.
Clinical re-assessment should be performed one or more times in 
the first year and yearly thereafter depending on the individual risk pro­
file. The need for late valve surgery is relatively low, ranging from 3% to 
11%.27,588,592 Blood testing for inflammatory markers (i.e. WBC, 
C-reactive protein, procalcitonin) should be performed early after fin­
ishing antimicrobial treatment and repeated thereafter when clinically 
indicated.592 Due to the increased risk of relapse for virulent microor­
ganisms, blood cultures are encouraged within the first week after fin­
ishing treatment.
The early period after discharge might be challenged by slow physical 
and mental recovery.603,604 Patients’ and families’ concerns should be 
addressed during follow-up. Supporting the family may indirectly sup­
port the patient during recovery and reduce the psychological burden. 
Cardiac rehabilitation, including physical exercise training and patient 
education, may be beneficial, and has been shown to be safe and feasible 
in stable patients at a minimum of 2 weeks after surgery for left-sided 
IE.605 Physical training should start as early as possible and can be 
adapted 
post-sternotomy 
with 
isolated 
lower-limb 
training. 
Adherence is improved if the delay to training is minimized, and rebuild­
ing muscle mass and reducing frailty should be a priority.
Patients, and their caregivers, should be informed of their risk of IE 
recurrence and be educated on preventive measures and self- 
monitoring. In particular, patients should be educated that new onset 
of fever, chills, or other signs of infection mandate immediate evalu­
ation, including procurement of blood cultures before empirical use 
of antibiotics, and that contact with the Heart Valve Centre is manda­
tory in case of suspected recurrent IE. Good oral health maintenance, 
preventive dentistry, and advice about skin hygiene, including advice on 
tattoos and skin piercing, are mandatory. Deficiencies in dental surveil­
lance contribute to the continuous gradual increase in the incidence of 
IE, which underlines the need for repeating the principles of IE preven­
tion at each follow-up visit. In PWID patients, follow-up care should in­
clude a strategy for addiction treatment, involve relevant addiction 
specialists before hospital discharge, and possibly including medication 
for opioid-use disorder.606,607
11.3. Long-term prognosis
Contemporary long-term survival rates after the completion of IE 
treatment are estimated to be ∼85–90% and 70–80% at 1 and 5 years, 
respectively.589,592–594,610,611 Impact of referral bias, however, should 
be taken into consideration.612 The main predictors of long-term 
mortality are age, co-morbidities, PWID, double valve infection, recur­
rences of IE, and HF, especially when cardiac surgery cannot be per­
formed.588,589,592,593,613 Compared with an age- and sex-matched 
general population, patients that survived a first episode of IE have sig­
nificantly worse survival when suffering relapses or reinfections.589,614
This excess mortality is especially high within the first few years after 
hospital discharge and can be explained by late complications such as 
HF, risk of recurrences, and higher patient vulnerability.589,611 In fact, 
most recurrences of IE and late cardiac surgeries occurred during this 
period of time.589,592,611
12. Management of specific 
situations
12.1. Prosthetic valve endocarditis
Prosthetic valve endocarditis is the most severe form of IE and occurs in 
1–6% of patients with valve prostheses,615 with an incidence of 
0.3–1.2% per patient-year.5,420,616,617 PVE accounts for 20–30% of all 
cases of IE,618 and may be more common after biological than after 
mechanical valve replacement surgery.619,620 PVE was observed in 
21% of cases of IE in a French survey,618 in 26% of cases in the Euro 
Heart Survey,419 and in 20% of cases in the ICE-PCS.621 Real-world 
Table 13 Factors associated with an increased rate of 
relapse of infective endocarditis
Inadequate antibiotic treatment (i.e. agent, dose, duration)
Resistant microorganisms (i.e. Brucella spp., Legionella spp., Chlamydia 
spp., Mycoplasma spp., Mycobacterium spp., Bartonella spp., C. Burnetii, 
fungi)
Infective endocarditis caused by S. aureus and Enterococcus spp.
Polymicrobial infection in people who inject drugs
Periannular extension
Prosthetic valve endocarditis
Persistent metastatic foci of infection (abscesses)
Resistance to conventional antibiotic regimens
Positive valve culture
Persistence of fever at the 7th post-operative day
Chronic kidney disease, especially on dialysis
High-risk behaviour, inability to adhere to medical treatment
Poor oral hygiene
© ESC 2023
Recommendation Table 18 — Recommendations for 
post-discharge follow-up
Recommendations
Classa
Levelb
Patient education on the risk of recurrence and 
preventive measures, with emphasis on dental health, 
and based on the individual risk profile, is 
recommended during follow-up.608
I
C
Addiction treatment for patients following 
PWID-related IE is recommended.606,607
I
C
Cardiac rehabilitation including physical exercise 
training should be considered in clinically stable 
patients based on an individual assessment.605,609
IIa
C
Psychosocial support may be considered to be 
integrated in follow-up care, including screening for 
anxiety and depression, and referral to relevant 
psychological treatment.605,609
IIb
C
© ESC 2023
IE, infective endocarditis; PWID, persons who inject drugs. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3999


<!-- PAGE 53 -->

### Page 53

observational studies demonstrated stable rates of IE, but a remarkable 
increase in PVE between 1998 and 2013.80 Recently, a further increase 
in PVE cases (31%) was observed in the EURO-ENDO registry.5 PVE is 
still associated with difficulties in diagnosis, determination of the opti­
mal therapeutic strategy, and poor prognosis.
12.1.1. Definition and pathophysiology
A distinction is commonly made between early PVE and late PVE based 
on the time since valve surgery, because of significant differences in the 
microbiological profiles between these two groups.622 However, the 
time to IE onset is prognostically less important than the connection 
of IE to the peri-operative period or to specific pathogens. Prosthetic 
valve endocarditis with an onset in the peri-operative period involves 
mainly S. aureus, Staphylococcus epidermidis, or nosocomial microorgan­
isms, such as Gram-negative pathogens or fungi. Late PVE more com­
monly mimics the pattern of NVE, which is mostly represented by 
streptococcal and staphylococcal infections.623 S. aureus is more com­
monly observed in patients with mechanical valves, while alpha- 
haemolytic streptococci, enterococci, and CoNS are more common 
in patients with bioprosthetic valves.624 PVE due to Mycobacterium chi­
maera is an uncommon form of nosocomial infection that can result 
from contaminated CPB heater-cooler systems. Such infections pre­
sent many months after the index operation and can therefore be chal­
lenging to identify, and are associated with high mortality.625
The pathogenesis of PVE differs according to both the type of con­
tamination and the type of prosthetic valve (see Supplementary data 
online, Section S6.1).
12.1.2. Diagnosis
Diagnosis is more difficult in PVE than in NVE. Clinical presentation is 
frequently atypical, particularly in the early post-operative period, in 
which fever and inflammatory syndromes are common in the absence 
of macroscopic alterations of the prosthesis on cardiac imaging. 
However, persistent fever should trigger the suspicion of PVE. As in 
NVE, diagnosis of PVE is based mainly on the results of echocardiog­
raphy and blood cultures. However, both are associated with a sensitiv­
ity of only 60% for the definite diagnosis of endocarditis.212
Although TOE is mandatory in suspected PVE (Figure 6), its diagnos­
tic value is lower than in NVE. Identification of a new periprosthetic leak 
is a major criterion of IE and urges additional imaging modality to con­
firm the diagnosis (see Section 5).533,626 Recently, nuclear techniques, 
particularly [18F]FDG-PET/CT, have been shown to improve the diag­
nostic accuracy of the Duke criteria and increase sensitivity.34,209
Combinations of different imaging techniques such as cardiac CT, nu­
clear imaging, and TOE, improve diagnostic accuracy and provide rele­
vant information in terms of prognosis.33,627 In select cases of 
suspected PVE, and non-diagnostic results for the above-listed exams, 
intracardiac echocardiography may be considered.
12.1.3. Prognosis and treatment
A high in-hospital mortality rate of 20–40% has been reported in 
PVE.628,629 Compared with NVE, PVE is associated with increased in- 
hospital mortality and morbidity as well as reduced long-term sur­
vival.88,630 Several factors have been associated with poor prognosis 
in PVE, including older age, diabetes mellitus, healthcare-associated in­
fections, and early PVE.312 Among the different causative organisms, 
staphylococcal or fungal infection seem to be more aggressive, whereas 
enterococcal infections are associated with similar mortality but higher 
recurrence 
rates.628
Haemodynamic 
instability, 
multivalvular 
involvement as well as involvement of the aortomitral fibrosa have 
been associated with worse outcomes. It is noteworthy that the 
most important risk factor for recurrent IE and mortality is withholding 
surgery despite an obvious indication.5
The best therapeutic option in PVE is still debated. Although surgery 
is generally considered the best option when PVE causes severe pros­
thetic dysfunction or HF, in the EURO-ENDO registry it was per­
formed in only 73% of patients with PVE despite a clear indication 
for surgical treatment.5 In a single-series study of 523 PVE patients, 
early surgery was a large independent predictor of early and 1-year sur­
vival.631 Conversely, after adjustment for differences in clinical charac­
teristics and survival bias, early valve replacement was not associated 
with lower mortality compared with medical therapy in a large inter­
national cohort.421 In this series, however, surgery was beneficial in 
the subgroup of patients with the strongest indications for surgery in­
cluding valve regurgitation, vegetation, and dehiscence or paravalvular 
abscess/fistula formation.421 Therefore, a surgical strategy is recom­
mended for PVE in high-risk subgroups identified by prognostic assess­
ment, i.e. PVE complicated with HF, severe prosthetic dysfunction, 
abscess, or persistent fever. Conversely, patients with uncomplicated 
non-staphylococcal late PVE can be managed conservatively.632–634
However, patients who are initially treated medically require close 
follow-up because of the risk of late events and the higher risk of re­
lapse or valvular dysfunction.
Surgery for PVE follows the general principles outlined for NVE. 
However, the reoperation setting and the higher incidence of peripros­
thetic tissue destruction increase the complexity of the procedure. 
Meticulous and radical debridement of the infected material, including 
the original prosthesis, suture, and pledgets, is recommended. The 
type of valve substitute used for PVE follows the same recommenda­
tions as for NVE (see also Section 10.3.1).
Early PVE following valve replacement surgery is a separate entity as­
sociated with a high mortality rate, where conservative treatment with 
antibiotics is unlikely to lead to a cure and repeat surgery should be per­
formed.621,635 Staphylococci, Cutibacteria, or similar species are the 
usual causative organisms.622,636
12.2. Endocarditis in the elderly
Characteristics of patients with IE have dramatically changed over re­
cent decades, with an increasing prevalence and specific features of IE 
in the elderly population.25,145,637,638 In this population, enterococci 
and S. aureus are reported to be the most frequent aetiological agents. 
In addition, the higher presence of intracardiac prosthetic devices 
(CIED and valvular prosthesis/repair including TAVI devices) and in­
creased incidence of healthcare-associated IE episodes are ob­
served.25,637 Finally, a lower risk of embolic episodes has been 
observed in this subgroup.462,639–641
Recommendation Table 19 — Recommendations for 
prosthetic valve endocarditis
Recommendations
Classa
Levelb
Surgery is recommended for early PVE (within 6 
months of valve surgery) with new valve replacement 
and complete debridement. 621,635
I
C
© ESC 2023
PVE, prosthetic valve endocarditis. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 54 -->

### Page 54

A number of studies have shown that cardiac surgery positively af­
fects the clinical outcome of IE patients. Nevertheless, old age, co- 
morbidities, and previous non-cardiac and cardiac procedures lead to 
surgical hesitancy by referring physicians, surgeons, and patients them­
selves.642 Moreover, these characteristics also influence the outcome of 
this fragile cohort.400,433 As a result, less frequent performance of cura­
tive surgery and increased mortality are typical hallmarks of IE episodes 
in elderly as compared with the younger population.640 In a recently 
published Swedish propensity analysis of IE patients from 2006 to 
2017, the authors found that surgery was underused in the elderly 
and that 1-year mortality was significantly higher in elderly patients 
who did not undergo surgery.641 In a sub-analysis of the ESC EORP 
EURO-ENDO registry, the indication for surgery was less often recog­
nized (51% vs. 57%) and surgery was far less frequently performed 
when indicated (35% vs. 68%) in patients >80 vs. <80 years. 
However, mortality of surgically treated patients was remarkably simi­
lar in patients <80 and >80 years after propensity matching (19.7% vs. 
20.0%). Age was also not demonstrated to be an independent predictor 
of mortality in this large prospective study.640,643 These findings suggest 
that performance of surgery in well-selected elderly patients is under­
utilized and may increase their chance of survival.
In elderly IE patients, functional and nutritional status are important 
predictors of outcomes.400 When considering cardiac surgery in elderly 
patients, functional and nutritional status, and their associated risks, 
should be accurately explored through a comprehensive assessment 
by geriatricians. In addition, the earliest possible discharge home to fa­
cilitate the patient’s functional recovery should be considered in this 
subgroup of patients.
12.3. Transcatheter prosthetic valve 
endocarditis
12.3.1. Endocarditis following transcatheter aortic 
valve implantation
The incidence of IE post-TAVI ranges from 0.3 to 1.9 per 100 patient- 
years,94,623,644–648 which is similar to that reported following surgical 
aortic valve replacement in both observational studies and 
RCTs.94,623,646,647 One recent study, however, reported a lower inci­
dence of PVE after TAVI compared with surgical prostheses.649 The 
risk of IE is higher within the first year following the procedure, and par­
ticularly within the initial 3 months.644,645,648,650–652 A modest decrease 
in the incidence of IE post-TAVI has been observed in recent years, par­
ticularly in the early period following the procedure, presumably related 
to multiple technical improvements, more streamlined procedures, and 
a reduction of periprocedural complications.650,652 A similar IE rate has 
been reported irrespective of transcatheter valve type,653 and predis­
posing factors, including younger age, male gender, renal dysfunction, 
and significant residual aortic regurgitation, have been identi­
fied.94,644–646,648,651,652
12.3.1.1. Diagnosis
The diagnosis of IE post-TAVI is challenging. The stent frame of trans­
catheter valves, with a much higher amount of metal surrounding the 
valve leaflets compared with surgical prostheses, and the characteristics 
of TAVI patients (frequently elderly with multiple co-morbidities) may 
increase the diagnostic challenges in this population. The clinical presen­
tation is frequently atypical, with fever lacking in 13–20% of pa­
tients.623,645,650 Enterococci and S. aureus are the two most common 
microorganisms involved in IE post-TAVI, followed by streptococci 
and CoNS.644–646,650
Some important aspects should be considered regarding TOE in pa­
tients with suspected IE post-TAVI: (i) no vegetations are detected in 
38–60% of cases;623,645,650,651 (ii) vegetations are located in the stent 
frame of the transcatheter valve (and not on the valve leaflets) in 
12% of cases, and this rate increases up to 19% in the presence of 
some self-expanding valve systems with a longer stent frame occupying 
the ascending aorta;653 and (iii) the vegetations are located outside the 
transcatheter valve in about one-third of cases, mainly at the level of the 
mitral valve.645,650,651 Nuclear imaging or CT have been useful to diag­
nose IE post-TAVI.654,655 The addition of [18F]FDG-PET/CT and/or 
CTA to the diagnostic work-up of IE in TAVI changed the final clinical 
diagnosis in 33% of patients.655 Intracardiac echocardiography may also 
be useful for detecting vegetations in patients with suspected IE after 
TAVI and negative TOE.165
12.3.1.2. Prognosis and treatment
Prognosis and treatment of post-TAVI PVE is complicated by the fact 
that patients are older and have more co-morbidities than post-surgical 
PVE patients. About two-thirds of patients with IE post-TAVI exhibit at 
least one complication, with acute kidney injury and HF being the most 
frequent adverse events.645,646,656 The in-hospital and 30-day mortality 
rates are very high, ranging from 16% to 36%,623,644–647,657 and increase 
up to 41–59% at 1-year follow-up.644,645,652,657 A higher patient risk 
profile, S. aureus, and the occurrence of IE complications have been 
identified as risk factors for increased mortality.645,652,657
Antimicrobial therapy for IE post-TAVI is similar to that of PVE (see 
Section 7). Similar to surgical PVE, cardiac surgery is considered the best 
option in the presence of IE complications, particularly severe prosthet­
ic failure or HF, but is infrequently performed. Surgery is performed in 
∼20% of cases (ranging from 3.8% to 31.3%),645,652,656 a much lower 
rate compared with NVE and surgical PVE. The characteristics of the 
TAVI population, with often advanced age and high or prohibitive sur­
gical risk, along with the potential difficulties associated with the re­
moval of some transcatheter valve systems (particularly those with a 
large amount of stent frame, frequently adherent to the ascending aorta 
after a few months following the TAVI procedure) may play a role in the 
low rate of surgical interventions.
To date, all studies but one failed to demonstrate the potential bene­
fit of surgery in IE post-TAVI patients,442,645,652,656,658 but the relatively 
small sample size of the studies and the multiplicity of potential con­
founders when comparing to those patients not receiving surgical treat­
ment precludes definite conclusions. The only study showing a 
beneficial effect of surgical intervention focused on those patients 
who had a local extension of the infection (i.e. abscess or fistula).442
The decision to proceed with surgery in IE post-TAVI patients should 
be individualized, balancing the surgical risks and the prognosis of med­
ical treatment alone. In cases with local extension of the infection, sur­
gery may be recommended in the absence of a prohibitive surgical risk. 
In cases with healed IE and valve prosthesis dysfunction, repeat trans­
catheter therapy (valve-in-valve procedure) can be performed in select 
patients.659 Such interventions should be performed at least 1–3 
months after the healed endocarditis episode and following a negative 
follow-up TOE.
12.3.2. Endocarditis following transcatheter 
pulmonary valve implantation
The incidence of IE post-transcatheter pulmonary valve implantation 
(TPVI) ranges from 1.6 to 4.0 per 100 patient-years,93,660–667 which 
seems to be higher than that reported following surgical pulmonary 
valve 
interventions 
(observational 
studies, 
no 
randomized 
data).662,663,667,668 While some studies suggest a higher risk associated 
with the use of bovine jugular vein valves,662,667,669 a recent large multi­
centre study including different transcatheter valve systems did not 
ESC Guidelines                                                                                                                                                                                          4001


<!-- PAGE 55 -->

### Page 55

observe differences between valve types.665 The most consistent fac­
tors associated with an increased risk of IE following TPVI have been 
younger age, a previous history of IE, and a higher transvalvular residual 
gradient.93,663,665
12.3.2.1. Diagnosis
The diagnosis of IE in TPVI recipients may be challenging, and the use of 
intracardiac echocardiography and [18F]FDG-PET/CT has been shown 
to be useful in cases with a clinical suspicion and negative TTE/ 
TOE.34,93,210,660,665,670 S. aureus and oral group streptococci species 
are the most common microorganisms causing IE post-TPVI.660,664–666
12.3.2.2. Prognosis and treatment
New moderate or severe prosthetic valve stenosis occurs much more 
frequently (one-third to one-half of patients) in post-TPVI PVE than in 
aortic PVE, and the rate of surgical valve replacement therapy ranges 
from 26% to 56%.93,660,661,664,665 The possibility of a transcatheter 
therapy (valve-in-valve intervention) for treating severe prosthesis dys­
function in cases with healed endocarditis or as an urgent treatment 
(balloon dilatation) in severe valve stenosis cases has also been re­
ported.660,665 A valve-in-valve intervention should be delayed at least 
1–3 months following antibiotic treatment of the endocarditis episode. 
The mortality rate related to the IE episode ranges from 0% to 
11%.93,660,661,664,665 This rate is much lower compared with TAVI pa­
tients, which is likely to be related to the younger and less co-morbid 
characteristics of the TPVI population.
12.4. Infective endocarditis affecting 
cardiac implantable electronic devices
Device-related infection is one of the most serious complications of 
CIED therapy and is associated with significant mortality and 
morbidity.671
12.4.1. Definitions of cardiac device infections
A recent EHRA consensus document has published criteria for CIED 
infection.130 Localized infections may be either superficial incisional in­
fections (acute infection without involvement of the pocket or hard­
ware) or isolated pocket infections (limited to the hardware in the 
pocket), and can be either acute or chronic. Systemic CIED infections 
may occur with or without pocket infection, and with or without visible 
vegetations on the tricuspid or pulmonary valves or pacing leads. 
Cardiovascular implanted electronic device-related IE is defined as evi­
dence of CIED infection with clinical signs of pocket infection and/or 
imaging findings (lead vegetations, positive FDG-PET on the gener­
ator/leads etc.) which fulfil the criteria for valvular IE (see Section 5).
12.4.2. Pathophysiology and microbiology
Cardiovascular implanted electronic device-related IE occurs by two 
mechanisms. Local infection usually results from bacterial flora from 
the patient’s skin that is introduced into the pocket at the time of inci­
sion despite surgical preparation.672 Seeding via bacteraemia from a dis­
tant focus is less frequent.673–676
Whereas CoNS are most frequently the cause of chronic pocket in­
fection, the most frequent agents identified with bacteraemia in CIED in­
fection are S. aureus and CoNS.677,678 Other causative organisms are 
Enterococcus spp., β-haemolytic streptococci, oral streptococci group, 
Cutibacterium acnes, and Corynebacterium spp.674,678,679 More rarely, sys­
temic infection is caused by Gram-negative (mainly P. aeruginosa or 
Serratia marcescens)680 or polymicrobial agents, whereas systemic fungal 
infections (Candida spp. and Aspergillus spp.)681 are exceptional.
12.4.3. Risk factors
Risk factors may be divided into patient-related, procedure-related, and 
device-related factors.118 The PADIT (Previous procedure on same 
pocket; Age; Depressed renal function; Immunocompromised; Type 
of procedure) study randomized 19 603 patients undergoing CIED im­
plantation to conventional treatment (pre-procedural cefazolin infu­
sion) vs. different regimens of incremental treatment.682 The primary 
outcome was 1-year hospitalization for device infection which was 
not significantly different between groups. A risk score for infection 
has been derived from the study (see Supplementary data online, 
Table S11)683 and has been validated externally.684 A web-based calcu­
lator is available (https://padit-calculator.ca).683
12.4.4. Prophylaxis
Antibiotic prophylaxis to prevent CIED-related IE before interventions, 
such as dental, respiratory, gastrointestinal, or genitourinary proce­
dures, is not warranted as the risk is very low.
Prevention of CIED infection at implantation hinges upon careful 
planning, pre-operative antibiotic prophylaxis, correction of modifiable 
risk factors, hygienic surgical environment and technique, ancillary mea­
sures in case of increased risk (e.g. use of an antibacterial envelope), and 
proper post-operative care.
Correction of modifiable risk factors includes general measures such 
as postponing the procedure in cases of fever or signs of infection and 
avoiding temporary pacing. Routine administration of prophylactic sys­
temic antibiotics within 1 h of incision is the standard of care.118 RCTs 
have used flucloxacillin (1–2 g i.v.)117 and first-generation cephalospor­
ins, such as cefazolin (1–2 g i.v.).116 Vancomycin (1–2 g over 60–90 min) 
may be used in case of allergy to cephalosporins with other alternatives, 
including teicoplanin and clindamycin.117 Coverage of MRSA should be 
guided by the prevalence in the implanting institution.
Haematoma is a major contributor to risk of infection, and all possible 
measures should be taken to avoid this complication.685,686 Another 
major risk factor is a revision with re-opening of the pocket (e.g. for 
lead repositioning). Technical aspects have recently been covered in de­
tail in an EHRA consensus document on CIED implantation.687
It is generally not recommended to wash the pocket with antibiotics, 
nor to administer antibiotic treatment post-operatively, as shown by 
the PADIT trial.682 An antibiotic mesh envelope, which locally releases 
minocycline and rifampin for a minimum of 7 days and is fully absorbed 
in ∼9 weeks, may, however, be useful to reduce risk of infection in se­
lected patients. The Worldwide Randomized Antibiotic Envelope 
Infection Prevention Trial (WRAP-IT) showed that the mesh envelope 
significantly reduces the incidence of CIED infection in patients at in­
creased risk (i.e. undergoing a pocket revision, generator replacement, 
system upgrade, or implantation of a cardiac resynchronization therapy 
[CRT]-implantable cardioverter defibrillator [ICD]).688 The number 
needed to treat was, however, high at 200, but is ∼50 in patients under­
going CRT reoperations (replacement/upgrade/revision) in a recent 
observational study.689
12.4.5. Diagnosis
Clinical presentation of CIED-associated IE is similar to valvular IE with 
patients frequently presenting with fever, chills, and embolic events. 
Signs of pocket infection (swelling, tenderness, erythema, purulent dis­
charge etc.) may or may not be present.
The probability that a positive blood culture in a CIED recipient re­
presents underlying device infection depends on the organism type and 
duration of bacteraemia. Suspicion of CIED-associated IE should be 
particularly high in the event of S. aureus bacteraemia.675 CIED infection 
is less likely with Gram-negative bacteraemia, and in these instances, the 
pocket usually shows signs of infection.680,690,691


<!-- PAGE 56 -->

### Page 56

Persistent/relapsing bacteraemia/fungaemia
Gram-negative
No vegetations and non-S. aureus
Vegetations and/or
S. aureus
Septic emboli or prosthetic valve
2 weeks of antibiotics
(Class IIb)
4 weeks of antibiotics
(Class IIa)
CIED reimplantationc
(Class I)
6 weeks of antibiotics
(Class IIa)
CIED extraction
Gram-positive or fungaemia
Antibiotic therapy covering MRSA
and Gram-negative bacteria
(Class I)
Suspicion of CIED-related IE
2023 ESC diagnostic criteria for IE
Repeat diagnostic tests within 7 days
Antimicrobial therapy
Bacteraemia/fungaemia without other major criteria or source of infection
Blood cultures
TTE and TOE (or intracardiac echocardiography)
[18F]FDG-PET/CT (or WBC SPECT)a
(Class I)
Possible IE
Definite IE
No IE
Cured
Probable isolated valve IEb
Definite CIED
involvement
(Class IIb)
(Class IIa)
(Class I)
Figure 13 Management of cardiovascular implanted electronic device-related infective endocarditis. [18F]FDG-PET/CT, 18F-fluorodeoxyglucose positron 
emission tomography/computed tomography; CIED, cardiovascular implanted electronic device; ESC, European Society of Cardiology; IE, infective endocar­
ditis; MRSA, methicillin-resistant S. aureus; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT/CT, white blood 
cell single photon emission tomography/computed tomography. aIf no signs of pocket infection and negative TOE. bTaking into account the identified patho­
gen, procedural risk, and requirement for valve surgery. cAt a distant site and postponed as long as possible (until signs and symptoms of infection have re­
solved and blood cultures are negative for >72 h in the absence of vegetations and /or ‘ghosts’, or otherwise after >2 weeks of negative blood cultures).
ESC Guidelines                                                                                                                                                                                          4003


<!-- PAGE 57 -->

### Page 57

Transthoracic echocardiography and TOE are both recommended 
in the case of suspected CIED-related IE.692–694 Intracardiac echocardi­
ography may also be used to visualize vegetations,695 and may be useful 
in patients in whom TOE is not possible. However, the absence of ve­
getations does not rule out IE, as these may be present on extracardiac 
segments of the lead which cannot be visualized. Repeating TTE and/or 
TOE within 5–7 days is recommended in case of initially negative exam­
ination when clinical suspicion of CIED-related IE remains high. It is im­
portant to note that fibrinous lead masses may be observed in 
asymptomatic CIED patients, and do not predict CIED-related IE 
over long-term follow-up.696
Diagnosis of CIED-related endocarditis by [18]FDG-PET/CT has 
good sensitivity and specificity,129 and is particularly useful in the setting 
of possible CIED-related IE without signs of pocket infection.238 Results 
should be interpreted with caution, however, if the CIED is recently im­
planted (<6 weeks).130
White blood cell SPECT/CT has also been used for diagnosing CIED 
infection but has limited availability.216,697 A chest X-ray or CT should 
be performed in all patients to evaluate the presence of pulmonary 
complications.
12.4.6. Antimicrobial therapy
Treatment of CIED infection involves early698,699 and complete removal of 
all parts of the system, combined with initial empirical antibiotic therapy 
directed at MRSA and Gram-negative bacteria, while awaiting identification 
of the pathogen.130,700,701 Antibiotic treatment follows the recommenda­
tions indicated in Section 7. In exceptional cases where complete device re­
moval is not possible, i.v. antibiotics for 4–6 weeks may be administered 
followed by close follow-up after interruption of antibiotic therapy or, al­
ternatively, individualized long-term suppressive oral therapy.
12.4.7. Device extraction
When CIED and lead extraction is required, such procedures should be 
performed in centres with the corresponding expertise. Complete 
CIED removal is recommended for all patients with confirmed infection 
of the lead(s), as conservative treatment is associated with increased mor­
tality.678,699 In patients with left-sided prosthetic heart valves and CIED in­
fection, complete CIED removal combined with prolonged (4–)6 week 
antibiotic therapy may prevent left-sided valve infection.130,702 Complete 
CIED extraction should also be considered in case of valvular IE without 
definite lead involvement, taking into account the identified pathogens 
(Staphylococcus spp. infections may be more prone to seed the 
CIED),673,675,676 procedural risk, and indication for valve surgery.
Complete device extraction should be considered even in the absence 
of vegetations in the setting of persistent or relapsing Gram-positive bac­
teraemia or fungaemia after a course of appropriate antibiotic therapy, if 
there is no other identified source (see Figure 13).681 In all instances of 
lead extraction, procedural risk should be carefully evaluated taking into ac­
count lead dwell time, pacemaker dependency, patient frailty, and other 
co-morbidities within the process of shared decision-making.703
Lead extraction should be performed, without delay (i.e. within the 
first days of admission), as this has been shown to be associated with 
improved outcomes.698,699,704 Percutaneous rather than surgical ex­
traction is the preferred procedure, but requires specialized tools 
and should be performed in centres with expertise in this technique 
and with onsite surgical backup, due to the risk of life-threatening tam­
ponade and vein laceration.
Large vegetations may be aspirated percutaneously before lead extrac­
tion to reduce risk associated with embolization.705 Surgical lead 
extraction should be considered in case of large vegetations (e.g. 
>20 mm)679 and if aspiration is not available or is unsuccessful. Surgical re­
moval is also the preferred technique if valve surgery is indicated. 
Hardware retrieved from extraction, especially the lead tip, should be cul­
tured.706 Sonication has been shown to increase diagnostic yield.707,708
12.4.8. Device reimplantation
The indication for reimplantation should always be carefully evaluated 
and no part of the removed CIED system should be reimplanted. 
Quality of evidence regarding timing of reimplantation is poor.709
Reimplantation should be performed at a site distant from that of the 
previous generator, and delayed until signs and symptoms of local 
and systemic infection have resolved and blood cultures are negative 
for at least 72 h after extraction in the absence of vegetations or 
‘ghosts’ (fibrous remnants after lead extraction, which have been asso­
ciated with death and reinfection),710 or after 2 weeks of negative blood 
cultures if vegetations were visualized.701,711
For patients with a high risk of sudden cardiac death, a wearable defib­
rillator is an option as a bridge to reimplantation. In pacemaker-dependent 
patients, an active-fixation lead may be introduced via the internal jugular 
vein and connected to an external pacemaker for up to 4–6 weeks, thereby 
preserving the contralateral side for definitive device reimplantation.712 As 
an alternative to delayed reimplantation in pacemaker-dependent patients, 
an epicardial pacemaker may be implanted before lead extraction, 
although this strategy has been associated with a higher risk of device 
re-intervention.713 Alternative devices such as leadless pacemakers714 or 
subcutaneous ICD715 may be implanted in selected patients if the risk of 
new infection is deemed high.
Recommendation Table 20 — Recommendations for 
cardiovascular implanted electronic device-related in­
fective endocarditis
Recommendations
Classa
Levelb
Antibiotic prophylaxis covering S. aureus is 
recommended for CIED implantation.118
I
A
TTE and TOE are both recommended in case of 
suspected CIED-related IE to identify 
vegetations.692–694
I
B
Complete system extraction without delay is 
recommended in patients with definite CIED-related 
IE under initial empirical antibiotic therapy.698,699
I
B
Obtaining at least three sets of blood cultures is 
recommended before prompt initiation of empirical 
antibiotic therapy for CIED infection,710 covering 
methicillin-resistant staphylococci and 
Gram-negative bacteria.
I
C
If CIED reimplantation is indicated after extraction 
for CIED-related IE, it is recommended to be 
performed at a site distant from the previous 
generator, as late as possible, once signs and 
symptoms of infection have abated and until blood 
cultures are negative for at least 72 h in the absence 
of vegetations, and negative for at least 2 weeks if 
vegetations were visualized.701,711
I
C
Continued


<!-- PAGE 58 -->

### Page 58

12.5. Infective endocarditis in patients 
admitted to intensive care units
Infective endocarditis is frequently associated with severe life-threatening 
cardiac and/or systemic complications and the number of patients requir­
ing intensive care unit (ICU) admission has steadily been growing in recent 
years, as shown in a large retrospective study.716 The need for ICU admis­
sion, advanced monitoring, vasoactive treatment, and organ support is 
most commonly prompted by the occurrence of septic shock, acute HF, 
and cardiogenic shock leading to multiorgan failure. Moreover, in recent 
years, an increase in healthcare-associated IE, usually of staphylococcal ori­
gin, predominantly in older patients with an increased number of co- 
morbidities, and more likely to lead to critical illness, has also been re­
ported.29,717–719Any IE patient requiring ICU admission should be urgently 
discussed within the Endocarditis Team.
In the largest multicentre retrospective series, focusing on critically 
ill IE patients with organ failure requiring ICU admission in France over 
an 18-year period, overall in-hospital mortality was 32%.716
Multivariate analysis showed age, Simplified Acute Physiology Score 
(SAPS) II score, organ failure, stroke, and Staphylococcus spp. to be as­
sociated with an increased risk of death. In contrast, cardiac surgery, 
CIED, male gender, and Streptococcus spp. as the causative micro­
organism of IE, were associated with a better survival.716 In another 
study that reported an even higher mortality (42%), four independent 
prognostic factors were identified: high SAPS II (>35 points) and 
Sequential Organ Failure Assessment (>8 points) scores, MRSA infec­
tion, and native valve IE.718
Right-sided IE, which is more commonly associated with PWID, ac­
counts for <10% of IE cases but is associated with high mortality in pa­
tients needing ICU admission.717
12.5.1. Causative microorganisms
The majority of retrospective series in the ICU setting point to 
Staphylococcus spp. as the main causative agent of IE episodes. Indeed, 
S. aureus has emerged as the most feared aetiological agent with the 
highest rates of complications and mortality, being responsible for up 
to 56% of IE cases in one observational study.719 Streptococcus spp., 
Enterococcus spp., Gram-negative bacilli, and Candida spp. are less fre­
quently reported.718,719 Identification of the infecting microorganism 
remains the mainstay of effective therapy in complicated IE cases. 
Hence, in patients with negative blood cultures, serological or molecu­
lar testing by PCR should be considered (see Section 5.3).
12.5.2. Diagnosis
The diverse nature, epidemiological profile, and presentation pheno­
type of IE in the ICU setting may hinder early diagnosis. In particular, 
pyrexial episodes suggestive of an alternative infective source and 
neurological manifestations, such as confusion, delirium, or focal symp­
toms may initially mislead the clinician from a diagnosis of IE.
The diagnosis of IE in ICUs follows the same modified criteria as in 
non-ICU patients (see Section 5). Transoesophageal echocardiography 
has a prominent role as a tool for diagnosis of IE and its complications in 
the ICU.720
12.5.3. Management
Antimicrobial therapy and indications for surgery in patients with IE are 
described in Sections 7 and 10, respectively. Surgical therapy has been 
associated with an improved early and late outcome both in the general 
population and in patients admitted to ICUs. Although surgery is the 
treatment of choice in about one-half of patients, surgical therapy in 
ICU patients is characterized by more complex procedures with in­
creased peri-operative mortality, as well as difficult post-operative 
care due to higher requirements of circulatory and pulmonary support. 
Five independent predictors of post-operative need for advanced circu­
latory support were found in one study of patients with IE: male sex, 
increased surgery duration, renal dysfunction (pre-operative estimated 
glomerular filtration <60 mL/min/m2), HF prior to surgery, and lower 
pre-operative platelet count.721
Extracorporeal membrane oxygenation is occasionally required in 
patients post-surgery but is associated with poor outcomes.722
Decision-making in ICU patients with IE should always be a product of 
consensus of the Endocarditis Team to determine the best management 
strategy. Pre-operative haemodynamic optimization and goal-directed 
therapy protocols including vasoactive drugs and mechanical circulatory 
support may be considered in these complex high-risk patients.721
12.6. Right-sided infective endocarditis
Right-sided IE accounts for ∼5–10% of patients with IE,723 but its fre­
quency may be increasing as its risk factors are increasing in some coun­
tries.133,724 Risk factors for right-sided IE include patients with CHD, 
indwelling catheters, and CIED, as well as immunocompromised and 
PWID patients. Of these, PWID is an increasingly common risk 
Complete CIED extraction should be considered in 
case of valvular IE, even without definite lead 
involvement, taking into account the identified 
pathogen and requirement for valve surgery.
IIa
C
In cases of possible CIED-related IE with occult 
Gram-positive bacteraemia or fungaemia, complete 
system removal should be considered in case 
bacteraemia/fungaemia persists after a course of 
antimicrobial therapy.673–676
IIa
C
Extension of antibiotic treatment of CIED-related 
endocarditis to (4–6) weeks following device 
extraction should be considered in the presence of 
septic emboli or prosthetic valves.702
IIa
C
Use of an antibiotic envelope may be considered in 
select high-risk patients undergoing CIED 
reimplantation to reduce risk of infection.688,689
IIb
B
In cases of possible CIED-related IE with occult 
Gram-negative bacteraemia, complete system 
removal may be considered in case of persistent/ 
relapsing bacteraemia after a course of antimicrobial 
therapy.680,690,691
IIb
C
In non-S. aureus CIED-related endocarditis without 
valve involvement or lead vegetations, and if 
follow-up blood cultures are negative without septic 
emboli, 2 weeks of antibiotic treatment may be 
considered following device extraction.
IIb
C
Removal of CIED after a single positive blood culture, 
with no other clinical evidence of infection, is not 
recommended.675
III
C
© ESC 2023
CIED, cardiovascular implanted electronic device; IE, infective endocarditis; TOE, 
transoesophageal echocardiography; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4005


<!-- PAGE 59 -->

### Page 59

factor,133,723 while patients with indwelling vascular catheters have the 
worst prognosis.725 IE of transcatheter pulmonary valves is covered in 
Section 12.2, whereas CIED-related right-sided IE is covered in Section 12.3.
The most common microorganism causing right-sided IE is S. aureus, 
accounting for the majority of patients.723,726 The tricuspid valve is 
much more commonly infected than the pulmonary valve in patients 
with right-sided IE.723,727 Right-sided IE may also involve non-functional 
embryonic remnants of the right atrium (e.g. Eustachian valve).723,727
Right-sided IE rarely spreads to involve the left-sided cardiac structures, 
whereas spread from left- to right-sided structures is not 
uncommon.728
12.6.1. Diagnosis and complications
Right-sided IE patients present with fever, bacteraemia, and pulmonary 
complaints (i.e. cough, chest pain, or haemoptysis). Right-sided HF may 
also occur due to tricuspid or pulmonary regurgitation, or to pulmon­
ary hypertension induced by multiple pulmonary septic emboli.133
Diagnosis is most frequently confirmed by echocardiographic findings of 
vegetations on the tricuspid valve or, less frequently, pulmonary valve. 
Adequate evaluation of the tricuspid valve may be performed with TTE, 
due to the anterior location of the valve and the large vegetations frequent­
ly observed in right-sided IE. Transoesophageal echocardiography is fre­
quently required, however, particularly for evaluation of the pulmonary 
valve or in patients with indwelling venous catheters or intracardiac de­
vices.729 Intracardiac echocardiography may also be helpful in select pa­
tients. Vegetations may be challenging to identify on the pulmonary valve 
even with TOE, especially in patients with a prosthetic valve in the pulmon­
ary position. [18]FDG-PET imaging may be very helpful in such pa­
tients.34,730 Perivalvular abscess formation and invasion into surrounding 
structures is rarely seen in right-sided IE, unless it is a secondary conse­
quence of left-sided IE.728 CT is useful in order to identify concomitant pul­
monary disease, including infarcts and abscess formation.
12.6.2. Endocarditis in people who inject drugs
Infective endocarditis in PWID is an increasing global phenom­
enon.10,132,133,141 Repeat i.v. injections result in contaminated particles 
that reach the tricuspid valve and right-heart chambers and can also 
lead to infection of left-heart structures, which is associated with worse 
prognosis.614 PWID patients also have an increased rate of human 
immunodeficiency virus (HIV) and hepatitis than other patients with 
right-sided IE.731 The majority of right-sided IE in PWID can be treated 
successfully with antibiotic therapy. Mortality rates of PWID are rela­
tively low, even when surgery is required, probably due to the young 
patient age.723 However, PWID have a markedly increased rate of IE 
recurrence, particularly in the first 6 months post-surgery.133,614,723,732
12.6.3. Prognosis and treatment
Right-sided IE is generally a more benign clinical entity than left-sided IE 
and can be medically managed in ∼90% of patients, with surgery re­
served for those who fail medical therapy.733
Patients with 
CIED-related right-sided IE have a worse prognosis as compared 
with non-CIED-related right-sided IE (see Section 12.4).723
725
Right-sided IE in immunocompromised patients, particularly fungal in­
fections, carries a very poor prognosis.
12.6.3.1. Antimicrobial therapy
S. aureus and CoNS are the cause of right-sided IE in a large proportion 
of cases, with S. aureus predominating in PWID and CoNS being more 
common in patients with indwelling devices.723,726 MRSA rates may be 
increasing over time, particularly in PWID.133 Right-sided IE due to 
Streptococcus spp. is unusual but can be observed in alcoholics and dia­
betics. P. aeruginosa and other Gram-negative organisms are rare causes 
of right-sided IE, while Candida albicans is mostly seen in immunocom­
promised patients.
Empirical antimicrobial therapy depends on the suspected micro­
organism, the type of drug and solvent used by the PWID, and the in­
fection location,734 but S. aureus must be initially covered in all cases. 
Initial treatment consists of penicillinase-resistant penicillin, vancomy­
cin, or daptomycin, depending on the local prevalence of MRSA,735 in 
combination with gentamicin. If the patient is a pentazocine addict, an 
anti-Pseudomonas agent may also be required, as the use of recreational 
drugs may also entail infections with Gram-negative bacteria.735 Very 
large vegetations and history of brown heroin use dissolved in lemon 
juice suggest infection for Candida spp. (not C. albicans), and therefore 
antifungal treatment should be added.736 Antifungals may be necessary 
in selected PWID, particularly if immunocompromised.737
Once the causative organisms have been isolated, therapy has to be 
adjusted. An RCT demonstrated that a 2-week treatment course may 
be sufficient and that aminoglycosides may be unnecessary.738 717
Two-week treatment with oxacillin (or cloxacillin) without gentamicin 
is effective when: 
(i) MSSA is the causative organism;
(ii) There is good clinical and microbiological response to treatment 
(>96 h);739
(iii) The vegetation size is ≤20 mm; and
(iv) There is an absence of metastatic sites of infection or empyema 
and cardiac or extracardiac complications,739,740 prosthetic valve 
or left-sided valve infection,741 and severe immunosuppression.742
Glycopeptides (vancomycin) should not be used in a 2-week treatment. 
The standard 4–6-week regimen should be used in the remaining patients 
or when therapy with antibiotics other than penicillinase-resistant penicil­
lins are used.330,739–744 When the conventional i.v. route therapy is not 
possible, S. aureus right-sided IE in PWID may also be treated with oral ci­
profloxacin (750 mg twice a day) plus rifampin (300 mg twice a day) if the 
strain is susceptible to both drugs, the case is uncomplicated, and patient 
adherence is monitored carefully.745 Partial oral antibiotic treatment 
may also be beneficial for PWID with IE.746
For organisms other than S. aureus, therapy in PWID does not differ 
from that in other patients.
12.6.3.2. Surgery
The commonly accepted indications for surgical treatment of right- 
sided IE in patients who are receiving appropriate antibiotic therapy 
are (see Recommendation Table 19): 
• Persistent bacteraemia after at least 1 week of appropriate antibiotic 
therapy.10
• Tight ventricular dysfunction secondary to acute severe tricuspid re­
gurgitation non-responsive to diuretics.479
• Respiratory insufficiency requiring ventilatory support after recur­
rent pulmonary emboli.747
• Involvement of left-sided structures;748,749 and
• Large residual tricuspid vegetations (>20 mm) after recurrent pul­
monary emboli.145,471
Patients should be individually assessed by the Endocarditis Team. An 
isolated vegetation is not an indication for surgery. Patients with


<!-- PAGE 60 -->

### Page 60

residual large vegetations frequently present with right-heart and/or re­
spiratory failure, as well as persistent sepsis.750
The common surgical strategies for tricuspid valve IE include valve re­
pair, replacement and, less commonly, surgical valvectomy.751 Tricuspid 
valve repair is more frequently performed than valve replacement in 
right-sided IE, although the extent of valve destruction may make repair 
impossible.725,752 Tricuspid valve repair may also be associated with 
better short- and long-term outcomes than replacement for right-sided 
IE, particularly with regards to recurrent infection and need for repeat 
surgery.479,723
When valve replacement for right-sided IE is required, bioprostheses 
are frequently preferred due to concerns with the management and 
risks of lifelong anticoagulation, especially in PWID, and the risks of 
thrombo-embolism for mechanical valves in the right heart.726
Prophylactic placement of permanent epicardial leads should be per­
formed at the time of tricuspid valve surgery for right-sided IE, particu­
larly if heart block is present in the operating room to prevent damage 
of a replaced valve during subsequent transvenous lead displacement 
and to lower the risk of reinfection.733
Recently, interest has been generated in the extraction of large vege­
tations using percutaneous extracorporeal circuitry for aspiration.753
The main goals have been debulking of septic intracardiac masses, redu­
cing the infectious load, and achieving clinical stability.754
12.7. Infective endocarditis in congenital 
heart disease
Although the incidence of CHD is relatively constant, the overall popu­
lation with CHD is constantly increasing due to increased survival fol­
lowing CHD surgery in childhood and increased longevity of adults 
with CHD. The presence of CHD, even after repair, is recognized as 
a lifelong potential substrate for IE. Congenital heart disease predis­
poses to IE via several mechanisms including turbulent non-laminar 
blood flow causing shear stress and endothelial damage, the presence 
of intracardiac foreign material such as prosthetic valves or CIED, cyan­
osis, and recurrent exposure to cardiac procedures.98
There are marked variations in susceptibility to IE between CHD 
lesions. Some simple conditions, such as secundum atrial septal defect, 
patent ductus arteriosus, and pulmonary valve stenosis, carry a low risk 
of IE, while others, such as bicuspid aortic valve carry a somewhat 
increased risk.8 However, CHD often presents with multiple cardiac 
lesions, each adding to the total risk of IE.8,756 In general terms, IE is 
more common in CHD with multiple defects and in patients with 
more complex CHD.757
Specific high-risk conditions are prosthetic valves, including transcath­
eter valves, valve repair using a prosthetic ring, previous IE, any unre­
paired cyanotic CHD, and any CHD repaired with prosthetic material 
for up to 6 months after the procedure, or lifelong if residual shunt or 
valvar regurgitation remains.758 Contemporary studies confirm the rela­
tively high risk of IE in CHD patients after valve surgery.8,47,90,759 Specific 
awareness is needed after TPVI (see Section 12.3.2).666,759,760
The distribution of causative microorganisms does not differ from 
the pattern found in acquired heart disease, with Streptococcus spp. 
and Staphylococcus spp. being the most common strains.98,757,761,762
As in other groups, the diagnosis of IE is often made late,757 highlighting 
the need to consider the diagnosis of IE in any CHD patient presenting 
with persisting fever or other signs of ongoing infection. Multiple blood 
cultures are essential before starting antibiotic treatment. The principal 
symptoms, complications, and basis for diagnosis do not differ from IE 
in general. However, in CHD right-sided IE is more frequent than in 
non-CHD-acquired cardiac disease.
Transthoracic echocardiography is sufficient in many cases to image 
the infectious lesions and their complications. However, complex anat­
omy and the presence of artificial material may reduce the rate of vege­
tation detection and other features of IE, thus favouring the addition of 
TOE, particularly in adults and larger children. Despite the improved 
sensitivity of TOE for the detection of IE, TOE may only perform simi­
larly to TTE for anterior structures of the heart, such as the right ven­
tricular outflow tract, or infected sites at distal structures, such as stents 
or other prosthetic material within branch pulmonary arteries. Hence, 
a negative study does not exclude the diagnosis of IE. In patients with 
prosthetic material advanced imaging such as [18F]FDG-PET/CT and 
PET/CTA, can increase the diagnostic accuracy.223
In addition to the usual Endocarditis Team (see Section 4), multidis­
ciplinary care of CHD patients with IE from diagnosis to treatment 
should be provided in specialized CHD centres with expertise in 
CHD cardiac imaging, CHD surgery, infectious disease, and intensive 
care. Surgical indications do not differ from those of acquired heart dis­
ease IE. Mortality rates in CHD vary from 6% to 15%.757,761–764 This 
better prognosis compared with acquired heart disease IE may reflect 
the higher proportion of right-heart IE, younger overall patient age, or 
the comprehensive care in CHD centres.
Primary prevention of IE in CHD patients and corresponding patient 
education is essential (see Section 3).765
Recommendation Table 21 — Recommendations for 
the 
surgical 
treatment 
of 
right-sided 
infective 
endocarditis
Recommendations
Classa
Levelb
Surgery is recommended in patients with right-sided IE who are receiving 
appropriate antibiotic therapy for the following scenarios:
Right ventricular dysfunction secondary to acute 
severe tricuspid regurgitation non-responsive to 
diuretics.479
I
B
Persistent vegetation with respiratory insufficiency 
requiring ventilatory support after recurrent 
pulmonary emboli.479,755
I
B
Large residual tricuspid vegetations (>20 mm) 
after recurrent septic pulmonary emboli.145,471
I
C
Patients with simultaneous involvement of 
left-heart structures.749
I
C
Tricuspid valve repair should be considered instead 
of valve replacement, when possible.479
IIa
B
Surgery should be considered in patients with 
right-sided IE who are receiving appropriate 
antibiotic therapy and present persistent 
bacteraemia/sepsis after at least 1 week of 
appropriate antibiotic therapy.436,755
IIa
C
Prophylactic placement of an epicardial pacing lead 
should be considered at the time of tricuspid valve 
surgical procedures.733
IIa
C
Debulking of right intra-atrial septic masses by 
aspiration may be considered in selected patients 
who are high risk for surgery.753
IIb
C
© ESC 2023
IE: infective endocarditis. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4007


<!-- PAGE 61 -->

### Page 61

12.8. Infective endocarditis in rheumatic 
heart disease
Infective endocarditis is a known complication of RHD,766 and acute 
rheumatic fever (the antecedent of RHD) may even present with con­
comitant IE.767 Of the 3343 participants enrolled in The Global 
Rheumatic Heart Disease Registry (REMEDY),768 133 (2.4%) had a his­
tory of IE at enrolment,769 and 20 (0.7%; 3.65 per 1000 patient-years) 
developed IE during the 27-month follow-up.770 These participants 
were young with a median age of 28 years (interquartile range 18–40 
years), 66.2% were women, and over 30% were children. The majority 
of the over 40 million patients with RHD771 live in low- and 
middle-income countries and face socioeconomic and health-system 
barriers772 to adequate prevention, early diagnosis, and advanced 
care and, therefore, are at particular risk of IE.773
Global access to surgery for RHD and RHD-associated complications 
is extremely limited.774 RHD patients presenting with fever, changing or 
new murmurs should be investigated for IE. In studies from RHD- 
endemic regions, RHD is the most common underlying cardiac condition, 
with significant mortality and morbidity.775–784 In those affected with oral 
bacteria-related IE linked to RHD, oral Streptococcus spp. was the main 
cause of IE associated with poor oral health status.785 In RHD-endemic 
countries, IE in children is strongly linked to RHD,786–788 and when caus­
ing HF, carries the highest case fatality rate.789 IE is associated with en­
hanced risk of death among patients with RHD undergoing isolated 
mitral valve replacement (odds ratio 5.22, 95% confidence interval 
[CI], 1368–19 915; P = 0.008).790 Pregnancy is a particularly high-risk 
period for women with RHD, with an increased risk of developing 
IE.791,792 However, high-income countries or countries with emerging 
economies are seeing less IE linked to RHD, as the incidence rates of 
RHD in these regions decrease.793–796
12.9. Infective endocarditis during 
pregnancy
Infective endocarditis in pregnancy is a rare but extremely serious con­
dition with high maternal and foetal morbidity and mortality, and is es­
timated to complicate ∼1 in 100 000 pregnancies.797–799 Maternal 
mortality approaches 18%, with most deaths relating to HF or an em­
bolic event, while pre-term birth is reported at 55.7% and foetal mor­
tality at 29%.800 Recurrent infective complications can occur in up to 
27% of women post-partum.801
The diagnosis must be considered in pregnant women with unex­
plained fever and cardiac signs (especially tachycardia), new or changing 
cardiac murmurs, and peripheral signs of septic emboli.802 Women with 
CHD, RHD,803 and structural heart disease, together with those with 
prosthetic heart valves and with PWID are at particular risk.800,804–807
The gravity of the condition requires the inclusion of gynaecologists, obste­
tricians, and neonatologists in the Endocarditis Team in any suspected cases, 
and a diagnosis and treatment plan should be formulated without delay, as 
this is key to saving the lives of mothers and infants.799,808,809 Management 
can be challenging, especially when the pregnant patient warrants a cardiac 
operation under CPB. Although this poses a considerable risk to the foetus, 
urgent surgery when indicated should not be delayed.799,810
12.10. Infective endocarditis in 
immunocompromised patients
12.10.1. Solid organ transplant recipients
The incidence of IE in recipients of solid organ transplantation (SOT) 
ranges between 1% and 2%.107 SOT recipients with IE are younger 
and have higher prevalence of co-morbidities (particularly renal and 
liver disease) compared with non-SOT patients with IE. Among the 
SOT patients with IE, the most common transplanted organ is the 
kidney (72%), followed by liver (17%), and pancreas (8%).811 Similar 
to non-SOT patients, aortic followed by mitral IE are the most common 
forms of IE while right-sided IE is uncommon. Interestingly, SOT pa­
tients with IE more frequently have atrial or ventricular vegetations 
without 
valve 
involvement 
(mural 
IE).107
In-hospital 
and 
healthcare-related IE are the most frequent causes of IE in recipients 
of SOT and the most frequent microorganism involved is S. aureus 
(34%), followed by Enterococcus spp. (17%), and Streptococcus spp. 
(11%).107,811
Surgical valve repair/replacement is less frequently performed in SOT 
patients with IE as compared with non-SOT patients. Interestingly, the 
outcomes of IE in patients with SOT do not differ from those of 
non-SOT with IE.107,811 The reasons for the similar outcomes may 
rely on the younger age of the SOT patients, the frequent contact 
with the healthcare system which may lead to early diagnosis and treat­
ment of IE, and the frequent involvement of infectious disease specialists 
in the care of hospitalized SOT patients. However, compared with SOT 
patients without IE, those who develop IE during the index transplant 
hospitalization have worse outcomes.811 The high levels of immunosup­
pression probably negatively impact the IE course in these patients.
Heart transplant recipients represent 10% of SOT with IE pa­
tients.811 Among 57 heart transplant recipients who developed IE, 
the most frequent organism was S. aureus (26%), followed by A. fumiga­
tus (19%), and E. faecalis (12%).105 The median time to IE presentation 
after heart transplant was 8 years and the mitral valve was the most fre­
quently affected, followed by mural and tricuspid valve IE. All-cause 
mortality in this group of patients is high (45%), and fungal aetiology 
is associated with worse outcomes. Similar to other SOT recipients, 
heart transplant recipients were not frequently referred to surgery 
(35%).105
12.10.2. Patients with human immunodeficiency virus
The advent of combined antiretroviral treatment has led to a reduction 
in the risk of developing acquired immune deficiency syndrome (AIDS) 
but people living with HIV remain a vulnerable population for IE.812 The 
incidence of IE in people living with HIV has decreased over the last two 
decades. A retrospective study from Spain has shown a reduction in the 
incidence of IE from 18.2 per 100 000 patient-years between 1997 and 
1999 to 2.9 events per 100 000 patient-years between 2000 and 
2014.813 Similarly, a registry from the United States of America 
reported a reduction in the incidence of IE from 148 in 2007 to 112 
in 2017.141 Patients living with HIV and presenting with IE are becoming 
older, and have a higher percentage of substance abuse and co- 
morbidities.141,813 Of importance, the number of patients living with 
HIV who are admitted with IE have higher frequency of CHD, prior 
valve surgery, CIED infection, and haemodialysis.141,813 The most fre­
quent microorganisms causing IE are Staphylococcus spp. (the majority 
of which is S. aureus), followed by Streptococcus spp., Gram-negative 
bacilli, and enterococci. It is important to note that over the last two 
decades, the frequency of CoNS as a cause of IE has decreased whereas 
the frequency of streptococci, Gram-negative bacilli, enterococci, and 
fungus has increased.813 Community-acquired IE has become the 
most frequent form while healthcare-associated IE rates have signifi­
cantly decreased over time.
The outcomes of IE in people living with HIV have improved over the 
years (from 23.9 to 5.5 deaths per 100 000 patient-years) and surgical


<!-- PAGE 62 -->

### Page 62

treatment should follow the same indications as in patients without 
HIV.813
12.10.3. Patients with neutropaenia
Neutropaenia is common in patients with haematological malignan­
cies and in patients receiving chemotherapy for other malignancies, 
but is rare in patients presenting with IE.814 Neutrophils play an im­
portant role in the pathogenesis of IE by producing layers of extracel­
lular traps that entrap bacteria-platelet aggregates, leading to 
expansion of these aggregates, vegetation growth, and the destruction 
of tissues.814 The diagnosis of IE can therefore be challenging in pa­
tients with neutropaenia, delaying the appropriate treatment, and 
worsening outcomes. Series reporting the clinical characteristics 
and outcomes of IE in patients with neutropaenia are anecdotal.814
As in any other immunocompromised patient with IE, antibiotic and 
surgical treatment are the same as in patients without neutropaenia. 
It is important to take into consideration the side effects of some anti­
biotics which may worsen the neutropaenia, such as cloxacillin and 
ceftaroline.815,816
12.11. Antithrombotic and anticoagulant 
therapy in infective endocarditis
Infective endocarditis by itself is not an indication for antithrombotics 
or anticoagulants, and bleeding complications or stroke may in contrast 
justify discontinuation or interruption of such therapies. Indications for 
antithrombotic therapy or anticoagulants (e.g. atrial fibrillation, valve 
prostheses, ischaemic heart disease, prior stroke, etc.) are prevalent 
in the general population and, as a result, the clinician is often faced 
with the challenge of these therapies in patients presenting with IE, es­
pecially in cases where surgery is part of the treatment course. For pa­
tients with IE and stroke, thrombolytic therapy is not recommended 
(see Section 9.1). However, thrombectomy may be considered in se­
lected cases with large vessel occlusion.
The level of evidence underlying the recommendations for 
antithrombotic and anticoagulant therapy in IE is low and should 
be discussed within the Endocarditis Team. Bridging with low- 
molecular-weight heparin/unfractionated heparin instead of oral antic­
oagulants should be considered early on in the IE course, especially for 
patients in whom surgery is indicated. To date, no data support initi­
ation of either antithrombotics nor anticoagulants for treatment or 
prevention of stroke in IE.
12.12. Non-bacterial thrombotic 
endocarditis
Non-bacterial thrombotic endocarditis (NBTE) is a rare condition with 
an incidence varying from 1.1% to 1.6% in patient-series from autopsy 
studies.818,819 Non-bacterial thrombotic endocarditis occurs in patients 
with a predisposing factor and/or a hypercoagulable state, such as sys­
temic lupus erythematous (SLE), APLs (Libman–Sacks endocarditis), 
cancer (marantic endocarditis), disseminated intravascular coagulation 
(DIC), or various other chronic diseases (tuberculosis or autoimmune 
disease).820,821 Increased production of coagulation factors, of cyto­
kines, and high tissue factor expression are potential mechanisms 
underlying NBTE in cancer patients.822
In a recent contemporary registry, 41% of NBTE patients had cancer, 
33% SLE, and 36% APLs, with 21% of patients having both SLE and 
APLs.823 Among the patients with malignancies, the three most fre­
quent cancers were lung adenocarcinoma, breast, and pancreatic can­
cer. Stroke was the most frequent clinical presentation at admission 
(60%), while HF was observed in 21% and acute coronary syndrome 
in 7% of patients. Transthoracic echocardiography was able to confirm 
the diagnosis in 45% of patients. The mitral valve was more often af­
fected (62%) than the aortic valve (24%).823
The diagnosis of NBTE remains challenging and should be suspected 
in patients presenting with systemic embolization and a predisposing 
factor (i.e. cancer, APLs, SLE). Laboratory findings of a hypercoagulable 
state (eg. lupus anticoagulant, anti-cardiolipin antibodies, and 
anti-β2-glycoprotein 1 antibodies or DIC) may be present, but are non- 
specific and may also be demonstrated in other IE patients with embolic 
events.162
Echocardiography diagnosis should attempt to differentiate 
non-bacterial thrombotic vegetation from IE, Lambl excrescences, or 
fibroelastoma, or other benign intracardiac masses/tumours.824
Libman–Sacks vegetations may present with various shapes (sessile, 
tubular, or coalescent), various levels of echogenicity (heterogeneously 
or homogeneously), could be nodular or protuberant, are generally lo­
cated near the leaflet’s edge of coaptation, and frequently have exten­
sions to the mid and basal portions of the leaflet. They are rarely 
associated with valve dysfunction and never with valve perforation, 
which is an important method of differentiating from bacterial IE.824
Compared with TOE, TTE has a lower sensitivity (63%), specificity 
(58%), negative predictive value (40%), and a moderate positive predict­
ive value (78%) for the detection of NBTE.823,824 Compared with 
two-dimensional TOE, three-dimensional TOE provides additional in­
formation and allows a better characterization of the vegetation.823
The treatment of the underlying cause (i.e. SLE or cancer) is crucial to 
prevent recurrent NBTE. Anticoagulant treatment should be consid­
ered in all patients and should be balanced against the individual 
Recommendation Table 22 — Recommendations for 
the use of antithrombotic therapy in infective 
endocarditis
Recommendation
Classa
Levelb
Interruption of antiplatelet or anticoagulant therapy 
is recommended in the presence of major bleeding 
(including intracranial haemorrhage).482,483
I
C
In patients with intracranial haemorrhage and a 
mechanical valve, reinitiating unfractionated heparin 
should be considered as soon as possible following 
multidisciplinary discussion.817
IIa
C
Continued
In the absence of stroke, replacement of oral 
anticoagulant therapy by unfractionated heparin 
under close monitoring should be considered in 
cases where indication for surgery is likely (e.g. S. 
aureus IE).451,817
IIa
C
Thrombolytic therapy is not recommended in 
patients with IE.481,491
III
C
© ESC 2023
IE, infective endocarditis. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4009


<!-- PAGE 63 -->

### Page 63

patient’s bleeding risk.821 Patients may be anticoagulated with 
low-molecular-weight heparin, vitamin K antagonists, or unfractionated 
heparin. There are no data to support the use of direct oral 
anticoagulants in NBTE. In a randomized open-label multicentre study 
comparing rivaroxaban and warfarin in patients with thrombotic APLs, 
the use of rivaroxaban was associated with an increased rate of 
thrombo-embolic events and major bleeding.825 The role of surgery 
is controversial and remains to be clarified. However, surgery should 
be considered in patients with severe valve dysfunction or with large 
vegetations.823
12.13. Infective endocarditis and 
malignancy
There are limited data on the prevalence, clinical presentation, manage­
ment, and outcome of IE in patients with malignancy. In a retrospective 
Japanese cohort study including 170 patients, 17.6% had active malig­
nancy.826 Compared with patients without malignancy, patients with 
malignancies were older, nosocomial IE was more frequent, and proce­
dures before IE (non-dental, i.v. catheter insertion, invasive endoscopic, 
or genitourinary procedures) were more frequent.826 Another recent 
study from the EURO-ENDO registry of 3085 patients with IE found a 
history of malignancy in 11.6% of patients.827 Patients with a history of 
malignancy had a similar rate of theoretical indications for surgery, but 
surgery was performed less often in this group. Mortality was higher in 
the malignancy group with independent predictors for mortality being 
elevated creatinine >2 mg/dL, congestive HF, and unperformed cardiac 
surgery when indicated.827 In IE patients with concomitant cancer, indi­
cations for valve surgery should be discussed within the Endocarditis 
Team, including a cardio-oncologist and the oncologist in charge of 
the patient, in order to take into account the risks and benefits of sur­
gery and cancer prognosis.
13. Patient-centred care and 
shared decision-making in infective 
endocarditis
13.1. What is patient-centred care and 
shared decision-making and why is it 
important?
Patient-centred care encourages involvement and collaboration be­
tween patients, families, and healthcare providers during all stages of 
diagnosis, treatment, and recovery.828–831 Core elements of patient- 
centred care include: involvement of family and caregivers, respect 
for patients’ preferences and values, care co-ordination and continuity, 
information and education, as well as physical comfort and emotional 
support (Figure 14).828–830
Shared decision-making involves a bidirectional process where pa­
tients, family, and healthcare providers share information and discuss 
care options in the context of the patients’ preferences, beliefs and va­
lues, and the best available evidence ensuring that the patient under­
stands the risks,832,833 benefits, and possible consequences of the 
different options.834–836 The majority of patients prefer sharing deci­
sions about their own health, if they are sufficiently informed and pre­
pared.837,838 Patient-centred care and shared decision-making have 
been shown to contribute to improved concordance between care 
providers and patients on treatment plans, as well as increased patient 
satisfaction, quality of life, and health outcomes.830,839–843
13.2. Patient-centred care and shared 
decision-making in infective endocarditis
The severity of IE, the complex and comprehensive diagnostics and 
treatment, as well as the long illness trajectory, put special emphasis 
on patient-centred care and shared decision-making in IE (Figure 14). 
Quality of life appears to be impaired in IE survivors, with a significant 
number of patients developing symptoms of anxiety, depression, or 
even post-traumatic stress disorder following IE treatment.604,844
The time of diagnosis is often emotionally distressing to the patient 
and family, as they face a life-threatening condition and lengthy 
treatment.845
During the diagnostic and active treatment phase, healthcare provi­
ders should make every effort to minimize patient discomfort (e.g. re­
lated to symptoms and diagnostic procedures), and alleviate distress in 
both patient and family by providing support and comprehensive and 
timely information about the patient’s condition, therapeutic options, 
and prognosis. Independent of the therapeutic strategy (i.e. surgical 
vs. conservative), patient-centred care is key to ensure a good physical 
and mental outcome during a lengthy treatment and hospitalization as­
sociated with IE. Maintaining continuity of care, when possible, by min­
imizing the number of providers the patient encounters and minimizing 
transfers between and within units, is all part of a patient-centred care 
approach. Allowing family visits at any time and providing the opportun­
ity to uphold personal integrity and autonomy are important issues for 
patients. National patient organizations and associations may be an op­
tion for offering information and support to patients and their families.
The role of outpatient antimicrobial treatment options in IE should 
be discussed using a shared decision-making approach, involving the pa­
tient’s partner or family if possible. The outpatient treatment should be 
in concordance with the patient’s and family’s preferences, also consid­
ering transportation and self-care abilities. To monitor possible compli­
cations, it is important to inform and educate patients and caregivers 
about the signs and symptoms of disease progression or recurrence.
The early period after discharge can be challenging for patients and their 
families, and patients report slow physical and mental recovery after IE, of­
ten extending longer than anticipated.603,604,846,847 Patient-centred care 
should therefore extend further than the clinical treatment at the hospital 
to ensure a good outcome after discharge. Though little research has ex­
plored patients’ and families’ needs for recovery and rehabilitation follow­
ing IE, patients with heart disease report experiencing new and continuous 
challenges and a lack of knowledge and understanding after discharge, 
which should be addressed to optimize recovery.848
It is recommended that a recovery plan is developed in collaboration 
with the patient and their caregivers and that the plan is reviewed and 
potentially adjusted following a short period after discharge.849
Physical exercise should be recommended based on an individual as­
sessment of functional capacity (guided by physicians and physiothera­
pists), and patient education and psychosocial support should address 
the main problems and concerns patients and families have. 
Importantly, patient education should also include information about 
the risk of recurrence and preventive measures described in Sections 3 
and 11. Special consideration should be taken for patients with no close 
relatives. Self-support groups or mentors may be introduced to patients 
without support networks. Also, follow-up by telephone from the ward 
staff, until full recovery has been reached, may be an option.
A palliative approach aims to improve the quality of life of patients 
and their families who are facing problems associated with life- 
threatening illness, which is relevant for many patients with IE. This ap­
proach includes a holistic, needs-based perspective with the aims of


<!-- PAGE 64 -->

### Page 64

assessing and improving symptom management, communication, 
advanced care planning, as well as psychosocial and spiritual needs.850
14. Sex differences
Female sex is less common in patients diagnosed with IE, being present 
in approximately one-third of cases; a finding that has been demon­
strated in multiple IE patient subpopulations and across different re­
gions.5,59,723,851,852 The reason why female sex is observed less 
frequently in IE is unknown and deserves further investigation. 
Possible reasons include underdiagnosis of IE in women, referral bias 
in published studies, intrinsic protective mechanisms against IE in 
women, and decreased incidence of risk factors for IE in women (e.g. 
bicuspid aortic valve disease, previous heart valve replacement surgery), 
among others. A recent nationwide population study of individual 
patient-level linkage data of 7513 patients hospitalized for IE in 
Scotland, however, demonstrated roughly equal proportions of male 
and female patients throughout the 25-year study period.27
Female patients with IE have been demonstrated to have a higher preva­
lence of several risk factors for IE in comparison to their male counterparts 
including older age, mitral valve involvement, S. aureus infection, neuro­
logical symptoms, and haemodialysis.853–856 However, men have a higher 
prevalence of other important risk factors including previous prosthetic 
valve replacement, periannular complications, CAD, and liver cirrhosis.855
Some studies have demonstrated higher mortality rates for female 
patients with IE,856 while others have demonstrated no differences in 
Family and caregiver involvement
Patients’
preferences and values
Care coordination and integration
Information and education
Physical comfort and emotional support
Continuity and transition
P
a ti e
n tc e
n tr e
d
 c a
r e
S
h a
r e
d
 
d e
ci si o
n
-
m a
k i
n g
Figure 14 Concept of patient-centred care in infective endocarditis.
ESC Guidelines                                                                                                                                                                                          4011


<!-- PAGE 65 -->

### Page 65

early and 1-year mortality rates between males and females.853,855,857
The abovementioned population study from Scotland showed lower 
mortality rates for women during the study period.27
Although surgery has been demonstrated to be protective against 
mortality in several clinical scenarios (see Section 8), surgery is per­
formed less frequently in female patients with IE.855,856 In a study using 
the National Inpatient Sample of 81 942 patients hospitalized for IE 
over an 11-year period, women were 43% less likely to undergo valve 
replacement surgery, a significant difference that remained after adjust­
ing for confounding factors.855 The reason for decreased surgery in fe­
male IE patients is unknown and requires further investigation.
Female sex has also been identified as an independent risk factor for 
mortality in prediction models for patients with IE undergoing sur­
gery.416 However, a single-centre study suggested that worse observed 
surgical outcomes in female patients with IE was related to their in­
creased risk factors and severity of presentation, rather than gender 
per se.854 In addition, a large multicentre registry of 4300 patients 
undergoing surgery for IE failed to identify female gender as an inde­
pendent predictor of mortality.852
15. Key messages
Prevention: 
• Populations at high risk of IE include patients with previous IE, pa­
tients with surgical or transcatheter prosthetic valves or post-cardiac 
valve repair, and patients with untreated CHD and surgically cor­
rected CHD.
• Prevention of IE comprise hygienic measures (including oral hygiene) 
for all individuals and antibiotic prophylaxis for patients at high risk of 
IE undergoing oro-dental procedures.
The Endocarditis Team: 
• The diagnosis and management of patients with IE should be dis­
cussed with the Endocarditis Team, which includes healthcare pro­
fessionals with the expertise to diagnose and treat IE and its 
complications.
• Uncomplicated IE can be managed in a Referring Centre that remains 
in early and regular communication with the Endocarditis Team of 
the Heart Valve Centre.
• Patients with complicated IE should be treated in the Heart Valve 
Centre, which must offer a wide range of ancillary specialty support 
including onsite cardiac surgery expertise.
Diagnosis: 
• The diagnosis of IE is based on major criteria, which include positive 
blood cultures and valvular and perivalvular/periprosthetic anatomic 
and metabolic lesions detected on imaging, and on minor criteria 
which have been updated to include frequent embolic vascular dis­
semination including asymptomatic lesions detected by imaging only.
• Clear diagnostic algorithms have been established to diagnose NVE, 
PVE, and right-sided IE.
Antimicrobial therapy – principles and methods: 
• Successful treatment of IE relies on microbial eradication by anti­
microbial drugs. Surgery contributes by removing infected material 
and draining abscesses.
• Antibiotic treatment of PVE should last longer (≥6 weeks) than that 
of NVE (2–6 weeks).
• In both NVE and PVE, the duration of treatment is based on the first 
day of effective antibiotic therapy (negative blood culture in the case 
of initial positive blood culture), not on the day of surgery.
• The initial choice of empirical treatment depends on the use of pre­
vious antibiotic therapy, whether IE is NVE or PVE (and if so, when 
surgery was performed [early vs. late PVE]), the place where the in­
fection took place (community, nosocomial, or non-nosocomial 
healthcare-associated IE), and knowledge of the local epidemiology.
• The antibiotic treatment of IE has two phases. The first phase con­
sists of 2 weeks of in-hospital i.v. treatment. In this initial phase, car­
diac surgery should be performed if indicated, infected foreign bodies 
should be removed, and cardiac as well as extracardiac abscesses 
should be drained. In the second phase, in selected patients, the anti­
biotic treatment can be completed within an outpatient parenteral or 
oral antibiotic programme for up to 6 weeks.
• Aminoglycosides are not recommended in staphylococcal NVE be­
cause their clinical benefits have not been demonstrated. In IE caused 
by other microorganisms in which aminoglycosides are indicated, 
they should be prescribed in a single daily dose to reduce 
nephrotoxicity.
• Rifampin should be used only in IE involving foreign material, such as 
PVE, after 3–5 days of effective antibiotic therapy.
• When daptomycin is indicated, it must be given at high doses (10 mg/ 
kg once daily) and combined with a second antibiotic (beta-lactams or 
fosfomycin in beta-lactam allergic patients) to increase activity and 
avoid the development of resistance.
• OPAT can only start when a TOE shows absence of local progression 
and complications (e.g. severe valvular dysfunction).
• In the OPAT programme, patients continue with the same antibiotics 
administered in the acute phase, if possible.
Indications for surgery and management of main infective 
endocarditis complications: 
• There are three main reasons to undergo surgery in the setting of 
acute IE: HF, uncontrolled infection, and prevention of septic 
embolization.
• While surgery during the acute phase of IE is usually performed on an 
urgent basis (i.e. the patient undergoes surgery within 3–5 days), 
some cases require emergency surgery (i.e. within 24 h), irrespective 
of the pre-operative duration of antibiotic treatment.
Other complications of infective endocarditis: 
• Stroke may be the first presenting symptom in patients with IE. 
Unexplained fever accompanying a stroke in a patient with risk fac­
tors for IE should trigger the suspicion of IE.
• Epicardial pacemaker implantation should be considered in patients 
undergoing surgery for IE with complete AVB and other risk factors.
• MRI or PET/CT are indicated in patients with suspected spondylodis­
citis and vertebral osteomyelitis complicating IE.
Surgical therapy principles and methods: 
• The indication to perform invasive coronary angiography or CTA 
prior to surgery for IE should be based on the presence of cardiovas­
cular risk factors in patients with aortic valve IE.
• Surgery should not be delayed in patients with non-haemorrhagic 
stroke and clear indications for surgery. In patients with significant


<!-- PAGE 66 -->

### Page 66

pre-operative haemorrhagic stroke, a delay in operative management 
(≥4 weeks) is generally recommended.
• The decision of not offering surgery when indicated should be made 
in the setting of an Endocarditis Team.
Outcome after discharge – follow-up and long-term 
prognosis: 
• Relapse is a repeat episode of IE caused by the same microorganism 
and represents a failure of treatment, and mandates a search for a 
persistent focus of infection and an evaluation towards surgical 
therapy.
• Reinfection is an infection caused by a different microorganism, usu­
ally more than 6 months after the initial episode.
• Once antibiotic treatment has been completed, blood cultures 
should be performed.
• Patients discharged after the first episode of IE should remain under 
close surveillance for potential long-term complications.
Management of specific situations: 
• Antibiotic prophylaxis to prevent CIED-related IE before dental and 
other non-cardiac interventions is not warranted.
• A single positive blood culture with no other clinical evidence of in­
fection should not result in removal of the CIED. Complete CIED re­
moval is recommended for all patients with confirmed infection of 
the lead(s).
• The indication for CIED reimplantation should always be re- 
evaluated and no part of the removed system should be reimplanted. 
In pacemaker-dependent patients, an active-fixation lead may be in­
troduced and connected to an external pacemaker for up to 6 weeks.
• Surgical treatment of right-sided IE is indicated in patients with per­
sistent bacteraemia, right ventricular dysfunction, recurrent septic 
pulmonary embolism and respiratory compromise, and involvement 
of left-sided structures.
• Multidisciplinary care of CHD patients with IE, from diagnosis to 
treatment, should be provided in specialized CHD centres with ex­
pertise in CHD cardiac imaging, CHD surgery, and intensive care.
Patient-centred care and shared decision-making in 
infective endocarditis: 
• In patients with IE, shared decision-making enables the integration of 
patients’ preferences, values, and priorities to achieve a good treat­
ment decision.
• In patients with IE and without support networks or severely 
impacted by social determinants, a recovery plan developed in 
collaboration with the patient should be established, highlighting 
the information about the risk of recurrence and preventive 
measures.
Sex differences: 
• Female sex is less common in patients diagnosed with IE, being pre­
sent in approximately one-third of cases.
16. Gaps in evidence
• The majority of the recommendations with a level of evidence B are 
based on observational studies rather than single RCTs or 
meta-analyses from RCTs.
Prevention: 
• In the intermediate or unknown risk condition groups, there is no evi­
dence to recommend antibiotic prophylaxis.
• There is currently no evidence to support the use of antibiotic prophy­
laxis after the implantation of a left atrial appendage occlusion device.
Diagnosis: 
• More data on the accuracy of diagnosis of culture-negative IE using 
molecular biology techniques, or the determination of bacterial/fun­
gal cell-free DNA in blood samples, is required.
• Standardization of the methodology to assess the size of the vegeta­
tions has not been established.
• More data on the diagnostic performance of intracardiac echocardi­
ography in PVE are needed.
• The role of [18F]FDG-PET/CT(A) in NVE needs to be established.
• Routine use of imaging tests to screen the presence of embolic 
events, especially brain imaging, is not well established.
• In fungal endocarditis, the role of molecular and biochemical indica­
tors to establish the diagnosis is not well studied.
Antimicrobial therapy – principles and methods: 
• Clinical trials are needed to assess the efficacy and safety of recom­
mended antimicrobial treatment regimens and new combinations 
or antimicrobials. Many recommendations come from clinical trials 
for bacteraemia and not for IE.
• Effective antibiotic treatment in patients with highly penicillin- 
resistant oral streptococci should be investigated.
• Randomized data to establish the best medical strategy in staphylo­
coccal IE are required.
• Effective antibiotic treatments for patients with HLAR E. faecalis IE 
and hypersensitivity to beta-lactams need further research.
• Effective treatments for vancomycin-resistant enterococcal IE need 
further research.
• Randomized head-to-head comparisons of different antibiotics to better 
judge efficacy and toxicity (e.g. for aminoglycosides) are needed.
• The duration of antibiotic treatment has been established empirically 
and no randomized data have been published.
• The efficacy of combined antifungal therapy has not been studied.
• The empirical use of an aminoglycoside-sparing empirical combin­
ation regimen has not been extensively studied.
• More data on implementation of oral treatment in large studies are 
needed.
Indications for surgery and management of main infective 
endocarditis complications: 
• The indication of surgical treatment in patients with IE rely mainly on 
expert opinion based on observational studies.
• RCTs are required to establish the indication and timing of surgery in 
patients with: 
• Increased surgical risk.
• Large vegetations but without other indications for surgery.
• Cerebral emboli or bleeding.
• Patients with uncontrolled infection.
• More data on the need and timing of coronary angiogram before 
endocarditis surgery.
• There is a lack of information on timing and sequence of interven­
tions in patients with multiple septic sources.
• More data are needed on the efficacy and safety of vegetation extrac­
tion systems in right-sided IE.
ESC Guidelines                                                                                                                                                                                          4013


<!-- PAGE 67 -->

### Page 67

Other complications of infective endocarditis: 
• There is limited information on the safety and efficacy of mechanical 
thrombectomy in IE-related embolic strokes.
• There are no prospective data on the timing and safety of splenec­
tomy for splenic abscess, complicating IE in relation to surgical valve 
treatment.
Surgical therapy principles and methods: 
• There is a significant need for scores to predict futility of surgical 
management in very high-risk patients.
• There is a lack of data on the most appropriate anticoagulation regi­
men in patients with PVE complicated by haemorrhagic stroke.
Outcome after discharge: follow-up and long-term 
prognosis: 
• Clinical trials are required to assess the efficacy of rehabilitation, 
including optimal timing, duration, methods, and components.
• Data on patient-reported outcomes during short- and long-term 
follow-up are needed.
Management of specific situations: 
• Additional data on the incidence, characteristics, and outcomes of IE 
in patients treated with transcatheter valve therapies or left atrial ap­
pendage occluders are needed.
• There is an unmet clinical question on the efficacy and safety of sur­
gical treatment of IE in patients previously treated with transcatheter 
valve therapies.
• Randomized data on the timing of CIED reimplantation after device 
removal after CIED infection are needed.
• There is a lack of evidence on whether or not CIED removal should 
be routinely performed in patients with left-sided IE.
• Randomized data on surgery in right-sided IE are required.
Patient-centred care and shared decision-making in 
infective endocarditis: 
• As no disease-specific evidence exists, data on patient-centred care 
and shared decision-making in IE is needed.
• Data on how patient-centred care and shared decision-making in pa­
tients with social and mental health vulnerabilities can improve their 
outcomes are lacking.
• Data on the effect of patient-centred care and shared decision- 
making interventions are required to implement effective strategies.
Sex differences: 
• Further data are required to determine why IE is less frequently ob­
served, and why the outcomes are worse, in female patients.
• The reasons for lower referral to surgery in female patients with IE as 
compared with male patients need to be determined and addressed.
Table 14 ‘What to do’ and ‘What not to do’
Recommendations
Classa
Levelb
Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing oro-dental procedures at increased 
risk of infective endocarditis
Antibiotic prophylaxis is recommended in patients with previous IE.
I
B
General prevention measures are recommended in individuals at high and intermediate risk of IE.
I
C
Antibiotic prophylaxis is recommended in patients with surgically implanted prosthetic valves and with any material used for surgical 
cardiac valve repair.
I
C
Antibiotic prophylaxis is recommended in patients with transcatheter implanted aortic and pulmonary valvular prostheses.
I
C
Antibiotic prophylaxis is recommended in patients with untreated cyanotic CHD, and patients treated with surgery or transcatheter 
procedures with post-operative palliative shunts, conduits, or other prostheses. After surgical repair, in the absence of residual defects 
or valve prostheses, antibiotic prophylaxis is recommended only for the first 6 months after the procedure.
I
C
Antibiotic prophylaxis is recommended in patients with ventricular assist devices.
I
C
Antibiotic prophylaxis is not recommended in other patients at low risk of IE.
III
C
Recommendations for infective endocarditis prevention in high-risk patients
Antibiotic prophylaxis is recommended in dental extractions, oral surgery procedures, and procedures requiring manipulation of the 
gingival or periapical region of the teeth.
I
B
Recommendations for infective endocarditis prevention in cardiac procedures
Pre-operative screening for nasal carriage of S. aureus is recommended before elective cardiac surgery or transcatheter valve 
implantation to treat carriers.
I
A
Peri-operative antibiotic prophylaxis is recommended before placement of a CIED.
I
A
Optimal pre-procedural aseptic measures of the site of implantation are recommended to prevent CIED infections.
I
B
Periprocedural antibiotic prophylaxis is recommended in patients undergoing surgical or transcatheter implantation of a prosthetic 
valve, intravascular prosthetic, or other foreign material.
I
B
Continued
17. ‘What to do’ and ‘What not to do’ messages from the Guidelines


<!-- PAGE 68 -->

### Page 68

Surgical standard aseptic measures are recommended during the insertion and manipulation of catheters in the catheterization 
laboratory environment.
I
C
Systematic skin or nasal decolonization without screening for S. aureus is not recommended.
III
C
Recommendations for the Endocarditis Team
Diagnosis and management of patients with complicated IE are recommended to be performed at an early stage in a Heart Valve 
Centre, with immediate surgical facilities and an ‘Endocarditis Team’ to improve the outcomes.
I
B
For patients with uncomplicated IE managed in a Referring Centre, early and regular communication between the local and the Heart 
Valve Centre endocarditis teams is recommended to improve the outcomes of the patients.
I
B
Recommendations for the role of echocardiography in infective endocarditis
A. Diagnosis
TTE is recommended as the first-line imaging modality in suspected IE.
I
B
TOE is recommended in all patients with clinical suspicion of IE and a negative or non-diagnostic TTE.
I
B
TOE is recommended in patients with clinical suspicion of IE, when a prosthetic heart valve or an intracardiac device is present.
I
B
Repeating TTE and/or TOE within 5–7 days is recommended in cases of initially negative or inconclusive examination when clinical 
suspicion of IE remains high.
I
C
TOE is recommended in patients with suspected IE, even in cases with positive TTE, except in isolated right-sided native valve IE with 
good quality TTE examination and unequivocal echocardiographic findings.
I
C
B. Follow-up under medical therapy
Repeating TTE and/or TOE is recommended as soon as a new complication of IE is suspected (new murmur, embolism, persisting 
fever and bacteraemia, HF, abscess, AVB).
I
B
TOE is recommended when the patient is stable before switching from intravenous to oral antibiotic therapy.
I
B
C. Intra-operative echocardiography
Intra-operative echocardiography is recommended in all cases of IE requiring surgery.
I
C
D. Following completion of therapy
TTE and/or TOE are recommended at completion of antibiotic therapy for evaluation of cardiac and valve morphology and function in 
patients with IE who did not undergo heart valve surgery.
I
C
Recommendations for the role of computed tomography, nuclear imaging, and magnetic resonance in infective endocarditis
Cardiac CTA is recommended in patients with possible NVE to detect valvular lesions and confirm the diagnosis of IE.
I
B
[18F]FDG-PET/CT(A) and cardiac CTA are recommended in possible PVE to detect valvular lesions and confirm the diagnosis of IE.
I
B
Cardiac CTA is recommended in NVE and PVE to diagnose paravalvular or periprosthetic complications if echocardiography is 
inconclusive.
I
B
Brain and whole-body imaging (CT, [18F]FDG-PET/CT, and/or MRI) are recommended in symptomatic patients with NVE and PVE to 
detect peripheral lesions or add minor diagnostic criteria.
I
B
Recommendations for antibiotic treatment of infective endocarditis due to oral streptococci and Streptococcus gallolyticus group
Penicillin-susceptible oral streptococci and Streptococcus gallolyticus group
Standard treatment: 4-week duration in NVE or 6-week duration in PVE
In patients with IE due to oral streptococci and S. gallolyticus group, penicillin G, amoxicillin, or ceftriaxone are recommended for 4 (in 
NVE) or 6 weeks (in PVE), using the following doses:
I
B
Adult antibiotic dosage and route
Penicillin G
12–18 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Paediatric antibiotic dosage and route
Penicillin G
200 000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg/day i.v. in 1 dose
Standard treatment: 2-week duration (not applicable to PVE)
2-week treatment with penicillin G, amoxicillin, ceftriaxone combined with gentamicin is recommended only for the treatment of 
non-complicated NVE due to oral streptococci and S. gallolyticus in patients with normal renal function using the following doses:
I
B
Adult antibiotic dosage and route
Penicillin G
12–18 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Continued
ESC Guidelines                                                                                                                                                                                          4015


<!-- PAGE 69 -->

### Page 69

Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Penicillin G
200 000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. in 1 dose
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose or 3 equally divided doses
Allergy to beta-lactams
In patients allergic to beta-lactams and with IE due to oral streptococci and S. gallolyticus, vancomycin for 4 weeks in NVE or for 6 
weeks in PVE is recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 or 3 equally divided doses
Oral streptococci and Streptococcus gallolyticus group susceptible, increased exposure or resistant to penicillin
In patients with NVE due to oral streptococci and S. gallolyticus, penicillin G, amoxicillin, or ceftriaxone for 4 weeks in combination with 
gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Penicillin G
24 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
In patients with PVE due to oral streptococci and S. gallolyticus, penicillin G, amoxicillin, or ceftriaxone for 6 weeks combined with 
gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Penicillin G
24 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
2 g/day i.v. in 1 dose
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Allergy to beta-lactams
In patients with NVE due to oral streptococci and S. gallolyticus and who are allergic to beta-lactams, vancomycin for 4 weeks is 
recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
In patients with PVE due to oral streptococci and S. gallolyticus and who are allergic to beta-lactams, vancomycin for 6 weeks combined 
with gentamicin for 2 weeks is recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Recommendations for antibiotic treatment of infective endocarditis due to Staphylococcus spp.
IE caused by methicillin-susceptible staphylococci
In patients with NVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin is recommended for 4–6 weeks using the 
following doses:
I
B
Adult antibiotic dosage and route
(Flu)cloxacillin
12 g/day i.v. in 4–6 doses
Cefazolin
6 g/day i.v. in 3 doses
Paediatric antibiotic dosage and route
(Flu)cloxacillin
200–300 mg/kg/day i.v. in 4–6 equally divided doses
Cefazolin
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
Continued


<!-- PAGE 70 -->

### Page 70

In patients with PVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin with rifampin for at least 6 weeks and 
gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
(Flu)cloxacillin
12 g/day i.v. in 4–6 doses
Cefazolin
6 g/day i.v. in 3 doses
Rifampin
900 mg/day i.v. or orally in 3 equally divided doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
(Flu)cloxacillin
200–300 mg/kg/day i.v. in 4–6 equally divided doses
Cefazolin
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Allergy to beta-lactams
In patients with NVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin for 4–6 weeks is 
recommended using the following doses:
I
B
Adult antibiotic dosage and route
Cefazolin
6 g/day i.v. in 3 doses
Paediatric antibiotic dosage and route
Cefazolin
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
In patients with PVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin combined with rifampin for at 
least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Cefazolin
6 g/day i.v. in 3 doses
Rifampin
900 mg/day i.v. or orally in 3 equally divided doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
Cefazolin
100 mg/kg/day i.v. in 3–4 doses, up to maximum of 6 g/day
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
IE caused by methicillin-resistant staphylococci
In patients with NVE due to methicillin-resistant staphylococci, vancomycin is recommended for 4–6 weeks using the following doses:
I
B
Adult antibiotic dosage and route
Vancomycin
30–60 mg/kg/day i.v. in 2–3 doses
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2–3 equally divided doses
In patients with PVE due to methicillin-resistant staphylococci, vancomycin with rifampin for at least 6 weeks and gentamicin for 2 
weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Vancomycin
30–60 mg/kg/day i.v. in 2–3 doses
Rifampin
900–1200 mg/day i.v. or orally in 2 or 3 divided doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2–3 equally divided doses
Rifampin
20 mg/kg/day i.v. or orally in 3 equally divided doses up to maximum of 900 mg/day
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses
Recommendations for antibiotic treatment of infective endocarditis due to Enterococcus spp.
Beta-lactam and gentamicin-susceptible strains
In patients with NVE due to non-HLAR Enterococcus spp., the combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks or 
with gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Amoxicillin
12 g/day i.v. in 4–6 doses
Ampicillin
12 g/day i.v. in 4–6 doses
Continued
ESC Guidelines                                                                                                                                                                                          4017


<!-- PAGE 71 -->

### Page 71

Ceftriaxone
4 g/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 3 equally divided doses
In patients with PVE and patients with complicated NVE or >3 months of symptoms due to non-HLAR Enterococcus spp., the combination 
of ampicillin or amoxicillin with ceftriaxone for 6 weeks or with gentamicin for 2 weeks is recommended using the following doses:
I
B
Adult antibiotic dosage and route
Amoxicillin
12 g/day i.v. in 4–6 doses
Ampicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 3 equally divided doses
High-level aminoglycoside resistance
In patients with NVE or PVE due to HLAR Enterococcus spp., the combination of ampicillin or amoxicillin and ceftriaxone for 6 weeks is 
recommended using the following doses:
I
B
Adult antibiotic dosage and route
Ampicillin
12 g/day i.v. in 4–6 doses
Amoxicillin
12 g/day i.v. in 4–6 doses
Ceftriaxone
4 g/day i.v. or i.m. in 2 doses
Paediatric antibiotic dosage and route
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Amoxicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to maximum of 12 g/day
Ceftriaxone
100 mg/kg i.v. or i.m. in 2 doses
Beta-lactam-resistant Enterococcus spp. (E. faecium)
In patients with IE due to beta-lactam-resistant Enterococcus spp. (E. faecium), vancomycin for 6 weeks combined with gentamicin for 2 
weeks is recommended using the following doses:
I
C
Adult antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2 doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Vancomycin
30 mg/kg/day i.v. in 2–3 equally divided doses
Gentamicin
3 mg/kg/day i.v. or i.m. in 1 dose
Vancomycin-resistant Enterococcus spp.
In patients with IE due to vancomycin-resistant Enterococcus spp., daptomycin combined with beta-lactams (ampicillin, ertapenem, or 
ceftaroline) or fosfomycin is recommended using the following doses:
I
C
Adult antibiotic dosage and route
Daptomycin
10–12 mg/kg/day i.v. in 1 dose
Ampicillin
12 g/day i.v. in 4–6 doses
Fosfomycin
12 g/day i.v. in 4 doses
Ceftaroline
1800 mg/day i.v. in 3 doses
Ertapenem
2 g/day i.v. or i.m. in 1 dose
Paediatric antibiotic dosage and route
Daptomycin
10–12 mg/kg/day i.v. in 1 dose (age-adjusted)
Ampicillin
200–300 mg/kg/day i.v. in 4–6 doses, up to a maximum of 12 g/day
Fosfomycin
2–3 g/day i.v. in 1 dose
Ceftaroline
24–36 mg/kg/day in 3 doses
Ertapenem
1 g/day i.v. or i.m. in 1 dose (if younger than 12 years, 15 mg/kg/dose [to a maximum of 500 mg] twice daily)
Continued


<!-- PAGE 72 -->

### Page 72

Recommendations for outpatient antibiotic treatment of infective endocarditis
Outpatient parenteral antibiotic treatment is not recommended in patients with IE caused by highly difficult-to-treat microorganisms, 
liver cirrhosis (Child–Pugh B or C), severe cerebral nervous system emboli, untreated large extracardiac abscesses, heart valve 
complications, or other severe conditions requiring surgery, severe post-surgical complications, and PWID-related IE.
III
C
Recommendations for the main indications of surgery in infective endocarditis (native valve endocarditis and prosthetic valve 
endocarditis)
(i) Heart failure
Emergency surgery is recommended in aortic or mitral NVE or PVE with severe acute regurgitation, obstruction, or fistula causing 
refractory pulmonary oedema or cardiogenic shock.
I
B
Urgent surgery is recommended in aortic or mitral NVE or PVE with severe acute regurgitation or obstruction causing symptoms of 
HF or echocardiographic signs of poor haemodynamic tolerance.
I
B
(ii) Uncontrolled infection
Urgent surgery is recommended in locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation, prosthetic 
dehiscence, new AVB).
I
B
Urgent or non-urgent surgery is recommended in IE caused by fungi or multiresistant organisms according to the haemodynamic 
condition of the patient.
I
C
(iii) Prevention of embolism
Urgent surgery is recommended in aortic or mitral NVE or PVE with persistent vegetations ≥10 mm after one or more embolic 
episodes despite appropriate antibiotic therapy.
I
B
Urgent surgery is recommended in IE with vegetation ≥10 mm and other indications for surgery.
I
C
Recommendations for the treatment of neurological complications of infective endocarditis
Brain CT or MRA is recommended in patients with IE and suspected infective cerebral aneurysms.
I
B
Neurosurgery or endovascular therapy is recommended for large aneurysms, those with continuous growth despite optimal antibiotic 
therapy, and ruptured intracranial infective cerebral aneurysms.
I
C
Thrombolytic therapy is not recommended in embolic stroke due to IE.
III
C
Recommendations for patients with musculoskeletal manifestations of infective endocarditis
MRI or PET/CT is recommended in patients with suspected spondylodiscitis and vertebral osteomyelitis complicating IE.
I
C
TTE/TOE is recommended to rule out IE in patients with spondylodiscitis and/or septic arthritis with positive blood cultures for typical 
IE microorganisms.
I
C
Recommendations for pre-operative coronary anatomy assessment in patients requiring surgery for infective endocarditis
In haemodynamically stable patients with aortic valve vegetations who require cardiac surgery and are high risk of CAD, a 
high-resolution multislice coronary CTA is recommended.
I
B
Invasive coronary angiography is recommended in patients requiring heart surgery who are high risk of CAD, in the absence of aortic 
valve vegetations.
I
C
Indications and timing of cardiac surgery after neurological complications in active infective endocarditis
After a transient ischaemic attack, cardiac surgery, if indicated, is recommended without delay.
I
B
After a stroke, surgery is recommended without any delay in the presence of HF, uncontrolled infection, abscess, or persistent high 
embolic risk, as long as coma is absent and the presence of cerebral haemorrhage has been excluded by cranial CT or MRI.
I
B
Recommendations for post-discharge follow-up
Patient education on the risk of recurrence and preventive measures, with emphasis on dental health, and based on the individual risk 
profile is recommended during follow-up.
I
C
Addiction treatment for patients following PWID-related IE is recommended.
I
C
Recommendations for prosthetic valve endocarditis
Surgery is recommended for early PVE (within 6 months of valve surgery) with new valve replacement and complete debridement.
I
C
Recommendations for cardiovascular implanted electronic device-related infective endocarditis
Antibiotic prophylaxis covering S. aureus is recommended for CIED implantation.
I
A
TTE and TOE are both recommended in cases of suspected CIED-related IE to identify vegetations.
I
B
Complete system extraction without delay is recommended in patients with definite CIED-related IE under initial empirical antibiotic 
therapy.
I
B
Continued
ESC Guidelines                                                                                                                                                                                          4019


<!-- PAGE 73 -->

### Page 73

### 18 Supplementary data

Supplementary data are available at European Heart Journal online.
19. Data availability
No new data were generated or analysed in support of this research.
20. Author information
Author/Task Force Member Affiliations: Nina Ajmone 
Marsan, Leiden University Medical Center, Leiden, Netherlands; 
Suzanne de Waha, Heart Center Leipzig at University of Leipzig, 
Leipzig, Germany; Nikolaos Bonaros, Medical University of 
Innsbruck, Innsbruck, Austria and University Hospital Innsbruck, 
Innsbruck, Austria; Margarita Brida, Medical Faculty University of 
Rijeka, Rijeka, Croatia and Adult Congenital Heart Centre and 
National Centre for Pulmonary Hypertension, Royal Brompton & 
Harefield Hospitals, London, United Kingdom; Haran Burri, 
University Hospital of Geneva, Geneva, Switzerland; Stefano 
Caselli, Hirslanden Klinik im Park, Zurich, Switzerland and University 
Heart Center, University Hospital Zurich, Zurich, Switzerland; 
Torsten Doenst, Friedrich-Schiller-University Jena, University 
Hospital, Jena, Germany; Stephane Ederhy, Hopital Saint-Antoine, 
Paris, France and Unité de cardio-oncologie, UNICO-GRECO, 
Hopital Saint-Antoine, Paris, France and Groupe de recherche clinique 
en cardio-oncologie, GRC n°27, Hopital Saint-Antoine, Paris, France; 
Paola Anna Erba, University of Milan Bicocca, Milan, Italy and 
Nuclear Medicine Department, ASST – Ospedale Papa Giovanni 
XXIII, Bergamo, Italy and Medical Imaging Center, Department of 
Nuclear Medicine & Molecular Imaging, University Medical Center 
Groningen, Groningen, Netherlands; Dan Foldager, ESC Patient 
Forum, Sophia Antipolis, France; Emil L. Fosbøl, University 
Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark; Jan 
Kovac, University of Leicester, Leicester, United Kingdom and 
RRCV Glenfield, University Hospitals of Leicester NHS Trust, 
Leicester, United Kingdom; Carlos A. Mestres, The University of 
the Free State, Bloemfontein, South Africa and Cardiac Surgery, 
University Hospital Zurich, Zurich, Switzerland; Owen I. Miller, 
Evelina London Children’s Hospital, London, United Kingdom and 
Department of Women and Children’s Health, Kings College 
London, London, United Kingdom; Jose M. Miro, Hospital Clinic - 
IDIBAPS, Barcelona, Spain and Faculty of Medicine, University of 
Barcelona, Barcelona, Spain and Centro de Investigación Biomédica 
en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud 
Carlos III, Madrid, Spain; Michal Pazdernik, Institute for Clinical 
and Experimental Medicine (IKEM), Prague, Czech Republic; Maria 
Nazarena Pizzi, Vall d´Hebron University Hospital, Barcelona, 
Spain; Eduard Quintana, Hospital Clínic de Barcelona, Barcelona, 
Spain 
and 
Departament 
de 
Cirurgia 
i 
Especialitats 
Medicoquirúrgiques, Facultat de Medicina i Ciències de la Salut, 
University of Barcelona, Barcelona, Spain; Trine Bernholdt 
Rasmussen, Herlev and Gentofte University Hospital, Hellerup, 
Denmark and Department of Clinical Medicine, Faculty of Health and 
Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 
Arsen D. Ristić, University Clinical Center of Serbia, Belgrade, 
Serbia and Faculty of Medicine, University of Belgrade, Belgrade, 
Serbia; Josep Rodés-Cabau, Quebec Heart and Lung Institute, 
Laval University, Quebec, Canada and Research and Innovation, 
Clínic Barcelona, Barcelona, Spain; Alessandro Sionis, Hospital de 
la Santa Creu i Sant Pau, Barcelona, Spain and Universitat Autònoma 
de Barcelona, Barcelona, Spain; Liesl Joanna Zühlke, Francie van 
Zijl Drive Parowvallei, Cape Town; PO Box 19070, Cape Town, 
South Africa and Division of Paediatric Cardiology, Department of 
Paediatrics, Institute of Child Health, Faculty of Health Sciences, 
University of Cape Town, Cape Town, South Africa.
Obtaining at least three sets of blood cultures is recommended before prompt initiation of empirical antibiotic therapy for CIED 
infection, covering methicillin-resistant staphylococci and Gram-negative bacteria.
I
C
If CIED reimplantation is indicated after extraction for CIED-related IE, it is recommended to be performed at a site distant from the 
previous generator, as late as possible, once signs and symptoms of infection have abated, and until blood cultures are negative for at 
least 72 h in the absence of vegetations, and negative for at least 2 weeks if vegetations were visualized.
I
C
Removal of CIED after a single positive blood culture, with no other clinical evidence of infection, is not recommended.
III
C
Recommendations for the surgical treatment of right-sided infective endocarditis
Surgery is recommended in patients with right-sided IE who are receiving appropriate antibiotic therapy for the following scenarios:
Right ventricular dysfunction secondary to acute severe tricuspid regurgitation non-responsive to diuretics.
I
B
Persistent vegetation with respiratory insufficiency requiring ventilatory support after recurrent pulmonary emboli.
I
B
Large residual tricuspid vegetations (>20 mm) after recurrent septic pulmonary emboli.
I
C
Patients with simultaneous involvement of left-heart structures.
I
C
Recommendations for the use of antithrombotic therapy in infective endocarditis
Interruption of antiplatelet or anticoagulant therapy is recommended in the presence of major bleeding (including intracranial 
haemorrhage).
I
C
Thrombolytic therapy is not recommended in patients with IE.
III
C
© ESC 2023
[18F]FDG-PET, 18F-fluorodeoxyglucose positron emission tomography; AVB, atrioventricular block; CAD, coronary artery disease; CHD, congenital heart disease; CIED, cardiovascular 
implanted electronic device; CT, computed tomography; CTA, computed tomography angiography; HF, heart failure; HLAR, high-level aminoglycoside resistance; IE, infective 
endocarditis; i.m., intramuscular; i.v., intravenous; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; NVE, native valve endocarditis; PET, positron emission 
tomography; PVE, prosthetic valve endocarditis; PWID, people who inject drugs; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 74 -->

### Page 74

### 21 Appendix

ESC Society Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document 
Reviewers: 
Bernard 
Iung 
(CPG 
Review 
Co-ordinator) 
(France), 
Bernard 
Prendergast 
(CPG 
Review 
Co-ordinator) (United Kingdom), Magdy Abdelhamid (Egypt), 
Marianna Adamo (Italy), Riccardo Asteggiano (Italy), Larry 
M. Baddour (United States of America), Jelena Čelutkienė (Lithuania), 
John Chambers (United Kingdom), Jean-Claude Deharo (France), 
Wolfram Doehner (Germany), Laura Dos Subira (Spain), Xavier 
Duval (France), Volkmar Falk (Germany), Laurent Fauchier (France), 
Nuria Fernandez-Hidalgo (Spain), Christian Giske (Sweden), Anežka 
Gombošová (Czechia), Gilbert Habib (France), Borja Ibanez (Spain), 
Tiny Jaarsma (Sweden), Lars Køber (Denmark), Konstantinos 
C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf 
Landmesser (Germany), Sandra B. Lauck (Canada), Basil S. Lewis 
(Israel), Maja-Lisa Løchen (Norway), John William McEvoy (Ireland), 
Borislava Mihaylova (United Kingdom), Richard Mindham (United 
Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen 
(Denmark), Jean-François Obadia (France), Agnes A. Pasquet 
(Belgium), Steffen Petersen (United Kingdom), Eva Prescott 
(Denmark), Susanna Price (United Kingdom), Amina Rakisheva 
(Kazakhstan), Archana Rao (United Kingdom), François Rouzet 
(France), Jonathan Sandoe (United Kingdom), Renate B. Schnabel 
(Germany), Christine Selton-Suty (France), Lars Sondergaard 
(Denmark), Martin Thornhill (United Kingdom), Konstantinos 
Toutouzas (Greece), Nico Van de Veire (Belgium), Isidre Vilacosta 
(Spain), Christiaan Vrints (Belgium), Olaf Wendler (United Kingdom).
ESC National Cardiac Societies actively involved in the review 
process of the 2023 Guidelines for the management of endocarditis.
Algeria: Algerian Society of Cardiology, Yasmina Benchabi; 
Armenia: Armenian Cardiologists Association, Aram Chilingaryan; 
Austria: Austrian Society of Cardiology, Sebastian J. Reinstadler; 
Azerbaijan: Azerbaijan Society of Cardiology, Fuad Samadov; 
Belgium: Belgian Society of Cardiology, Bernard Paelinck; Bosnia 
and Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Zumreta Kušljugić; Bulgaria: Bulgarian Society of 
Cardiology, Elena Kinova; Croatia: Croatian Cardiac Society, Maja 
Cikes; Cyprus: Cyprus Society of Cardiology, Ioannis Michaloliakos; 
Czechia: Czech Society of Cardiology, Martin Mates; Denmark: 
Danish Society of Cardiology, Jonas Agerlund Povlsen; Egypt: 
Egyptian Society of Cardiology, Mohammad Abdelghani; Estonia: 
Estonian Society of Cardiology, Liisi Küünal-Arge; Finland: Finnish 
Cardiac Society, Helena Rajala; France: French Society of 
Cardiology, Christine Selton-Suty; Georgia: Georgian Society of 
Cardiology, Zurab Pagava; Germany: German Cardiac Society, 
Marcus Franz; Greece: Hellenic Society of Cardiology, Alexandros 
Patrianakos Hungary: Hungarian Society of Cardiology, Judit Barta; 
Iceland: Icelandic Society of Cardiology, Þórdís Jóna Hrafnkelsdóttir; 
Ireland: Irish Cardiac Society, David Moore; Israel: Israel Heart 
Society, Katia Orvin; Italy: Italian Federation of Cardiology, Fabrizio 
Oliva; Kazakhstan: Association of Cardiologists of Kazakhstan, 
Gyulnar Zhussupova; Kosovo (Republic of): Kosovo Society of 
Cardiology, Gani Bajraktari; Kyrgyzstan: Kyrgyz Society of 
Cardiology, Alina Kerimkulova, Latvia: Latvian Society of Cardiology, 
Ginta Kamzola; Lebanon: Lebanese Society of Cardiology, Pierrette 
Habib; Lithuania: Lithuanian Society of Cardiology, Vaida Mizarienė; 
Luxembourg: Luxembourg Society of Cardiology, Rouguiatou Sow; 
Malta: Maltese Cardiac Society, Daniela Cassar Demarco; Moldova 
(Republic of): Moldavian Society of Cardiology, Elena Panfile; 
Morocco: Moroccan Society of Cardiology, Laila Bendriss; 
Netherlands: Netherlands Society of Cardiology, Wilco Tanis; 
North Macedonia: The National Society of Cardiology of North 
Macedonia, Irena Mitevska; Norway: Norwegian Society of 
Cardiology, Erlend Aune; Portugal: Portuguese Society of 
Cardiology, Manuel Antunes; Romania: Romanian Society of 
Cardiology, Bogdan A. Popescu; San Marino: San Marino Society of 
Cardiology, Roberto Bini; Serbia: Cardiology Society of Serbia, 
Milorad Tesic; Slovakia: Slovak Society of Cardiology, Marek Orban; 
Slovenia: Slovenian Society of Cardiology, Mojca Bervar; Spain: 
Spanish Society of Cardiology, Isidre Vilacosta; Sweden: Swedish 
Society of Cardiology, Christina Christersson; Switzerland: Swiss 
Society of Cardiology, Michelle Frank; Tunisia: Tunisian Society of 
Cardiology and Cardiovascular Surgery, Lilia Zakhama; Türkiye: 
Turkish Society of Cardiology, Gamze Babur Guler; Ukraine: 
Ukrainian Association of Cardiology, Sergii Cherniuk; United 
Kingdom of Great Britain and Northern Ireland: British 
Cardiovascular Society, Simon Woldman, Uzbekistan: Association 
of Cardiologists of Uzbekistan, Nigora Srojidinova.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
22. References
1. Global Burden of Disease Metrics. Institute for Health Metrics Evaluation. University of 
Washington, Seattle. Available at: https://vizhub.healthdata.org/gbd-compare/ (ac­
cessed October 2021).
2. Momtazmanesh S, Saeedi Moghaddam S, Malakan Rad E, Azadnajafabad S, Ebrahimi N, 
Mohammadi E, et al. Global, regional, and national burden and quality of care index of 
endocarditis: the global burden of disease study 1990–2019. Eur J Prev Cardiol 2022;29: 
1287–1297. https://doi.org/10.1093/eurjpc/zwab211
3. Chen H, Zhan Y, Zhang K, Gao Y, Chen L, Zhan J, et al. The global, regional, and na­
tional burden and trends of infective endocarditis from 1990 to 2019: results from the 
global burden of disease study 2019. Front Med (Lausanne) 2022;9:774224. https://doi. 
org/10.3389/fmed.2022.774224
4. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 
ESC guidelines for the management of infective endocarditis: the Task Force for the 
Management of Infective Endocarditis of the European Society of Cardiology (ESC). 
Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the 
European Association of nuclear medicine (EANM). Eur Heart J 2015;36: 
3075–3128. https://doi.org/10.1093/eurheartj/ehv319
5. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation, 
aetiology and outcome of infective endocarditis. Results of the ESC-EORP 
EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. 
Eur Heart J 2019;40:3222–3232. https://doi.org/10.1093/eurheartj/ehz620
6. Janszky I, Gemes K, Ahnve S, Asgeirsson H, Moller J. Invasive procedures associated 
with the development of infective endocarditis. J Am Coll Cardiol 2018;71: 
2744–2752. https://doi.org/10.1016/j.jacc.2018.03.532
7. Pericas JM, Llopis J, Jimenez-Exposito MJ, Kourany WM, Almirante B, Carosi G, et al. 
Infective endocarditis in patients on chronic hemodialysis. J Am Coll Cardiol 2021;77: 
1629–1640. https://doi.org/10.1016/j.jacc.2021.02.014
8. Kuijpers JM, Koolbergen DR, Groenink M, Peels KCH, Reichert CLA, Post MC, et al. 
Incidence, risk factors, and predictors of infective endocarditis in adult congenital heart 
disease: focus on the use of prosthetic material. Eur Heart J 2017;38:2048–2056. 
https://doi.org/10.1093/eurheartj/ehw591
ESC Guidelines                                                                                                                                                                                          4021


<!-- PAGE 75 -->

### Page 75

9. Sanaiha Y, Lyons R, Benharash P. Infective endocarditis in intravenous drug users. 
Trends Cardiovasc Med 2020;30:491–497. https://doi.org/10.1016/j.tcm.2019.11.007
10. Pericas JM, Llopis J, Athan E, Hernandez-Meneses M, Hannan MM, Murdoch DR, et al. 
Prospective cohort study of infective endocarditis in people who inject drugs. J Am Coll 
Cardiol 2021;77:544–555. https://doi.org/10.1016/j.jacc.2020.11.062
11. Thornhill MH, Crum A, Campbell R, Stone T, Lee EC, Bradburn M, et al. Temporal as­
sociation between invasive procedures and infective endocarditis. Heart 2023;109: 
223–231. https://doi.org/10.1136/heartjnl-2022-321519
12. Maeda K, Hirai Y, Nashi M, Yamamoto S, Taniike N, Takenobu T. Clinical features and 
antimicrobial susceptibility of oral bacteria isolated from the blood cultures of patients 
with infective endocarditis. J Dent Sci 2022;17:870–875. https://doi.org/10.1016/j.jds. 
2021.09.023
13. Thornhill MH, Gibson TB, Cutler E, Dayer MJ, Chu VH, Lockhart PB, et al. Antibiotic 
prophylaxis and incidence of endocarditis before and after the 2007 AHA recommen­
dations. J Am Coll Cardiol 2018;72:2443–2454. https://doi.org/10.1016/j.jacc.2018.08. 
2178
14. Thornhill MH, Dayer MJ, Nicholl J, Prendergast BD, Lockhart PB, Baddour LM. An 
alarming rise in incidence of infective endocarditis in England since 2009: why? 
Lancet 2020;395:1325–1327. https://doi.org/10.1016/S0140-6736(20)30530-4
15. Dayer MJ, Prendergast BD, Thornhill MH, Baddour LM. Why are we seeing an increas­
ing incidence of infective endocarditis in the UK? Br J Hosp Med (Lond) 2020;81:1–4. 
https://doi.org/10.12968/hmed.2020.0263
16. Quan TP, Muller-Pebody B, Fawcett N, Young BC, Minaji M, Sandoe J, et al. 
Investigation of the impact of the NICE guidelines regarding antibiotic prophylaxis dur­
ing invasive dental procedures on the incidence of infective endocarditis in England: an 
electronic health records study. BMC Med 2020;18:84. https://doi.org/10.1186/ 
s12916-020-01531-y
17. Vahasarja N, Lund B, Ternhag A, Gotrick B, Olaison L, Hultin M, et al. Incidence of in­
fective endocarditis caused by viridans group streptococci in Sweden – effect of ces­
sation of antibiotic prophylaxis in dentistry for risk individuals. J Oral Microbiol 2020;12: 
1768342. https://doi.org/10.1080/20002297.2020.1768342
18. Williams ML, Doyle MP, McNamara N, Tardo D, Mathew M, Robinson B. 
Epidemiology of infective endocarditis before versus after change of international 
guidelines: 
a 
systematic 
review. 
Ther 
Adv 
Cardiovasc 
Dis 
2021;15: 
17539447211002687. https://doi.org/10.1177/17539447211002687
19. Ostergaard L, Bruun NE, Voldstedlund M, Arpi M, Andersen CO, Schonheyder HC, 
et al. Prevalence of infective endocarditis in patients with positive blood cultures: a 
Danish nationwide study. Eur Heart J 2019;40:3237–3244. https://doi.org/10.1093/ 
eurheartj/ehz327
20. Kim I-C, Chang S, Hong G-R, Lee SH, Lee S, Ha J-W, et al. Comparison of cardiac com­
puted tomography with transesophageal echocardiography for identifying vegetation 
and intracardiac complications in patients with infective endocarditis in the era of 3-di­
mensional images. Circ Cardiovasc Imaging 2018;11:e006986. https://doi.org/10.1161/ 
CIRCIMAGING.117.006986
21. Salaun E, Habib G. Beyond standard echocardiography in infective endocarditis: com­
puted tomography, 3-dimensional imaging, and multi-imaging. Circ Cardiovasc Imaging 
2018;11:e007626. https://doi.org/10.1161/CIRCIMAGING.118.007626
22. Pizzi MN, Roque A, Fernandez-Hidalgo N, Cuellar-Calabria H, Ferreira-Gonzalez I, 
Gonzalez-Alujas MT, et al. Improving the diagnosis of infective endocarditis in pros­
thetic valves and intracardiac devices with 18F-fluordeoxyglucose positron emission 
tomography/computed tomography angiography: initial results at an infective endocar­
ditis referral center. Circulation 2015;132:1113–1126. https://doi.org/10.1161/ 
CIRCULATIONAHA.115.015316
23. DeSimone DC, Lahr BD, Anavekar NS, Sohail MR, Tleyjeh IM, Wilson WR, et al. 
Temporal trends of infective endocarditis in Olmsted County, Minnesota, between 
1970 and 2018: a population-based analysis. Open Forum Infect Dis 2021;8:ofab038. 
https://doi.org/10.1093/ofid/ofab038
24. Giannitsioti E, Pefanis A, Gogos C, Lekkou A, Dalekos GN, Gatselis N, et al. Evolution 
of epidemiological characteristics of infective endocarditis in Greece. Int J Infect Dis 
2021;106:213–220. https://doi.org/10.1016/j.ijid.2021.03.009
25. Jensen AD, Bundgaard H, Butt JH, Bruun NE, Voldstedlund M, Torp-Pedersen C, et al. 
Temporal changes in the incidence of infective endocarditis in Denmark 1997–2017: a 
nationwide study. Int J Cardiol 2021;326:145–152. https://doi.org/10.1016/j.ijcard.2020. 
10.029
26. Keller K, von Bardeleben RS, Ostad MA, Hobohm L, Munzel T, Konstantinides S, et al. 
Temporal trends in the prevalence of infective endocarditis in Germany between 2005 
and 2014. Am J Cardiol 2017;119:317–322. https://doi.org/10.1016/j.amjcard.2016.09. 
035
27. Shah ASV, McAllister DA, Gallacher P, Astengo F, Rodriguez Perez JA, Hall J, et al. 
Incidence, microbiology, and outcomes in patients hospitalized with infective endocar­
ditis. Circulation 2020;141:2067–2077. https://doi.org/10.1161/CIRCULATIONAHA. 
119.044913
28. Ortega-Loubon C, Munoz-Moreno MF, Andres-Garcia I, Alvarez FJ, Gomez-Sanchez E, 
Bustamante-Munguira J, et al. Nosocomial vs. community-acquired infective endocar­
ditis in Spain: location, trends, clinical presentation, etiology, and survival in the 21st 
century. J Clin Med 2019;8:1755. https://doi.org/10.3390/jcm8101755
29. Olmos C, Vilacosta I, Fernandez-Perez C, Bernal JL, Ferrera C, Garcia-Arribas D, et al. 
The evolving nature of infective endocarditis in Spain: a population-based study (2003 
to 2014). J Am Coll Cardiol 2017;70:2795–2804. https://doi.org/10.1016/j.jacc.2017.10. 
005
30. Altini C, Lavelli V, Niccoli-Asabella A, Sardaro A, Branca A, Santo G, et al. Comparison 
of the diagnostic value of MRI and whole body (18)F-FDG PET/CT in diagnosis of 
spondylodiscitis. J Clin Med 2020;9:1581. https://doi.org/10.3390/jcm9051581
31. Holle SLK, Andersen MH, Klein CF, Bruun NE, Tonder N, Haarmark C, et al. Clinical 
usefulness of FDG-PET/CT for identification of abnormal extra-cardiac foci in patients 
with infective endocarditis. Int J Cardiovasc Imaging 2020;36:939–946. https://doi.org/ 
10.1007/s10554-020-01787-8
32. Kim S-J, Pak K, Kim K, Lee JS. Comparing the diagnostic accuracies of F-18 fluorodeox­
yglucose positron emission tomography and magnetic resonance imaging for the de­
tection of spondylodiscitis: a meta-analysis. Spine (Phila Pa 1976) 2019;44: 
E414–E422. https://doi.org/10.1097/BRS.0000000000002861
33. Sifaoui I, Oliver L, Tacher V, Fiore A, Lepeule R, Moussafeur A, et al. Diagnostic per­
formance of transesophageal echocardiography and cardiac computed tomography in 
infective endocarditis. J Am Soc Echocardiogr 2020;33:1442–1453. https://doi.org/10. 
1016/j.echo.2020.07.017
34. Venet M, Jalal Z, Ly R, Malekzadeh-Milani S, Hascoet S, Fournier E, et al. Diagnostic va­
lue of (18)F-fluorodeoxyglucose positron emission tomography computed tomog­
raphy in prosthetic pulmonary valve infective endocarditis. JACC Cardiovasc Imaging 
2022;15:299–308. https://doi.org/10.1016/j.jcmg.2021.07.015
35. Wang TKM, Bin Saeedan M, Chan N, Obuchowski NA, Shrestha N, Xu B, et al. 
Complementary diagnostic and prognostic contributions of cardiac computed tomog­
raphy for infective endocarditis surgery. Circ Cardiovasc Imaging 2020;13:e011126. 
https://doi.org/10.1161/CIRCIMAGING.120.011126
36. Camou F, Dijos M, Barandon L, Cornolle C, Greib C, Laine M, et al. Management of 
infective endocarditis and multidisciplinary approach. Med Mal Infect 2019;49:17–22. 
https://doi.org/10.1016/j.medmal.2018.06.007
37. El-Dalati S, Cronin D, Riddell JT, Shea M, Weinberg RL, Washer L, et al. The clinical 
impact of implementation of a multidisciplinary endocarditis team. Ann Thorac Surg 
2022;113:118–124. https://doi.org/10.1016/j.athoracsur.2021.02.027
38. Elad B, Perl L, Hamdan A, Yahav D, Atamna A, Shaked H, et al. The clinical value of the 
endocarditis team: insights from before and after guidelines implementation strategy. 
Infection 2022; 50:57–64. https://doi.org/10.1007/s15010-021-01636-3
39. Gibbons EF, Huang G, Aldea G, Koomalsingh K, Klein JW, Dhanireddy S, et al. A multi­
disciplinary pathway for the diagnosis and treatment of infectious endocarditis. Crit 
Pathw Cardiol 2020;19:187–194. https://doi.org/10.1097/HPC.0000000000000224
40. Kaura A, Byrne J, Fife A, Deshpande R, Baghai M, Gunning M, et al. Inception of the 
‘endocarditis team’ is associated with improved survival in patients with infective endo­
carditis who are managed medically: findings from a before-and-after study. Open 
Heart 2017;4:e000699. https://doi.org/10.1136/openhrt-2017-000699
41. Ruch Y, Mazzucotelli JP, Lefebvre F, Martin A, Lefebvre N, Douiri N, et al. Impact of 
setting up an “endocarditis team” on the management of infective endocarditis. 
Open Forum Infect Dis 2019;6:ofz308. https://doi.org/10.1093/ofid/ofz308
42. European Committee on Antimicrobial Susceptibility Testing. The European Committee 
on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and 
Zone Diameters. Version 12.0, 2022. http://www.eucast.org.
43. Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus 
intravenous antibiotic treatment of endocarditis. N Engl J Med 2019;380:415–424. 
https://doi.org/10.1056/NEJMoa1808312
44. Wildenthal JA, Atkinson A, Lewis S, Sayood S, Nolan NS, Cabrera NL, et al. Outcomes 
of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in 
people who inject drugs. Clin Infect Dis 2022;76:487–496. https://doi.org/10.1093/cid/ 
ciac714
45. Pericas JM, Llopis J, Munoz P, Gonzalez-Ramallo V, Garcia-Leoni ME, de Alarcon A, 
et al. Outpatient parenteral antibiotic treatment vs hospitalization for infective endo­
carditis: validation of the OPAT-games criteria. Open Forum Infect Dis 2022;9:ofac442. 
https://doi.org/10.1093/ofid/ofac442
46. Fernandez-Galilea A, Estella A, Garcia-Garmendia JL, Loza A, Palacios-Garcia I, 
Sierra-Camerino R, et al. Clindamycin but not intravenous immunoglobulins reduces 
mortality in a retrospective cohort of critically ill patients with bacteremic group A 
streptococcal infections. Rev Esp Quimioter 2022;35:475–481. https://doi.org/10. 
37201/req/030.2022
47. Thornhill MH, Jones S, Prendergast B, Baddour LM, Chambers JB, Lockhart PB, et al. 
Quantifying infective endocarditis risk in patients with predisposing cardiac conditions. 
Eur Heart J 2018;39:586–595. https://doi.org/10.1093/eurheartj/ehx655
48. Duval X, Millot S, Chirouze C, Selton-Suty C, Moby V, Tattevin P, et al. Oral strepto­
coccal endocarditis, oral hygiene habits, and recent dental procedures: a case-control 
study. Clin Infect Dis 2017;64:1678–1685. https://doi.org/10.1093/cid/cix237
49. Lockhart PB, Brennan MT, Thornhill M, Michalowicz BS, Noll J, Bahrani-Mougeot FK, 
et al. Poor oral hygiene as a risk factor for infective endocarditis-related bacteremia. J 
Am Dent Assoc 2009;140:1238–1244. https://doi.org/10.14219/jada.archive.2009.0046


<!-- PAGE 76 -->

### Page 76

50. Sy RW, Kritharides L. Health care exposure and age in infective endocarditis: results of 
a contemporary population-based profile of 1536 patients in Australia. Eur Heart J 
2010;31:1890–1897. https://doi.org/10.1093/eurheartj/ehq110
51. Thornhill MH, Gibson TB, Yoon F, Dayer MJ, Prendergast BD, Lockhart PB, et al. 
Antibiotic prophylaxis against infective endocarditis before invasive dental procedures. 
J Am Coll Cardiol 2022;80:1029–1041. https://doi.org/10.1016/j.jacc.2022.06.030
52. Cahill TJ, Harrison JL, Jewell P, Onakpoya I, Chambers JB, Dayer M, et al. Antibiotic 
prophylaxis for infective endocarditis: a systematic review and meta-analysis. Heart 
2017;103:937–944. https://doi.org/10.1136/heartjnl-2015-309102
53. Glauser MP, Francioli P. Relevance of animal models to the prophylaxis of infective 
endocarditis. J Antimicrob Chemother 1987;20(Suppl A):87–98. https://doi.org/10. 
1093/jac/20.suppl_A.87
54. Lafaurie GI, Noriega LA, Torres CC, Castillo Y, Moscoso SB, Mosquera S, et al. Impact 
of antibiotic prophylaxis on the incidence, nature, magnitude, and duration of bacter­
emia associated with dental procedures: a systematic review. J Am Dent Assoc 2019; 
150:948–959.e4. https://doi.org/10.1016/j.adaj.2019.06.017
55. Overholser CD, Moreillon P, Glauser MP. Experimental bacterial endocarditis after 
dental extractions in rats with periodontitis. J Infect Dis 1987;155:107–112. https:// 
doi.org/10.1093/infdis/155.1.107
56. Veloso TR, Amiguet M, Rousson V, Giddey M, Vouillamoz J, Moreillon P, et al. 
Induction of experimental endocarditis by continuous low-grade bacteremia mimick­
ing spontaneous bacteremia in humans. Infect Immun 2011;79:2006–2011. https://doi. 
org/10.1128/IAI.01208-10
57. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. 
Prevention of infective endocarditis: guidelines from the American Heart 
Association: a guideline from the American Heart Association Rheumatic Fever, 
Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease 
in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular 
Surgery and Anesthesia, and the Quality of Care and Outcomes Research 
Interdisciplinary Working Group. Circulation 2007;116:1736–1754. https://doi.org/ 
10.1161/CIRCULATIONAHA.106.183095
58. Richey R, Wray D, Stokes T; Guideline Development Group. Prophylaxis against in­
fective endocarditis: summary of NICE guidance. BMJ 2008;336:770–771. https:// 
doi.org/10.1136/bmj.39510.423148.AD
59. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence 
of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series 
analysis. Lancet 2015;385:1219–1228. https://doi.org/10.1016/S0140-6736(14)62007-9
60. Tubiana S, Duval X, Alla F, Selton-Suty C, Tattevin P, Delahaye F, et al. The VIRSTA 
score, a prediction score to estimate risk of infective endocarditis and determine pri­
ority for echocardiography in patients with Staphylococcus aureus bacteremia. J Infect 
2016;72:544–553. https://doi.org/10.1016/j.jinf.2016.02.003
61. Thornhill MH, Lockhart PB, Prendergast B, Chambers JB, Shanson D. NICE and anti­
biotic prophylaxis to prevent endocarditis. Br Dent J 2015;218:619–621. https://doi. 
org/10.1038/sj.bdj.2015.496
62. Tubiana S, Blotiere PO, Hoen B, Lesclous P, Millot S, Rudant J, et al. Dental procedures, 
antibiotic prophylaxis, and endocarditis among people with prosthetic heart valves: na­
tionwide population based cohort and a case crossover study. BMJ 2017;358:j3776. 
https://doi.org/10.1136/bmj.j3776
63. Cloitre A, Duval X, Tubiana S, Giraud P, Veyrac G, Nosbaum A, et al. Antibiotic 
prophylaxis for the prevention of infective endocarditis for dental procedures is not 
associated with fatal adverse drug reactions in France. Med Oral Patol Oral Cir Bucal 
2019;24:e296–e304. https://doi.org/10.4317/medoral.22818
64. Gross AE, Suda KJ, Zhou J, Calip GS, Rowan SA, Hershow RC, et al. Serious 
antibiotic-related adverse effects following unnecessary dental prophylaxis in the 
United States. Infect Control Hosp Epidemiol 2021;42:110–112. https://doi.org/10. 
1017/ice.2020.1261
65. Khalil D, Hultin M, Rashid MU, Lund B. Oral microflora and selection of resistance after 
a single dose of amoxicillin. Clin Microbiol Infect 2016;22:949.e1–949.e4. https://doi.org/ 
10.1016/j.cmi.2016.08.008
66. Woodman AJ, Vidic J, Newman HN, Marsh PD. Effect of repeated high dose prophy­
laxis with amoxycillin on the resident oral flora of adult volunteers. J Med Microbiol 
1985;19:15–23. https://doi.org/10.1099/00222615-19-1-15
67. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the 
prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the 
Task Force on the prevention, diagnosis, and treatment of infective endocarditis of the 
European Society of Cardiology (ESC). Endorsed by the European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID) and the International Society of 
Chemotherapy (ISC) for infection and cancer. Eur Heart J 2009;30:2369–2413. 
https://doi.org/10.1093/eurheartj/ehp285
68. Bates KE, Hall M, Shah SS, Hill KD, Pasquali SK. Trends in infective endocarditis hospi­
talisations at United States children’s hospitals from 2003 to 2014: impact of the 2007 
American Heart Association antibiotic prophylaxis guidelines. Cardiol Young 2017;27: 
686–690. https://doi.org/10.1017/S1047951116001086
69. Bikdeli B, Wang Y, Kim N, Desai MM, Quagliarello V, Krumholz HM. Trends in hospi­
talization rates and outcomes of endocarditis among medicare beneficiaries. J Am Coll 
Cardiol 2013;62:2217–2226. https://doi.org/10.1016/j.jacc.2013.07.071
70. DeSimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, et al. 
Temporal trends in infective endocarditis epidemiology from 2007 to 2013 in Olmsted 
County, MN. Am Heart J 2015;170:830–836. https://doi.org/10.1016/j.ahj.2015.07.007
71. Desimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, et al. 
Incidence of infective endocarditis caused by viridans group streptococci before and 
after publication of the 2007 American Heart Association’s endocarditis prevention 
guidelines. Circulation 2012;126:60–64. https://doi.org/10.1161/CIRCULATIONAHA. 
112.095281
72. Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, et al. Temporal trends in 
infective endocarditis in the context of prophylaxis guideline modifications: three suc­
cessive population-based surveys. J Am Coll Cardiol 2012;59:1968–1976. https://doi. 
org/10.1016/j.jacc.2012.02.029
73. Garg P, Ko DT, Bray Jenkyn KM, Li L, Shariff SZ. Infective endocarditis hospitalizations 
and antibiotic prophylaxis rates before and after the 2007 American Heart Association 
guideline 
revision. 
Circulation 
2019;140:170–180. 
https://doi.org/10.1161/ 
CIRCULATIONAHA.118.037657
74. Mackie AS, Liu W, Savu A, Marelli AJ, Kaul P. Infective endocarditis hospitalizations be­
fore and after the 2007 American Heart Association prophylaxis guidelines. Can J 
Cardiol 2016;32:942–948. https://doi.org/10.1016/j.cjca.2015.09.021
75. Pasquali SK, He X, Mohamad Z, McCrindle BW, Newburger JW, Li JS, et al. Trends in 
endocarditis hospitalizations at US children’s hospitals: impact of the 2007 American 
Heart Association antibiotic prophylaxis guidelines. Am Heart J 2012;163:894–899. 
https://doi.org/10.1016/j.ahj.2012.03.002
76. Rogers AM, Schiller NB. Impact of the first nine months of revised infective endocar­
ditis prophylaxis guidelines at a university hospital: so far so good. J Am Soc Echocardiogr 
2008;21:775. https://doi.org/10.1016/j.echo.2008.04.001
77. Thornhill MH, Dayer MJ, Forde JM, Corey GR, Chu VH, Couper DJ, et al. Impact of the 
NICE guideline recommending cessation of antibiotic prophylaxis for prevention of in­
fective endocarditis: before and after study. BMJ 2011;342:d2392. https://doi.org/10. 
1136/bmj.d2392
78. Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, et al. Trends in infective 
endocarditis incidence, microbiology, and valve replacement in the United States from 
2000 to 2011. J Am Coll Cardiol 2015;65:2070–2076. https://doi.org/10.1016/j.jacc. 
2015.03.518
79. Sakai Bizmark R, Chang RR, Tsugawa Y, Zangwill KM, Kawachi I. Impact of AHA’s 2007 
guideline change on incidence of infective endocarditis in infants and children. Am Heart 
J 2017;189:110–119. https://doi.org/10.1016/j.ahj.2017.04.006
80. Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova NN. Trends in infective 
endocarditis in California and New York State, 1998–2013. JAMA 2017;317: 
1652–1660. https://doi.org/10.1001/jama.2017.4287
81. van den Brink FS, Swaans MJ, Hoogendijk MG, Alipour A, Kelder JC, Jaarsma W, et al. 
Increased incidence of infective endocarditis after the 2009 European Society of 
Cardiology guideline update: a nationwide study in the Netherlands. Eur Heart J 
Qual Care Clin Outcomes 2017;3:141–147. https://doi.org/10.1093/ehjqcco/qcw039
82. Talha KM, Baddour LM, Thornhill MH, Arshad V, Tariq W, Tleyjeh IM, et al. Escalating 
incidence of infective endocarditis in Europe in the 21st century. Open Heart 2021;8: 
e001846. https://doi.org/10.1136/openhrt-2021-001846
83. Wilson WR, Gewitz M, Lockhart PB, Bolger AF, DeSimone DC, Kazi DS, et al. 
Prevention of viridans group streptococcal infective endocarditis: a scientific statement 
from the American Heart Association. Circulation 2021;143:e963–e978. https://doi. 
org/10.1161/CIR.0000000000000969
84. Havers-Borgersen E, Butt JH, Ostergaard L, Bundgaard H, Smerup M, Bruun NE, et al. 
Recurrent infective endocarditis versus first-time infective endocarditis after heart 
valve surgery. Clin Res Cardiol 2020;109:1342–1351. https://doi.org/10.1007/s00392- 
020-01628-7
85. Calderon-Parra J, Kestler M, Ramos-Martinez A, Bouza E, Valerio M, de Alarcon A, 
et al. Clinical factors associated with reinfection versus relapse in infective endocarditis: 
prospective cohort study. J Clin Med 2021;10:748. https://doi.org/10.3390/ 
jcm10040748
86. Freitas-Ferraz AB, Tirado-Conte G, Vilacosta I, Olmos C, Saez C, Lopez J, et al. 
Contemporary epidemiology and outcomes in recurrent infective endocarditis. 
Heart 2020;106:596–602. https://doi.org/10.1136/heartjnl-2019-315433
87. Salem M, Friedrich C, Saad M, Frank D, Salem M, Puehler T, et al. Active infective native 
and prosthetic valve endocarditis: short- and long-term outcomes of patients after sur­
gical treatment. J Clin Med 2021;10:1868. https://doi.org/10.3390/jcm10091868
88. Luehr M, Bauernschmitt N, Peterss S, Li Y, Heyn O, Dashkevich A, et al. Incidence and 
surgical outcomes of patients with native and prosthetic aortic valve endocarditis. Ann 
Thorac Surg 2020;110:93–101. https://doi.org/10.1016/j.athoracsur.2019.10.029
89. Anantha-Narayanan M, Reddy YNV, Sundaram V, Murad MH, Erwin PJ, Baddour LM, 
et al. Endocarditis risk with bioprosthetic and mechanical valves: systematic review and 
meta-analysis. Heart 2020;106:1413–1419. https://doi.org/10.1136/heartjnl-2020- 
316718
90. Ostergaard L, Valeur N, Ihlemann N, Smerup MH, Bundgaard H, Gislason G, et al. 
Incidence and factors associated with infective endocarditis in patients undergoing left- 
sided heart valve replacement. Eur Heart J 2018;39:2668–2675. https://doi.org/10. 
1093/eurheartj/ehy153
ESC Guidelines                                                                                                                                                                                          4023


<!-- PAGE 77 -->

### Page 77

91. Alexis SL, Malik AH, George I, Hahn RT, Khalique OK, Seetharam K, et al. Infective 
endocarditis after surgical and transcatheter aortic valve replacement: a state of the 
art review. J Am Heart Assoc 2020;9:e017347. https://doi.org/10.1161/JAHA.120. 
017347
92. Lehner A, Haas NA, Dietl M, Jakob A, Schulze-Neick I, Dalla Pozza R, et al. The risk of 
infective endocarditis following interventional pulmonary valve implantation: a 
meta-analysis. J Cardiol 2019;74:197–205. https://doi.org/10.1016/j.jjcc.2019.04.007
93. McElhinney DB, Sondergaard L, Armstrong AK, Bergersen L, Padera RF, Balzer DT, 
et al. Endocarditis after transcatheter pulmonary valve replacement. J Am Coll Cardiol 
2018;72:2717–2728. https://doi.org/10.1016/j.jacc.2018.09.039
94. Summers MR, Leon MB, Smith CR, Kodali SK, Thourani VH, Herrmann HC, et al. 
Prosthetic valve endocarditis after TAVR and SAVR: insights from the PARTNER trials. 
Circulation 2019;140:1984–1994. https://doi.org/10.1161/CIRCULATIONAHA.119. 
041399
95. Asmarats L, Rodriguez-Gabella T, Chamandi C, Bernier M, Beaudoin J, O’Connor K, 
et al. Infective endocarditis following transcatheter edge-to-edge mitral valve repair: 
a systematic review. Catheter Cardiovasc Interv 2018;92:583–591. https://doi.org/10. 
1002/ccd.27632
96. Diller GP, Baumgartner H. Endocarditis in adults with congenital heart disease: new 
answers–new questions. Eur Heart J 2017;38:2057–2059. https://doi.org/10.1093/ 
eurheartj/ehx044
97. Ly R, Compain F, Gaye B, Pontnau F, Bouchard M, Mainardi JL, et al. Predictive factors 
of death associated with infective endocarditis in adult patients with congenital heart 
disease. Eur Heart J Acute Cardiovasc Care 2020. https://doi.org/10.1177/ 
2048872620901394
98. Snygg-Martin U, Giang KW, Dellborg M, Robertson J, Mandalenakis Z. Cumulative in­
cidence of infective endocarditis in patients with congenital heart disease: a nationwide, 
case-control study over nine decades. Clin Infect Dis 2021;73:1469–1475. https://doi. 
org/10.1093/cid/ciab478
99. Mylotte D, Rushani D, Therrien J, Guo L, Liu A, Guo K, et al. Incidence, predictors, and 
mortality of infective endocarditis in adults with congenital heart disease without pros­
thetic valves. Am J Cardiol 2017;120:2278–2283. https://doi.org/10.1016/j.amjcard. 
2017.08.051
100. Mandalenakis Z, Rosengren A, Skoglund K, Lappas G, Eriksson P, Dellborg M. 
Survivorship in children and young adults with congenital heart disease in Sweden. 
JAMA Intern Med 2017;177:224–230. https://doi.org/10.1001/jamainternmed.2016. 
7765
101. Rushani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, et al. Infective 
endocarditis in children with congenital heart disease: cumulative incidence and predic­
tors. Circulation 2013;128:1412–1419. https://doi.org/10.1161/CIRCULATIONAHA. 
113.001827
102. Patel S, Rizvi SSA, Choi JH, Horan DP, Weber MP, Maynes EJ, et al. Management and 
outcomes of left ventricular assist device-associated endocarditis: a systematic review. 
Ann Cardiothorac Surg 2019;8:600–609. https://doi.org/10.21037/acs.2019.04.04
103. Ostergaard L, Valeur N, Wang A, Bundgaard H, Aslam M, Gislason G, et al. Incidence of 
infective endocarditis in patients considered at moderate risk. Eur Heart J 2019;40: 
1355–1361. https://doi.org/10.1093/eurheartj/ehy629
104. Russell EA, Walsh WF, Costello B, McLellan AJA, Brown A, Reid CM, et al. Medical 
management of rheumatic heart disease: a systematic review of the evidence. 
Cardiol Rev 2018;26:187–195. https://doi.org/10.1097/CRD.0000000000000185
105. Jordan AM, Tatum R, Ahmad D, Patel SV, Maynes EJ, Weber MP, et al. Infective endo­
carditis following heart transplantation: a systematic review. Transplant Rev (Orlando) 
2021;36:100672. https://doi.org/10.1016/j.trre.2021.100672
106. Chuang S, Shrestha NK, Brizendine KD. Matched retrospective study of infective 
endocarditis among solid organ transplant recipients compared to non-transplant: 
seven-year experience in a US referral center. Transpl Infect Dis 2020;22:e13368. 
https://doi.org/10.1111/tid.13368
107. Martinez-Selles M, Valerio-Minero M, Farinas MC, Rodriguez-Abella H, Rodriguez ML, 
de Alarcon A, et al. Infective endocarditis in patients with solid organ transplantation. A 
nationwide descriptive study. Eur J Intern Med 2021;87:59–65. https://doi.org/10.1016/ 
j.ejim.2021.02.017
108. Duval X, Alla F, Hoen B, Danielou F, Larrieu S, Delahaye F, et al. Estimated risk of endo­
carditis in adults with predisposing cardiac conditions undergoing dental procedures 
with or without antibiotic prophylaxis. Clin Infect Dis 2006;42:e102–e107. https:// 
doi.org/10.1086/504385
109. Findler M, Chackartchi T, Regev E. Dental implants in patients at high risk for infective 
endocarditis: a preliminary study. Int J Oral Maxillofac Surg 2014;43:1282–1285. https:// 
doi.org/10.1016/j.ijom.2014.04.015
110. Thornhill MH, Dayer M, Lockhart PB, Prendergast B. Antibiotic prophylaxis of infective 
endocarditis. Curr Infect Dis Rep 2017;19:9. https://doi.org/10.1007/s11908-017-0564- 
y
111. Thornhill MH, Dayer MJ, Durkin MJ, Lockhart PB, Baddour LM. Risk of adverse reac­
tions to oral antibiotics prescribed by dentists. J Dent Res 2019;98:1081–1087. https:// 
doi.org/10.1177/0022034519863645
112. Thornhill MH, Dayer MJ, Prendergast B, Baddour LM, Jones S, Lockhart PB. Incidence 
and nature of adverse reactions to antibiotics used as endocarditis prophylaxis. J 
Antimicrob Chemother 2015;70:2382–2388. https://doi.org/10.1093/jac/dkv115
113. Verhoeven PO, Gagnaire J, Botelho-Nevers E, Grattard F, Carricajo A, Lucht F, et al. 
Detection and clinical relevance of Staphylococcus aureus nasal carriage: an update. 
Expert Rev Anti Infect Ther 2014;12:75–89. https://doi.org/10.1586/14787210.2014. 
859985
114. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, 
Roosendaal R, et al. Preventing surgical-site infections in nasal carriers of 
Staphylococcus aureus. N Engl J Med 2010;362:9–17. https://doi.org/10.1056/ 
NEJMoa0808939
115. Friedman AJ, Cosby R, Boyko S, Hatton-Bauer J, Turnbull G. Effective teaching strat­
egies and methods of delivery for patient education: a systematic review and practice 
guideline recommendations. J Cancer Educ 2011;26:12–21. https://doi.org/10.1007/ 
s13187-010-0183-x
116. de Oliveira JC, Martinelli M, Nishioka SA, Varejao T, Uipe D, Pedrosa AA, et al. Efficacy 
of antibiotic prophylaxis before the implantation of pacemakers and cardioverter- 
defibrillators: results of a large, prospective, randomized, double-blinded, placebo- 
controlled trial. Circ Arrhythm Electrophysiol 2009;2:29–34. https://doi.org/10.1161/ 
CIRCEP.108.795906
117. Mounsey JP, Griffith MJ, Tynan M, Gould FK, MacDermott AF, Gold RG, et al. 
Antibiotic prophylaxis in permanent pacemaker implantation: a prospective rando­
mised trial. Br Heart J 1994;72:339–343. https://doi.org/10.1136/hrt.72.4.339
118. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable elec­
tronic device infection: a systematic review and meta-analysis. Europace 2015;17: 
767–777. https://doi.org/10.1093/europace/euv053
119. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, et al. 
Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J 
Med 2010;362:18–26. https://doi.org/10.1056/NEJMoa0810988
120. Lador A, Nasir H, Mansur N, Sharoni E, Biderman P, Leibovici L, et al. Antibiotic 
prophylaxis in cardiac surgery: systematic review and meta-analysis. J Antimicrob 
Chemother 2012;67:541–550. https://doi.org/10.1093/jac/dkr470
121. Conen A, Stortecky S, Moreillon P, Hannan MM, Franzeck FC, Jeger R, et al. A review of 
recommendations for infective endocarditis prevention in patients undergoing trans­
catheter aortic valve implantation. EuroIntervention 2021;16:1135–1140. https://doi. 
org/10.4244/EIJ-D-19-00993
122. Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, Collart F, et al. Dramatic 
reduction in infective endocarditis-related mortality with a management-based ap­
proach. 
Arch 
Intern 
Med 
2009;169:1290–1298. 
https://doi.org/10.1001/ 
archinternmed.2009.192
123. Carrasco-Chinchilla F, Sanchez-Espin G, Ruiz-Morales J, Rodriguez-Bailon I, 
Melero-Tejedor JM, Ivanova-Georgieva R, et al. Influence of a multidisciplinary alert 
strategy on mortality due to left-sided infective endocarditis. Rev Esp Cardiol (Engl 
Ed) 2014;67:380–386. https://doi.org/10.1016/j.recesp.2013.09.012
124. Cervera C, del Rio A, Garcia L, Sala M, Almela M, Moreno A, et al. Efficacy and safety of 
outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospect­
ive study. Enferm Infecc Microbiol Clin 2011;29:587–592. https://doi.org/10.1016/j.eimc. 
2011.05.007
125. Chirillo F, Scotton P, Rocco F, Rigoli R, Borsatto F, Pedrocco A, et al. Impact of a multi­
disciplinary management strategy on the outcome of patients with native valve infect­
ive endocarditis. Am J Cardiol 2013;112:1171–1176. https://doi.org/10.1016/j.amjcard. 
2013.05.060
126. Okura T, Iwata K, Koyama T, Ebisawa K, Arakawa Y, Kusuki M, et al. Impact of infec­
tious disease consultation on management and outcomes of infective endocarditis. Ann 
Thorac Surg 2021;112:1228–1234. https://doi.org/10.1016/j.athoracsur.2020.09.044
127. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 
ACC/AHA guideline for the management of patients with valvular heart disease: a re­
port of the American College of Cardiology/American Heart Association Joint 
Committee on Clinical Practice Guidelines. Circulation 2021;143:e72–e227. https:// 
doi.org/10.1161/CIR.0000000000000923
128. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/ 
EACTS guidelines for the management of valvular heart disease. Eur Heart J 2022;43: 
561–632. https://doi.org/10.1093/eurheartj/ehab395
129. Wang TKM, Sanchez-Nadales A, Igbinomwanhia E, Cremer P, Griffin B, Xu B. 
Diagnosis of infective endocarditis by subtype using (18)F-fluorodeoxyglucose posi­
tron emission tomography/computed tomography: a contemporary meta-analysis. 
Circ Cardiovasc Imaging 2020;13:e010600. https://doi.org/10.1161/CIRCIMAGING. 
120.010600
130. Blomstrom-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, et al. 
European Heart Rhythm Association (EHRA) international consensus document on 
how to prevent, diagnose, and treat cardiac implantable electronic device infec­
tions–endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm 
Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International 
Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society 
of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the


<!-- PAGE 78 -->

### Page 78

European Association for Cardio-Thoracic Surgery (EACTS). Europace 2020;22: 
515–549. https://doi.org/10.1093/europace/euz246
131. Tagliari AP, Steckert GV, da Silveira LMV, Kochi AN, Wender OCB. Infective endocar­
ditis profile, prognostic factors and in-hospital mortality: 6-year trends from a tertiary 
university center in South America. J Card Surg 2020;35:1905–1911. https://doi.org/10. 
1111/jocs.14787
132. Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL. Trends in drug use-associated 
infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide dis­
charge data. Ann Intern Med 2019;170:31–40. https://doi.org/10.7326/M18-2124
133. Rudasill SE, Sanaiha Y, Mardock AL, Khoury H, Xing H, Antonios JW, et al. Clinical out­
comes of infective endocarditis in injection drug users. J Am Coll Cardiol 2019;73: 
559–570. https://doi.org/10.1016/j.jacc.2018.10.082
134. Mori M, Brown KJ, Bin Mahmood SU, Geirsson A, Mangi AA. Trends in infective endo­
carditis hospitalizations, characteristics, and valve operations in patients with opioid 
use disorders in the United States: 2005–2014. J Am Heart Assoc 2020;9:e012465. 
https://doi.org/10.1161/JAHA.119.012465
135. Geirsson A, Schranz A, Jawitz O, Mori M, Feng L, Zwischenberger BA, et al. The evolv­
ing burden of drug use associated infective endocarditis in the United States. Ann 
Thorac Surg 2020;110:1185–1192. https://doi.org/10.1016/j.athoracsur.2020.03.089
136. Mestres CA, Pare JC, Miro JM; Working Group on Infective Endocarditis of the 
Hospital Clínic de Barcelona. Organization and functioning of a multidisciplinary 
team for the diagnosis and treatment of infective endocarditis: a 30-year perspective 
(1985–2014). Rev Esp Cardiol (Engl Ed) 2015;68:363–368. https://doi.org/10.1016/j. 
recesp.2014.10.007
137. Erba PA, Lancellotti P, Vilacosta I, Gaemperli O, Rouzet F, Hacker M, et al. 
Recommendations on nuclear and multimodality imaging in IE and CIED infections. 
Eur J Nucl Med Mol Imaging 2018;45:1795–1815. https://doi.org/10.1007/s00259- 
018-4025-0
138. Schwiebert R, Baig W, Wu J, Sandoe JAT. Diagnostic accuracy of splinter haemor­
rhages in patients referred for suspected infective endocarditis. Heart 2022. https:// 
doi.org/10.1136/heartjnl-2022-321052
139. Grable C, Yusuf SW, Song J, Viola GM, Ulhaq O, Banchs J, et al. Characteristics of in­
fective endocarditis in a cancer population. Open Heart 2021;8:e001664. https://doi. 
org/10.1136/openhrt-2021-001664
140. Perez de Isla L, Zamorano J, Lennie V, Vazquez J, Ribera JM, Macaya C. Negative blood 
culture infective endocarditis in the elderly: long-term follow-up. Gerontology 2007;53: 
245–249. https://doi.org/10.1159/000101691
141. Wong CY, Zhu W, Aurigemma GP, Furukawa N, Teshale EH, Huang YA, et al. Infective 
endocarditis among persons aged 18–64 years living with human immunodeficiency 
virus, hepatitis C infection, or opioid use disorder, United States, 2007–2017. Clin 
Infect Dis 2021;72:1767–1781. https://doi.org/10.1093/cid/ciaa372
142. N’Guyen Y, Duval X, Revest M, Saada M, Erpelding ML, Selton-Suty C, et al. Time inter­
val between infective endocarditis first symptoms and diagnosis: relationship to infect­
ive endocarditis characteristics, microorganisms and prognosis. Ann Med 2017;49: 
117–125. https://doi.org/10.1080/07853890.2016.1235282
143. Niederman MS, Baron RM, Bouadma L, Calandra T, Daneman N, DeWaele J, et al. 
Initial antimicrobial management of sepsis. Crit Care 2021;25:307. https://doi.org/10. 
1186/s13054-021-03736-w
144. Snipsoyr MG, Ludvigsen M, Petersen E, Wiggers H, Honore B. A systematic review of 
biomarkers in the diagnosis of infective endocarditis. Int J Cardiol 2016;202:564–570. 
https://doi.org/10.1016/j.ijcard.2015.09.028
145. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr, Bayer AS, et al. Clinical pres­
entation, etiology, and outcome of infective endocarditis in the 21st century: the 
International Collaboration on Endocarditis–prospective cohort study. Arch Intern 
Med 2009;169:463–473. https://doi.org/10.1001/archinternmed.2008.603
146. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, Kapadia S, Lerakis S, Cheema AN, 
et al. Infective endocarditis after transcatheter aortic valve implantation: results from a 
large multicenter registry. Circulation 2015;131:1566–1574. https://doi.org/10.1161/ 
CIRCULATIONAHA.114.014089
147. Olmos C, Vilacosta I, Fernandez C, Lopez J, Sarria C, Ferrera C, et al. Contemporary 
epidemiology and prognosis of septic shock in infective endocarditis. Eur Heart J 2013; 
34:1999–2006. https://doi.org/10.1093/eurheartj/ehs336
148. Escola-Verge L, Fernandez-Hidalgo N, Larrosa MN, Fernandez-Galera R, Almirante B. 
Secular trends in the epidemiology and clinical characteristics of Enterococcus faecalis 
infective endocarditis at a referral center (2007–2018). Eur J Clin Microbiol Infect Dis 
2021;40:1137–1148. https://doi.org/10.1007/s10096-020-04117-x
149. Dahl A, Iversen K, Tonder N, Hoest N, Arpi M, Dalsgaard M, et al. Prevalence of in­
fective endocarditis in Enterococcus faecalis bacteremia. J Am Coll Cardiol 2019;74: 
193–201. https://doi.org/10.1016/j.jacc.2019.04.059
150. Lamy B, Dargere S, Arendrup MC, Parienti JJ, Tattevin P. How to optimize the use of 
blood cultures for the diagnosis of bloodstream infections? A state-of-the art. Front 
Microbiol 2016;7:697. https://doi.org/10.3389/fmicb.2016.00697
151. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications 
to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30: 
633–638. https://doi.org/10.1086/313753
152. La Scola B, Raoult D. Direct identification of bacteria in positive blood culture bottles 
by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. PLoS 
One 2009;4:e8041. https://doi.org/10.1371/journal.pone.0008041
153. Burckhardt I, Zimmermann S. Susceptibility testing of bacteria using MALDI-ToF mass 
spectrometry. Front Microbiol 2018;9:1744. https://doi.org/10.3389/fmicb.2018.01744
154. Pecoraro AJK, Herbst PG, Pienaar C, Taljaard J, Prozesky H, Janson J, et al. Modified 
Duke/European Society of Cardiology 2015 clinical criteria for infective endocarditis: 
time for an update? Open Heart 2022;9:e001856. https://doi.org/10.1136/openhrt- 
2021-001856
155. Kong WKF, Salsano A, Giacobbe DR, Popescu BA, Laroche C, Duval X, et al. 
Outcomes of culture-negative vs. culture-positive infective endocarditis: the 
ESC-EORP EURO-ENDO registry. Eur Heart J 2022;43:2770–2780. https://doi.org/ 
10.1093/eurheartj/ehac307
156. Fournier PE, Gouriet F, Casalta JP, Lepidi H, Chaudet H, Thuny F, et al. Blood culture- 
negative endocarditis: improving the diagnostic yield using new diagnostic tools. 
Medicine (Baltimore) 2017;96:e8392. https://doi.org/10.1097/MD.0000000000008392
157. Gouriet F, Samson L, Delaage M, Mainardi JL, Meconi S, Drancourt M, et al. Multiplexed 
whole bacterial antigen microarray, a new format for the automation of serodiagnosis: 
the culture-negative endocarditis paradigm. Clin Microbiol Infect 2008;14:1112–1118. 
https://doi.org/10.1111/j.1469-0691.2008.02094.x
158. Raoult D, Casalta JP, Richet H, Khan M, Bernit E, Rovery C, et al. Contribution of sys­
tematic serological testing in diagnosis of infective endocarditis. J Clin Microbiol 2005; 
43:5238–5242. https://doi.org/10.1128/JCM.43.10.5238-5242.2005
159. Hajduczenia MM, Klefisch FR, Hopf AGM, Grubitzsch H, Stegemann MS, Pfafflin F, et al. 
New perspectives for prosthetic valve endocarditis – impact of molecular imaging by 
fishseq diagnostics. Clin Infect Dis 2023;76:1050–1058. https://doi.org/10.1093/cid/ 
ciac860
160. Liesman RM, Pritt BS, Maleszewski JJ, Patel R. Laboratory diagnosis of infective endo­
carditis. J Clin Microbiol 2017;55:2599–2608. https://doi.org/10.1128/JCM.00635-17
161. Loyens M, Thuny F, Grisoli D, Fournier PE, Casalta J-P, Vitte J, et al. Link between endo­
carditis on porcine bioprosthetic valves and allergy to pork. Int J Cardiol 2013;167: 
600–602. https://doi.org/10.1016/j.ijcard.2012.09.233
162. Selton-Suty C, Maigrat CH, Devignes J, Goehringer F, Erpelding ML, Alla F, et al. 
Possible relationship between antiphospholipid antibodies and embolic events in in­
fective endocarditis. Heart 2018;104:509–516. https://doi.org/10.1136/heartjnl-2017- 
312359
163. Habib G, Badano L, Tribouilloy C, Vilacosta I, Zamorano JL, Galderisi M, et al. 
Recommendations for the practice of echocardiography in infective endocarditis. 
Eur J Echocardiogr 2010;11:202–219. https://doi.org/10.1093/ejechocard/jeq004
164. Erba PA, Pizzi MN, Roque A, Salaun E, Lancellotti P, Tornos P, et al. Multimodality im­
aging in infective endocarditis: an imaging team within the endocarditis team. Circulation 
2019;140:1753–1765. https://doi.org/10.1161/CIRCULATIONAHA.119.040228
165. Ostergaard L, Vejlstrup N, Kober L, Fosbol EL, Sondergaard L, Ihlemann N. Diagnostic 
potential of intracardiac echocardiography in patients with suspected prosthetic valve 
endocarditis. J Am Soc Echocardiogr 2019;32:1558–1564.e3. https://doi.org/10.1016/j. 
echo.2019.06.016
166. Bai AD, Steinberg M, Showler A, Burry L, Bhatia RS, Tomlinson GA, et al. Diagnostic 
accuracy of transthoracic echocardiography for infective endocarditis findings using 
transesophageal echocardiography as the reference standard: a meta-analysis. J Am 
Soc Echocardiogr 2017;30:639–646.e8. https://doi.org/10.1016/j.echo.2017.03.007
167. Chambers J, Sandoe J, Ray S, Prendergast B, Taggart D, Westaby S, et al. The infective 
endocarditis team: recommendations from an international working group. Heart 
2014;100:524–527. https://doi.org/10.1136/heartjnl-2013-304354
168. Jain V, Wang TKM, Bansal A, Farwati M, Gad M, Montane B, et al. Diagnostic perform­
ance of cardiac computed tomography versus transesophageal echocardiography in in­
fective endocarditis: a contemporary comparative meta-analysis. J Cardiovasc Comput 
Tomogr 2021;15:313–321. https://doi.org/10.1016/j.jcct.2020.11.008
169. Oliveira M, Guittet L, Hamon M, Hamon M. Comparative value of cardiac CT and 
transesophageal echocardiography in infective endocarditis: a systematic review and 
meta-analysis. Radiol Cardiothorac Imaging 2020;2:e190189. https://doi.org/10.1148/ 
ryct.2020190189
170. Palraj BR, Baddour LM, Hess EP, Steckelberg JM, Wilson WR, Lahr BD, et al. Predicting 
Risk of Endocarditis Using a Clinical Tool (PREDICT): scoring system to guide use of 
echocardiography in the management of Staphylococcus aureus bacteremia. Clin Infect 
Dis 2015;61:18–28. https://doi.org/10.1093/cid/civ235
171. Sunnerhagen T, Tornell A, Vikbrant M, Nilson B, Rasmussen M. HANDOC: a handy 
score to determine the need for echocardiography in non-beta-hemolytic streptococ­
cal bacteremia. Clin Infect Dis 2018;66:693–698. https://doi.org/10.1093/cid/cix880
172. Berge A, Krantz A, Ostlund H, Naucler P, Rasmussen M. The DENOVA score effi­
ciently identifies patients with monomicrobial Enterococcus faecalis bacteremia where 
echocardiography is not necessary. Infection 2019;47:45–50. https://doi.org/10.1007/ 
s15010-018-1208-3
173. Bouza E, Kestler M, Beca T, Mariscal G, Rodriguez-Creixems M, Bermejo J, et al. The 
NOVA score: a proposal to reduce the need for transesophageal echocardiography in 
patients with enterococcal bacteremia. Clin Infect Dis 2015;60:528–535. https://doi. 
org/10.1093/cid/ciu872
ESC Guidelines                                                                                                                                                                                          4025


<!-- PAGE 79 -->

### Page 79

174. Rasmussen RV, Host U, Arpi M, Hassager C, Johansen HK, Korup E, et al. Prevalence of 
infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of 
screening with echocardiography. Eur J Echocardiogr 2011;12:414–420. https://doi.org/ 
10.1093/ejechocard/jer023
175. van der Vaart TW, Prins JM, Soetekouw R, van Twillert G, Veenstra J, Herpers BL, et al. 
Prediction rules for ruling out endocarditis in patients with Staphylococcus aureus bac­
teremia. Clin Infect Dis 2022;74:1442–1449. https://doi.org/10.1093/cid/ciab632
176. Showler A, Burry L, Bai AD, Steinberg M, Ricciuto DR, Fernandes T, et al. Use of trans­
thoracic echocardiography in the management of low-risk Staphylococcus aureus bac­
teremia: results from a retrospective multicenter cohort study. JACC Cardiovasc 
Imaging 2015;8:924–931. https://doi.org/10.1016/j.jcmg.2015.02.027
177. Peinado-Acevedo JS, Hurtado-Guerra JJ, Hincapie C, Mesa-Abad J, Uribe-Delgado JR, 
Giraldo-Ramirez S, et al. Validation of VIRSTA and Predicting Risk of Endocarditis 
Using a Clinical Tool (PREDICT) scores to determine the priority of echocardiography 
in patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2021;73:e1151–­
e1157. https://doi.org/10.1093/cid/ciaa1844
178. Chamat-Hedemand S, Bruun NE, Ostergaard L, Arpi M, Fosbol E, Boel J, et al. Proposal 
for the use of echocardiography in bloodstream infections due to different streptococ­
cal species. BMC Infect Dis 2021;21:689. https://doi.org/10.1186/s12879-021-06391-2
179. Young WJ, Jeffery DA, Hua A, Primus C, Serafino Wani R, Das S, et al. 
Echocardiography in patients with infective endocarditis and the impact of diagnostic 
delays on clinical outcomes. Am J Cardiol 2018;122:650–655. https://doi.org/10.1016/j. 
amjcard.2018.04.039
180. Iversen K, Host N, Bruun NE, Elming H, Pump B, Christensen JJ, et al. Partial oral treat­
ment of endocarditis. Am Heart J 2013;165:116–122. https://doi.org/10.1016/j.ahj. 
2012.11.006
181. MacKay EJ, Zhang B, Augoustides JG, Groeneveld PW, Desai ND. Association of in­
traoperative transesophageal echocardiography and clinical outcomes after open car­
diac valve or proximal aortic surgery. JAMA Netw Open 2022;5:e2147820. https://doi. 
org/10.1001/jamanetworkopen.2021.47820
182. Gonzalez-Juanatey C, Gonzalez-Gay MA, Llorca J, Crespo F, Garcia-Porrua C, 
Corredoira J, et al. Rheumatic manifestations of infective endocarditis in non-addicts. 
A 12–year study. Medicine (Baltimore) 2001;80:9–19. https://doi.org/10.1097/ 
00005792-200101000-00002
183. Vallejo Camazon N, Cediel G, Nunez Aragon R, Mateu L, Llibre C, Sopena N, et al. 
Short- and long-term mortality in patients with left-sided infective endocarditis not 
undergoing surgery despite indication. Rev Esp Cardiol (Engl Ed) 2020;73:734–740. 
https://doi.org/10.1016/j.rec.2019.09.011
184. Vallejo Camazon N, Mateu L, Cediel G, Escola-Verge L, Fernandez-Hidalgo N, Gurgui 
Ferrer M, et al. Long-term antibiotic therapy in patients with surgery-indicated not 
undergoing surgery infective endocarditis. Cardiol J 2021;28:566–578. https://doi.org/ 
10.5603/CJ.a2021.0054
185. Chaosuwannakit N, Makarawate P. Value of cardiac computed tomography angiog­
raphy in pre-operative assessment of infective endocarditis. J Cardiothorac Surg 2019; 
14:56. https://doi.org/10.1186/s13019-019-0880-4
186. Fagman E, Flinck A, Snygg-Martin U, Olaison L, Bech-Hanssen O, Svensson G. Surgical 
decision-making in aortic prosthetic valve endocarditis: the influence of 
electrocardiogram-gated computed tomography. Eur J Cardiothorac Surg 2016;50: 
1165–1171. https://doi.org/10.1093/ejcts/ezw177
187. Abbara S, Blanke P, Maroules CD, Cheezum M, Choi AD, Han BK, et al. SCCT guide­
lines for the performance and acquisition of coronary computed tomographic angiog­
raphy: a report of the Society of Cardiovascular Computed Tomography Guidelines 
Committee: endorsed by the North American Society for Cardiovascular Imaging 
(NASCI). J Cardiovasc Comput Tomogr 2016;10:435–449. https://doi.org/10.1016/j. 
jcct.2016.10.002
188. Parra JA, Hernandez L, Munoz P, Blanco G, Rodriguez-Alvarez R, Vilar DR, et al. 
Detection of spleen, kidney and liver infarcts by abdominal computed tomography 
does not affect the outcome in patients with left-side infective endocarditis. 
Medicine 
(Baltimore) 
2018;97:e11952. 
https://doi.org/10.1097/MD. 
0000000000011952
189. Huang JS, Ho AS, Ahmed A, Bhalla S, Menias CO. Borne identity: CT imaging of vas­
cular infections. Emerg Radiol 2011;18:335–343. https://doi.org/10.1007/s10140-011- 
0946-7
190. Tonolini M, Petulla M, Bianco R. Mycotic visceral aneurysm complicating infectious 
endocarditis: imaging diagnosis and follow-up. J Emerg Trauma Shock 2012;5: 
201–203. https://doi.org/10.4103/0974-2700.96501
191. Gonzalez I, Sarria C, Lopez J, Vilacosta I, San Roman A, Olmos C, et al. Symptomatic 
peripheral mycotic aneurysms due to infective endocarditis: a contemporary profile. 
Medicine (Baltimore) 2014;93:42–52. https://doi.org/10.1097/MD.0000000000000014
192. Goddard AJ, Tan G, Becker J. Computed tomography angiography for the detection 
and characterization of intra-cranial aneurysms: current status. Clin Radiol 2005;60: 
1221–1236. https://doi.org/10.1016/j.crad.2005.06.007
193. Hekimian G, Kim M, Passefort S, Duval X, Wolff M, Leport C, et al. Preoperative use 
and safety of coronary angiography for acute aortic valve infective endocarditis. Heart 
2010;96:696–700. https://doi.org/10.1136/hrt.2009.183772
194. Lecomte R, Issa N, Gaborit B, Le Turnier P, Deschanvres C, Asseray N, et al. 
Risk-benefit assessment of systematic thoracoabdominal-pelvic computed tomog­
raphy in infective endocarditis. Clin Infect Dis 2019;69:1605–1612. https://doi.org/10. 
1093/cid/ciz014
195. Dursun M, Yilmaz S, Yilmaz E, Yilmaz R, Onur I, Oflaz H, et al. The utility of cardiac MRI 
in diagnosis of infective endocarditis: preliminary results. Diagn Interv Radiol 2015;21: 
28–33. https://doi.org/10.5152/dir.2014.14239
196. El Ouazzani J, Jandou I, Christophe Thuaire I. Thrombus or vegetation? Importance of 
cardiac MRI as a diagnostic tool based on case report and literature review. Ann Med 
Surg (Lond) 2020;60:690–694. https://doi.org/10.1016/j.amsu.2020.12.007
197. Snygg-Martin U, Gustafsson L, Rosengren L, Alsio A, Ackerholm P, Andersson R, et al. 
Cerebrovascular complications in patients with left-sided infective endocarditis are 
common: a prospective study using magnetic resonance imaging and neurochemical 
brain damage markers. Clin Infect Dis 2008;47:23–30. https://doi.org/10.1086/588663
198. Cooper HA, Thompson EC, Laureno R, Fuisz A, Mark AS, Lin M, et al. Subclinical brain 
embolization in left-sided infective endocarditis: results from the evaluation by MRI of 
the brains of patients with left-sided intracardiac solid masses (EMBOLISM) pilot study. 
Circulation 
2009;120:585–591. 
https://doi.org/10.1161/CIRCULATIONAHA.108. 
834432
199. Chakraborty T, Scharf E, DeSimone D, El Rafei A, Brinjikji W, Baddour LM, et al. 
Variable significance of brain MRI findings in infective endocarditis and its effect on sur­
gical decisions. Mayo Clin Proc 2019;94:1024–1032. https://doi.org/10.1016/j.mayocp. 
2018.09.015
200. Duval X, Iung B, Klein I, Brochet E, Thabut G, Arnoult F, et al. Effect of early cerebral 
magnetic resonance imaging on clinical decisions in infective endocarditis: a prospect­
ive study. Ann Intern Med 2010;152:497–504,W175. https://doi.org/10.7326/0003- 
4819-152-8-201004200-00006
201. Sotero FD, Rosario M, Fonseca AC, Ferro JM. Neurological complications of infective 
endocarditis. Curr Neurol Neurosci Rep 2019;19:23. https://doi.org/10.1007/s11910- 
019-0935-x
202. Fujimoto T, Morofuji Y, Matsunaga Y, Horie N, Izumo T, Tateishi Y, et al. Early diagno­
sis of infective endocarditis by brain T2*-weighted magnetic resonance imaging. Circ J 
2018;82:464–468. https://doi.org/10.1253/circj.CJ-17-0212
203. Haller S, Vernooij MW, Kuijer JPA, Larsson EM, Jager HR, Barkhof F. Cerebral micro­
bleeds: imaging and clinical significance. Radiology 2018;287:11–28. https://doi.org/10. 
1148/radiol.2018170803
204. Hess A, Klein I, Iung B, Lavallee P, Ilic-Habensus E, Dornic Q, et al. Brain MRI findings in 
neurologically asymptomatic patients with infective endocarditis. AJNR Am J Neuroradiol 
2013;34:1579–1584. https://doi.org/10.3174/ajnr.A3582
205. Iung B, Tubiana S, Klein I, Messika-Zeitoun D, Brochet E, Lepage L, et al. Determinants 
of cerebral lesions in endocarditis on systematic cerebral magnetic resonance imaging: 
a 
prospective 
study. 
Stroke 
2013;44:3056–3062. 
https://doi.org/10.1161/ 
STROKEAHA.113.001470
206. Foreman SC, Schwaiger BJ, Gempt J, Jungmann PM, Kehl V, Delbridge C, et al. MR and 
CT imaging to optimize CT-guided biopsies in suspected spondylodiscitis. World 
Neurosurg 2017;99:726–734.e7. https://doi.org/10.1016/j.wneu.2016.11.017
207. Dunbar JA, Sandoe JA, Rao AS, Crimmins DW, Baig W, Rankine JJ. The MRI appear­
ances of early vertebral osteomyelitis and discitis. Clin Radiol 2010;65:974–981. 
https://doi.org/10.1016/j.crad.2010.03.015
208. Gomes A, Glaudemans A, Touw DJ, van Melle JP, Willems TP, Maass AH, et al. 
Diagnostic value of imaging in infective endocarditis: a systematic review. Lancet 
Infect Dis 2017;17:e1–e14. https://doi.org/10.1016/S1473-3099(16)30141-4
209. Saby L, Laas O, Habib G, Cammilleri S, Mancini J, Tessonnier L, et al. Positron emission 
tomography/computed tomography for diagnosis of prosthetic valve endocarditis: in­
creased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll 
Cardiol 2013;61:2374–2382. https://doi.org/10.1016/j.jacc.2013.01.092
210. Swart LE, Gomes A, Scholtens AM, Sinha B, Tanis W, Lam M, et al. Improving the diag­
nostic performance of (18)F-fluorodeoxyglucose positron-emission tomography/ 
computed tomography in prosthetic heart valve endocarditis. Circulation 2018;138: 
1412–1427. https://doi.org/10.1161/CIRCULATIONAHA.118.035032
211. Duval X, Le Moing V, Tubiana S, Esposito-Farese M, Ilic-Habensus E, Leclercq F, et al. 
Impact of systematic whole-body 18F-fluorodeoxyglucose PET/CT on the manage­
ment of patients suspected of infective endocarditis: the prospective multicenter tep­
vendo study. Clin Infect Dis 2021;73:393–403. https://doi.org/10.1093/cid/ciaa666
212. Philip M, Tessonier L, Mancini J, Mainardi JL, Fernandez-Gerlinger MP, Lussato D, et al. 
Comparison between ESC and Duke criteria for the diagnosis of prosthetic valve in­
fective endocarditis. JACC Cardiovasc Imaging 2020;13:2605–2615. https://doi.org/10. 
1016/j.jcmg.2020.04.011
213. Erba PA, Conti U, Lazzeri E, Sollini M, Doria R, De Tommasi SM, et al. Added value of 
99mTc-HMPAO-labeled leukocyte SPECT/CT in the characterization and manage­
ment of patients with infectious endocarditis. J Nucl Med 2012;53:1235–1243. 
https://doi.org/10.2967/jnumed.111.099424
214. Rouzet F, Chequer R, Benali K, Lepage L, Ghodbane W, Duval X, et al. Respective per­
formance of 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of 
prosthetic valve endocarditis. J Nucl Med 2014;55:1980–1985. https://doi.org/10.2967/ 
jnumed.114.141895


<!-- PAGE 80 -->

### Page 80

215. Hyafil F, Rouzet F, Lepage L, Benali K, Raffoul R, Duval X, et al. Role of radiolabelled 
leucocyte scintigraphy in patients with a suspicion of prosthetic valve endocarditis 
and inconclusive echocardiography. Eur Heart J Cardiovasc Imaging 2013;14:586–594. 
https://doi.org/10.1093/ehjci/jet029
216. Holcman K, Szot W, Rubis P, Lesniak-Sobelga A, Hlawaty M, Wisniowska-Smialek S, 
et al. 99mTc-HMPAO-labeled leukocyte SPECT/CT and transthoracic echocardiog­
raphy diagnostic value in infective endocarditis. Int J Cardiovasc Imaging 2019;35: 
749–758. https://doi.org/10.1007/s10554-018-1487-x
217. Albano D, Dondi F, Gazzilli M, Giubbini R, Bertagna F. Meta-analysis of the diagnostic 
performance of (18)F-FDG-PET/CT imaging in native valve endocarditis. JACC 
Cardiovasc Imaging 2021;14:1063–1065. https://doi.org/10.1016/j.jcmg.2020.09.021
218. de Camargo RA, Sommer Bitencourt M, Meneghetti JC, Soares J, Goncalves LFT, 
Buchpiguel CA, et al. The role of 18F-fluorodeoxyglucose positron emission tomog­
raphy/computed tomography in the diagnosis of left-sided endocarditis: native vs pros­
thetic valves endocarditis. Clin Infect Dis 2020;70:583–594. https://doi.org/10.1093/cid/ 
ciz267
219. Pelletier-Galarneau M, Abikhzer G, Harel F, Dilsizian V. Detection of native and pros­
thetic valve endocarditis: incremental attributes of functional FDG PET/CT over mor­
phologic imaging. Curr Cardiol Rep 2020;22:93. https://doi.org/10.1007/s11886-020- 
01334-w
220. Pizzi MN, Fernandez-Hidalgo N. Optimizing the diagnostic workup of infective endo­
carditis: an urgent need for studies focused on defining the decision-making process. J 
Nucl Cardiol 2020;27:609–611. https://doi.org/10.1007/s12350-018-1434-1
221. Boursier C, Duval X, Bourdon A, Imbert L, Mahida B, Chevalier E, et al. ECG-gated 
cardiac FDG PET acquisitions significantly improve detectability of infective endocar­
ditis. JACC Cardiovasc Imaging 2020;13:2691–2693. https://doi.org/10.1016/j.jcmg.2020. 
06.036
222. Ishikita A, Sakamoto I, Yamamura K, Umemoto S, Nagata H, Kitamura Y, et al. 
Usefulness of (18)F-fluorodeoxyglucose positron emission tomography/computed 
tomography in the diagnosis of infective endocarditis in patients with adult congenital 
heart disease. Circ J 2021;85:1505–1513. https://doi.org/10.1253/circj.CJ-20-1067
223. Pizzi MN, Dos-Subira L, Roque A, Fernandez-Hidalgo N, Cuellar-Calabria H, Pijuan 
Domenech A, et al. (18)F-FDG-PET/CT angiography in the diagnosis of infective endo­
carditis and cardiac device infection in adult patients with congenital heart disease and 
prosthetic material. Int J Cardiol 2017;248:396–402. https://doi.org/10.1016/j.ijcard. 
2017.08.008
224. San S, Ravis E, Tessonier L, Philip M, Cammilleri S, Lavagna F, et al. Prognostic value of 
(18)F-fluorodeoxyglucose positron emission tomography/computed tomography in 
infective endocarditis. J Am Coll Cardiol 2019;74:1031–1040. https://doi.org/10.1016/ 
j.jacc.2019.06.050
225. Mikail N, Benali K, Mahida B, Vigne J, Hyafil F, Rouzet F, et al. (18)F-FDG-PET/CT im­
aging to diagnose septic emboli and mycotic aneurysms in patients with endocarditis 
and cardiac device infections. Curr Cardiol Rep 2018;20:14. https://doi.org/10.1007/ 
s11886-018-0956-0
226. Orvin K, Goldberg E, Bernstine H, Groshar D, Sagie A, Kornowski R, et al. The role of 
FDG-PET/CT imaging in early detection of extra-cardiac complications of infective 
endocarditis. Clin Microbiol Infect 2015;21:69–76. https://doi.org/10.1016/j.cmi.2014. 
08.012
227. Duval X, Iung B. Extracardiac imaging of infective endocarditis. Curr Infect Dis Rep 2017; 
19:24. https://doi.org/10.1007/s11908-017-0580-y
228. Kouijzer IJ, Bleeker-Rovers CP, Oyen WJ. 18F-FDG PET/CT for the detection of septic 
embolisms in patients with infectious endocarditis. J Nucl Med 2014;55:1045–1046. 
https://doi.org/10.2967/jnumed.114.140707
229. Germaini M, Boursier C, Goehringer F, Selton-Suty C, Lefevre B, Roch V, et al. The 
detection of infectious endocarditis may be enhanced by a repeat FDG-PET while 
maintaining patients on a ketogenic diet. J Nucl Cardiol 2022;29:3256–3262. https:// 
doi.org/10.1007/s12350-022-02921-w
230. Slart R, Glaudemans A, Gheysens O, Lubberink M, Kero T, Dweck MR, et al. 
Procedural recommendations of cardiac PET/CT imaging: standardization in 
inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular dis­
eases: a joint collaboration of the EACVI and the EANM. Eur J Nucl Med Mol Imaging 
2021;48:1016–1039. https://doi.org/10.1007/s00259-020-05066-5
231. Mathieu C, Mikail N, Benali K, Iung B, Duval X, Nataf P, et al. Characterization of (18) 
F-fluorodeoxyglucose uptake pattern in noninfected prosthetic heart valves. Circ 
Cardiovasc Imaging 2017;10:e005585. https://doi.org/10.1161/CIRCIMAGING.116. 
005585
232. Mistry NP, AlShaheen M, Leung E, Chow B, Wiefels C. Previous bioglue repair mim­
icking cardiac infection with (18)F-FDG PET imaging. J Nucl Cardiol 2023;30:420–424. 
https://doi.org/10.1007/s12350-021-02807-3
233. Scholtens AM, Swart LE, Verberne HJ, Tanis W, Lam MG, Budde RP. Confounders in 
FDG-PET/CT imaging of suspected prosthetic valve endocarditis. JACC Cardiovasc 
Imaging 2016;9:1462–1465. https://doi.org/10.1016/j.jcmg.2016.01.024
234. Roque A, Pizzi MN, Cuellar-Calabria H, Aguade-Bruix S. (18)F-FDG-PET/CT angiog­
raphy for the diagnosis of infective endocarditis. Curr Cardiol Rep 2017;19:15. https:// 
doi.org/10.1007/s11886-017-0824-3
235. Swart LE, Scholtens AM, Tanis W, Nieman K, Bogers A, Verzijlbergen FJ, et al. 
18F-fluorodeoxyglucose positron emission/computed tomography and computed 
tomography angiography in prosthetic heart valve endocarditis: from guidelines to clin­
ical practice. Eur Heart J 2018;39:3739–3749. https://doi.org/10.1093/eurheartj/ 
ehx784
236. Pizzi MN, Roque A, Cuellar-Calabria H, Fernandez-Hidalgo N, Ferreira-Gonzalez I, 
Gonzalez-Alujas MT, et al. (18)F-FDG-PET/CTA of prosthetic cardiac valves and valve- 
tube grafts: infective versus inflammatory patterns. JACC Cardiovasc Imaging 2016;9: 
1224–1227. https://doi.org/10.1016/j.jcmg.2016.05.013
237. Amraoui S, Tlili G, Sohal M, Berte B, Hindie E, Ritter P, et al. Contribution of PET im­
aging to the diagnosis of septic embolism in patients with pacing lead endocarditis. JACC 
Cardiovasc Imaging 2016;9:283–290. https://doi.org/10.1016/j.jcmg.2015.09.014
238. Calais J, Touati A, Grall N, Laouenan C, Benali K, Mahida B, et al. Diagnostic impact of 
(18)F-fluorodeoxyglucose positron emission tomography/computed tomography and 
white blood cell SPECT/computed tomography in patients with suspected cardiac im­
plantable electronic device chronic infection. Circ Cardiovasc Imaging 2019;12:e007188. 
https://doi.org/10.1161/CIRCIMAGING.117.007188
239. Chen W, Sajadi MM, Dilsizian V. Merits of FDG PET/CT and functional molecular im­
aging over anatomic imaging with echocardiography and CT angiography for the diag­
nosis of cardiac device infections. JACC Cardiovasc Imaging 2018;11:1679–1691. https:// 
doi.org/10.1016/j.jcmg.2018.08.026
240. Okazaki S, Yoshioka D, Sakaguchi M, Sawa Y, Mochizuki H, Kitagawa K. Acute ischemic 
brain lesions in infective endocarditis: incidence, related factors, and postoperative 
outcome. Cerebrovasc Dis 2013;35:155–162. https://doi.org/10.1159/000346101
241. Kestler M, Munoz P, Rodriguez-Creixems M, Rotger A, Jimenez-Requena F, Mari A, 
et al. Role of (18)F-FDG PET in patients with infectious endocarditis. J Nucl Med 
2014;55:1093–1098. https://doi.org/10.2967/jnumed.113.134981
242. Habib G, Derumeaux G, Avierinos JF, Casalta JP, Jamal F, Volot F, et al. Value and lim­
itations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol 
1999;33:2023–2029. https://doi.org/10.1016/S0735-1097(99)00116-3
243. Vieira ML, Grinberg M, Pomerantzeff PM, Andrade JL, Mansur AJ. Repeated echocar­
diographic examinations of patients with suspected infective endocarditis. Heart 2004; 
90:1020–1024. https://doi.org/10.1136/hrt.2003.025585
244. Hill EE, Herijgers P, Claus P, Vanderschueren S, Peetermans WE, Herregods MC. 
Abscess in infective endocarditis: the value of transesophageal echocardiography 
and outcome: a 5-year study. Am Heart J 2007;154:923–928. https://doi.org/10. 
1016/j.ahj.2007.06.028
245. Dahl A, Fowler VG, Miro JM, Bruun NE. Sign of the times: updating infective endocar­
ditis diagnostic criteria to recognize Enterococcus faecalis as a typical endocarditis bac­
terium. Clin Infect Dis 2022;75:1097–1102. https://doi.org/10.1093/cid/ciac181
246. Roque A, Pizzi MN, Fernandez-Hidalgo N, Permanyer E, Cuellar-Calabria H, 
Romero-Farina G, et al. Morpho-metabolic post-surgical patterns of non-infected 
prosthetic heart valves by [18F]FDG PET/CTA: “normality” is a possible diagnosis. 
Eur Heart J Cardiovasc Imaging 2020;21:24–33. https://doi.org/10.1093/ehjci/jez222
247. Anis HK, Miller EM, George J, Shrestha NK, Klika AK, Kamath AF, et al. Incidence and 
characteristics of osteoarticular infections in patients with infective endocarditis. 
Orthopedics 2020;43:24–29. https://doi.org/10.3928/01477447-20191031-02
248. Carbone A, Lieu A, Mouhat B, Santelli F, Philip M, Bohbot Y, et al. Spondylodiscitis 
complicating infective endocarditis. Heart 2020;106:1914–1918. https://doi.org/10. 
1136/heartjnl-2019-316492
249. Arvieux C, Common H. New diagnostic tools for prosthetic joint infection. Orthop 
Traumatol Surg Res 2019;105:S23–S30. https://doi.org/10.1016/j.otsr.2018.04.029
250. Park LP, Chu VH, Peterson G, Skoutelis A, Lejko-Zupa T, Bouza E, et al. Validated risk 
score for predicting 6-month mortality in infective endocarditis. J Am Heart Assoc 2016; 
5:e003016. https://doi.org/10.1161/JAHA.115.003016
251. Sevilla T, Lopez J, Gomez I, Vilacosta I, Sarria C, Garcia-Granja PE, et al. Evolution of 
prognosis in left-sided infective endocarditis: a propensity score analysis of 2 decades. 
J Am Coll Cardiol 2017;69:111–112. https://doi.org/10.1016/j.jacc.2016.10.052
252. Chandrasekar PH, Levine DP, Price S, Rybak MJ. Comparative efficacies of imipenem- 
cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin 
resistant Staphylococcus aureus. J Antimicrob Chemother 1988;21:461–469. https://doi. 
org/10.1093/jac/21.4.461
253. Durack DT, Pelletier LL, Petersdorf RG. Chemotherapy of experimental streptococcal 
endocarditis. II. Synergism between penicillin and streptomycin against penicillin- 
sensitive streptococci. J Clin Invest 1974;53:829–833. https://doi.org/10.1172/ 
JCI107622
254. Wilson WR, Geraci JE, Wilkowske CJ, Washington JA 2nd. Short-term intramuscular 
therapy with procaine penicillin plus streptomycin for infective endocarditis due to vir­
idans streptococci. Circulation 1978;57:1158–1161. https://doi.org/10.1161/01.CIR.57. 
6.1158
255. Lebeaux D, Fernandez-Hidalgo N, Pilmis B, Tattevin P, Mainardi JL. Aminoglycosides 
for infective endocarditis: time to say goodbye? Clin Microbiol Infect 2020;26: 
723–728. https://doi.org/10.1016/j.cmi.2019.10.017
256. Fernandez-Felix BM, Barca LV, Garcia-Esquinas E, Correa-Perez A, Fernandez-Hidalgo 
N, Muriel A, et al. Prognostic models for mortality after cardiac surgery in patients with 
ESC Guidelines                                                                                                                                                                                          4027


<!-- PAGE 81 -->

### Page 81

infective endocarditis: a systematic review and aggregation of prediction models. Clin 
Microbiol Infect 2021;27:1422–1430. https://doi.org/10.1016/j.cmi.2021.05.051
257. Hoiby N, Ciofu O, Johansen HK, Song Z-J, Moser C, Jensen PO, et al. The clinical im­
pact of bacterial biofilms. Int J Oral Sci 2011;3:55–65. https://doi.org/10.4248/ 
IJOS11026
258. Funane K, Tanaka Y, Hosaka T, Murakami K, Miyazaki T, Shiwa Y, et al. Combined drug 
resistance mutations substantially enhance enzyme production in paenibacillus agari­
devorans. J Bacteriol 2018;200:e00188-18. https://doi.org/10.1128/JB.00188-18
259. Knudsen GM, Ng Y, Gram L. Survival of bactericidal antibiotic treatment by a persister 
subpopulation of Listeria monocytogenes. Appl Environ Microbiol 2013;79:7390–7397. 
https://doi.org/10.1128/AEM.02184-13
260. Le Bot A, Lecomte R, Gazeau P, Benezit F, Arvieux C, Ansart S, et al. Is rifampin use 
associated with better outcome in staphylococcal prosthetic valve endocarditis? A 
multicenter retrospective study. Clin Infect Dis 2021;72:e249–e255. https://doi.org/ 
10.1093/cid/ciaa1040
261. Shrestha NK, Shah SY, Wang H, Hussain ST, Pettersson GB, Nowacki AS, et al. 
Rifampin for surgically treated staphylococcal infective endocarditis: a propensity 
score-adjusted cohort study. Ann Thorac Surg 2016;101:2243–2250. https://doi.org/ 
10.1016/j.athoracsur.2015.11.015
262. Marti-Carvajal AJ, Dayer M, Conterno LO, Gonzalez Garay AG, Marti-Amarista CE. A 
comparison of different antibiotic regimens for the treatment of infective endocarditis. 
Cochrane Database Syst Rev 2020;5:CD009880. https://doi.org/10.1002/14651858. 
CD009880.pub3
263. Tissot-Dupont H, Casalta JP, Gouriet F, Hubert S, Salaun E, Habib G, et al. International 
experts’ practice in the antibiotic therapy of infective endocarditis is not following the 
guidelines. Clin Microbiol Infect 2017;23:736–739. https://doi.org/10.1016/j.cmi.2017. 
03.007
264. Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial 
low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephro­
toxic. Clin Infect Dis 2009;48:713–721. https://doi.org/10.1086/597031
265. Pericas JM, Nathavitharana R, Garcia-de-la-Maria C, Falces C, Ambrosioni J, Almela M, 
et al. Endocarditis caused by highly penicillin-resistant viridans group streptococci: still 
room for vancomycin-based regimens. Antimicrob Agents Chemother 2019;63: 
e00516-19. https://doi.org/10.1128/AAC.00516-19
266. Dahl A, Rasmussen RV, Bundgaard H, Hassager C, Bruun LE, Lauridsen TK, et al. 
Enterococcus faecalis infective endocarditis: a pilot study of the relationship between 
duration of gentamicin treatment and outcome. Circulation 2013;127:1810–1817. 
https://doi.org/10.1161/CIRCULATIONAHA.112.001170
267. Miro JM, Garcia-de-la-Maria C, Armero Y, Soy D, Moreno A, del Rio A, et al. Addition 
of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treat­
ment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. 
Antimicrob Agents Chemother 2009;53:4172–4177. https://doi.org/10.1128/AAC. 
00051-09
268. Garrigos C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, et al. 
Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies 
in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. 
Antimicrob Agents Chemother 2013;57:606–610. https://doi.org/10.1128/AAC.01570- 
12
269. Peghin M, Russo A, Givone F, Ingani M, Graziano E, Bassetti M. Should high-dose dap­
tomycin be an alternative treatment regimen for enterococcal endocarditis? Infect Dis 
Ther 2019;8:695–702. https://doi.org/10.1007/s40121-019-00261-w
270. Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, et al. A multicentre 
evaluation of the effectiveness and safety of high-dose daptomycin for the treatment 
of infective endocarditis. J Antimicrob Chemother 2013;68:2921–2926. https://doi.org/ 
10.1093/jac/dkt294
271. Carugati M, Bayer AS, Miro JM, Park LP, Guimaraes AC, Skoutelis A, et al. High-dose 
daptomycin therapy for left-sided infective endocarditis: a prospective study from the 
international collaboration on endocarditis. Antimicrob Agents Chemother 2013;57: 
6213–6222. https://doi.org/10.1128/AAC.01563-13
272. Pujol M, Miro JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, et al. Daptomycin 
plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus 
bacteremia and endocarditis: a randomized clinical trial. Clin Infect Dis 2021;72: 
1517–1525. https://doi.org/10.1093/cid/ciaa1081
273. West KA, Sheeti A, Tamura MacKay K, Forrest GN. Eosinophilic syndromes asso­
ciated with daptomycin use: re-exposure hypersensitivity pneumonitis and prior per­
ipheral eosinophilia. Open Forum Infect Dis 2022;9:ofac065. https://doi.org/10.1093/ 
ofid/ofac065
274. Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Davila P, Iftimie S, Sequera S, et al. 
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocardi­
tis and/or bloodstream infection produced by Gram-positive cocci. Ann Clin Microbiol 
Antimicrob 2019;18:30. https://doi.org/10.1186/s12941-019-0329-6
275. Spaziante M, Franchi C, Taliani G, D’Avolio A, Pietropaolo V, Biliotti E, et al. Serum 
bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppres­
sive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report. 
Open Forum Infect Dis 2019;6:ofz427. https://doi.org/10.1093/ofid/ofz427
276. Abranches J, Zeng L, Kajfasz JK, Palmer SR, Chakraborty B, Wen ZT, et al. Biology of 
oral streptococci. Microbiol Spectr 2018;6. https://doi.org/10.1128/microbiolspec. 
GPP3-0042-2018
277. Westling K, Aufwerber E, Ekdahl C, Friman G, Gardlund B, Julander I, et al. Swedish 
guidelines for diagnosis and treatment of infective endocarditis. Scand J Infect Dis 
2007;39:929–946. https://doi.org/10.1080/00365540701534517
278. Gould FK, Denning DW, Elliott TS, Foweraker J, Perry JD, Prendergast BD, et al. 
Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report 
of the working party of the British Society for Antimicrobial Chemotherapy. J 
Antimicrob Chemother 2012;67:269–289. https://doi.org/10.1093/jac/dkr450
279. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective 
endocarditis in adults: diagnosis, antimicrobial therapy, and management of complica­
tions: a scientific statement for healthcare professionals from the American Heart 
Association. 
Circulation 
2015;132:1435–1486. 
https://doi.org/10.1161/CIR. 
0000000000000296
280. Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A. Treatment of streptococcal endo­
carditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and out­
patient treatment feasibility. JAMA 1992;267:264–267. https://doi.org/10.1001/jama. 
1992.03480020074034
281. Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a 
single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter 
study. Clin Infect Dis 1995;21:1406–1410. https://doi.org/10.1093/clinids/21.6.1406
282. Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D, et al. 
Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin 
once daily for two weeks for treatment of endocarditis due to penicillin-susceptible 
streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 1998;27: 
1470–1474. https://doi.org/10.1086/515038
283. Cremieux AC, Maziere B, Vallois JM, Ottaviani M, Azancot A, Raffoul H, et al. 
Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiog­
raphy. J Infect Dis 1989;159:938–944. https://doi.org/10.1093/infdis/159.5.938
284. Wilson AP, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective ana­
lysis of 104 cases. J Antimicrob Chemother 1996;38:507–521. https://doi.org/10.1093/ 
jac/38.3.507
285. Moet GJ, Dowzicky MJ, Jones RN. Tigecycline (GAR-936) activity against Streptococcus 
gallolyticus (bovis) and viridans group streptococci. Diagn Microbiol Infect Dis 2007;57: 
333–336. https://doi.org/10.1016/j.diagmicrobio.2006.08.001
286. Shelburne SA 3rd, Greenberg SB, Aslam S, Tweardy DJ. Successful ceftriaxone therapy 
of endocarditis due to penicillin non-susceptible viridans streptococci. J Infect 2007;54: 
e99–e101. https://doi.org/10.1016/j.jinf.2006.05.010
287. Hsu RB, Lin FY. Effect of penicillin resistance on presentation and outcome of none­
nterococcal streptococcal infective endocarditis. Cardiology 2006;105:234–239. 
https://doi.org/10.1159/000091821
288. Knoll B, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour LM. Infective endocarditis 
due to penicillin-resistant viridans group streptococci. Clin Infect Dis 2007;44: 
1585–1592. https://doi.org/10.1086/518174
289. Levy CS, Kogulan P, Gill VJ, Croxton MB, Kane JG, Lucey DR. Endocarditis caused by 
penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin 
Infect Dis 2001;33:577–579. https://doi.org/10.1086/321910
290. Pilmis B, Lourtet-Hascoet J, Barraud O, Piau C, Isnard C, Hery-Arnaud G, et al. Be care­
ful about MICs to amoxicillin for patients with streptococci-related infective endocar­
ditis. Int J Antimicrob Agents 2019;53:850–854. https://doi.org/10.1016/j.ijantimicag. 
2019.03.002
291. Matsuo T, Mori N, Sakurai A, Kanie T, Mikami Y, Uehara Y, et al. Effectiveness of dap­
tomycin against infective endocarditis caused by highly penicillin-resistant viridans 
group streptococci. IDCases 2021;24:e01113. https://doi.org/10.1016/j.idcr.2021. 
e01113
292. Hook EW 3rd, Johnson WD Jr. Vancomycin therapy of bacterial endocarditis. Am J 
Med 1978;65:411–415. https://doi.org/10.1016/0002-9343(78)90766-0
293. Beraud G, Tubiana S, Erpelding ML, Le Moing V, Chirouze C, Gorenne I, et al. 
Combined bacterial meningitis and infective endocarditis: when should we search 
for the other when either one is diagnosed? Infect Dis Ther 2022;11:1521–1540. 
https://doi.org/10.1007/s40121-022-00651-7
294. de Egea V, Munoz P, Valerio M, de Alarcon A, Lepe JA, Miro JM, et al. Characteristics 
and outcome of Streptococcus pneumoniae endocarditis in the xxi century: a systematic 
review of 111 cases (2000–2013). Medicine (Baltimore) 2015;94:e1562. https://doi.org/ 
10.1097/MD.0000000000001562
295. Martinez E, Miro JM, Almirante B, Aguado JM, Fernandez-Viladrich P, 
Fernandez-Guerrero ML, et al. Effect of penicillin resistance of Streptococcus pneumo­
niae on the presentation, prognosis, and treatment of pneumococcal endocarditis in 
adults. Clin Infect Dis 2002;35:130–139. https://doi.org/10.1086/341024
296. Perier A, Puyade M, Revest M, Tattevin P, Bernard L, Lemaignen A, et al. Prognosis of 
Streptococcus pneumoniae endocarditis in France, a multicenter observational study 
(2000–2015). Int J Cardiol 2019;288:102–106. https://doi.org/10.1016/j.ijcard.2019. 
04.048


<!-- PAGE 82 -->

### Page 82

297. Friedland IR, McCracken GH Jr. Management of infections caused by 
antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377–382. 
https://doi.org/10.1056/NEJM199408113310607
298. van Ettekoven CN, van de Beek D, Brouwer MC. Update on community-acquired bac­
terial meningitis: guidance and challenges. Clin Microbiol Infect 2017;23:601–606. 
https://doi.org/10.1016/j.cmi.2017.04.019
299. Fernandez Hidalgo N, Gharamti AA, Aznar ML, Almirante B, Yasmin M, Fortes CQ, 
et al. Beta-hemolytic streptococcal infective endocarditis: characteristics and out­
comes from a large, multinational cohort. Open Forum Infect Dis 2020;7:ofaa120. 
https://doi.org/10.1093/ofid/ofaa120
300. Lefort A, Lortholary O, Casassus P, Selton-Suty C, Guillevin L, Mainardi JL, et al. 
Comparison between adult endocarditis due to beta-hemolytic streptococci (ser­
ogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. 
Arch Intern Med 2002;162:2450–2456. https://doi.org/10.1001/archinte.162.21.2450
301. Sambola A, Miro JM, Tornos MP, Almirante B, Moreno-Torrico A, Gurgui M, et al. 
Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the 
literature, 1962–1998. Clin Infect Dis 2002;34:1576–1584. https://doi.org/10.1086/ 
340538
302. Adam EL, Siciliano RF, Gualandro DM, Calderaro D, Issa VS, Rossi F, et al. Case series 
of infective endocarditis caused by Granulicatella species. Int J Infect Dis 2015;31:56–58. 
https://doi.org/10.1016/j.ijid.2014.10.023
303. Giuliano S, Caccese R, Carfagna P, Vena A, Falcone M, Venditti M. Endocarditis caused 
by nutritionally variant streptococci: a case report and literature review. Infez Med 
2012;20:67–74.
304. Tellez A, Ambrosioni J, Hernandez-Meneses M, Llopis J, Ripa M, Chambers ST, et al. 
Clinical characteristics and outcome of infective endocarditis due to Abiotrophia and 
Granulicatella compared to Viridans group streptococci. J Infect 2022;85:137–146. 
https://doi.org/10.1016/j.jinf.2022.05.023
305. Fernandez-Hidalgo N, Ribera A, Larrosa MN, Viedma E, Origuen J, de Alarcon A, et al. 
Impact of Staphylococcus aureus phenotype and genotype on the clinical characteristics 
and outcome of infective endocarditis. A multicentre, longitudinal, prospective, obser­
vational study. Clin Microbiol Infect 2018;24:985–991. https://doi.org/10.1016/j.cmi. 
2017.12.002
306. Sandoe JA, Kerr KG, Reynolds GW, Jain S. Staphylococcus capitis endocarditis: two 
cases and review of the literature. Heart 1999;82:e1. https://doi.org/10.1136/hrt.82. 
3.e1
307. Cone LA, Sontz EM, Wilson JW, Mitruka SN. Staphylococcus capitis endocarditis due to 
a transvenous endocardial pacemaker infection: case report and review of 
Staphylococcus capitis endocarditis. Int J Infect Dis 2005;9:335–339. https://doi.org/10. 
1016/j.ijid.2004.08.004
308. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus 
aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a pro­
spective study. Ann Intern Med 1982;97:496–503. https://doi.org/10.7326/0003-4819- 
97-4-496
309. Apellaniz G, Valdes M, Perez R, Martin-Luengo F, Garcia A, Soria F, et al. [Teicoplanin 
versus cloxacillin, cloxacillin-gentamycin and vancomycin in the treatment of experi­
mental endocarditis caused by methicillin-sensitive Staphylococcus aureus]. Enferm 
Infecc Microbiol Clin 1991;9:208–210.
310. Huang C, Chen I, Lin L. Comparing the outcomes of ceftaroline plus vancomycin or 
daptomycin combination therapy versus vancomycin or daptomycin monotherapy 
in adults with methicillin-resistant Staphylococcus aureus bacteremia–a meta-analysis. 
Antibiotics (Basel) 2022;11:1104. https://doi.org/10.3390/antibiotics11081104
311. Veliev A, Nakipoglu Y. Investigation of Staphylococcus lugdunensis and selected coagu­
lase negative staphylococci isolated from blood culture bottles and determination of 
their sensitivities to antibiotics. Pak J Med Sci 2022;38:657–662. https://doi.org/10. 
12669/pjms.38.3.4738
312. Chirouze C, Cabell CH, Fowler VG Jr, Khayat N, Olaison L, Miro JM, et al. Prognostic 
factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from 
the International Collaboration on Endocarditis merged database. Clin Infect Dis 2004; 
38:1323–1327. https://doi.org/10.1086/383035
313. Oberbach A, Schlichting N, Hagl C, Lehmann S, Kullnick Y, Friedrich M, et al. Four dec­
ades of experience of prosthetic valve endocarditis reflect a high variety of diverse 
pathogens. Cardiovasc Res 2023;119:410–428. https://doi.org/10.1093/cvr/cvac055
314. Hassoun A. Treatment of Staphylococcus aureus prosthetic valve endocarditis. Am J 
Med 2007;120:e9, author reply e11. https://doi.org/10.1016/j.amjmed.2006.02.021
315. Marin M, Munoz P, Sanchez M, Del Rosal M, Alcala L, Rodriguez-Creixems M, et al. 
Molecular diagnosis of infective endocarditis by real-time broad-range polymerase 
chain reaction (PCR) and sequencing directly from heart valve tissue. Medicine 
(Baltimore) 2007;86:195–202. https://doi.org/10.1097/MD.0b013e31811f44ec
316. Martinez-Selles M, Munoz P, Arnaiz A, Moreno M, Galvez J, Rodriguez-Roda J, et al. 
Valve surgery in active infective endocarditis: a simple score to predict in-hospital prog­
nosis. Int J Cardiol 2014;175:133–137. https://doi.org/10.1016/j.ijcard.2014.04.266
317. Munoz P, Kestler M, De Alarcon A, Miro JM, Bermejo J, Rodriguez-Abella H, et al. 
Current epidemiology and outcome of infective endocarditis: a multicenter, prospect­
ive, cohort study. Medicine (Baltimore) 2015;94:e1816. https://doi.org/10.1097/MD. 
0000000000001816
318. Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, et al. Multiple combination 
bactericidal testing of staphylococcal biofilms from implant-associated infections. 
Antimicrob Agents Chemother 2006;50:55–61. https://doi.org/10.1128/AAC.50.1.55- 
61.2006
319. Saeed K, Bal AM, Gould IM, David MZ, Dryden M, Giannitsioti E, et al. An update on 
Staphylococcus aureus infective endocarditis from the International Society of 
Antimicrobial Chemotherapy (ISAC). Int J Antimicrob Agents 2019;53:9–15. https:// 
doi.org/10.1016/j.ijantimicag.2018.09.014
320. Ramos-Martinez A, Munoz Serrano A, de Alarcon Gonzalez A, Munoz P, 
Fernandez-Cruz A, Valerio M, et al. Gentamicin may have no effect on mortality of 
staphylococcal prosthetic valve endocarditis. J Infect Chemother 2018;24:555–562. 
https://doi.org/10.1016/j.jiac.2018.03.003
321. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treat­
ment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob 
Agents Chemother 2008;52:2463–2467. https://doi.org/10.1128/AAC.00300-08
322. Sader HS, Carvalhaes CG, Mendes RE. Ceftaroline activity against Staphylococcus aur­
eus isolated from patients with infective endocarditis, worldwide (2010–2019). Int J 
Infect Dis 2021;102:524–528. https://doi.org/10.1016/j.ijid.2020.11.130
323. Zasowski EJ, Trinh TD, Claeys KC, Lagnf AM, Bhatia S, Klinker KP, et al. Multicenter 
cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant 
Staphylococcus aureus bloodstream infection. Open Forum Infect Dis 2022;9:ofab606. 
https://doi.org/10.1093/ofid/ofab606
324. Sader HS, Mendes RE, Pfaller MA, Flamm RK. Antimicrobial activity of dalbavancin 
tested against Gram-positive organisms isolated from patients with infective endocar­
ditis in US and European medical centres. J Antimicrob Chemother 2019;74:1306–1310. 
https://doi.org/10.1093/jac/dkz006
325. Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, et al. Evaluation of 
vancomycin population susceptibility analysis profile as a predictor of outcomes for pa­
tients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. 
Antimicrob Agents Chemother 2014;58:4636–4641. https://doi.org/10.1128/AAC. 
02820-13
326. Ishaq H, Tariq W, Talha KM, Palraj BRV, Sohail MR, Baddour LM, et al. Association be­
tween high vancomycin minimum inhibitory concentration and clinical outcomes in pa­
tients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis. 
Infection 2021;49:803–811. https://doi.org/10.1007/s15010-020-01568-4
327. Maraolo AE, Giaccone A, Gentile I, Saracino A, Bavaro DF. Daptomycin versus vanco­
mycin for the treatment of methicillin-resistant Staphylococcus aureus bloodstream in­
fection with or without endocarditis: a systematic review and meta-analysis. Antibiotics 
(Basel) 2021;10:1014. https://doi.org/10.3390/antibiotics10081014
328. Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of vancomycin 
or daptomycin with vs without an antistaphylococcal beta-lactam on mortality, bacter­
emia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized 
clinical trial. JAMA 2020;323:527–537. https://doi.org/10.1001/jama.2020.0103
329. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of 
vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised 
consensus guideline and review by the American Society of Health-System 
Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious 
Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 
2020;71:1361–1364. https://doi.org/10.1093/cid/ciaa303
330. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. 
Daptomycin versus standard therapy for bacteremia and endocarditis caused by 
Staphylococcus aureus. N Engl J Med 2006;355:653–665. https://doi.org/10.1056/ 
NEJMoa053783
331. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, et al. Early use of daptomy­
cin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with 
vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. 
Clin Infect Dis 2013;56:1562–1569. https://doi.org/10.1093/cid/cit112
332. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. 
Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant 
Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a 
case-control study. Clin Infect Dis 2012;54:51–58. https://doi.org/10.1093/cid/cir764
333. Gould IM, Miro JM, Rybak MJ. Daptomycin: the role of high-dose and combination 
therapy for Gram-positive infections. Int J Antimicrob Agents 2013;42:202–210. 
https://doi.org/10.1016/j.ijantimicag.2013.05.005
334. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, et al. Use of antistaphylo­
coccal beta-lactams to increase daptomycin activity in eradicating persistent bacter­
emia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin 
binding. Clin Infect Dis 2011;53:158–163. https://doi.org/10.1093/cid/cir340
335. Miro JM, Entenza JM, Del Rio A, Velasco M, Castaneda X, Garcia de la Maria C, et al. 
High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin- 
susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob 
Agents Chemother 2012;56:4511–4515. https://doi.org/10.1128/AAC.06449-11
336. del Rio A, Gasch O, Moreno A, Pena C, Cuquet J, Soy D, et al. Efficacy and safety of 
fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocar­
ditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin 
Infect Dis 2014;59:1105–1112. https://doi.org/10.1093/cid/ciu580
ESC Guidelines                                                                                                                                                                                          4029


<!-- PAGE 83 -->

### Page 83

337. Tattevin P, Boutoille D, Vitrat V, Van Grunderbeeck N, Revest M, Dupont M, et al. 
Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: 
a multicentre observational study. J Antimicrob Chemother 2014;69:2010–2013. https:// 
doi.org/10.1093/jac/dku085
338. Vouillamoz J, Entenza JM, Feger C, Glauser MP, Moreillon P. Quinupristin-dalfopristin 
combined with beta-lactams for treatment of experimental endocarditis due to 
Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin 
B antibiotics. Antimicrob Agents Chemother 2000;44:1789–1795. https://doi.org/10. 
1128/AAC.44.7.1789-1795.2000
339. Guignard B, Entenza JM, Moreillon P. Beta-lactams against methicillin-resistant 
Staphylococcus aureus. Curr Opin Pharmacol 2005;5:479–489. https://doi.org/10.1016/j. 
coph.2005.06.002
340. Jang H-C, Kim S-H, Kim KH, Kim CJ, Lee S, Song K-H, et al. Salvage treatment for per­
sistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with 
or without carbapenem. Clin Infect Dis 2009;49:395–401. https://doi.org/10.1086/ 
600295
341. Perichon B, Courvalin P. Synergism between beta-lactams and glycopeptides against 
vana-type methicillin-resistant Staphylococcus aureus and heterologous expression of 
the vanA operon. Antimicrob Agents Chemother 2006;50:3622–3630. https://doi.org/ 
10.1128/AAC.00410-06
342. Casalta JP, Zaratzian C, Hubert S, Thuny F, Gouriet F, Habib G, et al. Treatment of 
Staphylococcus aureus endocarditis with high doses of trimethoprim/sulfamethoxazole 
and clindamycin-preliminary report. Int J Antimicrob Agents 2013;42:190–191. https:// 
doi.org/10.1016/j.ijantimicag.2013.05.002
343. Tissot-Dupont H, Gouriet F, Oliver L, Jamme M, Casalta JP, Jimeno MT, et al. 
High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus 
endocarditis. Int J Antimicrob Agents 2019;54:143–148. https://doi.org/10.1016/j. 
ijantimicag.2019.06.006
344. Lefevre B, Hoen B, Goehringer F, Sime WN, Aissa N, Alauzet C, et al. 
Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible 
Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study. 
Eur J Clin Microbiol Infect Dis 2021;40:2605–2616. https://doi.org/10.1007/s10096- 
021-04313-3
345. Jorgensen SCJ, Zasowski EJ, Trinh TD, Lagnf AM, Bhatia S, Sabagha N, et al. 
Daptomycin plus beta-lactam combination therapy for methicillin-resistant 
Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort 
study. Clin Infect Dis 2020;71:1–10. https://doi.org/10.1093/cid/ciz746
346. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams 
against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 
48:2871–2875. https://doi.org/10.1128/AAC.48.8.2871-2875.2004
347. Berti AD, Wergin JE, Girdaukas GG, Hetzel SJ, Sakoulas G, Rose WE. Altering the pro­
clivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus 
using combinations with other antibiotics. Antimicrob Agents Chemother 2012;56: 
5046–5053. https://doi.org/10.1128/AAC.00502-12
348. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, et al. 
Antimicrobial salvage therapy for persistent staphylococcal bacteremia using dapto­
mycin plus ceftaroline. Clin Ther 2014;36:1317–1333. https://doi.org/10.1016/j. 
clinthera.2014.05.061
349. Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, et al. Addition of cef­
taroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus 
aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 
2012;56:5296–5302. https://doi.org/10.1128/AAC.00797-12
350. Chirouze C, Athan E, Alla F, Chu VH, Ralph Corey G, Selton-Suty C, et al. Enterococcal 
endocarditis in the beginning of the 21st century: analysis from the International 
Collaboration on Endocarditis-prospective cohort study. Clin Microbiol Infect 2013; 
19:1140–1147. https://doi.org/10.1111/1469-0691.12166
351. Prematunge C, MacDougall C, Johnstone J, Adomako K, Lam F, Robertson J, et al. Vre 
and vse bacteremia outcomes in the era of effective vre therapy: a systematic review 
and meta-analysis. Infect Control Hosp Epidemiol 2016;37:26–35. https://doi.org/10. 
1017/ice.2015.228
352. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality asso­
ciated with vancomycin-resistant and vancomycin-susceptible enterococcal blood­
stream infections: a meta-analysis. Clin Infect Dis 2005;41:327–333. https://doi.org/ 
10.1086/430909
353. Lupia T, Roberto G, Scaglione L, Shbaklo N, De Benedetto I, Scabini S, et al. Clinical and 
microbiological characteristics of bloodstream infections caused by Enterococcus spp. 
within internal medicine wards: a two-year single-centre experience. Intern Emerg Med 
2022;17:1129–1137. https://doi.org/10.1007/s11739-022-02926-w
354. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A, et al. 
Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 
2001–2002: the BSAC bacteraemia resistance surveillance programme. J Antimicrob 
Chemother 2004;53:1018–1032. https://doi.org/10.1093/jac/dkh232
355. Pericas JM, Cervera C, del Rio A, Moreno A, Garcia de la Maria C, Almela M, et al. 
Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in 
the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin 
Microbiol Infect 2014;20:O1075–O1083. https://doi.org/10.1111/1469-0691.12756
356. Rottier WC, Pinholt M, van der Bij AK, Arpi M, Blank SN, Nabuurs-Franssen MH, et al. 
Attributable mortality of vancomycin resistance in ampicillin-resistant Enterococcus 
faecium bacteremia in Denmark and the Netherlands: a matched cohort study. 
Infect Control Hosp Epidemiol 2022;43:719–727. https://doi.org/10.1017/ice.2021.216
357. Pinholt M, Gumpert H, Bayliss S, Nielsen JB, Vorobieva V, Pedersen M, et al. Genomic 
analysis of 495 vancomycin-resistant enterococcus faecium reveals broad dissemin­
ation of a vanA plasmid in more than 19 clones from Copenhagen, Denmark. J 
Antimicrob Chemother 2017;72:40–47. https://doi.org/10.1093/jac/dkw360
358. Taji A, Heidari H, Shahini-Shamsabadi M, Motamedifar M. High-level resistance to ami­
noglycosides among multidrug resistant non-faecalis and non-faecium enterococci. Clin 
Lab 2022;68. https://doi.org/10.7754/Clin.Lab.2022.220222
359. Manoharan H, Lalitha AKV, Mariappan S, Sekar U, Venkataramana GP. Molecular char­
acterization of high-level aminoglycoside resistance among enterococcus species. J Lab 
Physicians 2022;14:290–294. https://doi.org/10.1055/s-0042-1742423
360. Fernandez-Hidalgo N, Almirante B, Gavalda J, Gurgui M, Pena C, de Alarcon A, et al. 
Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating 
Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013;56:1261–1268. 
https://doi.org/10.1093/cid/cit052
361. Gavalda J, Len O, Miro JM, Munoz P, Montejo M, Alarcon A, et al. Brief communication: 
treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann 
Intern 
Med 
2007;146:574–579. 
https://doi.org/10.7326/0003-4819-146-8- 
200704170-00008
362. Miro JM, Pericas JM, del Rio A; Hospital Clinic Endocarditis Study Group. A new era for 
treating Enterococcus faecalis endocarditis: ampicillin plus short-course gentamicin or 
ampicillin plus ceftriaxone: that is the question!. Circulation 2013;127:1763–1766. 
https://doi.org/10.1161/CIRCULATIONAHA.113.002431
363. Olaison L, Schadewitz K; Swedish Society of Infectious Diseases Quality Assurance 
Study Group for Endocarditis. Enterococcal endocarditis in Sweden, 1995–1999: 
can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002;34:159–166. 
https://doi.org/10.1086/338233
364. De Nadai T, Francois M, Sommet A, Dubois D, Metsu D, Grare M, et al. Efficacy of 
teicoplanin monotherapy following initial standard therapy in Enterococcus faecalis in­
fective endocarditis: a retrospective cohort study. Infection 2019;47:463–469. https:// 
doi.org/10.1007/s15010-019-01290-w
365. Escola-Verge L, Fernandez-Hidalgo N, Rodriguez-Pardo D, Pigrau C, Gonzalez-Lopez 
JJ, Bartolome R, et al. Teicoplanin for treating enterococcal infective endocarditis: a 
retrospective observational study from a referral centre in Spain. Int J Antimicrob 
Agents 2019;53:165–170. https://doi.org/10.1016/j.ijantimicag.2018.10.003
366. Herrera-Hidalgo L, Lomas-Cabezas JM, Lopez-Cortes LE, Luque-Marquez R, 
Lopez-Cortes LF, Martinez-Marcos FJ, et al. Ampicillin plus ceftriaxone combined ther­
apy for Enterococcus faecalis infective endocarditis in OPAT. J Clin Med 2021;11:7. 
https://doi.org/10.3390/jcm11010007
367. Herrera-Hidalgo L, Lopez-Cortes LE, Luque-Marquez R, Galvez-Acebal J, de Alarcon 
A, Lopez-Cortes LF, et al. Ampicillin and ceftriaxone solution stability at different tem­
peratures in outpatient parenteral antimicrobial therapy. Antimicrob Agents Chemother 
2020;64:e00309-20. https://doi.org/10.1128/AAC.00309-20
368. Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics 
quinupristin-dalfopristin and linezolid on outcome measure of patients with 
vancomycin-resistant enterococcus bacteremia. Clin Infect Dis 2008;46:30–36. 
https://doi.org/10.1086/523588
369. Wang JT, Yang CJ, Yang JL, Lin SW, Chuang YC, Sheng WH, et al. A high daptomycin 
dose is associated with better bacterial clearance in infections caused by vancomycin- 
resistant enterococcus faecium regardless of daptomycin minimum inhibitory concen­
tration in a rat infective endocarditis model. Microbiol Spectr 2022;10:e0255122. 
https://doi.org/10.1128/spectrum.02551-22
370. Blackberg A, Morenius C, Olaison L, Berge A, Rasmussen M. Infective endocarditis 
caused by HACEK group bacteria–a registry-based comparative study. Eur J Clin 
Microbiol Infect Dis 2021;40:1919–1924. https://doi.org/10.1007/s10096-021-04240-3
371. Paturel L, Casalta JP, Habib G, Nezri M, Raoult D. Actinobacillus actinomycetemcomi­
tans endocarditis. Clin Microbiol Infect 2004;10:98–118. https://doi.org/10.1111/j.1469- 
0691.2004.00794.x
372. Das M, Badley AD, Cockerill FR, Steckelberg JM, Wilson WR. Infective endocarditis 
caused by HACEK microorganisms. Annu Rev Med 1997;48:25–33. https://doi.org/ 
10.1146/annurev.med.48.1.25
373. Chambers ST, Murdoch D, Morris A, Holland D, Pappas P, Almela M, et al. HACEK 
infective endocarditis: characteristics and outcomes from a large, multi-national co­
hort. PLoS One 2013;8:e63181. https://doi.org/10.1371/journal.pone.0063181
374. Morpeth S, Murdoch D, Cabell CH, Karchmer AW, Pappas P, Levine D, et al. 
Non-HACEK Gram-negative bacillus endocarditis. Ann Intern Med 2007;147: 
829–835. https://doi.org/10.7326/0003-4819-147-12-200712180-00002
375. Lorenz A, Sobhanie MME, Orzel L, Coe K, Wardlow L. Clinical outcomes of combin­
ation versus monotherapy for Gram negative non-HACEK infective endocarditis. 
Diagn Microbiol Infect Dis 2021;101:115504. https://doi.org/10.1016/j.diagmicrobio. 
2021.115504


<!-- PAGE 84 -->

### Page 84

376. Veve MP, McCurry ED, Cooksey GE, Shorman MA. Epidemiology and outcomes of 
non-HACEK infective endocarditis in the southeast United States. PLoS One 2020; 
15:e0230199. https://doi.org/10.1371/journal.pone.0230199
377. Tattevin P, Watt G, Revest M, Arvieux C, Fournier PE. Update on blood culture- 
negative endocarditis. Med Mal Infect 2015;45:1–8. https://doi.org/10.1016/j.medmal. 
2014.11.003
378. Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etio­
logic diagnosis of 348 cases. Medicine (Baltimore) 2005;84:162–173. https://doi.org/10. 
1097/01.md.0000165658.82869.17
379. Raoult D, Fournier PE, Vandenesch F, Mainardi JL, Eykyn SJ, Nash J, et al. Outcome and 
treatment of Bartonella endocarditis. Arch Intern Med 2003;163:226–230. https://doi. 
org/10.1001/archinte.163.2.226
380. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, et al. Prevention of 
bacterial endocarditis. Recommendations by the American Heart Association. 
Circulation 1997;96:358–366. https://doi.org/10.1161/01.CIR.96.1.358
381. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations 
for treatment of human infections caused by Bartonella species. Antimicrob Agents 
Chemother 2004;48:1921–33. https://doi.org/10.1128/AAC.48.6.1921-1933.2004
382. Ghigo E, Capo C, Aurouze M, Tung CH, Gorvel JP, Raoult D, et al. Survival of 
Tropheryma whipplei, the agent of Whipple’s disease, requires phagosome acidification. 
Infect Immun 2002;70:1501–1506. https://doi.org/10.1128/IAI.70.3.1501-1506.2002
383. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev 
2001;14:177–207. https://doi.org/10.1128/CMR.14.1.177-207.2001
384. Garcia-Alvarez L, Sanz MM, Marin M, Farinas MC, Montejo M, Goikoetxea J, et al. 
Antimicrobial management of Tropheryma whipplei endocarditis: the Spanish collabor­
ation on endocarditis (games) experience. J Antimicrob Chemother 2019;74: 
1713–1717. https://doi.org/10.1093/jac/dkz059
385. Calderon Parra J, De Castro-Campos D, Munoz Garcia P, Olmedo Samperio M, Marin 
Arriaza M, De Alarcon A, et al. Non-HACEK Gram negative bacilli endocarditis: ana­
lysis of a national prospective cohort. Eur J Intern Med 2021;92:71–78. https://doi.org/ 
10.1016/j.ejim.2021.04.021
386. Tattevin P, Revest M, Lefort A, Michelet C, Lortholary O. Fungal endocarditis: current 
challenges. Int J Antimicrob Agents 2014;44:290–294. https://doi.org/10.1016/j. 
ijantimicag.2014.07.003
387. Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of Candida endocar­
ditis: a meta-analysis. Medicine (Baltimore) 2011;90:237–249. https://doi.org/10.1097/ 
MD.0b013e3182259d38
388. Kalokhe AS, Rouphael N, El Chami MF, Workowski KA, Ganesh G, Jacob JT. 
Aspergillus endocarditis: a review of the literature. Int J Infect Dis 2010;14:e1040–­
e1047. https://doi.org/10.1016/j.ijid.2010.08.005
389. Lye DC, Hughes A, O’Brien D, Athan E. Candida glabrata prosthetic valve endocarditis 
treated successfully with fluconazole plus caspofungin without surgery: a case report 
and literature review. Eur J Clin Microbiol Infect Dis 2005;24:753–755. https://doi.org/10. 
1007/s10096-005-0038-2
390. Valerio M, Camici M, Machado M, Galar A, Olmedo M, Sousa D, et al. Aspergillus endo­
carditis in the recent years, report of cases of a multicentric national cohort and litera­
ture review. Mycoses 2022;65:362–373. https://doi.org/10.1111/myc.13415
391. Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in 
adults: how many blood cultures are needed? J Clin Microbiol 2007;45:3546–3548. 
https://doi.org/10.1128/JCM.01555-07
392. Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, et al. Are all 
beta-lactams 
similarly 
effective 
in 
the 
treatment 
of 
methicillin-sensitive 
Staphylococcus aureus bacteraemia? Clin Microbiol Infect 2011;17:1581–1586. https:// 
doi.org/10.1111/j.1469-0691.2010.03425.x
393. Braquet P, Alla F, Cornu C, Goehringer F, Piroth L, Chirouze C, et al. Factors asso­
ciated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective 
cohort study. Clin Microbiol Infect 2016;22:948.e1–948.e7. https://doi.org/10.1016/j. 
cmi.2016.07.034
394. Willekens R, Puig-Asensio M, Suanzes P, Fernandez-Hidalgo N, Larrosa MN, 
Gonzalez-Lopez JJ, et al. Empirical use of beta-lactam/beta-lactamase inhibitor combi­
nations does not increase mortality compared with cloxacillin and cefazolin in 
methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted co­
hort study. J Antimicrob Chemother 2022;77:2288–2295. https://doi.org/10.1093/jac/ 
dkac152
395. VanEperen AS, Segreti J. Empirical therapy in methicillin-resistant Staphylococcus aureus 
infections: an up-to-date approach. J Infect Chemother 2016;22:351–359. https://doi. 
org/10.1016/j.jiac.2016.02.012
396. Rezar R, Jirak P, Lichtenauer M, Jung C, Lauten A, Hoppe UC, et al. Partial oral antibiot­
ic therapy is non-inferior to intravenous therapy in non-critically ill patients with infect­
ive endocarditis: review and meta-analysis. Wien Klin Wochenschr 2020;132:762–769. 
https://doi.org/10.1007/s00508-020-01614-z
397. Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS. Evaluation of a paradigm 
shift from intravenous antibiotics to oral step-down therapy for the treatment of in­
fective endocarditis: a narrative review. JAMA Intern Med 2020;180:769–777. https:// 
doi.org/10.1001/jamainternmed.2020.0555
398. Rajaratnam D, Rajaratnam R. Outpatient antimicrobial therapy for infective endocar­
ditis is safe. Heart Lung Circ 2021;30:207–215. https://doi.org/10.1016/j.hlc.2020.08. 
016
399. Perica SJ, Llopis J, Gonzalez-Ramallo V, Goenaga MA, Munoz P, Garcia-Leoni ME, et al. 
Outpatient parenteral antibiotic treatment for infective endocarditis: a prospective co­
hort study from the games cohort. Clin Infect Dis 2019;69:1690–1700. https://doi.org/ 
10.1093/cid/ciz030
400. Forestier E, Roubaud-Baudron C, Fraisse T, Patry C, Gavazzi G, Hoen B, et al. 
Comprehensive geriatric assessment in older patients suffering from infective endo­
carditis. A prospective multicentric cohort study. Clin Microbiol Infect 2019;25: 
1246–1252. https://doi.org/10.1016/j.cmi.2019.04.021
401. Pries-Heje MM, Wiingaard C, Ihlemann N, Gill SU, Bruun NE, Elming H, et al. Five-year 
outcomes of the partial oral treatment of endocarditis (POET) trial. N Engl J Med 2022; 
386:601–602. https://doi.org/10.1056/NEJMc2114046
402. Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. 
Dalbavancin as primary and sequential treatment for Gram-positive infective endocar­
ditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis 2018;67: 
795–798. https://doi.org/10.1093/cid/ciy279
403. Iung B, Doco-Lecompte T, Chocron S, Strady C, Delahaye F, Le Moing V, et al. Cardiac 
surgery during the acute phase of infective endocarditis: discrepancies between 
European Society of Cardiology guidelines and practices. Eur Heart J 2016;37: 
840–848. https://doi.org/10.1093/eurheartj/ehv650
404. Ostergaard L, Oestergaard LB, Lauridsen TK, Dahl A, Chaudry M, Gislason G, et al. 
Long-term causes of death in patients with infective endocarditis who undergo medical 
therapy only or surgical treatment: a nationwide population-based study. Eur J 
Cardiothorac Surg 2018;54:860–866. https://doi.org/10.1093/ejcts/ezy156
405. Arminanzas C, Farinas-Alvarez C, Zarauza J, Munoz P, Gonzalez Ramallo V, Martinez 
Selles M, et al. Role of age and comorbidities in mortality of patients with infective 
endocarditis. Eur J Intern Med 2019;64:63–71. https://doi.org/10.1016/j.ejim.2019.03. 
006
406. Diab M, Sponholz C, von Loeffelholz C, Scheffel P, Bauer M, Kortgen A, et al. Impact of 
perioperative liver dysfunction on in-hospital mortality and long-term survival in infect­
ive endocarditis patients. Infection 2017;45:857–866. https://doi.org/10.1007/s15010- 
017-1064-6
407. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. 
EuroSCORE II. Eur J Cardiothorac Surg 2012;41:734–744, discussion 744–745. 
https://doi.org/10.1093/ejcts/ezs043
408. Shahian DM, Jacobs JP, Badhwar V, Kurlansky PA, Furnary AP, Cleveland JC Jr, et al. The 
Society of Thoracic Surgeons 2018 adult cardiac surgery risk models: Part 1-back­
ground, design considerations, and model development. Ann Thorac Surg 2018;105: 
1411–1418. https://doi.org/10.1016/j.athoracsur.2018.03.002
409. Costa MA, Wollmann DR Jr, Campos AC, Cunha CL, Carvalho RG, Andrade DF, et al. 
Risk index for death by infective endocarditis: a multivariate logistic model. Rev Bras Cir 
Cardiovasc 2007;22:192–200. https://doi.org/10.1590/s0102-76382007000200007
410. De Feo M, Cotrufo M, Carozza A, De Santo LS, Amendolara F, Giordano S, et al. The 
need for a specific risk prediction system in native valve infective endocarditis surgery. 
Sci World J 2012;2012:307571. https://doi.org/10.1100/2012/307571
411. Di Mauro M, Dato GMA, Barili F, Gelsomino S, Sante P, Corte AD, et al. A predictive 
model for early mortality after surgical treatment of heart valve or prosthesis infective 
endocarditis. The endoscore. Int J Cardiol 2017;241:97–102. https://doi.org/10.1016/j. 
ijcard.2017.03.148
412. Fernandez-Hidalgo N, Ferreria-Gonzalez I, Marsal JR, Ribera A, Aznar ML, de Alarcon 
A, et al. A pragmatic approach for mortality prediction after surgery in infective endo­
carditis: optimizing and refining EuroSCORE. Clin Microbiol Infect 2018;24:1102.e7–­
1102.e15. https://doi.org/10.1016/j.cmi.2018.01.019
413. Gaca JG, Sheng S, Daneshmand MA, O’Brien S, Rankin JS, Brennan JM, et al. Outcomes 
for endocarditis surgery in North America: a simplified risk scoring system. J Thorac 
Cardiovasc Surg 2011;141:98–106.e2. https://doi.org/10.1016/j.jtcvs.2010.09.016
414. Gatti G, Perrotti A, Obadia JF, Duval X, Iung B, Alla F, et al. Simple scoring system to 
predict in-hospital mortality after surgery for infective endocarditis. J Am Heart Assoc 
2017;6:e004806. https://doi.org/10.1161/JAHA.116.004806
415. Chu VH, Park LP, Athan E, Delahaye F, Freiberger T, Lamas C, et al. Association be­
tween surgical indications, operative risk, and clinical outcome in infective endocarditis: 
a prospective study from the International Collaboration on Endocarditis. Circulation 
2015;131:131–140. https://doi.org/10.1161/CIRCULATIONAHA.114.012461
416. Varela Barca L, Fernandez-Felix BM, Navas Elorza E, Mestres CA, Munoz P, 
Cuerpo-Caballero G, et al. Prognostic assessment of valvular surgery in active infective 
endocarditis: multicentric nationwide validation of a new score developed from a 
meta-analysis. Eur J Cardiothorac Surg 2020;57:724–731. https://doi.org/10.1093/ejcts/ 
ezz328
417. Varela Barca L, Navas Elorza E, Fernandez-Hidalgo N, Moya Mur JL, Muriel Garcia A, 
Fernandez-Felix BM, et al. Prognostic factors of mortality after surgery in infective 
endocarditis: systematic review and meta-analysis. Infection 2019;47:879–895. 
https://doi.org/10.1007/s15010-019-01338-x
418. Fernandez-Cisneros A, Hernandez-Meneses M, Llopis J, Sandoval E, Pereda D, Alcocer 
J, et al. Risk scores’ performance and their impact on operative decision-making in left- 
ESC Guidelines                                                                                                                                                                                          4031


<!-- PAGE 85 -->

### Page 85

sided endocarditis: a cohort study. Eur J Clin Microbiol Infect Dis 2023;42:33–42. https:// 
doi.org/10.1007/s10096-022-04516-2
419. Tornos P, Iung B, Permanyer-Miralda G, Baron G, Delahaye F, Gohlke-Barwolf C, et al. 
Infective endocarditis in Europe: lessons from the Euro heart survey. Heart 2005;91: 
571–575. https://doi.org/10.1136/hrt.2003.032128
420. Kiefer T, Park L, Tribouilloy C, Cortes C, Casillo R, Chu V, et al. Association between 
valvular surgery and mortality among patients with infective endocarditis complicated 
by heart failure. JAMA 2011;306:2239–2247. https://doi.org/10.1001/jama.2011.1701
421. Lalani T, Chu VH, Park LP, Cecchi E, Corey GR, Durante-Mangoni E, et al. In-hospital 
and 1-year mortality in patients undergoing early surgery for prosthetic valve endocar­
ditis. JAMA Intern Med 2013;173:1495–1504. https://doi.org/10.1001/jamainternmed. 
2013.8203
422. Lopez J, Sevilla T, Vilacosta I, Garcia H, Sarria C, Pozo E, et al. Clinical significance of 
congestive heart failure in prosthetic valve endocarditis. A multicenter study with 
257 patients. Rev Esp Cardiol (Engl Ed) 2013;66:384–390. https://doi.org/10.1016/j. 
rec.2012.10.022
423. Nadji G, Rusinaru D, Remadi JP, Jeu A, Sorel C, Tribouilloy C. Heart failure in left-sided 
native valve infective endocarditis: characteristics, prognosis, and results of surgical 
treatment. Eur J Heart Fail 2009;11:668–675. https://doi.org/10.1093/eurjhf/hfp077
424. Pericas JM, Hernandez-Meneses M, Munoz P, Martinez-Selles M, Alvarez-Uria A, de 
Alarcon A, et al. Characteristics and outcome of acute heart failure in infective endo­
carditis: focus on cardiogenic shock. Clin Infect Dis 2021;73:765–774. https://doi.org/10. 
1093/cid/ciab098
425. Mir T, Uddin M, Qureshi WT, Regmi N, Tleyjeh IM, Saydain G. Predictors of complica­
tions secondary to infective endocarditis and their associated outcomes: a large cohort 
study from the national emergency database (2016–2018). Infect Dis Ther 2022;11: 
305–321. https://doi.org/10.1007/s40121-021-00563-y
426. Aksoy O, Sexton DJ, Wang A, Pappas PA, Kourany W, Chu V, et al. Early surgery in 
patients with infective endocarditis: a propensity score analysis. Clin Infect Dis 2007; 
44:364–372. https://doi.org/10.1086/510583
427. Habib G, Tribouilloy C, Thuny F, Giorgi R, Brahim A, Amazouz M, et al. Prosthetic valve 
endocarditis: who needs surgery? A multicentre study of 104 cases. Heart 2005;91: 
954–959. https://doi.org/10.1136/hrt.2004.046177
428. Nadji G, Goissen T, Brahim A, Coviaux F, Lorgeron N, Tribouilloy C. Impact of early 
surgery on 6-month outcome in acute infective endocarditis. Int J Cardiol 2008;129: 
227–232. https://doi.org/10.1016/j.ijcard.2007.07.087
429. Thuny F, Beurtheret S, Mancini J, Gariboldi V, Casalta JP, Riberi A, et al. The timing of 
surgery influences mortality and morbidity in adults with severe complicated infective 
endocarditis: a propensity analysis. Eur Heart J 2011;32:2027–2033. https://doi.org/10. 
1093/eurheartj/ehp089
430. Bohbot Y, Habib G, Laroche C, Stohr E, Chirouze C, Hernandez-Meneses M, et al. 
Characteristics, management, and outcomes of patients with left-sided infective endo­
carditis complicated by heart failure: a substudy of the ESC-EORP EURO-ENDO 
(European infective endocarditis) registry. Eur J Heart Fail 2022;24:1253–1265. 
https://doi.org/10.1002/ejhf.2525
431. Siciliano RF, Gualandro DM, Bittencourt MS, Paixao M, Marcondes-Braga F, Soeiro 
AM, et al. Biomarkers for prediction of mortality in left-sided infective endocarditis. 
Int J Infect Dis 2020;96:25–30. https://doi.org/10.1016/j.ijid.2020.03.009
432. Wei X-B, Liu Y-H, He P-C, Yu D-Q, Zhou Y-L, Tan N, et al. Prognostic value of 
N-terminal prohormone brain natriuretic peptide for in-hospital and long-term out­
comes in patients with infective endocarditis. Eur J Prev Cardiol 2017;24:676–684. 
https://doi.org/10.1177/2047487316686436
433. Ostergaard L, Dahl A, Bruun NE, Oestergaard LB, Lauridsen TK, Torp-Pedersen C, 
et al. Valve regurgitation in patients surviving endocarditis and the subsequent risk 
of heart failure. Heart 2020;106:1015–1022. https://doi.org/10.1136/heartjnl-2019- 
315715
434. Revilla A, Lopez J, Vilacosta I, Villacorta E, Rollan MJ, Echevarria JR, et al. Clinical and 
prognostic profile of patients with infective endocarditis who need urgent surgery. 
Eur Heart J 2007;28:65–71. https://doi.org/10.1093/eurheartj/ehl315
435. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. 
The third international consensus definitions for sepsis and septic shock (sepsis-3). 
JAMA 2016;315:801–810. https://doi.org/10.1001/jama.2016.0287
436. Pericas JM, Hernandez-Meneses M, Munoz P, Alvarez-Uria A, Pinilla-Llorente B, de 
Alarcon A, et al. Outcomes and risk factors of septic shock in patients with infective 
endocarditis: a prospective cohort study. Open Forum Infect Dis 2021;8:ofab119. 
https://doi.org/10.1093/ofid/ofab119
437. Lopez J, Sevilla T, Vilacosta I, Sarria C, Revilla A, Ortiz C, et al. Prognostic role of per­
sistent positive blood cultures after initiation of antibiotic therapy in left-sided infective 
endocarditis. Eur Heart J 2013;34:1749–1754. https://doi.org/10.1093/eurheartj/ 
ehs379
438. Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, et al. Guidelines on 
prevention, diagnosis and treatment of infective endocarditis executive summary; 
the task force on infective endocarditis of the European Society of Cardiology. Eur 
Heart J 2004;25:267–276. https://doi.org/10.1016/j.ehj.2003.11.008
439. Ramanathan A, Witten JC, Gordon SM, Griffin BP, Pettersson GB, Shrestha NK. 
Factors associated with local invasion in infective endocarditis: a nested case-control 
study. Clin Microbiol Infect 2021;27:1011–1014. https://doi.org/10.1016/j.cmi.2020.09. 
003
440. Kiyota Y, Della Corte A, Montiero Vieira V, Habchi K, Huang C-C, Della Ratta EE, et al. 
Risk and outcomes of aortic valve endocarditis among patients with bicuspid and tri­
cuspid aortic valves. Open Heart 2017;4:e000545. https://doi.org/10.1136/openhrt- 
2016-000545
441. Forteza A, Centeno J, Ospina V, Lunar IG, Sanchez V, Perez E, et al. Outcomes in aortic 
and mitral valve replacement with intervalvular fibrous body reconstruction. Ann 
Thorac Surg 2015;99:838–845. https://doi.org/10.1016/j.athoracsur.2014.09.052
442. Panagides V, Del Val D, Abdel-Wahab M, Mangner N, Durand E, Ihlemann N, et al. 
Perivalvular extension of infective endocarditis after transcatheter aortic valve replace­
ment. Clin Infect Dis 2022;75:638–646. https://doi.org/10.1093/cid/ciab1004
443. Sordelli C, Fele N, Mocerino R, Weisz SH, Ascione L, Caso P, et al. Infective endocar­
ditis: echocardiographic imaging and new imaging modalities. J Cardiovasc Echogr 2019; 
29:149–155. https://doi.org/10.4103/jcecho.jcecho_53_19
444. Ramos-Martinez A, Calderon-Parra J, Miro JM, Munoz P, Rodriguez-Abella H, Valerio 
M, et al. Effect of the type of surgical indication on mortality in patients with infective 
endocarditis who are rejected for surgical intervention. Int J Cardiol 2019;282:24–30. 
https://doi.org/10.1016/j.ijcard.2019.01.014
445. Anguera I, Miro JM, Vilacosta I, Almirante B, Anguita M, Munoz P, et al. Aorto-cavitary 
fistulous tract formation in infective endocarditis: clinical and echocardiographic fea­
tures of 76 cases and risk factors for mortality. Eur Heart J 2005;26:288–297. 
https://doi.org/10.1093/eurheartj/ehi034
446. Knosalla C, Weng Y, Yankah AC, Siniawski H, Hofmeister J, Hammerschmidt R, et al. 
Surgical treatment of active infective aortic valve endocarditis with associated perian­
nular abscess–11 year results. Eur Heart J 2000;21:490–497. https://doi.org/10.1053/ 
euhj.1999.1877
447. Baddley JW, Benjamin DK Jr, Patel M, Miro J, Athan E, Barsic B, et al. Candida infective 
endocarditis. Eur J Clin Microbiol Infect Dis 2008;27:519–529. https://doi.org/10.1007/ 
s10096-008-0466-x
448. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evi­
dence in the world literature, 1965–1995. Clin Infect Dis 2001;32:50–62. https://doi. 
org/10.1086/317550
449. Remadi JP, Habib G, Nadji G, Brahim A, Thuny F, Casalta JP, et al. Predictors of death 
and impact of surgery in Staphylococcus aureus infective endocarditis. Ann Thorac Surg 
2007;83:1295–1302. https://doi.org/10.1016/j.athoracsur.2006.09.093
450. Mamtani S, Aljanabi NM, Gupta Rauniyar RP, Acharya A, Malik BH. Candida endocar­
ditis: a review of the pathogenesis, morphology, risk factors, and management of an 
emerging and serious condition. Cureus 2020;12:e6695. https://doi.org/10.7759/ 
cureus.6695
451. Garcia-Cabrera E, Fernandez-Hidalgo N, Almirante B, Ivanova-Georgieva R, 
Noureddine M, Plata A, et al. Neurological complications of infective endocarditis: 
risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. 
Circulation 2013;127:2272–2284. https://doi.org/10.1161/CIRCULATIONAHA.112. 
000813
452. Selton-Suty C, Delahaye F, Tattevin P, Federspiel C, Le Moing V, Chirouze C, et al. 
Symptomatic and asymptomatic neurological complications of infective endocarditis: 
impact on surgical management and prognosis. PLoS One 2016;11:e0158522. https:// 
doi.org/10.1371/journal.pone.0158522
453. Diab M, Guenther A, Sponholz C, Lehmann T, Faerber G, Matz A, et al. Pre-operative 
stroke and neurological disability do not independently affect short- and long-term 
mortality in infective endocarditis patients. Clin Res Cardiol 2016;105:847–857. 
https://doi.org/10.1007/s00392-016-0993-x
454. Thuny F, Avierinos JF, Tribouilloy C, Giorgi R, Casalta JP, Milandre L, et al. Impact of 
cerebrovascular complications on mortality and neurologic outcome during infective 
endocarditis: a prospective multicentre study. Eur Heart J 2007;28:1155–1161. 
https://doi.org/10.1093/eurheartj/ehm005
455. Vilacosta I, Graupner C, San Roman JA, Sarria C, Ronderos R, Fernandez C, et al. Risk 
of embolization after institution of antibiotic therapy for infective endocarditis. J Am 
Coll Cardiol 2002;39:1489–1495. https://doi.org/10.1016/S0735-1097(02)01790-4
456. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, et al. The relation­
ship between the initiation of antimicrobial therapy and the incidence of stroke in in­
fective endocarditis: an analysis from the ICE prospective cohort study (ICE-PCS). Am 
Heart J 2007;154:1086–1094. https://doi.org/10.1016/j.ahj.2007.07.023
457. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, et al. Risk of em­
bolism and death in infective endocarditis: prognostic value of echocardiography: a 
prospective multicenter study. Circulation 2005;112:69–75. https://doi.org/10.1161/ 
CIRCULATIONAHA.104.493155
458. Cabell CH, Pond KK, Peterson GE, Durack DT, Corey GR, Anderson DJ, et al. The risk 
of stroke and death in patients with aortic and mitral valve endocarditis. Am Heart J 
2001;142:75–80. https://doi.org/10.1067/mhj.2001.115790
459. Kim D-H, Kang D-H, Lee M-Z, Yun S-C, Kim Y-J, Song J-M, et al. Impact of early surgery 
on embolic events in patients with infective endocarditis. Circulation 2010;122(11 
Suppl):S17–S22. https://doi.org/10.1161/CIRCULATIONAHA.109.927665
460. Mohananey D, Mohadjer A, Pettersson G, Navia J, Gordon S, Shrestha N, et al. 
Association of vegetation size with embolic risk in patients with infective endocarditis:


<!-- PAGE 86 -->

### Page 86

a systematic review and meta-analysis. JAMA Intern Med 2018;178:502–510. https://doi. 
org/10.1001/jamainternmed.2017.8653
461. Pergola V, Di Salvo G, Habib G, Avierinos JF, Philip E, Vailloud JM, et al. Comparison of 
clinical and echocardiographic characteristics of Streptococcus bovis endocarditis with 
that caused by other pathogens. Am J Cardiol 2001;88:871–875. https://doi.org/10. 
1016/S0002-9149(01)01914-2
462. Durante Mangoni E, Adinolfi LE, Tripodi MF, Andreana A, Gambardella M, Ragone E, 
et al. Risk factors for “major” embolic events in hospitalized patients with infective 
endocarditis. Am Heart J 2003;146:311–316. https://doi.org/10.1016/S0002-8703(02) 
94802-7
463. Young WJ, Hoare D, Bvekerwa I, Primus C, Wani RS, Das S, et al. Association of vege­
tation size with valve destruction, embolism and mortality. Heart Lung Circ 2021;30: 
854–860. https://doi.org/10.1016/j.hlc.2020.10.028
464. Cabezon G, Lopez J, Vilacosta I, Saez C, Garcia-Granja PE, Olmos C, et al. 
Reassessment of vegetation size as a sole indication for surgery in left-sided infective 
endocarditis. J Am Soc Echocardiogr 2022;35:570–575. https://doi.org/10.1016/j.echo. 
2021.12.013
465. Rizzi M, Ravasio V, Carobbio A, Mattucci I, Crapis M, Stellini R, et al. Predicting the oc­
currence of embolic events: an analysis of 1456 episodes of infective endocarditis from 
the Italian Study on Endocarditis (SEI). BMC Infect Dis 2014;14:230. https://doi.org/10. 
1186/1471-2334-14-230
466. Scheggi V, Alterini B, Olivotto I, Del Pace S, Zoppetti N, Tomberli B, et al. Embolic risk 
stratification and prognostic impact of early surgery in left-sided infective endocarditis. 
Eur J Intern Med 2020;78:82–87. https://doi.org/10.1016/j.ejim.2020.04.017
467. Shiue AB, Stancoven AB, Purcell JB, Pinkston K, Wang A, Khera A, et al. Relation of 
level of B-type natriuretic peptide with outcomes in patients with infective endocardi­
tis. Am J Cardiol 2010;106:1011–1015. https://doi.org/10.1016/j.amjcard.2010.05.034
468. Sorabella RA, Han SM, Grbic M, Wu YS, Takyama H, Kurlansky P, et al. Early operation 
for endocarditis complicated by preoperative cerebral emboli is not associated with 
worsened outcomes. Ann Thorac Surg 2015;100:501–508. https://doi.org/10.1016/j. 
athoracsur.2015.03.078
469. Diab M, Franz M, Hagel S, Guenther A, Struve A, Musleh R, et al. Impact of an in- 
hospital endocarditis team and a state-wide endocarditis network on perioperative 
outcomes. J Clin Med 2021;10:4734. https://doi.org/10.3390/jcm10204734
470. Hubert S, Thuny F, Resseguier N, Giorgi R, Tribouilloy C, Le Dolley Y, et al. Prediction 
of symptomatic embolism in infective endocarditis: construction and validation of a risk 
calculator in a multicenter cohort. J Am Coll Cardiol 2013;62:1384–1392. https://doi. 
org/10.1016/j.jacc.2013.07.029
471. Kang D-H, Kim Y-J, Kim S-H, Sun BJ, Kim D-H, Yun S-C, et al. Early surgery versus con­
ventional treatment for infective endocarditis. N Engl J Med 2012;366:2466–2473. 
https://doi.org/10.1056/NEJMoa1112843
472. Ferrera C, Vilacosta I, Fernandez C, Lopez J, Sarria C, Olmos C, et al. Early surgery for 
acute-onset infective endocarditis. Eur J Cardiothorac Surg 2018;54:1060–1066. https:// 
doi.org/10.1093/ejcts/ezy208
473. Kim YK, Choi CG, Jung J, Yu SN, Lee JY, Chong YP, et al. Effect of cerebral embolus size 
on the timing of cardiac surgery for infective endocarditis in patients with neurological 
complications. Eur J Clin Microbiol Infect Dis 2018;37:545–553. https://doi.org/10.1007/ 
s10096-017-3148-8
474. Dashkevich A, Bratkov G, Li Y, Joskowiak D, Peterss S, Juchem G, et al. Impact of op­
erative timing in infective endocarditis with cerebral embolism–the risk of intermediate 
deterioration. J Clin Med 2021;10:2136. https://doi.org/10.3390/jcm10102136
475. Hill EE, Herregods MC, Vanderschueren S, Claus P, Peetermans WE, Herijgers P. 
Outcome of patients requiring valve surgery during active infective endocarditis. Ann 
Thorac Surg 2008;85:1564–1569. https://doi.org/10.1016/j.athoracsur.2008.02.014
476. Anguera I, Miro JM, Cabell CH, Abrutyn E, Fowler VG Jr, Hoen B, et al. Clinical char­
acteristics and outcome of aortic endocarditis with periannular abscess in the 
International Collaboration on Endocarditis merged database. Am J Cardiol 2005;96: 
976–981. https://doi.org/10.1016/j.amjcard.2005.05.056
477. Handa K, Yoshioka D, Toda K, Yokoyama J-Y, Samura T, Suzuki K, et al. Surgical results 
for infective endocarditis complicated with cardiogenic shock. Circ J 2020;84:926–934. 
https://doi.org/10.1253/circj.CJ-19-0583
478. Fosbol EL, Park LP, Chu VH, Athan E, Delahaye F, Freiberger T, et al. The association 
between vegetation size and surgical treatment on 6-month mortality in left-sided in­
fective endocarditis. Eur Heart J 2019;40:2243–2251. https://doi.org/10.1093/ 
eurheartj/ehz204
479. Yanagawa B, Elbatarny M, Verma S, Hill S, Mazine A, Puskas JD, et al. Surgical 
management of tricuspid valve infective endocarditis: a systematic review and 
meta-analysis. Ann Thorac Surg 2018;106:708–714. https://doi.org/10.1016/j.athoracsur. 
2018.04.012
480. Ruttmann E, Willeit J, Ulmer H, Chevtchik O, Hofer D, Poewe W, et al. Neurological 
outcome of septic cardioembolic stroke after infective endocarditis. Stroke 2006;37: 
2094–2099. https://doi.org/10.1161/01.STR.0000229894.28591.3f
481. Asaithambi G, Adil MM, Qureshi AI. Thrombolysis for ischemic stroke associated with 
infective endocarditis: results from the nationwide inpatient sample. Stroke 2013;44: 
2917–2919. https://doi.org/10.1161/STROKEAHA.113.001602
482. Chan KL, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek MA, et al. A randomized trial 
of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll 
Cardiol 2003;42:775–780. https://doi.org/10.1016/S0735-1097(03)00829-5
483. Chan KL, Tam J, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, et al. Effect of long-term 
aspirin use on embolic events in infective endocarditis. Clin Infect Dis 2008;46: 
37–41. https://doi.org/10.1086/524021
484. Feil K, Kupper C, Tiedt S, Dimitriadis K, Herzberg M, Dorn F, et al. Safety and efficacy of 
mechanical thrombectomy in infective endocarditis: a matched case-control analysis 
from the German Stroke Registry-endovascular treatment. Eur J Neurol 2021;28: 
861–867. https://doi.org/10.1111/ene.14686
485. Park W, Ahn JS, Park JC, Kwun BD, Lee DH. Treatment strategy based on experience 
of treating intracranial infectious aneurysms. World Neurosurg 2017;97:351–359. 
https://doi.org/10.1016/j.wneu.2016.09.119
486. Davis KA, Huang G, Petty SA, Tan WA, Malaver D, Peacock JE Jr. The effect of preex­
isting anticoagulation on cerebrovascular events in left-sided infective endocarditis. Am 
J Med 2020;133:360–369. https://doi.org/10.1016/j.amjmed.2019.07.059
487. Alawieh A, Chaudry MI, Turner RD, Turk AS, Spiotta AM. Infectious intracranial aneur­
ysms: a systematic review of epidemiology, management, and outcomes. J Neurointerv 
Surg 2018;10:708–716. https://doi.org/10.1136/neurintsurg-2017-013603
488. Hui FK, Bain M, Obuchowski NA, Gordon S, Spiotta AM, Moskowitz S, et al. Mycotic 
aneurysm detection rates with cerebral angiography in patients with infective endocar­
ditis. J Neurointerv Surg 2015;7:449–452. https://doi.org/10.1136/neurintsurg-2014- 
011124
489. Goulenok T, Klein I, Mazighi M, Messika-Zeitoun D, Alexandra JF, Mourvillier B, et al. 
Infective endocarditis with symptomatic cerebral complications: contribution of cere­
bral magnetic resonance imaging. Cerebrovasc Dis 2013;35:327–336. https://doi.org/10. 
1159/000348317
490. Walkoff L, Brinjikji W, Rouchaud A, Caroff J, Kallmes DF. Comparing magnetic reson­
ance angiography (MRA) and computed tomography angiography (CTA) with conven­
tional angiography in the detection of distal territory cerebral mycotic and oncotic 
aneurysms. Interv Neuroradiol 2016;22:524–528. https://doi.org/10.1177/159101991 
6653247
491. Bettencourt S, Ferro JM. Acute ischemic stroke treatment in infective endocarditis: 
systematic review. J Stroke Cerebrovasc Dis 2020;29:104598. https://doi.org/10.1016/j. 
jstrokecerebrovasdis.2019.104598
492. Meshaal MS, Kassem HH, Samir A, Zakaria A, Baghdady Y, Rizk HH. Impact of routine 
cerebral CT angiography on treatment decisions in infective endocarditis. PLoS One 
2015;10:e0118616. https://doi.org/10.1371/journal.pone.0118616
493. White PM, Teasdale EM, Wardlaw JM, Easton V. Intracranial aneurysms: CT angiog­
raphy and MR angiography for detection prospective blinded comparison in a large pa­
tient cohort. Radiology 2001;219:739–749. https://doi.org/10.1148/radiology.219.3. 
r01ma16739
494. Boukobza M, Duval X, Laissy JP. Utility of susceptibility-weighted angiography se­
quence in the diagnosis of ruptured infectious aneurysms. World Neurosurg 2021; 
149:171–173. https://doi.org/10.1016/j.wneu.2021.02.103
495. Ragulojan R, Grupke S, Fraser JF. Systematic review of endovascular, surgical, and con­
servative options for infectious intracranial aneurysms and cardiac considerations. J 
Stroke Cerebrovasc Dis 2019;28:838–844. https://doi.org/10.1016/j.jstrokecerebrovas 
dis.2018.11.035
496. Shi H, Parikh NS, Esenwa C, Zampolin R, Shah H, Khasiyev F, et al. Neurological out­
comes of patients with mycotic aneurysms in infective endocarditis. Neurohospitalist 
2021;11:5–11. https://doi.org/10.1177/1941874420931233
497. Singla A, Fargen K, Blackburn S, Neal D, Martin TD, Hess PJ, et al. National treatment 
practices in the management of infectious intracranial aneurysms and infective endo­
carditis. J Neurointerv Surg 2016;8:741–746. https://doi.org/10.1136/neurintsurg-2015- 
011834
498. Ohtake M, Tateishi K, Ikegaya N, Iwata J, Yamanaka S, Murata H. Initial treatment strat­
egy for intracranial mycotic aneurysms: 2 case reports and literature review. World 
Neurosurg 2017;106:1051.e9–1051.e16. https://doi.org/10.1016/j.wneu.2017.07.016
499. Wilson WR, Bower TC, Creager MA, Amin-Hanjani S, O’Gara PT, Lockhart PB, et al. 
Vascular graft infections, mycotic aneurysms, and endovascular infections: a scientific 
statement from the American Heart Association. Circulation 2016;134:e412–e460. 
https://doi.org/10.1161/CIR.0000000000000457
500. Ting W, Silverman NA, Arzouman DA, Levitsky S. Splenic septic emboli in endocardi­
tis. Circulation 1990;82(5 Suppl):IV105–IV109.
501. Robinson SL, Saxe JM, Lucas CE, Arbulu A, Ledgerwood AM, Lucas WF. Splenic ab­
scess associated with endocarditis. Surgery 1992;112:781–786, discussion 786–787.
502. Hasan LZ, Shrestha NK, Dang V, Unai S, Pettersson G, El-Hayek K, et al. Surgical infect­
ive endocarditis and concurrent splenic abscess requiring splenectomy: a case series 
and review of the literature. Diagn Microbiol Infect Dis 2020;97:115082. https://doi. 
org/10.1016/j.diagmicrobio.2020.115082
503. Elasfar A, AlBaradai A, AlHarfi Z, Alassal M, Ghoneim A, AlGhofaili F. Splenic abscess 
associated with infective endocarditis; case series. J Saudi Heart Assoc 2015;27: 
210–215. https://doi.org/10.1016/j.jsha.2015.02.001
504. Bonfiglioli R, Nanni C, Morigi JJ, Graziosi M, Trapani F, Bartoletti M, et al. (1)(8)F-FDG 
PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with 
ESC Guidelines                                                                                                                                                                                          4033


<!-- PAGE 87 -->

### Page 87

suspected cardiac endocarditis. Eur J Nucl Med Mol Imaging 2013;40:1190–1196. 
https://doi.org/10.1007/s00259-013-2426-7
505. Simsir SA, Cheeseman SH, Lancey RA, Vander Salm TJ, Gammie JS. Staged laparoscop­
ic splenectomy and valve replacement in splenic abscess and infective endocarditis. Ann 
Thorac Surg 2003;75:1635–1637. https://doi.org/10.1016/S0003-4975(02)04769-0
506. Akhyari P, Mehrabi A, Adhiwana A, Kamiya H, Nimptsch K, Minol JP, et al. Is simultan­
eous splenectomy an additive risk factor in surgical treatment for active endocarditis? 
Langenbecks Arch Surg 2012;397:1261–1266. https://doi.org/10.1007/s00423-012- 
0931-y
507. Chou Y-H, Hsu C-C, Tiu C-M, Chang T. Splenic abscess: sonographic diagnosis and 
percutaneous drainage or aspiration. Gastrointest Radiol 1992;17:262–266. https:// 
doi.org/10.1007/BF01888563
508. Farres H, Felsher J, Banbury M, Brody F. Management of splenic abscess in a critically ill 
patient. Surg Laparosc Endosc Percutan Tech 2004;14:49–52. https://doi.org/10.1097/ 
00129689-200404000-00001
509. de la Cuerda F, Cecconi A, Martinez P, Cuesta J, Olivera MJ, Jimenez-Borreguero LJ, 
et al. Myocardial septic seeding secondary to infective endocarditis: diagnosis by cardiac 
magnetic resonance imaging. Int J Cardiovasc Imaging 2021;37:2545–2547. https://doi. 
org/10.1007/s10554-021-02225-z
510. Reyaldeen R, Wahi S, Cole C, Kaye G, Law P, Cooper C, et al. Concurrent native valve 
infective endocarditis and myocarditis: the key role of (18)F-FDG PET/CT. J Nucl 
Cardiol 2021;28:1781–1784. https://doi.org/10.1007/s12350-020-02108-1
511. Royston AP, Gosling OE. Patient with native valve infective endocarditis and concomi­
tant bacterial myopericarditis. BMJ Case Rep 2018;2018:bcr2018224907. https://doi. 
org/10.1136/bcr-2018-224907
512. Regueiro A, Falces C, Cervera C, Del Rio A, Pare JC, Mestres CA, et al. Risk factors for 
pericardial effusion in native valve infective endocarditis and its influence on outcome. 
Am J Cardiol 2013;112:1646–1651. https://doi.org/10.1016/j.amjcard.2013.07.024
513. Regueiro A, Falces C, Pericas JM, Munoz P, Martinez-Selles M, Valerio M, et al. Risk fac­
tors of pericardial effusion in native valve infective endocarditis and its influence on 
outcome: a multicenter prospective cohort study. Int J Cardiol 2018;273:193–198. 
https://doi.org/10.1016/j.ijcard.2018.08.010
514. Padala SK, Cabrera JA, Ellenbogen KA. Anatomy of the cardiac conduction system. 
Pacing Clin Electrophysiol 2021;44:15–25. https://doi.org/10.1111/pace.14107
515. Hill TE, Kiehl EL, Shrestha NK, Gordon SM, Pettersson GB, Mohan C, et al. Predictors 
of permanent pacemaker requirement after cardiac surgery for infective endocarditis. 
Eur Heart J Acute Cardiovasc Care 2021;10:329–334. https://doi.org/10.1177/ 
2048872619848661
516. Murillo O, Grau I, Gomez-Junyent J, Cabrera C, Ribera A, Tubau F, et al. Endocarditis 
associated with vertebral osteomyelitis and septic arthritis of the axial skeleton. 
Infection 2018;46:245–251. https://doi.org/10.1007/s15010-018-1121-9
517. Del Pace S, Scheggi V, Virgili G, Caciolli S, Olivotto I, Zoppetti N, et al. Endocarditis 
with spondylodiscitis: clinical characteristics and prognosis. BMC Cardiovasc Disord 
2021;21:186. https://doi.org/10.1186/s12872-021-01991-x
518. Aguilar-Company J, Pigrau C, Fernandez-Hidalgo N, Rodriguez-Pardo D, Falco V, Lung 
M, et al. Native vertebral osteomyelitis in aged patients: distinctive features. An obser­
vational cohort study. Infection 2018;46:679–686. https://doi.org/10.1007/s15010- 
018-1177-6
519. Koslow M, Kuperstein R, Eshed I, Perelman M, Maor E, Sidi Y. The unique clinical fea­
tures and outcome of infectious endocarditis and vertebral osteomyelitis co-infection. 
Am J Med 2014;127:669.e9–669.e15. https://doi.org/10.1016/j.amjmed.2014.02.023
520. Viezens L, Dreimann M, Strahl A, Heuer A, Koepke LG, Bay B, et al. Spontaneous spon­
dylodiscitis and endocarditis: interdisciplinary experience from a tertiary institutional 
case series and proposal of a treatment algorithm. Neurosurg Rev 2022;45: 
1335–1342. https://doi.org/10.1007/s10143-021-01640-z
521. Behmanesh B, Gessler F, Schnoes K, Dubinski D, Won S-Y, Konczalla J, et al. Infective 
endocarditis in patients with pyogenic spondylodiscitis: implications for diagnosis and 
therapy. Neurosurg Focus 2019;46:E2. https://doi.org/10.3171/2018.10.FOCUS18445
522. Tamura K. Clinical characteristics of infective endocarditis with vertebral osteomye­
litis. J Infect Chemother 2010;16:260–265. https://doi.org/10.1007/s10156-010-0046-8
523. Pigrau C, Almirante B, Flores X, Falco V, Rodriguez D, Gasser I, et al. Spontaneous pyo­
genic vertebral osteomyelitis and endocarditis: incidence, risk factors, and outcome. 
Am J Med 2005;118:1287. https://doi.org/10.1016/j.amjmed.2005.02.027
524. Smids C, Kouijzer IJ, Vos FJ, Sprong T, Hosman AJ, de Rooy JW, et al. A comparison of 
the diagnostic value of MRI and (18)F-FDG-PET/CT in suspected spondylodiscitis. 
Infection 2017;45:41–49. https://doi.org/10.1007/s15010-016-0914-y
525. Castagne B, Soubrier M, Prouteau J, Mrozek N, Lesens O, Tournadre A, et al. A six- 
week antibiotic treatment of endocarditis with spondylodiscitis is not associated 
with increased risk of relapse: a retrospective cohort study. Infect Dis Now 2021;51: 
253–259. https://doi.org/10.1016/j.medmal.2020.10.026
526. Pola E, Taccari F, Autore G, Giovannenze F, Pambianco V, Cauda R, et al. 
Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical 
features, prognostic factors and long-term outcomes in 207 patients. Eur Spine J 2018; 
27(Suppl 2):229–236. https://doi.org/10.1007/s00586-018-5598-9
527. Thomas P, Allal J, Bontoux D, Rossi F, Poupet JY, Petitalot JP, et al. Rheumatological 
manifestations of infective endocarditis. Ann Rheum Dis 1984;43:716–720. https:// 
doi.org/10.1136/ard.43.5.716
528. Ojeda J, Lopez-Lopez L, Gonzalez A, Vila LM. Infective endocarditis initially presenting 
with a dermatomyositis-like syndrome. BMJ Case Rep 2014;2014:bcr2013200865. 
https://doi.org/10.1136/bcr-2013-200865
529. Mahr A, Batteux F, Tubiana S, Goulvestre C, Wolff M, Papo T, et al. Brief report: preva­
lence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis 
Rheumatol 2014;66:1672–1677. https://doi.org/10.1002/art.38389
530. Lieber SB, Tishler O, Nasrullah K, Fowler ML, Shmerling RH, Paz Z. Clinical features of 
patients with septic arthritis and echocardiographic findings of infective endocarditis. 
Infection 2019;47:771–779. https://doi.org/10.1007/s15010-019-01302-9
531. Tahon J, Geselle PJ, Vandenberk B, Hill EE, Peetermans WE, Herijgers P, et al. 
Long-term follow-up of patients with infective endocarditis in a tertiary referral center. 
Int J Cardiol 2021;331:176–182. https://doi.org/10.1016/j.ijcard.2021.01.048
532. Ortiz-Soriano V, Donaldson K, Du G, Li Y, Lambert J, Cleland D, et al. Incidence and 
cost of acute kidney injury in hospitalized patients with infective endocarditis. J Clin 
Med 2019;8:927. https://doi.org/10.3390/jcm8070927
533. Khan MZ, Munir MB, Khan MU, Khan SU, Vasudevan A, Balla S. Contemporary trends 
and outcomes of prosthetic valve infective endocarditis in the United States: insights 
from the nationwide inpatient sample. Am J Med Sci 2021;362:472–479. https://doi. 
org/10.1016/j.amjms.2021.05.014
534. Gagneux-Brunon A, Pouvaret A, Maillard N, Berthelot P, Lutz MF, Cazorla C, et al. 
Acute kidney injury in infective endocarditis: a retrospective analysis. Med Mal Infect 
2019;49:527–533. https://doi.org/10.1016/j.medmal.2019.03.015
535. Von Tokarski F, Lemaignen A, Portais A, Fauchier L, Hennekinne F, Sautenet B, et al. 
Risk factors and outcomes of early acute kidney injury in infective endocarditis: a retro­
spective cohort study. Int J Infect Dis 2020;99:421–427. https://doi.org/10.1016/j.ijid. 
2020.08.022
536. Ritchie BM, Hirning BA, Stevens CA, Cohen SA, DeGrado JR. Risk factors for acute 
kidney injury associated with the treatment of bacterial endocarditis at a tertiary aca­
demic medical center. J Chemother 2017;29:292–298. https://doi.org/10.1080/ 
1120009X.2017.1296916
537. Petersen JK, Jensen AD, Bruun NE, Kamper AL, Butt JH, Havers-Borgersen E, et al. 
Outcome of dialysis-requiring acute kidney injury in patients with infective endocardi­
tis: a nationwide study. Clin Infect Dis 2021;72:e232–e239. https://doi.org/10.1093/cid/ 
ciaa1017
538. Li J, Zhou L, Gong X, Wang Y, Yao D, Li H. Abiotrophia defectiva as a rare cause of 
mitral valve infective endocarditis with mesenteric arterial branch pseudoaneurysm, 
splenic infarction, and renal infarction: a case report. Front Med (Lausanne) 2022;9: 
780828. https://doi.org/10.3389/fmed.2022.780828
539. Vasconcellos D, Weng B, Wu P, Thompson G, Sutjita M. Staphylococcus hominis infect­
ive endocarditis presenting with embolic splenic and renal infarcts and spinal discitis. 
Case Rep Infect Dis 2022;2022:7183049. https://doi.org/10.1155/2022/7183049
540. Boils CL, Nasr SH, Walker PD, Couser WG, Larsen CP. Update on 
endocarditis-associated glomerulonephritis. Kidney Int 2015;87:1241–9. https://doi. 
org/10.1038/ki.2014.424
541. Paul G, Michels G, Hohmann C, Pfister R, Mader N, Blanke L, et al. Contrast-enhanced 
ultrasound for the detection of abdominal complications in infective endocarditis: first 
experience from a prospective cohort. Ultrasound Med Biol 2020;46:2965–2971. 
https://doi.org/10.1016/j.ultrasmedbio.2020.07.027
542. Knol WG, Wahadat AR, Roos-Hesselink JW, Van Mieghem NM, Tanis W, Bogers A, 
et al. Screening for coronary artery disease in early surgical treatment of acute aortic 
valve infective endocarditis. Interact Cardiovasc Thorac Surg 2021;32:522–529. https:// 
doi.org/10.1093/icvts/ivaa313
543. Spanneut TA, Paquet P, Bauters C, Modine T, Richardson M, Bonello L, et al. Utility and 
safety of coronary angiography in patients with acute infective endocarditis who re­
quired surgery. J Thorac Cardiovasc Surg 2022;164:905–913.e19. https://doi.org/10. 
1016/j.jtcvs.2020.08.117
544. Laperche C, Lairez O, Ferrieres J, Robin G, Gautier M, Lavie Badie Y, et al. Coronary 
angiography in the setting of acute infective endocarditis requiring surgical treatment. 
Arch Cardiovasc Dis 2020;113:50–58. https://doi.org/10.1016/j.acvd.2019.09.007
545. Diab M, Lehmann T, Weber C, Petrov G, Luehr M, Akhyari P, et al. Role of concomi­
tant coronary artery bypass grafting in valve surgery for infective endocarditis. J Clin 
Med 2021;10:2867. https://doi.org/10.3390/jcm10132867
546. Ren X, Liu K, Zhang H, Meng Y, Li H, Sun X, et al. Coronary evaluation before heart 
valvular surgery by using coronary computed tomographic angiography versus invasive 
coronary angiography. J Am Heart Assoc 2021;10:e019531. https://doi.org/10.1161/ 
JAHA.120.019531
547. Shapira Y, Weisenberg DE, Vaturi M, Sharoni E, Raanani E, Sahar G, et al. The impact of 
intraoperative transesophageal echocardiography in infective endocarditis. Isr Med 
Assoc J 2007;9:299–302.
548. Paruk F, Sime FB, Lipman J, Roberts JA. Dosing antibiotic prophylaxis during cardiopul­
monary bypass–a higher level of complexity? A structured review. Int J Antimicrob 
Agents 2017;49:395–402. https://doi.org/10.1016/j.ijantimicag.2016.12.014


<!-- PAGE 88 -->

### Page 88

549. Datt V, Wadhhwa R, Sharma V, Virmani S, Minhas HS, Malik S. Vasoplegic syndrome 
after cardiovascular surgery: a review of pathophysiology and outcome-oriented 
therapeutic management. J Card Surg 2021;36:3749–3760. https://doi.org/10.1111/ 
jocs.15805
550. Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat re­
fractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg 2003;125: 
426–427. https://doi.org/10.1067/mtc.2003.140
551. Santer D, Miazza J, Koechlin L, Gahl B, Rrahmani B, Hollinger A, et al. Hemoadsorption 
during cardiopulmonary bypass in patients with endocarditis undergoing valve surgery: 
a retrospective single-center study. J Clin Med 2021;10:564. https://doi.org/10.3390/ 
jcm10040564
552. Diab M, Lehmann T, Bothe W, Akhyari P, Platzer S, Wendt D, et al. Cytokine hemoad­
sorption during cardiac surgery versus standard surgical care for infective endocarditis 
(REMOVE): results from a multicenter randomized controlled trial. Circulation 2022; 
145:959–968. https://doi.org/10.1161/CIRCULATIONAHA.121.056940
553. Pettersson GB, Hussain ST, Shrestha NK, Gordon S, Fraser TG, Ibrahim KS, et al. 
Infective endocarditis: an atlas of disease progression for describing, staging, coding, 
and understanding the pathology. J Thorac Cardiovasc Surg 2014;147:1142–1149.e2. 
https://doi.org/10.1016/j.jtcvs.2013.11.031
554. de Kerchove L, Vanoverschelde JL, Poncelet A, Glineur D, Rubay J, Zech F, et al. 
Reconstructive surgery in active mitral valve endocarditis: feasibility, safety and durabil­
ity. Eur J Cardiothorac Surg 2007;31:592–599. https://doi.org/10.1016/j.ejcts.2007.01. 
002
555. Defauw RJ, Tomsic A, van Brakel TJ, Marsan NA, Klautz RJM, Palmen M. A structured 
approach to native mitral valve infective endocarditis: is repair better than replace­
ment? Eur J Cardiothorac Surg 2020;58:544–550. https://doi.org/10.1093/ejcts/ezaa079
556. Toyoda N, Itagaki S, Egorova NN, Tannous H, Anyanwu AC, El-Eshmawi A, et al. 
Real-world outcomes of surgery for native mitral valve endocarditis. J Thorac 
Cardiovasc Surg 2017;154:1906–1912.e9. https://doi.org/10.1016/j.jtcvs.2017.07.077
557. Witten JC, Houghtaling PL, Shrestha NK, Gordon SM, Jaber W, Blackstone EH, et al. 
Aortic allograft infection risk. J Thorac Cardiovasc Surg 2023;165:1303–1315.e9. https:// 
doi.org/10.1016/j.jtcvs.2021.04.086
558. Witten JC, Durbak E, Houghtaling PL, Unai S, Roselli EE, Bakaeen FG, et al. 
Performance and durability of cryopreserved allograft aortic valve replacements. 
Ann Thorac Surg 2021;111:1893–1900. https://doi.org/10.1016/j.athoracsur.2020.07. 
033
559. Flynn CD, Curran NP, Chan S, Zegri-Reiriz I, Tauron M, Tian DH, et al. Systematic re­
view and meta-analysis of surgical outcomes comparing mechanical valve replacement 
and bioprosthetic valve replacement in infective endocarditis. Ann Cardiothorac Surg 
2019;8:587–599. https://doi.org/10.21037/acs.2019.10.03
560. Giambuzzi I, Bonalumi G, Di Mauro M, Roberto M, Corona S, Alamanni F, et al. Surgical 
aortic mitral curtain replacement: systematic review and metanalysis of early and long- 
term results. J Clin Med 2021;10:3163. https://doi.org/10.3390/jcm10143163
561. Murphy KM, Vikram HR. Heart transplantation for infective endocarditis: viable option 
for a limited few? Transpl Infect Dis 2019;21:e13006. https://doi.org/10.1111/tid.13006
562. Nappi F, Singh SSA, Spadaccio C, Acar C. Revisiting the guidelines and choice the ideal 
substitute for aortic valve endocarditis. Ann Transl Med 2020;8:952. https://doi.org/10. 
21037/atm-20-1522
563. Head SJ, Celik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replace­
ment. Eur Heart J 2017;38:2183–2191. https://doi.org/10.1093/eurheartj/ehx141
564. AATS Surgical Treatment of Infective Endocarditis Consensus Guidelines Writing 
Committee Chairs; Pettersson GB, Coselli JS, Writing C, Pettersson GB, Coselli JS, 
et al. 2016 the American Association for thoracic surgery (AATS) consensus guide­
lines: surgical treatment of infective endocarditis: executive summary. J Thorac 
Cardiovasc Surg 2017;153:1241–1258.e29. https://doi.org/10.1016/j.jtcvs.2016.09.093
565. Delahaye F, Chu VH, Altclas J, Barsic B, Delahaye A, Freiberger T, et al. One-year out­
come following biological or mechanical valve replacement for infective endocarditis. 
Int J Cardiol 2015;178:117–123. https://doi.org/10.1016/j.ijcard.2014.10.125
566. Cahill TJ, Baddour LM, Habib G, Hoen B, Salaun E, Pettersson GB, et al. Challenges in 
infective endocarditis. J Am Coll Cardiol 2017;69:325–344. https://doi.org/10.1016/j.jacc. 
2016.10.066
567. Samura T, Yoshioka D, Toda K, Sakaniwa R, Yokoyama J, Suzuki K, et al. Emergency 
valve surgery improves clinical results in patients with infective endocarditis compli­
cated with acute cerebral infarction: analysis using propensity score matchingdagger. 
Eur J Cardiothorac Surg 2019;56:942–949. https://doi.org/10.1093/ejcts/ezz100
568. Bonaros N, Czerny M, Pfausler B, Muller S, Bartel T, Thielmann M, et al. Infective endo­
carditis and neurologic events: indications and timing for surgical interventions. Eur 
Heart J Suppl 2020;22(Suppl M):M19–M25. https://doi.org/10.1093/eurheartj/suaa167
569. Barsic B, Dickerman S, Krajinovic V, Pappas P, Altclas J, Carosi G, et al. Influence of the 
timing of cardiac surgery on the outcome of patients with infective endocarditis and 
stroke. Clin Infect Dis 2013;56:209–217. https://doi.org/10.1093/cid/cis878
570. Suzuki M, Takanashi S, Ohshima Y, Nagatomo Y, Seki A, Takamisawa I, et al. Critical 
potential of early cardiac surgery for infective endocarditis with cardio-embolic 
strokes. Int J Cardiol 2017;227:222–224. https://doi.org/10.1016/j.ijcard.2016.11.143
571. Okita Y, Minakata K, Yasuno S, Uozumi R, Sato T, Ueshima K, et al. Optimal timing of 
surgery for active infective endocarditis with cerebral complications: a Japanese 
multicentre study. Eur J Cardiothorac Surg 2016;50:374–382. https://doi.org/10.1093/ 
ejcts/ezw035
572. Arregle F, Martel H, Philip M, Gouriet F, Casalta JP, Riberi A, et al. Infective endocarditis 
with neurological complications: delaying cardiac surgery is associated with worse out­
come. Arch Cardiovasc Dis 2021;114:527–536. https://doi.org/10.1016/j.acvd.2021.01. 
004
573. Matthews CR, Hartman T, Madison M, Villelli NW, Namburi N, Colgate CL, et al. 
Preoperative stroke before cardiac surgery does not increase risk of postoperative 
stroke. Sci Rep 2021;11:9025. https://doi.org/10.1038/s41598-021-88441-y
574. Murai R, Kaji S, Kitai T, Kim K, Ota M, Koyama T, et al. The clinical significance of cere­
bral microbleeds in infective endocarditis patients. Semin Thorac Cardiovasc Surg 2019; 
31:51–58. https://doi.org/10.1053/j.semtcvs.2018.09.020
575. Ruttmann E, Abfalterer H, Wagner J, Grimm M, Muller L, Bates K, et al. 
Endocarditis-related stroke is not a contraindication for early cardiac surgery: an inves­
tigation among 440 patients with left-sided endocarditis. Eur J Cardiothorac Surg 2020; 
58:1161–1167. https://doi.org/10.1093/ejcts/ezaa239
576. Small CN, Laurent D, Lucke-Wold B, Goutnik MA, Yue S, Chalouhi N, et al. Timing 
surgery and hemorrhagic complications in endocarditis with concomitant cerebral 
complications. Clin Neurol Neurosurg 2022;214:107171. https://doi.org/10.1016/j. 
clineuro.2022.107171
577. Tam DY, Yanagawa B, Verma S, Ruel M, Fremes SE, Mazine A, et al. Early vs late surgery 
for patients with endocarditis and neurological injury: a systematic review and 
meta-analysis. Can J Cardiol 2018;34:1185–1199. https://doi.org/10.1016/j.cjca.2018. 
05.010
578. Zhang LQ, Cho S-M, Rice CJ, Khoury J, Marquardt RJ, Buletko AB, et al. Valve surgery 
for infective endocarditis complicated by stroke: surgical timing and perioperative 
neurological complications. Eur J Neurol 2020;27:2430–2438. https://doi.org/10. 
1111/ene.14438
579. Jiad E, Gill SK, Krutikov M, Turner D, Parkinson MH, Curtis C, et al. When the heart 
rules the head: ischaemic stroke and intracerebral haemorrhage complicating infective 
endocarditis. Pract Neurol 2017;17:28–34. https://doi.org/10.1136/practneurol-2016- 
001469
580. Misfeld M, Girrbach F, Etz CD, Binner C, Aspern KV, Dohmen PM, et al. Surgery for 
infective endocarditis complicated by cerebral embolism: a consecutive series of 375 
patients. J Thorac Cardiovasc Surg 2014;147:1837–1844. https://doi.org/10.1016/j. 
jtcvs.2013.10.076
581. Kume Y, Fujita T, Fukushima S, Shimahara Y, Matsumoto Y, Yamashita K, et al. 
Intracranial mycotic aneurysm is associated with cerebral bleeding post-valve surgery 
for infective endocarditis. Interact Cardiovasc Thorac Surg 2018;27:635–641. https://doi. 
org/10.1093/icvts/ivy126
582. Salaun E, Touil A, Hubert S, Casalta JP, Gouriet F, Robinet-Borgomano E, et al. 
Intracranial haemorrhage in infective endocarditis. Arch Cardiovasc Dis 2018;111: 
712–721. https://doi.org/10.1016/j.acvd.2018.03.009
583. Musleh R, Schlattmann P, Caldonazo T, Kirov H, Witte OW, Doenst T, et al. Surgical 
timing in patients with infective endocarditis and with intracranial hemorrhage: a sys­
tematic review and meta-analysis. J Am Heart Assoc 2022;11:e024401. https://doi.org/ 
10.1161/JAHA.121.024401
584. Yoshioka D, Toda K, Sakaguchi T, Okazaki S, Yamauchi T, Miyagawa S, et al. Valve sur­
gery in active endocarditis patients complicated by intracranial haemorrhage: the influ­
ence of the timing of surgery on neurological outcomes. Eur J Cardiothorac Surg 2014; 
45:1082–1088. https://doi.org/10.1093/ejcts/ezt547
585. Manne MB, Shrestha NK, Lytle BW, Nowicki ER, Blackstone E, Gordon SM, et al. 
Outcomes after surgical treatment of native and prosthetic valve infective endocardi­
tis. Ann Thorac Surg 2012;93:489–493. https://doi.org/10.1016/j.athoracsur.2011.10. 
063
586. Wang A, Chu VH, Athan E, Delahaye F, Freiberger T, Lamas C, et al. Association be­
tween the timing of surgery for complicated, left-sided infective endocarditis and sur­
vival. Am Heart J 2019;210:108–116. https://doi.org/10.1016/j.ahj.2019.01.004
587. Champey J, Pavese P, Bouvaist H, Kastler A, Krainik A, Francois P. Value of brain MRI in 
infective endocarditis: a narrative literature review. Eur J Clin Microbiol Infect Dis 2016; 
35:159–168. https://doi.org/10.1007/s10096-015-2523-6
588. Martinez-Selles M, Munoz P, Estevez A, del Castillo R, Garcia-Fernandez MA, 
Rodriguez-Creixems M, et al. Long-term outcome of infective endocarditis in non- 
intravenous drug users. Mayo Clin Proc 2008;83:1213–1217. https://doi.org/10.4065/ 
83.11.1213
589. Thuny F, Giorgi R, Habachi R, Ansaldi S, Le Dolley Y, Casalta JP, et al. Excess mortality 
and morbidity in patients surviving infective endocarditis. Am Heart J 2012;164: 
94–101. https://doi.org/10.1016/j.ahj.2012.04.003
590. Agrawal A, Virk HUH, Riaz I, Jain D, Tripathi B, Krittanawong C, et al. Predictors of 
30-day re-admissions in patients with infective endocarditis: a national population 
based cohort study. Rev Cardiovasc Med 2020;21:123–127. https://doi.org/10.31083/ 
j.rcm.2020.01.552
591. Alagna L, Park LP, Nicholson BP, Keiger AJ, Strahilevitz J, Morris A, et al. Repeat endo­
carditis: analysis of risk factors based on the International Collaboration on 
Endocarditis – prospective cohort study. Clin Microbiol Infect 2014;20:566–575. 
https://doi.org/10.1111/1469-0691.12395
ESC Guidelines                                                                                                                                                                                          4035


<!-- PAGE 89 -->

### Page 89

### 592 Fernandez-Hidalgo N, Almirante B, Tornos P, Gonzalez-Alujas MT, Planes AM,

Galinanes M, et al. Immediate and long-term outcome of left-sided infective endocar­
ditis. A 12-year prospective study from a contemporary cohort in a referral hospital. 
Clin Microbiol Infect 2012;18:E522–E530. https://doi.org/10.1111/1469-0691.12033
593. Scheggi V, Merilli I, Marcucci R, Del Pace S, Olivotto I, Zoppetti N, et al. Predictors of 
mortality and adverse events in patients with infective endocarditis: a retrospective 
real world study in a surgical centre. BMC Cardiovasc Disord 2021;21:28. https://doi. 
org/10.1186/s12872-021-01853-6
594. Yoshioka D, Toda K, Yokoyama JY, Matsuura R, Miyagawa S, Kainuma S, et al. Diabetes 
mellitus adversely affects mortality and recurrence after valve surgery for infective 
endocarditis. J Thorac Cardiovasc Surg 2018;155:1021–1029.e5. https://doi.org/10. 
1016/j.jtcvs.2017.09.013
595. Citro R, Chan KL, Miglioranza MH, Laroche C, Benvenga RM, Furnaz S, et al. Clinical 
profile and outcome of recurrent infective endocarditis. Heart 2022;108: 
1729–1736. https://doi.org/10.1136/heartjnl-2021-320652
596. Chu VH, Sexton DJ, Cabell CH, Reller LB, Pappas PA, Singh RK, et al. Repeat infective 
endocarditis: differentiating relapse from reinfection. Clin Infect Dis 2005;41:406–409. 
https://doi.org/10.1086/431590
597. Inagaki K, Lucar J, Blackshear C, Hobbs CV. Methicillin-susceptible and methicillin- 
resistant Staphylococcus aureus bacteremia: nationwide estimates of 30-day readmis­
sion, in-hospital mortality, length of stay, and cost in the United States. Clin Infect 
Dis 2019;69:2112–2118. https://doi.org/10.1093/cid/ciz123
598. David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD. Surgical treat­
ment of active infective endocarditis: a continued challenge. J Thorac Cardiovasc Surg 
2007;133:144–9. https://doi.org/10.1016/j.jtcvs.2006.08.060
599. Fedoruk LM, Jamieson WR, Ling H, Macnab JS, Germann E, Karim SS, et al. Predictors 
of recurrence and reoperation for prosthetic valve endocarditis after valve replace­
ment surgery for native valve endocarditis. J Thorac Cardiovasc Surg 2009;137: 
326–333. https://doi.org/10.1016/j.jtcvs.2008.08.024
600. Moon MR, Miller DC, Moore KA, Oyer PE, Mitchell RS, Robbins RC, et al. Treatment 
of endocarditis with valve replacement: the question of tissue versus mechanical pros­
thesis. Ann Thorac Surg 2001;71:1164–1171. https://doi.org/10.1016/S0003-4975(00) 
02665-5
601. Toyoda N, Itagaki S, Tannous H, Egorova NN, Chikwe J. Bioprosthetic versus mech­
anical valve replacement for infective endocarditis: focus on recurrence rates. Ann 
Thorac Surg 2018;106:99–106. https://doi.org/10.1016/j.athoracsur.2017.12.046
602. Ostergaard L, Dahl A, Fosbol E, Bruun NE, Oestergaard LB, Lauridsen TK, et al. 
Residual vegetation after treatment for left-sided infective endocarditis and subse­
quent risk of stroke and recurrence of endocarditis. Int J Cardiol 2019;293:67–72. 
https://doi.org/10.1016/j.ijcard.2019.06.059
603. Rasmussen TB, Zwisler AD, Moons P, Berg SK. Insufficient living: experiences of recov­
ery after infective endocarditis. J Cardiovasc Nurs 2015;30:E11–E19. https://doi.org/10. 
1097/JCN.0000000000000144
604. Rasmussen TB, Zwisler AD, Thygesen LC, Bundgaard H, Moons P, Berg SK. High re­
admission rates and mental distress after infective endocarditis – results from the na­
tional population-based CopenHeart IE survey. Int J Cardiol 2017;235:133–140. https:// 
doi.org/10.1016/j.ijcard.2017.02.077
605. Rasmussen TB, Zwisler AD, Risom SS, Sibilitz KL, Christensen J, Bundgaard H, et al. 
Comprehensive cardiac rehabilitation for patients following infective endocarditis: re­
sults of the randomized CopenHeartIE trial. Eur J Cardiovasc Nurs 2022;21:261–270. 
https://doi.org/10.1093/eurjcn/zvab047
606. Price CN, Solomon DA, Johnson JA, Montgomery MW, Martin B, Suzuki J. Feasibility 
and safety of outpatient parenteral antimicrobial therapy in conjunction with addiction 
treatment for people who inject drugs. J Infect Dis 2020;222(Suppl 5):S494–S498. 
https://doi.org/10.1093/infdis/jiaa025
607. Kimmel SD, Walley AY, Li Y, Linas BP, Lodi S, Bernson D, et al. Association of treat­
ment with medications for opioid use disorder with mortality after hospitalization for 
injection drug use-associated infective endocarditis. JAMA Netw Open 2020;3: 
e2016228. https://doi.org/10.1001/jamanetworkopen.2020.16228
608. Hays LH. Infective endocarditis: call for education of adults with CHD: review of the 
evidence. Cardiol Young 2016;26:426–430. https://doi.org/10.1017/S104795111500 
2395
609. Abraham LN, Sibilitz KL, Berg SK, Tang LH, Risom SS, Lindschou J, et al. Exercise-based 
cardiac rehabilitation for adults after heart valve surgery. Cochrane Database Syst Rev 
2021;5:CD010876. https://doi.org/10.1002/14651858.CD010876.pub3
610. Abegaz TM, Bhagavathula AS, Gebreyohannes EA, Mekonnen AB, Abebe TB. Short- 
and long-term outcomes in infective endocarditis patients: a systematic review and 
meta-analysis. BMC Cardiovasc Disord 2017;17:291. https://doi.org/10.1186/s12872- 
017-0729-5
611. Ternhag A, Cederstrom A, Torner A, Westling K. A nationwide cohort study of mor­
tality risk and long-term prognosis in infective endocarditis in Sweden. PLoS One 2013; 
8:e67519. https://doi.org/10.1371/journal.pone.0067519
612. Collonnaz M, Erpelding ML, Alla F, Goehringer F, Delahaye F, Iung B, et al. Impact of 
referral bias on prognostic studies outcomes: insights from a population-based cohort 
study on infective endocarditis. Ann Epidemiol 2021;54:29–37. https://doi.org/10.1016/ 
j.annepidem.2020.09.008
613. Mokhles MM, Ciampichetti I, Head SJ, Takkenberg JJ, Bogers AJ. Survival of surgically 
treated infective endocarditis: a comparison with the general Dutch population. Ann 
Thorac Surg 2011;91:1407–1412. https://doi.org/10.1016/j.athoracsur.2011.02.007
614. Straw S, Baig MW, Gillott R, Wu J, Witte KK, O’Regan DJ, et al. Long-term outcomes 
are poor in intravenous drug users following infective endocarditis, even after surgery. 
Clin Infect Dis 2020;71:564–571. https://doi.org/10.1093/cid/ciz869
615. Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996;335: 
407–416. https://doi.org/10.1056/NEJM199608083350607
616. Moreillon P, Que YA. Infective endocarditis. Lancet 2004;363:139–149. https://doi.org/ 
10.1016/S0140-6736(03)15266-X
617. Hoen B, Alla F, Selton-Suty C, Beguinot I, Bouvet A, Briancon S, et al. Changing profile 
of infective endocarditis: results of a 1-year survey in France. JAMA 2002;288:75–81. 
https://doi.org/10.1001/jama.288.1.75
618. Selton-Suty C, Celard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, et al. 
Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population- 
based survey. Clin Infect Dis 2012;54:1230–1239. https://doi.org/10.1093/cid/cis199
619. Anantha Narayanan M, Mahfood Haddad T, Kalil AC, Kanmanthareddy A, Suri RM, 
Mansour G, et al. Early versus late surgical intervention or medical management for 
infective endocarditis: a systematic review and meta-analysis. Heart 2016;102: 
950–957. https://doi.org/10.1136/heartjnl-2015-308589
620. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS, et al. 
Long-term safety and effectiveness of mechanical versus biologic aortic valve pros­
theses in older patients: results from the Society of Thoracic Surgeons adult cardiac 
surgery national database. Circulation 2013;127:1647–1655. https://doi.org/10.1161/ 
CIRCULATIONAHA.113.002003
621. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L, Pare C, et al. Contemporary 
clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007;297: 
1354–1361. https://doi.org/10.1001/jama.297.12.1354
622. Lopez J, Revilla A, Vilacosta I, Villacorta E, Gonzalez-Juanatey C, Gomez I, et al. 
Definition, clinical profile, microbiological spectrum, and prognostic factors of 
early-onset prosthetic valve endocarditis. Eur Heart J 2007;28:760–765. https://doi. 
org/10.1093/eurheartj/ehl486
623. Moriyama N, Laakso T, Biancari F, Raivio P, Jalava MP, Jaakkola J, et al. Prosthetic valve 
endocarditis after transcatheter or surgical aortic valve replacement with a bioprosth­
esis: results from the FinnValve registry. EuroIntervention 2019;15:e500–e507. https:// 
doi.org/10.4244/EIJ-D-19-00247
624. Berisha B, Ragnarsson S, Olaison L, Rasmussen M. Microbiological etiology in prosthet­
ic valve endocarditis: a nationwide registry study. J Intern Med 2022;292:428–437. 
https://doi.org/10.1111/joim.13491
625. Kohler P, Kuster SP, Bloemberg G, Schulthess B, Frank M, Tanner FC, et al. 
Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated 
Mycobacterium chimaera infections subsequent to open heart surgery. Eur Heart J 
2015;36:2745–2753. https://doi.org/10.1093/eurheartj/ehv342
626. Chamat-Hedemand S, Dahl A, Ostergaard L, Arpi M, Fosbol E, Boel J, et al. Prevalence 
of infective endocarditis in streptococcal bloodstream infections is dependent on 
streptococcal species. Circulation 2020;142:720–730. https://doi.org/10.1161/ 
CIRCULATIONAHA.120.046723
627. Expert Panel on Cardiac Imaging; Malik SB, Hsu JY, Hurwitz Koweek LM, Ghoshhajra 
BB, Beache GM, et al. ACR appropriateness criteria(r) infective endocarditis. J Am Coll 
Radiol 2021;18:S52–S61. https://doi.org/10.1016/j.jacr.2021.01.010
628. Luciani N, Mossuto E, Ricci D, Luciani M, Russo M, Salsano A, et al. Prosthetic valve 
endocarditis: predictors of early outcome of surgical therapy. A multicentric study. 
Eur J Cardiothorac Surg 2017;52:768–774. https://doi.org/10.1093/ejcts/ezx169
629. Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Prosthetic valve 
endocarditis after surgical aortic valve replacement. Circulation 2017;136:329–331. 
https://doi.org/10.1161/CIRCULATIONAHA.117.028783
630. Erdem H, Puca E, Ruch Y, Santos L, Ghanem-Zoubi N, Argemi X, et al. Portraying in­
fective endocarditis: results of multinational ID-IRI study. Eur J Clin Microbiol Infect Dis 
2019;38:1753–1763. https://doi.org/10.1007/s10096-019-03607-x
631. Shrestha NK, Shah SY, Hussain ST, Pettersson GB, Griffin BP, Nowacki AS, et al. 
Association of surgical treatment with survival in patients with prosthetic valve endo­
carditis. Ann Thorac Surg 2020;109:1834–1843. https://doi.org/10.1016/j.athoracsur. 
2019.09.015
632. Truninger K, Attenhofer Jost CH, Seifert B, Vogt PR, Follath F, Schaffner A, et al. Long 
term follow up of prosthetic valve endocarditis: what characteristics identify patients 
who were treated successfully with antibiotics alone? Heart 1999;82:714–720. https:// 
doi.org/10.1136/hrt.82.6.714
633. Tornos P, Almirante B, Olona M, Permanyer G, Gonzalez T, Carballo J, et al. Clinical 
outcome and long-term prognosis of late prosthetic valve endocarditis: a 20-year ex­
perience. Clin Infect Dis 1997;24:381–386. https://doi.org/10.1093/clinids/24.3.381
634. Arnold CJ, Johnson M, Bayer AS, Bradley S, Giannitsioti E, Miro JM, et al. Candida in­
fective endocarditis: an observational cohort study with a focus on therapy. Antimicrob 
Agents Chemother 2015;59:2365–2373. https://doi.org/10.1128/AAC.04867-14
635. Castillo JC, Anguita MP, Torres F, Mesa D, Franco M, Gonzalez E, et al. Long-term 
prognosis of early and late prosthetic valve endocarditis. Am J Cardiol 2004;93: 
1185–1187. https://doi.org/10.1016/j.amjcard.2004.01.056


<!-- PAGE 90 -->

### Page 90

636. Chu VH, Miro JM, Hoen B, Cabell CH, Pappas PA, Jones P, et al. Coagulase-negative 
staphylococcal prosthetic valve endocarditis–a contemporary update based on the 
International Collaboration on Endocarditis: prospective cohort study. Heart 2009; 
95:570–576. https://doi.org/10.1136/hrt.2008.152975
637. Jensen AD, Ostergaard L, Petersen JK, Graversen PL, Butt JH, Hadji-Turdeghal K, et al. 
Temporal trends of mortality in patients with infective endocarditis: a nationwide 
study. Eur Heart J Qual Care Clin Outcomes 2022;9:24–33. https://doi.org/10.1093/ 
ehjqcco/qcac011
638. Slipczuk L, Codolosa JN, Davila CD, Romero-Corral A, Yun J, Pressman GS, et al. 
Infective endocarditis epidemiology over five decades: a systematic review. PLoS One 
2013;8:e82665. https://doi.org/10.1371/journal.pone.0082665
639. Oliver L, Lavoute C, Giorgi R, Salaun E, Hubert S, Casalta JP, et al. Infective endocarditis 
in octogenarians. Heart 2017;103:1602–1609. https://doi.org/10.1136/heartjnl-2016- 
310853
640. Pazdernik M, Iung B, Mutlu B, Alla F, Riezebos R, Kong W, et al. Surgery and outcome of 
infective endocarditis in octogenarians: prospective data from the ESC EORP 
EURO-ENDO registry. Infection 2022;50:1191–1202. https://doi.org/10.1007/ 
s15010-022-01792-0
641. Ragnarsson S, Salto-Alejandre S, Strom A, Olaison L, Rasmussen M. Surgery is under­
used in elderly patients with left-sided infective endocarditis: a nationwide registry 
study. J Am Heart Assoc 2021;10:e020221. https://doi.org/10.1161/JAHA.120.020221
642. Ghanta RK, Pettersson GB. Surgical treatment of infective endocarditis in elderly pa­
tients: the importance of shared decision making. J Am Heart Assoc 2021;10:e022186. 
https://doi.org/10.1161/JAHA.121.022186
643. Lopez J, Revilla A, Vilacosta I, Sevilla T, Villacorta E, Sarria C, et al. Age-dependent pro­
file of left-sided infective endocarditis: a 3-center experience. Circulation 2010;121: 
892–897. https://doi.org/10.1161/CIRCULATIONAHA.109.877365
644. Stortecky S, Heg D, Tueller D, Pilgrim T, Muller O, Noble S, et al. Infective endocarditis 
after transcatheter aortic valve replacement. J Am Coll Cardiol 2020;75:3020–3030. 
https://doi.org/10.1016/j.jacc.2020.04.044
645. Regueiro A, Linke A, Latib A, Ihlemann N, Urena M, Walther T, et al. Association be­
tween transcatheter aortic valve replacement and subsequent infective endocarditis 
and in-hospital death. JAMA 2016;316:1083–1092. https://doi.org/10.1001/jama. 
2016.12347
646. Kolte D, Goldsweig A, Kennedy KF, Abbott JD, Gordon PC, Sellke FW, et al. 
Comparison of incidence, predictors, and outcomes of early infective endocarditis 
after transcatheter aortic valve implantation versus surgical aortic valve replacement 
in the United States. Am J Cardiol 2018;122:2112–2119. https://doi.org/10.1016/j. 
amjcard.2018.08.054
647. Fauchier L, Bisson A, Herbert J, Lacour T, Bourguignon T, Etienne CS, et al. Incidence 
and outcomes of infective endocarditis after transcatheter aortic valve implantation 
versus surgical aortic valve replacement. Clin Microbiol Infect 2020;26:1368–1374. 
https://doi.org/10.1016/j.cmi.2020.01.036
648. Butt JH, Ihlemann N, De Backer O, Sondergaard L, Havers-Borgersen E, Gislason GH, 
et al. Long-term risk of infective endocarditis after transcatheter aortic valve replace­
ment. J Am Coll Cardiol 2019;73:1646–1655. https://doi.org/10.1016/j.jacc.2018.12.078
649. Cahill TJ, Raby J, Jewell PD, Brennan PF, Banning AP, Byrne J, et al. Risk of infective 
endocarditis after surgical and transcatheter aortic valve replacement. Heart 2022; 
108:639–647. https://doi.org/10.1136/heartjnl-2021-320080
650. Del Val D, Abdel-Wahab M, Linke A, Durand E, Ihlemann N, Urena M, et al. Temporal 
trends, characteristics, and outcomes of infective endocarditis after transcatheter aor­
tic valve replacement. Clin Infect Dis 2021;73:e3750–e3758. https://doi.org/10.1093/ 
cid/ciaa1941
651. Bjursten H, Rasmussen M, Nozohoor S, Gotberg M, Olaison L, Ruck A, et al. Infective 
endocarditis after transcatheter aortic valve implantation: a nationwide study. Eur 
Heart J 2019;40:3263–3269. https://doi.org/10.1093/eurheartj/ehz588
652. Mentias A, Girotra S, Desai MY, Horwitz PA, Rossen JD, Saad M, et al. Incidence, pre­
dictors, and outcomes of endocarditis after transcatheter aortic valve replacement in 
the United States. JACC Cardiovasc Interv 2020;13:1973–1982. https://doi.org/10.1016/ 
j.jcin.2020.05.012
653. Regueiro A, Linke A, Latib A, Ihlemann N, Urena M, Walther T, et al. Infective endo­
carditis following transcatheter aortic valve replacement: comparison of balloon- ver­
sus self-expandable valves. Circ Cardiovasc Interv 2019;12:e007938. https://doi.org/10. 
1161/CIRCINTERVENTIONS.119.007938
654. Salaun E, Sportouch L, Barral PA, Hubert S, Lavoute C, Casalta AC, et al. Diagnosis of 
infective endocarditis after TAVR: value of a multimodality imaging approach. JACC 
Cardiovasc Imaging 2018;11:143–146. https://doi.org/10.1016/j.jcmg.2017.05.016
655. Wahadat AR, Tanis W, Swart LE, Scholtens A, Krestin GP, van Mieghem N, et al. 
Added value of (18)F-FDG-PET/CT and cardiac CTA in suspected transcatheter aortic 
valve endocarditis. J Nucl Cardiol 2021;28:2072–2082. https://doi.org/10.1007/s12350- 
019-01963-x
656. Mangner N, Leontyev S, Woitek FJ, Kiefer P, Haussig S, Binner C, et al. Cardiac surgery 
compared with antibiotics only in patients developing infective endocarditis after 
transcatheter aortic valve replacement. J Am Heart Assoc 2018;7:e010027. https:// 
doi.org/10.1161/JAHA.118.010027
657. Del Val D, Trottier M, Alperi A, Muntane-Carol G, Faroux L, Delarochelliere R, et al. 
(18)F-fluorodeoxyglucose uptake pattern in noninfected transcatheter aortic valves. 
Circ Cardiovasc Imaging 2020;13:e011749. https://doi.org/10.1161/CIRCIMAGING. 
120.011749
658. Mangner N, del Val D, Abdel-Wahab M, Crusius L, Durand E, Ihlemann N. Surgical 
treatment of patients with infective endocarditis after transcatheter aortic valve im­
plantation. J Am Coll Cardiol 2022;79:772–785. https://doi.org/10.1016/j.jacc.2021.11. 
056
659. Santos-Martinez S, Alkhodair A, Nombela-Franco L, Saia F, Munoz-Garcia AJ, 
Gutierrez E, et al. Transcatheter aortic valve replacement for residual lesion of the aor­
tic valve following “healed” infective endocarditis. JACC Cardiovasc Interv 2020;13: 
1983–1996. https://doi.org/10.1016/j.jcin.2020.05.033
660. Bos D, De Wolf D, Cools B, Eyskens B, Hubrechts J, Boshoff D, et al. Infective endo­
carditis in patients after percutaneous pulmonary valve implantation with the stent- 
mounted bovine jugular vein valve: clinical experience and evaluation of the modified 
Duke criteria. Int J Cardiol 2021;323:40–46. https://doi.org/10.1016/j.ijcard.2020.08. 
058
661. Georgiev S, Ewert P, Eicken A, Hager A, Horer J, Cleuziou J, et al. Munich comparative 
study: prospective long-term outcome of the transcatheter melody valve versus sur­
gical pulmonary bioprosthesis with up to 12 years of follow-up. Circ Cardiovasc Interv 
2020;13:e008963. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008963
662. Groning M, Tahri NB, Sondergaard L, Helvind M, Ersboll MK, Orbaek Andersen H. 
Infective endocarditis in right ventricular outflow tract conduits: a register-based com­
parison of homografts, contegra grafts and melody transcatheter valves. Eur J 
Cardiothorac Surg 2019;56:87–93. https://doi.org/10.1093/ejcts/ezy478
663. Lluri G, Levi DS, Miller E, Hageman A, Sinha S, Sadeghi S, et al. Incidence and outcome 
of infective endocarditis following percutaneous versus surgical pulmonary valve re­
placement. Catheter Cardiovasc Interv 2018;91:277–284. https://doi.org/10.1002/ccd. 
27312
664. Malekzadeh-Milani S, Houeijeh A, Jalal Z, Hascoet S, Bakloul M, Aldebert P, et al. French 
national survey on infective endocarditis and the melody valve in percutaneous pul­
monary valve implantation. Arch Cardiovasc Dis 2018;111:497–506. https://doi.org/ 
10.1016/j.acvd.2017.10.007
665. McElhinney DB, Zhang Y, Aboulhosn JA, Morray BH, Biernacka EK, Qureshi AM, et al. 
Multicenter study of endocarditis after transcatheter pulmonary valve replacement. J 
Am Coll Cardiol 2021;78:575–589. https://doi.org/10.1016/j.jacc.2021.05.044
666. Nordmeyer J, Ewert P, Gewillig M, AlJufan M, Carminati M, Kretschmar O, et al. Acute 
and midterm outcomes of the post-approval MELODY registry: a multicentre registry 
of transcatheter pulmonary valve implantation. Eur Heart J 2019;40:2255–2264. 
https://doi.org/10.1093/eurheartj/ehz201
667. O’Donnell C, Holloway R, Tilton E, Stirling J, Finucane K, Wilson N. Infective endocar­
ditis following melody valve implantation: comparison with a surgical cohort. Cardiol 
Young 2017;27:294–301. https://doi.org/10.1017/S1047951116000494
668. Van Dijck I, Budts W, Cools B, Eyskens B, Boshoff DE, Heying R, et al. Infective endo­
carditis of a transcatheter pulmonary valve in comparison with surgical implants. Heart 
2015;101:788–793. https://doi.org/10.1136/heartjnl-2014-306761
669. Stammnitz C, Huscher D, Bauer UMM, Urban A, Nordmeyer J, Schubert S, et al. 
Nationwide registry-based analysis of infective endocarditis risk after pulmonary valve 
replacement. J Am Heart Assoc 2022;11:e022231. https://doi.org/10.1161/JAHA.121. 
022231
670. Cheung G, Vejlstrup N, Ihlemann N, Arnous S, Franzen O, Bundgaard H, et al. Infective 
endocarditis following percutaneous pulmonary valve replacement: diagnostic chal­
lenges and application of intra-cardiac echocardiography. Int J Cardiol 2013;169: 
425–429. https://doi.org/10.1016/j.ijcard.2013.10.016
671. Olsen T, Jorgensen OD, Nielsen JC, Thogersen AM, Philbert BT, Johansen JB. Incidence 
of device-related infection in 97 750 patients: clinical data from the complete Danish 
device-cohort (1982–2018). Eur Heart J 2019;40:1862–1869. https://doi.org/10.1093/ 
eurheartj/ehz316
672. Da Costa A, Lelievre H, Kirkorian G, Celard M, Chevalier P, Vandenesch F, et al. Role of 
the preaxillary flora in pacemaker infections: a prospective study. Circulation 1998;97: 
1791–1795. https://doi.org/10.1161/01.CIR.97.18.1791
673. Chamis AL, Peterson GE, Cabell CH, Corey GR, Sorrentino RA, Greenfield RA, et al. 
Staphylococcus aureus bacteremia in patients with permanent pacemakers or implanta­
ble cardioverter-defibrillators. Circulation 2001;104:1029–1033. https://doi.org/10. 
1161/hc3401.095097
674. Madhavan M, Sohail MR, Friedman PA, Hayes DL, Steckelberg JM, Wilson WR, et al. 
Outcomes in patients with cardiovascular implantable electronic devices and bacter­
emia caused by Gram-positive cocci other than Staphylococcus aureus. Circ Arrhythm 
Electrophysiol 2010;3:639–645. https://doi.org/10.1161/CIRCEP.110.957514
675. Sohail MR, Palraj BR, Khalid S, Uslan DZ, Al-Saffar F, Friedman PA, et al. Predicting risk 
of endovascular device infection in patients with Staphylococcus aureus bacteremia 
(PREDICT-SAB). Circ Arrhythm Electrophysiol 2015;8:137–144. https://doi.org/10. 
1161/CIRCEP.114.002199
676. Uslan DZ, Dowsley TF, Sohail MR, Hayes DL, Friedman PA, Wilson WR, et al. 
Cardiovascular 
implantable 
electronic 
device 
infection 
in 
patients 
with 
ESC Guidelines                                                                                                                                                                                          4037


<!-- PAGE 91 -->

### Page 91

Staphylococcus aureus bacteremia. Pacing Clin Electrophysiol 2010;33:407–413. https:// 
doi.org/10.1111/j.1540-8159.2009.02565.x
677. Hussein AA, Baghdy Y, Wazni OM, Brunner MP, Kabbach G, Shao M, et al. 
Microbiology of cardiac implantable electronic device infections. JACC Clin 
Electrophysiol 2016;2:498–505. https://doi.org/10.1016/j.jacep.2016.01.019
678. Mateos Gaitan R, Boix-Palop L, Munoz Garcia P, Mestres CA, Marin Arriaza M, Pedraz 
Prieto A, et al. Infective endocarditis in patients with cardiac implantable electronic de­
vices: a nationwide study. Europace 2020;22:1062–1070. https://doi.org/10.1093/ 
europace/euaa076
679. Arora Y, Perez AA, Carrillo RG. Influence of vegetation shape on outcomes in trans­
venous lead extractions: does shape matter? Heart Rhythm 2020;17:646–653. https:// 
doi.org/10.1016/j.hrthm.2019.11.015
680. Esquer Garrigos Z, George MP, Vijayvargiya P, Tan EM, Farid S, Abu Saleh OM, et al. 
Clinical presentation, management, and outcomes of cardiovascular implantable elec­
tronic device infections due to Gram-negative versus Gram-positive bacteria. Mayo 
Clin Proc 2019;94:1268–1277. https://doi.org/10.1016/j.mayocp.2018.11.029
681. Baman JR, Medhekar AN, Jain SK, Knight BP, Harrison LH, Smith B, et al. Management 
of systemic fungal infections in the presence of a cardiac implantable electronic device: 
a systematic review. Pacing Clin Electrophysiol 2021;44:159–166. https://doi.org/10. 
1111/pace.14090
682. Krahn AD, Longtin Y, Philippon F, Birnie DH, Manlucu J, Angaran P, et al. Prevention of 
arrhythmia device infection trial: the PADIT trial. J Am Coll Cardiol 2018;72:3098–3109. 
https://doi.org/10.1016/j.jacc.2018.09.068
683. Birnie DH, Wang J, Alings M, Philippon F, Parkash R, Manlucu J, et al. Risk factors for 
infections involving cardiac implanted electronic devices. J Am Coll Cardiol 2019;74: 
2845–2854. https://doi.org/10.1016/j.jacc.2019.09.060
684. Ahmed FZ, Blomstrom-Lundqvist C, Bloom H, Cooper C, Ellis C, Goette A, et al. Use 
of healthcare claims to validate the prevention of arrhythmia device infection trial car­
diac implantable electronic device infection risk score. Europace 2021;23:1446–1455. 
https://doi.org/10.1093/europace/euab028
685. Birnie DH, Healey JS, Wells GA, Ayala-Paredes F, Coutu B, Sumner GL, et al. 
Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in 
patients with moderate to high risk of arterial thrombo-embolic events (BRUISE 
CONTROL-2). Eur Heart J 2018;39:3973–3979. https://doi.org/10.1093/eurheartj/ 
ehy413
686. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or 
defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368: 
2084–2093. https://doi.org/10.1056/NEJMoa1302946
687. Burri H, Starck C, Auricchio A, Biffi M, Burri M, D’Avila A, et al. EHRA expert consen­
sus statement and practical guide on optimal implantation technique for conventional 
pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart 
Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the 
Latin-American Heart Rhythm Society (LAHRS). Europace 2021;23:983–1008. 
https://doi.org/10.1093/europace/euaa367
688. Tarakji KG, Mittal S, Kennergren C, Corey R, Poole JE, Schloss E, et al. Antibacterial 
envelope to prevent cardiac implantable device infection. N Engl J Med 2019;380: 
1895–1905. https://doi.org/10.1056/NEJMoa1901111
689. Frausing M, Nielsen JC, Johansen JB, Jorgensen OD, Gerdes C, Olsen T, et al. Rate of 
device-related infections using an antibacterial envelope in patients undergoing cardiac 
resynchronization therapy reoperations. Europace 2022;24:421–429. https://doi.org/ 
10.1093/europace/euab207
690. Uslan DZ, Sohail MR, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, et al. 
Frequency of permanent pacemaker or implantable cardioverter-defibrillator infection 
in patients with Gram-negative bacteremia. Clin Infect Dis 2006;43:731–736. https:// 
doi.org/10.1086/506942
691. Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM, et al. 
Permanent pacemaker and implantable cardioverter defibrillator infection: a 
population-based study. Arch Intern Med 2007;167:669–675. https://doi.org/10.1001/ 
archinte.167.7.669
692. Fowler VG Jr, Li J, Corey GR, Boley J, Marr KA, Gopal AK, et al. Role of echocardiog­
raphy in evaluation of patients with Staphylococcus aureus bacteremia: experience in 
103 patients. J Am Coll Cardiol 1997;30:1072–1078. https://doi.org/10.1016/S0735- 
1097(97)00250-7
693. Victor F, De Place C, Camus C, Le Breton H, Leclercq C, Pavin D, et al. Pacemaker lead 
infection: echocardiographic features, management, and outcome. Heart 1999;81: 
82–87. https://doi.org/10.1136/hrt.81.1.82
694. Vilacosta I, Sarria C, San Roman JA, Jimenez J, Castillo JA, Iturralde E, et al. Usefulness of 
transesophageal echocardiography for diagnosis of infected transvenous permanent 
pacemakers. Circulation 1994;89:2684–2687. https://doi.org/10.1161/01.CIR.89.6. 
2684
695. Narducci ML, Pelargonio G, Russo E, Marinaccio L, Di Monaco A, Perna F, et al. 
Usefulness of intracardiac echocardiography for the diagnosis of cardiovascular im­
plantable electronic device-related endocarditis. J Am Coll Cardiol 2013;61: 
1398–1405. https://doi.org/10.1016/j.jacc.2012.12.041
696. Golzio PG, Errigo D, Peyracchia M, Gallo E, Frea S, Castagno D, et al. Prevalence and 
prognosis of lead masses in patients with cardiac implantable electronic devices 
without infection. J Cardiovasc Med (Hagerstown) 2019;20:372–378. https://doi.org/ 
10.2459/JCM.0000000000000797
697. Erba PA, Sollini M, Conti U, Bandera F, Tascini C, De Tommasi SM, et al. Radiolabeled 
WBC scintigraphy in the diagnostic workup of patients with suspected device-related 
infections. JACC Cardiovasc Imaging 2013;6:1075–1086. https://doi.org/10.1016/j.jcmg. 
2013.08.001
698. Lin AY, Saul T, Aldaas OM, Lupercio F, Ho G, Pollema T, et al. Early versus delayed lead 
extraction in patients with infected cardiovascular implantable electronic devices. JACC 
Clin Electrophysiol 2021;7:755–763. https://doi.org/10.1016/j.jacep.2020.11.003
699. Le KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL, et al. Impact of timing of 
device removal on mortality in patients with cardiovascular implantable electronic de­
vice infections. Heart Rhythm 2011;8:1678–1685. https://doi.org/10.1016/j.hrthm. 
2011.05.015
700. Durante-Mangoni E, Casillo R, Bernardo M, Caianiello C, Mattucci I, Pinto D, et al. 
High-dose daptomycin for cardiac implantable electronic device-related infective 
endocarditis. Clin Infect Dis 2012;54:347–354. https://doi.org/10.1093/cid/cir805
701. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, et al. 
Management and outcome of permanent pacemaker and implantable cardioverter- 
defibrillator infections. J Am Coll Cardiol 2007;49:1851–1859. https://doi.org/10.1016/ 
j.jacc.2007.01.072
702. Huang X-M, Fu H-X, Zhong L, Cao J, Asirvatham SJ, Baddour LM, et al. Outcomes of 
transvenous lead extraction for cardiovascular implantable electronic device infections 
in patients with prosthetic heart valves. Circ Arrhythm Electrophysiol 2016;9:e004188. 
https://doi.org/10.1161/CIRCEP.116.004188
703. De Ciancio G, Erpelding ML, Filippetti L, Goehringer F, Blangy H, Huttin O, et al. 
Adherence to diagnostic and therapeutic practice guidelines for suspected cardiac im­
plantable electronic device infections. Arch Cardiovasc Dis 2021;114:634–646. https:// 
doi.org/10.1016/j.acvd.2021.06.010
704. Viganego F, O’Donoghue S, Eldadah Z, Shah MH, Rastogi M, Mazel JA, et al. Effect of 
early diagnosis and treatment with percutaneous lead extraction on survival in patients 
with cardiac device infections. Am J Cardiol 2012;109:1466–1471. https://doi.org/10. 
1016/j.amjcard.2012.01.360
705. Starck CT, Schaerf RHM, Breitenstein A, Najibi S, Conrad J, Berendt J, et al. 
Transcatheter aspiration of large pacemaker and implantable cardioverter-defibrillator 
lead vegetations facilitating safe transvenous lead extraction. Europace 2020;22: 
133–138. https://doi.org/10.1093/europace/euz283
706. Golzio PG, Vinci M, Anselmino M, Comoglio C, Rinaldi M, Trevi GP, et al. Accuracy of 
swabs, tissue specimens, and lead samples in diagnosis of cardiac rhythm management 
device infections. Pacing Clin Electrophysiol 2009;32(Suppl 1):S76–S80. https://doi.org/ 
10.1111/j.1540-8159.2008.02257.x
707. Nagpal A, Patel R, Greenwood-Quaintance KE, Baddour LM, Lynch DT, Lahr BD, et al. 
Usefulness of sonication of cardiovascular implantable electronic devices to enhance 
microbial detection. Am J Cardiol 2015;115:912–917. https://doi.org/10.1016/j. 
amjcard.2015.01.017
708. Rohacek M, Erne P, Kobza R, Pfyffer GE, Frei R, Weisser M. Infection of cardiovascular 
implantable electronic devices: detection with sonication, swab cultures, and blood 
cultures. Pacing Clin Electrophysiol 2015;38:247–253. https://doi.org/10.1111/pace. 
12529
709. Chew D, Somayaji R, Conly J, Exner D, Rennert-May E. Timing of device reimplanta­
tion and reinfection rates following cardiac implantable electronic device infection: a 
systematic review and meta-analysis. BMJ Open 2019;9:e029537. https://doi.org/10. 
1136/bmjopen-2019-029537
710. Diemberger I, Biffi M, Lorenzetti S, Martignani C, Raffaelli E, Ziacchi M, et al. Predictors 
of long-term survival free from relapses after extraction of infected CIED. Europace 
2018;20:1018–1027. https://doi.org/10.1093/europace/eux121
711. Chua JD, Wilkoff BL, Lee I, Juratli N, Longworth DL, Gordon SM. Diagnosis and man­
agement of infections involving implantable electrophysiologic cardiac devices. Ann 
Intern 
Med 
2000;133:604–608. 
https://doi.org/10.7326/0003-4819-133-8- 
200010170-00011
712. Kawata H, Pretorius V, Phan H, Mulpuru S, Gadiyaram V, Patel J, et al. Utility and safety 
of temporary pacing using active fixation leads and externalized re-usable permanent 
pacemakers after lead extraction. Europace 2013;15:1287–1291. https://doi.org/10. 
1093/europace/eut045
713. Perrin T, Maille B, Lemoine C, Resseguier N, Franceschi F, Koutbi L, et al. Comparison 
of epicardial vs. endocardial reimplantation in pacemaker-dependent patients with de­
vice infection. Europace 2018;20:e42–e50. https://doi.org/10.1093/europace/eux111
714. Zucchelli G, Barletta V, Della Tommasina V, Viani S, Parollo M, Mazzocchetti L, et al. 
Micra pacemaker implant after cardiac implantable electronic device extraction: feasi­
bility and long-term outcomes. Europace 2019;21:1229–1236. https://doi.org/10.1093/ 
europace/euz160
715. Chung DU, Tauber J, Kaiser L, Schlichting A, Pecha S, Sinning C, et al. Performance and 
outcome of the subcutaneous implantable cardioverter-defibrillator after transvenous 
lead extraction. Pacing Clin Electrophysiol 2021;44:247–257. https://doi.org/10.1111/ 
pace.14157


<!-- PAGE 92 -->

### Page 92

716. Joffre J, Dumas G, Aegerter P, Dubee V, Bige N, Preda G, et al. Epidemiology of infect­
ive endocarditis in French intensive care units over the 1997–2014 period-from 
CUB-rea network. Crit Care 2019;23:143. https://doi.org/10.1186/s13054-019-2387-8
717. Georges H, Leroy O, Airapetian N, Lamblin N, Zogheib E, Devos P, et al. Outcome and 
prognostic factors of patients with right-sided infective endocarditis requiring intensive 
care unit admission. BMC Infect Dis 2018;18:85. https://doi.org/10.1186/s12879-018- 
2989-9
718. Leroy O, Georges H, Devos P, Bitton S, De Sa N, Dedrie C, et al. Infective endocarditis 
requiring ICU admission: epidemiology and prognosis. Ann Intensive Care 2015;5:45. 
https://doi.org/10.1186/s13613-015-0091-7
719. Samol A, Kaese S, Bloch J, Gorlich D, Peters G, Waltenberger J, et al. Infective endo­
carditis on ICU: risk factors, outcome and long-term follow-up. Infection 2015;43: 
287–295. https://doi.org/10.1007/s15010-014-0715-0
720. Arntfield R, Lau V, Landry Y, Priestap F, Ball I. Impact of critical care transesophageal 
echocardiography in medical-surgical ICU patients: characteristics and results from 
274 consecutive examinations. J Intensive Care Med 2020;35:896–902. https://doi. 
org/10.1177/0885066618797271
721. Belletti A, Jacobs S, Affronti G, Mladenow A, Landoni G, Falk V, et al. Incidence and 
predictors of postoperative need for high-dose inotropic support in patients undergo­
ing cardiac surgery for infective endocarditis. J Cardiothorac Vasc Anesth 2018;32: 
2528–2536. https://doi.org/10.1053/j.jvca.2017.12.015
722. van den Brink FS, van Tooren R, Sonker U, Klein P, Waanders F, Zivelonghi C, et al. 
Veno arterial-extra corporal membrane oxygenation for the treatment of cardiac fail­
ure in patients with infective endocarditis. Perfusion 2019;34:613–617. https://doi.org/ 
10.1177/0267659119842807
723. Lassen H, Nielsen SL, Gill SUA, Johansen IS. The epidemiology of infective endocarditis 
with focus on non-device related right-sided infective endocarditis: a retrospective 
register-based study in the region of southern Denmark. Int J Infect Dis 2020;95: 
224–230. https://doi.org/10.1016/j.ijid.2020.04.011
724. Sridhar AR, Lavu M, Yarlagadda V, Reddy M, Gunda S, Afzal R, et al. Cardiac implantable 
electronic device-related infection and extraction trends in the U.S. Pacing Clin 
Electrophysiol 2017;40:286–293. https://doi.org/10.1111/pace.13009
725. Witten JC, Hussain ST, Shrestha NK, Gordon SM, Houghtaling PL, Bakaeen FG, et al. 
Surgical treatment of right-sided infective endocarditis. J Thorac Cardiovasc Surg 2019; 
157:1418–1427.e14. https://doi.org/10.1016/j.jtcvs.2018.07.112
726. Pfannmueller B, Kahmann M, Davierwala P, Misfeld M, Bakhtiary F, Binner C, et al. 
Tricuspid valve surgery in patients with isolated tricuspid valve endocarditis: analysis 
of perioperative parameters and long-term outcomes. Thorac Cardiovasc Surg 2017; 
65:626–633. https://doi.org/10.1055/s-0035-1564926
727. Isaza N, Shrestha NK, Gordon S, Pettersson GB, Unai S, Vega Brizneda M, et al. 
Contemporary outcomes of pulmonary valve endocarditis: a 16-year single centre ex­
perience. Heart Lung Circ 2020;29:1799–1807. https://doi.org/10.1016/j.hlc.2020.04. 
015
728. Hussain ST, Shrestha NK, Witten J, Gordon SM, Houghtaling PL, Tingleff J, et al. Rarity 
of invasiveness in right-sided infective endocarditis. J Thorac Cardiovasc Surg 2018;155: 
54–61.e1. https://doi.org/10.1016/j.jtcvs.2017.07.068
729. San Roman JA, Vilacosta I, Lopez J, Revilla A, Arnold R, Sevilla T, et al. Role of transthor­
acic and transesophageal echocardiography in right-sided endocarditis: one echocar­
diographic modality does not fit all. J Am Soc Echocardiogr 2012;25:807–814. https:// 
doi.org/10.1016/j.echo.2012.05.016
730. Anton-Vazquez V, Cannata A, Amin-Youssef G, Watson S, Fife A, Mulholland N, et al. 
Diagnostic value of (18)F-FDG PET/CT in infective endocarditis. Clin Res Cardiol 2022; 
111:673–679. https://doi.org/10.1007/s00392-021-01975-z
731. Weber C, Gassa A, Eghbalzadeh K, Merkle J, Djordjevic I, Maier J, et al. Characteristics 
and outcomes of patients with right-sided endocarditis undergoing cardiac surgery. 
Ann Cardiothorac Surg 2019;8:645–653. https://doi.org/10.21037/acs.2019.08.02
732. Shrestha NK, Jue J, Hussain ST, Jerry JM, Pettersson GB, Menon V, et al. Injection drug 
use and outcomes after surgical intervention for infective endocarditis. Ann Thorac Surg 
2015;100:875–882. https://doi.org/10.1016/j.athoracsur.2015.03.019
733. Hussain ST, Witten J, Shrestha NK, Blackstone EH, Pettersson GB. Tricuspid valve 
endocarditis. Ann Cardiothorac Surg 2017;6:255–261. https://doi.org/10.21037/acs. 
2017.03.09
734. Marks LR, Nolan NS, Liang SY, Durkin MJ, Weimer MB. Infectious complications of in­
jection drug use. Med Clin North Am 2022;106:187–200. https://doi.org/10.1016/j. 
mcna.2021.08.006
735. Kelly MC, Yeager SD, Shorman MA, Wright LR, Veve MP. Incidence and predictors of 
Gram-negative bacilli in hospitalized people who inject drugs with injection drug 
use-attributable infections. Antimicrob Agents Chemother 2021;65:e0092521. https:// 
doi.org/10.1128/AAC.00925-21
736. Bisbe J, Miro JM, Latorre X, Moreno A, Mallolas J, Gatell JM, et al. Disseminated can­
didiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect 
Dis 1992;15:910–923. https://doi.org/10.1093/clind/15.6.910
737. Meena DS, Kumar D, Agarwal M, Bohra GK, Choudhary R, Samantaray S, et al. Clinical 
features, diagnosis and treatment outcome of fungal endocarditis: a systematic review 
of reported cases. Mycoses 2022;65:294–302. https://doi.org/10.1111/myc.13398
738. Ribera E, Gomez-Jimenez J, Cortes E, del Valle O, Planes A, Gonzalez-Alujas T, et al. 
Effectiveness of cloxacillin with and without gentamicin in short-term therapy for 
right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann 
Intern 
Med 
1996;125:969–974. 
https://doi.org/10.7326/0003-4819-125-12- 
199612150-00005
739. Cahill TJ, Prendergast BD. Infective endocarditis. Lancet 2016;387:882–893. https:// 
doi.org/10.1016/S0140-6736(15)00067-7
740. Chong CZ, Cherian R, Ng P, Yeo TC, Ling LH, Soo WM, et al. Clinical outcomes of 
severe tricuspid valve infective endocarditis related to intravenous drug abuse – a 
case series. Acta Cardiol 2022;77:884–889. https://doi.org/10.1080/00015385.2021. 
1976448
741. Syed IM, Yanagawa B, Jeyaganth S, Verma S, Cheema AN. Injection drug use endocar­
ditis: an inner-city hospital experience. CJC Open 2021;3:896–903. https://doi.org/10. 
1016/j.cjco.2021.02.015
742. Chahoud J, Sharif Yakan A, Saad H, Kanj SS. Right-sided infective endocarditis and pul­
monary infiltrates: an update. Cardiol Rev 2016;24:230–237. https://doi.org/10.1097/ 
CRD.0000000000000095
743. Damlin A, Westling K. Patients with infective endocarditis and history of injection drug 
use in a Swedish referral hospital during 10 years. BMC Infect Dis 2021;21:236. https:// 
doi.org/10.1186/s12879-021-05914-1
744. Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MJ, Sheth A, et al. Daptomycin 
activity against Staphylococcus aureus following vancomycin exposure in an in vitro 
pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents 
Chemother 2008;52:831–836. https://doi.org/10.1128/AAC.00869-07
745. Al-Omari A, Cameron DW, Lee C, Corrales-Medina VF. Oral antibiotic therapy for 
the treatment of infective endocarditis: a systematic review. BMC Infect Dis 2014;14: 
140. https://doi.org/10.1186/1471-2334-14-140
746. Marks LR, Liang SY, Muthulingam D, Schwarz ES, Liss DB, Munigala S, et al. Evaluation 
of partial oral antibiotic treatment for persons who inject drugs and are hospitalized 
with invasive infections. Clin Infect Dis 2020;71:e650–e656. https://doi.org/10.1093/ 
cid/ciaa365
747. Slaughter MS, Badhwar V, Ising M, Ganzel BL, Sell-Dottin K, Jawitz OK, et al. Optimum 
surgical treatment for tricuspid valve infective endocarditis: an analysis of the Society of 
Thoracic Surgeons national database. J Thorac Cardiovasc Surg 2021;161:1227–­
1235.e1. https://doi.org/10.1016/j.jtcvs.2019.10.124
748. Misfeld M, Davierwala PM, Borger MA, Bakhtiary F. The “UFO” procedure. Ann 
Cardiothorac Surg 2019;8:691–698. https://doi.org/10.21037/acs.2019.11.05
749. Navia JL, Elgharably H, Hakim AH, Witten JC, Haupt MJ, Germano E, et al. Long-term 
outcomes of surgery for invasive valvular endocarditis involving the aortomitral fibrosa. 
Ann Thorac Surg 2019;108:1314–1323. https://doi.org/10.1016/j.athoracsur.2019.04. 
119
750. Nappi F, Spadaccio C, Mihos C, Shaikhrezai K, Acar C, Moon MR. The quest for the 
optimal surgical management of tricuspid valve endocarditis in the current era: a nar­
rative review. Ann Transl Med 2020;8:1628. https://doi.org/10.21037/atm-20-4685
751. Arbulu A, Holmes RJ, Asfaw I. Surgical treatment of intractable right-sided infective 
endocarditis in drug addicts: 25 years experience. J Heart Valve Dis 1993;2:129–137, 
discussion 138–139.
752. Brescia AA, Watt TMF, Williams AM, Romano MA, Bolling SF. Tricuspid valve leaflet 
repair and augmentation for infective endocarditis. Oper Tech Thorac Cardiovasc Surg 
2019;24:206–218. https://doi.org/10.1053/j.optechstcvs.2019.09.002
753. Randhawa VK, Rajani R. Novel frontiers for managing tricuspid valve endocarditis: tales 
of percutaneous extracorporeal circuitry. JACC Case Rep 2021;3:1350–1353. https:// 
doi.org/10.1016/j.jaccas.2021.06.026
754. Starck CT, Dreizler T, Falk V. The AngioVac system as a bail-out option in infective 
valve endocarditis. Ann Cardiothorac Surg 2019;8:675–677. https://doi.org/10.21037/ 
acs.2019.11.04
755. Luc JGY, Choi J-H, Kodia K, Weber MP, Horan DP, Maynes EJ, et al. Valvectomy versus 
replacement for the surgical treatment of infective tricuspid valve endocarditis: a sys­
tematic review and meta-analysis. Ann Cardiothorac Surg 2019;8:610–620. https://doi. 
org/10.21037/acs.2019.11.06
756. Gabriel HM, Heger M, Innerhofer P, Zehetgruber M, Mundigler G, Wimmer M, et al. 
Long-term outcome of patients with ventricular septal defect considered not to re­
quire surgical closure during childhood. J Am Coll Cardiol 2002;39:1066–1071. 
https://doi.org/10.1016/S0735-1097(02)01706-0
757. Moore B, Cao J, Kotchetkova I, Celermajer DS. Incidence, predictors and outcomes of 
infective endocarditis in a contemporary adult congenital heart disease population. Int J 
Cardiol 2017;249:161–165. https://doi.org/10.1016/j.ijcard.2017.08.035
758. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al. 
2021;42:563–645. https://doi.org/10.1093/eurheartj/ehaa554
759. Haas NA, Bach S, Vcasna R, Laser KT, Sandica E, Blanz U, et al. The risk of bacterial 
endocarditis after percutaneous and surgical biological pulmonary valve implantation. 
Int J Cardiol 2018;268:55–60. https://doi.org/10.1016/j.ijcard.2018.04.138
760. Hribernik I, Thomson J, Ho A, English K, Van Doorn C, Jaber O, et al. Comparative 
analysis of surgical and percutaneous pulmonary valve implants over a 20-year period. 
Eur J Cardiothorac Surg 2022;61:572–579. https://doi.org/10.1093/ejcts/ezab368
ESC Guidelines                                                                                                                                                                                          4039


<!-- PAGE 93 -->

### Page 93

761. Dolgner SJ, Arya B, Kronman MP, Chan T. Effect of congenital heart disease status on 
trends in pediatric infective endocarditis hospitalizations in the United States between 
2000 and 2012. Pediatr Cardiol 2019;40:319–329. https://doi.org/10.1007/s00246-018- 
2020-7
762. Jortveit J, Klcovansky J, Eskedal L, Birkeland S, Dohlen G, Holmstrom H. Endocarditis in 
children and adolescents with congenital heart defects: a Norwegian nationwide 
register-based cohort study. Arch Dis Child 2018;103:670–674. https://doi.org/10. 
1136/archdischild-2017-313917
763. Cahill TJ, Jewell PD, Denne L, Franklin RC, Frigiola A, Orchard E, et al. Contemporary 
epidemiology of infective endocarditis in patients with congenital heart disease: a UK 
prospective study. Am Heart J 2019;215:70–77. https://doi.org/10.1016/j.ahj.2019.05. 
014
764. Tutarel O, Alonso-Gonzalez R, Montanaro C, Schiff R, Uribarri A, Kempny A, et al. 
Infective endocarditis in adults with congenital heart disease remains a lethal disease. 
Heart 2018;104:161–165. https://doi.org/10.1136/heartjnl-2017-311650
765. Bauer UMM, Helm PC, Diller GP, Asfour B, Schlensak C, Schmitt K, et al. Are adults 
with congenital heart disease informed about their risk for infective endocarditis 
and treated in accordance to current guidelines? Int J Cardiol 2017;245:105–108. 
https://doi.org/10.1016/j.ijcard.2017.07.040
766. Watkins DA, Beaton AZ, Carapetis JR, Karthikeyan G, Mayosi BM, Wyber R, et al. 
Rheumatic heart disease worldwide: JACC Scientific Expert Panel. J Am Coll Cardiol 
2018;72:1397–1416. https://doi.org/10.1016/j.jacc.2018.06.063
767. Bajracharya S, Khanal B, Siwakoti S, Singh RR, Sharma SK. Microbiological and clinicoe­
pidemiological profile of a series of patients with infective endocarditis at a center in 
Eastern Nepal. Can J Infect Dis Med Microbiol 2021;2021:9980465. https://doi.org/10. 
1155/2021/9980465
768. Karthikeyan G, Zuhlke L, Engel M, Rangarajan S, Yusuf S, Teo K, et al. Rationale and 
design of a Global Rheumatic Heart Disease Registry: the REMEDY study. Am Heart 
J 2012;163:535–540.e1. https://doi.org/10.1016/j.ahj.2012.01.003
769. Zuhlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. 
Characteristics, complications, and gaps in evidence-based interventions in rheumatic 
heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur 
Heart J 2015;36:1115–1122a. https://doi.org/10.1093/eurheartj/ehu449
770. Zuhlke L, Karthikeyan G, Engel ME, Rangarajan S, Mackie P, Cupido-Katya Mauff B, et al. 
Clinical outcomes in 3343 children and adults with rheumatic heart disease from 14 
low- and middle-income countries: two-year follow-up of the Global Rheumatic 
Heart Disease Registry (the REMEDY study). Circulation 2016;134:1456–1466. 
https://doi.org/10.1161/CIRCULATIONAHA.116.024769
771. Rohn V, Laca B, Horn M, Vlk L, Antonova P, Mosna F. Surgery in drug use-associated 
infective endocarditis: long-term survival is negatively affected by recurrence. Interact 
Cardiovasc Thorac Surg 2020;30:528–534. https://doi.org/10.1093/icvts/ivz302
772. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, et al. 
Contemporary diagnosis and management of rheumatic heart disease: implications 
for closing the gap: a scientific statement from the American Heart Association. 
Circulation 2020;142:e337–e357. https://doi.org/10.1161/CIR.0000000000000921
773. Coates MM, Sliwa K, Watkins DA, Zuhlke L, Perel P, Berteletti F, et al. An investment 
case for the prevention and management of rheumatic heart disease in the African 
Union 2021–30: a modelling study. Lancet Glob Health 2021;9:e957–e966. https:// 
doi.org/10.1016/S2214-109X(21)00199-6
774. Zilla P, Yacoub M, Zuhlke L, Beyersdorf F, Sliwa K, Khubulava G, et al. Global unmet 
needs in cardiac surgery. Glob Heart 2018;13:293–303. https://doi.org/10.1016/j. 
gheart.2018.08.002
775. Mirabel M, Andre R, Barsoum P, Colboc H, Lacassin F, Noel B, et al. Ethnic disparities in 
the incidence of infective endocarditis in the Pacific. Int J Cardiol 2015;186:43–44. 
https://doi.org/10.1016/j.ijcard.2015.03.243
776. Mirabel M, Andre R, Barsoum Mikhail P, Colboc H, Lacassin F, Noel B, et al. Infective 
endocarditis in the Pacific: clinical characteristics, treatment and long-term outcomes. 
Open Heart 2015;2:e000183. https://doi.org/10.1136/openhrt-2014-000183
777. Kingue S, Ba SA, Balde D, Diarra MB, Anzouan-Kacou JB, Anisubia B, et al. The valvafric 
study: a registry of rheumatic heart disease in Western and Central Africa. Arch 
Cardiovasc Dis 2016;109:321–329. https://doi.org/10.1016/j.acvd.2015.12.004
778. Subbaraju P, Rai S, Morakhia J, Midha G, Kamath A, Saravu K. Clinical – microbiological 
characterization and risk factors of mortality in infective endocarditis from a tertiary 
care academic hospital in southern India. Indian Heart J 2018;70:259–265. https:// 
doi.org/10.1016/j.ihj.2017.08.007
779. Rwebembera J, Manyilirah W, Zhu ZW, Nabbaale J, Namuyonga J, Ssinabulya I, et al. 
Prevalence and characteristics of primary left-sided valve disease in a cohort of 
15,000 patients undergoing echocardiography studies in a tertiary hospital in 
Uganda. BMC Cardiovasc Disord 2018;18:82. https://doi.org/10.1186/s12872-018- 
0813-5
780. Pecoraro AJ, Doubell AF. Infective endocarditis in South Africa. Cardiovasc Diagn Ther 
2020;10:252–261. https://doi.org/10.21037/cdt.2019.06.03
781. Hajsadeghi S, Hassanzadeh M, Hajahmadi M, Kadivar M. Concurrent diagnosis of infect­
ive endocarditis and acute rheumatic fever: a case report. J Cardiol Cases 2018;17: 
147–150. https://doi.org/10.1016/j.jccase.2017.12.011
782. Gouriet F, Chaudet H, Gautret P, Pellegrin L, de Santi VP, Savini H, et al. Endocarditis in 
the Mediterranean Basin. New Microbes New Infect 2018;26:S43–S51. https://doi.org/ 
10.1016/j.nmni.2018.05.004
783. Dhar M, Kaeley N, Bhatt N, Ahmad S. Profile of newly diagnosed adult patients with 
rheumatic heart disease in sub-Himalayan region – a 5-year analysis. J Family Med Prim 
Care 2019;8:2933–2936. https://doi.org/10.4103/jfmpc.jfmpc_363_19
784. Blanchard V, Pagis B, Richaud R, Moronval F, Lutinier R, Gallais K, et al. Infective endo­
carditis in French Polynesia: epidemiology, treatments and outcomes. Arch Cardiovasc 
Dis 2020;113:252–262. https://doi.org/10.1016/j.acvd.2019.12.007
785. Montano TCP, Wanderley MIA, Sampaio RO, Alves CGB, Neves ILI, Lopes MA, et al. 
Demographic, cardiological, microbiologic, and dental profiles of Brazilian patients 
who developed oral bacteria-related endocarditis. Oral Surg Oral Med Oral Pathol 
Oral Radiol 2021;132:418–425. https://doi.org/10.1016/j.oooo.2021.07.007
786. Jomaa W, Ben Ali I, Abid D, Hajri Ernez S, Abid L, Triki F, et al. Clinical features and 
prognosis of infective endocarditis in children: insights from a Tunisian multicentre 
registry. Arch Cardiovasc Dis 2017;110:676–681. https://doi.org/10.1016/j.acvd.2016. 
12.018
787. Mahony M, Lean D, Pham L, Horvath R, Suna J, Ward C, et al. Infective endocarditis in 
children in Queensland, Australia: epidemiology, clinical features and outcome. Pediatr 
Infect Dis J 2021;40:617–622. https://doi.org/10.1097/INF.0000000000003110
788. Willoughby ML, Basera W, Perkins SR, Comitis GAM, Fourie B, Lawrenson JB, et al. 
Infective endocarditis in infants and children in the Western Cape, South Africa: a 
retrospective analysis. Cardiol Young 2019;29:1282–1286. https://doi.org/10.1017/ 
S1047951119002154
789. Nigussie B, Tadele H. Heart failure in Ethiopian children: mirroring the unmet cardiac 
services. Ethiop J Health Sci 2019;29:811–818. https://doi.org/10.4314/ejhs.v29i1.2
790. Moreira JL, Barletta P, Baucia JA. Morbidity and mortality in patients undergoing mitral 
valve replacement at a cardiovascular surgery referral service: a retrospective analysis. 
Braz J Cardiovasc Surg 2021;36:183–191. https://doi.org/10.21470/1678-9741-2019- 
0440
791. Mocumbi AO, Jamal KK, Mbakwem A, Shung-King M, Sliwa K. The Pan-African Society 
of Cardiology position paper on reproductive healthcare for women with rheumatic 
heart disease. Cardiovasc J Afr 2018;29:394–403. https://doi.org/10.5830/CVJA-2018- 
044
792. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, et al. Pregnancy 
outcomes in women with cardiovascular disease: evolving trends over 10 years in the 
ESC registry of pregnancy and cardiac disease (ROPAC). Eur Heart J 2019;40: 
3848–3855. https://doi.org/10.1093/eurheartj/ehz136
793. De Villiers MC, Viljoen CA, Manning K, Van der Westhuizen C, Seedat A, Rath M, et al. 
The changing landscape of infective endocarditis in South Africa. S Afr Med J 2019;109: 
592–596. https://doi.org/10.7196/SAMJ.2019.v109i8.13888
794. Sadeghpour A, Maleki M, Movassaghi M, Rezvani L, Noohi F, Boudagh S, et al. Iranian 
Registry of Infective Endocarditis (IRIE): time to relook at the guideline, regarding to 
regional differences. Int J Cardiol Heart Vasc 2020;26:100433. https://doi.org/10.1016/ 
j.ijcha.2019.100433
795. Wu Z, Chen Y, Xiao T, Niu T, Shi Q, Xiao Y. Epidemiology and risk factors of infective 
endocarditis in a tertiary hospital in China from 2007 to 2016. BMC Infect Dis 2020;20: 
428. https://doi.org/10.1186/s12879-020-05153-w
796. Xu H, Cai S, Dai H. Characteristics of infective endocarditis in a tertiary hospital in east 
China. PLoS One 2016;11:e0166764. https://doi.org/10.1371/journal.pone.0166764
797. Connolly C, O’Donoghue K, Doran H, McCarthy FP. Infective endocarditis in preg­
nancy: case report and review of the literature. Obstet Med 2015;8:102–104. https:// 
doi.org/10.1177/1753495X15572857
798. Yuan SM. Infective endocarditis during pregnancy. J Coll Physicians Surg Pak 2015;25: 
134–139.
799. Escola-Verge L, Rello P, Declerck C, Dubee V, Rouleau F, Duval X, et al. Infective endo­
carditis in pregnant women without intravenous drug use: a multicentre retrospective 
case series. J Antimicrob Chemother 2022;77:2701–2705. https://doi.org/10.1093/jac/ 
dkac258
800. Dagher MM, Eichenberger EM, Addae-Konadu KL, Dotters-Katz SK, Kohler CL, 
Fowler VG, et al. Maternal and fetal outcomes associated with infective endocarditis 
in pregnancy. Clin Infect Dis 2021;73:1571–1579. https://doi.org/10.1093/cid/ciab533
801. Morelli MK, Veve MP, Shorman MA. Maternal bacteremia caused by Staphylococcus 
aureus with a focus on infective endocarditis. Open Forum Infect Dis 2020;7:ofaa239. 
https://doi.org/10.1093/ofid/ofaa239
802. English N, Weston P. Multivalvular infective endocarditis in pregnancy presenting with 
septic pulmonary emboli. BMJ Case Rep 2015;2015:bcr2014209131. https://doi.org/ 
10.1136/bcr-2014-209131
803. Khanna R, Chandra D, Yadav S, Sahu A, Singh N, Kumar S, et al. Maternal and fetal out­
comes in pregnant females with rheumatic heart disease. Indian Heart J 2021;73: 
185–189. https://doi.org/10.1016/j.ihj.2021.01.012
804. Adesomo A, Gonzalez-Brown V, Rood KM. Infective endocarditis as a complication of 
intravenous drug use in pregnancy: a retrospective case series and literature review. 
AJP Rep 2020;10:e288–e293. https://doi.org/10.1055/s-0040-1716732


<!-- PAGE 94 -->

### Page 94

805. Dahshan D, Suliman M, Rahman EU, Curtis Z, Thompson E. Intravenous drug 
use-associated infective endocarditis in pregnant patients at a hospital in West 
Virginia. Cureus 2021;13:e17218. https://doi.org/10.7759/cureus.17218
806. Lin D, Mullan CW, Deshmukh U, Bahtiyar MO, Hosier H, Lipkind H, et al. Drug use 
associated tricuspid valve infective endocarditis in pregnancy. J Card Surg 2020;35: 
2392–2395. https://doi.org/10.1111/jocs.14888
807. Pfaller B, Sathananthan G, Grewal J, Mason J, D’Souza R, Spears D, et al. Preventing 
complications in pregnant women with cardiac disease. J Am Coll Cardiol 2020;75: 
1443–1452. https://doi.org/10.1016/j.jacc.2020.01.039
808. Botea R, Porterie J, Marcheix B, Breleur FO, Lavie-Badie Y. Infective endocarditis in a 
third trimester pregnant woman: team work is the best option. JACC Case Rep 2020;2: 
521–525. https://doi.org/10.1016/j.jaccas.2020.02.017
809. Wang J, Wang A, Cui Y, Wang C, Zhang J. Diagnosis and treatment of infective endo­
carditis in pregnancy: a case report. J Cardiothorac Surg 2020;15:109. https://doi.org/10. 
1186/s13019-020-01147-6
810. Liu Y, Han F, Zhuang J, Liu X, Chen J, Huang H, et al. Cardiac operation under cardio­
pulmonary bypass during pregnancy. J Cardiothorac Surg 2020;15:92. https://doi.org/10. 
1186/s13019-020-01136-9
811. Eichenberger EM, Dagher M, Sinclair MR, Maskarinec SA, Fowler VG Jr, Federspiel JJ. 
Infective endocarditis and solid organ transplantation: only worse outcomes during ini­
tial transplantation hospitalization. Am Heart J 2021;240:63–72. https://doi.org/10. 
1016/j.ahj.2021.06.007
812. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers 
2015;1:15035. https://doi.org/10.1038/nrdp.2015.35
813. Munoz-Moreno MF, Ryan P, Alvaro-Meca A, Valencia J, Tamayo E, Resino S. National 
temporal trend analysis of infective endocarditis among patients infected with HIV in 
Spain (1997–2014): a retrospective study. J Clin Med 2019;8:1167. https://doi.org/10. 
3390/jcm8081167
814. Beteille E, Guarana M, Nucci M. Infective endocarditis in neutropenic patients with vir­
idans streptococci bacteraemia. Clin Microbiol Infect 2018;24:916–917. https://doi.org/ 
10.1016/j.cmi.2018.03.012
815. Veve MP, Stuart M, Davis SL. Comparison of neutropenia associated with ceftaroline 
or ceftriaxone in patients receiving at least 7 days of therapy for severe infections. 
Pharmacotherapy 2019;39:809–815. https://doi.org/10.1002/phar.2301
816. Mani SSR, Iyyadurai R. Cloxacillin induced agranulocytosis: a rare adverse event of a 
commonly used antibiotic. Int J Immunopathol Pharmacol 2017;30:297–301. https:// 
doi.org/10.1177/0394632017724320
817. Tornos P, Almirante B, Mirabet S, Permanyer G, Pahissa A, Soler-Soler J. Infective 
endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy. 
Arch Intern Med 1999;159:473–475. https://doi.org/10.1001/archinte.159.5.473
818. Deppisch LM, Fayemi AO. Non-bacterial thrombotic endocarditis: clinicopathologic 
correlations. Am Heart J 1976;92:723–729. https://doi.org/10.1016/S0002-8703(76) 
80008-7
819. Llenas-Garcia 
J, 
Guerra-Vales 
JM, 
Montes-Moreno 
S, 
Lopez-Rios 
F, 
Castelbon-Fernandez FJ, Chimeno-Garcia J. [Nonbacterial thrombotic endocarditis: 
clinicopathologic study of a necropsy series]. Rev Esp Cardiol 2007;60:493–500. 
https://doi.org/10.1016/S1885-5857(07)60190-X
820. Lopez JA, Ross RS, Fishbein MC, Siegel RJ. Nonbacterial thrombotic endocarditis: a re­
view. Am Heart J 1987;113:773–784. https://doi.org/10.1016/0002-8703(87)90719-8
821. Quintero-Martinez JA, Hindy JR, El Zein S, Michelena HI, Nkomo VT, DeSimone DC, 
et al. Contemporary demographics, diagnostics and outcomes in non-bacterial throm­
botic endocarditis. Heart 2022. https://doi.org/10.1136/heartjnl-2022-320970
822. el-Shami K, Griffiths E, Streiff M. Nonbacterial thrombotic endocarditis in cancer pa­
tients: pathogenesis, diagnosis, and treatment. Oncologist 2007;12:518–523. https:// 
doi.org/10.1634/theoncologist.12-5-518
823. Zmaili MA, Alzubi JM, Kocyigit D, Bansal A, Samra GS, Grimm R, et al. A contemporary 
20-year Cleveland clinic experience of nonbacterial thrombotic endocarditis: etiology, 
echocardiographic imaging, management, and outcomes. Am J Med 2021;134: 
361–369. https://doi.org/10.1016/j.amjmed.2020.06.047
824. Roldan CA, Tolstrup K, Macias L, Qualls CR, Maynard D, Charlton G, et al. 
Libman-sacks endocarditis: detection, characterization, and clinical correlates by 
three-dimensional transesophageal echocardiography. J Am Soc Echocardiogr 2015; 
28:770–779. https://doi.org/10.1016/j.echo.2015.02.011
825. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs 
warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132: 
1365–1371. https://doi.org/10.1182/blood-2018-04-848333
826. Kim K, Kim D, Lee S-E, Cho IJ, Shim CY, Hong G-R, et al. Infective endocarditis in can­
cer patients – causative organisms, predisposing procedures, and prognosis differ from 
infective endocarditis in non-cancer patients. Circ J 2019;83:452–460. https://doi.org/ 
10.1253/circj.CJ-18-0609
827. Cosyns B, Roosens B, Lancellotti P, Laroche C, Dulgheru R, Scheggi V, et al. Cancer and 
infective endocarditis: characteristics and prognostic impact. Front Cardiovasc Med 
2021;8:766996. https://doi.org/10.3389/fcvm.2021.766996
828. Kitson A, Marshall A, Bassett K, Zeitz K. What are the core elements of patient- 
centred care? A narrative review and synthesis of the literature from health policy, 
medicine and nursing. J Adv Nurs 2013;69:4–15. https://doi.org/10.1111/j.1365-2648. 
2012.06064.x
829. Giusti A, Nkhoma K, Petrus R, Petersen I, Gwyther L, Farrant L, et al. The empirical 
evidence underpinning the concept and practice of person-centred care for serious 
illness: a systematic review. BMJ Glob Health 2020;5:e003330. https://doi.org/10. 
1136/bmjgh-2020-003330
830. Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, et al. Person-centered 
care–ready for prime time. Eur J Cardiovasc Nurs 2011;10:248–251. https://doi.org/10. 
1016/j.ejcnurse.2011.06.008
831. NEJM Catalyst. What is patient-centered care? New Engl J Med 2017;3.
832. Lauck SB, Lewis KB, Borregaard B, de Sousa I. “What is the right decision for me?” 
Integrating patient perspectives through shared decision-making for valvular heart dis­
ease therapy. Can J Cardiol 2021;37:1054–1063. https://doi.org/10.1016/j.cjca.2021.02. 
022
833. Oshima Lee E, Emanuel EJ. Shared decision making to improve care and reduce costs. 
N Engl J Med 2013;368:6–8. https://doi.org/10.1056/NEJMp1209500
834. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for 
people facing health treatment or screening decisions. Cochrane Database Syst Rev 
2017;4:CD001431. https://doi.org/10.1002/14651858.CD001431.pub5
835. R EGEAT. Shared Decision Making in Health Care: Achieving Evidence-Based Patient 
Choice. 3rd ed. Oxford University Press, 2016.
836. Carmona C, Crutwell J, Burnham M, Polak L, Guideline C. Shared decision-making: 
summary of NICE guidance. BMJ 2021;373:n1430. https://doi.org/10.1136/bmj.n1430
837. van de Pol MH, Fluit CR, Lagro J, Slaats YH, Olde Rikkert MG, Lagro-Janssen AL. Expert 
and patient consensus on a dynamic model for shared decision-making in frail older 
patients. Patient Educ Couns 2016;99:1069–1077. https://doi.org/10.1016/j.pec.2015. 
12.014
838. Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient prefer­
ences for shared decisions: a systematic review. Patient Educ Couns 2012;86:9–18. 
https://doi.org/10.1016/j.pec.2011.02.004
839. White DB, Angus DC, Shields AM, Buddadhumaruk P, Pidro C, Paner C, et al. A ran­
domized trial of a family-support intervention in intensive care units. N Engl J Med 
2018;378:2365–2375. https://doi.org/10.1056/NEJMoa1802637
840. Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision mak­
ing and patient outcomes. Med Decis Making 2015;35:114–131. https://doi.org/10. 
1177/0272989X14551638
841. McMillan SS, Kendall E, Sav A, King MA, Whitty JA, Kelly F, et al. Patient-centered ap­
proaches to health care: a systematic review of randomized controlled trials. Med Care 
Res Rev 2013;70:567–596. https://doi.org/10.1177/1077558713496318
842. Hibbard JH, Greene J. What the evidence shows about patient activation: better health 
outcomes and care experiences; fewer data on costs. Health Aff (Millwood) 2013;32: 
207–214. https://doi.org/10.1377/hlthaff.2012.1061
843. Dwamena F, Holmes-Rovner M, Gaulden CM, Jorgenson S, Sadigh G, Sikorskii A, et al. 
Interventions for providers to promote a patient-centred approach in clinical consul­
tations. Cochrane Database Syst Rev 2012;12:CD003267. https://doi.org/10.1002/ 
14651858.CD003267.pub2
844. Verhagen DW, Hermanides J, Korevaar JC, Bossuyt PM, van den Brink RB, Speelman P, 
et al. Health-related quality of life and posttraumatic stress disorder among survivors 
of left-sided native valve endocarditis. Clin Infect Dis 2009;48:1559–1565. https://doi. 
org/10.1086/598930
845. Berg SK, Preisler P, Pedersen BD. Patients perspective on endocarditis–an intermezzo 
in life. Eur J Cardiovasc Nurs 2010;9:126–131. https://doi.org/10.1016/j.ejcnurse.2009. 
11.007
846. Butt JH, Kragholm K, Dalager-Pedersen M, Rorth R, Kristensen SL, Chaudry MS, et al. 
Return to the workforce following infective endocarditis–a nationwide cohort study. 
Am Heart J 2018;195:130–138. https://doi.org/10.1016/j.ahj.2017.09.009
847. Havers-Borgersen E, Fosbol EL, Rorth R, Kragholm K, Kristensen SL, Bundgaard H, 
et al. Nursing home admission and initiation of domiciliary care following infective 
endocarditis. Glob Heart 2019;14:41–46.e2. https://doi.org/10.1016/j.gheart.2019.01. 
002
848. Wattel R. ESC involving patients: purpose & priorities. Eur Heart J 2018;39:3681. 
https://doi.org/10.1093/eurheartj/ehy644
849. Ulin K, Olsson LE, Wolf A, Ekman I. Person-centred care – an approach that improves 
the discharge process. Eur J Cardiovasc Nurs 2016;15:e19–e26. https://doi.org/10.1177/ 
1474515115569945
850. Hill L, Prager Geller T, Baruah R, Beattie JM, Boyne J, de Stoutz N, et al. Integration of a 
palliative approach into heart failure care: a European Society of Cardiology Heart 
Failure Association position paper. Eur J Heart Fail 2020;22:2327–2339. https://doi. 
org/10.1002/ejhf.1994
851. D’Alto M, Budts W, Diller GP, Mulder B, Egidy Assenza G, Oreto L, et al. Does gender 
affect the prognosis and risk of complications in patients with congenital heart disease 
in the modern era? Int J Cardiol 2019;290:156–161. https://doi.org/10.1016/j.ijcard. 
2019.05.010
852. Weber C, Petrov G, Luehr M, Aubin H, Tugtekin SM, Borger MA, et al. Surgical results 
for prosthetic versus native valve endocarditis: a multicenter analysis. J Thorac 
Cardiovasc Surg 2021;161:609–619.e10. https://doi.org/10.1016/j.jtcvs.2019.09.186
ESC Guidelines                                                                                                                                                                                          4041


<!-- PAGE 95 -->

### Page 95

853. Curlier E, Hoen B, Alla F, Selton-Suty C, Schubel L, Doco-Lecompte T, et al. 
Relationships between sex, early valve surgery and mortality in patients with left-sided 
infective endocarditis analysed in a population-based cohort study. Heart 2014;100: 
1173–1178. https://doi.org/10.1136/heartjnl-2013-304916
854. Weber C, Gassa A, Rokohl A, Sabashnikov A, Deppe AC, Eghbalzadeh K, et al. Severity 
of presentation, not sex, increases risk of surgery for infective endocarditis. Ann Thorac 
Surg 2019;107:1111–1117. https://doi.org/10.1016/j.athoracsur.2018.10.033
855. Bansal A, Cremer PC, Jaber WA, Rampersad P, Menon V. Sex differences in the util­
ization and outcomes of cardiac valve replacement surgery for infective endocarditis: 
insights from the national inpatient sample. J Am Heart Assoc 2021;10:e020095. https:// 
doi.org/10.1161/JAHA.120.020095
856. Varela Barca L, Vidal-Bonnet L, Farinas MC, Munoz P, Valerio Minero M, de Alarcon A, 
et al. Analysis of sex differences in the clinical presentation, management and prognosis 
of infective endocarditis in Spain. Heart 2021;107:1717–1724. https://doi.org/10.1136/ 
heartjnl-2021-319254
857. Ahtela E, Oksi J, Porela P, Ekstrom T, Rautava P, Kyto V. Trends in occurrence and 
30-day mortality of infective endocarditis in adults: population-based registry study 
in Finland. BMJ Open 2019;9:e026811. https://doi.org/10.1136/bmjopen-2018-026811

<!-- 2023_Heart_Failure_Update.md -->

# ESC Guidelines: Heart Failure Update (2023)

**Source**: `2023_Heart_Failure_Update.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 13

---

## Table of Contents

- [2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure](#2023-focused-update-of-the-2021-esc-guidelines-for) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 3)*
  - [2. Introduction](#2-introduction) *(p. 5)*
  - [3. Chronic heart failure](#3-chronic-heart-failure) *(p. 5)*
  - [4. Acute heart failure](#4-acute-heart-failure) *(p. 8)*
    - [4.1. Medical therapy](#41-medical-therapy) *(p. 8)*
      - [4.1.1. Diuretics](#411-diuretics) *(p. 8)*
      - [4.1.2. Sodium–glucose co-transporter 2 inhibitors](#412-sodium–glucose-co-transporter-2-inhibitors) *(p. 8)*
    - [4.2. Management strategies](#42-management-strategies) *(p. 8)*
      - [4.2.1. Admission phase](#421-admission-phase) *(p. 8)*
      - [4.2.2. Pre-discharge and early post-discharge phases](#422-pre-discharge-and-early-post-discharge-phases) *(p. 8)*
  - [5. Comorbidities](#5-comorbidities) *(p. 9)*
    - [5.1. Chronic kidney disease and type 2 diabetes mellitus](#51-chronic-kidney-disease-and-type-2-diabetes-mell) *(p. 9)*
      - [5.1.1. Sodium–glucose co-transporter 2 inhibitors](#511-sodium–glucose-co-transporter-2-inhibitors) *(p. 9)*
      - [5.1.2. Finerenone](#512-finerenone) *(p. 10)*
    - [5.2. Iron deficiency](#52-iron-deficiency) *(p. 10)*
  - [6. Data availability statement](#6-data-availability-statement) *(p. 11)*
  - [7. Author information](#7-author-information) *(p. 11)*
  - [Appendix](#appendix) *(p. 12)*
  - [9. References](#9-references) *(p. 12)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2023 Focused Update of the 2021 ESC 
Guidelines for the diagnosis and treatment 
of acute and chronic heart failure
Developed by the task force for the diagnosis and treatment of acute 
and chronic heart failure of the European Society of Cardiology (ESC)
With the special contribution of the Heart Failure Association (HFA) 
of the ESC
Authors/Task Force Members: Theresa A. McDonagh  *†, (Chairperson) (United 
Kingdom), Marco Metra  *†, (Chairperson) (Italy), Marianna Adamo  
‡, (Task Force 
Co-ordinator) (Italy), Roy S. Gardner  
‡, (Task Force Co-ordinator) (United Kingdom), 
Andreas Baumbach  
(United Kingdom), Michael Böhm  
(Germany), Haran Burri  
(Switzerland), Javed Butler  
(United States of America), Jelena Čelutkienė  
(Lithuania), Ovidiu Chioncel  
(Romania), John G.F. Cleland  
(United Kingdom), 
Maria Generosa Crespo-Leiro  
(Spain), Dimitrios Farmakis  
(Greece), 
Martine Gilard  
(France), Stephane Heymans  
(Netherlands), Arno W. Hoes  
(Netherlands), Tiny Jaarsma  
(Sweden), Ewa A. Jankowska  
(Poland), 
Mitja Lainscak  
(Slovenia), Carolyn S.P. Lam  
(Singapore), Alexander R. Lyon  
(United Kingdom), John J.V. McMurray  
(United Kingdom), Alexandre Mebazaa  
(France), Richard Mindham  
(United Kingdom), Claudio Muneretto  
(Italy), 
Massimo Francesco Piepoli  
(Italy), Susanna Price  
(United Kingdom),  
Giuseppe M.C. Rosano (United Kingdom), Frank Ruschitzka  
(Switzerland),  
Anne Kathrine Skibelund (Denmark), and ESC Scientific Document Group
* Corresponding authors: Theresa A. McDonagh, Cardiology Department, King’s College Hospital, Denmark Hill, London, SE5 9RS, United Kingdom. Tel: +44 203 299 325, 
E-mail: theresa.mcdonagh@kcl.ac.uk; Marco Metra, Institute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, 
University of Brescia, Brescia, Italy. Tel: +39 303 07221, E-mail: marco.metra@unibs.it
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in the Author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
Heart Failure Association (HFA).
Councils: Council of Cardio-Oncology.
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Myocardial and Pericardial Diseases.
Patient Forum 
The content of this European Society of Cardiology (ESC) Focused Update has been published for personal and educational use only. No commercial use is authorized. No part of this docu­
ment may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the 
publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
https://doi.org/10.1093/eurheartj/ehad195
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Rudolf A. de Boer, (CPG Review Co-ordinator) (Netherlands), P. Christian Schulze, (CPG 
Review Co-ordinator) (Germany), Elena Arbelo (Spain), Jozef Bartunek (Belgium), Johann Bauersachs (Germany), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Elisabetta Cerbai (Italy), Erwan Donal (France), 
Frank Edelmann (Germany), Gloria Färber (Germany), Bettina Heidecker (Germany), Borja Ibanez (Spain), 
Stefan James (Sweden), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Josep Masip (Spain), 
John William McEvoy (Ireland), Robert Mentz (United States of America), Borislava Mihaylova (United Kingdom), 
Jacob Eifer Møller (Denmark), Wilfried Mullens (Belgium), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen 
(Denmark), Agnes A. Pasquet (Belgium), Piotr Ponikowski (Poland), Eva Prescott (Denmark), Amina Rakisheva 
(Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Leyla Elif Sade (United States of America/Türkiye), 
Hannah Schaubroeck (Belgium), Elena Tessitore (Switzerland), Mariya Tokmakova (Bulgaria), Peter van der Meer 
(Netherlands), Isabelle C. Van Gelder (Netherlands), Mattias Van Heetvelde (Belgium), Christiaan Vrints 
(Belgium), Matthias Wilhelm (Switzerland), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands)
All experts involved in the development of this Focused Update have submitted declarations of interest. These 
have been compiled in a report and simultaneously published in a supplementary document to the Focused 
Update. The report is also available on the ESC website www.escardio.org/guidelines
See the European Heart Journal online for supplementary documents that include evidence tables.
Keywords 
Guidelines • Acute heart failure • Comorbidities • Chronic kidney disease hospitalization • Diagnosis • Ejection 
fraction • Heart failure • Multidisciplinary management • Natriuretic peptides • Neurohormonal antagonists • 
Pharmacotherapy • Prevention
Table of contents 
1. Preamble .............................................................................................................. 3629 
2. Introduction ....................................................................................................... 3631 
3. Chronic heart failure ...................................................................................... 3631 
4. Acute heart failure ........................................................................................... 3634 
4.1. Medical therapy .......................................................................................
3634 
4.1.1. Diuretics ............................................................................................. 3634 
4.1.2. Sodium–glucose co-transporter 2 inhibitors ...................... 3634 
4.2. Management strategies ........................................................................
3634 
4.2.1. Admission phase ............................................................................. 3634 
4.2.2. Pre-discharge and early post-discharge phases .................. 3634 
5. Comorbidities .................................................................................................... 3635 
5.1. Chronic kidney disease and type 2 diabetes mellitus .............
3635 
5.1.1. Sodium–glucose co-transporter 2 inhibitors ...................... 3635 
5.1.2. Finerenone ......................................................................................... 3636 
5.2. Iron deficiency .........................................................................................
3636 
6. Data availability statement ........................................................................... 3637 
7. Author information ......................................................................................... 3637 
8. Appendix ............................................................................................................. 3638 
9. References .......................................................................................................... 3638 
Tables of Recommendations 
Recommendation Table 1 — Recommendation for the treatment of 
patients with symptomatic heart failure with mildly reduced ejection 
fraction ...................................................................................................................... 3633 
Recommendation Table 2 — Recommendation for the treatment of 
patients with symptomatic heart failure with preserved ejection 
fraction ...................................................................................................................... 3633 
Recommendation Table 3 — Recommendation for pre-discharge 
and early post-discharge follow-up of patients hospitalized for acute 
heart failure ............................................................................................................. 3635 
Disclaimer. The ESC Guidelines and Focused Updates represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evi­
dence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and Focused Updates 
and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health pro­
fessionals are encouraged to take the ESC Guidelines and Focused Updates fully into account when exercising their clinical judgment, as well as in the determination and the implementation of 
preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines and Focused Updates do not override, in any way whatsoever, the individual responsibility of health 
professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, 
the patient’s caregiver. Nor do the ESC Guidelines and Focused Updates exempt health professionals from taking into full and careful consideration the relevant official updated recommenda­
tions or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and 
professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article is co-published with permission in the European Heart Journal and the European Journal of Heart Failure. All rights reserved. © The European Society of Cardiology 
2023. The articles are identical except for stylistic differences in keeping with each journal’s style. Either citation can be used when citing this article. For permissions, please e-mail: 
journals.permissions@oup.com


<!-- PAGE 3 -->

### Page 3

Recommendation Table 4 — Recommendations for the prevention 
of heart failure in patients with type 2 diabetes mellitus and chronic 
kidney disease ......................................................................................................... 3636 
Recommendation Table 5 — Recommendations for the 
management of iron deficiency in patients with heart failure ........... 3637  
List of tables 
Table 1 Classes of recommendations .......................................................... 3630 
Table 2 Levels of evidence ................................................................................ 3630 
Table 3 Definition of heart failure with reduced ejection fraction, 
mildly reduced ejection fraction, and preserved ejection fraction .. 3632  
List of figures 
Figure 1 Management of patients with heart failure with mildly 
reduced ejection fraction .................................................................................. 3633 
Figure 2 Management of patients with heart failure with preserved 
ejection fraction ..................................................................................................... 3633  
Abbreviations and acronyms 
ACE-I 
Angiotensin-converting enzyme inhibitor
ADVOR 
Acetazolamide in Decompensated Heart 
Failure with Volume Overload (trial)
AFFIRM-AHF 
A Randomized Double-blind Placebo 
Controlled Trial Comparing the Effects of 
Intravenous Ferric Carboxymaltose on 
Hospitalizations and Mortality in Iron Deficient 
Subjects Admitted for Acute Heart Failure (trial)
ARB 
Angiotensin receptor blocker
ARNI 
Angiotensin receptor–neprilysin inhibitor aRR 
Adjusted risk ratio
CI 
Confidence interval
CKD 
Chronic kidney disease
CLOROTIC 
Combination of Loop Diuretics with 
Hydrochlorothiazide in Acute Heart Failure 
(trial)
COACH 
Comparison of Outcomes and Access to Care 
for Heart Failure (trial)
COR 
Class of recommendation
CPG 
Clinical Practice Guidelines
CREDENCE 
Canagliflozin and Renal Events in Diabetes 
With Established Nephropathy Clinical 
Evaluation (trial)
CV 
Cardiovascular
DAPA-CKD 
Dapagliflozin And Prevention of Adverse 
outcomes in Chronic Kidney Disease (trial)
DAPA-HF 
Dapagliflozin And Prevention of Adverse 
outcomes in Heart Failure (trial)
DELIVER 
Dapagliflozin Evaluation to Improve the LIVEs 
of Patients with PReserved Ejection Fraction 
Heart Failure (trial)
eGFR 
Estimated glomerular filtration rate
EMPA-KIDNEY 
EMPAgliflozin once daily to assess cardio-renal 
outcomes in patients with chronic KIDNEY 
disease (trial)
EMPEROR- 
Empagliflozin Outcome Trial in Patients with 
Preserved 
Chronic Heart Failure with Preserved 
Ejection (trial)
EMPULSE 
Empagliflozin in Patients Hospitalized with Acute 
Heart Failure Who Have Been Stabilized (trial)
ESC 
European Society of Cardiology
FIDELIO-DKD 
Finerenone in Reducing Kidney Failure and 
Disease Progression in Diabetic Kidney 
Disease (trial)
FIGARO-DKD 
Finerenone in Reducing Cardiovascular 
Mortality and Morbidity in Diabetic Kidney 
Disease (trial)
HF 
Heart failure
HFmrEF 
Heart failure with mildly reduced ejection 
fraction
HFnEF 
Heart failure with normal ejection fraction
HFpEF 
Heart failure with preserved ejection fraction
HFrEF 
Heart failure with reduced ejection fraction
HR 
Hazard ratio
IRONMAN 
Effectiveness of Intravenous Iron Treatment 
versus Standard Care in Patients with Heart 
Failure and Iron Deficiency (trial)
i.v. 
Intravenous
KDIGO 
Kidney Disease: Improving Global Outcomes
LOE 
Level of evidence
LVEF 
Left ventricular ejection fraction
MRA 
Mineralocorticoid receptor antagonist
NT-proBNP 
N-terminal pro-B-type natriuretic peptide
NYHA 
New York Heart Association
OR 
Odds ratio
PIVOTAL 
Proactive IV Iron Therapy in Haemodialysis 
Patients (trial)
REVIVED-BCIS2 
Revascularization for Ischemic Ventricular 
Dysfunction (trial)
RR 
Risk ratio
SCORED 
Effect of Sotagliflozin on Cardiovascular and 
Renal Events in Patients with Type 2 
Diabetes and Moderate Renal Impairment 
Who Are at Cardiovascular Risk (trial)
SGLT2 
Sodium–glucose co-transporter 2
STRONG-HF 
Safety, Tolerability and Efficacy of Rapid 
Optimization, Helped by NT-proBNP Testing, of 
Heart Failure Therapies (trial)
T2DM 
Type 2 diabetes mellitus
TRANSFORM-HF 
Torsemide Comparison with Furosemide for 
Management of Heart Failure (trial)
TRILUMINATE 
Clinical Trial to Evaluate Cardiovascular 
Pivotal 
Outcomes in Patients Treated With the 
Tricuspid Valve Repair System Pivotal (trial)
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeutic 
approach for an individual patient with a given condition. Guidelines are in­
tended for use by health professionals and the European Society of 
Cardiology (ESC) makes its Guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It 
is also the health professional’s responsibility to verify the rules and 
ESC Guidelines                                                                                                                                                                                          3629


<!-- PAGE 4 -->

### Page 4

regulations applicable in each country to drugs and devices at the time 
of prescription and, where appropriate, to respect the ethical rules of 
their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated. ESC Policies and Procedures for for­
mulating and issuing ESC Guidelines can be found on the ESC website 
(https://www.escardio.org/Guidelines).
Interim Focused Updates are created when the publication of new 
evidence could influence clinical practice before the next full update 
of a guideline is published. This Focused Update provides new and re­
vised recommendations for the 2021 ESC Guidelines for the diagnosis 
and treatment of acute and chronic heart failure. View the full 2021 ESC 
Guidelines here: https://www.escardio.org/Guidelines/Clinical-Practice- 
Guidelines/Acute-and-Chronic-Heart-Failure.
The members of the Task Force were selected by the ESC to re­
present professionals involved with the medical care of patients with 
this pathology. The Task Force performed a critical evaluation of diag­
nostic and therapeutic approaches, including assessment of the risk– 
benefit ratio. The strength of every new or updated recommendation 
and the level of evidence supporting them were weighed and scored ac­
cording to predefined scales as outlined below. The Task Force followed 
ESC voting procedures and all approved recommendations were sub­
ject to a vote and achieved at least 75% agreement among voting 
members.
Table 1 Classes of recommendations
©ESC 2023
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2023
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2023
© ESC 2023


<!-- PAGE 5 -->

### Page 5

The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules and 
can be found on the ESC website (http://www.escardio.org/ 
guidelines) and have been compiled in a report published in a supple­
mentary document with the guidelines. The Task Force received its en­
tire financial support from the ESC without any involvement from the 
healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and coordinates the preparation of new Guidelines and Focused 
Updates and is responsible for the approval process. ESC Guidelines 
and Focused Updates undergo extensive review by the CPG 
Committee and external experts, including members from across the 
whole of the ESC region and from relevant ESC Subspecialty 
Communities and National Cardiac Societies. After appropriate revi­
sions, Guidelines and Focused Updates are signed off by all the experts 
involved in the Task Force. Finalized documents are signed off by the 
CPG Committee for publication in the European Heart Journal. This 
Focused Update was developed after careful consideration of the scien­
tific and medical knowledge and the evidence available at the time of 
writing. Tables of evidence summarizing the findings of studies 
informing development of the Focused Update are included. The ESC 
warns readers that the technical language may be misinterpreted and 
declines any responsibility in this respect.
Off-label use of medication may be presented in this Focused Update 
if a sufficient level of evidence shows that it can be considered medically 
appropriate for a given condition. However, the final decisions con­
cerning an individual patient must be made by the responsible health 
professional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
Since the publication of the 2021 ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure (HF),1 there have been sev­
eral randomized controlled trials that should change patient manage­
ment ahead of the next scheduled full guidelines. This 2023 Focused 
Update addresses changes in recommendations for the treatment of 
HF because of this new evidence. New evidence was considered until 
31 March 2023. All major randomized controlled clinical trials and 
meta-analyses were presented, discussed, and then voted upon for in­
clusion. Members with declared interests in specific topics were asked 
to abstain from voting on those topics. The trials were presented and 
discussed in detail before a consensus was reached about any possible 
classes of recommendations (COR) (Table 1) and levels of evidence 
(LOE) (Table 2) to be assigned.
The Task Force considered and discussed the following new trials 
and any meta-analyses including them: ADVOR (Acetazolamide in 
Decompensated Heart Failure with Volume Overload),2 CLOROTIC 
(Combination of Loop Diuretics with Hydrochlorothiazide in Acute 
Heart Failure),3 COACH (Comparison of Outcomes and Access to 
Care for Heart Failure),4 DAPA-CKD (Dapagliflozin And Prevention 
of Adverse outcomes in Chronic Kidney Disease),5 DELIVER 
(Dapagliflozin Evaluation to Improve the LIVEs of Patients with 
PReserved Ejection Fraction Heart Failure),6
EMPA-KIDNEY 
(EMPAgliflozin once daily to assess cardio-renal outcomes in patients 
with chronic KIDNEY disease),7 EMPEROR-Preserved (Empagliflozin 
Outcome Trial in Patients with Chronic Heart Failure with Preserved 
Ejection Fraction),8 EMPULSE (Empagliflozin in Patients Hospitalized 
with 
Acute 
Heart 
Failure 
Who 
Have 
Been 
Stabilized),9
FIDELIO-DKD (Finerenone in Reducing Kidney Failure and Disease 
Progression 
in 
Diabetic 
Kidney 
Disease),10
FIGARO-DKD 
(Finerenone in Reducing Cardiovascular Mortality and Morbidity in 
Diabetic Kidney Disease),11 IRONMAN (Effectiveness of Intravenous 
Iron Treatment versus Standard Care in Patients with Heart Failure 
and Iron Deficiency),12 PIVOTAL (Proactive IV Iron Therapy 
in Haemodialysis Patients),13,14 REVIVED-BCIS2 (Revascularization 
for Ischemic Ventricular Dysfunction),15
STRONG-HF (Safety, 
Tolerability and Efficacy of Rapid Optimization, Helped by 
NT-proBNP 
Testing, 
of 
Heart 
Failure 
Therapies),16
TRANSFORM-HF (Torsemide Comparison with Furosemide for 
Management of Heart Failure),17 and TRILUMINATE Pivotal (Clinical 
Trial to Evaluate Cardiovascular Outcomes in Patients Treated With 
the Tricuspid Valve Repair System Pivotal).18
Only results that would lead to new or changed class I/IIa recommen­
dations were selected for inclusion in Recommendation Tables. Trials 
that would have an impact upon recommendations in other ESC 
Guidelines under preparation have not been included to avoid discord­
ance. This is the case for REVIVED-BCIS2, which will be considered in 
the upcoming chronic coronary syndrome Guidelines.
In addition to selecting the trials to be included, the Task Force also 
discussed changing the description of HF with preserved ejection frac­
tion (HFpEF) to HF with normal ejection fraction (HFnEF) and the left 
ventricular ejection fraction (LVEF) threshold for HFnEF. The Task 
Force ultimately decided to keep the term HFpEF and left any further 
changes in terminology to be considered in the next ESC HF Guidelines.
In assigning recommendations, as in the 2021 ESC HF Guidelines, the 
Task Force focused on the primary endpoints of trials. This means that, 
for most HF trials, effective treatments reduce the risk of the time to 
first occurrence of the composite of either HF hospitalization or cardio­
vascular (CV) death (the correct convention for describing such a com­
posite). Of course, that does not mean each component is reduced 
individually. For total-event trials, where the primary composite out­
come included total (first and repeat) HF hospitalizations and all CV 
deaths, the convention for describing this composite, i.e. and not or, 
was used. Once again that does not mean that both components 
were reduced. All the new recommendations are additive to the re­
commendations of the 2021 ESC HF Guidelines and changed recom­
mendations substitute those of the 2021 ESC HF Guidelines.
After due deliberation, the Task Force decided to update recom­
mendations for the following sections of the 2021 ESC HF Guidelines: 
• Chronic HF: HF with mildly reduced ejection fraction (HFmrEF) and 
HFpEF
• Acute HF
• Comorbidities and prevention of HF.
3. Chronic heart failure
The original 2021 ESC HF Guidelines adopted the classification of 
chronic HF according to LVEF (Table 3).
ESC Guidelines                                                                                                                                                                                          3631


<!-- PAGE 6 -->

### Page 6

For those with HFmrEF, with LVEF between 41% and 49%, the Task 
Force made weak recommendations (COR IIb, LOE C) in the 2021 ESC 
HF Guidelines for the use of disease-modifying therapies that have class I 
evidence for use in HF with reduced ejection fraction (HFrEF). These 
were based on subgroup analyses of trials that were not specifically de­
signed to focus on HFmrEF, including trials where the overall endpoints 
were statistically neutral. The Task Force made no recommendations 
for the use of sodium–glucose co-transporter 2 (SGLT2) inhibitors.1
For those with HFpEF, the Task Force made no recommendations 
for the use of disease-modifying HFrEF therapies as clinical trials with 
angiotensin-converting enzyme inhibitors (ACE-I), angiotensin recep­
tor blockers (ARB), mineralocorticoid receptor antagonists (MRA), 
and angiotensin receptor–neprilysin inhibitors (ARNI) failed to meet 
their primary endpoints. There were no published trials with SGLT2 in­
hibitors to consider at the time.1
Since then, two trials have become available with the SGLT2 inhibi­
tors empagliflozin and dapagliflozin, in patients with HF and LVEF 
>40%, that justify an update in the recommendations for both 
HFmrEF and HFpEF.6,8
The first trial to report was the EMPEROR-Preserved trial.8 It re­
cruited 5988 patients with HF (New York Heart Association [NYHA] 
class II–IV) whose LVEF was >40% and who had raised plasma concen­
trations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
(>300 pg/mL for those in sinus rhythm or >900 pg/mL for those in at­
rial fibrillation). They were randomized to empagliflozin (10 mg once 
daily) or placebo. The primary outcome was a composite of CV death 
or hospitalization for HF. At a median follow-up of 26.2 months, empa­
gliflozin reduced the primary endpoint (hazard ratio [HR] 0.79, 95% 
confidence interval [CI] 0.69–0.90; P < .001). The effect was mainly dri­
ven by a reduction in HF hospitalizations with empagliflozin and there 
was no reduction in CV death. The effects were seen in patients with 
and without type 2 diabetes mellitus (T2DM).8 The majority of patients 
were on an ACE-I/ARB/ARNI (80%) and beta-blocker (86%) and 37% 
were on an MRA.19
A year later, the DELIVER trial reported on the effects of dapagliflo­
zin (10 mg once daily) compared with placebo in 6263 patients with HF 
(NYHA class II–IV).6 Patients had to have an LVEF >40% at the time of 
recruitment, but those who previously had an LVEF ≤40% that had im­
proved to >40% were also enrolled. Outpatients and inpatients hospi­
talized for HF were eligible. An elevated concentrations of natriuretic 
peptides were also a mandatory inclusion criterion (≥300 pg/mL in 
sinus rhythm or ≥600 pg/mL in atrial fibrillation).6,20,21
Dapagliflozin reduced the primary endpoint of CV death or worsen­
ing HF (HF hospitalization or urgent HF visit) (HR 0.82, 95% CI 0.73– 
0.92; P < .001). Once again, the principal effect was due to a reduction 
in worsening HF and there was no reduction in CV death. Dapagliflozin 
also improved symptom burden. The effects were independent of 
T2DM status.6 The efficacy of dapagliflozin was consistent in those 
who remained symptomatic, despite improved LVEF, suggesting that 
these patients may also benefit from SGLT2 inhibition.6,22 The benefit 
of dapagliflozin was also consistent across the range of LVEF studied.6,23
The background use of therapies for concomitant CV disease was high: 
77% were on a loop diuretic, 77% were on an ACE-I/ARB/ARNI, 83% 
were on a beta-blocker, and 43% were on an MRA.6
A subsequent aggregate data meta-analysis of the two trials con­
firmed a 20% reduction in the composite endpoint of CV death or first 
hospitalization for HF (HR 0.80, 95% CI 0.73–0.87; P < .001). CV death 
was not reduced significantly (HR 0.88, 95% CI 0.77–1.00; P = .052). HF 
hospitalization was reduced by 26% (HR 0.74, 95% CI 0.67–0.83; 
P < .001). There were consistent reductions in the primary endpoint 
across the LVEF range studied.24 Another individual patient data 
meta-analysis that incorporated data from DAPA-HF (Dapagliflozin 
And Prevention of Adverse outcomes in Heart Failure) in HFrEF with 
DELIVER confirmed that there was no evidence that the effect of 
dapagliflozin differed by ejection fraction.22 This also showed that dapa­
gliflozin reduced the risk of death from CV causes (HR 0.86, 95% CI 
0.76–0.97; P = .01).22
The Task Force discussed the results of these trials in depth, focusing 
particularly on the fact that they both met their primary endpoints, but 
they did so by a reduction in HF hospitalizations and not CV death. The 
Task Force decided to make recommendations on the primary end­
points. That is consistent with all the recommendations made in the 
2021 ESC HF Guidelines. The Task Force did not specify 
NT-proBNP thresholds for treatment, consistent with recommenda­
tions for other therapies in the original 2021 ESC HF Guidelines. 
However, it should be noted that, in the diagnostic algorithm for HF 
in the 2021 ESC HF Guidelines, raised concentrations of natriuretic 
peptides are usually implicit to that diagnosis. Taking these two trials 
into account, the following recommendations have been made for 
HFmrEF and HFpEF (see Figs 1 and 2, respectively).
Table 3 Definition of heart failure with reduced ejection fraction, mildly reduced ejection fraction, and preserved 
ejection fraction
Type of HF
HFrEF
HFmrEF
HFpEF
Criteria
1
Symptoms ± signsa
Symptoms ± signsa
Symptoms ± signsa
2
LVEF ≤40%
LVEF 41–49%b
LVEF ≥50%
3
–
–
Objective evidence of cardiac structural and/or functional abnormalities consistent with 
the presence of LV diastolic dysfunction/raised LV filling pressures, including raised 
natriuretic peptidesc
© ESC 2023
HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left 
ventricle; LVEF, left ventricular ejection fraction. 
aSigns may not be present in the early stages of HF (especially in HFpEF) and in optimally treated patients. 
bFor the diagnosis of HFmrEF, the presence of other evidence of structural heart disease (e.g. increased left atrial size, LV hypertrophy, or echocardiographic measures of impaired LV filling) 
makes the diagnosis more likely. 
cFor the diagnosis of HFpEF, the greater the number of abnormalities present, the higher the likelihood of HFpEF.


<!-- PAGE 7 -->

### Page 7

Recommendation Table 1 — Recommendation for the 
treatment of patients with symptomatic heart failure 
with mildly reduced ejection fraction
Recommendation
Classa
Levelb
An SGLT2 inhibitor (dapagliflozin or empagliflozin) is 
recommended in patients with HFmrEF to reduce 
the risk of HF hospitalization or CV death.c 6,8
I
A
© ESC 2023
CV, cardiovascular; HF, heart failure; HFmrEF, heart failure with mildly reduced ejection 
fraction; SGLT2, sodium–glucose co-transporter 2. 
aClass of recommendation. 
bLevel of evidence. 
cThis recommendation is based on the reduction of the primary composite endpoint used 
in the EMPEROR-Preserved and DELIVER trials and in a meta-analysis. However, it should 
be noted that there was a significant reduction only in HF hospitalizations and no reduction 
in CV death.
Recommendation Table 2 — Recommendation for the 
treatment of patients with symptomatic heart failure 
with preserved ejection fraction
Recommendation
Classa
Levelb
An SGLT2 inhibitor (dapagliflozin or empagliflozin) is 
recommended in patients with HFpEF to reduce the 
risk of HF hospitalization or CV death.c 6,8
I
A
© ESC 2023
CV, cardiovascular; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; 
SGLT2, sodium–glucose co-transporter 2. 
aClass of recommendation. 
bLevel of evidence. 
cThis recommendation is based on the reduction of the primary composite endpoint used 
in the EMPEROR-Preserved and DELIVER trials and in a meta-analysis. However, it should 
be noted that there was a significant reduction only in HF hospitalizations and no reduction 
in CV death.
Management of patients with HFmrEF
Diuretics for fluid retention
(Class I)
Dapagliflozin/
Empagliflozin
(Class I)
ACEI/ARNI/ARB
(Class IIb)
MRA
(Class IIb)
Beta-blocker
(Class IIb)
Figure 1 Management of patients with heart failure with mildly reduced ejection fraction. ACE-I, angiotensin-converting enzyme inhibitor; ARB, angio­
tensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; HFmrEF, heart failure with mildly reduced ejection fraction; MRA, mineralo­
corticoid receptor antagonist.
Management of patients with HFpEF
Diuretics for fluid retention
(Class I)
Treatment for aetiology,
CV and non-CV comorbodities
(Class I)
Dapagliflozin/
Empagliflozin
(Class I)
Figure 2 Management of patients with heart failure with preserved ejection fraction. CV, cardiovascular; HFpEF, heart failure with preserved ejection 
fraction.
ESC Guidelines                                                                                                                                                                                          3633


<!-- PAGE 8 -->

### Page 8

### 4 Acute heart failure

Treatment of acute HF was outlined in the recent 2021 ESC HF 
Guidelines and a Heart Failure Association scientific statement on 
HF.1,25 Since these publications, trials have been conducted with diure­
tics, as well as on management strategies for patients with acute HF. 
The results are summarized here.
4.1. Medical therapy
4.1.1. Diuretics
ADVOR was a multicentre, randomized, parallel-group, double-blind, 
placebo-controlled trial that enrolled 519 patients with acute decom­
pensated HF, clinical signs of volume overload (i.e. oedema, pleural 
effusion, or ascites), and an NT-proBNP level of >1000 pg/mL or a 
B-type natriuretic peptide level of >250 pg/mL. They were randomized 
to receive intravenous (i.v.) acetazolamide (500 mg once daily) or pla­
cebo added to standardized i.v. loop diuretic treatment.2 The primary 
endpoint of successful decongestion, defined as the absence of signs 
of volume overload, within 3 days after randomization and without 
an indication for escalation of decongestive therapy, was achieved in 
108 of 256 patients (42.2%) in the acetazolamide group and in 79 of 
259 patients (30.5%) in the placebo group (risk ratio [RR] 1.46, 95% 
CI 1.17–1.82; P < .001). Rehospitalization for HF or all-cause death oc­
curred in 76 patients (29.7%) in the acetazolamide group and in 72 pa­
tients (27.8%) in the placebo group (HR 1.07, 95% CI 0.78–1.48). 
Length of hospital stay was 1 day shorter with acetazolamide compared 
with placebo (8.8 [95% CI 8.0–9.5] vs. 9.9 [95% CI 9.1–10.8] days). No 
difference between the acetazolamide and placebo groups was found 
for other outcomes and adverse events.2 Although these results may 
support the addition of acetazolamide to a standard diuretic regimen 
to aid decongestion, further data on outcomes and safety are needed.
The CLOROTIC trial enrolled 230 patients with acute HF and ran­
domized them to oral hydrochlorothiazide (25–100 mg daily, depend­
ing on estimated glomerular filtration rate [eGFR]) or placebo, in 
addition to i.v. furosemide.3 The trial had two co-primary endpoints, 
change in body weight and change in patient-reported dyspnoea 
from baseline to 72 h after randomization. Patients on hydrochlor­
othiazide had a greater decrease in body weight at 72 h compared 
with those on placebo (−2.3 vs. −1.5 kg; adjusted estimated difference 
−1.14 kg, 95% CI −1.84 to −0.42 kg; P = .002). Changes in patient- 
reported dyspnoea were similar between the two groups.3 An increase 
in serum creatinine occurred more frequently in patients on hydro­
chlorothiazide (46.5%) compared with those on placebo (17.2%) 
(P < .001). The rates of HF rehospitalization and all-cause death were 
similar between groups, as was length of stay.3 The lack of an impact 
on clinical outcomes precludes any recommendation in the current 
guideline update. Further data on outcomes and safety are needed.
4.1.2. Sodium–glucose co-transporter 2 inhibitors
EMPULSE tested the efficacy of the early initiation of empagliflozin in pa­
tients hospitalized for acute HF.9 The primary endpoint was ‘clinical bene­
fit’, defined using a hierarchical composite of death from any cause, number 
of HF events, and time to first HF event, or a ≥5 point difference in change 
from baseline in the Kansas City Cardiomyopathy Questionnaire total 
symptom score at 90 days, assessed using the win-ratio method. HF events 
were defined as HF hospitalizations, urgent HF visits, and unplanned out­
patient HF visits. An event was considered HF-related only if worsening 
signs and symptoms of HF were present and an intensification of therapy 
(defined as an increase in oral or i.v. diuretics, augmentation of a vasoactive 
agent, or starting a mechanical or surgical intervention) was performed.9
Patients were randomized in hospital when clinically stable, with a median 
time from hospital admission to randomization of 3 days, and were treated 
for up to 90 days. The primary endpoint was achieved in more patients 
treated with empagliflozin compared with placebo (stratified win ratio 
1.36, 95% CI 1.09–1.68; P = .0054). Efficacy was independent of LVEF 
and diabetes status. From a safety perspective, the rate of adverse events 
was similar between the two treatment groups.9
These results are consistent with those shown for SGLT2 inhibitors 
in patients with chronic HF, regardless of LVEF, and also in those re­
cently hospitalized for HF, once clinically stable.9,26–28 Caution is, how­
ever, needed in patients with T2DM at risk of diabetic ketoacidosis, 
particularly those treated with insulin when carbohydrate intake is re­
duced or dose of insulin changed.29 SGLT2 inhibitors are not indicated 
in patients with type 1 diabetes.
4.2. Management strategies
Two large trials have been published since the last guidelines: COACH 
and STRONG-HF.
4.2.1. Admission phase
The COACH trial was a cross-sectional, stepped-wedge, cluster- 
randomized trial including 5452 patients (2972 during the control phase 
and 2480 during the intervention phase) enrolled at 10 centres in 
Ontario, Canada.4 During the intervention phase, hospital staff used the 
Emergency Heart Failure Mortality Risk Grade 30 Day Mortality-ST 
Depression (‘EHMRG30-ST’) score to ascertain whether patients had a 
low, intermediate, or high risk of death within 7 days or within 30 days. 
The study protocol recommended that low-risk patients be discharged 
early (in ≤3 days) and be treated with standardized outpatient care up 
to 30-day follow-up, whereas it was advised that intermediate- and high- 
risk patients be admitted to the hospital. Although early discharge oc­
curred at a similar rate in the intervention and control groups (57% vs. 
58%), the trial was successful in showing a 12% reduction in the primary 
outcome of all-cause death or CV hospitalization in the interventional arm 
compared with the control arm (HR 0.88, 95% CI 0.78–0.99), consistent 
with a favourable effect of post-discharge care.4 The trial may need fur­
ther confirmation multinationally before any recommendation on its ap­
proach can be offered in a guideline.
4.2.2. Pre-discharge and early post-discharge phases
The importance of pre-discharge and early post-discharge assessment in 
patients admitted to hospital for an episode of acute HF was already 
stressed in the original 2021 ESC HF Guidelines.1 The STRONG-HF trial 
recently showed the safety and efficacy of an approach based on starting 
and titrating oral medical therapy for HF within 2 days before anticipated 
hospital discharge and in follow-up visits occurring early after discharge.16
In this trial, 1078 patients hospitalized for acute HF, not already on full 
doses of evidence-based HF therapies, who were haemodynamically 
stable, with elevated NT-proBNP concentrations at screening 
(>2500 pg/mL), and a >10% decrease in concentration between screen­
ing and randomization, were randomly assigned, before discharge, to 
usual care or high-intensity care. Patients in the high-intensity care group 
received early and rapid intensification of oral HF treatment with ACE-I 
(or ARB) or ARNI, beta-blockers, and MRA.16
The goal of the first titration visit, which occurred within 48 h before 
hospital discharge, was to reach at least half of the target doses of re­
commended medications. Titration to full target doses of oral therapies 
was attempted within 2 weeks after discharge, with appropriate safety


<!-- PAGE 9 -->

### Page 9

monitoring. Follow-up visits, including physical examination and labora­
tory evaluation, including NT-proBNP measurement, were performed 
at 1, 2, 3, and 6 weeks after randomization to assess the safety and tol­
erability of medical therapy. Patients assigned to high-intensity care 
were more likely to receive full doses of oral therapies than those in 
the usual care group (renin–angiotensin system inhibitors 55% vs. 2%, 
beta-blockers 49% vs. 4%, and MRA 84% vs. 46%). The trial was 
stopped early for benefit. The primary outcome of HF readmission 
or all-cause death at 180 days occurred in 15.2% of patients in the high- 
intensity care group and in 23.3% of patients in the usual care group (ad­
justed RR [aRR] 0.66, 95% CI 0.50–0.86; P = .0021). Readmissions for 
HF were reduced (aRR 0.56, 95% CI 0.38–0.81; P = .0011), whereas all- 
cause death by day 180 was not (aRR 0.84, 95% CI 0.56–1.26; P = .42). 
Similar rates of serious adverse events (16% vs. 17%) and fatal adverse 
events (5% vs. 6%) were reported in each group.16
Based upon the results of STRONG-HF, high-intensity care for initi­
ation and rapid up-titration of oral HF therapies and close follow-up in 
the first 6 weeks after discharge for an acute HF hospitalization is re­
commended to reduce HF readmission or all-cause death. During the 
follow-up visits, particular attention should be paid to symptoms and 
signs of congestion, blood pressure, heart rate, NT-proBNP values, po­
tassium concentrations, and eGFR.
STRONG-HF has several limitations. First, the population was care­
fully selected, based on baseline NT-proBNP concentrations and their 
decline during hospitalization. Second, the majority of patients in the 
control group received less than half of full optimal doses of ACE-I/ 
ARB/ARNI and beta-blockers, and, although similar to many real-world 
clinical settings,30–33 their relative undertreatment may have favoured 
the high-intensity care arm. Third, the trial was initiated prior to current 
evidence and recommendations for SGLT2 inhibitors, which were not 
mandated in the protocol.
5. Comorbidities
5.1. Chronic kidney disease and type 2 
diabetes mellitus
The 2021 ESC HF Guidelines gave recommendations for the preven­
tion of HF in patients with diabetes. This update provides new recom­
mendations for prevention of HF in patients with chronic kidney 
disease (CKD) and T2DM.5,7,10,11,34,35
Previous trials have shown the effects of ARB in preventing HF events 
in patients with diabetic nephropathy.36,37 Both the Kidney Disease: 
Improving Global Outcomes (KDIGO) and the 2022 American 
Diabetes Association Standards of Medical Care in Diabetes and 
KDIGO recommendations indicate treatment with an ACE-I or ARB 
for patients with CKD, diabetes, and hypertension or albuminuria.38,39
5.1.1. Sodium–glucose co-transporter 2 inhibitors
Two randomized controlled trials, which were stopped early for effi­
cacy, and a meta-analysis were recently published. DAPA-CKD was a 
multicentre, double-blind, placebo-controlled, randomized trial includ­
ing both diabetic and non-diabetic patients with a urinary 
albumin-to-creatinine ratio ≥200 mg/g and an eGFR of 25–75 mL/ 
min/1.73 m2, who were randomly assigned 1:1 to dapagliflozin 10 mg 
once daily or placebo.5 Overall, 468 of the 4304 patients enrolled 
(11%) had a history of HF. During a median follow-up of 2.4 years, a re­
duction in the primary outcome, a composite of sustained decline in 
eGFR of ≥50%, end-stage kidney disease, or kidney-related or CV 
death, was reduced by 39% by dapagliflozin compared with placebo 
(HR 0.61, 95% CI 0.51–0.72; P < .001). Also, the risk of the secondary 
outcome of HF hospitalization or CV death was decreased by dapagli­
flozin compared with placebo (HR 0.71, 95% CI 0.55–0.92; P = .009) 
with, however, a relatively small absolute risk reduction (4.6% vs. 
6.4% with dapagliflozin vs. placebo).5
EMPA-KIDNEY enrolled a broader group of patients with CKD, 
compared with DAPA-CKD, including patients with eGFR 20–45 mL/ 
min/1.73 m2, even in the absence of albuminuria, or with an eGFR of 
45–90 mL/min/1.73 m2 and a urinary albumin-to-creatinine ratio 
≥200 mg/g. Patients were randomized 1:1 to empagliflozin 10 mg once 
daily or placebo.7 Overall, 658 of the 6609 patients enrolled (10%) had a 
history of HF. During a median follow-up of 2.0 years, a reduction in the 
primary composite endpoint of progression of kidney disease or CV death 
was observed.7 The risk of HF hospitalization or death for CV causes was 
not reduced significantly (HR 0.84, 95% CI 0.67–1.07; P = .15).7
DAPA-CKD, EMPA-KIDNEY, CREDENCE39a (Canagliflozin and Renal 
Events in Diabetes With Established Nephropathy Clinical Evaluation), 
and SCORED39b (Effect of Sotagliflozin on Cardiovascular and 
Renal Events in Patients with Type 2 Diabetes and Moderate Renal 
Impairment Who Are at Cardiovascular Risk) were included with 
HF trials in a recent meta-analysis.35 The reduction in HF hospitaliza­
tions and CV death was similar irrespective of a history of diabetes 
when both HF and CKD trials were included (HR 0.77, 95% CI 
0.73–0.81 in patients with T2DM, and HR 0.79, 95% CI 0.72–0.87 in those 
without T2DM). However, results were not significant in patients without 
diabetes when only CKD trials were included (HR for HF hospitalizations 
and CV death of 0.74, 95% CI 0.66–0.82 in patients with T2DM, and HR of 
0.95, 95% CI 0.65–1.40 in patients without T2DM).35 Based on these re­
sults, SGLT2 inhibitors are recommended in patients with CKD and 
T2DM, and with the additional characteristics of the participants in these 
trials, including an eGFR >20–25 mL/min/1.73 m2, to reduce the risk of 
HF hospitalization or CV death.
Recommendation Table 3 — Recommendation for 
pre-discharge and early post-discharge follow-up of 
patients hospitalized for acute heart failure
Recommendation
Classa
Levelb
An intensive strategy of initiation and rapid 
up-titration of evidence-based treatment before 
discharge and during frequent and careful follow-up 
visits in the first 6 weeks following a HF 
hospitalization is recommended to reduce the risk of 
HF rehospitalization or death.c,d,e 16
I
B
© ESC 2023
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, 
angiotensin receptor–neprilysin inhibitor; CV, cardiovascular; HF, heart failure; HFmrEF, 
heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved 
ejection fraction; HFrEF, heart failure with reduced ejection fraction; MRA, 
mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic 
peptide. 
aClass of recommendation. 
bLevel of evidence. 
cIn STRONG-HF, the use of ACE-I/ARB/ARNI, beta-blockers, and MRA was evaluated in 
patients with HFrEF, HFmrEF, and HFpEF. 
dThis recommendation is based on the reduction of the primary endpoint used in the 
STRONG-HF trial. However, it should be noted that there was a significant reduction 
only in HF hospitalization and no reduction in CV death or all-cause death alone and that 
these results were obtained in a specific patient population, not already on full doses of 
evidence-based HF therapies, who were haemodynamically stable, with elevated 
NT-proBNP concentrations at screening (>2500 pg/mL), and a >10% decrease in 
concentration between screening and randomization, according to the enrolment criteria. 
eAlthough STRONG-HF was based only on triple therapy with neurohormonal modulators, 
this recommendation also includes empagliflozin or dapagliflozin based on recent 
evidence.6,8,9
ESC Guidelines                                                                                                                                                                                          3635


<!-- PAGE 10 -->

### Page 10

5.1.2. Finerenone
The selective, non-steroidal, MRA finerenone was tested in two trials in 
patients with diabetic kidney disease. The FIDELIO-DKD trial enrolled 
5734 patients with a urinary albumin-to-creatinine ratio 30–300 mg/g, 
an eGFR 25–60 mL/min/1.73 m2, and diabetic retinopathy, or a urinary 
albumin-to-creatinine ratio 300–5000 mg/g and an eGFR 25–75 mL/ 
min/1.73 m2.10 The primary outcome of the trial, assessed in a 
time-to-event analysis, was a composite of kidney failure, a sustained 
decrease of ≥40% in the eGFR from baseline over a period of ≥4 
weeks, or death from renal causes. Kidney failure was defined as end- 
stage kidney disease or an eGFR <15 mL/min/1.73 m2; end-stage kidney 
disease was defined as the initiation of long-term dialysis (for ≥90 days) 
or kidney transplantation. The primary endpoint of the trial was re­
duced by finerenone compared with placebo by 18% (HR 0.82, 95% 
CI 0.73–0.93; P = .001), during a median follow-up of 2.6 years.10
There was no evidence of a reduction in HF hospitalizations with finer­
enone vs. placebo (HR 0.86, 95% CI 0.68–1.08), although finerenone 
was associated with a lower occurrence of the key secondary endpoint, 
a composite of CV death, non-fatal myocardial infarction, non-fatal 
stroke, and hospitalization for HF (HR 0.86, 95% CI 0.75–0.99; P  
= .03).10 Patients with HFrEF and NYHA class II–IV were excluded 
from the trial. However, patients with asymptomatic or NYHA class I 
HFrEF, or with HFmrEF or HFpEF, could be enrolled, so that 7.7% of 
the patients included had a history of HF. The effects of finerenone 
on the composite of CV and renal outcomes, including HF hospitaliza­
tions, were independent of a previous history of HF.34
In the more recent FIGARO-DKD trial, the primary outcome, as­
sessed in a time-to-event analysis, was a composite of death from CV 
causes, non-fatal myocardial infarction, non-fatal stroke, or hospitaliza­
tion for HF.11 The trial enrolled adult patients with T2DM and CKD 
treated with a renin–angiotensin system inhibitor at the maximum tol­
erated dose. CKD was defined according to one of two sets of criteria: 
persistent, moderately elevated albuminuria (urinary albumin-to-cre­
atinine ratio 30 to <300 mg/g) and an eGFR 25–90 mL/min/1.73 m2 
(i.e. stage 2 to 4 CKD); or persistent, severely elevated albuminuria 
(urinary albumin-to-creatinine ratio 300–5000 mg/g) and an eGFR 
>60 mL/min/1.73 m2 (i.e. stage 1 or 2 CKD). Patients were required 
to have a serum potassium level of ≤4.8 mmol/L at the time of screen­
ing.11 The trial included 7437 patients randomly assigned to finerenone 
or placebo.11 At a median follow-up of 3.4 years, the rate of the primary 
outcome, CV death, non-fatal myocardial infarction, non-fatal stroke, 
or HF hospitalization, was lower in the treatment arm compared 
with placebo (HR 0.87, 95% CI 0.76–0.98; P = .03). The benefit was dri­
ven by a numerically small, but statistically significant, lower incidence of 
HF hospitalization with finerenone vs. placebo (3.2% vs. 4.4%; HR 0.71, 
95% CI 0.56–0.90), with no differences in CV death.11 In both 
FIDELIO-DKD and FIGARO-DKD the occurrence of hyperkalaemia 
was higher in the finerenone group compared with the placebo group. 
However, the rate of adverse events was similar between the two arms.
A pre-specified individual patient-level, pooled analysis, including 
13 026 patients with diabetic kidney disease followed for a median 
of 3.0 years from both the FIDELIO-DKD and FIGARO-DKD trials, 
showed a reduction in the composite CV outcome, including CV 
death, non-fatal stroke, non-fatal myocardial infarction, and HF hospi­
talizations, as well as in HF hospitalizations alone with finerenone vs. 
placebo (HR 0.86, 95% CI 0.78–0.95; P = .0018; and HR 0.78, 95% CI 
0.66–0.92; P = .0030, respectively).40 Thus, finerenone is recom­
mended for the prevention of HF hospitalization in patients with 
CKD and T2DM.
5.2. Iron deficiency
Recommendations for the diagnosis and treatment of iron deficiency 
were given in the 2021 ESC HF Guidelines: COR I, LOE C for the diag­
nosis of iron deficiency, COR IIa, LOE A to improve HF symptoms, ex­
ercise capacity, and quality of life, and COR IIa, LOE B to reduce HF 
hospitalizations, for treatment with ferric carboxymaltose.1
A new trial, IRONMAN, has now been published.12 This was a pro­
spective, randomized, open-label, blinded-endpoint trial including pa­
tients with HF, LVEF ≤45%, and transferrin saturation <20% or 
serum ferritin <100 μg/L who were randomly allocated 1:1 to i.v. ferric 
derisomaltose or usual care. The patients included were mainly ambu­
latory, although 14% were enrolled during an HF hospitalization and 
18% had an HF hospitalization in the previous 6 months. After a median 
follow-up of 2.7 years, the rate ratio for the primary endpoint, a com­
posite of total (first and recurrent) HF hospitalizations and CV death, 
was 0.82 (95% CI 0.66–1.02; P = .070). Total hospital admissions for 
HF were not reduced significantly with ferric derisomaltose vs. usual 
care (16.7 vs. 20.9 per 100 patient-years; RR 0.80, 95% CI 0.62–1.03; 
P = .085). As in AFFIRM-AHF (A Randomized Double-blind Placebo 
Controlled Trial Comparing the Effects of Intravenous Ferric 
Carboxymaltose on Hospitalizations and Mortality in Iron Deficient 
Subjects Admitted for Acute Heart Failure),41 a pre-specified 
COVID-19 analysis, censoring follow-up on September 2020, showed 
a reduction in the risk of the primary endpoint with ferric derisomal­
tose vs. control (HR 0.76, 95% CI 0.58–1.00; P = .047). There was a 
statistically borderline improvement in the Minnesota Living with 
Heart Failure Questionnaire score with ferric derisomaltose (between 
treatment difference −3.33, 95% CI −6.67 to 0.00; P = .050), but no dif­
ference in EQ-5D visual analogue scale or EQ-5D index.12 Some of 
these findings in secondary outcomes might be explained by the lack 
of adjustment for multiple testing.42 Safety endpoints, i.e. death and 
hospitalization due to infection, did not differ between the two arms.12
Recommendation Table 4 — Recommendations for the 
prevention of heart failure in patients with type 2 
diabetes mellitus and chronic kidney disease
Recommendations
Classa
Levelb
In patients with T2DM and CKD,c SGLT2 inhibitors 
are recommended to reduce the risk of HF 
hospitalization or CV death.35
I
A
In patients with T2DM and CKD,c finerenone is 
recommended to reduce the risk of HF 
hospitalization.10,11,34,40
I
A
© ESC 2023
CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration 
rate; HF, heart failure; SGLT2, sodium–glucose co-transporter 2; T2DM, type 2 diabetes 
mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cCKD was defined as follows: an eGFR 25–75 mL/min/1.73 m2 and a urinary 
albumin-to-creatinine ratio ≥200–5000 mg/g in DAPA-CKD;5 an eGFR 20–45 mL/min/ 
1.73 m2 or an eGFR 45–90 mL/min/1.73 m2 with a urinary albumin-to-creatinine ratio 
≥200 mg/g 
in 
EMPA-KIDNEY;7
an 
eGFR 
25–60 mL/min/1.73 m2, 
a 
urinary 
albumin-to-creatinine ratio 30–300 mg/g, and diabetic retinopathy, or an eGFR 
25–75 mL/min/1.73 m2 and a urinary albumin-to-creatinine ratio 300–5000 mg/g, 
in 
FIDELIO-DKD;10
and 
an 
eGFR 
25–90 mL/min/1.73 m2 
and 
a 
urinary 
albumin-to-creatinine ratio 30 to <300 mg/g, or an eGFR >60 mL/min/1.73 m2 and a 
urinary albumin-to-creatinine ratio 300–5000 mg/g, in FIGARO-DKD.11


<!-- PAGE 11 -->

### Page 11

These results have been included in meta-analyses of the randomized 
controlled trials comparing the effects of i.v. iron therapy with standard 
of care or placebo in patients with HF and iron deficiency.43–46 In the ana­
lysis by Graham et al.44 including 10 trials with 3373 patients, i.v. iron re­
duced the composite of total HF hospitalizations and CV death (RR 
0.75, 95% CI 0.61–0.93; P < .01) and first HF hospitalization or CV death 
(odds ratio [OR] 0.72, 95% CI 0.53–0.99; P = .04). There was no effect on 
CV (OR 0.86, 95% CI 0.70–1.05; P = .14) or all-cause mortality (OR 0.93, 
95% CI 0.78–1.12; P = .47). Similar results were found in the other 
meta-analyses.43,45,46 In the PIVOTAL trial, a high-dose i.v. iron regimen, 
compared with a low-dose regimen, reduced the occurrence of first and 
recurrent HF events in patients undergoing dialysis for end-stage CKD.13,14
Based on trials and recent meta-analyses,13,14,41,43,45–49 i.v. iron supple­
mentation is now recommended in patients with HFrEF or HFmrEF, and 
iron deficiency, to improve symptoms and quality of life, and should be 
considered to reduce the risk of HF hospitalization. Iron deficiency was 
diagnosed by a low transferrin saturation (<20%) or a low serum ferritin 
concentration (<100 μg/L).12,41 Notably, in IRONMAN, patients were 
excluded if they had haemoglobin >13 g/dL (for women) and >14 g/dL 
(for men).12 The new recommendations are shown below.
6. Data availability statement
No new data were generated or analysed in support of this research.
7. Author information
Author/Task Force Member Affiliations: Marianna Adamo, 
ASST Spedali Civili di Brescia and Department of Medical and Surgical 
Specialties, Radiological Sciences and Public Health, University of 
Brescia, Institute of Cardiology, Brescia, Italy; Roy S. Gardner, 
Scottish National Advanced Heart Failure Service, Golden Jubilee 
National Hospital, Clydebank, Glasgow, United Kingdom; Andreas 
Baumbach, Queen Mary University of London, Barts Heart Center, 
London, United Kingdom; Michael Böhm, Internal Medicine Clinic 
III, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany, 
Internal Medicine Clinic III, Saarland University, Saarbrücken, 
Germany; Haran Burri, Cardiology Department, University Hospital 
of Geneva, Geneva, Switzerland; Javed Butler, Baylor Scott and 
White Research Institute, Baylor Scott and White Health, Dallas, TX, 
United States of America, Department of Medicine, University of 
Mississippi, Jackson, MS, United States of America; Jelena 
Čelutkienė, Clinic of Cardiac and Vascular Diseases, Vilnius 
University, Vilnius, Lithuania; Ovidiu Chioncel, ICCU, Emergency 
Institute for Cardiovascular Diseases ‘Prof. Dr.C.C.Iliescu’, Bucuresti, 
Romania, Department of Cardiology, University of Medicine Carol 
Davila, Bucuresti, Romania; John G.F. Cleland, British Heart 
Foundation Centre of Research Excellence, School of Cardiovascular 
and Metabolic Health, University of Glasgow, Glasgow, United 
Kingdom; Maria Generosa Crespo-Leiro, Cardiology, Complexo 
Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain, 
Physiotherapy, Medicine and Medical Sciences, University of A 
Coruña (UDC), A Coruña, Spain, Centro Investigación Biomédica en 
Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III, Madrid, 
Spain; Dimitrios Farmakis, Second Department of Cardiology, 
Athens University Hospital Attikon, National and Kapodistrian 
University of Athens Medical School, Athens, Greece; Martine 
Gilard, Cardiology, INSERM UMR 1304 GETBO, Brest University, 
Brest, France; Stephane Heymans, Department of Cardiology, 
Cardiovascular Research Institute Maastricht, University of Maastricht, 
Maastricht, Netherlands, Department of Cardiovascular Sciences, 
Leuven University, Leuven, Belgium; Arno W. Hoes, Julius Center 
for Health Sciences and Primary Care, University Medical Center 
Utrecht, Utrecht University, Utrecht, Netherlands; Tiny Jaarsma, 
Department of Health Medicine, Caring Science, Linköping University, 
Linköping, Sweden, Department of Nursing Science, Julius Center, 
University 
Medical 
Center, 
Utrecht, 
Netherlands; 
Ewa 
A. Jankowska, Institute of Heart Diseases, Wroclaw Medical 
University, Poland, Institute of Heart Diseases, University Hospital in 
Wroclaw, Poland; Mitja Lainscak, Faculty of Medicine, University of 
Ljubljana, Ljubljana, Slovenia, Division of Cardiology, General Hospital 
Murska Sobota, Murska Sobota, Slovenia; Carolyn S.P. Lam, 
Cardiology, National Heart Centre of Singapore, Singapore, 
Singapore, 
Cardiovascular 
Academic 
Clinical 
Programme, 
Duke-National University of Singapore, Singapore, Singapore; 
Alexander R. Lyon, Cardio-Oncology Service, Royal Brompton 
Hospital, London, United Kingdom; John J.V. McMurray, BHF 
Cardiovascular Research Centre, University of Glasgow, Glasgow, 
United Kingdom; Alexandre Mebazaa, Faculté Santé, Université 
Paris Cité, Paris, France, Anesthesia and Critical care, Assistance 
Publique-Hôpitaux de Paris, Paris, France, MASCOT INSERM, Paris, 
France; Richard Mindham (United Kingdom), ESC Patient Forum, 
Sophia Antipolis, France, Claudio Muneretto, Cardiac Surgery, 
University of Brescia, ASST Spedali Civili, Brescia, Italy; Massimo 
Francesco Piepoli, Cardiology, IRCCS Policlinico San Donato, San 
Donato Milanese, Italy, Dipartimento di Scienze Biomediche per la 
Salute, University of Milan, Milan, Italy; Susanna Price, Cardiology 
and critical care, Royal Brompton and Harefield Hospitals, London, 
United Kingdom, National Heart and Lung Institute, Imperial College, 
London, United Kingdom; Giuseppe M.C. Rosano, Basic and 
Clinical Research, IRCCS San Raffaele Roma, Rome, Italy; Frank 
Ruschitzka, Department of Cardiology, University Hospital Zurich 
and University of Zurich, Zurich, Switzerland; and Anne Kathrine 
Skibelund (Denmark), ESC Patient Forum, Sophia Antipolis, France.
Recommendation Table 5 — Recommendations for the 
management of iron deficiency in patients with heart 
failure
Recommendations
Classa
Levelb
Intravenous iron supplementation is recommended 
in symptomatic patients with HFrEF and HFmrEF, 
and iron deficiency, to alleviate HF symptoms and 
improve quality of life.c 12,41,47–49
I
A
Intravenous iron supplementation with ferric 
carboxymaltose or ferric derisomaltose should be 
considered in symptomatic patients with HFrEF and 
HFmrEF, and iron deficiency, to reduce the risk of HF 
hospitalization.c 12,41,43–46
IIa
A
© ESC 2023
HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, heart 
failure with reduced ejection fraction. 
aClass of recommendation. 
bLevel of evidence. 
cMost of the evidence refers to patients with left ventricular ejection fraction ≤45%.
ESC Guidelines                                                                                                                                                                                          3637


<!-- PAGE 12 -->

### Page 12

### 8 Appendix

ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Rudolf A. de Boer (CPG Review 
Co-ordinator) (Netherlands), P. Christian Schulze (CPG Review 
Co-ordinator) (Germany), Elena Arbelo (Spain), Jozef Bartunek 
(Belgium), Johann Bauersachs (Germany), Michael A. Borger 
(Germany), Sergio Buccheri (Sweden), Elisabetta Cerbai (Italy), Erwan 
Donal (France), Frank Edelmann (Germany), Gloria Färber (Germany), 
Bettina Heidecker (Germany), Borja Ibanez (Spain), Stefan James 
(Sweden), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), Josep Masip (Spain), John William McEvoy (Ireland), 
Robert Mentz (United States of America), Borislava Mihaylova (United 
Kingdom), Jacob Eifer Møller (Denmark), Wilfried Mullens (Belgium), Lis 
Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Piotr Ponikowski (Poland), Eva Prescott 
(Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier 
Rossello (Spain), Leyla Elif Sade (United States of America / Türkiye), 
Hannah Schaubroeck (Belgium), Elena Tessitore (Switzerland), Mariya 
Tokmakova (Bulgaria), Peter van der Meer (Netherlands), Isabelle 
C. Van Gelder (Netherlands), Mattias Van Heetvelde (Belgium), 
Christiaan Vrints (Belgium), Matthias Wilhelm (Switzerland), Adam 
Witkowski (Poland), and Katja Zeppenfeld (Netherlands).
ESC National Cardiac Societies actively involved in the review 
process of the 2023 Focused Update of the 2021 ESC Guidelines for 
the diagnosis and treatment of acute and chronic heart failure: 
Albania: Albanian Society of Cardiology, Naltin Shuka; Algeria: 
Algerian Society of Cardiology, Mohammed Chettibi; Armenia: 
Armenian Cardiologists Association, Hamlet Hayrapetyan; Austria: 
Austrian Society of Cardiology, Noemi Pavo; Azerbaijan: 
Azerbaijan Society of Cardiology, Aysel Islamli; Belgium: Belgian 
Society of Cardiology, Anne-Catherine Pouleur; Bosnia and 
Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of 
Cardiology, Mariya Tokmakova; Croatia: Croatian Cardiac Society, 
Davor Milicic; Cyprus: Cyprus Society of Cardiology, Theodoros 
Christodoulides; Czechia: Czech Society of Cardiology, Filip Malek; 
Denmark: Danish Society of Cardiology, Lars Køber; Egypt: 
Egyptian Society of Cardiology, Mohamed Abdel Ghany Koriem; 
Estonia: Estonian Society of Cardiology, Pentti Põder; Finland: 
Finnish Cardiac Society, Johan Lassus; France: French Society of 
Cardiology, François Roubille; Georgia: Georgian Society of 
Cardiology, Vaja Agladze; Germany: German Cardiac Society, 
Stefan Frantz; Greece: Hellenic Society of Cardiology, Alexia 
Stavrati; Hungary: Hungarian Society of Cardiology, Annamaria 
Kosztin; Iceland: Icelandic Society of Cardiology, Inga Jóna 
Ingimarsdóttir; Ireland: Irish Cardiac Society, Patricia Campbell; 
Israel: Israel Heart Society, Tal Hasin; Italy: Italian Federation of 
Cardiology, 
Fabrizio 
Oliva; 
Kazakhstan: 
Association 
of 
Cardiologists 
of 
Kazakhstan, 
Nazipa 
Aidargaliyeva; 
Kosovo 
(Republic of): Kosovo Society of Cardiology, Gani Bajraktari; 
Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov, 
Latvia: Latvian Society of Cardiology, Ginta Kamzola; Libya: Libyan 
Cardiac Society, Ali M. El Neihoum; Lithuania: Lithuanian Society of 
Cardiology, Diana Zaliaduonyte; Malta: Maltese Cardiac Society, 
Alice Moore; Moldova (Republic of): Moldavian Society of 
Cardiology, Eleonora Vataman; Montenegro: Montenegro Society 
of Cardiology, Aneta Boskovic; Morocco: Moroccan Society of 
Cardiology, Mohamed Alami; Netherlands: Netherlands Society of 
Cardiology, Olivier Manintveld; North Macedonia:The National 
Society of Cardiology of North Macedonia, Elizabeta Srbinovska 
Kostovska; Norway: Norwegian Society of Cardiology, Kaspar 
Broch; Poland: Polish Cardiac Society, Jadwiga Nessler; Portugal: 
Portuguese Society of Cardiology, Fatima Franco; Romania: 
Romanian Society of Cardiology, Bogdan A. Popescu; San Marino: 
San Marino Society of Cardiology, Marina Foscoli; Serbia: 
Cardiology Society of Serbia, Anastazija Stojsic Milosavljevic; 
Slovakia: Slovak Society of Cardiology, Eva Goncalvesova; 
Slovenia: Slovenian Society of Cardiology, Zlatko Fras; Spain: 
Spanish Society of Cardiology, Jose Gonzalez-Costello; Sweden: 
Swedish Society of Cardiology, Krister Lindmark; Switzerland: 
Swiss Society of Cardiology, Matthias Paul; Syrian Arab Republic: 
Syrian Cardiovascular Association, Abdulnasser Oudeh; Tunisia: 
Tunisian Society of Cardiology and Cardiovascular Surgery, Lilia 
Zakhama; Türkiye: Turkish Society of Cardiology, Ahmet Celik; 
Ukraine: Ukrainian Association of Cardiology, Leonid Voronkov; 
United Kingdom of Great Britain and Northern Ireland: 
British Cardiovascular Society, Andrew Clark; and Uzbekistan: 
Association of Cardiologists of Uzbekistan, Timur Abdullaev.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
9. References
1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 
2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368
2. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in 
acute decompensated heart failure with volume overload. N Engl J Med 2022;387: 
1185–95. https://doi.org/10.1056/NEJMoa2203094
3. Trullàs JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sánchez-Marteles M, 
Conde-Martel A, et al. Combining loop with thiazide diuretics for decompensated heart 
failure: the CLOROTIC trial. Eur Heart J 2023;44:411–21. https://doi.org/10.1093/ 
eurheartj/ehac689
4. Lee DS, Straus SE, Farkouh ME, Austin PC, Taljaard M, Chong A, et al. Trial of an inter­
vention to improve acute heart failure outcomes. N Engl J Med 2023;388:22–32. https:// 
doi.org/10.1056/NEJMoa2211680
5. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. 
Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436–46. 
https://doi.org/10.1056/NEJMoa2024816
6. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. 
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N 
Engl J Med 2022;387:1089–98. https://doi.org/10.1056/NEJMoa2206286
7. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney 
disease. N Engl J Med 2023;388:117–27. https://doi.org/10.1056/NEJMoa2204233
8. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in 
heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61. 
https://doi.org/10.1056/NEJMoa2107038
9. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The 
SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multi­
national randomized trial. Nat Med 2022;28:568–74. https://doi.org/10.1038/s41591- 
021-01659-1
10. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone 
on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219–29. 
https://doi.org/10.1056/NEJMoa2025845


<!-- PAGE 13 -->

### Page 13

11. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular 
events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021;385: 
2252–63. https://doi.org/10.1056/NEJMoa2110956
12. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric 
derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an 
investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 
2022;400:2199–209. https://doi.org/10.1016/S0140-6736(22)02083-9
13. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. Intravenous 
iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019;380:447–58. 
https://doi.org/10.1056/NEJMoa1810742
14. Jhund PS, Petrie MC, Robertson M, Mark PB, MacDonald MR, Connolly E, et al. Heart 
failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron 
therapy. JACC Heart Fail 2021;9:518–27. https://doi.org/10.1016/j.jchf.2021.04.005
15. Perera D, Clayton T, O’Kane PD, Greenwood JP, Weerackody R, Ryan M, et al. 
Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med 
2022;387:1351–60. https://doi.org/10.1056/NEJMoa2206606
16. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, 
tolerability and efficacy of up-titration of guideline-directed medical therapies for acute 
heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022; 
400:1938–52. https://doi.org/10.1016/S0140-6736(22)02076-1
17. Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al. Effect of torse­
mide vs furosemide after discharge on all-cause mortality in patients hospitalized with 
heart failure: the TRANSFORM-HF randomized clinical trial. JAMA 2023;329:214–23. 
https://doi.org/10.1001/jama.2022.23924
18. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter re­
pair for patients with tricuspid regurgitation. N Engl J Med 2023;388:1833–42. https:// 
doi.org/10.1056/NEJMoa2300525
19. Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, et al. Baseline 
characteristics of patients with heart failure with preserved ejection fraction in the 
EMPEROR-Preserved trial. Eur J Heart Fail 2020;22:2383–92. https://doi.org/10.1002/ 
ejhf.2064
20. Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, et al. 
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: ration­
ale and design of the DELIVER trial. Eur J Heart Fail 2021;23:1217–25. https://doi.org/10. 
1002/ejhf.2249
21. Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, 
et al. Baseline characteristics of patients with HF with mildly reduced and preserved 
ejection fraction: DELIVER trial. JACC Heart Fail 2022;10:184–97. https://doi.org/10. 
1016/j.jchf.2021.11.006
22. Vardeny O, Fang JC, Desai AS, Jhund PS, Claggett B, Vaduganathan M, et al. Dapagliflozin 
in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER 
trial. Nat Med 2022;28:2504–11. https://doi.org/10.1038/s41591-022-02102-9
23. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin 
across the range of ejection fraction in patients with heart failure: a patient-level, pooled 
meta-analysis of DAPA-HF and DELIVER. Nat Med 2022;28:1956–64. https://doi.org/ 
10.1038/s41591-022-01971-4
24. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. 
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five 
randomised controlled trials. Lancet 2022;400:757–67. https://doi.org/10.1016/S0140- 
6736(22)01429-5
25. Masip J, Frank Peacok W, Arrigo M, Rossello X, Platz E, Cullen L, et al. Acute Heart Failure 
in the 2021 ESC Heart Failure Guidelines: a scientific statement from the Association for 
Acute CardioVascular Care (ACVC) of the European Society of Cardiology. Eur Heart J 
Acute Cardiovasc Care 2022;11:173–85. https://doi.org/10.1093/ehjacc/zuab122
26. Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. 
Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or 
preserved ejection fraction. J Am Coll Cardiol 2022;80:1302–10. https://doi.org/10. 
1016/j.jacc.2022.07.021
27. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in 
patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384: 
117–28. https://doi.org/10.1056/NEJMoa2030183
28. Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, et al. Sodium–glucose 
co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and re­
duced ejection fraction. Eur J Heart Fail 2022;24:431–41. https://doi.org/10.1002/ejhf.2397
29. Liu J, Li L, Li S, Wang Y, Qin X, Deng K, et al. Sodium-glucose co-transporter-2 inhibitors 
and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review 
and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020;22: 
1619–27. https://doi.org/10.1111/dom.14075
30. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, et al. 
Improving evidence-based care for heart failure in outpatient cardiology practices: pri­
mary results of the registry to improve the use of evidence-based heart failure therapies 
in the outpatient setting (IMPROVE HF). Circulation 2010;122:585–96. https://doi.org/ 
10.1161/CIRCULATIONAHA.109.934471
31. Gheorghiade M, Albert NM, Curtis AB, Thomas Heywood J, McBride ML, Inge PJ, et al. 
Medication dosing in outpatients with heart failure after implementation of a practice- 
based performance improvement intervention: findings from IMPROVE HF. Congest 
Heart Fail 2012;18:9–17. https://doi.org/10.1111/j.1751-7133.2011.00250.x
32. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy 
for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll 
Cardiol 2018;72:351–66. https://doi.org/10.1016/j.jacc.2018.04.070
33. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. 
Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers 
in patients with heart failure: a prospective European study. Eur Heart J 2017;38: 
1883–90. https://doi.org/10.1093/eurheartj/ehx026
34. Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, et al. Finerenone in 
patients with chronic kidney disease and type 2 diabetes with and without heart failure: a 
prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail 2022;24: 
996–1005. https://doi.org/10.1002/ejhf.2469
35. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor 
Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects 
of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative 
meta-analysis of large placebo-controlled trials. Lancet 2022;400:1788–801. https:// 
doi.org/10.1016/S0140-6736(22)02074-8
36. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects 
of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and 
nephropathy. N Engl J Med 2001;345:861–9. https://doi.org/10.1056/NEJMoa011161
37. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of 
the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 
diabetes. N Engl J Med 2001;345:851–60. https://doi.org/10.1056/NEJMoa011303
38. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes man­
agement in chronic kidney disease: a consensus report by the American Diabetes 
Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). 
Diabetes Care 2022;45:3075–90. https://doi.org/10.2337/dci22-0027
39. House AA, Wanner C, Sarnak MJ, Pina IL, McIntyre CW, Komenda P, et al. Heart failure 
in chronic kidney disease: conclusions from a kidney disease: improving global outcomes 
(KDIGO) controversies conference. Kidney Int 2019;95:1304–17. https://doi.org/10. 
1016/j.kint.2019.02.022
39a. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, 
Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, Zeeuw D De, Greene T, 
Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner 
BM, Mahaffey KW. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. 
N Engl J Med 2019;380:2295–2306.
39b. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, 
Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray 
KK, Udell JA, Lopes RD, Lapuerta P, Steg PG. Sotagliflozin in Patients with Diabetes and 
Chronic Kidney Disease. N Engl J Med 2021;384:129–139.
40. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and 
kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney 
disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474–84. https://doi.org/10. 
1093/eurheartj/ehab777
41. Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric 
carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, 
double-blind, randomised, controlled trial. Lancet 2020;396:1895–904. https://doi.org/ 
10.1016/S0140-6736(20)32339-4
42. Pocock SJ, Rossello X, Owen R, Collier TJ, Stone GW, Rockhold FW. Primary and sec­
ondary outcome reporting in randomized trials: JACC state-of-the-art review. J Am Coll 
Cardiol 2021;78:827–39. https://doi.org/10.1016/j.jacc.2021.06.024
43. Salah HM, Savarese G, Rosano GMC, Ambrosy AP, Mentz RJ, Fudim M. Intravenous iron 
infusion in patients with heart failure: a systematic review and study-level meta-analysis. 
ESC Heart Fail 2023;10:1473–80. https://doi.org/10.1002/ehf2.14310
44. Graham FJ, Pellicori P, Kalra PR, Ford I, Bruzzese D, Cleland JGF. Intravenous iron in pa­
tients with heart failure and iron deficiency: an updated meta-analysis. Eur J Heart Fail 
2023;25:528–37. https://doi.org/10.1002/ejhf.2810
45. Vukadinovic D, Abdin A, Emrich I, Schulze PC, von Haehling S, Bohm M. Efficacy and safety of 
intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis. 
Clin Res Cardiol 2023;112:954–66. https://doi.org/10.1007/s00392-023-02207-2
46. Anker SD, Khan MS, Butler J, von Haehling S, Jankowska EA, Ponikowski P, et al. Effect of 
intravenous iron replacement on recurrent heart failure hospitalizations and cardiovas­
cular mortality in patients with heart failure and iron deficiency: a Bayesian 
meta-analysis. Eur J Heart Fail 2023. https://doi.org/10.1002/ejhf.2860
47. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. 
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 
2009;361:2436–48. https://doi.org/10.1056/NEJMoa0908355
48. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF, et al. The 
effect of intravenous ferric carboxymaltose on health-related quality of life in patients 
with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur 
Heart J 2013;34:30–8. https://doi.org/10.1093/eurheartj/ehr504
49. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. 
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in 
patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36: 
657–68. https://doi.org/10.1093/eurheartj/ehu385
ESC Guidelines                                                                                                                                                                                          3639
